<SEC-DOCUMENT>0001787306-26-000018.txt : 20260225
<SEC-HEADER>0001787306-26-000018.hdr.sgml : 20260225
<ACCEPTANCE-DATETIME>20260225160747
ACCESSION NUMBER:		0001787306-26-000018
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260225
DATE AS OF CHANGE:		20260225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcutis Biotherapeutics, Inc.
		CENTRAL INDEX KEY:			0001787306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				812974255
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39186
		FILM NUMBER:		26678554

	BUSINESS ADDRESS:	
		STREET 1:		3027 TOWNSGATE ROAD
		STREET 2:		SUITE 300
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91361
		BUSINESS PHONE:		805-418-5006

	MAIL ADDRESS:	
		STREET 1:		3027 TOWNSGATE ROAD
		STREET 2:		SUITE 300
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91361

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arcutis, Inc.
		DATE OF NAME CHANGE:	20190905
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arqt-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:631d5f47-b6cd-44b6-9ca1-ef826fe44260,g:a004ef44-2665-49af-8ba9-70d1dea45abd,d:2dffe4de76224390b628083ec6a2857c-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:arqt="http://arcutis.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arqt-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0001787306</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-36">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-71">364</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-72">360</ix:nonNumeric><ix:nonNumeric contextRef="c-58" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-426">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" id="f-608">http://fasb.org/us-gaap/2025#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" id="f-609">http://fasb.org/us-gaap/2025#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-142" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-663">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="c-170" name="arqt:LesseeOperatingLeaseAdditionalYearsOfRentPayments" id="f-724">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="c-10" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-739">http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-257" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-950">0.25</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arqt-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>arqt:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arqt:KeithLeonardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arqt:KeithLeonardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arqt:SueJeanLinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arqt:SueJeanLinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arqt:SueJeanLinTradingArrangementOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arqt:SueJeanLinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arqt:SueJeanLinTradingArrangementCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVEFoamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVEFoamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVEFoamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.15Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.15Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.15Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.05Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.05Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.05Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerFMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:MajorCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:MajorCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:MajorCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:FourCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:FiveCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arqt:PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arqt:PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:SatoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-27</xbrli:startDate><xbrli:endDate>2024-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:SatoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:SatoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:SatoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-07</xbrli:startDate><xbrli:endDate>2022-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-07</xbrli:startDate><xbrli:endDate>2022-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arqt:LeaseDescriptionAxis">arqt:WestlakeVillageCaliforniaLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arqt:LeaseDescriptionAxis">arqt:WestlakeVillageCaliforniaLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arqt:LeaseDescriptionAxis">arqt:WestlakeVillageCaliforniaLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:TrancheATermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:TrancheB1TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:TrancheB2TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:LoanAgreementTrancheC1ExpiringMarch312026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:LoanAgreementTrancheC2ExpiringJune302026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-08</xbrli:startDate><xbrli:endDate>2024-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-06-30</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2027-01-01</xbrli:startDate><xbrli:endDate>2027-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-08</xbrli:startDate><xbrli:endDate>2024-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-22</xbrli:startDate><xbrli:endDate>2021-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-09</xbrli:startDate><xbrli:endDate>2024-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:TrancheCTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:FirstEquityPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arqt:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arqt:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arqt:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-28</xbrli:startDate><xbrli:endDate>2024-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-06</xbrli:startDate><xbrli:endDate>2021-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2022EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2022EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2022EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-16</xbrli:startDate><xbrli:endDate>2024-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-13</xbrli:startDate><xbrli:endDate>2024-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">arqt:FirstGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-13</xbrli:startDate><xbrli:endDate>2024-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">arqt:SecondGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-13</xbrli:startDate><xbrli:endDate>2024-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">arqt:ThirdGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-13</xbrli:startDate><xbrli:endDate>2024-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-30</xbrli:startDate><xbrli:endDate>2020-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arqt:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arqt:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalRoflumilastProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalRoflumilastProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalRoflumilastProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalJAKInhibitorProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalJAKInhibitorProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalJAKInhibitorProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:OtherEarlyStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:OtherEarlyStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:OtherEarlyStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2dffe4de76224390b628083ec6a2857c_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:15.5pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:15.5pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:100%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">(Mark One)</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">   </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">OR</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">For transition period from </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">       </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%"> to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">       </span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%"> </span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-39186</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">ARCUTIS BIOTHERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">(Exact name of registrant as specified in its charter)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">81-2974255</ix:nonNumeric></span></div><div style="text-align:center;text-indent:9.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">(I.R.S. Employer Identification Number)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">3027 Townsgate Road</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Westlake Village</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-13">California</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">91361</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">805</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">418-5006</ix:nonNumeric></span></div><div style="text-align:center;text-indent:0.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center;text-indent:0.2pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.959%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ARQT</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">Securities registered pursuant to section 12(g) of the</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">Act: None</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by a check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9746; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the Registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the Registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2025, the aggregate market value of the Common Stock held by non-affiliates of the Registrant was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-30">1,527,940,146</ix:nonFraction>, based on the closing price of the Registrant's Common Stock on such date.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of the Registrant&#8217;s Common Stock outstanding as of February&#160;20, 2026 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">124,033,382</ix:nonFraction>.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">DOCUMENTS INCORPORATED BY REFERENCE:</span></td></tr><tr><td colspan="15" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true">Portions of the Registrant&#8217;s Proxy Statement for the registrant&#8217;s 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K to the extent stated herein. The Proxy Statement will be filed within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2025.</ix:nonNumeric>  </span></div></td></tr></table></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_16">Item 1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_19">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_22">Item 1B.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_22">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_25">Item 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_25">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_22">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_28">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_28">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_31">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_31">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_34">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_34">87</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_37">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_40">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_40">Market </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_40">f</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_40">or Registrant's Common Equity, Related Stockholder Matters </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_40">a</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_40">nd Issuer Purchases </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_40">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_40"> Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_40">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_43">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_43">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_43">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_46">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_46">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_67">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_67">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_67">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_70">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_70">Consolidated Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_70">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_73">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_73">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_73">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_76">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_76">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_79">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_79">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_79">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_85">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_85">Disclosure Regarding Foreign Jurisdictions </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_85">t</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_85">hat Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_85">106</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_88">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_91">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_91">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_91">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_94">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_94">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_94">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_97">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_97">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_97">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_100">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_100">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_100">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_103">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_103">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_103">106</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_106">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_109">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_1367">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_1367">tem 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_1367">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2dffe4de76224390b628083ec6a2857c_1367">110</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_181">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div id="i2dffe4de76224390b628083ec6a2857c_10"></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including the sections entitled &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and &#8220;Business&#8221; contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Arcutis Biotherapeutics, Inc. (Arcutis, the Company, we, us, or our) intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include, but are not limited to, statements about:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost, and timing of our plans to develop and commercialize immuno-dermatology drugs, including our current products of ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) cream 0.3% (ZORYVE cream 0.3%), ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) cream 0.15% (ZORYVE cream 0.15%), ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) cream 0.05% (ZORYVE cream 0.05%), ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(roflumilast) topical foam (ZORYVE foam), our product candidate ARQ-234, as well as  potential indications and other label expansions for ZORYVE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue as a going concern and to obtain funding for our operations, including funding necessary to complete further development and commercialization of our products and product candidates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy the conditions, covenants, and obligations under our amended loan and security agreement with SLR Investment Corp.;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of government regulations, including U.S. Food and Drug Administration (FDA) regulations;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future agreements, if any, with third parties in connection with the commercialization of our products and product candidates, if approved for commercial uses;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost, and timing of our product candidate development activities and planned clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products and product candidates, if approved for commercial uses;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential market size and the size of the patient populations for our products and product candidates, if approved for commercial uses;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential U.S. and Canadian market sales for our products and product candidates, if approved for commercial uses;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing, and manufacturing capabilities and strategy;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key management and technical personnel;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on information technology systems and the potential for cybersecurity incidents and risks associated with artificial intelligence;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to obtain, maintain, and enforce intellectual property protection for our products and product candidates; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements, and potential needs for additional financing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this Annual Report on Form 10-K may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K to conform these statements to actual results or to changes in our expectations, except as required by law.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K we have filed with the U.S. Securities and Exchange Commission (SEC) with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our business is subject to numerous risks and uncertainties, including those described in Part I Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We are a commercial-stage biopharmaceutical company with four products approved for commercial sale. We have incurred significant losses since our inception, and could continue to incur losses, which, together with our limited history as a commercial-stage company, makes it difficult to assess our future viability;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our capital requirements are difficult to predict and may change. We may require substantial additional financing to achieve our goals or for strategic purposes, and a failure to obtain this capital if or when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate certain operations, efforts, or strategic initiatives;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our future operating results to fall below expectations;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our estimated market opportunities are subject to numerous uncertainties and may prove to be inaccurate. If we have overestimated the size of our market opportunities, our future growth may be limited;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The terms of our loan and security agreement require us to meet certain operating and financial covenants, and place certain restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The sales, marketing, and distribution of ZORYVE or any future approved products may be unsuccessful or less successful than anticipated; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is dependent on the successful commercialization of ZORYVE and the development, regulatory approval, and commercialization of our product candidates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payers, or others in the medical community necessary for commercial success; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to achieve and maintain third-party payer coverage and adequate levels of reimbursement for ZORYVE or any of our product candidates for which we receive regulatory approval, or any future products we may seek to commercialize, their commercial success may be severely hindered; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would prevent or delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business, and our results of operations;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Certain of the endpoints in our planned clinical trials rely on a subjective assessment of the effect of the product candidate in the subject by either the physician or subject, and may prove difficult to meet in subjects with more severe disease, which exposes us to a variety of risks for the successful completion of our clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enrollment and retention of subjects in clinical trials is expensive and time-consuming and may result in additional costs and delays in our product development activities, or in the failure of such activities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs, or necessitate the abandonment or limitation of the development of some of our product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to increase the size of our organization, and we may experience difficulties in executing our growth strategy, managing any growth, and retaining talent; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not successful in acquiring, developing, and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications, and our operating results will suffer if we fail to compete effectively;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any collaboration arrangements that we have entered into or may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize future product candidates;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of ZORYVE or our current or future product candidates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third-party manufacturers to manufacture nonclinical, clinical, and commercial supplies of ZORYVE and our product candidates. The loss of these manufacturers or their sub-suppliers, their failure or inability to comply with manufacturing or other regulations, or their failure to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct our nonclinical studies and our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to our intellectual property could materially adversely impact our business, competitive position, financial condition, and results of operations; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to government regulation of our industry and required approvals could materially adversely impact our business, competitive position, financial condition, and results of operations.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRADEMARKS</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mark &#8220;Arcutis&#8221; and the Arcutis logo are our registered trademarks, and all product names are our common law trademarks. All other service marks, trademarks, and trade names appearing in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to herein appear without the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.</span></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET AND INDUSTRY DATA</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains estimates, projections and other statistical data and information concerning our industry, our business, and the markets for our product candidates. Some data and statistical information contained herein, including market size and opportunity figures for our product candidates, are based on management&#8217;s estimates and calculations, which are derived from our review and interpretation of the independent sources, our internal research, and knowledge of the industry and market in which we operate. Some data and statistical information are based on independent reports from third parties, including DR/Decision Resources, LLC, or Decision Resources Group, Global Data, and IQVIA, as well as reports that we commissioned from third parties. Decision Resources Group makes no representation or warranty as to the accuracy or completeness of the data, or DR Materials, set forth herein and shall have, and accept, no liability of any kind, whether in contract, tort (including negligence) or otherwise, to any third-party arising from or related to use of the DR Materials by us. Any use which we or a third-party makes of the DR Materials, or any reliance on it, or decisions to be made based on it, are the sole responsibilities of us and such third-party. In no way shall any data appearing in the DR Materials amount to any form of prediction of future events or circumstances and no such reliance may be inferred or implied.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This information, to the extent it contains estimates or projections, involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates or projections. Industry publications and other reports we have obtained from independent parties generally state that the data contained in these publications or other reports have been obtained in good faith or from sources considered to be reliable, but they do not guarantee the accuracy or completeness of such data. The industry in which we operate is subject to risks and uncertainties due to a variety of factors, including those described in the section entitled &#8220;Risk Factors.&#8221; These and other factors could cause results to differ materially from those expressed in these publications and reports.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div><span><br/></span></div><div id="i2dffe4de76224390b628083ec6a2857c_16"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.   BUSINESS</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions. We believe we have built a leading platform for dermatologic product development and commercialization. Our strategy is to focus on validated biological targets, and to use our drug development platform and deep dermatology expertise to develop and commercialize differentiated products that have the potential to address the major shortcomings of existing therapies in our targeted indications. We believe this strategy uniquely positions us to rapidly advance our goal of bridging the treatment innovation gap in dermatology, while maximizing our probability of technical success and financial resources. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We launched our lead product, ZORYVE cream 0.3%, in August 2022 after obtaining our initial FDA approval for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas (e.g. groin or axillae), in individuals 12 years of age or older. ZORYVE cream 0.3% is a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. ZORYVE cream 0.3% is approved for once-daily topical treatment of mild, moderate, and severe plaque psoriasis with no limitations on location or duration of use. In October 2023, we received FDA approval for an expanded indication in plaque psoriasis down to 6 years of age. In November 2025, our supplemental New Drug Application (sNDA) was accepted for filing by the FDA to potentially expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026. In June 2023, we had our first commercial launch outside of the United States following Health Canada approval of ZORYVE cream 0.3% for the treatment of plaque psoriasis in individuals 12 years or age or older. In February 2026, Health Canada accepted our Supplement to a New Drug Submission (SNDS) for ZORYVE cream 0.3% for individuals down to 2 years old.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, we received FDA approval for ZORYVE foam 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on severity, location, or duration of use. ZORYVE foam is a once-daily steroid-free foam and, as a PDE4 inhibitor, was the first drug approved for the treatment of seborrheic dermatitis with a new mechanism of action in over two decades. ZORYVE foam became commercially available in the United States in January 2024 and became commercially available in Canada in December 2024 following approval by Health Canada. We received FDA approval for ZORYVE foam for the treatment of plaque psoriasis of the scalp and body in adults and adolescents ages 12 and older in May 2025, followed by commercial launch in the United States in June 2025.  ZORYVE foam for the treatment of plaque psoriasis of the scalp and body in adults and adolescents ages 12 and older was also approved by Health Canada in October 2025, followed by commercial launch in November 2025. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also received FDA approval for, and commercially launched, ZORYVE cream 0.15% in July 2024 for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older, with no limitation on location, body surface area treated, concomitant use, or duration of use specified in the approved labelling. ZORYVE cream 0.15% was also approved by Health Canada in March 2025 and commercially launched in April 2025. We also received FDA approval for, and commercially launched, ZORYVE cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age in October 2025. ZORYVE cream 0.15% and ZORYVE cream 0.05% are once-daily, steroid-free creams that provide rapid disease clearance and significant reduction in itch, and have been specifically developed to be treatment options for long-term disease control. In February 2026, we announced positive topline data for INTEGUMENT-INFANT, a Phase 2 study to evaluate the safety and efficacy of investigational ZORYVE cream 0.05% in infants as young as 3 months to less than 2 years with atopic dermatitis. We intend to submit an sNDA to the FDA in the second quarter of 2026 based on the results of this trial to potentially expand the indication for ZORYVE cream 0.05% for the treatment of infants with atopic dermatitis down to the age of 3 months. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, we entered into a promotion agreement with Kowa Pharmaceuticals America, Inc. (Kowa) to leverage Kowa's primary care sales force to exclusively market and promote ZORYVE in the United States to primary care practitioners and pediatricians for all FDA-approved indications until at least July 2029. Under the terms of the agreement, Kowa will receive a commission from net sales attributed to Kowa. Promotion of ZORYVE in primary care and pediatrics under the Kowa agreement began in late September 2024. Effective January 23, 2026, we mutually agreed to terminate the promotion agreement. Following this termination, Kowa ceased all sales and promotions of ZORYVE and we will not be required to make any further payments to Kowa.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2023, we entered into a strategic collaboration and licensing agreement (the Huadong Agreement) for topical roflumilast in Greater China and Southeast Asia with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong). a wholly owned subsidiary of Huadong Medicine Co., Ltd. In February 2024, we entered into a a strategic collaboration and licensing agreement (the Sato Agreement) for topical roflumilast in Japan with Sato Pharmaceutical Co., Ltd.(Sato).</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we acquired Ducentis BioTherapeutics LTD (Ducentis) and its lead asset, DS-234 (now ARQ-234), a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 Receptor (CD200R). We plan to develop ARQ-234 in atopic dermatitis, where we believe it could be a highly complementary biologic treatment option to ZORYVE cream 0.15% in that indication, if approved. ARQ-234 could potentially be used to treat other inflammatory conditions as well. We submitted an Investigational New Drug application (IND) to the FDA in July 2025, and anticipate commencing a Phase 1 study of ARQ-234 in the first quarter of 2026.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we executed a licensing agreement with AstraZeneca AB (AstraZeneca) for exclusive worldwide rights to roflumilast as a topical product in humans solely for dermatological indications. Moreover, we have our own intellectual property portfolio around topical uses of roflumilast, with issued and pending formulation, pharmacokinetic, and method-of-use patents in the United States and other jurisdictions from several distinct patent families, which provides us with exclusivity in the United States for our product cream formulation through 2037 and foam formulation through 2042. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermatological diseases such as psoriasis, atopic dermatitis, and seborrheic dermatitis affect hundreds of millions of people worldwide each year, impacting their quality of life, and physical, functional, and emotional well-being. There are many approved treatments for these conditions, but a large opportunity remains due to issues with existing treatments. Topical treatments are used for nearly all patients, but existing topicals are limited by one or more of the following: modest response rates, side effects, patient adherence, application site restrictions, and limits on duration of therapy. Topical corticosteroids (TCS) are commonly used as the first-line therapy for the treatment of inflammatory skin conditions such as psoriasis, atopic dermatitis, and seborrheic dermatitis. While many patients see improvements, extended use of TCS carries the risk of a variety of significant side effects. The localized side effects of extended use of TCS at the site of application, such as skin barrier damage and striae, have long been established. More recently, there is an increasing appreciation for the potential systemic side effects of prolonged TCS use, such as hyperglycemia, adrenal insufficiency, and osteoporosis. As a result, TCS are typically used intermittently for brief periods, making them an insufficient therapeutic option for inflammatory skin diseases that are chronic in nature. In psoriasis, vitamin D analogs are also used, but have lower response rates than TCS and are frequently irritating. Topical tapinarof (Vtama</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) was approved in May 2022 for the treatment of adults with plaque psoriasis and in December 2024 for adults and children with atopic dermatitis, but this non-steroidal agent also carries significant application site reactions. In atopic dermatitis, topical calcineurin inhibitors (TCIs) and crisaborole (Eucrisa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a topical non-steroidal PDE4 inhibitor, are used, but have lower response rates than TCS and are associated with application site burning. TCIs also have a boxed warning for cancer risk. Topical ruxolitinib (Opzelura</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) was approved for the treatment of atopic dermatitis in September 2021, but carries an extensive boxed warning for numerous severe side effects, is limited to short-term, intermittent use, and is contraindicated for concomitant use with systemic therapies. In seborrheic dermatitis, in addition to TCS, topical antifungals are commonly used, but have limited efficacy.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologic and systemic therapies are also available for some diseases, but are typically indicated for a small percentage of the affected population with more severe disease.  Importantly, most patients on biologic and systemic therapies for inflammatory skin conditions still require adjunctive topical therapies to treat residual disease and occasional flaring of symptoms. Biologics for psoriasis have shown impressive response rates but are only indicated for a minority of patients with moderate-to-severe forms and can often leave patients with some degree of residual disease. Treatment with oral systemic therapies such as methotrexate and apremilast (Otezla</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) has also been limited due to modest symptomatic improvement and the frequency of adverse events. In atopic dermatitis, where biologic and systemic therapies have shown lower response rates, we see opportunity to both supplement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current therapies and to continue to advance the standard of care for patients, for example with regard to response rates and dosing frequency. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the limitations associated with existing treatments, we believe patients with inflammatory skin conditions and their dermatologists are dissatisfied with their current treatment options. We believe that there is a significant opportunity to leverage developments in other fields of medicine, particularly inflammation and immunology, to address the significant need for effective chronic treatments in immuno-dermatology. Our primary focus since our founding has been to address patients&#8217; significant need for innovative treatments that directly target molecular mediators of disease, have the potential to show significant symptomatic improvement, maintain a low risk of toxicity or side effects, and are suitable for chronic use on all areas of the body. Based on market research and our internal estimates, we estimate there is an overall actively prescription-treated patient market of approximately 17.0 million patients in the United States that are treated with topical therapies for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, with approximately 8.4 million treated in dermatology offices and the remaining approximately 8.6 million treated outside dermatology. Of the patients that are treated in dermatology offices, we estimate that approximately 3.7 million of these patients are covered by Medicare or Medicaid, while approximately 4.7 million are covered by private payers. Patients that are treated outside of dermatology offices are primarily treated by primary care providers and pediatricians, and the ratio of commercial to government insurance is similar. </span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Portfolio and Pipeline</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart summarizes our product portfolio and pipeline:</span></div><div style="text-align:center"><img src="arqt-20251231_g1.jpg" alt="Pipeline Chart from Annual Report 2026FEB05.jpg" style="height:311px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" id="i-1"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to leverage innovations in inflammation and immunology to identify molecules acting against validated biological targets in dermatology, and to develop and commercialize best-in-class products based on those molecules that address significant unmet needs in immuno-dermatology. The key pillars of our strategy are:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:5.5pt;text-decoration:underline">Grow</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> our core ZORYVE business as we establish ZORYVE as the foundational therapy for adults and children who need long-term therapeutic solutions for managing their plaque psoriasis, seborrheic dermatitis, and atopic dermatitis.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> A primary component of this pillar of our strategy is to provide a therapeutic alternative to TCS amidst the increasing calls for safer alternatives for the treatment of inflammatory dermatosis as the local and systemic side effects of prolonged topical steroid use become more broadly appreciated. This pillar also includes our efforts to extend the breadth of our prescribing base beyond dermatologists to primary care and pediatric health care providers, and to continue expanding insurance coverage for ZORYVE, particularly in Medicare and Medicaid. We believe further extension of our current indications and incremental clinical data generation to bolster ZORVYE's position in these indications is an additional important component of this growth strategy.</span></div><div style="padding-left:9pt;text-indent:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Expand</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> the ZORYVE franchise into additional indications through strategic lifecycle management</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our new indication expansion efforts will be guided by a large body of case reports received by our medical team from clinicians  who have used ZORYVE in various inflammatory dermatoses and seen encouraging signs of efficacy. We will seek to evaluate these potential signals of efficacy in a controlled setting with resource-efficient Phase 2 proof-of-concept trials before selecting potential indications to evaluate in Phase 3 pivotal trials. The decision on which programs to advance will be based on the collective data from across these proof-of-concept studies, feedback received from regulatory agencies, and analysis of the unmet need and market potential of these various indications. Initial diseases of interest that are currently being evaluated in ongoing Phase 2 trials are hidradenitis suppurativa and vitiligo. </span></div><div style="padding-left:9pt;text-indent:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt;text-decoration:underline">Build</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> our pipeline by advancing innovative medicines for patients, leveraging our leading drug development capabilities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our initial focus in building our pipeline is on advancing ARQ-234 through clinical development. We believe that ARQ-234 has the potential to have a very differentiated profile and could be a highly complimentary biologic treatment to ZORYVE for the treatment of atopic dermatitis, if approved. We believe our management team's experience in developing dermatological drugs, including biologics, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will enable us to effectively move ARQ-234 through the development process. ARQ-234 also has the potential to treat multiple other inflammatory diseases, which we may choose to pursue ourselves or through partnerships. Beyond ARQ-234, we will continue to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluate strategic opportunities to in-license or acquire select dermatology and inflammation and immunology (I&amp;I) assets. Leveraging our deep expertise in identifying promising drug candidates, we will continue to seek assets across treatment modalities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our team's capabilities in dermatological and I&amp;I clinical development and commercialization position us well to advance, register and commercialize drug candidates and to generate value with any future acquired assets.</span></div><div style="padding-left:9pt;text-indent:9pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><img src="arqt-20251231_g2.jpg" alt="image.jpg" style="height:287px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-2"/></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZORYVE Cream</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product, ZORYVE cream, offers symptomatic improvement in psoriasis and atopic dermatitis patients similar to a high potency steroid, but with a favorable tolerability profile, the ability to be used chronically, and little-to-no application site reactions associated with many existing topical treatments. ZORYVE cream is designed for simple once-a-day application for chronic use, does not burn or sting on application, and can be used on any part of the body, including sensitive or difficult-to-treat areas, such as the face and intertriginous regions. It quickly and easily rubs into the skin without leaving a greasy residue, does not stain clothing or bedding, or have an unpleasant smell. Roflumilast, the active pharmaceutical ingredient in ZORYVE, is a highly potent and selective PDE4 inhibitor. Roflumilast has demonstrated a potency advantage of approximately 25x to in excess of 300x compared to the active ingredients in the two other FDA-approved PDE4 inhibitors, Eucrisa and Otezla.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plaque Psoriasis</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the treatment of plaque psoriasis, ZORYVE cream 0.3% is currently commercially available in the United States and Canada for individuals 6 years and older, with no limitation on location or duration of use. Additionally, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE cream 0.3% for 2-5 year olds with plaque psoriasis has a PDUFA target action date of June 29, 2026.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Psoriasis Background</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Psoriasis is an immune disease that occurs in about 3% of the U.S. population, representing approximately 9&#160;million patients. About 90% of cases are plaque psoriasis, which is characterized by &#8220;plaques&#8221;, or raised, red areas of skin covered with a silver or white layer of dead skin cells referred to as &#8220;scale&#8221;. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and the plaques are often itchy and sometimes painful. Approximately 40% of plaque psoriasis patients have plaques on their scalp, about 15% have plaques in their intertriginous regions, approximately 10% have plaques on their face, and one in three has plaques on their elbows and knees. Each of these areas present a variety of treatment challenges which may be well suited to treatment with ZORYVE cream. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Psoriasis patients are generally characterized as mild, moderate, or severe, with approximately 75% experiencing a mild-to-moderate form of the disease and 25% experiencing a moderate-to-severe form of the disease. Pruritus (itching) is a particularly common and bothersome symptom for patients, which can be severe and impact sleep patterns. In addition, patients with plaque psoriasis can suffer substantial psychosocial impacts from their disease and have a 50% greater chance of depression than the general population.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Psoriasis Treatment Landscape</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of psoriasis patients are treated with topical therapies, of which there had been no novel treatments approved in over 20 years, until the approvals of ZORYVE cream and tapinarof in 2022. Despite their widespread use, other existing topical therapies all possess substantial shortcomings:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:5.5pt">Topical steroids</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are associated with a number of side effects, including, among others, hypothalamic-pituitary-adrenal (HPA) axis suppression, skin atrophy (thinning), striae (stretch marks), and telangiectasia (spider veins). Some of these side effects are irreversible. Growing evidence also points to risks of other systemic side effects, such as hyperglycemia, adrenal insufficiency, and osteoporosis. Consequently, high potency topical steroids are not recommended for chronic use, and physicians generally will not prescribe them for treatment on the face or in the intertriginous regions. </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:5.5pt">Vitamin D3 analogs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provide substantially less symptomatic improvement than high potency steroids and are frequently irritating. While they can be used chronically, tolerability issues with their use can be a challenge, and physicians generally will not prescribe them for use on the face or in the intertriginous regions.</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:5.5pt">Vitamin D3/steroid combinations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offer better symptomatic improvement than either of the two individual components alone, but still carry all of the adverse event risks associated with topical steroids, and are limited in their duration of use. </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Tapinarof</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a non-steroidal topical aryl hydrocarbon receptor (AhR) agonist approved in May 2022 for adults with plaque psoriasis. In clinical trials, treatment with tapinarof was associated with adverse events such as folliculitis, contact dermatitis, burning, stinging, and itching.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because high potency steroids and combinations containing high potency steroids provide robust symptomatic improvement for psoriasis patients, most physicians initiate treatment for nearly all patients with them. However, due to the limitations on duration of treatment between 2 and 8 weeks, most physicians will switch the patient to a low- to mid-potency steroid or to a vitamin D analog to manage the patient&#8217;s psoriasis chronically. These &#8220;step down&#8221; options provide less symptomatic improvement and are often irritating. Also, rebound is a known challenge with steroids, where the recurrence of psoriasis after steroid discontinuation is more severe than it was prior to steroid treatment. As a result, patients are constantly cycling between effective short courses of high potency steroids and less effective &#8220;step down&#8221; maintenance treatments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment with biologics remains restricted. In the United States, less than 33% of moderate-to-severe psoriasis patients (equivalent to 27% of all psoriasis patients) are on biologic therapy. The uptake of biologics has remained limited due to multiple factors, including the fact that they are indicated only for use in moderate-to-severe patients, their high cost and patient co-payments, reimbursement and access restrictions, perceived risk of side effects, and patient fear of injection.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment with non-biologic systemic therapy, such as methotrexate or Otezla is also limited. According to Decision Resources Group, non-biologic systemic therapy represents approximately 8% of patients worldwide and 11% of patients in the United States. The use of methotrexate has declined due to concerns about side effects and mandatory routine monitoring. Otezla has a limited U.S. market share in part due to its high annual price relative to topical treatments, modest symptomatic improvement, and frequent adverse events.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Psoriasis Key Completed Trials</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DERMIS-1 and DERMIS-2 pivotal Phase 3 studies</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DERMIS-1 and DERMIS-2 studies were identical pivotal Phase 3 randomized, parallel, double-blind, vehicle-controlled, multi-national, multicenter studies in which subjects age 2 years and above with mild, moderate, or severe chronic plaque psoriasis involving between 2% and 20% body surface area received 8 weeks of (i) ZORYVE cream 0.3% once daily or (ii) matching vehicle once daily. DERMIS-1 enrolled 439 subjects and DERMIS-2 enrolled 442 subjects.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results from the eight-week treatment period demonstrated statistically significant improvement compared to the matching vehicle on key efficacy endpoints. On the studies&#8217; primary efficacy endpoint of percentage of subjects achieving Investigator Global Assessment (IGA) success, which was defined as a score of &#8220;clear&#8221; or &#8220;almost clear&#8221; plus a 2-grade improvement from baseline at Week 8, 42.4% of subjects treated with ZORYVE cream achieved Investigator Global Assessment (IGA) Success, compared to 6.1% of subjects treated with vehicle (p &lt; 0.0001) in DERMIS-1, and 37.5% of subjects treated with ZORYVE cream achieved IGA Success, compared to 6.9% of subjects treated with vehicle (p&lt;0.0001) in DERMIS-2. ZORYVE cream also demonstrated statistically significant improvements over vehicle on key secondary endpoints, including on Intertriginous IGA Success, Psoriasis Area Severity Index-75, reductions in itch as measured by the Worst Itch-Numeric Rating Scale (WI-NRS), and patient perceptions of symptoms as measured by the Psoriasis Symptoms Diary (PSD). </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE cream was well tolerated by the patient populations, with rates of treatment-emergent adverse events (TEAEs) low and similar to vehicle, and most TEAEs assessed as mild-to-moderate in severity. Of the subjects treated with ZORYVE cream, five subjects (1.7%) in DERMIS-1 and one subject (0.3%) in DERMIS-2 discontinued the study due to a TEAE. There were no treatment-related serious adverse events. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARQ-151-202 (Long-Term Safety Study)</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term safety study was a Phase 2, multicenter, open-label study of the long-term safety and efficacy of ZORYVE cream 0.3% in adult subjects with chronic plaque psoriasis involving up to 25% total body surface area (BSA), evaluated in two cohorts: subjects who completed the ARQ-151-201 Phase 2b, randomized, controlled trial; and previously untreated subjects. All subjects applied ZORYVE cream once daily for 52 weeks at home. Approximately half (164 of 332) of the subjects entered this long-term study after completing treatment with ZORYVE cream 0.3% or 0.15% in the randomized Phase 2b study (ARQ-151-201) and therefore received up to 64 weeks of total treatment with ZORYVE cream (12 weeks in the randomized Phase 2b study and 52 weeks in the long-term safety study). Periodic clinic visits included assessments for clinical safety, application site reactions, and disease improvement or progression. The primary outcome measures of this long-term safety study were the occurrence of TEAEs and the occurrence of serious adverse events.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this open-label study, ZORYVE cream 0.3% applied once daily for up to 52 weeks demonstrated favorable safety and tolerability over the long-term treatment period, consistent with what was seen in the randomized Phase 2b study, with only 3.6% of subjects experiencing a treatment-related adverse event during 52 weeks of treatment. Additionally, a d</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">urable treatment effect was maintained through 52 to 64 weeks as 57.1% (n=185) of ZORYVE cream-treated patients achieved an IGA score of clear or almost clear (IGA 0/1) at any time during the study, and these participants had a median duration of IGA of clear or almost clear of more than 10 months (40.1 weeks). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At week 52 of the long-term safety study, 44.8% of all subjects attained an IGA Success of clear or almost clear, with 34.8% of subjects in Cohort 1 and 39.5% of subjects in Cohort 2 achieving IGA Success, defined as a score of clear or almost clear plus a 2-grade improvement from baseline. Additionally, of the subjects in the 12-week randomized Phase 2b study who were treated with ZORYVE cream 0.3% and who attained an IGA of clear or almost clear at 12 weeks in the first study, then continued on treatment in the long-term safety study, 66.7% </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had an IGA of clear or almost clear at the end of 64 weeks of treatment or their last visit. Of the 332 subjects in this study, 73.5% completed the full 52 weeks of open-label treatment, with only 3.9% of subjects discontinuing the study due to an adverse event and less than 1% of subjects discontinuing due to lack of efficacy. There were no treatment-related serious adverse events reported.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Atopic Dermatitis</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the treatment of atopic dermatitis, ZORYVE cream is currently available in the 0.15% concentration for individuals 6 years and older in the United States and Canada, and in the 0.05% concentration for children ages 2 to 5 in the United States, with no limitation on location or duration of use. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Atopic Dermatitis Background</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Atopic dermatitis is the most common type of eczema, affecting approximately 26 million people in the United States. Atopic dermatitis is the most common skin disease among children, with prevalence steadily increasing from 8% to 12% in the last two decades. Atopic dermatitis is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inflammation. This reaction produces a red, itchy rash, most frequently occurring on the face, arms and legs, and the rash can cover significant areas of the body. The rash causes significant pruritus (itching), which can lead to damage caused by scratching or rubbing and perpetuating an &#8216;itch-scratch&#8217; cycle.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the high proportion of pediatric patients, safety and tolerability of atopic dermatitis treatments is paramount. Atopic dermatitis imposes a substantial burden on the patient, parents, and family. Pediatric patients with atopic dermatitis can suffer from sleep disturbances, behavioral problems, irritability, crying, interference with normal childhood activities, and social functioning. Adults with atopic dermatitis also frequently suffer from sleep disturbances, emotional impacts, and impaired social functioning. Adults with atopic dermatitis also appear to be at a significantly increased risk of anxiety, depression, and suicidal ideation compared to the general population.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Atopic Dermatitis Treatment Landscape</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of atopic dermatitis patients are being treated with topical therapies, particularly low- to mid-potency topical steroids and TCIs. Despite their widespread use, existing topical therapies all possess substantial shortcomings:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:5.5pt">Topical steroids</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pose a particular concern in pediatric patients due to the risk of systemic absorption, and the consequent risk of HPA axis suppression, and potential developmental problems. Chronic use of topical steroids in atopic dermatitis patients is generally avoided. Many physicians are also reluctant to use steroids to treat atopic dermatitis on the face due to the increased risk of glaucoma and cataracts, or the diaper/groin region due to risk of skin thinning. There is also considerable concern among many parents about treating their children with steroids.</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:5.5pt">Topical calcineurin inhibitors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally seen as providing less symptomatic improvement than topical steroids and are also associated with some application site burning. In 2005 the FDA placed a boxed warning on the labels of both TCIs regarding a potential increased risk of cancers, especially lymphomas, associated with their use, which often creates significant parental resistance to their use.</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:5.5pt">Eucrisa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a topical non-steroidal PDE4 inhibitor approved by the FDA in 2016. Despite initial interest among the physician community to adopt the product, its growth has been hampered by frequent occurrences of application site burning and stinging as well as disadvantaged reimbursement status compared to other atopic dermatitis treatments.</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:5.5pt">Opzelura </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a topical JAK inhibitor approved in September 2021 for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The label carries an extensive boxed warning for serious infections, all-cause mortality, malignancy, major adverse cardiovascular events and thrombosis, as well as limitations on duration, body surface area, and concomitant use with immunosuppressive agents.<br/></span></div><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Tapinarof</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a non-steroidal topical aryl hydrocarbon receptor (AhR) agonist approved in May 2022 for adults with plaque psoriasis. In clinical trials, treatment with tapinarof was associated with certain adverse events such as folliculitis, contact dermatitis, burning, stinging, and itching.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment with biologics such as Dupixent</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as recently launched oral agents, remains highly restricted. In the United States, less than 11% of all atopic dermatitis patients are on biologic therapy. The uptake of biologics and systemic therapies is expected to grow, as the efficacy and dosing parameters of treatment options for moderate-to-severe disease states improve; however, similar to plaque psoriasis, we believe such use will ultimately remain limited due to multiple factors, including the fact that they are indicated only for use in moderate-to-severe patients, their high cost and patient co-payments, reimbursement and access restrictions, and patient fear of injection for biologics.  Additionally, in the atopic dermatitis context, systemic therapies often leave patients with residual symptoms, and patients can flare while on systemic therapy, creating the need for adjunctive topical treatment.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Atopic Dermatitis Key Completed Trials</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INTEGUMENT-1 and INTEGUMENT-2 pivotal Phase 3 studies</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our atopic dermatitis Phase 3 program includes three 4-week pivotal studies and a 52-week open-label extension study. INTEGUMENT-1 and INTEGUMENT-2 were multicenter, double-blind, vehicle-controlled Phase 3 studies, with more than 650 subjects in each study, ages 6 and above with mild to moderate atopic dermatitis. Subjects were randomized to receive once-daily topical applications of&#160;ZORYVE cream 0.15% or vehicle for 4 weeks. The primary endpoint was the proportion of all randomized subjects who attain IGA Success, defined as a validated Investigator Global Assessment &#8211; Atopic Dermatitis (vIGA-AD) score of &#8216;clear&#8217; or &#8216;almost clear&#8217; plus a 2-grade improvement from Baseline at Week 4. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both INTEGUMENT-1 and INTEGUMENT-2 met their primary endpoint. In INTEGUMENT-1, 32.0% of individuals treated with ZORYVE cream 0.15% achieved IGA Success, compared to 15.2% of individuals treated with vehicle (P&lt;0.0001). In INTEGUMENT-2, 28.9% of individuals treated with ZORYVE cream 0.15% achieved IGA Success at Week 4 compared to 12.0% of individuals treated with vehicle (P&lt;0.0001). ZORYVE cream also demonstrated rapid and statistically significant improvements compared to vehicle on key secondary endpoints, including, in INTEGUMENT-1, 43.2% of individuals treated with ZORYVE cream 0.15% achieving a 75% improvement in Eczema Area and Severity Index (EASI-75) at Week 4 compared to 22.0% treated with vehicle (P&lt;0.0001). In INTEGUMENT-2, 42.0% of individuals treated with ZORYVE cream 0.15% achieved an EASI-75 at Week 4 compared to 19.7% treated with vehicle (P&lt;0.0001).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an additional secondary endpoint, INTEGUMENT-1 evaluated reduction in itch in individuals 12 years of age and older, with 33.6% of individuals treated with ZORYVE cream achieving a 4-point reduction in WI-NRS at Week 4 (vs. 20.7% for vehicle-treated subjects [p&lt;0.01]). In INTEGUMENT-2, 30.2% of individuals treated with ZORYVE cream achieved a four-point reduction in WI-NRS at Week 4 (vs. 12.4% for vehicle-treated subjects, [P&lt;0.01]). In addition, individuals treated with ZORYVE cream reported reductions in itch from baseline as early as 48 hours from first application. ZORYVE cream 0.15% was well tolerated in both studies. The incidence of Treatment Emergent Adverse Events (TEAEs) was low in both active treatment and vehicle arms, with most TEAEs assessed as mild-to-moderate severity. Overall, incidence of adverse events were low, with no adverse event occurring in more than 3.5% of subjects in either arm for either INTEGUMENT-1 or INTEGUMENT-2. The most frequent adverse events (&#8805;1%) included COVID-19, application site pain, headache, nausea, vomiting, diarrhea, nasopharyngitis, and upper respiratory tract infection. Over 90% of patients who were randomized to ZORYVE cream in both studies completed the full 4 weeks, and there were few discontinuations due to adverse events.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INTEGUMENT-PED Trial</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we announced positive topline data from INTEGUMENT-PED Trial. This pivotal trial investigated ZORYVE cream 0.05% as a potential treatment for children 2 to 5 years of age with mild to moderate atopic dermatitis. The trial was a Phase 3, randomized, parallel group, double-blind, vehicle-controlled trial in which subjects ages 2 to 5 with mild to moderate atopic dermatitis involving 3% or greater body surface area received 4 weeks of (i) ZORYVE cream 0.05% once daily or (ii) vehicle once daily. A total of 652 children were enrolled in INTEGUMENT-PED.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results from the four-week treatment period demonstrated statistically significant improvements compared to matching vehicle. The primary endpoint was the percentage of patients achieving IGA Success, which is vIGA-AD score of "clear" or "almost clear" plus a 2-grade improvement from baseline, at Week 4. In the trial, 25.4% of patients treated with ZORYVE cream 0.05% achieved IGA Success, compared to 10.7% of patients treated with vehicle (P&lt;0.0001), with significant improvements observed as early as Week 1.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE cream 0.05% also demonstrated statistically significant improvements compared to vehicle on key secondary endpoints, which included EASI-75, the percentage of patients achieving IGA Success at Weeks 1 and 2, and the percentage of patients achieving a vIGA-AD score of &#8220;clear&#8221; or &#8220;almost clear&#8221; at Weeks 1 and 2, with significant improvements observed for these endpoints as early as Week 1. In the trial, 39.4% of patients treated with ZORYVE cream 0.05% achieved EASI 75 at Week 4, compared to 20.6% of patients treated with vehicle (p &lt; 0.0001). In addition, 21.2% of patients achieved IGA Success at Week 2, compared to 6.8% of patients treated with vehicle (P&lt;0.0001), and 9.4% of patients achieved IGA Success at Week 1, compared to 0.9% of patients treated with vehicle (P&lt;0.0001). In the trial, 35.3% of patients treated with ZORYVE cream 0.05% with an itch score of at least four at baseline achieved a four-point reduction in itch score compared to baseline, as measured by the WI-NRS, compared to 18.0% of patients treated with vehicle (P=0.0002).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE cream 0.05% was well-tolerated, with rates of treatment-emergent adverse events (TEAEs) low across the active treatment and vehicle arms. Overall, adverse events were uncommon, with no adverse event occurring in more than 4.1% of subjects in the trial. The only adverse event occurring in &gt;3% of subjects in either arm was upper respiratory tract infection, and the most frequent adverse events (&gt;2%) included upper respiratory tract infection, pyrexia, diarrhea, vomiting, and, in the vehicle arm only, atopic dermatitis.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the patients treated with ZORYVE cream 0.05% in the trial, 410 (93.8% of patients) completed the full 4 weeks, and there were few discontinuations due to adverse events in both the ZORYVE cream 0.05% group and vehicle group. Five patients treated with ZORYVE cream 0.05% (1.1% of patients treated with ZORYVE cream 0.05%) and four patients in the vehicle group (1.9% of patients treated with vehicle) discontinued the trial due to an adverse event. There were no treatment-related serious adverse events.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INTEGUMENT OLE (long range study)</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our INTEGUMENT-OLE study is a Phase 3, multicenter, open label extension study that has enrolled 1220 subjects who have completed INTEGUMENT-1, -2, or -PED. The study examines the long-term safety of ZORYVE cream 0.15% in subjects 6 years of age and older with atopic dermatitis and ZORYVE cream 0.05% in subjects 2 to 5 years of age with atopic dermatitis. The primary objective of the study is to assess the long-term safety based on the occurrence of adverse events and serious adverse events. Individuals that completed INTEGUMENT-1 and -2 are eligible to enroll for either 24 or 52 weeks of additional treatment, representing 28 or 56 weeks of treatment in aggregate. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In September 2023, we announced positive interim results from this ongoing study regarding subjects 6 years of age and older with atopic dermatitis. A total of 657 subjects had been enrolled in INTEGUMENT-OLE at such time. After 4 weeks of treatment, subjects who achieved a vIGA-AD score of &#8220;clear&#8221; transitioned to twice weekly maintenance dosing, after which any subjects who reached a vIGA-AD score of &#8220;mild&#8221; would resume once-daily dosing. Subjects could also resume once-daily dosing if signs or symptoms were not adequately controlled with maintenance dosing despite maintaining a vIGA-AD score of &#8220;almost clear.&#8221; More than two-thirds of participants who transitioned to maintenance dosing remained on the twice weekly maintenance dosing schedule for more than half of their time in the trial.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results from the study demonstrated long-term safety and a tolerability profile consistent with data from our INTEGUMENT-1 and -2 trials, with no new safety signals observed up to 56 weeks of treatment. Rates of TEAEs were generally consistent with INTEGUMENT-1 and -2, with 241 subjects (36.7% of subjects) experiencing any TEAE and 31 subjects (4.7% of subjects) experiencing treatment-related TEAEs. No adverse event occurred in more than 4.6% of subjects. The only adverse events occurring in &gt;2% of subjects included COVID-19, upper respiratory tract infection, nasopharyngitis and headache, and 21 subjects (3.2% of subjects) discontinued the study due to adverse events. There were eight subjects (1.2% of subjects) with serious adverse events and no treatment-related serious adverse events.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE cream 0.15% also performed well on secondary endpoints, including IGA Success, which was defined as a vIGA-AD score of "clear" or "almost clear" plus a 2-grade improvement from baseline in INTEGUMENT-1 or -2, and EASI-75. For example, 46.1% and 51.0% of patients treated with ZORYVE cream 0.15% achieved IGA Success in Week 28 and 56, respectively, compared to 41.5% and 44.6%, respectively, of patients treated with vehicle. In addition, 61.5% and 66.2% of patients treated with ZORYVE cream 0.15% achieved EASI-75 at Week 28 and 56, respectively, compared to 60.9% and 64.6%, respectively, of patients treated with vehicle. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, we announced positive results for subjects 2 to 5 years old. In the study, ZORYVE cream 0.05% was well-tolerated, with no new safety signals observed during treatment of up to 56 weeks in duration. Efficacy results were not only maintained but also improved over time, with 71.9% of participants who rolled over from the roflumilast cream 0.05% treatment arm in INTEGUMENT-PED achieving EASI 75 after 56 weeks. Overall incidence of adverse events was low, with most being mild to moderate in nature. The most frequently reported adverse events (&#8805;3%) included: upper respiratory tract infection, nasopharyngitis, pyrexia, influenza, COVID-19, and otitis media. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these results demonstrate the durability of treatment and the potential for improvement in patient symptoms over time.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INTEGUMENT-INFANT</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2026, we announced positive topline data from the INTEGUMENT-INFANT trial. The INTEGUMENT-INFANT Phase 2, open-label, multicenter study evaluated the safety and tolerability of ZORYVE cream 0.05% applied once-daily over a four-week period in 101 infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. The study builds upon the earlier Maximal Usage (MUSE) pharmacokinetic trial ARQ-151-105, which also evaluated ZORYVE cream 0.05% in this age group.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Results from this trial demonstrated that ZORYVE cream 0.05% was well tolerated with a safety profile consistent with previous ZORYVE clinical trials, with low overall incidence of adverse events with all being mild to moderate in severity.  ZORYVE cream improved the severity of disease and reduced the area of skin affected by atopic dermatitis, with 58% of participants achieving EASI-75 at Week 4.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We intend to present further details on the INTEGUMENT-INFANT study results at future medical meetings. </span></div><div><span><br/></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZORYVE Foam</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also developed a foam formulation of topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis. ZORYVE foam contains the same highly potent and selective PDE4 inhibitor in ZORYVE cream, and is nearly identical to ZORYVE cream, with all ingredients in the foam being the same as those in the cream, other than reduced oil content and the addition of a propellant in the can to create the foam. ZORYVE foam is a light foam that has been designed to deliver the drug to the scalp while not leaving a greasy residue or disturbing hair style. The foam breaks easily upon agitation, creating a thin solution that can be rubbed easily into the scalp. Additionally, the product does not melt on the fingers prior to application. ZORYVE foam will not stain clothing or bedding and does not have an unpleasant smell. ZORYVE foam is designed for simple once-a-day application and neither burns nor stings on application. We believe that ZORYVE foam offers physicians and patients a highly differentiated clinical profile that is ideally suited to address unmet needs in the topical treatment of seborrheic dermatitis and scalp and body psoriasis.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seborrheic Dermatitis</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE foam is currently commercially available in the United States and Canada, for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on location or duration of use. ZORYVE foam is a once-daily steroid-free foam and on approval was the first drug approved for the treatment of seborrheic dermatitis with a new mechanism of action in over two decades. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seborrheic Dermatitis Background</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seborrheic dermatitis is a common skin disease that is estimated to occur in more than 10 million people in the United States. The disease causes red patches covered with large, greasy, flaking yellow-gray scales, and is frequently itchy. It appears most often on the scalp, face (especially on the nose, eyebrows, ears, and eyelids), upper chest. While the pathogenesis of seborrheic dermatitis is not well understood, it is an inflammatory disease of the skin distinct from atopic dermatitis and psoriasis, it shares some features such as a skin barrier defect with atopic dermatitis and some inflammatory pathways in common with psoriasis. Seborrheic dermatitis is associated with an over-abundance of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Malassezia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a naturally occurring yeast found on normal skin but found in excess numbers on skin with seborrheic dermatitis where it may exacerbate the underlying skin inflammation that leads to the signs and symptoms well characterized in the disease. Seborrheic dermatitis can occur in adults, adolescents and infants, and in infants is commonly referred to as &#8220;cradle cap&#8221;.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Seborrheic Dermatitis Treatment Landscape</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of widely used treatments for seborrheic dermatitis, including antifungal agents, lower potency steroids, and immunomodulators.</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Topical steroids</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, mostly low- to mid-potency, are often prescribed for patients suffering from seborrheic dermatitis because of the inflammatory component of the disease. Due to the risks associated with steroid use, particularly on the face, physicians try to limit duration or avoid steroid therapy. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">TCIs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are also sometimes used off-label for the treatment of seborrheic dermatitis. These agents appear to provide symptomatic improvement in seborrheic dermatitis due to their anti-inflammatory effects. As previously noted, TCIs carry a boxed warning for the potential increased risk of cancers, especially lymphomas, associated with their use, and physicians generally try to avoid long-term use in patients suffering from seborrheic dermatitis. Additionally, TCIs only provide symptomatic improvement in seborrheic dermatitis in areas of skin that are very thin and where the drug can penetrate (i.e., largely the periocular areas only).</span></div><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Antifungal agents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, particularly azoles such as ketoconazole, are the cornerstone of therapy for seborrheic dermatitis. These agents are available in a variety of topical formulations, and oral antifungals are occasionally used in very severe cases. Antifungals in the treatment of seborrheic dermatitis are generally well-tolerated, although some patients experience irritant contact dermatitis, a burning or itching sensation, or dryness.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While physicians have a number of relatively inexpensive treatment options that provide symptomatic improvement for seborrheic dermatitis, the greatest unmet need relates to inadequate response to existing therapies in many patients, particularly in patients with more severe disease. Physicians report that up to one-third of severe patients suffering from seborrheic dermatitis, and a smaller percentage of mild- and moderate-severity patients, have an inadequate response to current seborrheic dermatitis treatments. Additionally, physicians are wary of using steroids on the face due to the risk of skin thinning, spider veins, folliculitis, and unnatural hair growth. Physicians are especially wary of using steroids near the eyes due to the potential increased risk of cataracts and glaucoma. Finally, many physicians are reluctant to treat chronically with steroids and TCIs, the main anti-inflammatory agents used in treatment of seborrheic dermatitis. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe ZORYVE foam presents a unique dual mechanism of action to treat patients with seborrheic dermatitis. Based on clinical data to date across indications, ZORYVE has demonstrated strong anti-inflammatory properties. In addition, a recent nonclinical study demonstrated that ZORYVE foam may also possess anti-fungal effects, specifically against </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Malassezia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the fungus implicated in seborrheic dermatitis. Because the pathogenesis of seborrheic dermatitis potentially includes both a fungal overgrowth component and an inflammatory component, ZORYVE foam&#8217;s putative dual mechanism of action may provide symptomatic improvement for patients not achieving suitable responses from currently available therapies. In addition to the opportunity in treatment resistant patients, we believe ZORYVE foam may be an option for some patients as a first-line therapy, especially patients with involvement of the face where other therapies are contraindicated.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seborrheic Dermatitis Key Completed Trials </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">STRATUM Pivotal Phase 3 Study</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STRATUM was a Phase 3, parallel group, double-blind, vehicle-controlled study of the safety and efficacy of ZORYVE foam 0.3% administered once-daily. A total of 457 subjects ages 9 and older with moderate to severe seborrheic dermatitis were enrolled in the study and randomized 2:1 to ZORYVE foam or vehicle. A significant percentage of patients had seborrheic dermatitis in more than one location on their body and more than half of patients had facial seborrheic dermatitis, including a subset with seborrheic dermatitis on their eyelids. The primary endpoint of the study was the proportion of subjects achieving IGA Success, defined as an IGA score of &#8220;clear&#8221; or &#8220;almost clear&#8221; plus a 2-point improvement at Week 8.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study met the primary endpoint, with 79.5% of individuals treated with ZORYVE foam achieving IGA Success at Week 8, compared to 58.0% of patients treated with vehicle (P&lt;0.0001). Improvement with ZORYVE foam was seen early, with ZORYVE separating statistically from vehicle on IGA Success at Week 2. In addition, 50.6% of patients treated with ZORYVE foam achieved an IGA score of clear at Week 8, compared to 28.2% of patients treated with vehicle (P&lt;0.0001). ZORYVE foam also demonstrated statistically significant improvements compared to vehicle on key secondary endpoints, including itch as measured by WI-NRS. 62.8% of patients with a WI-NRS of 4 or higher at baseline treated with ZORYVE foam achieved a 4-point or greater reduction in itch at </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Week 8, compared to 41% of patients treated with vehicle (P=0.0001). Individuals treated with ZORYVE foam reported a 28% improvement in itch from baseline as early as 48 hours after the first application, compared to only 13% of patients treated with vehicle (P=0.0024). </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE foam was well-tolerated. The incidence of TEAEs was low and similar between active treatment and vehicle, with most TEAEs assessed as mild-to-moderate severity. There were no treatment-related serious adverse events. Overall, the most common adverse events in the study population (over 1%) included nasopharyngitis, nausea, and headache. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARQ-154-214 (Long-Term Safety)</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Study ARQ-154-214 was a multicenter, open label Phase 2 long-term safety study of ZORYVE foam 0.3% applied once-daily in subjects with seborrheic dermatitis. This study included subjects who were treated previously in the Phase 2 trial (ARQ-154-203), as well as subjects naive to treatment with ZORYVE foam. Periodic clinic visits assessed clinical safety, application site reactions, and disease improvement, or progression. The study demonstrated sustained durability of results for up to 52 additional weeks of treatment, as well as a favorable safety and tolerability profile consistent with earlier Phase 2 and Phase 3 studies in seborrheic dermatitis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Scalp and Body Psoriasis</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE foam for the treatment of scalp and body psoriasis is currently commercially available in the United States for individuals down to age 12, with no limitation on location or duration of use.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Scalp Psoriasis Background</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scalp psoriasis is a manifestation of plaque psoriasis that occurs in nearly half of all psoriasis patients, characterized by plaques in the hair-bearing area of the scalp and sometimes extending to the forehead, back of the neck, or behind or inside the ears. These psoriatic plaques are identical to plaques on other body areas, however topical treatment of these plaques is complicated by the difficulty of delivering topical drugs under hair-bearing areas. As with psoriatic plaques on other parts of the body, psoriasis on the scalp is often itchy and is sometimes painful. Scalp psoriasis can also be associated with hair loss, likely due to damage to the hair from excessive scratching, rubbing, or combing of the affected area.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Scalp Psoriasis Treatment Landscape</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scalp psoriasis treatments are similar to plaque psoriasis treatments, given that the plaques are identical to the plaques in other body areas. Topical treatments for scalp psoriasis include TCS, vitamin D analogs, or the combination, in a topical formulation suitable for hair-bearing areas, such as shampoos, solutions, or foams. However, many of the current topical formulations for hair-bearing areas are poorly formulated and are not well-received by patients. Existing topical treatments for the scalp also suffer from the same efficacy, safety, tolerability, and patient acceptability issues as existing creams and ointments. While both biologics and systemic treatments will improve scalp psoriasis, they suffer from the same limitations on their use as in plaque psoriasis. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Scalp Psoriasis Key Completed Trials</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARRECTOR Pivotal Phase 3 Study</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ARRECTOR study was a parallel group, double blind, vehicle-controlled pivotal Phase 3 study of the safety and efficacy of ZORYVE foam 0.3% or a matching vehicle administered once-daily in subjects with scalp and body psoriasis ages 12 and older. A total of 432 subjects were enrolled in the study and randomized 2:1 to ZORYVE foam or vehicle. The co-primary endpoints of the study were the proportion of subjects achieving scalp IGA (S-IGA) Success and the proportion of subjects achieving body IGA (B-IGA) Success, with IGA Success on both endpoints defined as an IGA score of &#8216;clear&#8217; or &#8216;almost clear&#8217; plus a 2-point improvement from baseline after 8 weeks.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study met both co-primary endpoints and all secondary endpoints. Specifically, 67.3% of individuals treated with ZORYVE foam achieved S-IGA Success at Week 8, compared to 28.1% of individuals treated with vehicle (P&lt;0.0001), and 46.5% of individuals treated with ZORYVE foam achieved B-IGA Success at Week 8, compared to 20.8% of individuals treated with vehicle (P&lt;0.0001). ZORYVE foam also demonstrated statistically significant improvements compared to vehicle on all secondary endpoints, including scalp itch as measured by Scalp Itch Numeric Rating Scale (SI-NRS) and overall itch as measured by WI-NRS.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE foam was well-tolerated, with the incidence of TEAEs low and generally similar to vehicle, with most TEAEs assessed as mild-to-moderate severity. Overall, the most common adverse events in the study </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">population (over 2%) included headache, diarrhea, and COVID-19. In the study, 89.0% of patients who were treated with ZORYVE foam completed the full 8 weeks, and few subjects discontinued the study due to adverse events (2.5% of subjects treated with ZORYVE foam and 1.3% of the subjects in the vehicle group). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZORYVE Indication Expansion</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuing new patient populations that may benefit from ZORYVE has been a principal focus of our clinical development strategy from the outset. This is evidenced by the five additional approvals we have secured across plaque psoriasis, seborrheic dermatitis, and atopic dermatitis following our initial plaque psoriasis approval in 2022. We believe that there are additional skin diseases that may respond to, and more patients who may benefit from, ZORYVE. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This belief is supported by our understanding of ZORYVE's broadly applicable anti-inflammatory and antipruritic properties, its potential impact on stimulating melanocytes, and by the direct and ongoing feedback from health care providers in the field on their real-world ZORYVE experiences as well as their interest in non-steroidal therapies. As part of our obligations as the manufacturer of ZORYVE, our medical team monitors this clinical feedback. To date, we've identified more than 40 published case reports and case series from clinicians who have themselves determined to use ZORYVE in a multitude of other inflammatory dermatoses and have seen signs of potential efficacy.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe these reports are important signals of new opportunities for ZORYVE. In order to evaluate some of these signals of potential efficacy, we will selectively evaluate certain disease areas with clinical development programs, beginning with resource efficient Phase 2 proof-of-concept trials. We will decide which programs, if any, to advance through later stages of clinical development by considering data generated in a controlled clinical setting, feedback received from regulatory agencies, and analysis of unmet need and market potential. Initial diseases that we are currently evaluating as part of this effort are vitiligo and hidradenitis suppurativa. </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARQ-234</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we acquired Ducentis and its lead asset, DS-234 (now ARQ-234), a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor that is thought to be an important immunological checkpoint with a pivotal role in the maintenance of immune tolerance. Checkpoint agonism is an emerging immunomodulatory approach that works to amplify pathways that inhibit over-active immune cells and suppress unwanted immune responses. ARQ-234 binds to CD200R and has the potential to restore immune homeostasis by inducing inhibitory signaling on immune cells that regulate inflammation. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CD200R has been validated as a target in atopic dermatitis, with preclinical data for ARQ-234 and clinical data for a similar molecule that progressed to clinical development by another company each providing evidence of a robust and durable therapeutic response, even after discontinuation of treatment. Ducentis completed preclinical comparisons of ARQ-234 against the clinically-validated CD200R antibody. The data compare favorably across key metrics including potency, efficacy, and pharmacokinetics and indicated potential differentiation from the clinically-validated CD200R antibody with an improved ability to modulate the CD200R pathway, a longer half-life, and a higher steady state volume of distribution. We plan to develop ARQ-234 in atopic dermatitis, where it could be a potentially highly complementary treatment option to ZORYVE cream in that indication, if approved. We believe the acquisition of this asset is a transformative opportunity for Arcutis and, in leveraging our team's deep dermatology expertise and broad biologics experience, that our leadership and operational team will enable us to move ARQ-234 into the clinic and through the development process. We submitted an IND to the FDA in July 2025 and anticipate commencing a Phase 1 study of ARQ-234 in the first quarter of 2026. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARQ-252 and ARQ-255</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARQ-252 is an alternative topical cream formulation of ivarmacitinib that we had developed for chronic hand eczema and vitiligo. In May 2021, we announced that the Phase 1/2b study of ARQ-252 in chronic hand eczema did not meet its primary endpoint, with further analyses of the study pointing to inadequate local drug delivery to the skin. Importantly, there were no safety or tolerability issues seen in that study. Given these analyses, we also elected to terminate the Phase 2a clinical trial evaluating ARQ-252 as a potential treatment in vitiligo.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARQ-255 is a deep penetrating topical formulation of ivarmacitinib, a potent and highly selective topical Janus kinase type 1 (JAK 1) inhibitor, we had developed for the treatment of alopecia areata. Following the completion of a Phase 1b study in the middle of 2025, we elected to halt further development of the program.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industry is highly competitive, and is characterized by rapid and significant changes, intense competition, and a bias towards proprietary products. We face competition, and will continue to face new competition, from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, and generic drug companies. Any product, or product candidate that we successfully develop and commercialize, will compete with existing treatments, including those that may have achieved broad market acceptance, and any new treatment that may become available in the future.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have greater financial, technical, and human resources than we have. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop or market products or other novel therapies that offer more symptomatic improvement, have a lower risk of side effects, or are less costly than our current or future product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will be based in part on our ability to identify, develop, and commercialize a portfolio of products and product candidates that have a lower risk of side effects and/or provide more symptomatic improvement than competing products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several companies that are working to develop drugs that would compete against ZORYVE or our product candidates for the treatment of psoriasis and atopic dermatitis including a potential generic version of ZORYVE cream. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For psoriasis, our primary competitors include:</span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injected biologic therapies such as Skyrizi&#174;, marketed by AbbVie Inc., and Bimzelex&#174;, marketed by UCB, Inc.; </span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">non-injectable systemic therapies used to treat plaque psoriasis such as Otezla, marketed by Amgen Inc., and Sotyku, marketed by Bristol Myers Squibb; </span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">topical therapies such as VTAMA, marketed by Organon; </span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">branded and generic versions of clobetasol, such as Clobex&#174;, marketed by Galderma Laboratories, LP; </span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">generic versions of calcipotriene and the combination of betamethasone dipropionate/calcipotriene; and </span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other treatments including various lasers and ultraviolet light-based therapies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are several product candidates under development that could potentially be used to treat psoriasis and compete with ZORYVE and ARQ-234, including but not limited to: Ustekinumab biosimilars, under development by Biocon and others; lcotrokinra, under development through a collaboration between Johnson &amp; Johnson and Protagonist Therapeutics; ME3183, under development by Meiji Pharma; and Orismilast, under development by UNION.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For atopic dermatitis, our primary competitors include:</span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">topical therapies such as Eucrisa, marketed by Pfizer Inc.; Opzelura, marketed by Incyte Corporation; VTAMA, marketed by Organon; ADQUEY, marketed by Arcotech;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">generic and branded versions of low to mid-potency steroids, such as hydrocortisone or triamcinolone, including Kenalog, marketed by Bristol Meyers Squibb; </span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ANZUPGO, marketed by LEO Pharma, was recently approved for the topical treatment of moderate to severe chronic hand eczema; </span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injected biologic therapies approved for moderate-to-severe atopic dermatitis, including Dupixent&#174;, marketed by Sanofi and Regeneron Pharmaceuticals, Inc; Adbry&#174;, marketed by LEO Pharma, and Ebglyss&#174;, marketed by Eli Lilly and Company; and</span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">non-injectable systemic therapies approved for moderate-to-severe atopic dermatitis, including RINVOQ&#174;, marketed by AbbVie, and CIBINQO&#174;, marketed by Pfizer;  </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are several prescription product candidates under development that could potentially be used to treat atopic dermatitis and compete with ZORYVE cream and ARQ-234, including but not limited to: topical difamilast ointment (under development by Medimetriks/Otsuka Pharma); injectable rocatinlimab (under development by Kyowa Kirin); injectable amlitelimab (under development by Sanofi); APG777 (under development by Apogee Therapeutics); rezpegaldesleukin (under development by Nektar Therapeutics); temtokibart (under development by LEO Pharma); and JNJ-95475939 (under development by Janssen).</span></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Operations</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently commercialize ZORYVE and intend to commercialize our other product candidates ourselves in the United States and Canada. In the United States, we have built our commercial organization that includes marketing, market access, sales and marketing operations, professional relations, and a focused specialty sales force  targeting dermatologists and allergists. We expect to expand these operations as needed to support the growth of our business. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the termination of our promotion agreement with Kowa in January 2026, we plan to assume responsibility for sales and promotion of ZORYVE in the pediatric and primary care settings, initially through a small, targeted sales team focused on high-prescribing primary care and pediatric health care providers. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Canada, we have established the infrastructure we believe is necessary to support  commercialization of our products. We may also seek partners to access additional geographic markets. For example, we have partnered with companies to develop and commercialize roflumilast formulations for certain dermatological indications in Japan, China, and certain other countries within Asia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;padding-right:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &amp; Supply</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We  source all of our nonclinical, clinical, and commercial compound supply from third-party contract manufacturing organizations (CMOs). We also contract with well-established third-party manufacturers for our drug substance, drug product, and analytical testing. We use additional contract manufacturers to label, package, and store our products. We also have secondary suppliers to ensure redundant supply for our commercial products. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have personnel and third-party consultants with substantial technical and product development experience who actively manage the CMOs producing our products and plan to use such personnel to manage CMOs for any other product candidates or products that we may develop in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CMOs  are required to operate in full compliance with applicable regulatory requirements, including those of the FDA and Health Canada. Such requirements include adherence to FDA Good Laboratory Practices (GLP) and current Good Manufacturing Practices (cGMP) for the manufacture and testing of drug substance and drug product, as well as alignment with relevant International Council for Harmonization (ICH) guidelines. All of our CMO partners have extensive technical expertise and experience manufacturing our specific technology. We believe our supply arrangements are satisfactory for our current operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:18pt;padding-right:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining proprietary rights in our product candidates and technologies will assist in achieving the success of our business. One way in which we obtain and maintain such proprietary rights is by filing patent applications and maintaining patents covering our core technologies and product candidates. Our policy is to file such patent applications in the United States and select foreign countries to better protect our worldwide interests. We also seek to avoid infringing the proprietary rights of others. For this reason, we routinely monitor and evaluate third-party patents and publications, and, if necessary, take appropriate action based on that evaluation. Patent term is based on the filing or grant date of the patent, as well as the governing law of the country in which the patent is obtained. In the United States, some pharmaceutical patents are also eligible for Patent Term Extension (PTE), which can extend exclusivity for up to five additional years under certain conditions. The protection provided by a patent varies from country to country, and is dependent on the type of patent granted, the scope of the patent claims, and the legal remedies available in a given country.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we own or have an exclusive license to 29 issued U.S. patents and 59 issued foreign patents, which include granted European patent rights that have been validated in various European Patent Organization (EPO) member states, and 21 pending U.S. patent applications, 187 pending foreign patent applications, including 4 applications filed under the Patent Cooperation Treaty. Of these patents and patent applications, we have the following for roflumilast cream &amp; roflumilast foam, as of December&#160;31, 2025:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.187%"><tr><td style="width:1.0%"/><td style="width:31.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.768%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Roflumilast cream &amp; roflumilast foam</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patents Owned/Issued</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patents Pending</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bahrain</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eurasia</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kuwait</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oman</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qatar</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Arab Emirates</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent Cooperation Treaty</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Twelve of our U.S. patents are listed in the FDA&#8217;s Orange Book for our roflumilast 0.15% and 0.3% cream products, and thirteen of our U.S. patents are listed in the Orange Book patents for our roflumilast 0.3% foam product. The issued U.S. patent that we have licensed from AstraZeneca claiming a composition of matter encompassing roflumilast, the active pharmaceutical ingredient in roflumilast cream and roflumilast foam, expired on January 27, 2020. Data exclusivity for oral roflumilast expired on January 23, 2021. Our issued patents relating to a roflumilast cream and/or a roflumilast foam contain claims directed to, among other things, pharmaceutical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">compositions comprising roflumilast and hexylene glycol, pharmaceutical compositions comprising roflumilast and diethylene glycol monoethyl ether, pharmaceutical compositions comprising roflumilast and cetostearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate, methods of making such compositions, and methods of treatment using such compositions, methods of treating fungal infections by administering compositions comprising roflumilast, and methods for improving treatment adherence by improving delivery and extending the plasma half-life of a roflumilast composition. These issued U.S. patents relating to roflumilast cream and roflumilast foam will expire not earlier than June 2037. We also have a method of treatment patent for roflumilast foam in the treatment of seborrheic dermatitis which expires 2041. Additionally, we have a patent directed to the 0.3% roflumilast foam composition that expires in 2042. Our pending patents relating to roflumilast cream and roflumilast foam contain claims directed to, among other things, pharmaceutical compositions comprising roflumilast and diethylene glycol monoethyl ether, pharmaceutical compositions comprising roflumilast, cetostearyl alcohol, dicetyl phosphate, and/or ceteth-10 phosphate, methods of treatment using such compositions, methods of manufacturing such compositions, and other aspects of our roflumilast formulations, including unique pharmacokinetic aspects of topical roflumilast compositions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2025, we also have the following patents and patent applications for ARQ-234 and other CD200 mutant proteins:</span></div><div style="margin-top:8pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.187%"><tr><td style="width:1.0%"/><td style="width:31.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.768%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">ARQ-234 and other CD200 mutant proteins</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patents Owned/Issued</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patents Pending</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eurasia</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Great Britain</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent Cooperation Treaty</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45</span></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The issued U.S. patent for ARQ-234 is related to its composition of matter and currently projected to expire on July 14, 2038, unless any PTE is granted.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining patent protection is not the only method that we employ to protect our propriety rights. We also utilize other forms of intellectual property protection, including trademark, and trade secrets, when those other forms are better suited to protect a particular aspect of our intellectual property. Our belief is that our propriety rights are strengthened by our comprehensive approach to intellectual property protection.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining the confidential nature of our non-publicly disclosed products and technologies is of paramount importance. For this reason, our employees, contractors, consultants, and advisors are required to enter into </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nondisclosure and invention assignment agreements when their employment or engagement commences. Those individuals also enter into agreements that prohibit the communication or implementation of any third-party proprietary rights during the course of their employment with us. We also require any third-party that may receive our confidential information or materials to enter into confidentiality agreements prior to receipt of that information or material.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License, Collaboration, and Promotion Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kowa Promotion Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, we entered into a promotion agreement with Kowa to leverage Kowa's primary care sales force to exclusively market and promote ZORYVE in the United States to primary care practitioners and pediatricians for all FDA-approved indications until at least July 2029. Under the terms of the agreement, Kowa received a commission from net sales attributed to Kowa. Promotion of ZORYVE in primary care and pediatrics under the Kowa agreement began in late September 2024. Effective January 23, 2026, both parties mutually agreed to terminate the promotion agreement. Following this termination, Kowa ceased all sales and promotion of ZORYVE and we will not be required to make any further payments to Kowa.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sato License Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, we entered into the Sato Agreement with Sato. Pursuant to the Sato Agreement, we grant Sato an exclusive, sublicensable (under certain circumstances) license under certain patent rights and know-how controlled by us for Sato to develop, conduct medical affairs activities for, manufacture, commercialize, and otherwise exploit roflumilast formulations (the Sato Licensed Products) for all therapeutic uses for certain dermatological indications in humans (the Sato Field) in Japan. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sato Agreement sets forth each party&#8217;s respective obligations with respect to the development, medical affairs activities, manufacture and supply, and commercialization of the Sato Licensed Products. Pursuant to the terms of the Sato Agreement, Sato will, at its expense, develop, obtain regulatory approval for, commercialize, and conduct medical affairs activities related to the Sato Licensed Products in the Sato Field in Japan, subject to certain of our approval and oversight rights. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Sato Agreement, we received an upfront payment of $25.0&#160;million and will potentially receive additional payments (i) up to an aggregate amount of $10.0&#160;million upon the achievement of certain regulatory milestones and (ii) up to an aggregate amount of $30.0&#160;million upon the achievement of certain sales milestones. In addition, on a Sato Licensed Product-by-Sato Licensed Product basis, commencing from the first commercial sale of such Sato Licensed Product in Japan until the latest of (i) the expiration of the last valid claim in the intellectual property rights licensed by us to Sato under the Sato License Agreement covering such Sato Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Sato Licensed Product in Japan, or (iii) ten years after the first commercial sale of such Sato Licensed Product in Japan, we will receive low double-digit to mid-teen double-digit percentage royalties on Sato&#8217;s, its affiliates&#8217; and sublicensees&#8217; total annual net sales of all Sato Licensed Products, subject to certain royalty reductions. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Sato Agreement continues until, on a Sato Licensed Product-by-Sato Licensed Product basis, the expiration of the Royalty Term, which is the (i) the expiration of the last valid claim in the licensed technology covering such Sato Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Sato Licensed Product in Japan, or (iii) ten years after the first commercial sale of such Sato Licensed Product in Japan. The Sato Agreement may be terminated by either party in its entirety if the other party commits a material breach, subject to a cure period, or if the other party becomes insolvent. Sato may terminate the Sato Agreement at-will in its entirety upon 90 days&#8217; written notice. Unless unenforceable under applicable law, we may terminate the Sato Agreement in its entirety if Sato, its affiliate or sublicensee contests or assists a third party in contesting the scope, validity or enforceability of any patent or patent application licensed by us to Sato. We may also terminate the Sato Agreement if Sato or any director, officers, employee, agent, affiliate, sublicensee, or subcontractor is charged by a governmental authority for a violation of any anti-corruption, anti-money laundering, sanctions or export or import control laws or regulations, or, subject to the terms of the Sato Agreement, if Sato, its affiliates and sublicensees do not conduct any material development or commercialization activities of a Sato Licensed Product in Japan for a certain period of time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Huadong License and Collaboration Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2023, we entered the Huadong Agreement with Huadong, pursuant to which we granted to Huadong an exclusive, sublicensable (under certain circumstances) license under certain patent rights and know-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">how controlled by us for Huadong to develop, conduct medical affairs activities for, manufacture, commercialize, and otherwise exploit both cream and foam topical roflumilast for all therapeutic uses for certain dermatological indications (Huadong Licensed Products) in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and Southeast Asia (Indonesia, Singapore, The Philippines, Thailand, Myanmar, Brunei, Cambodia, Laos, Malaysia, and Vietnam) (Huadong Territories).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Huadong Agreement sets forth each party&#8217;s respective obligations with respect to the development, medical affairs activities, manufacture and supply, and commercialization of the Huadong Licensed Products. Pursuant to the terms of the Huadong Agreement, Huadong will, at its expense, develop, obtain regulatory approval for, commercialize and conduct medical affairs activities for the Huadong Licensed Products, subject to certain of our approval and oversight rights. We will retain exclusive rights for the development, manufacture and commercialization of topical roflumilast outside the Huadong Territories.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As consideration for the rights granted under the Huadong Agreement, we received a net payment of $27.0 million in September 2023, which consisted of a $30.0 million upfront payment less the applicable tax withholding obligation in China of $3.0 million. In addition, we received net payments of $2.7 million in March 2024, and $1.8 million in each of December 2024, March 2025, and November 2025, related to the achievement of a development and regulatory milestones less the applicable tax withholdings. We may also potentially receive additional payments (i) up to an aggregate amount of $15.0 million upon the achievement of certain development and regulatory milestones and (ii) up to an aggregate amount of $40.3 million upon the achievement of certain sales milestones. In addition, on a Huadong Licensed Product-by- Huadong Licensed Product and country or region-by-country or region basis, commencing from the first commercial sale of such Huadong Licensed Product in such country or region until the latest of (i) the expiration of the last valid claim in the intellectual property rights licensed by us to Huadong under the Huadong Agreement covering such Huadong Licensed Product in such country or region, (ii) the expiration of regulatory exclusivity for such Huadong Licensed Product in such country or region, or (iii) ten years after the first commercial sale of such Huadong Licensed Product in such country or region (the Royalty Term), we will receive low double-digit to high-teen double-digit percentage royalties on Huadong&#8217;s, its affiliates&#8217; and sublicensees&#8217; total net sales, subject to certain royalty reductions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The term of the Huadong Agreement continues until, on a Huadong Licensed Product-by-Huadong Licensed Product and country or region-by-country or region basis, the expiration of the Royalty Term. The Huadong Agreement may be terminated by either party in its entirety if the other party commits a material breach, subject to a cure period, or if the other party becomes insolvent. Huadong may terminate the Huadong Agreement at-will in its entirety upon 90 days&#8217; written notice. Unless unenforceable under applicable law, we may terminate the Huadong Agreement in its entirety if Huadong, its affiliate or sublicensee contests or assists a third party in contesting the scope, validity or enforceability of any patent or patent application licensed by us to Huadong. We may also terminate the Huadong Agreement if Huadong (a) is convicted in a final and non-appealable judgment of a violation of any anti-corruption, anti-money laundering, sanctions or export or import control laws or regulations or (b) any director, officer, employee, agent, affiliate, sublicensee or subcontractor of Huadong is convicted in a final and non-appealable judgment of a violation of any anti-corruption, anti-money laundering, sanctions or export or import control laws or regulations in relation to the performance of the Huadong Agreement or, subject to the terms of the Huadong Agreement, if Huadong, its affiliates and sublicensees do not conduct any material development or commercialization activities of a Huadong Licensed Product in the Huadong Territories for a certain period of time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">AstraZeneca</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we entered into an exclusive license agreement with AstraZeneca (the AstraZeneca License Agreement), pursuant to which we obtained a worldwide exclusive license, with the right to sublicense through multiple tiers, under certain AstraZeneca-controlled patent rights, know-how and regulatory documentation, to research, develop, manufacture, commercialize, and otherwise exploit products containing roflumilast in topical forms, as well as delivery systems sold with or for the administration of roflumilast (collectively, the AZ-Licensed Products) for all diagnostic, prophylactic, and therapeutic uses for human dermatological indications (collectively, the Dermatology Field). Under this agreement, we have sole responsibility for development, regulatory, and commercialization activities for the AZ-Licensed Products in the Dermatology Field, at our expense, and we shall use commercially reasonable efforts to develop, obtain, and maintain regulatory approvals for, and commercialize the AZ-Licensed Products in the Dermatology Field in each of the United States, Italy, Spain, Germany, the United Kingdom, France, China, and Japan. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid AstraZeneca an upfront non-refundable cash payment of $1.0 million and issued 484,388 shares of our Series B convertible preferred stock, valued at $3.0 million on the date of the AstraZeneca License Agreement. We subsequently paid AstraZeneca the first milestone cash payment of $2.0 million upon the completion of a Phase 2b study of roflumilast cream in plaque psoriasis in August 2019 for the achievement of positive Phase 2 data for an AZ-Licensed Product. We also paid AstraZeneca $7.5 million upon ZORYVE cream's FDA approval of ZORYVE </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cream 0.3% and have agreed to make additional cash payments to AstraZeneca of up to an aggregate of $5.0 million upon the achievement of specific regulatory approval milestones with respect to the AZ-Licensed Products. W</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e paid AstraZen</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eca</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.0 million in October 2024 upon achievement of $100.0 million in worldwide net sales and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.0 million in May 2025 upon achievement of $250.0 million in worldwide net sales. With respect to any AZ-Licensed Products we commercialize under the AstraZeneca License Agreement, we will pay AstraZeneca a low to high single-digit percentage royalty rate on our, our affiliates&#8217;, and our sublicensees&#8217; net sales of such AZ-Licensed Products, subject to specified reductions, until, as determined on an AZ-Licensed Product-by-AZ-Licensed Product and country-by-country basis, the later of the date of the expiration of the last-to-expire AstraZeneca-licensed patent right containing a valid claim in such country and ten years from the first commercial sale of such AZ-Licensed Product in such country. We began making quarterly royalty payments in the first quarter of 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement continues in effect until the expiration of all royalty obligations as described above, unless earlier terminated: (1)&#160;by either party upon written for the other party&#8217;s material breach or insolvency event if such party fails to cure such breach or the insolvency event is not dismissed within specified time periods; (2)&#160;by AstraZeneca if we, our affiliates, or our sublicensees take actions to invalidate AstraZeneca-licensed patent rights, or if we permanently cease development of all AZ-Licensed Products, and an AZ-Licensed Product is not being commercialized by us; or (3)&#160;by us upon 120 days&#8217; written notice or in the event of certain adverse clinical trial or other regulatory outcomes. In the event the agreement is terminated, except by us for AstraZeneca&#8217;s material breach or in the event of certain adverse clinical trial or other regulatory outcomes, we will be obligated to pay a termination fee in the amount of  $11.3 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Jiangsu Hengrui Medicine Co., Ltd</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into an exclusive option and license agreement (the Hengrui License Agreement) with Jiangsu Hengrui Medicine Co., Ltd (Hengrui), whereby Hengrui granted us an exclusive option to obtain certain exclusive rights to research, develop, and commercialize products containing the compound designated by Hengrui as ivarmacitinib, a potent and selective JAK1 inhibitor, in topical formulations for the treatment of skin diseases, disorders, and conditions (the Hengrui Field), in the United States, Japan, United Kingdom, and the European Union (the Territory).</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we exercised our exclusive option, and also contemporaneously amended the agreement to expand the Territory to additionally include Canada, and therefore now have a license from Hengrui under certain patent rights and know-how controlled by Hengrui to research, develop and commercialize products containing ivarmacitinib in the Hengrui Field in the Territory. Such license is sublicensable through multiple tiers, exclusive as to the patent rights licensed from Hengrui and nonexclusive with respect to the know-how licensed from Hengrui, and does not extend to patent rights for improvements to ivarmacitinib which Hengrui may come to control in the future unless otherwise mutually agreed by the parties. In addition, we have sole responsibility for development, regulatory, marketing and commercialization activities to be conducted for the licensed products in the Hengrui Field and in the Territory, at our sole cost and discretion, and shall use commercially reasonable efforts to (1)&#160;develop at least one licensed product and to (2)&#160;commercialize the licensed products following regulatory approval thereof. Pursuant to the Hengrui License Agreement, a joint coordination committee reviews the progress of development and commercialization of each parties&#8217; products containing ivarmacitinib in their respective territories and fields.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Hengrui License Agreement, if we acquire or develop certain JAK inhibitor products that are not controlled by Hengrui, or Competing Products, we must negotiate in good faith with Hengrui whether to terminate the agreement or license to Hengrui the right to develop and commercialize such Competing Product in China. During the term of the Hengrui License Agreement, Hengrui will not develop or commercialize ivarmacitinib or any licensed product in the Hengrui Field in the Territory. Additionally, if Hengrui decides to develop or commercialize a non-topical formulation of ivarmacitinib for the treatment of certain dermatologic indications in the Territory, we have the first right to negotiate a co-development and/or co-commercialization agreement with Hengrui for the same. We also have the right of first refusal if Hengrui decides to out-license a non-topical formulation of ivarmacitinib for the treatment of certain dermatologic indications in the Territory to a third-party during such period.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made a $0.4 million upfront non-refundable cash payment to Hengrui upon execution of the Hengrui License Agreement option and license agreement. We also made a $1.5 million cash payment in connection with the exercise of our exclusive option. In addition, we have agreed to make cash payments of up to an aggregate of $20.5&#160;million upon our achievement of specified clinical development and regulatory approval milestones with respect to the licensed products and cash payments of up to an additional aggregate of $200.0&#160;million in sales-based milestones based on achieving certain aggregate annual net sales volumes with respect to a licensed product. With respect to any products we commercialize under the agreement, we will pay tiered royalties to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hengrui on net sales of each licensed product by us, or our affiliates, or our sublicensees, ranging from mid single-digit to sub-teen percentage rates based on tiered annual net sales bands subject to specified reductions. We are obligated to pay royalties until the later of (1)&#160;the expiration of the last valid claim of the licensed patent rights covering such licensed product in such country and (2)&#160;the expiration of regulatory exclusivity for the relevant licensed product in the relevant country, on a licensed product-by-licensed product and country-by-country basis. Additionally, we are obligated to pay Hengrui a specified percentage, ranging from the low-thirties to the sub-teens, of certain non-royalty sublicensing income we receive from sublicensees of our rights to the licensed products, such percentage decreasing as the development stage of the licensed products advance.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement continues in effect until the expiration of our obligation to pay royalties as described above, unless earlier terminated in accordance with the following: (1)&#160;by either party upon written notice for the other party&#8217;s material breach or insolvency event if such party fails to cure such breach or the insolvency event is not dismissed within specified time periods; and (2)&#160;by us for convenience upon 90 days prior written notice to Hengrui and having discussed and consulted any potential cause or concern with Hengrui in good faith.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, we entered into a side letter agreement with Hengrui and one of its subsidiaries to extend certain rights and obligations under the Hengrui License Agreement to the subsidiary under specified circumstances, including a change of control of such subsidiary.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following the completion of a Phase 1b study for ARQ-255 in alopecia areata in the middle of 2025, we elected to halt further development of ARQ-255, a topical formulation of ivarmacitinib.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state, and local level, and in other countries and jurisdictions extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. We, along with any third-party contractors, will be required to navigate the various nonclinical, clinical, and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our products and product candidates. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Drug Development Process</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, and biologics under the FDCA and the Public Health Service Act (PHSA) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a drug or biologic may be marketed in the United States generally involves the following:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">completion of nonclinical laboratory tests, animal studies, and formulation studies in accordance with FDA&#8217;s Good Laboratory Practice (GLP) requirements and other applicable regulations;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">submission to the FDA of an IND which must become effective before human clinical trials may begin;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">approval</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by an independent Institutional Review Board (IRB) or ethics</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">committee</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at each</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">site before</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be initiated;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">performance of adequate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well-controlled</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials in accordance with good clinical practices (GCP) to establish the safety and efficacy of the proposed drug for its intended use, or with respect to biologics, the safety, purity, and potency of the proposed biologic for its intended use;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">preparation of and submission to the FDA of an New Drug Application (NDA) or a Biologics License Application (BLA) after completion of all pivotal trials, as applicable;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">satisfactory completion of an FDA advisory committee review, if applicable;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current cGMP requirements to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity, and potential inspection of selected clinical investigation sites to assess compliance with GCPs; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">FDA review and approval of the NDA or BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical product development for a new product or certain changes to an approved product in the United States typically involves nonclinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal studies to assess the characteristics and potential safety and activity of the product. The conduct of the nonclinical tests must comply with federal regulations and requirements, including GLP requirements, when applicable. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing, and control, and a proposed clinical trial protocol. Long-term nonclinical tests, such as animal studies evaluating reproductive toxicity and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational drug product to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted in accordance with GCP requirements, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, an independent IRB for each site proposing to conduct each clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support NDAs or BLAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap or be combined: </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">metabolism, and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule, and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger Phase 3 clinical trials.</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies, may be conducted after initial marketing approval, and may be used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, developers usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Review and Approval Process</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of the required clinical studies in accordance with all applicable regulatory requirements, an NDA or BLA is prepared and submitted to the FDA. FDA approval of the NDA or BLA is required before marketing of the product may begin in the United States. The NDA or BLA must include the results of all nonclinical, clinical, and other testing, and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by independent investigators. The cost of preparing and submitting an NDA or BLA is substantial. The submission of most NDAs and BLAs is additionally subject to a substantial application user fee, and the manufacturer and/or sponsor of an approved NDA or BLA is also subject to an annual program fee. Waivers of application user fees may be obtained in certain limited circumstances. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of an NDA or BLA to determine whether the application will be accepted for review, or &#8220;filed&#8221; by FDA, based on the FDA&#8217;s threshold determination that it is sufficiently complete to permit substantive review. The FDA may refuse to file any NDA or BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the additional information must be included in any resubmitted NDA or BLA, which is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth review. Under the PDUFA guidelines that are currently in effect, the FDA has a goal of ten months from the filing date to complete a standard review of an NDA for a drug that is a new molecular entity (NME), or a BLA for an organic biologic, and of ten months from the date of NDA or BLA receipt to complete a standard review of an NDA for a drug that is not an NME. These review periods may be reduced from ten months to six months for an application designated for priority review.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also refer applications for novel product candidates, or product candidates that present difficult questions of safety or efficacy, to an advisory committee&#8212;typically a panel that includes clinicians and other experts&#8212;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. Additionally, the FDA will generally inspect the facility or the facilities at which the drug is manufactured to ensure the facility is compliant with cGMP requirements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCPs.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA or BLA and conducts any necessary inspections, it will issue either an approval letter or a complete response letter (CRL).</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the NDA or BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the NDA or BLA in condition for approval, including requests for additional information or clarification. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA or BLA, the FDA will typically issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval of a product is granted, such approval will be granted for particular indications and may include limitations on the indicated uses for which such product may be marketed. For example, as a condition of approving an NDA or BLA, the FDA may require a risk evaluation and mitigation strategy (REMS) to help ensure that the benefits of the drug outweigh the potential risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicine by managing its safe use, and can include medication guides, communication plans for health care professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The FDA may also require one or more post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and the labeling and prescribing information for the product may be changed based on the results of these post-marketing studies. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the conditions established in an approved NDA or BLA, including changes in indications, labeling, or manufacturing processes or facilities, require a submission to the FDA in the form of an NDA or BLA supplement or as part of the NDA or BLA Annual Report. FDA approval prior to implementation is required for most major changes, and the FDA&#8217;s timeline for review varies according to the type of change being made. An NDA or BLA supplement for a new indication typically requires clinical data, and the FDA uses the same general procedures when reviewing such efficacy supplements as it does in reviewing original applications.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Information</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pediatric Research Equity Act (PREA) as amended, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, BLAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required clinical assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective, or with respect to biologic products, safe, pure, and potent. The sponsor or FDA may request a deferral of required pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the product is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. In addition, the Best Pharmaceuticals for Children Act, or BPCA, provides NDA and BLA holders a six month extension of any exclusivity&#8212;patent or nonpatent&#8212;for a drug, if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA offers a number of expedited development and review programs for qualifying product candidates. For example, the Fast Track program is intended to expedite or facilitate the process for reviewing new product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during development and, once an NDA or BLA is submitted, the product candidate may be eligible for priority review. A Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any marketing application for a drug submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. An NDA or BLA for a product candidate is eligible for priority review if the product candidate is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. For new-molecular-entity NDAs and original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled confirmatory clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory studies in a timely manner or if such studies fail to verify the predicted clinical benefit. In addition, the FDA requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast Track designation, Breakthrough Therapy designation, priority review, and accelerated approval do not change the standards for approval, but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan drug designation and exclusivity</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA or BLA, to market the "same drug," as determined by FDA, for the same approved use or indication within such disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs relating to the approved use or indication of patients with the rare disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same use or indication within the rare disease or condition, or the same drug for any use or indication within a different rare disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA or BLA application user fee.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A designated orphan drug many not receive orphan drug exclusivity if it is approved for a use that is broader than the disease or condition for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity within the relevant approved use or indication or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs relating to the approved use or indication of patients with the relevant rare disease or condition.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs (whether chemical or biologic) manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. There also are continuing, annual program fee requirements for any marketed products.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA or BLA. The FDA also may require post-market studies, a REMS, and/or surveillance to monitor the effects of an approved product, or may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMPs.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warning, or other safety information about the product;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">fines, warning letters, or holds on post-approval clinical trials;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">refusal of the FDA to approve pending NDAs or BLAs or supplements to approved NDAs or BLAs, or suspension, or revocation of product approvals;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety, purity, potency and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hatch-Waxman Act</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section&#160;505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section&#160;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A Section&#160;505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. However, a drug must meet certain criteria relative to the Listed Drug to be eligible to use the Section 505(b)(2) pathway as opposed to the abbreviated NDA ( ANDA) pathway, which is described below. Section&#160;505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an ANDA. An ANDA generally provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics, and intended use, among other things, to a previously approved product. ANDAs are termed &#8220;abbreviated&#8221; because they are generally not required to include nonclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo, or other testing. The generic version can often be substituted by pharmacists under prescriptions written for the reference listed drug.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book Listing</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#8217;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA or a Section&#160;505(b)(2) NDA.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon submission of an ANDA or Section&#160;505(b)(2) NDA, the applicant must certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book. Specifically, the applicant must certify that (i)&#160;the required patent information has not been filed; (ii)&#160;the listed patent has expired; (iii)&#160;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv)&#160;the listed patent is invalid or will not be infringed by the new product. The applicant may also elect to submit a statement certifying that its proposed label does not contain (or carve out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the application will not be approved until all the listed patents claiming the referenced product have expired.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the application until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the applicant, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor's decision to initiate patent litigation.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Exclusivity</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act establishes a period of non-patent data exclusivity for certain approved drug products during which the FDA cannot accept for review an ANDA or 505(b)(2) NDA that relies on the branded reference drug. For example, the holder of an NDA, including a 505(b)(2) NDA, may obtain five years of exclusivity upon NDA approval of a drug containing a new chemical entity, which is a drug that contains no active moiety that has been approved by the FDA in any other NDA. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another applicant that contains the previously approved active moiety. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or non-infringement.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act also provides three years of non-patent exclusivity to the holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the condition of the new drug&#8217;s approval.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Five year and three year exclusivity will not delay the submission or approval of a full 505(b)(1) NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars and Reference Product Exclusivity </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product be biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of its product. The BPCIA also created some exclusivity periods for biosimilars approved as interchangeable products. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Both drugs and biological products can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active ingredient and to patent terms. This six-month exclusivity, which runs from the end of existing regulatory exclusivity protection and patent terms, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of exclusivity or patent term remaining.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Health Care Laws</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain general business and marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes, false claims statutes, and other health care laws and regulations.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid, or other federally financed health care programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to commit a violation.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal civil and criminal false claims laws, including the federal civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Recently, several pharmaceutical and other health care companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Additionally, a violation of the U.S. federal Anti-Kickback Statute can serve as a basis for liability under the federal False Claims Act. The majority of states also have statutes or regulations similar to the federal Anti-Kickback Statute and False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other federal statutes pertaining to health care fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payer knows or should know is likely to influence the beneficiary to order a receive a reimbursable item or service from a particular supplier, and the additional federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) which prohibits, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any health care benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any health care benefit program in connection with the delivery of or payment for health care benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to commit a violation.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Physician Payments Sunshine Act requires certain manufacturers of prescription drugs to collect and report information on certain payments or transfers of value to physicians (defined broadly to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners or clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants and certified nurse-midwives) and teaching hospitals, as well as investment interests held by physicians and their immediate family members. The reported data is made available in searchable form on a public website on an annual basis. Failure to submit required information may result in civil monetary penalties. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, several states now require prescription drug companies to report certain expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual health care practitioners in these states. Other states prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals. Still other states require the posting of information relating to clinical studies and their outcomes. Some states require the reporting of certain pricing information, including information pertaining to and justifying price increases, or prohibit prescription drug price gouging. In addition, states such as California, Connecticut, Nevada, and Massachusetts require pharmaceutical companies to implement compliance programs and/or marketing codes. Several additional states are considering similar proposals. Certain states and local jurisdictions also require the registration of pharmaceutical sales representatives. Compliance with these laws is difficult and time-consuming, and companies that do not comply with these state laws face civil penalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that business arrangements with third parties comply with applicable health care laws and regulations involve substantial costs. If a drug company&#8217;s operations are found to be in violation of any such requirements, it may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of its operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, health care reimbursement or other federal or state government health care programs, including Medicare and Medicaid, integrity oversight and reporting obligations, imprisonment, and reputational harm. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action for an alleged or suspected violation can cause a drug company to incur significant legal expenses and divert management&#8217;s attention from the operation of the business, even if such action is successfully defended.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Formulary Coverage and Reimbursement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any new therapeutic product candidate. Sales in the United States will depend in part on the availability of sufficient formulary coverage and adequate reimbursement from third-party managed care organizations and private health insurers and government health payers such as Medicare, Medicaid, TRICARE, and the Veterans Administration. The ability for manufacturers to secure coverage for therapeutic product candidates can be subject to significant formulary restrictions or denial by payers.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern coverage, pricing, and reimbursement for new drugs (whether chemical or biologics) vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, a drug company can obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of that product.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A drug company&#8217;s ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government authorities, private health insurers, and other organizations. Even if one or more products are successfully brought to the market, these products may not be considered cost-effective, and the amount reimbursed for such products may be insufficient to allow them to be sold on a competitive basis. Increasingly, third-party payers who reimburse patients or health care providers, such as government and private insurers, are requiring that drug companies provide them rebates off list prices, and are seeking to reduce their prices to secure coverage. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A payer&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate or formulary position will be available. Delays can occur in obtaining reimbursement for newly-approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be reimbursed in all cases or at a rate that covers a drug company&#8217;s costs, including research, development, manufacture, sale, and distribution.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of products, in addition to their safety and efficacy. In order to obtain coverage for any product that might be approved for marketing, expensive studies may be required in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payers may not consider products to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable maintenance of price levels sufficient to realize an appropriate return on a drug company&#8217;s investment in drug development.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net prices for drugs may be reduced by mandatory discounts or rebates required by government health care programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Further, no uniform policy for coverage and reimbursement exists in the United States. Third-party payers often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement can differ significantly from payer to payer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Health Care Reform</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been, and continue to be, proposals by the federal government, state governments, regulators, and third-party payers to control or manage the increased costs of health care and, more generally, to reform the U.S. health care system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, the ACA was enacted in 2010, which substantially changed the way health care is financed by both governmental and private insurers and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, (i)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended manufacturer rebate liability to utilization by individuals enrolled in Medicaid managed care organizations, (ii)&#160;established annual nondeductible fees and taxes on manufacturers of certain branded prescription drugs and therapeutic biologics, and (iii)&#160;established a Center for Medicare and Medicaid Innovation at Centers for Medicare and Medicaid Services (CMS) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive, and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce health care expenditures. On March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price. On August&#160;2, 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers, which went into effect on April&#160;1, 2013, and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, unless additional Congressional action is taken. Moreover, on January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers. If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health, to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market, and sell any products we may develop.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most significantly, the Inflation Reduction Act, or IRA, was enacted in 2022. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap (with resulting prices for the initial ten drugs first effective in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), redesigns the Medicare Part D benefit (beginning in 2025), and replaces the Part D coverage gap discount program with a new discounting program (which began on January 1, 2025). The IRA permits the Secretary of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and for the subsequent 15 drugs, which will first be effective in 2027. Each year thereafter, more Part B and Part D products will become subject to the HHS price negotiation program. HHS has issued and will continue to issue guidance implementing the IRA, although the program is currently subject to legal challenges. While the impact of the IRA on us and the pharmaceutical industry is likely to be significant, the impact on us cannot be fully determined.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our ability to grow sales of ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any other product candidate that we commercialize in the Medicaid market.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current administration is pursuing a two-fold strategy to reduce drug costs in the United States. While it is unclear whether and how the proposals will be implemented, the policies are likely to have a negative impact on the pharmaceutical industry and may have a negative impact on revenues for ZORYVE. On the one hand, the current administration has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the United States to the lowest price in a group of other countries. In response, multiple manufacturers have entered into confidential pricing agreements with the federal government. On the other hand, the current administration is pursuing traditional regulatory pathways to impose drug pricing policies and published two proposed regulations in December 2025, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">referred to as Globe and Guard. If finalized, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government on a portion of the units of their drugs that are reimbursed by Medicare, with the rebate amount based on most favored nation pricing. Imposing a rebate in the United States that is based on drug prices outside the United States would mark a drastic and unprecedented shift in the U.S. pharmaceutical market, and while the impact of the Globe and Guard proposed regulations, if finalized, cannot yet be determined, it is likely to be significant. Even regulatory proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business. In addition, pharmaceutical pricing and marketing has long been the subject of considerable discussion in Congress and among policymakers, and it is possible that Congress could enact additional laws that negatively affect the pharmaceutical industry.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure, drug price increase disclosure, and other transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states, and at least one state board is imposing an upper payment limit. States are also seeking to implement general, across-the-board price caps for pharmaceuticals, or are seeking to regulate drug distribution. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that these laws that have been enacted and any future laws will result in additional downward pressure on coverage and the price that we receive for our products and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other health care reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. In addition, it is possible that there will be further legislation or regulation that could harm our business, financial condition, and results of operations. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and Security </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">processing. </span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources and Employees</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had 354 full-time employees. Of these full-time employees, two have an M.D., and four are Nurse Practitioners or Physician Assistants. From time to time, we also retain the services of independent contractors to support our organization. None of our employees are represented by a labor union or covered by collective bargaining agreements, and we believe our relationship with our employees is good.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain, and motivate selected employees through the granting of stock-based compensation awards and cash-based performance bonus awards.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical development business is fundamentally a people-centric, knowledge-based business. Additionally, one core element of our corporate strategy is to build an industry-leading team of dermatology experts. As such, we expend considerable management time and attention, and financial resources, to attracting, retaining, and motivating exceptional individuals at our company. These efforts include not only our recruitment and compensation programs, but equally importantly, include the corporate culture that we have built at the company, and the management practices we employ in order to obtain the best possible performance from our team. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information About Segments</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We view our operations and manage our business as one reportable segment. See Note 13 in the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Arcutis Biotherapeutics</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were formed under the laws of the State of Delaware in June 2016 under the name Arcutis, Inc. and changed our name to Arcutis Biotherapeutics, Inc. in October 2019. Our principal executive offices are located at 3027 Townsgate Road, Suite 300, Westlake Village, California 91361, and our telephone number is (805) 418-5006. Our website address is www.arcutis.com. The information found on or accessible through our website is not incorporated into, and does not form a part of, this Annual Report on Form 10-K.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the information requirements of the Securities Exchange Act of 1934, as amended, and we therefore file periodic reports, proxy statements, and other information with the SEC relating to our business, financial statements, and other matters. The SEC maintains an Internet site, www.sec.gov, that contains reports, proxy statements, and other information regarding issuers such as Arcutis Biotherapeutics, Inc.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about us, including free access to our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports as soon as reasonably practicable after they are filed with or furnished to the SEC, visit our website, www.arcutis.com. The information found on or accessible through our website is not incorporated into, and does not form a part of, this Annual Report on Form 10-K.</span></div><div id="i2dffe4de76224390b628083ec6a2857c_19"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.   RISK FACTORS</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking information based on our current expectations. Because our business is subject to many risks and our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our business, operating results, financial condition, and the trading price of our common stock. This discussion should be read in conjunction with the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations". The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects, and stock price. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Limited Operating History, Financial Condition, and Capital Requirements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a commercial-stage biopharmaceutical company with four products approved for commercial sale. We have incurred significant losses since our inception and could incur losses in the future, which, together with our limited history as a commercial-stage company, makes it difficult to assess our future viability.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We have a limited history as a commercial-stage company upon which you can evaluate our business and prospects, and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields. Our operations to date include organizing and staffing our company, business planning, raising capital, identifying potential product candidates, establishing licensing arrangements, undertaking various research and nonclinical studies, conducting clinical trials, establishing manufacturing and supply operations, and preparing for and launching commercialization activities. We have incurred losses in each year since our inception in June 2016. Our net loss for the year ended December 31, 2025 was approximately $16.1&#160;million. As of December&#160;31, 2025, we had an accumulated deficit of $1,138.1&#160;million. We commercially launched our first product, ZORYVE cream 0.3%, in August 2022; our second product, ZORYVE foam, in late January 2024; our third product, ZORYVE cream 0.15%, in July 2024; and our fourth product, ZORYVE cream 0.05%, in October 2025. We have generally and may incur losses until our revenue from product sales of ZORYVE and any other approved products exceeds expenses. We cannot anticipate when we will achieve sustained profitability. We will continue to incur research and development and other expenses related to our ongoing operations, our commercialization efforts, and the development of our product candidates. Losses have had and may have an adverse effect on our stockholders&#8217; equity and working capital. In addition, we may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">encounter unforeseen expenses, difficulties, complications, delays, and other known or unknown factors in achieving our business objectives. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the ongoing commercialization of products approved for commercial sale, and our development strategy and continued development of our pipeline of product candidates through clinical trials, our capital requirements are difficult to predict and may change. We may require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital if or when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate certain operations or efforts.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to expend substantial resources in connection with our commercialization efforts, the development of our current product candidates, the maintenance and expansion of our business operations and capabilities, and the development or acquisition of additional product candidates. These expenditures will include costs associated with marketing and selling any products approved for sale, including ZORYVE, conducting non-clinical studies and clinical trials, obtaining regulatory approvals, securing manufacturing and supply of product candidates, costs associated with in-licensing dermatology assets consistent with our core strategy, and other unanticipated costs. Because the outcome of any nonclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any of our product candidates. Similarly, due to the complexities of our recent transition to a commercial-stage company, it is challenging to estimate the actual amounts necessary to successfully commercialize any products approved for sale. Our operating expenses and capital requirements are difficult to predict, depend on many factors and are affected by, and are subject to assumptions regarding, among others: </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing, receipt, and amount of sales of any current and future products, including the success of our commercialization efforts involving ZORYVE; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">market acceptance of our current and future products, including ZORYVE, and the impact of competing products; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability of patients or health care providers to obtain coverage of or sufficient reimbursement for any current or future products;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to successfully execute on our business plan and our internal projections and estimates of costs and execution timing; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the scope, progress, results, and costs of developing product candidates and conducting nonclinical studies and clinical trials, including in connection with our current product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">suspensions or delays in enrollment of our ongoing and future clinical trials, issues with data collection, or changes to the number of subjects we decide to enroll in our clinical trials, including as a result of competing trials or otherwise; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the number and scope of clinical programs we decide to pursue, and the number and characteristics of any product candidates we develop or acquire; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing of, and the costs involved in, obtaining regulatory reviews and approvals for our product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the cost of manufacturing any current and future products and product candidates, including any products we successfully commercialize and the costs associated with building out our supply chain;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the cost of commercialization activities for any current and future products that are approved for sale, including marketing, sales, and distribution costs, and any discounts or rebates to obtain access;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to establish and maintain strategic collaborations, licensing, or other arrangements and the financial terms of any such agreements that we may enter into;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of any acquisitions or similar transactions or partnerships; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs related to milestone and royalty payments due to AstraZeneca, Hengrui, the former owners of Ducentis, which we acquired in September 2022, or any future collaboration or licensing partners upon the achievement of negotiated milestones;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any product liability or other lawsuits related to our products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the expenses needed to attract and retain skilled personnel; and </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing our intellectual property portfolio. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had capital resources consisting of cash, cash equivalents, and marketable securities of $221.0&#160;million. In addition, as of December&#160;31, 2025, we had $100.0 million outstanding under our loan and security agreement, or the Loan Agreement, with SLR Investment Corp.(SLR), and the lenders party thereto. If our capital resources are insufficient to satisfy our requirements, we may need to fund our operations through the sale of our equity securities, accessing or incurring additional debt, entering into licensing or collaboration agreements with partners, grants, or other sources of financing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such financing may result in dilution to stockholders, imposition of burdensome debt covenants and repayment obligations, or other restrictions that may affect our business. There can be no assurance that sufficient funds will be available to us at all or on attractive terms when needed from these sources. If we are unable to obtain additional funding from these or other sources when needed, it may be necessary to significantly reduce our current rate of spending through, among other things, reductions in staff and delaying, scaling back, or stopping certain research and development programs, nonclinical studies, clinical trials or other development activities, and commercialization efforts. We may also be required to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict, and could cause our future operating results to fall below expectations.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results may fluctuate due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to commercialize approved products and our ability to receive approval and commercialize our product candidates both within and outside of the United States;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">market acceptance of any current and future products and our ability to forecast demand for such products;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the level of demand for any current and future products, which may vary significantly;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability of patients or health care providers to obtain coverage of or sufficient reimbursement for any current or future products;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the willingness of patients to pay out-of-pocket for any current or future products in the absence of health insurance coverage or sufficient reimbursement;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to obtain and maintain good coverage and quality reimbursement of our products and future products;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">delays in the commencement, enrollment, and the timing of clinical testing for our product candidates, in light of competing trials or otherwise;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any delays in regulatory review and approval of product candidates in clinical development, or failure to obtain such approvals;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time and are subject to inflation and other drivers;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the cost of manufacturing any current and future products and product candidates, which may vary depending on U.S. FDA guidelines and requirements, and the quantity of production;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to obtain funding to develop our products and product candidates and operate our business;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expenditures that we will or may incur to acquire or develop additional product candidates and technologies, which may include obligations to make significant upfront and milestone payments;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">potential side effects of any current and future products and product candidates that could delay or prevent commercialization or cause an approved product to be taken off the market;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our dependency on Contract Research Organizations (CROs) to help manage our clinical trials, and third-party manufacturers for adequate supply or manufacturing capabilities;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to establish and maintain collaborations, licensing, or other arrangements;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to maintain and enforce our intellectual property position;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">costs related to and outcomes of potential litigation, potential government investigations, or other disputes;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to adequately support future growth;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to attract and retain key personnel to manage our business effectively;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">potential liabilities associated with hazardous materials;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to maintain adequate insurance policies; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">future accounting pronouncements or changes in our accounting policies.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our estimated market opportunities are subject to numerous uncertainties and may prove to be inaccurate. If we have overestimated the size of our market opportunities, our future growth may be limited.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimated addressable markets and market opportunities for our approved product and product candidates are based on a variety of inputs, including data published by third parties, our own market insights and internal market intelligence, and internally generated data and assumptions. We have not independently verified any third-party information and there can be no assurance as to its accuracy or completeness. Market opportunity estimates, whether obtained or derived from third-party sources or developed internally, are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. While we believe our market opportunity estimates are reasonable, such information is inherently imprecise. In addition, our assumptions and estimates of market opportunities are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including but not limited to those described herein. If this third-party or internally generated data prove to be inaccurate or we make errors in our assumptions based on that data, our actual market may be more limited than our estimates. In addition, these inaccuracies or errors may cause us to misallocate capital and other critical business resources, which could harm our business. The estimates of our market opportunities should not be taken as indicative of our ability to grow our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of our loan and security agreement require us to meet certain operating and financial covenants, and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had $100.0 million outstanding under our Loan Agreement. On August 9, 2024, we entered into a second amendment to the Loan Agreement, pursuant to which the terms were revised to, among others, permit us to make an optional partial prepayment of term loans outstanding during the period commencing on October 7, 2024 and ending on December 15, 2024, subject to a 1.0% prepayment penalty (the 2024 Partial Prepayment). On October 8, 2024, we made a 2024 Partial Prepayment of $100.0 million. In connection with the 2024 Partial Prepayment, we are obligated to pay a prepayment penalty of $1.0 million by June 30, 2026 and a final fee of $6.95 million, representing the final fee applicable to the amount of the 2024 Partial Prepayment, on January 1, 2027. As a result of such 2024 Partial Prepayment, subject to us generating a minimum net product revenue for the trailing six-month period ending as of the month prior to the borrowing date equal to 80% of our projected net product revenue as set forth in our annual plan for the respective period, we will be able to draw down a tranche C-1 term loan of up to $50.0 million and a tranche C-2 term loan of up to $50.0 million. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tranche C-1 term loan availability will expire on March 31, 2026 and the tranche C-2 term loan availability will expire on June 30, 2026. As security for the obligations under the Loan Agreement, we granted SLR, for the benefit of the lenders, a continuing security interest in substantially all of our assets, including our intellectual property, subject to certain exceptions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Loan Agreement contains a number of representations and warranties and affirmative and restrictive covenants, including financial covenants, and the terms may restrict our current and future operations, particularly our ability to respond to certain changes in our business or industry, or take future actions. The Loan Agreement includes a financial covenant whereby we must generate minimum net product revenue equal to 75% of our projected net product revenue as set forth in our annual plan for the respective period, tested on a trailing six-month basis as of the end of each month. Each annual plan shall be approved by our board of directors and SLR, in its capacity as collateral agent, in its reasonable discretion. Any failure by us to deliver such annual plan on or before December 15 of the prior year shall be an immediate event of default. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the debt under the Loan Agreement were accelerated due to an event of default or otherwise, we may not have sufficient cash or be able to sell sufficient assets to repay this debt, which would harm our business and financial condition. If we do not have or are unable to generate sufficient cash to repay our debt obligations when they become due and payable, either upon maturity or in the event of a default, our assets could be foreclosed upon and we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our ability to operate and continue our business as a going concern. Moreover, regardless of a potential event of default, the debt under the Loan Agreement matures and is due on August 1, 2029. As a result, we may need to refinance or secure separate financing in order to repay amounts outstanding when due, however, no assurance can be given that an extension will be granted, that we will be able to renegotiate the terms of the agreement with the lender, or that we will be able to secure separate debt or equity financing on favorable terms, if at all.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In order to service our indebtedness, we need to generate cash from our operating activities or additional equity or debt financings. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. We cannot assure that our business will be able to generate sufficient cash flow from operations or that future borrowings or other financings will be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are required to use cash from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital, capital expenditures or other general corporate purposes, we will be less able to plan for, or react to, changes in our business, industry, and in the economy generally. This may place us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in corporate governance policies and practices may impact our business. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to corporate governance, public disclosure and compliance practices, which continue to evolve based upon continuing legislative action, SEC rulemaking, stockholder activism and policy positions taken by large institutional stockholders and proxy advisors. As a result, the number of rules, regulations and standards applicable to us may become more burdensome to comply with, could increase scrutiny of our practices and policies by these or other groups and increase our legal and financial compliance costs and the amount of time management must devote to governance and compliance activities. For example, the SEC has recently adopted rules requiring that issuers provide significantly increased disclosures concerning cybersecurity matters and requiring public companies to adopt more stringent executive compensation clawback policies. </span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Development and Commercialization</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The sales, marketing, and distribution of ZORYVE or any future approved products may be unsuccessful or less successful than anticipated. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We began commercializing our first product in the United States in August 2022. As a company, we had no prior experience commercializing a product. The success of our commercialization efforts for ZORYVE and any future approved products is difficult to predict and subject to the effective execution of our business plan, including, among others, the continued development of our internal sales, marketing, and distribution capabilities and our ability to navigate the significant expenses and risks involved with the development and management of such capabilities. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, we have established an internal commercial infrastructure as well as a dermatologist-focused sales and distribution infrastructure to market ZORYVE and our product candidates in the United States and Canada, and have completed hiring in areas to support commercialization, including in sales management, sales </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">representatives, marketing, access and reimbursement, sales support, and distribution. There are significant expenses and risks involved with establishing our own sales, marketing, and distribution capabilities, including our ability to hire, retain, and appropriately incentivize qualified individuals, provide adequate training to sales and marketing personnel, and effectively manage geographically dispersed sales and marketing teams to generate sufficient demand. Any failure in the development of these capabilities could delay or negatively affect the success of our commercialization efforts and our business. For example, the commercialization of ZORYVE may not develop as planned or anticipated, which may require us to, among others, adjust or amend our business plan and incur significant expenses. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unsuccessful in accomplishing our objectives and executing on our business plan, or if the commercialization of ZORYVE or any future approved products does not develop as planned, we may require significant additional capital and financial resources, we may not become profitable, and we may not be able to compete against more established companies in our industry. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent on the successful commercialization of ZORYVE and the development, regulatory approval, and commercialization of our current product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have four products approved for commercial sale: ZORYVE cream 0.3%, a potent PDE4 inhibitor topical cream approved by the FDA in July 2022 for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older (subsequently expanded to patients 6 years of age and older); ZORYVE foam, a potent PDE4 inhibitor topical foam approved by the FDA in December 2023 for the treatment of seborrheic dermatitis in individuals aged 9 years and older; ZORYVE cream 0.15%, a potent PDE4 inhibitor topical cream for the treatment of atopic dermatitis in adults and pediatric patients 6 years of age and older approved by the FDA in July 2024; and ZORYVE foam, a potent PDE4 inhibitor topical foam approved by the FDA in May 2025 for the treatment of scalp and body psoriasis in adult and pediatric patients 6 years of age and older. We also received FDA approval for, and commercially launched, ZORYVE cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in children 2 to 5 years of age in October 2025. Our product candidate portfolio includes ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. We currently do not have drug discovery efforts, and we have no intention of developing a drug discovery capability. The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful commercialization of ZORYVE and the successful development, regulatory approval, and commercialization of other product candidates. We expect to conduct most of our clinical trials in the United States and Canada, with limited reliance on Australia, the Caribbean, and the European Union for clinical trial subjects. We currently anticipate seeking additional regulatory approvals in the United States and Canada but may in the future be subject to additional foreign regulatory authorities and may out-license our product candidates or approved products, if any, in additional foreign markets. In the future, we may also become dependent on other product candidates that we may develop, acquire, or in-license. The commercial success of ZORYVE and the clinical and commercial success of other product candidates will depend on a number of factors, including the following:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">timely completion of our nonclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate, including as a result of competitive trials, and will depend substantially upon the performance of third-party contractors;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">whether we are required by the FDA or similar foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">acceptance of our proposed indications and primary and secondary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the prevalence, duration, and severity of potential side effects or other safety issues experienced with ZORYVE or our product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">achieving, maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to ZORYVE or any of our product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the willingness of physicians and patients to utilize or adopt ZORYVE and our product candidates, if approved;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability of third parties upon which we rely to manufacture clinical trial and commercial supplies of ZORYVE or any of our product candidates to remain in good standing with relevant regulatory authorities and to develop, validate, and maintain commercially viable manufacturing processes that are compliant with cGMP;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to successfully implement and execute on a marketing strategy for ZORYVE and to commercialize any of our product candidates in the United States and internationally, if approved, whether alone or in collaboration with others;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the availability of coverage and adequate reimbursement from private third-party payers and governmental health care programs, such as Medicare and Medicaid; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">acceptance by physicians, payers, and patients of the benefits, safety, and efficacy of ZORYVE or any product candidates, if approved, including relative to alternative and competing treatments;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">patient demand for any approved products;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to establish and enforce intellectual property rights in and to any current and future products and product candidates; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to avoid third-party patent interference, intellectual property challenges, or intellectual property infringement claims; and </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to raise any additional required capital on acceptable terms, or at all. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because ZORYVE and each of our product candidates targets one or more indications in the medical dermatology field, if ZORYVE or any of our product candidates encounter safety or efficacy problems, developmental delays, regulatory issues, supply issues, or other problems, our development plans for the affected product or product candidate and some or all of our other product candidates could be significantly harmed, which would harm our business. Further, competitors who are developing products in the dermatology field or that target the same indications as us with products that have a similar mechanism of action may experience problems with their products that could indicate or result in class-wide problems or additional requirements that would potentially harm our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors outlined above, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize ZORYVE or our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of ZORYVE or our product candidates or any future product candidates to continue our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payers, or others in the medical community necessary for commercial success.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the marketing approval of ZORYVE and any other product candidates, such products may fail to gain sufficient market acceptance by physicians, patients, third-party payers, and others in the medical community. If ZORYVE or our other product candidates do not achieve an adequate level of acceptance, we may not generate adequate product revenue or become profitable. The degree of market acceptance will depend on a number of factors, including but not limited to:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the safety, efficacy, risk-benefit profile, and potential advantages compared to alternative or existing treatments, such as steroids topical treatments, oral treatments, and biologic injections for the treatment of psoriasis, which physicians may perceive to be adequately effective for some or all patients;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the prevalence and severity of any side effects and the difficulty of, or costs associated with, resolving such side effects;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the content of the approved product label, including any limitations or warnings contained in the labeling approved by FDA or other applicable foreign regulatory authorities;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any restrictions on the use of our products;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the effectiveness of our sales and marketing efforts;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the strength of our marketing and distribution support;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the cost of treatment in relation to alternative treatments, including any similar generic treatments and over-the-counter (OTC) treatments;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to offer our products for sale at competitive prices;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies over existing therapies;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the availability of coverage and adequate reimbursement from private third-party payers and governmental health care programs, such as Medicare and Medicaid; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the willingness of patients to pay out-of-pocket in the absence of health insurance coverage or sufficient reimbursement; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">utilization controls imposed by third-party payers, such as prior authorizations and step edits.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that ZORYVE or our current or future product candidates, if approved, will achieve market acceptance among physicians, patients, third-party payers, or others in the medical community necessary for commercial success. Any failure by ZORYVE or such other product candidates that obtain regulatory approval to achieve market acceptance or commercial success would harm our results of operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to achieve and maintain third-party payer coverage and adequate levels of reimbursement for ZORYVE or any of our product candidates for which we receive regulatory approval, or any future products we may seek to commercialize, their commercial success may be severely hindered.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For ZORYVE and any of our product candidates that become available by prescription only, our success will depend on the availability of coverage and adequate reimbursement for our product from third-party payers. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payers to reimburse all or part of the costs associated with their prescription drugs. The availability of coverage and adequate reimbursement from governmental health care programs, such as Medicare and Medicaid, and private third-party payers is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. If ZORYVE or any of our product candidates fail to demonstrate attractive efficacy and safety profiles, they may not qualify for coverage and reimbursement. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our prescription-only products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the market for ZORYVE and certain of our product candidates will depend significantly on access to third-party payers&#8217; drug formularies, or lists of medications for which third-party payers provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling health care costs. In addition, in the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payers. Therefore, coverage and reimbursement for drug products can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of ZORYVE and our product candidates to each payer separately, with no assurance that coverage and adequate reimbursement will be obtained.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we believe that future coverage and reimbursement will likely be subject to increased restrictions in both the United States and in international markets. Third-party coverage and reimbursement for ZORYVE and any of our product candidates for which we may receive regulatory approval may not be available or adequate in either the United States or international markets, which could harm our business, financial condition, operating results, and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of failure for our product candidates is high. It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete nonclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans, or with respect to our product candidates regulated as biologics, the safety, purity, and potency of such product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is inherently uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of nonclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, nonclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in nonclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during or as a result of clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">clinical site closures, delays to patient enrollment, subjects discontinuing treatment or follow-up visits, issues with data collection, or changes to trial protocols as a result of competing trials or otherwise;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">regulators or independent institutional review boards (IRBs) may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">clinical trials of our product candidates may produce negative or inconclusive results, including failure to demonstrate statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the number of subjects required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials, or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, or IRBs to suspend or terminate the trials;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">regulators or IRBs may require that we or our investigators suspend or terminate clinical development for various reasons, including noncompliance with regulatory requirements, or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the data safety monitoring board for such trial, or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or side effects, failure to demonstrate a benefit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain regulatory approval for an expansion of our product labels or approval of our product candidates under applicable regulatory requirements. The denial or delay of any such approval would prevent or delay commercialization of additional indications or our product candidates and adversely impact our potential to generate revenue, our business, and our results of operations.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To gain approval to expand the label of our products or market our product candidates, we must provide the FDA and foreign regulatory authorities with nonclinical and clinical data that adequately demonstrate the safety and efficacy, or as applicable, the safety, purity, and potency of the product for the intended indication applied for in the applicable regulatory filing. Product development is a long, expensive, and uncertain process, and delay or failure can occur at any stage of any of our nonclinical and clinical development programs. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after promising results in earlier nonclinical or clinical studies. These setbacks have been caused by, among other things, nonclinical findings made while clinical studies were underway and safety or efficacy observations made in clinical studies, including previously unreported adverse events. Success in nonclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant regulatory risk involving our products and product candidates, and we cannot provide assurance that any of our products will gain expanded labels or that our product candidates will obtain regulatory approval for commercialization as expected, or at all. The research, testing, manufacturing, labeling, approval, sale, marketing, and distribution of drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. We are not permitted to market expanded indications of our products or any product candidates in the United States or in any foreign countries until they receive the requisite approval from the applicable regulatory authorities of such jurisdictions, including pricing approval in the EU.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or any foreign regulatory authorities can delay, limit, or deny approval of expanded labels for our products or our product candidates for many reasons, including:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory authority that any of our product candidates is safe and effective or, with respect to product candidates regulated as biologics, safe, pure, and potent for the requested indication;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA or other relevant foreign regulatory authorities may disagree with the number, design, size, conduct, or implementation of our clinical trials;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA or other relevant foreign regulatory authorities may not find the data from nonclinical studies or clinical trials sufficient to demonstrate that the clinical and other benefits of these products candidates outweigh their safety risks or that there is an acceptable risk-benefit profile;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the results of our clinical trials may not meet the level of statistical significance or clinical meaningfulness required by the FDA or other relevant foreign regulatory authorities for marketing approval;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA&#8217;s or the applicable foreign regulatory authority&#8217;s requirement for additional nonclinical studies or clinical trials which would increase our costs and prolong our development timelines;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA or other relevant foreign regulatory authorities may disagree with our interpretation of data or significance of results from the nonclinical studies and clinical trials of any product or product candidate, or may require that we conduct additional studies;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA or other relevant foreign regulatory authorities may not accept data generated from our clinical trial sites;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the CROs that we retain to conduct clinical trials may take actions outside of our control, or otherwise commit errors or breaches of protocols, that adversely impact our clinical trials and ability to obtain market approvals;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">if an NDA, BLA, or other foreign application is reviewed by an advisory committee, the FDA or other relevant foreign regulatory authority, as the case may be, may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA or other relevant foreign regulatory authority, as the case may be, require, as a condition of approval, additional nonclinical studies or clinical trials, limitations on approved labeling, or distribution and use restrictions;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA or other relevant foreign regulatory authorities may require development of a Risk Evaluation and Mitigation Strategy (REMS), or its equivalent, as a condition of approval;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA or other relevant foreign regulatory authorities may require additional post-marketing studies and/or a patient registry, which would be costly;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA or other relevant foreign regulatory authorities may find the chemistry, manufacturing, and controls data insufficient to support the quality of our product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA or other relevant foreign regulatory authorities may identify deficiencies in the manufacturing processes or facilities of our third-party manufacturers;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA or other relevant foreign regulatory authorities may change their approval policies or adopt new regulations;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA&#8217;s or the applicable foreign regulatory authority&#8217;s non-approval of the formulation, dosing, labeling, or specifications;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the FDA&#8217;s or the applicable foreign regulatory authority&#8217;s failure to approve the manufacturing processes of third-party manufacturers upon which we rely or the failure of the facilities of our third-party manufacturers to maintain a compliance status acceptable to the FDA or the applicable foreign regulatory authority; or</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory authorities to significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of biopharmaceutical products in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we eventually complete clinical testing and receive approval from the FDA or applicable foreign agencies for any of our product candidates, the FDA or the applicable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or the applicable foreign regulatory authority also may approve our lead product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA, or applicable foreign regulatory authority, may not approve our product candidates with the labeling that we believe is necessary or desirable, or may approve them with labeling that includes warnings or precautions or limitations of use that may not be desirable, for the successful commercialization of such product candidates. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially adversely impact our business and prospects.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose topline or preliminary data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a full analyses of all data related to the particular trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, topline or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, topline, or preliminary data and final data could significantly harm our business prospects.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product, and our business in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities, or otherwise regarding a particular drug, product candidate, or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects, or financial condition may be harmed.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of the endpoints in our planned clinical trials rely on a subjective assessment of the effect of the product candidate in the subject by either the physician or patient, and may prove difficult to meet in patients with more severe disease, which exposes us to a variety of risks for the successful completion of our clinical trials.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our primary and secondary endpoints in our clinical trials, including our already completed and planned clinical trials in atopic dermatitis, scalp and body psoriasis, vitiligo, and hidradenitis suppurativa involve subjective assessments by physician and subjects, which can increase the uncertainty of clinical trial outcomes. For example, one of the secondary endpoints requires subjects to report pruritus (itching) as measured by the WI-NRS and complete or deliver patient or caregiver reported outcomes over the course of our clinical trials. This and other assessments are inherently subjective, which can increase the variability of clinical results across clinical trials and create a significant degree of uncertainty in determining overall clinical benefit. Such assessments can be influenced by factors outside of our control, and can vary widely from day-to-day for a particular patient, and from patient-to-patient and site-to-site within a clinical trial. In addition, frequent reporting requirements may lead to rating fatigue and a loss of accuracy and reliability of the data resulting from our clinical trials. Further, the FDA or comparable foreign regulatory authority may not accept such patient or caregiver reported outcomes as sufficiently validated. Accordingly, these subjective assessments can complicate clinical trial design, adversely impact the ability of a study to show a statistically significant improvement, and generally adversely impact a clinical development program by introducing additional uncertainties.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of patient reported outcome instruments in our clinical trials and the inclusion of such data in any product labeling depends on, but is not limited to, the FDA&#8217;s review of the following:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the relevance and importance of the concept(s) of interest to the target patient population;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the strengths and limitations of the instrument within the given context of use;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the design and conduct of the trials;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the adequacy of the submitted data, for example, rigorous data collection and methods to handle missing data; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the magnitude of the statistically significant treatment effect should be meaningful to subjects.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, different results may be achieved depending upon the characteristics of the population enrolled in our studies and which analysis population is used to analyze results. For example, the primary endpoint in a number of our clinical trials, including our Phase 3 clinical trials of ZORYVE cream in plaque psoriasis and atopic dermatitis and our Phase 3 clinical trials of ZORYVE foam in seborrheic dermatitis and scalp and body psoriasis, was or is based on the percentage of subjects achieving a score of &#8220;clear&#8221; or &#8220;almost clear&#8221; plus at least a 2-grade improvement from baseline on the 5 point IGA scale, referred to as IGA Success. Success in our clinical trials with these or similar endpoints, requires the enrollment of subjects with conditions that are severe enough to facilitate a 2-grade improvement in the IGA scale, but not so severe that they cannot achieve a &#8220;clear&#8221; or &#8220;almost clear&#8221; in IGA </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">score in light of the severity of their disease. It is therefore possible that we enroll subjects with conditions so severe that they do not or are unable to realize an IGA of 0 (clear) or 1 (almost clear) during the period covered by the clinical trial. There can be no guarantee that clinical trials will produce the same statistically significant results in IGA Success, which may serve as the primary endpoint, as prior clinical trials, and there can be no guarantee that the characteristics of the population enrolled in any clinical trial does not adversely impact the results reported for such trial, any of which could have an adverse effect on our ability to secure regulatory approval for our product candidates.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enrollment and retention of subjects in clinical trials is expensive and time-consuming and may result in additional costs and delays in our product development activities, or in the failure of such activities.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate, timely enroll or continue clinical trials if we are unable to locate and enroll a sufficient number of eligible subjects to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Patient enrollment is affected by a variety of factors, including but not limited to:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the severity of the disease under investigation;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the selection of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the eligibility criteria for the study in question;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the frequency and extent of clinical trial site visits and study assessments;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the perceived risks and benefits of the product candidate under study;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the patient referral practices of physicians;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to monitor subjects adequately during and after treatment; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the proximity and availability of clinical trial sites for prospective subjects. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, it may be more challenging to identify and enroll certain patient populations or groups, such as pediatric patients, and we experienced enrollment delays in our INTEGUMENT-PED pediatric trial. In addition, our competitors have previously conducted, are currently conducting, and may in the future conduct clinical trials for product candidates that treat the same indications as our product candidates, and subjects who are otherwise eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any negative results that we may report in nonclinical studies or clinical trials of our product candidates may make it difficult or impossible to recruit and retain subjects in other clinical trials of that same or any similar product candidate. Our inability to enroll a sufficient number of subjects for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether, and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, including as a result of launching additional clinical sites, which would cause the value of our company to decline and impede our ability to obtain additional financing.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs, or necessitate the abandonment or limitation of the development of some of our product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue our development of our product candidates and initiate additional nonclinical studies or clinical trials of these or future product candidates, if any, serious adverse events, unacceptable levels of toxicity, undesirable side effects or unexpected characteristics may emerge, causing us to abandon these product candidates or limit their development to more narrow uses, lower potency levels or subpopulations in which the serious adverse events, unacceptable levels of toxicity, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk/benefit perspective.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are associated with adverse effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development, institute burdensome monitoring programs, or limit development to more narrow uses, or lower or less frequent dosing in which the side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective. The FDA or an IRB, or similar regulatory authorities outside the United States, may also require that we suspend, discontinue, or limit our clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials based on safety information. Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates. Many product candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented further development of the product candidate.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, following marketing approval of any of our product candidates, we or others may identify undesirable side effects caused by such products, which could result in a number of potentially significant negative consequences, including:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">regulatory authorities may withdraw approvals of such product;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">regulatory authorities may require additional warnings on the labels;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we may be required to implement a REMS;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we may be required to conduct Phase 4 clinical trials as post-marketing requirements;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our reputation and physician or patient acceptance of our products may suffer.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance and could significantly harm our business, results of operations, and prospects.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a company, we have obtained marketing approval for only four products and we may be unable to successfully obtain marketing approval in a timely manner, or at all, for any of our other product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining marketing approval or an additional indication for a product candidate is a complicated process. Due to the complexities of the marketing approval process, this process and the related activities may require more time and/or cost more than we anticipate, and we may be unable to successfully complete such process and related activities for any of our product candidates. Failure to successfully complete, or delays in, our pivotal trials or related regulatory submissions would prevent us from or delay us in obtaining regulatory approval for our product candidates.&#160;In addition, it is possible that the FDA may refuse to file for substantive review any NDAs, BLAs, or supplements that we submit for our product candidates or may conclude after review of our applications that they are insufficient to obtain marketing approval of our product candidates. If the FDA does not accept for filing or approve any applications for our product candidates, it may require that we conduct additional clinical, nonclinical, or manufacturing validation studies and submit such data before it will reconsider such applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA, BLA, or supplement, or any other applications that we submit may be delayed by several years or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve any NDAs, BLAs, or supplements that we may submit. Additionally, similar risks could apply to receipt of marketing authorizations by comparable regulatory authorities in foreign jurisdictions.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may choose not to continue developing or commercializing ZORYVE or any of our product candidates at any time during development or after approval, which would reduce or eliminate our potential return on investment for ZORYVE, and our product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time, we may decide to discontinue the development or commercialization of any of our products or product candidates for a variety of reasons, including the appearance of new technologies that render our product obsolete, competition from a competing product, and changes in, or our inability to comply with, applicable regulatory requirements. If we terminate a program in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity to allocate those resources to potentially more productive uses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we seek to market products in countries other than the United States or Canada, we will need to comply with the regulations of each country in which we seek to market our products.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No product or product candidate is currently approved for sale by any government authority in any jurisdiction other than the United States and Canada. If we fail to comply with regulatory requirements in any market we decide to enter, or to obtain and maintain required approvals, or if regulatory approvals in the relevant markets are delayed, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. Marketing approval in one jurisdiction, such as in the United States or Canada, does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the regulatory process in others. Failure to obtain a marketing approval in countries in which we seek to market our products or any delay or setback in obtaining such approval would impair our ability to develop foreign markets for any of our products.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our license agreements and share purchase agreement with Ducentis Biotherapeutics obligate us to make certain milestone and royalty payments, some of which have been or will be triggered prior to commercialization of the applicable product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the milestone payments payable by us to AstraZeneca and Hengrui under our licensing agreements are due upon events that will occur prior to our planned commercialization of the applicable product or product candidate. Accordingly, we have been and will in the future be required to make such payments prior to the generation of any revenue from sales of the respective product or product candidate.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we paid AstraZeneca $2.0&#160;million upon the completion of a Phase&#160;2b study of ZORYVE cream in plaque psoriasis in August 2019, $7.5 million in August 2022 upon FDA approval to commercialize ZORYVE cream 0.3% in the United States, $5.0 million in October 2024 upon achievement of $100.0 million in worldwide net sales, and $10.0&#160;million in May 2025 upon achievement of $250.0&#160;million in worldwide net sales. We are required to make additional cash payments to AstraZeneca of up to an aggregate of $5.0&#160;million upon the achievement of specified regulatory approval milestones with respect to the AZ-Licensed Products. With respect to any AZ-Licensed Products we commercialize under the agreement, we will pay AstraZeneca a low-to-high single-digit percentage royalty rate on our, our affiliates&#8217;, and our sublicensees&#8217; net sales of such AZ-Licensed Products until, as determined on an AZ-Licensed Product-by-AZ-Licensed Product and country-by-country basis, the later of (i) the expiration of the last-to-expire AstraZeneca-licensed patent right containing a valid claim in such country and (ii) ten years from the first commercial sale of such AZ-Licensed Product in such country.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the share purchase agreement with Ducentis, we agreed to make certain contingent payments, which may become payable upon the achievement of certain development, regulatory, and commercial milestones. We estimate that these contingent payments may be up to an aggregate of approximately $400 million, although the actual amount may differ depending on whether the applicable milestones are achieved. In addition, if applicable, we will make payments amounting to a mid-single-digit percentage of any annual net sales of Ducentis&#8217;s products exceeding $1.5 billion. As of December&#160;31, 2025, none of the milestones were probable of achievement and, accordingly, no amounts have been recognized in the accompanying consolidated financial statements with respect to these contingent payments.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will have the funds necessary to make such payments, or be able to raise such funds when needed, on terms acceptable to us, or at all. Furthermore, if we are forced to raise additional funds, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves. If we are unable to raise additional funds or maintain sufficient liquidity to make our payment obligations if and when they become due, including payment obligations under agreements noted above with AstraZeneca, Hengrui and Ducentis, we may be in material breach of our agreements and our counterparties may seek legal action or remedies against us (including by seeking to terminate the relevant agreements), which would harm our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications, and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for dermatological therapies are competitive and are characterized by significant technological development and new product introduction. For example, there are several large and small pharmaceutical companies focused on delivering therapeutics for our targeted inflammatory and medical dermatological indications. We anticipate that we will face significant competition for ZORYVE and for other product candidates, if approved, from other approved therapies or drugs that become available in the future for the treatment of our target </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indications. ZORYVE and our product candidates may also compete with unregulated, unapproved, and&#160;off-label&#160;treatments. Even if another branded or generic product or OTC product is less effective than ZORYVE and our product candidates, a less effective branded, generic, or OTC product may be more quickly adopted by physicians and patients than ZORYVE or our product candidates based upon cost or convenience.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE and certain of our product candidates, if approved, will have to compete with existing therapies, some of which are widely known and accepted by physicians and patients. To compete successfully in these markets, we will have to demonstrate that the relative cost, safety, and efficacy of our approved products, if any, provide an attractive alternative to existing and other new therapies to gain a share of some patients&#8217; discretionary budgets and for physicians&#8217; attention within their clinical practices. Some of the companies that offer competing products also have a broad range of other product offerings, large direct sales forces, and long-term customer relationships with our target physicians, which could inhibit our market penetration efforts. Such competition could lead to reduced market share for ZORYVE or our product candidates and contribute to downward pressure on the pricing of ZORYVE or our product candidates, which could harm our business, financial condition, operating results, and prospects.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several companies that are working to develop drugs that would compete against ZORYVE or our product candidates for the treatment of psoriasis and atopic dermatitis, including a potential generic version of ZORYVE cream. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For plaque psoriasis, our primary competitors include injected biologic therapies such as Humira, marketed by AbbVie Inc. and Eisai Co., Ltd., and Enbrel, marketed by Amgen Inc.; Pfizer Inc., and Takeda Pharmaceutical Company Limited; non-injectable systemic therapies used to treat plaque psoriasis such as Otezla, marketed by Amgen Inc., and Sotyktu, marketed by Bristol Myers Squibb; topical therapies such as Vtama, marketed by Organon &amp; Co.; branded and generic versions of clobetasol, such as Clobex, marketed by Galderma Laboratories, LP; generic versions of calcipotriene and the combination of betamethasone dipropionate/calcipotriene; and other treatments including various lasers and ultraviolet light-based therapies. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For atopic dermatitis, our primary competitors include topical therapies such as Eucrisa, marketed by Pfizer Inc.; Opzelura, marketed by Incyte Corporation, Vtama, marketed by Organon &amp; Co., and generic and branded versions of low to mid-potency steroids such as hydrocortisone or triamcinolone. In the moderate-to-severe setting, the injected biologic therapies Dupixent, marketed by Regeneron Pharmaceuticals, Inc; Adbry, marketed by LEO Pharma; and Ebglyss, marketed by Eli Lilly &amp; Co. Non-injectable systemic therapies RINVOQ and CIBINQO are also approved in moderate-to-severe atopic dermatitis. In addition, there are several prescription product candidates under development that could potentially be used to treat atopic dermatitis and compete with ZORYVE cream and ARQ-234, including but not limited to: topical difamilast ointment, under development by Medimetriks/Otsuka Pharma, injectable rocatinlimab, under development by Amgen, and injectable amlitelimab, under development by Sanofi.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our existing or potential competitors have substantially greater financial, technical, and human resources than we do and significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United States and in foreign countries. Many of our current and potential future competitors also have significantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a smaller number of our competitors. Competition may reduce the number and types of subjects available to us to participate in clinical trials, because some subjects who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to less stringent regulatory requirements in certain foreign countries, there are many more dermatological products and procedures available for use in those international markets than are approved for use in the United States. In certain international markets, there are also fewer limitations on the claims that our competitors can make about the effectiveness of their products and the manner in which they can market their products. As a result, we expect to face more competition in these markets than in the United States.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete successfully will depend largely on our ability to:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">develop and commercialize therapies that have a competitive product profile or are superior to other products in the market;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">demonstrate through our clinical trials that ZORYVE and our product candidates are differentiated from existing and future therapies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">attract qualified scientific, product development, and commercial personnel;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">obtain patent or other proprietary protection for our technologies, ZORYVE, and product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">obtain required regulatory approvals, including approvals to market our product candidates in ways that are differentiated from existing and future therapies and OTC products and treatments;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">successfully commercialize ZORYVE and our product candidates, if approved;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third-party payers; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">successfully collaborate with pharmaceutical companies in the discovery, development, and commercialization of new therapies.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of our competitors&#8217; products could limit the demand and the price we are able to charge as well as the reimbursement and quality of coverage for ZORYVE or any product candidate we develop. The inability to compete with existing or subsequently introduced drugs or OTC treatments would have an adverse impact on our business, financial condition, and prospects. Furthermore, upon the expiration or loss of any patent protection for any of our approved products, or upon the &#8220;at-risk&#8221; launch, despite pending patent infringement litigation against the generic product or its equivalent, by a generic competitor of a generic version of any of our approved products, which may be sold at significantly lower prices than our products, we could lose a significant portion of sales of that product in a short period of time, which would adversely affect our business, financial condition, operating results and prospects.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to increase the size of our organization, and we may experience difficulties in executing our growth strategy, managing any growth, and retaining talent.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had 354 full-time employees. In order to effectively execute our growth strategy, we may need to identify, recruit, retain, incentivize, and integrate additional employees in order to expand our ability to:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">drive adoption, demand and reimbursement for ZORYVE and any future products and indications approved for marketing;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">establish and maintain relationships with development and commercialization partners;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manage our clinical trials effectively;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manage our internal development and operational efforts effectively, including in respect of product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continue to improve our operational, financial, management, and regulatory compliance controls and reporting systems and procedures, particularly as we scale our organization; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manage our third-party supply and manufacturing operations effectively and in a cost-effective manner, while increasing production capabilities for ZORYVE and our product candidates to commercial levels.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully identify, recruit, retain, incentivize, and integrate additional employees and otherwise expand our managerial, operational, financial, and other resources, our business and operational performance could be materially and adversely affected.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not successful in acquiring, developing, and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our effort will focus on the continued nonclinical and clinical testing and potential approval of our current product candidates, a key element of our strategy is to acquire, develop, and commercialize a diverse portfolio of product candidates to serve the dermatology market. We do not currently intend to conduct drug discovery efforts, but rather we intend to formulate, acquire, or in-license rights to existing molecules to develop for dermatological indications. In addition, while we believe that our strategy allows us to move more rapidly through clinical development and at a potentially lower cost, we may be unable to progress product candidates more quickly or at a lower cost.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we seek to identify and acquire or&#160;in-license&#160;additional product candidates in the dermatology field, our process for doing so may be slow and may ultimately be unsuccessful for a number of reasons, including those discussed in these risk factors and also:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">potential product candidates may, upon further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">potential product candidates may not be effective in treating their targeted diseases; or</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the acquisition or in-licensing transactions can entail numerous operational and functional risks, including exposure to unknown liabilities, disruption of our business, or incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, or higher than expected acquisition or integration costs.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to focus our efforts and resources on in-licensing or acquiring a potential product candidate that ultimately proves to be unsuccessful. We also cannot be certain that, following an acquisition or&#160;in-licensing&#160;transaction, we will achieve the revenue or specific net income that justifies such transaction. If we are unable to identify and acquire suitable product candidates for clinical development, this would adversely impact our business strategy, our financial position, and share price.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and future collaboration arrangements may not be successful, which could adversely affect our ability to develop and commercialize future product candidates.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into a strategic collaboration and licensing agreement for topical roflumilast in Greater China and Southeast Asia with Huadong, and a strategic collaboration and licensing agreement for topical roflumilast in Japan with Sato. In the future, we may seek additional collaboration arrangements for the commercialization, or potentially for the development, of certain of our product candidates depending on the merits of retaining commercialization rights for ourselves, as compared to entering into collaboration arrangements. To the extent that we decide to enter into future collaboration agreements, we will face significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document, implement, and maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements. The terms of any collaborations or other arrangements that we may establish may not be favorable to us. Our current and future collaborations may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include risks that:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to their acquisition of competitive products or their internal development of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a collaborator with sales, marketing, manufacturing, and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities, including with respect to accessing primary care and pediatric practices; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">collaborators are or may in the future be entitled to fees, royalties, profit sharing, and other consideration, which may limit or otherwise negatively impact our profit and financial performance;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we have and could in the future grant exclusive rights to our collaborators that prevent us from collaborating with others;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">disputes may arise between us and a collaborator that causes the delay or termination of the research, development, or commercialization of our current or future product candidates or that results in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">collaborators may own or co-own intellectual property covering products that result from our collaborating with them, and in such cases, would result in us not having the exclusive right to develop or commercialize such intellectual property;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaborations; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws, resulting in civil or criminal proceedings.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, there can be no assurance that any collaboration or other strategic transaction will achieve the expected synergies. For example, such transactions may require us to incur non-recurring or other charges, increase our near- and long-term expenditures, and pose significant integration or implementation challenges or disrupt our management or business. These transactions entail numerous operational and financial risks, including exposure to unknown liabilities; dependence upon the performance and discretion of counterparties that we do not control and that may underperform or fail; disruption of our business; diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs; and higher-than-expected collaboration costs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of ZORYVE or our current or future product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our ZORYVE or our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">decreased demand for ZORYVE or our current or future product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">injury to our reputation;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">costs to defend the related litigation;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">loss of revenue; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the inability to commercialize ZORYVE or our current or any future product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZORYVE or current or any future&#160;product candidates we develop. Although we currently carry product liability insurance covering our products and product candidates, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess&#160;of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. </span></div><div style="margin-top:8pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could undermine the credibility of our operating results, harm investors&#8217; views of us and, as a result, the value of our common stock.<br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, our management is required to report upon the effectiveness of our internal control over financial reporting and, since we are no longer a smaller reporting company, our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting beginning with this Annual Report on Form 10-K. The rules governing the standards that must be met for our management and our independent registered public accounting firm to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. In connection with our and our independent registered public accounting firm&#8217;s evaluations of our internal control over financial reporting, we may need to upgrade our systems, including information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us or our independent registered public accounting firm conducted in connection with Section 404 of the Sarbanes-Oxley Act of 2002 may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock. Internal control deficiencies could also result in a restatement of our financial results in the future. We could become subject to stockholder or other third-party litigation, as well as investigations by the SEC, the stock exchange on which our securities are listed, or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions, payment of damages or other penalties. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Select Market, or other adverse consequences that would materially harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our information technology systems, and any failure of these systems, including due to the use of artificial intelligence (AI), or those of our CROs or other contractors or consultants we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations, financial condition, and prospects.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store, and transmit large amounts of confidential information, including intellectual property, proprietary business information, preclinical and clinical trial data, and personal information (collectively, Confidential Information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our information technology systems and infrastructure, and those of our current and any future service providers, strategic partners, and other collaborators, contractors, and consultants, are vulnerable to attack, damage, and interruption from computer viruses and malware</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e.g., ransomware), misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, malicious code, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyber-attacks or cyber intrusions over the Internet, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, and sophisticated nation-state and nation-state-supported actors. While our controls and procedures help enable us to protect from or respond to cybersecurity threats, there can be no assurance that these controls and procedures will be adequate to protect us from any cyber incident. The threats are always evolving, will become more advanced with the use of AI, and may become increasingly difficult or impossible to detect and prevent. In the future, our existing controls and procedures may become inadequate and may require significant additional resources to enhance systems and controls or to investigate and remediate any security vulnerabilities. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusions, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. Bad actors use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, Confidential Information, and intellectual property. If we or our third-party vendors were to experience a significant cybersecurity breach of our or their information systems or data, the costs associated with the investigation, remediation, and potential notification of the breach to counterparties and data subjects could be material. In addition, our remediation efforts may not be successful. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information. There can also be no assurance that our and our third-party service providers', strategic partners', contractors', consultants', CROs' and collaborators' cybersecurity risk management program and processes, including policies, controls, or procedures, will be fully implemented, complied with or effective in protecting our systems, networks, and Confidential Information. Additionally, if we, our third-party vendors or partners experience an actual or perceived breach or data privacy or security incident, we may lose valuable intellectual property and Confidential Information, and our reputation and the public perception of the effectiveness of our security measures could be harmed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and certain of our service providers are from time to time subject to cyber-attacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss, corruption or unauthorized disclosure of our trade secrets, personal information or other proprietary or sensitive information or other similar disruptions. It could also expose us to risks, including an inability to provide our services and fulfill contractual demands, and could cause management distraction and the obligation to devote significant financial and other resources to mitigate such problems, which would increase our future information security costs, including through organizational changes, deploying additional personnel, reinforcing administrative, physical and technical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">safeguards, further training of employees, changing third-party vendor control practices and engaging third-party subject matter experts and consultants and reduce the demand for our technology and services.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted. In addition, the prevalent use of mobile devices and employees and contractors working from home and/or remote locations that access Confidential Information increases the risk of data security breaches, which could lead to the loss of Confidential Information or other intellectual property. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs, and security vulnerabilities could be significant and are likely to increase in the future. These costs include, but are not limited to, retaining the services of cybersecurity providers; compliance costs arising out of existing and future cybersecurity, data protection and privacy laws and regulations; and costs related to maintaining redundant networks, data backups and other damage-mitigation measures. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, and other harm to our business and our competitive position. Any security compromise affecting us, our service providers, strategic partners, other contractors, consultants, or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny. If such an event were to occur, it could result in a material disruption of our product development programs and commercial operations. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a computer security breach affects our systems or results in the unauthorized release of confidential, proprietary, or personal information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, supervisory bodies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable. Any adverse impact to the availability, integrity or confidentiality of our or third-party systems or Confidential Information can result in legal claims or proceedings (such as class actions), regulatory investigations and enforcement actions, fines and penalties, negative reputational impacts that cause us to lose existing or future customers, and/or significant incident response, system restoration or remediation and future compliance costs. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations, and financial condition. Further, our existing insurance policies may not cover, or may cover only a portion of, any potential claims related to security breaches to which we are exposed or may not be adequate to indemnify us for all or any portion of liabilities that may be imposed. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal, and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act (collectively, the CCPA) requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. Additional compliance investment and potential business process changes may also be required. Similar laws have been passed in other states, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also expect that there will continue to be new laws, regulations, and industry standards concerning privacy, data protection, and information security proposed and enacted in various jurisdictions. For example, Washington State enacted the &#8220;My Health My Data Act,&#8221; which broadly defines consumer health data, creates a private right of action to allow individuals to sue for violations of the law, imposes stringent consent requirements, and grants consumers certain rights with respect to their health data, including the right  to request deletion of their information. Consumer health data is defined to include personal information that is linked or reasonably linkable to a consumer and that identifies a consumer&#8217;s past, present, or future physical or mental health status; consumer health data also includes information that is derived or extrapolated from non-health information, such as algorithms and machine learning. Other states, including Connecticut and Nevada, have also passed similar laws regulating consumer health data, and given the increased focus on the use of health data by entities that are not subject to HIPAA, additional states are expected to pass consumer health privacy laws.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the Federal Trade Commission (the &#8220;FTC&#8221;) and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Failure to comply with anti-corruption and anti-money laundering laws, including the FCPA and similar laws associated with our activities outside of the United States, as well as export and import controls, customs, and economic and trade sanctions laws, could subject us to penalties and other adverse consequences.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-bribery or anti-corruption laws, regulations and rules in the United States and other countries in which we and our partners operate. These laws generally prohibit companies and their employees and third-party intermediaries from corruptly promising, authorizing, offering, or providing, directly or indirectly, improper payments of anything of value to government officials, political parties, and private-sector recipients for the purpose of obtaining or retaining business, directing business to any person, or securing any improper advantage. Certain laws also prohibit soliciting or receiving bribes or improper payments. In many foreign countries, including countries in which we or our partners may conduct business, it may be a local custom that businesses engage in practices that are prohibited by the FCPA or other applicable laws and regulations. As our business expands and we engage with international partners through collaboration, licensing and other agreements, the applicability of the FCPA and other anti-bribery laws to our operations, and the potential risk of violations of such laws, will increase. We face significant risks if we or any of our directors, officers, employees, agents or other partners or representatives fail to comply with these laws and governmental authorities in the United States and elsewhere could seek to impose substantial civil and/or criminal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fines and penalties which could have a material adverse effect on our business, reputation, financial condition, and results of operations.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our employees, contractors, and agents, and companies to which we outsource or license certain activities, may take actions in violation of our internal policies or applicable law. Any such violation could have an adverse effect on our reputation, business, results of operations, and prospects. Further, any violation of the FCPA, other applicable anti-corruption laws, or anti-money laundering laws could result in whistleblower complaints, adverse media coverage, investigations, loss of export privileges, severe criminal or civil sanctions, any of which could have a materially adverse effect on our reputation, business, results of operations, and prospects. In addition, responding to any enforcement action may result in a significant diversion of management&#8217;s attention and resources and significant defense costs and other professional fees.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our approved products, or our failure to obtain any required import or export authorization for our approved products, when applicable, could harm our business and adversely affect our growth. We could be subject to future enforcement action with respect to compliance with governmental export and import controls, customs laws, and economic and trade sanctions laws, and such enforcement could result in penalties, costs, and restrictions on export privileges that could have an adverse effect on our business, reputation, financial condition, and results of operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial partners, as well as our employees and independent contractors, including principal investigators, consultants, suppliers, service providers, and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our commercial partners, as well as our employees and independent contractors, including principal investigators, consultants, suppliers, service providers, and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar foreign regulatory authorities, including those laws that require the reporting of true, complete, and accurate information to such foreign regulatory authorities; manufacturing standards; U.S. federal and state health care fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete, and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our nonclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. health care programs, imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use, and disposal of hazardous materials owned by us, including the components of our product and product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party manufacturers to manufacture nonclinical, clinical and commercial supplies of ZORYVE and our product candidates. The loss of these manufacturers or their sub-suppliers, or their failure to provide us with sufficient quantities at acceptable quality levels, or at all, would materially and adversely affect our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have the infrastructure or capability internally to manufacture supplies of ZORYVE or our product candidates or the materials necessary to produce ZORYVE or our product candidates for use in the conduct of our nonclinical studies or clinical trials, and we lack the internal resources and the capability to manufacture ZORYVE or any of our product candidates on a nonclinical, clinical or commercial scale. Instead, we currently rely on single source third-party manufacturers to manufacture nonclinical, clinical, and commercial supplies of ZORYVE and intend to rely on third-party manufacturers for any future approved product. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the manufacturers of our products rely on suppliers of raw materials and components used in the production of our products. Some of these materials are available from only one source. If there is a disruption beyond our planned safety stock to one or more of our third-party suppliers&#8217; relevant operations, we will have no other means of producing ZORYVE or our product candidates until they restore the affected facilities or they procure alternative manufacturing facilities or sources of supply. Our ability to commercialize ZORYVE or to progress our nonclinical and clinical programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory, or reputational issues. Additionally, any damage to or destruction of our third-party manufacturer&#8217;s facilities or equipment may significantly impair our ability to manufacture ZORYVE or our product candidates on a timely basis.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, there are a limited number of suppliers for materials we use in ZORYVE and our product candidates, which exposes us to the risk of disruption in the supply of the materials necessary to manufacture ZORYVE and our product candidates for our nonclinical studies and clinical trials, and for commercial sale. We do not have control over the process or timing of the acquisition or manufacture of materials by our manufacturers. In addition, any significant delay in, or quality control problems with respect to, the supply of ZORYVE or a product candidate, or the raw material components thereof, for an ongoing study or trial could considerably delay completion of our nonclinical studies or clinical trials, product testing and potential regulatory approval of our product candidates. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to manufacture our product candidates in the quantities that we believe would be required to meet anticipated market demand, our third-party manufacturers may need to increase manufacturing capacity and, in some cases, we are securing alternative sources of commercial supply, which could involve significant challenges and may require additional regulatory approvals. Neither we nor our third-party manufacturers may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. If either we or our manufacturers are unable to purchase the raw materials necessary for the manufacture of our product candidates on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the commercial launch of any future product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of such product candidates, if approved, or impact the costs of procuring sufficient demand of materials or costs of manufacturing the product. Additionally, the imposition of tariffs and other orders or restrictions impacting trade could adversely impact our business, including by increasing or otherwise impacting the costs and expenses we incur in connection with our operations and supply chain. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our third-party manufacturers fail to comply with manufacturing or other regulations, our financial results and financial condition will be adversely affected.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for the manufacture of ZORYVE or our product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before commencing with commercial manufacturing, the processes and systems used in the manufacture of products and product candidates must be approved and each facility must have a compliance status that is acceptable to the FDA and other regulatory authorities. In addition, pharmaceutical manufacturing facilities are continuously subject to inspection by the FDA and foreign regulatory authorities before and after product approval. Due to the complexity of the processes used to manufacture pharmaceutical products and product candidates, any potential third-party manufacturer may be unable to continue to pass or initially pass federal, state, or international regulatory inspections.&#160;Furthermore, although we have very limited control over the operations of our contract manufacturers, we are responsible for ensuring compliance with applicable laws and regulations, including cGMPs.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third-party manufacturer with whom we contract is unable to comply with applicable laws and regulations including cGMPs, we may be subject to fines, unanticipated compliance expenses, recall or seizure of our products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions would adversely affect our financial results and financial condition.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our nonclinical studies and our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to independently conduct nonclinical studies and clinical trials. We rely on third parties, such as CROs, to conduct nonclinical studies and clinical trials of our product candidates. The third parties with whom we contract for execution of our nonclinical studies and clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we have limited ability to control the amount or timing of resources that they devote to our programs. These third parties may also have relationships with other commercial entities, some of which may compete with us. In some cases, these third parties could terminate their agreements with us without cause. Furthermore, external events could interfere with some operations of these third parties.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we rely on third parties to conduct our nonclinical studies and clinical trials, we remain responsible for ensuring that each of our nonclinical studies and clinical trials is conducted in&#160;accordance with its investigational plan and protocol. Moreover, the FDA and foreign regulatory authorities require us to comply with regulations and standards, including some regulations commonly referred to as GCPs, for conducting, monitoring, recording, and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that appropriate human subjects protections are in place, including that the trial subjects are adequately informed of the potential risks and other consequences of participating in clinical trials.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the execution of nonclinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. If the third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties, which could be difficult, costly, or impossible, and our clinical trials may be extended, delayed or terminated, or may need to be repeated, which would have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain, maintain or enforce patent rights or other intellectual property rights that cover ZORYVE or our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success with respect to ZORYVE and our product candidates and technologies will depend in part on our and our licensors&#8217; ability to obtain and maintain patent protection in both the United States and other countries, to preserve our trade secrets and to prevent third parties from infringing upon our proprietary rights. Our ability to protect ZORYVE and any of our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio includes patents and patent applications in the United States and foreign jurisdictions where we believe there is a market opportunity for our products. The covered technology and the scope of coverage vary from country to country. For those countries where we do not have granted patents, we may not have any ability to prevent the unauthorized use of our technologies. Any patents that we may obtain may be narrow in scope and thus easily circumvented by competitors. Further, in countries where we do not have granted patents, third parties may be able to make, use, or sell products identical to or substantially similar to, ZORYVE and our product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current licensors, or any future licensors or licensees may not be able to prepare, file, and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current licensors, or any future licensors or licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, our patents and applications may not be prosecuted, and as a result may not be able to be enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope, or patent term adjustments. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods, and know-how to our processes, methods, and know-how which we consider our trade secrets. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition, and operating results.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to legal standards relating to patentability, validity, enforceability, and claim scope of patents covering pharmaceutical inventions, our and our licensor&#8217;s ability to obtain, maintain, and enforce patents is uncertain and involves complex legal and factual questions. Accordingly, rights under our existing patents or any patents we might obtain or license may not cover ZORYVE or our product candidates or may not provide us with sufficient protection for ZORYVE or our product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic pharmaceutical companies. For example, even if patent protection for our product candidates is successfully obtained, we may face competition from generic or biosimilar medications once the patent has expired. Manufacturers of generic or biosimilar drugs may also challenge the scope, validity, or enforceability of the patents to which we have rights in court or before a patent office, and we may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively. On February 14, 2024, we received a Paragraph IV Notice Letter advising that Padagis Israel Pharmaceuticals Ltd. (Padagis) had submitted an ANDA to the FDA seeking authorization to manufacture, use, sell, and import a generic version of ZORYVE cream 0.3%. On July 16, 2024 and September 12, 2024, we received additional Paragraph IV Notice Letters from Padagis. Padagis' Paragraph IV certifications stated that our patents listed in the FDA's Orange Book will not be infringed by Padagis&#8217; proposed product, are invalid and/or are unenforceable. We filed suit against Padagis in the U.S. District Court for the District of Delaware on March 27, 2024, for infringement of certain of our patents and amended our complaint on July 19, 2024, to add additional patents to our infringement allegations. On August 2, 2024, Padagis responded to the first amended complaint, denying infringement and asserting counterclaims seeking a declaratory judgment that the asserted patents are not infringed, invalid, and/or unenforceable. The complaint triggered the automatic 30-month stay of FDA approval of the ANDA, expiring on August 14, 2026. In March 2025, Arcutis agreed to file a joint stipulation to stay the ongoing patent litigation with </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Padagis at the request of Padagi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2025, the court stayed the case and cancelled all case deadlines, including the trial. The 30-month stay of FDA approval will be extended for each day the stay in the case is in place, starting March 24, 2025, until the stay in the case is lifted. We plan to vigorously defend our extensive intellectual property rights in ZORYVE cream 0.3%.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. Even with respect to our patents that have issued or will issue, we cannot guarantee that the claims of these patents are or will be held valid or enforceable by the courts or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors in the field of dermatologic therapeutics have created a substantial amount of prior art, including scientific publications, patents and patent applications. Our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Although we believe that our technology includes certain inventions that are unique and not duplicative of any prior art, we do not have outstanding issued patents covering all of the recent developments in our technology and we are unsure of the patent protection that we will be successful in obtaining, if any, over such aspects of our technology. Even if patents do successfully issue covering such aspects of our technology, third parties may design around or challenge the validity, enforceability, or scope of such issued patents or any other issued patents we own or license, which may result in such patents being narrowed, invalidated, or held unenforceable. If the breadth or strength of protection provided by the patents we own or license with respect to ZORYVE or our product candidates is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize, ZORYVE our product candidates. Even if the patent applications that we own or license issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or drugs in a non-infringing manner.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign jurisdictions do not provide intellectual property rights to the same extent as in the United States and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property in foreign jurisdictions, our business prospects could be substantially harmed. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection of our proprietary rights is uncertain. Patent protection may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we might not have been the first to invent or the first to file the inventions covered by each of our pending patent applications and issued patents;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the patents of others may have an adverse effect on our business;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any patents we obtain or our licensors&#8217; issued patents may not encompass commercially viable products, may not provide us with any competitive advantages or may be challenged by third parties;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">for some product candidates, we expect that composition of matter patent protection for the API will not be available at the time we expect to commercialize, and we will therefore need to rely on formulation, method of use, and other forms of claims for patent protection;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any patents we obtain or our in-licensed issued patents may not be valid or enforceable; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we may not develop additional proprietary technologies that are patentable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20&#160;years after it is filed. Various extensions may be available; however, the life of a patent and the protection it affords are limited. In addition to potentially being open to competition from generic versions without patent protection for ZORYVE or our product candidates, the extensive period of time between patent filing and regulatory approval for a product candidate limits the time during which we can market a product candidate under patent protection, which may particularly affect the profitability of our early-stage product candidates. Our issued U.S. patents relating to ZORYVE</span><span style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">are currently projected to expire in mid-2037, our method of treatment patent specifically for roflumilast foam in the treatment of seborrheic dermatitis is currently projected to expire in 2041, and our patent related to ZORYVE foam is currently projected to expire in 2042. Additionally, an issued U.S. patent related to the composition of matter in ARQ-234 is currently projected to expire on July 14, 2038, unless any PTE is granted. Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented know-how by entering into confidentiality agreements with third parties and intellectual property protection agreements with certain employees, consultants, and advisors, third parties may still obtain this information or we may be unable to protect our rights. We also have limited control over the protection of trade secrets used by our suppliers, manufacturers, and other third parties. There can be no assurance that binding agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets and unpatented know-how will not otherwise become known or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secret information.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to claims alleging infringement of third parties&#8217; patents or proprietary rights and/or claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development and commercialization of ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE cream 0.05%, ZORYVE foam, ARQ-234, or any other product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been many lawsuits and other proceedings asserting patents and other intellectual property rights in the pharmaceutical and biotechnology industries. There can be no assurance that our exploitation of ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE cream 0.05%, ZORYVE foam, or ARQ-234 will not infringe existing or future third-party patents. Because patent applications can take many years to issue and may be confidential for 18&#160;months or more after filing, there may be applications now pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE cream 0.05%, ZORYVE foam, or ARQ-234. Moreover, we may face claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. We may be unaware of one or more issued patents that would be infringed by the manufacture, sale, or use of ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE cream 0.05%, ZORYVE foam, or ARQ-234.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to third-party claims in the future against us or our collaborators that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents. We may be required to indemnify future collaborators against such claims. If a patent&#160;infringement suit were brought against us or our future collaborators, we or they could be forced to stop or delay research, development, manufacturing, or sales of the product or product candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we or our collaborators may choose to seek, or be required to seek, a license from the third-party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our future collaborators were able to obtain a license, the rights obtained may be nonexclusive, which would not confer a competitive advantage to us from an exclusivity perspective. Ultimately, we could be prevented from commercializing a product, or forced to redesign it, or to cease some aspect of our business operations if, as a result of actual or threatened patent infringement claims, we or our collaborators are unable to enter into licenses on acceptable terms to necessary third-party patent rights. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to infringement claims against us, if third parties prepare and file patent applications in the United States that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the U.S. Patent and Trademark Office (USPTO), to determine which party is entitled to a patent on the disputed invention. We may also become&#160;involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. For example, Teva Pharmaceutical Industries Ltd. filed Oppositions with the European </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patent Office against two of our European patents, European Patent Nos. EP 3634380 B1 and EP 3684334 B1, on September 20, 2024 and August 13, 2024, respectively. After Oral Proceedings for each of the respective patents, the EPO panel found in favor of Arcutis and maintained both patents.  Both decisions are subject to potential appeals by Teva. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that we, our employees or our licensors have misappropriated their intellectual property, including trade secrets, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees and our licensor&#8217;s employees were previously employed at other biotechnology or pharmaceutical companies. Although we and our licensors try to ensure that our employees and our licensor&#8217;s employees do not use the proprietary information or know-how of others in their work for us, including by contract, we or our licensors may be subject to claims that these employees, our licensors or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may in the future be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensor fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we and our licensor are successful in prosecuting or defending against such claims, litigation could result in substantial costs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The validity, scope, and enforceability of any patents listed in the Orange Book that cover ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE Cream 0.05%, or ZORYVE foam can be challenged by competitors.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">One or more third parties may challenge the patents covering ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE foam, or ZORYVE cream 0.05%, which could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or a finding of non-infringement. For example, if a third-party files an ANDA for a generic drug bioequivalent to ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE cream 0.05%, or ZORYVE foam, and relies in whole or in part on studies conducted by or for us, the third-party will be required to certify to the FDA that either: (1)&#160;there is no patent information listed in the FDA&#8217;s Orange Book with respect to our NDA for the applicable approved drug candidate; (2)&#160;the patents listed in the Orange Book have expired; (3)&#160;the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4)&#160;the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third-party&#8217;s generic drug. A certification that the new drug will not infringe the Orange Book-listed patents for the applicable approved drug candidate, or that such patents are invalid, is called a paragraph&#160;IV certification. If the third-party submits a paragraph&#160;IV certification to the FDA, a notice of the paragraph&#160;IV certification must also be sent to us once the third-party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45&#160;days of receipt of the notice automatically prevents the FDA from approving the third-party&#8217;s ANDA until the earliest of 30&#160;months from the date of receipt of the notice or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third-party. If we do not file&#160;a patent infringement lawsuit within the required 45-day period, the third-party&#8217;s ANDA will not be subject to the 30-month stay of FDA Approval. Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with ZORYVE or our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 14, 2024, we received a Paragraph IV Notice Letter advising that Padagis had submitted an ANDA to the FDA seeking authorization to manufacture, use, sell, and import a generic version of ZORYVE 0.3% cream. On July 16, 2024, and September 12, 2024, we received additional Paragraph IV Notice Letters from Padagis. Padagis' Paragraph IV certifications stated that our patents listed in the Orange Book will not be infringed by Padagis&#8217; proposed product, are invalid, and/or are unenforceable. We filed suit against Padagis in the U.S. District Court for the District of Delaware on March 27, 2024, for infringement of certain of our patents and amended our complaint on July 19, 2024, to add additional patents to our infringement allegations. On August 2, 2024, Padagis responded to the first amended complaint, denying infringement and asserting counterclaims seeking a declaratory judgment that the asserted patents are not infringed, invalid, and/or unenforceable. The complaint triggered the automatic 30-month stay of FDA approval of the ANDA, expiring on August 14, 2026.  In March 2025, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Arcutis agreed to file a joint stipulation to stay the ongoing patent litigation with </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Padagis at the request of Padagi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">s.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 3, 2025, the court stayed the case and cancelled all case deadlines, including the trial. The 30-month stay of FDA approval will be extended for each day the stay in the case is in place, starting March 24, 2025, until the stay in the case is lifted. We plan to vigorously defend our extensive intellectual property rights in ZORYVE 0.3% cream as appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term of ZORYVE or our product candidates, our business may be materially harmed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial success will largely depend on our ability to obtain and maintain patent and other intellectual property in the United States and other countries with respect to our proprietary technology, ZORYVE, other product candidates, and our target indications. Our issued U.S. patents, with claims encompassing ZORYVE, directed to roflumilast formulations with reduced crystal growth and beneficial pharmacokinetic parameters and methods of treatment with a topical roflumilast formulation with an extended half-life and that decrease gastrointestinal side effects relative to oral roflumilast formulations are currently projected to expire in mid-2037. We also have a method of treatment patent specifically for roflumilast foam in the treatment of seborrheic dermatitis which is projected to expire 2041. We also have a composition patent that covers ZORYVE foam which is projected to expire in 2042. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after such candidates begin to be commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration, and specifics of FDA marketing approval of our product candidates, one or more of the U.S. patents covering our product candidates may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (or any additional indications approved during the period of extension). This extension is limited to only one patent that covers the approved product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and nonclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license additional intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional third parties, apart from our current licensors, may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of these third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms. Such a license may not be available, or it may not be available on commercially reasonable terms, in which case our business would be harmed. The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we in-license, and any failure by us or our licensors to obtain, maintain, defend, and enforce these rights could harm our business. In some cases we may not have control over the prosecution, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintenance, or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance, and defense process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend, and enforce the licensed patents.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, and defending patents on ZORYVE and product candidates, including all of the licensed rights under our exclusive supply and license agreements with AstraZeneca, in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries, including China and certain other developing countries, do not protect intellectual property rights, particularly those relating to biotechnology, to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States has enacted and implemented wide-ranging patent reform legislation, and that legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The U.S. Patent Office recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement, and defense of our patents and pending patent applications.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable,&#160;paid-up&#160;license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with&#160;&#8220;march-in&#160;rights.&#8221;&#160;March-in&#160;rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. Having a mandatory nonexclusive license grant may diminish the value of our patents as well as making it more difficult to protect our products.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, a new unitary patent system took effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unified Patent Court (UPC). As the UPC is a new court system, there is little precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits,&#160;non-payment&#160;of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering ZORYVE or any of our product candidates, our competitors might be able to enter the market earlier than anticipated, which would harm our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic, or conflict with third-party rights. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. In addition, third parties may file first for our trademarks in certain countries. If they succeeded in registering such trademarks, and if we were not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. In such cases, over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then our marketing abilities may be impacted.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require final regulatory approval of, and registered trademarks for, any commercial tradename and registered trademarks for a commercial trade name for our product candidates in the United States or foreign jurisdictions and failure to secure such approval in a timely fashion could adversely affect our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received Registrations and Notices of Allowance from the USPTO for commercial trade names for certain of our lead product candidates in the United States. We will be required to obtain similar approvals in certain foreign jurisdictions and will be required to undertake similar registrations with respect to any future product candidates. During trademark registration proceedings, we may receive rejections and may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. While we have received Notices of Allowance from the USPTO for commercial trade names for certain of our lead product candidates, we have not received final FDA Approval of such names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to protect our proprietary information and technology adequately. Although we use reasonable efforts to protect our proprietary information, technology, and know-how, our employees, consultants, contractors, outside scientific advisors, licensors, or licensees may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third-party illegally obtained and is using any of our proprietary information, technology or know-how is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect proprietary information, technology, and know-how. We rely, in part, on non-disclosure and confidentiality agreements with our employees, consultants and other parties to protect our proprietary information, technology, and know-how. These agreements may be breached and we may not have adequate remedies for any breach. Moreover, others may independently develop similar or equivalent proprietary information, and third parties may otherwise gain access to our proprietary knowledge.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under any license, collaboration, or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed or acquired certain intellectual property rights covering ZORYVE from AstraZeneca. We are heavily dependent on our agreements with such third parties for ZORYVE. If, for any reason, one or more of our agreements with such third parties is terminated or we otherwise lose those rights, it could harm our business. Our license and other agreements impose, and any future collaboration agreements or license agreements we enter into are likely to impose various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any such material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell products that are covered by the licensed technology, or having to negotiate new or reinstated licenses on less favorable terms, or enable a competitor to gain access to the licensed technology.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents, or other intellectual property or the patents of our licensors, which could be expensive and time-consuming.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to file infringement claims or inform and cooperate with our licensors to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly, or amended such that they do not cover ZORYVE or our product candidates. Moreover, such adverse determinations could put our patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope to cover ZORYVE or our product candidates or to prevent others from marketing similar products.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference, derivation, or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to our patent applications or those of our licensors or potential partners. Litigation or USPTO proceedings brought by us may fail or may be invoked against us by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs. We may not be able, alone or with our licensors or potential partners, to prevent misappropriation </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our and our licensors avoiding infringement and other violations of the patents and proprietary rights of third parties. However, our research, development, and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, inter partes review and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent was to be held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture, or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants, or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting&#160;know-how&#160;and inventions.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing, or otherwise commercializing our products, services, and technology. Any uncertainties resulting from the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business, results of operation, financial condition, or cash flows.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments, which could adversely impact the price of our common shares. If securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. The occurrence of any of these events may harm our business, results of operation, financial condition, or cash flows.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot provide any assurances that third-party patents do not exist which might be enforced against our drugs or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of our product candidates, we will be subject to extensive and ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals or other marketing authorizations we have or will obtain, including for ZORYVE or our product candidates that obtain approval in the future, may be subject to limitations on the indicated uses for which the product may be marketed or the conditions of approval or marketing authorization, or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS as a condition of approval of our products and product candidates, such as ZORYVE, and ARQ-234, which could include requirements for a medication guide, physician communication plans, or additional elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export, and recordkeeping for ZORYVE, and if approved, our other product candidates, will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with ZORYVE or our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">restrictions on the marketing or manufacturing of ZORYVE or our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">fines, warning letters, or untitled letters or holds on clinical trials;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">refusal by the FDA to accept new marketing applications or supplements, approve or otherwise authorize for marketing pending applications or supplements to applications filed by us or suspension or revocation of approvals or other marketing authorizations;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action, which would adversely affect our business, prospects, financial condition, and results of operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or policy changes could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current U.S. presidential administration has issued certain policies and executive orders directed toward reducing the employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA&#8217;s ability to conduct routine activities. If a government shutdown occurs, or if funding shortages, staffing limitations, or similar factors hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, such events could significantly impact the ability of the FDA or other such regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to health care laws and regulations relating to our business, and could face substantial penalties if we are determined not to have fully complied with such laws, which would have an adverse impact on our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, health care professionals, consultants, third-party payers, customers, and patients may expose us to broadly applicable fraud and abuse and other health care laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute any products for which we obtain marketing approval. Such laws include:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a U.S. health care program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the U.S. federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, health care benefits, items, or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the U.S. Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives) and teaching hospitals, the ownership and investment interests held by such physicians and their immediate family members;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows, or should know, it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">analogous state and non-U.S. laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales, and marketing arrangements and claims involving health care items or services reimbursed by non-governmental third-party payers, including private insurers; state laws that require pharmaceutical and device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. government, or otherwise restrict payments that may be made to health care providers and other potential referral sources; and state laws and regulations that require manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures and pricing information.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities may conclude that our business practices, including our consulting arrangements with and/or ownership interests by physicians and other health care providers, do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable health care laws. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. health care programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have conducted and may in the future conduct clinical trials for ZORYVE and our product candidates outside the United States and the FDA and applicable foreign regulatory authorities may not accept data from such trials.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted and may in the future choose to conduct one or more of our clinical trials outside the United States, including in Canada, the Caribbean, Australia and Europe. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the study was not otherwise subject to an IND, the FDA will not accept the data as support for an application for marketing approval unless the study was well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation and regulation may increase the difficulty and cost for us to commercialize ZORYVE and to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some non-U.S. jurisdictions, there have been, and we expect there will continue to be, a number of legislative, regulatory, and executive changes and proposed changes regarding the health care system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell ZORYVE or any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the ACA was enacted in the United States in 2010. The ACA substantially changed the way health care is financed by both governmental and private insurers and significantly affects the U.S. pharmaceutical industry. Among the provisions of the ACA of importance to ZORYVE and our potential product candidates are the following:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an annual, nondeductible fee payable by any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an extension of rebate liability from fee-for-service Medicaid utilization to include utilization by Medicaid managed care organizations;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expansion of the entities eligible for discounts under the Public Health Service 340B drug pricing program; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an independent payment advisory board that will submit recommendations to Congress to reduce Medicare spending if projected Medicare spending exceeds a specified growth rate.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. <br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate cap beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Most significantly, the Inflation Reduction Act (IRA) was enacted in 2022. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap (with resulting prices for the initial ten drugs first effective in 2026); imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2025); and replaces the Part D coverage gap discount program with a new discounting program (which began on January 1, 2025). The IRA permits the Secretary of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and for the subsequent 15 drugs, which will first be effective in 2027. Each year thereafter, more Part B and Part D products will become subject to the HHS price negotiation program. HHS has issued and will continue to issue guidance implementing the IRA, although the program is currently subject to legal challenges. While the impact of the IRA on us and the pharmaceutical industry is likely to be significant, the impact on us cannot be fully determined.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the IRA manufacturer discount program that replaced the coverage gap discount program as of January 1, 2025, manufacturers must give a 10% discount on Part D drugs in the initial coverage phase and a 20% discount on Part D drugs in the so-called &#8220;catastrophic phase&#8221; (the phase after the patient incurs costs above the initial phase out-of-pocket threshold, which is $2,000 beginning in 2025). The IRA allows the 10 and 20% discounts to be phased in over time for certain drugs for &#8220;specified manufacturers.&#8221; In April 2024, CMS informed us that we are deemed not eligible for the phase-in. We continue to evaluate the potential impact of this status on our future revenues.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program.  Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our ability to grow sales of ZORYVE or any other product candidate that we commercialize in the Medicaid market.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current administration is pursuing a twofold strategy to reduce drug costs in the United States.  While it is unclear whether and how current proposals will be implemented, the current administration's policies are likely to have a negative impact on the pharmaceutical industry and may have a negative impact on revenues for our products and affect our ability to invest in the clinical development of new products. On the one hand, the current administration is threatening to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the United States to the lowest price in a group of other countries.  In response, multiple manufacturers have entered into confidential pricing agreements with the federal government.  On the other hand, the current administration is pursuing traditional regulatory pathways to impose drug pricing policies and published two proposed regulations in December 2025, referred to as Globe and Guard. If finalized, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government on a portion of the units of their drugs that are reimbursed by Medicare, with the rebate amount based on most favored nation pricing. Imposing a rebate in the United States that is based on drug prices outside the United States would mark a drastic and unprecedented shift in the U.S. pharmaceutical market. While the impact of the Globe and Guard proposed regulations, if finalized, cannot yet be determined, it is likely to be significant.  Even regulatory proposals or executive actions that are ultimately deemed unlawful or not implemented could negatively impact the U.S. pharmaceutical sector and our business.  In addition, pharmaceutical pricing and marketing have long been the subject of considerable discussion in Congress and among policymakers, and it is possible that Congress could enact additional laws that negatively affect the pharmaceutical industry. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states in the United States have also enacted legislation and implementing regulations designed to control pharmaceutical product pricing, and additional states may do so.  Such measures include price or patient reimbursement constraints, mandatory discounts, reduced formulary flexibility, marketing cost disclosure, drug price increase reporting, and other transparency measures.  Some states have enacted legislation creating so-called prescription drug affordability boards, and at least one state is attempting to impose price limits through such a board.  Other states are also seeking to implement general, across-the-board price caps for pharmaceuticals, are seeking to regulate drug distribution, or are pursuing pathways to import drugs from Canada.  While we cannot predict with certainty the impact any federal or state health reform measures will have on us, such changes could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impose new or more stringent regulatory requirements on our activities, affect the prices we may obtain, increase our discount and rebate liability, or result in reduced reimbursement for ZORYVE or our product candidates, if approved, any of which could adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products to purchase and which suppliers will be included in their prescription drug and other health care programs.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that other health care reform measures that may be adopted in the future, may result in more rigorous coverage criteria, new payment methodologies, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to new requirements or policies, or if we are not able to maintain regulatory compliance, our product candidates be subject to enforcement action and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the Medicaid Drug Rebate Program (MDRP), and other federal and state government pricing programs in the United States, and we may participate in additional government pricing programs in the future. These programs generally require manufacturers to pay rebates or otherwise provide discounts to government payers in connection with drugs that are dispensed to beneficiaries of these programs. As a condition of having federal funds being made available for covered outpatient drugs under Medicaid and Medicare Part B, a manufacturer must enroll in the MDRP. Under this program, the manufacturer must pay a rebate to state Medicaid programs for each unit of a covered outpatient drug dispensed to a Medicaid beneficiary and paid for by a state Medicaid program. Medicaid drug rebates are based on pricing data that the manufacturer must report on a monthly and quarterly basis to CMS. For the MDRP, this data includes the average manufacturer price (AMP) for each drug and, in the case of an innovator product, the best price (BP). If a manufacturer becomes aware that its MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, the manufacturer must resubmit the corrected data for up to three years after the data originally was due. In addition, there is increased focus by the Office of Inspector General within the U.S. Department of Health and Human Services on the methodologies used by manufacturers to calculate AMP, and BP, to assess manufacturer compliance with MDRP reporting requirements. If a manufacturer fails to provide information timely or is found to have knowingly submitted false information to the government, the manufacturer may be subject to civil monetary penalties and other sanctions, including termination from the MDRP, which would result in payment not being available for its covered outpatient drugs under Medicaid or, if applicable, Medicare Part B. Failure to make necessary disclosures and/or to identify overpayments could result in allegations against a manufacturer under the Federal False Claims Act and other laws and regulations. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that a manufacturer that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program (the 340B program) in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. The 340B program is administered by the Health Resources and Services Administration (HRSA) and requires a participating manufacturer to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for its covered outpatient drugs used in an outpatient setting. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. Manufacturers must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B-eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if passed, would further expand the 340B </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to be eligible to have drug products paid for with federal funds under Medicaid and Medicare Part B and purchased by certain federal agencies and grantees, a manufacturer also must participate in the U.S. Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) pricing program. Under the VA/FSS program, the manufacturer must report the Non-Federal Average Manufacturer Price (Non-FAMP) for its covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). The manufacturer must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If a manufacturer fails to provide timely information or is found to have knowingly submitted false information, the manufacturer may be subject to civil monetary penalties.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states continue to consider and have enacted legislation to limit the growth of health care costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations are complex, vary among products and programs, and are often subject to interpretation by manufacturers, governmental or regulatory agencies, and the courts. The terms, scope and complexity of these government pricing programs change frequently, as do interpretations of applicable requirements for pricing and rebate calculations. Responding to current and future changes may increase our costs and the complexity of compliance will be time consuming. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial condition. Price recalculations under the MDRP also may affect the ceiling price at which we may be required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. In the event that CMS were to terminate a manufacturer&#8217;s Medicaid rebate agreement, no federal payments would be available under Medicaid or Medicare for its covered outpatient drugs. There can be no assurance that submissions we make will not be found to be incomplete or incorrect.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If ZORYVE or any of our product candidates that are approved for marketing are found to have been improperly promoted for off-label uses by us, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA and other foreign regulatory authorities strictly regulate the marketing of and promotional claims that are made about drug products. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other foreign regulatory authorities consistent with the product&#8217;s approved labeling. Any regulatory approval that the FDA or a foreign regulatory authority grants is limited to those specific diseases and indications for which a product is deemed to be safe and effective. For example, the FDA-approved label for ZORYVE cream 0.3% is limited to the topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older; the label for ZORYVE cream 0.15% is limited to the topical treatment of atopic dermatitis in patients 6 years of age and older; the label for ZORYVE cream 0.05% is limited to the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients 2 to 5 years of age;  and the label for ZORYVE foam 0.3% is limited to the treatment of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">seborrheic dermatitis in adult and pediatric patients 9 years of age and older and the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. We are not permitted to promote these products for any other uses, unless and until such uses are approved.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we believe ZORYVE and our product candidates may exhibit a lower risk of side effects or more favorable tolerability profile or better symptomatic improvement than other products for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indications we are studying, without head-to-head data, we will be unable to make comparative claims for ZORYVE or our product candidates, if approved. If we are found to have promoted ZORYVE or any of our product candidates, if approved, for off-label uses, we may become subject to significant liability, which would materially harm our business. Both federal and state governments have levied large civil and criminal fines against companies for alleged improper promotion and have enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our brand and reputation could be damaged. The FDA has also previously requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use or in a manner inconsistent with approved labeling, we could be subject to FDA regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine, or criminal penalties. It is also possible that other federal, state, or foreign enforcement authorities might take action if they determine our business activities constitute promotion of an off-label use or promotion inconsistent with the label, which could result in significant penalties, including criminal, civil or administrative penalties, damages, fines, disgorgement, exclusion from participation in government health care programs and the curtailment or restructuring of our operations.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot promote to or incentivize a physician on the use of ZORYVE outside of our approved indications. However, we cannot prevent a physician from using ZORYVE or our product candidates in ways that fall outside the scope of the approved indications, as he or she may deem appropriate in his or her independent medical judgment. Physicians and patients may also misuse ZORYVE or our product candidates or use improper techniques, which may lead to adverse results, side effects or injury and, potentially, subsequent product liability claims. Furthermore, the use of ZORYVE or our product candidates for indications other than those approved by the FDA and/or other regulatory authorities may not effectively treat such conditions, which could harm our brand and reputation among both physicians and patients.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional funds by issuing securities may cause dilution to existing stockholders, raising additional funds through debt financings may involve restrictive covenants, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our available cash and marketable securities balances, amounts available under the Loan Agreement and anticipated future cash flows from operations are insufficient to satisfy our liquidity requirements, we may need to fund our operations through the sale of our equity securities, accessing or incurring additional debt, entering into licensing or collaboration agreements with partners, grants, or other sources of financing. To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#8217; ownership may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that could harm the rights of a common stockholder. Additionally, any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. For example, our current Loan Agreement prohibits us from incurring certain additional indebtedness without the consent of our lender and restricts our ability to pay dividends. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we amended and restated our sales agreement, or Sales Agreement, with Cowen and Company, LLC, or Cowen, to reset the shares available for sale, from time to time, through our at-the-market equity offering program to such number of shares as would generate aggregate gross sales proceeds of up to $100.0 million. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Moreover, certain holders of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once registered, such shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of our outstanding warrant or options, or the perception that such sales may occur, could adversely affect the market price of our common stock.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and research and development income tax credit carryforwards may be limited. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. federal net operating loss (NOL) carryforwards generated in tax years beginning before January 1, 2018, may only be carried forward for 20 years under applicable U.S. tax law. Under current law, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change U.S. tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our NOL carryforwards generated in tax years beginning before January 1, 2018, may expire prior to being used, and the deductibility of certain of our NOL carryforwards generated in tax years beginning after December 31, 2017, will be subject to a limitation based upon the timing of ownership changes and the year of generation of the NOLs. In addition, we believe that we have had ownership changes in the past and may have additional ownership changes in the future. These ownership changes could limit our ability to use all of our NOL carryforwards, credit carryforwards, or other tax attributes. Similar provisions of state law also may apply to limit the use of our state net operating loss carryforwards or other tax attributes. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, in June 2024, California enacted Senate Bill 167 (SB 167), which, with certain exceptions, suspends the ability to use California net operating losses to offset California income and limits the ability to use California business tax credits to offset California taxes, for taxable years beginning after 2023 and before 2027. While SB 167 did not have a material impact on us in 2025, it is possible that it may in future years.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a classified board of directors with three year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability of our board of directors to alter our bylaws without obtaining stockholder approval;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the required approval of a super-majority of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the requirement that a special meeting of stockholders may be called only by the chief executive officer or the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the anti-takeover provisions contained in Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our restated certificate of incorporation, or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth and pay our loan. In addition, the terms of our Loan Agreement restrict our ability to pay dividends to limited circumstances. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Macroeconomic factors, including unfavorable or uncertain global and regional economic, political and health conditions, could adversely affect our business, financial condition or results of operations. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by global or regional economic, political and health conditions. For example, various macroeconomic factors could adversely affect our business, financial condition and results of operations, including changes in inflation, interest rates and overall economic conditions and uncertainties, including those resulting from political instability (including workforce uncertainty), political uncertainty (such as during transitional periods for new administrations and changes to leadership positions within government or national offices, agencies, and divisions), conflicts, trade disputes between nations and the current and future conditions in the global financial markets. For example, if inflation or other factors were to significantly increase our business costs, we may be unable to manage such increased expenses or pass through price increases to purchasers of our approved products. In addition, the imposition of tariffs and other orders or restrictions impacting trade could adversely impact our business, including by increasing or otherwise impacting the costs and expenses we incur in connection with our operations and supply chain, and by potentially increasing the price of our products to purchasers of our approved products. The actual impacts of any tariffs and other orders or restrictions are subject to a number of factors including the effective date and duration of such tariffs, orders and restrictions, the amount, scope and nature of such inputs, any countermeasures that the target countries may take and any mitigating actions that may become available. A global financial crisis or global or regional political and economic instability, wars, terrorism, civil unrest, outbreaks of disease, and other unexpected events, such as supply chain constraints or disruptions, could cause extreme volatility and disrupt our business. Business disruptions could include, among others, disruptions to our commercial activities, including due to supply chain or distribution constraints or challenges, clinical enrollment, clinical site availability, patient accessibility and conduct of our clinical trials, as well as temporary closures of our facilities and the facilities of suppliers or contract manufacturers in the biotechnology supply chain. In addition, during certain crises and events, patients may prioritize other items over certain or all of their treatments and/or medications, which could have a negative impact on our commercial sales. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A severe or prolonged economic downturn, political disruption or adverse health conditions could result in a variety of risks to our business, including our ability to raise capital when needed on acceptable terms, if at all. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The stock price of our common stock may be volatile or may decline.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">limited daily trading volume resulting in the lack of a liquid market;</span></div><div style="padding-left:9pt;text-indent:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the success of, and fluctuations in, the commercial sales of ZORYVE or any product candidates approved for commercialization in the future;</span></div><div style="padding-left:9pt;text-indent:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the development status of our product candidates, including whether we discontinue development or if any of our product candidates receive regulatory approval;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the performance of third parties on whom we rely for clinical trials, manufacturing, marketing, sales and distribution, including their ability to comply with regulatory requirements;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">regulatory, legal or political developments in the United States and foreign countries;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the results of our clinical trials and nonclinical studies;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the clinical results of our competitors or potential competitors;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the execution of our partnering and manufacturing arrangements;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our execution of collaboration, promotion, licensing or other arrangements, and the timing of payments we may make or receive under these arrangements;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">variations in the level of expenses related to our nonclinical and clinical development programs, including relating to the timing of invoices from, and other billing practices of, our CROs and clinical trial sites;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">variations in the level of expenses related to our commercialization activities for ZORYVE or any of our product candidates, if approved;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">overall performance of the equity markets;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">changes in operating performance and stock market valuations of other pharmaceutical companies;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">market conditions or trends in our industry or the economy as a whole, including as a result of market volatility related to global health concerns;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the public&#8217;s response to press releases or other public announcements by us or third parties, including our filings with the SEC, and announcements relating to acquisitions, strategic transactions, licenses, joint ventures, capital commitments, intellectual property, litigation or other disputes impacting us or our business;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">developments with respect to our intellectual property rights and in general;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our commencement of, or involvement in, actual or threatened litigation or other legal disputes, including intellectual property and other matters;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">FDA or foreign regulatory actions affecting us or our industry;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">changes in the structure of health care payment systems;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">changes in financial estimates by any securities analysts who follow our common stock, our failure to meet these estimates or failure of those analysts to initiate or maintain coverage of our common stock;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">ratings downgrades by any securities analysts who follow our common stock;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the development and sustainability of an active trading market for our common stock;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the size of our market float;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the expiration of market standoff or contractual lock-up agreements and future sales of our common stock by our officers, directors and significant stockholders;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">recruitment or departure of key personnel;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">changes in accounting principles;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">other events or factors, including those resulting from war, incidents of terrorism, natural disasters or responses to these events; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any other factors discussed in this report.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many pharmaceutical companies. Stock prices of many pharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were involved in securities litigation, we could incur substantial costs and our resources and the attention of management could be diverted from our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If only a limited number of securities or industry analysts commence coverage of us or the few analysts that have initiated coverage, drop coverage, the trading price for our stock would be negatively impacted. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop our current and any future product candidates, commercialize ZORYVE or our product candidates or otherwise implement our business plan.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive pharmaceuticals industry depends upon our ability to attract and retain highly qualified managerial, scientific, medical, sales and marketing, and other personnel. We are highly dependent on our management and scientific personnel, including our Chief Executive Officer, Todd Franklin Watanabe; our Chief Financial Officer, Latha Vairavan; our Chief Technical Officer, Bethany Dudek; our Chief Medical Officer, Patrick Burnett, M.D., Ph.D; and our Chief Commercial Officer, L. Todd Edwards. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of our product pipeline, completion of our planned clinical trials, commercialization of our products, or in-licensing or acquisition of new assets and could negatively impact our ability to successfully implement our business plan. If we lose the services of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ all of our executive officers and key personnel on an at-will basis and their employment can be terminated by us or them at any time, for any reason and without notice. In order to retain valuable employees at our company, in addition to salary and cash incentives, we provide stock options and restricted stock units (RSUs) that vest over time. The value to employees of stock options and RSUs that vest over time will be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract offers from other companies.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. We could have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts. Many of the other pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different risk profiles and longer histories in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will harm our ability to implement our business strategy and achieve our business objectives.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have scientific and clinical advisors who assist us in formulating our development and clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters and other facilities are located in the Northern Los Angeles Area, which in the past has experienced both severe earthquakes and wildfires. We do not carry earthquake insurance. Earthquakes, wildfires or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a natural disaster, power outage or other event occurred, including an epidemic, pandemic or contagious disease outbreak that disrupted operations, we may experience difficulties in operating our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our third-party manufacturers or suppliers are similarly vulnerable to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use, or other tax laws, statutes, rules, regulations, or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed, modified, or applied adversely to us. The current administration and Congress may propose various U.S. federal tax law changes, which, if enacted, could have a material impact on our business, cash flows, financial condition, or results of operations. Furthermore, it is uncertain if and to what extent various states will conform to federal tax laws. Future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense. For example, on July 4, 2025, the One Big Beautiful Bill Act was signed into law, which makes a number of changes to U.S. federal income tax law. The bill includes an estimated $1 trillion in cuts to Medicaid spending, implemented through Medicaid work requirements, patient cost-sharing, and a phasedown of Medicaid provider taxes and state-directed payments. Such reductions in Medicaid spending could result in lower revenue for life science companies. We are continuing to analyze the potential impact of the bill on our operations, business, and financial performance.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Organization for Economic Co-operation and Development (OECD) announced the OECD/G20 Inclusive Framework on Base Erosion and Profit Shifting (Framework), which agreed to a two-pillar solution to address tax challenges arising from digitalization of the economy. In December 2021, the OECD released Pillar Two Model Rules defining the global minimum tax rules, which contemplate a minimum tax rate of 15%. To date, various jurisdictions have enacted, or are in the process of enacting, legislation on these rules, and the OECD continues to release additional guidance. While it is uncertain whether the United States will enact legislation to adopt the minimum tax directive, certain countries in which we operate have adopted legislation to implement the minimum tax directive. Further, the OECD issued administrative guidance providing transition and safe harbor rules that could delay the impact of the minimum tax directive. While we continue to monitor the implementation of the Framework and its potential impact, we currently do not expect the Framework to have a material impact on us.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to additional tax liabilities</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, local, and foreign income taxes in the United States, withholding taxes and transaction taxes in foreign jurisdictions.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in evaluating our tax positions and our worldwide provision for taxes. During the ordinary course of business, there are many activities and transactions for which the ultimate tax determination is uncertain. We may be audited in various jurisdictions, and such jurisdictions may assess additional income, sales, and value-added or other taxes against us. Although we believe our tax estimates are reasonable, the final determination of any tax audits could</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be materially different from our historical tax provisions and accruals, which could have a material adverse effect on our operating results or cash flows in the period for which a determination is made.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future litigation could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Lawsuits and other administrative or legal proceedings, including intellectual property litigation or other legal proceedings relating to intellectual property claims, that may arise in the course of our operations can involve substantial costs, including the costs associated with investigation, litigation and possible settlement, judgment, penalty or fine. In addition, lawsuits and other legal proceedings may be time-consuming to defend or prosecute and may require a commitment of management and personnel resources that will be diverted from our normal business operations. Although we generally maintain insurance to mitigate certain costs, there can be no assurance that costs associated with lawsuits or other legal proceedings will not exceed the limits of insurance policies. Moreover, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may be unable to continue to maintain our existing insurance at a reasonable cost, if at all, or to secure additional coverage, which may result in costs associated with lawsuits and other legal proceedings being uninsured. Our business, financial condition and results of operations could be adversely affected if a judgment, settlement penalty or fine is not fully covered by insurance.</span></div><div id="i2dffe4de76224390b628083ec6a2857c_22"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.   UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2dffe4de76224390b628083ec6a2857c_25"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C.   CYBERSECURITY</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-37" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-38" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-39">Our cybersecurity risk management program is integrated into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas</ix:nonNumeric></ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-40"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key elements of our cybersecurity risk management program include, but are not limited to, the following:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity awareness training of our employees, including incident response personnel, and senior management; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-41">a third-party risk management process for key service providers based on our assessment of their criticality to our operations and respective risk profile, suppliers, and vendors;</ix:nonNumeric></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information, as well as risks of data leakage and unauthorized access to sensitive information; and</span></div><div style="margin-bottom:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing review of the controls framework to support the security of emerging technologies, including AI and generative AI (GenAI), ensuring alignment with evolving risks and regulatory expectations.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our and our third-party service providers&#8217;, strategic partners&#8217;, contractors&#8217;, consultants&#8217;, and collaborators&#8217; cybersecurity risk management program and processes, including policies, controls, or procedures, will be fully implemented, complied with, or effective in protecting our systems and information.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-42">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition</ix:nonNumeric>. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See Part I, Item 1A. Risk Factors: &#8220;We depend on our information technology systems, and any failure of these systems or those of our CROs or other contractors or consultants that we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations, financial condition, and prospects.&#8221;</span></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Governance</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-44" continuedAt="f-44-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-43" escape="true">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program.</ix:nonNumeric> Our Audit Committee Chair, Sue-Jean Lin, has expertise in both cybersecurity risk management and AI.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><ix:continuation id="f-44-1" continuedAt="f-44-2"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-45">The Audit Committee receives quarterly reports from our Chief Digital &amp; Technology Officer and internal security staff on developments in our information technology (IT) infrastructure and cybersecurity program. This includes updates, as appropriate, on key IT initiatives, new and existing cybersecurity risks, and how management is managing those risks. In addition, the Chief Digital &amp; Technology Officer updates the Audit Committee, where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant per our established severity and response framework.</ix:nonNumeric> </span></div></ix:continuation><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-47" escape="true"><ix:continuation id="f-44-2"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-46">The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program and an annual report from management on our cybersecurity risks.</ix:nonNumeric></ix:continuation></ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-49" continuedAt="f-49-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-48" continuedAt="f-48-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cyber<ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-50">security technology team</ix:nonNumeric>, led by the Vice President, Core Technology &amp; Security (VP CT&amp;S), is responsible for managing and directing day-to-day assessment and management of material risks from cybersecurity threats, including oversight of our cybersecurity tools, controls, and strategies to protect organizational assets, networks, and data. The VP CT&amp;S, who reports to our Chief Digital and Technology Officer, has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-51" escape="true">He is an ISACA certified security manager and has over 20 years of experience in IT, with over 10 years specifically focused on cybersecurity risk management.</ix:nonNumeric> </span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-52" escape="true"><ix:continuation id="f-49-1"><ix:continuation id="f-48-1"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our VP CT&amp;S takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public, or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our IT environment.</span></ix:continuation></ix:continuation></ix:nonNumeric><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div id="i2dffe4de76224390b628083ec6a2857c_28"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.   PROPERTIES</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located in Westlake Village, California, where we lease 22,643 square feet of office space. </span></div><div id="i2dffe4de76224390b628083ec6a2857c_31"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.   LEGAL PROCEEDINGS</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arcutis Biotherapeutics, Inc. filed a lawsuit against Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (collectively, Padagis) in the U.S. District Court for the District of Delaware on March 27, 2024, based on the submission to the FDA of an ANDA seeking approval to market and sell a generic version of Arcutis&#8217; ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.3% cream for the treatment of plaque psoriasis. The Company asserts infringement of the following eleven patents, which are listed in the FDA&#8217;s Orange Book for Arcutis&#8217; ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.3% cream: 9,884,050; 9,907,788; 10,940,142; 11,129,818; 11,793,796; 11,819,496; 11,992,480; 12,005,051; 12,005,052; 12,011,437; and 12,016,848 (collectively, Asserted Patents). Arcutis seeks a judgment that Padagis has infringed or will infringe one or more claims of each of the Asserted Patents and based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Padagis&#8217;s proposed generic product before expiration of each of the Asserted Patents found to be infringed. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, Arcutis agreed to file a joint stipulation to stay the ongoing patent litigation with </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Padagis at the request of Padagi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2025, the court stayed the case and cancelled all case deadlines, including the trial. The automatic 30-month stay of FDA approval of Padagis&#8217;s ANDA seeking approval for Arcutis&#8217;s ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.3% cream was set to expire on August 14, 2026. The 30-month stay will be extended for each day the stay is in place, starting March 24, 2025, until the stay is lifted.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Teva Pharmaceutical Industries Ltd. filed oppositions with the EPO against two of our European patents in the third quarter of 2024. After oral proceedings for each of the respective patents, the EPO panel found in favor of Arcutis and maintained both patents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may from time to time be involved in various legal proceedings of a character normally incident to the ordinary course of our business. We are not currently a defendant in any material litigation or other material legal proceedings.</span></div><div id="i2dffe4de76224390b628083ec6a2857c_34"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.   MINE SAFETY DISCLOSURES</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2dffe4de76224390b628083ec6a2857c_37"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">87</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.   MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information for Common Stock</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#8220;ARQT&#8221; since the commencement of our IPO on January 31, 2020. Prior to that time there was no public market for our common stock. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;20, 2026, there were approximately 56 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares the cumulative total return on an indexed basis of a $100 investment made at the beginning of the five-year period ended December 31, 2025, in the Company's common stock, the Nasdaq Composite Index (&#x5E;IXIC), and the Nasdaq Biotechnology Index (&#x5E;NBI). The cumulative total return reflects market prices at the end of each year and assumes reinvestment of gross dividends. The stock price performance shown in the graph represents past performance and should not be considered indicative of future stock price performance. This graph shall not be deemed &#8220;soliciting material&#8221; or deemed &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that Section, and shall not be deemed incorporated by reference into any of our filings under the Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><img src="arqt-20251231_g3.jpg" alt="2602" style="height:500px;margin-bottom:5pt;vertical-align:text-bottom;width:750px" id="i-3"/></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cumulative Total Return Comparison</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:39.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcutis Biotherapeutics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$73.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$52.61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$49.52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$103.23</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Composite Index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$121.39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$81.21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$116.47</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$149.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$180.33</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Biotechnology Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$99.37</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$88.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$91.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$119.92</span></td></tr></table></div><div id="i2dffe4de76224390b628083ec6a2857c_43"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. RESERVED</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">89</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with our audited financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. For a discussion of the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023, refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December&#160;31, 2024. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans, objectives, expectations, projections and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors identified below and those set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results and the timing of selected events could differ materially from the forward-looking statements contained in the following discussion and analysis. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div id="i2dffe4de76224390b628083ec6a2857c_49"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions. We believe we have built a leading platform for dermatologic product development and commercialization. Our strategy is to focus on validated biological targets, and to use our drug development platform and deep dermatology expertise to develop and commercialize differentiated products that have the potential to address the major shortcomings of existing therapies in our targeted indications. We believe this strategy uniquely positions us to rapidly advance our goal of bridging the treatment innovation gap in dermatology, while maximizing our probability of technical success and financial resources. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We launched our lead product, ZORYVE cream 0.3%, in August 2022 after obtaining our initial FDA approval for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas (e.g. groin or axillae), in individuals 12 years of age or older. ZORYVE cream 0.3% is a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. ZORYVE cream 0.3% is approved for once-daily topical treatment of mild, moderate, and severe plaque psoriasis with no limitations on location or duration of use. In October 2023, we received FDA approval for an expanded indication in plaque psoriasis down to 6 years of age. In November 2025, our supplemental New Drug Application (sNDA) was accepted for filing by the FDA to potentially expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026. In June 2023, we had our first commercial launch outside of the United States following Health Canada approval of ZORYVE cream 0.3% for the treatment of plaque psoriasis in individuals 12 years or age or older. In February 2026, Health Canada accepted our Supplement to a New Drug Submission (SNDS) for ZORYVE cream 0.3% for individuals down to 2 years old.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, we received FDA approval for ZORYVE foam 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on severity, location, or duration of use. ZORYVE foam is a once-daily steroid-free foam and, as a PDE4 inhibitor, was the first drug approved for the treatment of seborrheic dermatitis with a new mechanism of action in over two decades. ZORYVE foam became commercially available in the United States in January 2024 and became commercially available in Canada in December 2024 following approval by Health Canada. We received FDA approval for ZORYVE foam for the treatment of plaque psoriasis of the scalp and body in adults and adolescents ages 12 and older in May 2025, followed by commercial launch in the United States in June 2025.  ZORYVE foam for the treatment of plaque psoriasis of the scalp and body in adults and adolescents ages 12 and older was also approved by Health Canada in October 2025, followed by commercial launch in November 2025. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also received FDA approval for, and commercially launched, ZORYVE cream 0.15% in July 2024 for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older, with no limitation on location, body surface area treated, concomitant use, or duration of use specified in the approved labelling. ZORYVE cream 0.15% was also approved by Health Canada in March 2025 and commercially launched in April 2025. We also received FDA approval for, and commercially launched, ZORYVE cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age in October 2025. ZORYVE cream 0.15% and ZORYVE cream 0.05% are once-daily, steroid-free creams that provide rapid disease clearance and significant reduction in itch, and have been specifically developed to be treatment options for long-term disease control. In February 2026, we announced positive topline data for INTEGUMENT-INFANT, a Phase 2 study to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluate the safety and efficacy of investigational ZORYVE cream 0.05% in infants as young as 3 months to less than 2 years with atopic dermatitis. We intend to submit an sNDA to the FDA in the second quarter of 2026 based on the results of this trial to potentially expand the indication for ZORYVE cream 0.05% for the treatment of infants with atopic dermatitis down to the age of 3 months. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, we entered into a promotion agreement with Kowa Pharmaceuticals America, Inc. (Kowa) to leverage Kowa's primary care sales force to exclusively market and promote ZORYVE in the United States to primary care practitioners and pediatricians for all FDA-approved indications until at least July 2029. Under the terms of the agreement, Kowa will receive a commission from net sales attributed to Kowa. Promotion of ZORYVE in primary care and pediatrics under the Kowa agreement began in late September 2024. Effective January 23, 2026, we mutually agreed to terminate the promotion agreement. Following this termination, Kowa ceased all sales and promotions of ZORYVE and we will not be required to make any further payments to Kowa.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2023, we entered into a strategic collaboration and licensing agreement (the Huadong Agreement) for topical roflumilast in Greater China and Southeast Asia with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong). a wholly owned subsidiary of Huadong Medicine Co., Ltd. In February 2024, we entered into a a strategic collaboration and licensing agreement (the Sato Agreement) for topical roflumilast in Japan with Sato Pharmaceutical Co., Ltd.(Sato).</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we acquired Ducentis BioTherapeutics LTD (Ducentis) and its lead asset, DS-234 (now ARQ-234), a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 Receptor (CD200R). We plan to develop ARQ-234 in atopic dermatitis, where we believe it could be a highly complementary biologic treatment option to ZORYVE cream 0.15% in that indication, if approved. ARQ-234 could potentially be used to treat other inflammatory conditions as well. We submitted an Investigational New Drug application (IND) to the FDA in July 2025, and anticipate commencing a Phase 1 study of ARQ-234 in the first quarter of 2026.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we executed a licensing agreement with AstraZeneca AB (AstraZeneca) for exclusive worldwide rights to roflumilast as a topical product in humans solely for dermatological indications. Moreover, we have our own intellectual property portfolio around topical uses of roflumilast, with issued and pending formulation, pharmacokinetic, and method-of-use patents in the United States and other jurisdictions from several distinct patent families, which provides us with exclusivity in the United States for our product cream formulation through 2037 and foam formulation through 2042. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred annual net losses in each year since inception, including net losses of $16.1 million, $140.0 million and $262.1 million for the years ended December 31, 2025, 2024 and 2023, respectively. As of December&#160;31, 2025, we had an accumulated deficit of $1,138.1 million and cash, cash equivalents, restricted cash and marketable securities of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$221.3 million. As of December 31, 2025, we had $100.0&#160;million outstanding under the Loan Agreement. We paid down $100.0 million of principal related to the Loan Agreement using available cash in October 2024, with the right to re-draw that principal for a defined period. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The extent of any net income or losses for future periods is uncertain and we may continue to incur net losses in future periods. We expect to continue to incur significant expenses as we commercialize ZORYVE, and as we advance our product candidates and label extensions through clinical trials, regulatory submissions and commercialization. We expect to incur commercialization expenses related to the sales, marketing, manufacturing, and distribution of ZORYVE, while we focus our clinical development spend on ARQ-234 and ZORYVE label expansions. While we do not anticipate the need to obtain funds through financings or other sources to support our current planned operations, if our available cash and marketable securities balances and anticipated future cash flows from operations are insufficient to cover these expenses, we may need to fund our operations through equity or debt financings or other sources, such as future potential collaboration agreements. Adequate funding may not be available to us on acceptable terms, or at all. Any failure to obtain sufficient funds on acceptable terms if or when needed could have a material adverse effect on our business, results of operations, and financial condition. </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">91</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, in conjunction with the launch of our first FDA-approved product, we began to recognize revenue from product sales, net of deductions. Below are the time periods that we began to recognize product revenue, net of deductions, related to the launches of each of our products and indications:</span></div><div style="margin-top:8pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:20.283%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.837%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.749%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product/Indication</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Concentration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr style="height:16pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zoryve cream for Plaque Psoriasis</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 12 yrs</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 12 yrs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-11 yrs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zoryve foam for Seborrheic Dermatitis</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 9 yrs</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 9 yrs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zoryve cream for Atopic Dermatitis</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 6 yrs</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 6 yrs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 yrs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zoryve foam for Scalp &amp; Body Psoriasis</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 12 yrs</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 12 yrs</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November</span></div></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue recognized to date is derived primarily from upfront license fees and milestone payments received pursuant to the Sato Agreement and Huadong Agreement. We expect that any other revenue we generate pursuant to these agreements will fluctuate from period to period as a result of the timing of potential milestone achievement and any potential regulatory approvals within the respective Sato Territory and Huadong Territory.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes direct and indirect costs related to the manufacturing and distribution of ZORYVE, including raw materials, third-party manufacturing costs, packaging services, and freight-in, as well as royalties payable on our net product sales and amortization of intangible assets associated with ZORYVE. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the date on which the initial regulatory approval was received for each product, costs of inventory production were recorded as research and development expense. As of December&#160;31, 2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and December&#160;31, 2024, the value of this expensed inventory, mostly at the raw materials stage, was approximately $2.6 million and $5.5&#160;million, respectively. Subsequent to initial regulatory approval, costs of production are capitalized into inventory, and as that inventory is sold and revenue is recognized, the cost of the inventory is recognized in cost of sales. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have focused significant resources on our research and development activities, including conducting nonclinical studies and clinical trials, manufacturing development efforts, activities related to regulatory filings for our product candidates, and medical affairs activities related to ZORYVE. Research and development costs are expensed as incurred. These costs include direct program expenses, which are payments made to third parties that specifically relate to our research and development, such as payments to clinical research organizations, clinical investigators, manufacturing of clinical material, nonclinical testing and consultants. In addition, employee costs, including salaries, payroll taxes, benefits, stock-based compensation and travel, for employees contributing to research and development activities are classified as research and development costs. We allocate direct external costs on a program specific basis, such as the topical roflumilast program. Our internal costs are primarily related to personnel or professional services and apply across programs, and thus are not allocable on a program specific basis.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur research and development expenses in the future as we develop our product candidates. In particular, we expect to incur research and development expenses for the development of ARQ-234 for atopic dermatitis and for ZORYVE label expansions and life cycle management.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered, and may continue to enter, into in-license agreements to access and utilize certain molecules for the treatment of dermatological diseases and disorders. We evaluate if the in-license agreement is an acquisition of an asset or a business. To date, none of our license agreements have been considered to be an acquisition of a business. For asset acquisitions, the upfront payments, as well as any milestone payments made before regulatory approval, are immediately recognized as research and development expense, provided there is no alternative future use of the rights in other research and development projects.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing, or costs required to complete the remaining development of ZORYVE cream and ZORYVE foam, ARQ-234, or any other product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates. See &#8220;Risk Factors&#8221; for a discussion of the risks and uncertainties associated with the development of our product candidates.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist primarily of salaries and related costs, including payroll taxes, benefits, stock-based compensation, and travel, for sales, commercial operations, human resources, information technology, and finance employees. Other selling, general and administrative expenses include costs related to sales and marketing of ZORYVE; commission paid to Kowa under our promotion agreement; professional services costs for patent protection, accounting, auditing, tax, and general legal services; other outside services and consulting costs; information technology; and other overhead. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash, cash equivalents, and marketable securities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense is related to interest incurred on our debt.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes is primarily related to foreign income tax expense, foreign withholding taxes incurred in relation payments received pursuant to our in-license agreements and state income tax expense related to jurisdictions with minimum taxes or taxes based on revenue. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">93</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2025 and 2024</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.3%</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE foam</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.15%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.05%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,530&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Not applicable</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net, for ZORYVE cream 0.3% increased by $35.9 million for the year ended December 31, 2025 compared to the year ended December 31, 2024, primarily driven by greater patient demand in the United States and Canada.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net, for ZORYVE foam increased by $110.4 million for the year ended December 31, 2025 compared to the year ended December 31, 2024, primarily driven by greater patient demand for seborrheic dermatitis in the United States, the commercial launch of ZORYVE foam for plaque psoriasis of the scalp and body in the United States in June 2025, as well as the commercial launch of ZORYVE foam for seborrheic dermatitis in Canada in December 2024.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net, for ZORYVE cream 0.15% increased by $58.4 million for the year ended December 31, 2025 compared to the year ended December 31, 2024, primarily driven by its commercial launch in the United States in July 2024.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net, for ZORYVE cream 0.05% increased by $0.9 million for the year ended December 31, 2025 due to its commercial launch in the United States in October 2025.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue in the year ended December 31, 2025 is a result of milestone payments earned and received in connection with the Huadong License and Collaboration Agreement of $4.0 million. Other revenue for the year ended December 31, 2024 is a result of license revenues received in connection with the Sato License Agreement of $25.0 million and the Huadong License and Collaboration Agreement of $5.0 million. See Note 7 to the consolidated financial statements for additional information.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased by $17.6 million for the year ended December 31, 2025 compared to the year ended December 31, 2024, and was due to the increase in cost of products sold consistent with the growth in ZORYVE cream and foam product revenue and related increase in royalty expense, coupled by a $2.7 million  increase in amortization expense recorded in connection with the AstraZeneca milestones achieved in the first quarter of 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct external costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Topical roflumilast program</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topical JAK inhibitor program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other early stage programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and personnel-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased slightly by $0.6&#160;million, or 1%, for the year ended December 31, 2025 compared to the year ended December 31, 2024. The increase in the topical roflumilast direct program costs was primarily due to expenses related to the Phase 2 study of ZORYVE cream 0.05% for the treatment of atopic dermatitis in infants and the 2024 comparative period included reductions in expense as a result of the close-out of certain clinical studies. The decrease in the topical JAK inhibitor direct program costs resulted from the completion of a Phase 1b study in our ARQ-255 program for the treatment of alopecia areata. Lower direct costs associated with our other early stage programs was primarily due to a reduction in ARQ-234 preclinical costs and clinical manufacturing in 2025, as compared to 2024, ahead of the anticipated initiation of our Phase 1 study of ARQ-234 in the first quarter of 2026.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development expenses to increase in 2026, primarily due to our clinical development program for ARQ-234, as well as the development costs associated with ZORYVE label expansions and life cycle management efforts.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $45.2&#160;million for the year ended December 31, 2025 compared to the year ended December 31, 2024. The increase was primarily due to an increase in sales and marketing expenses of $30.8&#160;million and an increase in compensation and personnel related expenses of $13.3&#160;million. These increases were primarily due to our continued commercialization efforts for ZORYVE.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our selling, general and administrative expenses to increase in future periods as we continue to commercialize ZORYVE and potentially other product candidates, as well as support our operations. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased by $7.2&#160;million for the year ended December 31, 2025 compared to the year ended December 31, 2024, primarily due to lower cash, cash equivalents, and marketable securities balances, coupled with the impact of lower investment yields resulting from reductions in market interest rates. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased by $15.1&#160;million for the year ended December 31, 2025 compared to the year ended December 31, 2024, due to a lower outstanding principal balance on our long-term debt driven by our $100.0 million principal paydown in October 2024, coupled with the impact of lower interest rates. See Note 9 to the consolidated financial statements for additional information.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense continues to not be material, as we remain in a loss position for the year ended December 31, 2025. The income tax expense for the periods presented primarily related to withholding taxes on payments received in connection with the Huadong License and Collaboration Agreement and tax on the income earned in Canada. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">95</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity, Capital Resources and Requirements</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of capital to date have been private placements of preferred stock, our IPO completed in January 2020, our follow-on financings in October 2020, February 2021, August 2022, October 2023, and March 2024, our Loan Agreement, our ATM program, and revenue from the sale of ZORYVE products. We have incurred annual operating losses since our inception and have an accumulated deficit as a result of ongoing efforts to develop and commercialize our products and product candidates, including conducting nonclinical and clinical trials and providing selling, general and administrative support for these operations. As of December&#160;31, 2025 and 2024, we had cash, cash equivalents, restricted cash, and marketable securities of $221.3 million and $228.6 million, respectively, and an accumulated deficit of $1,138.1 million and $1,121.9 million, respectively. We maintain cash balances with financial institutions in excess of insured limits. As of December&#160;31, 2025, we had $100.0&#160;million outstanding under the Loan Agreement. We paid down $100.0 million of principal related to the Loan Agreement using available cash in October 2024, with the right to re-draw that principal for a defined period.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources will be sufficient to meet the projected operating requirements for at least 12 months from the date of issuance of our financial statements.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to satisfy our requirements, we may need to fund our operations through the sale of our equity securities, accessing or incurring additional debt, entering into licensing or collaboration agreements with partners, grants, or other sources of financing. There can be no assurance that sufficient funds will be available to us at all or on attractive terms when needed from these sources. If we are unable to obtain additional funding from these or other sources if or when needed it may be necessary to significantly reduce our current rate of spending through, among other things, reductions in staff and delaying, scaling back, or stopping certain research and development programs, nonclinical studies, clinical trials or other development activities, and commercialization efforts. In addition, market conditions impacting financial institutions could impact our ability to access some or all of our cash, cash equivalents and marketable securities, and we may be unable to obtain alternative funding when and as needed on acceptable terms, if at all. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our projected operating requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Any future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing, receipt, and amount of sales of any current and future products;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the scope, progress, results, and costs of researching and developing our product candidates or any future product candidates, and conducting nonclinical studies and clinical trials, in particular our planned or ongoing development activities and our formulation and nonclinical efforts;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">suspensions or delays in the enrollment or changes to the number of subjects we decide to enroll in our ongoing clinical trials; </span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the number and scope of clinical programs we decide to pursue, and the number and characteristics of any product candidates we develop or acquire;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing of, and the costs involved in, obtaining regulatory approvals for any future product candidates;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the number and characteristics of any additional product candidates we develop or acquire;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the cost of manufacturing ZORYVE or any future product candidates and any products we successfully commercialize, including costs associated with building out our supply chain;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the cost of commercialization activities for ZORYVE or any future product candidates that are approved for sale, including marketing, sales and distribution costs, and any discounts or rebates to obtain access;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to acquire attractive assets or businesses or to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs related to milestone payments to AstraZeneca or any future collaborator or licensing partner, upon the achievement of predetermined milestones;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any product liability or other lawsuits related to our products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the expenses needed to attract and retain skilled personnel;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any disputes, lawsuits, or other legal proceedings related to contracts or employment matters;</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing our intellectual property portfolio; and</span></div><div style="margin-top:8pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">costs associated with any adverse market conditions or other macroeconomic factors. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2021, we entered into a loan and security agreement (the Prior Loan Agreement) with SLR and the lenders party thereto. The Prior Loan Agreement was amended and restated on January 10, 2023 (the AR Loan Agreement) to include Arcutis Canada, Inc., a corporation incorporated under the laws of the Province of Ontario, as a borrower and party. On November 1, 2023, we entered into an amendment to the AR Loan Agreement to, among others, (i) modify the financial covenant relating to minimum net product revenue, and (ii) include an additional minimum financing covenant. On August 9, 2024, we entered into a second amendment to the AR Loan Agreement (the AR Loan Agreement, as amended by the first and second amendments, the Loan Agreement) to, among others, (i) permit, during the period commencing on October 7, 2024 and ending on December 15, 2024, an optional partial prepayment of term loans outstanding, subject to a 1.0% prepayment penalty (the 2024 Partial Prepayment), (ii) add the tranche C-1 and tranche C-2 term loans, and (iii) facilitate certain other changes, including with respect to the applicable interest rate and maturity date in the event of a 2024 Partial Prepayment. The term loan facility is comprised of (i) a tranche A term loan of $75.0 million, (ii) a tranche B-1 term loan of $50.0 million, (iii) a tranche B-2 term loan of up to $75.0 million, (iv) a tranche C-1 term loan of up to $50.0 million, and (v) a tranche C-2 term loan of up to $50.0 million (collectively, the Term Loans). The tranche A term loan was funded in December 2021. With the approval of ZORYVE cream 0.3% on July 29, 2022, the tranche B term loans were funded in August 2022. As of December&#160;31, 2025 and 2024, the aggregate principal amount outstanding under the Loan Agreement was $100.0 million.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we made a 2024 Partial Prepayment of $100.0 million, which reduced the aggregate principal amount outstanding under the Loan Agreement to $100.0 million. In connection with the 2024 Partial Prepayment, we are obligated to pay a prepayment penalty of $1.0 million by June 30, 2026 and a final fee of $6.95 million, representing the final fee applicable to the amount of the 2024 Partial Prepayment, on January 1, 2027. As a result of such 2024 Partial Prepayment, subject to us generating a minimum net product revenue for the trailing six (6) month period ending as of the month prior to the borrowing date equal to 80% of our projected net product revenue as set forth in its annual plan for the respective period, we will be able to draw down the tranche C-1 and tranche C-2 term loans. The tranche C-1 term loan availability will expire on March 31, 2026 and the tranche C-2 term loan availability will expire on June 30, 2026. In addition, as a result of the 2024 Partial Prepayment, (i) the maturity date of the Loan Agreement is August 1, 2029 (such date, the Maturity Date), (ii) the applicable per annum interest rate is equal to 5.95% plus the greater of (a) 2.50% per annum and (b) the one-month Secured Overnight Financing Rate (SOFR), (iii) we are no longer subject to certain cost and purchase price restrictions regarding acquisitions, and (iv) we may prepay principal amounts outstanding under the Term Loans in minimum increments of $25.0 million, subject to a prepayment premium of (a) 3.0% for any prepayment made prior to the first anniversary of the second amendment, (b) 2.0% for any prepayment made prior after the first anniversary of the second amendment and prior to the second anniversary of the second amendment, or (c) 1.0% for any prepayment made prior after the second anniversary of the second amendment and prior to the Maturity Date.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts outstanding under the Term Loans will generally accrue interest at a floating rate equal to the applicable rate in effect from time to time, as determined by SLR on the third business day prior to the funding date of the applicable Term Loan and on the first business day of the month prior to each payment date of each Term Loan. Prior to the 2024 Partial Prepayment, the applicable rate was a per annum interest rate equal to 7.45% plus the greater of (a) 0.10% and (b) the one-month SOFR. As a result of such 2024 Partial Prepayment, the applicable interest rate will be a per annum interest rate equal to 5.95% plus the greater of (a) 2.50% and (b) the one-month SOFR. On December&#160;31, 2025, the rate was 9.79%. The benchmark SOFR is subject to change in the event of certain events with respect to the benchmark rate. Interest payments are payable monthly following the funding of any Term Loan. Any principal amounts outstanding under the Term Loans, if not repaid or prepaid, are due and payable on August 1, 2029. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As security for the obligations under the Loan Agreement, we granted SLR, for the benefit of the lenders, a continuing security interest in substantially all of our assets, including our intellectual property, subject to certain exceptions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Term Loans are accelerated due to, among others, the occurrence of a bankruptcy or insolvency event, we are required to make certain mandatory prepayments of (i) all principal amounts outstanding under the Term Loans, plus accrued and unpaid interest thereon through the prepayment date, (ii) any fees applicable by reason of such prepayment, (iii) the prepayment premiums set forth in the paragraph above, plus (iv) all other obligations that are due and payable, including expenses and interest at the Default Rate (as defined below) with respect to any past due amounts.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We also agreed to a financial covenant whereby we must generate a minimum net product revenue equal to 75% of our projected net product revenue as set forth in our annual plan for the respective period, tested on a trailing six-month basis as of the end of each month. Each annual plan shall be approved by our board of directors and SLR, in its capacity as collateral agent, in its reasonable discretion. Any failure by us to deliver such annual plan on or before December 15 of the prior year shall be an immediate event of default.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Loan Agreement contains customary events of default that entitle the lenders to cause any indebtedness under the Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the Term Loans. Upon the occurrence and for the duration of an event of default, an additional default interest rate (the Default Rate) equal to 4.0% per annum will apply to all obligations owed under the Loan Agreement.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Loan Agreement, we are obligated to pay (i) a final fee equal to 6.95% of the aggregate original principal amount of the Term Loans outstanding as of the date of the second amendment, (x) with respect to any 2024 Partial Prepayment, upon the earliest to occur of (A) January 1, 2027, (B) the acceleration of all outstanding Term Loans and (C) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, and (y) with respect to the Term Loans outstanding as of the date of the second amendment (other than 2024 Partial Prepayment), upon the earliest to occur of (A) the Maturity Date, (B) the acceleration of all outstanding Term Loans and (C) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, (ii) a 2.00% fee with respect to tranche C term loans, due and payable on the earliest to occur of (A) the Maturity Date, (B) the acceleration of all outstanding Term Loans and (C) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, (iii) a 2.00% extension fee with respect to tranche C term loans which remain unfunded after December 31, 2025, which shall accrue during the period commencing January 1, 2026, and ending on the earliest to occur of (A) the expiration of the tranche C term loan availability, and (B) the date on which tranche C term loan is fully drawn, and (iv) a certain amount of lenders&#8217; expenses incurred in connection with the execution of the Loan Agreement. Additionally, in connection with the original Prior Loan Agreement, we previously had entered into an Exit Fee Agreement, whereby we agreed to pay an exit fee in the amount of 3.0% of each Term Loan funded upon (i) any change of control transaction or (ii) a revenue milestone, calculated on a trailing six-month basis. Notwithstanding the prepayment or termination of the Term Loan, the exit fee will expire 10 years from the date of the Loan Agreement.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were in compliance with all covenants under the Loan Agreement as of December&#160;31, 2025.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our cash flows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:67.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.195%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in) investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,737)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,371)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, net cash used in operating activities was $5.6 million, which consisted of a net loss of $16.1 million and a change in net operating assets and liabilities of $34.8 million, partially offset by net non-cash and other charges of $45.3 million. The change in net operating assets and liabilities was primarily due to an increase in accounts receivable of $73.2 million driven by higher sales, coupled with a $7.3 million increase in inventories to support higher unit demand, partially offset by a $50.0 million increase in accrued liabilities driven by higher accrued sales deductions associated with higher sales volume. The net non-cash and other charges were primarily related to stock-based compensation expense of $40.4 million.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, net cash used in operating activities was $112.2 million, which consisted of a net loss of $140.0 million and a change in net operating assets and liabilities of $15.1 million, partially offset by net non-cash and other charges of $43.0 million. The change in net operating assets and liabilities was primarily due to an increase in accounts receivable of $47.3 million, offset by an increase in accounts payable and accrued liabilities of $34.3 million. The net non-cash and other charges were primarily related to stock-based compensation expense of $41.7 million.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by (Used in) Investing Activities</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, net cash used in investing activities was $30.3 million, which was comprised primarily of purchases of marketable securities of $247.0 million, coupled with a milestone payment made to AstraZeneca of $10.0 million, partially offset by the proceeds from the maturities of marketable securities of $227.4 million.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, net cash provided by investing activities was $28.8 million, which was comprised primarily of the proceeds from the maturities of marketable securities of $288.8 million, partially offset by purchases of marketable securities of $254.8 million, as well as a milestone payment made to AstraZeneca of $5.0 million.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, net cash provided by financing activities was $7.0 million, which was comprised of net proceeds from employee stock award transactions. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, net cash provided by financing activities was $66.2 million, which was comprised primarily of the net cash proceeds received from our 2024 public stock offering of $161.7 million, offset by the 2024 Partial Prepayment of our long-term debt of $100.0 million. </span></div><div id="i2dffe4de76224390b628083ec6a2857c_61"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Contingent Liabilities</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our significant contractual obligations as of December&#160;31, 2025:</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Facility Operating Lease</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a facility in Westlake Village, California under an operating lease that commenced in February 2019 and was amended in April 2020 in order to relocate to a new expanded space. In August 2025, we entered into a second amendment to extend the term of the lease by five years, extending the lease expiration from August 2028 to July 2033. The total commitment under the operating lease agreement, as amended, is $8.1&#160;million, including $0.8&#160;million for 2026, $0.5&#160;million for the year 2027, $0.9&#160;million for the year 2028, $1.3&#160;million for the year 2029, and $1.3&#160;million for the year 2030. See Note 8 to the consolidated financial statements for additional information.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt Obligations </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had $100.0 million outstanding under our Loan Agreement. The undiscounted future payments of principal and interest under the Loan Agreement as of December&#160;31, 2025 is $156.4&#160;million, including $12.9&#160;million for the year 2026, $18.3&#160;million for the year 2027, $11.5&#160;million for the year 2028, and $113.7&#160;million for the year 2029. See Note 9 to the consolidated financial statements for additional information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements &amp; Ducentis Acquisition</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of our in-license agreements and our acquisition of Ducentis require us to pay potential future payments based on product development and commercial success. The amount and timing of such payments are unknown or uncertain. These</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> potential obligations are further described in Note 7 to the consolidated financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Agreements</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into manufacturing supply agreements for the commercial supply of ZORYVE, which include certain minimum purchase commitments.  As of December 31, 2025, firm future purchase commitments that are subject to these agreements with a term of greater than one year, excluding those recognized on the consolidated balance sheets, are $1.7&#160;million in 2026 and $0.9&#160;million in 2027, respectively. These future purchase commitments do not represent all of our anticipated purchases, but instead represents only the contractually obligated minimum purchases or firm commitments of non-cancelable minimum amounts.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future, but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our certificate of incorporation and bylaws, we have indemnification obligations to our officers and directors for specified events or occurrences, subject to some limits, while they are serving at our request in such capacities. There have been no claims to date, and we have director and officer insurance that may enable us to recover a portion of any amounts paid for future potential claims.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are more fully described in the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following are critical to the process of making significant judgments and estimates in the preparation of our consolidated financial statements and understanding and evaluating our reported financial results.</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Accrued Research and Development Expenses</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record prepaid expenses and accrued liabilities for estimated research and development activities conducted by third-party service providers, which include the conduct of nonclinical studies, clinical studies, clinical trials and contract manufacturing activities. These costs are a significant component of our research and development expenses. Research and development costs are expensed as incurred unless there is an alternative future use in other research and development projects. We accrue for these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are recorded as prepaid expenses until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. Additionally, if expectations change such that we do not expect goods to be delivered or services to be rendered, such prepayments are charged to expense. Our objective is to reflect the appropriate expense in our consolidated financial statements by matching those costs with the period in which the services and efforts are expended. We account for these expenses according to the progress of the trial as measured by underlying activity, such as patient progression, and the timing of various aspects of the trial utilizing financial models taking into consideration discussions with applicable personnel and outside service providers. In this manner, our clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from CROs, contract manufacturers and other third-party vendors. Although we expect our estimates to be materially consistent with actual amounts incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in our reporting changes in estimates in any particular period. We make significant judgments and estimates in determining the prepaid expense and accrued liabilities balance in each reporting period. As actual costs become known, we adjust the relevant balances. We have not experienced any material differences between our estimates as of December&#160;31, 2025 and 2024 and actual costs incurred.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue, Net</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606), we recognize revenue when a customer obtains control of promised goods or services. We record the amount of revenue that reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We only apply the five-step model to contracts when it is probable that it will collect the consideration to which we are entitled in exchange for the goods or services that we transfer to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our product to our customers in the United States and Canada. Our customers subsequently resell the products to pharmacies, health care providers, and patients. In accordance with ASC 606, we recognize net product revenue from sales when the customers obtain control of our products, which typically occurs upon delivery to the Customer. Our payment terms are generally between 30 - 65 days.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales are recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution service fees, (b) government and private payer rebates, chargebacks, discounts and fees, (c) product returns and (d) costs of co-pay assistance programs for patients, as well as other sales deductions. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to trade receivables, net if payable to a customer or accrued liabilities if payable to a third-party. Where appropriate, we utilize the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is recognized as product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Service Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We engage with wholesalers and specialty pharmacies to distribute our products to end customers. We pay the wholesalers and certain specialty pharmacies a fee for services such as: data reporting, inventory management, chargeback administration, and service level commitment. We estimate the amount of distribution services fees to be paid to the customers and adjust the transaction price with the amount of such estimate at the time of sale to the customer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Pay Discounts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We provide our customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. We estimate the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from its gross product revenue and accounts receivable at the time such revenue is recognized.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We provide customers a credit for all products returned in accordance with our returned goods policy. Once the product is returned, it is destroyed. We do not record a right-of-return asset.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the early product launch period, we estimated a provision for sales returns based on industry data and adjusted the transaction price for such estimates at the time of sale to the customer. As we continue to collect history for our actual product returns, we have and will continue to refine our returns rate and adjust our accrual if they vary from estimates, which affects product revenue, net in the period of adjustment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargeback</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: A chargeback is the difference between the manufacturer's invoice price to the wholesaler and the wholesaler&#8217;s customer's contract price. The wholesaler tracks these sales and "charges back" the manufacturer for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. We estimate the percentage of goods sold that are eligible for chargeback and adjust the transaction price for such discount at the time of sale to the customer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Patients who meet certain eligibility requirements may receive co-payment assistance. We recognize contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Discounts:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We accrue rebates for contractually agreed-upon discounts with private payers and mandated discounts under government programs such as the Medicaid Drug Rebate Program in the United States. Our estimates for expected utilization of private payer rebates are based on data received from our customers. Our estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launch. Rebates are generally invoiced and paid in arrears. The accrual balance consists invoiced amounts not yet paid as well as an estimate of the amount expected to be incurred but not yet invoiced to us as of the end of the reporting period. If actual rebates vary from estimates, we may need to adjust accruals, which would affect product revenue, net in the period of adjustment.</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Income Taxes</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 to our consolidated financial statements for a complete discussion of the components of our income tax expense, as well as the temporary differences that exist as of December&#160;31, 2025.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated effective income tax rate is influenced by enacted tax laws and tax planning opportunities available to us in the various jurisdictions in which we conduct business. Significant judgment is required in  interpreting each jurisdiction's tax laws and evaluating our tax positions, including those that may be uncertain. We are also required to exercise judgment with respect to the realization of our net deferred tax assets. We evaluate all positive and negative evidence and exercise judgment regarding past and future events to determine if it is more likely than not that all or some portion of the deferred tax assets may not be realized. If appropriate, a valuation allowance is recorded against deferred tax assets to offset future tax benefits that may not be realized.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that there is a reasonable likelihood that there will be a material change in our liability for uncertain income tax positions or our effective income tax rate. However, if actual results are not consistent with our estimates or assumptions, we may be exposed to losses that could be material. We recorded a valuation allowance of $255.5 million as of December&#160;31, 2025 related primarily to net operating loss carryforwards, capitalized research expenses, tax credit carryforwards and accruals/reserves that are not currently deductible for tax purposes.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to our consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">102</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. As of December&#160;31, 2025, we had cash and cash equivalents of $42.9 million, restricted cash of $0.3 million and marketable securities of $178.1 million, which consist of bank deposits, money market funds, commercial paper, government securities, and corporate debt securities. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. Because our investments are primarily short-term in duration, we believe that this exposure to interest rate risk is not significant, and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December&#160;31, 2025, we had $100.0&#160;million outstanding under our Loan Agreement. Amounts outstanding under our Loan Agreement bear interest at a floating rate equal a per annum interest rate equal to 5.95% plus the greater of (a) 2.50% and (b) the one-month Secured Overnight Financing Rate (SOFR). The benchmark SOFR is subject to change in the event of certain events with respect to the benchmark rate. As a result, we are exposed to risks related to our indebtedness from changes in interest rates. Based on the amount outstanding under our Loan Agreement as of December&#160;31, 2025, for every 100 basis point increase in the interest rates, we would incur approximately $1.0&#160;million of additional annual interest expense. We do not currently engage in hedging transactions to manage our exposure to interest rate risk, but higher interest expense would be offset in part by higher earnings on our cash and marketable securities. We may in the future use swaps, caps, collars, structured collars or other common derivative financial instruments to reduce interest rate risk. It is difficult to predict the effect that future hedging activities would have on our operating results.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our transactions occur in U.S. dollars, however, we are exposed to foreign currency exchange risk as our Canadian subsidiary operates with the Canadian dollar as its functional currency. The fluctuation in the value of the U.S. dollar against the Canadian dollar affects the reported amounts of expenses, assets and liabilities. If we would expand our international operations, our exposure to exchange rate fluctuations may increase. As of December&#160;31, 2025, we had cash balances denominated in Canadian dollars of $8.0 million. We currently do not hedge any foreign currency exposure. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have a material impact on our consolidated financial statements. </span></div><div id="i2dffe4de76224390b628083ec6a2857c_70"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements, together with the independent registered public accounting firm report thereon, are set forth in Part IV Item 15, &#8220;Exhibits, Financial Statement Schedules&#8221; of this Annual Report on Form 10-K.</span></div><div id="i2dffe4de76224390b628083ec6a2857c_73"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2dffe4de76224390b628083ec6a2857c_76"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. CONTROLS AND PROCEDURES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on an evaluation under the supervision of and with the participation of our management, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) under the Exchange Act) were effective as of December&#160;31, 2025 to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such required information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Inherent Limitations over Controls and Procedures</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Management conducted an assessment of the effectiveness of our internal control over financial reporting based our assessment on the criteria set forth in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management concluded that our internal control over financial reporting was effective as of December&#160;31, 2025. The effectiveness of our internal control over financial reporting as of December&#160;31, 2025 has been audited by an independent registered public accounting firm, as stated in their report included in Part IV Item 15, &#8220;Exhibits, Financial Statement Schedules&#8221; of this Annual Report on Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in connection with management's evaluation during the three months ended December&#160;31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Arcutis Biotherapeutics, Inc.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited Arcutis Biotherapeutics, Inc.&#8217;s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Arcutis Biotherapeutics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes and our report dated February 25, 2026 expressed an unqualified opinion thereon.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Los Angeles, California</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 25, 2026</span></div><div style="margin-top:8pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">105</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-53"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-54"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-55">OTHER INFORMATION</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-5" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-56" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-5" name="ecd:TrdArrAdoptionDate" id="f-57">November 18, 2025</ix:nonNumeric>, <ix:nonNumeric contextRef="c-5" name="ecd:TrdArrIndName" id="f-58">Keith Leonard</ix:nonNumeric>, a <ix:nonNumeric contextRef="c-5" name="ecd:TrdArrIndTitle" id="f-59">member of our Board of Directors</ix:nonNumeric>, entered into a Rule 10b5-1 <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-60">trading plan</ix:nonNumeric>, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential exercise and sale of up to <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-61">39,272</ix:nonFraction> options held by Mr. Leonard between February 17, 2026 and <ix:nonNumeric contextRef="c-5" name="ecd:TrdArrExpirationDate" id="f-62">February 16, 2027</ix:nonNumeric>.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-63" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-7" name="ecd:TrdArrAdoptionDate" id="f-64">December 13, 2025</ix:nonNumeric>, <ix:nonNumeric contextRef="c-7" name="ecd:TrdArrIndName" id="f-65">Sue-Jean Lin</ix:nonNumeric>, a <ix:nonNumeric contextRef="c-7" name="ecd:TrdArrIndTitle" id="f-66">member of our Board of Directors</ix:nonNumeric>, entered into a Rule 10b5-1 <ix:nonNumeric contextRef="c-7" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-67">trading plan</ix:nonNumeric>, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential exercise and sale of up to <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-68">77,880</ix:nonFraction> options, as well as the potential sale of up to <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-69">13,004</ix:nonFraction> shares of Common Stock held by Ms. Lin between February 24, 2026 and <ix:nonNumeric contextRef="c-7" name="ecd:TrdArrExpirationDate" id="f-70">February 19, 2027</ix:nonNumeric>.</span></div></ix:nonNumeric><div id="i2dffe4de76224390b628083ec6a2857c_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2dffe4de76224390b628083ec6a2857c_88"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div id="i2dffe4de76224390b628083ec6a2857c_91"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted an <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-73">insider trading policy</ix:nonNumeric> and procedures governing the purchase, sale, and/or other dispositions of our securities by directors, officers, employees and other covered persons that we believe are reasonably designed to promote compliance with insider trading laws, rules and regulations, and the listing requirements of the Nasdaq Global Select Market. This policy imposes regular blackout periods during which certain individuals may not transact in our securities and pre-clearance procedures for transactions by certain specified individuals, including, among others, the members of our board of directors and our executive officers. In addition, this policy prohibits certain transactions that we have determined are higher risk or for which there is a heightened appearance of potential improper or inappropriate conduct, including short sales of our securities, options trading in puts, calls or other derivative securities involving our equity securities, hedging transactions, and margin accounts and pledging of our securities. We regularly review our insider trading policy with our board of directors and management. A copy of our insider trading policy and procedures is filed as Exhibit 19 to this Annual Report on Form 10-K. Further, the company will not transact in any of its own securities unless in compliance with U.S. securities laws.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining information required by this item is incorporated by reference to our definitive proxy statement relating to our 2026 Annual Meeting of Stockholders (the 2026 Proxy Statement) to be filed with the SEC within 120 days of December&#160;31, 2025. </span></div><div id="i2dffe4de76224390b628083ec6a2857c_94"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.  EXECUTIVE COMPENSATION</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2026 Proxy Statement. </span></div><div id="i2dffe4de76224390b628083ec6a2857c_97"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2026 Proxy Statement. </span></div><div id="i2dffe4de76224390b628083ec6a2857c_100"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.  CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2026 Proxy Statement. </span></div><div id="i2dffe4de76224390b628083ec6a2857c_103"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.  PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2026 Proxy Statement.</span></div><div id="i2dffe4de76224390b628083ec6a2857c_106"></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div id="i2dffe4de76224390b628083ec6a2857c_109"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Financial Statement Schedules.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial statements are included herein:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Financial Statements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_115">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-74">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_118">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_121">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_124">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_127">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_130">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules are omitted because they are not applicable, not required, or because the required information is included in the consolidated financial statements or notes thereto. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Exhibits.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.676%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730620000010/exhibit31postipocertif.htm">Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730620000010/exhibit32postipobylaws.htm">Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex41.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/21/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, dated October 8, 2019, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/21/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit43descriptionofregi.htm">Description of Arcutis Biotherapeutics&#8217; Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000162828023034917/exhibit41-8xk.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/23/23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex101.htm">Form of Indemnity Agreement.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/6/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex102.htm">2017 Stock Incentive Plan and forms of award agreements.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/6/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex103.htm">2020 Stock Incentive Plan and forms of award agreements.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/21/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex104.htm">2020 Employee Stock Purchase Plan and forms of award agreements.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/21/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730622000009/exhibit1052022employmentin.htm">2022 Employment Inducement Incentive Plan and forms of award agreements.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/22/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex105.htm">Offer Letter, dated January 9, 2020, by and between the Registrant and Todd Franklin Watanabe.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/21/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#8224;&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex1012.htm">License Agreement, dated July 23, 2018, by and between AstraZeneca AB and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/6/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#8224;&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex1014.htm">Collaboration Agreement, dated June 28, 2019, by and between Hawkeye Therapeutics, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/6/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex1017.htm">Severance &amp; Change in Control Agreement, by and between the Registrant and Todd Franklin Watanabe.  </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/21/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16&#8224;&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000162828021002272/arcutis-interquimapisupply.htm">Supply Agreement, dated November 24, 2020, by and between Registrant and Interquim, S.A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#8224;&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000162828021009291/chi-arcutis3plagreement.htm">Exclusive Distribution Agreement, dated February 8, 2021, by and between the Registrant and Cardinal Health 105, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18&#8224;&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730622000071/exhibit102amendmentno1supp.htm">Amendment No. 1, dated October 5, 2022, to the Supply Agreement, dated November 24, 2020, by and among the Registrant and Interquim, S.A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/8/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730621000030/exhibit101dptmanufacturing.htm">Supply and Manufacturing Agreement, dated September 15, 2021, between DPT Laboratories, Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/4/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730622000009/exhibit1031-masarumatsudao.htm">Offer Letter, dated December 13, 2021, by and between the Registrant and Mas Matsuda.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/22/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730622000009/exhibit1032-severanceandch.htm">Severance &amp; Change in Control Agreement, by and between the Registrant and Mas Matsuda.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/22/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730622000071/arcutis-ducentisredacted.htm">Share Purchase Agreement, dated September 7, 2022, by and among the Registrant, Ducentis Biotherapeutics LTD and the certain stockholders of Ducentis Biotherapeutics LTD.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/8/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730623000023/arqtxslrxarcutisxamendedan.htm">Amended and Restated Loan and Security Agreement, dated January 10, 2023, by and among the Registrant, SLR Investment Corp. and the lenders party thereto.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730623000124/slrfirstamendmenttoarloa.htm">First Amendment to Amended and Restated Loan and Security Agreement dated November 1, 2023, by and among the Registrant, SLR Investment Corp., and the lenders party thereto.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/3/23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.676%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730623000023/a1036-nonxemployeedirector.htm">Non-Employee Director Compensation Program</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730623000023/a1037-nonxemployeedirector.htm">Form of Non-Employee Director RSU Deferral Election</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730623000124/huadonglicenseandcollabo.htm">License Agreement, dated August 10, 2023, by and between the Registrant and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/3/23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730623000109/offerofemploymentlarryto.htm">Employment Agreement, dated September 16, 2023, by and between Todd Edwards and the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/27/23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730623000109/severanceandchangeincont.htm">Severance and Change in Control Agreement, dated September 16, 2023, by and between Todd Edwards and the Registrant </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/27/23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000162828024002763/exhibit12-sx3.htm">Amended and Restated Sales Agreement, dated January 31, 2024, by and between the Registrant and Cowen and Company, LLC </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/31/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730624000079/exhibit103satoagreement.htm">License Agreement, dated February 27, 2024, by and between the Registrant and Sato Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/14/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730624000079/exh104amendmenttohuadong-a.htm">First Amendment to the License Agreement, dated February 18, 2024, by and between the Registrant and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/14/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730624000124/exhibit101secondamendmentt.htm">Second Amendment to Amended and Restated Loan and Security Agreement, dated August 9, 2024, by and among the Registrant, Arcutis Canada, Inc., SLR Investment Corp., and the lenders party thereto.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/14/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/exhibit101boramanufacturin.htm">Manufacturing Supply Agreement, dated November 8, 2023, by and between the Registrant and Bora Pharmaceuticals Services Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/exhibit102boraamendmentno1.htm">Amendment No. 1 to the Manufacturing Supply Agreement, dated March 22, 2024, by and between the Registrant and Bora Pharmaceuticals Services Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/exhibit103boraamendmentno2.htm">Amendment No. 2 to the Manufacturing Supply Agreement, dated as of May 14, 2025, by and between the Registrant and Bora Pharmaceuticals Services Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730625000058/exhibit101severancechangei.htm">Severance &amp; Change in Control Agreement, dated April 10, 2025, by and between the Registrant and Latha Vairavan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/10/25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730625000096/exhibit101.htm">Amended and Restated Non-Employee Director Compensation Program.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/17/25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730625000147/a8-kexhibit101.htm">Transition and Consulting Agreement, dated December 3, 2025, by and between the Company and Bhaskar Chaudhuri.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000162828020010816/arcutisexhibit101-8xk.htm">Offer Letter, dated July 7, 2020, by and between</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000162828020010816/arcutisexhibit101-8xk.htm"> the Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000162828020010816/arcutisexhibit101-8xk.htm"> and Patrick Burnett</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/29/20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000162828020010816/arcutisexhibit102-8xk.htm">Severance &amp; Change in Control Agreement, dated July 28, 2020, by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000162828020010816/arcutisexhibit102-8xk.htm">the Registrant </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000162828020010816/arcutisexhibit102-8xk.htm">and Patrick Burnett</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/29/20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1049lathavairavanof.htm">Offer L</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1049lathavairavanof.htm">etter, dated February 4, 2020, by and between the Registrant and Latha Vairavan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730624000031/exhibit19insidertradingpol.htm">Insider Trading Policy and Procedures</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211listofsubsidiari.htm">List of Subsid</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211listofsubsidiari.htm">iaries</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211listofsubsidiari.htm"> of the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211listofsubsidiari.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.676%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231-auditorsconsent.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_181">Power of Attorney (included in the signature page to this Annual Report on Form 10-K).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit311ceoq42025.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit312cfoq42025.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit321ceocfoq42025.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1787306/000178730624000031/exhibit971clawbackpolicy.htm">Arcutis Biotherapeutics, Inc. Policy for Recovery of Erroneously Awarded Compensation</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulation&#160;S-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#x5E;&#160;&#160;&#160;&#160;Registrant has omitted schedules and exhibits pursuant to Item&#160;601(a)(5) of Regulation&#160;S-K. The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div id="i2dffe4de76224390b628083ec6a2857c_1367"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.  FORM 10-K SUMMARY</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">110</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Report of Independent Registered Public Accounting Firm</span></div><div id="i2dffe4de76224390b628083ec6a2857c_115"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Arcutis Biotherapeutics, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Arcutis Biotherapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in stockholders' equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 25, 2026 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the SEC and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Critical Audit Matter</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Sales deductions</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Description of </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">the Matter</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, the Company recorded accrued sales deductions of $78.3 million. As described in Note 2 to the consolidated financial statements, revenues from product sales are recognized net of variable consideration for invoice discounts for prompt payment and distribution service fees, government and private payer rebates, chargebacks, discounts and fees, product returns and costs of co-pay assistance programs, which are collectively recorded at the time of sale.  Reserves are established for the estimates of variable considerations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing the accrued liabilities related to private payer rebates required significant judgment. The accrued sales deductions related to private payer rebates are based on data received from its customers, current contractual arrangements, specific known market events and trends, external historical data, and forecasted customer buying patterns and patient utilization. Auditing the Company&#8217;s accounting for accrued sales deductions related to co-pay assistance programs requires a higher degree of judgment to evaluate the relevance and reliability of audit evidence. The accrued sales deductions related to co-pay assistance programs are estimated based on historical program payments and utilization. </span></div></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Addressed the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Matter in Our</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Audit</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the accrued sales deduction processes. This included testing controls over management&#8217;s review of significant assumptions and inputs used in the estimate of sales deductions, including actual sales, contractual terms, historical experience, and distributor inventory levels.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To test the adequacy of the Company&#8217;s accrued sales deductions for private payer rebates and co-pay assistance we obtained management&#8217;s calculations for the estimates and performed the following procedures, among others. For accrued private payer rebates, we tested management&#8217;s estimation process by developing an independent expectation of the estimated accrual balance based upon actual historical payment data. We agreed terms and conditions for a sample of contracts to the executed agreement and tested a sample of payments made throughout the year. For accrued co-pay assistance programs, we assessed the company&#8217;s assumptions of distributor inventory quantities by agreeing the quantities to third party reports.  We also assessed the historical share and payment rate assumptions by testing a sample of the historical payments and program utilization.</span></div></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-75">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2019.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-76">Los Angeles, California</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 25, 2026</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt;text-indent:22.3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and par value)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-77">42,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-78">71,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="f-79">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="f-80">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">178,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">156,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">146,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">73,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-85">22,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-86">14,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">21,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">19,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">411,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">335,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-91">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-92">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-93">14,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-94">9,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-95">4,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-96">1,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-97">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-98">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-99">432,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-100">348,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-101">12,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-102">14,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-103">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-105">116,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-106">66,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-107">129,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-108">81,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, long-term</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-109">5,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-110">2,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-111">107,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-112">107,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-113">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-114">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-115">243,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-116">191,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 8)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-10" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-117"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-11" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-118"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-119"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-120">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-121"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-122">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-123"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-124">123,332,672</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-125"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-126">117,848,033</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2025 and 2024, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-127">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-128">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-129">1,327,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-130">1,279,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-131">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-132">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-133">1,138,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-134">1,121,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-135">189,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-136">157,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-137">432,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-138">348,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_121"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share data)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-139">372,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-140">166,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-141">29,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-142">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-143">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-144">30,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-145">376,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-146">196,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-147">59,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-148">36,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-149">19,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-150">4,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-151">77,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-152">76,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-153">110,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-154">274,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-155">229,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-156">185,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-157">388,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-158">324,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-159">300,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-160">12,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-161">128,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-162">241,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-163">8,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-164">16,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-165">12,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-166">12,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-167">27,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-168">29,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-169">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-170">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-171">731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-172">14,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-173">139,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-174">259,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-175">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-176">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-177">3,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-178">16,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-179">140,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-180">262,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized income (loss) on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-181">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-182">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-183">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-184">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-185">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-186">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-187">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-188">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-189">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-190">16,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-191">140,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-192">261,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-193"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-194">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-195"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-196">1.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-197"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-198">3.78</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-199"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-200">127,234</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-201"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-202">120,958</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-203"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-204">69,305</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_124"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.104%"><tr><td style="width:1.0%"/><td style="width:33.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.846%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#8212;December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-205">61,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-206">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-207">930,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">1,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">719,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-210">209,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares of common stock for public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-211">6,546</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-212">33,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-213">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-214">95,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-215">95,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares of common stock net of discount and issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-216">116</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-217">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="f-218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-219">3,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-220">3,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon the exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-221">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-222">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-223">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon the vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-224">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lapse of repurchasing rights related to common stock issued pursuant to early exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" scale="3" id="f-225">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" format="ixt:fixed-zero" scale="3" id="f-227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued pursuant to the ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-228">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-229">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-230">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-231">38,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-232">38,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-233">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-234">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-235">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-236">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-237">262,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-238">262,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#8212;December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-239">96,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-240">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-241">1,070,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-242">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">981,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-244">88,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares of common stock for public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-245">10,820</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-246">18,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-247">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-248">161,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-249">161,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon the exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-250">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-251">2,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-252">2,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon the vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="f-253">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued pursuant to the ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-254">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-255">1,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-256">1,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-257">42,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-258">42,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-259">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-260">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-261">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-262">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-263">140,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-264">140,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#8212;December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-265">117,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-266">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-267">1,279,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-268">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-269">1,121,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-270">157,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon the exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-271">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-272">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-273">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon the vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="f-274">2,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of pre-funded warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="arqt:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="f-275">2,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued pursuant to the ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-276">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-277">2,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-278">2,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-279">41,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-280">41,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-281">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-282">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-283">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-284">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-285">16,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-286">16,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#8212;December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-287">123,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-288">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-289">1,327,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-290">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-291">1,138,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-292">189,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_127"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_109">Index to Financial Statements</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.292%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-293">16,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-294">140,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-295">262,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-296">40,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-297">41,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-298">38,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-299">4,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-300">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-301">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-302">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-303">5,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-304">4,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net accretion on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-305">2,094</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-306">6,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-307">6,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other non-cash items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-308">652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-309">769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-310">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-311">73,163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-312">47,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-313">17,349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-314">7,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-315">400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-316">5,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-317">2,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-318">948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-319">8,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-320">1,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-321">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-322">3,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-323">50,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-324">32,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-325">5,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="arqt:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-326">680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="arqt:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-327">735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="arqt:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-328">657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 79.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-329">5,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-330">112,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-331">247,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-332">246,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-333">254,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-334">225,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-335">227,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-336">288,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-337">406,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-338">686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-339">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-340">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Milestone payment for intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-341">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-342">5,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-344">30,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-345">28,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-346">180,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-348">161,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-351">100,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-353">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-354">2,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-355">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock for ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="f-356">2,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="f-357">1,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="f-358">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arqt:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="arqt:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="arqt:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-361">95,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from issuance of shares under ATM, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arqt:ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="arqt:ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="arqt:ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-364">3,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 79.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-365">6,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-366">66,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-367">101,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-368">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-369">235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-370">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-371">28,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-372">17,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-373">34,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-374">71,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-375">89,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-376">54,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-377">43,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-378">71,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-379">89,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-380">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest expense paid in cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-383">10,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-384">22,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-385">25,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_130"></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i2dffe4de76224390b628083ec6a2857c_133"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-386" continuedAt="f-386-1" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="f-386-1"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arcutis Biotherapeutics, Inc. (the Company) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The Company&#8217;s strategy is to focus on validated biological targets and to use its drug development platform and deep dermatology expertise to develop differentiated products that have the potential to address the major shortcomings of existing therapies in its targeted indications.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received U.S. Food and Drug Administration (FDA) approval of its first product, ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) cream 0.3% (ZORYVE cream 0.3%), in July 2022, for the treatment of plaque psoriasis, including intertriginous psoriasis, in individuals 12 years of age and older (subsequently approved down to 6 years old in October 2023), and began U.S. commercialization in August 2022. The Company also received Health Canada approval of ZORYVE cream 0.3% in plaque psoriasis in April 2023 and began Canadian commercialization in June 2023. The Company received FDA approval of ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) topical foam 0.3% (ZORYVE foam), in December 2023, for the treatment of seborrheic dermatitis in individuals 9 years of age and older, and began U.S. commercialization in January 2024. The Company received FDA approval of ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) cream 0.15% (ZORYVE cream 0.15%) and began U.S. commercialization, in July 2024, for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. The Company received Health Canada approval of ZORYVE foam for seborrheic dermatitis in October 2024, and began Canadian commercialization in December 2024. The Company received Health Canada approval for ZORYVE cream 0.15% for atopic dermatitis in March 2025, and began Canadian commercialization in April 2025. The Company also received FDA approval of ZORYVE foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and adolescents 12 years of age and older in May 2025, and began U.S. commercialization in June 2025. The Company received FDA approval of ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) cream 0.05% (ZORYVE cream 0.05%) in October 2025 and began commercialization for the topical treatment of mild to moderate atopic dermatitis in children ages 2 to 5 years of age.  The Company received Health Canada approval for ZORYVE foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and adolescents 12 years of age and older in October 2025, and began Canadian commercialization in November 2025.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred significant annual losses and negative cash flows from operations since its inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-387">1,138.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-388">1,121.9</ix:nonFraction> million as of December&#160;31, 2025 and 2024, respectively. The Company may continue to incur operating losses. The Company had cash, cash equivalents, restricted cash, and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="arqt:CashCashEquivalentsAndMarketableSecurities" scale="6" id="f-389">221.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="arqt:CashCashEquivalentsAndMarketableSecurities" scale="6" id="f-390">228.6</ix:nonFraction>&#160;million as of December&#160;31, 2025 and 2024, respectively. The Company had $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-391">100.0</ix:nonFraction>&#160;million outstanding under the Loan Agreement as of December&#160;31, 2025. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing capital resources will be sufficient to meet the projected operating requirements for at least 12 months from the date of issuance of its financial statements. If the Company's available cash, cash equivalents and marketable securities and anticipated future cash flows from operations are insufficient to satisfy its liquidity requirements, the Company may need to raise additional capital to fund its operations. No assurance can be given as to whether additional financing will be available on terms acceptable to the Company or at all. If sufficient funds on acceptable terms are not available when needed, the Company may be required to curtail certain planned activities. Failure to manage discretionary spending or raise additional funds, as needed, may adversely impact the Company&#8217;s ability to achieve its intended business objectives and have an adverse effect on its results of operations and future prospects.</span></div></ix:continuation><div id="i2dffe4de76224390b628083ec6a2857c_139"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-392" continuedAt="f-392-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-392-1" continuedAt="f-392-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-393" continuedAt="f-393-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-393-1">The Company&#8217;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP).</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-394" continuedAt="f-394-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and all intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-392-2" continuedAt="f-392-3"><ix:continuation id="f-394-1"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts, which are not material, have been reclassified to conform to current year presentation in the consolidated balance sheets, consolidated statements of operations and comprehensive loss, consolidated statement of cash flows and the notes to the consolidated financial statements.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-395" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions include those related to revenue recognition, accrued and prepaid research and development expenses, and income taxes. Additionally, the Company uses available market information to assess the fair value of its marketable securities. The Company regularly evaluates its estimates using historical experience, expectations of future impacts and other assumptions that the Company believes are reasonable, and the Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. If actual results differ from those estimates, the Company includes the updates in its consolidated financial statements in the period the actual amounts become known.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-396" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-397" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with original maturities of greater than three months are classified as marketable securities on the balance sheet. Marketable securities consist of investment grade short to intermediate-term fixed income investments that have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the consolidated balance sheets due to their highly liquid nature and availability for use in current operations. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive income (loss) on the consolidated balance sheets. Realized gains and losses as well as credit losses, if any, on marketable securities are included in other income (expense), net in the statements of operations and comprehensive loss. Interest on marketable securities is included in interest income in the statements of operations and comprehensive loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. In making this judgment, the Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost, the Company's intent to sell or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, the financial condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular security. To date, <ix:nonFraction unitRef="usd" contextRef="c-10" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="f-398">no</ix:nonFraction> such credit losses have occurred or have been recorded. The cost of investments sold is based on the specific-identification method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-399" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables, net</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s trade accounts receivable consists of amounts due primarily from pharmaceutical wholesalers and specialty pharmacy providers in the United States and Canada (collectively, its customers) related to sales of ZORYVE and have standard payment terms. For certain customers, the trade accounts receivable for the customer is net of distribution service fees, prompt pay discounts, and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company will reserve against trade accounts receivable for estimated credit losses that may arise and any amounts determined to be uncollectible will be written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was not material as of December&#160;31, 2025 and 2024 and the amounts of trade receivable amounts written off for the years ended December&#160;31, 2025, 2024, and 2023 were not material.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-392-3" continuedAt="f-392-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-400" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories at the lower-of-cost or net realizable value. The Company determines the cost of its inventories, which includes costs related to products held for sale in the ordinary course of business, products in process of production for such sale, and items to be currently consumed in the production of goods to be available for sale, on a first-in, first-out (FIFO) basis. Due to the nature of the Company&#8217;s supply chain process, inventory that is owned by the Company is physically stored at third-party warehouses, logistics providers, and contract manufacturers. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. If they occur, such charges are recorded as a component of cost of sales in the consolidated statements of operations and comprehensive loss. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products that may be used in clinical development programs are excluded from inventory and their costs are charged to research and development expense in the consolidated statement of operations as incurred, as long as they do not have an alternative use. Prior to the initial dates of regulatory approval, costs related to the production of inventory were recorded as research and development expense on the Company&#8217;s consolidated statements of operations and comprehensive loss in the period incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-401" continuedAt="f-401-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, net</span></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-401-1" continuedAt="f-401-2">The Company paid a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval" scale="6" id="f-402">7.5</ix:nonFraction>&#160;million to AstraZeneca in the third quarter of 2022 related to the FDA approval and launch of ZORYVE cream 0.3%. This milestone payment was capitalized as an intangible asset and will be amortized to cost of sales over its useful life of <ix:nonNumeric contextRef="c-52" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-403">10</ix:nonNumeric> years from the date of first commercial sale, as this is the minimum amount of time that the related License Agreement will be in effect. The Company paid additional milestone payments of $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" scale="6" id="f-404">5.0</ix:nonFraction>&#160;million related to the achievement of $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" scale="6" id="f-405">100.0</ix:nonFraction>&#160;million worldwide net sales in October 2024 and $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" scale="6" id="f-406">10.0</ix:nonFraction>&#160;million related to the achievement of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" scale="6" id="f-407">250.0</ix:nonFraction>&#160;million worldwide net sales in May 2025. These milestone payments were recorded as cumulative catch-up adjustments to the carrying value of the intangible asset.</ix:continuation> Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-408">4.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-409">2.0</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-410">0.8</ix:nonFraction>&#160;million for the years ended December&#160;31, 2025, 2024, and 2023</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. See Note 7. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-411" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future amortization expense for the intangible assets subsequent to December&#160;31, 2025 is as follows (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"/><td style="width:76.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-412">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-413">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-414">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-415">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-416">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-417">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-418">14,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:continuation id="f-401-2"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its long-lived assets, including intangibles, for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results. <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-419"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-420"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-421">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses were recorded for the years ended December&#160;31, 2025, 2024, and 2023.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-392-4" continuedAt="f-392-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="f-422" continuedAt="f-422-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Other Investments</span></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-422-1">The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity (VIE). If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company&#8217;s consolidated financial statements. The Company&#8217;s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-423" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by either the financial institutions holding its cash or by its customers owing trade receivables to the extent recorded on the consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance sheets. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for credit losses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-424" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments, in addition to those presented in Note 4, include cash equivalents, accounts receivable, accounts payable, accrued liabilities, and long-term debt. The carrying amount of cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to their short maturities. As the long-term debt is subject to variable interest rates that are based on market rates which regularly reset, the Company believes that the carrying value of the long-term debt approximates its fair value.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis on the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-425" continuedAt="f-425-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-425-1">Property and equipment are stated at cost less accumulated depreciation. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets which range from <span style="-sec-ix-hidden:f-426">two</span> to <ix:nonNumeric contextRef="c-59" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-427">five years</ix:nonNumeric>. Leasehold improvements are depreciated on a straight-line basis over the shorter of their estimated useful lives or lease terms. Maintenance and repairs are expensed as incurred. The Company reviews the carrying values of its property and equipment for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-428"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-429"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-430">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairments recognized during the years ended December 31, 2025, 2024 and 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-392-5" continuedAt="f-392-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-431" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information available at lease commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the lease liability, includes any lease payments made prior to or on lease commencement and is adjusted for lease incentives and initial direct costs incurred, as applicable. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreements includes lease and non-lease components and the Company has elected to not separate such components for all classes of assets. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with terms of 12 months or less (short-term leases) for all classes of assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="arqt:AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock" id="f-432" continuedAt="f-432-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Prepaid Research and Development Expenses</span></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-432-1">The Company records prepaid expenses and accrued liabilities for estimated research and development activities conducted by third-party service providers, which include the conduct of nonclinical studies, clinical trials, and contract manufacturing activities. These costs are a significant component of the Company&#8217;s research and development expenses. The Company records these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid costs balances in each reporting period. As actual costs become known, the Company adjusts its balances for these activities.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-433" continuedAt="f-433-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its product to its customers in the United States and Canada. The Company&#8217;s customers subsequently resell the products to pharmacies, health care providers, and patients. In accordance with ASC 606, the Company recognizes net product revenue from sales when the customers obtain control of the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-433-1" continuedAt="f-433-2"><ix:continuation id="f-392-6" continuedAt="f-392-7"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s products, which typically occurs upon delivery to the customer. The Company&#8217;s payment terms are generally between <ix:nonNumeric contextRef="c-60" name="arqt:ProductRevenuePaymentTerm" format="ixt-sec:durday" id="f-434">30</ix:nonNumeric> - <ix:nonNumeric contextRef="c-61" name="arqt:ProductRevenuePaymentTerm" format="ixt-sec:durday" id="f-435">65</ix:nonNumeric> days.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales are recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution service fees, (b) government and private payer rebates, chargebacks, discounts and fees, (c) product returns and (d) costs of co-pay assistance programs for patients, as well as other sales deductions. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to trade receivables, net if payable to a customer or accrued liabilities if payable to a third-party. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is recognized as product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results vary from the Company&#8217;s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Service Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: data reporting, inventory management, chargeback administration, and service level commitment. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Pay Discounts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company provides some of its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from its gross product revenue and accounts receivable at the time such revenue is recognized.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company provides customers a credit for all products returned in accordance with the Company&#8217;s returned goods policy. Once the product is returned, it is destroyed. The Company does not record a right-of-return asset.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the early product launch period, the Company estimated its provision for sales returns based on industry data and adjusted the transaction price for such estimates at the time of sale to the customer. As the Company continues to collect data on its actual product returns, it has and will continue to refine its estimated returns rate and adjust its accrual, which affects revenue in the period of adjustment. No such material adjustments were recorded for the year ended December 31, 2025. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargeback</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: A chargeback is the difference between the manufacturer's invoice price to the wholesaler and the wholesaler&#8217;s customer's contract price. The wholesaler tracks these sales and "charges back" the manufacturer for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price for such discount at the time of sale to the customer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Discounts:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accrues rebates for contractually agreed-upon discounts with private payers and mandated discounts under government programs such as the Medicaid Drug Rebate Program in the United States. The Company's estimates for expected utilization of private payer rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-392-7" continuedAt="f-392-8"><ix:continuation id="f-433-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates are generally invoiced and paid in arrears. The accrual balance consists of invoiced amounts not yet paid as well as an estimate of the amount expected to be incurred but not yet invoiced to the Company as of the end of the reporting period. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product revenue, net in the period of adjustment.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="arqt:RevenueNotFromContractWithCustomerPolicyPolicyTextBlock" id="f-436" escape="true"><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other revenue is related to the Huadong License and Collaboration Agreement and Sato License Agreement. See Note 7. The Company evaluated the agreements with Huadong and Sato and determined that they are within the scope of ASC 606. The Company applied the five-step model as required by ASC 606 to determine revenue recognition.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The nonrefundable upfront payments received in connection with the transfer of the license and related know-how to Huadong in September 2023 and to Sato in March 2024 were determined to be distinct performance obligations, and therefore were recognized in Other revenue. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluated whether the development and regulatory milestones are considered probable of being reached and determined that their achievement is highly dependent on factors outside of the Company&#8217;s control. Therefore, these payments are subject to significant revenue reversal and are therefore not included in the transaction price. At the end of each reporting period, the Company will re-evaluate the probability of achievement of each milestone and, if necessary, adjust its estimate of the overall transaction price and accordingly recognize the related revenue once the probability of significant reversal of revenue is low. Any such adjustments are recorded on a cumulative catch-up basis, and would be reported in Other revenue in the period of adjustment. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sales milestones and royalties will be recognized in Other revenue when the related sales occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-437" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes direct and indirect costs related to the manufacturing and distribution of ZORYVE, including raw materials, third-party manufacturing costs, packaging services, freight-in, third-party royalties payable on the Company&#8217;s net product revenue, and amortization of certain intangible assets associated with ZORYVE. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon related FDA approval dates for each product. As a result, manufacturing and other inventory costs incurred prior to FDA approval were expensed and, therefore, are not included in cost of sales.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-438" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, license fees, stock-based compensation expense, materials, supplies, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company&#8217;s license agreements have been considered an acquisition of a business. For asset acquisitions, contingent consideration is recognized when the contingency is resolved and the consideration is paid or becomes payable. The upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when paid or become payable, provided there is no alternative future use of the rights in other research and development projects.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-439" continuedAt="f-439-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are expensed as incurred and consist primarily of salaries and related costs, including payroll taxes, benefits, stock-based compensation, and travel, and costs related to sales and marketing of ZORYVE. Other selling, general and administrative expenses include legal costs of pursuing patent protection of the Company's intellectual property, insurance, and professional services fees for auditing, tax, </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-392-8" continuedAt="f-392-9"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-439-1">and general legal services.</ix:continuation> Advertising costs are expensed as incurred and were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-440">25.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-441">6.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-442">11.2</ix:nonFraction>&#160;million for the years ended December&#160;31, 2025, 2024, and 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-443" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for such awards is the date of grant and the expense is recognized on a straight-line basis over the expected vesting period. For share-based awards that vest subject to a performance condition, the Company will recognize compensation cost for awards if and when the Company concludes that it is probable that the awards with a performance condition will be achieved on an accelerated attribution method. The Company accounts for forfeitures as they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-444" continuedAt="f-444-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets for the United States have been fully offset by a valuation allowance. The Company has an immaterial deferred tax asset related to foreign jurisdictions which is not offset by a valuation allowance.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-444-1">The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit.</ix:continuation> To date, there have been <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-445"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-446"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-447">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> interest or penalties incurred in relation to the unrecognized tax benefits.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-448" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company translates the assets and liabilities of its foreign subsidiaries where the local currencies have been determined to be the functional currencies into U.S. dollars using current exchange rates. Adjustments for foreign currency translation adjustments are recognized in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. The earnings or loss of these subsidiaries are translated in U.S. dollars using average exchange rates in effect during each reporting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="arqt:CoPromotionAgreementsPolicyPolicyTextBlock" id="f-449" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promotion Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n July 2024, the Company entered into a promotion agreement with Kowa Pharmaceuticals America, Inc. (Kowa) to leverage Kowa's primary care sales force to exclusively market and promote ZORYVE to primary care practitioners and pediatricians for all FDA-approved indications until July 2029. The Company recognizes all revenue and Kowa receives a commission for the net sales attributed to Kowa. The commission is recorded in selling, general and administrative expense. For the years ended December&#160;31, 2025 and 2024, revenue from sales attributed to Kowa and related commissions paid or owed to Kowa were not material. Effective January 23, 2026, Kowa and the Company mutually agreed to terminate the promotion agreement. Following this termination, Kowa ceased all sales and promotions of ZORYVE and the Company will not be required to make any further payments to Kowa.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-450" continuedAt="f-450-1" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of any recent Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB). Other than the ASUs listed below, all other ASUs were assessed and determined to be either not applicable to the Company or are expected to have minimal impact on the Company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-450-1"><ix:continuation id="f-392-9"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Improvements to Income Tax Disclosures, which requires qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The Company adopted the guidance for the year ended December 31, 2025 and applied any presentational changes from this new standard to all prior years to allow for comparability. See Note 11. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_142"></div><hr style="page-break-after:always"/><div style="min-height:76.46pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-451" continuedAt="f-451-1" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="f-451-1" continuedAt="f-451-2"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized under guidance within ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-452" continuedAt="f-452-1" escape="true">The following table presents the Company's disaggregated revenue for the periods presented (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-452-1"><div style="margin-top:8pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:52.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.732%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.732%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.3%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-453">120,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-454">85,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-455">29,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE foam</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-456">181,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-457">71,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.15%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-459">68,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-460">9,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.05%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="f-462">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-465">372,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-466">166,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-467">29,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-468">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-469">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-470">30,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-471">376,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-472">196,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-473">59,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue relates primarily to the Sato and Huadong licensing agreements. See Note 7.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net outside the United States represented less than 10% of the Company&#8217;s consolidated product revenue, net for the years ended December 31, 2025, 2024 and 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-474" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major customers are defined as customers that individually accounted for greater than 10% of the Company's revenue. The following table presents each major customer that accounted for more than 10% of its gross product sales.</span></div><div style="margin-top:8pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:52.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.732%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.732%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of gross product sales</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-475">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-476">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-477">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-478">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-479">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-480">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-481">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-482">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-483">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-484">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer E</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-485">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer F</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-486">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross product sales from major customers</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-487">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-488">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-489">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">* Represents less than 10% of respective balance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-451-2">As of December&#160;31, 2025, amounts due from four of these customers each exceeded 10% of gross trade receivables and accounted for <ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-490">60</ix:nonFraction>% of net trade receivables on a combined basis. As of December&#160;31, 2024, amounts due from five of these customers each exceeded 10% of gross trade receivables and accounted for <ix:nonFraction unitRef="number" contextRef="c-90" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-491">69</ix:nonFraction>% of net trade receivables on a combined basis.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_145"></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-492" continuedAt="f-492-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-492-1" continuedAt="f-492-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-493" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-494">37,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-497">37,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-499">5,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-501">5,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-503">14,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-505">14,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-507">78,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-509">78,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-510">84,522</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-513">84,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-514">122,063</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-515">98,919</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-517">220,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></div></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-518">71,335</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-519">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-521">71,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-522">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-523">5,042</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-525">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-526">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-527">83,955</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-529">83,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-530">67,623</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-531">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-533">67,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-534">138,958</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-535">88,997</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-537">227,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and U.S. Treasury and agency securities are valued based on quoted market prices in active markets, with no valuation adjustment.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper, certificates of deposit and corporate debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-492-2" continuedAt="f-492-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-539" continuedAt="f-539-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-538" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated value of the Company&#8217;s cash, cash equivalents and marketable securities, and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-540">37,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="arqt:CashAndCashEquivalentsUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="arqt:CashAndCashEquivalentsUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="f-542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-543">37,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-544">5,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="arqt:CashAndCashEquivalentsUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-545">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="arqt:CashAndCashEquivalentsUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="f-546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-547">5,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-548">42,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:CashAndCashEquivalentsUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:CashAndCashEquivalentsUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="f-550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-551">42,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-552">14,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-553">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-554">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-555">14,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-556">78,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-557">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-558">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-559">78,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-560">84,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-561">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-562">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-563">84,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-564">177,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-565">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-566">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-567">178,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-568">71,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="arqt:CashAndCashEquivalentsUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="arqt:CashAndCashEquivalentsUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="f-570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-571">71,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-572">71,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:CashAndCashEquivalentsUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:CashAndCashEquivalentsUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="f-574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-575">71,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-576">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-578">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-579">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-580">83,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-581">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-583">83,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-584">67,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-585">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-587">67,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-588">156,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-589">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-591">156,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, no significant facts or circumstances were present to indicate a deterioration in the creditworthiness of the issuers of the available-for-sale securities. The Company generally holds its marketable securities until maturity and does not intend to sell, and is not required to sell, the investments that are in an unrealized loss position before the recovery of their amortized cost basis. For all securities with a fair value less than its amortized cost basis, the Company determined the decline in fair value below amortized cost basis to be non-credit related and no allowance for losses has been recorded. As of December&#160;31, 2025, there were no individual securities that were in a significant unrealized loss position. To date, the Company has not recorded any impairment charges on available-for-sale securities.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the practical expedient to exclude the applicable accrued interest from both the fair value and the amortized cost basis of its available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable related to available-for-sale securities is presented in prepaid expenses and other current assets, separate from marketable securities, on the consolidated balance sheet. As of December&#160;31, 2025 and 2024, accrued interest receivable was immaterial. The Company has made an accounting policy election not to recognize an allowance for credit losses for accrued interest receivables on available-for-sale securities and to write-off any uncollectible accrued interest receivable by recognizing credit loss expense. The Company has not written off any accrued interest receivables for the years ended December&#160;31, 2025 and 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-492-3" continuedAt="f-492-4"><ix:continuation id="f-539-1"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the amortized cost and fair value of marketable securities by contractual maturity were as follows: </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturing within one year</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-592">138,281</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-593">138,395</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-594">143,708</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-595">144,018</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturing in one to five years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-596">39,681</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-597">39,680</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-598">12,593</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-599">12,602</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-600">177,962</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-601">178,075</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-602">156,301</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-603">156,620</ix:nonFraction></span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-604" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in the fair value of the embedded derivative instrument for the year ended December&#160;31, 2025 and 2024 (in thousands). There was <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:fixed-zero" scale="0" id="f-605">no</ix:nonFraction> activity for the year ended December&#160;31, 2023. </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="f-606">570</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="f-607">849</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-608"><span style="-sec-ix-hidden:f-609">Loss (gain) from changes in fair value</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-610">139</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-611">279</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="f-612">431</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="f-613">570</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-492-4">The fair value of the Company&#8217;s embedded derivative instrument is based on significant inputs not observed in the market, and thus represents a Level 3 measurement. See Note 9 for further discussion on the embedded derivative instrument.</ix:continuation> </span></div><div id="i2dffe4de76224390b628083ec6a2857c_148"></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-614" continuedAt="f-614-1" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="f-614-1" continuedAt="f-614-2"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-615" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-616">5,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-617">4,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-618">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="f-619">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-620">12,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-621">9,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-622">22,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-623">14,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-624" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid co-pay assistance program and rebates</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:PrepaidCopayAssistanceProgramAndRebates" format="ixt:num-dot-decimal" scale="3" id="f-625">9,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:PrepaidCopayAssistanceProgramAndRebates" format="ixt:num-dot-decimal" scale="3" id="f-626">7,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:PrepaidClinicalTrialTestCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-627">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:PrepaidClinicalTrialTestCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-628">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-629">9,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-630">9,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-631">21,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-632">19,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-614-2"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-633" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:AccruedSalesDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-634">78,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:AccruedSalesDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-635">38,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-636">20,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-637">20,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:ClinicalTrialAccrualCurrent" scale="3" id="f-638">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:ClinicalTrialAccrualCurrent" format="ixt:fixed-zero" scale="3" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-640">17,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-641">7,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-642">116,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-643">66,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2dffe4de76224390b628083ec6a2857c_151"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-644" continuedAt="f-644-1" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><ix:continuation id="f-644-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-645" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-646">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-647">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-648">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-649">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-650">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-651">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-652">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-653">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-654">4,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-655">3,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-656">3,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-657">2,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-658">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-659">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-660">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-661">0.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-662">0.8</ix:nonFraction> million for the years ended December&#160;31, 2025, 2024, and 2023 respectively. Leasehold improvements are depreciated over the term of the lease, which is the shorter of the improvements' expected useful lives and the lease term. All other fixed asset depreciation is recorded using the straight-line method over the estimated useful lives of the assets (<span style="-sec-ix-hidden:f-663">two</span> to <ix:nonNumeric contextRef="c-143" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-664">five years</ix:nonNumeric>).</span></div></ix:continuation><div id="i2dffe4de76224390b628083ec6a2857c_154"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="arqt:LicenseAgreementsAndAcquisitionsTextBlock" id="f-665" continuedAt="f-665-1" escape="true">License Agreements &amp; Ducentis Acquisition</ix:nonNumeric></span></div><ix:continuation id="f-665-1" continuedAt="f-665-2"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sato License Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, the Company entered into a license agreement with Sato Pharmaceutical Co., Ltd. (Sato). Pursuant to the terms of the license agreement with Sato (the Sato Agreement), the Company grants to Sato an exclusive, sublicensable (under certain circumstances) license under certain patent rights and know-how controlled by the Company for Sato to develop, conduct medical affairs activities for, manufacture, commercialize and otherwise exploit roflumilast formulations (the Sato Licensed Products) for all therapeutic uses for certain dermatological indications in humans (the Sato Field) in Japan. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sato Agreement sets forth each party&#8217;s respective obligations with respect to the development, medical affairs activities, manufacture, supply and commercialization of the Sato Licensed Products. Pursuant to the terms of the Sato Agreement, Sato will, at its expense, develop, obtain regulatory approval for, commercialize and conduct medical affairs activities related to the Sato Licensed Products in the Sato Field in Japan, subject to certain of the Company&#8217;s approval and oversight rights. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Sato Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="arqt:ContractNotWithCustomerUpfrontPaymentReceivedNet" scale="6" id="f-666">25.0</ix:nonFraction>&#160;million and will potentially receive additional payments (i) up to an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones" scale="6" id="f-667">10.0</ix:nonFraction>&#160;million upon the achievement of certain regulatory milestones and (ii) up to an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones" scale="6" id="f-668">30.0</ix:nonFraction>&#160;million upon the achievement of certain sales milestones. In addition, on a Sato Licensed Product-by-Sato Licensed Product basis, commencing from the first commercial sale of such Sato Licensed Product in Japan until the latest of (i) the expiration of the last valid claim in the intellectual property rights licensed by the Company to Sato under the Sato Agreement covering such Sato Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Sato Licensed Product in Japan, or (iii) <ix:nonNumeric contextRef="c-144" name="arqt:LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" format="ixt-sec:durwordsen" id="f-669">ten years</ix:nonNumeric> after the first commercial sale of such Sato Licensed Product in Japan, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-665-2" continuedAt="f-665-3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company will receive low double-digit to mid-teen double-digit percentage royalties on Sato&#8217;s, its affiliates&#8217; and sublicensees&#8217; total annual net sales of all Sato Licensed Products, subject to certain royalty reductions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The term of the Sato Agreement continues until, on a Sato Licensed Product-by-Sato Licensed Product basis, the expiration of the Royalty Term, which is the (i) the expiration of the last valid claim in the licensed technology covering such Sato Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product in Japan, or (iii) <ix:nonNumeric contextRef="c-144" name="arqt:LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" format="ixt-sec:durwordsen" id="f-670">ten years</ix:nonNumeric> after the first commercial sale of such Licensed Product in Japan. The Sato Agreement may be terminated by either party in its entirety if the other party commits a material breach, subject to a cure period, or if the other party becomes insolvent. Sato may terminate the Sato Agreement at-will in its entirety upon <ix:nonNumeric contextRef="c-144" name="arqt:LicenseAgreementTerminationNumberOfDaysForWrittenNotice" format="ixt-sec:durday" id="f-671">90</ix:nonNumeric> days&#8217; written notice. Unless unenforceable under applicable law, the Company may terminate the Sato Agreement in its entirety if Sato, its affiliate or sublicensee contests or assists a third party in contesting the scope, validity or enforceability of any patent or patent application licensed by the Company to Sato. The Company may also terminate the Sato Agreement if Sato or any director, officers, employee, agent, affiliate, sublicensee or subcontractor is charged by a governmental authority for a violation of any anti-corruption, anti-money laundering, sanctions or export or import control laws or regulations, or, subject to the terms of the Sato Agreement, if Sato, its affiliates and sublicensees do not conduct any material development or commercialization activities of a Sato Licensed Product in Japan for a certain period of time.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-146" decimals="INF" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-672">no</ix:nonFraction> other revenue recorded pursuant to the Sato Agreement for the year ended December 31, 2025 and $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="f-673">25.0</ix:nonFraction>&#160;million recorded for the year ended December 31, 2024.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Huadong License Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (Huadong), a wholly owned subsidiary of Huadong Medicine Co., Ltd. Pursuant to the terms of the agreement, the Company granted to Huadong an exclusive, sublicensable (under certain circumstances) license under certain patent rights and know-how controlled by the Company for Huadong to develop, conduct medical affairs activities for, manufacture, commercialize, and otherwise exploit both cream and foam topical roflumilast for all therapeutic uses for certain dermatological indications (Huadong Licensed Products) in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and Southeast Asia (Indonesia, Singapore, The Philippines, Thailand, Myanmar, Brunei, Cambodia, Laos, Malaysia, and Vietnam) (Huadong Territories).</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Huadong will, at its expense, develop, obtain regulatory approval for, commercialize, and conduct medical affairs activities for the Huadong Licensed Products, subject to certain of the Company&#8217;s approval and oversight rights. The Company will retain exclusive rights for the development, manufacture and commercialization of topical roflumilast outside the Huadong Territories.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the rights granted under the license agreement with Huadong (the Huadong Agreement), Huadong paid the Company a non-refundable upfront fee pursuant to the terms of the agreement, upon closing in September 2023. The Company received a net payment of $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="arqt:ContractNotWithCustomerUpfrontPaymentNet" scale="6" id="f-674">27.0</ix:nonFraction>&#160;million, which consisted of a $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="f-675">30.0</ix:nonFraction>&#160;million upfront payment less the applicable tax withholding obligation in China of $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation" scale="6" id="f-676">3.0</ix:nonFraction>&#160;million. In addition, the Company received a net payment of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="arqt:ContractNotWithCustomerUpfrontPaymentNet" scale="6" id="f-677">2.7</ix:nonFraction>&#160;million in March 2024 related to the achievement of a development and regulatory milestone less the applicable tax withholding. The Company received a net payment of $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="arqt:ContractNotWithCustomerUpfrontPaymentNet" scale="6" id="f-678"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="arqt:ContractNotWithCustomerUpfrontPaymentNet" scale="6" id="f-679"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="arqt:ContractNotWithCustomerUpfrontPaymentNet" scale="6" id="f-680">1.8</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million in each of December 2024, March 2025 and November 2025, related to the achievement of development and regulatory milestones less the applicable tax withholding. The Company may also potentially receive additional payments: (i) up to an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones" scale="6" id="f-681">15.0</ix:nonFraction>&#160;million upon the achievement of certain development and regulatory milestones, (ii) up to an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones" scale="6" id="f-682">40.3</ix:nonFraction>&#160;million upon the achievement of certain sales milestones, and (iii) low double-digit to high-teen double-digit tiered percentage royalties on net sales of the Huadong Licensed Products, all of which would be subject to applicable tax withholding obligations.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Huadong Agreement continues on a Huadong Licensed Product-by-Huadong Licensed Product and country or region-by-country or region basis, until the expiration of the Royalty Term, which is: (i) the date of expiration of the last valid patent claim related to the Huadong Licensed Products, (ii) <ix:nonNumeric contextRef="c-154" name="arqt:LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" format="ixt-sec:durwordsen" id="f-683">ten years</ix:nonNumeric> after the first commercial sale of a Huadong Licensed Product and (iii) the expiration of any regulatory exclusivity as to a Huadong Licensed Product. The Huadong Agreement may be terminated by both parties under certain circumstances.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-665-3" continuedAt="f-665-4"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue and related income tax expense related to the Huadong agreement was $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="f-684">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation" scale="6" id="f-685">0.4</ix:nonFraction> million, respectively, for the year ended December&#160;31, 2025. Other revenue and related tax income expense related to the Huadong agreement was $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="f-686">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation" scale="6" id="f-687">0.5</ix:nonFraction> million, respectively, for the year ended December&#160;31, 2024. Other revenue and related income tax expense related to the Huadong agreement was $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="f-688">30.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation" scale="6" id="f-689">3.0</ix:nonFraction> million, respectively, for the year ended December&#160;31, 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca License Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company entered into an exclusive license agreement with AstraZeneca AB (AstraZeneca), granting the Company a worldwide exclusive license, with the right to sublicense through multiple tiers, under certain AstraZeneca-controlled patent rights, know-how and regulatory documentation, to research, develop, manufacture, commercialize and otherwise exploit products containing roflumilast in topical forms, as well as delivery systems sold with or for the administration of roflumilast (collectively, the AZ-Licensed Products), for all diagnostic, prophylactic and therapeutic uses for human dermatological indications (the Dermatology Field). Under the license agreement with AstraZeneca (the AstraZeneca Agreement), the Company has sole responsibility for development, regulatory and commercialization activities for the AZ-Licensed Products in the Dermatology Field, at its expense, and it shall use commercially reasonable efforts to develop, obtain and maintain regulatory approvals for, and commercialize the AZ-Licensed Products in the Dermatology Field in each of the United States, Italy, Spain, Germany, the United Kingdom, France, China and Japan.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval" scale="6" id="f-690">7.5</ix:nonFraction>&#160;million to AstraZeneca as a result of the approval of ZORYVE cream 0.3%, which was recorded as an intangible asset. In October 2024, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" scale="6" id="f-691">5.0</ix:nonFraction>&#160;million to AstraZeneca upon achievement of $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" scale="6" id="f-692">100.0</ix:nonFraction>&#160;million in worldwide net sales, which was recorded as a cumulative catch-up adjustment to the carrying value of the intangible asset. In May 2025, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" scale="6" id="f-693">10.0</ix:nonFraction>&#160;million to AstraZeneca upon achievement of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" scale="6" id="f-694">250.0</ix:nonFraction>&#160;million in worldwide net sales and was recorded as a cumulative catch-up adjustment to the carrying value of the intangible asset. The Company is amortizing the intangible asset to cost of sales over its useful life of <ix:nonNumeric contextRef="c-158" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-695">10</ix:nonNumeric> years from the date of first commercial sale as this is the minimum amount of time that the related AstraZeneca Agreement will be in effect. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-696">4.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-697">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-698">0.8</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the years ended December&#160;31, 2025, 2024, and 2023,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreed to make additional cash payments to AstraZeneca of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments" scale="6" id="f-699">5.0</ix:nonFraction> million upon the achievement of specified regulatory approval milestones with respect to the AZ-Licensed Products. With respect to any AZ-Licensed Products the Company commercializes under the AstraZeneca Agreement, it will pay AstraZeneca a low to high single-digit percentage royalty rate on the Company&#8217;s, its affiliates&#8217; and its sublicensees&#8217; net sales of such AZ-Licensed Products, subject to specified reductions, until, as determined on an AZ-Licensed Product-by-AZ-Licensed Product and country-by-country basis, the later of the date of the expiration of the last-to-expire AstraZeneca-licensed patent right containing a valid claim in such country and <ix:nonNumeric contextRef="c-1" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale" format="ixt-sec:durwordsen" id="f-700">ten years</ix:nonNumeric> from the first commercial sale of such AZ-Licensed Product in such country. As a result of the commercialization of ZORYVE cream in August 2022, the Company began accruing royalties payable to AstraZeneca, which are recorded in cost of sales and accrued liabilities. Royalty expense during the years ended December&#160;31, 2025, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:RoyaltyExpense" scale="6" id="f-701">11.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:RoyaltyExpense" scale="6" id="f-702">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:RoyaltyExpense" scale="6" id="f-703">0.9</ix:nonFraction> million, respectively. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hengrui Exclusive Option and License Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company entered into an exclusive option and license agreement, or the Hengrui License Agreement, with Jiangsu Hengrui Medicine Co., Ltd. (Hengrui), whereby Hengrui granted the Company an exclusive option to obtain certain exclusive rights to research, develop, and commercialize products containing the compound designated by Hengrui as ivarmacitinib, a Janus kinase type 1 inhibitor, in topical formulations for the treatment of skin diseases, disorders, and conditions in the United States, Japan, and the European Union (including for clarity the United Kingdom). In December 2019, the Company exercised its exclusive option under the agreement and contemporaneously amended the agreement to expand the territory to additionally include Canada. In addition, the Company has agreed to make cash payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments" scale="6" id="f-704">20.5</ix:nonFraction> million upon achievement of specified clinical development and regulatory approval milestones with respect to the licensed products and cash payments of up to an additional aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" scale="6" id="f-705">200.0</ix:nonFraction> million in sales-based milestones based on certain aggregate annual net sales volumes with respect to a licensed product. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to any products the Company commercializes under the Hengrui License Agreement, it will pay tiered royalties to Hengrui on net sales of each licensed product by the Company, or its affiliates, or its sublicensees, ranging from mid single-digit to sub-teen percentage rates based on tiered annual net sales bands </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-665-4"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to specified reductions. The Company is obligated to pay royalties until the later of (1)&#160;expiration of the last valid claim of the licensed patent rights covering such licensed product in such country and (2)&#160;expiration of regulatory exclusivity for the relevant licensed product in the relevant country, on a licensed product-by-licensed product and country-by-country basis. Additionally, the Company is obligated to pay Hengrui a specified percentage, ranging from the low-thirties to the sub-teens, of certain non-royalty sublicensing income it receives from sublicensees of its rights to the licensed products, such percentage decreasing as the development stage of the licensed products advance.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a side letter agreement with Hengrui and one of its subsidiaries to extend certain rights and obligations under the Hengrui License Agreement to the subsidiary under specified circumstances, including a change of control of such subsidiary. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-159" decimals="INF" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:fixed-zero" scale="0" id="f-706"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="INF" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:fixed-zero" scale="0" id="f-707"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="INF" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:fixed-zero" scale="0" id="f-708">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> payments made or due in connection with Hengrui for the years ended December 31, 2025, 2024 and 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of a Phase 1b study in the middle of 2025, the Company elected to halt further development of ARQ-255, a topical formulation of ivarmacitinib, for the treatment of alopecia areata. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ducentis Biotherapeutics LTD Acquisition</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2022, the Company entered into a Share Purchase Agreement with Ducentis Biotherapeutics LTD (Ducentis) and certain stockholders of Ducentis, pursuant to which the Company acquired all of the outstanding equity interests in Ducentis for (i) <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="arqt:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-709">610,258</ix:nonFraction> shares of the Company's common stock, valued at approximately $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" scale="6" id="f-710">12.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="arqt:AssetAcquisitionConsiderationTransferredGross" scale="6" id="f-711">15.9</ix:nonFraction>&#160;million in cash, inclusive of liabilities acquired, and (ii) contingent payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="arqt:AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount" scale="6" id="f-712">400</ix:nonFraction>&#160;million, which may become payable upon the achievement of certain development, regulatory, and commercial milestones (the Acquisition). Such contingent payments include a $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="arqt:AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones" scale="6" id="f-713">10.0</ix:nonFraction>&#160;million payment due within <ix:nonNumeric contextRef="c-162" name="arqt:AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment" format="ixt-sec:durwordsen" id="f-714">one year</ix:nonNumeric> from the first dosing of the first human subject enrolled in the first Phase 1 clinical trial of a therapeutic drug containing Ducentis' DS-234 product candidate, now ARQ-234. The Company anticipates commencing such Phase 1 study in the first quarter of 2026. In addition, if applicable, the Company will make payments amounting to a mid-single-digit percentage of any annual net sales of certain products exceeding $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-8" name="arqt:AssetAcquisitionAnnualNetSalesOfAcquireeThreshold" scale="9" id="f-715">1.5</ix:nonFraction>&#160;billion. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for this purchase of equity interests in Ducentis as an in-process research and development (IPR&amp;D) asset acquisition as it has no alternative future use, and recorded a $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-716">29.6</ix:nonFraction>&#160;million charge to research and development expense on the acquisition date. Any contingent payments made under the Share Purchase Agreement will be recorded when it is probable that they will occur and they can be reasonably estimated, at which point the Company will determine whether the payment should be expensed or capitalized depending on whether the IPR&amp;D has achieved market acceptance. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-165" decimals="INF" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt-sec:numwordsen" id="f-717"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="INF" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt-sec:numwordsen" id="f-718"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="INF" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt-sec:numwordsen" id="f-719">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> payments made or due for the years ended December 31, 2025, 2024 and 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Share Purchase Agreement, the Company will develop and seek FDA approval of a therapeutic product containing ARQ-234 for an atopic dermatitis indication, and if FDA approval of ARQ-234 is obtained by the Company, to commercially launch it in the United States.</span></div></ix:continuation><div id="i2dffe4de76224390b628083ec6a2857c_157"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-720" continuedAt="f-720-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-720-1" continuedAt="f-720-2"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company's lease for its corporate headquarters (<ix:nonFraction unitRef="sqft" contextRef="c-168" decimals="0" name="arqt:LesseeOperatingLeaseOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="f-721">22,643</ix:nonFraction> square feet of office space) commenced in February 2019 and was amended in April 2020 in order to relocate to a new expanded space. In August 2025, the Company entered into a second amendment to extend the term of the lease by <ix:nonNumeric contextRef="c-169" name="arqt:LesseeOperatingLeaseExtensionTerm" format="ixt-sec:durwordsen" id="f-722">five years</ix:nonNumeric>, extending the lease expiration from August 2028 to July 2033. This second amendment had a net effect of increasing the Company's future lease payments by approximately $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="arqt:LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments" scale="6" id="f-723">5.4</ix:nonFraction>&#160;million, primarily due to the <span style="-sec-ix-hidden:f-724">five</span> additional years of rent payments. In accordance with ASC 842, the Company remeasured the present value of the aggregate lease payments over the amended lease term and recorded an increase to the Company&#8217;s operating lease liabilities and existing right-of-use lease asset of approximately $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="arqt:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="6" id="f-725"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-726">2.9</ix:nonFraction></ix:nonFraction>&#160;million in the third quarter 2025 as a result of this remeasurement.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease also requires the Company to have an available letter of credit which has a related restricted cash account of  $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="f-727">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="f-728">0.6</ix:nonFraction>&#160;million as of December&#160;31, 2025 and 2024, respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-720-2" continuedAt="f-720-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-729" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum annual rental payments of the Company&#8217;s operating lease liability as of December&#160;31, 2025 are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-730">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-731">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-732">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-733">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-734">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-735">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-736">8,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-737">2,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-738">5,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-739">Accrued and other current liabilities</span></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-740">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, long-term</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-741">5,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-742">5,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs recognized was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-743">0.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-744">0.7</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-745">0.7</ix:nonFraction>&#160;million for the years ended December&#160;31, 2025, 2024, and 2023, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-746" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information represents supplemental disclosure for the consolidated statements of cash flows related to the Company&#8217;s operating lease (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-747">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-748">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-749">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to the operating lease:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-750">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-11" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-751">3.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-752">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-753">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Agreements</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into manufacturing supply agreements for the commercial supply of ZORYVE which include certain minimum purchase commitments. As of December 31, 2025, firm future purchase commitments that are subject to these agreements with a term of greater than one year, excluding those recognized on the consolidated balance sheets, are $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear" scale="6" id="f-754">1.7</ix:nonFraction>&#160;million in 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear" scale="6" id="f-755">0.9</ix:nonFraction>&#160;million in 2027, respectively. These future purchase commitments do not represent all of the Company&#8217;s anticipated purchases, but instead represents only the contractually obligated minimum purchases or firm commitments of non-cancelable minimum amounts.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-720-3" continuedAt="f-720-4"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reason of their status or service as directors or officers to the fullest extent permitted by the provisions of the Company's Bylaws and the Delaware General Corporation Law. The Company currently has directors&#8217; and officers&#8217; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes any potential loss exposure under these indemnification agreements in excess of applicable insurance coverage is minimal.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingencies</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company may be involved in legal proceedings, as well as demands, claims, and threatened litigation, which arise in the normal course of business or otherwise. The ultimate outcome of any litigation is uncertain, and unfavorable outcomes could have a negative impact on the Company's results of operations and financial condition. Regardless of outcome, litigation can have an adverse impact on the Company because of the defense costs, the diversion of management resources, and other factors. </span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-720-4">As of December 31, 2025 and 2024, the Company determined that no loss contingencies from legal proceedings&#8212;including the patent infringement complaint filed against the Company by Teva Pharmaceutical Industries, Ltd.&#8212;met the threshold of "probable" and "reasonably estimable", as defined in ASC 450.</ix:continuation> </span></div><div id="i2dffe4de76224390b628083ec6a2857c_160"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:LongTermDebtTextBlock" id="f-756" continuedAt="f-756-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-756-1" continuedAt="f-756-2"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2021, the Company entered into a loan and security agreement (the Prior Loan Agreement) with SLR Investment Corp. (SLR) and the lenders party thereto. The Prior Loan Agreement was amended and restated on January 10, 2023 (the AR Loan Agreement) to include Arcutis Canada, Inc. as a borrower and party. On November 1, 2023, the Company entered into an amendment to the AR Loan Agreement to, among others, (i) modify the financial covenant relating to minimum net product revenue, and (ii) include an additional minimum financing covenant. On August 9, 2024, the Company entered into a second amendment to the AR Loan Agreement (the AR Loan Agreement, as amended by the first and second amendments, the Loan Agreement), which it determined to be a modification, to, among others, (i) permit, during the period commencing on October 7, 2024 and ending on December 15, 2024, an optional partial prepayment of term loans outstanding, subject to a <ix:nonFraction unitRef="number" contextRef="c-174" decimals="INF" name="arqt:DebtInstrumentPrepaymentPremium" scale="-2" id="f-757">1.0</ix:nonFraction>% prepayment penalty (the 2024 Partial Prepayment), (ii) add the tranche C-1 and tranche C-2 term loans, and (iii) facilitate certain other changes, including with respect to the applicable interest rate and maturity date in the event of a 2024 Partial Prepayment. As security for the obligations under the Loan Agreement, the Company granted SLR, for the benefit of the lenders, a continuing security interest in substantially all of the Company's assets, including its intellectual property, subject to certain exceptions. The term loan facility is comprised of (i) a tranche A term loan of $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="arqt:DebtInstrumentMaximumBorrowingCapacity" scale="6" id="f-758">75.0</ix:nonFraction>&#160;million, (ii) a tranche B-1 term loan of $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="arqt:DebtInstrumentMaximumBorrowingCapacity" scale="6" id="f-759">50.0</ix:nonFraction>&#160;million, (iii) a tranche B-2 term loan of up to $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="arqt:DebtInstrumentMaximumBorrowingCapacity" scale="6" id="f-760">75.0</ix:nonFraction>&#160;million, (iv) a tranche C-1 term loan of up to $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="arqt:DebtInstrumentMaximumBorrowingCapacity" scale="6" id="f-761">50.0</ix:nonFraction>&#160;million, and (v) a tranche C-2 term loan of up to $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="arqt:DebtInstrumentMaximumBorrowingCapacity" scale="6" id="f-762">50.0</ix:nonFraction>&#160;million (collectively, the Term Loans). The tranche A term loan was funded on December 22, 2021. With the approval of ZORYVE cream 0.3% on July 29, 2022, the tranche B term loans were funded on August 2, 2022. As of December&#160;31, 2025 and 2024, the aggregate principal amount outstanding under the Loan Agreement was $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="f-763"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="f-764">100.0</ix:nonFraction></ix:nonFraction>&#160;million. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 8, 2024, the Company made a 2024 Partial Prepayment of $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" id="f-765">100.0</ix:nonFraction>&#160;million, which reduced the aggregate principal amount outstanding under the Loan Agreement to $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="f-766">100.0</ix:nonFraction>&#160;million. In connection with the 2024 Partial Prepayment, the Company is obligated to pay a prepayment penalty of $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="arqt:DebtInstrumentPrepaymentPenalty" scale="6" id="f-767">1.0</ix:nonFraction>&#160;million by June 30, 2026 and a final fee of $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-4" name="arqt:DebtInstrumentPrepaymentPenalty" scale="6" id="f-768">6.95</ix:nonFraction>&#160;million, representing the final fee applicable to the amount of the 2024 Partial Prepayment, on January 1, 2027.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of such 2024 Partial Prepayment, subject to the Company generating a minimum net product revenue for the trailing six (<ix:nonNumeric contextRef="c-181" name="arqt:DebtInstrumentFundingAvailabilityCovenantPeriod" format="ixt-sec:durmonth" id="f-769">6</ix:nonNumeric>) month period ending as of the month prior to the borrowing date equal to <ix:nonFraction unitRef="number" contextRef="c-182" decimals="INF" name="arqt:DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue" scale="-2" id="f-770">80</ix:nonFraction>% of the Company&#8217;s projected net product revenue as set forth in its annual plan for the respective period, the Company will be able to draw down the tranche C-1 and tranche C-2 term loans. The tranche C-1 term loan availability will expire on March 31, 2026 and the tranche C-2 term loan availability will expire on June 30, 2026. In addition, as a result of the 2024 Partial Prepayment, (i) the maturity date of the Loan Agreement is August 1, 2029, (ii) the applicable per annum interest rate is equal to <ix:nonFraction unitRef="number" contextRef="c-182" decimals="INF" name="arqt:DebtInstrumentInterestRateStatedPercentagePartialPrepayment" scale="-2" id="f-771">5.95</ix:nonFraction>% plus the greater of (a) <ix:nonFraction unitRef="number" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-772">2.50</ix:nonFraction>% per annum and (b) the one-month Secured Overnight Financing Rate (SOFR), (iii) the Company is no longer subject to certain cost and purchase price restrictions regarding acquisitions, and (iv) the Company may prepay principal amounts outstanding under the Term Loans in minimum increments of $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" id="f-773">25.0</ix:nonFraction>&#160;million, subject to a prepayment premium of (a) <ix:nonFraction unitRef="number" contextRef="c-186" decimals="INF" name="arqt:DebtInstrumentPrepaymentPremium" scale="-2" id="f-774">3.0</ix:nonFraction>% for any prepayment made prior to the first anniversary of the second amendment, (b) <ix:nonFraction unitRef="number" contextRef="c-187" decimals="INF" name="arqt:DebtInstrumentPrepaymentPremium" scale="-2" id="f-775">2.0</ix:nonFraction>% for any prepayment made prior after the first anniversary of the second amendment and prior to the second anniversary of the second amendment, or (c) <ix:nonFraction unitRef="number" contextRef="c-188" decimals="INF" name="arqt:DebtInstrumentPrepaymentPremium" scale="-2" id="f-776">1.0</ix:nonFraction>% </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-756-2" continuedAt="f-756-3"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for any prepayment made prior after the second anniversary of the second amendment and prior to the maturity date.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Principal amounts outstanding under the Term Loans will accrue interest at a floating rate equal to the applicable rate in effect from time to time, as determined by SLR on the third business day prior to the funding date of the applicable Term Loan and on the first business day of the month prior to each payment date of each Term Loan. Prior to the 2024 Partial Prepayment, the applicable rate was a per annum interest rate equal to <ix:nonFraction unitRef="number" contextRef="c-189" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-777">7.45</ix:nonFraction>% plus the greater of (a) <ix:nonFraction unitRef="number" contextRef="c-190" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-778">0.10</ix:nonFraction>% and (b) the one-month SOFR. As a result of such 2024 Partial Prepayment, the applicable interest rate will be a per annum interest rate equal to <ix:nonFraction unitRef="number" contextRef="c-182" decimals="INF" name="arqt:DebtInstrumentInterestRateStatedPercentagePartialPrepayment" scale="-2" id="f-779">5.95</ix:nonFraction>% plus the greater of (a) <ix:nonFraction unitRef="number" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-780">2.50</ix:nonFraction>% and (b) the one-month SOFR. On December&#160;31, 2025, the rate was <ix:nonFraction unitRef="number" contextRef="c-50" decimals="4" name="arqt:DebtInstrumentInterestRateAtPeriodEnd" scale="-2" id="f-781">9.79</ix:nonFraction>%. The benchmark SOFR is subject to change in the event of certain events with respect to the benchmark rate. Interest payments are payable monthly following the funding of any Term Loan. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Term Loans are accelerated due to, among others, the occurrence of a bankruptcy or insolvency event, the Company is required to make mandatory prepayments of (i) all principal amounts outstanding under the Term Loans, plus accrued and unpaid interest thereon through the prepayment date, (ii) any fees applicable by reason of such prepayment, (iii) the prepayment premiums set forth in the paragraph above, plus (iv) all other obligations that are due and payable, including expenses and interest at the Default Rate (as defined below) with respect to any past due amounts.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on the Company&#8217;s ability to dispose of its business or property, to change its line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on its property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. The Company also agreed to a financial covenant whereby the Company must generate a minimum net product revenue equal to <ix:nonFraction unitRef="number" contextRef="c-174" decimals="INF" name="arqt:DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue" scale="-2" id="f-782">75</ix:nonFraction>% of its projected net product revenue as set forth in the Company's annual plan for the respective period, tested on a trailing <ix:nonNumeric contextRef="c-191" name="arqt:DebtInstrumentFundingAvailabilityCovenantPeriod" format="ixt-sec:durwordsen" id="f-783">six-month</ix:nonNumeric> basis, as of the end of each month. Each annual plan shall be approved by the Company&#8217;s board of directors and SLR, in its capacity as collateral agent, in its reasonable discretion. Any failure by the Company to deliver such annual plan on or before December 15 of the prior year shall be an immediate event of default. The Company was in compliance with all covenants under the Loan Agreement as of December&#160;31, 2025.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Loan Agreement contains customary events of default that entitle the lenders to cause any indebtedness under the Loan Agreement to become immediately due and payable, and to exercise remedies against the Company and the collateral securing the Term Loans. Under the Loan Agreement, an event of default will occur if, among other things, the Company fails to make payments under the Loan Agreement, the Company breaches any of the covenants under the Loan Agreement, subject to specified cure periods with respect to certain breaches, the lenders determine that a material adverse change has occurred, or the Company or the Company's assets become subject to certain legal proceedings, such as bankruptcy proceedings. Upon the occurrence and for the duration of an event of default, an additional default interest rate, or the Default Rate, equal to <ix:nonFraction unitRef="number" contextRef="c-189" decimals="3" name="arqt:DebtInstrumentDefaultRate" scale="-2" id="f-784">4.0</ix:nonFraction>% per annum will apply to all obligations owed under the Loan Agreement. The prepayment upon default and other potential additional interest provisions under the Loan Agreement were determined to be a compound embedded derivative instrument to be bifurcated from the loan and accounted for as a separate liability for accounting purposes under the guidance in ASC 815, Derivatives and Hedging. At the inception of the Loan Agreement, the fair value of the embedded derivative was determined to be immaterial. The embedded derivative instrument is remeasured at fair value each reporting period with any future changes in fair value reported in Other income, net in the consolidated statement of operations and comprehensive loss. The amounts recognized in Other income, net related to the change in fair value of the embedded derivative instrument during the year ended December 31, 2025 and 2024 were not material. No gain or loss was recognized during the year ended December 31, 2023. The fair value of the embedded derivative instrument as of December&#160;31, 2025 and 2024 was a liability of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="f-785">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="f-786">0.6</ix:nonFraction> million, respectively, and is included in Other-long term liabilities in the accompanying consolidated balance sheets. See Note 4.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n connection with the Loan Agreement, the Company is obligated to pay (i) a final fee equal to <ix:nonFraction unitRef="number" contextRef="c-189" decimals="4" name="arqt:DebtInstrumentFinalFeePercentage" scale="-2" id="f-787">6.95</ix:nonFraction>% of the aggregate original principal amount of the Term Loans outstanding as of the date of the second amendment (x) with respect to any 2024 Partial Prepayment, upon the earliest to occur of (a) January 1, 2027, (b) the acceleration of all </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-756-3"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding Term Loans and (c) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, and (y) with respect to the Term Loans outstanding as of the date of the second amendment (other than the 2024 Partial Prepayment), upon the earliest to occur of (a) the maturity date, (b) the acceleration of all outstanding Term Loans and (c) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, (ii) a <ix:nonFraction unitRef="number" contextRef="c-192" decimals="4" name="arqt:DebtInstrumentFinalFeePercentage" scale="-2" id="f-788">2.00</ix:nonFraction>% fee with respect to tranche C term loans, due and payable on the earliest to occur of (a) the maturity date, (b) the acceleration of all outstanding Term Loans and (c) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, (iii) a <ix:nonFraction unitRef="number" contextRef="c-192" decimals="3" name="arqt:DebtInstrumentExtensionFeePercentage" scale="-2" id="f-789">2.00</ix:nonFraction>% extension fee with respect to tranche C term loans which remain unfunded after December 31, 2025, which shall accrue during the period commencing January 1, 2026, and ending on the earliest to occur of (a) the expiration of the tranche C term loan availability, and (b) the date on which tranche C term loan is fully drawn, and (iv) a certain amount of lenders&#8217; expenses incurred in connection with the execution of the Loan Agreement. Additionally, in connection with the original Prior Loan Agreement, the Company previously had entered into an Exit Fee Agreement, whereby the Company agreed to pay an exit fee in the amount of <ix:nonFraction unitRef="number" contextRef="c-189" decimals="3" name="arqt:DebtInstrumentExitFeePercentage" scale="-2" id="f-790">3.0</ix:nonFraction>% of each Term Loan funded upon (i) any change of control transaction or (ii) a revenue milestone, calculated on a trailing <ix:nonNumeric contextRef="c-190" name="arqt:DebtInstrumentFundingAvailabilityCovenantPeriod" format="ixt-sec:durwordsen" id="f-791">six-month</ix:nonNumeric> basis. Notwithstanding the prepayment or termination of the Term Loan, the exit fee will expire <ix:nonNumeric contextRef="c-190" name="arqt:DebtInstrumentExitFeeExpirationPeriod" format="ixt-sec:duryear" id="f-792">10</ix:nonNumeric> years from the date of the Loan Agreement.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt issuance costs have been recorded as a debt discount which are being accreted to interest expense through the maturity date of the term loan. Interest expense is calculated using the effective interest method, and is inclusive of non-cash amortization of debt issuance costs. The final maturity payment of $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="arqt:DebtInstrumentDeferredFinalFeeGross" scale="6" id="f-793">13.9</ix:nonFraction>&#160;million is recognized over the life of the term loan through interest expense. At December&#160;31, 2025 and 2024, the effective interest rate was <ix:nonFraction unitRef="number" contextRef="c-50" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-794">10.92</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-180" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-795">11.57</ix:nonFraction>%, respectively. Interest expense relating to the term loan was $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-796">12.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-797">27.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-798">29.7</ix:nonFraction>&#160;million, respectively, for the years ended December&#160;31, 2025, 2024 and 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-799" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to the Company's long-term debt (in thousands): </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-800">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-801">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued final fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:DebtInstrumentAccruedFinalFee" format="ixt:num-dot-decimal" scale="3" id="f-802">8,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:DebtInstrumentAccruedFinalFee" format="ixt:num-dot-decimal" scale="3" id="f-803">7,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued prepayment penalty</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:DebtInstrumentAccruedPrepaymentPenalty" format="ixt:num-dot-decimal" scale="3" id="f-804">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:DebtInstrumentAccruedPrepaymentPenalty" format="ixt:num-dot-decimal" scale="3" id="f-805">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="f-806">865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-807">1,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-808">108,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-809">107,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-810">1,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-812">107,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-813">107,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the contractual maturity of the Company's long term debt, a payment of principal and final fees of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="f-814">107.0</ix:nonFraction> million is due on August 1, 2029.</span></div></ix:continuation><div id="i2dffe4de76224390b628083ec6a2857c_166"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-815" continuedAt="f-815-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="f-815-1" continuedAt="f-815-2"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's authorized capital stock consists of <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CapitalUnitsAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-816">310,000,000</ix:nonFraction> shares, all with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-817">0.0001</ix:nonFraction> per share, of which <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-818">300,000,000</ix:nonFraction> shares are designated as common stock and <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-819">10,000,000</ix:nonFraction> shares are designated as preferred stock. There were <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-820"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-821">no</ix:nonFraction></ix:nonFraction> shares of preferred stock outstanding as of December&#160;31, 2025 and 2024. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-815-2" continuedAt="f-815-3"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Company completed a public sale of its common stock, receiving aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-822">95.8</ix:nonFraction>&#160;million. In addition to the sale of common stock, the Company issued prefunded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-823">7,500,000</ix:nonFraction> shares of the Company's common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-824">2.4999</ix:nonFraction> per underlying share of common stock. The exercise price of the warrants is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-825">0.0001</ix:nonFraction> per underlying share of common stock, were fully exercisable upon issuance, and have no expiration date. In October 2025, certain prefunded warrants were exercised, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-826">2,285,000</ix:nonFraction> shares. As of December&#160;31, 2025, prefunded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-827">5,215,000</ix:nonFraction> shares of the Company's common stock remained outstanding. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company completed a public sale of its common stock, receiving aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-828">161.7</ix:nonFraction>&#160;million.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market (ATM) Offerings</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2021, the Company entered into a sales agreement (Sales Agreement) with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through ATM offerings for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="arqt:SaleOfStockAuthorizedConsiderationOnTransaction" scale="6" id="f-829">100.0</ix:nonFraction>&#160;million. Cowen will act as the Company's sales agent for the ATM program and is entitled to compensation for its services up to <ix:nonFraction unitRef="number" contextRef="c-202" decimals="2" name="arqt:SaleOfStockAgentFeePercentageOfGrossProceeds" scale="-2" id="f-830">3</ix:nonFraction>% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In December 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-831">1,250,000</ix:nonFraction> shares under the ATM for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-204" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-832">2.60</ix:nonFraction> per share and received $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-833">3.1</ix:nonFraction>&#160;million in net proceeds. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Company amended and restated its Sales Agreement with Cowen to reset the ATM program and provide for the offer and sale of shares of common stock having an aggregate gross offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="arqt:SaleOfStockAuthorizedConsiderationOnTransaction" scale="6" id="f-834">100.0</ix:nonFraction>&#160;million. All other terms of the amended and restated Sales Agreement are substantially the same as the original Sales Agreement. The Company has not yet issued or sold any common stock under the amended and restated Sales Agreement.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company&#8217;s board of directors approved the 2020 Equity Incentive Plan (2020 Plan), which became effective January 30, 2020 in connection with the IPO. The 2020 Plan serves as the successor incentive award plan to the Company&#8217;s 2017 Equity Incentive Plan (2017 Plan) and initially reserved <ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-835">2,134,000</ix:nonFraction> shares of common stock available for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit (RSU) awards, and other stock-based awards, plus <ix:nonFraction unitRef="shares" contextRef="c-207" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-836">1,550,150</ix:nonFraction> shares of common stock that were reserved for issuance pursuant to future awards under the 2017 Plan at the time the 2020 Plan became effective, plus shares represented by awards outstanding under the 2017 Plan that are forfeited or lapsed unexercised and which following the effective date of the 2020 Plan are not issued under the 2017 Plan. In addition, the 2020 Plan reserve will increase on January 1 of each year beginning in 2021 through 2030, by an amount equal to the lesser of (a) <ix:nonFraction unitRef="number" contextRef="c-206" decimals="INF" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="f-837">4</ix:nonFraction>% of the shares of stock outstanding (on an as converted basis) on the day immediately prior to the date of increase and (b) such smaller number of shares of stock as determined by the Company's board of directors; provided, however, that no more than <ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" format="ixt:num-dot-decimal" scale="0" id="f-838">11,000,000</ix:nonFraction> shares of stock may be issued upon the exercise of incentive stock options. Accordingly, on January 1, 2026, 2025 and 2024, the 2020 Plan reserve increased by <ix:nonFraction unitRef="shares" contextRef="c-208" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-839">4,933,306</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-209" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-840">4,713,921</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-210" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-841">3,871,494</ix:nonFraction> shares, respectively. As of December&#160;31, 2025, the Company had <ix:nonFraction unitRef="shares" contextRef="c-211" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-842">4,093,603</ix:nonFraction> shares available for future grant under the 2020 Plan.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors, and consultants of the Company under terms and provisions established by the board of directors. Under the terms of the 2020 Plan, options may be granted at an exercise price not less than fair market value. The Company generally grants stock-based awards with service conditions. Options granted typically vest over a <ix:nonNumeric contextRef="c-212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-843">four-year</ix:nonNumeric> period but may be granted with different vesting terms.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Company&#8217;s IPO and in connection with the effectiveness of the Company&#8217;s 2020 Plan, the 2017 Plan terminated and no further awards will be granted under that plan. However, all outstanding awards under the 2017 Plan will continue to be governed by their existing terms.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-815-3" continuedAt="f-815-4"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, the Company&#8217;s board of directors approved the 2022 Employment Inducement Incentive Plan (2022 Plan). The 2022 Plan initially reserved <ix:nonFraction unitRef="shares" contextRef="c-213" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-844">1,250,000</ix:nonFraction> shares of common stock available for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, RSU awards, and other stock-based awards. In November 2022, the 2022 Plan reserve was increased by <ix:nonFraction unitRef="shares" contextRef="c-214" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-845">1,500,000</ix:nonFraction>. As of December&#160;31, 2025, the Company had <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-846">111,533</ix:nonFraction> shares available for future grant under the 2022 Plan.</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Stock Option Exchange Program</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 16, 2024, the Company commenced an offer to certain eligible employees and consultants to exchange certain outstanding eligible options to purchase shares of the Company&#8217;s common stock for a lesser number of restricted stock unit (RSU) awards pursuant to an option exchange program (the Option Exchange). The Option Exchange expired on February 12, 2024. Pursuant to the Option Exchange, eligible option holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-847">5,059,129</ix:nonFraction> shares of the Company&#8217;s common stock, representing approximately <ix:nonFraction unitRef="number" contextRef="c-217" decimals="2" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged" scale="-2" id="f-848">98</ix:nonFraction>% of the total shares of common stock underlying the eligible options. On February 13, 2024, immediately following the expiration of the Option Exchange, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-218" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-849">2,129,594</ix:nonFraction> shares of Replacement RSU Awards, pursuant to the terms of the Option Exchange. The Replacement RSU Awards will vest based on continued service with the Company over a period of either <ix:nonNumeric contextRef="c-219" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-850">1</ix:nonNumeric>, <ix:nonNumeric contextRef="c-220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-851">2</ix:nonNumeric> or <ix:nonNumeric contextRef="c-221" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-852">3</ix:nonNumeric> years, depending on the grant date of the exchanged options.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange of stock options was treated as a modification for accounting purposes, which requires an incremental expense of $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="f-853">8.6</ix:nonFraction>&#160;million to be recognized for the Replacement RSU Awards over their new service periods (<ix:nonNumeric contextRef="c-223" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear" id="f-854">1</ix:nonNumeric> - <ix:nonNumeric contextRef="c-224" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear" id="f-855">3</ix:nonNumeric> years). In addition, any unamortized expense remaining on the exchanged options as of the modification will be recognized over their original remaining service period.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-856" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes option activity:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.185%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value ($ in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-857">5,342,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-858">6.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-859">8.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-860">43,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-861">2,345,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-862">14.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-863">714,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-864">6.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-865">534,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-866">9.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-867">2,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-868">26.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-869">6,436,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-870">9.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-871">7.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-872">127,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable&#8212;December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-873">2,903,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-874">8.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-875">6.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-876">59,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of December&#160;31, 2025. The intrinsic value of options exercised for the years ended December&#160;31, 2025, 2024, and 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-877">10.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-878">4.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-879">1.2</ix:nonFraction> million, respectively.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant-date fair value of the options vested during the years ended December&#160;31, 2025, 2024, and 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-880">8.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-881">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-882">28.0</ix:nonFraction> million, respectively. The weighted-average grant-date fair value of options granted during the years ended December&#160;31, 2025, 2024, and 2023 were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-883">9.94</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-884">3.70</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-885">8.01</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-815-4" continuedAt="f-815-5"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-886" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding the Company's RSUs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-225" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-887">6,055,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-225" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-888">8.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-226" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-889">3,063,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-226" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-890">14.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-226" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-891">2,275,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-226" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="f-892">8.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-226" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-893">835,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-226" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-894">10.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested Balance&#8212;December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-227" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-895">6,007,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-227" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-896">10.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of an RSU equals the closing price of the Company's common stock on the grant date. The total grant-date fair value of the RSUs vested during the years ended December&#160;31, 2025, 2024, and 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-897">18.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-898">17.4</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-899">9.3</ix:nonFraction>&#160;million, respectively. RSUs generally vest equally over <ix:nonNumeric contextRef="c-226" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-900">four years</ix:nonNumeric>, except for those issued in connection with the Option Exchange, as previously described.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-901" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-902">12,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-903">13,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-904">15,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-905">28,028</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-906">28,221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-907">23,269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-908">40,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-909">41,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-910">38,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-911">25.7</ix:nonFraction> million of total unrecognized compensation cost related to unvested options that are expected to vest, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-237" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-912">2.6</ix:nonNumeric> years. As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-913">47.5</ix:nonFraction> million of total unrecognized compensation cost related to RSUs that are expected to vest, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-226" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-914">2.8</ix:nonNumeric> years.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the fair value of the stock options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of common stock&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses its closing stock price as reported on Nasdaq on the grant date for the fair value of its stock.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding. The Company uses the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term as it does not have sufficient prior exercise data to calculate based on historical data.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company uses its own historical stock price for expected volatility. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Yield</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="c-238" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-915">zero</ix:nonFraction>.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-815-5" continuedAt="f-815-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-916" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards granted was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-239" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-917">5.3</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="c-240" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-918">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-241" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-919">1.8</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="c-242" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-920">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-243" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-921">5.0</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="c-244" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-922">6.1</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-237" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-923">72.9</ix:nonFraction>&#160;&#8211;&#160;<ix:nonFraction unitRef="number" contextRef="c-237" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-924">79.5</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-245" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-925">79.1</ix:nonFraction>&#160;&#8211;&#160;<ix:nonFraction unitRef="number" contextRef="c-245" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-926">83.2</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-246" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-927">75.2</ix:nonFraction>%&#160;&#8211; <ix:nonFraction unitRef="number" contextRef="c-246" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-928">78.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-237" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-929">3.7</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="c-237" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-930">4.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-245" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-931">3.6</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="c-245" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-932">5.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-246" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-933">3.5</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="c-246" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-934">4.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-237" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-935">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-245" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-936">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-246" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-937">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the 2020 Employee Stock Purchase Plan, or the ESPP, which became effective on January 30, 2020 in connection with the IPO. The ESPP is designed to allow the Company&#8217;s eligible employees to purchase shares of the Company&#8217;s common stock, at semi-annual intervals, with their accumulated payroll deductions. Under the ESPP, participants are offered the option to purchase shares of the Company&#8217;s common stock at a discount during a series of successive offering periods. The option purchase price will be the lower of <ix:nonFraction unitRef="number" contextRef="c-247" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-938">85</ix:nonFraction>% of the closing trading price per share of the Company&#8217;s common stock on the first trading date of an offering period in which a participant is enrolled or <ix:nonFraction unitRef="number" contextRef="c-247" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-939">85</ix:nonFraction>% of the closing trading price per share on the purchase date, which will occur on the last trading day of each offering period. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP is intended to qualify under Section 423 of the U.S. Internal Revenue Service Code of 1986, as amended. The maximum number of the Company&#8217;s common stock which will be authorized for sale under the ESPP is equal to the sum of (a) <ix:nonFraction unitRef="shares" contextRef="c-248" decimals="INF" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-940">351,000</ix:nonFraction> shares of common stock and (b) an annual increase on the first day of each year beginning in 2021 and ending in 2030, equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-249" decimals="INF" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="f-941">1</ix:nonFraction>% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company&#8217;s board of directors; provided, however, no more than <ix:nonFraction unitRef="shares" contextRef="c-248" decimals="INF" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="f-942">5,265,000</ix:nonFraction> shares of the Company&#8217;s common stock may be issued under the ESPP. Accordingly, on January 1, 2026, 2025 and 2024, the ESPP reserve increased by <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-943">1,216,890</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-944">1,178,480</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-252" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-945">967,873</ix:nonFraction> shares, respectively. As of December&#160;31, 2025, the Company had <ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-946">2,806,818</ix:nonFraction> shares available for future grant under the ESPP. </span></div></ix:continuation><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-815-6">Stock-based compensation expense related to the ESPP was $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-947">1.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-948">0.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-949">0.9</ix:nonFraction> million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.</ix:continuation> </span></div><div id="i2dffe4de76224390b628083ec6a2857c_172"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-951" continuedAt="f-951-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-951-1" continuedAt="f-951-2"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-952">1.2</ix:nonFraction>&#160;million during the year ended December&#160;31, 2025. Of the $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-953">1.2</ix:nonFraction> million recorded, $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arqt:ForeignWithholdingIncomeTaxes" scale="6" id="f-954">0.4</ix:nonFraction> million was related to foreign withholding taxes on the milestone payments received in connection with the Huadong Agreement and the remaining related to U.S. state income tax expense and other foreign tax expense. The Company recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-955">0.6</ix:nonFraction>&#160;million during the year ended December&#160;31, 2024. Of the $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-956">0.6</ix:nonFraction>&#160;million recorded, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="arqt:ForeignWithholdingIncomeTaxes" scale="6" id="f-957">0.5</ix:nonFraction>&#160;million was related to foreign withholding taxes on the up-front fee in connection with the Huadong Agreement and the remaining was related to other foreign tax expense. The Company recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-958">3.1</ix:nonFraction> million during the year ended December&#160;31, 2023. Of the $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-959">3.1</ix:nonFraction> million recorded, $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="arqt:ForeignWithholdingIncomeTaxes" scale="6" id="f-960">3.0</ix:nonFraction>&#160;million was related to foreign withholding taxes on the up-front fee in connection with the Huadong Agreement and the remaining was related to other foreign tax expense.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-961" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of loss before income taxes for domestic and foreign locations for the years ended December&#160;31, 2025, 2024 and 2023 (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-962">8,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-963">130,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-964">255,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-965">6,726</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-966">9,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-967">3,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-968">14,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-969">139,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-970">259,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-951-2" continuedAt="f-951-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-971" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of provision for income taxes for the years ended December&#160;31, 2025, 2024 and 2023 is as follows (in thousands):&#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax provision:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-975">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-978">844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-979">799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-980">3,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-981">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-982">799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-983">3,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-984">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-986">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-990">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-991">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred </span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-993">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-994">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-996">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-997">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-998">3,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-999" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax computed at federal statutory rates to the reported provision for income taxes for the years ended December&#160;31, 2025, 2024 and 2023 is as follows (in thousands)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:32.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax U.S. federal statutory rate</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1000">3,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1001">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1002">29,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1003">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1004">54,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1005">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local income tax, net of federal income tax effect</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-1006">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1007">5.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-1008">11,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1009">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-1010">1,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1011">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax effects</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory tax rate differential</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1012">319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-258" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1013">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1014">389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-259" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1015">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1016">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-260" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1017">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowances</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1018">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-258" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1019">13.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1020">2,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-259" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1021">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="f-1022">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-260" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1023">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-1024">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-258" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1025">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="3" id="f-1026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-259" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-1027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="3" id="f-1028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-260" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-1029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1030">402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-261" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1031">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1032">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-262" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1033">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-1034">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-263" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1035">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1036">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-264" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1037">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="3" id="f-1038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-265" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="f-1039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1040">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-266" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="f-1041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-1042">1,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1043">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="f-1044">804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1045">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-1046">4,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1047">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowances</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1048">3,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-267" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1049">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1050">37,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-268" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1051">27.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1052">52,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-269" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1053">20.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nontaxable or nondeductible items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sec. 162(m) limitation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" format="ixt:num-dot-decimal" scale="3" id="f-1054">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" scale="-2" id="f-1055">9.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" scale="3" id="f-1056">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" scale="-2" id="f-1057">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" format="ixt:num-dot-decimal" scale="3" id="f-1058">3,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" scale="-2" id="f-1059">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1060">3,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1061">21.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="f-1062">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1063">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1064">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1065">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-1066">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1067">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-1068">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1069">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-1070">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" format="ixt:fixed-zero" scale="-2" id="f-1071">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-1072">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-267" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1073">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-1074">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-268" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1075">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-1076">867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-269" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1077">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1078">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1079">7.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1080">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1081">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1082">3,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1083">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The prior years included in the effective tax rate table have been recast from the financial statements filed previously to align with the new presentation created through adherence to ASU 2023-09. Consideration has only been given to 2025 amounts in terms of the balances that are separately stated within the table.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The states and local jurisdictions that contribute to a majority (greater than 50%) of the tax effect in this category include Texas, California and New York based on the distribution of sales and the current year state income tax obligations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-951-3" continuedAt="f-951-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1084" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components deferred tax assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1085">180,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1086">171,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1087">1,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1088">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1089">15,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1090">14,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and expenditure capitalization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:DeferredTaxAssetsResearchAndExpenditureCapitalization" format="ixt:num-dot-decimal" scale="3" id="f-1091">23,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:DeferredTaxAssetsResearchAndExpenditureCapitalization" format="ixt:num-dot-decimal" scale="3" id="f-1092">36,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-1093">25,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-1094">16,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1095">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:DeferredTaxAssetsLeaseLiability" scale="3" id="f-1096">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1097">7,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1098">15,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1099">256,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1100">256,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1101">255,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1102">256,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1103">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="f-1104">693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-1105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-1106">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="arqt:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1107">1,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="arqt:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="f-1108">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1109">1,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="f-1110">541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net deferred tax assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="f-1111">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="f-1112">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates the positive and negative evidence in determining the realizability of its deferred tax assets. Based upon the weight of available evidence, which includes historical operating performance and reported cumulative net losses since inception, a valuation allowance on the majority of net deferred tax assets has been recorded as of December&#160;31, 2025 and 2024. The Company intend to maintain its substantially full valuation allowance on its deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The Company has an immaterial deferred tax asset related to a foreign jurisdiction. The valuation allowance decreased by approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-1113">0.8</ix:nonFraction> million and increased by approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-1114">40.1</ix:nonFraction> million during the years ended December&#160;31, 2025 and 2024, respectively, due to similar changes in the underlying deferred tax asset balances.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has net operating loss (NOL) carryforwards for federal and state income tax purposes of $<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1115">761.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1116">636.1</ix:nonFraction> million, respectively, as of December&#160;31, 2025. Of the federal NOLs, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-1117">3.5</ix:nonFraction> million originated before the 2018 tax year and will expire beginning in 2036. Under the Tax Cuts and Jobs Act of 2017, the remaining $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="f-1118">757.8</ix:nonFraction> million of NOLs generated after December 31, 2017 will be carried forward indefinitely and will be available to offset 80% of taxable income in future years. Of the $<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1119">636.1</ix:nonFraction> million in state net operating loss carryforwards, $<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-1120">550.2</ix:nonFraction> million will begin to expire in 2027 and the remaining NOLs carry forward indefinitely. In addition, the Company has foreign NOL carry forwards of $<ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="f-1121">23.2</ix:nonFraction>&#160;million as of December&#160;31, 2025, which can be carried forward indefinitely.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company also had federal and California research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="f-1122">23.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="f-1123">4.6</ix:nonFraction> million, respectively. The federal research and development tax credit carryforwards will begin to expire in 2037. The California research and development tax credit carryforwards are available indefinitely.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Internal Revenue Code Sections 382, as amended, and 383, substantial restrictions exist on the utilization of tax attributes in the event a corporation experienced an &#8220;ownership change.&#8221; Generally, a Section 382 &#8220;ownership change&#8221; occurs if one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Accordingly, the Company's ability to utilize net operating loss and tax credit carryforwards may be limited as a result of such ownership changes, and such a limitation could result in the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-951-4"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expiration of carryforwards before they are utilized. The Company has completed Section 382 studies that concluded the Company has experienced ownership changes since inception. However, this is not expected to result in the expiration of federal tax attribute carryforwards prior to utilization. Similar rules may apply under state tax laws. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted into law. The OBBBA contains numerous business tax provisions, including business extenders made permanent such as restoration of 100% bonus depreciation, IRC Section 174 expensing for US-based research, and the EBITDA-based business interest expense limitation under Section 163(j). The enacted legislation had an immaterial impact on the Company&#8217;s effective tax rate for the year ended December 31, 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1124" escape="true"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the unrecognized tax benefits (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1125">42,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1126">41,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1127">42,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to tax positions taken during a prior year</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1128">403</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-1129">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-1130">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decreases related to tax positions taken during a prior year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1131">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1132">131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1133">3,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to tax positions taken during the current year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-1134">784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1135">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1136">1,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1137">43,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1138">42,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1139">41,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1140">43.4</ix:nonFraction> million at December&#160;31, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="arqt:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" scale="6" id="f-1141">36.2</ix:nonFraction> million of tax benefits that, if recognized, would not impact the Company's income tax benefit or effective tax rate to the extent that the Company continues to maintain a full valuation allowance against its deferred tax assets.  </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files tax returns in the United States, state jurisdictions, Canada, and the United Kingdom. The tax years for 2016 and forward are subject to examination by the U.S. tax authorities and the tax years for 2016 and forward are subject to examination by the state tax authorities. Due to net operating loss carryforwards and research and development credits in the United States and state tax jurisdictions, all years effectively remain open. The Company is subject to examination by the tax authorities in Canada and the United Kingdom for the year ended December 31, 2022 to the present period. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company's policy to recognize interest and/or penalties related to uncertain tax benefits as a component of the provision for income taxes. For the years ended December&#160;31, 2025, 2024 and 2023, the Company has <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-1142"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-1143"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-1144">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognized any interest or penalties related to income taxes. The Company has <ix:nonFraction unitRef="usd" contextRef="c-10" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-1145"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-1146">no</ix:nonFraction></ix:nonFraction> accrued interest and penalties as of December&#160;31, 2025 and 2024 due to available tax losses.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of cash income taxes paid were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="0" id="f-1147"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="0" id="f-1148"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="0" id="f-1149">not</ix:nonFraction></ix:nonFraction></ix:nonFraction> material for the years ended December&#160;31, 2025, 2024 and 2023.</span></div></ix:continuation><div id="i2dffe4de76224390b628083ec6a2857c_175"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1150" continuedAt="f-1150-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="f-1150-1" continuedAt="f-1150-2"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average common shares outstanding. Pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1151">6,941,438</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-275" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1152">7,500,000</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1153">1,417,808</ix:nonFraction> shares of the Company's stock were included in the weighted-average common shares outstanding used in calculating net loss per share for the years ended December&#160;31, 2025, 2024 and 2023, respectively, as the exercise price of the pre-funded warrants is negligible and the pre-funded warrants are fully vested and exercisable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-1150-2"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential dilutive securities, which include unvested RSUs and unvested performance-based RSUs for which established performance criteria have been achieved as of the end of the respective periods, vested and unvested options to purchase common stock and shares to be issued under the Company's employee stock purchase plan (ESPP), have been excluded from the calculation of diluted net loss per common share in each period in which the Company recorded a net loss, as the effect is antidilutive. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1154" continuedAt="f-1154-1" escape="true">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:</ix:nonNumeric></span></div><ix:continuation id="f-1154-1"><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1155">6,436,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-278" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1156">5,342,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-279" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1157">7,919,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to future vesting</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1158">6,007,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1159">6,055,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1160">2,929,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares subject to future issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1161">11,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-284" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1162">16,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-285" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1163">26,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1164">12,456,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1165">11,414,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1166">10,875,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_178"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2dffe4de76224390b628083ec6a2857c_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1167" continuedAt="f-1167-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-1167-1" continuedAt="f-1167-2"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="f-1168">one</ix:nonFraction> reportable segment relating to the development and commercialization of treatments for dermatological diseases. The Company&#8217;s Chief Operating Decision Maker (CODM) is its Chief Executive Officer. The CODM evaluates financial information on a consolidated basis for the purposes of allocating resources and assessing performance. Substantially all of the Company's assets are located in the United States.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1169" continuedAt="f-1169-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1170">376,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1171">196,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1172">59,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1173">32,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1174">17,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1175">4,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Topical roflumilast program costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1176">10,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1177">5,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1178">35,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Topical JAK inhibitor program costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1179">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1180">2,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1181">3,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other early-stage programs costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1182">6,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1183">11,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1184">5,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development compensation and personnel-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="arqt:ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1185">39,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="arqt:ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1186">39,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="arqt:ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1187">44,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1188">274,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1189">228,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1190">184,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-1191">24,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-1192">20,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-1193">22,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1194">388,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1195">324,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1196">300,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1197">12,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1198">128,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1199">241,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-1200">8,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-1201">16,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-1202">12,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1203">12,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1204">27,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1205">29,712</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1206">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1207">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1208">731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1209">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1210">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1211">3,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment and consolidated net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1212">16,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1213">140,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1214">262,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="f-1169-1"><ix:continuation id="f-1167-2">(1) Other segment expenses include professional services related to research and development, medical affairs, depreciation and amortization expenses.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><div id="i2dffe4de76224390b628083ec6a2857c_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:5.517%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.255%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARCUTIS BIOTHERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Todd Franklin Watanabe</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Franklin Watanabe</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div><div><span><br/></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Latha Vairavan</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latha Vairavan</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div><div><span><br/></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">POWER OF ATTORNEY</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Todd Franklin Watanabe, Latha Vairavan and Mas Matsuda, his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or their, his or her substitutes or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Todd Franklin Watanabe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Franklin Watanabe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Latha Vairavan</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/>(Principal Accounting and Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latha Vairavan</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Keith R. Leonard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Chairman</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Keith R. Leonard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Terrie Curran</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terrie Curran</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Halley E. Gilbert</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Halley E. Gilbert</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Patrick J. Heron</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patrick J. Heron</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Neha Krishnamohan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neha Krishnamohan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sue-Jean Lin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sue-Jean Lin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Amit Munshi</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amit Munshi</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Howard G. Welgus</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2026</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Howard G. Welgus, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>exhibit43descriptionofregi.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="icd508428ee64413b87a42448fa36e36a_37"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:112%">Exhibit 4.3</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-indent:47.05pt"><font><br></font></div><div style="text-indent:47.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of March 1, 2020, Arcutis Biotherapeutics, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The shares are listed on The Nasdaq Global Select Market under the trading symbol &#8220;ARQT.&#8221; </font></div><div style="text-indent:47.05pt"><font><br></font></div><div style="text-indent:47.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following summary describes our common stock and the material provisions of our restated certificate of incorporation, our restated bylaws, the amended and restated investors&#8217; rights agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">investors&#8217; rights agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) to which we and certain of our stockholders are parties and of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our certificate of incorporation, bylaws and investors&#8217; rights agreement, filed as exhibits 3.1, 3.2 and 4.2, respectively, to our </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Annual Report on Form 10-K</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> filed with the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Securities Exchange Commission</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">, of which this Exhibit 4.3 is a part. We encourage you to read those documents and the DGCL carefully.</font></div><div style="text-indent:47.05pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">General</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">    &#160;&#160;&#160;&#160;Our authorized capital stock consists of&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">300,000,000 shares of common stock, par value $0.0001 per share&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">10,000,000 shares of preferred stock, par value $0.0001 per share.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Common Stock</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Dividend Rights</font></div><div style="text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. </font></div><div style="text-indent:30.6pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Voting Rights</font></div><div style="margin-bottom:8pt;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate of incorporation establishes a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">No Preemptive or Similar Rights</font></div><div style="margin-bottom:8pt;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Right to Receive Liquidation Distributions</font></div><div style="margin-bottom:8pt;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Preferred Stock</font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of our restated certificate of incorporation, our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors is also authorized to increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could among other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock.</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Pre-Funded Warrants</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In October 2023, in an underwritten public offering of our common stock, we issued and sold, in lieu of common stock for certain investors, pre-funded warrants to purchase 7,500,000 shares of our common stock at a public offering price of $2.4999 per underlying share of common stock. The exercise price of the warrants is $0.0001 per underlying share of common stock. The pre-funded warrants are exercisable at any time. In October 2025, certain pre-funded warrants were exercised, and as of December 31, 2025, pre-funded warrants to purchase 5,215,000 shares of our common stock remained outstanding.</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Fully Paid and Nonassessable</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">All outstanding shares of common stock are fully paid and non-assessable.</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Registration Rights</font></div><div style="margin-bottom:8pt;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of our amended and restated investors&#8217; rights agreement certain holders of shares of our common stock are entitled to rights with respect to the registration of these shares under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as described below. We refer to these shares collectively as registrable securities. We generally will pay all expenses, other than underwriting discounts, selling commissions and stock transfer taxes incurred in connection with each of the registrations described above, including the fees and disbursements, not to exceed $50,000, of one counsel for the selling holders.</font></div><div style="margin-bottom:8pt;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Beginning 180 days after the completion of our initial public offering, the holders of at least 10% of the then-outstanding registrable securities may make a request to us for the registration under the Securities Act of registrable securities if the aggregate price to the public of the shares offered is at least $10.0 million. We are only required to file two registration statements that are declared effective upon exercise of these demand registration rights. </font></div><div style="margin-bottom:8pt;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Any holder or group of holders of at least 10% of then-outstanding registrable securities can request that we register all or part of their shares on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Form</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> S-3 if we are eligible to file a registration statement on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Form</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> S-3 and if the aggregate price to the public of the shares offered is at least $1.0 million. The stockholders may only require us to effect two registration statements on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Form</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> S-3 in a 12-month period.</font></div><div style="margin-bottom:8pt;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If we register any of our securities for public sale, holders of then-outstanding registrable securities, or their permitted transferees, will have the right to include their registrable securities in the registration statement. </font></div><div style="margin-bottom:8pt;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The registration rights will expire, with respect to any particular holder of these rights, on the earliest to occur of (a) at such time that all of the holder&#8217;s registrable securities can be sold without limitation in any three-month period without registration in compliance with Rule 144 or a similar exemption under the Securities Act and (b) seven years following the completion of our initial public offering.</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Anti-Takeover Provisions</font></div><div style="margin-bottom:8pt;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The provisions of the DGCL, our restated certificate of incorporation and our restated bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Delaware Law</font></div><div style="margin-bottom:8pt;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to the provisions of Section 203 of the DGCL . Under Section 203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless&#58;</font></div><div style="padding-left:36pt;text-indent:12.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19.9pt">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="text-indent:30.6pt"><font><br></font></div><div style="padding-left:36pt;text-indent:12.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19.9pt">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers, and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="text-indent:30.6pt"><font><br></font></div><div style="padding-left:36pt;text-indent:12.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19.9pt">at or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div><div><font><br></font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under Section 203, a &#8220;business combination&#8221; includes&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder, subject to limited exceptions&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59; or</font></div><div style="padding-left:36pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In general, Section 203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Restated Certificate of Incorporation and Restated Bylaw Provisions</font></div><div style="text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our restated certificate of incorporation and our restated bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following&#58;</font></div><div style="text-indent:30.6pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:12.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19.2pt">Board of Directors Vacancies. Our restated certificate of incorporation and restated bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:12.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19.2pt">Classified Board. Our restated certificate of incorporation and restated bylaws provide that our board of directors is classified into three classes of directors, each with staggered three-year terms. A third </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:12.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19.2pt">Stockholder Action&#59; Special Meetings of Stockholders. Our restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairman of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:12.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19.2pt">Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:12.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19.2pt">No Cumulative Voting. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws do not provide for cumulative voting.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:12.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19.2pt">Directors Removed Only for Cause. Our restated certificate of incorporation provides that stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least two-thirds of our outstanding common stock.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:12.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19.2pt">Amendment of Charter Provisions. Any amendment of the above provisions in our restated certificate of incorporation requires approval by holders of at least two-thirds of our outstanding common stock.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:12.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19.2pt">Issuance of Undesignated Preferred Stock. Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means.</font></div><div style="padding-left:36pt;text-indent:12.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19.2pt">Choice of Forum. Our restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf&#59; any action asserting a breach of fiduciary duty&#59; any action asserting a claim against us arising pursuant to the DGCL, our restated certificate of incorporation or our restated bylaws&#59; or any action asserting a claim against us that is governed by the internal affairs </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">doctrine. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</font></div><div style="text-indent:30.6pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Transfer Agent and Registrar</font></div><div style="text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The transfer agent and registrar for our common stock is Equiniti Trust Company. The transfer agent&#8217;s address is 1110 Centre Pointe Curve, Suite 101, Mendota Heights, MN 55120-4101.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.49
<SEQUENCE>3
<FILENAME>exhibit1049lathavairavanof.htm
<DESCRIPTION>EX-10.49
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i080d3aa8efda4c27a181856d8593b307_37"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.49</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">4 February 2020</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Latha Vairavan</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">c&#47;o Arcutis Biotherapeutics</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Re&#58;      Offer of Employment by Arcutis, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Dear Latha&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">I am very pleased to confirm our offer to you of employment with Arcutis, Inc. (the &#8220;Company&#8221;).  You will initially report to the Vice President, Finance in the position of Executive Director, Financial Planning and Analysis.  Your first day of employment will be March 1st, 2020.  The terms of our offer and the benefits currently provided by the Company are as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Starting Salary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  Your starting monthly salary will be eighteen thousand three hundred thirty three dollars and thirty three cents ($18,333.33), which is an annualized salary of two hundred twenty thousand dollars ($220,000) per year and will be subject to annual review.   </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  You will also be eligible to be paid an annual performance cash award. This incentive will be targeted at 20% of your actual earnings in a given calendar year.  The actual amount paid will be tied to the achievement of annual corporate and personal goals. Your payment will be subject to applicable withholding.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> In addition, you will be eligible to participate in regular health insurance, bonus and other employee benefit plans established by the Company for its employees from time to time.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  You will be eligible to participate in our Equity Incentive Plan, and stock options will be awarded to you at the discretion of the Board of Directors under our 2020 Equity Incentive Plan (the &#8220;Plan&#8221;).  Any options granted will vest at the rate of twenty-five percent (25%) at the end of your first anniversary with the Company, and an additional 2.0833% per month thereafter, so long as you remain employed by the Company.  However, the grant of such options by the Company is subject to the Board&#8217;s approval and this promise to recommend such approval is not a promise of compensation and is not intended to create any obligation on the part of the Company.  Further details on the Plan and any specific option grant to you will be provided upon approval of such grant by the Company's Board of Directors. The Company reserves the right to change or otherwise modify, in its sole discretion, the preceding terms of employment</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  As an employee of the Company, you will have access to certain confidential information of the Company and you may, during the course of your employment, develop certain information or inventions that will be the property of the Company.  To protect the interests of the Company, you will need to sign the Company&#8217;s standard &#8220;Employee Invention Assignment and Confidentiality Agreement&#8221; as a condition of your employment.  We wish to impress upon you that we do not want you to, and we hereby direct you not to, bring with you any confidential or proprietary material of any former employer or to violate any other obligations you may have to any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">former employer.  During the period that you render services to the Company, you agree to not engage in any employment, business or activity that is in any way competitive with the business or proposed business of the Company.  You will disclose to the Company in writing any other gainful employment, business or activity that you are currently associated with or participate in that competes with the Company.  You will not assist any other person or organization in competing with the Company or in preparing to engage in competition with the business or proposed business of the Company.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">No Breach of Obligations to Prior Employers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  You represent that your signing of this offer letter, agreement(s) concerning stock options granted to you, if any, under the Plan (as defined above) and the Company&#8217;s Employee Invention Assignment and Confidentiality Agreement and your commencement of employment with the Company will not violate any agreement currently in place between yourself and current or past employers.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">At Will Employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  While we look forward to a long and profitable relationship, should you decide to accept our offer, you will be an at-will employee of the Company, which means the employment relationship can be terminated by either of us for any reason, at any time, with or without prior notice and with or without cause.  Any statements or representations to the contrary (and, indeed, any statements contradicting any provision in this letter) should be regarded by you as ineffective.  Further, your participation in any stock option or benefit program is not to be regarded as assuring you of continuing employment for any particular period of time.  Any modification or change in your at will employment status may only occur by way of a written employment agreement signed by you and the Chief Executive Officer of the Company.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Authorization to Work</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  Please note that because of employer regulations adopted in the Immigration Reform and Control Act of 1986, within three (3) business days of starting your new position you will need to present documentation demonstrating that you have authorization to work in the United States.  If you have questions about this requirement, which applies to U.S. citizens and non-U.S. citizens alike, you may contact our personnel office.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt;text-decoration:underline">Arbitration and Class Action Waiver</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  You and the Company agree to submit to mandatory binding arbitration any and all claims arising out of or related to your employment with the Company and the termination thereof, including, but not limited to, claims for unpaid wages, wrongful termination, torts, stock or stock options or other ownership interest in the Company, and&#47;or discrimination (including harassment) based upon any federal, state or local ordinance, statute, regulation or constitutional provision except that each party may, at its, his or her option, seek injunctive relief in court related to the improper use, disclosure or misappropriation of a party&#8217;s private, proprietary, confidential or trade secret information (collectively, &#8220;Arbitrable Claims&#8221;).  Further, to the fullest extent permitted by law, you and the Company agree that no class or collective actions can be asserted in arbitration or otherwise.  All claims, whether in arbitration or otherwise, must be brought solely in your or the Company&#8217;s individual capacity, and not as a plaintiff or class member in any purported class or collective proceeding.  Nothing in this Arbitration and Class Action Waiver section, however, restricts your right, if any, to file in court a representative action under California Labor Code Sections 2698, et seq.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">SUBJECT TO THE ABOVE PROVISO, THE PARTIES HEREBY WAIVE ANY RIGHTS THEY MAY HAVE TO TRIAL BY JURY IN REGARD TO ARBITRABLE CLAIMS.  THE PARTIES FURTHER WAIVE ANY RIGHTS THEY MAY HAVE TO PURSUE OR PARTICIPATE IN A CLASS OR COLLECTIVE ACTION PERTAINING TO ANY ARBITRABLE CLAIMS BETWEEN YOU AND THE COMPANY.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">This Agreement does not restrict your right to file administrative claims you may bring before any government agency where, as a matter of law, the parties may not restrict the employee&#8217;s ability to file such claims (including, but not limited to, the National Labor Relations Board, the Equal Employment Opportunity Commission and the Department of Labor).  However, the parties agree that, to the fullest extent permitted by law, arbitration shall be the exclusive remedy for the subject matter of such administrative claims.  The arbitration shall be conducted in San Francisco County, California through JAMS before a single neutral arbitrator, in accordance with the JAMS employment arbitration rules then in effect.  The JAMS rules may be found and reviewed at </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  If you are unable to access these rules, please let me know and I will provide you with a hardcopy.  The arbitrator shall issue a written decision that contains the essential findings and conclusions on which the decision is based. </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">10. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  This offer, once accepted, constitutes the entire agreement between you and the Company with respect to the subject matter hereof and supersedes all prior offers, negotiations and agreements, if any, whether written or oral, relating to such subject matter.  You acknowledge that neither the Company nor its agents have made any promise, representation or warranty whatsoever, either express or implied, written or oral, which is not contained in this agreement for the purpose of inducing you to execute the agreement, and you acknowledge that you have executed this agreement in reliance only upon such promises, representations and warranties as are contained herein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Acceptance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  This offer will remain open until Monday, February 10th, 2020.  If you decide to accept our offer, and I hope you will, please sign the enclosed copy of this letter in the space indicated and return it to me.  Your signature will acknowledge that you have read and understood and agreed to the terms and conditions of this offer letter and the attached documents, if any.  Should you have anything else that you wish to discuss, please do not hesitate to call me.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">We look forward to the opportunity to welcome you to the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Very truly yours,</font></div><div><font><br></font></div><div style="text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Frank Watanabe</font><font style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">President and CEO</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">I have read and understood this offer letter and hereby acknowledge, accept and agree to the terms as set forth above and further acknowledge that no other commitments were made to me as part of my employment offer except as specifically set forth herein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">  &#47;s&#47; Latha Vairavan                                             </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">            Date signed&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">   02&#47;04&#47;2020                            </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">Latha Vairavan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>exhibit211listofsubsidiari.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i68cea4f566dd4c139813d08aaec1332f_37"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> Exhibit 21.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">LIST OF SUBSIDIARIES</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following is a list of subsidiaries of the Company as of December 31, 2025&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%;text-decoration:underline">Subsidiary Legal Name</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">                                                  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%;text-decoration:underline">State or other Jurisdiction of Incorporation or Organization              </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Arcutis Canada, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">                                                 &#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Canada</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Ducentis Biotherapeutics Ltd.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">                                           &#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">United Kingdom</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exhibit231-auditorsconsent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i22ad552b00ed4c06b4858fc20d79ff7f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:127%">Exhibit 23.1</font></div><div style="margin-bottom:4pt;text-align:center"><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#333333;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#333333;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:150%">(1) Registration Statement (Form S-3 No. 333-276794) of Arcutis Biotherapeutics, Inc., </font></div><div style="margin-bottom:4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:150%">(2) Registration Statement (Form S-8 No. 333-236178) pertaining to the 2017 Equity Incentive Plan, the 2020 Equity Incentive Plan, and the 2020 Employee Stock Purchase Plan of Arcutis Biotherapeutics, Inc., </font></div><div style="margin-bottom:4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:150%">(3) Registration Statement (Form S-8 No. 333-253155) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of Arcutis Biotherapeutics, Inc.,</font></div><div style="margin-bottom:4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:150%">(4) Registration Statement (Form S-8 No. 333-262902) pertaining to the 2020 Equity Incentive Plan, the 2020 Employee Stock Purchase Plan, and the 2022 Employment Inducement Incentive Plan of Arcutis Biotherapeutics, Inc.,</font></div><div style="margin-bottom:4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:150%">(5) Registration Statement (Form S-8 No. 333-270136) pertaining to the 2020 Equity Incentive Plan, the 2020 Employee Stock Purchase Plan, and the 2022 Employment Inducement Incentive Plan of Arcutis Biotherapeutics, Inc., </font></div><div style="margin-bottom:4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:150%">(6) Registration Statement (Form S-8 No. 333-277405) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of Arcutis Biotherapeutics, Inc., and</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:150%">(7) Registration Statement (Form S-8 No. 333-285203) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:150%">of our reports dated February 25, 2026, with respect to the consolidated financial statements of Arcutis Biotherapeutics, Inc. and the effectiveness of internal control over financial reporting of Arcutis Biotherapeutics, Inc. included in this Annual Report (Form 10-K) of Arcutis Biotherapeutics, Inc. for the year ended December 31, 2025.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:127%">Los Angeles, California</font></div><div><font style="color:#333333;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:127%">February 25, 2026</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exhibit311ceoq42025.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ia115f345e411409498fa619c41e4a9cb_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Todd Franklin Watanabe, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Arcutis Biotherapeutics, Inc.&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.000%"><tr><td style="width:1.0%"></td><td style="width:37.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; February&#160;25, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Todd Franklin Watanabe</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Todd Franklin Watanabe</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">President, Chief Executive Officer and Director</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                    </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exhibit312cfoq42025.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i91398bd0bd264d94bb37c046b57b9ff9_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">I, Latha Vairavan, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Arcutis Biotherapeutics, Inc.&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.000%"><tr><td style="width:1.0%"></td><td style="width:37.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; February&#160;25, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Latha Vairavan</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Latha Vairavan </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Accounting and Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                    </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exhibit321ceocfoq42025.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i931524fcf8564e3e9c17213f33a25059_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Arcutis Biotherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Todd Franklin Watanabe, Chief Executive Officer of the Company, and Latha Vairavan, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;padding-left:36pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:37.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; February&#160;25, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Todd Franklin Watanabe</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Todd Franklin Watanabe</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">President, Chief Executive Officer and Director</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Latha Vairavan</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Latha Vairavan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Accounting and Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                    </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>arqt-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:631d5f47-b6cd-44b6-9ca1-ef826fe44260,g:a004ef44-2665-49af-8ba9-70d1dea45abd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arqt="http://arcutis.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://arcutis.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arqt-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arqt-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arqt-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arqt-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://arcutis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://arcutis.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://arcutis.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://arcutis.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" roleURI="http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical">
        <link:definition>9952155 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://arcutis.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://arcutis.com/role/DescriptionofBusiness">
        <link:definition>9952157 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://arcutis.com/role/Revenues">
        <link:definition>9952159 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://arcutis.com/role/FairValueMeasurements">
        <link:definition>9952160 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://arcutis.com/role/BalanceSheetComponents">
        <link:definition>9952161 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://arcutis.com/role/PropertyandEquipmentnet">
        <link:definition>9952162 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDucentisAcquisition" roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisition">
        <link:definition>9952163 - Disclosure - License Agreements &amp; Ducentis Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://arcutis.com/role/CommitmentsandContingencies">
        <link:definition>9952164 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://arcutis.com/role/Debt">
        <link:definition>9952165 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://arcutis.com/role/StockholdersEquity">
        <link:definition>9952166 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://arcutis.com/role/IncomeTaxes">
        <link:definition>9952167 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://arcutis.com/role/NetLossPerShare">
        <link:definition>9952168 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://arcutis.com/role/SegmentReporting">
        <link:definition>9952169 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://arcutis.com/role/RevenuesTables">
        <link:definition>9955513 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://arcutis.com/role/FairValueMeasurementsTables">
        <link:definition>9955514 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://arcutis.com/role/BalanceSheetComponentsTables">
        <link:definition>9955515 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://arcutis.com/role/PropertyandEquipmentnetTables">
        <link:definition>9955516 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://arcutis.com/role/CommitmentsandContingenciesTables">
        <link:definition>9955517 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://arcutis.com/role/DebtTables">
        <link:definition>9955518 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://arcutis.com/role/StockBasedCompensationTables">
        <link:definition>9955519 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://arcutis.com/role/IncomeTaxesTables">
        <link:definition>9955520 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://arcutis.com/role/NetLossPerShareTables">
        <link:definition>9955521 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://arcutis.com/role/SegmentReportingTables">
        <link:definition>9955522 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://arcutis.com/role/DescriptionofBusinessDetails">
        <link:definition>9955523 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955524 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails">
        <link:definition>9955525 - Disclosure - Summary of Significant Accounting Policies - Finite-Lived Intangible Assets, Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesScheduleofDisaggregationofRevenueDetails" roleURI="http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails">
        <link:definition>9955526 - Disclosure - Revenues - Schedule of Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://arcutis.com/role/RevenuesNarrativeDetails">
        <link:definition>9955527 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesGrossProductSalesandAccountsReceivableNetDetails" roleURI="http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails">
        <link:definition>9955528 - Disclosure - Revenues - Gross Product Sales and Accounts Receivable Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" roleURI="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails">
        <link:definition>9955529 - Disclosure - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>9955530 - Disclosure - Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails" roleURI="http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails">
        <link:definition>9955531 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost and Fair Value of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails" roleURI="http://arcutis.com/role/FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails">
        <link:definition>9955532 - Disclosure - Fair Value Measurements - Change In The Fair Value Of The Embedded Derivative Instrument (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsInventoriesDetails" roleURI="http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails">
        <link:definition>9955533 - Disclosure - Balance Sheet Components - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>9955534 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails">
        <link:definition>9955535 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" roleURI="http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails">
        <link:definition>9955536 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetNarrativeDetails" roleURI="http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails">
        <link:definition>9955537 - Disclosure - Property and Equipment, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails" roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails">
        <link:definition>9955538 - Disclosure - License Agreements &amp; Ducentis Acquisition - Sato License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDucentisAcquisitionHuadongDetails" roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails">
        <link:definition>9955539 - Disclosure - License Agreements &amp; Ducentis Acquisition - Huadong (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDucentisAcquisitionAstraZenecaDetails" roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails">
        <link:definition>9955540 - Disclosure - License Agreements &amp; Ducentis Acquisition - AstraZeneca (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDucentisAcquisitionHengruiDetails" roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails">
        <link:definition>9955541 - Disclosure - License Agreements &amp; Ducentis Acquisition - Hengrui (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails" roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails">
        <link:definition>9955542 - Disclosure - License Agreements &amp; Ducentis Acquisition - Ducentis Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>9955543 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeasePaymentsDetails" roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails">
        <link:definition>9955544 - Disclosure - Commitments and Contingencies - Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeasePaymentsDetails_1" roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1">
        <link:definition>9955544 - Disclosure - Commitments and Contingencies - Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails" roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails">
        <link:definition>9955545 - Disclosure - Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseAdditionalInformationDetails" roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseAdditionalInformationDetails">
        <link:definition>9955546 - Disclosure - Commitments and Contingencies - Operating Lease Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://arcutis.com/role/DebtNarrativeDetails">
        <link:definition>9955547 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofLongTermDebtDetails" roleURI="http://arcutis.com/role/DebtScheduleofLongTermDebtDetails">
        <link:definition>9955548 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofLongTermDebtDetails_1" roleURI="http://arcutis.com/role/DebtScheduleofLongTermDebtDetails_1">
        <link:definition>9955548 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://arcutis.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9955549 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockOptionActivityDetails" roleURI="http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails">
        <link:definition>9955550 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" roleURI="http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails">
        <link:definition>9955551 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockBasedCompensationExpenseDetails" roleURI="http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9955552 - Disclosure - Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails" roleURI="http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails">
        <link:definition>9955553 - Disclosure - Stockholders' Equity - Schedule of Assumptions in Calculating Stock Option Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://arcutis.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955554 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails" roleURI="http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails">
        <link:definition>9955555 - Disclosure - Income Taxes - Reconciliation of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxExpenseDetails" roleURI="http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails">
        <link:definition>9955556 - Disclosure - Income Taxes - Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9955557 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955558 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://arcutis.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>9955559 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareNarrativeDetails" roleURI="http://arcutis.com/role/NetLossPerShareNarrativeDetails">
        <link:definition>9955560 - Disclosure - Net Loss Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDilutiveSharesDetails" roleURI="http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails">
        <link:definition>9955561 - Disclosure - Net Loss Per Share - Dilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingDetails" roleURI="http://arcutis.com/role/SegmentReportingDetails">
        <link:definition>9955562 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>9955563 - Disclosure - Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arqt_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arqt_SecondaryEquityPublicOfferingMember" abstract="true" name="SecondaryEquityPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" abstract="false" name="StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" abstract="false" name="StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract" abstract="true" name="LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arqt_LicenseAgreementsAndAcquisitionsTextBlock" abstract="false" name="LicenseAgreementsAndAcquisitionsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock" abstract="false" name="AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock" abstract="false" name="RevenueNotFromContractWithCustomerPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arqt_CoPromotionAgreementsPolicyPolicyTextBlock" abstract="false" name="CoPromotionAgreementsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arqt_LoanAgreementMember" abstract="true" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_CashCashEquivalentsAndMarketableSecurities" abstract="false" name="CashCashEquivalentsAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ProductRevenuePaymentTerm" abstract="false" name="ProductRevenuePaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_ZORYVECream0.3Member" abstract="true" name="ZORYVECream0.3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_ZORYVEFoamMember" abstract="true" name="ZORYVEFoamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_ZORYVECream0.15Member" abstract="true" name="ZORYVECream0.15Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_ZORYVECream0.05Member" abstract="true" name="ZORYVECream0.05Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_FourCustomersMember" abstract="true" name="FourCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_FiveCustomersMember" abstract="true" name="FiveCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_CustomerDMember" abstract="true" name="CustomerDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_CustomerEMember" abstract="true" name="CustomerEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_CustomerFMember" abstract="true" name="CustomerFMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_MajorCustomersMember" abstract="true" name="MajorCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" abstract="false" name="CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_CashAndCashEquivalentsUnrealizedGain" abstract="false" name="CashAndCashEquivalentsUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_CashAndCashEquivalentsUnrealizedLoss" abstract="false" name="CashAndCashEquivalentsUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_PrepaidCopayAssistanceProgramAndRebates" abstract="false" name="PrepaidCopayAssistanceProgramAndRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_PrepaidClinicalTrialTestCostsCurrent" abstract="false" name="PrepaidClinicalTrialTestCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_AccruedSalesDiscounts" abstract="false" name="AccruedSalesDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ClinicalTrialAccrualCurrent" abstract="false" name="ClinicalTrialAccrualCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember" abstract="true" name="PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_SatoMember" abstract="true" name="SatoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet" abstract="false" name="ContractNotWithCustomerUpfrontPaymentReceivedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" abstract="false" name="LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice" abstract="false" name="LicenseAgreementTerminationNumberOfDaysForWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_HuadongMember" abstract="true" name="HuadongMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_ContractNotWithCustomerUpfrontPaymentNet" abstract="false" name="ContractNotWithCustomerUpfrontPaymentNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation" abstract="false" name="ContractNotWithCustomerLiabilityTaxWithholdingObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_HengruiMember" abstract="true" name="HengruiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_DucentisBiotherapeuticsLTDEquityInterestsMember" abstract="true" name="DucentisBiotherapeuticsLTDEquityInterestsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" abstract="false" name="AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_AssetAcquisitionConsiderationTransferredGross" abstract="false" name="AssetAcquisitionConsiderationTransferredGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount" abstract="false" name="AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones" abstract="false" name="AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment" abstract="false" name="AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold" abstract="false" name="AssetAcquisitionAnnualNetSalesOfAcquireeThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_LeaseDescriptionAxis" abstract="true" name="LeaseDescriptionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="arqt_LeaseDescriptionDomain" abstract="true" name="LeaseDescriptionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_WestlakeVillageCaliforniaLeaseArrangementMember" abstract="true" name="WestlakeVillageCaliforniaLeaseArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_LesseeOperatingLeaseOfficeSpace" abstract="false" name="LesseeOperatingLeaseOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="arqt_LesseeOperatingLeaseExtensionTerm" abstract="false" name="LesseeOperatingLeaseExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments" abstract="false" name="LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments" abstract="false" name="LesseeOperatingLeaseAdditionalYearsOfRentPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_DebtInstrumentTrancheAxis" abstract="true" name="DebtInstrumentTrancheAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="arqt_DebtInstrumentTrancheDomain" abstract="true" name="DebtInstrumentTrancheDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_TrancheATermLoanMember" abstract="true" name="TrancheATermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_TrancheB1TermLoanMember" abstract="true" name="TrancheB1TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_TrancheB2TermLoanMember" abstract="true" name="TrancheB2TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_LoanAgreementTrancheC1ExpiringMarch312026Member" abstract="true" name="LoanAgreementTrancheC1ExpiringMarch312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_LoanAgreementTrancheC2ExpiringJune302026Member" abstract="true" name="LoanAgreementTrancheC2ExpiringJune302026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_TrancheCTermLoanMember" abstract="true" name="TrancheCTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_DebtInstrumentPrepaymentPremium" abstract="false" name="DebtInstrumentPrepaymentPremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arqt_DebtInstrumentMaximumBorrowingCapacity" abstract="false" name="DebtInstrumentMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_DebtInstrumentPrepaymentPenalty" abstract="false" name="DebtInstrumentPrepaymentPenalty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_DebtInstrumentFundingAvailabilityCovenantPeriod" abstract="false" name="DebtInstrumentFundingAvailabilityCovenantPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue" abstract="false" name="DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment" abstract="false" name="DebtInstrumentInterestRateStatedPercentagePartialPrepayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="arqt_DebtInstrumentInterestRateAtPeriodEnd" abstract="false" name="DebtInstrumentInterestRateAtPeriodEnd" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arqt_DebtInstrumentDefaultRate" abstract="false" name="DebtInstrumentDefaultRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arqt_DebtInstrumentFinalFeePercentage" abstract="false" name="DebtInstrumentFinalFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arqt_DebtInstrumentExtensionFeePercentage" abstract="false" name="DebtInstrumentExtensionFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arqt_DebtInstrumentExitFeePercentage" abstract="false" name="DebtInstrumentExitFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arqt_DebtInstrumentExitFeeExpirationPeriod" abstract="false" name="DebtInstrumentExitFeeExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_DebtInstrumentDeferredFinalFeeGross" abstract="false" name="DebtInstrumentDeferredFinalFeeGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_DebtInstrumentAccruedFinalFee" abstract="false" name="DebtInstrumentAccruedFinalFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_DebtInstrumentAccruedPrepaymentPenalty" abstract="false" name="DebtInstrumentAccruedPrepaymentPenalty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_FirstEquityPublicOfferingMember" abstract="true" name="FirstEquityPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_AtTheMarketMember" abstract="true" name="AtTheMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_PrefundedWarrantMember" abstract="true" name="PrefundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_CowenAndCompanyLLCMember" abstract="true" name="CowenAndCompanyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_A2020EquityIncentivePlanMember" abstract="true" name="A2020EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_A2017EquityIncentivePlanMember" abstract="true" name="A2017EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_A2022EmploymentInducementIncentivePlanMember" abstract="true" name="A2022EmploymentInducementIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_StockOptionExchangeMember" abstract="true" name="StockOptionExchangeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_FirstGrantDateMember" abstract="true" name="FirstGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_SecondGrantDateMember" abstract="true" name="SecondGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_ThirdGrantDateMember" abstract="true" name="ThirdGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_SaleOfStockAuthorizedConsiderationOnTransaction" abstract="false" name="SaleOfStockAuthorizedConsiderationOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_SaleOfStockAgentFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockAgentFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_ForeignWithholdingIncomeTaxes" abstract="false" name="ForeignWithholdingIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" abstract="false" name="UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization" abstract="false" name="DeferredTaxAssetsResearchAndExpenditureCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_TopicalRoflumilastProgramMember" abstract="true" name="TopicalRoflumilastProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_TopicalJAKInhibitorProgramMember" abstract="true" name="TopicalJAKInhibitorProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_OtherEarlyStageProgramsMember" abstract="true" name="OtherEarlyStageProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" abstract="false" name="ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_KeithLeonardMember" abstract="true" name="KeithLeonardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_SueJeanLinMember" abstract="true" name="SueJeanLinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_SueJeanLinTradingArrangementOptionsMember" abstract="true" name="SueJeanLinTradingArrangementOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arqt_SueJeanLinTradingArrangementCommonStockMember" abstract="true" name="SueJeanLinTradingArrangementCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>arqt-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:631d5f47-b6cd-44b6-9ca1-ef826fe44260,g:a004ef44-2665-49af-8ba9-70d1dea45abd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_706190cb-8c8a-4862-bc0e-6b841a0d52d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d49cfeaf-4dc2-4b3a-8874-964ad76bba0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_706190cb-8c8a-4862-bc0e-6b841a0d52d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d49cfeaf-4dc2-4b3a-8874-964ad76bba0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_978bec45-82ff-425b-a739-220cb4de938f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_706190cb-8c8a-4862-bc0e-6b841a0d52d6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_978bec45-82ff-425b-a739-220cb4de938f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bd8219ad-f884-414b-8a87-a9b08bcf4296" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_706190cb-8c8a-4862-bc0e-6b841a0d52d6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bd8219ad-f884-414b-8a87-a9b08bcf4296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_04bd8106-1b80-492d-8ed8-3eacdca98b22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_706190cb-8c8a-4862-bc0e-6b841a0d52d6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_04bd8106-1b80-492d-8ed8-3eacdca98b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_204638e8-573a-4283-8606-1e4acd97284f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_706190cb-8c8a-4862-bc0e-6b841a0d52d6" xlink:to="loc_us-gaap_InventoryNet_204638e8-573a-4283-8606-1e4acd97284f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b3304327-f889-45d2-8db5-13b3ffc5570e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_706190cb-8c8a-4862-bc0e-6b841a0d52d6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b3304327-f889-45d2-8db5-13b3ffc5570e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6bd4e6d0-8c0d-47a9-8e32-b11d2f07ad4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3360dfec-1118-4a0c-8c56-b78f453ad70a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6bd4e6d0-8c0d-47a9-8e32-b11d2f07ad4e" xlink:to="loc_us-gaap_AccountsPayableCurrent_3360dfec-1118-4a0c-8c56-b78f453ad70a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5df661c7-b814-4d85-a979-f895495eb51e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6bd4e6d0-8c0d-47a9-8e32-b11d2f07ad4e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5df661c7-b814-4d85-a979-f895495eb51e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b1df431a-ea7e-42fe-879c-368ef6a00adc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6bd4e6d0-8c0d-47a9-8e32-b11d2f07ad4e" xlink:to="loc_us-gaap_LongTermDebtCurrent_b1df431a-ea7e-42fe-879c-368ef6a00adc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7e4c14a4-1a83-4337-9fc6-2a58e7822f93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e872da75-c238-4a73-836b-39270f8d3347" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e4c14a4-1a83-4337-9fc6-2a58e7822f93" xlink:to="loc_us-gaap_AssetsCurrent_e872da75-c238-4a73-836b-39270f8d3347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10af5fa8-7ea4-4d03-a123-e6c1d6178767" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e4c14a4-1a83-4337-9fc6-2a58e7822f93" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10af5fa8-7ea4-4d03-a123-e6c1d6178767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1bc2a52e-aa0a-4e06-9341-bb2411fcac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e4c14a4-1a83-4337-9fc6-2a58e7822f93" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1bc2a52e-aa0a-4e06-9341-bb2411fcac8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a96ce281-69f0-420f-9b5b-1b72a3386fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e4c14a4-1a83-4337-9fc6-2a58e7822f93" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a96ce281-69f0-420f-9b5b-1b72a3386fa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0d1fb880-8157-4b7d-aa0c-be83ef1e7b15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e4c14a4-1a83-4337-9fc6-2a58e7822f93" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0d1fb880-8157-4b7d-aa0c-be83ef1e7b15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e1bb604-9389-45d8-866e-2d43b29d1175" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c29f7532-217c-489a-9c61-81b40f9f4533" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e1bb604-9389-45d8-866e-2d43b29d1175" xlink:to="loc_us-gaap_Liabilities_c29f7532-217c-489a-9c61-81b40f9f4533" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bcad7a33-5f1b-45f2-afc1-fce71ce19739" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e1bb604-9389-45d8-866e-2d43b29d1175" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bcad7a33-5f1b-45f2-afc1-fce71ce19739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bff28f40-de1e-4689-81e8-e3a89c1c05b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e1bb604-9389-45d8-866e-2d43b29d1175" xlink:to="loc_us-gaap_StockholdersEquity_bff28f40-de1e-4689-81e8-e3a89c1c05b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_640088e4-2cc5-46da-b48e-a966c6a330b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6142ab61-f643-4e52-a924-60bf5396731d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_640088e4-2cc5-46da-b48e-a966c6a330b9" xlink:to="loc_us-gaap_LiabilitiesCurrent_6142ab61-f643-4e52-a924-60bf5396731d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bef0917f-1121-4027-a803-19e2aedbe6df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_640088e4-2cc5-46da-b48e-a966c6a330b9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bef0917f-1121-4027-a803-19e2aedbe6df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_15d7a6c1-7b25-4a13-984e-b7523e66e3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_640088e4-2cc5-46da-b48e-a966c6a330b9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_15d7a6c1-7b25-4a13-984e-b7523e66e3eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_441a3f35-336e-419c-b6a7-bb37dcd2b0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_640088e4-2cc5-46da-b48e-a966c6a330b9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_441a3f35-336e-419c-b6a7-bb37dcd2b0ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_95bacae1-fe5e-46b6-99c2-851182679911" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9d179063-40d3-4b5c-a412-58d89bcb7313" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_95bacae1-fe5e-46b6-99c2-851182679911" xlink:to="loc_us-gaap_CommonStockValue_9d179063-40d3-4b5c-a412-58d89bcb7313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_30623e69-ff0c-446b-bf27-c108aba97daf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_95bacae1-fe5e-46b6-99c2-851182679911" xlink:to="loc_us-gaap_AdditionalPaidInCapital_30623e69-ff0c-446b-bf27-c108aba97daf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc32a3c2-6b47-4948-ac57-a9458ac06351" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_95bacae1-fe5e-46b6-99c2-851182679911" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc32a3c2-6b47-4948-ac57-a9458ac06351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a749b6e-6472-4738-b559-ee4a4dae8812" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_95bacae1-fe5e-46b6-99c2-851182679911" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a749b6e-6472-4738-b559-ee4a4dae8812" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d42d4bb3-ae4f-4052-a8e4-892eeef6fe98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2849913e-0ea6-45d8-9fd2-08a177ac8e36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d42d4bb3-ae4f-4052-a8e4-892eeef6fe98" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2849913e-0ea6-45d8-9fd2-08a177ac8e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_56eeac85-9237-45cc-a54f-3943173565d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d42d4bb3-ae4f-4052-a8e4-892eeef6fe98" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_56eeac85-9237-45cc-a54f-3943173565d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_25163f0e-796f-4eae-ac3c-ed4c89ff96fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d42d4bb3-ae4f-4052-a8e4-892eeef6fe98" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_25163f0e-796f-4eae-ac3c-ed4c89ff96fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_cb3eb420-4418-4fb8-959a-ba567a421a70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_aa52afef-4715-422b-bff1-b325bd5fac0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cb3eb420-4418-4fb8-959a-ba567a421a70" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_aa52afef-4715-422b-bff1-b325bd5fac0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_430927b1-6af0-4f29-a979-44fefe9649b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cb3eb420-4418-4fb8-959a-ba567a421a70" xlink:to="loc_us-gaap_OperatingIncomeLoss_430927b1-6af0-4f29-a979-44fefe9649b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_6b865b11-b44b-44d7-85c1-5f98a8f80b79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cb3eb420-4418-4fb8-959a-ba567a421a70" xlink:to="loc_us-gaap_InterestExpenseNonoperating_6b865b11-b44b-44d7-85c1-5f98a8f80b79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_019bfeb8-a7a8-7015-bce7-df6d91747607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cb3eb420-4418-4fb8-959a-ba567a421a70" xlink:to="loc_us-gaap_InterestIncomeOther_019bfeb8-a7a8-7015-bce7-df6d91747607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e4c6da6a-834d-446e-a19b-09add69f2f12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_267311d4-8ab8-4c55-8888-6eed18e5d12a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e4c6da6a-834d-446e-a19b-09add69f2f12" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_267311d4-8ab8-4c55-8888-6eed18e5d12a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4518a44c-7279-4419-adcd-975de065dda7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e4c6da6a-834d-446e-a19b-09add69f2f12" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4518a44c-7279-4419-adcd-975de065dda7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6fa5181c-bbfb-4b77-9387-4f4053342437" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e8427c5d-aef5-4d3d-824b-5c39c1ab3254" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6fa5181c-bbfb-4b77-9387-4f4053342437" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e8427c5d-aef5-4d3d-824b-5c39c1ab3254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d4d1f5c2-c2f6-4e61-a80d-9dca74fda7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6fa5181c-bbfb-4b77-9387-4f4053342437" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d4d1f5c2-c2f6-4e61-a80d-9dca74fda7a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2412599c-787a-46af-8741-002c501cd8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_345b08c7-8c65-4f02-b5cb-f5f6e59c935b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2412599c-787a-46af-8741-002c501cd8d6" xlink:to="loc_us-gaap_CostsAndExpenses_345b08c7-8c65-4f02-b5cb-f5f6e59c935b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2a967df1-33a9-4ce3-9295-eab6bcd02cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2412599c-787a-46af-8741-002c501cd8d6" xlink:to="loc_us-gaap_Revenues_2a967df1-33a9-4ce3-9295-eab6bcd02cb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_80f7170e-7ded-4f8e-ae90-386fbec7c756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b4430453-cd4b-42a1-85a6-4c286dd2a870" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_80f7170e-7ded-4f8e-ae90-386fbec7c756" xlink:to="loc_us-gaap_NetIncomeLoss_b4430453-cd4b-42a1-85a6-4c286dd2a870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_dde5f807-9544-470d-8c09-897f7a45c404" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_80f7170e-7ded-4f8e-ae90-386fbec7c756" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_dde5f807-9544-470d-8c09-897f7a45c404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cd20f435-6749-4aaf-9e23-fc253192d401" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_a0ca00f5-cedd-4bca-af5d-402388814b51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_cd20f435-6749-4aaf-9e23-fc253192d401" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_a0ca00f5-cedd-4bca-af5d-402388814b51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a656ccd3-66d1-4331-8b30-c22a9b43cd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_cd20f435-6749-4aaf-9e23-fc253192d401" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a656ccd3-66d1-4331-8b30-c22a9b43cd1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b89fb0a-a1b4-4196-a190-d0d836055431" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ee57028-aff3-4432-b293-dc9c95e6fb03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b89fb0a-a1b4-4196-a190-d0d836055431" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ee57028-aff3-4432-b293-dc9c95e6fb03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1046980b-4174-46b6-9bf3-35b848910750" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b89fb0a-a1b4-4196-a190-d0d836055431" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1046980b-4174-46b6-9bf3-35b848910750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b43e2a1e-fc22-4e41-8534-df0eb0d00c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b89fb0a-a1b4-4196-a190-d0d836055431" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b43e2a1e-fc22-4e41-8534-df0eb0d00c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4dffd671-346e-4750-bd2d-36e8d38578f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b89fb0a-a1b4-4196-a190-d0d836055431" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4dffd671-346e-4750-bd2d-36e8d38578f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_374535ad-1322-4ee8-b870-a123be1521b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_37b3ce9b-42e3-41d3-ba83-da4d1f27e41a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_374535ad-1322-4ee8-b870-a123be1521b6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_37b3ce9b-42e3-41d3-ba83-da4d1f27e41a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5416d0d6-2daf-4cfe-98c0-81ffda1f3477" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_374535ad-1322-4ee8-b870-a123be1521b6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5416d0d6-2daf-4cfe-98c0-81ffda1f3477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cebc7d27-24ad-45c0-a752-1842a641998b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_374535ad-1322-4ee8-b870-a123be1521b6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cebc7d27-24ad-45c0-a752-1842a641998b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts_7a4fd80f-5820-4dc4-9b1c-a21babedd94d" xlink:href="arqt-20251231.xsd#arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_374535ad-1322-4ee8-b870-a123be1521b6" xlink:to="loc_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts_7a4fd80f-5820-4dc4-9b1c-a21babedd94d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b8b58a21-62fa-4801-a522-d95f26fed1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_374535ad-1322-4ee8-b870-a123be1521b6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b8b58a21-62fa-4801-a522-d95f26fed1a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_ad170a9d-b7fe-4574-b836-994a0ed70a5b" xlink:href="arqt-20251231.xsd#arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_374535ad-1322-4ee8-b870-a123be1521b6" xlink:to="loc_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_ad170a9d-b7fe-4574-b836-994a0ed70a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e959690a-9970-4018-aa84-9e41a776fbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_NetIncomeLoss_e959690a-9970-4018-aa84-9e41a776fbf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_03f048dc-59d8-4c49-8924-99712824fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_03f048dc-59d8-4c49-8924-99712824fe36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7a229c8c-f7e6-4def-83ac-611f56e54175" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7a229c8c-f7e6-4def-83ac-611f56e54175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_792f9853-c61b-4bb7-8bed-0afa196777f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_PaidInKindInterest_792f9853-c61b-4bb7-8bed-0afa196777f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f27ea096-5a0a-47f0-9c1c-d823307a3131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_ShareBasedCompensation_f27ea096-5a0a-47f0-9c1c-d823307a3131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_510bbf7d-d9b4-4f75-8a24-0103fd968501" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_510bbf7d-d9b4-4f75-8a24-0103fd968501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bef443eb-dfbf-4e89-b580-787d1f690159" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bef443eb-dfbf-4e89-b580-787d1f690159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9292b387-810b-4e76-8059-2f44e3b26570" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9292b387-810b-4e76-8059-2f44e3b26570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3783bfe1-b51d-4a27-be70-b256dcff0eef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3783bfe1-b51d-4a27-be70-b256dcff0eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_96df772c-6edf-4f44-b1d2-caaafed3a12e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_96df772c-6edf-4f44-b1d2-caaafed3a12e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_5e0036ec-bf0e-47c0-95c4-b10e36e4dd90" xlink:href="arqt-20251231.xsd#arqt_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_5e0036ec-bf0e-47c0-95c4-b10e36e4dd90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_03f0beb1-aec6-448e-9f81-c2495f138e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5036d264-3afb-4f3a-a98b-20707454c824" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_03f0beb1-aec6-448e-9f81-c2495f138e2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78f6a758-8b29-448c-b86c-6c5d28b2251d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_beefcf94-6423-42f5-b098-ac7426638048" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78f6a758-8b29-448c-b86c-6c5d28b2251d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_beefcf94-6423-42f5-b098-ac7426638048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_18c7bf39-ffbf-4384-be53-f454c1350789" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78f6a758-8b29-448c-b86c-6c5d28b2251d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_18c7bf39-ffbf-4384-be53-f454c1350789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2b0578d2-ead5-4ecb-8dce-0371f5da452b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78f6a758-8b29-448c-b86c-6c5d28b2251d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2b0578d2-ead5-4ecb-8dce-0371f5da452b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0c2156d7-b2c8-476a-9bb5-561b1d91b466" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78f6a758-8b29-448c-b86c-6c5d28b2251d" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0c2156d7-b2c8-476a-9bb5-561b1d91b466" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f4a1bc6-3a14-4128-9a98-0f3b343e1483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a46a5c73-fd7a-4f49-ad55-57998ee6be52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f4a1bc6-3a14-4128-9a98-0f3b343e1483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a46a5c73-fd7a-4f49-ad55-57998ee6be52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_32051148-4fe7-4c4e-9743-97a357dbca41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f4a1bc6-3a14-4128-9a98-0f3b343e1483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_32051148-4fe7-4c4e-9743-97a357dbca41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9fff2ccb-fa17-4c32-9122-3b376847de47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f4a1bc6-3a14-4128-9a98-0f3b343e1483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9fff2ccb-fa17-4c32-9122-3b376847de47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_58076b84-51d7-4c79-9934-5aeeb8630262" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f4a1bc6-3a14-4128-9a98-0f3b343e1483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_58076b84-51d7-4c79-9934-5aeeb8630262" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8fc44bac-4c40-431a-b64a-c437dbdcdaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f4a1bc6-3a14-4128-9a98-0f3b343e1483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8fc44bac-4c40-431a-b64a-c437dbdcdaaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ff3d903b-9786-4083-821f-09f48c88f928" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f4a1bc6-3a14-4128-9a98-0f3b343e1483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ff3d903b-9786-4083-821f-09f48c88f928" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f93608d4-4397-4e71-8434-beff1393b192" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e93742ff-0b72-4bf0-bbcc-f996f8cf4e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f93608d4-4397-4e71-8434-beff1393b192" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e93742ff-0b72-4bf0-bbcc-f996f8cf4e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_af010f76-abaa-4bd7-b2ec-262dd2e6c011" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f93608d4-4397-4e71-8434-beff1393b192" xlink:to="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_af010f76-abaa-4bd7-b2ec-262dd2e6c011" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b679ace4-34b9-4dc3-8079-78c9e5a0906f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0961256b-d276-4523-b261-9c0843cee09e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b679ace4-34b9-4dc3-8079-78c9e5a0906f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0961256b-d276-4523-b261-9c0843cee09e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fbf07be9-5345-4c0a-b901-083de770cfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b679ace4-34b9-4dc3-8079-78c9e5a0906f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fbf07be9-5345-4c0a-b901-083de770cfe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f25df2c1-1b52-44af-be17-bbf2a97d6e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b679ace4-34b9-4dc3-8079-78c9e5a0906f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f25df2c1-1b52-44af-be17-bbf2a97d6e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2525ea8b-da42-46a8-a175-0f3ef7ac8985" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsUnrealizedLoss_db4a8eb6-16fb-4291-881c-b1664d2a055a" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsUnrealizedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2525ea8b-da42-46a8-a175-0f3ef7ac8985" xlink:to="loc_arqt_CashAndCashEquivalentsUnrealizedLoss_db4a8eb6-16fb-4291-881c-b1664d2a055a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2cd9716a-0729-4ff5-b5e7-e482c7d88eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2525ea8b-da42-46a8-a175-0f3ef7ac8985" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2cd9716a-0729-4ff5-b5e7-e482c7d88eaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsUnrealizedGain_d2ecb80b-d1ed-4d34-8b4c-395d7783b81c" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsUnrealizedGain"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2525ea8b-da42-46a8-a175-0f3ef7ac8985" xlink:to="loc_arqt_CashAndCashEquivalentsUnrealizedGain_d2ecb80b-d1ed-4d34-8b4c-395d7783b81c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019c2774-2f77-772c-a7ee-f45091b831a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c2774-2f77-77b1-ae1f-c3abee908b69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019c2774-2f77-772c-a7ee-f45091b831a5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c2774-2f77-77b1-ae1f-c3abee908b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c2774-2f77-7f94-8ba5-83985e1ba6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019c2774-2f77-772c-a7ee-f45091b831a5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c2774-2f77-7f94-8ba5-83985e1ba6b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c2774-4af3-7a0f-9883-9438df019e79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c2774-4af3-7f8a-a3c4-86c8c4f2f223" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c2774-4af3-7a0f-9883-9438df019e79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c2774-4af3-7f8a-a3c4-86c8c4f2f223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c2774-4af3-7739-a5b1-2210cfbd7507" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c2774-4af3-7a0f-9883-9438df019e79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c2774-4af3-7739-a5b1-2210cfbd7507" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#BalanceSheetComponentsInventoriesDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_af32877f-3bf4-465e-91d5-c69fa578d6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1a36da8a-940b-4ef8-bbb4-b4a6c8e5843b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_af32877f-3bf4-465e-91d5-c69fa578d6d6" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1a36da8a-940b-4ef8-bbb4-b4a6c8e5843b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4a80f096-b211-4815-93c2-f299ab294e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_af32877f-3bf4-465e-91d5-c69fa578d6d6" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4a80f096-b211-4815-93c2-f299ab294e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_cf5f1999-fb8b-4cb2-9fea-077c9edddd85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_af32877f-3bf4-465e-91d5-c69fa578d6d6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_cf5f1999-fb8b-4cb2-9fea-077c9edddd85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4e045117-ca19-453d-aba0-7f67b18df9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrepaidCopayAssistanceProgramAndRebates_16bdaa6a-5f84-488f-aaf0-9fef718dfccc" xlink:href="arqt-20251231.xsd#arqt_PrepaidCopayAssistanceProgramAndRebates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4e045117-ca19-453d-aba0-7f67b18df9bd" xlink:to="loc_arqt_PrepaidCopayAssistanceProgramAndRebates_16bdaa6a-5f84-488f-aaf0-9fef718dfccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrepaidClinicalTrialTestCostsCurrent_2554cfd6-aade-4bf5-8ced-c587a45115c5" xlink:href="arqt-20251231.xsd#arqt_PrepaidClinicalTrialTestCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4e045117-ca19-453d-aba0-7f67b18df9bd" xlink:to="loc_arqt_PrepaidClinicalTrialTestCostsCurrent_2554cfd6-aade-4bf5-8ced-c587a45115c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_bada4644-3844-4c89-82f6-678489688d40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4e045117-ca19-453d-aba0-7f67b18df9bd" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_bada4644-3844-4c89-82f6-678489688d40" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3e6825bc-fb41-4816-ac7a-f7652981deb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6495962e-cee8-4c0c-9746-75da1a6f35e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e6825bc-fb41-4816-ac7a-f7652981deb8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6495962e-cee8-4c0c-9746-75da1a6f35e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AccruedSalesDiscounts_0603cc3d-1e0c-4cdb-acf0-a8cff4ab71f2" xlink:href="arqt-20251231.xsd#arqt_AccruedSalesDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e6825bc-fb41-4816-ac7a-f7652981deb8" xlink:to="loc_arqt_AccruedSalesDiscounts_0603cc3d-1e0c-4cdb-acf0-a8cff4ab71f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ClinicalTrialAccrualCurrent_65f5da26-4b3e-4663-956f-9504497fc502" xlink:href="arqt-20251231.xsd#arqt_ClinicalTrialAccrualCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e6825bc-fb41-4816-ac7a-f7652981deb8" xlink:to="loc_arqt_ClinicalTrialAccrualCurrent_65f5da26-4b3e-4663-956f-9504497fc502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3155f72a-895b-48e7-83ed-64814201ea29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e6825bc-fb41-4816-ac7a-f7652981deb8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3155f72a-895b-48e7-83ed-64814201ea29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3961d72d-cb32-4732-b364-9065f448e160" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4c95ea82-fa07-4bf1-9882-771fe3ef4699" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3961d72d-cb32-4732-b364-9065f448e160" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4c95ea82-fa07-4bf1-9882-771fe3ef4699" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5bc98ca4-0603-4da4-8534-198c706f21cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3961d72d-cb32-4732-b364-9065f448e160" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5bc98ca4-0603-4da4-8534-198c706f21cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#CommitmentsandContingenciesOperatingLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e65105a3-4c46-4645-a435-80f771f8d448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dcc161ad-04ca-4e71-949c-ea58c11a4cee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e65105a3-4c46-4645-a435-80f771f8d448" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dcc161ad-04ca-4e71-949c-ea58c11a4cee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fd1be2eb-b904-46fd-abd1-2fa1ffd9d25b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e65105a3-4c46-4645-a435-80f771f8d448" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fd1be2eb-b904-46fd-abd1-2fa1ffd9d25b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d1079961-550e-4864-8dc3-64c0c1d03a44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e65105a3-4c46-4645-a435-80f771f8d448" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d1079961-550e-4864-8dc3-64c0c1d03a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1d49d789-618a-46c4-94bb-e8544902ccdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e65105a3-4c46-4645-a435-80f771f8d448" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1d49d789-618a-46c4-94bb-e8544902ccdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_019bfefd-e34e-707c-aef0-190d72f96398" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e65105a3-4c46-4645-a435-80f771f8d448" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_019bfefd-e34e-707c-aef0-190d72f96398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_019bfefd-e34e-79d3-a31f-e09a5a81b124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e65105a3-4c46-4645-a435-80f771f8d448" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_019bfefd-e34e-79d3-a31f-e09a5a81b124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9bd11c55-3c8f-4a92-8421-bd158823e1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_30e2de6d-6c64-4db9-9122-e74a17553faf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_9bd11c55-3c8f-4a92-8421-bd158823e1cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_30e2de6d-6c64-4db9-9122-e74a17553faf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9ae15f9-82b3-4f18-901f-b2ac7d020c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_9bd11c55-3c8f-4a92-8421-bd158823e1cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9ae15f9-82b3-4f18-901f-b2ac7d020c9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="arqt-20251231.xsd#CommitmentsandContingenciesOperatingLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2a9d358-73a2-4ce7-af8b-2e0a0530cb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_31ad82c7-3ce4-4ce2-bd57-e6f10a2bda74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2a9d358-73a2-4ce7-af8b-2e0a0530cb3f" xlink:to="loc_us-gaap_OperatingLeaseLiability_31ad82c7-3ce4-4ce2-bd57-e6f10a2bda74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2a666d61-801d-469c-8917-b32c84e6bf56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2a9d358-73a2-4ce7-af8b-2e0a0530cb3f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2a666d61-801d-469c-8917-b32c84e6bf56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e061eca9-6d15-4808-a018-41e9f1dee4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5cd1449c-ad19-4dc3-b556-d8ebac493fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e061eca9-6d15-4808-a018-41e9f1dee4bb" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5cd1449c-ad19-4dc3-b556-d8ebac493fa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c35f8da4-1c3f-4837-836b-5d7ff9a7c464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e061eca9-6d15-4808-a018-41e9f1dee4bb" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c35f8da4-1c3f-4837-836b-5d7ff9a7c464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentAccruedPrepaymentPenalty_4015f943-6db9-4f0f-a927-22ebf738d8ac" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentAccruedPrepaymentPenalty"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e061eca9-6d15-4808-a018-41e9f1dee4bb" xlink:to="loc_arqt_DebtInstrumentAccruedPrepaymentPenalty_4015f943-6db9-4f0f-a927-22ebf738d8ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentAccruedFinalFee_55d70784-1916-4a60-9698-67a53f3c440c" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentAccruedFinalFee"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e061eca9-6d15-4808-a018-41e9f1dee4bb" xlink:to="loc_arqt_DebtInstrumentAccruedFinalFee_55d70784-1916-4a60-9698-67a53f3c440c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/DebtScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="arqt-20251231.xsd#DebtScheduleofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/DebtScheduleofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_72a6e586-52ab-4d5e-ae07-ee426c5f4dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b24c5843-4f4f-4ed1-a818-1b6450682e54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_72a6e586-52ab-4d5e-ae07-ee426c5f4dd4" xlink:to="loc_us-gaap_LongTermDebtCurrent_b24c5843-4f4f-4ed1-a818-1b6450682e54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_76790548-4f28-42b3-aa67-bc7bd074da76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_72a6e586-52ab-4d5e-ae07-ee426c5f4dd4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_76790548-4f28-42b3-aa67-bc7bd074da76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_4e52ef39-d722-4286-a87d-ae4abb8a40e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_85297311-55dd-4391-8cbe-672dc7fd8f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_4e52ef39-d722-4286-a87d-ae4abb8a40e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_85297311-55dd-4391-8cbe-672dc7fd8f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2e031dac-d4fd-4fb7-b8d8-4641154a0f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_4e52ef39-d722-4286-a87d-ae4abb8a40e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2e031dac-d4fd-4fb7-b8d8-4641154a0f5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bafe43ad-8e98-4c4d-a246-dcfe602a813d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_582ee3a5-6a9c-4dfe-891b-03eee2ef7ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bafe43ad-8e98-4c4d-a246-dcfe602a813d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_582ee3a5-6a9c-4dfe-891b-03eee2ef7ba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_33ac5e09-bd03-4948-a8d7-028cdc262ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bafe43ad-8e98-4c4d-a246-dcfe602a813d" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_33ac5e09-bd03-4948-a8d7-028cdc262ea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d7bf8f3c-89a5-41b5-879d-3b48cab13e25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bafe43ad-8e98-4c4d-a246-dcfe602a813d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d7bf8f3c-89a5-41b5-879d-3b48cab13e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cebf1e56-6151-4a47-9e0d-e3028b9d5ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4aa7a659-a214-4d39-a8ad-45abb7ff0359" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cebf1e56-6151-4a47-9e0d-e3028b9d5ca9" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4aa7a659-a214-4d39-a8ad-45abb7ff0359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_63ef9f51-3ca8-4435-a524-b766956497b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cebf1e56-6151-4a47-9e0d-e3028b9d5ca9" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_63ef9f51-3ca8-4435-a524-b766956497b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_324f8a51-db7f-4ff4-a130-bf422686143f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cebf1e56-6151-4a47-9e0d-e3028b9d5ca9" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_324f8a51-db7f-4ff4-a130-bf422686143f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b4d85694-1fd3-4b0e-b134-6685d0323223" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d7caf63e-6e29-4bfb-b878-24156c69a080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b4d85694-1fd3-4b0e-b134-6685d0323223" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d7caf63e-6e29-4bfb-b878-24156c69a080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f5ceb57c-14f7-4533-bda7-57964c9feceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b4d85694-1fd3-4b0e-b134-6685d0323223" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f5ceb57c-14f7-4533-bda7-57964c9feceb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7a9e-915c-1e075fd4a802" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019bb77d-b394-7647-9e94-00285fa81bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7a9e-915c-1e075fd4a802" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019bb77d-b394-7647-9e94-00285fa81bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent_019c272e-42d2-7f6a-bd3c-4b47819f58b0" xlink:href="arqt-20251231.xsd#arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7a9e-915c-1e075fd4a802" xlink:to="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent_019c272e-42d2-7f6a-bd3c-4b47819f58b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019bb77d-b394-7b59-98a0-54bd809105b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7a9e-915c-1e075fd4a802" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019bb77d-b394-7b59-98a0-54bd809105b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019bb77d-b394-7bfc-acaf-571fd0dae850" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7a9e-915c-1e075fd4a802" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019bb77d-b394-7bfc-acaf-571fd0dae850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019bb77d-b394-7953-b83f-b4785cb456d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7a9e-915c-1e075fd4a802" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019bb77d-b394-7953-b83f-b4785cb456d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019bb77d-b394-71fb-83dd-1747e562ee55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7a9e-915c-1e075fd4a802" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019bb77d-b394-71fb-83dd-1747e562ee55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb77d-b394-7446-bdb4-03d5e8e84eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7a9e-915c-1e075fd4a802" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb77d-b394-7446-bdb4-03d5e8e84eb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019bb77d-b394-7faf-9c4b-3e0603d6743b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7a9e-915c-1e075fd4a802" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019bb77d-b394-7faf-9c4b-3e0603d6743b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019bb77d-b394-74a6-b62e-214b65888b73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7a9e-915c-1e075fd4a802" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019bb77d-b394-74a6-b62e-214b65888b73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019bb77d-84d3-7354-8926-a1018e73f0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019bb77d-84d3-7be9-8990-53340c9a9565" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019bb77d-84d3-7354-8926-a1018e73f0d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019bb77d-84d3-7be9-8990-53340c9a9565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount_019c2730-4d1f-7e45-ac73-786cacc57032" xlink:href="arqt-20251231.xsd#arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019bb77d-84d3-7354-8926-a1018e73f0d6" xlink:to="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount_019c2730-4d1f-7e45-ac73-786cacc57032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019bb77d-84d3-7718-9100-53166ed49649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019bb77d-84d3-7354-8926-a1018e73f0d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019bb77d-84d3-7718-9100-53166ed49649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019bb77d-84d3-785b-b761-a13f07450a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019bb77d-84d3-7354-8926-a1018e73f0d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019bb77d-84d3-785b-b761-a13f07450a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_019bb77d-84d3-78a8-bab7-dff20d0af1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019bb77d-84d3-7354-8926-a1018e73f0d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_019bb77d-84d3-78a8-bab7-dff20d0af1e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019bb77d-84d3-7ecf-a3bc-8c181034ac7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019bb77d-84d3-7354-8926-a1018e73f0d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019bb77d-84d3-7ecf-a3bc-8c181034ac7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb77d-84d3-75ca-9c39-e00c785d09d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019bb77d-84d3-7354-8926-a1018e73f0d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb77d-84d3-75ca-9c39-e00c785d09d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019bb77d-84d3-7bb6-87e1-2ff14e926b21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019bb77d-84d3-7354-8926-a1018e73f0d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019bb77d-84d3-7bb6-87e1-2ff14e926b21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019bb77d-84d3-786c-8d0e-0dee56d22d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019bb77d-84d3-7354-8926-a1018e73f0d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019bb77d-84d3-786c-8d0e-0dee56d22d7f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_cd1fea51-df27-4d0c-a00c-7cecd63e0da9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f16fc3b0-ea81-4a24-8602-91021e836301" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd1fea51-df27-4d0c-a00c-7cecd63e0da9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f16fc3b0-ea81-4a24-8602-91021e836301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5e4a482d-0e5c-46c3-85ff-4240b9913a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd1fea51-df27-4d0c-a00c-7cecd63e0da9" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5e4a482d-0e5c-46c3-85ff-4240b9913a1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7a284bb6-2e2a-4b88-8824-22076cae7f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd1fea51-df27-4d0c-a00c-7cecd63e0da9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7a284bb6-2e2a-4b88-8824-22076cae7f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization_1946e2cb-800d-4add-8e8a-3b214dfab40f" xlink:href="arqt-20251231.xsd#arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd1fea51-df27-4d0c-a00c-7cecd63e0da9" xlink:to="loc_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization_1946e2cb-800d-4add-8e8a-3b214dfab40f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4ec53365-a478-4ccd-b34c-15b8308f5d86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd1fea51-df27-4d0c-a00c-7cecd63e0da9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4ec53365-a478-4ccd-b34c-15b8308f5d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredTaxAssetsLeaseLiability_4f2b2472-546b-4256-b3fe-da19a33779ef" xlink:href="arqt-20251231.xsd#arqt_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd1fea51-df27-4d0c-a00c-7cecd63e0da9" xlink:to="loc_arqt_DeferredTaxAssetsLeaseLiability_4f2b2472-546b-4256-b3fe-da19a33779ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0d47f887-b4ff-4f6b-8e1b-254fb2ae2249" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd1fea51-df27-4d0c-a00c-7cecd63e0da9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0d47f887-b4ff-4f6b-8e1b-254fb2ae2249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8e33ca3c-c88f-47cf-ba0d-ff45ec5e83ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6874d3b7-3988-4c0c-9d6c-a1719090f580" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_8e33ca3c-c88f-47cf-ba0d-ff45ec5e83ee" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6874d3b7-3988-4c0c-9d6c-a1719090f580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredTaxLiabilitiesRightOfUseAsset_8300e620-d9cc-47f3-af74-e70facc0ff88" xlink:href="arqt-20251231.xsd#arqt_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_8e33ca3c-c88f-47cf-ba0d-ff45ec5e83ee" xlink:to="loc_arqt_DeferredTaxLiabilitiesRightOfUseAsset_8300e620-d9cc-47f3-af74-e70facc0ff88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_da410d28-efe3-4b35-83ec-a2f9f056a89a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_019c4c2f-b82d-73e4-be7f-99fddf56f1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_da410d28-efe3-4b35-83ec-a2f9f056a89a" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_019c4c2f-b82d-73e4-be7f-99fddf56f1e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_019c4c2f-b82d-7e12-89ba-8cf38d73bc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_da410d28-efe3-4b35-83ec-a2f9f056a89a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_019c4c2f-b82d-7e12-89ba-8cf38d73bc8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a1df86c4-f916-426d-9e05-226725d0f211" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019c4c18-07d5-7040-b48d-c726bbe15957" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a1df86c4-f916-426d-9e05-226725d0f211" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019c4c18-07d5-7040-b48d-c726bbe15957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0db2ed19-2c40-48a5-a1b4-4014ca973ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a1df86c4-f916-426d-9e05-226725d0f211" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0db2ed19-2c40-48a5-a1b4-4014ca973ece" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_475b2549-670b-47a6-9f2e-f19ab0f5167f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses_dc5095b0-207c-41b0-a214-e36db8b3ba5a" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_475b2549-670b-47a6-9f2e-f19ab0f5167f" xlink:to="loc_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses_dc5095b0-207c-41b0-a214-e36db8b3ba5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_182871d8-f1a2-4761-bf23-b035a38565b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_475b2549-670b-47a6-9f2e-f19ab0f5167f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_182871d8-f1a2-4761-bf23-b035a38565b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_94290784-cf4c-4804-bbf1-9ac40fc702b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_475b2549-670b-47a6-9f2e-f19ab0f5167f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_94290784-cf4c-4804-bbf1-9ac40fc702b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_d9bfcbd7-b2c5-4729-9e92-9a8830885b85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_475b2549-670b-47a6-9f2e-f19ab0f5167f" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_d9bfcbd7-b2c5-4729-9e92-9a8830885b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_402be5ce-a946-4c12-b09f-998d1d92f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_475b2549-670b-47a6-9f2e-f19ab0f5167f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_402be5ce-a946-4c12-b09f-998d1d92f6ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_65cd147d-5e7b-4561-85f3-ee13396aa189" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_13b9b02a-aa48-41de-8349-541ed3cd1138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_65cd147d-5e7b-4561-85f3-ee13396aa189" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_13b9b02a-aa48-41de-8349-541ed3cd1138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5104322b-11b5-4ff6-93db-2f2ce4e3e947" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_65cd147d-5e7b-4561-85f3-ee13396aa189" xlink:to="loc_us-gaap_OperatingIncomeLoss_5104322b-11b5-4ff6-93db-2f2ce4e3e947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_6b74bf7e-cbf7-4189-9898-12c6c0c1e376" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_65cd147d-5e7b-4561-85f3-ee13396aa189" xlink:to="loc_us-gaap_InterestExpenseNonoperating_6b74bf7e-cbf7-4189-9898-12c6c0c1e376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b8150e78-a6bf-4fe9-83f6-8c2e94baf36d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_65cd147d-5e7b-4561-85f3-ee13396aa189" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b8150e78-a6bf-4fe9-83f6-8c2e94baf36d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_019bff77-f4a0-7078-8f79-160454e9edfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_65cd147d-5e7b-4561-85f3-ee13396aa189" xlink:to="loc_us-gaap_InterestIncomeOther_019bff77-f4a0-7078-8f79-160454e9edfd" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>arqt-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:631d5f47-b6cd-44b6-9ca1-ef826fe44260,g:a004ef44-2665-49af-8ba9-70d1dea45abd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5f9462ae-04c7-48b3-9b2c-bd2fa1387689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_33302b67-bb1d-414f-9e42-1c2ac30609fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5f9462ae-04c7-48b3-9b2c-bd2fa1387689" xlink:to="loc_us-gaap_StatementTable_33302b67-bb1d-414f-9e42-1c2ac30609fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_753d2561-52a5-4410-9533-9ddf51e9f478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_33302b67-bb1d-414f-9e42-1c2ac30609fc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_753d2561-52a5-4410-9533-9ddf51e9f478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_753d2561-52a5-4410-9533-9ddf51e9f478_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_753d2561-52a5-4410-9533-9ddf51e9f478" xlink:to="loc_us-gaap_EquityComponentDomain_753d2561-52a5-4410-9533-9ddf51e9f478_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_753d2561-52a5-4410-9533-9ddf51e9f478" xlink:to="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8894c657-0af0-4a24-8d62-415c8c0badc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:to="loc_us-gaap_CommonStockMember_8894c657-0af0-4a24-8d62-415c8c0badc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ba6c71ec-68de-44e0-a1c2-3a70d167ebd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ba6c71ec-68de-44e0-a1c2-3a70d167ebd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_473eb4d7-1650-492d-8b0c-35f4b16e8e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_473eb4d7-1650-492d-8b0c-35f4b16e8e9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c7e5f1e7-c5dc-4eba-a12f-265031e40645" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:to="loc_us-gaap_RetainedEarningsMember_c7e5f1e7-c5dc-4eba-a12f-265031e40645" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6ffdb220-f9aa-4496-9db8-e489d35e35a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_33302b67-bb1d-414f-9e42-1c2ac30609fc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6ffdb220-f9aa-4496-9db8-e489d35e35a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ffdb220-f9aa-4496-9db8-e489d35e35a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6ffdb220-f9aa-4496-9db8-e489d35e35a0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ffdb220-f9aa-4496-9db8-e489d35e35a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13e0679f-3ca4-4c23-a46a-740bd333ba91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6ffdb220-f9aa-4496-9db8-e489d35e35a0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13e0679f-3ca4-4c23-a46a-740bd333ba91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SecondaryEquityPublicOfferingMember_d69b7b65-2037-4119-8cf8-7f92ebd4e995" xlink:href="arqt-20251231.xsd#arqt_SecondaryEquityPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13e0679f-3ca4-4c23-a46a-740bd333ba91" xlink:to="loc_arqt_SecondaryEquityPublicOfferingMember_d69b7b65-2037-4119-8cf8-7f92ebd4e995" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5f9462ae-04c7-48b3-9b2c-bd2fa1387689" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_05cf6b73-e45f-4280-aa8d-5d4411e32260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_SharesOutstanding_05cf6b73-e45f-4280-aa8d-5d4411e32260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_90774caa-6803-4600-841f-d61a9f1067dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockholdersEquity_90774caa-6803-4600-841f-d61a9f1067dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cb1e0d5d-f744-4b7c-a8fa-5b62314a3443" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cb1e0d5d-f744-4b7c-a8fa-5b62314a3443" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13196159-9338-4236-a3a5-fdb6456dd6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13196159-9338-4236-a3a5-fdb6456dd6c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f61ce4e0-1b9c-432f-83be-3a5316419bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f61ce4e0-1b9c-432f-83be-3a5316419bdc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3ae91bd5-62bb-4aa4-96d4-a9442f9b1e76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3ae91bd5-62bb-4aa4-96d4-a9442f9b1e76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_90422e98-8ebb-45b0-b332-c3d329eb5696" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_90422e98-8ebb-45b0-b332-c3d329eb5696" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_11f4bab4-c1f3-42b3-8aed-897f63ad5102" xlink:href="arqt-20251231.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_11f4bab4-c1f3-42b3-8aed-897f63ad5102" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_02e768f1-d374-4a2a-b1f3-f012c1784cb9" xlink:href="arqt-20251231.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_02e768f1-d374-4a2a-b1f3-f012c1784cb9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodSharesWarrantsExercised_019bfec1-260b-7bc5-88ba-9beb0c5286f0" xlink:href="arqt-20251231.xsd#arqt_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_arqt_StockIssuedDuringPeriodSharesWarrantsExercised_019bfec1-260b-7bc5-88ba-9beb0c5286f0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_56f1869e-e3df-44fe-b542-47c0fbdaa281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_56f1869e-e3df-44fe-b542-47c0fbdaa281" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b1116994-3bd4-420e-ad74-77cd3777a59a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b1116994-3bd4-420e-ad74-77cd3777a59a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_afac1fd3-8273-4eb3-a158-fe8713b6e47c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_afac1fd3-8273-4eb3-a158-fe8713b6e47c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_43bee982-b0c0-486e-a69a-cc0d96b4643c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_43bee982-b0c0-486e-a69a-cc0d96b4643c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4736daae-6974-4461-a621-09f6cc4aa30c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4736daae-6974-4461-a621-09f6cc4aa30c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f653ee36-5469-4674-8d39-8fedea7b9ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_NetIncomeLoss_f653ee36-5469-4674-8d39-8fedea7b9ff5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_aa97cc4e-8053-45e6-ad35-2c71cc45458e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4ee5bfcd-0c59-4e9c-82c3-59cdba5baad1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_60cdc28d-b082-43be-8cb8-b0155cfea18a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d941dc1d-bcba-4743-aaee-628fcb80e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_60cdc28d-b082-43be-8cb8-b0155cfea18a" xlink:to="loc_us-gaap_StatementTable_d941dc1d-bcba-4743-aaee-628fcb80e21b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8dd14ca4-69bc-49a0-9e72-1e5118e90d41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d941dc1d-bcba-4743-aaee-628fcb80e21b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8dd14ca4-69bc-49a0-9e72-1e5118e90d41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8dd14ca4-69bc-49a0-9e72-1e5118e90d41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8dd14ca4-69bc-49a0-9e72-1e5118e90d41" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8dd14ca4-69bc-49a0-9e72-1e5118e90d41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5081a274-54fd-4514-89dc-8861edc5d257" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8dd14ca4-69bc-49a0-9e72-1e5118e90d41" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5081a274-54fd-4514-89dc-8861edc5d257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SecondaryEquityPublicOfferingMember_92a4c63a-7000-4d4f-9477-621803637ec4" xlink:href="arqt-20251231.xsd#arqt_SecondaryEquityPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5081a274-54fd-4514-89dc-8861edc5d257" xlink:to="loc_arqt_SecondaryEquityPublicOfferingMember_92a4c63a-7000-4d4f-9477-621803637ec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019bfebe-41ca-7afc-b735-b3783f6f6670" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d941dc1d-bcba-4743-aaee-628fcb80e21b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019bfebe-41ca-7afc-b735-b3783f6f6670" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019bfebe-41ca-7afc-b735-b3783f6f6670_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019bfebe-41ca-7afc-b735-b3783f6f6670" xlink:to="loc_us-gaap_EquityComponentDomain_019bfebe-41ca-7afc-b735-b3783f6f6670_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019bfebe-41ca-72fa-b75d-f4892f1dd6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019bfebe-41ca-7afc-b735-b3783f6f6670" xlink:to="loc_us-gaap_EquityComponentDomain_019bfebe-41ca-72fa-b75d-f4892f1dd6ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019bfebe-41ca-7b1b-b495-ffd139389e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019bfebe-41ca-72fa-b75d-f4892f1dd6ea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019bfebe-41ca-7b1b-b495-ffd139389e6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019bfebf-887b-729d-9817-faf787e68a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019bfebe-41ca-72fa-b75d-f4892f1dd6ea" xlink:to="loc_us-gaap_CommonStockMember_019bfebf-887b-729d-9817-faf787e68a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_edd84077-6d3c-40f9-87f9-15460f56fd68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60cdc28d-b082-43be-8cb8-b0155cfea18a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_edd84077-6d3c-40f9-87f9-15460f56fd68" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_019bfec5-e300-7d3a-ba65-964b462b9e62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09041ab8-b053-418c-85b9-5fe1828f82af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019bfec5-e300-7d3a-ba65-964b462b9e62" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09041ab8-b053-418c-85b9-5fe1828f82af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019bfec5-e300-7bcf-aebc-fa74ec647dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09041ab8-b053-418c-85b9-5fe1828f82af" xlink:to="loc_us-gaap_DebtInstrumentAxis_019bfec5-e300-7bcf-aebc-fa74ec647dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019bfec5-e300-7bcf-aebc-fa74ec647dd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019bfec5-e300-7bcf-aebc-fa74ec647dd3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019bfec5-e300-7bcf-aebc-fa74ec647dd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019bfec5-e300-7933-905c-c6b251263f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019bfec5-e300-7bcf-aebc-fa74ec647dd3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019bfec5-e300-7933-905c-c6b251263f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementMember_019bfec5-e300-731d-9059-26acba247a67" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019bfec5-e300-7933-905c-c6b251263f23" xlink:to="loc_arqt_LoanAgreementMember_019bfec5-e300-731d-9059-26acba247a67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019bfec5-e300-7653-b790-deb8d96b4ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09041ab8-b053-418c-85b9-5fe1828f82af" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019bfec5-e300-7653-b790-deb8d96b4ce2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019bfec5-e300-7653-b790-deb8d96b4ce2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019bfec5-e300-7653-b790-deb8d96b4ce2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019bfec5-e300-7653-b790-deb8d96b4ce2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019bfec5-e300-7358-bbd5-78ff77a0333d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019bfec5-e300-7653-b790-deb8d96b4ce2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019bfec5-e300-7358-bbd5-78ff77a0333d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019bfec5-e300-77ba-991d-8a7de2c453bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019bfec5-e300-7358-bbd5-78ff77a0333d" xlink:to="loc_us-gaap_SecuredDebtMember_019bfec5-e300-77ba-991d-8a7de2c453bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019bfec5-e300-721b-b87b-ed86f71a1d68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019bfec5-e300-7d3a-ba65-964b462b9e62" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019bfec5-e300-721b-b87b-ed86f71a1d68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashCashEquivalentsAndMarketableSecurities_019bfec5-e300-7bc5-af90-e61ff5e83f56" xlink:href="arqt-20251231.xsd#arqt_CashCashEquivalentsAndMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019bfec5-e300-7d3a-ba65-964b462b9e62" xlink:to="loc_arqt_CashCashEquivalentsAndMarketableSecurities_019bfec5-e300-7bc5-af90-e61ff5e83f56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019bfec5-e300-7946-9eab-10a5ee499312" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019bfec5-e300-7d3a-ba65-964b462b9e62" xlink:to="loc_us-gaap_LongTermDebt_019bfec5-e300-7946-9eab-10a5ee499312" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_10869eb1-0bae-47f0-9ac5-e53003cc7eb3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:to="loc_srt_RangeAxis_10869eb1-0bae-47f0-9ac5-e53003cc7eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_10869eb1-0bae-47f0-9ac5-e53003cc7eb3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_10869eb1-0bae-47f0-9ac5-e53003cc7eb3" xlink:to="loc_srt_RangeMember_10869eb1-0bae-47f0-9ac5-e53003cc7eb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_179cd4b2-fa17-45e8-9a97-454d0c551c74" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_10869eb1-0bae-47f0-9ac5-e53003cc7eb3" xlink:to="loc_srt_RangeMember_179cd4b2-fa17-45e8-9a97-454d0c551c74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_249185f0-d082-4c67-a46e-4b3d0fcbd4fe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_179cd4b2-fa17-45e8-9a97-454d0c551c74" xlink:to="loc_srt_MinimumMember_249185f0-d082-4c67-a46e-4b3d0fcbd4fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d26a160-ae15-4ec7-93db-f83200be09e1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_179cd4b2-fa17-45e8-9a97-454d0c551c74" xlink:to="loc_srt_MaximumMember_1d26a160-ae15-4ec7-93db-f83200be09e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8129562b-55e3-4dda-a329-b7e5117b0444" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8129562b-55e3-4dda-a329-b7e5117b0444" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8129562b-55e3-4dda-a329-b7e5117b0444_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8129562b-55e3-4dda-a329-b7e5117b0444" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8129562b-55e3-4dda-a329-b7e5117b0444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40ed39c1-5e8b-4eea-9132-fab6de93a083" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8129562b-55e3-4dda-a329-b7e5117b0444" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40ed39c1-5e8b-4eea-9132-fab6de93a083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_7b39cc9e-6186-4f65-b3b9-bb4f9f1da32d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40ed39c1-5e8b-4eea-9132-fab6de93a083" xlink:to="loc_us-gaap_PatentsMember_7b39cc9e-6186-4f65-b3b9-bb4f9f1da32d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f57ab9ad-bdc3-40d6-8745-4f1a5d67be03" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:to="loc_srt_CounterpartyNameAxis_f57ab9ad-bdc3-40d6-8745-4f1a5d67be03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f57ab9ad-bdc3-40d6-8745-4f1a5d67be03_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f57ab9ad-bdc3-40d6-8745-4f1a5d67be03" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f57ab9ad-bdc3-40d6-8745-4f1a5d67be03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40a5e2a7-4873-4ab0-926b-f71a550f3fb2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f57ab9ad-bdc3-40d6-8745-4f1a5d67be03" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40a5e2a7-4873-4ab0-926b-f71a550f3fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AstraZenecaMember_4c7e175b-e187-4f0f-a51e-2f11cff1e38d" xlink:href="arqt-20251231.xsd#arqt_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40a5e2a7-4873-4ab0-926b-f71a550f3fb2" xlink:to="loc_arqt_AstraZenecaMember_4c7e175b-e187-4f0f-a51e-2f11cff1e38d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_cfe85cbc-69bc-4cac-a894-2fafe8b3e06c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_cfe85cbc-69bc-4cac-a894-2fafe8b3e06c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_36463934-69e9-47db-9797-c1129890a1eb" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_36463934-69e9-47db-9797-c1129890a1eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72518094-2cd5-49d1-a25b-adb31d2938d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72518094-2cd5-49d1-a25b-adb31d2938d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_019c71cf-bd7a-7fd2-9391-2ac2d5b6aa12" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_019c71cf-bd7a-7fd2-9391-2ac2d5b6aa12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_30bae120-fb2e-4fcf-a459-e1972bc1f0a0" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_30bae120-fb2e-4fcf-a459-e1972bc1f0a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fdf030ac-e354-4f25-970e-219028ad5fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fdf030ac-e354-4f25-970e-219028ad5fd1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_019c274e-e894-7da6-8bb3-9b23da999743" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_019c274e-e894-7da6-8bb3-9b23da999743" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ff26ce60-8c04-4c3a-aa4a-2559058eed77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ff26ce60-8c04-4c3a-aa4a-2559058eed77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_637dd07b-a192-49bd-9bda-cfc782fde6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_637dd07b-a192-49bd-9bda-cfc782fde6d2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ProductRevenuePaymentTerm_e7fc31ae-237a-479b-8542-1673d6e2d012" xlink:href="arqt-20251231.xsd#arqt_ProductRevenuePaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_arqt_ProductRevenuePaymentTerm_e7fc31ae-237a-479b-8542-1673d6e2d012" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_225dd2a6-8b0f-4a51-ba1f-1e934295cee2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_AdvertisingExpense_225dd2a6-8b0f-4a51-ba1f-1e934295cee2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_11bd81aa-fc99-462f-a9f8-339e4e1fb490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_11bd81aa-fc99-462f-a9f8-339e4e1fb490" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#RevenuesScheduleofDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ebdb1f5b-4d4a-4fb6-84e1-b2b1017f7b55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_88f0686f-d8c5-4f2d-8718-cb4648327ded" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebdb1f5b-4d4a-4fb6-84e1-b2b1017f7b55" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_88f0686f-d8c5-4f2d-8718-cb4648327ded" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_53c2675b-e780-4919-9bfc-b0d12ee91779" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_88f0686f-d8c5-4f2d-8718-cb4648327ded" xlink:to="loc_srt_ProductOrServiceAxis_53c2675b-e780-4919-9bfc-b0d12ee91779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53c2675b-e780-4919-9bfc-b0d12ee91779_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_53c2675b-e780-4919-9bfc-b0d12ee91779" xlink:to="loc_srt_ProductsAndServicesDomain_53c2675b-e780-4919-9bfc-b0d12ee91779_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_53c2675b-e780-4919-9bfc-b0d12ee91779" xlink:to="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVECream0.3Member_9806f8f0-7211-445a-8fae-d7f4ce02d5e2" xlink:href="arqt-20251231.xsd#arqt_ZORYVECream0.3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:to="loc_arqt_ZORYVECream0.3Member_9806f8f0-7211-445a-8fae-d7f4ce02d5e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVEFoamMember_eb296daf-6c52-4b6d-a3fb-2eba6588781b" xlink:href="arqt-20251231.xsd#arqt_ZORYVEFoamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:to="loc_arqt_ZORYVEFoamMember_eb296daf-6c52-4b6d-a3fb-2eba6588781b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVECream0.15Member_02cafb30-9aa4-4880-832d-a5761d443eb4" xlink:href="arqt-20251231.xsd#arqt_ZORYVECream0.15Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:to="loc_arqt_ZORYVECream0.15Member_02cafb30-9aa4-4880-832d-a5761d443eb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVECream0.05Member_019bfec9-2cf0-70e5-b30b-f9fa09086143" xlink:href="arqt-20251231.xsd#arqt_ZORYVECream0.05Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:to="loc_arqt_ZORYVECream0.05Member_019bfec9-2cf0-70e5-b30b-f9fa09086143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3b534fbd-7cae-4605-b5e8-c23428fd8a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebdb1f5b-4d4a-4fb6-84e1-b2b1017f7b55" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3b534fbd-7cae-4605-b5e8-c23428fd8a1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_d40458ac-1f98-4271-8c6a-79004c298837" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebdb1f5b-4d4a-4fb6-84e1-b2b1017f7b55" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_d40458ac-1f98-4271-8c6a-79004c298837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_63e1b89c-da79-4ba5-bd49-9d7d917fefef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebdb1f5b-4d4a-4fb6-84e1-b2b1017f7b55" xlink:to="loc_us-gaap_Revenues_63e1b89c-da79-4ba5-bd49-9d7d917fefef" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019c275e-7338-76c1-a48f-548ee594caa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019c275e-7338-76c1-a48f-548ee594caa9" xlink:to="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c275e-7338-7017-ac9b-e67de508bb05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c275e-7338-7017-ac9b-e67de508bb05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c275e-7338-7017-ac9b-e67de508bb05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c275e-7338-7017-ac9b-e67de508bb05" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c275e-7338-7017-ac9b-e67de508bb05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c275e-7338-7dbb-a87a-457d6bdee322" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c275e-7338-7017-ac9b-e67de508bb05" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c275e-7338-7dbb-a87a-457d6bdee322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_019c275f-64e8-7870-bb31-8d0f8c885187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c275e-7338-7dbb-a87a-457d6bdee322" xlink:to="loc_us-gaap_AccountsReceivableMember_019c275f-64e8-7870-bb31-8d0f8c885187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019c275e-7338-7d5c-8182-24c0341a5cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019c275e-7338-7d5c-8182-24c0341a5cdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019c275e-7338-7d5c-8182-24c0341a5cdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019c275e-7338-7d5c-8182-24c0341a5cdf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019c275e-7338-7d5c-8182-24c0341a5cdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019c275e-7338-7626-bae4-7ddfe06b6df0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019c275e-7338-7d5c-8182-24c0341a5cdf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019c275e-7338-7626-bae4-7ddfe06b6df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_019c275e-7338-748a-ab2e-f538b0f2c563" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019c275e-7338-7626-bae4-7ddfe06b6df0" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_019c275e-7338-748a-ab2e-f538b0f2c563" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019c275f-64e8-7a6a-94ff-827f3e182945" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:to="loc_srt_MajorCustomersAxis_019c275f-64e8-7a6a-94ff-827f3e182945" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c275f-64e8-7a6a-94ff-827f3e182945_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_019c275f-64e8-7a6a-94ff-827f3e182945" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c275f-64e8-7a6a-94ff-827f3e182945_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c275f-64e8-7e06-aa76-6d23d8696b0b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_019c275f-64e8-7a6a-94ff-827f3e182945" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c275f-64e8-7e06-aa76-6d23d8696b0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FourCustomersMember_019c275f-64e8-7bc2-b374-ae15727d18e8" xlink:href="arqt-20251231.xsd#arqt_FourCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c275f-64e8-7e06-aa76-6d23d8696b0b" xlink:to="loc_arqt_FourCustomersMember_019c275f-64e8-7bc2-b374-ae15727d18e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FiveCustomersMember_019c275f-64e8-7bdc-bd94-a463e8ad704b" xlink:href="arqt-20251231.xsd#arqt_FiveCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c275f-64e8-7e06-aa76-6d23d8696b0b" xlink:to="loc_arqt_FiveCustomersMember_019c275f-64e8-7bdc-bd94-a463e8ad704b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019c275e-7338-70e6-b5c4-4da4df01a001" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019c275e-7338-76c1-a48f-548ee594caa9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019c275e-7338-70e6-b5c4-4da4df01a001" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#RevenuesGrossProductSalesandAccountsReceivableNetDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7cce8d5d-b278-4534-9abd-651ca4dd7d07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7cce8d5d-b278-4534-9abd-651ca4dd7d07" xlink:to="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_31ea6d84-f6a7-48c8-8bda-699118acfb3a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:to="loc_srt_MajorCustomersAxis_31ea6d84-f6a7-48c8-8bda-699118acfb3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_31ea6d84-f6a7-48c8-8bda-699118acfb3a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_31ea6d84-f6a7-48c8-8bda-699118acfb3a" xlink:to="loc_srt_NameOfMajorCustomerDomain_31ea6d84-f6a7-48c8-8bda-699118acfb3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_31ea6d84-f6a7-48c8-8bda-699118acfb3a" xlink:to="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerAMember_9a79a941-02c8-4e7e-a5d3-819d8b0b8b1d" xlink:href="arqt-20251231.xsd#arqt_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerAMember_9a79a941-02c8-4e7e-a5d3-819d8b0b8b1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerBMember_ac1c2466-b830-450c-b3db-b50c87d14d91" xlink:href="arqt-20251231.xsd#arqt_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerBMember_ac1c2466-b830-450c-b3db-b50c87d14d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerCMember_73bb0df7-7a19-434c-ac26-3e452f0639f2" xlink:href="arqt-20251231.xsd#arqt_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerCMember_73bb0df7-7a19-434c-ac26-3e452f0639f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerDMember_458a6552-6047-42dd-a495-6e19bb8c85ef" xlink:href="arqt-20251231.xsd#arqt_CustomerDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerDMember_458a6552-6047-42dd-a495-6e19bb8c85ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerEMember_81030680-bf05-4dd4-94cf-683e7c4a5e62" xlink:href="arqt-20251231.xsd#arqt_CustomerEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerEMember_81030680-bf05-4dd4-94cf-683e7c4a5e62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerFMember_44f974d4-3ee1-4d9d-b2da-6ce68ce93d0e" xlink:href="arqt-20251231.xsd#arqt_CustomerFMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerFMember_44f974d4-3ee1-4d9d-b2da-6ce68ce93d0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_MajorCustomersMember_5375367f-e9e4-4a8b-a829-70baa03bcdb4" xlink:href="arqt-20251231.xsd#arqt_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_MajorCustomersMember_5375367f-e9e4-4a8b-a829-70baa03bcdb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb04b893-c345-43d2-86f9-1cc043e710f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb04b893-c345-43d2-86f9-1cc043e710f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb04b893-c345-43d2-86f9-1cc043e710f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb04b893-c345-43d2-86f9-1cc043e710f7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb04b893-c345-43d2-86f9-1cc043e710f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fa6b473-6119-47fa-9733-a30cb747c9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb04b893-c345-43d2-86f9-1cc043e710f7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fa6b473-6119-47fa-9733-a30cb747c9d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_11e281c8-6b69-46c4-8080-e66d49678335" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fa6b473-6119-47fa-9733-a30cb747c9d1" xlink:to="loc_us-gaap_SalesMember_11e281c8-6b69-46c4-8080-e66d49678335" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b337f741-df3a-433f-a59f-1bdc08ce8080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fa6b473-6119-47fa-9733-a30cb747c9d1" xlink:to="loc_us-gaap_AccountsReceivableMember_b337f741-df3a-433f-a59f-1bdc08ce8080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fe0ac1ca-eb0d-4706-834f-4e45577b2490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fe0ac1ca-eb0d-4706-834f-4e45577b2490" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fe0ac1ca-eb0d-4706-834f-4e45577b2490_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fe0ac1ca-eb0d-4706-834f-4e45577b2490" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fe0ac1ca-eb0d-4706-834f-4e45577b2490_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4e330f94-49d6-4b3c-a9f4-31a678f510fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fe0ac1ca-eb0d-4706-834f-4e45577b2490" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4e330f94-49d6-4b3c-a9f4-31a678f510fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_37063b04-8e13-4eab-af7a-080634a40ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4e330f94-49d6-4b3c-a9f4-31a678f510fe" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_37063b04-8e13-4eab-af7a-080634a40ac1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_cc3dceb9-02e7-41c9-ab54-54552dd68f33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7cce8d5d-b278-4534-9abd-651ca4dd7d07" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_cc3dceb9-02e7-41c9-ab54-54552dd68f33" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3dd875ee-2985-4438-9b9e-b10be9e64eca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3dd875ee-2985-4438-9b9e-b10be9e64eca" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a8623f9-3c95-42b7-ba35-4eab1eb590ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a8623f9-3c95-42b7-ba35-4eab1eb590ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a8623f9-3c95-42b7-ba35-4eab1eb590ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a8623f9-3c95-42b7-ba35-4eab1eb590ea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a8623f9-3c95-42b7-ba35-4eab1eb590ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66dd3690-2745-430e-a00e-f3a9caab0f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a8623f9-3c95-42b7-ba35-4eab1eb590ea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66dd3690-2745-430e-a00e-f3a9caab0f81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1fdc15ad-a406-4db7-ab8a-4da6d4e44e49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66dd3690-2745-430e-a00e-f3a9caab0f81" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1fdc15ad-a406-4db7-ab8a-4da6d4e44e49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9355feea-eacc-4e68-849e-dc249c311392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66dd3690-2745-430e-a00e-f3a9caab0f81" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9355feea-eacc-4e68-849e-dc249c311392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6db592df-43d3-4840-871c-67db4b8b2bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66dd3690-2745-430e-a00e-f3a9caab0f81" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6db592df-43d3-4840-871c-67db4b8b2bfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_547ade91-bd52-4b7b-a41a-51c91b453ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_547ade91-bd52-4b7b-a41a-51c91b453ef7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_547ade91-bd52-4b7b-a41a-51c91b453ef7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_547ade91-bd52-4b7b-a41a-51c91b453ef7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_547ade91-bd52-4b7b-a41a-51c91b453ef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1adacb49-0290-4be7-a436-b5ec2dd2d13f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_547ade91-bd52-4b7b-a41a-51c91b453ef7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1adacb49-0290-4be7-a436-b5ec2dd2d13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_11969e45-b4bf-4639-ae9d-22591dd5bbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1adacb49-0290-4be7-a436-b5ec2dd2d13f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_11969e45-b4bf-4639-ae9d-22591dd5bbdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8fa2a97e-05e7-4a90-b1c4-47c470e83ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8fa2a97e-05e7-4a90-b1c4-47c470e83ec8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa2a97e-05e7-4a90-b1c4-47c470e83ec8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8fa2a97e-05e7-4a90-b1c4-47c470e83ec8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa2a97e-05e7-4a90-b1c4-47c470e83ec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8fa2a97e-05e7-4a90-b1c4-47c470e83ec8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_37c3cc9c-aa1f-4de7-9373-a80bfe43c377" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:to="loc_us-gaap_CertificatesOfDepositMember_37c3cc9c-aa1f-4de7-9373-a80bfe43c377" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019bfee6-1456-7b3a-9fd9-d42830e7a6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:to="loc_us-gaap_CommercialPaperMember_019bfee6-1456-7b3a-9fd9-d42830e7a6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4dbdb1f7-bd56-466a-a716-30e70bb96099" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4dbdb1f7-bd56-466a-a716-30e70bb96099" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_db1bfac6-908b-42d7-b804-2d3ff31921e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_db1bfac6-908b-42d7-b804-2d3ff31921e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_57d9b737-2bd5-492a-bc35-b94b3762aba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3dd875ee-2985-4438-9b9e-b10be9e64eca" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_57d9b737-2bd5-492a-bc35-b94b3762aba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_81930c1e-e443-4b8b-b0a2-5b01d65acd34" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3dd875ee-2985-4438-9b9e-b10be9e64eca" xlink:to="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_81930c1e-e443-4b8b-b0a2-5b01d65acd34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9851f86a-5116-4c5a-93c0-c8f744598794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3dd875ee-2985-4438-9b9e-b10be9e64eca" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9851f86a-5116-4c5a-93c0-c8f744598794" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_44043011-c432-4f0a-83d1-176539603990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_44043011-c432-4f0a-83d1-176539603990" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_e7f4afde-38e9-4e17-8ed1-9d2f0c623d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_44043011-c432-4f0a-83d1-176539603990" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_e7f4afde-38e9-4e17-8ed1-9d2f0c623d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e7f4afde-38e9-4e17-8ed1-9d2f0c623d0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e7f4afde-38e9-4e17-8ed1-9d2f0c623d0c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e7f4afde-38e9-4e17-8ed1-9d2f0c623d0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf979070-a22a-4b85-8b91-e193c2eb886f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e7f4afde-38e9-4e17-8ed1-9d2f0c623d0c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf979070-a22a-4b85-8b91-e193c2eb886f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e905414c-e6c3-4870-b1ba-e72bfff69cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf979070-a22a-4b85-8b91-e193c2eb886f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e905414c-e6c3-4870-b1ba-e72bfff69cd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_019c2766-433d-743a-b09a-439244d10ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf979070-a22a-4b85-8b91-e193c2eb886f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_019c2766-433d-743a-b09a-439244d10ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d0bd701-43e9-4dd7-ad05-b86092df6081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d0bd701-43e9-4dd7-ad05-b86092df6081" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsUnrealizedGain_ce7359f9-7a8c-45e1-ba95-ea641da98167" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:to="loc_arqt_CashAndCashEquivalentsUnrealizedGain_ce7359f9-7a8c-45e1-ba95-ea641da98167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsUnrealizedLoss_1ed275bb-6ef2-46a2-a508-47cd5ef3456e" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:to="loc_arqt_CashAndCashEquivalentsUnrealizedLoss_1ed275bb-6ef2-46a2-a508-47cd5ef3456e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4cb6d784-1c7f-477d-a5af-816ee39b5205" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4cb6d784-1c7f-477d-a5af-816ee39b5205" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cd147a8-e2a7-49e3-aed7-42764ee805d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cd147a8-e2a7-49e3-aed7-42764ee805d8" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9ef6003c-e5f3-4091-a943-428bc614b703" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cd147a8-e2a7-49e3-aed7-42764ee805d8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9ef6003c-e5f3-4091-a943-428bc614b703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ef6003c-e5f3-4091-a943-428bc614b703_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9ef6003c-e5f3-4091-a943-428bc614b703" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ef6003c-e5f3-4091-a943-428bc614b703_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9ef6003c-e5f3-4091-a943-428bc614b703" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f006b0fa-907c-4ca9-b4c5-7ac781da0c62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f006b0fa-907c-4ca9-b4c5-7ac781da0c62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_79df31f6-e482-46bc-8b69-a07487816d76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:to="loc_us-gaap_CommercialPaperMember_79df31f6-e482-46bc-8b69-a07487816d76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ae71c303-1f32-4525-a18c-940ed0172843" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ae71c303-1f32-4525-a18c-940ed0172843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8326b104-536a-48c3-a2e2-faef32557bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8326b104-536a-48c3-a2e2-faef32557bf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a1f816f4-8d58-441b-9ad5-a48895809113" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a1f816f4-8d58-441b-9ad5-a48895809113" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_22ee1a14-d1bf-43c2-bd96-bf055f39d757" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_22ee1a14-d1bf-43c2-bd96-bf055f39d757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_823f81a1-e410-4381-bb7c-8356a80a118f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_823f81a1-e410-4381-bb7c-8356a80a118f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f803d9d-b710-4fc1-821c-f84a4a66af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f803d9d-b710-4fc1-821c-f84a4a66af6a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a6ab69f-7795-4738-8495-bf5acb940c53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f254621-27ea-4abc-8823-202670f7acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a6ab69f-7795-4738-8495-bf5acb940c53" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f254621-27ea-4abc-8823-202670f7acb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afe3dc7-6710-485c-9ffd-8be444d193b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f254621-27ea-4abc-8823-202670f7acb2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afe3dc7-6710-485c-9ffd-8be444d193b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afe3dc7-6710-485c-9ffd-8be444d193b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afe3dc7-6710-485c-9ffd-8be444d193b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afe3dc7-6710-485c-9ffd-8be444d193b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afe3dc7-6710-485c-9ffd-8be444d193b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0bf35704-1d1f-410f-aae8-175c5e6edfde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:to="loc_us-gaap_ComputerEquipmentMember_0bf35704-1d1f-410f-aae8-175c5e6edfde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_89543baf-eceb-4004-9339-ed62c20b436b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_89543baf-eceb-4004-9339-ed62c20b436b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_27d84aa0-b965-412f-ab84-7107010135b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_27d84aa0-b965-412f-ab84-7107010135b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_686b760c-5a38-45e5-858f-2cb0ceb0f8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_686b760c-5a38-45e5-858f-2cb0ceb0f8ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b60b4a45-f95a-412f-b3c9-b9b616361dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a6ab69f-7795-4738-8495-bf5acb940c53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b60b4a45-f95a-412f-b3c9-b9b616361dc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7ec8e0c3-e949-42f9-bb11-05ef9ba0b045" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a6ab69f-7795-4738-8495-bf5acb940c53" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7ec8e0c3-e949-42f9-bb11-05ef9ba0b045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9f733b9e-63c0-4503-b61f-e9395c0d3841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a6ab69f-7795-4738-8495-bf5acb940c53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9f733b9e-63c0-4503-b61f-e9395c0d3841" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#PropertyandEquipmentnetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4bac26ec-cab1-4a02-bf10-a3004b9af0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_514dd829-78bc-4aed-848a-92f2bc38d67b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4bac26ec-cab1-4a02-bf10-a3004b9af0ec" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_514dd829-78bc-4aed-848a-92f2bc38d67b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_368690a1-ebf5-4b3f-99df-5e64a3ea6b41" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_514dd829-78bc-4aed-848a-92f2bc38d67b" xlink:to="loc_srt_RangeAxis_368690a1-ebf5-4b3f-99df-5e64a3ea6b41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_368690a1-ebf5-4b3f-99df-5e64a3ea6b41_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_368690a1-ebf5-4b3f-99df-5e64a3ea6b41" xlink:to="loc_srt_RangeMember_368690a1-ebf5-4b3f-99df-5e64a3ea6b41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17802714-46cc-41b9-b1f9-2f98bf56b5b7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_368690a1-ebf5-4b3f-99df-5e64a3ea6b41" xlink:to="loc_srt_RangeMember_17802714-46cc-41b9-b1f9-2f98bf56b5b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_01088cef-2545-4729-a074-7557e55d35b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17802714-46cc-41b9-b1f9-2f98bf56b5b7" xlink:to="loc_srt_MinimumMember_01088cef-2545-4729-a074-7557e55d35b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e73d9b29-6395-4578-95f0-9d3a650f6f9d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17802714-46cc-41b9-b1f9-2f98bf56b5b7" xlink:to="loc_srt_MaximumMember_e73d9b29-6395-4578-95f0-9d3a650f6f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d4e0fa5-6616-4c86-a74d-20ba58933081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_514dd829-78bc-4aed-848a-92f2bc38d67b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d4e0fa5-6616-4c86-a74d-20ba58933081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d4e0fa5-6616-4c86-a74d-20ba58933081_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d4e0fa5-6616-4c86-a74d-20ba58933081" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d4e0fa5-6616-4c86-a74d-20ba58933081_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b32ad70-6ee6-4858-9514-c6bf8185f2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d4e0fa5-6616-4c86-a74d-20ba58933081" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b32ad70-6ee6-4858-9514-c6bf8185f2f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember_46e3af7d-5fbc-45ac-bc01-328e4ef6c0bb" xlink:href="arqt-20251231.xsd#arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b32ad70-6ee6-4858-9514-c6bf8185f2f0" xlink:to="loc_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember_46e3af7d-5fbc-45ac-bc01-328e4ef6c0bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4004e933-e6d5-4f71-8dbf-1708c2c94a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4bac26ec-cab1-4a02-bf10-a3004b9af0ec" xlink:to="loc_us-gaap_Depreciation_4004e933-e6d5-4f71-8dbf-1708c2c94a63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_64d2095d-d935-4c66-983e-fd07f0b11b68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4bac26ec-cab1-4a02-bf10-a3004b9af0ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_64d2095d-d935-4c66-983e-fd07f0b11b68" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eb941b96-19eb-4652-b389-2abdb91f46cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eb941b96-19eb-4652-b389-2abdb91f46cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4458729e-8c73-4da2-8623-f159ceeeef34" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eb941b96-19eb-4652-b389-2abdb91f46cd" xlink:to="loc_srt_CounterpartyNameAxis_4458729e-8c73-4da2-8623-f159ceeeef34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4458729e-8c73-4da2-8623-f159ceeeef34_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4458729e-8c73-4da2-8623-f159ceeeef34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4458729e-8c73-4da2-8623-f159ceeeef34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b0acfa8c-cd9a-4efd-a547-9530cd21afd4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4458729e-8c73-4da2-8623-f159ceeeef34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b0acfa8c-cd9a-4efd-a547-9530cd21afd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SatoMember_0091c4ca-1cfe-454b-88bf-9845c26e9bbe" xlink:href="arqt-20251231.xsd#arqt_SatoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b0acfa8c-cd9a-4efd-a547-9530cd21afd4" xlink:to="loc_arqt_SatoMember_0091c4ca-1cfe-454b-88bf-9845c26e9bbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet_e4cb6c1f-3fa3-43e7-af4e-fb21c3ad83cf" xlink:href="arqt-20251231.xsd#arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet_e4cb6c1f-3fa3-43e7-af4e-fb21c3ad83cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_a08a03d9-9b79-43f1-b9a0-2af3c33b09b0" xlink:href="arqt-20251231.xsd#arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_a08a03d9-9b79-43f1-b9a0-2af3c33b09b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_27b87820-648e-42cb-8b0f-e506127cce15" xlink:href="arqt-20251231.xsd#arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_27b87820-648e-42cb-8b0f-e506127cce15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_d7c00a23-85aa-42a5-8f75-41f1330a65c9" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_d7c00a23-85aa-42a5-8f75-41f1330a65c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice_b7806a46-7399-4f3b-9a47-35ed2b300fa1" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice_b7806a46-7399-4f3b-9a47-35ed2b300fa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_893d244f-8013-4057-a937-aa3c73937795" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_893d244f-8013-4057-a937-aa3c73937795" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisitionHuadongDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76f5dfca-744c-41f5-bfe0-e4cc1584c35f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76f5dfca-744c-41f5-bfe0-e4cc1584c35f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f8df5d0a-786a-4294-a7df-0a549f2a3ac6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76f5dfca-744c-41f5-bfe0-e4cc1584c35f" xlink:to="loc_srt_CounterpartyNameAxis_f8df5d0a-786a-4294-a7df-0a549f2a3ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8df5d0a-786a-4294-a7df-0a549f2a3ac6_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f8df5d0a-786a-4294-a7df-0a549f2a3ac6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8df5d0a-786a-4294-a7df-0a549f2a3ac6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a71692f-6c76-4749-a653-b3ef6c64ec68" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f8df5d0a-786a-4294-a7df-0a549f2a3ac6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a71692f-6c76-4749-a653-b3ef6c64ec68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HuadongMember_0ae19bd2-c94d-4785-baa1-cbf35e1f7410" xlink:href="arqt-20251231.xsd#arqt_HuadongMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a71692f-6c76-4749-a653-b3ef6c64ec68" xlink:to="loc_arqt_HuadongMember_0ae19bd2-c94d-4785-baa1-cbf35e1f7410" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ContractNotWithCustomerUpfrontPaymentNet_a5fe1934-8f24-432a-a508-a6c2928f762a" xlink:href="arqt-20251231.xsd#arqt_ContractNotWithCustomerUpfrontPaymentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_arqt_ContractNotWithCustomerUpfrontPaymentNet_a5fe1934-8f24-432a-a508-a6c2928f762a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_239ec7b2-1fcc-43c2-a519-ad9af399b264" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_239ec7b2-1fcc-43c2-a519-ad9af399b264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation_ae0850a5-5b2a-4bc4-b37f-3dcdaf5db1a9" xlink:href="arqt-20251231.xsd#arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation_ae0850a5-5b2a-4bc4-b37f-3dcdaf5db1a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_20d34383-6cc6-4ba2-afc3-ccbc632a4d64" xlink:href="arqt-20251231.xsd#arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_20d34383-6cc6-4ba2-afc3-ccbc632a4d64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_4533f625-67b7-47fb-9a9d-448299070564" xlink:href="arqt-20251231.xsd#arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_4533f625-67b7-47fb-9a9d-448299070564" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_0354db54-b3f5-4a33-942e-ba9a7c4944b8" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_0354db54-b3f5-4a33-942e-ba9a7c4944b8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisitionAstraZenecaDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97e87b5-5e90-49ab-bfb6-a7c52de137ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97e87b5-5e90-49ab-bfb6-a7c52de137ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c2457495-12e3-4fb4-9120-39ebefcc4888" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97e87b5-5e90-49ab-bfb6-a7c52de137ca" xlink:to="loc_srt_CounterpartyNameAxis_c2457495-12e3-4fb4-9120-39ebefcc4888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c2457495-12e3-4fb4-9120-39ebefcc4888_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c2457495-12e3-4fb4-9120-39ebefcc4888" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c2457495-12e3-4fb4-9120-39ebefcc4888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52e0e0ef-2a20-47d1-aac6-a451bf4046de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c2457495-12e3-4fb4-9120-39ebefcc4888" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52e0e0ef-2a20-47d1-aac6-a451bf4046de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AstraZenecaMember_e72d493a-4d63-4a1e-bd34-2208f64b0ddd" xlink:href="arqt-20251231.xsd#arqt_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52e0e0ef-2a20-47d1-aac6-a451bf4046de" xlink:to="loc_arqt_AstraZenecaMember_e72d493a-4d63-4a1e-bd34-2208f64b0ddd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_6d4ed269-cca5-406f-84b7-0a00fcd42a07" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_6d4ed269-cca5-406f-84b7-0a00fcd42a07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_188b474d-cdd8-4b8f-bde6-3908a8e5e7d2" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_188b474d-cdd8-4b8f-bde6-3908a8e5e7d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_f1914747-5823-45ab-aeef-9c895cf7666e" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_f1914747-5823-45ab-aeef-9c895cf7666e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_38568fcf-f724-4d71-bb25-1f5197045c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_38568fcf-f724-4d71-bb25-1f5197045c8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_876ab59e-0082-465d-9121-af8594ea451e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_876ab59e-0082-465d-9121-af8594ea451e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_5402f012-d36c-4c36-9330-5a4d35596b6b" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_5402f012-d36c-4c36-9330-5a4d35596b6b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale_019c90a2-7a16-7175-b158-3ab679fa8077" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale_019c90a2-7a16-7175-b158-3ab679fa8077" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_2d1e70ef-2176-49f6-906a-700ea23ad3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_us-gaap_RoyaltyExpense_2d1e70ef-2176-49f6-906a-700ea23ad3bc" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisitionHengruiDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_17b71c16-4490-4dad-9268-1b9c10a4e532" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b286e42f-101b-48cc-b931-bb7b3f656b23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_17b71c16-4490-4dad-9268-1b9c10a4e532" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b286e42f-101b-48cc-b931-bb7b3f656b23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_848ee34a-7383-4df7-ba87-023aaca62bb1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b286e42f-101b-48cc-b931-bb7b3f656b23" xlink:to="loc_srt_CounterpartyNameAxis_848ee34a-7383-4df7-ba87-023aaca62bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848ee34a-7383-4df7-ba87-023aaca62bb1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_848ee34a-7383-4df7-ba87-023aaca62bb1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848ee34a-7383-4df7-ba87-023aaca62bb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdb5ab06-1f96-4319-9ae0-91a0ff19ebe1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_848ee34a-7383-4df7-ba87-023aaca62bb1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdb5ab06-1f96-4319-9ae0-91a0ff19ebe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HengruiMember_60e6a3b5-6821-4bb6-a5c4-63f2ae15cd64" xlink:href="arqt-20251231.xsd#arqt_HengruiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdb5ab06-1f96-4319-9ae0-91a0ff19ebe1" xlink:to="loc_arqt_HengruiMember_60e6a3b5-6821-4bb6-a5c4-63f2ae15cd64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_86aad90d-5c5a-4f27-8901-60e4bd07def9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_17b71c16-4490-4dad-9268-1b9c10a4e532" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_86aad90d-5c5a-4f27-8901-60e4bd07def9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_89c86933-d8ef-467a-ba4f-4b912adb4e83" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_17b71c16-4490-4dad-9268-1b9c10a4e532" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_89c86933-d8ef-467a-ba4f-4b912adb4e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_2a0ee42a-42e0-42b9-81cd-d9bd0d1b412d" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_17b71c16-4490-4dad-9268-1b9c10a4e532" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_2a0ee42a-42e0-42b9-81cd-d9bd0d1b412d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_40c967b3-da56-4572-8199-4341a2c3ffae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_us-gaap_AssetAcquisitionTable_40c967b3-da56-4572-8199-4341a2c3ffae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_5bcb4c66-da35-4c40-9d48-7f94464733f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_40c967b3-da56-4572-8199-4341a2c3ffae" xlink:to="loc_us-gaap_AssetAcquisitionAxis_5bcb4c66-da35-4c40-9d48-7f94464733f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_5bcb4c66-da35-4c40-9d48-7f94464733f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_5bcb4c66-da35-4c40-9d48-7f94464733f4" xlink:to="loc_us-gaap_AssetAcquisitionDomain_5bcb4c66-da35-4c40-9d48-7f94464733f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1a7ece1d-3226-47f4-b09a-3a3ddaedf043" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_5bcb4c66-da35-4c40-9d48-7f94464733f4" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1a7ece1d-3226-47f4-b09a-3a3ddaedf043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember_13e724b9-a92f-4846-979a-37b25426c227" xlink:href="arqt-20251231.xsd#arqt_DucentisBiotherapeuticsLTDEquityInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1a7ece1d-3226-47f4-b09a-3a3ddaedf043" xlink:to="loc_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember_13e724b9-a92f-4846-979a-37b25426c227" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5a30366a-76e9-4e45-b25b-80215332ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_40c967b3-da56-4572-8199-4341a2c3ffae" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5a30366a-76e9-4e45-b25b-80215332ddba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5a30366a-76e9-4e45-b25b-80215332ddba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a30366a-76e9-4e45-b25b-80215332ddba" xlink:to="loc_us-gaap_EquityComponentDomain_5a30366a-76e9-4e45-b25b-80215332ddba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3e8d8a91-9156-4b40-b279-3da620ecb63e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a30366a-76e9-4e45-b25b-80215332ddba" xlink:to="loc_us-gaap_EquityComponentDomain_3e8d8a91-9156-4b40-b279-3da620ecb63e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c903e704-9b5d-4360-bf09-14e4347b6dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3e8d8a91-9156-4b40-b279-3da620ecb63e" xlink:to="loc_us-gaap_CommonStockMember_c903e704-9b5d-4360-bf09-14e4347b6dfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_0bc13ec3-60d8-4696-af19-db3771527840" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_0bc13ec3-60d8-4696-af19-db3771527840" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_4901a10a-e895-41c0-a166-f805c44505bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_4901a10a-e895-41c0-a166-f805c44505bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionConsiderationTransferredGross_d51c95ba-0d97-4d8d-b72b-38c3b69adaab" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionConsiderationTransferredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionConsiderationTransferredGross_d51c95ba-0d97-4d8d-b72b-38c3b69adaab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount_928c16a3-9a73-4191-86c0-7191e52eedaa" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount_928c16a3-9a73-4191-86c0-7191e52eedaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones_7a783210-7deb-4f29-8e92-d0695f2d24e5" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones_7a783210-7deb-4f29-8e92-d0695f2d24e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment_019c909f-364d-704d-bf5b-102a6e87499a" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment_019c909f-364d-704d-bf5b-102a6e87499a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold_4215d112-c99f-4b73-b589-92bcc0264f85" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold_4215d112-c99f-4b73-b589-92bcc0264f85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c1ccd668-48b7-4230-868b-5a9658bb797b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c1ccd668-48b7-4230-868b-5a9658bb797b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_83415f7b-9d26-4c32-90be-b69f6a11e089" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_83415f7b-9d26-4c32-90be-b69f6a11e089" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1a0b8b81-af8d-4479-9cba-1474560606bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1a0b8b81-af8d-4479-9cba-1474560606bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionAxis_9e65c5a9-ab30-4d9f-9617-d1b773242521" xlink:href="arqt-20251231.xsd#arqt_LeaseDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1a0b8b81-af8d-4479-9cba-1474560606bb" xlink:to="loc_arqt_LeaseDescriptionAxis_9e65c5a9-ab30-4d9f-9617-d1b773242521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionDomain_9e65c5a9-ab30-4d9f-9617-d1b773242521_default" xlink:href="arqt-20251231.xsd#arqt_LeaseDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_arqt_LeaseDescriptionAxis_9e65c5a9-ab30-4d9f-9617-d1b773242521" xlink:to="loc_arqt_LeaseDescriptionDomain_9e65c5a9-ab30-4d9f-9617-d1b773242521_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionDomain_9c3a73c6-c812-4e59-b055-69f1488c7987" xlink:href="arqt-20251231.xsd#arqt_LeaseDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_arqt_LeaseDescriptionAxis_9e65c5a9-ab30-4d9f-9617-d1b773242521" xlink:to="loc_arqt_LeaseDescriptionDomain_9c3a73c6-c812-4e59-b055-69f1488c7987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_209609ac-acfe-4b1e-8ac5-e0ee112c1b0c" xlink:href="arqt-20251231.xsd#arqt_WestlakeVillageCaliforniaLeaseArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arqt_LeaseDescriptionDomain_9c3a73c6-c812-4e59-b055-69f1488c7987" xlink:to="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_209609ac-acfe-4b1e-8ac5-e0ee112c1b0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseOfficeSpace_019bb752-cd60-7f38-b7b2-6fa6b98f9566" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_arqt_LesseeOperatingLeaseOfficeSpace_019bb752-cd60-7f38-b7b2-6fa6b98f9566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseExtensionTerm_019bb752-cd60-7bf6-8755-6e4a99f706e4" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_arqt_LesseeOperatingLeaseExtensionTerm_019bb752-cd60-7bf6-8755-6e4a99f706e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments_019bb752-cd60-7561-acb1-b3a951515d75" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments_019bb752-cd60-7561-acb1-b3a951515d75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments_019bb752-cd60-7ca6-93db-8bd7a28aeac7" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments_019bb752-cd60-7ca6-93db-8bd7a28aeac7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_019bb752-cd60-7c87-b8c3-052d6b64abd3" xlink:href="arqt-20251231.xsd#arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_019bb752-cd60-7c87-b8c3-052d6b64abd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019bb752-cd60-707f-b095-2361c47e59a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019bb752-cd60-707f-b095-2361c47e59a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_4e3939c0-bf6b-49f6-9c48-91733e27a2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_4e3939c0-bf6b-49f6-9c48-91733e27a2b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_7d51ba1a-1ccd-4d6d-8772-f638363c6dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_OperatingLeaseCost_7d51ba1a-1ccd-4d6d-8772-f638363c6dd4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_019c4b62-4756-71a4-a1fb-1c68d6da17f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_019c4b62-4756-71a4-a1fb-1c68d6da17f2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_019c4b62-4756-7193-a84c-d509a1f90f04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_019c4b62-4756-7193-a84c-d509a1f90f04" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_351b01c9-1a5d-4591-916e-dbab70e77971" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_351b01c9-1a5d-4591-916e-dbab70e77971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_351b01c9-1a5d-4591-916e-dbab70e77971_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_351b01c9-1a5d-4591-916e-dbab70e77971" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_351b01c9-1a5d-4591-916e-dbab70e77971_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ae1048b5-7804-495b-8b37-debe6ac598ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_351b01c9-1a5d-4591-916e-dbab70e77971" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ae1048b5-7804-495b-8b37-debe6ac598ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_117102c3-c31f-4708-b441-c14513fd32b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ae1048b5-7804-495b-8b37-debe6ac598ec" xlink:to="loc_us-gaap_SecuredDebtMember_117102c3-c31f-4708-b441-c14513fd32b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8b482a79-09a4-411c-b765-7441ec3404a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_us-gaap_DebtInstrumentAxis_8b482a79-09a4-411c-b765-7441ec3404a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8b482a79-09a4-411c-b765-7441ec3404a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8b482a79-09a4-411c-b765-7441ec3404a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8b482a79-09a4-411c-b765-7441ec3404a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4d2b04a2-afa9-4d97-abcf-4548095dc981" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8b482a79-09a4-411c-b765-7441ec3404a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4d2b04a2-afa9-4d97-abcf-4548095dc981" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementMember_7a956c67-5088-461b-85b6-b148469f2ab8" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4d2b04a2-afa9-4d97-abcf-4548095dc981" xlink:to="loc_arqt_LoanAgreementMember_7a956c67-5088-461b-85b6-b148469f2ab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentTrancheAxis_2ae01361-df66-4aad-9d06-d2cb71de68f4" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_arqt_DebtInstrumentTrancheAxis_2ae01361-df66-4aad-9d06-d2cb71de68f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentTrancheDomain_2ae01361-df66-4aad-9d06-d2cb71de68f4_default" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_arqt_DebtInstrumentTrancheAxis_2ae01361-df66-4aad-9d06-d2cb71de68f4" xlink:to="loc_arqt_DebtInstrumentTrancheDomain_2ae01361-df66-4aad-9d06-d2cb71de68f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_arqt_DebtInstrumentTrancheAxis_2ae01361-df66-4aad-9d06-d2cb71de68f4" xlink:to="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheATermLoanMember_f534189c-4490-4d89-8da9-77365f1a1534" xlink:href="arqt-20251231.xsd#arqt_TrancheATermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_TrancheATermLoanMember_f534189c-4490-4d89-8da9-77365f1a1534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheB1TermLoanMember_122179ff-4f7f-4a38-b41d-741b2040f3da" xlink:href="arqt-20251231.xsd#arqt_TrancheB1TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_TrancheB1TermLoanMember_122179ff-4f7f-4a38-b41d-741b2040f3da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheB2TermLoanMember_fc79309c-51ec-46db-b936-6d2a1c2dc556" xlink:href="arqt-20251231.xsd#arqt_TrancheB2TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_TrancheB2TermLoanMember_fc79309c-51ec-46db-b936-6d2a1c2dc556" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member_fa11b352-3ffa-4df6-89df-d16c96b0f92f" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementTrancheC1ExpiringMarch312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member_fa11b352-3ffa-4df6-89df-d16c96b0f92f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementTrancheC2ExpiringJune302026Member_1e0e7685-9d1b-4082-8582-612159cdb388" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementTrancheC2ExpiringJune302026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_LoanAgreementTrancheC2ExpiringJune302026Member_1e0e7685-9d1b-4082-8582-612159cdb388" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheCTermLoanMember_ae6dea3c-da3b-4ffa-9921-cb6ac44c7905" xlink:href="arqt-20251231.xsd#arqt_TrancheCTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_TrancheCTermLoanMember_ae6dea3c-da3b-4ffa-9921-cb6ac44c7905" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_29d6058a-948c-4ce0-ad22-7f926cf06a2a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_srt_RangeAxis_29d6058a-948c-4ce0-ad22-7f926cf06a2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_29d6058a-948c-4ce0-ad22-7f926cf06a2a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_29d6058a-948c-4ce0-ad22-7f926cf06a2a" xlink:to="loc_srt_RangeMember_29d6058a-948c-4ce0-ad22-7f926cf06a2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd0ca12f-6bb8-4130-a544-70c191418857" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_29d6058a-948c-4ce0-ad22-7f926cf06a2a" xlink:to="loc_srt_RangeMember_fd0ca12f-6bb8-4130-a544-70c191418857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_de886774-6e24-4db9-b01b-15bf728cc4dd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fd0ca12f-6bb8-4130-a544-70c191418857" xlink:to="loc_srt_MinimumMember_de886774-6e24-4db9-b01b-15bf728cc4dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_95495b48-9d52-4599-8d7e-08320d04421d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_95495b48-9d52-4599-8d7e-08320d04421d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_95495b48-9d52-4599-8d7e-08320d04421d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_95495b48-9d52-4599-8d7e-08320d04421d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_95495b48-9d52-4599-8d7e-08320d04421d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_61f71b76-9f19-48d9-8d54-6cb4c006c6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_95495b48-9d52-4599-8d7e-08320d04421d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_61f71b76-9f19-48d9-8d54-6cb4c006c6cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_393ba811-441d-4f9d-b7ac-6368d69f5d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_61f71b76-9f19-48d9-8d54-6cb4c006c6cd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_393ba811-441d-4f9d-b7ac-6368d69f5d0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_af3ceb4b-056e-4775-9a4f-37694bca8d32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_61f71b76-9f19-48d9-8d54-6cb4c006c6cd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_af3ceb4b-056e-4775-9a4f-37694bca8d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a3b425cd-44de-4c79-8849-5be9902e378a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_61f71b76-9f19-48d9-8d54-6cb4c006c6cd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a3b425cd-44de-4c79-8849-5be9902e378a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3e3b2ba9-857d-41bb-b67d-a670e50fd90b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_srt_StatementScenarioAxis_3e3b2ba9-857d-41bb-b67d-a670e50fd90b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3e3b2ba9-857d-41bb-b67d-a670e50fd90b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3e3b2ba9-857d-41bb-b67d-a670e50fd90b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3e3b2ba9-857d-41bb-b67d-a670e50fd90b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e8c5333a-e9b3-43a3-b809-34688b2a9edb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3e3b2ba9-857d-41bb-b67d-a670e50fd90b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e8c5333a-e9b3-43a3-b809-34688b2a9edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_574765e1-0888-4a8e-a4c5-3e124da60dbe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e8c5333a-e9b3-43a3-b809-34688b2a9edb" xlink:to="loc_srt_ScenarioForecastMember_574765e1-0888-4a8e-a4c5-3e124da60dbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentPrepaymentPremium_56089c6e-7cd4-442a-8a5a-1a867d89759b" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentPrepaymentPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentPrepaymentPremium_56089c6e-7cd4-442a-8a5a-1a867d89759b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentMaximumBorrowingCapacity_5e7870a2-bf76-4c15-9803-4fba110303db" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentMaximumBorrowingCapacity_5e7870a2-bf76-4c15-9803-4fba110303db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_48d58d45-696c-4b88-a532-479dce9c00bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_48d58d45-696c-4b88-a532-479dce9c00bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9e63d400-46ab-4866-9e4f-3c8bc8a786d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9e63d400-46ab-4866-9e4f-3c8bc8a786d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentPrepaymentPenalty_cf420d1e-c273-418b-96cb-3e2e342d3e7f" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentPrepaymentPenalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentPrepaymentPenalty_cf420d1e-c273-418b-96cb-3e2e342d3e7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod_b9f0e3ec-9ad5-4260-8ffc-c4f323d4708d" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentFundingAvailabilityCovenantPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod_b9f0e3ec-9ad5-4260-8ffc-c4f323d4708d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue_27b8c71b-3a2a-4bb2-857a-08a3c6f534f1" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue_27b8c71b-3a2a-4bb2-857a-08a3c6f534f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment_47f31c7d-1d58-43e6-8e16-0c18d012639e" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment_47f31c7d-1d58-43e6-8e16-0c18d012639e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e0311a35-db7a-4229-9ccc-18bab7c79f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e0311a35-db7a-4229-9ccc-18bab7c79f3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2d76f5b0-6762-4c01-8b0d-98093f1dcaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2d76f5b0-6762-4c01-8b0d-98093f1dcaf3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentInterestRateAtPeriodEnd_16ad130c-96de-4c69-8898-aac3f587595c" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentInterestRateAtPeriodEnd_16ad130c-96de-4c69-8898-aac3f587595c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentDefaultRate_36167b6c-a10d-44da-a4b6-6a665a13a4f5" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentDefaultRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentDefaultRate_36167b6c-a10d-44da-a4b6-6a665a13a4f5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_2d355a8e-3a29-4ade-ac2f-ef9f9183ca90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_2d355a8e-3a29-4ade-ac2f-ef9f9183ca90" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentFinalFeePercentage_6eaa038c-9687-4a04-8a8b-f5e30cd926bf" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentFinalFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentFinalFeePercentage_6eaa038c-9687-4a04-8a8b-f5e30cd926bf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentExtensionFeePercentage_a9e33607-b63c-41c6-919a-efc473427b8a" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentExtensionFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentExtensionFeePercentage_a9e33607-b63c-41c6-919a-efc473427b8a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentExitFeePercentage_14ba7129-3439-4261-9820-97aeb6dc1051" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentExitFeePercentage_14ba7129-3439-4261-9820-97aeb6dc1051" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentExitFeeExpirationPeriod_e757f442-0a5f-4fbd-af3f-9af654a6b61b" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentExitFeeExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentExitFeeExpirationPeriod_e757f442-0a5f-4fbd-af3f-9af654a6b61b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentDeferredFinalFeeGross_9927ea2d-d76a-46ab-81ec-bf4dc5447dbd" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentDeferredFinalFeeGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentDeferredFinalFeeGross_9927ea2d-d76a-46ab-81ec-bf4dc5447dbd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9d72cf0a-7165-4207-8b5e-a875fd396972" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9d72cf0a-7165-4207-8b5e-a875fd396972" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_11f03823-40e9-49fa-b796-2566582e6acc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_InterestExpenseDebt_11f03823-40e9-49fa-b796-2566582e6acc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019c8aea-a58f-752d-87dd-9c004aac608a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019c8aea-a58f-752d-87dd-9c004aac608a" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019bff58-eb90-701e-be7f-35a8aff1f5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019bff58-eb90-701e-be7f-35a8aff1f5b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019bff58-eb90-701e-be7f-35a8aff1f5b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019bff58-eb90-701e-be7f-35a8aff1f5b5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019bff58-eb90-701e-be7f-35a8aff1f5b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019bff58-eb90-7b2a-92ce-a078d44f6062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019bff58-eb90-701e-be7f-35a8aff1f5b5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019bff58-eb90-7b2a-92ce-a078d44f6062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FirstEquityPublicOfferingMember_019bff58-eb90-7530-a1cf-034202ab5a34" xlink:href="arqt-20251231.xsd#arqt_FirstEquityPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019bff58-eb90-7b2a-92ce-a078d44f6062" xlink:to="loc_arqt_FirstEquityPublicOfferingMember_019bff58-eb90-7530-a1cf-034202ab5a34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AtTheMarketMember_019bff59-1a5b-7415-9d68-88e7b09bcaf4" xlink:href="arqt-20251231.xsd#arqt_AtTheMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019bff58-eb90-7b2a-92ce-a078d44f6062" xlink:to="loc_arqt_AtTheMarketMember_019bff59-1a5b-7415-9d68-88e7b09bcaf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019bff58-eb90-7522-aa8b-21fa0184846a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019bff58-eb90-7522-aa8b-21fa0184846a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019bff58-eb90-7522-aa8b-21fa0184846a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019bff58-eb90-7522-aa8b-21fa0184846a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019bff58-eb90-7522-aa8b-21fa0184846a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019bff58-eb90-754c-8b3f-a4fabda0f475" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019bff58-eb90-7522-aa8b-21fa0184846a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019bff58-eb90-754c-8b3f-a4fabda0f475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrefundedWarrantMember_019bff58-eb90-78e0-82fd-a31c178a96cb" xlink:href="arqt-20251231.xsd#arqt_PrefundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019bff58-eb90-754c-8b3f-a4fabda0f475" xlink:to="loc_arqt_PrefundedWarrantMember_019bff58-eb90-78e0-82fd-a31c178a96cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019bff59-1a5b-7c2e-98e1-cc52bf365fdd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_srt_CounterpartyNameAxis_019bff59-1a5b-7c2e-98e1-cc52bf365fdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019bff59-1a5b-7c2e-98e1-cc52bf365fdd_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019bff59-1a5b-7c2e-98e1-cc52bf365fdd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019bff59-1a5b-7c2e-98e1-cc52bf365fdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019bff59-1a5b-711b-a3a2-5404f449937b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019bff59-1a5b-7c2e-98e1-cc52bf365fdd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019bff59-1a5b-711b-a3a2-5404f449937b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CowenAndCompanyLLCMember_019bff59-1a5b-7507-a2f6-61f171d908af" xlink:href="arqt-20251231.xsd#arqt_CowenAndCompanyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019bff59-1a5b-711b-a3a2-5404f449937b" xlink:to="loc_arqt_CowenAndCompanyLLCMember_019bff59-1a5b-7507-a2f6-61f171d908af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019bff59-1a5b-7034-8bf4-33e557aa3425" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019bff59-1a5b-7034-8bf4-33e557aa3425" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019bff59-1a5b-7034-8bf4-33e557aa3425_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019bff59-1a5b-7034-8bf4-33e557aa3425" xlink:to="loc_us-gaap_ClassOfStockDomain_019bff59-1a5b-7034-8bf4-33e557aa3425_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019bff59-1a5b-7e05-9302-a04c883bdc58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019bff59-1a5b-7034-8bf4-33e557aa3425" xlink:to="loc_us-gaap_ClassOfStockDomain_019bff59-1a5b-7e05-9302-a04c883bdc58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019bff59-1a5b-731b-a22f-811acf183731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019bff59-1a5b-7e05-9302-a04c883bdc58" xlink:to="loc_us-gaap_CommonStockMember_019bff59-1a5b-731b-a22f-811acf183731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019bff59-418d-7706-af49-b49b6b97cac8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_PlanNameAxis_019bff59-418d-7706-af49-b49b6b97cac8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019bff59-418d-7706-af49-b49b6b97cac8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019bff59-418d-7706-af49-b49b6b97cac8" xlink:to="loc_us-gaap_PlanNameDomain_019bff59-418d-7706-af49-b49b6b97cac8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019bff59-418d-7706-af49-b49b6b97cac8" xlink:to="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2020EquityIncentivePlanMember_019bff59-418d-7998-a47b-93aa45e60081" xlink:href="arqt-20251231.xsd#arqt_A2020EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:to="loc_arqt_A2020EquityIncentivePlanMember_019bff59-418d-7998-a47b-93aa45e60081" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2017EquityIncentivePlanMember_019bff59-418d-7f8c-9ded-08df09de2102" xlink:href="arqt-20251231.xsd#arqt_A2017EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:to="loc_arqt_A2017EquityIncentivePlanMember_019bff59-418d-7f8c-9ded-08df09de2102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2022EmploymentInducementIncentivePlanMember_019bff59-418d-7dc6-9b29-5079a9906cbe" xlink:href="arqt-20251231.xsd#arqt_A2022EmploymentInducementIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:to="loc_arqt_A2022EmploymentInducementIncentivePlanMember_019bff59-418d-7dc6-9b29-5079a9906cbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockOptionExchangeMember_019bff59-64bf-789f-8cbd-06014a8d119a" xlink:href="arqt-20251231.xsd#arqt_StockOptionExchangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:to="loc_arqt_StockOptionExchangeMember_019bff59-64bf-789f-8cbd-06014a8d119a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019bff59-418d-7c99-8216-fb86d94f38e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019bff59-418d-7c99-8216-fb86d94f38e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019bff59-418d-7c99-8216-fb86d94f38e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019bff59-418d-7c99-8216-fb86d94f38e7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019bff59-418d-7c99-8216-fb86d94f38e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019bff59-418d-7778-b11f-4811e180af58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019bff59-418d-7c99-8216-fb86d94f38e7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019bff59-418d-7778-b11f-4811e180af58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019bff59-418d-7335-af75-4821952a9501" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019bff59-418d-7778-b11f-4811e180af58" xlink:to="loc_us-gaap_SubsequentEventMember_019bff59-418d-7335-af75-4821952a9501" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019bff59-418d-7b68-8259-f18a6d1b9bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_AwardTypeAxis_019bff59-418d-7b68-8259-f18a6d1b9bf1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7b68-8259-f18a6d1b9bf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019bff59-418d-7b68-8259-f18a6d1b9bf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7b68-8259-f18a6d1b9bf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019bff59-418d-7b68-8259-f18a6d1b9bf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019bff59-418d-7fc9-ac2f-1bae2c3790e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019bff59-418d-7fc9-ac2f-1bae2c3790e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019bff59-64bf-71a1-b1ab-65cc459b4415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019bff59-64bf-71a1-b1ab-65cc459b4415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019bff59-f853-717a-afd6-fdd52f5b9b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:to="loc_us-gaap_EmployeeStockMember_019bff59-f853-717a-afd6-fdd52f5b9b8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_019bff60-ee7c-7143-9e2b-e663cf99aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:to="loc_us-gaap_RestrictedStockMember_019bff60-ee7c-7143-9e2b-e663cf99aa47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_019bff59-64bf-7ccd-9996-c9243549b4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_AwardDateAxis_019bff59-64bf-7ccd-9996-c9243549b4b4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_019bff59-64bf-7ccd-9996-c9243549b4b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_019bff59-64bf-7ccd-9996-c9243549b4b4" xlink:to="loc_us-gaap_AwardDateDomain_019bff59-64bf-7ccd-9996-c9243549b4b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_019bff59-64bf-79b3-8a9f-ed61f51eb012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_019bff59-64bf-7ccd-9996-c9243549b4b4" xlink:to="loc_us-gaap_AwardDateDomain_019bff59-64bf-79b3-8a9f-ed61f51eb012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FirstGrantDateMember_019bff59-64bf-77bc-8afe-c18e156b2a54" xlink:href="arqt-20251231.xsd#arqt_FirstGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_019bff59-64bf-79b3-8a9f-ed61f51eb012" xlink:to="loc_arqt_FirstGrantDateMember_019bff59-64bf-77bc-8afe-c18e156b2a54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SecondGrantDateMember_019bff59-64bf-7f0f-b137-d492c0d3827c" xlink:href="arqt-20251231.xsd#arqt_SecondGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_019bff59-64bf-79b3-8a9f-ed61f51eb012" xlink:to="loc_arqt_SecondGrantDateMember_019bff59-64bf-7f0f-b137-d492c0d3827c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ThirdGrantDateMember_019bff59-64bf-7723-84f3-bccc2b64fc50" xlink:href="arqt-20251231.xsd#arqt_ThirdGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_019bff59-64bf-79b3-8a9f-ed61f51eb012" xlink:to="loc_arqt_ThirdGrantDateMember_019bff59-64bf-7723-84f3-bccc2b64fc50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019bff59-64bf-7d46-b9c4-92cb99ef130f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_srt_RangeAxis_019bff59-64bf-7d46-b9c4-92cb99ef130f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019bff59-64bf-7d46-b9c4-92cb99ef130f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019bff59-64bf-7d46-b9c4-92cb99ef130f" xlink:to="loc_srt_RangeMember_019bff59-64bf-7d46-b9c4-92cb99ef130f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019bff59-64bf-7f1d-a6c8-ac9392104552" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019bff59-64bf-7d46-b9c4-92cb99ef130f" xlink:to="loc_srt_RangeMember_019bff59-64bf-7f1d-a6c8-ac9392104552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019bff59-64bf-73b3-8b61-11c880af7557" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019bff59-64bf-7f1d-a6c8-ac9392104552" xlink:to="loc_srt_MinimumMember_019bff59-64bf-73b3-8b61-11c880af7557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019bff59-64bf-78c6-99f0-68ecbe3dc541" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019bff59-64bf-7f1d-a6c8-ac9392104552" xlink:to="loc_srt_MaximumMember_019bff59-64bf-78c6-99f0-68ecbe3dc541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019bff5a-1b14-7151-a51f-00ab8f4a51d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019bff5a-1b14-7151-a51f-00ab8f4a51d3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019bff5a-1b14-7151-a51f-00ab8f4a51d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019bff5a-1b14-7151-a51f-00ab8f4a51d3" xlink:to="loc_us-gaap_EquityComponentDomain_019bff5a-1b14-7151-a51f-00ab8f4a51d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019bff5a-1b14-7da2-bba5-ca4b2d746752" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019bff5a-1b14-7151-a51f-00ab8f4a51d3" xlink:to="loc_us-gaap_EquityComponentDomain_019bff5a-1b14-7da2-bba5-ca4b2d746752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019bff5a-1b14-7f7c-91e1-3fa885cdb566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019bff5a-1b14-7da2-bba5-ca4b2d746752" xlink:to="loc_us-gaap_CommonStockMember_019bff5a-1b14-7f7c-91e1-3fa885cdb566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_019bff60-ee7c-7353-bc7a-3dedf807e67d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_VestingAxis_019bff60-ee7c-7353-bc7a-3dedf807e67d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019bff60-ee7c-7353-bc7a-3dedf807e67d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_019bff60-ee7c-7353-bc7a-3dedf807e67d" xlink:to="loc_us-gaap_VestingDomain_019bff60-ee7c-7353-bc7a-3dedf807e67d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019bff60-ee7c-7ace-871c-c77121905acf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_019bff60-ee7c-7353-bc7a-3dedf807e67d" xlink:to="loc_us-gaap_VestingDomain_019bff60-ee7c-7ace-871c-c77121905acf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019bff60-ee7c-747d-bfec-7229274221f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_019bff60-ee7c-7ace-871c-c77121905acf" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019bff60-ee7c-747d-bfec-7229274221f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalUnitsAuthorized_019bff58-eb90-721b-80b7-1fca6b1f1b29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_CapitalUnitsAuthorized_019bff58-eb90-721b-80b7-1fca6b1f1b29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019bff58-eb90-77ff-b6a7-b6a8edc9cb57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019bff58-eb90-77ff-b6a7-b6a8edc9cb57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019bff58-eb90-7270-a661-cbf5cb411a24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019bff58-eb90-7270-a661-cbf5cb411a24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019bff58-eb90-7f92-90a0-c182612f21d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019bff58-eb90-7f92-90a0-c182612f21d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019c2740-1984-751c-99b4-60cf9be06121" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019c2740-1984-751c-99b4-60cf9be06121" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019bff58-eb90-7abc-9f39-35edc5b32175" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019bff58-eb90-7abc-9f39-35edc5b32175" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019bff58-eb90-7abf-b3ee-b3b7c1fb17f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019bff58-eb90-7abf-b3ee-b3b7c1fb17f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019bff58-eb90-7a2a-aeda-efb2523872ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019bff58-eb90-7a2a-aeda-efb2523872ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019bff58-eb90-7c05-9c1a-d243d54cc1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019bff58-eb90-7c05-9c1a-d243d54cc1ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019c2738-0542-7399-a931-3b985451b799" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019c2738-0542-7399-a931-3b985451b799" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019bff58-eb90-716f-a972-d263afec640a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019bff58-eb90-716f-a972-d263afec640a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SaleOfStockAuthorizedConsiderationOnTransaction_019bff59-1a5b-7ea0-adb8-4b3d56461601" xlink:href="arqt-20251231.xsd#arqt_SaleOfStockAuthorizedConsiderationOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_SaleOfStockAuthorizedConsiderationOnTransaction_019bff59-1a5b-7ea0-adb8-4b3d56461601" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds_019bff59-1a5b-779c-9194-5dd809c84525" xlink:href="arqt-20251231.xsd#arqt_SaleOfStockAgentFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds_019bff59-1a5b-779c-9194-5dd809c84525" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019bff59-418d-7998-89eb-1bd67a36de1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019bff59-418d-7998-89eb-1bd67a36de1d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_019bff59-418d-75d0-a94a-0b8a2e9608ce" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_019bff59-418d-75d0-a94a-0b8a2e9608ce" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_019bff59-418d-72c6-9630-f26e44675637" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_019bff59-418d-72c6-9630-f26e44675637" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019bff59-418d-7fc9-b03d-3f31f8592066" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019bff59-418d-7fc9-b03d-3f31f8592066" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019bff59-418d-7943-a60d-d87a544deb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019bff59-418d-7943-a60d-d87a544deb1f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019bff59-418d-7ba2-bfad-560ee6abb968" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019bff59-418d-7ba2-bfad-560ee6abb968" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019bff59-64bf-7641-9b17-7f06affd437f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019bff59-64bf-7641-9b17-7f06affd437f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged_019bff59-64bf-78db-946c-c5f276a91843" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged_019bff59-64bf-78db-946c-c5f276a91843" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019bff59-64bf-7e5b-8cb3-db86efbc4ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019bff59-64bf-7e5b-8cb3-db86efbc4ee0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_019bff59-64bf-75c4-a79e-35dfc1771cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_019bff59-64bf-75c4-a79e-35dfc1771cfd" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019bff59-64bf-706a-8a18-f9b41b7f1ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019bff59-64bf-706a-8a18-f9b41b7f1ac0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019bff59-87f9-7a12-9508-390a59c7de99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019bff59-87f9-7a12-9508-390a59c7de99" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019bff59-87f9-7e5c-b809-1b223b140615" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019bff59-87f9-7e5c-b809-1b223b140615" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019bff59-87f9-7453-ae6a-bfca28975bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019bff59-87f9-7453-ae6a-bfca28975bf8" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c277f-9cd9-7aba-a3ba-e4c7345037d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c277f-9cd9-7aba-a3ba-e4c7345037d6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019bff59-d6d9-7b16-86a8-c5655e998c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019bff59-d6d9-7b16-86a8-c5655e998c1e" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019bff59-d6d9-717f-afa3-5b1d87a38bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019bff59-d6d9-717f-afa3-5b1d87a38bd9" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019bff59-d6d9-7186-858e-accdd463f979" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019bff59-d6d9-7186-858e-accdd463f979" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019bff59-f853-710b-b845-0669763341a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019bff59-f853-710b-b845-0669763341a8" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_019bff5a-1b14-7618-93e6-42d243a80287" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_019bff5a-1b14-7618-93e6-42d243a80287" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_019bff5a-1b14-72a6-a0ed-684223b8169f" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_019bff5a-1b14-72a6-a0ed-684223b8169f" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019bff5a-1b14-7a2c-87b1-27c2a0274fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019bff5a-1b14-7a2c-87b1-27c2a0274fc9" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019bff60-ee7c-7116-83f6-2df70ee8880d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019bff60-ee7c-7116-83f6-2df70ee8880d" xlink:type="arc" order="35"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54057065-5bb0-4cdf-b4e7-73ee5d503cde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_809537f3-a2c7-41f4-9b01-ec4b94906563" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54057065-5bb0-4cdf-b4e7-73ee5d503cde" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_809537f3-a2c7-41f4-9b01-ec4b94906563" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2332c351-9702-4882-8026-55ee51a15f51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_809537f3-a2c7-41f4-9b01-ec4b94906563" xlink:to="loc_us-gaap_AwardTypeAxis_2332c351-9702-4882-8026-55ee51a15f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2332c351-9702-4882-8026-55ee51a15f51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2332c351-9702-4882-8026-55ee51a15f51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2332c351-9702-4882-8026-55ee51a15f51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b173172d-0e62-4619-a5f6-9277787123dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2332c351-9702-4882-8026-55ee51a15f51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b173172d-0e62-4619-a5f6-9277787123dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bbff6e10-e7d4-4a30-a72d-2d08fc212dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b173172d-0e62-4619-a5f6-9277787123dd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bbff6e10-e7d4-4a30-a72d-2d08fc212dfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54057065-5bb0-4cdf-b4e7-73ee5d503cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f52b6e08-33f0-4692-9fa9-0e198081df6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f52b6e08-33f0-4692-9fa9-0e198081df6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d43783d-2249-475b-8a06-a4dcc6fb8ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d43783d-2249-475b-8a06-a4dcc6fb8ecf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d21c2ae3-dc70-4b05-aba0-a594525fa581" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d21c2ae3-dc70-4b05-aba0-a594525fa581" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d9d07f35-5084-4a11-b617-8d32f1b1a6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d9d07f35-5084-4a11-b617-8d32f1b1a6d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51a7cc8c-e950-4c96-b8ad-e80d1734e392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54057065-5bb0-4cdf-b4e7-73ee5d503cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c98e068d-886e-4708-b449-dfe3d27dccb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c98e068d-886e-4708-b449-dfe3d27dccb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_efb74921-914c-4528-82f4-8c3680dcce5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_efb74921-914c-4528-82f4-8c3680dcce5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_16ad7663-8430-409d-93a6-9e7c1f0a0b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_16ad7663-8430-409d-93a6-9e7c1f0a0b6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_628b2ff2-507d-49db-9278-00fab5259e41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_628b2ff2-507d-49db-9278-00fab5259e41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6935a86c-d968-4cf9-b0b3-fde2faad78b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockholdersEquityScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2080f01a-86e2-4bac-8746-63626bf31be5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c2ead47-52da-4891-848f-26c1a26c39f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2080f01a-86e2-4bac-8746-63626bf31be5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c2ead47-52da-4891-848f-26c1a26c39f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ca2579c2-df05-4fb2-a375-a877426e92f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c2ead47-52da-4891-848f-26c1a26c39f1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ca2579c2-df05-4fb2-a375-a877426e92f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca2579c2-df05-4fb2-a375-a877426e92f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ca2579c2-df05-4fb2-a375-a877426e92f7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca2579c2-df05-4fb2-a375-a877426e92f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b086a9cc-ca72-430b-ba4a-9ec1f9404d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ca2579c2-df05-4fb2-a375-a877426e92f7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b086a9cc-ca72-430b-ba4a-9ec1f9404d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eaadacaf-beb9-4696-8a8f-506d7736692a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b086a9cc-ca72-430b-ba4a-9ec1f9404d5d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eaadacaf-beb9-4696-8a8f-506d7736692a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d0bc3c0e-1209-4b19-9600-eb4e9656e591" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b086a9cc-ca72-430b-ba4a-9ec1f9404d5d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d0bc3c0e-1209-4b19-9600-eb4e9656e591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_eaefc9d1-8e01-4031-93af-ee9b2cd05f82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2080f01a-86e2-4bac-8746-63626bf31be5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_eaefc9d1-8e01-4031-93af-ee9b2cd05f82" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_729cdca0-f388-4ea0-b8a7-d9934448ce2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_729cdca0-f388-4ea0-b8a7-d9934448ce2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8390b01c-cea7-4ca8-b4d1-a7e6863b4da5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_729cdca0-f388-4ea0-b8a7-d9934448ce2d" xlink:to="loc_srt_RangeAxis_8390b01c-cea7-4ca8-b4d1-a7e6863b4da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8390b01c-cea7-4ca8-b4d1-a7e6863b4da5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8390b01c-cea7-4ca8-b4d1-a7e6863b4da5" xlink:to="loc_srt_RangeMember_8390b01c-cea7-4ca8-b4d1-a7e6863b4da5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b76a27c-d978-40c3-8e0a-50d9cfc1eb14" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8390b01c-cea7-4ca8-b4d1-a7e6863b4da5" xlink:to="loc_srt_RangeMember_1b76a27c-d978-40c3-8e0a-50d9cfc1eb14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d09a8dc9-91eb-4bc8-ae79-184c7bb342cb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b76a27c-d978-40c3-8e0a-50d9cfc1eb14" xlink:to="loc_srt_MinimumMember_d09a8dc9-91eb-4bc8-ae79-184c7bb342cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b80c851c-e61b-45a1-b4e3-dda443dcbc47" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b76a27c-d978-40c3-8e0a-50d9cfc1eb14" xlink:to="loc_srt_MaximumMember_b80c851c-e61b-45a1-b4e3-dda443dcbc47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_93a57728-1f35-4552-9c12-98eaee3c0de7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_729cdca0-f388-4ea0-b8a7-d9934448ce2d" xlink:to="loc_us-gaap_AwardTypeAxis_93a57728-1f35-4552-9c12-98eaee3c0de7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93a57728-1f35-4552-9c12-98eaee3c0de7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_93a57728-1f35-4552-9c12-98eaee3c0de7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93a57728-1f35-4552-9c12-98eaee3c0de7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2ce9383-104e-4611-a83e-2b97072a5f74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_93a57728-1f35-4552-9c12-98eaee3c0de7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2ce9383-104e-4611-a83e-2b97072a5f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_44da2b9c-09bb-4a8b-b564-07c8807de899" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2ce9383-104e-4611-a83e-2b97072a5f74" xlink:to="loc_us-gaap_EmployeeStockOptionMember_44da2b9c-09bb-4a8b-b564-07c8807de899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1a70480-5603-4f51-bb6a-1145e3517744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1a70480-5603-4f51-bb6a-1145e3517744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f0bc1aa4-1f0f-4243-9279-285491d089a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f0bc1aa4-1f0f-4243-9279-285491d089a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_675cd3c8-0907-45ba-8030-f44f9fd1cc54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_675cd3c8-0907-45ba-8030-f44f9fd1cc54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b50c4ce3-8f34-4480-8cfd-3e7271b0958c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b50c4ce3-8f34-4480-8cfd-3e7271b0958c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_eb8f0d14-38c9-4943-99ac-46a96cdd30dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_eb8f0d14-38c9-4943-99ac-46a96cdd30dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ddf35966-a6cf-4748-b281-776f5d92f794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ddf35966-a6cf-4748-b281-776f5d92f794" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_988291ec-68df-4316-8176-aa515d6e9446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_988291ec-68df-4316-8176-aa515d6e9446" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019bff72-4831-7ae0-a72c-255920d46421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_988291ec-68df-4316-8176-aa515d6e9446" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019bff72-4831-7ae0-a72c-255920d46421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7ae0-a72c-255920d46421_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019bff72-4831-7ae0-a72c-255920d46421" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7ae0-a72c-255920d46421_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7354-9482-c7516e2a8ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019bff72-4831-7ae0-a72c-255920d46421" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7354-9482-c7516e2a8ec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019bff72-4831-79cc-ba9d-558f02cdc6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7354-9482-c7516e2a8ec3" xlink:to="loc_us-gaap_DomesticCountryMember_019bff72-4831-79cc-ba9d-558f02cdc6ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019bff72-4831-7ddf-8262-421b452acd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7354-9482-c7516e2a8ec3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019bff72-4831-7ddf-8262-421b452acd9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019bff72-4831-76d0-8546-84f48309ebc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7354-9482-c7516e2a8ec3" xlink:to="loc_us-gaap_ForeignCountryMember_019bff72-4831-76d0-8546-84f48309ebc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_019bff72-4831-7204-b978-5b81caeec786" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_988291ec-68df-4316-8176-aa515d6e9446" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_019bff72-4831-7204-b978-5b81caeec786" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_019bff72-4831-7204-b978-5b81caeec786_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_019bff72-4831-7204-b978-5b81caeec786" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_019bff72-4831-7204-b978-5b81caeec786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_019bff72-4831-7de7-870e-92c81dd8d83c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_019bff72-4831-7204-b978-5b81caeec786" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_019bff72-4831-7de7-870e-92c81dd8d83c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_019bff72-4831-73f0-8ecc-bd5d498269af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_019bff72-4831-7de7-870e-92c81dd8d83c" xlink:to="loc_us-gaap_ResearchMember_019bff72-4831-73f0-8ecc-bd5d498269af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019bff71-d85c-783c-828a-c11c04aecd76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019bff71-d85c-783c-828a-c11c04aecd76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ForeignWithholdingIncomeTaxes_019bff71-d85c-70a7-989e-0575ad28f27b" xlink:href="arqt-20251231.xsd#arqt_ForeignWithholdingIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_arqt_ForeignWithholdingIncomeTaxes_019bff71-d85c-70a7-989e-0575ad28f27b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019bff72-4831-732d-9b46-5c29fd796926" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019bff72-4831-732d-9b46-5c29fd796926" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_019bff72-4831-7b3c-a275-3b1b22c4a59a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_OperatingLossCarryforwards_019bff72-4831-7b3c-a275-3b1b22c4a59a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_019bff72-4831-7032-9663-6f6bd599e1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_019bff72-4831-7032-9663-6f6bd599e1c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_019bff72-4831-70c2-a925-257d33d8d364" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_019bff72-4831-70c2-a925-257d33d8d364" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_019bff72-4831-7226-b8a1-bef69efe0b20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_019bff72-4831-7226-b8a1-bef69efe0b20" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_019bff72-89b2-70fb-81c0-52d813f979d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_019bff72-89b2-70fb-81c0-52d813f979d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_019c8aec-b8f4-7672-9579-6056e9551b93" xlink:href="arqt-20251231.xsd#arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_019c8aec-b8f4-7672-9579-6056e9551b93" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_019bff72-89b2-78ca-a34d-eba8ee652451" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_019bff72-89b2-78ca-a34d-eba8ee652451" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_019c4c3a-6bc4-7ad5-8eb7-77d3053844d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_019c4c3a-6bc4-7ad5-8eb7-77d3053844d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019c76d1-490f-7366-aebd-bbd4967e55f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019c76d1-490f-7366-aebd-bbd4967e55f2" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7043-9c3b-7ee5-b836-7dc80f974a50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7043-9c3b-77f1-9af8-157afae3152e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7043-9c3b-7ee5-b836-7dc80f974a50" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7043-9c3b-77f1-9af8-157afae3152e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c7043-9c3b-7a75-9f33-86135b7587a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7043-9c3b-77f1-9af8-157afae3152e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c7043-9c3b-7a75-9f33-86135b7587a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c7043-9c3b-7a75-9f33-86135b7587a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c7043-9c3b-7a75-9f33-86135b7587a7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c7043-9c3b-7a75-9f33-86135b7587a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c7043-9c3b-7086-8f7c-77d413753feb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c7043-9c3b-7a75-9f33-86135b7587a7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c7043-9c3b-7086-8f7c-77d413753feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019c7047-5dbf-701e-81a0-462a47227775" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7043-9c3b-7086-8f7c-77d413753feb" xlink:to="loc_us-gaap_ForeignCountryMember_019c7047-5dbf-701e-81a0-462a47227775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019c7043-9c3b-71c0-817b-38d95bb89f32" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignCountryMember_019c7047-5dbf-701e-81a0-462a47227775" xlink:to="loc_country_GB_019c7043-9c3b-71c0-817b-38d95bb89f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_019c7043-9c3b-729a-a217-953bc53fad01" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignCountryMember_019c7047-5dbf-701e-81a0-462a47227775" xlink:to="loc_country_CN_019c7043-9c3b-729a-a217-953bc53fad01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c7043-9c3b-7666-8c64-6aaf4150dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignCountryMember_019c7047-5dbf-701e-81a0-462a47227775" xlink:to="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c7043-9c3b-7666-8c64-6aaf4150dfe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019c7046-6e22-7dc8-8ada-d12e4ace38e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7043-9c3b-7086-8f7c-77d413753feb" xlink:to="loc_us-gaap_DomesticCountryMember_019c7046-6e22-7dc8-8ada-d12e4ace38e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019c7049-61a4-7185-8e82-d9144ecd335e" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019c7046-6e22-7dc8-8ada-d12e4ace38e2" xlink:to="loc_country_US_019c7049-61a4-7185-8e82-d9144ecd335e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7043-9c3b-7ee5-b836-7dc80f974a50" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019bb779-5e2f-78d6-823f-a4a90502054a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019bb779-5e2f-78d6-823f-a4a90502054a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019bb779-5e2f-765c-a3a0-7ed47db18cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019bb779-5e2f-765c-a3a0-7ed47db18cfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019bb779-5e2f-7ec2-89f4-38a822c5f7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019bb779-5e2f-7ec2-89f4-38a822c5f7bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7043-9c3b-749e-a57c-37dedaf610db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7043-9c3b-749e-a57c-37dedaf610db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_019bb779-5e2f-7853-9fae-4711abd739ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_019bb779-5e2f-7853-9fae-4711abd739ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount_019bb779-5e2f-7a89-bf08-29c7fbe6868e" xlink:href="arqt-20251231.xsd#arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount_019bb779-5e2f-7a89-bf08-29c7fbe6868e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb779-5e2f-7aa5-b7bd-69eb8dd49062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb779-5e2f-7aa5-b7bd-69eb8dd49062" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019bb779-5e2f-78a7-8de9-3ff68f0f6e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019bb779-5e2f-78a7-8de9-3ff68f0f6e91" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019bb779-5e2f-791b-a0db-a10146e62881" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019bb779-5e2f-791b-a0db-a10146e62881" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019bb779-5e2f-7e2d-aa5d-2a89b73f8168" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019bb779-5e2f-7e2d-aa5d-2a89b73f8168" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7043-9c3b-7ee5-b836-7dc80f974a50" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019bb779-5e2f-7b96-8076-9cb3411289db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019bb779-5e2f-7b96-8076-9cb3411289db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019bb779-5e2f-7c1d-9f3e-189d8ffaf588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019bb779-5e2f-7c1d-9f3e-189d8ffaf588" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019bb779-5e2f-781d-8086-aea6868b15f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019bb779-5e2f-781d-8086-aea6868b15f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7043-9c3b-7afa-979f-27972f839e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7043-9c3b-7afa-979f-27972f839e63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019bb779-5e2f-74e9-bf80-79121f7ebc25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019bb779-5e2f-74e9-bf80-79121f7ebc25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent_019bb779-5e2f-742f-989f-f7751b24ee8b" xlink:href="arqt-20251231.xsd#arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent_019bb779-5e2f-742f-989f-f7751b24ee8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb779-5e2f-7e61-b89a-dcf37b800cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb779-5e2f-7e61-b89a-dcf37b800cc2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019bb779-5e2f-72be-90da-96583b2ae91a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019bb779-5e2f-72be-90da-96583b2ae91a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019bb779-5e2f-75b8-8975-f91877ebd627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019bb779-5e2f-75b8-8975-f91877ebd627" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb779-5e2f-70c2-bd7c-89d5765c8875" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb779-5e2f-70c2-bd7c-89d5765c8875" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#NetLossPerShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6bd0ae9e-9e9d-4c95-b659-da182ec01b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc52aec-c1f8-4769-9963-16b96aec9a36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6bd0ae9e-9e9d-4c95-b659-da182ec01b8d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc52aec-c1f8-4769-9963-16b96aec9a36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a3eef0a0-1838-45cc-8259-037ad2e7b929" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc52aec-c1f8-4769-9963-16b96aec9a36" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a3eef0a0-1838-45cc-8259-037ad2e7b929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a3eef0a0-1838-45cc-8259-037ad2e7b929_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a3eef0a0-1838-45cc-8259-037ad2e7b929" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a3eef0a0-1838-45cc-8259-037ad2e7b929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2175d501-0f3f-4a55-b82c-00664ce402b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a3eef0a0-1838-45cc-8259-037ad2e7b929" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2175d501-0f3f-4a55-b82c-00664ce402b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrefundedWarrantMember_e279c06f-fa78-4bbe-8c1a-d63e9d33a0d1" xlink:href="arqt-20251231.xsd#arqt_PrefundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2175d501-0f3f-4a55-b82c-00664ce402b0" xlink:to="loc_arqt_PrefundedWarrantMember_e279c06f-fa78-4bbe-8c1a-d63e9d33a0d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bb99daab-2614-485a-8734-5efa10948724" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6bd0ae9e-9e9d-4c95-b659-da182ec01b8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bb99daab-2614-485a-8734-5efa10948724" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#NetLossPerShareDilutiveSharesDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd3abb84-8c07-4520-906a-5c7ed6ad30ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_123a562f-03d0-41a9-b369-2957486be486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd3abb84-8c07-4520-906a-5c7ed6ad30ff" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_123a562f-03d0-41a9-b369-2957486be486" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f0e68a68-dbdd-4d73-8a34-7f814ab2d9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_123a562f-03d0-41a9-b369-2957486be486" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f0e68a68-dbdd-4d73-8a34-7f814ab2d9a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0e68a68-dbdd-4d73-8a34-7f814ab2d9a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f0e68a68-dbdd-4d73-8a34-7f814ab2d9a4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0e68a68-dbdd-4d73-8a34-7f814ab2d9a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb9e827e-e67d-428b-aea1-9b83a7c367bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f0e68a68-dbdd-4d73-8a34-7f814ab2d9a4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb9e827e-e67d-428b-aea1-9b83a7c367bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1bfa420b-c496-4dd9-b18f-12f9a2f200ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb9e827e-e67d-428b-aea1-9b83a7c367bc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1bfa420b-c496-4dd9-b18f-12f9a2f200ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e4eb1238-0d03-4492-95d5-e83d1d110b51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb9e827e-e67d-428b-aea1-9b83a7c367bc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e4eb1238-0d03-4492-95d5-e83d1d110b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_feddebf7-e66d-4447-838b-8f5c8f676d07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb9e827e-e67d-428b-aea1-9b83a7c367bc" xlink:to="loc_us-gaap_EmployeeStockMember_feddebf7-e66d-4447-838b-8f5c8f676d07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00530c58-2efd-4642-86aa-158b1ab4e228" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd3abb84-8c07-4520-906a-5c7ed6ad30ff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00530c58-2efd-4642-86aa-158b1ab4e228" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f48121a4-02cc-4417-9211-7dbeba7db345" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f48121a4-02cc-4417-9211-7dbeba7db345" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5227099f-d86f-4a8f-9839-95265c4fdc29" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f48121a4-02cc-4417-9211-7dbeba7db345" xlink:to="loc_srt_ProductOrServiceAxis_5227099f-d86f-4a8f-9839-95265c4fdc29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5227099f-d86f-4a8f-9839-95265c4fdc29_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5227099f-d86f-4a8f-9839-95265c4fdc29" xlink:to="loc_srt_ProductsAndServicesDomain_5227099f-d86f-4a8f-9839-95265c4fdc29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ffece591-bc0f-46be-acca-a6751f7d15ad" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5227099f-d86f-4a8f-9839-95265c4fdc29" xlink:to="loc_srt_ProductsAndServicesDomain_ffece591-bc0f-46be-acca-a6751f7d15ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TopicalRoflumilastProgramMember_4eb1ccd4-3307-4eec-b33b-fc0dbf9e1667" xlink:href="arqt-20251231.xsd#arqt_TopicalRoflumilastProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ffece591-bc0f-46be-acca-a6751f7d15ad" xlink:to="loc_arqt_TopicalRoflumilastProgramMember_4eb1ccd4-3307-4eec-b33b-fc0dbf9e1667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TopicalJAKInhibitorProgramMember_f2f1031a-97f2-410c-b55b-cc2031b5df4e" xlink:href="arqt-20251231.xsd#arqt_TopicalJAKInhibitorProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ffece591-bc0f-46be-acca-a6751f7d15ad" xlink:to="loc_arqt_TopicalJAKInhibitorProgramMember_f2f1031a-97f2-410c-b55b-cc2031b5df4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_OtherEarlyStageProgramsMember_ea763137-2908-4513-872f-635104ee17cc" xlink:href="arqt-20251231.xsd#arqt_OtherEarlyStageProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ffece591-bc0f-46be-acca-a6751f7d15ad" xlink:to="loc_arqt_OtherEarlyStageProgramsMember_ea763137-2908-4513-872f-635104ee17cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_653ba100-7a07-4a8a-8c3c-70f3c04d5572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f48121a4-02cc-4417-9211-7dbeba7db345" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_653ba100-7a07-4a8a-8c3c-70f3c04d5572" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_653ba100-7a07-4a8a-8c3c-70f3c04d5572_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_653ba100-7a07-4a8a-8c3c-70f3c04d5572" xlink:to="loc_us-gaap_SegmentDomain_653ba100-7a07-4a8a-8c3c-70f3c04d5572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_21429af8-7a4b-44ba-813e-128caaf71f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_653ba100-7a07-4a8a-8c3c-70f3c04d5572" xlink:to="loc_us-gaap_SegmentDomain_21429af8-7a4b-44ba-813e-128caaf71f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ReportableSegmentMember_9ba99159-ba36-4c55-bdea-87145be49b86" xlink:href="arqt-20251231.xsd#arqt_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_21429af8-7a4b-44ba-813e-128caaf71f3c" xlink:to="loc_arqt_ReportableSegmentMember_9ba99159-ba36-4c55-bdea-87145be49b86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_937cf224-1169-49b8-969e-e2d6f92d0fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_Revenues_937cf224-1169-49b8-969e-e2d6f92d0fbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_014fbff2-0691-48ad-98f8-f82cd01763ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_014fbff2-0691-48ad-98f8-f82cd01763ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cb782317-ea0f-48e4-875d-c4e70ebafa23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cb782317-ea0f-48e4-875d-c4e70ebafa23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses_9a7483c7-64d2-4537-83df-f4df0752987f" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses_9a7483c7-64d2-4537-83df-f4df0752987f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1df2e330-9ecf-40ad-bd36-49e4087b841e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1df2e330-9ecf-40ad-bd36-49e4087b841e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_b3c247a7-f8dd-4fd9-a814-773c2ec68c23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_b3c247a7-f8dd-4fd9-a814-773c2ec68c23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fb607651-27a6-4ae9-b37a-9b7b0d1c9b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_CostsAndExpenses_fb607651-27a6-4ae9-b37a-9b7b0d1c9b3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c6653eb7-2ab3-43cc-9c0a-70a03d49fc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_OperatingIncomeLoss_c6653eb7-2ab3-43cc-9c0a-70a03d49fc7e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_019bff77-62b0-7c34-889d-3f9d10b726d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_InterestIncomeOther_019bff77-62b0-7c34-889d-3f9d10b726d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_38fc2d10-48db-4f1b-9a43-70aa7663e6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_InterestExpenseNonoperating_38fc2d10-48db-4f1b-9a43-70aa7663e6e7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e575ec28-33cb-4c0a-aae9-66d46f7f8629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e575ec28-33cb-4c0a-aae9-66d46f7f8629" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2d5d4e4a-128d-48d1-b60c-fdc548d28a70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2d5d4e4a-128d-48d1-b60c-fdc548d28a70" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bf65b7eb-35b6-49a5-b9d9-e8a838f968a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_NetIncomeLoss_bf65b7eb-35b6-49a5-b9d9-e8a838f968a5" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_KeithLeonardMember_019b0c71-0f81-7fd9-b846-05c726c85aa2" xlink:href="arqt-20251231.xsd#arqt_KeithLeonardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arqt_KeithLeonardMember_019b0c71-0f81-7fd9-b846-05c726c85aa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SueJeanLinMember_019b0c6b-b144-7472-87f2-35507f93d8a7" xlink:href="arqt-20251231.xsd#arqt_SueJeanLinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arqt_SueJeanLinMember_019b0c6b-b144-7472-87f2-35507f93d8a7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SueJeanLinTradingArrangementOptionsMember_019bb748-194a-7b72-bbdd-b8a1b82320d8" xlink:href="arqt-20251231.xsd#arqt_SueJeanLinTradingArrangementOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arqt_SueJeanLinTradingArrangementOptionsMember_019bb748-194a-7b72-bbdd-b8a1b82320d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SueJeanLinTradingArrangementCommonStockMember_019b6f98-118c-7520-8f59-fa99caff672c" xlink:href="arqt-20251231.xsd#arqt_SueJeanLinTradingArrangementCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arqt_SueJeanLinTradingArrangementCommonStockMember_019b6f98-118c-7520-8f59-fa99caff672c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="41"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>arqt-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:631d5f47-b6cd-44b6-9ca1-ef826fe44260,g:a004ef44-2665-49af-8ba9-70d1dea45abd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_arqt_ReportableSegmentMember_24564a1d-1d82-4d69-8c36-e0cbab79103d_terseLabel_en-US" xlink:label="lab_arqt_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_arqt_ReportableSegmentMember_label_en-US" xlink:label="lab_arqt_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_arqt_ReportableSegmentMember_documentation_en-US" xlink:label="lab_arqt_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ReportableSegmentMember" xlink:href="arqt-20251231.xsd#arqt_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ReportableSegmentMember" xlink:to="lab_arqt_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_bfa2ca2d-6e2c-4b05-8739-fd90a0e05cb3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_addaf4b8-8fa7-4bcb-b0db-434bfb6630d3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_58724427-3e32-4497-ad5e-8148f37d43b2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_019bb785-3271-72a3-a65e-eed665b55693_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7528a785-c325-4a13-846c-11442d288313_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CoPromotionAgreementsPolicyPolicyTextBlock_a5490b0b-f3db-449f-af70-70bed0571792_terseLabel_en-US" xlink:label="lab_arqt_CoPromotionAgreementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promotion Agreement</link:label>
    <link:label id="lab_arqt_CoPromotionAgreementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_arqt_CoPromotionAgreementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-Promotion Agreements, Policy [Policy Text Block]</link:label>
    <link:label id="lab_arqt_CoPromotionAgreementsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_arqt_CoPromotionAgreementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-Promotion Agreements, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CoPromotionAgreementsPolicyPolicyTextBlock" xlink:href="arqt-20251231.xsd#arqt_CoPromotionAgreementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CoPromotionAgreementsPolicyPolicyTextBlock" xlink:to="lab_arqt_CoPromotionAgreementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_f48c49de-a739-44c3-8a5d-04eae58dcf8d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_92b8031b-e95e-43d2-ab62-d1d5dab3351e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_410ace9d-d0d2-4edb-ab91-16bd1eb3ddb1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued pursuant to the ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b4fab512-1a0b-4d80-9e82-92ad9d8c2b80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_60437bd0-ed14-4cf1-92cb-d63e71c95476_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_FourCustomersMember_0e866aff-c6c7-4f2a-a496-2b96eeecf0e0_terseLabel_en-US" xlink:label="lab_arqt_FourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Four Customers</link:label>
    <link:label id="lab_arqt_FourCustomersMember_label_en-US" xlink:label="lab_arqt_FourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four Customers [Member]</link:label>
    <link:label id="lab_arqt_FourCustomersMember_documentation_en-US" xlink:label="lab_arqt_FourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FourCustomersMember" xlink:href="arqt-20251231.xsd#arqt_FourCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_FourCustomersMember" xlink:to="lab_arqt_FourCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4ec4360d-025c-4365-97de-7d35c6568f5b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue_8583392d-babe-456c-b897-3798ce48c199_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum net product revenue as a percentage of projected monthly net revenue</link:label>
    <link:label id="lab_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue_label_en-US" xlink:label="lab_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Net Product Revenue As A Percentage Of Projected Net Product Revenue</link:label>
    <link:label id="lab_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Net Product Revenue As A Percentage Of Projected Net Product Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue" xlink:to="lab_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CustomerEMember_d4bd482a-b158-4f71-b4a8-5e9c7273536f_terseLabel_en-US" xlink:label="lab_arqt_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer E</link:label>
    <link:label id="lab_arqt_CustomerEMember_label_en-US" xlink:label="lab_arqt_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer E [Member]</link:label>
    <link:label id="lab_arqt_CustomerEMember_documentation_en-US" xlink:label="lab_arqt_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerEMember" xlink:href="arqt-20251231.xsd#arqt_CustomerEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CustomerEMember" xlink:to="lab_arqt_CustomerEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_b60da7f2-e910-4220-b456-baade0782720_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_beda8d6f-471c-4eca-ade4-2a619ef8c44f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0d49d84d-cb25-46e2-b813-931284c053c9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ddcd1ab9-c53e-4127-9535-c70c109259b1_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41c1cd5e-c3d1-45ac-bb9f-25559b6af75a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-774c-8273-4599fc96e16d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0ff51f0b-ebf4-4e1b-bb0f-6cc22384274e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ea61e19e-664d-4fee-85ac-35c4af67d431_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_50706158-c86d-4a9c-9f50-678d12572f2e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_793a70b7-fd44-4350-8b45-f20bb9d1b406_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_9b54af4e-745f-4f81-bb01-e8db5f3bff2b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CashAndCashEquivalentsUnrealizedLoss_0d485ae2-1737-4f77-91cb-a60fcc868c7b_negatedTerseLabel_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_arqt_CashAndCashEquivalentsUnrealizedLoss_label_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents, Unrealized Loss</link:label>
    <link:label id="lab_arqt_CashAndCashEquivalentsUnrealizedLoss_documentation_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsUnrealizedLoss" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CashAndCashEquivalentsUnrealizedLoss" xlink:to="lab_arqt_CashAndCashEquivalentsUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_22473ed7-5d83-4c4c-86b5-8e20d1d35292_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_dfd42e2f-7f2f-482c-82c6-d1418612fcf7_terseLabel_en-US" xlink:label="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, variable consideration amount, regulatory milestones</link:label>
    <link:label id="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_label_en-US" xlink:label="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones</link:label>
    <link:label id="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_documentation_en-US" xlink:label="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones" xlink:href="arqt-20251231.xsd#arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones" xlink:to="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale_019c90a2-7a16-7342-8288-493ccbfb1c9d_terseLabel_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Years from first commercial sale</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale_label_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Years From First Commercial Sale</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale_documentation_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Years From First Commercial Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale" xlink:to="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9e72edf5-a246-42b5-8ab2-ce6075396646_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_0645a68b-0433-4bd0-8ac6-88593d6390cd_terseLabel_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lapse of repurchasing rights related to common stock issued pursuant to early exercises</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_label_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Lapse Of Repurchase Rights Pursuant To Early Stock Exercises</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_documentation_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Lapse Of Repurchase Rights Pursuant To Early Stock Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:href="arqt-20251231.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:to="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_332caf39-d6d2-4fc0-bb23-2747ad844be0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20d1c9a1-d969-4a60-bb3b-8e6635a3ace3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_b1dce63d-c7e9-44bc-bf2c-75d7fff8b375_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_230f0871-c579-4c97-a598-eaf43f1199a5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_467277ee-c38b-4418-b97b-345772b8738b_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_019c8aec-b8f4-7de7-950a-38885f20b4ad_terseLabel_en-US" xlink:label="lab_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would not impact effective tax rate</link:label>
    <link:label id="lab_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_label_en-US" xlink:label="lab_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</link:label>
    <link:label id="lab_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_documentation_en-US" xlink:label="lab_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:href="arqt-20251231.xsd#arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:to="lab_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8e964452-85c5-4e3f-b9da-1c30e0126ea1_netLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cb7afec3-2fac-431e-ae23-47c4bbdaf253_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds and cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7b038011-cdb7-4010-8cb2-79db38a55d88_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9186e6bf-24d5-4ce7-b810-1f283fec2463_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ac9fced4-39e3-4131-a73c-c3dec23576ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_991871cd-2aaf-42c1-be9a-1210149769ac_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_A2017EquityIncentivePlanMember_84f429a4-6e3f-4b7f-87ff-693714e2f099_terseLabel_en-US" xlink:label="lab_arqt_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_arqt_A2017EquityIncentivePlanMember_label_en-US" xlink:label="lab_arqt_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_arqt_A2017EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_arqt_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2017EquityIncentivePlanMember" xlink:href="arqt-20251231.xsd#arqt_A2017EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_A2017EquityIncentivePlanMember" xlink:to="lab_arqt_A2017EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f223f350-6edc-4a43-8d8d-273fd2987051_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_34c0a726-e49f-4cc8-9d77-017eca9087a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_1e1eaf6b-bca2-4a9f-83c8-f13a357adb0e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e048f895-1f81-4bdd-90dc-ffaeec0593ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeaseOfficeSpace_019bb752-cd60-75ac-bc28-8c98b245b5a4_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office space (in square feet)</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseOfficeSpace_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Office Space</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseOfficeSpace_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseOfficeSpace" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeaseOfficeSpace" xlink:to="lab_arqt_LesseeOperatingLeaseOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7774028e-d615-4813-b469-0ac4ab271f77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6c9e239b-ce29-4324-a6b6-2bf738336711_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior to December 22, 2022</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1ea1f0a0-b8a5-4340-b20b-3128793b0cf5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_44d7d164-6c58-46de-bfe6-5f507cd0e4b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentDefaultRate_4d50efe8-62eb-464d-9aa5-a2abe40b9095_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentDefaultRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Default rate (as a percent)</link:label>
    <link:label id="lab_arqt_DebtInstrumentDefaultRate_label_en-US" xlink:label="lab_arqt_DebtInstrumentDefaultRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Rate</link:label>
    <link:label id="lab_arqt_DebtInstrumentDefaultRate_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentDefaultRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentDefaultRate" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentDefaultRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentDefaultRate" xlink:to="lab_arqt_DebtInstrumentDefaultRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d8b25778-0c9d-4390-83a4-52d39ddb981e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_698bca19-ee5d-49e1-a38e-2203e6999cf8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_925d9a96-5491-4743-9adc-86069502e4f5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b9b92199-7a9e-4f5a-a967-3381a6928224_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a6934680-325d-4033-91a8-e415c7944cab_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_f750f837-c6f2-48d3-857b-a3fede8590b4_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8a8f6568-c7a1-43aa-8e60-9233c028aa4a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_HuadongMember_fd86edd5-a9a1-4577-b6d6-62a0d64f5cd7_terseLabel_en-US" xlink:label="lab_arqt_HuadongMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Huadong</link:label>
    <link:label id="lab_arqt_HuadongMember_label_en-US" xlink:label="lab_arqt_HuadongMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Huadong [Member]</link:label>
    <link:label id="lab_arqt_HuadongMember_documentation_en-US" xlink:label="lab_arqt_HuadongMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Huadong</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HuadongMember" xlink:href="arqt-20251231.xsd#arqt_HuadongMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_HuadongMember" xlink:to="lab_arqt_HuadongMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ZORYVECream0.15Member_dfa3419e-7f1c-4c7d-9c89-6de3761e0e2a_terseLabel_en-US" xlink:label="lab_arqt_ZORYVECream0.15Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZORYVE cream 0.15%</link:label>
    <link:label id="lab_arqt_ZORYVECream0.15Member_label_en-US" xlink:label="lab_arqt_ZORYVECream0.15Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZORYVE Cream 0.15% [Member]</link:label>
    <link:label id="lab_arqt_ZORYVECream0.15Member_documentation_en-US" xlink:label="lab_arqt_ZORYVECream0.15Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZORYVE Cream 0.15%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVECream0.15Member" xlink:href="arqt-20251231.xsd#arqt_ZORYVECream0.15Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ZORYVECream0.15Member" xlink:to="lab_arqt_ZORYVECream0.15Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_HengruiMember_212b5f25-0a4a-4498-8e92-f5c52d7ed789_terseLabel_en-US" xlink:label="lab_arqt_HengruiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hengrui</link:label>
    <link:label id="lab_arqt_HengruiMember_label_en-US" xlink:label="lab_arqt_HengruiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hengrui [Member]</link:label>
    <link:label id="lab_arqt_HengruiMember_documentation_en-US" xlink:label="lab_arqt_HengruiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hengrui</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HengruiMember" xlink:href="arqt-20251231.xsd#arqt_HengruiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_HengruiMember" xlink:to="lab_arqt_HengruiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_38caca9d-37e9-4d04-a346-0469135b57be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c1a08b47-f5a2-4355-a338-c9391dea0378_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_300acfca-1fb8-4e36-9a88-3c7093bb9213_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019bb771-0deb-73a1-b216-fbb2cde2b5ca_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowances</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4447f42b-c652-460a-bb3b-581d9aca0082_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_019c4e7d-afaf-7807-a54a-58873efb2c7f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b989373b-f242-444b-bc22-760683418ac5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_bce7fa32-8763-43e4-9713-f190cc03465d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs subject to future vesting</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9fe294c7-61f5-4ddd-abe7-c5569cee533e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_717cb5df-0107-481b-81d6-3b04467d1267_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment for intangible asset</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_301d57b0-63b6-4bee-bd1f-26b93cc1684c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_960936d8-1d9d-4e8b-8be2-6e9303fca2b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33847973-2143-4653-b70a-1164c39d95fe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_d96a1cb9-3441-4110-9a99-3b296b42b09f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_77f6c84f-e594-48ad-8384-6b925676b2fe_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts_11a083b3-a5e9-4972-8e62-5813563185af_terseLabel_en-US" xlink:label="lab_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of shares under ATM, net of issuance costs</link:label>
    <link:label id="lab_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts_label_en-US" xlink:label="lab_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Shares Under At-the-Market Offering, Net of Issuance Costs</link:label>
    <link:label id="lab_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Shares Under At-the-Market Offering, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" xlink:href="arqt-20251231.xsd#arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" xlink:to="lab_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_830955e9-ecb0-4079-9998-70d4422d2f46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_d0c0f26b-cb87-4709-972b-876636cfba31_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_19347f44-0930-438e-9af8-dc43a580f248_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax provision:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_af53a04f-f7ff-4c2e-b67a-2da7909819d3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3b1a0060-f06b-4f0e-a2b0-75b148f7ab9f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d1d7decf-57a5-47dd-ad9f-d376d393a4e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a8b642a4-c6c3-4063-8e21-3d6fd446867f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_51494e56-5720-4abd-a99a-668850ace4ba_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06deef97-3fc7-4d6f-91bc-db2cee040ea8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b01331c3-a5dd-4566-a788-7220173d5e2a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1137186f-148b-4e92-91b9-196132a11d53_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ZORYVECream0.3Member_ce69388d-82af-4a0b-9fe2-0ff71ce336c1_terseLabel_en-US" xlink:label="lab_arqt_ZORYVECream0.3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZORYVE cream 0.3%</link:label>
    <link:label id="lab_arqt_ZORYVECream0.3Member_label_en-US" xlink:label="lab_arqt_ZORYVECream0.3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZORYVE Cream 0.3% [Member]</link:label>
    <link:label id="lab_arqt_ZORYVECream0.3Member_documentation_en-US" xlink:label="lab_arqt_ZORYVECream0.3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZORYVE Cream 0.3%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVECream0.3Member" xlink:href="arqt-20251231.xsd#arqt_ZORYVECream0.3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ZORYVECream0.3Member" xlink:to="lab_arqt_ZORYVECream0.3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d282ddd2-b970-41be-b03b-d2a3c3be133a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ae97c125-353e-4c80-ab93-7060c11f2223_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c94b5f7e-48f8-4ad2-b788-f735c5b83d3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_49f56acf-9a72-4c03-9cbd-bbb4d1182677_terseLabel_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum shares to be issued</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_label_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_documentation_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:to="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_18f3e271-c856-4673-a727-07bb38e8d11f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ef6bb479-7b39-4383-84f2-991befb91511_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_5900d7c3-e449-4768-913a-dfea7778554c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_9b0ae227-06f5-487c-8326-6ecb2cfff802_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b8fdb22f-2ce3-4559-a343-0776d1ff5b83_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_32d50ca2-c991-43c4-b616-c4cd3ad8d95e_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b7c7d924-320e-4cd8-b4ca-a6dadf27b9a8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8d33f115-87a0-45a1-acd5-6cc56f1b2c5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_93cf4eef-6167-41d3-8965-cf464a0c528a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b3f05728-69b9-4eed-82ad-01e52a8f6ec8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c0af2d47-e2b2-47ee-97d5-5b0cf52a8228_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2a42215e-92d3-4d1b-9495-60f7ad7fbebc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_af047602-ede1-44fa-890c-d586f7465186_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7043-9c3b-7eba-b8dd-fd1e5bbcd4c9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_bc3dc549-3d20-4d3d-8f39-83fe6ee0ba04_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_3b4fbff6-8f5c-48d3-8bf3-3d6e12b2f887_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3c293c84-d099-4adb-9781-c56d92b86aae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions in Calculating Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_318717f5-918b-47df-877c-976cdce7ba24_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_7afaf67b-9082-4b3a-a720-e211dc2bee6b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4effaa0a-78c9-4854-9505-a905ad7e0afe_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds and cash</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_1df435e5-f038-4658-ab9b-91a41aa09702_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After December 22, 2023 and prior to December 22, 2025</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8b91b6c6-e86a-473c-8363-2129504e5565_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f6eed9c2-8d92-4c4a-abf9-92fb5c807fbe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_56e60b4d-39f7-417e-901a-4ef77f22c284_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_TrancheB1TermLoanMember_9f6fb016-9371-4fd7-87b4-c71c3677b4db_terseLabel_en-US" xlink:label="lab_arqt_TrancheB1TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche B-1 term loan</link:label>
    <link:label id="lab_arqt_TrancheB1TermLoanMember_label_en-US" xlink:label="lab_arqt_TrancheB1TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche B-1 Term Loan [Member]</link:label>
    <link:label id="lab_arqt_TrancheB1TermLoanMember_documentation_en-US" xlink:label="lab_arqt_TrancheB1TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche B-1 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheB1TermLoanMember" xlink:href="arqt-20251231.xsd#arqt_TrancheB1TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_TrancheB1TermLoanMember" xlink:to="lab_arqt_TrancheB1TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_9afecf61-2727-4bee-b4b0-ea3f73b9ada9_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_af05d908-8310-472c-afc8-2b9e0c555dd8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_28dae23e-4c3e-49aa-b6dc-417a960f30b5_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Product Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_65fcb38f-df63-433c-9145-c52667ea634b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments_019bb752-cd60-77a7-8af4-0f2f58b6d827_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future lease rent payment commitments</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Increase In Future Lease Rent Payment Commitments</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Increase In Future Lease Rent Payment Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments" xlink:to="lab_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_359432c6-2d33-419e-85e9-c01c199db9be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a106e36f-68cd-4d17-aa2d-6beaa5b92f73_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0cc9ca79-e9a1-4a0f-8c0c-658902330cda_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon the vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_8aa0c23c-528d-475a-8cf8-d8d733358aa7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_897499bc-2a03-4b3a-aa5f-c0d1540eeb2d_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8200eb33-46ed-4115-aead-45109f327e8d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_cf34459f-44c3-490d-892b-54fe8cecef73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c7c8a66b-f198-4f58-bfe9-676a9a320e4f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_OtherEarlyStageProgramsMember_33a8b1be-eec0-4eb1-b902-f7ba2355cd39_terseLabel_en-US" xlink:label="lab_arqt_OtherEarlyStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other early-stage programs costs</link:label>
    <link:label id="lab_arqt_OtherEarlyStageProgramsMember_label_en-US" xlink:label="lab_arqt_OtherEarlyStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Early-Stage Programs [Member]</link:label>
    <link:label id="lab_arqt_OtherEarlyStageProgramsMember_documentation_en-US" xlink:label="lab_arqt_OtherEarlyStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Early-Stage Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_OtherEarlyStageProgramsMember" xlink:href="arqt-20251231.xsd#arqt_OtherEarlyStageProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_OtherEarlyStageProgramsMember" xlink:to="lab_arqt_OtherEarlyStageProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_101a0429-4c67-4f49-966d-6fb3d8690f41_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e73bf162-9afd-4ab5-a55f-2d160d1a4186_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb775-24ea-7682-928f-ca863e023f28_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_bb61b654-0ffd-4ad4-85f1-4619eadf1ca9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Periodic principal payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_79013254-c3e6-4526-b3c0-5cb8acfc1984_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f95f1fb3-acc2-45b8-be1f-4a3e77ac0e91_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a85f0dc-681d-4538-a706-9b72e7a371af_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalUnitsAuthorized_019bff58-eb90-71d6-89b4-62139c4e98ae_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalUnitsAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital stock</link:label>
    <link:label id="lab_us-gaap_CapitalUnitsAuthorized_label_en-US" xlink:label="lab_us-gaap_CapitalUnitsAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Units, Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalUnitsAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitsAuthorized" xlink:to="lab_us-gaap_CapitalUnitsAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_18320321-fdb9-49f6-8569-b4673fad0624_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_906608ee-5135-4793-8b41-b082813acef0_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cea4d733-2ac1-42b9-b736-0b3419b2a80a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_a0ee76d6-ba04-4acb-a9e7-6ac2f39ac5c5_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_b7a0a5c5-1c79-448d-b12a-d71588c79e06_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_A2020EquityIncentivePlanMember_982a7cbc-957d-44bc-b6d8-c00f40e7e6b7_terseLabel_en-US" xlink:label="lab_arqt_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:label id="lab_arqt_A2020EquityIncentivePlanMember_label_en-US" xlink:label="lab_arqt_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_arqt_A2020EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_arqt_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2020EquityIncentivePlanMember" xlink:href="arqt-20251231.xsd#arqt_A2020EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_A2020EquityIncentivePlanMember" xlink:to="lab_arqt_A2020EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_PrepaidCopayAssistanceProgramAndRebates_de629a67-4545-4cad-b337-8b7d3e826f19_terseLabel_en-US" xlink:label="lab_arqt_PrepaidCopayAssistanceProgramAndRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid co-pay assistance program and rebates</link:label>
    <link:label id="lab_arqt_PrepaidCopayAssistanceProgramAndRebates_label_en-US" xlink:label="lab_arqt_PrepaidCopayAssistanceProgramAndRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Copay Assistance Program And Rebates</link:label>
    <link:label id="lab_arqt_PrepaidCopayAssistanceProgramAndRebates_documentation_en-US" xlink:label="lab_arqt_PrepaidCopayAssistanceProgramAndRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Copay Assistance Program And Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrepaidCopayAssistanceProgramAndRebates" xlink:href="arqt-20251231.xsd#arqt_PrepaidCopayAssistanceProgramAndRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_PrepaidCopayAssistanceProgramAndRebates" xlink:to="lab_arqt_PrepaidCopayAssistanceProgramAndRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d48cb10d-7963-4b5b-b702-1f394673070e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9c92921e-bf12-44ae-a4cf-1c76639fe096_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First anniversary date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d58578cb-c5cc-4325-87d1-12c78c3e44c2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_cf9abb31-7f30-439c-a42c-75fe6eeb6523_terseLabel_en-US" xlink:label="lab_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of years after first commercial sale to receive royalties</link:label>
    <link:label id="lab_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_label_en-US" xlink:label="lab_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Number Of Years After First Commercial Sale To Receive Royalties</link:label>
    <link:label id="lab_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_documentation_en-US" xlink:label="lab_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Number Of Years After First Commercial Sale To Receive Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" xlink:to="lab_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_98ca98b7-eaf4-400a-ae8c-90cd9b5a690b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Change in the Fair Value of Embedded Derivative Instrument</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_32544e20-e15d-454f-87a9-c1497bb12a5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_b58ebceb-718c-40ac-b04c-3171feac99ed_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses_3b27b3ff-d1a3-4583-812f-02da15499154_terseLabel_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development compensation and personnel-related expenses</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses_label_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Compensation And Personnel-Related Expenses</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses_documentation_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Compensation And Personnel-Related Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" xlink:to="lab_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d9de464f-823f-4c4e-8874-61939197d3d6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_ab15e041-5829-4d47-bbf3-62c9c6302919_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019bb76a-8de9-76b6-be61-2700148fa295_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax U.S. federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_dbb12389-50ec-4d51-b863-3f162f346aeb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a826c0ce-36f8-47c4-825d-710a32b70633_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_8f925976-2531-4ce5-8211-adfb0aceac29_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f3f61f11-3953-4482-86ef-9310c8fcdd67_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_33a60dd4-ba4c-4f7b-957c-4af6fb1e18a7_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_f4645172-6e34-4a04-88d8-d6b3d1c61145_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice_262e5591-21f9-40c2-b229-b9e1e46d64ae_terseLabel_en-US" xlink:label="lab_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of days for written notice</link:label>
    <link:label id="lab_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice_label_en-US" xlink:label="lab_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Termination, Number Of Days For Written Notice</link:label>
    <link:label id="lab_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice_documentation_en-US" xlink:label="lab_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Termination, Number Of Days For Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice" xlink:to="lab_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c89b0669-e521-4716-a1fb-720bfb98c112_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_1cb8b7f1-b2b3-44cc-94e8-aa692097d7d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5044cd1d-f8d7-40a3-9172-15c5bb4884d2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_29436909-93fa-46da-9fde-bdfe2de47bba_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4abdc75d-c5d9-450c-b574-7059a6b60b59_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_a552c284-a3fc-480c-bc9d-c10847d3cecc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5d4f99ee-a245-4beb-b82a-f6193a75da83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6035c81c-24c8-4f11-a8eb-e3f809f2f05d_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_88bcf0d9-e4bf-44a2-843f-e75b36f666f3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_aa569537-80ee-4d66-b757-c20d2283aaef_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_36606232-b2da-48aa-a5f9-cf79cf6312c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1febff70-3235-4edb-aa47-8b5d3c947a94_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentAccruedPrepaymentPenalty_e21f98fe-d3d3-41e9-a25b-1e749503e7c6_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentAccruedPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued prepayment penalty</link:label>
    <link:label id="lab_arqt_DebtInstrumentAccruedPrepaymentPenalty_label_en-US" xlink:label="lab_arqt_DebtInstrumentAccruedPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Accrued Prepayment Penalty</link:label>
    <link:label id="lab_arqt_DebtInstrumentAccruedPrepaymentPenalty_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentAccruedPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Accrued Prepayment Penalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentAccruedPrepaymentPenalty" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentAccruedPrepaymentPenalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentAccruedPrepaymentPenalty" xlink:to="lab_arqt_DebtInstrumentAccruedPrepaymentPenalty" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CustomerFMember_2beeefc8-49d1-4487-8178-220a85d873a9_terseLabel_en-US" xlink:label="lab_arqt_CustomerFMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer F</link:label>
    <link:label id="lab_arqt_CustomerFMember_label_en-US" xlink:label="lab_arqt_CustomerFMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer F [Member]</link:label>
    <link:label id="lab_arqt_CustomerFMember_documentation_en-US" xlink:label="lab_arqt_CustomerFMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer F</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerFMember" xlink:href="arqt-20251231.xsd#arqt_CustomerFMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CustomerFMember" xlink:to="lab_arqt_CustomerFMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_83cfde8b-77ea-407a-ac8d-7946647ced79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value ($ in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f7409ec9-b8d5-401e-abac-1cd906a0fa4a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_6de97617-bc86-4654-89b6-20d6d72eca7a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_64bcf6b8-77a2-4d74-ac4d-bf80fdcec994_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued pursuant to the ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_222d9962-bf8e-4ff8-87d6-584a50a65512_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_019c4e67-0198-7015-b6bb-c52526d71374_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_0b44bb26-a1f9-4322-96d5-c9e5e94c6228_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1a5e9dc-da07-4aca-a15a-16025c4f084d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76b934f2-c0d3-41a5-adab-ae558a3d0139_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_dc98afe1-fd2d-430e-b9f5-95504eb1731a_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of the embedded derivative instrument</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_503c43b2-e663-4860-8937-c17903e6f11a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_43fe787c-8cbf-49b4-9d0e-0c870df2617b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_688cc822-a7a6-43df-a461-f5c3c87bc56c_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_d17ffe7e-b786-42fc-8877-ff744d93a62e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-cash items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_e9fb9be9-9d6b-485f-a25e-ab8c94989f9b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_85ff97f9-e53a-4659-aa9b-fcc883bc60f8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax provision:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_37bb6737-c4cf-4708-8c8b-78bdd1d76f3e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1b33782b-4475-4618-950e-1060845eb1bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_875228d8-f2ba-4cd4-a484-c314bdc8a867_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_019bff6f-cb38-7be2-a1b9-f114e640267f_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c2770-49d0-7d4f-a0cb-3b7d6e0d78d7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one to five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019bb76b-ef8b-787d-9648-db33adb66cb5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax effects</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_24de3715-c9a5-4a13-904d-f933f74ebba3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_fd7c06c9-178f-4dc6-a965-aa881f35aed4_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ESPP shares subject to future issuance</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_47805723-b826-4182-b236-01f753961976_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_886fc4b0-2db6-4f24-b4ca-8341326de23e_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AstraZenecaMember_e696646d-44f0-4a53-b926-8036addb7f31_terseLabel_en-US" xlink:label="lab_arqt_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_arqt_AstraZenecaMember_label_en-US" xlink:label="lab_arqt_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_arqt_AstraZenecaMember_documentation_en-US" xlink:label="lab_arqt_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AstraZenecaMember" xlink:href="arqt-20251231.xsd#arqt_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AstraZenecaMember" xlink:to="lab_arqt_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4da43693-60e0-4d64-87aa-7bd7d4e3bf46_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_25bc1d28-eac3-416e-ae7b-8c495cbcda22_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CowenAndCompanyLLCMember_6b9bbb5b-2be1-4fed-9cb0-d1b9a0ac6b1c_terseLabel_en-US" xlink:label="lab_arqt_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cowen</link:label>
    <link:label id="lab_arqt_CowenAndCompanyLLCMember_label_en-US" xlink:label="lab_arqt_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cowen And Company LLC [Member]</link:label>
    <link:label id="lab_arqt_CowenAndCompanyLLCMember_documentation_en-US" xlink:label="lab_arqt_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cowen And Company LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CowenAndCompanyLLCMember" xlink:href="arqt-20251231.xsd#arqt_CowenAndCompanyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CowenAndCompanyLLCMember" xlink:to="lab_arqt_CowenAndCompanyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentExitFeeExpirationPeriod_ffc31fa2-2eeb-4d3e-ac9e-8825634ae65c_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentExitFeeExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit fee expiration period (in years)</link:label>
    <link:label id="lab_arqt_DebtInstrumentExitFeeExpirationPeriod_label_en-US" xlink:label="lab_arqt_DebtInstrumentExitFeeExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee, Expiration Period</link:label>
    <link:label id="lab_arqt_DebtInstrumentExitFeeExpirationPeriod_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentExitFeeExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentExitFeeExpirationPeriod" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentExitFeeExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentExitFeeExpirationPeriod" xlink:to="lab_arqt_DebtInstrumentExitFeeExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_b15b20a2-e4bc-4d32-9cf0-324485d39aa1_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_fae946e4-b898-49cf-b372-d2e40ccbfc0b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_TrancheB2TermLoanMember_0e333ca5-55d4-460f-a39f-31a4f7fa4864_terseLabel_en-US" xlink:label="lab_arqt_TrancheB2TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche B-2 term loan</link:label>
    <link:label id="lab_arqt_TrancheB2TermLoanMember_label_en-US" xlink:label="lab_arqt_TrancheB2TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche B-2 Term Loan [Member]</link:label>
    <link:label id="lab_arqt_TrancheB2TermLoanMember_documentation_en-US" xlink:label="lab_arqt_TrancheB2TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche B-2 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheB2TermLoanMember" xlink:href="arqt-20251231.xsd#arqt_TrancheB2TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_TrancheB2TermLoanMember" xlink:to="lab_arqt_TrancheB2TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_cd7b167c-eeb1-4e7b-b3c9-f88262b69e76_terseLabel_en-US" xlink:label="lab_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs</link:label>
    <link:label id="lab_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_label_en-US" xlink:label="lab_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Pre-Funded Warrants, Net Of Issuance Costs</link:label>
    <link:label id="lab_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Pre-Funded Warrants, Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:href="arqt-20251231.xsd#arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:to="lab_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019bb775-de19-7888-ac52-e7ba1b266030_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_TopicalRoflumilastProgramMember_d2cca623-bdfc-405b-822e-b9dd2db0fbc2_terseLabel_en-US" xlink:label="lab_arqt_TopicalRoflumilastProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Topical roflumilast program costs</link:label>
    <link:label id="lab_arqt_TopicalRoflumilastProgramMember_label_en-US" xlink:label="lab_arqt_TopicalRoflumilastProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Topical Roflumilast Program [Member]</link:label>
    <link:label id="lab_arqt_TopicalRoflumilastProgramMember_documentation_en-US" xlink:label="lab_arqt_TopicalRoflumilastProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Topical Roflumilast Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TopicalRoflumilastProgramMember" xlink:href="arqt-20251231.xsd#arqt_TopicalRoflumilastProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_TopicalRoflumilastProgramMember" xlink:to="lab_arqt_TopicalRoflumilastProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f64bafbd-6dc0-4b0f-aeaa-3565932c0a21_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_55b75b13-a2be-46e3-9075-08c439c583cb_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3209cb3b-9a29-43cb-ae65-695cb66d87f1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f4397d4a-7efb-477d-b04e-ce38a46a1c71_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ZORYVECream0.05Member_019bfec9-2cf1-7566-a159-d86023ba4aba_terseLabel_en-US" xlink:label="lab_arqt_ZORYVECream0.05Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZORYVE cream 0.05%</link:label>
    <link:label id="lab_arqt_ZORYVECream0.05Member_label_en-US" xlink:label="lab_arqt_ZORYVECream0.05Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZORYVE cream 0.05% [Member]</link:label>
    <link:label id="lab_arqt_ZORYVECream0.05Member_documentation_en-US" xlink:label="lab_arqt_ZORYVECream0.05Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZORYVE cream 0.05%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVECream0.05Member" xlink:href="arqt-20251231.xsd#arqt_ZORYVECream0.05Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ZORYVECream0.05Member" xlink:to="lab_arqt_ZORYVECream0.05Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_ad3aa5f7-6936-4592-85ee-0a2a87187e81_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a7c20ff2-a786-4507-a798-0f006c443457_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_69c8374d-3dd8-489a-b5a8-dc2f32a5658d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentPrepaymentPenalty_196efa90-a448-45f4-9a4a-7cd54aa3a684_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, prepayment penalty</link:label>
    <link:label id="lab_arqt_DebtInstrumentPrepaymentPenalty_label_en-US" xlink:label="lab_arqt_DebtInstrumentPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty</link:label>
    <link:label id="lab_arqt_DebtInstrumentPrepaymentPenalty_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentPrepaymentPenalty" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentPrepaymentPenalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentPrepaymentPenalty" xlink:to="lab_arqt_DebtInstrumentPrepaymentPenalty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_019c274e-e894-7b22-9e17-c8d26377d07e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_a0a87789-c5bb-4199-87a0-8d0b3133c619_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0ed46c5a-3b94-43ed-b291-bab5c7c37177_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_90ff180a-3ec4-40bf-993f-eed5a60e4c69_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f13d45a4-7c39-4085-b665-4b4dc03b182a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in computing net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_69242bda-a06f-4534-a048-b5e9ca90ba46_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total grant-date fair value of the options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_19c1feeb-fb64-4864-926a-96569934d3a8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses and current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8b8942ec-75ec-4d3c-9646-931b361cded9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_118b1c89-bd8e-4ddc-955b-463235c302c3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_290b2b19-3f91-4d36-b83b-f088641893c1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_21c94ccf-3b39-4a4e-954f-bb21ba13277f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fea871c3-95de-418a-85e2-0b01110ac6a1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_36222b89-9efc-4bb0-83d0-961b0d8b651e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred, equity interest issued and issuable</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_627eb9e5-10dc-425a-b855-e8fe71a3e5b0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8adb90e6-c6fe-4618-b32c-8cf7f5688ca8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c2770-49d0-7de0-81cf-95a6303c6355_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one to five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_f19c7db8-de51-42d4-a6da-3941f9a31ff1_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Major Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CustomerDMember_f011d652-99e3-4770-85c1-26e011eee693_terseLabel_en-US" xlink:label="lab_arqt_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer D</link:label>
    <link:label id="lab_arqt_CustomerDMember_label_en-US" xlink:label="lab_arqt_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_arqt_CustomerDMember_documentation_en-US" xlink:label="lab_arqt_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerDMember" xlink:href="arqt-20251231.xsd#arqt_CustomerDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CustomerDMember" xlink:to="lab_arqt_CustomerDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_137f5bee-3cd2-41e8-8b28-223f9ad296c5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_42813349-0d08-43eb-8236-3889181fa754_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb79c878-1e55-45a9-9e2d-d5a926511f27_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_36c29703-8a04-4594-aa47-c07d6d437c25_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_019bff6f-cb38-7038-8a43-edce3b071ba3_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8c553498-a023-40b5-b38f-2d21f6cedf28_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_597202aa-5218-4d3a-b625-6c5a67770340_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining contractual term, exercisable (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019bb752-cd60-79dc-9cc5-003bc670f8b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_f765adec-ccde-429d-b0ed-eac028afb111_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_37fc83c1-ff3d-4e2b-b601-251e66fdf4bf_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f6dbc46f-d626-4419-9f50-605cdd4da48c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a6cb9204-ad49-4372-97ad-39e5b3009f01_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3aabcee8-0cce-44b8-88f1-fe288730741c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3308c16b-e2ee-4560-a4fa-52d85ede4ea9_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_832d42b6-87af-4ceb-aee2-66e4883d9570_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_06c4e577-d4bb-40b9-9c04-3a06057cbfe0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3fbf0fb6-3a54-4875-a186-a1fd0b0dcd10_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockIssuedDuringPeriodSharesWarrantsExercised_019bfec1-260b-7ea0-b1c7-74b692cf498b_terseLabel_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of pre-funded warrants (in shares)</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="arqt-20251231.xsd#arqt_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_arqt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7c895c46-df77-4b3f-9003-3de5d96827d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised during the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CustomerAMember_04c85cd2-3a21-46fe-97e8-685ce627aaec_terseLabel_en-US" xlink:label="lab_arqt_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_arqt_CustomerAMember_label_en-US" xlink:label="lab_arqt_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_arqt_CustomerAMember_documentation_en-US" xlink:label="lab_arqt_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerAMember" xlink:href="arqt-20251231.xsd#arqt_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CustomerAMember" xlink:to="lab_arqt_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_SecondGrantDateMember_f750521c-cd3a-466d-87b7-c65b9f5c4110_terseLabel_en-US" xlink:label="lab_arqt_SecondGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Grant Date</link:label>
    <link:label id="lab_arqt_SecondGrantDateMember_label_en-US" xlink:label="lab_arqt_SecondGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Grant Date [Member]</link:label>
    <link:label id="lab_arqt_SecondGrantDateMember_documentation_en-US" xlink:label="lab_arqt_SecondGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SecondGrantDateMember" xlink:href="arqt-20251231.xsd#arqt_SecondGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_SecondGrantDateMember" xlink:to="lab_arqt_SecondGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_22183a44-1f96-4dbd-bc3a-e29d6093a613_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_60da8ac8-02a6-4a98-89b3-2d4582c34930_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5da8c0eb-e57c-480a-b4d4-663dc3b2b01f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_686aa87c-e3dd-41c1-84ed-14fa065b890b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8ec5d543-9786-49f6-a0ab-c0dde8af8c09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5cac9e2a-4893-4046-b708-152f8ce0571b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_18a98fc7-11c4-46a8-bada-9b0817c18b2a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_929764c8-c8dd-4714-9591-4d6eca1c95f3_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37fea04b-fbc7-4434-8cf7-dc221fa43d64_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_ab235d4b-51ad-4316-a114-dbbce35e8316_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_37fa3118-d4ad-4dc4-aaf7-b9d6ea14a8c8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5da7951e-4bee-4173-bd7e-810e0186892f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fdf5139b-05d1-4597-91d7-0957e2758308_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_35cc2237-1a04-4bdb-b9de-47f6ae57064c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CustomerCMember_bc5c17a0-84f2-41ec-a91c-e030380232ca_terseLabel_en-US" xlink:label="lab_arqt_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_arqt_CustomerCMember_label_en-US" xlink:label="lab_arqt_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_arqt_CustomerCMember_documentation_en-US" xlink:label="lab_arqt_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerCMember" xlink:href="arqt-20251231.xsd#arqt_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CustomerCMember" xlink:to="lab_arqt_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_cfc17329-adb2-492d-ae99-6ac3e919255b_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_272c932a-cd43-447a-b6ba-5a338a1ecf80_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4fbf4924-0dff-4684-b06a-efc151626208_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_582b7c10-4e1e-4af3-b0df-314cbbfedfb3_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_019c7046-ac27-7c6c-8bfc-ff309f732041_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_7e229ce1-4df8-4e50-b5cb-b027035124d1_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) from changes in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bbe9f469-b01e-45dc-a77d-dc51baa879ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_45f71f4a-4909-4570-857d-776ed5329a94_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_367a83fb-b22f-4570-9007-521a97e31892_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019bb776-3af2-7095-9306-13278993e12a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_019bff72-1117-75e5-bea0-b26e3eb545e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3c75f64a-2332-4dcc-bce7-eb5eace45ceb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_761b5495-51e2-4640-99f2-e5af1cac47b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8690b0ee-c16c-471b-9333-59bda5032f18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_13788feb-e679-42c5-bcbd-97aaed4c2136_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1c7b98fe-2b42-47e8-b18a-59cd9d719075_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0b6ad019-9ae7-424a-b2ff-6cd1bf1be53e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d8d73c8-240f-4f09-b166-429959be24c2_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_37dfc79b-bb44-403e-afe9-83a27511aade_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_65381298-f59e-408d-a63d-15d015c676ce_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList_6b3c3f31-fa48-453d-8a78-0252e193698a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1b2eeb7b-05df-45df-9cfd-ed45f1fc36b0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5cf417d0-1130-4038-8098-2a06ebf76ccb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_d1e1fe5e-616b-4445-bfac-848ba5048c8c_terseLabel_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product milestone payment for first product approval</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_label_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payment For First Product Approval</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_documentation_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payment For First Product Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval" xlink:to="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a502d0a7-9f80-4049-b636-fe8f0ce24c9c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a10499b8-8971-4faa-b7b0-c393119032a2_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5642bcfe-2855-4a74-a135-6e5d4d8529de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_71d07c01-3b19-4834-83ef-1bc5509a1d9a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2e304d30-33a7-473b-b88a-018de90d5448_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock for ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8190cd04-5ad2-4c0f-ae9f-3f209ab562c0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c2771-d59f-7ac6-892c-af8b2aed1c80_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a23e1e54-dc32-4967-a376-ab2bf7cdb197_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax U.S. federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_07abf53e-4233-4402-b959-e6f3ec4a34a2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_5a92183f-7099-4bbf-84cd-2c1bf28bc435_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb775-7d7a-7bb7-b475-4e31c247ce9f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019bb76a-e07c-7e02-bb63-a6c0666c0831_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal (national) income tax effect</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold_ecc735c1-f035-4962-97ca-c589110c1d04_terseLabel_en-US" xlink:label="lab_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual net sales</link:label>
    <link:label id="lab_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold_label_en-US" xlink:label="lab_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Annual Net Sales of Acquiree Threshold</link:label>
    <link:label id="lab_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold_documentation_en-US" xlink:label="lab_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Annual Net Sales of Acquiree Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold" xlink:to="lab_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_197b5f94-6c11-4937-84ea-096cb13720ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ffff2443-26e5-42b6-b0bf-088149e94689_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6c68db44-6dcb-4a59-af57-2945fcfa3236_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones_443a98cc-1ce3-464a-a994-c0f1f9d635de_terseLabel_en-US" xlink:label="lab_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration to be transferred</link:label>
    <link:label id="lab_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones_label_en-US" xlink:label="lab_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration To Be Transferred Upon The Achievement Of Regulatory Milestones</link:label>
    <link:label id="lab_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones_documentation_en-US" xlink:label="lab_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration To Be Transferred Upon The Achievement Of Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones" xlink:to="lab_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_517599b9-e869-45f1-8296-45d41b474a19_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6915c25a-0e94-4058-a03b-d162ee6e7d33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_800be5c8-9ee5-4db0-b6b6-15b20d2f27bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2f44219e-970b-49b0-947f-040d4b550f4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6dd6930e-1c31-4a40-858c-12416e94aa58_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2afbae0f-eb95-42f3-be26-d8b022c9ed10_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d4de743d-93bc-4724-8d71-5701c05e4686_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cb09eb9a-4573-4e67-9d73-2633627393e5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially antidilutive shares excluded from the calculation of net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_75e9bb67-3603-4bca-8b53-110b77f3b9cb_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e14c8aa-f9a6-4243-8520-314b06892c02_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1de7346e-e079-4f44-90f3-e569a0b80c9a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_28ba2424-3788-436c-b3d0-bcc3235b5b58_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_657b95b0-fe6b-481c-9ac3-cdb4bcfcb815_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentTrancheDomain_2cf2000b-61a9-4fc7-b7e5-a4a481d084ab_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche [Domain]</link:label>
    <link:label id="lab_arqt_DebtInstrumentTrancheDomain_label_en-US" xlink:label="lab_arqt_DebtInstrumentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche [Domain]</link:label>
    <link:label id="lab_arqt_DebtInstrumentTrancheDomain_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentTrancheDomain" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentTrancheDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentTrancheDomain" xlink:to="lab_arqt_DebtInstrumentTrancheDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_175f52c7-e291-4655-8ec0-c6edbd04a12e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_SueJeanLinTradingArrangementCommonStockMember_label_en-US" xlink:label="lab_arqt_SueJeanLinTradingArrangementCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sue-Jean Lin Trading Arrangement, Common Stock [Member]</link:label>
    <link:label id="lab_arqt_SueJeanLinTradingArrangementCommonStockMember_documentation_en-US" xlink:label="lab_arqt_SueJeanLinTradingArrangementCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sue-Jean Lin Trading Arrangement, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SueJeanLinTradingArrangementCommonStockMember" xlink:href="arqt-20251231.xsd#arqt_SueJeanLinTradingArrangementCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_SueJeanLinTradingArrangementCommonStockMember" xlink:to="lab_arqt_SueJeanLinTradingArrangementCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_cd6c41af-5668-42d0-9154-c3b98b3105cc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019bb785-58cd-769e-9f75-09f816c5036a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_1ed1a869-4bd2-43da-a146-a54a8d635e92_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_09f1b114-ce8f-437d-a45d-b72ff1f1b673_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4cea4ee4-af0e-470d-9405-ce9468ea4825_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ThirdGrantDateMember_008da7e6-d94b-4832-9088-50289c44cee0_terseLabel_en-US" xlink:label="lab_arqt_ThirdGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third Grant Date</link:label>
    <link:label id="lab_arqt_ThirdGrantDateMember_label_en-US" xlink:label="lab_arqt_ThirdGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Grant Date [Member]</link:label>
    <link:label id="lab_arqt_ThirdGrantDateMember_documentation_en-US" xlink:label="lab_arqt_ThirdGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ThirdGrantDateMember" xlink:href="arqt-20251231.xsd#arqt_ThirdGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ThirdGrantDateMember" xlink:to="lab_arqt_ThirdGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentExtensionFeePercentage_86a231af-ac02-408c-b129-6d2b0dc290bb_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentExtensionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension fee</link:label>
    <link:label id="lab_arqt_DebtInstrumentExtensionFeePercentage_label_en-US" xlink:label="lab_arqt_DebtInstrumentExtensionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Extension Fee, Percentage</link:label>
    <link:label id="lab_arqt_DebtInstrumentExtensionFeePercentage_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentExtensionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Extension Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentExtensionFeePercentage" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentExtensionFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentExtensionFeePercentage" xlink:to="lab_arqt_DebtInstrumentExtensionFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentInterestRateAtPeriodEnd_337c5f14-3354-440a-b0f8-ece7fa315a18_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate at end of period</link:label>
    <link:label id="lab_arqt_DebtInstrumentInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_arqt_DebtInstrumentInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate At Period End</link:label>
    <link:label id="lab_arqt_DebtInstrumentInterestRateAtPeriodEnd_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate At Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentInterestRateAtPeriodEnd" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentInterestRateAtPeriodEnd" xlink:to="lab_arqt_DebtInstrumentInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9efa0de6-c5e6-47c1-932b-2305f1a8b314_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_11fa811b-12c1-49a5-8f34-da10f91daa76_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity, due 2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_71273669-f64a-4fab-a559-f73f05cfcfdc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_477c005e-94cc-4d16-86b4-ef681fc000f5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_610d2a6b-9316-4c92-8c64-21a572b12d82_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b1793c09-bfbc-4f52-80cd-a59452c2df34_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod_ecbb12e3-ec0d-4716-9ddd-14d2bc1e2d32_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Covenant period</link:label>
    <link:label id="lab_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod_label_en-US" xlink:label="lab_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Funding Availability, Covenant, Period</link:label>
    <link:label id="lab_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Funding Availability, Covenant, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentFundingAvailabilityCovenantPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod" xlink:to="lab_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_595bd946-5480-430e-af00-bcd4ab123d8c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_41cca095-7ba5-484f-8322-04ca0d42892a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fe9d5cb2-742a-4532-a271-8808f944a2f4_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_508f0ef8-566e-4aaa-a5c5-ffe06386c5b1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_168fac37-77c5-4a90-a461-7306069e9743_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_ac8acb78-3c0a-4098-9597-b15b58574fb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8dd95eab-2ffd-4d33-a7c0-85259424d912_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f6700e39-38fe-4cfc-9fe4-a378b25149e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock_019c650b-d251-7065-9ed3-e5ef3a187557_terseLabel_en-US" xlink:label="lab_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and Prepaid Research and Development Expenses</link:label>
    <link:label id="lab_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued and Prepaid Research and Development Expenses, Policy [Policy Text Block]</link:label>
    <link:label id="lab_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued and Prepaid Research and Development Expenses, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:href="arqt-20251231.xsd#arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:to="lab_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_63224d54-40b8-4eeb-a67a-ed17663d5bcc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c688109-ebc8-444f-927c-5e2fde04889d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_d71a2f0a-c3b5-4a14-85a5-95ef960eed4e_terseLabel_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum milestone payments for licensed products</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_label_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payments</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_documentation_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments" xlink:to="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ace822a7-0dc6-4f4e-a269-182665b93b05_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_019bfeef-6fe9-72a8-b9d0-5632d8b93484_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_019c4e88-37d8-7e41-8ff3-6d265b01c036_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AssetAcquisitionConsiderationTransferredGross_a37abbe8-fac8-40b5-ac0c-811e5c83ce26_terseLabel_en-US" xlink:label="lab_arqt_AssetAcquisitionConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_arqt_AssetAcquisitionConsiderationTransferredGross_label_en-US" xlink:label="lab_arqt_AssetAcquisitionConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Gross</link:label>
    <link:label id="lab_arqt_AssetAcquisitionConsiderationTransferredGross_documentation_en-US" xlink:label="lab_arqt_AssetAcquisitionConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionConsiderationTransferredGross" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionConsiderationTransferredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AssetAcquisitionConsiderationTransferredGross" xlink:to="lab_arqt_AssetAcquisitionConsiderationTransferredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_9d88ff6b-7dcb-4c6e-ab11-5cf251122cb3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases related to tax positions taken during a prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_6ddaafa1-10ca-4817-93b0-585181409fa5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount_46540fc8-9ae9-4e77-91ad-6d5b48daacd7_terseLabel_en-US" xlink:label="lab_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future payable milestone payment</link:label>
    <link:label id="lab_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount_label_en-US" xlink:label="lab_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Payments, Milestones, Or Royalties, Future Payable Amount</link:label>
    <link:label id="lab_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount_documentation_en-US" xlink:label="lab_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Payments, Milestones, Or Royalties, Future Payable Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount" xlink:to="lab_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_89eeee7c-6087-4f95-8b92-d97e2314217e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member_6e15a9f7-89fb-4d7f-8672-574402932e7b_terseLabel_en-US" xlink:label="lab_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Agreement, Tranche C-1, Expiring March 31, 2026</link:label>
    <link:label id="lab_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member_label_en-US" xlink:label="lab_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement, Tranche C-1, Expiring March 31, 2026 [Member]</link:label>
    <link:label id="lab_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member_documentation_en-US" xlink:label="lab_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Agreement, Tranche C-1, Expiring March 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementTrancheC1ExpiringMarch312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member" xlink:to="lab_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_341ad0e0-b5bc-4606-be72-3b3ed1116c99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_d196d5c8-7d66-48eb-b6a7-fb94623c44c1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_22a02bca-59a9-4120-a84e-ab1ecf82d0bb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_e6bad72b-bc8b-40cb-8722-02e6545c7f6e_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_718ebc2a-46c0-41dc-93e5-a98b656e1b95_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AuditInformationAbstract_label_en-US" xlink:label="lab_arqt_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_arqt_AuditInformationAbstract_documentation_en-US" xlink:label="lab_arqt_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AuditInformationAbstract" xlink:href="arqt-20251231.xsd#arqt_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AuditInformationAbstract" xlink:to="lab_arqt_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_7d1c2460-1be9-4c8b-b2e6-ad59c619d181_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f47ac304-35f7-4931-b3dc-96e48463a095_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_34f71bb7-724f-435b-bfd9-bca393b9a9bc_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7a0cda3e-02d1-40f2-b6a7-70c688c3cf7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_7ce319cb-9380-4128-b7aa-5cdcbd15c472_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentFinalFeePercentage_2f4e6564-38a4-4487-8c90-d93461be66b0_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentFinalFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final fee (as a percent)</link:label>
    <link:label id="lab_arqt_DebtInstrumentFinalFeePercentage_label_en-US" xlink:label="lab_arqt_DebtInstrumentFinalFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Final Fee, Percentage</link:label>
    <link:label id="lab_arqt_DebtInstrumentFinalFeePercentage_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentFinalFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Final Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentFinalFeePercentage" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentFinalFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentFinalFeePercentage" xlink:to="lab_arqt_DebtInstrumentFinalFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_539c9911-4b11-44e5-9ce9-f35578d8f03a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0868c345-1775-4122-ac06-9f7122811006_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_6043c005-c12d-4ed4-99a8-9ab2b9bc35f3_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_00e92c8f-c18b-4351-8f50-4927ea4ae57f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9c3f89d1-21e9-40ca-ab43-e6c0cfa4da68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_34d32655-ba2f-4c7d-bf9c-4b1d7780a67b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_535a3df0-8816-4a48-9349-803a9a5231f0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f8cee78a-99af-4d35-bd9a-92f59149f0e7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d1b11b28-fc68-4988-a59b-6feaba21bbc2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_230a407a-16ff-4a63-8e64-534cd4c56100_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8655b0b1-a994-41e2-ad4e-fe57d0e47695_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_c8503320-ca4d-4eed-8c6f-07b38c6ba0a4_terseLabel_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in shares available for grant, percentage of shares outstanding (as a percent)</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_label_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_documentation_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:to="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_FiveCustomersMember_1a714990-8f12-490e-93ea-cd3fa383d8f2_terseLabel_en-US" xlink:label="lab_arqt_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Five Customers</link:label>
    <link:label id="lab_arqt_FiveCustomersMember_label_en-US" xlink:label="lab_arqt_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five Customers [Member]</link:label>
    <link:label id="lab_arqt_FiveCustomersMember_documentation_en-US" xlink:label="lab_arqt_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Five Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FiveCustomersMember" xlink:href="arqt-20251231.xsd#arqt_FiveCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_FiveCustomersMember" xlink:to="lab_arqt_FiveCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_80b5d8d2-5316-4eb7-9f18-d0631843d541_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_849a64f4-8ed5-4306-b3ce-591d0d60ccdf_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c277f-9cd9-701c-ae72-c05d05342ff7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5581e0d7-7d4d-471f-b6b6-dfce77798b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_dfce9aac-a07b-40c3-b2a3-a1c812abd4b8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_bcc80778-6858-4d5e-8e55-ecd66a9d6e3d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_337cb605-81e0-47b4-bdd1-5141eaca82de_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_SaleOfStockAuthorizedConsiderationOnTransaction_d2d33446-2ee4-40c3-ac71-dc0eebe6eab1_terseLabel_en-US" xlink:label="lab_arqt_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares of common stock for sales agreement</link:label>
    <link:label id="lab_arqt_SaleOfStockAuthorizedConsiderationOnTransaction_label_en-US" xlink:label="lab_arqt_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Authorized Consideration On Transaction</link:label>
    <link:label id="lab_arqt_SaleOfStockAuthorizedConsiderationOnTransaction_documentation_en-US" xlink:label="lab_arqt_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Authorized Consideration On Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:href="arqt-20251231.xsd#arqt_SaleOfStockAuthorizedConsiderationOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:to="lab_arqt_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_7842aa57-0b67-48b2-a78b-be316b05f4e3_terseLabel_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual net sales</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_label_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Annual Worldwide Net Sales Threshold</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_documentation_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Annual Worldwide Net Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" xlink:to="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_SueJeanLinMember_label_en-US" xlink:label="lab_arqt_SueJeanLinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sue-Jean Lin [Member]</link:label>
    <link:label id="lab_arqt_SueJeanLinMember_documentation_en-US" xlink:label="lab_arqt_SueJeanLinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sue-Jean Lin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SueJeanLinMember" xlink:href="arqt-20251231.xsd#arqt_SueJeanLinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_SueJeanLinMember" xlink:to="lab_arqt_SueJeanLinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_328117f4-391d-44ec-84b1-3cdb56b7873f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_473242f3-5140-4322-8f8b-b2e30f979f68_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ba3b652c-e309-4426-9057-f1ea6dbed99f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_8d493e12-aa26-43ea-90e1-24f3480b7c47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_204a0a5f-fce0-496d-8ae7-a1ce7cc7ddde_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a3f76edd-8f42-427d-a4d5-1236cbcd9207_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_13f6b8a7-9b42-480b-b488-91dde5409cea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_db985f84-21b4-478c-9d5d-82a80f1ff9d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Loss before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c2770-49d0-74be-9dec-54496ec6930d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_fe062994-52e2-4981-b711-5f48b9aaaea8_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_20c21351-1d82-4178-be53-dea74b760b52_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_42e2756c-3d5c-4ebc-aa69-5d9a08fa4c95_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_a01edb5d-2b06-4563-880e-ad56283be115_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total carrying value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_02af6be1-1cb5-4862-9efc-3da2b1c2b3e5_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_cc475eeb-9189-46d2-80b9-d9a98a597d82_terseLabel_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized for sale under the ESPP (in shares)</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_label_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Base Amount Of Common Stock Shares Authorized</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_documentation_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Base Amount Of Common Stock Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:to="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_cdd2b498-60e2-4e3a-8d06-bc866492ee62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_910d3547-f973-4f62-abd2-09d01aa0c9ca_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds_fde2c4d7-3619-42ee-8f9a-bc463092b440_terseLabel_en-US" xlink:label="lab_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share sales agreement, percentage of gross sales price (as a percent)</link:label>
    <link:label id="lab_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:href="arqt-20251231.xsd#arqt_SaleOfStockAgentFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:to="lab_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_09496457-98e2-4e98-a3a2-e1ef72e0ccea_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_fa231f36-bf47-406e-9d91-3434abc0f147_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LoanAgreementTrancheC2ExpiringJune302026Member_ec596f62-6c62-4e9d-948f-a4b459783ed6_terseLabel_en-US" xlink:label="lab_arqt_LoanAgreementTrancheC2ExpiringJune302026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Agreement, Tranche C-2, Expiring June 30, 2026</link:label>
    <link:label id="lab_arqt_LoanAgreementTrancheC2ExpiringJune302026Member_label_en-US" xlink:label="lab_arqt_LoanAgreementTrancheC2ExpiringJune302026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement, Tranche C-2, Expiring June 30, 2026 [Member]</link:label>
    <link:label id="lab_arqt_LoanAgreementTrancheC2ExpiringJune302026Member_documentation_en-US" xlink:label="lab_arqt_LoanAgreementTrancheC2ExpiringJune302026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Agreement, Tranche C-2, Expiring June 30, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementTrancheC2ExpiringJune302026Member" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementTrancheC2ExpiringJune302026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LoanAgreementTrancheC2ExpiringJune302026Member" xlink:to="lab_arqt_LoanAgreementTrancheC2ExpiringJune302026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a18eb4e-d08c-4760-89f8-e2d605fa53dc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_871a86bf-062c-4d32-8f45-cbcc48a49f14_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment expenses</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_PrepaidClinicalTrialTestCostsCurrent_c66a476f-73ca-4541-b527-e59f7482fdc0_terseLabel_en-US" xlink:label="lab_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid clinical trial costs</link:label>
    <link:label id="lab_arqt_PrepaidClinicalTrialTestCostsCurrent_label_en-US" xlink:label="lab_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Clinical Trial Test Costs, Current</link:label>
    <link:label id="lab_arqt_PrepaidClinicalTrialTestCostsCurrent_documentation_en-US" xlink:label="lab_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Clinical Trial Test Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:href="arqt-20251231.xsd#arqt_PrepaidClinicalTrialTestCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:to="lab_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_e5b119a5-536c-4b37-9fce-78dbc2f8c838_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_d0e9d264-81c1-4f14-bfb7-0ce9f96e1531_terseLabel_en-US" xlink:label="lab_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest issued or issuable, number of shares (in shares)</link:label>
    <link:label id="lab_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_label_en-US" xlink:label="lab_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:label id="lab_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_documentation_en-US" xlink:label="lab_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:to="lab_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0c4966d0-cb8e-4afa-8de6-92e0373b8f48_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_76fc17c2-a0c6-465b-8a23-38f47a6dbd77_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation of Other Investments</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_74c82e6e-0d26-47a9-a842-6c8f9ac08992_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e2c62591-38c3-46ed-aad3-2d26f9d624f7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_22fc5a0b-45e3-4c37-ae02-48b81720e631_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2dddaf68-0748-46f0-970c-a0d7c6218b2b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_cb29d522-8848-4eb2-b372-2c65ec3a19c7_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_85a3d701-d674-40cd-a5c3-f89fa0dba6c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal (national) income tax effect</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeaseExtensionTerm_019bb752-cd60-7219-a1a9-56de3334ef29_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension term of the lease (in years)</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseExtensionTerm_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Extension Term</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseExtensionTerm_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseExtensionTerm" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeaseExtensionTerm" xlink:to="lab_arqt_LesseeOperatingLeaseExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_bdbabfd6-258a-4c2d-8ca4-a51207d88fbf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation_ef0cc378-3d50-4a35-9cfb-f47007dfc7ba_terseLabel_en-US" xlink:label="lab_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax withholding obligation</link:label>
    <link:label id="lab_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation_label_en-US" xlink:label="lab_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Not With Customer, Liability, Tax Withholding Obligation</link:label>
    <link:label id="lab_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation_documentation_en-US" xlink:label="lab_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Not With Customer, Liability, Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation" xlink:href="arqt-20251231.xsd#arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation" xlink:to="lab_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_27362fe3-dab3-40c0-a145-4d7dfdd6c2c8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_685adc21-2498-4943-8c97-629f0fc17fb3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_019bb752-cd60-73e0-b329-273a22e347e0_terseLabel_en-US" xlink:label="lab_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="arqt-20251231.xsd#arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockOptionExchangeMember_19e6fa61-8b5a-4f4f-ace1-c536dd44449d_terseLabel_en-US" xlink:label="lab_arqt_StockOptionExchangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Exchange</link:label>
    <link:label id="lab_arqt_StockOptionExchangeMember_label_en-US" xlink:label="lab_arqt_StockOptionExchangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Exchange [Member]</link:label>
    <link:label id="lab_arqt_StockOptionExchangeMember_documentation_en-US" xlink:label="lab_arqt_StockOptionExchangeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Option Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockOptionExchangeMember" xlink:href="arqt-20251231.xsd#arqt_StockOptionExchangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockOptionExchangeMember" xlink:to="lab_arqt_StockOptionExchangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment_08ef409f-cb17-4a78-9af4-f74de2c2eed5_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, stated percentage, partial prepayment</link:label>
    <link:label id="lab_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment_label_en-US" xlink:label="lab_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage, Partial Prepayment</link:label>
    <link:label id="lab_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage, Partial Prepayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment" xlink:to="lab_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_FirstGrantDateMember_efc27486-c7ac-4018-9102-3f0acd7f97b3_terseLabel_en-US" xlink:label="lab_arqt_FirstGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Date One</link:label>
    <link:label id="lab_arqt_FirstGrantDateMember_label_en-US" xlink:label="lab_arqt_FirstGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Grant Date [Member]</link:label>
    <link:label id="lab_arqt_FirstGrantDateMember_documentation_en-US" xlink:label="lab_arqt_FirstGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FirstGrantDateMember" xlink:href="arqt-20251231.xsd#arqt_FirstGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_FirstGrantDateMember" xlink:to="lab_arqt_FirstGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_019c7049-61a4-7ae8-a550-2eadfb2c56d0_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CustomerBMember_476709bf-d427-4a49-bccb-ce46f6016f2d_terseLabel_en-US" xlink:label="lab_arqt_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_arqt_CustomerBMember_label_en-US" xlink:label="lab_arqt_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_arqt_CustomerBMember_documentation_en-US" xlink:label="lab_arqt_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerBMember" xlink:href="arqt-20251231.xsd#arqt_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CustomerBMember" xlink:to="lab_arqt_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4adb497f-e8a1-4488-990a-640d180b6c21_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9b886bc4-c641-4ee1-ab85-4b0c9f0a3b8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowances</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_33ffa67e-7f46-4d06-8a5f-7dbb140a4e0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6197f465-4ead-4d8a-ad09-fba4e642b273_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_41a53b2e-81e8-478b-83cf-82278de9ee6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6c6d43dc-355c-41b1-b563-89c95a4ce564_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84657c3e-3763-44c0-8024-5eb8eed9773f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28363c80-fc7e-4d47-8961-84df9b1e12fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_37f95652-c45f-4287-8b06-8800a1153da0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_PrefundedWarrantMember_45062dfe-0a25-4f17-a2f6-212df5809c84_terseLabel_en-US" xlink:label="lab_arqt_PrefundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prefunded Warrant</link:label>
    <link:label id="lab_arqt_PrefundedWarrantMember_label_en-US" xlink:label="lab_arqt_PrefundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prefunded Warrant [Member]</link:label>
    <link:label id="lab_arqt_PrefundedWarrantMember_documentation_en-US" xlink:label="lab_arqt_PrefundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prefunded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrefundedWarrantMember" xlink:href="arqt-20251231.xsd#arqt_PrefundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_PrefundedWarrantMember" xlink:to="lab_arqt_PrefundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6545616d-7ff8-43d0-8ec2-30d1107d5b2a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_6f16638d-20be-4332-bd8e-cbb4c9f2e19e_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_902dd281-fd7d-4f92-96a7-ef6ba38d07dd_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent_019c272c-f911-764c-a7b7-b43e154fbbeb_terseLabel_en-US" xlink:label="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec. 162(m) limitation</link:label>
    <link:label id="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent_label_en-US" xlink:label="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Limitation, Percent</link:label>
    <link:label id="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent_documentation_en-US" xlink:label="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Limitation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" xlink:href="arqt-20251231.xsd#arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" xlink:to="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a295798f-b3f0-42ae-99c2-d1c936fc58a4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LeaseDescriptionDomain_aac78445-04b5-4df9-8e98-b2d3969ecf09_terseLabel_en-US" xlink:label="lab_arqt_LeaseDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Description [Domain]</link:label>
    <link:label id="lab_arqt_LeaseDescriptionDomain_label_en-US" xlink:label="lab_arqt_LeaseDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Description [Domain]</link:label>
    <link:label id="lab_arqt_LeaseDescriptionDomain_documentation_en-US" xlink:label="lab_arqt_LeaseDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionDomain" xlink:href="arqt-20251231.xsd#arqt_LeaseDescriptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LeaseDescriptionDomain" xlink:to="lab_arqt_LeaseDescriptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a87bf410-19f3-4637-a00b-fe6a723279eb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet_8119015d-b581-40fc-9cae-d44fdead00c6_terseLabel_en-US" xlink:label="lab_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received before taxes</link:label>
    <link:label id="lab_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet_label_en-US" xlink:label="lab_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Not With Customer, Upfront Payment Received, Net</link:label>
    <link:label id="lab_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet_documentation_en-US" xlink:label="lab_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Not With Customer, Upfront Payment Received, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet" xlink:href="arqt-20251231.xsd#arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet" xlink:to="lab_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7043-9c3b-743f-aeb6-e4753d37bae4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_420a6eb8-cc43-43ed-9d65-52404952c02b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ab7fea0d-345c-4b91-b492-0bbc94af2b73_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_45f6517c-ec87-4e3b-b233-88b69d9905e3_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentTrancheAxis_93c1a6a7-1257-4fd1-af79-9906e00d1be3_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche [Axis]</link:label>
    <link:label id="lab_arqt_DebtInstrumentTrancheAxis_label_en-US" xlink:label="lab_arqt_DebtInstrumentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche [Axis]</link:label>
    <link:label id="lab_arqt_DebtInstrumentTrancheAxis_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentTrancheAxis" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentTrancheAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentTrancheAxis" xlink:to="lab_arqt_DebtInstrumentTrancheAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5a2ca1bf-7bf7-47aa-8901-c2808f483f53_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment_019c909f-364d-73f9-95c4-63b987d132bd_terseLabel_en-US" xlink:label="lab_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration, duration due within</link:label>
    <link:label id="lab_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment_label_en-US" xlink:label="lab_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Payments, Duration Due Within First Enrollment</link:label>
    <link:label id="lab_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment_documentation_en-US" xlink:label="lab_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Payments, Duration Due Within First Enrollment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment" xlink:to="lab_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_12fe118c-4491-4588-94ce-bae1d86631d1_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_806c30cd-50d0-488a-9a3a-15a0bbbe4a66_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_d06f0dd4-7513-4eab-941e-1f9205058000_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_4e34ce3e-c63e-4a3e-9e91-b59f9cb9e25e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_a60daea5-f7d9-47d7-8d88-77e03d95cc49_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_d740fe67-2f60-4d38-8242-fdfc52027f02_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58f35787-bd1e-46a9-9e50-e44d516a9dc7_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0faba274-2336-4832-a27f-4f4a5e846d8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_688e299d-2b41-47db-8b7e-bb95e5a938e8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3346a8ff-e9e4-4dc1-bdb2-f38a94619189_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7918-85c4-698186a71b7a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_d6151eb7-558e-405c-a435-af8a7005def3_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LicenseAgreementsAndAcquisitionsTextBlock_019c273b-db6d-7f5a-9669-95320aa59af5_terseLabel_en-US" xlink:label="lab_arqt_LicenseAgreementsAndAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements &amp; Ducentis Acquisition</link:label>
    <link:label id="lab_arqt_LicenseAgreementsAndAcquisitionsTextBlock_label_en-US" xlink:label="lab_arqt_LicenseAgreementsAndAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements And Acquisitions [Text Block]</link:label>
    <link:label id="lab_arqt_LicenseAgreementsAndAcquisitionsTextBlock_documentation_en-US" xlink:label="lab_arqt_LicenseAgreementsAndAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreements And Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementsAndAcquisitionsTextBlock" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementsAndAcquisitionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LicenseAgreementsAndAcquisitionsTextBlock" xlink:to="lab_arqt_LicenseAgreementsAndAcquisitionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a71d7ee-0b2f-481d-86af-653c87285d97_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_KeithLeonardMember_label_en-US" xlink:label="lab_arqt_KeithLeonardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Keith Leonard [Member]</link:label>
    <link:label id="lab_arqt_KeithLeonardMember_documentation_en-US" xlink:label="lab_arqt_KeithLeonardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Keith Leonard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_KeithLeonardMember" xlink:href="arqt-20251231.xsd#arqt_KeithLeonardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_KeithLeonardMember" xlink:to="lab_arqt_KeithLeonardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f3252714-f73c-4ee9-8cf4-974c5f263ee6_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense paid in cash</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_322abbef-66da-4a2a-8890-fca5f356938f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6c9a14b3-2e5a-4f43-96d0-cba1e60bb0eb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_cb589066-8d24-4f7f-aa85-677e90765fae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb77d-b394-7288-9fbc-62cd8954ad48_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f659dae3-e531-40b3-82c3-72e6453ef51c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreases related to tax positions taken during a prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a86292db-7131-45d0-9933-6e5510079b9c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Straight-line rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_01b496df-9ea5-4dfa-8e3d-b32e2d5d4626_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_564bdd17-dbe9-425c-88c8-4270bef6bd21_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition period for unrecognized compensation costs related to unvested options expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_73697c47-18ff-48d9-8321-24c9504cde85_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon the exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a2dfda06-2358-49d0-89e9-bc24975e5b02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_570c6c8b-49f5-4df4-87f4-bcff05f49fb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CashAndCashEquivalentsUnrealizedGain_d0c9d6c1-86d7-4b64-9400-8c2f21d301d2_terseLabel_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_arqt_CashAndCashEquivalentsUnrealizedGain_label_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents, Unrealized Gain</link:label>
    <link:label id="lab_arqt_CashAndCashEquivalentsUnrealizedGain_documentation_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsUnrealizedGain" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CashAndCashEquivalentsUnrealizedGain" xlink:to="lab_arqt_CashAndCashEquivalentsUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b99f19c7-2c1d-4cba-9535-426e0b9ee71a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_55767c34-82c3-40c0-ba0c-a3760239d901_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95f70da6-3700-4308-8e47-a542e5f7c212_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_a3204dc0-eba8-4f5a-ae49-44c68329c885_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_92587bcb-725d-4de1-8faa-81e16a35dd65_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_bd6f438b-6258-4a77-a8c2-9a470e90e3c0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged_a696ae7f-d221-4fab-bbb3-ad8f0e13479e_terseLabel_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of eligible options exchanged</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged_label_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Of Eligible Options Exchanged</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged_documentation_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Of Eligible Options Exchanged</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged" xlink:to="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eead2938-3ebf-43fd-8acf-6e58e0b74c51_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AtTheMarketMember_7dfee2c2-3775-4ab5-831b-7959f5384c2e_terseLabel_en-US" xlink:label="lab_arqt_AtTheMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market</link:label>
    <link:label id="lab_arqt_AtTheMarketMember_label_en-US" xlink:label="lab_arqt_AtTheMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market [Member]</link:label>
    <link:label id="lab_arqt_AtTheMarketMember_documentation_en-US" xlink:label="lab_arqt_AtTheMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AtTheMarketMember" xlink:href="arqt-20251231.xsd#arqt_AtTheMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AtTheMarketMember" xlink:to="lab_arqt_AtTheMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentDeferredFinalFeeGross_a10b86a5-b4fa-40cc-9cf0-e93ad448b50a_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentDeferredFinalFeeGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred final fee</link:label>
    <link:label id="lab_arqt_DebtInstrumentDeferredFinalFeeGross_label_en-US" xlink:label="lab_arqt_DebtInstrumentDeferredFinalFeeGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Deferred Final Fee, Gross</link:label>
    <link:label id="lab_arqt_DebtInstrumentDeferredFinalFeeGross_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentDeferredFinalFeeGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Deferred Final Fee, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentDeferredFinalFeeGross" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentDeferredFinalFeeGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentDeferredFinalFeeGross" xlink:to="lab_arqt_DebtInstrumentDeferredFinalFeeGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a11a1579-eec2-4daf-8186-6dce31d943ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_e5afbe73-de2e-4313-9c81-3f2fc80b37bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e7dd96fc-239e-43b2-a468-24872fe64056_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_7359728e-62d7-40ce-a785-6ddcbd2295ce_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_7bad685b-66c0-4237-9b72-c96e6b7502fe_terseLabel_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Based number of options issuable (in shares)</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_label_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Base Number Of Options Issuable</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_documentation_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Base Number Of Options Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:to="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_fdecdad1-f180-4c2b-a0c4-8943daa79ed3_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Receivables, net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_SecondaryEquityPublicOfferingMember_c07e14d9-6741-47b0-bbc2-15721e8dc537_terseLabel_en-US" xlink:label="lab_arqt_SecondaryEquityPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secondary Equity Public Offering</link:label>
    <link:label id="lab_arqt_SecondaryEquityPublicOfferingMember_label_en-US" xlink:label="lab_arqt_SecondaryEquityPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secondary Equity Public Offering [Member]</link:label>
    <link:label id="lab_arqt_SecondaryEquityPublicOfferingMember_documentation_en-US" xlink:label="lab_arqt_SecondaryEquityPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secondary Equity Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SecondaryEquityPublicOfferingMember" xlink:href="arqt-20251231.xsd#arqt_SecondaryEquityPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_SecondaryEquityPublicOfferingMember" xlink:to="lab_arqt_SecondaryEquityPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_97b3fc51-524a-4c46-92ad-7797e360709e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax effects</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e52d5283-d56d-4da9-9f00-00ffc35a0bb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_0e759db2-bb41-445f-bb21-c948b279694e_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_63cbdab9-9c11-4363-8230-ecadb5de4131_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_093b49d7-6ee8-47f0-a4ef-1d7d9fc66080_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c937bff6-8483-45c9-a4d2-091b75b7de82_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_SatoMember_44ceffca-12e8-4a3b-98a7-aa30b3a6b2b4_terseLabel_en-US" xlink:label="lab_arqt_SatoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sato</link:label>
    <link:label id="lab_arqt_SatoMember_label_en-US" xlink:label="lab_arqt_SatoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sato [Member]</link:label>
    <link:label id="lab_arqt_SatoMember_documentation_en-US" xlink:label="lab_arqt_SatoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sato</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SatoMember" xlink:href="arqt-20251231.xsd#arqt_SatoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_SatoMember" xlink:to="lab_arqt_SatoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bc61258b-ca5f-4dc6-b233-cd5af4c0242b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_01a6a980-bf12-4bda-957a-b83c622431e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c1902b26-c5fc-435d-b3a7-a949dc83c484_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d82b020d-03d8-4466-86ee-a52e06f72945_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ce377d10-1c1d-4c7c-b2a5-a0392589e915_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_88ffd865-9667-463d-8f11-6abc8b8e2094_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9166906b-ea3e-4880-9a9c-1391c9da302e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4a5f665b-d138-497e-87d9-600362f515a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_36daf808-4219-466e-a7a5-74541cd38dc3_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_05731b9f-6b72-4e8d-ba62-93a5c3252e0f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_88f31089-08d1-462d-815a-ff5b5f776288_terseLabel_en-US" xlink:label="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:label id="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="arqt-20251231.xsd#arqt_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_83f0d2ef-508c-486a-98b8-fb4d02e1f047_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c3c0f706-8a30-419a-a3ca-877b9f50fdd8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentAccruedFinalFee_d03eed37-5c7b-441b-bfa5-11f8042008fa_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentAccruedFinalFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued final fee</link:label>
    <link:label id="lab_arqt_DebtInstrumentAccruedFinalFee_label_en-US" xlink:label="lab_arqt_DebtInstrumentAccruedFinalFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Accrued Final Fee</link:label>
    <link:label id="lab_arqt_DebtInstrumentAccruedFinalFee_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentAccruedFinalFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Accrued Final Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentAccruedFinalFee" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentAccruedFinalFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentAccruedFinalFee" xlink:to="lab_arqt_DebtInstrumentAccruedFinalFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_a42a8fac-d465-4bfe-81ee-7729b5b1b723_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After December 22, 2002 and prior to December 22, 2023</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_83a55721-7f3b-4459-a10b-7a0cfce02114_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b59fbcea-6e2b-4a57-8a0a-146127107acd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24f7cab8-fd7d-4c43-b9ac-cd4aef917d39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_035f4694-6981-4eb5-8087-89862ce02292_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_669f7dbd-2b90-49e7-ba95-940b32d967bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_019c4b62-4756-70f8-b406-793fe4eab80d_terseLabel_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future purchase commitments in 2027</link:label>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recorded Unconditional Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_3ed6f692-4b5a-42bd-8c15-85f9d32efd7a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_TrancheATermLoanMember_5819b034-c779-4f39-8e78-8fd353c008ef_terseLabel_en-US" xlink:label="lab_arqt_TrancheATermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche A term loan</link:label>
    <link:label id="lab_arqt_TrancheATermLoanMember_label_en-US" xlink:label="lab_arqt_TrancheATermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche A Term Loan [Member]</link:label>
    <link:label id="lab_arqt_TrancheATermLoanMember_documentation_en-US" xlink:label="lab_arqt_TrancheATermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche A Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheATermLoanMember" xlink:href="arqt-20251231.xsd#arqt_TrancheATermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_TrancheATermLoanMember" xlink:to="lab_arqt_TrancheATermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_b1eea0e4-99db-4177-8374-920e475e0643_terseLabel_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum milestone payments for net worldwide sales</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_label_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_documentation_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:to="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_20d8ce9a-23cb-44c4-928f-95af39ddae8a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cf8e08ea-b910-46ca-bcbb-6ae6f11d334e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b937a43f-876a-4723-a564-d62752125e6e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_a1c2ada6-5e65-43a3-b0d2-05ff7b0b9ac7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, cash payment</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_c0c9859c-bd28-4461-8767-86aeae1d5479_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_bc57bad2-05d0-4e3f-bad7-bb9e0c8a2c7f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_label_en-US" xlink:label="lab_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements And Ducentis Acquisition Disclosure [Abstract]</link:label>
    <link:label id="lab_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_documentation_en-US" xlink:label="lab_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreements And Ducentis Acquisition Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract" xlink:to="lab_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_df1bd6db-a1b5-40ba-beb5-8cfac80990e6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_406aad6e-fa22-4bb6-83c1-5ad92ae54acf_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_8c2a4cde-deec-4d98-bd4f-5ea6e32e919e_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_9e5cd80e-40ce-4639-8021-ad7bbb604e1b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_53bb739a-17dc-48bf-888a-27d81ae45f26_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ec588743-e683-4073-87bd-0752416a97f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1f320f35-906a-4db7-8b1d-c0be082c8767_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e2780287-9136-44e9-a6bc-2dfe73df5e17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ClinicalTrialAccrualCurrent_9461ebbf-1539-43a7-b3e2-2441523fb82a_terseLabel_en-US" xlink:label="lab_arqt_ClinicalTrialAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial accruals</link:label>
    <link:label id="lab_arqt_ClinicalTrialAccrualCurrent_label_en-US" xlink:label="lab_arqt_ClinicalTrialAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Accrual, Current</link:label>
    <link:label id="lab_arqt_ClinicalTrialAccrualCurrent_documentation_en-US" xlink:label="lab_arqt_ClinicalTrialAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ClinicalTrialAccrualCurrent" xlink:href="arqt-20251231.xsd#arqt_ClinicalTrialAccrualCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ClinicalTrialAccrualCurrent" xlink:to="lab_arqt_ClinicalTrialAccrualCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_879782d3-ed4e-4972-8b85-d2159d784d0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_MajorCustomersMember_a14e37df-2ad8-449b-822a-06fb7a8c5fcb_terseLabel_en-US" xlink:label="lab_arqt_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers</link:label>
    <link:label id="lab_arqt_MajorCustomersMember_label_en-US" xlink:label="lab_arqt_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customers [Member]</link:label>
    <link:label id="lab_arqt_MajorCustomersMember_documentation_en-US" xlink:label="lab_arqt_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_MajorCustomersMember" xlink:href="arqt-20251231.xsd#arqt_MajorCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_MajorCustomersMember" xlink:to="lab_arqt_MajorCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7b3f8395-c1e1-41ab-9136-42c194776a8a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to acquire shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_191ca57c-b98d-458f-aeae-08e6228f129b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d31521f1-60c8-4b12-857d-2c081d899a7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c2773-57fd-7768-b128-d1c2b5b84b57_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0c140981-4084-47d5-b2e8-cc650343d3cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_5bead88f-023c-4810-b3e4-a62d3c313761_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4135d682-e3f0-4cac-a740-d354675162b5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 300,000,000 shares authorized; 123,332,672 and 117,848,033 shares issued and outstanding at December&#160;31, 2025 and 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_65e0d910-d42d-4e0b-8948-ca377c78a448_terseLabel_en-US" xlink:label="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate amount to be received upon achievement of sales milestones</link:label>
    <link:label id="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_label_en-US" xlink:label="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount, Sales Milestones</link:label>
    <link:label id="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_documentation_en-US" xlink:label="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount, Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones" xlink:href="arqt-20251231.xsd#arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones" xlink:to="lab_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e04102eb-d63b-4167-a5d3-5b6707ecbdb0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember_d32abb21-2637-4625-bd62-433d78d14e00_terseLabel_en-US" xlink:label="lab_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ducentis Biotherapeutics LTD Equity Interests</link:label>
    <link:label id="lab_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember_label_en-US" xlink:label="lab_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ducentis Biotherapeutics LTD Equity Interests [Member]</link:label>
    <link:label id="lab_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember_documentation_en-US" xlink:label="lab_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ducentis Biotherapeutics LTD Equity Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember" xlink:href="arqt-20251231.xsd#arqt_DucentisBiotherapeuticsLTDEquityInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember" xlink:to="lab_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_SueJeanLinTradingArrangementOptionsMember_label_en-US" xlink:label="lab_arqt_SueJeanLinTradingArrangementOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sue-Jean Lin Trading Arrangement, Options [Member]</link:label>
    <link:label id="lab_arqt_SueJeanLinTradingArrangementOptionsMember_documentation_en-US" xlink:label="lab_arqt_SueJeanLinTradingArrangementOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sue-Jean Lin Trading Arrangement, Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SueJeanLinTradingArrangementOptionsMember" xlink:href="arqt-20251231.xsd#arqt_SueJeanLinTradingArrangementOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_SueJeanLinTradingArrangementOptionsMember" xlink:to="lab_arqt_SueJeanLinTradingArrangementOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ProductRevenuePaymentTerm_d5de1f83-f300-4a84-ac10-d5637926c9fa_terseLabel_en-US" xlink:label="lab_arqt_ProductRevenuePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment terms (in days)</link:label>
    <link:label id="lab_arqt_ProductRevenuePaymentTerm_label_en-US" xlink:label="lab_arqt_ProductRevenuePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Revenue, Payment Term</link:label>
    <link:label id="lab_arqt_ProductRevenuePaymentTerm_documentation_en-US" xlink:label="lab_arqt_ProductRevenuePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Revenue, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ProductRevenuePaymentTerm" xlink:href="arqt-20251231.xsd#arqt_ProductRevenuePaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ProductRevenuePaymentTerm" xlink:to="lab_arqt_ProductRevenuePaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_ac84a92b-4bec-4473-a4cf-2ae21cd12336_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_800f7fb0-73c8-4f1d-ade5-44f574a5a51a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_36425af9-0524-430b-a625-864a343b2109_terseLabel_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales milestone payment</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_label_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Sales Milestone Payments</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_documentation_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Sales Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" xlink:to="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_deec1cb0-a1c2-413d-9640-34547e82fdba_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LeaseDescriptionAxis_e0e36846-22c0-4879-8a0c-45e5cb2b9784_terseLabel_en-US" xlink:label="lab_arqt_LeaseDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Description [Axis]</link:label>
    <link:label id="lab_arqt_LeaseDescriptionAxis_label_en-US" xlink:label="lab_arqt_LeaseDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Description [Axis]</link:label>
    <link:label id="lab_arqt_LeaseDescriptionAxis_documentation_en-US" xlink:label="lab_arqt_LeaseDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionAxis" xlink:href="arqt-20251231.xsd#arqt_LeaseDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LeaseDescriptionAxis" xlink:to="lab_arqt_LeaseDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_5db1550e-739a-4e84-a5f7-33476175b3e8_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5fae2dec-7cdb-465d-8211-d08e9eb4a9d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d5576fbc-497f-40be-bb8e-6123512e2646_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_TopicalJAKInhibitorProgramMember_8b88448b-3d89-4f5f-83bd-805126417b1f_terseLabel_en-US" xlink:label="lab_arqt_TopicalJAKInhibitorProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Topical JAK inhibitor program costs</link:label>
    <link:label id="lab_arqt_TopicalJAKInhibitorProgramMember_label_en-US" xlink:label="lab_arqt_TopicalJAKInhibitorProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Topical JAK Inhibitor Program [Member]</link:label>
    <link:label id="lab_arqt_TopicalJAKInhibitorProgramMember_documentation_en-US" xlink:label="lab_arqt_TopicalJAKInhibitorProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Topical JAK Inhibitor Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TopicalJAKInhibitorProgramMember" xlink:href="arqt-20251231.xsd#arqt_TopicalJAKInhibitorProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_TopicalJAKInhibitorProgramMember" xlink:to="lab_arqt_TopicalJAKInhibitorProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_664b2c0d-997f-4c89-9960-371489b2b05f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award requisite service period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_16a05274-c010-432d-9d92-93e376238ea0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_631ab9d6-cb55-44d5-8877-0f6798b51a33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount_019c272f-3054-7cd5-972f-ba7cb0b95eb8_terseLabel_en-US" xlink:label="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec. 162(m) limitation</link:label>
    <link:label id="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount_label_en-US" xlink:label="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Limitation, Amount</link:label>
    <link:label id="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount_documentation_en-US" xlink:label="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Limitation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" xlink:href="arqt-20251231.xsd#arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" xlink:to="lab_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentExitFeePercentage_13900457-c000-4e6d-832a-ee7660bd0c05_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit fee (as a percent)</link:label>
    <link:label id="lab_arqt_DebtInstrumentExitFeePercentage_label_en-US" xlink:label="lab_arqt_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee, Percentage</link:label>
    <link:label id="lab_arqt_DebtInstrumentExitFeePercentage_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentExitFeePercentage" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentExitFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentExitFeePercentage" xlink:to="lab_arqt_DebtInstrumentExitFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d05b1300-2739-4cf5-88ac-bbfefeb24407_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock, as a percentage of closing trading price per share (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c2772-9720-7de5-a8d8-039f4325a775_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_TrancheCTermLoanMember_987a19b7-6949-43c3-b978-6aed8276c936_terseLabel_en-US" xlink:label="lab_arqt_TrancheCTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche C term loan</link:label>
    <link:label id="lab_arqt_TrancheCTermLoanMember_label_en-US" xlink:label="lab_arqt_TrancheCTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche C Term Loan [Member]</link:label>
    <link:label id="lab_arqt_TrancheCTermLoanMember_documentation_en-US" xlink:label="lab_arqt_TrancheCTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche C Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheCTermLoanMember" xlink:href="arqt-20251231.xsd#arqt_TrancheCTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_TrancheCTermLoanMember" xlink:to="lab_arqt_TrancheCTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_2764ff37-69a6-4496-a332-6d825a76a62b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_919eb952-e3b5-4da8-8be3-c48eeed65e92_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_ef373ce0-3feb-4c22-ac5d-40111f52a6f2_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a5c8e8a2-cfd4-41a6-b122-c360e38612cb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_06ed9874-d3f6-49c8-ae98-1c2ba6e3ff49_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ac57e5ff-8269-4f78-9a91-353418f6f892_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_2da96667-38aa-4412-a45c-b3a5e6667b4e_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DeferredTaxLiabilitiesRightOfUseAsset_729d4622-4de5-4e48-b5b8-6a7b1b377774_negatedTerseLabel_en-US" xlink:label="lab_arqt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_arqt_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_arqt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right-Of-Use Asset</link:label>
    <link:label id="lab_arqt_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_arqt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="arqt-20251231.xsd#arqt_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_arqt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_019bfeef-0545-725b-a329-c1a6da9eca2c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_502584b8-1075-4291-a207-80046497d0d9_terseLabel_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and debt securities, available for sale</link:label>
    <link:label id="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_label_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure</link:label>
    <link:label id="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_documentation_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:to="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_894cc2b4-7c1f-4235-a1d7-8e6abcba4490_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potentially Dilutive Shares Excluded</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_FirstEquityPublicOfferingMember_019c2739-59b4-7380-bbfa-d482933a5c19_terseLabel_en-US" xlink:label="lab_arqt_FirstEquityPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Equity Public Offering</link:label>
    <link:label id="lab_arqt_FirstEquityPublicOfferingMember_label_en-US" xlink:label="lab_arqt_FirstEquityPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Equity Public Offering [Member]</link:label>
    <link:label id="lab_arqt_FirstEquityPublicOfferingMember_documentation_en-US" xlink:label="lab_arqt_FirstEquityPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Equity Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FirstEquityPublicOfferingMember" xlink:href="arqt-20251231.xsd#arqt_FirstEquityPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_FirstEquityPublicOfferingMember" xlink:to="lab_arqt_FirstEquityPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e5f180fa-2918-4d73-95ee-10e9d1a6e71d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments_019bb752-cd60-7666-8ce4-82e01af548d1_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional years of rent payments (in years)</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Additional Years Of Rent Payments</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Additional Years Of Rent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments" xlink:to="lab_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c777bd91-7933-472d-98bd-54b77e1128e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_60a552b6-b7cd-4986-9439-b728c9d56b6c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_f51d5f35-8e2f-4d5d-88aa-4c05993663a1_terseLabel_en-US" xlink:label="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Westlake Village, California Lease Arrangement</link:label>
    <link:label id="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_label_en-US" xlink:label="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Westlake Village, California Lease Arrangement [Member]</link:label>
    <link:label id="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_documentation_en-US" xlink:label="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Westlake Village, California Lease Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:href="arqt-20251231.xsd#arqt_WestlakeVillageCaliforniaLeaseArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:to="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7fd8750c-654b-4cc5-bba8-48b8760bb30b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3e43fce1-8f1b-41c7-a102-d56d1f316993_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_90b4faad-666e-4160-a229-94a045f67fe2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock_31cd2c33-ca36-4550-9cf0-4911c1007256_terseLabel_en-US" xlink:label="lab_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Revenue</link:label>
    <link:label id="lab_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock_label_en-US" xlink:label="lab_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Not From Contract With Customer, Policy [Policy Text Block]</link:label>
    <link:label id="lab_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Not From Contract With Customer, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock" xlink:href="arqt-20251231.xsd#arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock" xlink:to="lab_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_a3eb2bda-345a-4bf4-a379-1e1f745e18a1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b91c62a2-047d-45b0-b662-df90eae9c939_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_89d48953-5c4a-48f0-b13f-968f5e386037_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period of stock-based awards granted (in share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019bb777-4f6a-7cf7-9d45-163f8b84dfbc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_54e93130-f90d-4ba2-be32-34cc308682a7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a8f6423d-8b3b-4495-9b53-438d7d88cd0b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_0a202515-60e6-47b1-9f3b-9b4cd4eb694d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Not from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_f8f82f48-b408-49e2-9b61-e05f97433c13_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_cd96def0-b579-4a3d-8bd4-5729f5356faa_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c47998d7-671a-4b8b-b356-53885340e4c7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2df720c3-fb21-4024-bdef-97002faf0e47_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_d26af26b-861a-4612-b24f-c2c1ea273cb0_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of embedded derivative instrument</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_019c4b62-4756-756f-b4a9-973b198f2642_terseLabel_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future purchase commitment in 2026</link:label>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_label_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recorded Unconditional Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:to="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DeferredTaxAssetsLeaseLiability_019c6514-1d76-77e4-91d8-686ee53aa5ff_terseLabel_en-US" xlink:label="lab_arqt_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_arqt_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_arqt_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_arqt_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_arqt_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredTaxAssetsLeaseLiability" xlink:href="arqt-20251231.xsd#arqt_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DeferredTaxAssetsLeaseLiability" xlink:to="lab_arqt_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_2368de20-d57a-45e2-b2b6-6e9c3df8a10e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental cost of plan modification</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_bb74147f-61d2-41b3-998d-acaa34257511_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AccruedSalesDiscounts_d3475bec-5d3a-4a43-a695-867ae08780db_terseLabel_en-US" xlink:label="lab_arqt_AccruedSalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued sales deductions</link:label>
    <link:label id="lab_arqt_AccruedSalesDiscounts_label_en-US" xlink:label="lab_arqt_AccruedSalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Discounts</link:label>
    <link:label id="lab_arqt_AccruedSalesDiscounts_documentation_en-US" xlink:label="lab_arqt_AccruedSalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Sales Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AccruedSalesDiscounts" xlink:href="arqt-20251231.xsd#arqt_AccruedSalesDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AccruedSalesDiscounts" xlink:to="lab_arqt_AccruedSalesDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_a36bcde6-9bde-4629-8a6c-1f65b7c6c677_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_50d8f2e4-4a27-49f7-aab9-fbf20b614c5a_terseLabel_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lapse of repurchase rights related to common stock issued pursuant to early exercises (in shares)</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_label_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Lapse of Repurchase Rights Related to Common Stock Issued Pursuant to Early Exercises, Shares</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_documentation_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Lapse of Repurchase Rights Related to Common Stock Issued Pursuant to Early Exercises, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:href="arqt-20251231.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:to="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ZORYVEFoamMember_72f8d550-a72b-4ddd-9fa5-7d24ce8ccf97_terseLabel_en-US" xlink:label="lab_arqt_ZORYVEFoamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZORYVE foam</link:label>
    <link:label id="lab_arqt_ZORYVEFoamMember_label_en-US" xlink:label="lab_arqt_ZORYVEFoamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZORYVE Foam [Member]</link:label>
    <link:label id="lab_arqt_ZORYVEFoamMember_documentation_en-US" xlink:label="lab_arqt_ZORYVEFoamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZORYVE Foam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVEFoamMember" xlink:href="arqt-20251231.xsd#arqt_ZORYVEFoamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ZORYVEFoamMember" xlink:to="lab_arqt_ZORYVEFoamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a698a706-e82f-49c1-a825-be52bcfca47f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_37198243-757a-4dfb-8518-eaf713632b9d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember_6d4c8687-90ee-42f2-afcc-b24c47bc2fe8_terseLabel_en-US" xlink:label="lab_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, excluding leasehold improvements</link:label>
    <link:label id="lab_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember_label_en-US" xlink:label="lab_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Excluding Leasehold Improvements [Member]</link:label>
    <link:label id="lab_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Excluding Leasehold Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember" xlink:href="arqt-20251231.xsd#arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember" xlink:to="lab_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_95ba9ca6-8d9c-482d-812b-087dfda350af_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f389244b-240c-44b4-8b16-b6470175f002_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_27b5467d-718d-40db-9451-933eb797578c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f5a4cfcd-17cf-4d25-8eb5-8ff4c303df28_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignTaxJurisdictionOtherMember_019c2732-3a4f-7fba-9159-be1642fd99b4_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ForeignTaxJurisdictionOtherMember_label_en-US" xlink:label="lab_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:to="lab_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7546c3e7-1530-43f6-b792-abb4c3599ece_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_94da9d1b-bc0b-4bb5-b722-8cbf5156a16d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_4209f1a1-d0dc-46b2-bee3-5660d48f8d9c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ForeignWithholdingIncomeTaxes_45c03a1b-0e80-449a-9d29-f8a7df5d9481_terseLabel_en-US" xlink:label="lab_arqt_ForeignWithholdingIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign withholding income tax</link:label>
    <link:label id="lab_arqt_ForeignWithholdingIncomeTaxes_label_en-US" xlink:label="lab_arqt_ForeignWithholdingIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Withholding Income Taxes</link:label>
    <link:label id="lab_arqt_ForeignWithholdingIncomeTaxes_documentation_en-US" xlink:label="lab_arqt_ForeignWithholdingIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Withholding Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ForeignWithholdingIncomeTaxes" xlink:href="arqt-20251231.xsd#arqt_ForeignWithholdingIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ForeignWithholdingIncomeTaxes" xlink:to="lab_arqt_ForeignWithholdingIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CashCashEquivalentsAndMarketableSecurities_fad5b0ec-0f0f-45d5-99b3-defcc75df5a6_terseLabel_en-US" xlink:label="lab_arqt_CashCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and marketable securities</link:label>
    <link:label id="lab_arqt_CashCashEquivalentsAndMarketableSecurities_label_en-US" xlink:label="lab_arqt_CashCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_arqt_CashCashEquivalentsAndMarketableSecurities_documentation_en-US" xlink:label="lab_arqt_CashCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashCashEquivalentsAndMarketableSecurities" xlink:href="arqt-20251231.xsd#arqt_CashCashEquivalentsAndMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CashCashEquivalentsAndMarketableSecurities" xlink:to="lab_arqt_CashCashEquivalentsAndMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_0c11599d-75f8-4701-a548-4911e7086dae_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f10995a0-12fc-4f8b-9c09-ed4bf48ee25f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d250f02c-ac62-45b9-8c69-b2d936065476_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_019c4c3a-6bc4-7b3d-953a-7ff71d00abe7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_22fc7b12-98b0-47ea-9ca3-272c2a2c8425_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c4952561-b307-40f5-ab49-4a47e678c5cb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in computing net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3126940a-2470-4cf1-b747-b00bbc6e84dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9555726f-46ea-48f2-a520-d5180cd69906_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_3271ec03-9186-48db-98a2-0b143f85be40_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ContractNotWithCustomerUpfrontPaymentNet_da2c4f95-b666-4f7b-84eb-f6ff7d32410e_terseLabel_en-US" xlink:label="lab_arqt_ContractNotWithCustomerUpfrontPaymentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net payment received</link:label>
    <link:label id="lab_arqt_ContractNotWithCustomerUpfrontPaymentNet_label_en-US" xlink:label="lab_arqt_ContractNotWithCustomerUpfrontPaymentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Not With Customer, Upfront Payment, Net</link:label>
    <link:label id="lab_arqt_ContractNotWithCustomerUpfrontPaymentNet_documentation_en-US" xlink:label="lab_arqt_ContractNotWithCustomerUpfrontPaymentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Not With Customer, Upfront Payment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ContractNotWithCustomerUpfrontPaymentNet" xlink:href="arqt-20251231.xsd#arqt_ContractNotWithCustomerUpfrontPaymentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ContractNotWithCustomerUpfrontPaymentNet" xlink:to="lab_arqt_ContractNotWithCustomerUpfrontPaymentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LoanAgreementMember_8c31de5f-2d7c-4854-b972-1f77c5c6e2c6_terseLabel_en-US" xlink:label="lab_arqt_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan agreement</link:label>
    <link:label id="lab_arqt_LoanAgreementMember_label_en-US" xlink:label="lab_arqt_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement [Member]</link:label>
    <link:label id="lab_arqt_LoanAgreementMember_documentation_en-US" xlink:label="lab_arqt_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementMember" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LoanAgreementMember" xlink:to="lab_arqt_LoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization_87cfa8cd-85b5-44b4-9322-b14106e8827b_terseLabel_en-US" xlink:label="lab_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and expenditure capitalization</link:label>
    <link:label id="lab_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization_label_en-US" xlink:label="lab_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Research And Expenditure Capitalization</link:label>
    <link:label id="lab_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization_documentation_en-US" xlink:label="lab_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Research And Expenditure Capitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization" xlink:href="arqt-20251231.xsd#arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization" xlink:to="lab_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67e07dd9-df1a-4f70-814c-1e0d0d1803cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_abff5c24-51fa-4eb6-88d2-2788cb8c792d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_55225fb3-3a0a-44fe-9fab-fdf491a3ea84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8b339e44-cb51-45e1-88ce-d44b942cdad7_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d5b08d04-2466-4152-ba15-53a82a518e4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0af1e5b3-541c-4237-9627-4f528ef87592_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8306b43b-05d0-4e04-85ee-1af393b26a8f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_e8ee3373-1326-4413-a3e5-a6f892a0904a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentMaximumBorrowingCapacity_29f5cccc-853a-44a8-8f6d-6d6eb905d287_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_arqt_DebtInstrumentMaximumBorrowingCapacity_label_en-US" xlink:label="lab_arqt_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_arqt_DebtInstrumentMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentMaximumBorrowingCapacity" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentMaximumBorrowingCapacity" xlink:to="lab_arqt_DebtInstrumentMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b8920285-61c8-4c8b-9259-62e21a1c75a0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases related to tax positions taken during the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019c76d1-f60b-7778-987f-8261f96b65f4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_30c1f633-effd-4387-bf8a-5ddffb82ee23_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DebtInstrumentPrepaymentPremium_9faa6c19-7b31-4650-913f-9394ff78b9eb_terseLabel_en-US" xlink:label="lab_arqt_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium (as a percent)</link:label>
    <link:label id="lab_arqt_DebtInstrumentPrepaymentPremium_label_en-US" xlink:label="lab_arqt_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium</link:label>
    <link:label id="lab_arqt_DebtInstrumentPrepaymentPremium_documentation_en-US" xlink:label="lab_arqt_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentPrepaymentPremium" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentPrepaymentPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DebtInstrumentPrepaymentPremium" xlink:to="lab_arqt_DebtInstrumentPrepaymentPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_47462957-eeaf-44b4-a532-62cd7283dd71_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_A2022EmploymentInducementIncentivePlanMember_6f03bfa6-3861-4b8f-97e5-0bcaf907ee0a_terseLabel_en-US" xlink:label="lab_arqt_A2022EmploymentInducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Employment Inducement Incentive Plan</link:label>
    <link:label id="lab_arqt_A2022EmploymentInducementIncentivePlanMember_label_en-US" xlink:label="lab_arqt_A2022EmploymentInducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Employment Inducement Incentive Plan [Member]</link:label>
    <link:label id="lab_arqt_A2022EmploymentInducementIncentivePlanMember_documentation_en-US" xlink:label="lab_arqt_A2022EmploymentInducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Employment Inducement Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2022EmploymentInducementIncentivePlanMember" xlink:href="arqt-20251231.xsd#arqt_A2022EmploymentInducementIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_A2022EmploymentInducementIncentivePlanMember" xlink:to="lab_arqt_A2022EmploymentInducementIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_62d651d0-4960-449b-a769-929fef16be37_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6241beab-3152-4b1e-9ba4-ead64d414a00_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c2774-4af3-7b2c-80c9-c0ec015b58bf_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_a3427abd-8dd8-43be-b623-298bd9d5b863_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c5a04c8e-ddad-4eb9-9163-1b0430641816_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_a1bac047-32ed-4196-8606-892c13c9ce76_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>arqt-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:631d5f47-b6cd-44b6-9ca1-ef826fe44260,g:a004ef44-2665-49af-8ba9-70d1dea45abd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcutis.com/role/CoverPage" xlink:type="simple" xlink:href="arqt-20251231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2e8f7903-8f0c-42c5-a764-c650c3ab42b9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_DocumentType_2e8f7903-8f0c-42c5-a764-c650c3ab42b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a269bae6-ecdf-4721-bc16-72578c6aae3b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_DocumentAnnualReport_a269bae6-ecdf-4721-bc16-72578c6aae3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d395713a-706f-4754-96f1-feb64061c43f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_DocumentPeriodEndDate_d395713a-706f-4754-96f1-feb64061c43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d059301d-c036-40b0-a594-7f16b858efca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_CurrentFiscalYearEndDate_d059301d-c036-40b0-a594-7f16b858efca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_351f7516-b7d9-4858-9254-baa00160e0f8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_DocumentTransitionReport_351f7516-b7d9-4858-9254-baa00160e0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1fc9e2ec-dee4-4e89-8952-55de713d2878" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityFileNumber_1fc9e2ec-dee4-4e89-8952-55de713d2878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cb481528-5045-4ad9-b060-e6a967cf185d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityRegistrantName_cb481528-5045-4ad9-b060-e6a967cf185d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a11de265-52d4-4e92-bc00-4772ed1a88b4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a11de265-52d4-4e92-bc00-4772ed1a88b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0f53a10f-e573-48f8-9c20-b6bfb9b68a11" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityTaxIdentificationNumber_0f53a10f-e573-48f8-9c20-b6bfb9b68a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5ca3eca3-226c-42ff-97b5-6d3b3a26fc33" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityAddressAddressLine1_5ca3eca3-226c-42ff-97b5-6d3b3a26fc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_72566d3e-5b87-4fc5-b96f-02c03096bdc7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityAddressAddressLine2_72566d3e-5b87-4fc5-b96f-02c03096bdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_689ac553-6b72-4bee-9b77-7866fc62bdb2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityAddressCityOrTown_689ac553-6b72-4bee-9b77-7866fc62bdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d96e0589-59ea-4fce-a40e-0bd904e59ef4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityAddressStateOrProvince_d96e0589-59ea-4fce-a40e-0bd904e59ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ecac4ded-bb00-4b04-bc94-3e7546151a62" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityAddressPostalZipCode_ecac4ded-bb00-4b04-bc94-3e7546151a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1fb7f126-2678-4cac-bf43-e9ab58d58060" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_CityAreaCode_1fb7f126-2678-4cac-bf43-e9ab58d58060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_50d3d2ff-2ef6-486c-a078-0aff927d87a5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_LocalPhoneNumber_50d3d2ff-2ef6-486c-a078-0aff927d87a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_438293b5-4141-476f-be31-65ad8ef9efb0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_Security12bTitle_438293b5-4141-476f-be31-65ad8ef9efb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_efe25d67-86fc-48b9-808c-67c218e2d068" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_TradingSymbol_efe25d67-86fc-48b9-808c-67c218e2d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9818c51d-6a2a-467c-afae-af5c43f6bc56" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_SecurityExchangeName_9818c51d-6a2a-467c-afae-af5c43f6bc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a2e2e3a4-e870-4510-a76d-bf72271cedae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a2e2e3a4-e870-4510-a76d-bf72271cedae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_112cf77c-2419-42f6-9362-c4ff484ef042" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityVoluntaryFilers_112cf77c-2419-42f6-9362-c4ff484ef042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3e275a0a-fe05-4d46-a385-d81de16dc5b0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityCurrentReportingStatus_3e275a0a-fe05-4d46-a385-d81de16dc5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d4a3371a-4528-46e6-8f36-9b995f884093" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityInteractiveDataCurrent_d4a3371a-4528-46e6-8f36-9b995f884093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a1d09022-d09f-498e-82fb-a4c25e859a09" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityFilerCategory_a1d09022-d09f-498e-82fb-a4c25e859a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d219989c-0a6b-4969-b84e-d88a26e066a5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntitySmallBusiness_d219989c-0a6b-4969-b84e-d88a26e066a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9d4a54ad-2b45-4839-9cee-cee0e82d9bfc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityEmergingGrowthCompany_9d4a54ad-2b45-4839-9cee-cee0e82d9bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_bdb18c3e-2b4b-4ca5-bba6-c446162e34ca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_IcfrAuditorAttestationFlag_bdb18c3e-2b4b-4ca5-bba6-c446162e34ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_6e584177-263e-44d2-bd7f-cc84c4d1d277" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_6e584177-263e-44d2-bd7f-cc84c4d1d277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_74a4a650-7730-4492-ac3f-d3be16adc6b1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityShellCompany_74a4a650-7730-4492-ac3f-d3be16adc6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_fd4f2302-ed0b-48ed-a812-c033329c2d89" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityPublicFloat_fd4f2302-ed0b-48ed-a812-c033329c2d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cb53c514-6c2c-4c35-ab16-605b643aa952" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cb53c514-6c2c-4c35-ab16-605b643aa952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_47d2d8e9-f0f5-418e-b933-05fbd5f02162" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_47d2d8e9-f0f5-418e-b933-05fbd5f02162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_404080c8-0cb9-444b-9773-fa20b398df60" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_EntityCentralIndexKey_404080c8-0cb9-444b-9773-fa20b398df60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e58c245b-2445-4843-a1e0-604473ee3dc2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_DocumentFiscalYearFocus_e58c245b-2445-4843-a1e0-604473ee3dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_36ce3ddd-5ab4-4034-a57a-862280f306c0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_DocumentFiscalPeriodFocus_36ce3ddd-5ab4-4034-a57a-862280f306c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_11a416e6-b923-43cb-863d-9c973ee89a44" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d98cddd8-a6f9-4a97-87d3-dfcdf2734851" xlink:to="loc_dei_AmendmentFlag_11a416e6-b923-43cb-863d-9c973ee89a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/AuditInformation" xlink:type="simple" xlink:href="arqt-20251231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AuditInformationAbstract_141b124f-98d9-4e45-afc5-1f538e34abb6" xlink:href="arqt-20251231.xsd#arqt_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_6c59f460-d7dd-4f72-a195-86017b8ca05c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_AuditInformationAbstract_141b124f-98d9-4e45-afc5-1f538e34abb6" xlink:to="loc_dei_AuditorFirmId_6c59f460-d7dd-4f72-a195-86017b8ca05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_aadda02a-4871-49d1-a91d-f8e8f346d231" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_AuditInformationAbstract_141b124f-98d9-4e45-afc5-1f538e34abb6" xlink:to="loc_dei_AuditorName_aadda02a-4871-49d1-a91d-f8e8f346d231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_2c38091e-168b-4fc2-8984-0de2e0ed232c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_AuditInformationAbstract_141b124f-98d9-4e45-afc5-1f538e34abb6" xlink:to="loc_dei_AuditorLocation_2c38091e-168b-4fc2-8984-0de2e0ed232c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_75ffa8a1-bb77-4f26-bcb5-9ae6976a61fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_24bdbf80-d31e-4df5-8f73-80bfd38be590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75ffa8a1-bb77-4f26-bcb5-9ae6976a61fd" xlink:to="loc_us-gaap_AssetsAbstract_24bdbf80-d31e-4df5-8f73-80bfd38be590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2c321837-e68d-4166-a317-2652b31cb214" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24bdbf80-d31e-4df5-8f73-80bfd38be590" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2c321837-e68d-4166-a317-2652b31cb214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e500cc3f-9721-4507-8495-0fcefc4c7103" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c321837-e68d-4166-a317-2652b31cb214" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e500cc3f-9721-4507-8495-0fcefc4c7103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9fa39ff2-984b-477d-9aad-22881fbbbc75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c321837-e68d-4166-a317-2652b31cb214" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_9fa39ff2-984b-477d-9aad-22881fbbbc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9bb24170-029c-4bd9-a5f3-3b65f446df50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c321837-e68d-4166-a317-2652b31cb214" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9bb24170-029c-4bd9-a5f3-3b65f446df50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0e3d7d72-e8a9-4984-b941-9b0335e5cfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c321837-e68d-4166-a317-2652b31cb214" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0e3d7d72-e8a9-4984-b941-9b0335e5cfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0e2c89f2-a698-412e-b972-d76201cd25a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c321837-e68d-4166-a317-2652b31cb214" xlink:to="loc_us-gaap_InventoryNet_0e2c89f2-a698-412e-b972-d76201cd25a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_69339f6e-b746-4cad-ac8c-4e105124e3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c321837-e68d-4166-a317-2652b31cb214" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_69339f6e-b746-4cad-ac8c-4e105124e3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c2b8b9e5-ea4e-4008-b549-135811b51d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c321837-e68d-4166-a317-2652b31cb214" xlink:to="loc_us-gaap_AssetsCurrent_c2b8b9e5-ea4e-4008-b549-135811b51d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_43b921b0-1e7d-42cd-b353-fd7cda91cf36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24bdbf80-d31e-4df5-8f73-80bfd38be590" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_43b921b0-1e7d-42cd-b353-fd7cda91cf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ca9f5a3-57f6-4c31-bd61-eabfb8c8710d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24bdbf80-d31e-4df5-8f73-80bfd38be590" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ca9f5a3-57f6-4c31-bd61-eabfb8c8710d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9a05d40d-ca93-47be-babf-9610d24ed3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24bdbf80-d31e-4df5-8f73-80bfd38be590" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9a05d40d-ca93-47be-babf-9610d24ed3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b98f700d-0c6c-4a03-b725-5a272d8eaaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24bdbf80-d31e-4df5-8f73-80bfd38be590" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b98f700d-0c6c-4a03-b725-5a272d8eaaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c3e8a4ac-2bfb-4fac-983a-94a728965936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24bdbf80-d31e-4df5-8f73-80bfd38be590" xlink:to="loc_us-gaap_Assets_c3e8a4ac-2bfb-4fac-983a-94a728965936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_942e68ce-c040-42a9-8ae7-5e47ab70e4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75ffa8a1-bb77-4f26-bcb5-9ae6976a61fd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_942e68ce-c040-42a9-8ae7-5e47ab70e4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4ced4f81-4213-4bd8-9e74-24ee74676677" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_942e68ce-c040-42a9-8ae7-5e47ab70e4c9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4ced4f81-4213-4bd8-9e74-24ee74676677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dd5d40c1-5e26-4db9-90d4-ad696cb38182" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4ced4f81-4213-4bd8-9e74-24ee74676677" xlink:to="loc_us-gaap_AccountsPayableCurrent_dd5d40c1-5e26-4db9-90d4-ad696cb38182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_033d14d8-541d-4569-8eca-a2a89065af60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4ced4f81-4213-4bd8-9e74-24ee74676677" xlink:to="loc_us-gaap_LongTermDebtCurrent_033d14d8-541d-4569-8eca-a2a89065af60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_94241721-797b-485d-ba8d-c253f881a704" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4ced4f81-4213-4bd8-9e74-24ee74676677" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_94241721-797b-485d-ba8d-c253f881a704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_35782e57-0e4c-414b-aa0a-f5d57f19ff58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4ced4f81-4213-4bd8-9e74-24ee74676677" xlink:to="loc_us-gaap_LiabilitiesCurrent_35782e57-0e4c-414b-aa0a-f5d57f19ff58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c5aeacf8-8bc5-4de1-bdc6-a9291894d17d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_942e68ce-c040-42a9-8ae7-5e47ab70e4c9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c5aeacf8-8bc5-4de1-bdc6-a9291894d17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa3ad7de-6e9b-4624-a702-1621d0bf8d68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_942e68ce-c040-42a9-8ae7-5e47ab70e4c9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aa3ad7de-6e9b-4624-a702-1621d0bf8d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ec6e7bfa-b6fe-461c-8008-c9e073e67c87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_942e68ce-c040-42a9-8ae7-5e47ab70e4c9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ec6e7bfa-b6fe-461c-8008-c9e073e67c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1b1975aa-c606-4829-96fd-36167e4e459e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_942e68ce-c040-42a9-8ae7-5e47ab70e4c9" xlink:to="loc_us-gaap_Liabilities_1b1975aa-c606-4829-96fd-36167e4e459e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87345c61-e6b4-40b2-8e2c-6c85546c7464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_942e68ce-c040-42a9-8ae7-5e47ab70e4c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_87345c61-e6b4-40b2-8e2c-6c85546c7464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_01e0eb91-063f-4cf6-9f19-370e15a8330d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_942e68ce-c040-42a9-8ae7-5e47ab70e4c9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_01e0eb91-063f-4cf6-9f19-370e15a8330d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cd95f1b2-7b68-4132-b255-cc159136ee4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01e0eb91-063f-4cf6-9f19-370e15a8330d" xlink:to="loc_us-gaap_CommonStockValue_cd95f1b2-7b68-4132-b255-cc159136ee4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dc5f22fe-9e0e-428b-a22b-47bc1fb664d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01e0eb91-063f-4cf6-9f19-370e15a8330d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dc5f22fe-9e0e-428b-a22b-47bc1fb664d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7afc66ef-f6a4-4fde-b054-9b69f5c41138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01e0eb91-063f-4cf6-9f19-370e15a8330d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7afc66ef-f6a4-4fde-b054-9b69f5c41138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a064b398-e591-4ffa-b978-7ff62f874002" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01e0eb91-063f-4cf6-9f19-370e15a8330d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a064b398-e591-4ffa-b978-7ff62f874002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7eec9d38-e2d4-481a-a29c-3596c3e394b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01e0eb91-063f-4cf6-9f19-370e15a8330d" xlink:to="loc_us-gaap_StockholdersEquity_7eec9d38-e2d4-481a-a29c-3596c3e394b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9162eb1f-9c98-4af0-be3b-f27ccc22aeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_942e68ce-c040-42a9-8ae7-5e47ab70e4c9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9162eb1f-9c98-4af0-be3b-f27ccc22aeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_417d22fa-a9b0-47e9-ab81-581718173e25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_af3de334-e801-4003-8d21-0d25659975f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_417d22fa-a9b0-47e9-ab81-581718173e25" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_af3de334-e801-4003-8d21-0d25659975f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3421d850-96f3-4978-aead-7f93cd7c0fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_417d22fa-a9b0-47e9-ab81-581718173e25" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3421d850-96f3-4978-aead-7f93cd7c0fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_28d0e900-84c7-4cc7-9b40-5d4c7231a5db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_417d22fa-a9b0-47e9-ab81-581718173e25" xlink:to="loc_us-gaap_CommonStockSharesIssued_28d0e900-84c7-4cc7-9b40-5d4c7231a5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b9899cc4-d556-4f1a-beed-ff453e68840e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_417d22fa-a9b0-47e9-ab81-581718173e25" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b9899cc4-d556-4f1a-beed-ff453e68840e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_80757d92-c26a-4d18-a6f2-f869e833f048" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:to="loc_us-gaap_RevenuesAbstract_80757d92-c26a-4d18-a6f2-f869e833f048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cb34f434-7b64-4df8-84b2-f83bf187290a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_80757d92-c26a-4d18-a6f2-f869e833f048" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cb34f434-7b64-4df8-84b2-f83bf187290a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_e554051c-3adf-4552-a2af-4d0ee174bd87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_80757d92-c26a-4d18-a6f2-f869e833f048" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_e554051c-3adf-4552-a2af-4d0ee174bd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_06fd5504-cd89-4d59-b204-70d2c7c51d19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_80757d92-c26a-4d18-a6f2-f869e833f048" xlink:to="loc_us-gaap_Revenues_06fd5504-cd89-4d59-b204-70d2c7c51d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2dc48630-eada-4f13-b690-349bc94237cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2dc48630-eada-4f13-b690-349bc94237cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3b50e6db-b44b-45be-82b0-1dda1c5a377a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2dc48630-eada-4f13-b690-349bc94237cb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3b50e6db-b44b-45be-82b0-1dda1c5a377a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c5af15e7-a6b9-42e5-9055-ce32d1ecbb03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2dc48630-eada-4f13-b690-349bc94237cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c5af15e7-a6b9-42e5-9055-ce32d1ecbb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8859c813-0737-4ed2-a611-74954d8081f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2dc48630-eada-4f13-b690-349bc94237cb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8859c813-0737-4ed2-a611-74954d8081f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d325a127-65d8-4417-b7ee-84b9f47d0fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2dc48630-eada-4f13-b690-349bc94237cb" xlink:to="loc_us-gaap_CostsAndExpenses_d325a127-65d8-4417-b7ee-84b9f47d0fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_33beef48-678e-46f6-a1d1-0dfbc2d1f2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:to="loc_us-gaap_OperatingIncomeLoss_33beef48-678e-46f6-a1d1-0dfbc2d1f2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_21962913-353c-4db9-a690-7a8c6f3d2774" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_21962913-353c-4db9-a690-7a8c6f3d2774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_019bfeb5-02e1-7fac-8507-ab3f60804c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_21962913-353c-4db9-a690-7a8c6f3d2774" xlink:to="loc_us-gaap_InterestIncomeOther_019bfeb5-02e1-7fac-8507-ab3f60804c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_d3a09711-d55e-43fc-b712-bf3742548b69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_21962913-353c-4db9-a690-7a8c6f3d2774" xlink:to="loc_us-gaap_InterestExpenseNonoperating_d3a09711-d55e-43fc-b712-bf3742548b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1196fb0e-3294-4ab2-9367-19d21567eddc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_21962913-353c-4db9-a690-7a8c6f3d2774" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1196fb0e-3294-4ab2-9367-19d21567eddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_c427dc49-1b05-40d0-bba5-8b3e5067a643" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_c427dc49-1b05-40d0-bba5-8b3e5067a643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cc72d888-1a84-4064-8fb1-cc34105b0d22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cc72d888-1a84-4064-8fb1-cc34105b0d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25e577a5-bdbb-4b5c-a783-69c4627a9583" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:to="loc_us-gaap_NetIncomeLoss_25e577a5-bdbb-4b5c-a783-69c4627a9583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c5dcfb7f-505a-4aa0-8b3a-2c96465c01a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c5dcfb7f-505a-4aa0-8b3a-2c96465c01a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_05768d64-483b-4c19-b0bc-9df4ef0fa3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c5dcfb7f-505a-4aa0-8b3a-2c96465c01a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_05768d64-483b-4c19-b0bc-9df4ef0fa3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1fc68da3-3493-4fed-9d08-a99e79454a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c5dcfb7f-505a-4aa0-8b3a-2c96465c01a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1fc68da3-3493-4fed-9d08-a99e79454a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ac4d6aa8-15a4-4edd-81a2-5416d76dc191" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c5dcfb7f-505a-4aa0-8b3a-2c96465c01a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ac4d6aa8-15a4-4edd-81a2-5416d76dc191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_78179b70-42bc-4a23-b1ff-3ff978b51e08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_78179b70-42bc-4a23-b1ff-3ff978b51e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_4cc833a6-dbc3-42f2-bc82-ae08259de2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_40ec0887-2229-4fa6-823d-fcd624f139f3" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_4cc833a6-dbc3-42f2-bc82-ae08259de2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_157b4182-5179-4f26-b3fd-1be1b7155381" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4cc833a6-dbc3-42f2-bc82-ae08259de2a5" xlink:to="loc_us-gaap_EarningsPerShareBasic_157b4182-5179-4f26-b3fd-1be1b7155381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2b05b92e-2171-4e41-834b-a8c5de4622df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4cc833a6-dbc3-42f2-bc82-ae08259de2a5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2b05b92e-2171-4e41-834b-a8c5de4622df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4eb4e7b3-baac-46e1-8805-2f7d5a8356fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4cc833a6-dbc3-42f2-bc82-ae08259de2a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4eb4e7b3-baac-46e1-8805-2f7d5a8356fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7321ecdb-8d18-4600-a75c-54a55257195f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4cc833a6-dbc3-42f2-bc82-ae08259de2a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7321ecdb-8d18-4600-a75c-54a55257195f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e49f5252-8f34-42a4-b1d8-6d8ce7070b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_33302b67-bb1d-414f-9e42-1c2ac30609fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e49f5252-8f34-42a4-b1d8-6d8ce7070b8b" xlink:to="loc_us-gaap_StatementTable_33302b67-bb1d-414f-9e42-1c2ac30609fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_753d2561-52a5-4410-9533-9ddf51e9f478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33302b67-bb1d-414f-9e42-1c2ac30609fc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_753d2561-52a5-4410-9533-9ddf51e9f478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_753d2561-52a5-4410-9533-9ddf51e9f478" xlink:to="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8894c657-0af0-4a24-8d62-415c8c0badc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:to="loc_us-gaap_CommonStockMember_8894c657-0af0-4a24-8d62-415c8c0badc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ba6c71ec-68de-44e0-a1c2-3a70d167ebd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ba6c71ec-68de-44e0-a1c2-3a70d167ebd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_473eb4d7-1650-492d-8b0c-35f4b16e8e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_473eb4d7-1650-492d-8b0c-35f4b16e8e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c7e5f1e7-c5dc-4eba-a12f-265031e40645" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5460011f-e49e-40c0-aafa-ed341d902a10" xlink:to="loc_us-gaap_RetainedEarningsMember_c7e5f1e7-c5dc-4eba-a12f-265031e40645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6ffdb220-f9aa-4496-9db8-e489d35e35a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33302b67-bb1d-414f-9e42-1c2ac30609fc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6ffdb220-f9aa-4496-9db8-e489d35e35a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13e0679f-3ca4-4c23-a46a-740bd333ba91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6ffdb220-f9aa-4496-9db8-e489d35e35a0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13e0679f-3ca4-4c23-a46a-740bd333ba91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SecondaryEquityPublicOfferingMember_d69b7b65-2037-4119-8cf8-7f92ebd4e995" xlink:href="arqt-20251231.xsd#arqt_SecondaryEquityPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13e0679f-3ca4-4c23-a46a-740bd333ba91" xlink:to="loc_arqt_SecondaryEquityPublicOfferingMember_d69b7b65-2037-4119-8cf8-7f92ebd4e995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5f9462ae-04c7-48b3-9b2c-bd2fa1387689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33302b67-bb1d-414f-9e42-1c2ac30609fc" xlink:to="loc_us-gaap_StatementLineItems_5f9462ae-04c7-48b3-9b2c-bd2fa1387689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5f9462ae-04c7-48b3-9b2c-bd2fa1387689" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_05cf6b73-e45f-4280-aa8d-5d4411e32260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_SharesOutstanding_05cf6b73-e45f-4280-aa8d-5d4411e32260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_90774caa-6803-4600-841f-d61a9f1067dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockholdersEquity_90774caa-6803-4600-841f-d61a9f1067dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cb1e0d5d-f744-4b7c-a8fa-5b62314a3443" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cb1e0d5d-f744-4b7c-a8fa-5b62314a3443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13196159-9338-4236-a3a5-fdb6456dd6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13196159-9338-4236-a3a5-fdb6456dd6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f61ce4e0-1b9c-432f-83be-3a5316419bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f61ce4e0-1b9c-432f-83be-3a5316419bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3ae91bd5-62bb-4aa4-96d4-a9442f9b1e76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3ae91bd5-62bb-4aa4-96d4-a9442f9b1e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_90422e98-8ebb-45b0-b332-c3d329eb5696" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_90422e98-8ebb-45b0-b332-c3d329eb5696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_11f4bab4-c1f3-42b3-8aed-897f63ad5102" xlink:href="arqt-20251231.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_11f4bab4-c1f3-42b3-8aed-897f63ad5102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_02e768f1-d374-4a2a-b1f3-f012c1784cb9" xlink:href="arqt-20251231.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_02e768f1-d374-4a2a-b1f3-f012c1784cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodSharesWarrantsExercised_019bfec1-260b-7bc5-88ba-9beb0c5286f0" xlink:href="arqt-20251231.xsd#arqt_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_arqt_StockIssuedDuringPeriodSharesWarrantsExercised_019bfec1-260b-7bc5-88ba-9beb0c5286f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_56f1869e-e3df-44fe-b542-47c0fbdaa281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_56f1869e-e3df-44fe-b542-47c0fbdaa281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b1116994-3bd4-420e-ad74-77cd3777a59a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b1116994-3bd4-420e-ad74-77cd3777a59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_afac1fd3-8273-4eb3-a158-fe8713b6e47c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_afac1fd3-8273-4eb3-a158-fe8713b6e47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_43bee982-b0c0-486e-a69a-cc0d96b4643c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_43bee982-b0c0-486e-a69a-cc0d96b4643c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4736daae-6974-4461-a621-09f6cc4aa30c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4736daae-6974-4461-a621-09f6cc4aa30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f653ee36-5469-4674-8d39-8fedea7b9ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_NetIncomeLoss_f653ee36-5469-4674-8d39-8fedea7b9ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_aa97cc4e-8053-45e6-ad35-2c71cc45458e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_SharesOutstanding_aa97cc4e-8053-45e6-ad35-2c71cc45458e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4ee5bfcd-0c59-4e9c-82c3-59cdba5baad1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e7b8c91-d02e-476b-be5c-bd826e90c05f" xlink:to="loc_us-gaap_StockholdersEquity_4ee5bfcd-0c59-4e9c-82c3-59cdba5baad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7ddf408c-0c4e-45be-a281-9a7fdb2ee7be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d941dc1d-bcba-4743-aaee-628fcb80e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7ddf408c-0c4e-45be-a281-9a7fdb2ee7be" xlink:to="loc_us-gaap_StatementTable_d941dc1d-bcba-4743-aaee-628fcb80e21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8dd14ca4-69bc-49a0-9e72-1e5118e90d41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d941dc1d-bcba-4743-aaee-628fcb80e21b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8dd14ca4-69bc-49a0-9e72-1e5118e90d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5081a274-54fd-4514-89dc-8861edc5d257" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8dd14ca4-69bc-49a0-9e72-1e5118e90d41" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5081a274-54fd-4514-89dc-8861edc5d257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SecondaryEquityPublicOfferingMember_92a4c63a-7000-4d4f-9477-621803637ec4" xlink:href="arqt-20251231.xsd#arqt_SecondaryEquityPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5081a274-54fd-4514-89dc-8861edc5d257" xlink:to="loc_arqt_SecondaryEquityPublicOfferingMember_92a4c63a-7000-4d4f-9477-621803637ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019bfebe-41ca-7afc-b735-b3783f6f6670" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d941dc1d-bcba-4743-aaee-628fcb80e21b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019bfebe-41ca-7afc-b735-b3783f6f6670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019bfebe-41ca-72fa-b75d-f4892f1dd6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019bfebe-41ca-7afc-b735-b3783f6f6670" xlink:to="loc_us-gaap_EquityComponentDomain_019bfebe-41ca-72fa-b75d-f4892f1dd6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019bfebe-41ca-7b1b-b495-ffd139389e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019bfebe-41ca-72fa-b75d-f4892f1dd6ea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019bfebe-41ca-7b1b-b495-ffd139389e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019bfebf-887b-729d-9817-faf787e68a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019bfebe-41ca-72fa-b75d-f4892f1dd6ea" xlink:to="loc_us-gaap_CommonStockMember_019bfebf-887b-729d-9817-faf787e68a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_60cdc28d-b082-43be-8cb8-b0155cfea18a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d941dc1d-bcba-4743-aaee-628fcb80e21b" xlink:to="loc_us-gaap_StatementLineItems_60cdc28d-b082-43be-8cb8-b0155cfea18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_edd84077-6d3c-40f9-87f9-15460f56fd68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60cdc28d-b082-43be-8cb8-b0155cfea18a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_edd84077-6d3c-40f9-87f9-15460f56fd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arqt-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fb865dd0-3cb9-49b5-a471-8edf58a27440" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6cd8011e-8690-4fdb-8a0a-f82c17046e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fb865dd0-3cb9-49b5-a471-8edf58a27440" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6cd8011e-8690-4fdb-8a0a-f82c17046e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb1a0fbb-379e-4bc3-a4e6-5f25600e40e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6cd8011e-8690-4fdb-8a0a-f82c17046e8a" xlink:to="loc_us-gaap_NetIncomeLoss_cb1a0fbb-379e-4bc3-a4e6-5f25600e40e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635e3f8a-983b-4bb8-af2c-84635d0d8d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6cd8011e-8690-4fdb-8a0a-f82c17046e8a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635e3f8a-983b-4bb8-af2c-84635d0d8d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6261f6cd-f5e4-4a21-ac66-e7e69a6e191c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635e3f8a-983b-4bb8-af2c-84635d0d8d4d" xlink:to="loc_us-gaap_ShareBasedCompensation_6261f6cd-f5e4-4a21-ac66-e7e69a6e191c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_50f11b25-4f19-420f-9629-1d500410ebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635e3f8a-983b-4bb8-af2c-84635d0d8d4d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_50f11b25-4f19-420f-9629-1d500410ebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_86579ee4-eaea-4474-9c10-da4564582aab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635e3f8a-983b-4bb8-af2c-84635d0d8d4d" xlink:to="loc_us-gaap_PaidInKindInterest_86579ee4-eaea-4474-9c10-da4564582aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7d730573-7984-4dd8-bc55-7e1bbc83221c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635e3f8a-983b-4bb8-af2c-84635d0d8d4d" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7d730573-7984-4dd8-bc55-7e1bbc83221c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9d343d58-fa21-441e-90df-c49ebfd159ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635e3f8a-983b-4bb8-af2c-84635d0d8d4d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9d343d58-fa21-441e-90df-c49ebfd159ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_156c4bfc-5380-42e5-a091-620b19b45d29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635e3f8a-983b-4bb8-af2c-84635d0d8d4d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_156c4bfc-5380-42e5-a091-620b19b45d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_80083d2e-c1c3-46b2-b0d9-a43c6063d8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_156c4bfc-5380-42e5-a091-620b19b45d29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_80083d2e-c1c3-46b2-b0d9-a43c6063d8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_54d43675-f643-4213-99ad-afe4fb5fc7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_156c4bfc-5380-42e5-a091-620b19b45d29" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_54d43675-f643-4213-99ad-afe4fb5fc7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_edbef193-9047-4936-a64b-76a3f1a08cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_156c4bfc-5380-42e5-a091-620b19b45d29" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_edbef193-9047-4936-a64b-76a3f1a08cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5250bbe7-508c-4578-9d43-1bbf53c55904" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_156c4bfc-5380-42e5-a091-620b19b45d29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5250bbe7-508c-4578-9d43-1bbf53c55904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_94d44329-36c0-4b1e-ac93-343576dd2131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_156c4bfc-5380-42e5-a091-620b19b45d29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_94d44329-36c0-4b1e-ac93-343576dd2131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_b0fe4596-9ac8-4d69-aa20-1dd49cf3c504" xlink:href="arqt-20251231.xsd#arqt_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_156c4bfc-5380-42e5-a091-620b19b45d29" xlink:to="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_b0fe4596-9ac8-4d69-aa20-1dd49cf3c504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1cc6b646-06be-43f8-9411-bb1aff4a9b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6cd8011e-8690-4fdb-8a0a-f82c17046e8a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1cc6b646-06be-43f8-9411-bb1aff4a9b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e4c7f1-f4c4-4ffa-bfd6-692c7cd03f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fb865dd0-3cb9-49b5-a471-8edf58a27440" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e4c7f1-f4c4-4ffa-bfd6-692c7cd03f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_aa2263a2-565b-4f58-98e6-0c3b04c90a29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e4c7f1-f4c4-4ffa-bfd6-692c7cd03f4e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_aa2263a2-565b-4f58-98e6-0c3b04c90a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_fad4016c-1ac2-40a1-9285-e544a5f300e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e4c7f1-f4c4-4ffa-bfd6-692c7cd03f4e" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_fad4016c-1ac2-40a1-9285-e544a5f300e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_896a2f9d-96f1-4928-b481-08d38dd95709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e4c7f1-f4c4-4ffa-bfd6-692c7cd03f4e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_896a2f9d-96f1-4928-b481-08d38dd95709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8939154e-7379-42f4-a68f-ce2d3e6afb99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e4c7f1-f4c4-4ffa-bfd6-692c7cd03f4e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8939154e-7379-42f4-a68f-ce2d3e6afb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7b7c782-d876-46b9-a993-98d1b2c503f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e4c7f1-f4c4-4ffa-bfd6-692c7cd03f4e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7b7c782-d876-46b9-a993-98d1b2c503f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2149254-48c4-4daf-8b0a-499f2c0d0717" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fb865dd0-3cb9-49b5-a471-8edf58a27440" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2149254-48c4-4daf-8b0a-499f2c0d0717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_49d7d2b3-a2b3-4c67-ba7c-1b227dd1e2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2149254-48c4-4daf-8b0a-499f2c0d0717" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_49d7d2b3-a2b3-4c67-ba7c-1b227dd1e2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a5ead54d-9834-400d-b545-46cd0d13fd60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2149254-48c4-4daf-8b0a-499f2c0d0717" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a5ead54d-9834-400d-b545-46cd0d13fd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a9f9fa36-6991-454c-92bb-c34bb9c44f61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2149254-48c4-4daf-8b0a-499f2c0d0717" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a9f9fa36-6991-454c-92bb-c34bb9c44f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_e84af306-69f3-412f-99b7-b6f70bd3ddae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2149254-48c4-4daf-8b0a-499f2c0d0717" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_e84af306-69f3-412f-99b7-b6f70bd3ddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_fa6943bf-2a4c-4b8f-810a-d2280bbe190c" xlink:href="arqt-20251231.xsd#arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2149254-48c4-4daf-8b0a-499f2c0d0717" xlink:to="loc_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_fa6943bf-2a4c-4b8f-810a-d2280bbe190c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts_9508470a-1994-4032-8ec2-90bc156aeb27" xlink:href="arqt-20251231.xsd#arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2149254-48c4-4daf-8b0a-499f2c0d0717" xlink:to="loc_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts_9508470a-1994-4032-8ec2-90bc156aeb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75c43934-11cb-440f-b0e8-a3bef75fe4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2149254-48c4-4daf-8b0a-499f2c0d0717" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75c43934-11cb-440f-b0e8-a3bef75fe4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_ffae7282-fc54-401c-a3e0-9d140a4a61b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fb865dd0-3cb9-49b5-a471-8edf58a27440" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_ffae7282-fc54-401c-a3e0-9d140a4a61b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16c2f0a9-696e-461f-8eed-e555b2cef933" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fb865dd0-3cb9-49b5-a471-8edf58a27440" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16c2f0a9-696e-461f-8eed-e555b2cef933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_646fd96d-a1ac-4733-b46d-c9d909518a38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fb865dd0-3cb9-49b5-a471-8edf58a27440" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_646fd96d-a1ac-4733-b46d-c9d909518a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d3522f4-0405-4fc7-8057-0e81d9c2328c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fb865dd0-3cb9-49b5-a471-8edf58a27440" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d3522f4-0405-4fc7-8057-0e81d9c2328c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8d092b92-21db-451a-9db0-4f29b579cd58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fb865dd0-3cb9-49b5-a471-8edf58a27440" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8d092b92-21db-451a-9db0-4f29b579cd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_981c4f40-4267-421e-9230-61133b3266ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8d092b92-21db-451a-9db0-4f29b579cd58" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_981c4f40-4267-421e-9230-61133b3266ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7adfe67b-621d-418c-af55-7afd951d7a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fb865dd0-3cb9-49b5-a471-8edf58a27440" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7adfe67b-621d-418c-af55-7afd951d7a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b90293f7-d945-41c8-83fa-9e650140670b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7adfe67b-621d-418c-af55-7afd951d7a5c" xlink:to="loc_us-gaap_InterestPaidNet_b90293f7-d945-41c8-83fa-9e650140670b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="arqt-20251231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_066d32c7-748d-4919-b160-063d7e1e9041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8faee072-58fc-49bb-994d-d5af03ef495c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_066d32c7-748d-4919-b160-063d7e1e9041" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8faee072-58fc-49bb-994d-d5af03ef495c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="arqt-20251231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_750e1354-e2df-4160-b416-4b34cf379b37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ddd1a0d7-9e74-41cd-aad1-f789599e870f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_750e1354-e2df-4160-b416-4b34cf379b37" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ddd1a0d7-9e74-41cd-aad1-f789599e870f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/Revenues" xlink:type="simple" xlink:href="arqt-20251231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c12ddd15-32da-48ac-8ab8-50a4f8db8f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7955915c-a4a6-476d-91e2-4bb3e81d3b42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c12ddd15-32da-48ac-8ab8-50a4f8db8f8b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7955915c-a4a6-476d-91e2-4bb3e81d3b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eede7ad0-f83b-49a7-ba9a-54a6cc8a3be8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_80d02533-5326-4403-85e4-c997fe5af535" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eede7ad0-f83b-49a7-ba9a-54a6cc8a3be8" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_80d02533-5326-4403-85e4-c997fe5af535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="arqt-20251231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_240edd2b-f2c4-4865-8b22-01c9c0b8745d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_28b96ebf-56a9-4fc0-950c-bda4d405b0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_240edd2b-f2c4-4865-8b22-01c9c0b8745d" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_28b96ebf-56a9-4fc0-950c-bda4d405b0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="arqt-20251231.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dd785c76-0f99-4169-9493-a67782898b12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_944a38dc-39ea-4f27-843a-93b8953e810d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dd785c76-0f99-4169-9493-a67782898b12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_944a38dc-39ea-4f27-843a-93b8953e810d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisition" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisition"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_99a2299c-ecc4-441e-be6b-817d7be71044" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementsAndAcquisitionsTextBlock_30f157a7-e9ce-4101-ab05-bfab0a59e1e2" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementsAndAcquisitionsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_99a2299c-ecc4-441e-be6b-817d7be71044" xlink:to="loc_arqt_LicenseAgreementsAndAcquisitionsTextBlock_30f157a7-e9ce-4101-ab05-bfab0a59e1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arqt-20251231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3896230-b0c8-4e26-b27a-75d66cfe0540" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f232fa07-59f8-49ca-83ed-04470e004527" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3896230-b0c8-4e26-b27a-75d66cfe0540" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f232fa07-59f8-49ca-83ed-04470e004527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/Debt" xlink:type="simple" xlink:href="arqt-20251231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a79c8be4-c817-45df-a267-cc00b44fad18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_27d420b2-122a-4476-ad34-c83aaeaa73dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a79c8be4-c817-45df-a267-cc00b44fad18" xlink:to="loc_us-gaap_LongTermDebtTextBlock_27d420b2-122a-4476-ad34-c83aaeaa73dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockholdersEquity" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98bbcf02-bd97-45a9-a2da-015043a069ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_861b7bc4-214a-460c-bd4a-16400a635ead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98bbcf02-bd97-45a9-a2da-015043a069ad" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_861b7bc4-214a-460c-bd4a-16400a635ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxes" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_92939b58-0f1c-43f3-8136-b58ebe6a2ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5a199e0e-e56e-4a76-91f0-be2dbe2513b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_92939b58-0f1c-43f3-8136-b58ebe6a2ebd" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5a199e0e-e56e-4a76-91f0-be2dbe2513b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShare" xlink:type="simple" xlink:href="arqt-20251231.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dbfbf917-4629-4363-bbad-93b7db839e17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f2e1ac29-7c85-48b3-82cf-775cf1df8d74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dbfbf917-4629-4363-bbad-93b7db839e17" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f2e1ac29-7c85-48b3-82cf-775cf1df8d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SegmentReporting" xlink:type="simple" xlink:href="arqt-20251231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b03829d1-d72b-47c6-b82f-e741f756170c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_e1fc8d9b-041d-4467-9a74-cf6b08a463db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b03829d1-d72b-47c6-b82f-e741f756170c" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_e1fc8d9b-041d-4467-9a74-cf6b08a463db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arqt-20251231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f23699cd-591d-41f6-bfdc-f63c52b82e87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f23699cd-591d-41f6-bfdc-f63c52b82e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_bee53ec2-085b-486d-95af-d06f00baa76e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_bee53ec2-085b-486d-95af-d06f00baa76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_182983f1-f46e-4077-8b14-5d9a17aa04a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_UseOfEstimates_182983f1-f46e-4077-8b14-5d9a17aa04a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9c7af55a-60ce-4454-b89c-de7b98483cda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9c7af55a-60ce-4454-b89c-de7b98483cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_9f01f6e6-d886-473c-82f5-162a80d070df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_9f01f6e6-d886-473c-82f5-162a80d070df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_779ebc1e-28ba-413d-9f02-8d40e62c547e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_779ebc1e-28ba-413d-9f02-8d40e62c547e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_eb8bffec-6321-41b7-80c9-6030e58e70bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_eb8bffec-6321-41b7-80c9-6030e58e70bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9c885445-9aff-440a-b5d1-338a45901fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9c885445-9aff-440a-b5d1-338a45901fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_218d9f73-a746-4271-935e-a2501c4048e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_218d9f73-a746-4271-935e-a2501c4048e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_a954352d-eac7-4a8d-9d3f-98ea5e56ee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_a954352d-eac7-4a8d-9d3f-98ea5e56ee9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7b7aceda-f89d-47ff-88a5-8e0a7d3bcb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7b7aceda-f89d-47ff-88a5-8e0a7d3bcb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f44ea5c9-cf16-4965-a597-72643cf2302a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f44ea5c9-cf16-4965-a597-72643cf2302a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_70b7e122-1edd-4813-a9f4-0c3d3b952ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_70b7e122-1edd-4813-a9f4-0c3d3b952ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock_019c650b-d251-75d3-87b4-399729914fce" xlink:href="arqt-20251231.xsd#arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock_019c650b-d251-75d3-87b4-399729914fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_108cc2af-1c90-43e9-8b71-94d2378944a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_108cc2af-1c90-43e9-8b71-94d2378944a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock_4b3b0d64-0149-4bf6-8c7f-3e7dbd0cd1bc" xlink:href="arqt-20251231.xsd#arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock_4b3b0d64-0149-4bf6-8c7f-3e7dbd0cd1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_3232e2fd-434c-4caa-ac2e-9395ae99a74c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_3232e2fd-434c-4caa-ac2e-9395ae99a74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7d4f0036-eee6-439b-a88d-693fba5d12ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7d4f0036-eee6-439b-a88d-693fba5d12ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_c574663f-cd05-4425-a929-e0e12804d311" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_c574663f-cd05-4425-a929-e0e12804d311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0e8b3f3b-d565-4af8-a6a2-fb6b06a3050c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0e8b3f3b-d565-4af8-a6a2-fb6b06a3050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_90183e5d-0994-40ee-9f35-fa37e52cf9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_90183e5d-0994-40ee-9f35-fa37e52cf9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_83308679-bebb-42c8-aeff-5284c958b9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_83308679-bebb-42c8-aeff-5284c958b9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CoPromotionAgreementsPolicyPolicyTextBlock_e1107761-bcdc-41dd-818f-0d682ecb9079" xlink:href="arqt-20251231.xsd#arqt_CoPromotionAgreementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_arqt_CoPromotionAgreementsPolicyPolicyTextBlock_e1107761-bcdc-41dd-818f-0d682ecb9079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8c3f0cc3-9303-4522-bb60-f6871c15dd47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a989f5c-a43c-40a1-ab5b-6bdad11b195a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8c3f0cc3-9303-4522-bb60-f6871c15dd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b668f47e-b21f-40ce-a35b-54aaa60094d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4abb067b-33fa-4e9f-b72e-d6b43dc5dd42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b668f47e-b21f-40ce-a35b-54aaa60094d4" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4abb067b-33fa-4e9f-b72e-d6b43dc5dd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/RevenuesTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e9a57d39-851e-40de-9062-3ef4d94a433d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f7cc4863-2685-4bbe-ad37-2fff0f4df5af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e9a57d39-851e-40de-9062-3ef4d94a433d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f7cc4863-2685-4bbe-ad37-2fff0f4df5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_fe6fe528-34ad-4567-b949-42415b1d9cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e9a57d39-851e-40de-9062-3ef4d94a433d" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_fe6fe528-34ad-4567-b949-42415b1d9cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dc42fe82-d29b-4231-892b-fdaa365d4d36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ef117183-e4b2-46ff-a20e-07b1ed0376be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dc42fe82-d29b-4231-892b-fdaa365d4d36" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ef117183-e4b2-46ff-a20e-07b1ed0376be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_35e890c3-3eb1-4aae-89bf-1cd98ef317be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dc42fe82-d29b-4231-892b-fdaa365d4d36" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_35e890c3-3eb1-4aae-89bf-1cd98ef317be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019c276a-a0f0-7aaf-b4bb-399ef299b916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dc42fe82-d29b-4231-892b-fdaa365d4d36" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019c276a-a0f0-7aaf-b4bb-399ef299b916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_13d99137-7b5c-4166-b5cf-8771bc6ca47e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dc42fe82-d29b-4231-892b-fdaa365d4d36" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_13d99137-7b5c-4166-b5cf-8771bc6ca47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bb9783d9-fc24-45c6-9bfe-0515c6dc30ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5b7d63f4-0d3e-401d-ab7e-c2f4808c6ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bb9783d9-fc24-45c6-9bfe-0515c6dc30ac" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5b7d63f4-0d3e-401d-ab7e-c2f4808c6ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_6076b1c4-eafc-41a5-b301-445e1c46f143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bb9783d9-fc24-45c6-9bfe-0515c6dc30ac" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_6076b1c4-eafc-41a5-b301-445e1c46f143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_cd42520c-da53-4920-aeeb-f4d4a618cb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bb9783d9-fc24-45c6-9bfe-0515c6dc30ac" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_cd42520c-da53-4920-aeeb-f4d4a618cb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5181d8ed-6ffe-4dff-a98e-56776df2de27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6c6e1bcc-3b12-4bc4-a2bc-9eb099be8fba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5181d8ed-6ffe-4dff-a98e-56776df2de27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6c6e1bcc-3b12-4bc4-a2bc-9eb099be8fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0b39104e-e8cc-4ec4-a7ff-91a74f7212e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ca835ff4-2e03-4f84-87d8-9df854c45bed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0b39104e-e8cc-4ec4-a7ff-91a74f7212e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ca835ff4-2e03-4f84-87d8-9df854c45bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ed3f0dc1-eeb6-4e66-b45b-2adf80331eec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0b39104e-e8cc-4ec4-a7ff-91a74f7212e3" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_ed3f0dc1-eeb6-4e66-b45b-2adf80331eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/DebtTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1385e30f-7e03-4e56-a3b2-db2206c13fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f0c24230-e51c-4794-b1af-02c3f201ac17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1385e30f-7e03-4e56-a3b2-db2206c13fb6" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f0c24230-e51c-4794-b1af-02c3f201ac17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_623e2b0a-ef57-4948-bf15-e6664f03b125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5feaf80b-7a52-4f1e-908d-180d42068a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_623e2b0a-ef57-4948-bf15-e6664f03b125" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5feaf80b-7a52-4f1e-908d-180d42068a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_caaa832c-5bda-4a16-a53c-143d263bee7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_623e2b0a-ef57-4948-bf15-e6664f03b125" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_caaa832c-5bda-4a16-a53c-143d263bee7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_40b33a0e-8475-4997-a09a-d141b2c83fae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_623e2b0a-ef57-4948-bf15-e6664f03b125" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_40b33a0e-8475-4997-a09a-d141b2c83fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bd1d8eba-687b-4e5c-a878-ced63949f86c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_623e2b0a-ef57-4948-bf15-e6664f03b125" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bd1d8eba-687b-4e5c-a878-ced63949f86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b12a6245-4a3d-4ba5-8a2f-997ab50a7d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_38dbc8e5-d951-4a61-9894-550cf62d2d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b12a6245-4a3d-4ba5-8a2f-997ab50a7d4c" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_38dbc8e5-d951-4a61-9894-550cf62d2d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9ff4f323-023e-464a-96a4-10e2eb9b62c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b12a6245-4a3d-4ba5-8a2f-997ab50a7d4c" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9ff4f323-023e-464a-96a4-10e2eb9b62c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8ecea09f-a8cc-4f5a-b1b3-6c4c81fa64b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b12a6245-4a3d-4ba5-8a2f-997ab50a7d4c" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8ecea09f-a8cc-4f5a-b1b3-6c4c81fa64b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6b737cb6-0622-46a9-ae79-0152410e0d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b12a6245-4a3d-4ba5-8a2f-997ab50a7d4c" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6b737cb6-0622-46a9-ae79-0152410e0d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0d2d56dd-f46c-4a99-9be2-9d9e3b5345bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b12a6245-4a3d-4ba5-8a2f-997ab50a7d4c" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0d2d56dd-f46c-4a99-9be2-9d9e3b5345bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_abd0e9b6-1e27-4a4c-8608-b00ec1f190ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_227f12b1-503a-4148-9fcb-ab6415189bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_abd0e9b6-1e27-4a4c-8608-b00ec1f190ff" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_227f12b1-503a-4148-9fcb-ab6415189bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="arqt-20251231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9f4c685e-a10a-4fa3-90af-007d255c1241" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_fefd4012-a183-44c2-b9aa-15a97619b935" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9f4c685e-a10a-4fa3-90af-007d255c1241" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_fefd4012-a183-44c2-b9aa-15a97619b935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d3496752-5148-4dbc-b883-9a1592b6c0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09041ab8-b053-418c-85b9-5fe1828f82af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d3496752-5148-4dbc-b883-9a1592b6c0a4" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09041ab8-b053-418c-85b9-5fe1828f82af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019bfec5-e300-7bcf-aebc-fa74ec647dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09041ab8-b053-418c-85b9-5fe1828f82af" xlink:to="loc_us-gaap_DebtInstrumentAxis_019bfec5-e300-7bcf-aebc-fa74ec647dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019bfec5-e300-7933-905c-c6b251263f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019bfec5-e300-7bcf-aebc-fa74ec647dd3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019bfec5-e300-7933-905c-c6b251263f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementMember_019bfec5-e300-731d-9059-26acba247a67" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019bfec5-e300-7933-905c-c6b251263f23" xlink:to="loc_arqt_LoanAgreementMember_019bfec5-e300-731d-9059-26acba247a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019bfec5-e300-7653-b790-deb8d96b4ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09041ab8-b053-418c-85b9-5fe1828f82af" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019bfec5-e300-7653-b790-deb8d96b4ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019bfec5-e300-7358-bbd5-78ff77a0333d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019bfec5-e300-7653-b790-deb8d96b4ce2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019bfec5-e300-7358-bbd5-78ff77a0333d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019bfec5-e300-77ba-991d-8a7de2c453bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019bfec5-e300-7358-bbd5-78ff77a0333d" xlink:to="loc_us-gaap_SecuredDebtMember_019bfec5-e300-77ba-991d-8a7de2c453bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_019bfec5-e300-7d3a-ba65-964b462b9e62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09041ab8-b053-418c-85b9-5fe1828f82af" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_019bfec5-e300-7d3a-ba65-964b462b9e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019bfec5-e300-721b-b87b-ed86f71a1d68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019bfec5-e300-7d3a-ba65-964b462b9e62" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019bfec5-e300-721b-b87b-ed86f71a1d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashCashEquivalentsAndMarketableSecurities_019bfec5-e300-7bc5-af90-e61ff5e83f56" xlink:href="arqt-20251231.xsd#arqt_CashCashEquivalentsAndMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019bfec5-e300-7d3a-ba65-964b462b9e62" xlink:to="loc_arqt_CashCashEquivalentsAndMarketableSecurities_019bfec5-e300-7bc5-af90-e61ff5e83f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019bfec5-e300-7946-9eab-10a5ee499312" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019bfec5-e300-7d3a-ba65-964b462b9e62" xlink:to="loc_us-gaap_LongTermDebt_019bfec5-e300-7946-9eab-10a5ee499312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_df1e47fd-c6f1-40a5-8972-28d8222ca7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df1e47fd-c6f1-40a5-8972-28d8222ca7ec" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_10869eb1-0bae-47f0-9ac5-e53003cc7eb3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:to="loc_srt_RangeAxis_10869eb1-0bae-47f0-9ac5-e53003cc7eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_179cd4b2-fa17-45e8-9a97-454d0c551c74" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_10869eb1-0bae-47f0-9ac5-e53003cc7eb3" xlink:to="loc_srt_RangeMember_179cd4b2-fa17-45e8-9a97-454d0c551c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_249185f0-d082-4c67-a46e-4b3d0fcbd4fe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_179cd4b2-fa17-45e8-9a97-454d0c551c74" xlink:to="loc_srt_MinimumMember_249185f0-d082-4c67-a46e-4b3d0fcbd4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d26a160-ae15-4ec7-93db-f83200be09e1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_179cd4b2-fa17-45e8-9a97-454d0c551c74" xlink:to="loc_srt_MaximumMember_1d26a160-ae15-4ec7-93db-f83200be09e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8129562b-55e3-4dda-a329-b7e5117b0444" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8129562b-55e3-4dda-a329-b7e5117b0444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40ed39c1-5e8b-4eea-9132-fab6de93a083" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8129562b-55e3-4dda-a329-b7e5117b0444" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40ed39c1-5e8b-4eea-9132-fab6de93a083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_7b39cc9e-6186-4f65-b3b9-bb4f9f1da32d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40ed39c1-5e8b-4eea-9132-fab6de93a083" xlink:to="loc_us-gaap_PatentsMember_7b39cc9e-6186-4f65-b3b9-bb4f9f1da32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f57ab9ad-bdc3-40d6-8745-4f1a5d67be03" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:to="loc_srt_CounterpartyNameAxis_f57ab9ad-bdc3-40d6-8745-4f1a5d67be03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40a5e2a7-4873-4ab0-926b-f71a550f3fb2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f57ab9ad-bdc3-40d6-8745-4f1a5d67be03" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40a5e2a7-4873-4ab0-926b-f71a550f3fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AstraZenecaMember_4c7e175b-e187-4f0f-a51e-2f11cff1e38d" xlink:href="arqt-20251231.xsd#arqt_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40a5e2a7-4873-4ab0-926b-f71a550f3fb2" xlink:to="loc_arqt_AstraZenecaMember_4c7e175b-e187-4f0f-a51e-2f11cff1e38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_47edc181-a4ec-4504-83e2-ee9687c98169" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_cfe85cbc-69bc-4cac-a894-2fafe8b3e06c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_cfe85cbc-69bc-4cac-a894-2fafe8b3e06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_36463934-69e9-47db-9797-c1129890a1eb" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_36463934-69e9-47db-9797-c1129890a1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72518094-2cd5-49d1-a25b-adb31d2938d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72518094-2cd5-49d1-a25b-adb31d2938d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_019c71cf-bd7a-7fd2-9391-2ac2d5b6aa12" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_019c71cf-bd7a-7fd2-9391-2ac2d5b6aa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_30bae120-fb2e-4fcf-a459-e1972bc1f0a0" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_30bae120-fb2e-4fcf-a459-e1972bc1f0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fdf030ac-e354-4f25-970e-219028ad5fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fdf030ac-e354-4f25-970e-219028ad5fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_019c274e-e894-7da6-8bb3-9b23da999743" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_019c274e-e894-7da6-8bb3-9b23da999743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ff26ce60-8c04-4c3a-aa4a-2559058eed77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ff26ce60-8c04-4c3a-aa4a-2559058eed77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_637dd07b-a192-49bd-9bda-cfc782fde6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_637dd07b-a192-49bd-9bda-cfc782fde6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ProductRevenuePaymentTerm_e7fc31ae-237a-479b-8542-1673d6e2d012" xlink:href="arqt-20251231.xsd#arqt_ProductRevenuePaymentTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_arqt_ProductRevenuePaymentTerm_e7fc31ae-237a-479b-8542-1673d6e2d012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_225dd2a6-8b0f-4a51-ba1f-1e934295cee2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_AdvertisingExpense_225dd2a6-8b0f-4a51-ba1f-1e934295cee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_11bd81aa-fc99-462f-a9f8-339e4e1fb490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76f3126c-45b9-453d-a13e-41481e735dcf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_11bd81aa-fc99-462f-a9f8-339e4e1fb490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_be5e1224-c6ff-48df-888d-7281343c8bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cea4e8d3-06e7-4907-a214-a2a1b378c0df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be5e1224-c6ff-48df-888d-7281343c8bcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cea4e8d3-06e7-4907-a214-a2a1b378c0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7e4f9ae9-5ff0-495a-ba9e-ba25d408d644" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be5e1224-c6ff-48df-888d-7281343c8bcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7e4f9ae9-5ff0-495a-ba9e-ba25d408d644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4fd7040e-0034-428f-8207-71ca7f0fa109" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be5e1224-c6ff-48df-888d-7281343c8bcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4fd7040e-0034-428f-8207-71ca7f0fa109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_99292823-94a9-45cb-8111-b26103789a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be5e1224-c6ff-48df-888d-7281343c8bcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_99292823-94a9-45cb-8111-b26103789a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2a5c281a-a9b7-4221-926e-ebfc8b814dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be5e1224-c6ff-48df-888d-7281343c8bcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2a5c281a-a9b7-4221-926e-ebfc8b814dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5511c660-fce2-4b2b-bfba-ce96f96f5cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be5e1224-c6ff-48df-888d-7281343c8bcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5511c660-fce2-4b2b-bfba-ce96f96f5cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_57ba3d96-c59b-48d4-8e6e-76846b748f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be5e1224-c6ff-48df-888d-7281343c8bcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_57ba3d96-c59b-48d4-8e6e-76846b748f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#RevenuesScheduleofDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6fd47cdd-ad84-42e8-909d-0870f0da46ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_88f0686f-d8c5-4f2d-8718-cb4648327ded" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6fd47cdd-ad84-42e8-909d-0870f0da46ff" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_88f0686f-d8c5-4f2d-8718-cb4648327ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_53c2675b-e780-4919-9bfc-b0d12ee91779" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_88f0686f-d8c5-4f2d-8718-cb4648327ded" xlink:to="loc_srt_ProductOrServiceAxis_53c2675b-e780-4919-9bfc-b0d12ee91779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_53c2675b-e780-4919-9bfc-b0d12ee91779" xlink:to="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVECream0.3Member_9806f8f0-7211-445a-8fae-d7f4ce02d5e2" xlink:href="arqt-20251231.xsd#arqt_ZORYVECream0.3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:to="loc_arqt_ZORYVECream0.3Member_9806f8f0-7211-445a-8fae-d7f4ce02d5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVEFoamMember_eb296daf-6c52-4b6d-a3fb-2eba6588781b" xlink:href="arqt-20251231.xsd#arqt_ZORYVEFoamMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:to="loc_arqt_ZORYVEFoamMember_eb296daf-6c52-4b6d-a3fb-2eba6588781b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVECream0.15Member_02cafb30-9aa4-4880-832d-a5761d443eb4" xlink:href="arqt-20251231.xsd#arqt_ZORYVECream0.15Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:to="loc_arqt_ZORYVECream0.15Member_02cafb30-9aa4-4880-832d-a5761d443eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ZORYVECream0.05Member_019bfec9-2cf0-70e5-b30b-f9fa09086143" xlink:href="arqt-20251231.xsd#arqt_ZORYVECream0.05Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00992dee-8a7f-4db0-9568-b79f0a97532b" xlink:to="loc_arqt_ZORYVECream0.05Member_019bfec9-2cf0-70e5-b30b-f9fa09086143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ebdb1f5b-4d4a-4fb6-84e1-b2b1017f7b55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_88f0686f-d8c5-4f2d-8718-cb4648327ded" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ebdb1f5b-4d4a-4fb6-84e1-b2b1017f7b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3b534fbd-7cae-4605-b5e8-c23428fd8a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebdb1f5b-4d4a-4fb6-84e1-b2b1017f7b55" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3b534fbd-7cae-4605-b5e8-c23428fd8a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_d40458ac-1f98-4271-8c6a-79004c298837" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebdb1f5b-4d4a-4fb6-84e1-b2b1017f7b55" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_d40458ac-1f98-4271-8c6a-79004c298837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_63e1b89c-da79-4ba5-bd49-9d7d917fefef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebdb1f5b-4d4a-4fb6-84e1-b2b1017f7b55" xlink:to="loc_us-gaap_Revenues_63e1b89c-da79-4ba5-bd49-9d7d917fefef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c275d-e9d7-744d-ab32-57377e7d5ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c275d-e9d7-744d-ab32-57377e7d5ec9" xlink:to="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c275e-7338-7017-ac9b-e67de508bb05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c275e-7338-7017-ac9b-e67de508bb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c275e-7338-7dbb-a87a-457d6bdee322" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019c275e-7338-7017-ac9b-e67de508bb05" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c275e-7338-7dbb-a87a-457d6bdee322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_019c275f-64e8-7870-bb31-8d0f8c885187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019c275e-7338-7dbb-a87a-457d6bdee322" xlink:to="loc_us-gaap_AccountsReceivableMember_019c275f-64e8-7870-bb31-8d0f8c885187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019c275e-7338-7d5c-8182-24c0341a5cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019c275e-7338-7d5c-8182-24c0341a5cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019c275e-7338-7626-bae4-7ddfe06b6df0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019c275e-7338-7d5c-8182-24c0341a5cdf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019c275e-7338-7626-bae4-7ddfe06b6df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_019c275e-7338-748a-ab2e-f538b0f2c563" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019c275e-7338-7626-bae4-7ddfe06b6df0" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_019c275e-7338-748a-ab2e-f538b0f2c563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019c275f-64e8-7a6a-94ff-827f3e182945" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:to="loc_srt_MajorCustomersAxis_019c275f-64e8-7a6a-94ff-827f3e182945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c275f-64e8-7e06-aa76-6d23d8696b0b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_019c275f-64e8-7a6a-94ff-827f3e182945" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c275f-64e8-7e06-aa76-6d23d8696b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FourCustomersMember_019c275f-64e8-7bc2-b374-ae15727d18e8" xlink:href="arqt-20251231.xsd#arqt_FourCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c275f-64e8-7e06-aa76-6d23d8696b0b" xlink:to="loc_arqt_FourCustomersMember_019c275f-64e8-7bc2-b374-ae15727d18e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FiveCustomersMember_019c275f-64e8-7bdc-bd94-a463e8ad704b" xlink:href="arqt-20251231.xsd#arqt_FiveCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c275f-64e8-7e06-aa76-6d23d8696b0b" xlink:to="loc_arqt_FiveCustomersMember_019c275f-64e8-7bdc-bd94-a463e8ad704b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019c275e-7338-76c1-a48f-548ee594caa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019c275e-7338-7af7-9fcd-b350eedb0f21" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_019c275e-7338-76c1-a48f-548ee594caa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019c275e-7338-70e6-b5c4-4da4df01a001" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019c275e-7338-76c1-a48f-548ee594caa9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019c275e-7338-70e6-b5c4-4da4df01a001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#RevenuesGrossProductSalesandAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9c06654b-c459-4968-a5ac-e84f3dadd7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9c06654b-c459-4968-a5ac-e84f3dadd7e4" xlink:to="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_31ea6d84-f6a7-48c8-8bda-699118acfb3a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:to="loc_srt_MajorCustomersAxis_31ea6d84-f6a7-48c8-8bda-699118acfb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_31ea6d84-f6a7-48c8-8bda-699118acfb3a" xlink:to="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerAMember_9a79a941-02c8-4e7e-a5d3-819d8b0b8b1d" xlink:href="arqt-20251231.xsd#arqt_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerAMember_9a79a941-02c8-4e7e-a5d3-819d8b0b8b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerBMember_ac1c2466-b830-450c-b3db-b50c87d14d91" xlink:href="arqt-20251231.xsd#arqt_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerBMember_ac1c2466-b830-450c-b3db-b50c87d14d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerCMember_73bb0df7-7a19-434c-ac26-3e452f0639f2" xlink:href="arqt-20251231.xsd#arqt_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerCMember_73bb0df7-7a19-434c-ac26-3e452f0639f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerDMember_458a6552-6047-42dd-a495-6e19bb8c85ef" xlink:href="arqt-20251231.xsd#arqt_CustomerDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerDMember_458a6552-6047-42dd-a495-6e19bb8c85ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerEMember_81030680-bf05-4dd4-94cf-683e7c4a5e62" xlink:href="arqt-20251231.xsd#arqt_CustomerEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerEMember_81030680-bf05-4dd4-94cf-683e7c4a5e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CustomerFMember_44f974d4-3ee1-4d9d-b2da-6ce68ce93d0e" xlink:href="arqt-20251231.xsd#arqt_CustomerFMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_CustomerFMember_44f974d4-3ee1-4d9d-b2da-6ce68ce93d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_MajorCustomersMember_5375367f-e9e4-4a8b-a829-70baa03bcdb4" xlink:href="arqt-20251231.xsd#arqt_MajorCustomersMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_be5f4caa-0ab3-49bb-a172-cdd7dba6edd8" xlink:to="loc_arqt_MajorCustomersMember_5375367f-e9e4-4a8b-a829-70baa03bcdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb04b893-c345-43d2-86f9-1cc043e710f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb04b893-c345-43d2-86f9-1cc043e710f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fa6b473-6119-47fa-9733-a30cb747c9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb04b893-c345-43d2-86f9-1cc043e710f7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fa6b473-6119-47fa-9733-a30cb747c9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_11e281c8-6b69-46c4-8080-e66d49678335" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fa6b473-6119-47fa-9733-a30cb747c9d1" xlink:to="loc_us-gaap_SalesMember_11e281c8-6b69-46c4-8080-e66d49678335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b337f741-df3a-433f-a59f-1bdc08ce8080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fa6b473-6119-47fa-9733-a30cb747c9d1" xlink:to="loc_us-gaap_AccountsReceivableMember_b337f741-df3a-433f-a59f-1bdc08ce8080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fe0ac1ca-eb0d-4706-834f-4e45577b2490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fe0ac1ca-eb0d-4706-834f-4e45577b2490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4e330f94-49d6-4b3c-a9f4-31a678f510fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fe0ac1ca-eb0d-4706-834f-4e45577b2490" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4e330f94-49d6-4b3c-a9f4-31a678f510fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_37063b04-8e13-4eab-af7a-080634a40ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4e330f94-49d6-4b3c-a9f4-31a678f510fe" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_37063b04-8e13-4eab-af7a-080634a40ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7cce8d5d-b278-4534-9abd-651ca4dd7d07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6c3a55cd-ed6e-4d1a-aeaa-812d8a304f49" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_7cce8d5d-b278-4534-9abd-651ca4dd7d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_cc3dceb9-02e7-41c9-ab54-54552dd68f33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7cce8d5d-b278-4534-9abd-651ca4dd7d07" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_cc3dceb9-02e7-41c9-ab54-54552dd68f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a3a97078-bfc1-41ba-b3e3-0bcba085d170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a3a97078-bfc1-41ba-b3e3-0bcba085d170" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a8623f9-3c95-42b7-ba35-4eab1eb590ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a8623f9-3c95-42b7-ba35-4eab1eb590ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66dd3690-2745-430e-a00e-f3a9caab0f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a8623f9-3c95-42b7-ba35-4eab1eb590ea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66dd3690-2745-430e-a00e-f3a9caab0f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1fdc15ad-a406-4db7-ab8a-4da6d4e44e49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66dd3690-2745-430e-a00e-f3a9caab0f81" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1fdc15ad-a406-4db7-ab8a-4da6d4e44e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9355feea-eacc-4e68-849e-dc249c311392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66dd3690-2745-430e-a00e-f3a9caab0f81" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9355feea-eacc-4e68-849e-dc249c311392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6db592df-43d3-4840-871c-67db4b8b2bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66dd3690-2745-430e-a00e-f3a9caab0f81" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6db592df-43d3-4840-871c-67db4b8b2bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_547ade91-bd52-4b7b-a41a-51c91b453ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_547ade91-bd52-4b7b-a41a-51c91b453ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1adacb49-0290-4be7-a436-b5ec2dd2d13f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_547ade91-bd52-4b7b-a41a-51c91b453ef7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1adacb49-0290-4be7-a436-b5ec2dd2d13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_11969e45-b4bf-4639-ae9d-22591dd5bbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1adacb49-0290-4be7-a436-b5ec2dd2d13f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_11969e45-b4bf-4639-ae9d-22591dd5bbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8fa2a97e-05e7-4a90-b1c4-47c470e83ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8fa2a97e-05e7-4a90-b1c4-47c470e83ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8fa2a97e-05e7-4a90-b1c4-47c470e83ec8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_37c3cc9c-aa1f-4de7-9373-a80bfe43c377" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:to="loc_us-gaap_CertificatesOfDepositMember_37c3cc9c-aa1f-4de7-9373-a80bfe43c377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019bfee6-1456-7b3a-9fd9-d42830e7a6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:to="loc_us-gaap_CommercialPaperMember_019bfee6-1456-7b3a-9fd9-d42830e7a6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4dbdb1f7-bd56-466a-a716-30e70bb96099" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4dbdb1f7-bd56-466a-a716-30e70bb96099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_db1bfac6-908b-42d7-b804-2d3ff31921e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3fda37d1-9188-4a11-8476-42d85eb7caaa" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_db1bfac6-908b-42d7-b804-2d3ff31921e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3dd875ee-2985-4438-9b9e-b10be9e64eca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c478336e-8388-4d80-9cea-bd95a494a2f3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3dd875ee-2985-4438-9b9e-b10be9e64eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_57d9b737-2bd5-492a-bc35-b94b3762aba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3dd875ee-2985-4438-9b9e-b10be9e64eca" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_57d9b737-2bd5-492a-bc35-b94b3762aba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_81930c1e-e443-4b8b-b0a2-5b01d65acd34" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3dd875ee-2985-4438-9b9e-b10be9e64eca" xlink:to="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_81930c1e-e443-4b8b-b0a2-5b01d65acd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9851f86a-5116-4c5a-93c0-c8f744598794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3dd875ee-2985-4438-9b9e-b10be9e64eca" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9851f86a-5116-4c5a-93c0-c8f744598794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2ce5e992-4aaa-417a-b53e-3658a7da8e42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_44043011-c432-4f0a-83d1-176539603990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2ce5e992-4aaa-417a-b53e-3658a7da8e42" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_44043011-c432-4f0a-83d1-176539603990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_e7f4afde-38e9-4e17-8ed1-9d2f0c623d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_44043011-c432-4f0a-83d1-176539603990" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_e7f4afde-38e9-4e17-8ed1-9d2f0c623d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf979070-a22a-4b85-8b91-e193c2eb886f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e7f4afde-38e9-4e17-8ed1-9d2f0c623d0c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf979070-a22a-4b85-8b91-e193c2eb886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e905414c-e6c3-4870-b1ba-e72bfff69cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf979070-a22a-4b85-8b91-e193c2eb886f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e905414c-e6c3-4870-b1ba-e72bfff69cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_019c2766-433d-743a-b09a-439244d10ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf979070-a22a-4b85-8b91-e193c2eb886f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_019c2766-433d-743a-b09a-439244d10ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_44043011-c432-4f0a-83d1-176539603990" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d0bd701-43e9-4dd7-ad05-b86092df6081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d0bd701-43e9-4dd7-ad05-b86092df6081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsUnrealizedGain_ce7359f9-7a8c-45e1-ba95-ea641da98167" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:to="loc_arqt_CashAndCashEquivalentsUnrealizedGain_ce7359f9-7a8c-45e1-ba95-ea641da98167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsUnrealizedLoss_1ed275bb-6ef2-46a2-a508-47cd5ef3456e" xlink:href="arqt-20251231.xsd#arqt_CashAndCashEquivalentsUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:to="loc_arqt_CashAndCashEquivalentsUnrealizedLoss_1ed275bb-6ef2-46a2-a508-47cd5ef3456e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4cb6d784-1c7f-477d-a5af-816ee39b5205" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5d96ad13-1de7-4e85-99f3-874f8ac08206" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4cb6d784-1c7f-477d-a5af-816ee39b5205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cd147a8-e2a7-49e3-aed7-42764ee805d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2ce5e992-4aaa-417a-b53e-3658a7da8e42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cd147a8-e2a7-49e3-aed7-42764ee805d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9ef6003c-e5f3-4091-a943-428bc614b703" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cd147a8-e2a7-49e3-aed7-42764ee805d8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9ef6003c-e5f3-4091-a943-428bc614b703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9ef6003c-e5f3-4091-a943-428bc614b703" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f006b0fa-907c-4ca9-b4c5-7ac781da0c62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f006b0fa-907c-4ca9-b4c5-7ac781da0c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_79df31f6-e482-46bc-8b69-a07487816d76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:to="loc_us-gaap_CommercialPaperMember_79df31f6-e482-46bc-8b69-a07487816d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ae71c303-1f32-4525-a18c-940ed0172843" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ae71c303-1f32-4525-a18c-940ed0172843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8326b104-536a-48c3-a2e2-faef32557bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6200d95d-119f-4fdb-8c18-03cdaad805f9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8326b104-536a-48c3-a2e2-faef32557bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1cd147a8-e2a7-49e3-aed7-42764ee805d8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a1f816f4-8d58-441b-9ad5-a48895809113" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a1f816f4-8d58-441b-9ad5-a48895809113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_22ee1a14-d1bf-43c2-bd96-bf055f39d757" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_22ee1a14-d1bf-43c2-bd96-bf055f39d757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_823f81a1-e410-4381-bb7c-8356a80a118f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_823f81a1-e410-4381-bb7c-8356a80a118f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f803d9d-b710-4fc1-821c-f84a4a66af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d9f1e912-e525-4c2b-bba7-e55831647759" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f803d9d-b710-4fc1-821c-f84a4a66af6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c276f-2d21-7754-aea7-0a33daf233ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c2772-9720-7cd7-a6d2-c98f2f790c45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c276f-2d21-7754-aea7-0a33daf233ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c2772-9720-7cd7-a6d2-c98f2f790c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c2771-d59f-7561-b44a-017918c37856" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c2772-9720-7cd7-a6d2-c98f2f790c45" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c2771-d59f-7561-b44a-017918c37856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c2770-49d0-7b87-ada3-3c5c546298e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c2772-9720-7cd7-a6d2-c98f2f790c45" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c2770-49d0-7b87-ada3-3c5c546298e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019c2770-49d0-7444-8e4c-b7814914ce15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c2772-9720-7cd7-a6d2-c98f2f790c45" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019c2770-49d0-7444-8e4c-b7814914ce15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c2773-57fd-76e7-819c-3e0be535b272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c276f-2d21-7754-aea7-0a33daf233ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c2773-57fd-76e7-819c-3e0be535b272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c2770-49d0-7b35-b1c8-e0140820c067" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c2773-57fd-76e7-819c-3e0be535b272" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c2770-49d0-7b35-b1c8-e0140820c067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c2770-49d0-7c97-b8b4-12fb9f70eafc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c2773-57fd-76e7-819c-3e0be535b272" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c2770-49d0-7c97-b8b4-12fb9f70eafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c2770-49d0-7a80-b807-ae74d2b9e46d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c2773-57fd-76e7-819c-3e0be535b272" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c2770-49d0-7a80-b807-ae74d2b9e46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_41323b0c-b1da-4da1-92fd-cf2040310400" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_6fcf1375-7bfc-42a8-91ae-da911fb202ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_41323b0c-b1da-4da1-92fd-cf2040310400" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_6fcf1375-7bfc-42a8-91ae-da911fb202ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_796fca48-4c18-4ffb-8ea6-b2d2e0a14e39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_41323b0c-b1da-4da1-92fd-cf2040310400" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_796fca48-4c18-4ffb-8ea6-b2d2e0a14e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_0dc3fd86-8a6e-4810-9339-23a94836cc37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_796fca48-4c18-4ffb-8ea6-b2d2e0a14e39" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_0dc3fd86-8a6e-4810-9339-23a94836cc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_32651703-0d50-48ce-a4ed-37ca5db9bb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_796fca48-4c18-4ffb-8ea6-b2d2e0a14e39" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_32651703-0d50-48ce-a4ed-37ca5db9bb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_8108948c-ff6a-40e8-97c9-a8c6c051fc27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_796fca48-4c18-4ffb-8ea6-b2d2e0a14e39" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_8108948c-ff6a-40e8-97c9-a8c6c051fc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList_f3e72a54-d2a4-4df2-b536-2e9bc474cd64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_41323b0c-b1da-4da1-92fd-cf2040310400" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList_f3e72a54-d2a4-4df2-b536-2e9bc474cd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#BalanceSheetComponentsInventoriesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_af7989f2-f608-4c52-b134-3fb0f7d806b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_afc51f45-105d-4edb-963b-40d891d0879d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_af7989f2-f608-4c52-b134-3fb0f7d806b9" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_afc51f45-105d-4edb-963b-40d891d0879d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ea8f95a9-e89c-4fa8-8cfd-99e001873473" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_af7989f2-f608-4c52-b134-3fb0f7d806b9" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ea8f95a9-e89c-4fa8-8cfd-99e001873473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f9c2029e-8628-48cc-978a-3f8e56ac0bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_af7989f2-f608-4c52-b134-3fb0f7d806b9" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f9c2029e-8628-48cc-978a-3f8e56ac0bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_61a98e2c-cb01-4477-b378-f8702e1aff40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_af7989f2-f608-4c52-b134-3fb0f7d806b9" xlink:to="loc_us-gaap_InventoryNet_61a98e2c-cb01-4477-b378-f8702e1aff40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9d618f96-93cb-464b-ae14-83941c011f00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrepaidCopayAssistanceProgramAndRebates_c57c20cc-0e70-4393-a97f-56d94550ec5c" xlink:href="arqt-20251231.xsd#arqt_PrepaidCopayAssistanceProgramAndRebates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9d618f96-93cb-464b-ae14-83941c011f00" xlink:to="loc_arqt_PrepaidCopayAssistanceProgramAndRebates_c57c20cc-0e70-4393-a97f-56d94550ec5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrepaidClinicalTrialTestCostsCurrent_8a0b668f-7de3-4aa7-bb00-fc1943c7994b" xlink:href="arqt-20251231.xsd#arqt_PrepaidClinicalTrialTestCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9d618f96-93cb-464b-ae14-83941c011f00" xlink:to="loc_arqt_PrepaidClinicalTrialTestCostsCurrent_8a0b668f-7de3-4aa7-bb00-fc1943c7994b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_8bc4bff3-03fd-495c-8738-e92f868b9c37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9d618f96-93cb-464b-ae14-83941c011f00" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_8bc4bff3-03fd-495c-8738-e92f868b9c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bb7e27cb-b6ec-4971-bdc7-6bc36e9e5904" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9d618f96-93cb-464b-ae14-83941c011f00" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bb7e27cb-b6ec-4971-bdc7-6bc36e9e5904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_185945ec-8000-4f03-baae-853cdab949db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AccruedSalesDiscounts_d7887e45-bd00-4c06-9db2-765db0da3856" xlink:href="arqt-20251231.xsd#arqt_AccruedSalesDiscounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_185945ec-8000-4f03-baae-853cdab949db" xlink:to="loc_arqt_AccruedSalesDiscounts_d7887e45-bd00-4c06-9db2-765db0da3856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_59e408fe-ba6e-40ae-b564-15b876291d20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_185945ec-8000-4f03-baae-853cdab949db" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_59e408fe-ba6e-40ae-b564-15b876291d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ClinicalTrialAccrualCurrent_c6ffda2b-4f16-4ee6-a363-774d5fe80fd2" xlink:href="arqt-20251231.xsd#arqt_ClinicalTrialAccrualCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_185945ec-8000-4f03-baae-853cdab949db" xlink:to="loc_arqt_ClinicalTrialAccrualCurrent_c6ffda2b-4f16-4ee6-a363-774d5fe80fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2986e388-9239-4c52-b4a2-59cb1e0eb263" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_185945ec-8000-4f03-baae-853cdab949db" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2986e388-9239-4c52-b4a2-59cb1e0eb263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_61d84d0f-e1c9-4e82-be6d-b1f16ec5aaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_185945ec-8000-4f03-baae-853cdab949db" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_61d84d0f-e1c9-4e82-be6d-b1f16ec5aaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f7f925be-3480-439a-8341-7345dd5f0cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f254621-27ea-4abc-8823-202670f7acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f7f925be-3480-439a-8341-7345dd5f0cbf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f254621-27ea-4abc-8823-202670f7acb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afe3dc7-6710-485c-9ffd-8be444d193b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f254621-27ea-4abc-8823-202670f7acb2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afe3dc7-6710-485c-9ffd-8be444d193b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afe3dc7-6710-485c-9ffd-8be444d193b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0bf35704-1d1f-410f-aae8-175c5e6edfde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:to="loc_us-gaap_ComputerEquipmentMember_0bf35704-1d1f-410f-aae8-175c5e6edfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_89543baf-eceb-4004-9339-ed62c20b436b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_89543baf-eceb-4004-9339-ed62c20b436b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_27d84aa0-b965-412f-ab84-7107010135b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_27d84aa0-b965-412f-ab84-7107010135b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_686b760c-5a38-45e5-858f-2cb0ceb0f8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_046428d1-7300-4dbd-88b9-285e4ccec53b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_686b760c-5a38-45e5-858f-2cb0ceb0f8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a6ab69f-7795-4738-8495-bf5acb940c53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f254621-27ea-4abc-8823-202670f7acb2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a6ab69f-7795-4738-8495-bf5acb940c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b60b4a45-f95a-412f-b3c9-b9b616361dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a6ab69f-7795-4738-8495-bf5acb940c53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b60b4a45-f95a-412f-b3c9-b9b616361dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7ec8e0c3-e949-42f9-bb11-05ef9ba0b045" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a6ab69f-7795-4738-8495-bf5acb940c53" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7ec8e0c3-e949-42f9-bb11-05ef9ba0b045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9f733b9e-63c0-4503-b61f-e9395c0d3841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a6ab69f-7795-4738-8495-bf5acb940c53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9f733b9e-63c0-4503-b61f-e9395c0d3841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#PropertyandEquipmentnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5fe6bdc1-3d94-45c1-a06b-63b610ebadf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_514dd829-78bc-4aed-848a-92f2bc38d67b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5fe6bdc1-3d94-45c1-a06b-63b610ebadf6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_514dd829-78bc-4aed-848a-92f2bc38d67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_368690a1-ebf5-4b3f-99df-5e64a3ea6b41" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_514dd829-78bc-4aed-848a-92f2bc38d67b" xlink:to="loc_srt_RangeAxis_368690a1-ebf5-4b3f-99df-5e64a3ea6b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17802714-46cc-41b9-b1f9-2f98bf56b5b7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_368690a1-ebf5-4b3f-99df-5e64a3ea6b41" xlink:to="loc_srt_RangeMember_17802714-46cc-41b9-b1f9-2f98bf56b5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_01088cef-2545-4729-a074-7557e55d35b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_17802714-46cc-41b9-b1f9-2f98bf56b5b7" xlink:to="loc_srt_MinimumMember_01088cef-2545-4729-a074-7557e55d35b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e73d9b29-6395-4578-95f0-9d3a650f6f9d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_17802714-46cc-41b9-b1f9-2f98bf56b5b7" xlink:to="loc_srt_MaximumMember_e73d9b29-6395-4578-95f0-9d3a650f6f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d4e0fa5-6616-4c86-a74d-20ba58933081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_514dd829-78bc-4aed-848a-92f2bc38d67b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d4e0fa5-6616-4c86-a74d-20ba58933081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b32ad70-6ee6-4858-9514-c6bf8185f2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d4e0fa5-6616-4c86-a74d-20ba58933081" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b32ad70-6ee6-4858-9514-c6bf8185f2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember_46e3af7d-5fbc-45ac-bc01-328e4ef6c0bb" xlink:href="arqt-20251231.xsd#arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b32ad70-6ee6-4858-9514-c6bf8185f2f0" xlink:to="loc_arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember_46e3af7d-5fbc-45ac-bc01-328e4ef6c0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4bac26ec-cab1-4a02-bf10-a3004b9af0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_514dd829-78bc-4aed-848a-92f2bc38d67b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4bac26ec-cab1-4a02-bf10-a3004b9af0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4004e933-e6d5-4f71-8dbf-1708c2c94a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4bac26ec-cab1-4a02-bf10-a3004b9af0ec" xlink:to="loc_us-gaap_Depreciation_4004e933-e6d5-4f71-8dbf-1708c2c94a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_64d2095d-d935-4c66-983e-fd07f0b11b68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4bac26ec-cab1-4a02-bf10-a3004b9af0ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_64d2095d-d935-4c66-983e-fd07f0b11b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_fcce6ebf-48f2-4e3f-b31c-4a9d3c1aa13e" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eb941b96-19eb-4652-b389-2abdb91f46cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_fcce6ebf-48f2-4e3f-b31c-4a9d3c1aa13e" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eb941b96-19eb-4652-b389-2abdb91f46cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4458729e-8c73-4da2-8623-f159ceeeef34" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eb941b96-19eb-4652-b389-2abdb91f46cd" xlink:to="loc_srt_CounterpartyNameAxis_4458729e-8c73-4da2-8623-f159ceeeef34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b0acfa8c-cd9a-4efd-a547-9530cd21afd4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4458729e-8c73-4da2-8623-f159ceeeef34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b0acfa8c-cd9a-4efd-a547-9530cd21afd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SatoMember_0091c4ca-1cfe-454b-88bf-9845c26e9bbe" xlink:href="arqt-20251231.xsd#arqt_SatoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b0acfa8c-cd9a-4efd-a547-9530cd21afd4" xlink:to="loc_arqt_SatoMember_0091c4ca-1cfe-454b-88bf-9845c26e9bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eb941b96-19eb-4652-b389-2abdb91f46cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet_e4cb6c1f-3fa3-43e7-af4e-fb21c3ad83cf" xlink:href="arqt-20251231.xsd#arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet_e4cb6c1f-3fa3-43e7-af4e-fb21c3ad83cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_a08a03d9-9b79-43f1-b9a0-2af3c33b09b0" xlink:href="arqt-20251231.xsd#arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_a08a03d9-9b79-43f1-b9a0-2af3c33b09b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_27b87820-648e-42cb-8b0f-e506127cce15" xlink:href="arqt-20251231.xsd#arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_27b87820-648e-42cb-8b0f-e506127cce15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_d7c00a23-85aa-42a5-8f75-41f1330a65c9" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_d7c00a23-85aa-42a5-8f75-41f1330a65c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice_b7806a46-7399-4f3b-9a47-35ed2b300fa1" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice_b7806a46-7399-4f3b-9a47-35ed2b300fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_893d244f-8013-4057-a937-aa3c73937795" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6af08aa5-85ef-4d0c-9d3e-a65df92efcc4" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_893d244f-8013-4057-a937-aa3c73937795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisitionHuadongDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_4f65d83b-6e2d-41f2-bc24-68761dac86d9" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76f5dfca-744c-41f5-bfe0-e4cc1584c35f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_4f65d83b-6e2d-41f2-bc24-68761dac86d9" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76f5dfca-744c-41f5-bfe0-e4cc1584c35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f8df5d0a-786a-4294-a7df-0a549f2a3ac6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76f5dfca-744c-41f5-bfe0-e4cc1584c35f" xlink:to="loc_srt_CounterpartyNameAxis_f8df5d0a-786a-4294-a7df-0a549f2a3ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a71692f-6c76-4749-a653-b3ef6c64ec68" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f8df5d0a-786a-4294-a7df-0a549f2a3ac6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a71692f-6c76-4749-a653-b3ef6c64ec68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HuadongMember_0ae19bd2-c94d-4785-baa1-cbf35e1f7410" xlink:href="arqt-20251231.xsd#arqt_HuadongMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a71692f-6c76-4749-a653-b3ef6c64ec68" xlink:to="loc_arqt_HuadongMember_0ae19bd2-c94d-4785-baa1-cbf35e1f7410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76f5dfca-744c-41f5-bfe0-e4cc1584c35f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ContractNotWithCustomerUpfrontPaymentNet_a5fe1934-8f24-432a-a508-a6c2928f762a" xlink:href="arqt-20251231.xsd#arqt_ContractNotWithCustomerUpfrontPaymentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_arqt_ContractNotWithCustomerUpfrontPaymentNet_a5fe1934-8f24-432a-a508-a6c2928f762a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_239ec7b2-1fcc-43c2-a519-ad9af399b264" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_239ec7b2-1fcc-43c2-a519-ad9af399b264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation_ae0850a5-5b2a-4bc4-b37f-3dcdaf5db1a9" xlink:href="arqt-20251231.xsd#arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation_ae0850a5-5b2a-4bc4-b37f-3dcdaf5db1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_20d34383-6cc6-4ba2-afc3-ccbc632a4d64" xlink:href="arqt-20251231.xsd#arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones_20d34383-6cc6-4ba2-afc3-ccbc632a4d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_4533f625-67b7-47fb-9a9d-448299070564" xlink:href="arqt-20251231.xsd#arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones_4533f625-67b7-47fb-9a9d-448299070564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_0354db54-b3f5-4a33-942e-ba9a7c4944b8" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_102edfef-43e3-4a2e-8cee-f99697bd4188" xlink:to="loc_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties_0354db54-b3f5-4a33-942e-ba9a7c4944b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisitionAstraZenecaDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_9b11b2e7-4c37-4942-abff-3cfbb352d8fd" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97e87b5-5e90-49ab-bfb6-a7c52de137ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_9b11b2e7-4c37-4942-abff-3cfbb352d8fd" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97e87b5-5e90-49ab-bfb6-a7c52de137ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c2457495-12e3-4fb4-9120-39ebefcc4888" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97e87b5-5e90-49ab-bfb6-a7c52de137ca" xlink:to="loc_srt_CounterpartyNameAxis_c2457495-12e3-4fb4-9120-39ebefcc4888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52e0e0ef-2a20-47d1-aac6-a451bf4046de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c2457495-12e3-4fb4-9120-39ebefcc4888" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52e0e0ef-2a20-47d1-aac6-a451bf4046de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AstraZenecaMember_e72d493a-4d63-4a1e-bd34-2208f64b0ddd" xlink:href="arqt-20251231.xsd#arqt_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52e0e0ef-2a20-47d1-aac6-a451bf4046de" xlink:to="loc_arqt_AstraZenecaMember_e72d493a-4d63-4a1e-bd34-2208f64b0ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97e87b5-5e90-49ab-bfb6-a7c52de137ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_6d4ed269-cca5-406f-84b7-0a00fcd42a07" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval_6d4ed269-cca5-406f-84b7-0a00fcd42a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_188b474d-cdd8-4b8f-bde6-3908a8e5e7d2" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments_188b474d-cdd8-4b8f-bde6-3908a8e5e7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_f1914747-5823-45ab-aeef-9c895cf7666e" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold_f1914747-5823-45ab-aeef-9c895cf7666e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_38568fcf-f724-4d71-bb25-1f5197045c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_38568fcf-f724-4d71-bb25-1f5197045c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_876ab59e-0082-465d-9121-af8594ea451e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_876ab59e-0082-465d-9121-af8594ea451e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_5402f012-d36c-4c36-9330-5a4d35596b6b" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_5402f012-d36c-4c36-9330-5a4d35596b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale_019c90a2-7a16-7175-b158-3ab679fa8077" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale_019c90a2-7a16-7175-b158-3ab679fa8077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_2d1e70ef-2176-49f6-906a-700ea23ad3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6ac76bdd-a36c-4f1c-aa58-d4cb7a49371e" xlink:to="loc_us-gaap_RoyaltyExpense_2d1e70ef-2176-49f6-906a-700ea23ad3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisitionHengruiDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_c7a50601-e149-456e-9688-6990ffe141a2" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b286e42f-101b-48cc-b931-bb7b3f656b23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_c7a50601-e149-456e-9688-6990ffe141a2" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b286e42f-101b-48cc-b931-bb7b3f656b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_848ee34a-7383-4df7-ba87-023aaca62bb1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b286e42f-101b-48cc-b931-bb7b3f656b23" xlink:to="loc_srt_CounterpartyNameAxis_848ee34a-7383-4df7-ba87-023aaca62bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdb5ab06-1f96-4319-9ae0-91a0ff19ebe1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_848ee34a-7383-4df7-ba87-023aaca62bb1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdb5ab06-1f96-4319-9ae0-91a0ff19ebe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HengruiMember_60e6a3b5-6821-4bb6-a5c4-63f2ae15cd64" xlink:href="arqt-20251231.xsd#arqt_HengruiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdb5ab06-1f96-4319-9ae0-91a0ff19ebe1" xlink:to="loc_arqt_HengruiMember_60e6a3b5-6821-4bb6-a5c4-63f2ae15cd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_17b71c16-4490-4dad-9268-1b9c10a4e532" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b286e42f-101b-48cc-b931-bb7b3f656b23" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_17b71c16-4490-4dad-9268-1b9c10a4e532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_86aad90d-5c5a-4f27-8901-60e4bd07def9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_17b71c16-4490-4dad-9268-1b9c10a4e532" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_86aad90d-5c5a-4f27-8901-60e4bd07def9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_89c86933-d8ef-467a-ba4f-4b912adb4e83" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_17b71c16-4490-4dad-9268-1b9c10a4e532" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments_89c86933-d8ef-467a-ba4f-4b912adb4e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_2a0ee42a-42e0-42b9-81cd-d9bd0d1b412d" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_17b71c16-4490-4dad-9268-1b9c10a4e532" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_2a0ee42a-42e0-42b9-81cd-d9bd0d1b412d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_914e5c08-19da-448f-8259-e6e857ade319" xlink:href="arqt-20251231.xsd#arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_40c967b3-da56-4572-8199-4341a2c3ffae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract_914e5c08-19da-448f-8259-e6e857ade319" xlink:to="loc_us-gaap_AssetAcquisitionTable_40c967b3-da56-4572-8199-4341a2c3ffae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_5bcb4c66-da35-4c40-9d48-7f94464733f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_40c967b3-da56-4572-8199-4341a2c3ffae" xlink:to="loc_us-gaap_AssetAcquisitionAxis_5bcb4c66-da35-4c40-9d48-7f94464733f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1a7ece1d-3226-47f4-b09a-3a3ddaedf043" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_5bcb4c66-da35-4c40-9d48-7f94464733f4" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1a7ece1d-3226-47f4-b09a-3a3ddaedf043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember_13e724b9-a92f-4846-979a-37b25426c227" xlink:href="arqt-20251231.xsd#arqt_DucentisBiotherapeuticsLTDEquityInterestsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1a7ece1d-3226-47f4-b09a-3a3ddaedf043" xlink:to="loc_arqt_DucentisBiotherapeuticsLTDEquityInterestsMember_13e724b9-a92f-4846-979a-37b25426c227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5a30366a-76e9-4e45-b25b-80215332ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_40c967b3-da56-4572-8199-4341a2c3ffae" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5a30366a-76e9-4e45-b25b-80215332ddba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3e8d8a91-9156-4b40-b279-3da620ecb63e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a30366a-76e9-4e45-b25b-80215332ddba" xlink:to="loc_us-gaap_EquityComponentDomain_3e8d8a91-9156-4b40-b279-3da620ecb63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c903e704-9b5d-4360-bf09-14e4347b6dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3e8d8a91-9156-4b40-b279-3da620ecb63e" xlink:to="loc_us-gaap_CommonStockMember_c903e704-9b5d-4360-bf09-14e4347b6dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_40c967b3-da56-4572-8199-4341a2c3ffae" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_0bc13ec3-60d8-4696-af19-db3771527840" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_0bc13ec3-60d8-4696-af19-db3771527840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_4901a10a-e895-41c0-a166-f805c44505bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_4901a10a-e895-41c0-a166-f805c44505bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionConsiderationTransferredGross_d51c95ba-0d97-4d8d-b72b-38c3b69adaab" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionConsiderationTransferredGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionConsiderationTransferredGross_d51c95ba-0d97-4d8d-b72b-38c3b69adaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount_928c16a3-9a73-4191-86c0-7191e52eedaa" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount_928c16a3-9a73-4191-86c0-7191e52eedaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones_7a783210-7deb-4f29-8e92-d0695f2d24e5" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones_7a783210-7deb-4f29-8e92-d0695f2d24e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment_019c909f-364d-704d-bf5b-102a6e87499a" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment_019c909f-364d-704d-bf5b-102a6e87499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold_4215d112-c99f-4b73-b589-92bcc0264f85" xlink:href="arqt-20251231.xsd#arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold_4215d112-c99f-4b73-b589-92bcc0264f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c1ccd668-48b7-4230-868b-5a9658bb797b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c1ccd668-48b7-4230-868b-5a9658bb797b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_83415f7b-9d26-4c32-90be-b69f6a11e089" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_bd458f31-5673-4bd7-acb4-5d2025929ca9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_83415f7b-9d26-4c32-90be-b69f6a11e089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51fbb991-8df3-4533-9955-644433c3d62c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1a0b8b81-af8d-4479-9cba-1474560606bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51fbb991-8df3-4533-9955-644433c3d62c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1a0b8b81-af8d-4479-9cba-1474560606bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionAxis_9e65c5a9-ab30-4d9f-9617-d1b773242521" xlink:href="arqt-20251231.xsd#arqt_LeaseDescriptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1a0b8b81-af8d-4479-9cba-1474560606bb" xlink:to="loc_arqt_LeaseDescriptionAxis_9e65c5a9-ab30-4d9f-9617-d1b773242521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionDomain_9c3a73c6-c812-4e59-b055-69f1488c7987" xlink:href="arqt-20251231.xsd#arqt_LeaseDescriptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_LeaseDescriptionAxis_9e65c5a9-ab30-4d9f-9617-d1b773242521" xlink:to="loc_arqt_LeaseDescriptionDomain_9c3a73c6-c812-4e59-b055-69f1488c7987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_209609ac-acfe-4b1e-8ac5-e0ee112c1b0c" xlink:href="arqt-20251231.xsd#arqt_WestlakeVillageCaliforniaLeaseArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_LeaseDescriptionDomain_9c3a73c6-c812-4e59-b055-69f1488c7987" xlink:to="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_209609ac-acfe-4b1e-8ac5-e0ee112c1b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1a0b8b81-af8d-4479-9cba-1474560606bb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseOfficeSpace_019bb752-cd60-7f38-b7b2-6fa6b98f9566" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseOfficeSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_arqt_LesseeOperatingLeaseOfficeSpace_019bb752-cd60-7f38-b7b2-6fa6b98f9566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseExtensionTerm_019bb752-cd60-7bf6-8755-6e4a99f706e4" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseExtensionTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_arqt_LesseeOperatingLeaseExtensionTerm_019bb752-cd60-7bf6-8755-6e4a99f706e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments_019bb752-cd60-7561-acb1-b3a951515d75" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments_019bb752-cd60-7561-acb1-b3a951515d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments_019bb752-cd60-7ca6-93db-8bd7a28aeac7" xlink:href="arqt-20251231.xsd#arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments_019bb752-cd60-7ca6-93db-8bd7a28aeac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_019bb752-cd60-7c87-b8c3-052d6b64abd3" xlink:href="arqt-20251231.xsd#arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_019bb752-cd60-7c87-b8c3-052d6b64abd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019bb752-cd60-707f-b095-2361c47e59a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019bb752-cd60-707f-b095-2361c47e59a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_4e3939c0-bf6b-49f6-9c48-91733e27a2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_4e3939c0-bf6b-49f6-9c48-91733e27a2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_7d51ba1a-1ccd-4d6d-8772-f638363c6dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_OperatingLeaseCost_7d51ba1a-1ccd-4d6d-8772-f638363c6dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_019c4b62-4756-71a4-a1fb-1c68d6da17f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_019c4b62-4756-71a4-a1fb-1c68d6da17f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_019c4b62-4756-7193-a84c-d509a1f90f04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1fa2d6a-d4bd-4ffe-b14d-13af3a202116" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_019c4b62-4756-7193-a84c-d509a1f90f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#CommitmentsandContingenciesOperatingLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637e3c0a-e807-4a2d-aa5a-6bfaa6c1edf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637e3c0a-e807-4a2d-aa5a-6bfaa6c1edf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5e79ee90-d8e4-4cc4-9dee-d75bff5176cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5e79ee90-d8e4-4cc4-9dee-d75bff5176cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2d7c367a-2534-4f12-ada7-6affaee57e09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2d7c367a-2534-4f12-ada7-6affaee57e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d6158dcf-6da7-45d0-91e8-0b14f0f0566f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d6158dcf-6da7-45d0-91e8-0b14f0f0566f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_019bfeef-0545-7f82-b087-03e2bcef3483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_019bfeef-0545-7f82-b087-03e2bcef3483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_019bfeef-6fe9-7266-bbce-7703f5dde2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_019bfeef-6fe9-7266-bbce-7703f5dde2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13a414a3-268c-4e88-b439-caaa59a2e924" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13a414a3-268c-4e88-b439-caaa59a2e924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2d6b884a-bbd5-4906-b4eb-59850c5c3765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2d6b884a-bbd5-4906-b4eb-59850c5c3765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1dda01e2-87b3-4abf-a725-e8aa790e30df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_OperatingLeaseLiability_1dda01e2-87b3-4abf-a725-e8aa790e30df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c951c07-e3f3-47f8-bc37-797eae52864a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c951c07-e3f3-47f8-bc37-797eae52864a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da8b6b41-5df5-4b2c-9668-a37cb95191bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da8b6b41-5df5-4b2c-9668-a37cb95191bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_802b93b6-d52a-44c5-bdac-907704543363" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_OperatingLeaseLiability_802b93b6-d52a-44c5-bdac-907704543363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_019c4e88-37d8-7b1a-8674-279e66b482bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07d01220-0a42-4567-bf8d-79049ac6910b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_019c4e88-37d8-7b1a-8674-279e66b482bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_519f8537-4783-4cd7-bbee-c8d53c5b3b54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_779a156b-4285-4d41-9bb7-87acc0cdee14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_519f8537-4783-4cd7-bbee-c8d53c5b3b54" xlink:to="loc_us-gaap_OperatingLeasePayments_779a156b-4285-4d41-9bb7-87acc0cdee14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseAdditionalInformationDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#CommitmentsandContingenciesOperatingLeaseAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1deb7e00-2ed3-44d5-8c55-f7183d9588c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fca5f89a-0ec9-429c-a3bc-ed202ccde3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1deb7e00-2ed3-44d5-8c55-f7183d9588c3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fca5f89a-0ec9-429c-a3bc-ed202ccde3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f8945e5b-1bbd-493e-9154-d5f27736b8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1deb7e00-2ed3-44d5-8c55-f7183d9588c3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f8945e5b-1bbd-493e-9154-d5f27736b8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5934cb2d-d717-4063-beab-20d1e9f8511e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5934cb2d-d717-4063-beab-20d1e9f8511e" xlink:to="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_351b01c9-1a5d-4591-916e-dbab70e77971" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_351b01c9-1a5d-4591-916e-dbab70e77971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ae1048b5-7804-495b-8b37-debe6ac598ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_351b01c9-1a5d-4591-916e-dbab70e77971" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ae1048b5-7804-495b-8b37-debe6ac598ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_117102c3-c31f-4708-b441-c14513fd32b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ae1048b5-7804-495b-8b37-debe6ac598ec" xlink:to="loc_us-gaap_SecuredDebtMember_117102c3-c31f-4708-b441-c14513fd32b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8b482a79-09a4-411c-b765-7441ec3404a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_us-gaap_DebtInstrumentAxis_8b482a79-09a4-411c-b765-7441ec3404a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4d2b04a2-afa9-4d97-abcf-4548095dc981" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8b482a79-09a4-411c-b765-7441ec3404a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4d2b04a2-afa9-4d97-abcf-4548095dc981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementMember_7a956c67-5088-461b-85b6-b148469f2ab8" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4d2b04a2-afa9-4d97-abcf-4548095dc981" xlink:to="loc_arqt_LoanAgreementMember_7a956c67-5088-461b-85b6-b148469f2ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentTrancheAxis_2ae01361-df66-4aad-9d06-d2cb71de68f4" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentTrancheAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_arqt_DebtInstrumentTrancheAxis_2ae01361-df66-4aad-9d06-d2cb71de68f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_DebtInstrumentTrancheAxis_2ae01361-df66-4aad-9d06-d2cb71de68f4" xlink:to="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheATermLoanMember_f534189c-4490-4d89-8da9-77365f1a1534" xlink:href="arqt-20251231.xsd#arqt_TrancheATermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_TrancheATermLoanMember_f534189c-4490-4d89-8da9-77365f1a1534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheB1TermLoanMember_122179ff-4f7f-4a38-b41d-741b2040f3da" xlink:href="arqt-20251231.xsd#arqt_TrancheB1TermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_TrancheB1TermLoanMember_122179ff-4f7f-4a38-b41d-741b2040f3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheB2TermLoanMember_fc79309c-51ec-46db-b936-6d2a1c2dc556" xlink:href="arqt-20251231.xsd#arqt_TrancheB2TermLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_TrancheB2TermLoanMember_fc79309c-51ec-46db-b936-6d2a1c2dc556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member_fa11b352-3ffa-4df6-89df-d16c96b0f92f" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementTrancheC1ExpiringMarch312026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_LoanAgreementTrancheC1ExpiringMarch312026Member_fa11b352-3ffa-4df6-89df-d16c96b0f92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LoanAgreementTrancheC2ExpiringJune302026Member_1e0e7685-9d1b-4082-8582-612159cdb388" xlink:href="arqt-20251231.xsd#arqt_LoanAgreementTrancheC2ExpiringJune302026Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_LoanAgreementTrancheC2ExpiringJune302026Member_1e0e7685-9d1b-4082-8582-612159cdb388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TrancheCTermLoanMember_ae6dea3c-da3b-4ffa-9921-cb6ac44c7905" xlink:href="arqt-20251231.xsd#arqt_TrancheCTermLoanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_DebtInstrumentTrancheDomain_88360cd8-7e95-4357-9632-e66cadf9dd40" xlink:to="loc_arqt_TrancheCTermLoanMember_ae6dea3c-da3b-4ffa-9921-cb6ac44c7905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_29d6058a-948c-4ce0-ad22-7f926cf06a2a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_srt_RangeAxis_29d6058a-948c-4ce0-ad22-7f926cf06a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd0ca12f-6bb8-4130-a544-70c191418857" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_29d6058a-948c-4ce0-ad22-7f926cf06a2a" xlink:to="loc_srt_RangeMember_fd0ca12f-6bb8-4130-a544-70c191418857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_de886774-6e24-4db9-b01b-15bf728cc4dd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fd0ca12f-6bb8-4130-a544-70c191418857" xlink:to="loc_srt_MinimumMember_de886774-6e24-4db9-b01b-15bf728cc4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_95495b48-9d52-4599-8d7e-08320d04421d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_95495b48-9d52-4599-8d7e-08320d04421d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_61f71b76-9f19-48d9-8d54-6cb4c006c6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_95495b48-9d52-4599-8d7e-08320d04421d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_61f71b76-9f19-48d9-8d54-6cb4c006c6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_393ba811-441d-4f9d-b7ac-6368d69f5d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_61f71b76-9f19-48d9-8d54-6cb4c006c6cd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_393ba811-441d-4f9d-b7ac-6368d69f5d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_af3ceb4b-056e-4775-9a4f-37694bca8d32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_61f71b76-9f19-48d9-8d54-6cb4c006c6cd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_af3ceb4b-056e-4775-9a4f-37694bca8d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a3b425cd-44de-4c79-8849-5be9902e378a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_61f71b76-9f19-48d9-8d54-6cb4c006c6cd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a3b425cd-44de-4c79-8849-5be9902e378a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3e3b2ba9-857d-41bb-b67d-a670e50fd90b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_srt_StatementScenarioAxis_3e3b2ba9-857d-41bb-b67d-a670e50fd90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e8c5333a-e9b3-43a3-b809-34688b2a9edb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3e3b2ba9-857d-41bb-b67d-a670e50fd90b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e8c5333a-e9b3-43a3-b809-34688b2a9edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_574765e1-0888-4a8e-a4c5-3e124da60dbe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e8c5333a-e9b3-43a3-b809-34688b2a9edb" xlink:to="loc_srt_ScenarioForecastMember_574765e1-0888-4a8e-a4c5-3e124da60dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1050879-37d6-49a8-8ce4-1af859068614" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentPrepaymentPremium_56089c6e-7cd4-442a-8a5a-1a867d89759b" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentPrepaymentPremium"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentPrepaymentPremium_56089c6e-7cd4-442a-8a5a-1a867d89759b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentMaximumBorrowingCapacity_5e7870a2-bf76-4c15-9803-4fba110303db" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentMaximumBorrowingCapacity_5e7870a2-bf76-4c15-9803-4fba110303db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_48d58d45-696c-4b88-a532-479dce9c00bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_48d58d45-696c-4b88-a532-479dce9c00bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9e63d400-46ab-4866-9e4f-3c8bc8a786d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9e63d400-46ab-4866-9e4f-3c8bc8a786d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentPrepaymentPenalty_cf420d1e-c273-418b-96cb-3e2e342d3e7f" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentPrepaymentPenalty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentPrepaymentPenalty_cf420d1e-c273-418b-96cb-3e2e342d3e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod_b9f0e3ec-9ad5-4260-8ffc-c4f323d4708d" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentFundingAvailabilityCovenantPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod_b9f0e3ec-9ad5-4260-8ffc-c4f323d4708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue_27b8c71b-3a2a-4bb2-857a-08a3c6f534f1" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue_27b8c71b-3a2a-4bb2-857a-08a3c6f534f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment_47f31c7d-1d58-43e6-8e16-0c18d012639e" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment_47f31c7d-1d58-43e6-8e16-0c18d012639e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e0311a35-db7a-4229-9ccc-18bab7c79f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e0311a35-db7a-4229-9ccc-18bab7c79f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2d76f5b0-6762-4c01-8b0d-98093f1dcaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2d76f5b0-6762-4c01-8b0d-98093f1dcaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentInterestRateAtPeriodEnd_16ad130c-96de-4c69-8898-aac3f587595c" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentInterestRateAtPeriodEnd"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentInterestRateAtPeriodEnd_16ad130c-96de-4c69-8898-aac3f587595c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentDefaultRate_36167b6c-a10d-44da-a4b6-6a665a13a4f5" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentDefaultRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentDefaultRate_36167b6c-a10d-44da-a4b6-6a665a13a4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_2d355a8e-3a29-4ade-ac2f-ef9f9183ca90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_2d355a8e-3a29-4ade-ac2f-ef9f9183ca90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentFinalFeePercentage_6eaa038c-9687-4a04-8a8b-f5e30cd926bf" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentFinalFeePercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentFinalFeePercentage_6eaa038c-9687-4a04-8a8b-f5e30cd926bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentExtensionFeePercentage_a9e33607-b63c-41c6-919a-efc473427b8a" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentExtensionFeePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentExtensionFeePercentage_a9e33607-b63c-41c6-919a-efc473427b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentExitFeePercentage_14ba7129-3439-4261-9820-97aeb6dc1051" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentExitFeePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentExitFeePercentage_14ba7129-3439-4261-9820-97aeb6dc1051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentExitFeeExpirationPeriod_e757f442-0a5f-4fbd-af3f-9af654a6b61b" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentExitFeeExpirationPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentExitFeeExpirationPeriod_e757f442-0a5f-4fbd-af3f-9af654a6b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentDeferredFinalFeeGross_9927ea2d-d76a-46ab-81ec-bf4dc5447dbd" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentDeferredFinalFeeGross"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_arqt_DebtInstrumentDeferredFinalFeeGross_9927ea2d-d76a-46ab-81ec-bf4dc5447dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9d72cf0a-7165-4207-8b5e-a875fd396972" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9d72cf0a-7165-4207-8b5e-a875fd396972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_11f03823-40e9-49fa-b796-2566582e6acc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_InterestExpenseDebt_11f03823-40e9-49fa-b796-2566582e6acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019c8aea-a58f-752d-87dd-9c004aac608a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9033cfe1-8c0f-4096-a1c5-c99faa20525e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019c8aea-a58f-752d-87dd-9c004aac608a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ba5db694-0900-450e-a5ee-f29c512d805d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_035ca12e-2a8b-45be-a983-c3172d68f35f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ba5db694-0900-450e-a5ee-f29c512d805d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_035ca12e-2a8b-45be-a983-c3172d68f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentAccruedFinalFee_61578a8e-6519-4ee3-8c7e-87dceaa53abf" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentAccruedFinalFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ba5db694-0900-450e-a5ee-f29c512d805d" xlink:to="loc_arqt_DebtInstrumentAccruedFinalFee_61578a8e-6519-4ee3-8c7e-87dceaa53abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DebtInstrumentAccruedPrepaymentPenalty_da28ee17-8eee-4c1d-97b7-c78d5b208463" xlink:href="arqt-20251231.xsd#arqt_DebtInstrumentAccruedPrepaymentPenalty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ba5db694-0900-450e-a5ee-f29c512d805d" xlink:to="loc_arqt_DebtInstrumentAccruedPrepaymentPenalty_da28ee17-8eee-4c1d-97b7-c78d5b208463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_95eaa910-2c9e-4ff2-8c27-98b2fa1e8bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ba5db694-0900-450e-a5ee-f29c512d805d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_95eaa910-2c9e-4ff2-8c27-98b2fa1e8bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_318bc63a-36f4-4481-9c5b-cb3b4ec20273" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ba5db694-0900-450e-a5ee-f29c512d805d" xlink:to="loc_us-gaap_LongTermDebt_318bc63a-36f4-4481-9c5b-cb3b4ec20273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_841b2af7-4a07-499c-bc81-b23e34921b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ba5db694-0900-450e-a5ee-f29c512d805d" xlink:to="loc_us-gaap_LongTermDebtCurrent_841b2af7-4a07-499c-bc81-b23e34921b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_28019e90-3ea4-4f4c-aa27-435d5f1a527d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ba5db694-0900-450e-a5ee-f29c512d805d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_28019e90-3ea4-4f4c-aa27-435d5f1a527d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f4ed1b5-91d2-4bbc-b378-4876c72b69fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f4ed1b5-91d2-4bbc-b378-4876c72b69fa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019bff58-eb90-701e-be7f-35a8aff1f5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019bff58-eb90-701e-be7f-35a8aff1f5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019bff58-eb90-7b2a-92ce-a078d44f6062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019bff58-eb90-701e-be7f-35a8aff1f5b5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019bff58-eb90-7b2a-92ce-a078d44f6062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FirstEquityPublicOfferingMember_019bff58-eb90-7530-a1cf-034202ab5a34" xlink:href="arqt-20251231.xsd#arqt_FirstEquityPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019bff58-eb90-7b2a-92ce-a078d44f6062" xlink:to="loc_arqt_FirstEquityPublicOfferingMember_019bff58-eb90-7530-a1cf-034202ab5a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AtTheMarketMember_019bff59-1a5b-7415-9d68-88e7b09bcaf4" xlink:href="arqt-20251231.xsd#arqt_AtTheMarketMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019bff58-eb90-7b2a-92ce-a078d44f6062" xlink:to="loc_arqt_AtTheMarketMember_019bff59-1a5b-7415-9d68-88e7b09bcaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019bff58-eb90-7522-aa8b-21fa0184846a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019bff58-eb90-7522-aa8b-21fa0184846a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019bff58-eb90-754c-8b3f-a4fabda0f475" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019bff58-eb90-7522-aa8b-21fa0184846a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019bff58-eb90-754c-8b3f-a4fabda0f475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrefundedWarrantMember_019bff58-eb90-78e0-82fd-a31c178a96cb" xlink:href="arqt-20251231.xsd#arqt_PrefundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019bff58-eb90-754c-8b3f-a4fabda0f475" xlink:to="loc_arqt_PrefundedWarrantMember_019bff58-eb90-78e0-82fd-a31c178a96cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019bff59-1a5b-7c2e-98e1-cc52bf365fdd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_srt_CounterpartyNameAxis_019bff59-1a5b-7c2e-98e1-cc52bf365fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019bff59-1a5b-711b-a3a2-5404f449937b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019bff59-1a5b-7c2e-98e1-cc52bf365fdd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019bff59-1a5b-711b-a3a2-5404f449937b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CowenAndCompanyLLCMember_019bff59-1a5b-7507-a2f6-61f171d908af" xlink:href="arqt-20251231.xsd#arqt_CowenAndCompanyLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019bff59-1a5b-711b-a3a2-5404f449937b" xlink:to="loc_arqt_CowenAndCompanyLLCMember_019bff59-1a5b-7507-a2f6-61f171d908af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019bff59-1a5b-7034-8bf4-33e557aa3425" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019bff59-1a5b-7034-8bf4-33e557aa3425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019bff59-1a5b-7e05-9302-a04c883bdc58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019bff59-1a5b-7034-8bf4-33e557aa3425" xlink:to="loc_us-gaap_ClassOfStockDomain_019bff59-1a5b-7e05-9302-a04c883bdc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019bff59-1a5b-731b-a22f-811acf183731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019bff59-1a5b-7e05-9302-a04c883bdc58" xlink:to="loc_us-gaap_CommonStockMember_019bff59-1a5b-731b-a22f-811acf183731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019bff59-418d-7706-af49-b49b6b97cac8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_PlanNameAxis_019bff59-418d-7706-af49-b49b6b97cac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019bff59-418d-7706-af49-b49b6b97cac8" xlink:to="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2020EquityIncentivePlanMember_019bff59-418d-7998-a47b-93aa45e60081" xlink:href="arqt-20251231.xsd#arqt_A2020EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:to="loc_arqt_A2020EquityIncentivePlanMember_019bff59-418d-7998-a47b-93aa45e60081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2017EquityIncentivePlanMember_019bff59-418d-7f8c-9ded-08df09de2102" xlink:href="arqt-20251231.xsd#arqt_A2017EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:to="loc_arqt_A2017EquityIncentivePlanMember_019bff59-418d-7f8c-9ded-08df09de2102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2022EmploymentInducementIncentivePlanMember_019bff59-418d-7dc6-9b29-5079a9906cbe" xlink:href="arqt-20251231.xsd#arqt_A2022EmploymentInducementIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:to="loc_arqt_A2022EmploymentInducementIncentivePlanMember_019bff59-418d-7dc6-9b29-5079a9906cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockOptionExchangeMember_019bff59-64bf-789f-8cbd-06014a8d119a" xlink:href="arqt-20251231.xsd#arqt_StockOptionExchangeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019bff59-418d-710c-b3ed-d738dd7bd9cf" xlink:to="loc_arqt_StockOptionExchangeMember_019bff59-64bf-789f-8cbd-06014a8d119a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019bff59-418d-7c99-8216-fb86d94f38e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019bff59-418d-7c99-8216-fb86d94f38e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019bff59-418d-7778-b11f-4811e180af58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019bff59-418d-7c99-8216-fb86d94f38e7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019bff59-418d-7778-b11f-4811e180af58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019bff59-418d-7335-af75-4821952a9501" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019bff59-418d-7778-b11f-4811e180af58" xlink:to="loc_us-gaap_SubsequentEventMember_019bff59-418d-7335-af75-4821952a9501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019bff59-418d-7b68-8259-f18a6d1b9bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_AwardTypeAxis_019bff59-418d-7b68-8259-f18a6d1b9bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019bff59-418d-7b68-8259-f18a6d1b9bf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019bff59-418d-7fc9-ac2f-1bae2c3790e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019bff59-418d-7fc9-ac2f-1bae2c3790e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019bff59-64bf-71a1-b1ab-65cc459b4415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019bff59-64bf-71a1-b1ab-65cc459b4415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019bff59-f853-717a-afd6-fdd52f5b9b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:to="loc_us-gaap_EmployeeStockMember_019bff59-f853-717a-afd6-fdd52f5b9b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_019bff60-ee7c-7143-9e2b-e663cf99aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019bff59-418d-7edf-9b39-42affad0a2eb" xlink:to="loc_us-gaap_RestrictedStockMember_019bff60-ee7c-7143-9e2b-e663cf99aa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_019bff59-64bf-7ccd-9996-c9243549b4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_AwardDateAxis_019bff59-64bf-7ccd-9996-c9243549b4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_019bff59-64bf-79b3-8a9f-ed61f51eb012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_019bff59-64bf-7ccd-9996-c9243549b4b4" xlink:to="loc_us-gaap_AwardDateDomain_019bff59-64bf-79b3-8a9f-ed61f51eb012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_FirstGrantDateMember_019bff59-64bf-77bc-8afe-c18e156b2a54" xlink:href="arqt-20251231.xsd#arqt_FirstGrantDateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_019bff59-64bf-79b3-8a9f-ed61f51eb012" xlink:to="loc_arqt_FirstGrantDateMember_019bff59-64bf-77bc-8afe-c18e156b2a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SecondGrantDateMember_019bff59-64bf-7f0f-b137-d492c0d3827c" xlink:href="arqt-20251231.xsd#arqt_SecondGrantDateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_019bff59-64bf-79b3-8a9f-ed61f51eb012" xlink:to="loc_arqt_SecondGrantDateMember_019bff59-64bf-7f0f-b137-d492c0d3827c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ThirdGrantDateMember_019bff59-64bf-7723-84f3-bccc2b64fc50" xlink:href="arqt-20251231.xsd#arqt_ThirdGrantDateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_019bff59-64bf-79b3-8a9f-ed61f51eb012" xlink:to="loc_arqt_ThirdGrantDateMember_019bff59-64bf-7723-84f3-bccc2b64fc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019bff59-64bf-7d46-b9c4-92cb99ef130f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_srt_RangeAxis_019bff59-64bf-7d46-b9c4-92cb99ef130f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019bff59-64bf-7f1d-a6c8-ac9392104552" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019bff59-64bf-7d46-b9c4-92cb99ef130f" xlink:to="loc_srt_RangeMember_019bff59-64bf-7f1d-a6c8-ac9392104552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019bff59-64bf-73b3-8b61-11c880af7557" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019bff59-64bf-7f1d-a6c8-ac9392104552" xlink:to="loc_srt_MinimumMember_019bff59-64bf-73b3-8b61-11c880af7557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019bff59-64bf-78c6-99f0-68ecbe3dc541" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019bff59-64bf-7f1d-a6c8-ac9392104552" xlink:to="loc_srt_MaximumMember_019bff59-64bf-78c6-99f0-68ecbe3dc541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019bff5a-1b14-7151-a51f-00ab8f4a51d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019bff5a-1b14-7151-a51f-00ab8f4a51d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019bff5a-1b14-7da2-bba5-ca4b2d746752" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019bff5a-1b14-7151-a51f-00ab8f4a51d3" xlink:to="loc_us-gaap_EquityComponentDomain_019bff5a-1b14-7da2-bba5-ca4b2d746752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019bff5a-1b14-7f7c-91e1-3fa885cdb566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019bff5a-1b14-7da2-bba5-ca4b2d746752" xlink:to="loc_us-gaap_CommonStockMember_019bff5a-1b14-7f7c-91e1-3fa885cdb566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_019bff60-ee7c-7353-bc7a-3dedf807e67d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_VestingAxis_019bff60-ee7c-7353-bc7a-3dedf807e67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019bff60-ee7c-7ace-871c-c77121905acf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_019bff60-ee7c-7353-bc7a-3dedf807e67d" xlink:to="loc_us-gaap_VestingDomain_019bff60-ee7c-7ace-871c-c77121905acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019bff60-ee7c-747d-bfec-7229274221f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_019bff60-ee7c-7ace-871c-c77121905acf" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019bff60-ee7c-747d-bfec-7229274221f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3dd9ef0c-5ad6-4dab-9531-e899e4b04baf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalUnitsAuthorized_019bff58-eb90-721b-80b7-1fca6b1f1b29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_CapitalUnitsAuthorized_019bff58-eb90-721b-80b7-1fca6b1f1b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019bff58-eb90-77ff-b6a7-b6a8edc9cb57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019bff58-eb90-77ff-b6a7-b6a8edc9cb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019bff58-eb90-7270-a661-cbf5cb411a24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019bff58-eb90-7270-a661-cbf5cb411a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019bff58-eb90-7f92-90a0-c182612f21d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019bff58-eb90-7f92-90a0-c182612f21d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019c2740-1984-751c-99b4-60cf9be06121" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019c2740-1984-751c-99b4-60cf9be06121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019bff58-eb90-7abc-9f39-35edc5b32175" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019bff58-eb90-7abc-9f39-35edc5b32175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019bff58-eb90-7abf-b3ee-b3b7c1fb17f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019bff58-eb90-7abf-b3ee-b3b7c1fb17f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019bff58-eb90-7a2a-aeda-efb2523872ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019bff58-eb90-7a2a-aeda-efb2523872ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019bff58-eb90-7c05-9c1a-d243d54cc1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019bff58-eb90-7c05-9c1a-d243d54cc1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019c2738-0542-7399-a931-3b985451b799" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019c2738-0542-7399-a931-3b985451b799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019bff58-eb90-716f-a972-d263afec640a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019bff58-eb90-716f-a972-d263afec640a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SaleOfStockAuthorizedConsiderationOnTransaction_019bff59-1a5b-7ea0-adb8-4b3d56461601" xlink:href="arqt-20251231.xsd#arqt_SaleOfStockAuthorizedConsiderationOnTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_SaleOfStockAuthorizedConsiderationOnTransaction_019bff59-1a5b-7ea0-adb8-4b3d56461601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds_019bff59-1a5b-779c-9194-5dd809c84525" xlink:href="arqt-20251231.xsd#arqt_SaleOfStockAgentFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds_019bff59-1a5b-779c-9194-5dd809c84525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019bff59-418d-7998-89eb-1bd67a36de1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019bff59-418d-7998-89eb-1bd67a36de1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_019bff59-418d-75d0-a94a-0b8a2e9608ce" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_019bff59-418d-75d0-a94a-0b8a2e9608ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_019bff59-418d-72c6-9630-f26e44675637" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_019bff59-418d-72c6-9630-f26e44675637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019bff59-418d-7fc9-b03d-3f31f8592066" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019bff59-418d-7fc9-b03d-3f31f8592066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019bff59-418d-7943-a60d-d87a544deb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019bff59-418d-7943-a60d-d87a544deb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019bff59-418d-7ba2-bfad-560ee6abb968" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019bff59-418d-7ba2-bfad-560ee6abb968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019bff59-64bf-7641-9b17-7f06affd437f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019bff59-64bf-7641-9b17-7f06affd437f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged_019bff59-64bf-78db-946c-c5f276a91843" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged_019bff59-64bf-78db-946c-c5f276a91843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019bff59-64bf-7e5b-8cb3-db86efbc4ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019bff59-64bf-7e5b-8cb3-db86efbc4ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_019bff59-64bf-75c4-a79e-35dfc1771cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_019bff59-64bf-75c4-a79e-35dfc1771cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019bff59-64bf-706a-8a18-f9b41b7f1ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019bff59-64bf-706a-8a18-f9b41b7f1ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019bff59-87f9-7a12-9508-390a59c7de99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019bff59-87f9-7a12-9508-390a59c7de99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019bff59-87f9-7e5c-b809-1b223b140615" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019bff59-87f9-7e5c-b809-1b223b140615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019bff59-87f9-7453-ae6a-bfca28975bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019bff59-87f9-7453-ae6a-bfca28975bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c277f-9cd9-7aba-a3ba-e4c7345037d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c277f-9cd9-7aba-a3ba-e4c7345037d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019bff59-d6d9-7b16-86a8-c5655e998c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019bff59-d6d9-7b16-86a8-c5655e998c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019bff59-d6d9-717f-afa3-5b1d87a38bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019bff59-d6d9-717f-afa3-5b1d87a38bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019bff59-d6d9-7186-858e-accdd463f979" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019bff59-d6d9-7186-858e-accdd463f979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019bff59-f853-710b-b845-0669763341a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019bff59-f853-710b-b845-0669763341a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_019bff5a-1b14-7618-93e6-42d243a80287" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_019bff5a-1b14-7618-93e6-42d243a80287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_019bff5a-1b14-72a6-a0ed-684223b8169f" xlink:href="arqt-20251231.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_019bff5a-1b14-72a6-a0ed-684223b8169f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019bff5a-1b14-7a2c-87b1-27c2a0274fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019bff5a-1b14-7a2c-87b1-27c2a0274fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019bff60-ee7c-7116-83f6-2df70ee8880d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019bff58-eb90-7cdf-9794-082866b40c3e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019bff60-ee7c-7116-83f6-2df70ee8880d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockholdersEquityScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a71b2782-2614-49e6-84cc-37b24a479582" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c2a34d0b-0e2a-4769-86cf-fdcc1138f5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a71b2782-2614-49e6-84cc-37b24a479582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c2a34d0b-0e2a-4769-86cf-fdcc1138f5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab01bcc4-51a8-4bdf-8817-6e4fedf87ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c2a34d0b-0e2a-4769-86cf-fdcc1138f5ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab01bcc4-51a8-4bdf-8817-6e4fedf87ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8adf9a8f-a32d-4a55-81d4-92530482055e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c2a34d0b-0e2a-4769-86cf-fdcc1138f5ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8adf9a8f-a32d-4a55-81d4-92530482055e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0827ae3b-fcd9-42b5-aa0e-7be748a535d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c2a34d0b-0e2a-4769-86cf-fdcc1138f5ed" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0827ae3b-fcd9-42b5-aa0e-7be748a535d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c32f0aec-7589-4379-a4ef-48995542a24d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c2a34d0b-0e2a-4769-86cf-fdcc1138f5ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c32f0aec-7589-4379-a4ef-48995542a24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_60c981ec-ab68-4f3f-834e-d5a7c6243901" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c2a34d0b-0e2a-4769-86cf-fdcc1138f5ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_60c981ec-ab68-4f3f-834e-d5a7c6243901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64632ea2-28a1-4124-b84c-5e277419cd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c2a34d0b-0e2a-4769-86cf-fdcc1138f5ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64632ea2-28a1-4124-b84c-5e277419cd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a84dd68c-6317-4775-ba7a-4ed30d88e574" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a71b2782-2614-49e6-84cc-37b24a479582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a84dd68c-6317-4775-ba7a-4ed30d88e574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e39324e3-7365-4b8c-a029-ad99277cdb97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a84dd68c-6317-4775-ba7a-4ed30d88e574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e39324e3-7365-4b8c-a029-ad99277cdb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b4779fc1-8024-436e-8588-fe20b2f70b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a84dd68c-6317-4775-ba7a-4ed30d88e574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b4779fc1-8024-436e-8588-fe20b2f70b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c52ff684-d2b8-428d-9854-a35b0cbd7ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a84dd68c-6317-4775-ba7a-4ed30d88e574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c52ff684-d2b8-428d-9854-a35b0cbd7ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1360f131-0f93-4fac-8f0b-6316780efae1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a84dd68c-6317-4775-ba7a-4ed30d88e574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1360f131-0f93-4fac-8f0b-6316780efae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_83d151f3-a471-486e-98af-5c1723c823dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a84dd68c-6317-4775-ba7a-4ed30d88e574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_83d151f3-a471-486e-98af-5c1723c823dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_57d10166-ff1f-4373-9c83-a0db09eadf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a84dd68c-6317-4775-ba7a-4ed30d88e574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_57d10166-ff1f-4373-9c83-a0db09eadf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1373eed7-ba4c-41f9-8843-207426338ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a71b2782-2614-49e6-84cc-37b24a479582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1373eed7-ba4c-41f9-8843-207426338ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50ac2434-b296-400f-b389-d6b09ae29f43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1373eed7-ba4c-41f9-8843-207426338ef4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50ac2434-b296-400f-b389-d6b09ae29f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_db1a4986-a17a-4ec1-bdc3-8805ccb29c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1373eed7-ba4c-41f9-8843-207426338ef4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_db1a4986-a17a-4ec1-bdc3-8805ccb29c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ccda7c5d-c505-4351-8a66-84ae063213ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1373eed7-ba4c-41f9-8843-207426338ef4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ccda7c5d-c505-4351-8a66-84ae063213ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dfa8d65e-8868-435e-a7a9-be7fb42f008f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1373eed7-ba4c-41f9-8843-207426338ef4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dfa8d65e-8868-435e-a7a9-be7fb42f008f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7a6c3d63-b5f8-4aea-a75c-68e8760fd42b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1373eed7-ba4c-41f9-8843-207426338ef4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7a6c3d63-b5f8-4aea-a75c-68e8760fd42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ce683963-3696-45cc-bb54-907320cf634d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1373eed7-ba4c-41f9-8843-207426338ef4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ce683963-3696-45cc-bb54-907320cf634d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3d04152-1174-4bda-b86c-0f0d1fd7cd68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_809537f3-a2c7-41f4-9b01-ec4b94906563" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3d04152-1174-4bda-b86c-0f0d1fd7cd68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_809537f3-a2c7-41f4-9b01-ec4b94906563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2332c351-9702-4882-8026-55ee51a15f51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_809537f3-a2c7-41f4-9b01-ec4b94906563" xlink:to="loc_us-gaap_AwardTypeAxis_2332c351-9702-4882-8026-55ee51a15f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b173172d-0e62-4619-a5f6-9277787123dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2332c351-9702-4882-8026-55ee51a15f51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b173172d-0e62-4619-a5f6-9277787123dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bbff6e10-e7d4-4a30-a72d-2d08fc212dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b173172d-0e62-4619-a5f6-9277787123dd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bbff6e10-e7d4-4a30-a72d-2d08fc212dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54057065-5bb0-4cdf-b4e7-73ee5d503cde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_809537f3-a2c7-41f4-9b01-ec4b94906563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54057065-5bb0-4cdf-b4e7-73ee5d503cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54057065-5bb0-4cdf-b4e7-73ee5d503cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f52b6e08-33f0-4692-9fa9-0e198081df6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f52b6e08-33f0-4692-9fa9-0e198081df6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d43783d-2249-475b-8a06-a4dcc6fb8ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3d43783d-2249-475b-8a06-a4dcc6fb8ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d21c2ae3-dc70-4b05-aba0-a594525fa581" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d21c2ae3-dc70-4b05-aba0-a594525fa581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d9d07f35-5084-4a11-b617-8d32f1b1a6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d9d07f35-5084-4a11-b617-8d32f1b1a6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51a7cc8c-e950-4c96-b8ad-e80d1734e392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9f6851f2-1ac3-4ed1-91b0-6e9867160e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51a7cc8c-e950-4c96-b8ad-e80d1734e392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54057065-5bb0-4cdf-b4e7-73ee5d503cde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c98e068d-886e-4708-b449-dfe3d27dccb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c98e068d-886e-4708-b449-dfe3d27dccb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_efb74921-914c-4528-82f4-8c3680dcce5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_efb74921-914c-4528-82f4-8c3680dcce5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_16ad7663-8430-409d-93a6-9e7c1f0a0b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_16ad7663-8430-409d-93a6-9e7c1f0a0b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_628b2ff2-507d-49db-9278-00fab5259e41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_628b2ff2-507d-49db-9278-00fab5259e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6935a86c-d968-4cf9-b0b3-fde2faad78b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_adcee6e9-9311-4a6d-b806-3d06ce8935a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6935a86c-d968-4cf9-b0b3-fde2faad78b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockholdersEquityScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c588f72d-bce9-4928-8325-a3925b7cdf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c2ead47-52da-4891-848f-26c1a26c39f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c588f72d-bce9-4928-8325-a3925b7cdf9a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c2ead47-52da-4891-848f-26c1a26c39f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ca2579c2-df05-4fb2-a375-a877426e92f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c2ead47-52da-4891-848f-26c1a26c39f1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ca2579c2-df05-4fb2-a375-a877426e92f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b086a9cc-ca72-430b-ba4a-9ec1f9404d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ca2579c2-df05-4fb2-a375-a877426e92f7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b086a9cc-ca72-430b-ba4a-9ec1f9404d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eaadacaf-beb9-4696-8a8f-506d7736692a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b086a9cc-ca72-430b-ba4a-9ec1f9404d5d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eaadacaf-beb9-4696-8a8f-506d7736692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d0bc3c0e-1209-4b19-9600-eb4e9656e591" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b086a9cc-ca72-430b-ba4a-9ec1f9404d5d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d0bc3c0e-1209-4b19-9600-eb4e9656e591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2080f01a-86e2-4bac-8746-63626bf31be5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c2ead47-52da-4891-848f-26c1a26c39f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2080f01a-86e2-4bac-8746-63626bf31be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_eaefc9d1-8e01-4031-93af-ee9b2cd05f82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2080f01a-86e2-4bac-8746-63626bf31be5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_eaefc9d1-8e01-4031-93af-ee9b2cd05f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9ffe9e3-bd79-4c24-9b04-b51242d803bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_729cdca0-f388-4ea0-b8a7-d9934448ce2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9ffe9e3-bd79-4c24-9b04-b51242d803bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_729cdca0-f388-4ea0-b8a7-d9934448ce2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8390b01c-cea7-4ca8-b4d1-a7e6863b4da5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_729cdca0-f388-4ea0-b8a7-d9934448ce2d" xlink:to="loc_srt_RangeAxis_8390b01c-cea7-4ca8-b4d1-a7e6863b4da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b76a27c-d978-40c3-8e0a-50d9cfc1eb14" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8390b01c-cea7-4ca8-b4d1-a7e6863b4da5" xlink:to="loc_srt_RangeMember_1b76a27c-d978-40c3-8e0a-50d9cfc1eb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d09a8dc9-91eb-4bc8-ae79-184c7bb342cb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b76a27c-d978-40c3-8e0a-50d9cfc1eb14" xlink:to="loc_srt_MinimumMember_d09a8dc9-91eb-4bc8-ae79-184c7bb342cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b80c851c-e61b-45a1-b4e3-dda443dcbc47" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b76a27c-d978-40c3-8e0a-50d9cfc1eb14" xlink:to="loc_srt_MaximumMember_b80c851c-e61b-45a1-b4e3-dda443dcbc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_93a57728-1f35-4552-9c12-98eaee3c0de7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_729cdca0-f388-4ea0-b8a7-d9934448ce2d" xlink:to="loc_us-gaap_AwardTypeAxis_93a57728-1f35-4552-9c12-98eaee3c0de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2ce9383-104e-4611-a83e-2b97072a5f74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_93a57728-1f35-4552-9c12-98eaee3c0de7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2ce9383-104e-4611-a83e-2b97072a5f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_44da2b9c-09bb-4a8b-b564-07c8807de899" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2ce9383-104e-4611-a83e-2b97072a5f74" xlink:to="loc_us-gaap_EmployeeStockOptionMember_44da2b9c-09bb-4a8b-b564-07c8807de899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_729cdca0-f388-4ea0-b8a7-d9934448ce2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1a70480-5603-4f51-bb6a-1145e3517744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1a70480-5603-4f51-bb6a-1145e3517744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f0bc1aa4-1f0f-4243-9279-285491d089a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f0bc1aa4-1f0f-4243-9279-285491d089a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_675cd3c8-0907-45ba-8030-f44f9fd1cc54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_675cd3c8-0907-45ba-8030-f44f9fd1cc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b50c4ce3-8f34-4480-8cfd-3e7271b0958c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b50c4ce3-8f34-4480-8cfd-3e7271b0958c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_eb8f0d14-38c9-4943-99ac-46a96cdd30dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_eb8f0d14-38c9-4943-99ac-46a96cdd30dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ddf35966-a6cf-4748-b281-776f5d92f794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b0cf4053-6e12-4a0a-82d2-0a03a2c020e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ddf35966-a6cf-4748-b281-776f5d92f794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d7688504-30e2-4be9-aa3c-0dad6e9d2064" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_988291ec-68df-4316-8176-aa515d6e9446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d7688504-30e2-4be9-aa3c-0dad6e9d2064" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_988291ec-68df-4316-8176-aa515d6e9446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019bff72-4831-7ae0-a72c-255920d46421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_988291ec-68df-4316-8176-aa515d6e9446" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019bff72-4831-7ae0-a72c-255920d46421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7354-9482-c7516e2a8ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019bff72-4831-7ae0-a72c-255920d46421" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7354-9482-c7516e2a8ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019bff72-4831-79cc-ba9d-558f02cdc6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7354-9482-c7516e2a8ec3" xlink:to="loc_us-gaap_DomesticCountryMember_019bff72-4831-79cc-ba9d-558f02cdc6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019bff72-4831-7ddf-8262-421b452acd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7354-9482-c7516e2a8ec3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019bff72-4831-7ddf-8262-421b452acd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019bff72-4831-76d0-8546-84f48309ebc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019bff72-4831-7354-9482-c7516e2a8ec3" xlink:to="loc_us-gaap_ForeignCountryMember_019bff72-4831-76d0-8546-84f48309ebc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_019bff72-4831-7204-b978-5b81caeec786" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_988291ec-68df-4316-8176-aa515d6e9446" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_019bff72-4831-7204-b978-5b81caeec786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_019bff72-4831-7de7-870e-92c81dd8d83c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_019bff72-4831-7204-b978-5b81caeec786" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_019bff72-4831-7de7-870e-92c81dd8d83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_019bff72-4831-73f0-8ecc-bd5d498269af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_019bff72-4831-7de7-870e-92c81dd8d83c" xlink:to="loc_us-gaap_ResearchMember_019bff72-4831-73f0-8ecc-bd5d498269af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_988291ec-68df-4316-8176-aa515d6e9446" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019bff71-d85c-783c-828a-c11c04aecd76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019bff71-d85c-783c-828a-c11c04aecd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ForeignWithholdingIncomeTaxes_019bff71-d85c-70a7-989e-0575ad28f27b" xlink:href="arqt-20251231.xsd#arqt_ForeignWithholdingIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_arqt_ForeignWithholdingIncomeTaxes_019bff71-d85c-70a7-989e-0575ad28f27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019bff72-4831-732d-9b46-5c29fd796926" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019bff72-4831-732d-9b46-5c29fd796926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_019bff72-4831-7b3c-a275-3b1b22c4a59a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_OperatingLossCarryforwards_019bff72-4831-7b3c-a275-3b1b22c4a59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_019bff72-4831-7032-9663-6f6bd599e1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_019bff72-4831-7032-9663-6f6bd599e1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_019bff72-4831-70c2-a925-257d33d8d364" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_019bff72-4831-70c2-a925-257d33d8d364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_019bff72-4831-7226-b8a1-bef69efe0b20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_019bff72-4831-7226-b8a1-bef69efe0b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_019bff72-89b2-70fb-81c0-52d813f979d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_019bff72-89b2-70fb-81c0-52d813f979d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_019c8aec-b8f4-7672-9579-6056e9551b93" xlink:href="arqt-20251231.xsd#arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_019c8aec-b8f4-7672-9579-6056e9551b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_019bff72-89b2-78ca-a34d-eba8ee652451" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_019bff72-89b2-78ca-a34d-eba8ee652451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_019c4c3a-6bc4-7ad5-8eb7-77d3053844d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_019c4c3a-6bc4-7ad5-8eb7-77d3053844d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019c76d1-490f-7366-aebd-bbd4967e55f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_019bff71-d85c-7048-ac67-8a9df231ae69" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019c76d1-490f-7366-aebd-bbd4967e55f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fbc84f64-51b0-4f6e-b2e7-ec0e8b3c7c98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f37c9c7b-f599-4269-afb5-c5d59d619be3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbc84f64-51b0-4f6e-b2e7-ec0e8b3c7c98" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f37c9c7b-f599-4269-afb5-c5d59d619be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5d4d3a11-f952-4a56-a074-7c1b12e290f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbc84f64-51b0-4f6e-b2e7-ec0e8b3c7c98" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5d4d3a11-f952-4a56-a074-7c1b12e290f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_421b98b1-c8cb-41a7-acff-0a271f8e75db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbc84f64-51b0-4f6e-b2e7-ec0e8b3c7c98" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_421b98b1-c8cb-41a7-acff-0a271f8e75db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9ffce638-642c-4e55-8fe0-72b5b8754fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_048957de-f051-4481-b0c1-1eaf7bfaf582" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9ffce638-642c-4e55-8fe0-72b5b8754fb9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_048957de-f051-4481-b0c1-1eaf7bfaf582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cfdc7dd4-7fc7-4d5c-bad7-25fe6b3d424f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_048957de-f051-4481-b0c1-1eaf7bfaf582" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cfdc7dd4-7fc7-4d5c-bad7-25fe6b3d424f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49624aba-7cfb-4a0f-aa59-be02c8b65c07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_048957de-f051-4481-b0c1-1eaf7bfaf582" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49624aba-7cfb-4a0f-aa59-be02c8b65c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ba619bd7-a4b6-4159-a42a-8940f30a5da8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_048957de-f051-4481-b0c1-1eaf7bfaf582" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ba619bd7-a4b6-4159-a42a-8940f30a5da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8f338812-c308-4c29-a708-f19fde9e99ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_048957de-f051-4481-b0c1-1eaf7bfaf582" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8f338812-c308-4c29-a708-f19fde9e99ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d0c8c26b-df95-4748-868b-9b1484499978" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9ffce638-642c-4e55-8fe0-72b5b8754fb9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d0c8c26b-df95-4748-868b-9b1484499978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e829c0ae-d87d-4dbf-9aed-3cd95c12bcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d0c8c26b-df95-4748-868b-9b1484499978" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e829c0ae-d87d-4dbf-9aed-3cd95c12bcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2656cb39-e77c-43f5-a291-deda71324ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d0c8c26b-df95-4748-868b-9b1484499978" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2656cb39-e77c-43f5-a291-deda71324ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e4a6f948-27a9-4d15-be49-1dd237293ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d0c8c26b-df95-4748-868b-9b1484499978" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e4a6f948-27a9-4d15-be49-1dd237293ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6f120c33-acb6-4118-a87e-f9aa42099744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d0c8c26b-df95-4748-868b-9b1484499978" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6f120c33-acb6-4118-a87e-f9aa42099744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0d383661-83e3-4d38-965e-1e019b472ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9ffce638-642c-4e55-8fe0-72b5b8754fb9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0d383661-83e3-4d38-965e-1e019b472ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c0c89c35-bd7f-4e93-b1c7-b7f077dd43a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7043-9c3b-77f1-9af8-157afae3152e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c0c89c35-bd7f-4e93-b1c7-b7f077dd43a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7043-9c3b-77f1-9af8-157afae3152e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c7043-9c3b-7a75-9f33-86135b7587a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7043-9c3b-77f1-9af8-157afae3152e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c7043-9c3b-7a75-9f33-86135b7587a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c7043-9c3b-7086-8f7c-77d413753feb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c7043-9c3b-7a75-9f33-86135b7587a7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c7043-9c3b-7086-8f7c-77d413753feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019c7047-5dbf-701e-81a0-462a47227775" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7043-9c3b-7086-8f7c-77d413753feb" xlink:to="loc_us-gaap_ForeignCountryMember_019c7047-5dbf-701e-81a0-462a47227775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019c7043-9c3b-71c0-817b-38d95bb89f32" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCountryMember_019c7047-5dbf-701e-81a0-462a47227775" xlink:to="loc_country_GB_019c7043-9c3b-71c0-817b-38d95bb89f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_019c7043-9c3b-729a-a217-953bc53fad01" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCountryMember_019c7047-5dbf-701e-81a0-462a47227775" xlink:to="loc_country_CN_019c7043-9c3b-729a-a217-953bc53fad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c7043-9c3b-7666-8c64-6aaf4150dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCountryMember_019c7047-5dbf-701e-81a0-462a47227775" xlink:to="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c7043-9c3b-7666-8c64-6aaf4150dfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019c7046-6e22-7dc8-8ada-d12e4ace38e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7043-9c3b-7086-8f7c-77d413753feb" xlink:to="loc_us-gaap_DomesticCountryMember_019c7046-6e22-7dc8-8ada-d12e4ace38e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019c7049-61a4-7185-8e82-d9144ecd335e" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019c7046-6e22-7dc8-8ada-d12e4ace38e2" xlink:to="loc_country_US_019c7049-61a4-7185-8e82-d9144ecd335e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7043-9c3b-7ee5-b836-7dc80f974a50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7043-9c3b-77f1-9af8-157afae3152e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7043-9c3b-7ee5-b836-7dc80f974a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7043-9c3b-7ee5-b836-7dc80f974a50" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019bb779-5e2f-78d6-823f-a4a90502054a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019bb779-5e2f-78d6-823f-a4a90502054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019bb779-5e2f-765c-a3a0-7ed47db18cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019bb779-5e2f-765c-a3a0-7ed47db18cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019bb779-5e2f-7ec2-89f4-38a822c5f7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019bb779-5e2f-7ec2-89f4-38a822c5f7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7043-9c3b-749e-a57c-37dedaf610db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7043-9c3b-749e-a57c-37dedaf610db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_019bb779-5e2f-7853-9fae-4711abd739ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_019bb779-5e2f-7853-9fae-4711abd739ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount_019bb779-5e2f-7a89-bf08-29c7fbe6868e" xlink:href="arqt-20251231.xsd#arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount_019bb779-5e2f-7a89-bf08-29c7fbe6868e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb779-5e2f-7aa5-b7bd-69eb8dd49062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb779-5e2f-7aa5-b7bd-69eb8dd49062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019bb779-5e2f-78a7-8de9-3ff68f0f6e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019bb779-5e2f-78a7-8de9-3ff68f0f6e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019bb779-5e2f-791b-a0db-a10146e62881" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019bb779-5e2f-791b-a0db-a10146e62881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019bb779-5e2f-7e2d-aa5d-2a89b73f8168" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019bb780-5c57-7db1-a881-471787f4471a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019bb779-5e2f-7e2d-aa5d-2a89b73f8168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7043-9c3b-7ee5-b836-7dc80f974a50" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019bb779-5e2f-7b96-8076-9cb3411289db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019bb779-5e2f-7b96-8076-9cb3411289db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019bb779-5e2f-7c1d-9f3e-189d8ffaf588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019bb779-5e2f-7c1d-9f3e-189d8ffaf588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019bb779-5e2f-781d-8086-aea6868b15f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019bb779-5e2f-781d-8086-aea6868b15f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7043-9c3b-7afa-979f-27972f839e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7043-9c3b-7afa-979f-27972f839e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019bb779-5e2f-74e9-bf80-79121f7ebc25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019bb779-5e2f-74e9-bf80-79121f7ebc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent_019bb779-5e2f-742f-989f-f7751b24ee8b" xlink:href="arqt-20251231.xsd#arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent_019bb779-5e2f-742f-989f-f7751b24ee8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb779-5e2f-7e61-b89a-dcf37b800cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019bb779-5e2f-7e61-b89a-dcf37b800cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019bb779-5e2f-72be-90da-96583b2ae91a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019bb779-5e2f-72be-90da-96583b2ae91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019bb779-5e2f-75b8-8975-f91877ebd627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019bb779-5e2f-75b8-8975-f91877ebd627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb779-5e2f-70c2-bd7c-89d5765c8875" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019bb77e-b5a0-7f44-b776-a0bcd2a7a98f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019bb779-5e2f-70c2-bd7c-89d5765c8875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dd5caa43-c608-4beb-9e33-27b1468771ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd5caa43-c608-4beb-9e33-27b1468771ee" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9161b881-8528-4ad5-9002-346a078b3cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9161b881-8528-4ad5-9002-346a078b3cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_83fc8ee9-9667-4b6b-b33f-0cb8b4abd6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_83fc8ee9-9667-4b6b-b33f-0cb8b4abd6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_04c50f22-79f3-4b2a-9bee-637f3862ce8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_04c50f22-79f3-4b2a-9bee-637f3862ce8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization_7b33ecf1-7884-47b3-822a-f526c95b237d" xlink:href="arqt-20251231.xsd#arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:to="loc_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization_7b33ecf1-7884-47b3-822a-f526c95b237d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_5260f641-fc32-40d1-81fa-5b6db6748112" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_5260f641-fc32-40d1-81fa-5b6db6748112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredTaxAssetsLeaseLiability_dca2abcd-7496-48e3-82ba-1d93503076eb" xlink:href="arqt-20251231.xsd#arqt_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:to="loc_arqt_DeferredTaxAssetsLeaseLiability_dca2abcd-7496-48e3-82ba-1d93503076eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c7d72f95-1292-4a08-b77f-29d80e03aa95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c7d72f95-1292-4a08-b77f-29d80e03aa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d9f975d0-9ac5-4bd9-8837-fc4a39715de9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d9f975d0-9ac5-4bd9-8837-fc4a39715de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7bd72d3b-46bf-4219-9ba7-b648bf355517" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7bd72d3b-46bf-4219-9ba7-b648bf355517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9d6e47bb-d43b-4bc6-8a0b-673a7761d261" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_c4eaf243-5fad-4e1c-898f-8013658710ca" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_9d6e47bb-d43b-4bc6-8a0b-673a7761d261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c57015a5-4727-42c2-9208-5f822f60f8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd5caa43-c608-4beb-9e33-27b1468771ee" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c57015a5-4727-42c2-9208-5f822f60f8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0445ec19-3bd1-43f3-94c6-90768474dd35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c57015a5-4727-42c2-9208-5f822f60f8aa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0445ec19-3bd1-43f3-94c6-90768474dd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredTaxLiabilitiesRightOfUseAsset_001c241b-a684-4db3-bd0b-eab8993fa83c" xlink:href="arqt-20251231.xsd#arqt_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c57015a5-4727-42c2-9208-5f822f60f8aa" xlink:to="loc_arqt_DeferredTaxLiabilitiesRightOfUseAsset_001c241b-a684-4db3-bd0b-eab8993fa83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_82beced9-c45e-499e-851e-f632547e50c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c57015a5-4727-42c2-9208-5f822f60f8aa" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_82beced9-c45e-499e-851e-f632547e50c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1278a6e4-9715-4b81-8fc4-f5336a7297ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd5caa43-c608-4beb-9e33-27b1468771ee" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1278a6e4-9715-4b81-8fc4-f5336a7297ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c0f26400-dc04-4e83-bb5c-694e5ca3f272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1278a6e4-9715-4b81-8fc4-f5336a7297ac" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c0f26400-dc04-4e83-bb5c-694e5ca3f272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ba960e81-c15a-4713-afbc-b237a075dfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_86fa9c63-3872-4f8d-b7b8-567223b1e255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ba960e81-c15a-4713-afbc-b237a075dfe9" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_86fa9c63-3872-4f8d-b7b8-567223b1e255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_90d3e19e-5fd1-48b1-8672-4eff847e46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_86fa9c63-3872-4f8d-b7b8-567223b1e255" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_90d3e19e-5fd1-48b1-8672-4eff847e46d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_019c2799-b27d-757e-8d47-f29aeabbaf25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_86fa9c63-3872-4f8d-b7b8-567223b1e255" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_019c2799-b27d-757e-8d47-f29aeabbaf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a3d24f58-faf3-433a-840c-af6b9c1aa4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_86fa9c63-3872-4f8d-b7b8-567223b1e255" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a3d24f58-faf3-433a-840c-af6b9c1aa4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_dc5be57e-db54-4d86-8fbd-b082878d6c07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_86fa9c63-3872-4f8d-b7b8-567223b1e255" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_dc5be57e-db54-4d86-8fbd-b082878d6c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_0f4adb15-a3f5-40f6-acf2-57dba153ead9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_86fa9c63-3872-4f8d-b7b8-567223b1e255" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_0f4adb15-a3f5-40f6-acf2-57dba153ead9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#NetLossPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b9675992-1540-4f07-b908-a9f7e1e85b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc52aec-c1f8-4769-9963-16b96aec9a36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b9675992-1540-4f07-b908-a9f7e1e85b5a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc52aec-c1f8-4769-9963-16b96aec9a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a3eef0a0-1838-45cc-8259-037ad2e7b929" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc52aec-c1f8-4769-9963-16b96aec9a36" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a3eef0a0-1838-45cc-8259-037ad2e7b929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2175d501-0f3f-4a55-b82c-00664ce402b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a3eef0a0-1838-45cc-8259-037ad2e7b929" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2175d501-0f3f-4a55-b82c-00664ce402b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrefundedWarrantMember_e279c06f-fa78-4bbe-8c1a-d63e9d33a0d1" xlink:href="arqt-20251231.xsd#arqt_PrefundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2175d501-0f3f-4a55-b82c-00664ce402b0" xlink:to="loc_arqt_PrefundedWarrantMember_e279c06f-fa78-4bbe-8c1a-d63e9d33a0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6bd0ae9e-9e9d-4c95-b659-da182ec01b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc52aec-c1f8-4769-9963-16b96aec9a36" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6bd0ae9e-9e9d-4c95-b659-da182ec01b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bb99daab-2614-485a-8734-5efa10948724" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6bd0ae9e-9e9d-4c95-b659-da182ec01b8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bb99daab-2614-485a-8734-5efa10948724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#NetLossPerShareDilutiveSharesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cefc4763-f5ea-4e43-b327-35cc095ffeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_123a562f-03d0-41a9-b369-2957486be486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cefc4763-f5ea-4e43-b327-35cc095ffeb9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_123a562f-03d0-41a9-b369-2957486be486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f0e68a68-dbdd-4d73-8a34-7f814ab2d9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_123a562f-03d0-41a9-b369-2957486be486" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f0e68a68-dbdd-4d73-8a34-7f814ab2d9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb9e827e-e67d-428b-aea1-9b83a7c367bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f0e68a68-dbdd-4d73-8a34-7f814ab2d9a4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb9e827e-e67d-428b-aea1-9b83a7c367bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1bfa420b-c496-4dd9-b18f-12f9a2f200ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb9e827e-e67d-428b-aea1-9b83a7c367bc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1bfa420b-c496-4dd9-b18f-12f9a2f200ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e4eb1238-0d03-4492-95d5-e83d1d110b51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb9e827e-e67d-428b-aea1-9b83a7c367bc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e4eb1238-0d03-4492-95d5-e83d1d110b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_feddebf7-e66d-4447-838b-8f5c8f676d07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb9e827e-e67d-428b-aea1-9b83a7c367bc" xlink:to="loc_us-gaap_EmployeeStockMember_feddebf7-e66d-4447-838b-8f5c8f676d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd3abb84-8c07-4520-906a-5c7ed6ad30ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_123a562f-03d0-41a9-b369-2957486be486" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd3abb84-8c07-4520-906a-5c7ed6ad30ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00530c58-2efd-4642-86aa-158b1ab4e228" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd3abb84-8c07-4520-906a-5c7ed6ad30ff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00530c58-2efd-4642-86aa-158b1ab4e228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#SegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6f4764e0-8a51-4e77-80a4-5c0910132999" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c8c06e91-fc57-46db-a4c9-03966dc77ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6f4764e0-8a51-4e77-80a4-5c0910132999" xlink:to="loc_us-gaap_NumberOfReportableSegments_c8c06e91-fc57-46db-a4c9-03966dc77ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="arqt-20251231.xsd#SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6a92de5f-1324-4d79-840d-daf73d139eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f48121a4-02cc-4417-9211-7dbeba7db345" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6a92de5f-1324-4d79-840d-daf73d139eab" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f48121a4-02cc-4417-9211-7dbeba7db345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5227099f-d86f-4a8f-9839-95265c4fdc29" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f48121a4-02cc-4417-9211-7dbeba7db345" xlink:to="loc_srt_ProductOrServiceAxis_5227099f-d86f-4a8f-9839-95265c4fdc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ffece591-bc0f-46be-acca-a6751f7d15ad" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5227099f-d86f-4a8f-9839-95265c4fdc29" xlink:to="loc_srt_ProductsAndServicesDomain_ffece591-bc0f-46be-acca-a6751f7d15ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TopicalRoflumilastProgramMember_4eb1ccd4-3307-4eec-b33b-fc0dbf9e1667" xlink:href="arqt-20251231.xsd#arqt_TopicalRoflumilastProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ffece591-bc0f-46be-acca-a6751f7d15ad" xlink:to="loc_arqt_TopicalRoflumilastProgramMember_4eb1ccd4-3307-4eec-b33b-fc0dbf9e1667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TopicalJAKInhibitorProgramMember_f2f1031a-97f2-410c-b55b-cc2031b5df4e" xlink:href="arqt-20251231.xsd#arqt_TopicalJAKInhibitorProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ffece591-bc0f-46be-acca-a6751f7d15ad" xlink:to="loc_arqt_TopicalJAKInhibitorProgramMember_f2f1031a-97f2-410c-b55b-cc2031b5df4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_OtherEarlyStageProgramsMember_ea763137-2908-4513-872f-635104ee17cc" xlink:href="arqt-20251231.xsd#arqt_OtherEarlyStageProgramsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ffece591-bc0f-46be-acca-a6751f7d15ad" xlink:to="loc_arqt_OtherEarlyStageProgramsMember_ea763137-2908-4513-872f-635104ee17cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_653ba100-7a07-4a8a-8c3c-70f3c04d5572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f48121a4-02cc-4417-9211-7dbeba7db345" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_653ba100-7a07-4a8a-8c3c-70f3c04d5572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_21429af8-7a4b-44ba-813e-128caaf71f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_653ba100-7a07-4a8a-8c3c-70f3c04d5572" xlink:to="loc_us-gaap_SegmentDomain_21429af8-7a4b-44ba-813e-128caaf71f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ReportableSegmentMember_9ba99159-ba36-4c55-bdea-87145be49b86" xlink:href="arqt-20251231.xsd#arqt_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_21429af8-7a4b-44ba-813e-128caaf71f3c" xlink:to="loc_arqt_ReportableSegmentMember_9ba99159-ba36-4c55-bdea-87145be49b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f48121a4-02cc-4417-9211-7dbeba7db345" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_937cf224-1169-49b8-969e-e2d6f92d0fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_Revenues_937cf224-1169-49b8-969e-e2d6f92d0fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_014fbff2-0691-48ad-98f8-f82cd01763ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_014fbff2-0691-48ad-98f8-f82cd01763ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cb782317-ea0f-48e4-875d-c4e70ebafa23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cb782317-ea0f-48e4-875d-c4e70ebafa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses_9a7483c7-64d2-4537-83df-f4df0752987f" xlink:href="arqt-20251231.xsd#arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses_9a7483c7-64d2-4537-83df-f4df0752987f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1df2e330-9ecf-40ad-bd36-49e4087b841e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1df2e330-9ecf-40ad-bd36-49e4087b841e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_b3c247a7-f8dd-4fd9-a814-773c2ec68c23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_b3c247a7-f8dd-4fd9-a814-773c2ec68c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fb607651-27a6-4ae9-b37a-9b7b0d1c9b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_CostsAndExpenses_fb607651-27a6-4ae9-b37a-9b7b0d1c9b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c6653eb7-2ab3-43cc-9c0a-70a03d49fc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_OperatingIncomeLoss_c6653eb7-2ab3-43cc-9c0a-70a03d49fc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_019bff77-62b0-7c34-889d-3f9d10b726d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_InterestIncomeOther_019bff77-62b0-7c34-889d-3f9d10b726d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_38fc2d10-48db-4f1b-9a43-70aa7663e6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_InterestExpenseNonoperating_38fc2d10-48db-4f1b-9a43-70aa7663e6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e575ec28-33cb-4c0a-aae9-66d46f7f8629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e575ec28-33cb-4c0a-aae9-66d46f7f8629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2d5d4e4a-128d-48d1-b60c-fdc548d28a70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2d5d4e4a-128d-48d1-b60c-fdc548d28a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bf65b7eb-35b6-49a5-b9d9-e8a838f968a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56bb08df-f544-4c57-8588-c26541811440" xlink:to="loc_us-gaap_NetIncomeLoss_bf65b7eb-35b6-49a5-b9d9-e8a838f968a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SueJeanLinTradingArrangementOptionsMember" xlink:href="arqt-20251231.xsd#arqt_SueJeanLinTradingArrangementOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arqt_SueJeanLinTradingArrangementOptionsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SueJeanLinTradingArrangementCommonStockMember" xlink:href="arqt-20251231.xsd#arqt_SueJeanLinTradingArrangementCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arqt_SueJeanLinTradingArrangementCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_KeithLeonardMember" xlink:href="arqt-20251231.xsd#arqt_KeithLeonardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arqt_KeithLeonardMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_SueJeanLinMember" xlink:href="arqt-20251231.xsd#arqt_SueJeanLinMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arqt_SueJeanLinMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>arqt-20251231_g1.jpg
<TEXT>
begin 644 arqt-20251231_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0M"2@# 2(  A$! Q$!_\0
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MPY(]BQ]ONO\ GYF_[[-'V^Z_Y^9O^^S5>BCZU7_Y^/[V')'L6/M]U_S\S?\
M?9H^WW7_ #\S?]]FJ]%'UJO_ ,_'][#DCV+'V^Z_Y^9O^^S1]ONO^?F;_OLU
M7HH^M5_^?C^]AR1[%C[?=?\ /S-_WV:/M]U_S\S?]]FJ]%'UJO\ \_'][#DC
MV+'V^Z_Y^9O^^S1]ONO^?F;_ +[-5Z*/K5?_ )^/[V')'L6/M]U_S\S?]]FC
M[?=?\_,W_?9JO11]:K_\_'][#DCV+'V^Z_Y^9O\ OLT?;[K_ )^9O^^S5>BC
MZU7_ .?C^]AR1[%C[?=?\_,W_?9H^WW7_/S-_P!]FJ]%'UJO_P _'][#DCV+
M'V^Z_P"?F;_OLT?;[K_GYF_[[-5Z*/K5?_GX_O8<D>Q8^WW7_/S-_P!]FC[?
M=?\ /S-_WV:KT4?6J_\ S\?WL.2/8L?;[K_GYF_[[-'V^Z_Y^9O^^S5>BCZU
M7_Y^/[V')'L6/M]U_P _,W_?9H^WW7_/S-_WV:KT4?6J_P#S\?WL.2/8L?;[
MK_GYF_[[-'V^Z_Y^9O\ OLU7HH^M5_\ GX_O8<D>Q8^WW7_/S-_WV:/M]U_S
M\S?]]FJ]%'UJO_S\?WL.2/8L?;[K_GYF_P"^S1]ONO\ GYF_[[-5Z*/K5?\
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MS-_WV:KT4?6J_P#S\?WL.2/8L?;[K_GYF_[[-'V^Z_Y^9O\ OLU7HH^M5_\
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M_P"?F;_OLT?;[K_GYF_[[-5Z*/K5?_GX_O8<D>Q8^WW7_/S-_P!]FC[?=?\
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MYF_[[-5Z*/K5?_GX_O8<D>Q8^WW7_/S-_P!]FC[?=?\ /S-_WV:KT4?6J_\
MS\?WL.2/8L?;[K_GYF_[[-'V^Z_Y^9O^^S5>BCZU7_Y^/[V')'L6/M]U_P _
M,W_?9H^WW7_/S-_WV:KT4?6J_P#S\?WL.2/8L?;[K_GYF_[[-'V^Z_Y^9O\
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M TW_ )\;?_OV*/[ TW_GQM_^_8K0HH_LW _\^(?^ K_(/;5/YG]YG_V!IO\
MSXV__?L4?V!IO_/C;_\ ?L5H44?V;@?^?$/_  %?Y![:I_,_O,_^P--_Y\;?
M_OV*/[ TW_GQM_\ OV*T**/[-P/_ #XA_P" K_(/;5/YG]YG_P!@:;_SXV__
M '[%']@:;_SXV_\ W[%:%%']FX'_ )\0_P# 5_D'MJG\S^\S_P"P--_Y\;?_
M +]BC^P--_Y\;?\ []BM"BC^S<#_ ,^(?^ K_(/;5/YG]YG_ -@:;_SXV_\
MW[%']@:;_P ^-O\ ]^Q6A11_9N!_Y\0_\!7^0>VJ?S/[S/\ [ TW_GQM_P#O
MV*/[ TW_ )\;?_OV*T**/[-P/_/B'_@*_P @]M4_F?WF?_8&F_\ /C;_ /?L
M4?V!IO\ SXV__?L5H44?V;@?^?$/_ 5_D'MJG\S^\S_[ TW_ )\;?_OV*/[
MTW_GQM_^_8K0HH_LW _\^(?^ K_(/;5/YG]YG_V!IO\ SXV__?L4?V!IO_/C
M;_\ ?L5H44?V;@?^?$/_  %?Y![:I_,_O,_^P--_Y\;?_OV*/[ TW_GQM_\
MOV*T**/[-P/_ #XA_P" K_(/;5/YG]YG_P!@:;_SXV__ '[%']@:;_SXV_\
MW[%:%%']FX'_ )\0_P# 5_D'MJG\S^\S_P"P--_Y\;?_ +]BC^P--_Y\;?\
M[]BM"BC^S<#_ ,^(?^ K_(/;5/YG]YG_ -@:;_SXV_\ W[%']@:;_P ^-O\
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M -@:;_SXV_\ W[%']@:;_P ^-O\ ]^Q6A11_9N!_Y\0_\!7^0>VJ?S/[S/\
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MQM_^_8K0HH_LW _\^(?^ K_(/;5/YG]YG_V!IO\ SXV__?L4?V!IO_/C;_\
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M  %?Y![:I_,_O,_^P--_Y\;?_OV*/[ TW_GQM_\ OV*T**/[-P/_ #XA_P"
MK_(/;5/YG]YG_P!@:;_SXV__ '[%']@:;_SXV_\ W[%:%%']FX'_ )\0_P#
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M_GQM_P#OV*/[ TW_ )\;?_OV*T**/[-P/_/B'_@*_P @]M4_F?WF?_8&F_\
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M )\;?_OV*T**/[-P/_/B'_@*_P @]M4_F?WF?_8&F_\ /C;_ /?L4?V!IO\
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M /?L4?V!IO\ SXV__?L5H44?V;@?^?$/_ 5_D'MJG\S^\\?O5"7DZJ-JB1@
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M4 T ?HA17G7A[]HWX3>+]:M-'T+XH>#-:U>[?R[>PT[Q!:3SS-C.U(TD+,<
MG ':O1: "BO,M3_:>^#FBZE=Z?J'Q9\#6%_:2O!<6MSXDLXY89%)5T=&D!5@
M000>01BNL\'?$+PK\1-/-_X4\2Z/XFL02OVG1[^*[CR#@C=&S#KQ0!N7-S#9
MV\MQ<2I!!$ADDED8*J*!DDD\  9.367X2\9>'_'VB1:SX8US3?$>D2LR1ZAI
M-Y'=6[LIPP$D9*D@@@X/!KF_CSX.T'X@_!GQGX<\4:S_ ,([X>U'2YX+[5C.
MD LXBI+2L[_*%7&3NXP"#Q7B_P#P3\^!?@3X _"36K#P7\3=.^*-O=ZH]QJ&
MMZ7/ UI',(T B58I)!&5CV$AG).0> 0  ?4M%>5?\-8_!#_HLGP__P#"HL?_
M ([7?^&?%FA^--*BU/P]K.GZ[ILP#1WFF727$+@]"'0D$?0T :U%%<9XN^-'
MP^^'^IP:;XH\=^&O#>HS_P"JM-7UBWM9I.GW4D<$]1T'<4 =G69K/B;1_#GV
M?^U=5L=,^T31V\/VRY2'S9)'6.-%W$;F9W1 !R690.2*O6US#>0)/!*D\,@R
MDD;!E8>H(ZU^2G[=_P#RE2^"W_7SX;_].3T ?JMXN\:^'OA_HLFL>*->TSPW
MI$;K&]_J]Y':P*S'"@R2,%!)X SS6M#-'<PQS0R++%(H=)$8%64C(((Z@U\N
M?\%"?@-X%^/7PLT33?&_Q-T_X5QV6J">QU?5IX5M9)C&P:)DEEB#L4W$8<$8
M)Y&0?8?A+I'A+X.? ;PQ8Z;XEMKSP5H6BQ&'Q%>7L1@DM$C#"X:<$1["OS;@
M=N.^* /1J*\J_P"&L?@A_P!%D^'_ /X5%C_\=KT30/$6E>*])MM4T34[/6=,
MN4$D%[I]PD\,JD AE="58$$$$'H10!HT4A( R>!7$V?QP^'.H^*6\,VGC_PM
M=>)%8JVCPZS;/> @9(,(??G'/2@#MZ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME^W)_P %,H_BIH&ESVW@/PH5D%Y<QLA$$4+);AL$CS9)6+[,C";NNTY -_\
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M8^+_ (PU2+38+L:=##H[(DOF[1+Y,7FK(L,$2R+A0K%C(3D$,6/VA/@IK_\
MP2M^+W@CX@_#'Q)JFK^%-5E:"ZLM4E0/,8R&>UG**JNLB,2KA 5*L>H!.O\
M\$[OVMO#G[&$GCSX2?&>VOO!D\>K-?"[DM);CR;GRTBEAD2)6?E8XV1U#*P+
M'(&TFM^WA^T9I_[?7Q$^'/PH^"L-QXCMXKMYFU&:TE@26XD 0, ZAUBC0.SN
MR#[W^SR ?8O_  4ZU>#Q!^P)XJU2U)-K>_V3<Q$]=CWENR_H17RO^Q=_P3#^
M%O[1G[-_A7X@>)-?\7V.LZJUXL\&E7EK';KY5W-"NU9+9V&5C4G+'DGH.*^H
M_P#@IAHD?AK_ ()]^)=(B;?%IZ:1:(W3(CN[=0>_I6S_ ,$L?^3&?AW_ -=-
M3_\ 3C<T ?/_ /P6!\):=X!_9:^$_AG1XC!I6CZM#I]I&V"5BBLI$0$@#)PH
MR:Z'X&?\$F?A%+X>^'WCL^(_&HU=K73];,(OK/[/Y^R.;;M^R[MF[C&[.._>
MK_\ P6A\+ZAK'[-?AS5[2W:>TT?Q'%)>,O\ RQCDAEC5S[;VC7ZN*O\ P%_X
M*>_ G0_@1X%T[Q)XKGT_Q3IVC6>GWVEKI-TQ\^*)(W*R",Q;25+ E^ >: /#
M_P#@N3_R&O@[_P!>^J_^A6E>_P#PU_X)'?!_X=>-_"OC+3?$GC>?4]"U&UU>
MVBNKZS:%YH95E17"VBDJ64 @,#C.".M> ?\ !<<@ZS\'<<C[/JO_ *%:5^K=
ME_QYP?\ 7-?Y4 ?D7\96\3_\%&_V\]5^$2>)9=&^''@ZXN T4"DA%M2(;F<(
M3B29YG,:N>%1@0#A@^C^UA_P3(TO]F/X6W/Q5^$GC'Q.NM>%Y([R>/4KF$RB
M+>%:6&6*.(HR;@Q!SE0W?@XVH>*/^'>?_!2SQ7XI\6:3?OX&\8->2QZE%&'/
MV:\E2X>2,#[_ ),ZA&3[VU<@$E=WJ/[=7_!27X5?$+]G_7O OPQUB?Q9K_B5
M$L'8:9<V\5M S@R$^<D99R!M4*#RV3TP0#ZA_9&^/&H?M&?L@:=XPUI477C8
MW=AJ31X"RSP[D,H   WJ%<C& 7(' !KXU_X(9_\ 'Y\9_P#KGH_\[VOK;]@K
MX):[\(/V,]#\-:]:FR\0ZE!=ZA/9L"&@:X+&.-P>CB/R]PXPV1VR?A'_ ((\
M_&3PY\*?BKXU\#>)Y+O3=?\ %LEC9Z9"UI(V;BW-SYD4FT$QM^]'+  ;6R10
M!U?[?'_*4SX&?]=/#G_IUEKWO_@K-^TUK_P-^$>@^&/"6IRZ/K_B^>>*6_MR
M5FALH57SO+<'Y'9I8EW==N_&#R/!/V^/^4IGP,_ZZ>'/_3K+7JG_  6:^">K
M>.?A1X2\>:/9W-__ ,(E<W$6HQVZAO*M+A4)G8==J/"@)'02$G@$@ YSX;?\
M$6?!NH_"_3+CQAXS\16_C:ZM%FG_ +*:W%C:RL-PC$;Q,\@3.TMYB[L9 7.*
MA_X)G?$_QM\)?V@O''[,_C*^?5;'1EN7TR623<+:2!U!6+.2(I8W$@7/R[1Q
M\S8]:^&G_!6OX&:C\+M*U'Q5K5]H'BN.T5;W05TNYG<SJH#>5*B&(JQ!*EG4
MX(W!3Q7AW_!.'3/$?[0W[9OQ)_:$N]*;3/#,@NHK=Y%8!IYF18H5/1RD"'>0
M>"5X^;@ _52OR(^,/[-W[$GAGQ]XBD\:_'G78O$.H:G=W,UKX=*7<%F[2EFA
M80V<^THS%<,X/!&,@U^D7[59UX?LU?$\^&#>#7AX=OC9G3\_:=_DM_J]OS;\
M9QM^;.,<XK\>?V+!^QV? &J']H WO_"7?;V^SB3^T_L_V78FS9]A_BW>9G?[
M8H ]6_X);^-8? W[8_BSX=^"_%USXH^&>IVEW-:2RPR0)<M$4:&X,4BJR2!-
MR-P,YZ$!<='_ ,%R?^0U\'?^O?5?_0K2N/\ V#O^$ _X>9:O_P *M_Y)_P#8
M;[^Q_P#CX_U/D)G_ (^/WOWMWW^:[#_@N3_R&O@[_P!>^J_^A6E &Y\>O^"0
M'P]\&_!'Q5XH\%^)_%DOB/1],EU2&VU>>UGMYQ%&9'BVI!$P+*I ;=P<9!KV
MO_@DY\:]<^*?[,EY;>)[Z74+KPMJDFFQ7]S(7DDMO*CE0.QY)7>R@_W56OIO
MXU?\D"\>?]BS?_\ I+)7Q'_P12@2Z^ 7Q!AD&8Y/$11ATR#:Q T ?/7PE^'&
MK_\ !5K]I_QOXC\8^)[_ $SP)X?PT%I8X\Z&VE=UM;> .&2(E8F=W*MEE/RG
M=E<S_@HG^P5\/_V1_ /A37/!^L>)=2N]5U-[*=-;N;>5%01,X*B*",@Y ZD_
M2MC]DGXLVO\ P35_::^)'@#XI6-_9:%JACA36(X#(=D+RFUN0BY+Q2I*W*9*
MG (R&QL_\%2OVN_A+^T;\-/!FE?#OQ9_PD-_I^KO=7,/]FW=MY<9A90V9HD!
MY(& 2: /U6^$?_)*/!?_ &!++_T0E?#_ /P6Q_Y-R\%_]C7%_P"D=U7W!\(_
M^24>"_\ L"67_HA*^'_^"V/_ ";EX+_[&N+_ -([J@#G/V>?^"3/P=\?_"3X
M<>.=7UOQC)J&L:-I^L7=BE[:"T:26%)7C"FV+^62Q&-^<?Q9YKE_V_/&WB[]
MI_\ :^\-_LO>%=;&B>'(VMDU%55A'+<-%]J>24 CS4A@",D? WAN<X*_?G[(
M?_)J?P=_[%#2?_22*OSQ_;4BU+]D/_@HIX5^/DVBWNJ^$=6:&>:6';M\P6IL
M[F!#P!((0)5#$!BW!P&V@'2_'#_@CUX5\"?";6O$OP[\7^)YO&.AV;ZC#%J<
MUNT-RT*[V6/RXHVB<A3M)9L'&?6OH#_@EY^T?KW[0?[/L\?BJX>_\1>&+[^R
MY=0D;=)>0F-7AD?_ &\%D)[^6&))8UQ?[0?_  57^"W_  I7Q)!X$U^X\1^+
M=2TZ6TLM/.E74"P2RILWRO*B+M3<20C$G;@=<UH?\$A_@QKOPO\ V==1USQ!
M9OI]QXLU+^T+2VE5ED%HD:I&[J<8WGS& [J5.?FP #XC^!_[,?A;]J_]OCXT
M^#_%U_J^G:9:WVN:HDNBS113&5-32, F2.0;<3-D;<Y Y]>P_;/_ &%?^&$]
M*\+?%SX1>,?$*/I^II;S2ZA-"UU:2NK&.5'CCC5D;:R,C*<AP#D%A6=^RU\=
M_ W[/'_!0WXV^)?B#KG]@:+<7&NV$5U]DGN=T[:I&ZIMA1V&5C<Y(QQUY%=O
M_P %#OVX_"W[4OA?0?@_\&DU#Q?-JFI07%S>Q6$L(G9=PBMHHY%61FWD,Q*
M *N"<G ![?\ MU?$EOC#_P $O[+QM) MK/KMOHU]/ ARL<KS1&10>X#;@#Z"
MO<?^"=/_ "95\*_^P=+_ .E,M>6?M-_L\:_H_P#P3"/P\LH_[3U_PUHFGSW$
M=N"WF-;21RW&P 9.%$A [[17D_\ P3__ ."B7P?^%_[-7A_P/\1/$UQX<UW0
M)+B!#+IES<I<PO,\L;(T$;XVB380VT_+WZT <C^P/_RE,^.?_73Q'_Z=8JX;
M]O<VOC;_ (**6_AGXT>(]4\,?"^&*W2RO;52XMK.2V#&6)=K@;[E61WVG&TY
M&$&.E_X)O^)M-\:?\%)?BYXAT:Y^V:/JUOKM_97/ELGFP2ZE"\;[6 9<JP.&
M (SR!7U=^TY^TO\ LF^(/%NN_#+XV^1/J.A.(G-[H]U.8VDA23,%Q;(SH=LH
M!(*D%3Z D R_V2?V"?@9\/?B+HGQ7^%WCZ_\;PV$,\4)GU"TOH%>2-HBP>"-
M-CA688;/5N,]/!?^"S^G1:Q\4_@E83,RPW45W [1D!@K3VZG&<\X->+_  K\
M0>$? '_!0GP!:_LP:_K>K>#-7O[.WOK:Y\^-)8G=A=QE)%1Y(HX=TBF0$JP)
MYV@U[O\ \%K]&U73-5^#OC*U@+V-E+>6K3D92.XW0RQ*P_V@DA'^XU 'T#\&
M_P#@E5\)O@A\3O#_ (ZT+Q#XSN]7T2X^T6\.HWMH\#MM9<.$M58C#'HPK[,K
MY9\!_P#!2[X!_$/5_"^AZ5XLN9/$FOW5M80Z4^E74;17$S!%1Y'C$7#,!D.?
M;-?4U 'X=? _]F/PM^U?^WQ\:?!_BZ_U?3M,M;[7-42719HHIC*FII& 3)'(
M-N)FR-N<@<^O<_M8_L:ZG_P3P/AOXQ?!OQIKGV>WOTL;E-2:-YX2X9EWM&B)
M)"YCVLC)U*]<\<Y^S-^T%X*_9O\ ^"A_QD\2>/-0FTO1+V]US3%NX;62X\N5
M]320%EC!;;MB?D GIQ7H?_!2']NWP)^T5\-M$^&'PEN[SQ;=:IJL,]W<1:=<
M0YV9$5O%'(BN\CR.IX4CY,#);@ ^T_BW\28OC#_P3P\8>-HK?[(NO> +N_:W
M)SY3O9L73/?#9&?:O!?^"-O_ ":7X^_[&>\_](+2O9_&GP\OOA-_P3/U_P '
MZH4.J:/\.KFUO!&VY!.+-O,"GN Y8 ]P*\8_X(V_\FE^/O\ L9[S_P!(+2@#
MXZ_X)P?L7>"?VP+CX@)XRU37]-'A];!K7^PKB"+?YYN-^_S89,X\E<8QU.<\
M8] ^.7PA\1?\$IOC5X+\<?#SQ/JFL>"M;F:&[L;XJ'F2(J9+:XV (^Y')1]H
M*D,0!C)P/^"5O[57PW_9GU;XBQ_$76I]"AUZ.P^R726,US'F#[3O#"%68']Z
MF/E(Z]*Z7]O[]I;2/V[/B)\-/A7\&_M'B* 7KG[=):30+/=3;47".H=8XD#N
M[LHP&)Z*20#[L_;\_::N_@/^RM<>*O#5R;37O$+P:;H]SMRT+SQM(90,$!EB
M20@GC=MK\QOA1\-/V1?%'@:VUOXM_'KQ5%\0M45KS4(-.TRZ9+:=R699)'LI
MC.^2"SAP"=V">M?H;_P4T^ &J_$;]CJ&P\.P3ZGJ/@RXM=42U@3=+<P0PO!+
M@=RL<IDP.3Y> "3BOB;]FKQ%^PAKGPLT>'XM>%+KPWXXLX5M]0GDN]:N(;^1
M0!]HC^RR,J[^I0JFUMP ( ) /2?^"4?QDE\+?'_QE\&-)\5/XO\ AS+#=:AH
M%Z\<L(#1R*0Z12HKQ^9&Y+I@ .F1G))H_MW_ /*5+X+?]?/AO_TY/7TO^Q+X
M5_9)\0_$;7]?^ 6@W":[X=MHHKC5)9]2$9CN?,&U$NY3G_4G)*#&5P>3CY9_
MX*8:S'\-/^"AWPI\:ZO!<#0["WT;4I)8HR=\=MJ$CRJG8L O3_:7U% 'N7_!
M;'_DW+P7_P!C7%_Z1W5>GWG_ "BB7_LDL?\ Z:Q7AW_!6OX@Z'\5?V//AGXM
M\-7;WVA:OXDAN;2XDA>%G0VET,E' 8<@]1^E>XWG_**)?^R2Q_\ IK% 'PW_
M ,$\_P#@GQ\._P!K3X/Z[XK\7ZSXGT[4;'7I=+BBT2ZMXHC$MO!*"PD@D.[,
MS#((& ..YZC]E/3?$/[%G_!2&Y^"=IK5UJW@_6F> I.=JS(]I]IMYR@)42J5
M$;,,9&_@ @#W3_@BC_R;+XN_[&^X_P#2*SKS/XF_\IK/"7^[:_\ IM>@#HO^
M"NO[1NHZ)JGA'X+Z7XA?PQINOP+?>)-1C20[;*25H41M@+-'\DSNB\L%48(.
M#\L>-O@S^Q7;?#G4F\+?'WQ+=^.(;-WL_P"T=%NEL+FX"DJC(M@'C5FP,^8V
MW.>>E>]?\%A_A)<Z5\5/AY\7[G0I?$?A"."'2-:LEE:&,^3</,D;RI\\8G26
M1 X^Z8^N2,U- U;_ ()HZOH5M?7NB7FB7DL0>33+R3Q \\+8R4+12/&2#QD.
M1[T ?2?_  2A^/>O_&K]G:[L?%%]+JNK^%M1_LQ+ZXDWS36QC5X?,8\EERZ9
M.20@R2<U]JU\^_L4>$_@MIGPE/B7X&Z)/HOA/Q%=2R-]IGN9))I()'@+$7$C
MLH_=D@9'!!(!-?05 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:$#GA0F%XP!@5](44 >2?&[]E'X5_M&/HC?$+PJNO_V*DL=@%O[JT$"R;-X
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M% !7SW\0/^"?_P"S[\3M<DU?7OAEIC:C*[R2S:=/<:?YKN=S.ZVTD8=B>=S
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M%4#+$DXY)J/QEX(\/?$3P[=:#XIT2P\0Z+<X\ZPU.V2>%R#E258$9! (/4$
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M[I^HZS/)YL]_;3SV4T[;0N9'MY$+\*!\V>GO7N5% 'E/P=_98^$WP!<S> O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \AO_P#C^N?^NC?S-5ZL
M7_\ Q_7/_71OYFJ]?PQBOX]3U?YGZ+#X4>K:!_R!+'_KBO\ *BC0/^0)8_\
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M.RD]JNT %%%% !1110 4444 %%%4DUBPEU.334OK9]1C3S'M%F4RHG'S%,Y
MY'..XH NT444 %%%% !1110 5S7B/Q]IGA?6])TN]%P;G4G$<)BCRJDL%!8Y
M'<CIFNEJO/8VUS-#+-;Q2RPG=$\B!FC/JI/3\* +%%%% !1110 4444 %%%%
M !1110 4444 %%<WXG^)/A'P5JND:9XA\4Z+H.I:Q)Y.FV>IZC#;37LFY5V0
MH[ R-N=!A03EE'<5TE !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '-:_X^TSPWXATK1KL3F[U)@L+1IN0$MM&XY[GT!KI:KS6-M<3Q3RV
M\4LT)S'(Z LA_P!D]OPJQ0 4444 %%%% !1110 4444 %%%% !17/?\ "P_"
MO_"9?\(A_P )-H__  EGD_:?[!^WQ?;_ "L9\SR-V_;CG=C%=#0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7*:UX]BT;QGI/AYM/N9I+]-XN
M4^XG)'XXQD^@(KJZ3'- "T444 %%%% !1110 4444 %%%% !117$?%_XS^#O
M@-X-D\5^.M8_L/0(YX[9KO[+-<8D<D*-D*.W.#SC% ';T53TC5;77M)LM2L9
M?/LKR!+B"7:5WQNH93@@$9!!P1FKE !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 <W?>/M+T_QA9^&I?/\ [1NH_,1ECS&.N 3G.3M/08]ZZ2J[
MV%M)=QW;VT374:E4G:,%U!Z@-U JQ0 4444 %%%% !1110 4444 %%%% !11
M10 45G>(/$6E>$]&N]7UO4[/1M)LT\RYO]0N$@@A7IN>1R%4<CDFCP_XBTKQ
M9HUIJ^B:G9ZSI-XGF6U_I]PD\$R]-R2(2K#@\@T :-%%% !1110 4444 %%%
M% !1110 445S=M\2?"-YXUNO!UOXIT6?Q=:1":XT"+4(6OX8RJL'> -YBKM=
M#DKC#J>XH Z2BBB@ HHHH **** "BBB@ HHHH **** *>KZBND:5>7S123K;
M0O,8HAEW"@G 'KQ67X'\6Q^-O#T.JQVDMFLC,OER\]#C(/<>]=!2  # X% "
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%4M,UBPUJ%YM/OK:_BC<QN]K,LBJX )4E2<'D<>XH NT444 %
M%%% !7*:#X^BUWQ?K&@+I]S!)IPR;B0?(_('X9SD>HR:ZNDQS0 M%%% !111
M0 4444 >0W__ !_7/_71OYFJ]6+_ /X_KG_KHW\S5>OX8Q7\>IZO\S]%A\*/
M5M _Y EC_P!<5_E11H'_ "!+'_KBO\J*_M7+?]QH?X(_DC\_K?Q)>K/*:***
M_B$_0SUW3O\ D'VO_7)?Y"K-5M._Y!]K_P!<E_D*LU_<^%_@4_1?D?G4_B84
M445TD!1110 4444 %(1FEJ&[CEFM9DAD\F9D94DQG8V.#CV- #;*PM=.A,5I
M;16L18L4A0(N3U.!WJQ7*_#K0-=\.Z++;:_JO]K7;3LZ2;V?8A P-S $\Y/M
MFNJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** .0\=:'XFU>^T>30-7338()2UTCY&\9&#P#NZ$;3@<UU]<W
MXJ\?:1X-NM.M]2DD22^<I%Y<>X#! );T'S"NDI@%%%%( HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#C_&OAKQ!K>L:)<:/K;:9:VLNZZA#LOFKD'H.&X!
M&UN.:["N8\5?$+2O!^IZ78WXG,VH/LC,,>Y4Y RQR.,D=,GVKIZ "BBB@ HH
MHH **** ,#Q]<S67@7Q'<6\KP7$6FW,D<L;%61A$Q!!'((/.17Y/_L6? _XX
M?M@_"K5O&8_:G\?^$S8ZS+I L3?7UX)-D$$OF>9]MCQGS\;=IQMSGG _5WXC
M_P#)//%'_8+NO_1+5^0/_!/CQY^U1X8^"FN67P.^''AGQ=X4DU^>2YU'6;B.
M.>*]-M;!XU#WL'RB,0L/D(RQY/0 'T]^S3^T1\7_ (7?M?7O[.?QHUVV\:O>
MP276A>(XK=8I7 A:=,[57*M&DN0X++(I 9EP:]W\??\ !0K]G_X7^,M6\*>)
MO'W]F:_I4YMKRT_L;4)?*D !*[X[=E;KU!(KR[]E[]C+XC:9^T1K'QZ^.GB+
M2]:\=31R0:;IVC@O;V2LGE;MS*H7;%NC5%!X<LS%B:\S_9T^&7@_XF_\%$_V
MF;7QAX4T/Q7;6KI+!#KFFPWJ1.9%!9%E5@I(XR* /O?PY\8?!/BSX=+X]TOQ
M3IESX,,,EPVN-<+';1QH2'+NV FTJ0=V,$'->7>$OV_/V?O''C/_ (1;1_B=
MI<VLF8P(EQ#/;032;P@6*>6-8I"S$;=CG=U7(YKY5_X*RQOX$^'GP:^%G@;P
MUI^F>%]<URXD?1=/4:?I\LL3Q&*VD6(QJJ2274CGYD^9-V01N'D7Q+_9A_:5
M^)/@2;PQ_P ,D_"?PL&">7J_AI;&SU&$J0<K/_:+%LXP=X8$$]^: /V"O+RW
MTZTFNKN>.VM8$,DL\SA$C4#)9F/  '))KY_L_P#@H-^SSJ'C:+PG;?%#2Y]8
MFE$,92"X-H[E=P NO+\@YZ#]YRWR_>XKY1_;\UWXA^!_V"/@[X.\4WTVA:]J
M]S8Z1XGF:XCF)$5NY9))$8A@61'8J>=A&2"<_8_@O]B[X'^#- T:QT[X9^&)
M9--$,D&JS:;%)?-)&0RRFY(,A;<H;.Z@#Y2^*_\ RF>^$G_8N/\ ^DFI5Z9^
MTU\-_ ?B/]MSX%Z[KWQ:UCPGXLL]O]D^$[6PGFBU/9,SG9.@V6_F$F.7?GS(
MU5?EQFO,_BO_ ,IGOA)_V+C_ /I)J5;'[8?_ "D?_9=_[:?^C6H ^HOC?^UQ
M\)OV<=6TW3/B)XK_ .$>O=2@:YM8O[.N[GS(U;:3F&)P.>,$@U6^#_[9OP6^
M/.M'1_ _CZPU;5^=FGSPSV=Q+@9/EQW"(TF!DG:#C!]*^5OVXO#VE>*_^"@O
M[-&D:WIEGK&E7B217-A?VZ3P3H96^5XW!5A[$5S/_!2CX-^"/@9X@^"'CKX?
M>%M)\%ZW#XHBMW.@6<=C',H*2*72(*"04(SC.&(- 'N7[:_A7X?:[\<_@)<^
M+_BOJW@'6K;6-VC:18Z?<7*:M+YL*[!)&"L#;GC0N_&V1AC&2/JOQEXW\/\
MPZ\.W6O^*-:L/#VBVNWSM0U*X6"%"2%4%F(&22 !U)( YKX!_P""FG_)T_[)
M/_8Q_P#M]I]-_;UL4^-?[<GP#^"WB?[4GP_NX?[6NH8IC$E[,SW"F/<.0=MN
MJ9!# 3MC:2#0!]5?"[]MWX'_ !H\8#PKX/\ B!8ZKK[LR164EM<6S3E0S$1&
M:-!+@(Q^0G@9[BKGQD_;%^#?P UA-(\=^.K+1=68*QL(X)[NX16&59XX(W9
M1T+  UM^%_V:/A-X'\0:3KOASX;>%M UK2PXM-1TO28+:XCWQF-LR(H9LHS
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M]0NGMX@ME9ED2W2XB5=S2LQ(/7)P<U=^,NM_M$_\$W!X3\3ZE\7Y_C+X O\
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MFU_QWXEL?#6E9*)->.=TSA2Q2*-07D?:I(5 6..!7*?!;]KCX1?M#:A<:?\
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M4?';]KS]H'QK\8O@Q=WVB:[\&OA[KWB:*'2]*6XDM+_5(XKF!)7N\;7*%9T
MC($9#'[^ U?KA7YS_P#!5'_DNW[)G_8R7/\ Z5:90!^C%%%% !1110 4444
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M%<D$@C.,@]*_4&OR^_X*HV?B+4OVJOV;[3PC?V^E^+)[R.+1[^[4-#;7K7T
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M"KH$!+ A@01V.>E?-_[3?@G0;S_@FMJMB^DV:VFG>#[6\LX8H%1;>6.*-U=
M!\ISGIZGUKSCP;^U7I?[,_\ P3.^%7BG7=$'BN\O;9=)T_296"Q32+),4,C%
M6VHB0YZ$Y50,9R #J_!W_!7SX!^+/%D>BW#>)/#D$LGE1ZOK.GQ)9,=X4$M'
M,[H#G=N=%  .XCI7TQ\9_CYX%_9_\"_\)?XWUR+2]%>5(()$5II+F1QE4B1
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M&^RY,>1"=V]>LT;\ U^RUM<Q7EM%<02+-!*@DCD0Y5E(R"#W!%?C)X@_;7^
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MI?CKX3?;)IK32KEM:T$WNU)WM)'V3*8P2%VMY3D!F&Z=N> 3#X'\ >&/B/\
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MR')Q@  ^Z/#WQ=\&^+_ =SXTT#Q%9:]X8MH99Y=0TIS=*JQ*6D&V,,Q8 'Y
M-W8#)JI\&_CCX'_:!\)/XF\ :_%XAT1+E[-[A(986CF0*61HY55U.'4\J,A@
M1P:^$_V1]*M?@U_P4G^-WPB\*IY/P]N=+&H'2 Q>""79:R#:"3@+]JECQZ$
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MK@\ [L -\IP.?R["@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M V5.0RJ>>E6?V8OA-^TSX5\9R:G\;/BSHOB_1(K"2SMM%TBT7:SL4(FDD%O
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M+Q5HOC?]BOQ/X$UNS^)GB[XC_#G7=?M]"U[3/&]VFHW=FUSA(;N"YVHZJKJ
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M]+L]XHKY9O?V1OB#X=AN/$/A?]H?XB7OCA%,L</B*]ANM$N7'/EM8^6%C5B
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MHB:E:PRP1EVC*3 9!'7IP15:V\B-.;S-RBBBI+"BBB@ HHHH **** "BBB@
MHHHH **** "BBO.]6^/O@O3=0?3[6_N?$%\DC0R0>'[&?41#(H)*2O"C)$>,
M?O&7G ZFLJE6G1CSU9**[MV7XC2;=D>B45YI<_'S1-/@>>]T/Q3;6Z EI$T*
MXN2!_N0*[G\%-=9X3\?>'?'4,\F@ZS::H;=MEQ%!(#+;L1G;+&?FC;'9@#6&
M'QF&Q5_J]2,[=FG^0Y1E'XE8WZ***["0HHHH **** "BBB@ HHHH **** "B
MBB@ KG/"7A#4-(\9:SJUQK4U[:7BGR[-\[8\L".^/E *C Z&NCK \+?$"QU[
MQ=JN@PP3QW-@K%I)% 1MK!6QWZD8]16M.]]#*I:VIVM%%%=9R!1110 4444
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MN&='B<C!9)$970X)&5(-<C\(_P!CCX,_ S5_[6\%> M/TK51G9?SRS7D\60
M?+DG>1DR!_"1W]32320VFS@OC/\ \G[?LY_]@KQ)_P"DT=>P?%7X3_#OXZVO
M_"-^,=+T[7;BS_TF*,R[+VR)X$L3H1)$>GS*1GBMK6OACX:\0^/O#GC2_P!,
M^T>)O#L5S!IE]Y\J_9TN%"S#8K!&W  993CMBN&^,?[(/P@^/VLPZOX\\$VN
MMZK%&L2WR7,]K.47.U6>"1"P&3@,2!FE?8=MSS#X+:QJWPD_:CO/@M8^-=3^
M(/@Y_#KZY&=;NQ>7^@3+<>7]F>X W-&P8;5D.Y=H XZ_6-<%\)?@/\/_ ($Z
M3)IO@+PII_ANWEV^<]LA::; P/,F<M))C_:8]3ZFN]I-W!*R"BBBD4%%%% !
M1110!3O='L=2GMYKNS@N9;=M\,DL89HVXY4GIT'Y"KE<IXOTCQ)J&K:-+HNI
M1V5G!+NNHW)!<9'L=PQD8./\.KIO8E;O0****104444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5.\T:P
MU&YM[BZLX+B>V;=#++&&:,\'*D].@_*KE<KXITKQ)?:_HT^D:C'::=!(&NXF
MX9QN&>QW?+D8XY_1K?<EG54444B@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"G=:+87]Y;W=S
M903W-N<PS21AGC/L3TJY7*^)-*\27GB;1KG2M2CM=*@8&[MW/,@W<\8YRO'4
M8ZUU5-]-25U"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !3'MXGE25HT:1,[7*@E?7!I]<IK7A;5=1\
M9:7JMMK4EKI]LH$UD"VV0@DG@'!SD YZ8IK43=CJZ***0PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*<NCV$^HQ:A)9P27T2[([ED!D4<\!NO<_F:N5RNHZ7XFE\<6-W:ZC%'X?2/$
M]J?O,W.>,<YR.<\8_/JJ;)04444B@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ (# @@$'UID,*01B.*-8HUZ*@P!^%5M9M)]0TF\MK:Y:TN)H72.X7K&Q
M! 8?2LSP1H6H>'= BLM2U%M3N5=F,S$G )^[D\G'OZT[:$WU-^BBBD4%%%%
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MG<>><5=MB>Y[1^SWXIU3QS\!/AOXCUNY^VZSJ_AO3K^]N?+6/S9Y;:-Y'VH
MJY9B<* !V KT"OE>T\:ZU\./^":6A>*/#MY_9VN:5\-["[L[KRDE\J5;&(JV
MQU96^C BOH3X9ZO=^(/AQX4U2_E^T7]]I-I<W$NT+OD>%&9L* !DDG  '-0U
MU*3.DHKPC]FWXF^)?'_C[XX:;KVI?;[+PWXN?2]*B\B*/[/;"&-@F44%^6)W
M,2?>O.+GQ'\;OCK\>?BUX-\&_%'3OA?HG@>]L((IH?"\.J7-V+BU$F',\@4
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MMQ)N558#DJI8CN :]0^%7Q:\+?&KPC%XD\(ZD-1TUI7MY T;136\R'#PRQL
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MHHH **** "BBB@#G_$WC73?#5S:6=U<>1>7N5M\QLZAL@ MCMDBL;[%\2O\
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M>%H[J^8+$JZ+=,.2 ,D7/&2<5ZK5*^T/3]2NK:YN[*"XN+5MT,DD8+1GU!_
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M ."BY_\ DJC[%\2O^@SX5_\ !1<__)5=S11<+'#?8OB5_P!!GPK_ ."BY_\
MDJC[%\2O^@SX5_\ !1<__)5=S11<+'#?8OB5_P!!GPK_ ."BY_\ DJC[%\2O
M^@SX5_\ !1<__)5=S11<+'#?8OB5_P!!GPK_ ."BY_\ DJC[%\2O^@SX5_\
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M_P#!1<__ "57<T47"QPWV+XE?]!GPK_X*+G_ .2J/L7Q*_Z#/A7_ ,%%S_\
M)5=S11<+'#?8OB5_T&?"O_@HN?\ Y*H^Q?$K_H,^%?\ P47/_P E5W-%%PL<
M-]B^)7_09\*_^"BY_P#DJC[%\2O^@SX5_P#!1<__ "57<T47"QPWV+XE?]!G
MPK_X*+G_ .2J/L7Q*_Z#/A7_ ,%%S_\ )5=S11<+'#?8OB5_T&?"O_@HN?\
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M,^%?_!1<_P#R57<T47"QPWV+XE?]!GPK_P""BY_^2J/L7Q*_Z#/A7_P47/\
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M $&?"O\ X*+G_P"2J[FBBX6.&^Q?$K_H,^%?_!1<_P#R51]B^)7_ $&?"O\
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M5W]/TVS@ANIIHX8TFE WR*@#/CID]ZT@US:F=1/ET-.BBBNLY HHHH ****
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MPHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXJL- G6<WMX 49$!1<D@;CG/)!Z U4;]"96ZG1T445)04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '*
M:A8>)Y/'5C=6M]$GAU(\3VYQN+8.>,9)SMP<\8_/JZQ+KQGI-EXDM]"EN2NI
M3KN2/82.^ 6Q@$X/^2*VZIWTN2K:A1114E!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %/6;2XO])O+:UN#9W,L3)'.O6-B,!A]*S/ ^AZEX>\/Q6>J:BV
MIW:NS&9F+8!/"@GDX]ZU=6U*'1M,NK^XW>1;1-*^P9;:!DX%4/"?BNR\9:.F
MHV"RI"79"DZA64CKG!(].A[U6MO(G2_F;-%%%24%%%% !1110 4444 %%%%
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MZ0?#L\$-NLN;L2A>5R,=0>,;L@<\_EU=4]D2MV%%%%24%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 4-1T'3M6GM9[VRANIK9M\+RH"8SUR/R'Y5?KE/%]
MCXGNM6T9]"O(;:RCDS>))C+C(]0<C&[@8_ECJZ;V1*W>@4444B@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "J&H:#IVJ7=K=7=E#<W%JVZ&21 3&<@Y'X@'\*OUROBFR\3W.O:-)HU
MY#!ID<@-Y&^-S#<,]0<_+D #'--;DRVV.JHHHI%!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M"]T'3M2O[6]NK*&>[M3F&:1 60YSP?KS5^N5\26/B>X\3:--I%Y#!I$;#[9%
M)C+#=\W;GY>!@]:ZJFR5UT"BBBD4%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4$MA;3W,5S);Q27$0(CE9
M73/7!ZC\*GKE-;\.Z[?>,]*U&SU@VNDVZ@7%EN8>8<DG@<-D$#GIC(IH3.KH
MHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH H3:!IUQJL.IRV4,FH0KMCN&0%U'/0_B?SJ_7*:C:>
M*7\<V$UI=0IX<6/]_"<;BW.>V<],8/;\^KILE=0HHHI%!1110 4444 %%%%
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MN!D<=<Y/2M*?Q&53X3N:***[#D"BBB@ HHHH \AO_P#C^N?^NC?S-5ZL7_\
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8VK>,-)T/5K'3;VZ\F\O2!#'L)SDX&2!@9/'-;-
M9U]X=TW5-0M;ZZLH9[NT.89G7+(>O'X\CT/-:--V$K]0HHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MG=4\=Z7H_B?3]!N#-]NO0#&53*+DD+DY[D$<9]\5T55IM,L[B\ANY;2"2ZA!
M$4[Q@N@/7:V,C\*:MU$[]"S1112&%%%% !1110 4444 %%%% !1110 4444
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M#?\ _']<_P#71OYFJ]6+_P#X_KG_ *Z-_,U7K^&,5_'J>K_,_18?"CU;0/\
MD"6/_7%?Y44:!_R!+'_KBO\ *BO[5RW_ '&A_@C^2/S^M_$EZL\IHHHK^(3]
M#/7=._Y!]K_UR7^0JS5;3O\ D'VO_7)?Y"K-?W/A?X%/T7Y'YU/XF%%%%=)
M4444 %%%% !69J4$=SYL,J"2*1=KHW1@1@@UIUE:JTJI.T"+).$)C1C@,V.
M3]:QJ[&M+XC&\,>$]-\(6,EKID+0Q22&5@SEB6.!U/L *V*YKP#?^(=1TB:3
MQ'9QV5X)F6-$&-R8!!(R>Y(_"NEKGE>^ITQM;0****DH**** "BBB@ HHHH
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M$N70^E_VE_BKX(^%_P (/%5QXUU?3[*SN-,N($L;J5/-O6>)PL,<9.9&;#
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7.>$]"\06/C36;_4-76[TB=2+6T!;,?S C@C"X
M (XSG.371UD>&O'6E:WXFU+1+621KZR#&4,A"G:P5L'V) _EFM:=[Z&52UM3
MK:***ZSD"BBB@ HHHH \AO\ _C^N?^NC?S-5ZL7_ /Q_7/\ UT;^9JO7\,8K
M^/4]7^9^BP^%'JV@?\@2Q_ZXK_*BC0/^0)8_]<5_E17]JY;_ +C0_P $?R1^
M?UOXDO5GE-%%%?Q"?H9Z[IW_ "#[7_KDO\A5FJVG?\@^U_ZY+_(59K^Y\+_
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MCTSYA!),6\V1&7I&>#CKU['G_ 'QJ^/7B'QEI6G>)_V;_P#A$M!N9MEYK?\
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M]5;DC<I!Y//->->%/^"=_P"SQX*U=-3TOX:6?VV,#8][?WEXJ$,&#*DTSJK
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M_P E4AW.XHKA_P#A'OB#_P!#IH__ (3S?_)5'_"/?$'_ *'31_\ PGF_^2J
MN=Q17#_\(]\0?^ATT?\ \)YO_DJC_A'OB#_T.FC_ /A/-_\ )5 7.XHKA_\
MA'OB#_T.FC_^$\W_ ,E4?\(]\0?^ATT?_P )YO\ Y*H"YW%%</\ \(]\0?\
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M[BBN'_X1[X@_]#IH_P#X3S?_ "51_P (]\0?^ATT?_PGF_\ DJ@+G<45P_\
MPCWQ!_Z'31__  GF_P#DJC_A'OB#_P!#IH__ (3S?_)5 7.XHKA_^$>^(/\
MT.FC_P#A/-_\E4?\(]\0?^ATT?\ \)YO_DJ@+G<45P__  CWQ!_Z'31__">;
M_P"2J/\ A'OB#_T.FC_^$\W_ ,E4!<[BBN'_ .$>^(/_ $.FC_\ A/-_\E4?
M\(]\0?\ H=-'_P#">;_Y*H"YW%%</_PCWQ!_Z'31_P#PGF_^2J/^$>^(/_0Z
M:/\ ^$\W_P E4!<[BBN'_P"$>^(/_0Z:/_X3S?\ R51_PCWQ!_Z'31__  GF
M_P#DJ@+G<45P_P#PCWQ!_P"ATT?_ ,)YO_DJC_A'OB#_ -#IH_\ X3S?_)5
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M_P"ATT?_ ,)YO_DJC_A'OB#_ -#IH_\ X3S?_)5 7.XHKA_^$>^(/_0Z:/\
M^$\W_P E4?\ "/?$'_H=-'_\)YO_ )*H"YW%%</_ ,(]\0?^ATT?_P )YO\
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M_P#A/-_\E4!<[BBN'_X1[X@_]#IH_P#X3S?_ "51_P (]\0?^ATT?_PGF_\
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M?_"/?$'_ *'31_\ PGF_^2J;7F)/R.XHKA_^$>^(/_0Z:/\ ^$\W_P E4?\
M"/?$'_H=-'_\)YO_ )*I#N=Q17#_ /"/?$'_ *'31_\ PGF_^2J/^$>^(/\
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M_P!#IH__ (3S?_)5 7.XHKA_^$>^(/\ T.FC_P#A/-_\E4?\(]\0?^ATT?\
M\)YO_DJ@+G<45P__  CWQ!_Z'31__">;_P"2J/\ A'OB#_T.FC_^$\W_ ,E4
M!<[BBN'_ .$>^(/_ $.FC_\ A/-_\E4?\(]\0?\ H=-'_P#">;_Y*H"YW%%<
M/_PCWQ!_Z'31_P#PGF_^2J/^$>^(/_0Z:/\ ^$\W_P E4!<[BBN'_P"$>^(/
M_0Z:/_X3S?\ R51_PCWQ!_Z'31__  GF_P#DJ@+G;2Q)<1/'(BRQ.I5D<9#
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MO_DJC_A'OB#_ -#IH_\ X3S?_)5 7.XHKA_^$>^(/_0Z:/\ ^$\W_P E4?\
M"/?$'_H=-'_\)YO_ )*H"YW%%</_ ,(]\0?^ATT?_P )YO\ Y*H_X1[X@_\
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MT8IG(![$BOD[]N*XT/5?B!\"]+T-H;CXLQ^-K&3318R*+VVL%R]ZTF#N$!C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#)N/%6DVFO0:++>HFISKOC@*G)'/?& >#P3FM:LJX\+:5
M=Z]!K,ME&^I0+LCG).0.>V<$\GDC-:M-VZ"5^H4444AA1110 4444 %%%% !
M1110 4444 %%%% !1110 54UC2;77M(O=,OHA/97L$EM/$W1XW4JP/U!(JW1
M0!X'\-[Z[CT630-7<MK_ (>D_LN_+@!I2@'E7&,_=FC*2CTWD=5('65+\4OA
ME?ZWJ$'BKPG/;V7C"SA\@QW;,EIJMN"6%M<,H8J Q)24*S1EF(5E9T;C](^(
M^G7>J?V+J\4_ACQ*O#:/K $,KG ),#9V7"#</GB9U!."0P('\Q\5<+XC*\3/
M$4(.5"3;37V;]'V2Z/:WF?383%QJQ49/WOS.KHHK \2^/-#\)O%!J%\OV^<'
M[/IULC3WEP1U$4$8:20]/NJ>O-? 4J-2O-4Z47*3V25W]R/0<E%7D[%WQ)XA
ML_"F@WVKW[,MI:1F1Q&I9W/0(BCEF8D*JCDD@#DUU7P9\,7_ (6^']E'K""/
M7;^274]10-O$=Q/(TK1!N,B,,(@?[L8KD/!_PYUOQGXDT_Q1XQMVTC3-.?SM
M*\+%UD;SN-MU>,N5,B\[(E)5,[R6?;Y7L]?TCP7PY4R:A+$XI6JU+:?RKMZO
M=_+S/FL;B57DHQV04445^E'G!1110 4444 %%%% !1110 4444 %%%% %;4M
M1@TG3[F]NFV6]O&TLC 9(4#)XJGX8\3V'B[2UU#3G=X"Y0^8NUE8=0?S%:4T
M,=Q$\,J++%(I5T<9# ]01Z5#IVFVFD6JVME;16ENN2L<*!5!/7@4]+$ZW+-%
M%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *R?#GCC2=:\2ZCHMK,SWUDI,JE"%^5@K8/?!
M(!K6J/2-%L+/4KJ]@LX(;RX&)9TC =_J>I[5I"W-J95+\NAM4445V'(%%%%
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M#)^1]R\]*]9HIW>X610T#0--\*Z)8Z/HUA;:7I5C"MO:V5I&(XH8U&%55'
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MT1],ET>[AM-.:7,;RWDTD:HB1@.V0QR8^*^Q:*$T@:N<3\$_A=8?!3X3^%O
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MVV"-LDL<X[#CGC)Q36Y,MC5HHHI%!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '*>)1XK_ .$F
MT4Z,8?[&W#[<)-F<;N<YY^[TV]^O%=765J7BG2M(U.RT^\O8X+R\.((FSESG
M YQ@9/ SU/2M6J>RT)6["BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE=:TWQ-/XRTNZL-0BAT*-0+
MJV;@L<G/8YR" .>,5U58>H>--)TOQ%9Z)<7!34+M08XPA(Y) R>V2#5*_0F5
MNIN4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '*:A_PE7_  G5C]D\G_A&O*_TC.S=NYSU^;/3
M&./6NKK+N/%.E6FN0:/+>QIJ4Z[X[<YR1]<8'0\'KBM2J?0E=0HHHJ2@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ%X9TCQ=I4^EZ[I5CK6
MF3J4FLM1MTGAD!&"&1P01C/45I44 <#'\!? $**D/AFUMXU&%BMV>-%'H%5@
M /8"M[PE\/?"_@..=/#?A[2]"$[%YCI]I'"96/=RH!8].3FN@HK*%*G3;<(I
M-]D%V]PHHHK4 HHHH **** "BBB@ HHHH **** "BBB@ HHHH IZQ%=W&DWL
M=A,L%\\+""1QPKX.TG\<5F>"+/6[#0(H=?NDO-0#L3(ASA2> 3@9-:^HW\&E
MV-Q>73^5;P(TDCX)PH&2<"J?AOQ+8>*]+6_TZ4RVY8IEE*D,.H(/X?G5:V)T
MN:E%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<YX3TSQ-;>,]8N=2U&*XT213]DMTZI\
MP*\8XPN0>>2<UT=9?AWQKI.L^(M0T:TN#)?V2GS4*$#Y6"M@]\$@'ZUK3O<R
MJ6MJ=511176<@4444 %%%% 'D-__ ,?US_UT;^9JO5B__P"/ZY_ZZ-_,U7K^
M&,5_'J>K_,_18?"CU;0/^0)8_P#7%?Y44:!_R!+'_KBO\J*_M7+?]QH?X(_D
MC\_K?Q)>K/*:***_B$_0SUW3O^0?:_\ 7)?Y"K-5M._Y!]K_ -<E_D*LU_<^
M%_@4_1?D?G4_B84445TD!1110 4444 %9]WQ.WTK0K*U6V2\2>"3)CE0HV#@
MX(P>:QJ_":TOB(+6]M[Z(R6T\=Q&"5WQ.&&>XR*FKG_!?@JQ\#:;+9V,DTL<
MDIE9IV!.2 .P Z 5T%<SM?0ZE>VH4444AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &-KWA#2?$\]E-J5H+B2S;?"
M2Q&#P2#@\C@<'TK9KE/&MQXI@O=('AV"":W:7%V92O"Y&.I'&-V2.>/SZNJ=
M[(E;L****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RM8\*Z3K]Y9W6
MH627,]FV^!V)&TYSV.",@<'(K5KE?%[^*EU71QH$<#6)E_TTR%<[<CKNYQC/
MW>:ZJJ>R)6["BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*CT7P]IJ,EK91.[A S,[$LY+,2S,26)))/-=+5\UGH1RZ:GREXY^([?M%_\
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M4****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<IK5MXID\9Z5+IUS#'H"J/M43;=Q.3GJ,\C&,'K75UC
MW_B[2=-URTT>YNUCU&[ ,4.TG.<@9(&!G!QGTJE?H2_,V****DH**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#E-0N/%*^.K&*UMX&\-M'F>4[=P;!SWSGIC QS^75UG3^(M,MM8ATJ6
M^A349EW1VY;YF'^0?RK1ILE!1112*"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!-X6F^UW4S':&TYL+>HY_NB+,H'3?!&3TKZ%K^I^%L[>>9>JU3^)%\LO7O\
M-?C<^5Q5#V%3E6SV"BBBOL#D"BBB@ HHHH **** "BBB@ HHHH *YSPG;^*H
M_&>LR:I<02:$RG['&@7</F&WH,\+D'/4]*Z.L[P_XPTC6->O])M+Q9M0LP?.
MB"D;<, <$C!P2 <5K3O<RJ6Y3IZ***ZSD"BBB@ HHHH \AO_ /C^N?\ KHW\
MS5>K%_\ \?US_P!=&_F:KU_#&*_CU/5_F?HL/A1ZMH'_ "!+'_KBO\J*- _Y
M EC_ -<5_E17]JY;_N-#_!'\D?G];^)+U9Y31117\0GZ&>NZ=_R#[7_KDO\
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M_"'>%?$6@75UH<$=L^BZ9J$,LUE&JX17B1BR# XR!TI-6!.YV-%%%26%%%%
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M_P#DS7:T47"QQ7_%QO\ J5__ "9H_P"+C?\ 4K_^3-=K11<+'%?\7&_ZE?\
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MU*__ ),UVM%%PL<5_P 7&_ZE?_R9H_XN-_U*_P#Y,UVM%%PL<5_Q<;_J5_\
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M*_XN-_U*_P#Y,T?\7&_ZE?\ \F:[6BBX6.*_XN-_U*__ ),T?\7&_P"I7_\
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M&>E>CURNM1>*F\9:6^G2P+X?51]K1MNXG)SU&>FW&._6FA,J?\7&_P"I7_\
M)FC_ (N-_P!2O_Y,UVM%*X['%?\ %QO^I7_\F:/^+C?]2O\ ^3-=K11<+'%?
M\7&_ZE?_ ,F:/^+C?]2O_P"3-=K11<+'%?\ %QO^I7_\F:/^+C?]2O\ ^3-=
MK11<+'%?\7&_ZE?_ ,F:/^+C?]2O_P"3-=K11<+'%?\ %QO^I7_\F:/^+C?]
M2O\ ^3-=K11<+'%?\7&_ZE?_ ,F:/^+C?]2O_P"3-=K11<+'%?\ %QO^I7_\
MF:/^+C?]2O\ ^3-=K11<+'%?\7&_ZE?_ ,F:/^+C?]2O_P"3-=K11<+'%?\
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MQQ7_ !<;_J5__)FC_BXW_4K_ /DS7:T47"QQ7_%QO^I7_P#)FC_BXW_4K_\
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MYXP>M?0M?T)X<86I2P-;$26DY*W_ &ZM7][M\CYW,I)U%%=$<5_Q<;_J5_\
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M+#4[VV\V[LCF%MQ X.1D=\'FMNF[=!*_4****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R;[Q7I.FZU:
M:3<WJ1:A= && JQ+ G Y P,D'&3S6M65>^%M*U'6;35;FRCEU"U&(ISG*]>V
M<'&3C/3/%-6ZB=^AJT444AA1110 4444 %%%% !1110 4444 %%%% !1110
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MK91PW]V")IUSEN03WP,D G'6M*=N;4RJ7Y=#HJ***[#D"BBB@ HHHH \AO\
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MKJZHWFN:?87UK9W-Y#!=71Q##(X#2'V%7J;)74****104444 %%%% !1110
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MCT33HKRSEDQ=R/U1<@>HQP2<\]/SZJJ=[(E6NPHHHJ2@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M/6_!>D^(=5L-1OH&DNK%@T+*Y4<$$9 Z@$9K<KE?%6J>);+7M&@TC3HKO3II
M +N9^2@W#/<8^7)SS51O?0F5K:G54445)04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!AZSX+T
MG7M9L-4O8&DN[$@PL'('!W#([X/-;E<KXDU7Q+9^)]'MM*TZ.ZTJ9@+N=^L8
MW<\YXPO(X.:ZJJ=[*Y*M=V"BBBI*"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)OO"FDZEK=IJUS9I+J-J
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M#?\ _']<_P#71OYFJ]6+_P#X_KG_ *Z-_,U7K^&,5_'J>K_,_18?"CU;0/\
MD"6/_7%?Y44:!_R!+'_KBO\ *BO[5RW_ '&A_@C^2/S^M_$EZL\IHHHK^(3]
M#/7=._Y!]K_UR7^0JS5;3O\ D'VO_7)?Y"K-?W/A?X%/T7Y'YU/XF%%%%=)
M4444 %%%% !65JDZVB3SLK,L:%RJ#)( SP/6M6L^[_U[?A6-7X36E\1RO@3Q
MM;^.]*FOK>VEM5BF,)27!R0 <@CV(KI*1$6-<*H4>@&!2US.U]#J5TM0HHHI
M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#O]J#48[BTS*GV<S IO8!DPV,AR,C.:U2Z&3?4^COVW?^31_BS_ -B_=?\
MH->:?!'X)_'V+POX!U27]I/SO#JV>GW+Z!_P@FGKOM0D;&V\\/O&4^3S,;N_
M6MOXX?$.V^-'_!/+Q;XSTY0(=;\%RWYB!SY3&'=+&<9Y1@ZGW4U[+\"-2MM7
M^"/P^O;.9)[:?P_821R(P(8&WC[BIV16[.$^/_QI\4>'O&GA+X9?#>PT^_\
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M,FO;.&:!(IC"R3@9R #G@D="*Z*N>5[ZG3&UM HHHJ2@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E/&NN^(='O=)
MCT32%U*&XE*W+L&/ECC'0C;P3R<CBNKJM>:G::>\*75W!;/.VR)9I ID;T7)
MY/L*LTWL2MPIEQ$9X)8UD>%G4J)(\;D)'49!&1[BGT4BCA_@O\(-$^!7P[TW
MP;X?FOKO3[)II3=ZG,)KJYEED:2265P!N=F=B2 .PQQ7;R1K*C(ZAD8$%6&0
M1W!%>.?%K]L/X.? WQ!%H7C;QW8Z/K$F#]A2&:ZEC!Z&184?RP>H+XKTWPEX
MPT/Q[X>L]>\.:M9ZWHUXF^WOK&998I!G!PR^A!!'4$$'D4W?=DIK9'&_"#X
M^&/@O\.;[P)HYN]0\+7-U=SK8:HT<J017#%I+9 J*/)RS85MQ^8Y8UY9H'[
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MZR6VPJQ(!W<>M?1FJZKX>^&WA&6\O[BP\-^&M'M1NDD*6]K:0( % Z*B@8
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MKN(!/0?B/6L#_A--8_Z$'Q#_ -_]._\ DNJZ$HZRBN3_ .$TUC_H0?$/_?\
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MA_[_ .G?_)= 7.LHKD_^$TUC_H0?$/\ W_T[_P"2Z/\ A--8_P"A!\0_]_\
M3O\ Y+H"YUE%<G_PFFL?]"#XA_[_ .G?_)='_"::Q_T(/B'_ +_Z=_\ )= 7
M.LHKD_\ A--8_P"A!\0_]_\ 3O\ Y+H_X336/^A!\0_]_P#3O_DN@+G645R?
M_"::Q_T(/B'_ +_Z=_\ )='_  FFL?\ 0@^(?^_^G?\ R70%QWB76?$=CXFT
M6UTO3$N]+G8"[N&!)C&[!YS\N!SR#GI755Q%S\2[NRN[>UN/!NMPW-P2(89+
MO3 \F/[H^V9-6_\ A--8_P"A!\0_]_\ 3O\ Y+JGT$CK**Y/_A--8_Z$'Q#_
M -_]._\ DNC_ (336/\ H0?$/_?_ $[_ .2ZD=SK**Y/_A--8_Z$'Q#_ -_]
M._\ DNC_ (336/\ H0?$/_?_ $[_ .2Z N=917)_\)IK'_0@^(?^_P#IW_R7
M1_PFFL?]"#XA_P"_^G?_ "70%SK**Y/_ (336/\ H0?$/_?_ $[_ .2Z/^$T
MUC_H0?$/_?\ T[_Y+H"YUE%<G_PFFL?]"#XA_P"_^G?_ "71_P )IK'_ $(/
MB'_O_IW_ ,ET!<ZRBN3_ .$TUC_H0?$/_?\ T[_Y+H_X336/^A!\0_\ ?_3O
M_DN@+G645R?_  FFL?\ 0@^(?^_^G?\ R71_PFFL?]"#XA_[_P"G?_)= 7.L
MHKD_^$TUC_H0?$/_ '_T[_Y+H_X336/^A!\0_P#?_3O_ )+H"YUE%<G_ ,)I
MK'_0@^(?^_\ IW_R71_PFFL?]"#XA_[_ .G?_)= 7.LHKD_^$TUC_H0?$/\
MW_T[_P"2Z/\ A--8_P"A!\0_]_\ 3O\ Y+H"YUE%<G_PFFL?]"#XA_[_ .G?
M_)='_"::Q_T(/B'_ +_Z=_\ )= 7.LHKD_\ A--8_P"A!\0_]_\ 3O\ Y+H_
MX336/^A!\0_]_P#3O_DN@+G645R?_"::Q_T(/B'_ +_Z=_\ )='_  FFL?\
M0@^(?^_^G?\ R70%SK**Y/\ X336/^A!\0_]_P#3O_DNC_A--8_Z$'Q#_P!_
M]._^2Z N=97*:U<^*8_&>E1:=;0R: RC[5*VW<#DYZG/ QC ZTG_  FFL?\
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M_?\ T[_Y+H_X336/^A!\0_\ ?_3O_DN@+G645R?_  FFL?\ 0@^(?^_^G?\
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M .$TUC_H0?$/_?\ T[_Y+H_X336/^A!\0_\ ?_3O_DN@+G645R?_  FFL?\
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MW3M.#4K9E/=%?]I.SLO@Y^TO\#_B=I0_LRX\1Z[_ ,(3KRVR!5U&&[1C;F4
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MWQ!IFOZ+;:5I*WUA<R!;J<JQ,8W#/(("\9.3D&JC>^A,K6U.KHHHJ2@HHHH
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?O?
MVE7WBFU\02QR'4+==JD/A#C(!(]1FN@KE-0U[7[?QU8:;;Z0)M$ECW37NULJ
M><_-G QQP1DUU=4[Z7)5M;!1114E!1110 4444 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH *S?#_@W2-'\0W^L6EKY6H7@(FD#G!R0S8&<#)
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MLYV1(%&?7 J:N9VOH=2O;4****0PHHHH **** "BBB@ HHHH **** "BBB@
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MIN\W>-FS;G&ULY[5ZC11?6XDM+&-XS\8:3\/_">K>)-=NX[#1]*MGN[JXD8
M)&HR>O?L!W) [UY!^QYX3U:Q^'VK^-_$MK+9^)_B#J\_B>[M;@8EM()<+:6S
M# P8[=(@1C(8L#GK7K?C/P+H'Q%T7^Q_$NE6VLZ7Y\5S]DNEW(9(G$D;$=\,
MH..G'/%;M%]+!;4****104444 %%%% !1110 4444 %%%% %:[U.SL)88[J[
M@MY)VV0I-(%,C>B@GD\C@>M6:YWQ+X$TOQ7J&FWM\)O.L'WQ^4^T-R#AN.F0
M.F#[UT5-V$KA1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 56N=4L[*>""XNH()YSMBCDD"M(?1
M03DGITJS7/>(/ NF>)=8TS4KP3?:=/8-'Y;[5;!! ;CH",\8IJW43OT.AHHH
MI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** *MQJ=G:74%M/=P0W$Y(BBDD"M(?]D$Y/X5:KG=
M=\":9XBUW3=7NQ-]JL"#$(WPK8;<-PQV//&*Z*F["5^H4444AA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M1N=<TZRU.WT^>]ABOK@;HH'<!W'L/P/Y5>K#U#P7I.J>(K/6[BW+ZA:*!'('
M('!)&1WP2::MU$[]#<HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH K/J5I'?1V;W4*7DBEDMVD
MD9>Y"YR1UJS7.WO@33+_ ,6VOB*4S?;[= BJKXC/4 D8SD9/0UT5-VZ"5^H4
M444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $<]Q%:02332+%%&I=W<X
M50!R2>PJ#2]6LM;LTN["YCN[=B0)(FR,CJ*?J%A!JMC<6=RGFV\\;1R)G&5(
MP>>U4_#?AJP\*:6MAIT1BMPQ?#,6)8]22?P_*GI86MS4HHHI#"BBB@ HHHH
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MW"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#?\ _']<_P#71OYFJ]6+_P#X_KG_ *Z-_,U7K^&,5_'J>K_,_18?"CU;0/\
MD"6/_7%?Y44:!_R!+'_KBO\ *BO[5RW_ '&A_@C^2/S^M_$EZL\IHHHK^(3]
M#/7=._Y!]K_UR7^0JS5;3O\ D'VO_7)?Y"K-?W/A?X%/T7Y'YU/XF%%%%=)
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MXT25<W-T0<H<G/.<# P0,<YJE?H3*W4ZNBBBI*"BBB@ HHHH **** "BBB@
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M EC_ -<5_E17]JY;_N-#_!'\D?G];^)+U9Y31117\0GZ&>NZ=_R#[7_KDO\
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M3ZUI6IW<DZ3Z>X>-8G 5L,& .1Z@=,4U;J)WZ'24444AA1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ;+*EO$\DCK%$BEF=S@*!R22>@J&PU&UU6
MU6YL[F*Z@;[LL+AU..O(I-2TZ#5]/N;*Y4O;W$;1.H."5(P>:H^%_"]CX0TE
M=/T]7$ =G)D;<S,>I)_(4]+$ZW->BBBD4%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-TK5K*
MZU&YLX;N"6[@'[V!) 7CSZCJ*=6/X;\"Z5HGB?4M;M4D%]?*PE+/E1N8,V!V
MR0#6E.W-J95+\NAUU%%%=AR!1110 4444 >0W_\ Q_7/_71OYFJ]6+__ (_K
MG_KHW\S5>OX8Q7\>IZO\S]%A\*/5M _Y EC_ -<5_E11H'_($L?^N*_RHK^U
M<M_W&A_@C^2/S^M_$EZL\IHHHK^(3]#/7=._Y!]K_P!<E_D*LU6T[_D'VO\
MUR7^0JS7]SX7^!3]%^1^=3^)A111720?%W_!03Q?\0-;\;?!OX+?#_Q/-X)N
MOB!J%V-0UZV=EEAM[=(RRJ5PW(D=L*R%C&J[@&8U\O\ PU_97\4^.OCS\;?A
M_<?'_P >V-K\/HK-[:\_M.4R7?G0L[LZF7"JI7''9A7Z$?&_0OA/JGQ2^$=U
MX\U./3O&=EJ4\OA"/[2\,L]Q^Z$J*%^^/]4"IX.0"#FO'/VIO^"?>E_%WX@Z
MM\2=%^).N?#&]O[ 6_B0:3 TL>I6L:88,J21MN,:JISO4A%^0G.0#>_X)?\
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M ;C5FS_;"\;>"_$6A6GQE^"&I?##1-<OXM+LM?MM?M=:M4N9,A$G\A08@Q
M8YZ\X )I\K%S(^I:*Y[XA>/]!^%G@K5_%?B?4$TO0M*MS<W5TX+;5'   R68
MD@!0"22 .37SXO[67Q5U&)/$&C_LT>*;_P  M']H75)=:LH-3DA(R'3323(V
M05(7>#@GTI)-C;2/HKQIKE]X:\(ZQJVFZ-<>(M0LK62X@TJTD6.6[=5)$2,W
M +8P,U1^&'Q'T7XN> M'\6Z!/YVF:G )55N'A<$K)%(/X9$<,C*>C*1VIGPN
M^*'AWXQ>"-/\5>%[W[;I5X& WH4EAD4E7BE0\I(K @J>A'I7B_P.E3X:?M2?
M%_X90,%T?4X;;QSI5JH(6V^T$P7B*.@4SQ"08P,RMQG)IV%?5'TG1114E!11
M10 4444 %%%% 'G/Q2^+]M\,]8T"UN_LL<.HNP>6YEV852H./3&[.3Q5[_A>
M7P^_Z''1_P#P+7_&NSENH;=XDEECC:5MJ*[ %SZ#U-2U5U;8FSON</\ \+R^
M'W_0XZ/_ .!:_P"-'_"\OA]_T..C_P#@6O\ C7<44M!ZG#_\+R^'W_0XZ/\
M^!:_XT?\+R^'W_0XZ/\ ^!:_XUW%%&@:G#_\+R^'W_0XZ/\ ^!:_XT?\+R^'
MW_0XZ/\ ^!:_XUW%%&@:G#_\+R^'W_0XZ/\ ^!:_XT?\+R^'W_0XZ/\ ^!:_
MXUW%%&@:G#_\+R^'W_0XZ/\ ^!:_XT?\+R^'W_0XZ/\ ^!:_XUW%%&@:G#_\
M+R^'W_0XZ/\ ^!:_XT?\+R^'W_0XZ/\ ^!:_XUW%%&@:G#_\+R^'W_0XZ/\
M^!:_XT?\+R^'W_0XZ/\ ^!:_XUW%%&@:G#_\+R^'W_0XZ/\ ^!:_XT?\+R^'
MW_0XZ/\ ^!:_XUW%%&@:G#_\+R^'W_0XZ/\ ^!:_XT?\+R^'W_0XZ/\ ^!:_
MXUW%%&@:G#_\+R^'W_0XZ/\ ^!:_XT?\+R^'W_0XZ/\ ^!:_XUW%%&@:G#_\
M+R^'W_0XZ/\ ^!:_XT?\+R^'W_0XZ/\ ^!:_XUW%%&@:G#_\+R^'W_0XZ/\
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M..C_ /@6O^-'_"\OA]_T..C_ /@6O^-=Q17Z'H>?J</_ ,+R^'W_ $..C_\
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M?#[_ *''1_\ P+7_ !H_X7E\/O\ H<='_P# M?\ &NXHHT#4X?\ X7E\/O\
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M\6/V2OA#\;_$EEXA\;^!]/UO6;0($O6DE@=U7E5E,3KYJC^[)N&.,8IGP ^
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MWVG^(K:<\@M&+02 <=<,H//\Z?\ \%1&:']BSQK<1LT<]O=:;+%*C$-&XOX
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MMU8>J8G[($*:;\:OVFM-TR*.'P[%XQBN(%AXC%W+:H;L #@'<$S[FEOU$_\
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MQ$-P!Z ] 2>:J-[Z$RM;4ZJBBBI*"BBB@ HHHH **** "BBB@ HHHH ****
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MN%!N+W:Q\LY(/(X7  //7.!51OT)E;J=71114E!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <S?^ ;#
M4/&5GXCDFN%O+9 BQJP\ML9 )&,_Q'H>WUKIJY34?%NHVGCJQT2+1I9K">/>
M]^,[4/.>V,# SD]_IGJZIWTN2K:V"BBBI*"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW,5)')0X'!KE=9_X*%_M#:CI%]:6_P"R#XTM;B>"2*.=[74)!&S*0&*_8AN
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M7Q'\--.\2^(])UB>XN8IM/8,L<3 *^&W#/&1SZ5U/V./T/YT_9,2JHH45?\
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M_KG_ *Z-_,U7K^&,5_'J>K_,_18?"CU;0/\ D"6/_7%?Y44:!_R!+'_KBO\
M*BO[5RW_ '&A_@C^2/S^M_$EZL\IHHHK^(3]#/7=._Y!]K_UR7^0JS5;3O\
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M7Q)\-3_$6;P)'JL4GBV#3AJTNF*CEX[0R",2,V-H!8@ $Y/) P#734 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q_C3QG
MJ/AG6-$L[+1)M3AOI=DLT><1#*CL#SR3SCI]<=A3'FCC9%=U0N=JAC@L?04^
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KC_%OC34/#WB/0].M=$FU"WOY DMTF<1 L!V!Z
M9W'../T["F/*D;*K.JLYPH)P6^E #Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./\4^-
M-0T'Q5HFEVVB37]M?,%ENH\XBRV/3' ^8Y(X_.NPIC2HCHC.JN_W5)Y;UQ3Z
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@C]G"/P!^R[X5T/XA^ ],M?%EM->FZBU*RMYYP&NI6CRX#9^1EQSP.*^A?\
MA4?@7_H2_#W_ (*H/_B* (OA%\6?#?QR^'FD^-_"-U+>^'M4\W[+/- T+MY<
MSPOE& (P\;#D=LUV54]*TBQT&PBL=-LK?3K*+/EVUI$L4:9))PJ@ 9))X[DU
M<H *CFA2XADBE021.I5D;D,#P0:DJ&[,RVLQMU5K@(QC5SA2V. ?;- &;X9\
M)Z5X/LI+32;46L$DAE9=[.2QP,Y8D] !6Q7*_#NY\3W6C3-XJMX[>^$["-8]
MN3'@8)VDCKD?05U5 D,EC\V)TW,FX$;D."/<'UKY8_X8%_ZN-_: _P#"Y_\
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M@'<<XX'Y-".OHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBF_M$?!#Q?-\1_#OQF^$S6)^(N@VCZ9>:/J+"*V\0:8[AVM7E_Y9R*P+1N>
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M (U1_P +@TW_ * /BS_PF[W_ .-4 =W17"?\+@TW_H ^+/\ PF[W_P"-4?\
M"X--_P"@#XL_\)N]_P#C5 '=T5PG_"X--_Z /BS_ ,)N]_\ C5'_  N#3?\
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M!IO_ $ ?%G_A-WO_ ,:H_P"%P:;_ - 'Q9_X3=[_ /&J .[HKA/^%P:;_P!
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M!IO_ $ ?%G_A-WO_ ,:H_P"%P:;_ - 'Q9_X3=[_ /&J .[HKA/^%P:;_P!
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M^%P:;_T ?%G_ (3=[_\ &J/^%P:;_P! 'Q9_X3=[_P#&J .[HKA/^%P:;_T
M?%G_ (3=[_\ &J/^%P:;_P! 'Q9_X3=[_P#&J .[HKA/^%P:;_T ?%G_ (3=
M[_\ &J/^%P:;_P! 'Q9_X3=[_P#&J .[HKA/^%P:;_T ?%G_ (3=[_\ &J/^
M%P:;_P! 'Q9_X3=[_P#&J .[HKA/^%P:;_T ?%G_ (3=[_\ &J/^%P:;_P!
M'Q9_X3=[_P#&J .[HKA/^%P:;_T ?%G_ (3=[_\ &J/^%P:;_P! 'Q9_X3=[
M_P#&J .[HKA/^%P:;_T ?%G_ (3=[_\ &J/^%P:;_P! 'Q9_X3=[_P#&J .[
MHKA/^%P:;_T ?%G_ (3=[_\ &J/^%P:;_P! 'Q9_X3=[_P#&J .[HKA/^%P:
M;_T ?%G_ (3=[_\ &J/^%P:;_P! 'Q9_X3=[_P#&J .[HKA/^%P:;_T ?%G_
M (3=[_\ &J/^%P:;_P! 'Q9_X3=[_P#&J .[HKA/^%P:;_T ?%G_ (3=[_\
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M:H_X7!IO_0!\6?\ A-WO_P :H [NBN$_X7!IO_0!\6?^$W>__&J/^%P:;_T
M?%G_ (3=[_\ &J .[HKA/^%P:;_T ?%G_A-WO_QJC_A<&F_] 'Q9_P"$W>__
M !J@#N68*"2< <DFFPSQW$2R12++&W1T8$'\:\[UGXEZ1KFD7NG3Z'XO2&ZA
M>%VC\.7H8!A@D'RNO-9O@GQ?HG@;0DTNTT?QE<1J[2%YO#EYDD]<8BP![4 >
MM45PG_"X--_Z /BS_P )N]_^-4?\+@TW_H ^+/\ PF[W_P"-4 =W17"?\+@T
MW_H ^+/_  F[W_XU1_PN#3?^@#XL_P#";O?_ (U0!W=%<)_PN#3?^@#XL_\
M";O?_C5'_"X--_Z /BS_ ,)N]_\ C5 '=T5PG_"X--_Z /BS_P )N]_^-4?\
M+@TW_H ^+/\ PF[W_P"-4 =W17"?\+@TW_H ^+/_  F[W_XU1_PN#3?^@#XL
M_P#";O?_ (U0!W=%<)_PN#3?^@#XL_\ ";O?_C5'_"X--_Z /BS_ ,)N]_\
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M?\+@TW_H ^+/_";O?_C5?K9XAW=%<)_PN#3?^@#XL_\ ";O?_C5'_"X--_Z
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MM?\ KDO\A5FO[GPO\"GZ+\C\ZG\3"BBBND@**** "BBB@ J&[:9+29K=%DN
MA,:,<!FQP">W-34UF"*68A0!DD\ "@#E_AWJ/B34]'FD\3V4=C>B=EC2,8W1
MX!!(R>Y(_#\:ZJJ.DZU8:[;&XTZ]@OH Q0R6\@<!AU&1WY'YU>H *^+/C+I/
MB7XU_MU1_"EOB9XW\"^$;7P OB18_!6JC3IY+P7Y@R\FQBR%'Y4\953VY^TZ
M^"/C%XR\=>!_^"EOV_X??#O_ (69K4GPM2"72/[<@TGRH#J9+3^=,"K89478
M.3YF>BF@#N?&/[.GQ2^!'@W5/%/PP^.WC3Q'J.D12:C+H7Q)NH]:M-12.-BT
M/F;(Y(<@ @JW4=MV1]$?!7XF6WQE^$OA+QQ:6[V<.O:;#??9G.3$SJ-R9[X;
M(SWQ7R1XY_:)^.GQ-\9Z=\$-7^'NC_ +5O&NG72VWB#6M>CULR0J LR6B6Z+
M&UP$8X1W& <\?+GO_P!K&_?]D;]@37=.\$2SV[Z'I%IH.GW9DQ-&)9([=IMP
MZ/M=F!'\6,8H [/Q]^W?\!/AEXM/AGQ#\2M,M=:640R06T4]VL#Y *RR0QND
M9!/(=ACG.,&O9_#/B?2/&>@V6MZ#J=KK.CWL8FMKZQF66&9#T*LI(-<K\'O@
MQX5^#/PRTGP9X=TBTM-*MK-+>95B&;MMOSR2G&79R6)+?WCVKPOX V,/PA_;
M)^+7PNT+=;>#=1T>R\86&D1J%MM-N))&AN5A 'RK(P5]O0$< <T >8?'_P".
M/P^^%'_!2'0M4^+.JQ:?X9T/P 9-%>>PFO%M]2FO2#(B11NRN8D<;\  (.0<
M9]0^,'[07PY_:+_8V^.6N_#K7%\06EEX=OK&[NA8W%JRN+9W5")HT9@ Y(P"
M/F/O5'3_ /E*]J?_ &24?^G2.O6?VS_^32_B_P#]BMJ'_HAZ ,_X!>-]%^&W
M[$WPS\4^([W^SM"TGP-I5W>W?E/+Y42V419MB*S-]%!/M7M.BZQ9^(=&L-5T
M^;[187UO'=6\NTKOC=0R-A@",@@X(!KY!\7?\HEX/^R6V/\ Z015],?!;_DC
MG@3_ + -A_Z3I0!9\&_$_P ,_$'5O$^FZ!J?V^]\-:@=+U6+[/+']FN0H8QY
M=0'X8'*$CGK7G7Q7_;7^"/P0URXT;QE\0=/TO6+>18I]/@AGO+B%F0.-\<".
MR J0<L .1ZUQ/[&W_)5OVF_^R@2?^DT50_LQPHW[7O[5DI13(NJ:&JN1R =/
MY /H<#\A0!W_ (6_;3^!OC+P7?>+-,^)N@G0[%UCNIKR8VDL#,S*@>&8)(NX
MJVW*_-M)&157X4?MR? SXW>)X_#O@[X@V6HZW-Q#8W-K<V4DYP3MB%Q''YC8
M4G"Y( Z5Y+\;?!WA73O^"C7P#OYO#NG75[XDTG6[6ZDFM$DWO;P>=%*<_P :
MY==^"<''3IJ?\%1+"UT[]EN]\:16L!\1^$M7TS5-)OGCS);S"]B3*MP0"'.0
M#SQZ"@#T[]L3P]\.O$?P4N8/BGK^J^&O"$&I6,\NH:.TJSK.+A!"O[N.1L-(
M5!PO&<@J0&' _P#!2V(0?L@ZW&I)5-4T=068L<"_@')/7ZTG_!2F;[3^QYK,
MV,>9J>COCTS?VYJ7_@IG_P FC:__ -A;2/\ TX04 ?4%]>P:98W%Y=2"&VMX
MVFED;HB*,DGZ &OG32_^"CW[-^K^)ET*#XIZ;'>M,\ ENK2ZM[3<N<DW,D2P
MA>#AB^T\8)R,^\^,O%NA^!/"VJ>(/$FHV^E:%I\#37EY=MB..,=2?7J!@<DD
M =:^1/B1^U]X#^*/PXUOPT_P5^*NM>!]0TV6&+Q G@:1](6,PD+,C%MZJF>&
M$?!7(XYH ^Q-7\0:7X?T.ZUK4]1M-/T>T@:YN+^ZF6."*)1N,C.2%"@<Y)QB
MO!O#O_!0O]GGQ7XQA\+Z7\2[*YUF:X-I#&;&[CAFEW;0J3M"(GW'A2K$-D;<
MY%>1>$_ASXJ_:._X)?>!_#^DWD=UX@ETNRECAU"4K%?I:W(86TK?W72()D\=
M,\9KUGX=?M7^ /$.KZ3\._&?AN\^%7C%]J6GA;Q5IX@MYG0KM%I. 8)@"5V[
M6#'(PO!P 0_\%!?B-JWPJ_9RN?$.CZU=^'YH=9TV.>^LG9)5MVN468 K\W*%
MAQSZ5H?#7]OWX"_%_P ;Z7X0\(^._P"UO$6INZ6EG_8]_#YK*C.PWR0*@PJ,
M>2.GK7/?\%(?^3;XO^QFT7_TNBKZEH **** "BBB@#D/'/CZ3P9>Z/;IH]QJ
M?]H2F,O"<"/D>QR>2<<=#S77T44 %5M1D:+3[ET.UUB9@1V.#5FJNJ_\@N\_
MZXO_ .@F@#\_OV2/@/XC_:F_9_\ #/Q/\6?'_P",VF^(-=:[^TVOA[Q4+*R3
MR;N:!/+A$)"96)2<'DDGO7I_C/Q'\6/V,UM?%'B/QA<?%SX.1RI#K4NI6*)K
MNB([*BW*/"H6YB5CEPRA@#QGJ+W_  2T_P"3%OAO_O:G_P"G*ZKU_P#:A_LG
M_AFWXI?VY_R"?^$8U+[3CKM^S2=/]K.,>^* /2+*]@U*SM[NUE6>VN(UEBE0
MY5T895@?0@@UX1XS_;U^ '@#Q@/"^M_$W2H-9$_V:2*VCFNHH)=^PI+-#&T<
M15LAM[+MP<XP:\7^('Q0\2_"#_@D]HOB&VEN+?Q&?!^E6$5P[%98/M A@\S)
MY#+'(2#Z@4?"O]I'PC\)/ACIO@;0?V6/CE!H5M:K;S0?\( I6[.W#R2YF_>,
MYR6+9SF@#[7T+7M-\4:-9:OHVH6NJZ5>Q+/;7UE,LT,\;#(='4D,".X->%_$
M+]OW]G[X7:_/HGB'XEZ=%JEO))#/;Z?;7-^89$.UTD-O%($8'(*L0<@^AKB?
M^"==IJVB^%_B7I3^#O%7@CP>GBJXO?#&D>+=*?3[BVLKA5D,*(<C8DF\#:S#
MGKDFKO\ P3WAC7PK\89A&HE?XGZ^C2!1N*B5" 3Z#<V/J?6@#W>[^-'@;3_A
MG:_$.\\3V%CX*N8(;F+6KN3R8&CE($;98 _,64 $9YKQ[2_^"D/[-NK^(DT6
M#XI:?'>/*T(ENK*[M[4,N<DW$D*Q!>#AB^T\8)R*RO\ @I?&D/[(FNHBA$&J
MZ1A5& /^)A!7OOQ0\$:)XX^&?B#PYK.FV][H]UITT#VLD8**OED J/X2.Q'3
M Q0!YE\3/V[_ ("_"'7#HWB?XD:;;:HI(DMK"&XU!HB IQ)]FCD\LX8<-@GG
M'0UZSX"^(/AOXH^&+7Q%X2UNR\0Z'=;A#?6$HDC8@X9<CHP(P0>0>HKY[_X)
MG+I=[^Q5\/+VSTJSL9+FWN8;IK>V2(W#Q7<\1>3'WV.S))Y.3ZUC?LB16_A#
M]K']JCP1I-K#8>'K/5=(UBVM+=-B13W=HSSD < ,54X [?2@#U3XR_MG?!K]
MG[Q'#H'CWQM#H>LRQ"=;);&ZNI AQAF$$3[0<\%L9P<9P<=S\*_C#X*^-WA>
M/Q%X%\26/B72&(1IK-_FB<J&\N5" \3[64E'"L,C(KRKXC?MF>"/A_XWU7PY
MH?A3QC\2_%5@8XM6M/ 'A]M2DLN&*K/)E4!7/W=Q(W].N/(_V3_&^E>*?VV/
MBM<>'?#&O>!=-UCPOIVHZAX=\0Z2VF7,=\DSQF1H#QDHP.Y20VX\F@#0^(_[
M8'AK]G_]MKQ+I?Q*\;W>A>#7\(V3Z;8FWN;FW^UO.YD<1P1OABB#YF'3@'DU
M[[\-?CM\-_VG?A[XAU'P5XCEUOP]%YVFW]Y#:W-F\+&(,X7S8T?(20$,H/7@
MY%>8>#O^4D/Q$_[)_IO_ *5/7TIXC_Y%[5/^O67_ - - 'B_[/-AX(\)_LE:
M8GPIU_4]>\&VVE7DFDZOJ;2?:9,-+EB'CC*XD# #8H  P,8KY]_9B_X*8?!K
M0_@-X.L?B3\4+F3QU%:M_:SWFEZC=2F8R.?FD2!E;@KC:2 , =,5Z-^PO_RC
MI\(?]@+4O_1]S76_\$]?^3,/A3_V"C_Z.DH TOVB=!^&OBG7O@YJ'CCQ#JVC
M74'BFWD\,IICS(M]J+QMY4,NR-B$*@G)*=P6 8@^B?%3XP^"O@CX7D\1>.O$
MECX:TA246:\?YI7"EO+B0 O*^U6(1 S'!P*\)_;@_P"1Q_9J_P"RH:;_ .BI
MJM_M3> O%,'Q:^%_Q9T7PH_Q%TKP8M]%?>%;=D^U_P"D(BK=VJ2?(\L>W[O#
M$'Y30!VWP9_;&^#O[0>MSZ-X!\:V^NZM#&9FLC9W-K+Y8ZN%FC0LHR 2,@$@
M=2*]GKR'X.?M'?#;X]:K=0^'[PP>+M)0I>:'K=B]EJ]@IVE@T,JA]O*99,KD
M@9SQ7KDF[8VW[V#CZT ?'.@V7C']M[Q-XSU5/B'XM^&?PNT#69]"T6#P5>I8
MWVK2VYVSW<MSM=A$7^5$  P#GFNH^"WC#QG\)/V@+SX'^.?$5[XVTV^T;^W?
M"GBC4UC%Y+%&XCN+2Y90/,D0D.'QDKG)Y %'_@E]YW_#&_A;[9_R$O[0U7[;
MG&[S_M\^[..,].E5?VA?._X;^_96^R[O,^S^)?M&S/\ JOL*_>QVSZ]\4 ?7
M%>:?&GX6>(_BM:Z;IND?$?7?A[I*^;_:3>&TA2^NU90J+'<.K&#;ESN49R5Q
MC%>EU2UK^T/[&O\ ^R/LO]K?9Y/LGVW=Y'G;3Y?F;?FV;L9QSC.* /B_QKH'
MCC]B7QC\-];TSXJ>,_B/X$\2>)K;PWK.B>.;U-3N8FN@5BN+>XVHZ[&C^X.#
MGW->U?M9_$/Q'X.\+^#O#_A*_71?$'C?Q19>&(-9:-9#IT<PDDFG16RID$<3
MA 01N8<5\X?$3Q+\7?AM\2O"'CW]I[P]H&O?#?0K^)[&\^']TZZ;H6H2,L,=
M]=V]R!/-CS"JL&VQG>=K,R5]B_&7X1:-\<_ IT'4[JZLBES!J6G:KIL@6XL+
MN%P\%S$Q!&Y6&>0002#UH \%TWPOXL_96^-'PUTR+XF^+OB-X0\>:C<Z3J%C
MXVO5OKFSNUMI)XKBVF"*4C_<E6B^[\V1STZCQSXIUOXR_M*Z-\.O"VLZAI'A
MGP.T6N^,=0TRY>!KF=U/V/2_,C8-AAF:5>A38#G<:X/QOX"UO]G?3G^,'Q4^
M)6H_&GQAX?233O!.DRZ5!I5NE]=@0Q1B&#<))Y"VPS'HA8XXS5?P#XT\3?LY
MV ^'GA7X?WOQE^.&J1?\)9XU:VU2#3[6"YNG_P"6MY.,8&UDBC )V1#.,T ?
M:=%>:_ KXW67QO\ #>I7B:/?^&=;T;49=)UC0-5V?:;"ZCP2C%25965E97!P
MRL"*]*H **** "BBB@ HHHH X_QIXZN/"FKZ)8PZ//J*ZA+Y;RQ$@1\@>AR>
M<XXZ?EV%-+ 8R>O3WIU !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7(>+?'<_AGQ'H>F1:1/
M?1ZC($>XC) BRP7C@Y(SDYQQ^G7TTL!C)Z]/>@!U%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% ''^*/'<_AWQ5HFD1Z//?1ZBP5KF,D"++;>F#G'4\C KL*0L 0,\GI2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5R&N>,M2TOQSI.B0:)-=6-VFZ2^7.V,Y(/08^7 )R>_Y]
M?4;31I(D;.JR/G:A/+8ZX% $E%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <?J7CNXL/B!I_AQ=
M&GF@N8M[7RD[5X;MC! QR<]_;GL*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"EK5]+IFD7MW!;/>S00O(EM']Z4@$A1]>E9/@+Q+>^*_#L6H
M7VFOI<[.R^2^>0#PPR <'^E=$2 ,G@4V*5)D#QNLB-R&4Y!_&@!]%%% !111
M0 4444 %%%% !1110 4444 %>,_'ZWAT7Q#X#\6RI$L-K>RZ'<W4C!?(AOA&
M$Y/7?=06<>.YD7TKV:L?Q;X6T_QMX:U+0=5B:;3]0@:WF5'*, 1]Y6'*L#@A
MAR" 1R*\W,L%',<'5P<W93BUZ7V?R>IK2J.E4C-=#S&BN4T75M1\+:VO@SQ=
M(5U^%3]BU%TV0ZU O2>(CY?-Q_K(A\R,"0-A1CU=?QCC\!B,LQ$L+BH\LH_C
MYKNGT9]]2JQK04X/1A115+6];T_PWI%WJFK7UOIFFVD;37%W=R".*% ,EF8\
M #U-<"3DU&*NV:-VU.:^+RSW_@/4-#LI&BU3Q%MT*R:, NDMT?)\P \'RU9I
M3GC;&Q/ KZ3M[=+2WB@B&V.-0BCT &!7B?PD\*W_ (V\36_CW7+";3=,LD=/
M#FFWD92?YU*R7TR'E'="4C0_,L;.6PTA5/<:_JO@?)*N39:WB%:I4?,UV5M$
M_/KY7L?&9CB(UZON;(****_1#RPHHHH **** "BBB@ HHHH **** "N/\.>,
M]2UGQGK.CW.AS65G99\J]?.V7# #MCY@2PP>@KL*C6:-Y'C5U:1,;D!Y7/3(
MH DHHHH **** "BBB@#R&_\ ^/ZY_P"NC?S-5ZL7_P#Q_7/_ %T;^9JO7\,8
MK^/4]7^9^BP^%'JV@?\ ($L?^N*_RHHT#_D"6/\ UQ7^5%?VKEO^XT/\$?R1
M^?UOXDO5GE-%%%?Q"?H9Z[IW_(/M?^N2_P A5FJVG?\ (/M?^N2_R%6:_N?"
M_P "GZ+\C\ZG\3"BBBND@**** "BBB@ J*YMX[RWE@F020RH4=3T92,$?E4M
M0W;RQVDSP1B6=48QQDX#-C@9[9- &1X1\&:9X(T^6STN.1(I93*YD<N2Q '7
MZ "MVN5^'>L^(-;T::;Q'IJZ9>+.R(BJ4W)@$'!)[DCWQ754 %?+T'@_7E_X
M*6W'B@Z)J(\-'X6C3QK/V23[&;K^U%?R/.QL\S9\VS.['.,5]0T4 >2?M.?
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M1\+O$?Q@_9G\3^'O"5DFI^(!-9W]M8-*(C<^1=13-&K'@,51@,\$X'>O?:*
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAFOE)VQ\D'C!'& 3DCK3$=?1112&%%%% !1110 4444 %%%% !1110 4444
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M6_&FLZ)+HL]G;V )2]<G;)A@!QC'S [AST% '84444 %%%% !1110!Y#?_\
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M(U>:./:]S##;K/%N(QDJ^#DYX&.PQ]@T %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!R'BCXA+X9\5Z'HATV>Z.IL%\^,X$>6V],
M?-CJ>1@<\UU]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<AKOCN?1_'&D: FCSW,-\H9KU20L>
M21P,<XQD\C (KKZ0D ^YH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./U+XA+IWQ T_PP=,G
ME-W%YGVM3\J]?X<<CY3DYXKL*** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 4=;TP:UH][I[320+=0O"98CAEW C(_.LS
MP+X0C\#^'HM*BNY;Q4=G\R48ZGH!V'_UZT]:U+^QM(O;X027/V:%Y?)B^\^T
M9P/RK)\ ^+SXX\.1:J;%]/WNR>4[;P<'J&P,@_3UH$=)1110,**** "BBB@
MHHHH **** "BBB@ JEK6LV/AW1[W5=3NHK'3K*![FYN9FVI%&BEF=CV  )J[
M7CW[0LIUL^$O".?]&U;4?ME^@D9"]I: 3;>.H:?[*K*>&1G!!!Q7!C\93R_"
M5<74V@F_N6WSV-*5-U9J"ZG%.E]\8=0B\1^*H94T0.)M%\,7"XBMT!#1W%TA
M^_<G ;:V5B^4*-X9V["BBOXUS3-<5G&)EBL5*[>RZ)=EV7],^]HT84(*$$%8
M_BGPCI?C/3&L=4MVDC!WQ30RM#/;N.DD,J$/%(.H="&'8UL45YE.I.E-5*;:
MDM4UHT;-*2LR7X0?$+5X=>F\"^+K@WVJPVYNM*UQE5/[6M5.UU=5P!<193S
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MC0_P1_)'Y_6_B2]6>4T445_$)^AGKNG?\@^U_P"N2_R%6:K:=_R#[7_KDO\
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MT_\ ^1Z/^$$\4_\ 12M9_P#!=I__ ,CUW=% '"?\()XI_P"BE:S_ ."[3_\
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MI6L_^"[3_P#Y'H_X03Q3_P!%*UG_ ,%VG_\ R/7=T4 <)_P@GBG_ **5K/\
MX+M/_P#D>C_A!/%/_12M9_\ !=I__P CUW=% '"?\()XI_Z*5K/_ (+M/_\
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MB@#A/^$$\4_]%*UG_P %VG__ "/1_P ()XI_Z*5K/_@NT_\ ^1Z[NB@#A/\
MA!/%/_12M9_\%VG_ /R/1_P@GBG_ **5K/\ X+M/_P#D>N[HH X3_A!/%/\
MT4K6?_!=I_\ \CT?\()XI_Z*5K/_ (+M/_\ D>N[HH X3_A!/%/_ $4K6?\
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M$$\4_P#12M9_\%VG_P#R/1_P@GBG_HI6L_\ @NT__P"1Z[NB@#A/^$$\4_\
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M[_8[/YKKL')Z!<G _'UH Q_^$$\4_P#12M9_\%VG_P#R/1_P@GBG_HI6L_\
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M=0*"QM-(NYYS)]WRUA<MGVP#7H7A_P"'GBZTT#38)OB1K*S16T2.OV"P.&"
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MV]S>V?EVVXGA0S*1DD8P*^K=5U6ST/3+O4=0N8[.QM(FGGN)FVI&B@EF8]@
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MT^MZU9>'-&OM6U*YCL].L8'N;FXE.$BC12S,3Z  FO@S7O$WB:S_ &>OC/\
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MG\1;;P9J^C6$UE<7+ZE+Y:O%C"#('?J<L.!774UD5R"R@D'()'0TZ@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KD?%GQ$MO"?B'1-)FL[BXDU.0(LD>,)E@H^O)&1V%==32
MBLRDJ"5Y!(Z4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y'Q/\1+;PQXIT71)K.XGD
MU)@JS1XVIEMHXZGGKZ#UKKJ:45F5BH)7H2.13J "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X_7?B
M$FB>-])\.'3;B=]04-]I0X5,DCICG&,GI@'O7844 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M <CJ7Q$MM-\>V'A=K*X>>ZCWBX7&Q<@D<=2/E.3VKKJ9L4N'V@L!@-CD4^@
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M\DX#% =P]7\.?L^_"[P==F[T#X;>$-$NCC,^FZ%:V[G'3YDC![FN^50H
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M5')/8>E=?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '(>,_!-[XHU?1KRVUN?3(["7?)!$"1+\P/
M8CG@CG/7\^OKDO&/Q%L_!FK:/87-I<7$FI2;$>$#:GS*O.>IRPX%=;0(****
M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/(/4'N/?ZT =%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK]<]A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M12VT5PR&2))"AW*74':?4>E2T %5=5_Y!=Y_UQ?_ -!-6JJZK_R"[S_KB_\
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M7$V2 2"Y(&0/E5>!7C_[ /G65Y^T5I<VX?9?BQK;QHS9VI)Y17&#@9QG'N:
M/H#XT_\ )'/'?_8!O_\ TG>N,_8P_P"32_A!_P!BMI__ *(2NS^-/_)'/'?_
M & ;_P#])WKC/V,/^32_A!_V*VG_ /HA* /%/^"G5_J.E>&O@9>Z/I?]N:O;
M?$_2)K/2_M"V_P!LF5)S'#YK?+'O8!=YX7.3TKI_^&A_VG?^C1O_ #)6E_\
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M#T!(\Z_:+_;Y^"GQ6^!7Q!\">%?$FI:OXWUO1+S3;/P]%X>U$7;7+Q,OE$&
M*&4YW?-@;3R: .MUC_E%#'_V26#_ --:5V7[.O[,_P (Q\&/AGK/_"L/!_\
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M47*P6T$VT@M&C_O"O0DKZ4S]L7]DOX-:;^S%\1=6TOX:>&M"U71M O+RQO\
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M    %8?[%7P'^&OQ%TKXOZSXK^'WA?Q1JW_"RM>MA>ZUH]O>2B)9E*H&D1B
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M2-8:*[SQ@)#/$L;9YY:=,8'K\O;> OBWX=^(4]S8V,T]CK=J@DNM%U.$V][
MI. YC;[Z$\"1"R$@X8UQU87BKPC;>)XK:43S:;J]B_GZ=J]F0MS92_WT)!!!
MZ,C JZY5@02*>4^(^-I55#,HJ<'NTK27GIH_2R]0KY53DKT79_@?0=%>>_!W
MXBW/CG2+^QUF**U\5:'.MGJL,",D,C% \=Q"&R3%*A##D[6#H26C:O0J_H:A
M7IXFE&M1=XR2:?=,^7E%P;C+=!1116Y(4444 %%%% !1110 4444 %<EK7Q$
MM-$\::7X<DM+F2XOU#+,BC8N20/K]TYQTKK:8T2,ZN44NN=K$<C/7% #Z***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7):!\1+3Q!XPU;P]%9W,,^G!BTTB@(^U@IQW')X]1S76TQ8HTD>144.^-S
M<MCID]Z 'T444 %%%% !1110!Y#?_P#']<_]=&_F:KU8O_\ C^N?^NC?S-5Z
M_AC%?QZGJ_S/T6'PH]6T#_D"6/\ UQ7^5%&@?\@2Q_ZXK_*BO[5RW_<:'^"/
MY(_/ZW\27JSRFBBBOXA/T,]=T[_D'VO_ %R7^0JS5;3O^0?:_P#7)?Y"K-?W
M/A?X%/T7Y'YU/XF%%%%=) 4444 %%%% !4-W ;FTFA61X6D1D$D?#+D8R/<5
M-4-W<+:6LT[*S+$C.5098@#. .YH YOX=^"YO VC3V4^IR:H\D[3"212NT$
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M_P"%/Z;_ -![Q9_X4E[_ /':/^%/Z;_T'O%G_A27O_QV@#NZ*X3_ (4_IO\
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M@#NZ*X3_ (4_IO\ T'O%G_A27O\ \=H_X4_IO_0>\6?^%)>__': .[HKA/\
MA3^F_P#0>\6?^%)>_P#QVC_A3^F_]![Q9_X4E[_\=H [NBN$_P"%/Z;_ -![
MQ9_X4E[_ /':/^%/Z;_T'O%G_A27O_QV@#NZ*X3_ (4_IO\ T'O%G_A27O\
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M_0>\6?\ A27O_P =H_X4_IO_ $'O%G_A27O_ ,=H [NBN$_X4_IO_0>\6?\
MA27O_P =H_X4_IO_ $'O%G_A27O_ ,=H [NBN$_X4_IO_0>\6?\ A27O_P =
MH_X4_IO_ $'O%G_A27O_ ,=H [NBN$_X4_IO_0>\6?\ A27O_P =H_X4_IO_
M $'O%G_A27O_ ,=H [NBN$_X4_IO_0>\6?\ A27O_P =H_X4_IO_ $'O%G_A
M27O_ ,=H [NBN$_X4_IO_0>\6?\ A27O_P =H_X4_IO_ $'O%G_A27O_ ,=H
M [NBN$_X4_IO_0>\6?\ A27O_P =H_X4_IO_ $'O%G_A27O_ ,=H [NBN$_X
M4_IO_0>\6?\ A27O_P =H_X4_IO_ $'O%G_A27O_ ,=H [NBN$_X4_IO_0>\
M6?\ A27O_P =H_X4_IO_ $'O%G_A27O_ ,=H ZW6["75-'O;."Y>SFGA>-+B
M/[T9((##Z5E> O#5[X4\.Q:??:D^J3J[-YSYX!/"C))P/ZUS6L_#32-#TB]U
M&?7/%[PVL+S.L?B.]+$*,D >;UXK,\$>$-$\<Z"FJ6NK^,;:-G:,QS>)+S(*
M^A$O(H ];HKA/^%/Z;_T'O%G_A27O_QVC_A3^F_]![Q9_P"%)>__ !V@#NZ*
MX3_A3^F_]![Q9_X4E[_\=H_X4_IO_0>\6?\ A27O_P =H [NBN$_X4_IO_0>
M\6?^%)>__':/^%/Z;_T'O%G_ (4E[_\ ': .[HKA/^%/Z;_T'O%G_A27O_QV
MC_A3^F_]![Q9_P"%)>__ !V@#NZ*X3_A3^F_]![Q9_X4E[_\=H_X4_IO_0>\
M6?\ A27O_P =H [NBN$_X4_IO_0>\6?^%)>__':/^%/Z;_T'O%G_ (4E[_\
M': .[HKA/^%/Z;_T'O%G_A27O_QVC_A3^F_]![Q9_P"%)>__ !V@#NZ*X3_A
M3^F_]![Q9_X4E[_\=H_X4_IO_0>\6?\ A27O_P =H [NBN$_X4_IO_0>\6?^
M%)>__':/^%/Z;_T'O%G_ (4E[_\ ': .[HKA/^%/Z;_T'O%G_A27O_QVC_A3
M^F_]![Q9_P"%)>__ !V@#NZ*X3_A3^F_]![Q9_X4E[_\=H_X4_IO_0>\6?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"H9K2"XEBDEACDDA.Z-W0$H>Y![?A4U<?XM\*ZUK?B/0[[3M;?3K.SDW7%LK
M,!*-P)X'!R,C!XH ["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KE=9^(>G:)XPTWP[/#<O>7RADD1!Y:[B0,G.>JGH.*ZJH)+."6XCG>
M"-YXP0DK("R9ZX/44 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!RVH?$33--\:V?AB6.X-]=
M)N614'EKD$@$YSS@]!Z>^.IJ![*WDNDNFMXFN44JLQ0%U![ ]0.:GH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** *6L:I#HFDWFH7 <P6L33.$&6
M(4$G _"LWP7XPM/'&AIJ=E'+#$9&C,<X 8,/H2#U'2MUE#J58!@1@@\@BH[:
MUALH%AMX4@A7[L<2A5'T H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y70?B)IWB'
MQ9JOA^WAN4N]/W%Y)$ 1]K!6P<^I'7KU%=54,=G!%/).D$:32X\R14 9\=,G
MJ: )J*** "BBB@ HHHH \AO_ /C^N?\ KHW\S5>K%_\ \?US_P!=&_F:KU_#
M&*_CU/5_F?HL/A1ZMH'_ "!+'_KBO\J*- _Y EC_ -<5_E17]JY;_N-#_!'\
MD?G];^)+U9Y31117\0GZ&>NZ=_R#[7_KDO\ (59JMIW_ "#[7_KDO\A5FO[G
MPO\  I^B_(_.I_$PHHHKI("BBB@ HHHH *ANXGN+6:*.4P2.C*LJ\E"1P?PZ
MU-4-U<I9VLUQ*2(HD,C$#)P!D\4 <W\._#.J^%=&FM=7U9]8N'G:1979FV*0
M!MRQSV)_&NJKG/ _CK3_ !]IDU]I\4\4<4QA9;A0&R #G@D="*Z.@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH X_P <^&_$&O7VC2:+K1TJ&UF+W,89E\T9&/N_>Q@_*>.:["N8\7_$'2O!
M-WIMOJ/GF2_<I'Y,>X+@@%FY''S#ID^U=/0(****!A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '(>-/#6OZWK&B7.D:VVF6MK+NNH S+YJY!Z#AN 1AN.
M:Z^N8\5?$+2O!^IZ78WXG,VH/LC,,>Y4Y RQR.,D=,GVKIZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N/\7>&->UGQ%H=YI>MMIUC:2!KJV#,HE&X$\#AL@8PW KL*YCQ)
M\0=+\*ZYI6E7JW!N=1<+$T48*KE@H+'([GMF@1T]%%% PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#D/%'AG7]5\5:)?Z=K;:?IMHP-U:!F'G#=D\#ALCCYNG6NOKF/$/Q"TK
MPSXBTK1KP7!N]1(6)HXP47+;1N.<\GC@&NGH$%%%% PHHHH **** "BBB@ H
MHHH **** "BBJFH:M8Z3&)+Z]M[.,_Q7$JQC\R: +=%5-/U:QU>(R6-Y;WL8
MZO;RK(!^(/L:MT %%%% !1110 4444 %%%% !1110 4444 %<?KGA36M1\<Z
M1JUKK;VFEVJ 3V + 2'))X'!W @<],5V%<OK'Q#TS1/%VF^'9TN&O;Y0R.B
MHN20N3G/)4] :8CJ****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ./U+PUX@NO'^GZM;ZVT&B0Q;
M9=/#, YY_A^Z<YZGD8XKL*YF_P#B#I6G^,K/PS*)SJ%TF]65 8UX) )SG)P>
M@-=-3$%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6NVG9TDWL^Q"!A=S $]"?;/%=70 4444 %%%% !1110 4444 %%%% !1110
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M?\+-U+_HGGBS_OBR_P#DFN[HH X3_A9NI?\ 1//%G_?%E_\ )-'_  LW4O\
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MN".O')%>FU4NM)L;ZYM[BYL[>XN+<[H998E9XCZJ2,CH.GI0!Q__  LW4O\
MHGGBS_OBR_\ DFC_ (6;J7_1//%G_?%E_P#)-=W10!PG_"S=2_Z)YXL_[XLO
M_DFC_A9NI?\ 1//%G_?%E_\ )-=W10!PG_"S=2_Z)YXL_P"^++_Y)H_X6;J7
M_1//%G_?%E_\DUW=% '"?\+-U+_HGGBS_OBR_P#DFC_A9NI?]$\\6?\ ?%E_
M\DUW=% '"?\ "S=2_P"B>>+/^^++_P"2:/\ A9NI?]$\\6?]\67_ ,DUW=%
M'"?\+-U+_HGGBS_OBR_^2:/^%FZE_P!$\\6?]\67_P DUW=% '"?\+-U+_HG
MGBS_ +XLO_DFC_A9NI?]$\\6?]\67_R37=T4 <)_PLW4O^B>>+/^^++_ .2:
M/^%FZE_T3SQ9_P!\67_R37=T4 <)_P +-U+_ *)YXL_[XLO_ ))H_P"%FZE_
MT3SQ9_WQ9?\ R37=T4 <)_PLW4O^B>>+/^^++_Y)H_X6;J7_ $3SQ9_WQ9?_
M "37=T4 <)_PLW4O^B>>+/\ OBR_^2:/^%FZE_T3SQ9_WQ9?_)-=W10!PG_"
MS=2_Z)YXL_[XLO\ Y)H_X6;J7_1//%G_ 'Q9?_)-=W10!PG_  LW4O\ HGGB
MS_OBR_\ DFC_ (6;J7_1//%G_?%E_P#)-=W10!PG_"S=2_Z)YXL_[XLO_DFC
M_A9NI?\ 1//%G_?%E_\ )-=W10!PG_"S=2_Z)YXL_P"^++_Y)H_X6;J7_1//
M%G_?%E_\DUW=% '"?\+-U+_HGGBS_OBR_P#DFC_A9NI?]$\\6?\ ?%E_\DUW
M=% 'F5_\<K?2KV&RO_"/B2SOKC:+>UECM=\V6VC;BX(Z\<D5I?\ "S=2_P"B
M>>+/^^++_P"2:["YTFRO+JWN;BSMY[FW.89I8E9XS_LL1D?A5N@#A/\ A9NI
M?]$\\6?]\67_ ,DT?\+-U+_HGGBS_OBR_P#DFN[HH X3_A9NI?\ 1//%G_?%
ME_\ )-'_  LW4O\ HGGBS_OBR_\ DFN[HH X3_A9NI?]$\\6?]\67_R31_PL
MW4O^B>>+/^^++_Y)KNZ* .$_X6;J7_1//%G_ 'Q9?_)-'_"S=2_Z)YXL_P"^
M++_Y)KNZ* .$_P"%FZE_T3SQ9_WQ9?\ R31_PLW4O^B>>+/^^++_ .2:[NB@
M#A/^%FZE_P!$\\6?]\67_P DUY1X1O)=8\9?$?5;BTO=/N+O74!L]0\OS;=8
M["SC5,(S* =I?&X\R,>,X'TE7S[JT$7A3XX^*=,<^6/$L$/B&TWO_K7CBBL[
MI4!/'EB*T9L<9N0>I-?F_B!1J5<CFZ?V91;]+V_-H]7+)*.)5^J9N4445_*Y
M]F%%%% '(^+M5N_#_COX9ZI96]S?2QZ[-!+862QF>[ADTV\!C7S&4##B.4\C
MB$UZS_PLW4O^B>>+/^^++_Y)KSO0K1/%/QR\.6BQ+-'X8M9];GER,V\\T;VE
ML,>KQR7QSV$?O7O]?U5P!1J4LBIN:^)R:]+V_0^,S.2>)=NECA/^%FZE_P!$
M\\6?]\67_P DT?\ "S=2_P"B>>+/^^++_P"2:[NBOT8\HX3_ (6;J7_1//%G
M_?%E_P#)-'_"S=2_Z)YXL_[XLO\ Y)KNZ* .$_X6;J7_ $3SQ9_WQ9?_ "31
M_P +-U+_ *)YXL_[XLO_ ))KNZ* .$_X6;J7_1//%G_?%E_\DT?\+-U+_HGG
MBS_OBR_^2:[NB@#A/^%FZE_T3SQ9_P!\67_R31_PLW4O^B>>+/\ OBR_^2:[
MNB@#A/\ A9NI?]$\\6?]\67_ ,DUG77QQM[#48M-NO"7B.VU2;;Y-E)':^9*
M&. 5Q.5Z@]2.E>F55FTRSN+V&\EM()+N $13O&#)&#U"MC(_"@#CO^%FZE_T
M3SQ9_P!\67_R31_PLW4O^B>>+/\ OBR_^2:[NB@#A/\ A9NI?]$\\6?]\67_
M ,DT?\+-U+_HGGBS_OBR_P#DFN[HH X3_A9NI?\ 1//%G_?%E_\ )-'_  LW
M4O\ HGGBS_OBR_\ DFN[HH X3_A9NI?]$\\6?]\67_R31_PLW4O^B>>+/^^+
M+_Y)KNZ* .$_X6;J7_1//%G_ 'Q9?_)-'_"S=2_Z)YXL_P"^++_Y)KNZ* .$
M_P"%FZE_T3SQ9_WQ9?\ R31_PLW4O^B>>+/^^++_ .2:[NB@#A/^%FZE_P!$
M\\6?]\67_P DT?\ "S=2_P"B>>+/^^++_P"2:[NB@#A/^%FZE_T3SQ9_WQ9?
M_)-'_"S=2_Z)YXL_[XLO_DFN[HH X3_A9NI?]$\\6?\ ?%E_\DT?\+-U+_HG
MGBS_ +XLO_DFN[HH X3_ (6;J7_1//%G_?%E_P#)-'_"S=2_Z)YXL_[XLO\
MY)KNZ* .$_X6;J7_ $3SQ9_WQ9?_ "31_P +-U+_ *)YXL_[XLO_ ))KNZ*
M.$_X6;J7_1//%G_?%E_\DT?\+-U+_HGGBS_OBR_^2:[NB@#A/^%FZE_T3SQ9
M_P!\67_R31_PLW4O^B>>+/\ OBR_^2:[NB@#A/\ A9NI?]$\\6?]\67_ ,DT
M?\+-U+_HGGBS_OBR_P#DFN[HH X3_A9NI?\ 1//%G_?%E_\ )-'_  LW4O\
MHGGBS_OBR_\ DFN[HH \RG^.5O:ZFFES>$?$<.K28\NQ:.U\QP>A'^D;>QZF
MM+_A9NI?]$\\6?\ ?%E_\DUV$FE64VH17TEG;O?1+LCN6B4RHO.0&QD#D]/6
MK= '"?\ "S=2_P"B>>+/^^++_P"2:/\ A9NI?]$\\6?]\67_ ,DUW=% '"?\
M+-U+_HGGBS_OBR_^2:/^%FZE_P!$\\6?]\67_P DUW=% '"?\+-U+_HGGBS_
M +XLO_DFC_A9NI?]$\\6?]\67_R37=T4 <)_PLW4O^B>>+/^^++_ .2:/^%F
MZE_T3SQ9_P!\67_R37=T4 <)_P +-U+_ *)YXL_[XLO_ ))H_P"%FZE_T3SQ
M9_WQ9?\ R37=T4 <)_PLW4O^B>>+/^^++_Y)H_X6;J7_ $3SQ9_WQ9?_ "37
M=T4 <)_PLW4O^B>>+/\ OBR_^2:/^%FZE_T3SQ9_WQ9?_)-=W10!PG_"S=2_
MZ)YXL_[XLO\ Y)H_X6;J7_1//%G_ 'Q9?_)-=W10!PG_  LW4O\ HGGBS_OB
MR_\ DFC_ (6;J7_1//%G_?%E_P#)-=W10!PG_"S=2_Z)YXL_[XLO_DFC_A9N
MI?\ 1//%G_?%E_\ )-=W10!PG_"S=2_Z)YXL_P"^++_Y)H_X6;J7_1//%G_?
M%E_\DUW=% '"?\+-U+_HGGBS_OBR_P#DFC_A9NI?]$\\6?\ ?%E_\DUW=% '
M"?\ "S=2_P"B>>+/^^++_P"2:/\ A9NI?]$\\6?]\67_ ,DUW=% '"?\+-U+
M_HGGBS_OBR_^2:/^%FZE_P!$\\6?]\67_P DUW=% '"?\+-U+_HGGBS_ +XL
MO_DFC_A9NI?]$\\6?]\67_R37=T4 <)_PLW4O^B>>+/^^++_ .2:/^%FZE_T
M3SQ9_P!\67_R37=T4 <)_P +-U+_ *)YXL_[XLO_ ))H_P"%FZE_T3SQ9_WQ
M9?\ R37=T4 <)_PLW4O^B>>+/^^++_Y)H_X6;J7_ $3SQ9_WQ9?_ "37=T4
M<)_PLW4O^B>>+/\ OBR_^2:/^%FZE_T3SQ9_WQ9?_)-=W10!Y]=_%BZT^UEN
M;OP%XJM[:%2\LSI9[44<DG%R3@>U1:9\9?[=MS<Z5X,\3:G:!B@N+>.T"$CJ
M/FN >_I7H<D:2QM&ZAT8%65AD$'J"*BL;"UTRV2VL[:&TMT^[#!&$1?H!Q0!
MQG_"S=2_Z)YXL_[XLO\ Y)H_X6;J7_1//%G_ 'Q9?_)-=W10!PG_  LW4O\
MHGGBS_OBR_\ DFC_ (6;J7_1//%G_?%E_P#)-=W10!PG_"S=2_Z)YXL_[XLO
M_DFC_A9NI?\ 1//%G_?%E_\ )-=W10!PG_"S=2_Z)YXL_P"^++_Y)H_X6;J7
M_1//%G_?%E_\DUW=% '"?\+-U+_HGGBS_OBR_P#DFC_A9NI?]$\\6?\ ?%E_
M\DUW=% '"?\ "S=2_P"B>>+/^^++_P"2:/\ A9NI?]$\\6?]\67_ ,DUW=%
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M9\80:_<7>G7-O+I'B*PP+_1KS GMB>C#L\;$';*N58#@\$#H*ZCQM\-/#WQ
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M\=:5K?B?4M$M7D-]8JQE#)A3M8*V#WP2!5QJ.3M8B5-15[G74445L9!1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *J7>D65_<V]Q<V<$\]LVZ&22,,T9]5)Z5;KE?%.D>([_Q!HMQ
MI&I1VFG02 W<+$@N-PSV.[*Y&#C!_1K<E['54444B@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"I=:197MW;W5Q9P37-N2899(PSQG_9)Y%6ZY3Q)I'B2]\3:-<Z7J4=KI<#
MW<#$@R#=SQCYLKQR1BNKIL2"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "JL^E65S>PWDUI!+=P B*=
MXP70'KM;J/P]:M5RFM:+XBN_&>E7MCJB6^BPJ!<VA)!<Y.>,8;((')XQ31+.
MKHHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS^U3^SEXG_9A\6:)X=U?P_XKU_7[46FE:=HUL'N%N"ZM'*P"@Q;" _S8)*X
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M])L/@I'X?URQM]6M+"ZEU=;Q;:9%E2-W *"78P!(!7=SC%>D_!;]HO5O&7Q
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MUV&GW(?BSXPU[P+X'O=6\,>$+WQUKJM'%::)97$=NTTCN%!>60XCC7.6;!P
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M*1D$<@BO)_A5X=DTCXK_ !3O'^*LWC7[;>VTG_"*O/&X\,CROEBV!V9/,'S
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M2R@>^B7;'<M&#(@YX#=1U/YFKE-VZ"5^H4444AA1110 4444 %%%% !1110
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MEO:M+(PCC3YF9N   <DU$_A9</B1QW@&W\26^CRKXFFCGO3,QC,>W(3 QG:
M.N?PKIJRO#WB?3/%5F]UI5T+N!',;,%92&P#C# 'H16K7&]]3KCMH9GBCQ'I
M_@[PWJNO:M<)::7I=K+>W<[D 1Q1H7=B3Z!2:^)/@+^R9??&WP8_Q=UKXJ_$
M_P #:_\ $&YE\07&F^$/$:V%JL$KM]D4J(269;?R1DD^@X%?<.MZ'IWB72+O
M2M7T^UU72[R,PW-E?0+-!.AX*.C JRGN",58M+2"PM(;6UACMK:%!'%#"H1(
MT48"J!P    !33LM :ON?!W[2/[$FH^"?A;J/C[P_P#%[XI^,/%7@AD\2:38
M>+?$']I6GFV["1SY0B5MQC$@!5@><'()%>Z_''QYIWQ1_84\=^+])8MIVM^!
M+V_ASP562S=MI]P201Z@U[]/!'<PR0S1K+%(I1XW&593P01W%8EGX!\,:?X/
M;PG:^'-)MO"S026QT.&QB2Q,+YWQF +LVMN;*XP<G/6CFON+EML>?_LPZ;::
MS^R5\*;"^MX[NQNO!>EP3V\RADDC:RC#*P/4$$@BO*?@)?W'[+_QJF^ .L7=
MQ<>#M8BFU?X?7][,',<*G-QI98_,S1$ETSD["<GH*^JM)TFQT'2[/3-,LK?3
MM-LH4M[6SM(EBA@B10J(B* %50  H&   *J:SX3T3Q'>Z7>:KHVGZG=Z7/\
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M_8U^ ?BKQ/X6\):'H,%OM>WTO2[2'3[:ZOI62&(R>6JJ,DIN<]%3K@5Y_P#
M'QK\$OA;::AX@\0_'#P'XF^)7B';-K_B*?Q+8[I&ZBWA'F_N[>/HJ#CC)YZ?
M2_BOP;H'CS19='\3:'IOB'2)65Y+#5;2.ZMW*D%28Y 5)! (R."*X7_AE3X)
M_P#1'O /_A,67_QJG=6U%9WT.Z\*>,M \>:+%K'AG7--\0Z1*S)'?Z5=QW5N
MY4D,!)&2I(((.#P17G=C^UW\$;\3;?BSX.MGAE:&2*^UJWM9%=3AALE=6Z]\
M8KT3PIX-T#P'HL6C^&=#TWP]I$3,\=AI5I':VZ%B2Q$<8"@DDDX')-<YXI^
MOPS\=:HVI^)/AUX3\0ZFR[#>ZKH=K<S$9+8WNA.,LQZ]2:6@]3YX^%&O:7\:
M?VZ];^(GP]!N_!&F>#UT35O$5LKK::M?M<^9''$2 LIB1>77..%Z;<]AXW_8
M>TGQA\2O$OC>S^+'Q5\'ZIXADADO;?PMXC2QMF\J,1QJ%$))"J#@,QQN.,9K
MZ+L;"VTRTCM;.WAM+:,82&! B*,YX X'4U/1S=A*/<_.;Q[^R-_9?[77PK\+
M?\+H^+UY_:NBZO<_VU=>*M^I6?E"/]W;S>5^[1]WSC!W8'2OT3LK;['9P6_F
MRS^5&L?FS-N=\#&YCW)ZDU1NO"VC7VOV.NW.DV%QK=C%)#::E+;(US;I)CS$
MCD(W(K8&0" <#-:E#=QI6"BBBI*"BBB@ HHHH **** .5\::=XFOKW26T"_B
MM((Y2;I9/XAE<=CD8W<<=?RZJL/Q'XSTGPK/8PZE<&&2\<I$ A;I@$G'0<C\
MZW*IWLB5:["F7%Q':02SS.L4,2EW=C@*H&22?I3Z*DH^%_@U^R[\-OVS+7Q/
M\:OB?X7GU^?Q7K=Q)H(FO[VS-MI$&+>V79'*GWA"TF2.=XQ[]9XQ_P""6O[/
MFI>$M:M-"\#-I&M3V<T=C?IK5_(;><H1')MDG9&VM@X8$'N*^O**OF?1D<JZ
MGR%\/M6US]J'_@GEK6@"-CXZ30;WPO?VMTP5_P"T[5#$5<CA6<JC>WF5!\#_
M -O?X8V'@;P9X(\0RZ[I'Q,LM.M--O/"+>'K][U+B.%%< "';MP"^21A>3BO
ML2BE=!9]SY>^/WAW6OA-^T/X4^/6A^'=0\4Z5%HTWA;Q38Z1&9KR"Q:43Q7<
M40YD$<@.]5&[;CT)&)XT_;F\*_%WPGJ_@_X(QZMXZ^(>J6\FG0VL>C75M!I4
MLBLGG7DLT:)&B?,3@G)0BOKRBB_<+=CY7^+7PN3X*?\ !./Q3X&6X2[?0_!<
M]I+<1KM6:41$RN!DX#.6./>N;^#_ .WS\)O 7PB\ ^'O&,_B+PEXCM]%L[.'
M2=3\.WK37ICA2-7MVBC>.5),*48/R'7IFO?/VH?!FL_$7]GCXA^&/#UG_:&N
M:MHMS:6=KYJ1>;*R$*N]RJKD]V('O70?!O0+_P *?"'P/HFJ0?9=3TW0K&SN
MH-ZOY<T=NB.NY20<,",@D''!IW5M0L[Z'BO[-OAWQ%X^^-7Q ^./B+0[KPS8
M:]96FB>&M*U.#RKY=.AR[3SKDE#+(P8(<$ <CH:K?LS?\G9_M4_]A70__2 U
M]1T4KCL?&.B^,(OV&OBQ\3+?Q?H>L)\+/&6LR^++'Q9IEC+>VVGW4RH+JWNE
MB5GCY4,K8P5!P.#CW+X+?M4_#G]H?4KZU^'^JWNOP64/F3Z@=)NK:U5@R@Q"
M2:- 9 '5MHSPP->N44-I@DT%%%%24%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!ROB_3?$M[JNCR:)J$=I9Q2YNXWZLN0?0
MYX!&..OY=56#XC\<:/X5N[*VU.Y,$MV2(\(6 &0,L1T&2*Q?^%Y?#[_H<='_
M / M?\:IWLM"5:[U.XHKA_\ A>7P^_Z''1__  +7_&C_ (7E\/O^AQT?_P "
MU_QI68[H[BBN'_X7E\/O^AQT?_P+7_&C_A>7P^_Z''1__ M?\:+,+H[BBN'_
M .%Y?#[_ *''1_\ P+7_ !H_X7E\/O\ H<='_P# M?\ &BS"Z.XHKA_^%Y?#
M[_H<='_\"U_QH_X7E\/O^AQT?_P+7_&BS"Z.XHKA_P#A>7P^_P"AQT?_ ,"U
M_P :/^%Y?#[_ *''1_\ P+7_ !HLPNCN**X?_A>7P^_Z''1__ M?\:/^%Y?#
M[_H<='_\"U_QHLPNB7XM>-;GP-X.DN=-BCN-=OIH].TN"7E&NI3M5F&1E$&Z
M1P#G9&V.:X?PAX5@\(Z0+2.:6]NI7:XO=0N<&>]N&YDFD(ZLQ[#@ !0 J@#.
M\8>/=%^(/Q=\%Z?HFHV6M6&FZ=J>JSRVTZR&WN0;:W@XZ_-'<7?(Z8([UUE?
MSWXB9E5J8R&7IVA!)M=Y/OZ+;U9]#EU)*#J=6%%%%?D1[ 5RNFW[?"[XD6-]
M &3PSXJNUL=3A&!':Z@XQ;W0R1M\U@MNX .YY(#@8<GJJX_XQ6LMU\*_%AMY
M%@O(--GNK6=TWB*XB0RPR;<C.V1$;&1TZBOH^'\RJ95F5*O!Z72DN\6[/_->
M=CFQ-)5:3BSZ HK@;7X\> +FUAE;Q=I$;2(&*&[4[<C.*F_X7E\/O^AQT?\
M\"U_QK^OK,^/NCN**X?_ (7E\/O^AQT?_P "U_QH_P"%Y?#[_H<='_\  M?\
M:+,+H[BBN'_X7E\/O^AQT?\ \"U_QH_X7E\/O^AQT?\ \"U_QHLPNCN**X?_
M (7E\/O^AQT?_P "U_QH_P"%Y?#[_H<='_\  M?\:+,+H[BBN'_X7E\/O^AQ
MT?\ \"U_QH_X7E\/O^AQT?\ \"U_QHLPNCN**X?_ (7E\/O^AQT?_P "U_QH
M_P"%Y?#[_H<='_\  M?\:+,+H[BN5\4Z;XEO-?T:;1[^*VTV*0&\B?@N-PSV
M.<C(QQ_A1_X7E\/O^AQT?_P+7_&FM\;_  03&8?$%K=Q,2&FMF\R.+'=V'"T
MU>^B)E:VK.ZHKA_^%Y?#[_H<='_\"U_QH_X7E\/O^AQT?_P+7_&E9E71W%%<
M/_PO+X??]#CH_P#X%K_C1_PO+X??]#CH_P#X%K_C19A='<45P_\ PO+X??\
M0XZ/_P"!:_XT?\+R^'W_ $..C_\ @6O^-%F%T=Q17#_\+R^'W_0XZ/\ ^!:_
MXT?\+R^'W_0XZ/\ ^!:_XT6871W%%</_ ,+R^'W_ $..C_\ @6O^-'_"\OA]
M_P!#CH__ (%K_C19A='<45P__"\OA]_T..C_ /@6O^-'_"\OA]_T..C_ /@6
MO^-%F%T=Q17#_P#"\OA]_P!#CH__ (%K_C1_PO+X??\ 0XZ/_P"!:_XT6871
MW%%</_PO+X??]#CH_P#X%K_C1_PO+X??]#CH_P#X%K_C19A='<45P_\ PO+X
M??\ 0XZ/_P"!:_XT?\+R^'W_ $..C_\ @6O^-%F%T=Q17#_\+R^'W_0XZ/\
M^!:_XT?\+R^'W_0XZ/\ ^!:_XT6871W%%</_ ,+R^'W_ $..C_\ @6O^-'_"
M\OA]_P!#CH__ (%K_C19A='<45P__"\OA]_T..C_ /@6O^-'_"\OA]_T..C_
M /@6O^-%F%T=Q17#_P#"\OA]_P!#CH__ (%K_C1_PO+X??\ 0XZ/_P"!:_XT
M6871W%%</_PO+X??]#CH_P#X%K_C1_PO+X??]#CH_P#X%K_C19A='<45P_\
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M#[_H<='_ / M?\:/^%Y?#[_H<='_ / M?\:+,+H[BBN'_P"%Y?#[_H<='_\
M M?\:/\ A>7P^_Z''1__  +7_&BS"Z.XHKA_^%Y?#[_H<='_ / M?\:/^%Y?
M#[_H<='_ / M?\:+,+H[BBN'_P"%Y?#[_H<='_\  M?\:/\ A>7P^_Z''1__
M  +7_&BS"Z.XHKA_^%Y?#[_H<='_ / M?\:/^%Y?#[_H<='_ / M?\:+,+H[
MBBN'_P"%Y?#[_H<='_\  M?\:/\ A>7P^_Z''1__  +7_&BS"Z.XHKA_^%Y?
M#[_H<='_ / M?\:/^%Y?#[_H<='_ / M?\:+,+H[BBN'_P"%Y?#[_H<='_\
M M?\:/\ A>7P^_Z''1__  +7_&BS"Z.XHKA_^%Y?#[_H<='_ / M?\:/^%Y?
M#[_H<='_ / M?\:+,+H[BBN'_P"%Y?#[_H<='_\  M?\:/\ A>7P^_Z''1__
M  +7_&BS"Z.XHKA_^%Y?#[_H<='_ / M?\:/^%Y?#[_H<='_ / M?\:+,+H[
MBBN'_P"%Y?#[_H<='_\  M?\:/\ A>7P^_Z''1__  +7_&BS"Z.XHKA_^%Y?
M#[_H<='_ / M?\:/^%Y?#[_H<='_ / M?\:+,+H[BBN'_P"%Y?#[_H<='_\
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M<45P_P#PO+X??]#CH_\ X%K_ (T?\+R^'W_0XZ/_ .!:_P"-%F%T=Q17#_\
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M?\@^U_ZY+_(59JMIW_(/M?\ KDO\A5FO[GPO\"GZ+\C\ZG\3"N+^+WQ>\+_
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MQ+8^)[CQ-HTVD7L-OI,;#[9%)C+#=\W&.<KP,$<^G6NKILE=0HHHI%!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 51N=#T^\U*WOY[*&6]MQB*X= 73Z'\3^=7JY76;#Q//XTTJXL+V*+08U
MQ=0-]YCDYXQSD;0.>/YM$LZJBBBD4%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0ET'3I]5AU*2RA>_
MA79'<L@+J.> ?Q/YFK]<IJ%AXGD\=6%S:WL2>'5CQ/;G&XGYL\8R3]W!S_\
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MQ%IWB2T>YTR[CNX$<QLZ C# 9QS]16C65X>\,:9X4LGM-+MA:PNYD9=[-EB
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M?#QGXKM-'FTW3]0MFA A@D,D:>?+YJC!VY&WK@<?=%%%)NX)6"BBBD4%%%%
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M9<>)95D\?ZQ'K]F&W#P_86YMM./H)P69[C'H[",]X\XKUM$6)%1%"(H "J,
M =A2T5]3@\#ALOI*CA::A'LOU[OS9RSG*H^:3NPHHHKN("BBB@ HHHH ****
M "BBB@ HHHH *Q-9\8Z3X?U.PT^^N?*NKU@L*!"V<G R0.!GCFMNL_4/#^FZ
MK>6MU>64-Q<6K;H9)$R4.0>/Q --6ZB=^AH4444AA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&+J_C'2="UBPTR]N?*O+T@0IL)!R<#)Q@9/%;59][X?T[4K^UO;JRAGN[4YA
MF=,LASG@_7FM"F[=!*_4****0PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Q-0\9:3I>OV>C7%SLU"[&8HP
MA/4D#)'3)!Q]*VZH76@:=>ZI;ZC/90RWUN,13NH+(.3P?Q/YTU;J)WZ%^BBB
MD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#$NO&6DV7B.WT*:ZVZE.NY(MC$=\ G& 3@_E]*VZH3^'
M]-N=6AU.6RADU"%=L=RR NHYZ'\3^=7Z;MT$K]0HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *^H7\&EV-Q>7,GE6\"-)(Y&<*!DG'>JGAWQ)8>*M
M-6_TV8S6Y8IEE*D,.H(/X5?N;>*\@D@GC66&12CQN,A@>H(]*@TK2;/1+-+6
MPMH[2V4DB.-<#)ZFGI8G6Y;HHHI%!1110 4444 %%%% !1110 4444 %%%%
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MS.3G(9>-IZKM7'2@#Z_^'^I>&]9\%Z/J7A V3>&;ZW6[L&TZ-8X'BD^<,J@
M#.XD\=2<\UT-?(O_  2IU*YU']B;P8+F9YOL]S?P1%V+%8Q=RD+SV&2 .PKZ
MZH *HZP9EL)#;JK3@'RU<X4M@XS[9Q5ZJNH,J0;F(50<DG@ 8J)_"RX?$CC?
M -QXDN-'E;Q-#'!>B9A&(]N2F!C.TD=<_A7352TG6K#7;8W&GW<5Y &*&2%]
MP##J/U'YU=KC>YV+8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ=U#)H3J?LD2 ;E.X;>V>%R#D\DUT=4-!\6Z3JVNW^DVMVLM_9J?.A"D;<$
M\D8."0#CI6M.]S*I;E.EHHHKK.0**** "BBB@#R&_P#^/ZY_ZZ-_,U7JQ?\
M_']<_P#71OYFJ]?PQBOX]3U?YGZ+#X4>K:!_R!+'_KBO\J*- _Y EC_UQ7^5
M%?VKEO\ N-#_  1_)'Y_6_B2]6>4T445_$)^AGKNG?\ (/M?^N2_R%6:K:=_
MR#[7_KDO\A5FO[GPO\"GZ+\C\ZG\3"J6LZ5;Z[I%]IMVN^UO()+>91W1U*L.
M?8FKM%=)!\4?\.A/V>O^?#Q#_P"#=O\ XFC_ (="?L]?\^'B'_P;M_\ $U]K
MT4 <%\$/@IX9_9\^'=CX)\(Q7,.AV<DLL2W<QFDW2.7;+$#/+&N]HHH *CFA
MCN87BE0/&ZE65NA!X(J2B@#%\,>$-)\'V#V>E6HMX'D,K NSDL<#JQ)Z "MC
M8O\ ='Y4ZB@!NQ?[H_*C8O\ ='Y4ZBE8=QNQ?[H_*C8O]T?E3J*+!<;L7^Z/
MRHV+_='Y4ZBBP7&[%_NC\J-B_P!T?E3J*+!<;L7^Z/RHV+_='Y4ZBBP7&[%_
MNC\J-B_W1^5.HHL%QNQ?[H_*C8O]T?E3J*+!<;L7^Z/RHV+_ '1^5.HHL%QN
MQ?[H_*C8O]T?E3J*+!<;L7^Z/RHV+_='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%Q
MNQ?[H_*C8O\ ='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%S+U7PUI>N2VDNH6$-W)
M:OYD+2+DHW'3\AQ["M+8O]T?E3J*8ANQ?[H_*C8O]T?E3J*5AW&[%_NC\J-B
M_P!T?E3J*+!<;L7^Z/RHV+_='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%QNQ?[H_*
MC8O]T?E3J*+!<;L7^Z/RHV+_ '1^5.HHL%QNQ?[H_*C8O]T?E3J*+!<;L7^Z
M/RHV+_='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%QNQ?[H_*C8O\ ='Y4ZBBP7&[%
M_NC\J-B_W1^5.HHL%QNQ?[H_*C8O]T?E3J*+!<;L7^Z/RHV+_='Y4ZBBP7&[
M%_NC\J-B_P!T?E3J*+!<;L7^Z/RHV+_='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%
MQNQ?[H_*C8O]T?E3J*+!<;L7^Z/RHV+_ '1^5.HHL%QNQ?[H_*C8O]T?E3J*
M+!<S-3\-Z7K5S9W%]8PW4UH_F0/(N3&W'(_(?D*T=B_W1^5.HIB&[%_NC\J-
MB_W1^5.HI6'<;L7^Z/RHV+_='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%QNQ?[H_*
MC8O]T?E3J*+!<;L7^Z/RHV+_ '1^5.HHL%QNQ?[H_*C8O]T?E3J*+!<;L7^Z
M/RHV+_='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%QNQ?[H_*C8O\ ='Y4ZBBP7&[%
M_NC\J-B_W1^5.HHL%QNQ?[H_*C8O]T?E3J*+!<;L7^Z/RHV+_='Y4ZBBP7&[
M%_NC\J-B_P!T?E3J*+!<;L7^Z/RHV+_='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%
MQNQ?[H_*L[4?#>EZO>V=W>6$%S<V;;X))%R8SUR/Q /U&:TZ*8ANQ?[H_*C8
MO]T?E3J*5AW&[%_NC\J-B_W1^5.HHL%QNQ?[H_*C8O\ ='Y4ZBBP7&[%_NC\
MJ-B_W1^5.HHL%QNQ?[H_*C8O]T?E3J*+!<;L7^Z/RHV+_='Y4ZBBP7&[%_NC
M\J-B_P!T?E3J*+!<;L7^Z/RHV+_='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%QNQ?
M[H_*C8O]T?E3J*+!<;L7^Z/RHV+_ '1^5.HHL%QNQ?[H_*C8O]T?E3J*+!<;
ML7^Z/RHV+_='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%QNQ?[H_*C8O\ ='Y4ZBBP
M7&[%_NC\J-B_W1^5.HHL%S,O_#6EZGJ%I?7=C#/>6AW03.OS(>O'X\UH[%_N
MC\J=13$-V+_='Y4;%_NC\J=12L.XW8O]T?E1L7^Z/RIU%%@N-V+_ '1^5&Q?
M[H_*G446"XW8O]T?E1L7^Z/RIU%%@N-V+_='Y4;%_NC\J=118+C=B_W1^5&Q
M?[H_*G446"XW8O\ ='Y4;%_NC\J=118+C=B_W1^5&Q?[H_*G446"XW8O]T?E
M1L7^Z/RIU%%@N-V+_='Y4;%_NC\J=118+C=B_P!T?E1L7^Z/RIU%%@N-V+_=
M'Y4;%_NC\J=118+C=B_W1^5&Q?[H_*G446"XW8O]T?E1L7^Z/RIU%%@N-V+_
M '1^59UWX;TN^U:VU.XL89K^V&V&=ERR#GI^9_.M.BF(;L7^Z/RHV+_='Y4Z
MBE8=QNQ?[H_*C8O]T?E3J*+!<;L7^Z/RHV+_ '1^5.HHL%QNQ?[H_*C8O]T?
ME3J*+!<;L7^Z/RHV+_='Y4ZBBP7&[%_NC\J-B_W1^5.HHL%QNQ?[H_*C8O\
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M=:^/+:"VAB-M*2B*I((["I?^%A6O_/K-^8K^ML/Q?D4*,(RQ*NDNC[>A\3/
MXER;4/R.LHKD_P#A85K_ ,^LWYBC_A85K_SZS?F*W_UQR'_H*7W2_P B/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R
M#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)
M_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.L
MHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_
M .%A6O\ SZS?F*/^%A6O_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K
M_P ^LWYBC_A85K_SZS?F*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWY
MBC_A85K_ ,^LWYBC_7'(?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%
MA6O_ #ZS?F*/]<<A_P"@I?=+_(/J&)_D_(ZRBN3_ .%A6O\ SZS?F*/^%A6O
M_/K-^8H_UQR'_H*7W2_R#ZAB?Y/R.LHKD_\ A85K_P ^LWYBC_A85K_SZS?F
M*/\ 7'(?^@I?=+_(/J&)_D_(ZRBN3_X6%:_\^LWYBC_A85K_ ,^LWYBC_7'(
M?^@I?=+_ "#ZAB?Y/R.LHKD_^%A6O_/K-^8H_P"%A6O_ #ZS?F*/]<<A_P"@
MI?=+_(/J&)_D_(XV_P#^/ZY_ZZ-_,U7J2YE$UQ+(!@.Y8 ^YS4=?R3B)*=:<
MH[-O\S[>.D4CU;0/^0)8_P#7%?Y44:!_R!+'_KBO\J*_M?+?]QH?X(_DC\^K
M?Q)>K/*:***_B$_0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ]6T#_D"6/_ %Q7^5%&@?\ ($L?^N*_RHK^WLM_W&A_@C^2/SRM
&_$EZL__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>arqt-20251231_g2.jpg
<TEXT>
begin 644 arqt-20251231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (G!.\# 2(  A$! Q$!_\0
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MNON.!_X0'4/^>UM_WTW_ ,31_P (#J'_ #VMO^^F_P#B:[ZBC_B$G#'\D_\
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M\]K;_OIO_B:[ZBC_ (A)PQ_)/_P-A_:>([K[C@?^$!U#_GM;?]]-_P#$T?\
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M\(#J'_/:V_[Z;_XFN^HH_P"(2<,?R3_\#8?VGB.Z^XX'_A =0_Y[6W_?3?\
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M,?R3_P# V']IXCNON.!_X0'4/^>UM_WTW_Q-'_" ZA_SVMO^^F_^)KOJ*/\
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M%^(OB[XG^!3K/C7X>W7PSUD7<D T2\OEO',:A2LN\(G#9(QMXVT >C45Y/\
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M2;PMHWQ#^+/A;Q#X8O;.Y\%ZG%I&F6^E7/V^_P#$5R[RH([>U$:%6_=9^^P
M/)'&<;Q)_P %!OB9X%M9==\4_LL>--&\%P@23:N+Y99X(N,O) (0(\<_>D '
M&2* /MZBOGV]_;G^%4?P0TGXFZ?J=UK>GZQ-]BTS1-.M_-U6\ON,V:6X.?.&
M1D$[0"#N(92?(O$__!0?XG>";277O$'[*WC73/!<(,LVK/>AKB"$<EY;<0?N
M\#KN< =S0!]OT5Y[\"OCOX/_ &C/AY9^,O!6H&]TN=C%+#,H2XM)@ 6AF0$[
M7&0<9(((()!!/H5 !7Q/\0/VP_B3\8?BKK7PQ_9G\.:9K5QH4A@USQQKS-_9
MEE*"08XP/OD,I&[YMV&VH5&^OJGXQ:W=^&OA'XWU?3Y3!?Z?H=]=V\HZI(EN
M[*?P(%?-W_!*#POI^A_L4^$M2M($CO-<O-0OKZ4 ;I95O);=23WQ'!&.?2@#
M*D^$?[;^FQ_VC;_'7P7K%XOSG1KSP_%#:,>I03);^9CL#Q[XKH_V;_VR?$'B
M7XI77P:^-7A6'P#\6;>$W%HMM)NL-9A )+VY+-@[59L!F!"/R"I4?65?*?[9
M?[//BOXJ?$WX%>-/ ^GPRZSX/\2Q7.H7C7,<#I8&2)Y!\Q'F#]V?E&?O,,?,
M: /JRBBOASX:_P#!4WPYX\^$B^)9/ FJMXQOM=GT/1O V@7/]IW^HF*""5IP
M1%'LC'G@$E3C:<;N0 #[CHKYS^!/[27Q-^)WQ!?P]XR^ &O_  UTYK26[AUN
M\U%;NW;8R@1OB% CMO&%W$G#'HI->C?'C]H'P1^S=X&E\5>.=6&G6 ?R;>")
M?,N+N4C(BAC'+-QGL ,DD 9H ]&HKXFM_P!O?XL^(+--:\,_LG^-=5\+2+YD
M5]=7XMKJ6/\ O);>0Y8$8(VL0>Q[U[+^S7^V%X'_ &F1J=AHZ:AX>\6Z02NJ
M>%M>A^SW]H0VTG;DAE#<$CE<@,%) H ]THKPG]KO]IY_V4?!&@^+)_"S>)=&
MO-9ATO4)4OOLS6$<BLPGQY3^8!L(V_+R0,\U[G%*D\22Q.LD;J&5T.0P/0@]
MQ0 ^BOF/]I7]N31/V;_C9\-?A[?Z%_:C>+94^V:@+\0?V5#).L,<QC,;>8I;
MS"?F3 C/7M].4 %<7\9/B[X=^!'PWUCQSXLFGM_#^E>3]IDMH3-(/-F2%,(.
M3EY%'XYKSWQ1^U -&_:T\)? [3/#)U>[U;29=9U+6?MWE)I<*B79F+RV\PL8
M@/O+CS$KYE_X*E?&3XAK\(OB3X!'P?OSX!9=,)^(?]JI]G'^DVLW_'MY6?\
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M_;/PK^"G@#6)/#6L_$K4I+2\UV E9;.SC,8DV$$$%O,))4@XC*@C=71?#O\
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M 7]E#PWIGC']B?X9Z%K-G%J.DZEX/M+2[M)UW)-$]N%92/0@FO /V.]?U/\
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MX*6_LT_"KX+_  I\ :OX(\%:1X9UFY\;V%I)<V,9622 P7+,G)^[N2,GW H
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MW564*/8"OTEKX*_9ZU>WUO\ X*L_M&7%LP>--"L[8D'/SQ1V,3C\&1A7WK0
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MR1EE/*G:PR#TK9HH ^%_^"=?_)>/VOO^R@W'_I5>U]T5\+_\$Z_^2\?M??\
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MGQ;_ .28G_CA^9ZV6?[PO1FSX!_Y \W_ %W;_P!!6NEKFO /_('F_P"N[?\
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MX(\+>"=4\&?#76[?X@?%#Q!!)IFD:9X9D%]Y$TH*>8[Q;E!3<6"9+$@# &2
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M#^J=% !7Q#_P2,^'7BKX9?LW>)-+\7^&M7\+:E-XMN;F.SUJQEM)GB-G9J)
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M>,_VBOV(=%A^'WB/X7ZG\;? 6E PZ%XD\(DR7L=L#^[AEMP&?"C  (&T<!G
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MXPO+TZC-J%_<3W*FY+;O-6&21HE;=R-J#! QC KVZB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P/C[_D,0
M_P#7!?\ T)J[ZN!\??\ (8A_ZX+_ .A-7XSXM_\ ),3_ ,</S/6RS_>%Z,V?
M /\ R!YO^N[?^@K72US7@'_D#S?]=V_]!6NEKZG@+_DF,#_@7YLYL;_O$_4*
M***^].(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N!\??\
M(8A_ZX+_ .A-7?5P/C[_ )#$/_7!?_0FK\9\6_\ DF)_XX?F>MEG^\+T9L^
M?^0/-_UW;_T%:Z6N:\ _\@>;_KNW_H*UTM?4\!?\DQ@?\"_-G-C?]XGZA111
M7WIQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?"<G^L;ZFONROB?Q1X:U#PIJ\UAJ,/DSH<@CE7'8J>XJHD2/6/
M@W\9#9F'0M=FS <);7;G[GHK'T]#7OX(8 @Y!Z$5\)5[=\&_C(;-H="UZ<FW
M.$MKMS]P]D8^GH:;0)GT!12 A@"#D'D$4M06%%%% !1110 5P/C[_D,0_P#7
M!?\ T)J[ZN!\??\ (8A_ZX+_ .A-7XSXM_\ ),3_ ,</S/6RS_>%Z,V? /\
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MR^YG:T5Q7_"Y?!W_ $&/_)6;_P"(H_X7+X._Z#'_ )*S?_$4?V[E/_073_\
M X_YA]3Q/_/N7W,[6BN*_P"%R^#O^@Q_Y*S?_$4?\+E\'?\ 08_\E9O_ (BC
M^W<I_P"@NG_X''_,/J>)_P"?<ON9VM%<5_PN7P=_T&/_ "5F_P#B*/\ A<O@
M[_H,?^2LW_Q%']NY3_T%T_\ P./^8?4\3_S[E]S.UHKBO^%R^#O^@Q_Y*S?_
M !%'_"Y?!W_08_\ )6;_ .(H_MW*?^@NG_X''_,/J>)_Y]R^YG:T5Q7_  N7
MP=_T&/\ R5F_^(H_X7+X._Z#'_DK-_\ $4?V[E/_ $%T_P#P./\ F'U/$_\
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M<ON9VM%<5_PN7P=_T&/_ "5F_P#B*/\ A<O@[_H,?^2LW_Q%']NY3_T%T_\
MP./^8?4\3_S[E]S.UHKBO^%R^#O^@Q_Y*S?_ !%'_"Y?!W_08_\ )6;_ .(H
M_MW*?^@NG_X''_,/J>)_Y]R^YG:T5Q7_  N7P=_T&/\ R5F_^(H_X7+X._Z#
M'_DK-_\ $4?V[E/_ $%T_P#P./\ F'U/$_\ /N7W,[6BN*_X7+X._P"@Q_Y*
MS?\ Q%'_  N7P=_T&/\ R5F_^(H_MW*?^@NG_P"!Q_S#ZGB?^?<ON9VM%<5_
MPN7P=_T&/_)6;_XBC_A<O@[_ *#'_DK-_P#$4?V[E/\ T%T__ X_YA]3Q/\
MS[E]S.UHKBO^%R^#O^@Q_P"2LW_Q%!^,W@X?\QC_ ,EIO_B*/[=RG_H+I_\
M@<?\P^IXG_GW+[F=K17%#XS>#CTUC/\ V[3?_$4?\+E\'?\ 08_\E9O_ (BC
M^W<I?_,73_\  X_YA]3Q/_/N7W,[6BN*_P"%R^#O^@Q_Y*S?_$4?\+E\'?\
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MR^YG:T5Q7_"Y?!W_ $&/_)6;_P"(H_X7+X._Z#'_ )*S?_$4?V[E/_073_\
M X_YA]3Q/_/N7W,[6BN*_P"%R^#O^@Q_Y*S?_$4?\+E\'?\ 08_\E9O_ (BC
M^W<I_P"@NG_X''_,/J>)_P"?<ON9VM%<5_PN7P=_T&/_ "5F_P#B*/\ A<O@
M[_H,?^2LW_Q%']NY3_T%T_\ P./^8?4\3_S[E]S.UHKBO^%R^#O^@Q_Y*S?_
M !%'_"Y?!W_08_\ )6;_ .(H_MW*?^@NG_X''_,/J>)_Y]R^YG:T5Q7_  N7
MP=_T&/\ R5F_^(H_X7+X._Z#'_DK-_\ $4?V[E/_ $%T_P#P./\ F'U/$_\
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M<ON9VM%<5_PN7P=_T&/_ "5F_P#B*/\ A<O@[_H,?^2LW_Q%']NY3_T%T_\
MP./^8?4\3_S[E]S.UHKBO^%R^#O^@Q_Y*S?_ !%'_"Y?!W_08_\ )6;_ .(H
M_MW*?^@NG_X''_,/J>)_Y]R^YG:T5Q7_  N7P=_T&/\ R5F_^(H_X7+X._Z#
M'_DK-_\ $4?V[E/_ $%T_P#P./\ F'U/$_\ /N7W,[6BN*_X7+X._P"@Q_Y*
MS?\ Q%'_  N7P=_T&/\ R5F_^(H_MW*?^@NG_P"!Q_S#ZGB?^?<ON9VM%<5_
MPN7P=_T&/_)6;_XBC_A<O@[_ *#'_DK-_P#$4?V[E/\ T%T__ X_YA]3Q/\
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M]3%_Y)?_ &RC_AG#_J8O_)+_ .V4?ZE9_P#] _\ Y-#_ .2#^UL%_/\ @_\
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M-'_$-<7_ -!$?N8?V_2_Y]LUZ*R//D_YZ/\ ]]&CSY/^>C_]]&C_ (AKB_\
MH(C]S#^WZ7_/MFO161Y\G_/1_P#OHT>?)_ST?_OHT?\ $-<7_P!!$?N8?V_2
M_P"?;->BLCSY/^>C_P#?1H\^3_GH_P#WT:/^(:XO_H(C]S#^WZ7_ #[9KT5D
M>?)_ST?_ +Z-'GR?\]'_ .^C1_Q#7%_]!$?N8?V_2_Y]LUZ*R//D_P">C_\
M?1H\^3_GH_\ WT:/^(:XO_H(C]S#^WZ7_/MFO161Y\G_ #T?_OHT>?)_ST?_
M +Z-'_$-<7_T$1^YA_;]+_GVS7HK(\^3_GH__?1H\^3_ )Z/_P!]&C_B&N+_
M .@B/W,/[?I?\^V:]%9'GR?\]'_[Z-'GR?\ /1_^^C1_Q#7%_P#01'[F']OT
MO^?;->BLCSY/^>C_ /?1H\^3_GH__?1H_P"(:XO_ *"(_<P_M^E_S[9KT5D>
M?)_ST?\ [Z-'GR?\]'_[Z-'_ !#7%_\ 01'[F']OTO\ GVS7HK(\^3_GH_\
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M\TGH<_1117.:!1110 4444 %%%% !1110 4444 %%%% ':_!K_DI.C_]MO\
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M69V)P  .I)[5'6]X!_Y'KPY_V$K;_P!&K0 ?\(#XG_Z%S5O_  !E_P#B:/\
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M_P E)_\ XBOD&BCZE3[O^OD']ET>[_#_ "/K[_A?7@3_ *#O_DI/_P#$4?\
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MO,?\*_-A1117ZF?.A1110 5\7^/O^1Z\1_\ 82N?_1K5]H5\7^/O^1Z\1_\
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MB,^9JRW5R(U%)I)/57_KS.(HHHK0U"BBB@ HHHH **** "BBB@#[U_X=9?\
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M3CP+8ZQ/%)"N6&[."2. >G<"N-T_4[S2;D7%C=SV5P 0);>0QN >HR#FJU%
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M#G':J=%% &U;>-?$-G;QP6^O:G!!&H1(H[R154#H  < 5)_PGWB?_H8]6_\
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M/E+9Z\8KC]?_ .4G_AK_ +![_P#IMN*UE.,ZDG%_99M*I&I5G*+NN1D_Q?\
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M@^]Z.X]/04GP;^#9N3!KVO08B&'MK.0?>]'8>GH*]]    & .U-L$@    &
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M-6=6G-T(M^_\+[=_NW7K8Q/!NG^&_%/CV]T]K#R=-NTD2Q3S9,QLHRK9W9Y
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MOQ2KVL!\,CZ'+/@EZG9_"BZ\$V/BAKGQU-XFM]-AA\RUF\)M MVET'0HV9N
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MS"=VX$ ALYXK.HIV0[(NZSK>H^(]3N-2U:_NM4U&X(::[O9FFFD. ,L[$DG
M Y/:I]5\4ZUKMAIUCJ6KW^HV6FQF*QMKNY>6.U0XRL2L2$!VKPN!P/2LNBBR
M"R-SPQXZ\2>"999/#OB'5=!DFP)'TR]EMB^.F2C#/4]?6J_B+Q5K7B^_^VZ[
MK%_K5[MV_:=1N7N),=<;G)..36712LKW%97O;4****904444 %%%% '[UT44
M5\D?"!1110 4444 %>!_![X-FZ>'7]=@Q"3YEK9R#[WH[CT]!^->^44Q6$
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M7OA?6=,MFN+S2+ZTMUP&EGMG11DX&21BN]M=.F^('PMTZQTUQ/JVC3/YEJS
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MJB1212VB[]IV!2& Y'3.>@S[&HO'5DW@_P"%6A>&[YU76);QK^:W5@QB3:P
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M\2/^Q:U+_P!)9*_%*O:P'PR/H<L^"7J%%%%>F>T%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?O71117R1\(%%%% !1110 4444 %%%% !1110 4444 %%
M%% !7 ^/O^0Q#_UP7_T)J[ZN!\??\AB'_K@O_H35^,^+?_),3_QP_,];+/\
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M_*GWQ_\ D _MG$?RQ_'_ #/F_P#X5'XL_P"@3_Y,P_\ Q='_  J/Q9_T"?\
MR9A_^+KZ0HH_XA]E?_/RI]\?_D _MG$?RQ_'_,^;_P#A4?BS_H$_^3,/_P 7
M1_PJ/Q9_T"?_ "9A_P#BZ^D**/\ B'V5_P#/RI]\?_D _MG$?RQ_'_,^;_\
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M7W.19-A\DPTL-AI-Q<G+WK-W:2Z)=CQ<;B9XNHIS2O:VGS"BBBOHC@"BBB@
MKS_4_A'X3U+4KN[N=)\RXN)GED?[3*-S,22<!\#D]J] K.E_UK_4UE4;6QI!
M)[G#?\*6\&?] ;_R:F_^+H_X4MX,_P"@-_Y-3?\ Q==O16/-+N:\L>QQ'_"E
MO!G_ $!O_)J;_P"+H_X4MX,_Z W_ )-3?_%UV]%'-+N'+'L<1_PI;P9_T!O_
M ":F_P#BZ/\ A2W@S_H#?^34W_Q==O11S2[ARQ['$?\ "EO!G_0&_P#)J;_X
MNC_A2W@S_H#?^34W_P 77;T4<TNX<L>QQ'_"EO!G_0&_\FIO_BZ/^%+>#/\
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MBCVD^[#GEW.$_P"%"?#+_HG7A/\ \$=K_P#$4?\ "A/AE_T3KPG_ .".U_\
MB*[NBCVD^[#GEW.$_P"%"?#+_HG7A/\ \$=K_P#$4?\ "A/AE_T3KPG_ .".
MU_\ B*[NBCVD^[#GEW.$_P"%"?#+_HG7A/\ \$=K_P#$4?\ "A/AE_T3KPG_
M .".U_\ B*[NBCVD^[#GEW.$_P"%"?#+_HG7A/\ \$=K_P#$4?\ "A/AE_T3
MKPG_ .".U_\ B*[NBCVD^[#GEW.$_P"%"?#+_HG7A/\ \$=K_P#$4?\ "A/A
ME_T3KPG_ .".U_\ B*[NBCVD^[#GEW.$_P"%"?#+_HG7A/\ \$=K_P#$4?\
M"A/AE_T3KPG_ .".U_\ B*[NBCVD^[#GEW.$_P"%"?#+_HG7A/\ \$=K_P#$
M4?\ "A/AE_T3KPG_ .".U_\ B*[NBCVD^[#GEW.$_P"%"?#+_HG7A/\ \$=K
M_P#$4?\ "A/AE_T3KPG_ .".U_\ B*[NBCVD^[#GEW.$_P"%"?#+_HG7A/\
M\$=K_P#$4?\ "A/AE_T3KPG_ .".U_\ B*[NBCVD^[#GEW.$_P"%"?#+_HG7
MA/\ \$=K_P#$4?\ "A/AE_T3KPG_ .".U_\ B*[NBCVD^[#GEW.$_P"%"?#+
M_HG7A/\ \$=K_P#$4?\ "A/AE_T3KPG_ .".U_\ B*[NBCVD^[#GEW.$_P"%
M"?#+_HG7A/\ \$=K_P#$4?\ "A/AE_T3KPG_ .".U_\ B*[NBCVD^[#GEW.$
M_P"%"?#+_HG7A/\ \$=K_P#$4?\ "A/AE_T3KPG_ .".U_\ B*[NBCVD^[#G
MEW-.BBBNHX0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X'Q]_R&(?\
MK@O_ *$U=]7 ^/O^0Q#_ -<%_P#0FK\9\6_^28G_ (X?F>MEG^\+T9L^ ?\
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M\R/6:*\1O?BC\0=;^+GC+P3X6TG0W31A9RQZGJGG+'$DD =UE"-EV9F 7:%
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MO+4L$\R/?\PP_P I!_I7'Z)\5OB?X\\:^--!\,Z5X:@M_#^I2VO]I:KYXC9
MQ")L1B6D.UB6&% QQG&5R,.9'OM<WX*^(WASXBPWTWAW5(]3CL9S;7#(CILD
M';Y@,CW&0>QKG/A+\3M1\87VO^'O$FF0Z/XMT"5$O+>VD+031R#='-$6YVD
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MKIMN\C2M%9PK$A=OO,0H R>Y[TG*ZL"C9W/(?V=_^1M^+_\ V-4_\JL_M?\
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ME^SQH.F:)X4UN33/%*^+TU#6KF]N-1CMA;KY[!%D54'RXW*3E<+\W'%8WQM
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M;$>00/;(./;%=54=M;0V5M%;V\2001((XXHE"JB@8"@#@ #C%25F]RT%%%%
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MUKH%4*H50  , #M4R:>PTFMQ:***DH**** "BBB@#3HHHKM.0**** "BBB@
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M$YXI<KV'S(]MK/TCQ#I7B!)WTO4K/4EMY##,UG.DHCD'5&VDX8>AYKDOA?\
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M.2Y+AD(4C&,Y(KT_X6^)/$>J>&_-\3^&XO#$-M;PF"8ZFET+A-A+.VU5\O
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MAOQIX<^#VL3>)?BJFJ03B*/^R3HMK;BZ?S4.Q'7Y_E^]QV7GC-=9\1?^2A?
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M\?Y5>KHI[&$]PHHHK4S"BBB@ K.E_P!:_P!36C6=+_K7^IK&ILC6GN-HHHK
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M*** "BBB@ HHHH **** "BBB@ HHHH *X'Q]_P AB'_K@O\ Z$U=]7 ^/O\
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M\?Y5>KHI[&$]PHHHK4S"BBB@ K.E_P!:_P!36C6=+_K7^IK&ILC6GN-HHHK
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M(QA)4]#UX]"?K7(2? GQ!XGO--C\<_$"X\5:)83I<II4>F1623R)]PS.C$N
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M>(I?'MYX%\<:986/B&.S_M"TO-)=VM+V#=M)4/\ ,K*>Q)SSTQSY1^S?XO\
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MRCK&TEV(MP]QOR/<4<EVT'-I<^F/&FLS>'/!VNZM;+&]Q86$]U$LH)0LD;,
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M?;$\NEQ\VMCVZBBBH+"BBB@ IT7^M3ZBFTZ+_6I]136XGL:-%%%=ARA1110
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MYG.?V)8_#;]IWPY:>'+6+2=-\3:5<C4+"T01P/)#ETE"#@-VR ._J<YGPR\
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MZU])457/W)Y3A?&?@ >,?@]J/A6:SM+*>ZTWREMK(;;>&X"AD"<#Y%D (X'
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M1D8SUXKW^BCFON@Y;;'SE=> ]2\ _LG>-(-:V+K>I07FJ7T41RL4LI!V ]\
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M)1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3HO\
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M10JC\@*3=HV"WO7+M%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4Z+_6I]13:=%_K4^HIK<3V-&BBBNPY0HHHH 9+_JG^AK/K0E_
MU3_0UGUA4W1M3V"BBBL34**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH TZ*
M**[3D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@?'W_(8A_P"N"_\
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MJ[ZN!\??\AB'_K@O_H35^,^+?_),3_QP_,];+/\ >%Z,V? /_('F_P"N[?\
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MH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\
MD-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\
M_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_
M  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_
M(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U
M:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V
M?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"
MM_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$
M'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111
M_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&
MG^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G
M[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+
M]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_P
MH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\
MD-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\
M_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_
M  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_
M(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U
M:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V
M?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"
MM_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$
M'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111
M_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&
MG^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G
M[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+
M]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_P
MH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\
MD-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\
M_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_
M  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_
M(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U
M:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V
M?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"
MM_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$
M'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111
M_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&
MG^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G
M[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+
M]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_P
MH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\
MD-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\
M_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_
M  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_
M(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U
M:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V
M?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"
MM_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$
M'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111
M_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&
MG^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G
M[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+
M]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_P
MH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\
MD-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\
M_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_
M  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_
M(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U
M:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V
M?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"
MM_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$
M'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111
M_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&
MG^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G
M[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+
M]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_P
MH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\
MD-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\
M_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_
M  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_
M(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U
M:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&G^%%%'^M?$'_ $,*W_@V
M?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G[_\ (:?X444?ZU\0?]#"
MM_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+]7_Y^_\ R&G^%%%'^M?$
M'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_PH_X2_5_^?O\ \AI_A111
M_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\ D-/\*/\ A+]7_P"?O_R&
MG^%%%'^M?$'_ $,*W_@V?_R0?5J'\B^Y!_PE^K_\_?\ Y#3_  H_X2_5_P#G
M[_\ (:?X444?ZU\0?]#"M_X-G_\ )!]6H?R+[D'_  E^K_\ /W_Y#3_"C_A+
M]7_Y^_\ R&G^%%%'^M?$'_0PK?\ @V?_ ,D'U:A_(ON0?\)?J_\ S]_^0T_P
MH_X2_5_^?O\ \AI_A111_K7Q!_T,*W_@V?\ \D'U:A_(ON0?\)?J_P#S]_\
MD-/\*S]0U*YU299;J3S9 NT':!QDGL/<T45Q8O/<VS"E[#&8NI4AO:4Y25_1
,MHJ-&E!WA%)^A__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>arqt-20251231_g3.jpg
<TEXT>
begin 644 arqt-20251231_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR*VD\0:-9ZA'+=:8MR)#;F>)26A\P12%-P&X(2,@5M4 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?@KIWPK\'?\%DO^#J7XG?"G]KJQ;Q'\.?@'X3NCX=\#WTS?
M89OL4MA:&.1 1N22\O9;IQT?RTC?<@VG]ZJ_$3_@H)\#/VPO^".G_!:/4_\
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M::Y?0^*?&&IZI<VWAO3+.SG-I,LEN)G>:Y:YVI$T<NQU8L8]J,:]H_X)C?\
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MPY!="!]7U2?=Y-OYA#"- J2RN^&*QPN0K'"G\W/%_P#P69_X.&/V7O@+H?\
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MX>TCQ=IZ7MM:6T>I3:=#(D<@*I*EM8*J.N&0R.5(8YKPO_@FC^TG\2/V4O\
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M@DOK*#2+2(6QGO\ 59!=-]I0-<1Q)%!'$Q>9#DA2K<O^WI\,OB3J_P#P=O\
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M?ZW<>&=)^$OV:XUV/3)I+.W9;/Q&H22?:45OFCX9LY=?44 =A^Q__P %A?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N,MOV?/@_9_M WG[4]MX,1?
M'M_X0@\+W?B#[9.6DTF&YDNH[;RB_E +--(^\('.[!8@ #LZ* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **P? 7Q3^&OQ336
M)?AKX^T?7U\/Z]=:'KK:/J,=P-/U.V8+<6<VPGRYXR0'C;#*2,@5O4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#]C#XKZUX4O-WA'QOJ&M:Y;M"P-K:ZY=75[92R#&41HUMDR?XYT'5@*^A?\
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ML_V6_P!2CBD !V,><5%_PF/AC_H-0?\ ?57I;.TF;?-:QNWJR FF_P!G:?\
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M%?2M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P##PC_@[7U]_%/^F^$OV4OAOCP]:R_-!_:K1P*TA3H)5N=2G8-U_P! B/\
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M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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M;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
MP+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_
M  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
MV**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_
M (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK
M'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!
M](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
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M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
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MQTW0-+T^."SM;95VB%(4 14 XV@8KP3X5?\ !'3_ ()?? _XY)^TC\)_V(_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%>:_'7]K+X+?L^VKQ^-/$JSZILW0Z'IV);
MM^,C*Y C!_O.5![9Z5U8+ XS,<0J&%IN<WLHJ[_X;SV1R8W'X++<.\1BJBA!
M;N3LO^'[+=GI5>/?'[]M[X(_ 19M*OM9_MK78P0-$TEU=T;TE?[L/N#EL'(4
MU\]:G\<_VS/VX=0F\-_!3P[+X7\+,YCN+V&=HDV]")KO +''6.(9P>5;K7K7
MP!_X)O\ PA^%QA\0?$4KXMUI2'_TR+%E"_7Y83GS/K(2#U"J:^X7#62<.KVF
M?U[U/^?%)IR])RVCYI.]MF?"OB?/>(VZ?#U#EI_\_P"JFH>L(;R\FU:^C1Y!
M)KO[;?[?4S6VB6Q\*>"9F*NZN\%K)'GD-)CS+L^H4;,CD+UKWGX ?L"?!+X(
M^1K6I6 \2Z]'AO[3U6$&.%_6&'E4]03N8'HPKW"***")8((U1$4*B(N H'0
M=A3J\[,^,\?BL,\'@(+#8?\ DIZ-_P".7Q2??9/JF>CE7!.7X7$K&X^;Q6)_
MGJ:I?X(?#%=MVNC04445\<?:!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 445S7Q.^,'PU^#>@GQ'\2?%]II=O@^4LSYEG(_ACC7+2'V
M4&M:%"OBJJI48N4GHDDVWZ):F5>O0PM&56M)1C'5MM))>;>B.EKB?C)^T/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6K5KU'4J2<I/5MN[;\VS[VE2I4*:ITHJ,5HDE9)>26P4445F:!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !16#X"^*?PU^*::Q+\-?'VCZ^OA_7KK0]=;
M1]1CN!I^IVS!;BSFV$^7/&2 \;8921D"MZ@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:A!;**22^2"BBBN<Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK_@VUU33M$_X-XO ^M:QX.U/Q%:6>F^,9[KP_HL*R7FIQIK&ILUK C.BM+(
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M9%%',D[R++YS%1'M .=^Q5^QQ\6_&_\ P:H_M.?%'3_#-X\FN_$BQ\0Z+;K
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M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
MX0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_
M )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC
M_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]
M_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F
M]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+
M:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ M
MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -
MBBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/
M^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_
M .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](
M_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!]
M(_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GY
MO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_G
MYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\
M"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P
M+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@
M#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:
MC_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q
M_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?
M2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0
M?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y
M^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_
MY^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?
M_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_
M\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"V
MH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "
MVH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BB
ML?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$
M'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^
M$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/
M^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2
M/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;
MW_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO
M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HKR[XU?%/X'? #1_[4^(WC&X@FD0M::9;W;27=
MS_N1@YQGC<<*#U(KY8U'XN?M/_MHZ]/X0_9_\-WV@^&P_EW=\]\X 4_\][GH
M,CGRHQNP2/G'-?49+PEF><4GB96HX=?%5F^6*]+_ !/R771M'RN><7Y7DU58
M:-ZV(E\-*FN:;];?"O-]-4F?1W[0/[=OP3^ YGT0:B=?U^+*G1]*E!\I_2:7
ME8O<?,X_NU\_>7^VY^WY+F0_\(IX(G;_ &[>UEC^G^LNSC_MGD?P5Z_\"/\
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M_P _-[_X%M7 =YL45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME%-XK$_RP^"'G.?PKT^3L=;\:_\ @I)>:UK'_"MOV4?"MQK>JW+F&'6)+)I
MS?\ 3O;XW2'ON< #'W6'-4/A/_P3R^('Q4U\?%+]L#QI>W5U<$.VBQWGF3N.
MH268'$:CIY<70'AEQBOH_P""G[.?PD^ &C_V9\.?#$<,\B!;K5+C$EW<_P"_
M(1G&>=JX4=@*[FNG$<783*:,L+P[1]C%Z.K*SK3^>T%Y+U5F<N'X/QF;UHXK
MB2M[:2UC2C=48?+>;\Y>CNC+\&^"/"'P\\/P^%O _ARTTO3[<?NK6SA"*#W8
MX^\Q[L<D]R:U***^$J5*E6;G-MR>K;U;?FS[ZG3IT::A3245HDM$EV2"BBBH
M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVMUD/),TC?/<-GKT7J"''-?4NG:;IVCV$.EZ180VMK;QA(+:VB"1QJ.BJJ@
M >@KZ+^T^&.%/=RR"Q6)7_+V:_=Q?_3N'5KI)^J;6A\Y_9?%'%OO9I-X7#/_
M )<P?[R2_P"GD^B?6*Z:-)ZGBW[.O[!OP=^ X@UZ^M!XB\11X;^UM2A&R!_6
M"+E8_9CN?T89Q7M]%%?%YEFN8YQB7B,95<YOJ^GDELEY))'VV693EN3858?!
M4E3@NBZ^;>[?FVV%%%%>>>B%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45
M@^ OBG\-?BFFL2_#7Q]H^OKX?UZZT/76T?48[@:?J=LP6XLYMA/ESQD@/&V&
M4D9 K>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBO$_VB?V[?@Y\!!/H=O>#Q!XACRO]CZ;,-L+^D\O*
MQ_[HW/\ [/>N_+<KS#-\4L/@Z3G-]%^;>R7F[(\_,\UR[)L*\1C:JIP75O\
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MHKX<^["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?#8?!T(T:$%"$=$DDDO1(****Q-@HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^3!7D_)W^XY,@XW^#EPN.?3:E5?E_))]MF^[>GPG/Q!P-\?-B\ NN]:DO/\
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MHTSYD8>Q;%=A1_K5D>3Z9+@8J2_Y>5O?GZJ/PQ?I?T#_ %3S[.=<\Q\G%_\
M+JC^[AZ.7Q27K9^9\S_"?_@E[\$?!OE:A\1M3O?%5ZN"T4K&VM ?^N:'>W_
MG(/I7T-X6\'>$_ ^DIH7@SPU8:591_=M=/M$A3/KA0 3[]:TJ*^8S7B#.L[G
MS8ZO*?DW[J](JT5\D?4Y3P]DF10Y<#0C3\TO>?K)WD_FPHHHKQSV0HHHH **
M** "BBB@ HHHH *" 1@BBB@#YC_:<_X)X^'O'5Y)\2/@-<1^&_$T4GGFSA8Q
M6MU(#D,A7_CWESR&7Y2>H!):N4^!?[>_C?X5^(_^%+?MB:+>6=W:,(4UZ:W/
MFQCHIN%7_6H1TF3.1@D-DM7V/7"_'3]G7X7_ +0WAS^P?B#H8>:)3]AU2VPE
MU:,>Z/@\>JG*GN. 1]UEW%>'QF$CEV?P=:BM(S7\6G_AE]I?W7^*21\%F7"6
M(P6+EF7#\U1K/64'_"J^4H_9?]Y?@VV=CI&L:3X@TN#6]"U."\L[J(26UU:R
MB2.5#T967((]Q5FO@V:R_:C_ .";OB,W5E(WB;X?W%SEP0WV9LG^(<FTF/J,
MJQQ]_&!]8_ +]I?X6_M%^'_[5\"ZQMO84!U#1KLA;JU/^TN?F7/1URI]0<@<
M.><*8C+<.L=A)JOA9;5(]/*:WB_73YZ'=D7%N'S/$/ XR#P^+CO3EU\X/:<?
M37Y:GH-%%%?)GUX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8
MWCOXA>"?ACX<F\6^/O$MII6GP#Y[B[DP">RJ.KL>RJ"3V%72I5:U14Z<7*3T
M22NV^R2,ZM6E0INI4DHQ6K;=DEW;>QLUY5^T/^V%\(/V=+1[3Q#JG]HZX8\V
M^@:>X:<Y'!D/2%>G+<D?=#5X!\3?VY_C1^T1XD?X3?L?^$-0A2;*RZSY0%TZ
M9P7!/R6L?^VQW=.4/%=G^SQ_P3=\*>$[M/'?Q^U!/%.O22><U@[,]G%(3DF0
MM\UPV>I;"\GY6ZU]]1X6R[(J4<3Q'4Y6]8T(6=27^+I!>NN^J>A^?U^*\RSZ
MM+"\-T^9+25>::I1[\O6;]--M&M3S&+3?VOO^"B6HK<ZC-_PBW@/SLH-KI:L
MH/55X>\D&.IP@(/*9Q7U'^S_ /LG?"']G33U/@_1?M.K/'MNM>OP'N9<]0IQ
MB-/]E<9XSN/->E0006L"6UM"D<<:!8XT4!54#   Z "G5Y><\78W,L/]2PT%
MA\*MJ<-$_.;WF^]].MKZGJY)P?@<LQ/UW%3>(Q3WJSU:\H+:"[6UZ7MH%%%%
M?)'UX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%8OCSXC>!?AAH+^)_B#XJLM)L8^//O)@N\_W5'5V_V5!)]*^5/BC_ ,%(
MO&'C[6S\.OV2OA]>7]]<$I%JUU8F65NVZ*W&< ==\G '5!7R7$O''#?"<5''
M5OWLOAIP7-4DWLHP6NO1NR\SS<?FV!RY6K2]Y[16LGZ+^D?4OQ&^*OP[^$>A
M-XD^(_BZSTFT&=C74OSRD?PQH,M(WLH)KY4^(_\ P43^)OQ8UYOAQ^R+\.KV
M:YFRJZK<6?G7!'0ND(RD2C^_(2,'D+2?#G_@G;\3_BUKR_$?]KKXBWLUQ-AF
MTJWO/.N".H1YCE(E']R,$8/!6OJSX<?"GX=?"/05\-_#CPC9Z3:#&];:/YY2
M/XI'.6D;W8DU\;_QL?CC_J5X-_\ ;V*FORI7_P# XO\ F1Y?_"[F_P#U#TOO
MJ/\ ^1_->9\M?"__ ()O>,O'^MCXB_M;?$&\O[V<AY=)MKXRRMWVRW!R% Z;
M(^,='%?5?@+X<>!/A?H*>&/A]X5LM)L8_P#EA9PA=Y_O.WWG;_:8DGUK:HK[
M+AG@?AOA.+E@:/[V7Q59OFJ2;W<IO77JE9>1ZF RG Y<KT8^\]Y/63]7_EH%
M%%%?6GI!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<K\2_CA\)/@]9F\
M^)/C_3M*^7<EO-/NGD'JD2YD?\%-;8?#XC%552H0<Y/9)-M_):F.(Q.'PE)U
M:\U"*W<FDEZMZ'54=.M?(OQ&_P""IFG75_\ \(U^S_\ #"]UN^E;9;7>IQLJ
MNW;9;Q9DD!]V0^U<U_PI;_@H5^U?^]^*GBR3PKH4_P!ZPNI/LJ%#_#]EA^=R
M/28@^]?:4. \PHTE7S:M#"4W_P _'[[_ ,,%JWY.S/B*_'^75JKH911GBZB_
MY]KW%_BJ/1+S5T?17Q9_;2_9T^#WF6OB#Q_!?7\>0=+T3%U/N'\+;3LC/L[+
M7@&O?\%#/V@_C5JDGA;]EWX,SQDG;]NEMC>W" ]'( $,/_ ]X]Z])^$W_!,W
MX ^ ?+O_ !H+OQ9?)@DZ@WE6P;U$,9Y'L[.*]_T'P]H'A;2X]$\,Z'9Z=9PC
M$5I8VRQ1)]%4 "M?K_ ^2:83#RQ=1?:J^[3OW4%JUY2,O[/X[SS_ 'S$1P=-
M_8I>]4MV=1Z)^<?N/C71_P!@+]ICX[:C%XF_:@^,<ULA;>-/%R;R>/U55!$$
M/_ "P]J][^$W[#W[.'PA\J[TGP)%JNH1X(U/7B+J7(Z,%8"-#[J@->MT5Y>9
M\:\0YG3]BZOLZ72%-<D4NUEJUZMGJY7P1PYE=7VRI>UJ]9U'SS;[WEHGZ)"*
MJJH50  , #M2T45\H?6A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% $.HZ=I^KV$VEZM8PW5K<1F.XMKB(/'*A&"K*>&!'4&OD7X^_\$_?$
MO@?Q!_PN7]D+5[G3-2M',[:##<E'4]_LSD]#WB?@@D XPE?8%%>YD?$.9\/X
MAU,++W9:2@]837:4>OKNNC/"SWAS*^(<.J>*C[T=8SCI.#[QET]-GU1\M?LT
M_P#!1'3/$>H+\,?VCK1?#GB."3[/_:4\1@MYY <%9E;'V>3/7/R$Y^YPM?4B
M.DBAT8,K#((.017DO[2W['/PN_:1T]KW5+8:5XACCVVFOV<0\S@<+*O F3V)
M##^%ASGYN\'_ !H_:3_X)^^);?X<?&O19]>\&O)LT^XCD+JL8[VLS=,#DP/C
M';9G<?J:F2Y-Q;!U\DM2Q&\L/)Z/NZ4G:_\ A>WDK7^3IYWG?"%14,]O5PVT
M<1%:KLJL5=K_ !+?S=[?=E%<U\*_B]\/?C3X6B\8?#GQ'#J%H^!*JG$MN^/]
M7(AY1AZ'KU&00:Z6OS^O0K86M*E6BXRB[--6:?FF?HE"O0Q5&-:C)2C)733N
MFNZ:"BBBLC4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "@D*"S$  <DUP7QS_:4^$O[/
M>C?VE\0?$2K=21EK/2+3$EW<_P"ZF1@=MS$+[YKY0U?XF?M;_P#!0359O"_P
MTTA_#/@KS#'=S"9D@9>XGG W3M@_ZJ,8Y&5_BKZK).$L?FU%XNK)4,,MZL](
M_P#;JWD^R6E]+IGR>><7Y?E%=82E%U\3+X:4-9?]O/:*[MZVULT>N?M'_P#!
M1?X=?"V2;PC\*HHO%7B'<8]T#DV5M)TPSKS*V?X$]P64\5YEX$_8_P#VBOVM
MO$</Q1_:L\6W^EZ8WS6FELH2Y,9YV10XV6J'U8%SC)4YW5[O^SA^P_\ "+]G
MN.'6DM!KGB-5!?7-0A&8F[^1'R(A[\OR?FQQ7LU>Q5XFRGAZF\/P[3]]Z2Q$
MU>;[\B>D%^-MU=7/&I<+YOQ'46(XCJ>XM8X>#M!=N>2UF_G:^SL['._#+X3?
M#SX.>&T\*?#CPM;:99K@R"%<O,V/OR.<M(WNQ/ITKHJ**^"K5ZV)JRJU9.4G
MJVW=M^;>Y^@4*%'#48TJ,5&,=$DK)+LDM@HHHK(U"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUA->3[^3U]5J?29!Q/EO$$)*BW"K#2=.2M.#\UV\UIZ/0T:***^>/H@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***\-_:2_;Q^$OP$$_A[3)U\0^)$RO\ 95C,/+MF_P"F\HR$Q_=&7]0
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M\JTZ-;,^'^N\4<8Z8%/!X1_\O)+][-?W(_83_F>O5/='SW\#?^"<=_K>L_\
M"T/VL?$<^M:M=2":311>M("W_3Q/G,A_V$.T8^\PXKZPT?1M(\/:7!HF@Z7;
MV5E:QB.VM+2%8XXE'1550 !["K-%?*YWQ%FO$%93Q<[I?#%:0BNT8[+UW[MG
MUF1\.91P]0<,'3LW\4GK.3[RD]7WMMV2"BBBO$/="BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ***\T\:?&^^_P"$HMO"?PWL4U&X%P!<.!N63!YC3VZY?H/UKY/B[C7A_@C
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M_LJTO;O2IB+GRR?(FAM]/NI986Q)&J?,HR,@'[XU_/=\$_V?OC)_P<E_MO\
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MX\FN_$BQ\0Z+;K V;S3='GL?METGK&@-[D^MHX[5V/\ P4:_X*"?LS_M"_\
M!M7^S+^R'\'/BEI/B+XHRWWAK0[_ , :3=K/JU@^F6<]K(\ULA,D0>98%BW
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M26_#T7Z8NE_\B']H<0K_ )@E_P"#(_Y'V-#<VUQG[/<(^.NQP<?E3Z^,)O\
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MHXBFITI*47U3NOO1ZD91G&\7=&Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M6A1L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-
M[_X%M1_P@^D?\_-[_P"!;4 9WQ<^#'PY^./A9_"/Q'\.Q7UN<FWF^[-:N1]^
M)QRC=.G!Z$$<5\=>)_A5^TS_ ,$\O$D_COX3ZO+XA\$RRA[^&2,M&$]+F)?]
M6P' G3 Z9(SL/VM_P@^D?\_-[_X%M39/ >B31M#--=NCJ0RM=,00>H(KZ?(>
M*<;DT)8:I%5L-/XJ4]8OS7\LO-==6G9'RN?\*8+.ZD<33DZ.)A\-6&DEY/\
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M2/\ GYO?_ MJ^\/8-BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\
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MZN]TF[N4NS,<SHQH?4L"N6DMWUF^[\NR_P"&6Q16/_P@^D?\_-[_ .!;4?\
M"#Z1_P _-[_X%M7[(>";%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q
M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M+$X96&593D$>M<GXQ^"O@;Q?ON)-/^Q73<_:K(!"3ZLOW6_+/O7#2>"OC/\
M"-S<^$=2;4]/4Y,$2EQCWB/(^J$GWKQ_];?%+@+W>)<!_:&%7_,3A%^\2[U,
M.[>K<+1BNYO]1R;,M<)4]E/^2>WRE_GJ>S45YMX1_:/\/ZBXL/&%B^F7 .UI
M5!>(GW_B3Z$'ZUZ'8ZA8ZI:I?:;>17$+C*2PR!E;Z$5^E<*<=\)<;8;VV38N
M-6V\;VG'_%"5IQ[7:L^C9Y.-RW'9=/EQ$''SZ/T>Q-1117UQPA1110 4444
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MC=K_ "E%5IO^">G['\Q+'X0A2>Z:[?C'X"?%'+XVQVEE[]5B%^06XL76B_\
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MQ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;,+2 G\@?:G+^SK_ ,%.-0'V:Y^.A@1?E$A\3RKD#C.8XRWY\_C7VE17Q_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*_9[H****XSL"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME_X>$?\ !VOK[^*?]-\)?LI?#?'AZUE^:#^U6C@5I"G02K<ZE.P;K_H$1_A
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MUM(I+2V,EL;%+M;)5\F1+@*R1S 21!)B0@+9 /Z**_GN^"?[/WQD_P"#DO\
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %0WVGV&J6S6>I64-Q"WWHIXPZG\#4U%15
MI4JU-TZD5*+T::NFNS3W&I.+NGJ<!XG_ &=/ ^M[I]',VES'IY)WQY]T;^A%
M<U_PB7QX^&/S^'-3;4[).D,;>: /3RWY'_ /SKV2BOR/./!+@O&XMX[*U/+\
M5TJX6;I/YP7N-=URIOJSW*'$.84X>SK6JP[37-^._P")Y9H'[2MO'/\ V?XY
M\-S6<RG$DMLI(!]T;YE_,UZ!X=\9^%O%<7F^'M<M[GC)C1\.OU4X8?B*=K_A
M+PUXIA\CQ!HEO=#&%:2/YE^C#D?@:\_\1?LTZ:TOV_P7K\UC,IW1Q3DLH/LX
MPR_^/5Y7+XX<&?"Z.<X==[8?$V]=:4K+UE)FU^'<?_-0E_X%#_-?DCU&BO&_
M^$@^/OPP^76K%M5L8^LK@S+CUWK\Z_\  ORKHO"_[1_@O6-L&NPS:9,>ID'F
M19_WE&1^(%>GE/C=P;B<6L!F_M,NQ/\ S[Q4'2^:F_W;79N2OV,:_#V/A#VE
M"U6'>#O^&_X'H5%0:=JFF:Q:B]TG4(;F%NDL$H=3^(J>OUVC6HXBE&K2DI1D
MKIIW37=-:-'ARC*,K25F%%%%:""BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH;^_LM+LI=1U&Z2&"%"
MTLLC8"@=S45:M.C3E4J248Q3;;=DDMVWT2ZL:3D[+<?<7$%I ]U=3+'%&I:2
M1VPJJ.223T%>.^-O'WB+XOZW_P (#\/(W%B3BXN.5\U0>68_PQCTZG\A4?B?
MQ9XH^.OB#_A#_!<3P:3&P,\S@@. ?OR>@]$ZGZ]/3_ W@30_ .CKI>CQ9=L&
MYN7'SS-ZGV]!T'YFOYYQ^:YQXV8ZIE>2U)4,EIMQKXE:3Q+6]*@^E/I.?7;5
M>[/ZFE1H</4U6Q"4L0]8PZ0_O2\^R_X=0?#OX<Z)\/-)^QV"B6YE -W>,OS2
MGT]E'8?S/-=#117[MDV397P]EE++LNI*E1IJT8QV2_-MO5MW;;;;;9\WB,16
MQ59U:LKR>[84445Z9B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<]XG^%?@3
MQ;NDU708EG;K<VP\N3/J2OWOQS70T5YF;9)D^?81X7,L/"M3?V9Q4EZV:=GY
M[HVH8BOAI\]&3B^Z=CR/4?V??%7AFZ;5/AOXOD5QR(I9#%(1Z;EX;\0!4,'Q
MC^*G@&5;+XB>%FN(@<"=H_+9OHZ@HWY?C7L5-G@AN8F@N85DC<89'4$$>A!Z
MU^15O!6ADM66(X.S*MELV[\D9>UP[?\ >HU&U_Y-9=$>Y'B"6(CR8^E&LN_P
MR_\  E_D<EX8^.'P^\3;8O[6^PSM_P L;\"/GV;.T_GGVKKD=)$$D;AE895@
M<@BN+\4? 3X?^(MTUK8-IT[<^98G:N?=#\N/IBN1?X7?&3X<N;CP)XC:]ME.
M?L\;[<_6)\J?P)-9_P"MWBWP?IQ!E,<=07_+[!.\[=Y8>=I-]^5J*']1R3'_
M .ZU_9R_EJ;?*2T^_4]CHKR;2/VC-7T:Z_LKXB>$I8)5X>2!"CCW,;_S!'TK
MO?#/Q'\%^+P%T/7X9)3_ ,N\AV2?]\M@G\,BOL.%_%;@/BZI[# XR,:^SI5+
MTZJ?;DG9MKKR\R\SAQF2YE@5S5*;<?YEJOO7ZV-RBBBOT0\H**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***I>(?$.D>%M)EU
MK7+Q8;>(<L>K'LH'<GTKGQ6+PN!PT\1B9J%."<I2DTE%+5MMZ));ME0A.I-0
M@KM[)$FKZQIN@Z;+JVKWB06\"[I)'/ _Q/H.IKQS5=9\7?M!^(_[#T)'L]$M
MI TCN. /[[X^\Q[+V_,TCR>,/VB/$GEQ!['0K23DGE4]S_?D(_!0?S]>\-^&
MM&\):1%HNA68A@C'_ G;NS'N3ZU_/=2KF_CMC'2H.>'X?A*TI:QJ8UQ>L8[.
M-!-:O>6WQ:4_J5&APW3YI6EBFM%NJ=^_>7Y>F\7A#P?HG@G1DT70[;8B\R2-
MR\K=V8]S_+M6I117] 9?E^!RK!4\'@Z:ITJ:48QBK**6R21\Q5JU*U1U*CO)
MZML****[#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** *NKZ'HVOVQL];TN"ZB_N3Q!@/<9Z'W%<#XG_9K\*ZB6N/#-_/ILO58R3+
M%GZ$[A^9^E>D45\?Q1P!P;QG3Y<YP4*SV4FK37I4C::^4K'?@\SQ^7N^'J./
MET^YZ?@>-_9_V@OA?_J';5[&/L,W"X^G$BCZ<5L>&OVEO#UXPM/%FE3Z?*#A
MI8P9(P>^1]Y?I@UZ96/XE\ >#_%RG^W]!@F<C G"[9!_P-<']<5^=_\ $->.
M^$_>X0SN3IK;#XQ>VI?X8U%^\IQ\HIONSU/[6RW&Z8[#J_\ -3]U_-;-^I;T
M7Q'H/B.V^UZ%J]O=ICDP2ABOU'4'V-7:\HUK]F^ZTZY_M3X?>*YK:9.8X[ER
MI'TD3D?E^-4Q\0_C;\-6$7C/0FO[1.#/(F>/:5./^^@31_Q%KB#A=\G&F35<
M/%;XBA^_P_\ BER^_379-2D']B87&:Y?B%-_RR]V7ROH_P $>QT5PWAC]H+P
M#K^V'4+F33)SU6['R9]G'&/<XKM;6ZM;V!;JRN8YHG&4DB<,K#V(ZU^H\.\7
M\+\6X?V^3XRG7CUY9)R7^*/Q1])),\?%8'&8&?+7IN/JOR>S^1)1117T9R!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%8_C;QOH?@/1VU?6I^3D06Z'Y
MYF_NJ/YGH*X<SS/+\FP%3'8ZJJ=&FG*4I.R275O\NK>BU-*-&K7JJG35Y/1)
M$WBOQ9HG@S1Y-:UVZ$<2<(@Y:1NRJ.Y/_P!<\5Y+8:=XO_:&\2?VIJK/9:':
MR$(J]%']U<_><]V[?D*=X>\,^*_CUXA_X2KQ9(]MH\+D0Q(2 1G[D?\ [,__
M .H>QZ;IMAI%C%IFF6B06\*!8HHQ@**_ L/A,W\=,9'%8V,\/D$)7ITG>-3&
M-/2=3K&C?6,=Y;[V<?II3H<.4W"FU+$O=[JGY+O+N^GYLT71-+\.Z9%H^C6:
M06\*XCC0?J?4GN3UJU117]"X?#X?"8>%"A!0A!)1BDDDEHDDM$DM$D?+SG*<
MG*3NWNPHHHK8D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHK"^)?Q.^'/P9\"ZE\4/BYXZTGPSX;T:#S]6U[7=0CM;2SCW!=\LLA"HN6
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M.-:"WY=UZQW7XGHM% ((R#17[$>"%%%% !1110 4444 %%%% !1110 4444
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
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MT?8X:D^;#8%NZ3Z5<1TE4[0:M'9I:I^K7QV%RG#O#9?+FG+XZG_ML>R\^IL
M!0%48 Z 45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5^]['S1L45C_ /"#
MZ1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/
MS>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_
M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
M;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6
MU'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45
MC_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@
M^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P
M@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_
MS\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1
M_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M4EGX2TVQNDNX
M;BZ+1ME0]RQ'XB@#4HHHH **** "BBB@ HHHH *^7?\ @J1_P2@_9J_X*E_
MS4?AU\4_"NAZ=XP&G?9O"?Q)E\/K=ZCX>)E5V,1$D3NAPP,1D"$MNQD5]144
M >??LT?LJ_L\_L>_#*W^$/[-7P?\/^#-!A?S9;'P_IJ6ZW,Y4*T\I'S2R$*
M7<LV !G %>/?$?\ X(I?\$I/BW\9)_C[\1/V$_ .I^*;N]-Y?WLFF,D-Y<%M
MS2SVJ,MO.[-DLTD;%R26R2:^HJ* .?\ &?PG^%_Q%^&UY\&_'GP[T36/"6H:
M;_9][X9U'3(IK":TVA1 T#*4*   +C P,8P*\@_93_X)9?\ !/7]B#QE?_$7
M]E;]E#PKX/U_486AN=:LK>2:Z6%B"T4<L[NT,;$#*1E5.T9!P*]_HH \Q?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &7%O!=P/:W4"21R*5DCD4%6!Z@@]17E?CCX':IH-_P#\)?\
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M-*E!6C&*48I>27X]WJ]3YRM6JXBHZE23E)[M[A1117<9A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M))KJCY[%83$X*LZ5>+C)=_ZU7F%%%%>X<X4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCT2X$,Y@ADU!9&1X)7-NL@B18PT32(JEW!_.[]I?_@BK^U-\&O\ @GI\5_\
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MO#.GZK=&[N)[E6*@8BN"HX]A4'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
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M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,+@,-##X:FH4X*T8Q244ELDE9)+LCYN<YU)N4W=O=O<****Z"0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /+_BM\>?B5\/O%S^'/"_[,OBCQ3:+
MD@U;29X5A9F'*8<YR.]<W_PUA\;/^C'_ !W_ .!5M_\ %5[I10!X7_PUA\;/
M^C'_ !W_ .!5M_\ %4?\-8?&S_HQ_P =_P#@5;?_ !5>Z44 >%_\-8?&S_HQ
M_P =_P#@5;?_ !5'_#6'QL_Z,?\ '?\ X%6W_P 57NE% 'A?_#6'QL_Z,?\
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M_P"&L/C9_P!&/^.__ JV_P#BJ/\ AK#XV?\ 1C_CO_P*MO\ XJO=** /"_\
MAK#XV?\ 1C_CO_P*MO\ XJC_ (:P^-G_ $8_X[_\"K;_ .*KW2B@#PO_ (:P
M^-G_ $8_X[_\"K;_ .*H_P"&L/C9_P!&/^.__ JV_P#BJ]THH \+_P"&L/C9
M_P!&/^.__ JV_P#BJ/\ AK#XV?\ 1C_CO_P*MO\ XJO=** /"_\ AK#XV?\
M1C_CO_P*MO\ XJC_ (:P^-G_ $8_X[_\"K;_ .*KW2B@#PO_ (:P^-G_ $8_
MX[_\"K;_ .*H_P"&L/C9_P!&/^.__ JV_P#BJ]THH \+_P"&L/C9_P!&/^._
M_ JV_P#BJ/\ AK#XV?\ 1C_CO_P*MO\ XJO=** /"_\ AK#XV?\ 1C_CO_P*
MMO\ XJC_ (:P^-G_ $8_X[_\"K;_ .*KW2B@#PO_ (:P^-G_ $8_X[_\"K;_
M .*H_P"&L/C9_P!&/^.__ JV_P#BJ]THH \+_P"&L/C9_P!&/^.__ JV_P#B
MJ/\ AK#XV?\ 1C_CO_P*MO\ XJO=** /"_\ AK#XV?\ 1C_CO_P*MO\ XJC_
M (:P^-G_ $8_X[_\"K;_ .*KW2B@#PO_ (:P^-G_ $8_X[_\"K;_ .*H_P"&
ML/C9_P!&/^.__ JV_P#BJ]THH \+_P"&L/C9_P!&/^.__ JV_P#BJQ?$_P"W
M9\1_"6L:-H>N?L<>,+:XUV]-KIL-QJ%NKW$H7<50#.YL#."1]:^CJ\+_ &L/
M^2V? _\ ['N7_P!)FH /^&L/C9_T8_X[_P# JV_^*H_X:P^-G_1C_CO_ ,"K
M;_XJO=** /"_^&L/C9_T8_X[_P# JV_^*H_X:P^-G_1C_CO_ ,"K;_XJO=**
M /"_^&L/C9_T8_X[_P# JV_^*H_X:P^-G_1C_CO_ ,"K;_XJO=** /"_^&L/
MC9_T8_X[_P# JV_^*H_X:P^-G_1C_CO_ ,"K;_XJO=** /"_^&L/C9_T8_X[
M_P# JV_^*H_X:P^-G_1C_CO_ ,"K;_XJO=** /"_^&L/C9_T8_X[_P# JV_^
M*H_X:P^-G_1C_CO_ ,"K;_XJO=** /"_^&L/C9_T8_X[_P# JV_^*H_X:P^-
MG_1C_CO_ ,"K;_XJO=** /"_^&L/C9_T8_X[_P# JV_^*H_X:P^-G_1C_CO_
M ,"K;_XJO=** /"_^&L/C9_T8_X[_P# JV_^*H_X:P^-G_1C_CO_ ,"K;_XJ
MO=** /"_^&L/C9_T8_X[_P# JV_^*H_X:P^-G_1C_CO_ ,"K;_XJO=** /"_
M^&L/C9_T8_X[_P# JV_^*H_X:P^-G_1C_CO_ ,"K;_XJO=** /"_^&L/C9_T
M8_X[_P# JV_^*H_X:P^-G_1C_CO_ ,"K;_XJO=** /"_^&L/C9_T8_X[_P#
MJV_^*H_X:P^-G_1C_CO_ ,"K;_XJO=** /"_^&L/C9_T8_X[_P# JV_^*K%\
M"_MV?$?XB:/+KGA;]CCQA?6\-[-:R36>H6[HLL;;74D[?F!X(Q^)KZ.KPO\
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M6'QL_P"C'_'?_@5;?_%5[I10!X7_ ,-8?&S_ *,?\=_^!5M_\51_PUA\;/\
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M_P =_P#@5;?_ !5>Z44 >%_\-8?&S_HQ_P =_P#@5;?_ !5'_#6'QL_Z,?\
M'?\ X%6W_P 57NE% 'A?_#6'QL_Z,?\ '?\ X%6W_P 51_PUA\;/^C'_ !W_
M .!5M_\ %5[I10!X7_PUA\;/^C'_ !W_ .!5M_\ %4?\-8?&S_HQ_P =_P#@
M5;?_ !5>Z44 >%_\-8?&S_HQ_P =_P#@5;?_ !5'_#6'QL_Z,?\ '?\ X%6W
M_P 57NE% 'A?_#6'QL_Z,?\ '?\ X%6W_P 51_PUA\;/^C'_ !W_ .!5M_\
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M8_X[_P# JV_^*H_X:P^-G_1C_CO_ ,"K;_XJO=** /"_^&L/C9_T8_X[_P#
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M<@%E"D@9P/9: "BBB@ HHHH **** "BBB@ HHHH ***^"/\ @M1_P7*^#?\
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M-=?^,/Q2\1PZ/X:\+:-<ZKK^JSH[)9V=O$TLTK! 6(5%8X4$G' )K\9?!O\
MP<I?%S]L[_@M+\&OV;?V0+>ZT/X!^(]8;3;N^\0^&HEN_%VU;CS+R)ID,EM
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MU[_@J3K?A.U\.:WX<\":]=:QH\+%[9=8TY)D5(#)DF.:5(BBL25\X(S,5+$
M^ZZ*_(0?\% /^"XD?_!-/]EG3/@/\*+[XG?&_P"/\#ZCXF^+.K^!570O"6G7
M5SYFGM<K86\=K;EK6>$^9*I4)!(Q21I%QN_\$X_^"GG_  4N^''_  5>O_\
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MC^-OBCPWJ/C;XD:J]QYZ1W-M;W-S;Z<LI_U\AGFE,DHXDFG(&Y41CS7[6?\
MP:H_#;]K?]K_ ,:_MG>*?V]_B3I'B?QCX@GU('2]-ME.FQ,/+AM89=P?RXH
MD"\Y*( :TO!'_!L58_#_ /9M^+_[.ND_\%%_B1J4/Q>T33-*U'5/$FFQWITV
MWM-0BO'$,?GJ"9O+\IB6'R,W6@#K/^"%NJ_!+_@G!_P0Z^&/QD_:Q^+6B>"K
M?QW/<^*]=\1>*-12VBNKK59Y)K7YW/SR/9I;8 R6V$CBOC__ (.#O@1X@_9"
M^+?PV_X+OZ-^T5!\:=&;XF:<WA3X3?$5);OP_I]K<V37-O)I86?"+MLQ*=J
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M#O\ P2F^#WQ1\2?#GX?Z)JMK>W]]ID<5W>ZWY3RSN+MI JR-+=2)<LP  >%
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M\%=.\<>$H?VG/V[?BY\7_AIX NQ-X+^$_B>^*:78H""(&'FNHA(4!T@CM]X
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M]M\4_!_0M2\S3KKY@1$"TBHZ+@!#<0SLH5<LV* /;O\ @B1\5_@__P %4_\
M@D7\.=0^.7[+7@B#3/"VI?V.?!L>@I)H8N=*<+;7-O:S;U"A3&^UMVV4/@G
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MC_LB:+^R+X$^(.I^)]-T74KZ\BUC5[6.&>1KJX>=E*Q_* I<@>PH ^@:***
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MNUU75ET=)[C7[#2(!&MM(@D183*Z12%P6VF/A3G( ,W_ ()[WWP6_P""1O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M? ^W_90\9:38Z=XIM=7N_$VF:MH%O>)J'V6:Q$<9>12\2E9I%)C93ALY! (
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MEUX[_MGXC'2;7PUX+U6_L;=)-5\13PF-;UK=$$.4"37CQ*@C(A9 H! KQO\
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MI\%FNL6QN)TMKY88$2),M!/$1&@7;#&_66OO>@ HHHH **** "BBB@ HHHH
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M /[2/ARZ\8_L[?'+P?X^TBQOVL;W5?!?B:UU6VM[I41V@>6VD=4D"21L4)#
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M7F7[/7[:7[(G[6BWO_#,7[37@7Q])IJAM1M_"?BBUOIK12<!I8XG+QJ3P"P
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M*+2;2]DM/#-NLK_V>HNHI8XGN5@F!D"B1"UL5($ASC?\'"W_  4K_:4_8^\
M_#7]ES_@G[?L?V@?C/XMBLO"45II=K?36EA"Z^=*(;J.2'=+(\,"F5"H1IW!
M!BW  _1JBOCG_@A/_P %&+__ (*8_P#!/+PO\:/'>J13_$#09I/#OQ)C2WCA
M;^U[8+FX,4:JL?GPO#<;5545I610 F!^>/\ P0*_X.2OV@OVH/VW-3_8X_X*
M"^/=(OSXP=H/AIKMMHMMIXM]2A9S]@E\A$5_M$?^K9OF\V)4&3,, '[J45^;
M'BO_ (*.?M8:5_P<L>&?^";]EXYLE^$VI?#B35[O0CHEL9VNQIEW<!Q<E/.
M\R)#M#8XQT-?+/B'_@H!_P %\/VNO^"P/Q\_8!_8%_:3^'/A[3OAE?7U[I]O
MXW\,VBQ1Z;#<VUN(Q.MC<222;[E#\PY 8[N " ?N;17XR_"G_@J/_P %HOV
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MH/QO\:/C/XRT\:?J_P 1/'MRK2Q6G[K,4$0+%-PAA4L[N52%$38NX, >L_\
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M'_A!\,?#T.D>'/"VBVNDZ#I=N24M+.WB6*&(%B20J(HR22<9))H _&+]L/\
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MS\0/%/Q%UBP\0>-M>U.0WVCQ"QM;C[5%(7Q#-YEU-.9B,L=H.53%?J-^R_\
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MC]IO0?'7PEAU-+KX4Z?8>'$L]0LS-)+)>27KA,EV)B"KYLR\,04&$'4>.?\
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M_P#\%E?V%X?V2OA[IW@Q?%GQ2T:;Q%X3T69UM$:WU[2XX+U8&8B-Y5DDC9E
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M38K*75_MMQ>LH/SD+NS&I6OLO_@G+_P;C_LW?L-_M%_\-D?%GXY>,_C=\5X
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M>KERL8)9G=SR\CNSR.YY9W9CR:_-S_@Y"^%^N_ KXN?LS?\ !87PEH\]S:_
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MTZ:/1_C!X_N= ^%L]Q$4>XT"RN&#7 SU1_*LXNV'LY1V%?J]0 4444 %%%%
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M^-7PGL#XH_:)LO"$GQJCD62/^VFFET&&2WF4, BK'<3183:0&/?FOMGX:_\
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M']KYO@AIMS\5KGPC8^(S\0;EI'U))WUF& 0K(6PL"VK>0(0-FT;L;_GKGO\
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M;J4^DW8NM*FO[&.9[.<=)8BX)C<8X9<'WK2HHH **** "BBB@ HHHH ****
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K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 20, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCUTIS BIOTHERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2974255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3027 Townsgate Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Westlake Village<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">418-5006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARQT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,527,940,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,033,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant&#8217;s Proxy Statement for the registrant&#8217;s 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K to the extent stated herein. The Proxy Statement will be filed within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001787306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Los Angeles, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 42,907<span></span>
</td>
<td class="nump">$ 71,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">178,075<span></span>
</td>
<td class="nump">156,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">146,229<span></span>
</td>
<td class="nump">73,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">22,634<span></span>
</td>
<td class="nump">14,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">21,079<span></span>
</td>
<td class="nump">19,656<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">411,232<span></span>
</td>
<td class="nump">335,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">14,812<span></span>
</td>
<td class="nump">9,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">4,467<span></span>
</td>
<td class="nump">1,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,419<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">432,973<span></span>
</td>
<td class="nump">348,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,528<span></span>
</td>
<td class="nump">14,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">116,310<span></span>
</td>
<td class="nump">66,793<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">129,838<span></span>
</td>
<td class="nump">81,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long-term</a></td>
<td class="nump">5,266<span></span>
</td>
<td class="nump">2,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">107,959<span></span>
</td>
<td class="nump">107,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">243,494<span></span>
</td>
<td class="nump">191,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized; 123,332,672 and 117,848,033 shares issued and outstanding at December&#160;31, 2025 and 2024, respectively</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,327,595<span></span>
</td>
<td class="nump">1,279,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,138,084)<span></span>
</td>
<td class="num">(1,121,943)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">189,479<span></span>
</td>
<td class="nump">157,541<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 432,973<span></span>
</td>
<td class="nump">$ 348,889<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">123,332,672<span></span>
</td>
<td class="nump">117,848,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">123,332,672<span></span>
</td>
<td class="nump">117,848,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 372,072<span></span>
</td>
<td class="nump">$ 166,542<span></span>
</td>
<td class="nump">$ 29,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Other revenue</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,420<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">376,072<span></span>
</td>
<td class="nump">196,542<span></span>
</td>
<td class="nump">59,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">36,695<span></span>
</td>
<td class="nump">19,128<span></span>
</td>
<td class="nump">4,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">77,051<span></span>
</td>
<td class="nump">76,420<span></span>
</td>
<td class="nump">110,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">274,553<span></span>
</td>
<td class="nump">229,391<span></span>
</td>
<td class="nump">185,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">388,299<span></span>
</td>
<td class="nump">324,939<span></span>
</td>
<td class="nump">300,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,227)<span></span>
</td>
<td class="num">(128,397)<span></span>
</td>
<td class="num">(241,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">8,897<span></span>
</td>
<td class="nump">16,126<span></span>
</td>
<td class="nump">12,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(12,083)<span></span>
</td>
<td class="num">(27,168)<span></span>
</td>
<td class="num">(29,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(731)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(14,970)<span></span>
</td>
<td class="num">(139,392)<span></span>
</td>
<td class="num">(259,027)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="nump">3,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,141)<span></span>
</td>
<td class="num">(140,039)<span></span>
</td>
<td class="num">(262,140)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="num">(206)<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">169<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (16,178)<span></span>
</td>
<td class="num">$ (140,050)<span></span>
</td>
<td class="num">$ (261,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in USD per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
<td class="num">$ (3.78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in USD per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
<td class="num">$ (3.78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share, basic (in shares)</a></td>
<td class="nump">127,234,000<span></span>
</td>
<td class="nump">120,958,000<span></span>
</td>
<td class="nump">69,305,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share, diluted (in shares)</a></td>
<td class="nump">127,234,000<span></span>
</td>
<td class="nump">120,958,000<span></span>
</td>
<td class="nump">69,305,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Secondary Equity Public Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Secondary Equity Public Offering</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Secondary Equity Public Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,037,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 209,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 930,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,086)<span></span>
</td>
<td class="num">$ (719,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">33,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares of common stock, net of issuance costs</a></td>
<td class="nump">3,136<span></span>
</td>
<td class="nump">$ 95,765<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3,136<span></span>
</td>
<td class="nump">$ 95,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon the exercise of stock options</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon the vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises', window );">Lapse of repurchasing rights related to common stock issued pursuant to early exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued pursuant to the ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued pursuant to the ESPP</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">38,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(262,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(262,140)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,787,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">88,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,070,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(981,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon the exercise of stock options</a></td>
<td class="nump">2,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon the vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued pursuant to the ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued pursuant to the ESPP</a></td>
<td class="nump">1,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">42,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(140,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,039)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,848,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 157,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,279,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(1,121,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon the exercise of stock options (in shares)</a></td>
<td class="nump">714,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon the exercise of stock options</a></td>
<td class="nump">$ 4,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon the vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued pursuant to the ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued pursuant to the ESPP</a></td>
<td class="nump">2,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">41,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,141)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 189,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,327,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
<td class="num">$ (1,138,084)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Lapse Of Repurchase Rights Pursuant To Early Stock Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Lapse of Repurchase Rights Related to Common Stock Issued Pursuant to Early Exercises, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_SecondaryEquityPublicOfferingMember', window );">Secondary Equity Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 10,820<span></span>
</td>
<td class="nump">$ 6,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_SecondaryEquityPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arqt_SecondaryEquityPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,141)<span></span>
</td>
<td class="num">$ (140,039)<span></span>
</td>
<td class="num">$ (262,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">40,364<span></span>
</td>
<td class="nump">41,730<span></span>
</td>
<td class="nump">38,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="nump">5,404<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion on marketable securities</a></td>
<td class="num">(2,094)<span></span>
</td>
<td class="num">(6,901)<span></span>
</td>
<td class="num">(6,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items, net</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="nump">1,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(73,163)<span></span>
</td>
<td class="num">(47,259)<span></span>
</td>
<td class="num">(17,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(7,329)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="num">(5,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,007)<span></span>
</td>
<td class="num">(948)<span></span>
</td>
<td class="num">(8,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,694)<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
<td class="nump">3,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">50,044<span></span>
</td>
<td class="nump">32,033<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(680)<span></span>
</td>
<td class="num">(735)<span></span>
</td>
<td class="num">(657)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,625)<span></span>
</td>
<td class="num">(112,158)<span></span>
</td>
<td class="num">(247,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(246,986)<span></span>
</td>
<td class="num">(254,820)<span></span>
</td>
<td class="num">(225,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">227,419<span></span>
</td>
<td class="nump">288,783<span></span>
</td>
<td class="nump">406,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(686)<span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Milestone payment for intangible asset</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(30,253)<span></span>
</td>
<td class="nump">28,820<span></span>
</td>
<td class="nump">180,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">161,682<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">4,597<span></span>
</td>
<td class="nump">2,807<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of common stock for ESPP</a></td>
<td class="nump">2,376<span></span>
</td>
<td class="nump">1,713<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts', window );">Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">95,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts', window );">Proceeds from issuance of shares under ATM, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,973<span></span>
</td>
<td class="nump">66,202<span></span>
</td>
<td class="nump">101,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">168<span></span>
</td>
<td class="num">(235)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(28,737)<span></span>
</td>
<td class="num">(17,371)<span></span>
</td>
<td class="nump">34,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">71,952<span></span>
</td>
<td class="nump">89,323<span></span>
</td>
<td class="nump">54,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">43,215<span></span>
</td>
<td class="nump">71,952<span></span>
</td>
<td class="nump">89,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest expense paid in cash</a></td>
<td class="nump">$ 10,327<span></span>
</td>
<td class="nump">$ 22,209<span></span>
</td>
<td class="nump">$ 25,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock And Pre-Funded Warrants, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Shares Under At-the-Market Offering, Net of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arcutis Biotherapeutics, Inc. (the Company) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The Company&#8217;s strategy is to focus on validated biological targets and to use its drug development platform and deep dermatology expertise to develop differentiated products that have the potential to address the major shortcomings of existing therapies in its targeted indications.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received U.S. Food and Drug Administration (FDA) approval of its first product, ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) cream 0.3% (ZORYVE cream 0.3%), in July 2022, for the treatment of plaque psoriasis, including intertriginous psoriasis, in individuals 12 years of age and older (subsequently approved down to 6 years old in October 2023), and began U.S. commercialization in August 2022. The Company also received Health Canada approval of ZORYVE cream 0.3% in plaque psoriasis in April 2023 and began Canadian commercialization in June 2023. The Company received FDA approval of ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) topical foam 0.3% (ZORYVE foam), in December 2023, for the treatment of seborrheic dermatitis in individuals 9 years of age and older, and began U.S. commercialization in January 2024. The Company received FDA approval of ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) cream 0.15% (ZORYVE cream 0.15%) and began U.S. commercialization, in July 2024, for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. The Company received Health Canada approval of ZORYVE foam for seborrheic dermatitis in October 2024, and began Canadian commercialization in December 2024. The Company received Health Canada approval for ZORYVE cream 0.15% for atopic dermatitis in March 2025, and began Canadian commercialization in April 2025. The Company also received FDA approval of ZORYVE foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and adolescents 12 years of age and older in May 2025, and began U.S. commercialization in June 2025. The Company received FDA approval of ZORYVE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (roflumilast) cream 0.05% (ZORYVE cream 0.05%) in October 2025 and began commercialization for the topical treatment of mild to moderate atopic dermatitis in children ages 2 to 5 years of age.  The Company received Health Canada approval for ZORYVE foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and adolescents 12 years of age and older in October 2025, and began Canadian commercialization in November 2025.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred significant annual losses and negative cash flows from operations since its inception and had an accumulated deficit of $1,138.1 million and $1,121.9 million as of December&#160;31, 2025 and 2024, respectively. The Company may continue to incur operating losses. The Company had cash, cash equivalents, restricted cash, and marketable securities of $221.3&#160;million and $228.6&#160;million as of December&#160;31, 2025 and 2024, respectively. The Company had $100.0&#160;million outstanding under the Loan Agreement as of December&#160;31, 2025. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing capital resources will be sufficient to meet the projected operating requirements for at least 12 months from the date of issuance of its financial statements. If the Company's available cash, cash equivalents and marketable securities and anticipated future cash flows from operations are insufficient to satisfy its liquidity requirements, the Company may need to raise additional capital to fund its operations. No assurance can be given as to whether additional financing will be available on terms acceptable to the Company or at all. If sufficient funds on acceptable terms are not available when needed, the Company may be required to curtail certain planned activities. Failure to manage discretionary spending or raise additional funds, as needed, may adversely impact the Company&#8217;s ability to achieve its intended business objectives and have an adverse effect on its results of operations and future prospects.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and all intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts, which are not material, have been reclassified to conform to current year presentation in the consolidated balance sheets, consolidated statements of operations and comprehensive loss, consolidated statement of cash flows and the notes to the consolidated financial statements.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions include those related to revenue recognition, accrued and prepaid research and development expenses, and income taxes. Additionally, the Company uses available market information to assess the fair value of its marketable securities. The Company regularly evaluates its estimates using historical experience, expectations of future impacts and other assumptions that the Company believes are reasonable, and the Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. If actual results differ from those estimates, the Company includes the updates in its consolidated financial statements in the period the actual amounts become known.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with original maturities of greater than three months are classified as marketable securities on the balance sheet. Marketable securities consist of investment grade short to intermediate-term fixed income investments that have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the consolidated balance sheets due to their highly liquid nature and availability for use in current operations. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive income (loss) on the consolidated balance sheets. Realized gains and losses as well as credit losses, if any, on marketable securities are included in other income (expense), net in the statements of operations and comprehensive loss. Interest on marketable securities is included in interest income in the statements of operations and comprehensive loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. In making this judgment, the Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost, the Company's intent to sell or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, the financial condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular security. To date, no such credit losses have occurred or have been recorded. The cost of investments sold is based on the specific-identification method.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables, net</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s trade accounts receivable consists of amounts due primarily from pharmaceutical wholesalers and specialty pharmacy providers in the United States and Canada (collectively, its customers) related to sales of ZORYVE and have standard payment terms. For certain customers, the trade accounts receivable for the customer is net of distribution service fees, prompt pay discounts, and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company will reserve against trade accounts receivable for estimated credit losses that may arise and any amounts determined to be uncollectible will be written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was not material as of December&#160;31, 2025 and 2024 and the amounts of trade receivable amounts written off for the years ended December&#160;31, 2025, 2024, and 2023 were not material.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories at the lower-of-cost or net realizable value. The Company determines the cost of its inventories, which includes costs related to products held for sale in the ordinary course of business, products in process of production for such sale, and items to be currently consumed in the production of goods to be available for sale, on a first-in, first-out (FIFO) basis. Due to the nature of the Company&#8217;s supply chain process, inventory that is owned by the Company is physically stored at third-party warehouses, logistics providers, and contract manufacturers. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. If they occur, such charges are recorded as a component of cost of sales in the consolidated statements of operations and comprehensive loss. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products that may be used in clinical development programs are excluded from inventory and their costs are charged to research and development expense in the consolidated statement of operations as incurred, as long as they do not have an alternative use. Prior to the initial dates of regulatory approval, costs related to the production of inventory were recorded as research and development expense on the Company&#8217;s consolidated statements of operations and comprehensive loss in the period incurred.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, net</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid a milestone payment of $7.5&#160;million to AstraZeneca in the third quarter of 2022 related to the FDA approval and launch of ZORYVE cream 0.3%. This milestone payment was capitalized as an intangible asset and will be amortized to cost of sales over its useful life of 10 years from the date of first commercial sale, as this is the minimum amount of time that the related License Agreement will be in effect. The Company paid additional milestone payments of $5.0&#160;million related to the achievement of $100.0&#160;million worldwide net sales in October 2024 and $10.0&#160;million related to the achievement of $250.0&#160;million worldwide net sales in May 2025. These milestone payments were recorded as cumulative catch-up adjustments to the carrying value of the intangible asset. Amortization expense was $4.7&#160;million, $2.0&#160;million, and $0.8&#160;million for the years ended December&#160;31, 2025, 2024, and 2023</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. See Note 7. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future amortization expense for the intangible assets subsequent to December&#160;31, 2025 is as follows (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:76.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its long-lived assets, including intangibles, for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results. No impairment losses were recorded for the years ended December&#160;31, 2025, 2024, and 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Other Investments</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity (VIE). If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company&#8217;s consolidated financial statements. The Company&#8217;s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by either the financial institutions holding its cash or by its customers owing trade receivables to the extent recorded on the consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance sheets. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for credit losses.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments, in addition to those presented in Note 4, include cash equivalents, accounts receivable, accounts payable, accrued liabilities, and long-term debt. The carrying amount of cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to their short maturities. As the long-term debt is subject to variable interest rates that are based on market rates which regularly reset, the Company believes that the carrying value of the long-term debt approximates its fair value.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis on the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets which range from <span style="-sec-ix-hidden:f-426">two</span> to five years. Leasehold improvements are depreciated on a straight-line basis over the shorter of their estimated useful lives or lease terms. Maintenance and repairs are expensed as incurred. The Company reviews the carrying values of its property and equipment for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. There were no impairments recognized during the years ended December 31, 2025, 2024 and 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information available at lease commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the lease liability, includes any lease payments made prior to or on lease commencement and is adjusted for lease incentives and initial direct costs incurred, as applicable. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreements includes lease and non-lease components and the Company has elected to not separate such components for all classes of assets. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with terms of 12 months or less (short-term leases) for all classes of assets.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Prepaid Research and Development Expenses</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records prepaid expenses and accrued liabilities for estimated research and development activities conducted by third-party service providers, which include the conduct of nonclinical studies, clinical trials, and contract manufacturing activities. These costs are a significant component of the Company&#8217;s research and development expenses. The Company records these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid costs balances in each reporting period. As actual costs become known, the Company adjusts its balances for these activities. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its product to its customers in the United States and Canada. The Company&#8217;s customers subsequently resell the products to pharmacies, health care providers, and patients. In accordance with ASC 606, the Company recognizes net product revenue from sales when the customers obtain control of the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s products, which typically occurs upon delivery to the customer. The Company&#8217;s payment terms are generally between 30 - 65 days.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales are recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution service fees, (b) government and private payer rebates, chargebacks, discounts and fees, (c) product returns and (d) costs of co-pay assistance programs for patients, as well as other sales deductions. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to trade receivables, net if payable to a customer or accrued liabilities if payable to a third-party. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is recognized as product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results vary from the Company&#8217;s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Service Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: data reporting, inventory management, chargeback administration, and service level commitment. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Pay Discounts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company provides some of its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from its gross product revenue and accounts receivable at the time such revenue is recognized.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company provides customers a credit for all products returned in accordance with the Company&#8217;s returned goods policy. Once the product is returned, it is destroyed. The Company does not record a right-of-return asset.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the early product launch period, the Company estimated its provision for sales returns based on industry data and adjusted the transaction price for such estimates at the time of sale to the customer. As the Company continues to collect data on its actual product returns, it has and will continue to refine its estimated returns rate and adjust its accrual, which affects revenue in the period of adjustment. No such material adjustments were recorded for the year ended December 31, 2025. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargeback</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: A chargeback is the difference between the manufacturer's invoice price to the wholesaler and the wholesaler&#8217;s customer's contract price. The wholesaler tracks these sales and "charges back" the manufacturer for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price for such discount at the time of sale to the customer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Discounts:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accrues rebates for contractually agreed-upon discounts with private payers and mandated discounts under government programs such as the Medicaid Drug Rebate Program in the United States. The Company's estimates for expected utilization of private payer rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates are generally invoiced and paid in arrears. The accrual balance consists of invoiced amounts not yet paid as well as an estimate of the amount expected to be incurred but not yet invoiced to the Company as of the end of the reporting period. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product revenue, net in the period of adjustment.</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other revenue is related to the Huadong License and Collaboration Agreement and Sato License Agreement. See Note 7. The Company evaluated the agreements with Huadong and Sato and determined that they are within the scope of ASC 606. The Company applied the five-step model as required by ASC 606 to determine revenue recognition.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The nonrefundable upfront payments received in connection with the transfer of the license and related know-how to Huadong in September 2023 and to Sato in March 2024 were determined to be distinct performance obligations, and therefore were recognized in Other revenue. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluated whether the development and regulatory milestones are considered probable of being reached and determined that their achievement is highly dependent on factors outside of the Company&#8217;s control. Therefore, these payments are subject to significant revenue reversal and are therefore not included in the transaction price. At the end of each reporting period, the Company will re-evaluate the probability of achievement of each milestone and, if necessary, adjust its estimate of the overall transaction price and accordingly recognize the related revenue once the probability of significant reversal of revenue is low. Any such adjustments are recorded on a cumulative catch-up basis, and would be reported in Other revenue in the period of adjustment. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sales milestones and royalties will be recognized in Other revenue when the related sales occur.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes direct and indirect costs related to the manufacturing and distribution of ZORYVE, including raw materials, third-party manufacturing costs, packaging services, freight-in, third-party royalties payable on the Company&#8217;s net product revenue, and amortization of certain intangible assets associated with ZORYVE. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon related FDA approval dates for each product. As a result, manufacturing and other inventory costs incurred prior to FDA approval were expensed and, therefore, are not included in cost of sales.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, license fees, stock-based compensation expense, materials, supplies, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company&#8217;s license agreements have been considered an acquisition of a business. For asset acquisitions, contingent consideration is recognized when the contingency is resolved and the consideration is paid or becomes payable. The upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when paid or become payable, provided there is no alternative future use of the rights in other research and development projects.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are expensed as incurred and consist primarily of salaries and related costs, including payroll taxes, benefits, stock-based compensation, and travel, and costs related to sales and marketing of ZORYVE. Other selling, general and administrative expenses include legal costs of pursuing patent protection of the Company's intellectual property, insurance, and professional services fees for auditing, tax, </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and general legal services. Advertising costs are expensed as incurred and were $25.3&#160;million, $6.9&#160;million, $11.2&#160;million for the years ended December&#160;31, 2025, 2024, and 2023, respectively.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for such awards is the date of grant and the expense is recognized on a straight-line basis over the expected vesting period. For share-based awards that vest subject to a performance condition, the Company will recognize compensation cost for awards if and when the Company concludes that it is probable that the awards with a performance condition will be achieved on an accelerated attribution method. The Company accounts for forfeitures as they occur.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets for the United States have been fully offset by a valuation allowance. The Company has an immaterial deferred tax asset related to foreign jurisdictions which is not offset by a valuation allowance.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties incurred in relation to the unrecognized tax benefits.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company translates the assets and liabilities of its foreign subsidiaries where the local currencies have been determined to be the functional currencies into U.S. dollars using current exchange rates. Adjustments for foreign currency translation adjustments are recognized in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. The earnings or loss of these subsidiaries are translated in U.S. dollars using average exchange rates in effect during each reporting period.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promotion Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n July 2024, the Company entered into a promotion agreement with Kowa Pharmaceuticals America, Inc. (Kowa) to leverage Kowa's primary care sales force to exclusively market and promote ZORYVE to primary care practitioners and pediatricians for all FDA-approved indications until July 2029. The Company recognizes all revenue and Kowa receives a commission for the net sales attributed to Kowa. The commission is recorded in selling, general and administrative expense. For the years ended December&#160;31, 2025 and 2024, revenue from sales attributed to Kowa and related commissions paid or owed to Kowa were not material. Effective January 23, 2026, Kowa and the Company mutually agreed to terminate the promotion agreement. Following this termination, Kowa ceased all sales and promotions of ZORYVE and the Company will not be required to make any further payments to Kowa.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of any recent Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB). Other than the ASUs listed below, all other ASUs were assessed and determined to be either not applicable to the Company or are expected to have minimal impact on the Company's consolidated financial statements.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Improvements to Income Tax Disclosures, which requires qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The Company adopted the guidance for the year ended December 31, 2025 and applied any presentational changes from this new standard to all prior years to allow for comparability. See Note 11. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized under guidance within ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table presents the Company's disaggregated revenue for the periods presented (in thousands):</span></div><div style="margin-top:8pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:52.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.3%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE foam</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.15%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.05%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,542&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue relates primarily to the Sato and Huadong licensing agreements. See Note 7.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net outside the United States represented less than 10% of the Company&#8217;s consolidated product revenue, net for the years ended December 31, 2025, 2024 and 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major customers are defined as customers that individually accounted for greater than 10% of the Company's revenue. The following table presents each major customer that accounted for more than 10% of its gross product sales.</span></div><div style="margin-top:8pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:52.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of gross product sales</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer E</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer F</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross product sales from major customers</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">* Represents less than 10% of respective balance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div>As of December&#160;31, 2025, amounts due from four of these customers each exceeded 10% of gross trade receivables and accounted for 60% of net trade receivables on a combined basis. As of December&#160;31, 2024, amounts due from five of these customers each exceeded 10% of gross trade receivables and accounted for 69% of net trade receivables on a combined basis.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,063</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,919</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></div></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,955</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,623</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,958</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,997</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and U.S. Treasury and agency securities are valued based on quoted market prices in active markets, with no valuation adjustment.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper, certificates of deposit and corporate debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated value of the Company&#8217;s cash, cash equivalents and marketable securities, and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,301&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,620&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, no significant facts or circumstances were present to indicate a deterioration in the creditworthiness of the issuers of the available-for-sale securities. The Company generally holds its marketable securities until maturity and does not intend to sell, and is not required to sell, the investments that are in an unrealized loss position before the recovery of their amortized cost basis. For all securities with a fair value less than its amortized cost basis, the Company determined the decline in fair value below amortized cost basis to be non-credit related and no allowance for losses has been recorded. As of December&#160;31, 2025, there were no individual securities that were in a significant unrealized loss position. To date, the Company has not recorded any impairment charges on available-for-sale securities.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the practical expedient to exclude the applicable accrued interest from both the fair value and the amortized cost basis of its available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable related to available-for-sale securities is presented in prepaid expenses and other current assets, separate from marketable securities, on the consolidated balance sheet. As of December&#160;31, 2025 and 2024, accrued interest receivable was immaterial. The Company has made an accounting policy election not to recognize an allowance for credit losses for accrued interest receivables on available-for-sale securities and to write-off any uncollectible accrued interest receivable by recognizing credit loss expense. The Company has not written off any accrued interest receivables for the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the amortized cost and fair value of marketable securities by contractual maturity were as follows: </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturing within one year</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,281</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,395</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,708</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturing in one to five years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,681</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,680</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,593</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,602</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,962</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,075</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,301</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,620</span></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in the fair value of the embedded derivative instrument for the year ended December&#160;31, 2025 and 2024 (in thousands). There was no activity for the year ended December&#160;31, 2023. </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-608"><span style="-sec-ix-hidden:f-609">Loss (gain) from changes in fair value</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570</span></td></tr></table></div>The fair value of the Company&#8217;s embedded derivative instrument is based on significant inputs not observed in the market, and thus represents a Level 3 measurement. See Note 9 for further discussion on the embedded derivative instrument.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,634&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid co-pay assistance program and rebates</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,079&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,656&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,793&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $0.7 million, $0.6 million, and $0.8 million for the years ended December&#160;31, 2025, 2024, and 2023 respectively. Leasehold improvements are depreciated over the term of the lease, which is the shorter of the improvements' expected useful lives and the lease term. All other fixed asset depreciation is recorded using the straight-line method over the estimated useful lives of the assets (<span style="-sec-ix-hidden:f-663">two</span> to five years).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements &amp; Ducentis Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract', window );"><strong>License Agreements And Ducentis Acquisition Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_LicenseAgreementsAndAcquisitionsTextBlock', window );">License Agreements &amp; Ducentis Acquisition</a></td>
<td class="text">License Agreements &amp; Ducentis Acquisition<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sato License Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, the Company entered into a license agreement with Sato Pharmaceutical Co., Ltd. (Sato). Pursuant to the terms of the license agreement with Sato (the Sato Agreement), the Company grants to Sato an exclusive, sublicensable (under certain circumstances) license under certain patent rights and know-how controlled by the Company for Sato to develop, conduct medical affairs activities for, manufacture, commercialize and otherwise exploit roflumilast formulations (the Sato Licensed Products) for all therapeutic uses for certain dermatological indications in humans (the Sato Field) in Japan. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sato Agreement sets forth each party&#8217;s respective obligations with respect to the development, medical affairs activities, manufacture, supply and commercialization of the Sato Licensed Products. Pursuant to the terms of the Sato Agreement, Sato will, at its expense, develop, obtain regulatory approval for, commercialize and conduct medical affairs activities related to the Sato Licensed Products in the Sato Field in Japan, subject to certain of the Company&#8217;s approval and oversight rights. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Sato Agreement, the Company received an upfront payment of $25.0&#160;million and will potentially receive additional payments (i) up to an aggregate amount of $10.0&#160;million upon the achievement of certain regulatory milestones and (ii) up to an aggregate amount of $30.0&#160;million upon the achievement of certain sales milestones. In addition, on a Sato Licensed Product-by-Sato Licensed Product basis, commencing from the first commercial sale of such Sato Licensed Product in Japan until the latest of (i) the expiration of the last valid claim in the intellectual property rights licensed by the Company to Sato under the Sato Agreement covering such Sato Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Sato Licensed Product in Japan, or (iii) ten years after the first commercial sale of such Sato Licensed Product in Japan, </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company will receive low double-digit to mid-teen double-digit percentage royalties on Sato&#8217;s, its affiliates&#8217; and sublicensees&#8217; total annual net sales of all Sato Licensed Products, subject to certain royalty reductions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The term of the Sato Agreement continues until, on a Sato Licensed Product-by-Sato Licensed Product basis, the expiration of the Royalty Term, which is the (i) the expiration of the last valid claim in the licensed technology covering such Sato Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product in Japan, or (iii) ten years after the first commercial sale of such Licensed Product in Japan. The Sato Agreement may be terminated by either party in its entirety if the other party commits a material breach, subject to a cure period, or if the other party becomes insolvent. Sato may terminate the Sato Agreement at-will in its entirety upon 90 days&#8217; written notice. Unless unenforceable under applicable law, the Company may terminate the Sato Agreement in its entirety if Sato, its affiliate or sublicensee contests or assists a third party in contesting the scope, validity or enforceability of any patent or patent application licensed by the Company to Sato. The Company may also terminate the Sato Agreement if Sato or any director, officers, employee, agent, affiliate, sublicensee or subcontractor is charged by a governmental authority for a violation of any anti-corruption, anti-money laundering, sanctions or export or import control laws or regulations, or, subject to the terms of the Sato Agreement, if Sato, its affiliates and sublicensees do not conduct any material development or commercialization activities of a Sato Licensed Product in Japan for a certain period of time.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no other revenue recorded pursuant to the Sato Agreement for the year ended December 31, 2025 and $25.0&#160;million recorded for the year ended December 31, 2024.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Huadong License Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (Huadong), a wholly owned subsidiary of Huadong Medicine Co., Ltd. Pursuant to the terms of the agreement, the Company granted to Huadong an exclusive, sublicensable (under certain circumstances) license under certain patent rights and know-how controlled by the Company for Huadong to develop, conduct medical affairs activities for, manufacture, commercialize, and otherwise exploit both cream and foam topical roflumilast for all therapeutic uses for certain dermatological indications (Huadong Licensed Products) in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and Southeast Asia (Indonesia, Singapore, The Philippines, Thailand, Myanmar, Brunei, Cambodia, Laos, Malaysia, and Vietnam) (Huadong Territories).</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Huadong will, at its expense, develop, obtain regulatory approval for, commercialize, and conduct medical affairs activities for the Huadong Licensed Products, subject to certain of the Company&#8217;s approval and oversight rights. The Company will retain exclusive rights for the development, manufacture and commercialization of topical roflumilast outside the Huadong Territories.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the rights granted under the license agreement with Huadong (the Huadong Agreement), Huadong paid the Company a non-refundable upfront fee pursuant to the terms of the agreement, upon closing in September 2023. The Company received a net payment of $27.0&#160;million, which consisted of a $30.0&#160;million upfront payment less the applicable tax withholding obligation in China of $3.0&#160;million. In addition, the Company received a net payment of $2.7&#160;million in March 2024 related to the achievement of a development and regulatory milestone less the applicable tax withholding. The Company received a net payment of $1.8&#160;million in each of December 2024, March 2025 and November 2025, related to the achievement of development and regulatory milestones less the applicable tax withholding. The Company may also potentially receive additional payments: (i) up to an aggregate amount of $15.0&#160;million upon the achievement of certain development and regulatory milestones, (ii) up to an aggregate amount of $40.3&#160;million upon the achievement of certain sales milestones, and (iii) low double-digit to high-teen double-digit tiered percentage royalties on net sales of the Huadong Licensed Products, all of which would be subject to applicable tax withholding obligations.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Huadong Agreement continues on a Huadong Licensed Product-by-Huadong Licensed Product and country or region-by-country or region basis, until the expiration of the Royalty Term, which is: (i) the date of expiration of the last valid patent claim related to the Huadong Licensed Products, (ii) ten years after the first commercial sale of a Huadong Licensed Product and (iii) the expiration of any regulatory exclusivity as to a Huadong Licensed Product. The Huadong Agreement may be terminated by both parties under certain circumstances.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue and related income tax expense related to the Huadong agreement was $4.0 million and $0.4 million, respectively, for the year ended December&#160;31, 2025. Other revenue and related tax income expense related to the Huadong agreement was $5.0 million and $0.5 million, respectively, for the year ended December&#160;31, 2024. Other revenue and related income tax expense related to the Huadong agreement was $30.0 million and $3.0 million, respectively, for the year ended December&#160;31, 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca License Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company entered into an exclusive license agreement with AstraZeneca AB (AstraZeneca), granting the Company a worldwide exclusive license, with the right to sublicense through multiple tiers, under certain AstraZeneca-controlled patent rights, know-how and regulatory documentation, to research, develop, manufacture, commercialize and otherwise exploit products containing roflumilast in topical forms, as well as delivery systems sold with or for the administration of roflumilast (collectively, the AZ-Licensed Products), for all diagnostic, prophylactic and therapeutic uses for human dermatological indications (the Dermatology Field). Under the license agreement with AstraZeneca (the AstraZeneca Agreement), the Company has sole responsibility for development, regulatory and commercialization activities for the AZ-Licensed Products in the Dermatology Field, at its expense, and it shall use commercially reasonable efforts to develop, obtain and maintain regulatory approvals for, and commercialize the AZ-Licensed Products in the Dermatology Field in each of the United States, Italy, Spain, Germany, the United Kingdom, France, China and Japan.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, the Company paid $7.5&#160;million to AstraZeneca as a result of the approval of ZORYVE cream 0.3%, which was recorded as an intangible asset. In October 2024, the Company paid $5.0&#160;million to AstraZeneca upon achievement of $100.0&#160;million in worldwide net sales, which was recorded as a cumulative catch-up adjustment to the carrying value of the intangible asset. In May 2025, the Company paid $10.0&#160;million to AstraZeneca upon achievement of $250.0&#160;million in worldwide net sales and was recorded as a cumulative catch-up adjustment to the carrying value of the intangible asset. The Company is amortizing the intangible asset to cost of sales over its useful life of 10 years from the date of first commercial sale as this is the minimum amount of time that the related AstraZeneca Agreement will be in effect. Amortization expense was $4.7&#160;million, $2.0&#160;million and $0.8&#160;million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the years ended December&#160;31, 2025, 2024, and 2023,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreed to make additional cash payments to AstraZeneca of up to an aggregate of $5.0 million upon the achievement of specified regulatory approval milestones with respect to the AZ-Licensed Products. With respect to any AZ-Licensed Products the Company commercializes under the AstraZeneca Agreement, it will pay AstraZeneca a low to high single-digit percentage royalty rate on the Company&#8217;s, its affiliates&#8217; and its sublicensees&#8217; net sales of such AZ-Licensed Products, subject to specified reductions, until, as determined on an AZ-Licensed Product-by-AZ-Licensed Product and country-by-country basis, the later of the date of the expiration of the last-to-expire AstraZeneca-licensed patent right containing a valid claim in such country and ten years from the first commercial sale of such AZ-Licensed Product in such country. As a result of the commercialization of ZORYVE cream in August 2022, the Company began accruing royalties payable to AstraZeneca, which are recorded in cost of sales and accrued liabilities. Royalty expense during the years ended December&#160;31, 2025, 2024 and 2023 was $11.2 million, $5.0 million and $0.9 million, respectively. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hengrui Exclusive Option and License Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company entered into an exclusive option and license agreement, or the Hengrui License Agreement, with Jiangsu Hengrui Medicine Co., Ltd. (Hengrui), whereby Hengrui granted the Company an exclusive option to obtain certain exclusive rights to research, develop, and commercialize products containing the compound designated by Hengrui as ivarmacitinib, a Janus kinase type 1 inhibitor, in topical formulations for the treatment of skin diseases, disorders, and conditions in the United States, Japan, and the European Union (including for clarity the United Kingdom). In December 2019, the Company exercised its exclusive option under the agreement and contemporaneously amended the agreement to expand the territory to additionally include Canada. In addition, the Company has agreed to make cash payments of up to an aggregate of $20.5 million upon achievement of specified clinical development and regulatory approval milestones with respect to the licensed products and cash payments of up to an additional aggregate of $200.0 million in sales-based milestones based on certain aggregate annual net sales volumes with respect to a licensed product. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to any products the Company commercializes under the Hengrui License Agreement, it will pay tiered royalties to Hengrui on net sales of each licensed product by the Company, or its affiliates, or its sublicensees, ranging from mid single-digit to sub-teen percentage rates based on tiered annual net sales bands </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to specified reductions. The Company is obligated to pay royalties until the later of (1)&#160;expiration of the last valid claim of the licensed patent rights covering such licensed product in such country and (2)&#160;expiration of regulatory exclusivity for the relevant licensed product in the relevant country, on a licensed product-by-licensed product and country-by-country basis. Additionally, the Company is obligated to pay Hengrui a specified percentage, ranging from the low-thirties to the sub-teens, of certain non-royalty sublicensing income it receives from sublicensees of its rights to the licensed products, such percentage decreasing as the development stage of the licensed products advance.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a side letter agreement with Hengrui and one of its subsidiaries to extend certain rights and obligations under the Hengrui License Agreement to the subsidiary under specified circumstances, including a change of control of such subsidiary. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no payments made or due in connection with Hengrui for the years ended December 31, 2025, 2024 and 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of a Phase 1b study in the middle of 2025, the Company elected to halt further development of ARQ-255, a topical formulation of ivarmacitinib, for the treatment of alopecia areata. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ducentis Biotherapeutics LTD Acquisition</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2022, the Company entered into a Share Purchase Agreement with Ducentis Biotherapeutics LTD (Ducentis) and certain stockholders of Ducentis, pursuant to which the Company acquired all of the outstanding equity interests in Ducentis for (i) 610,258 shares of the Company's common stock, valued at approximately $12.5&#160;million and $15.9&#160;million in cash, inclusive of liabilities acquired, and (ii) contingent payments of up to an aggregate of $400&#160;million, which may become payable upon the achievement of certain development, regulatory, and commercial milestones (the Acquisition). Such contingent payments include a $10.0&#160;million payment due within one year from the first dosing of the first human subject enrolled in the first Phase 1 clinical trial of a therapeutic drug containing Ducentis' DS-234 product candidate, now ARQ-234. The Company anticipates commencing such Phase 1 study in the first quarter of 2026. In addition, if applicable, the Company will make payments amounting to a mid-single-digit percentage of any annual net sales of certain products exceeding $1.5&#160;billion. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for this purchase of equity interests in Ducentis as an in-process research and development (IPR&amp;D) asset acquisition as it has no alternative future use, and recorded a $29.6&#160;million charge to research and development expense on the acquisition date. Any contingent payments made under the Share Purchase Agreement will be recorded when it is probable that they will occur and they can be reasonably estimated, at which point the Company will determine whether the payment should be expensed or capitalized depending on whether the IPR&amp;D has achieved market acceptance. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no payments made or due for the years ended December 31, 2025, 2024 and 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Share Purchase Agreement, the Company will develop and seek FDA approval of a therapeutic product containing ARQ-234 for an atopic dermatitis indication, and if FDA approval of ARQ-234 is obtained by the Company, to commercially launch it in the United States.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LicenseAgreementsAndAcquisitionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreements And Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LicenseAgreementsAndAcquisitionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreements And Ducentis Acquisition Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company's lease for its corporate headquarters (22,643 square feet of office space) commenced in February 2019 and was amended in April 2020 in order to relocate to a new expanded space. In August 2025, the Company entered into a second amendment to extend the term of the lease by five years, extending the lease expiration from August 2028 to July 2033. This second amendment had a net effect of increasing the Company's future lease payments by approximately $5.4&#160;million, primarily due to the <span style="-sec-ix-hidden:f-724">five</span> additional years of rent payments. In accordance with ASC 842, the Company remeasured the present value of the aggregate lease payments over the amended lease term and recorded an increase to the Company&#8217;s operating lease liabilities and existing right-of-use lease asset of approximately $2.9&#160;million in the third quarter 2025 as a result of this remeasurement.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease also requires the Company to have an available letter of credit which has a related restricted cash account of  $0.3&#160;million and $0.6&#160;million as of December&#160;31, 2025 and 2024, respectively. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum annual rental payments of the Company&#8217;s operating lease liability as of December&#160;31, 2025 are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-739">Accrued and other current liabilities</span></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, long-term</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs recognized was $0.8&#160;million, $0.7&#160;million, and $0.7&#160;million for the years ended December&#160;31, 2025, 2024, and 2023, respectively. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information represents supplemental disclosure for the consolidated statements of cash flows related to the Company&#8217;s operating lease (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to the operating lease:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Agreements</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into manufacturing supply agreements for the commercial supply of ZORYVE which include certain minimum purchase commitments. As of December 31, 2025, firm future purchase commitments that are subject to these agreements with a term of greater than one year, excluding those recognized on the consolidated balance sheets, are $1.7&#160;million in 2026 and $0.9&#160;million in 2027, respectively. These future purchase commitments do not represent all of the Company&#8217;s anticipated purchases, but instead represents only the contractually obligated minimum purchases or firm commitments of non-cancelable minimum amounts.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reason of their status or service as directors or officers to the fullest extent permitted by the provisions of the Company's Bylaws and the Delaware General Corporation Law. The Company currently has directors&#8217; and officers&#8217; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes any potential loss exposure under these indemnification agreements in excess of applicable insurance coverage is minimal.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingencies</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company may be involved in legal proceedings, as well as demands, claims, and threatened litigation, which arise in the normal course of business or otherwise. The ultimate outcome of any litigation is uncertain, and unfavorable outcomes could have a negative impact on the Company's results of operations and financial condition. Regardless of outcome, litigation can have an adverse impact on the Company because of the defense costs, the diversion of management resources, and other factors. </span></div>As of December 31, 2025 and 2024, the Company determined that no loss contingencies from legal proceedings&#8212;including the patent infringement complaint filed against the Company by Teva Pharmaceutical Industries, Ltd.&#8212;met the threshold of "probable" and "reasonably estimable", as defined in ASC 450.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2021, the Company entered into a loan and security agreement (the Prior Loan Agreement) with SLR Investment Corp. (SLR) and the lenders party thereto. The Prior Loan Agreement was amended and restated on January 10, 2023 (the AR Loan Agreement) to include Arcutis Canada, Inc. as a borrower and party. On November 1, 2023, the Company entered into an amendment to the AR Loan Agreement to, among others, (i) modify the financial covenant relating to minimum net product revenue, and (ii) include an additional minimum financing covenant. On August 9, 2024, the Company entered into a second amendment to the AR Loan Agreement (the AR Loan Agreement, as amended by the first and second amendments, the Loan Agreement), which it determined to be a modification, to, among others, (i) permit, during the period commencing on October 7, 2024 and ending on December 15, 2024, an optional partial prepayment of term loans outstanding, subject to a 1.0% prepayment penalty (the 2024 Partial Prepayment), (ii) add the tranche C-1 and tranche C-2 term loans, and (iii) facilitate certain other changes, including with respect to the applicable interest rate and maturity date in the event of a 2024 Partial Prepayment. As security for the obligations under the Loan Agreement, the Company granted SLR, for the benefit of the lenders, a continuing security interest in substantially all of the Company's assets, including its intellectual property, subject to certain exceptions. The term loan facility is comprised of (i) a tranche A term loan of $75.0&#160;million, (ii) a tranche B-1 term loan of $50.0&#160;million, (iii) a tranche B-2 term loan of up to $75.0&#160;million, (iv) a tranche C-1 term loan of up to $50.0&#160;million, and (v) a tranche C-2 term loan of up to $50.0&#160;million (collectively, the Term Loans). The tranche A term loan was funded on December 22, 2021. With the approval of ZORYVE cream 0.3% on July 29, 2022, the tranche B term loans were funded on August 2, 2022. As of December&#160;31, 2025 and 2024, the aggregate principal amount outstanding under the Loan Agreement was $100.0&#160;million. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 8, 2024, the Company made a 2024 Partial Prepayment of $100.0&#160;million, which reduced the aggregate principal amount outstanding under the Loan Agreement to $100.0&#160;million. In connection with the 2024 Partial Prepayment, the Company is obligated to pay a prepayment penalty of $1.0&#160;million by June 30, 2026 and a final fee of $6.95&#160;million, representing the final fee applicable to the amount of the 2024 Partial Prepayment, on January 1, 2027.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of such 2024 Partial Prepayment, subject to the Company generating a minimum net product revenue for the trailing six (6) month period ending as of the month prior to the borrowing date equal to 80% of the Company&#8217;s projected net product revenue as set forth in its annual plan for the respective period, the Company will be able to draw down the tranche C-1 and tranche C-2 term loans. The tranche C-1 term loan availability will expire on March 31, 2026 and the tranche C-2 term loan availability will expire on June 30, 2026. In addition, as a result of the 2024 Partial Prepayment, (i) the maturity date of the Loan Agreement is August 1, 2029, (ii) the applicable per annum interest rate is equal to 5.95% plus the greater of (a) 2.50% per annum and (b) the one-month Secured Overnight Financing Rate (SOFR), (iii) the Company is no longer subject to certain cost and purchase price restrictions regarding acquisitions, and (iv) the Company may prepay principal amounts outstanding under the Term Loans in minimum increments of $25.0&#160;million, subject to a prepayment premium of (a) 3.0% for any prepayment made prior to the first anniversary of the second amendment, (b) 2.0% for any prepayment made prior after the first anniversary of the second amendment and prior to the second anniversary of the second amendment, or (c) 1.0% </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for any prepayment made prior after the second anniversary of the second amendment and prior to the maturity date.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Principal amounts outstanding under the Term Loans will accrue interest at a floating rate equal to the applicable rate in effect from time to time, as determined by SLR on the third business day prior to the funding date of the applicable Term Loan and on the first business day of the month prior to each payment date of each Term Loan. Prior to the 2024 Partial Prepayment, the applicable rate was a per annum interest rate equal to 7.45% plus the greater of (a) 0.10% and (b) the one-month SOFR. As a result of such 2024 Partial Prepayment, the applicable interest rate will be a per annum interest rate equal to 5.95% plus the greater of (a) 2.50% and (b) the one-month SOFR. On December&#160;31, 2025, the rate was 9.79%. The benchmark SOFR is subject to change in the event of certain events with respect to the benchmark rate. Interest payments are payable monthly following the funding of any Term Loan. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Term Loans are accelerated due to, among others, the occurrence of a bankruptcy or insolvency event, the Company is required to make mandatory prepayments of (i) all principal amounts outstanding under the Term Loans, plus accrued and unpaid interest thereon through the prepayment date, (ii) any fees applicable by reason of such prepayment, (iii) the prepayment premiums set forth in the paragraph above, plus (iv) all other obligations that are due and payable, including expenses and interest at the Default Rate (as defined below) with respect to any past due amounts.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on the Company&#8217;s ability to dispose of its business or property, to change its line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on its property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. The Company also agreed to a financial covenant whereby the Company must generate a minimum net product revenue equal to 75% of its projected net product revenue as set forth in the Company's annual plan for the respective period, tested on a trailing six-month basis, as of the end of each month. Each annual plan shall be approved by the Company&#8217;s board of directors and SLR, in its capacity as collateral agent, in its reasonable discretion. Any failure by the Company to deliver such annual plan on or before December 15 of the prior year shall be an immediate event of default. The Company was in compliance with all covenants under the Loan Agreement as of December&#160;31, 2025.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Loan Agreement contains customary events of default that entitle the lenders to cause any indebtedness under the Loan Agreement to become immediately due and payable, and to exercise remedies against the Company and the collateral securing the Term Loans. Under the Loan Agreement, an event of default will occur if, among other things, the Company fails to make payments under the Loan Agreement, the Company breaches any of the covenants under the Loan Agreement, subject to specified cure periods with respect to certain breaches, the lenders determine that a material adverse change has occurred, or the Company or the Company's assets become subject to certain legal proceedings, such as bankruptcy proceedings. Upon the occurrence and for the duration of an event of default, an additional default interest rate, or the Default Rate, equal to 4.0% per annum will apply to all obligations owed under the Loan Agreement. The prepayment upon default and other potential additional interest provisions under the Loan Agreement were determined to be a compound embedded derivative instrument to be bifurcated from the loan and accounted for as a separate liability for accounting purposes under the guidance in ASC 815, Derivatives and Hedging. At the inception of the Loan Agreement, the fair value of the embedded derivative was determined to be immaterial. The embedded derivative instrument is remeasured at fair value each reporting period with any future changes in fair value reported in Other income, net in the consolidated statement of operations and comprehensive loss. The amounts recognized in Other income, net related to the change in fair value of the embedded derivative instrument during the year ended December 31, 2025 and 2024 were not material. No gain or loss was recognized during the year ended December 31, 2023. The fair value of the embedded derivative instrument as of December&#160;31, 2025 and 2024 was a liability of $0.4 million and $0.6 million, respectively, and is included in Other-long term liabilities in the accompanying consolidated balance sheets. See Note 4.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n connection with the Loan Agreement, the Company is obligated to pay (i) a final fee equal to 6.95% of the aggregate original principal amount of the Term Loans outstanding as of the date of the second amendment (x) with respect to any 2024 Partial Prepayment, upon the earliest to occur of (a) January 1, 2027, (b) the acceleration of all </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding Term Loans and (c) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, and (y) with respect to the Term Loans outstanding as of the date of the second amendment (other than the 2024 Partial Prepayment), upon the earliest to occur of (a) the maturity date, (b) the acceleration of all outstanding Term Loans and (c) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, (ii) a 2.00% fee with respect to tranche C term loans, due and payable on the earliest to occur of (a) the maturity date, (b) the acceleration of all outstanding Term Loans and (c) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, (iii) a 2.00% extension fee with respect to tranche C term loans which remain unfunded after December 31, 2025, which shall accrue during the period commencing January 1, 2026, and ending on the earliest to occur of (a) the expiration of the tranche C term loan availability, and (b) the date on which tranche C term loan is fully drawn, and (iv) a certain amount of lenders&#8217; expenses incurred in connection with the execution of the Loan Agreement. Additionally, in connection with the original Prior Loan Agreement, the Company previously had entered into an Exit Fee Agreement, whereby the Company agreed to pay an exit fee in the amount of 3.0% of each Term Loan funded upon (i) any change of control transaction or (ii) a revenue milestone, calculated on a trailing six-month basis. Notwithstanding the prepayment or termination of the Term Loan, the exit fee will expire 10 years from the date of the Loan Agreement.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt issuance costs have been recorded as a debt discount which are being accreted to interest expense through the maturity date of the term loan. Interest expense is calculated using the effective interest method, and is inclusive of non-cash amortization of debt issuance costs. The final maturity payment of $13.9&#160;million is recognized over the life of the term loan through interest expense. At December&#160;31, 2025 and 2024, the effective interest rate was 10.92% and 11.57%, respectively. Interest expense relating to the term loan was $12.1&#160;million, $27.2&#160;million and $29.7&#160;million, respectively, for the years ended December&#160;31, 2025, 2024 and 2023.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to the Company's long-term debt (in thousands): </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued final fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued prepayment penalty</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,203&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the contractual maturity of the Company's long term debt, a payment of principal and final fees of $107.0 million is due on August 1, 2029.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's authorized capital stock consists of 310,000,000 shares, all with a par value of $0.0001 per share, of which 300,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock. There were no shares of preferred stock outstanding as of December&#160;31, 2025 and 2024. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Company completed a public sale of its common stock, receiving aggregate net proceeds of $95.8&#160;million. In addition to the sale of common stock, the Company issued prefunded warrants to purchase 7,500,000 shares of the Company's common stock at $2.4999 per underlying share of common stock. The exercise price of the warrants is $0.0001 per underlying share of common stock, were fully exercisable upon issuance, and have no expiration date. In October 2025, certain prefunded warrants were exercised, resulting in the issuance of 2,285,000 shares. As of December&#160;31, 2025, prefunded warrants to purchase 5,215,000 shares of the Company's common stock remained outstanding. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company completed a public sale of its common stock, receiving aggregate net proceeds of $161.7&#160;million.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market (ATM) Offerings</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2021, the Company entered into a sales agreement (Sales Agreement) with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through ATM offerings for an aggregate offering price of up to $100.0&#160;million. Cowen will act as the Company's sales agent for the ATM program and is entitled to compensation for its services up to 3% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In December 2023, the Company sold 1,250,000 shares under the ATM for $2.60 per share and received $3.1&#160;million in net proceeds. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Company amended and restated its Sales Agreement with Cowen to reset the ATM program and provide for the offer and sale of shares of common stock having an aggregate gross offering price of up to $100.0&#160;million. All other terms of the amended and restated Sales Agreement are substantially the same as the original Sales Agreement. The Company has not yet issued or sold any common stock under the amended and restated Sales Agreement.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company&#8217;s board of directors approved the 2020 Equity Incentive Plan (2020 Plan), which became effective January 30, 2020 in connection with the IPO. The 2020 Plan serves as the successor incentive award plan to the Company&#8217;s 2017 Equity Incentive Plan (2017 Plan) and initially reserved 2,134,000 shares of common stock available for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit (RSU) awards, and other stock-based awards, plus 1,550,150 shares of common stock that were reserved for issuance pursuant to future awards under the 2017 Plan at the time the 2020 Plan became effective, plus shares represented by awards outstanding under the 2017 Plan that are forfeited or lapsed unexercised and which following the effective date of the 2020 Plan are not issued under the 2017 Plan. In addition, the 2020 Plan reserve will increase on January 1 of each year beginning in 2021 through 2030, by an amount equal to the lesser of (a) 4% of the shares of stock outstanding (on an as converted basis) on the day immediately prior to the date of increase and (b) such smaller number of shares of stock as determined by the Company's board of directors; provided, however, that no more than 11,000,000 shares of stock may be issued upon the exercise of incentive stock options. Accordingly, on January 1, 2026, 2025 and 2024, the 2020 Plan reserve increased by 4,933,306, 4,713,921, and 3,871,494 shares, respectively. As of December&#160;31, 2025, the Company had 4,093,603 shares available for future grant under the 2020 Plan.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors, and consultants of the Company under terms and provisions established by the board of directors. Under the terms of the 2020 Plan, options may be granted at an exercise price not less than fair market value. The Company generally grants stock-based awards with service conditions. Options granted typically vest over a four-year period but may be granted with different vesting terms.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Company&#8217;s IPO and in connection with the effectiveness of the Company&#8217;s 2020 Plan, the 2017 Plan terminated and no further awards will be granted under that plan. However, all outstanding awards under the 2017 Plan will continue to be governed by their existing terms.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, the Company&#8217;s board of directors approved the 2022 Employment Inducement Incentive Plan (2022 Plan). The 2022 Plan initially reserved 1,250,000 shares of common stock available for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, RSU awards, and other stock-based awards. In November 2022, the 2022 Plan reserve was increased by 1,500,000. As of December&#160;31, 2025, the Company had 111,533 shares available for future grant under the 2022 Plan.</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Stock Option Exchange Program</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 16, 2024, the Company commenced an offer to certain eligible employees and consultants to exchange certain outstanding eligible options to purchase shares of the Company&#8217;s common stock for a lesser number of restricted stock unit (RSU) awards pursuant to an option exchange program (the Option Exchange). The Option Exchange expired on February 12, 2024. Pursuant to the Option Exchange, eligible option holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of 5,059,129 shares of the Company&#8217;s common stock, representing approximately 98% of the total shares of common stock underlying the eligible options. On February 13, 2024, immediately following the expiration of the Option Exchange, the Company granted 2,129,594 shares of Replacement RSU Awards, pursuant to the terms of the Option Exchange. The Replacement RSU Awards will vest based on continued service with the Company over a period of either 1, 2 or 3 years, depending on the grant date of the exchanged options.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange of stock options was treated as a modification for accounting purposes, which requires an incremental expense of $8.6&#160;million to be recognized for the Replacement RSU Awards over their new service periods (1 - 3 years). In addition, any unamortized expense remaining on the exchanged options as of the modification will be recognized over their original remaining service period.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Activity</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes option activity:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value ($ in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(714,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,865)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,436,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable&#8212;December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903,391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of December&#160;31, 2025. The intrinsic value of options exercised for the years ended December&#160;31, 2025, 2024, and 2023 were $10.0 million, $4.2 million and $1.2 million, respectively.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant-date fair value of the options vested during the years ended December&#160;31, 2025, 2024, and 2023 were $8.5 million, $4.0 million and $28.0 million, respectively. The weighted-average grant-date fair value of options granted during the years ended December&#160;31, 2025, 2024, and 2023 were $9.94, $3.70 and $8.01, respectively.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Activity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding the Company's RSUs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,055,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,275,607)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested Balance&#8212;December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,007,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of an RSU equals the closing price of the Company's common stock on the grant date. The total grant-date fair value of the RSUs vested during the years ended December&#160;31, 2025, 2024, and 2023 were $18.8&#160;million, $17.4&#160;million, and $9.3&#160;million, respectively. RSUs generally vest equally over four years, except for those issued in connection with the Option Exchange, as previously described.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,028&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $25.7 million of total unrecognized compensation cost related to unvested options that are expected to vest, which is expected to be recognized over a weighted-average period of 2.6 years. As of December&#160;31, 2025, there was $47.5 million of total unrecognized compensation cost related to RSUs that are expected to vest, which is expected to be recognized over a weighted-average period of 2.8 years.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the fair value of the stock options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of common stock&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses its closing stock price as reported on Nasdaq on the grant date for the fair value of its stock.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding. The Company uses the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term as it does not have sufficient prior exercise data to calculate based on historical data.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company uses its own historical stock price for expected volatility. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Yield</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards granted was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 &#8211; 6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 &#8211; 6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 &#8211; 6.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.9&#160;&#8211;&#160;79.5%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.1&#160;&#8211;&#160;83.2%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.2%&#160;&#8211; 78.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 &#8211; 4.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 &#8211; 5.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 &#8211; 4.7%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the 2020 Employee Stock Purchase Plan, or the ESPP, which became effective on January 30, 2020 in connection with the IPO. The ESPP is designed to allow the Company&#8217;s eligible employees to purchase shares of the Company&#8217;s common stock, at semi-annual intervals, with their accumulated payroll deductions. Under the ESPP, participants are offered the option to purchase shares of the Company&#8217;s common stock at a discount during a series of successive offering periods. The option purchase price will be the lower of 85% of the closing trading price per share of the Company&#8217;s common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each offering period. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP is intended to qualify under Section 423 of the U.S. Internal Revenue Service Code of 1986, as amended. The maximum number of the Company&#8217;s common stock which will be authorized for sale under the ESPP is equal to the sum of (a) 351,000 shares of common stock and (b) an annual increase on the first day of each year beginning in 2021 and ending in 2030, equal to the lesser of (i) 1% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company&#8217;s board of directors; provided, however, no more than 5,265,000 shares of the Company&#8217;s common stock may be issued under the ESPP. Accordingly, on January 1, 2026, 2025 and 2024, the ESPP reserve increased by 1,216,890, 1,178,480, and 967,873 shares, respectively. As of December&#160;31, 2025, the Company had 2,806,818 shares available for future grant under the ESPP. </span></div>Stock-based compensation expense related to the ESPP was $1.0 million, $0.9 million, and $0.9 million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $1.2&#160;million during the year ended December&#160;31, 2025. Of the $1.2 million recorded, $0.4 million was related to foreign withholding taxes on the milestone payments received in connection with the Huadong Agreement and the remaining related to U.S. state income tax expense and other foreign tax expense. The Company recorded income tax expense of $0.6&#160;million during the year ended December&#160;31, 2024. Of the $0.6&#160;million recorded, $0.5&#160;million was related to foreign withholding taxes on the up-front fee in connection with the Huadong Agreement and the remaining was related to other foreign tax expense. The Company recorded income tax expense of $3.1 million during the year ended December&#160;31, 2023. Of the $3.1 million recorded, $3.0&#160;million was related to foreign withholding taxes on the up-front fee in connection with the Huadong Agreement and the remaining was related to other foreign tax expense.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of loss before income taxes for domestic and foreign locations for the years ended December&#160;31, 2025, 2024 and 2023 (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130,372)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,653)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,726)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,970)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,392)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259,027)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of provision for income taxes for the years ended December&#160;31, 2025, 2024 and 2023 is as follows (in thousands):&#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax provision:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred </span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax computed at federal statutory rates to the reported provision for income taxes for the years ended December&#160;31, 2025, 2024 and 2023 is as follows (in thousands)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:32.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax U.S. federal statutory rate</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,272)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,396)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local income tax, net of federal income tax effect</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax effects</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory tax rate differential</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowances</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowances</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nontaxable or nondeductible items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sec. 162(m) limitation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The prior years included in the effective tax rate table have been recast from the financial statements filed previously to align with the new presentation created through adherence to ASU 2023-09. Consideration has only been given to 2025 amounts in terms of the balances that are separately stated within the table.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The states and local jurisdictions that contribute to a majority (greater than 50%) of the tax effect in this category include Texas, California and New York based on the distribution of sales and the current year state income tax obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components deferred tax assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and expenditure capitalization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,110)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(541)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net deferred tax assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates the positive and negative evidence in determining the realizability of its deferred tax assets. Based upon the weight of available evidence, which includes historical operating performance and reported cumulative net losses since inception, a valuation allowance on the majority of net deferred tax assets has been recorded as of December&#160;31, 2025 and 2024. The Company intend to maintain its substantially full valuation allowance on its deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The Company has an immaterial deferred tax asset related to a foreign jurisdiction. The valuation allowance decreased by approximately $0.8 million and increased by approximately $40.1 million during the years ended December&#160;31, 2025 and 2024, respectively, due to similar changes in the underlying deferred tax asset balances.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has net operating loss (NOL) carryforwards for federal and state income tax purposes of $761.3 million and $636.1 million, respectively, as of December&#160;31, 2025. Of the federal NOLs, $3.5 million originated before the 2018 tax year and will expire beginning in 2036. Under the Tax Cuts and Jobs Act of 2017, the remaining $757.8 million of NOLs generated after December 31, 2017 will be carried forward indefinitely and will be available to offset 80% of taxable income in future years. Of the $636.1 million in state net operating loss carryforwards, $550.2 million will begin to expire in 2027 and the remaining NOLs carry forward indefinitely. In addition, the Company has foreign NOL carry forwards of $23.2&#160;million as of December&#160;31, 2025, which can be carried forward indefinitely.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company also had federal and California research and development tax credit carryforwards of $23.2 million and $4.6 million, respectively. The federal research and development tax credit carryforwards will begin to expire in 2037. The California research and development tax credit carryforwards are available indefinitely.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Internal Revenue Code Sections 382, as amended, and 383, substantial restrictions exist on the utilization of tax attributes in the event a corporation experienced an &#8220;ownership change.&#8221; Generally, a Section 382 &#8220;ownership change&#8221; occurs if one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Accordingly, the Company's ability to utilize net operating loss and tax credit carryforwards may be limited as a result of such ownership changes, and such a limitation could result in the </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expiration of carryforwards before they are utilized. The Company has completed Section 382 studies that concluded the Company has experienced ownership changes since inception. However, this is not expected to result in the expiration of federal tax attribute carryforwards prior to utilization. Similar rules may apply under state tax laws. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted into law. The OBBBA contains numerous business tax provisions, including business extenders made permanent such as restoration of 100% bonus depreciation, IRC Section 174 expensing for US-based research, and the EBITDA-based business interest expense limitation under Section 163(j). The enacted legislation had an immaterial impact on the Company&#8217;s effective tax rate for the year ended December 31, 2025.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the unrecognized tax benefits (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to tax positions taken during a prior year</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decreases related to tax positions taken during a prior year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,097)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to tax positions taken during the current year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,390&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in unrecognized tax benefits of $43.4 million at December&#160;31, 2025 was $36.2 million of tax benefits that, if recognized, would not impact the Company's income tax benefit or effective tax rate to the extent that the Company continues to maintain a full valuation allowance against its deferred tax assets.  </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files tax returns in the United States, state jurisdictions, Canada, and the United Kingdom. The tax years for 2016 and forward are subject to examination by the U.S. tax authorities and the tax years for 2016 and forward are subject to examination by the state tax authorities. Due to net operating loss carryforwards and research and development credits in the United States and state tax jurisdictions, all years effectively remain open. The Company is subject to examination by the tax authorities in Canada and the United Kingdom for the year ended December 31, 2022 to the present period. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company's policy to recognize interest and/or penalties related to uncertain tax benefits as a component of the provision for income taxes. For the years ended December&#160;31, 2025, 2024 and 2023, the Company has not recognized any interest or penalties related to income taxes. The Company has no accrued interest and penalties as of December&#160;31, 2025 and 2024 due to available tax losses.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of cash income taxes paid were not material for the years ended December&#160;31, 2025, 2024 and 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average common shares outstanding. Pre-funded warrants to purchase 6,941,438, 7,500,000, and 1,417,808 shares of the Company's stock were included in the weighted-average common shares outstanding used in calculating net loss per share for the years ended December&#160;31, 2025, 2024 and 2023, respectively, as the exercise price of the pre-funded warrants is negligible and the pre-funded warrants are fully vested and exercisable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential dilutive securities, which include unvested RSUs and unvested performance-based RSUs for which established performance criteria have been achieved as of the end of the respective periods, vested and unvested options to purchase common stock and shares to be issued under the Company's employee stock purchase plan (ESPP), have been excluded from the calculation of diluted net loss per common share in each period in which the Company recorded a net loss, as the effect is antidilutive. The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,436,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,919,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to future vesting</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,007,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,055,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,929,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares subject to future issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,456,103&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,875,669&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases. The Company&#8217;s Chief Operating Decision Maker (CODM) is its Chief Executive Officer. The CODM evaluates financial information on a consolidated basis for the purposes of allocating resources and assessing performance. Substantially all of the Company's assets are located in the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Topical roflumilast program costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Topical JAK inhibitor program costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other early-stage programs costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development compensation and personnel-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,707&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,397)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment and consolidated net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,141)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,039)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Other segment expenses include professional services related to research and development, medical affairs, depreciation and amortization expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arqt_KeithLeonardMember', window );">Keith Leonard [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2025, Keith Leonard, a member of our Board of Directors, entered into a Rule 10b5-1 trading plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential exercise and sale of up to 39,272 options held by Mr. Leonard between February 17, 2026 and February 16, 2027.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Keith Leonard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">member of our Board of Directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 18, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">February 16, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">364 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">39,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arqt_SueJeanLinMember', window );">Sue-Jean Lin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2025, Sue-Jean Lin, a member of our Board of Directors, entered into a Rule 10b5-1 trading plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential exercise and sale of up to 77,880 options, as well as the potential sale of up to 13,004 shares of Common Stock held by Ms. Lin between February 24, 2026 and February 19, 2027.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Sue-Jean Lin<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">member of our Board of Directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 13, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">February 19, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">360 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arqt_SueJeanLinTradingArrangementOptionsMember', window );">Sue-Jean Lin Trading Arrangement, Options [Member] | Sue-Jean Lin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">77,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arqt_SueJeanLinTradingArrangementCommonStockMember', window );">Sue-Jean Lin Trading Arrangement, Common Stock [Member] | Sue-Jean Lin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">13,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arqt_KeithLeonardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arqt_KeithLeonardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arqt_SueJeanLinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arqt_SueJeanLinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arqt_SueJeanLinTradingArrangementOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arqt_SueJeanLinTradingArrangementOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arqt_SueJeanLinTradingArrangementCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arqt_SueJeanLinTradingArrangementCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program is integrated into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key elements of our cybersecurity risk management program include, but are not limited to, the following:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity awareness training of our employees, including incident response personnel, and senior management; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a third-party risk management process for key service providers based on our assessment of their criticality to our operations and respective risk profile, suppliers, and vendors;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information, as well as risks of data leakage and unauthorized access to sensitive information; and</span></div><div style="margin-bottom:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing review of the controls framework to support the security of emerging technologies, including AI and generative AI (GenAI), ensuring alignment with evolving risks and regulatory expectations.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our and our third-party service providers&#8217;, strategic partners&#8217;, contractors&#8217;, consultants&#8217;, and collaborators&#8217; cybersecurity risk management program and processes, including policies, controls, or procedures, will be fully implemented, complied with, or effective in protecting our systems and information.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See Part I, Item 1A. Risk Factors: &#8220;We depend on our information technology systems, and any failure of these systems or those of our CROs or other contractors or consultants that we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations, financial condition, and prospects.&#8221;</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our cybersecurity risk management program is integrated into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program. Our Audit Committee Chair, Sue-Jean Lin, has expertise in both cybersecurity risk management and AI.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee receives quarterly reports from our Chief Digital &amp; Technology Officer and internal security staff on developments in our information technology (IT) infrastructure and cybersecurity program. This includes updates, as appropriate, on key IT initiatives, new and existing cybersecurity risks, and how management is managing those risks. In addition, the Chief Digital &amp; Technology Officer updates the Audit Committee, where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant per our established severity and response framework. </span></div>The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program and an annual report from management on our cybersecurity risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program and an annual report from management on our cybersecurity risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity technology team, led by the Vice President, Core Technology &amp; Security (VP CT&amp;S), is responsible for managing and directing day-to-day assessment and management of material risks from cybersecurity threats, including oversight of our cybersecurity tools, controls, and strategies to protect organizational assets, networks, and data. The VP CT&amp;S, who reports to our Chief Digital and Technology Officer, has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. He is an ISACA certified security manager and has over 20 years of experience in IT, with over 10 years specifically focused on cybersecurity risk management. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our VP CT&amp;S takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public, or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our IT environment.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity technology team, led by the Vice President, Core Technology &amp; Security (VP CT&amp;S), is responsible for managing and directing day-to-day assessment and management of material risks from cybersecurity threats, including oversight of our cybersecurity tools, controls, and strategies to protect organizational assets, networks, and data. The VP CT&amp;S, who reports to our Chief Digital and Technology Officer, has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. He is an ISACA certified security manager and has over 20 years of experience in IT, with over 10 years specifically focused on cybersecurity risk management. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our VP CT&amp;S takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public, or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our IT environment.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">He is an ISACA certified security manager and has over 20 years of experience in IT, with over 10 years specifically focused on cybersecurity risk management.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our VP CT&amp;S takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public, or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our IT environment.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div>The Company&#8217;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and all intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts, which are not material, have been reclassified to conform to current year presentation in the consolidated balance sheets, consolidated statements of operations and comprehensive loss, consolidated statement of cash flows and the notes to the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions include those related to revenue recognition, accrued and prepaid research and development expenses, and income taxes. Additionally, the Company uses available market information to assess the fair value of its marketable securities. The Company regularly evaluates its estimates using historical experience, expectations of future impacts and other assumptions that the Company believes are reasonable, and the Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. If actual results differ from those estimates, the Company includes the updates in its consolidated financial statements in the period the actual amounts become known.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with original maturities of greater than three months are classified as marketable securities on the balance sheet. Marketable securities consist of investment grade short to intermediate-term fixed income investments that have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the consolidated balance sheets due to their highly liquid nature and availability for use in current operations. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive income (loss) on the consolidated balance sheets. Realized gains and losses as well as credit losses, if any, on marketable securities are included in other income (expense), net in the statements of operations and comprehensive loss. Interest on marketable securities is included in interest income in the statements of operations and comprehensive loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. In making this judgment, the Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost, the Company's intent to sell or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, the financial condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular security. To date, no such credit losses have occurred or have been recorded. The cost of investments sold is based on the specific-identification method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Receivables, net</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables, net</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s trade accounts receivable consists of amounts due primarily from pharmaceutical wholesalers and specialty pharmacy providers in the United States and Canada (collectively, its customers) related to sales of ZORYVE and have standard payment terms. For certain customers, the trade accounts receivable for the customer is net of distribution service fees, prompt pay discounts, and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company will reserve against trade accounts receivable for estimated credit losses that may arise and any amounts determined to be uncollectible will be written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was not material as of December&#160;31, 2025 and 2024 and the amounts of trade receivable amounts written off for the years ended December&#160;31, 2025, 2024, and 2023 were not material.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories at the lower-of-cost or net realizable value. The Company determines the cost of its inventories, which includes costs related to products held for sale in the ordinary course of business, products in process of production for such sale, and items to be currently consumed in the production of goods to be available for sale, on a first-in, first-out (FIFO) basis. Due to the nature of the Company&#8217;s supply chain process, inventory that is owned by the Company is physically stored at third-party warehouses, logistics providers, and contract manufacturers. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. If they occur, such charges are recorded as a component of cost of sales in the consolidated statements of operations and comprehensive loss. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products that may be used in clinical development programs are excluded from inventory and their costs are charged to research and development expense in the consolidated statement of operations as incurred, as long as they do not have an alternative use. Prior to the initial dates of regulatory approval, costs related to the production of inventory were recorded as research and development expense on the Company&#8217;s consolidated statements of operations and comprehensive loss in the period incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets, net</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, net</span></div>The Company paid a milestone payment of $7.5&#160;million to AstraZeneca in the third quarter of 2022 related to the FDA approval and launch of ZORYVE cream 0.3%. This milestone payment was capitalized as an intangible asset and will be amortized to cost of sales over its useful life of 10 years from the date of first commercial sale, as this is the minimum amount of time that the related License Agreement will be in effect. The Company paid additional milestone payments of $5.0&#160;million related to the achievement of $100.0&#160;million worldwide net sales in October 2024 and $10.0&#160;million related to the achievement of $250.0&#160;million worldwide net sales in May 2025. These milestone payments were recorded as cumulative catch-up adjustments to the carrying value of the intangible asset.<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its long-lived assets, including intangibles, for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results. No impairment losses were recorded for the years ended December&#160;31, 2025, 2024, and 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Valuation of Other Investments</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Other Investments</span></div>The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity (VIE). If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company&#8217;s consolidated financial statements. The Company&#8217;s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by either the financial institutions holding its cash or by its customers owing trade receivables to the extent recorded on the consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance sheets. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for credit losses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments, in addition to those presented in Note 4, include cash equivalents, accounts receivable, accounts payable, accrued liabilities, and long-term debt. The carrying amount of cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to their short maturities. As the long-term debt is subject to variable interest rates that are based on market rates which regularly reset, the Company believes that the carrying value of the long-term debt approximates its fair value.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis on the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div>Property and equipment are stated at cost less accumulated depreciation. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets which range from <span style="-sec-ix-hidden:f-426">two</span> to five years. Leasehold improvements are depreciated on a straight-line basis over the shorter of their estimated useful lives or lease terms. Maintenance and repairs are expensed as incurred. The Company reviews the carrying values of its property and equipment for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information available at lease commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the lease liability, includes any lease payments made prior to or on lease commencement and is adjusted for lease incentives and initial direct costs incurred, as applicable. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreements includes lease and non-lease components and the Company has elected to not separate such components for all classes of assets. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with terms of 12 months or less (short-term leases) for all classes of assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock', window );">Accrued and Prepaid Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Prepaid Research and Development Expenses</span></div>The Company records prepaid expenses and accrued liabilities for estimated research and development activities conducted by third-party service providers, which include the conduct of nonclinical studies, clinical trials, and contract manufacturing activities. These costs are a significant component of the Company&#8217;s research and development expenses. The Company records these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid costs balances in each reporting period. As actual costs become known, the Company adjusts its balances for these activities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its product to its customers in the United States and Canada. The Company&#8217;s customers subsequently resell the products to pharmacies, health care providers, and patients. In accordance with ASC 606, the Company recognizes net product revenue from sales when the customers obtain control of the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s products, which typically occurs upon delivery to the customer. The Company&#8217;s payment terms are generally between 30 - 65 days.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales are recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution service fees, (b) government and private payer rebates, chargebacks, discounts and fees, (c) product returns and (d) costs of co-pay assistance programs for patients, as well as other sales deductions. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to trade receivables, net if payable to a customer or accrued liabilities if payable to a third-party. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is recognized as product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results vary from the Company&#8217;s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Service Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: data reporting, inventory management, chargeback administration, and service level commitment. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Pay Discounts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company provides some of its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from its gross product revenue and accounts receivable at the time such revenue is recognized.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company provides customers a credit for all products returned in accordance with the Company&#8217;s returned goods policy. Once the product is returned, it is destroyed. The Company does not record a right-of-return asset.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the early product launch period, the Company estimated its provision for sales returns based on industry data and adjusted the transaction price for such estimates at the time of sale to the customer. As the Company continues to collect data on its actual product returns, it has and will continue to refine its estimated returns rate and adjust its accrual, which affects revenue in the period of adjustment. No such material adjustments were recorded for the year ended December 31, 2025. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargeback</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: A chargeback is the difference between the manufacturer's invoice price to the wholesaler and the wholesaler&#8217;s customer's contract price. The wholesaler tracks these sales and "charges back" the manufacturer for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price for such discount at the time of sale to the customer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Discounts:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accrues rebates for contractually agreed-upon discounts with private payers and mandated discounts under government programs such as the Medicaid Drug Rebate Program in the United States. The Company's estimates for expected utilization of private payer rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates are generally invoiced and paid in arrears. The accrual balance consists of invoiced amounts not yet paid as well as an estimate of the amount expected to be incurred but not yet invoiced to the Company as of the end of the reporting period. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product revenue, net in the period of adjustment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock', window );">Other Revenue</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other revenue is related to the Huadong License and Collaboration Agreement and Sato License Agreement. See Note 7. The Company evaluated the agreements with Huadong and Sato and determined that they are within the scope of ASC 606. The Company applied the five-step model as required by ASC 606 to determine revenue recognition.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The nonrefundable upfront payments received in connection with the transfer of the license and related know-how to Huadong in September 2023 and to Sato in March 2024 were determined to be distinct performance obligations, and therefore were recognized in Other revenue. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluated whether the development and regulatory milestones are considered probable of being reached and determined that their achievement is highly dependent on factors outside of the Company&#8217;s control. Therefore, these payments are subject to significant revenue reversal and are therefore not included in the transaction price. At the end of each reporting period, the Company will re-evaluate the probability of achievement of each milestone and, if necessary, adjust its estimate of the overall transaction price and accordingly recognize the related revenue once the probability of significant reversal of revenue is low. Any such adjustments are recorded on a cumulative catch-up basis, and would be reported in Other revenue in the period of adjustment. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sales milestones and royalties will be recognized in Other revenue when the related sales occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes direct and indirect costs related to the manufacturing and distribution of ZORYVE, including raw materials, third-party manufacturing costs, packaging services, freight-in, third-party royalties payable on the Company&#8217;s net product revenue, and amortization of certain intangible assets associated with ZORYVE. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon related FDA approval dates for each product. As a result, manufacturing and other inventory costs incurred prior to FDA approval were expensed and, therefore, are not included in cost of sales.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, license fees, stock-based compensation expense, materials, supplies, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company&#8217;s license agreements have been considered an acquisition of a business. For asset acquisitions, contingent consideration is recognized when the contingency is resolved and the consideration is paid or becomes payable. The upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when paid or become payable, provided there is no alternative future use of the rights in other research and development projects.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are expensed as incurred and consist primarily of salaries and related costs, including payroll taxes, benefits, stock-based compensation, and travel, and costs related to sales and marketing of ZORYVE. Other selling, general and administrative expenses include legal costs of pursuing patent protection of the Company's intellectual property, insurance, and professional services fees for auditing, tax, </span></div>and general legal services.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for such awards is the date of grant and the expense is recognized on a straight-line basis over the expected vesting period. For share-based awards that vest subject to a performance condition, the Company will recognize compensation cost for awards if and when the Company concludes that it is probable that the awards with a performance condition will be achieved on an accelerated attribution method. The Company accounts for forfeitures as they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets for the United States have been fully offset by a valuation allowance. The Company has an immaterial deferred tax asset related to foreign jurisdictions which is not offset by a valuation allowance.</span></div>The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company translates the assets and liabilities of its foreign subsidiaries where the local currencies have been determined to be the functional currencies into U.S. dollars using current exchange rates. Adjustments for foreign currency translation adjustments are recognized in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. The earnings or loss of these subsidiaries are translated in U.S. dollars using average exchange rates in effect during each reporting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CoPromotionAgreementsPolicyPolicyTextBlock', window );">Promotion Agreement</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promotion Agreement</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n July 2024, the Company entered into a promotion agreement with Kowa Pharmaceuticals America, Inc. (Kowa) to leverage Kowa's primary care sales force to exclusively market and promote ZORYVE to primary care practitioners and pediatricians for all FDA-approved indications until July 2029. The Company recognizes all revenue and Kowa receives a commission for the net sales attributed to Kowa. The commission is recorded in selling, general and administrative expense. For the years ended December&#160;31, 2025 and 2024, revenue from sales attributed to Kowa and related commissions paid or owed to Kowa were not material. Effective January 23, 2026, Kowa and the Company mutually agreed to terminate the promotion agreement. Following this termination, Kowa ceased all sales and promotions of ZORYVE and the Company will not be required to make any further payments to Kowa.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of any recent Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB). Other than the ASUs listed below, all other ASUs were assessed and determined to be either not applicable to the Company or are expected to have minimal impact on the Company's consolidated financial statements.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Improvements to Income Tax Disclosures, which requires qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The Company adopted the guidance for the year ended December 31, 2025 and applied any presentational changes from this new standard to all prior years to allow for comparability. See Note 11. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued and Prepaid Research and Development Expenses, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_CoPromotionAgreementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co-Promotion Agreements, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_CoPromotionAgreementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Not From Contract With Customer, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Paragraph 2AA<br> -Subparagraph (a)<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AA<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future amortization expense for the intangible assets subsequent to December&#160;31, 2025 is as follows (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:76.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text">The following table presents the Company's disaggregated revenue for the periods presented (in thousands):<div style="margin-top:8pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:52.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.3%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE foam</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.15%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZORYVE cream 0.05%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,542&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Major Customers</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major customers are defined as customers that individually accounted for greater than 10% of the Company's revenue. The following table presents each major customer that accounted for more than 10% of its gross product sales.</span></div><div style="margin-top:8pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:52.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of gross product sales</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer E</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer F</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross product sales from major customers</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">* Represents less than 10% of respective balance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,063</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,919</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></div></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,955</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,623</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,958</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,997</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated value of the Company&#8217;s cash, cash equivalents and marketable securities, and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,301&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,620&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated value of the Company&#8217;s cash, cash equivalents and marketable securities, and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,301&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,620&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the amortized cost and fair value of marketable securities by contractual maturity were as follows: </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturing within one year</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,281</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,395</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,708</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturing in one to five years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,681</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,680</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,593</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,602</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,962</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,075</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,301</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,620</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Change in the Fair Value of Embedded Derivative Instrument</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in the fair value of the embedded derivative instrument for the year ended December&#160;31, 2025 and 2024 (in thousands). There was no activity for the year ended December&#160;31, 2023. </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-608"><span style="-sec-ix-hidden:f-609">Loss (gain) from changes in fair value</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,634&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid co-pay assistance program and rebates</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,079&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,656&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,793&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Payments</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum annual rental payments of the Company&#8217;s operating lease liability as of December&#160;31, 2025 are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-739">Accrued and other current liabilities</span></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, long-term</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information represents supplemental disclosure for the consolidated statements of cash flows related to the Company&#8217;s operating lease (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to the operating lease:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to the Company's long-term debt (in thousands): </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued final fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued prepayment penalty</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,203&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes option activity:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value ($ in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(714,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,865)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,436,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable&#8212;December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903,391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding the Company's RSUs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,055,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,275,607)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested Balance&#8212;December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,007,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,028&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions in Calculating Stock Option Awards</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards granted was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 &#8211; 6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 &#8211; 6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 &#8211; 6.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.9&#160;&#8211;&#160;79.5%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.1&#160;&#8211;&#160;83.2%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.2%&#160;&#8211; 78.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 &#8211; 4.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 &#8211; 5.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 &#8211; 4.7%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss before Income Tax, Domestic and Foreign</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of loss before income taxes for domestic and foreign locations for the years ended December&#160;31, 2025, 2024 and 2023 (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130,372)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,653)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,726)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,970)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,392)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259,027)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of provision for income taxes for the years ended December&#160;31, 2025, 2024 and 2023 is as follows (in thousands):&#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax provision:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred </span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax computed at federal statutory rates to the reported provision for income taxes for the years ended December&#160;31, 2025, 2024 and 2023 is as follows (in thousands)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:32.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax U.S. federal statutory rate</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,272)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,396)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local income tax, net of federal income tax effect</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax effects</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory tax rate differential</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowances</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowances</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nontaxable or nondeductible items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sec. 162(m) limitation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The prior years included in the effective tax rate table have been recast from the financial statements filed previously to align with the new presentation created through adherence to ASU 2023-09. Consideration has only been given to 2025 amounts in terms of the balances that are separately stated within the table.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The states and local jurisdictions that contribute to a majority (greater than 50%) of the tax effect in this category include Texas, California and New York based on the distribution of sales and the current year state income tax obligations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components deferred tax assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and expenditure capitalization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,110)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(541)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net deferred tax assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the unrecognized tax benefits (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to tax positions taken during a prior year</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decreases related to tax positions taken during a prior year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,097)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to tax positions taken during the current year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,390&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Shares Excluded</a></td>
<td class="text">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:<div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,436,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,919,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to future vesting</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,007,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,055,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,929,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares subject to future issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,456,103&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,875,669&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Topical roflumilast program costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Topical JAK inhibitor program costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other early-stage programs costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development compensation and personnel-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,707&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,397)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment and consolidated net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,141)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,039)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Other segment expenses include professional services related to research and development, medical affairs, depreciation and amortization expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (1,138,084)<span></span>
</td>
<td class="num">$ (1,121,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashCashEquivalentsAndMarketableSecurities', window );">Cash, cash equivalents, restricted cash and marketable securities</a></td>
<td class="nump">221,300<span></span>
</td>
<td class="nump">228,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">108,959<span></span>
</td>
<td class="nump">$ 107,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arqt_LoanAgreementMember', window );">Loan agreement | Secured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_CashCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents and Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_CashCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arqt_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arqt_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,667,000<span></span>
</td>
<td class="nump">$ 1,959,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Tangible asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,300,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">11,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, income tax penalties and interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arqt_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval', window );">Product milestone payment for first product approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments', window );">Sales milestone payment</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold', window );">Annual net sales</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents | AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ProductRevenuePaymentTerm', window );">Payment terms (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ProductRevenuePaymentTerm', window );">Payment terms (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">65 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ProductRevenuePaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Revenue, Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ProductRevenuePaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Annual Worldwide Net Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payment For First Product Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arqt_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arqt_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Finite-Lived Intangible Assets, Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 2,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,562<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization</a></td>
<td class="nump">$ 14,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Schedule of Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 372,072<span></span>
</td>
<td class="nump">$ 166,542<span></span>
</td>
<td class="nump">$ 29,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Other revenue</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,420<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">376,072<span></span>
</td>
<td class="nump">196,542<span></span>
</td>
<td class="nump">59,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=arqt_ZORYVECream0.3Member', window );">ZORYVE cream 0.3%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">120,995<span></span>
</td>
<td class="nump">85,082<span></span>
</td>
<td class="nump">29,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=arqt_ZORYVEFoamMember', window );">ZORYVE foam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">181,892<span></span>
</td>
<td class="nump">71,539<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=arqt_ZORYVECream0.15Member', window );">ZORYVE cream 0.15%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">68,274<span></span>
</td>
<td class="nump">9,921<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=arqt_ZORYVECream0.05Member', window );">ZORYVE cream 0.05%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 911<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arqt_ZORYVECream0.3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arqt_ZORYVECream0.3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arqt_ZORYVEFoamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arqt_ZORYVEFoamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arqt_ZORYVECream0.15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arqt_ZORYVECream0.15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arqt_ZORYVECream0.05Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arqt_ZORYVECream0.05Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details) - Accounts Receivable - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Four Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Five Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arqt_FourCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arqt_FourCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arqt_FiveCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arqt_FiveCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Gross Product Sales and Accounts Receivable Net (Details) - Gross Product Sales - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arqt_CustomerAMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arqt_CustomerBMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arqt_CustomerCMember', window );">Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arqt_CustomerDMember', window );">Customer D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arqt_CustomerEMember', window );">Customer E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arqt_CustomerFMember', window );">Customer F</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arqt_MajorCustomersMember', window );">Major Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arqt_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arqt_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arqt_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arqt_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arqt_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arqt_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arqt_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arqt_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arqt_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arqt_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arqt_CustomerFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arqt_CustomerFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arqt_MajorCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arqt_MajorCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds and cash</a></td>
<td class="nump">$ 42,907<span></span>
</td>
<td class="nump">$ 71,335<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">220,982<span></span>
</td>
<td class="nump">227,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">5,366<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">14,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">78,764<span></span>
</td>
<td class="nump">83,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">84,522<span></span>
</td>
<td class="nump">67,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds and cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds and cash</a></td>
<td class="nump">37,541<span></span>
</td>
<td class="nump">71,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">122,063<span></span>
</td>
<td class="nump">138,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">84,522<span></span>
</td>
<td class="nump">67,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds and cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds and cash</a></td>
<td class="nump">37,541<span></span>
</td>
<td class="nump">71,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">98,919<span></span>
</td>
<td class="nump">88,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">5,366<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">14,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">78,764<span></span>
</td>
<td class="nump">83,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds and cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds and cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds and cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds and cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">$ 42,907<span></span>
</td>
<td class="nump">$ 71,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsUnrealizedGain', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">42,907<span></span>
</td>
<td class="nump">71,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">177,962<span></span>
</td>
<td class="nump">156,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">178,075<span></span>
</td>
<td class="nump">156,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">14,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">14,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">78,687<span></span>
</td>
<td class="nump">83,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">78,764<span></span>
</td>
<td class="nump">83,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">84,493<span></span>
</td>
<td class="nump">67,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">84,522<span></span>
</td>
<td class="nump">67,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds and cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">37,541<span></span>
</td>
<td class="nump">71,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsUnrealizedGain', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">37,541<span></span>
</td>
<td class="nump">$ 71,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">5,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsUnrealizedGain', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">$ 5,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_CashAndCashEquivalentsUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_CashAndCashEquivalentsUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_CashAndCashEquivalentsUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_CashAndCashEquivalentsUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Amortized Cost and Fair Value of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Maturing within one year</a></td>
<td class="nump">$ 138,281<span></span>
</td>
<td class="nump">$ 143,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Maturing in one to five years</a></td>
<td class="nump">39,681<span></span>
</td>
<td class="nump">12,593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">177,962<span></span>
</td>
<td class="nump">156,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing within one year</a></td>
<td class="nump">138,395<span></span>
</td>
<td class="nump">144,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing in one to five years</a></td>
<td class="nump">39,680<span></span>
</td>
<td class="nump">12,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 178,075<span></span>
</td>
<td class="nump">$ 156,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Change In The Fair Value Of The Embedded Derivative Instrument (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of embedded derivative instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning balance</a></td>
<td class="nump">$ 570,000<span></span>
</td>
<td class="nump">$ 849,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Loss (gain) from changes in fair value</a></td>
<td class="num">(139,000)<span></span>
</td>
<td class="num">(279,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending balance</a></td>
<td class="nump">$ 431,000<span></span>
</td>
<td class="nump">$ 570,000<span></span>
</td>
<td class="nump">$ 849,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other income (expense), net<span></span>
</td>
<td class="text">Other income (expense), net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481116/815-15-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 5,047<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">5,033<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">12,554<span></span>
</td>
<td class="nump">9,642<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 22,634<span></span>
</td>
<td class="nump">$ 14,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_PrepaidCopayAssistanceProgramAndRebates', window );">Prepaid co-pay assistance program and rebates</a></td>
<td class="nump">$ 9,485<span></span>
</td>
<td class="nump">$ 7,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_PrepaidClinicalTrialTestCostsCurrent', window );">Prepaid clinical trial costs</a></td>
<td class="nump">2,577<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and current assets</a></td>
<td class="nump">9,017<span></span>
</td>
<td class="nump">9,043<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 21,079<span></span>
</td>
<td class="nump">$ 19,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_PrepaidClinicalTrialTestCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical Trial Test Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_PrepaidClinicalTrialTestCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_PrepaidCopayAssistanceProgramAndRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Copay Assistance Program And Rebates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_PrepaidCopayAssistanceProgramAndRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_AccruedSalesDiscounts', window );">Accrued sales deductions</a></td>
<td class="nump">$ 78,308<span></span>
</td>
<td class="nump">$ 38,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">20,533<span></span>
</td>
<td class="nump">20,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ClinicalTrialAccrualCurrent', window );">Clinical trial accruals</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">17,044<span></span>
</td>
<td class="nump">7,616<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 116,310<span></span>
</td>
<td class="nump">$ 66,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_AccruedSalesDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_AccruedSalesDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ClinicalTrialAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Accrual, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ClinicalTrialAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,291<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(3,248)<span></span>
</td>
<td class="num">(2,564)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,349<span></span>
</td>
<td class="nump">1,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,270<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,568<span></span>
</td>
<td class="nump">$ 1,568<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Property, plant and equipment, excluding leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Property, plant and equipment, excluding leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements &amp; Ducentis Acquisition - Sato License Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 27, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 30,420,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arqt_SatoMember', window );">Sato</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet', window );">Upfront payment received before taxes</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones', window );">Revenue, remaining performance obligation, variable consideration amount, regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones', window );">Aggregate amount to be received upon achievement of sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties', window );">Number of years after first commercial sale to receive royalties</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice', window );">Number of days for written notice</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Not With Customer, Upfront Payment Received, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Number Of Years After First Commercial Sale To Receive Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Termination, Number Of Days For Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount, Sales Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arqt_SatoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arqt_SatoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements &amp; Ducentis Acquisition - Huadong (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arqt_HuadongMember', window );">Huadong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ContractNotWithCustomerUpfrontPaymentNet', window );">Net payment received</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation', window );">Tax withholding obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones', window );">Revenue, remaining performance obligation, variable consideration amount, regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones', window );">Aggregate amount to be received upon achievement of sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties', window );">Number of years after first commercial sale to receive royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Not With Customer, Liability, Tax Withholding Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ContractNotWithCustomerUpfrontPaymentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Not With Customer, Upfront Payment, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ContractNotWithCustomerUpfrontPaymentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Number Of Years After First Commercial Sale To Receive Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount, Sales Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arqt_HuadongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arqt_HuadongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements &amp; Ducentis Acquisition - AstraZeneca (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,667<span></span>
</td>
<td class="nump">$ 1,959<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale', window );">Years from first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arqt_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval', window );">Product milestone payment for first product approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments', window );">Sales milestone payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold', window );">Annual net sales</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments', window );">Maximum milestone payments for licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Annual Worldwide Net Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payment For First Product Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Years From First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arqt_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arqt_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements &amp; Ducentis Acquisition - Hengrui (Details) - Hengrui - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">License agreement, cash payment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments', window );">Maximum milestone payments for licensed products</a></td>
<td class="nump">20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments', window );">Maximum milestone payments for net worldwide sales</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arqt_HengruiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arqt_HengruiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements &amp; Ducentis Acquisition - Ducentis Acquisition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 07, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,051,000<span></span>
</td>
<td class="nump">$ 76,420,000<span></span>
</td>
<td class="nump">$ 110,575,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arqt_DucentisBiotherapeuticsLTDEquityInterestsMember', window );">Ducentis Biotherapeutics LTD Equity Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares', window );">Equity interest issued or issuable, number of shares (in shares)</a></td>
<td class="nump">610,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_AssetAcquisitionConsiderationTransferredGross', window );">Consideration transferred</a></td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount', window );">Future payable milestone payment</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones', window );">Contingent consideration to be transferred</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment', window );">Contingent consideration, duration due within</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold', window );">Annual net sales</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">License agreement, cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arqt_DucentisBiotherapeuticsLTDEquityInterestsMember', window );">Ducentis Biotherapeutics LTD Equity Interests | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Consideration transferred, equity interest issued and issuable</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Annual Net Sales of Acquiree Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_AssetAcquisitionConsiderationTransferredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_AssetAcquisitionConsiderationTransferredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration To Be Transferred Upon The Achievement Of Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Payments, Duration Due Within First Enrollment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Payments, Milestones, Or Royalties, Future Payable Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=arqt_DucentisBiotherapeuticsLTDEquityInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=arqt_DucentisBiotherapeuticsLTDEquityInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_LesseeOperatingLeaseOfficeSpace', window );">Office space (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments', window );">Future lease rent payment commitments</a></td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments', window );">Additional years of rent payments (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Straight-line rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear', window );">Future purchase commitment in 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear', window );">Future purchase commitments in 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_LeaseDescriptionAxis=arqt_WestlakeVillageCaliforniaLeaseArrangementMember', window );">Westlake Village, California Lease Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_LesseeOperatingLeaseExtensionTerm', window );">Extension term of the lease (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Additional Years Of Rent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeaseExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeaseExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Increase In Future Lease Rent Payment Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeaseOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Office Space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeaseOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LeaseDescriptionAxis=arqt_WestlakeVillageCaliforniaLeaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LeaseDescriptionAxis=arqt_WestlakeVillageCaliforniaLeaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">8,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest</a></td>
<td class="num">(2,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">5,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long-term</a></td>
<td class="nump">5,266<span></span>
</td>
<td class="nump">$ 2,562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 5,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="nump">$ 994<span></span>
</td>
<td class="nump">$ 965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate (as a percent)</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2027</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Oct. 08, 2024</div></th>
<th class="th"><div>Aug. 09, 2024</div></th>
<th class="th"><div>Dec. 22, 2021</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Maturity, due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Periodic principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod', window );">Covenant period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue', window );">Minimum net product revenue as a percentage of projected monthly net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment', window );">Interest rate, stated percentage, partial prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentInterestRateAtPeriodEnd', window );">Interest rate at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.79%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentDefaultRate', window );">Default rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of the embedded derivative instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentFinalFeePercentage', window );">Final fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentExitFeePercentage', window );">Exit fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentExitFeeExpirationPeriod', window );">Exit fee expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentDeferredFinalFeeGross', window );">Deferred final fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.92%<span></span>
</td>
<td class="nump">11.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="nump">$ 27,200<span></span>
</td>
<td class="nump">$ 29,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentPrepaymentPenalty', window );">Debt instrument, prepayment penalty</a></td>
<td class="nump">$ 6,950<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | Prior to December 22, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | After December 22, 2002 and prior to December 22, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | After December 22, 2023 and prior to December 22, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Periodic principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | Tranche A term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | Tranche B-1 term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | Tranche B-2 term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | Loan Agreement, Tranche C-1, Expiring March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | Loan Agreement, Tranche C-2, Expiring June 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured debt | Loan agreement | Tranche C term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentFinalFeePercentage', window );">Final fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentExtensionFeePercentage', window );">Extension fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Net Product Revenue As A Percentage Of Projected Net Product Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentDefaultRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentDefaultRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentDeferredFinalFeeGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Deferred Final Fee, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentDeferredFinalFeeGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentExitFeeExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentExitFeeExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentExtensionFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Extension Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentExtensionFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentFinalFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Final Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentFinalFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentFundingAvailabilityCovenantPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Funding Availability, Covenant, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentFundingAvailabilityCovenantPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate At Period End</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Stated Percentage, Partial Prepayment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentPrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentPrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentPrepaymentPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentPrepaymentPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arqt_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arqt_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentTrancheAxis=arqt_TrancheATermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentTrancheAxis=arqt_TrancheATermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentTrancheAxis=arqt_TrancheB1TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentTrancheAxis=arqt_TrancheB1TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentTrancheAxis=arqt_TrancheB2TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentTrancheAxis=arqt_TrancheB2TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentTrancheAxis=arqt_LoanAgreementTrancheC1ExpiringMarch312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentTrancheAxis=arqt_LoanAgreementTrancheC1ExpiringMarch312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentTrancheAxis=arqt_LoanAgreementTrancheC2ExpiringJune302026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentTrancheAxis=arqt_LoanAgreementTrancheC2ExpiringJune302026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentTrancheAxis=arqt_TrancheCTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentTrancheAxis=arqt_TrancheCTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentAccruedFinalFee', window );">Accrued final fee</a></td>
<td class="nump">8,824<span></span>
</td>
<td class="nump">7,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DebtInstrumentAccruedPrepaymentPenalty', window );">Accrued prepayment penalty</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(865)<span></span>
</td>
<td class="num">(1,121)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value of debt</a></td>
<td class="nump">108,959<span></span>
</td>
<td class="nump">107,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">$ 107,959<span></span>
</td>
<td class="nump">$ 107,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentAccruedFinalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accrued Final Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentAccruedFinalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DebtInstrumentAccruedPrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accrued Prepayment Penalty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DebtInstrumentAccruedPrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 13, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 16, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 06, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 161,682<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised during the period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total grant-date fair value of the options vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.94<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="nump">$ 8.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,364<span></span>
</td>
<td class="nump">$ 41,730<span></span>
</td>
<td class="nump">$ 38,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognition period for unrecognized compensation costs related to unvested options expected to vest (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock-based awards granted (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,063,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total grant-date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,800<span></span>
</td>
<td class="nump">$ 17,400<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognition period for unrecognized compensation costs related to unvested options expected to vest (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding', window );">Increase in shares available for grant, percentage of shares outstanding (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, as a percentage of closing trading price per share (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,178,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,806,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized', window );">Number of shares authorized for sale under the ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable', window );">Maximum shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | First anniversary date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Employee Stock Purchase Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">1,216,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_A2020EquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding', window );">Increase in shares available for grant, percentage of shares outstanding (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable', window );">Based number of options issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,713,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,871,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,093,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_A2020EquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock-based awards granted (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_A2020EquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">4,933,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_A2017EquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,550,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_A2022EmploymentInducementIncentivePlanMember', window );">2022 Employment Inducement Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_StockOptionExchangeMember', window );">Stock Option Exchange | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged', window );">Percentage of eligible options exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_StockOptionExchangeMember', window );">Stock Option Exchange | RSUs subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental cost of plan modification | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_StockOptionExchangeMember', window );">Stock Option Exchange | RSUs subject to future vesting | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_StockOptionExchangeMember', window );">Stock Option Exchange | RSUs subject to future vesting | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_StockOptionExchangeMember', window );">Stock Option Exchange | RSUs subject to future vesting | Grant Date One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock-based awards granted (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_StockOptionExchangeMember', window );">Stock Option Exchange | RSUs subject to future vesting | Second Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock-based awards granted (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_StockOptionExchangeMember', window );">Stock Option Exchange | RSUs subject to future vesting | Third Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock-based awards granted (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Stock Option Exchange | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,059,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Stock Option Exchange | RSUs subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,129,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=arqt_PrefundedWarrantMember', window );">Prefunded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to acquire shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,417,808<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,941,438<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">1,417,808<span></span>
</td>
<td class="nump">2,285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_FirstEquityPublicOfferingMember', window );">First Equity Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_AtTheMarketMember', window );">At-The-Market | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_SaleOfStockAuthorizedConsiderationOnTransaction', window );">Issuance of shares of common stock for sales agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_AtTheMarketMember', window );">At-The-Market | Cowen | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_SaleOfStockAuthorizedConsiderationOnTransaction', window );">Issuance of shares of common stock for sales agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds', window );">Share sales agreement, percentage of gross sales price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_SaleOfStockAgentFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_SaleOfStockAgentFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_SaleOfStockAuthorizedConsiderationOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Consideration On Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_SaleOfStockAuthorizedConsiderationOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Base Amount Of Common Stock Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Base Number Of Options Issuable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Of Eligible Options Exchanged</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arqt_A2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arqt_A2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arqt_A2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arqt_A2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arqt_A2022EmploymentInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arqt_A2022EmploymentInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arqt_StockOptionExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arqt_StockOptionExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=arqt_FirstGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=arqt_FirstGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=arqt_SecondGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=arqt_SecondGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=arqt_ThirdGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=arqt_ThirdGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=arqt_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=arqt_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_FirstEquityPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arqt_FirstEquityPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arqt_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arqt_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arqt_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance, number of options (in shares)</a></td>
<td class="nump">5,342,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,345,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(714,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(534,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(2,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, number of options (in shares)</a></td>
<td class="nump">6,436,972<span></span>
</td>
<td class="nump">5,342,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">14.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">6.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">9.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">26.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 9.17<span></span>
</td>
<td class="nump">$ 6.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,903,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Term (Years)</a></td>
<td class="text">7 years 9 months<span></span>
</td>
<td class="text">8 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Remaining contractual term, exercisable (years)</a></td>
<td class="text">6 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value ($ in thousands)</a></td>
<td class="nump">$ 127,945<span></span>
</td>
<td class="nump">$ 43,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 59,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) - RSUs subject to future vesting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">6,055,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,063,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(2,275,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(835,383)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">6,007,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">14.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">8.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">10.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 40,364<span></span>
</td>
<td class="nump">$ 41,730<span></span>
</td>
<td class="nump">$ 38,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">12,336<span></span>
</td>
<td class="nump">13,509<span></span>
</td>
<td class="nump">15,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 28,028<span></span>
</td>
<td class="nump">$ 28,221<span></span>
</td>
<td class="nump">$ 23,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Assumptions in Calculating Stock Option Awards (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">72.90%<span></span>
</td>
<td class="nump">79.10%<span></span>
</td>
<td class="nump">75.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">79.50%<span></span>
</td>
<td class="nump">83.20%<span></span>
</td>
<td class="nump">78.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 1,171,000<span></span>
</td>
<td class="nump">$ 647,000<span></span>
</td>
<td class="nump">$ 3,113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ForeignWithholdingIncomeTaxes', window );">Foreign withholding income tax</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">40,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">757,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">43,382,000<span></span>
</td>
<td class="nump">42,286,000<span></span>
</td>
<td class="nump">41,390,000<span></span>
</td>
<td class="nump">$ 42,505,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would not impact effective tax rate</a></td>
<td class="nump">36,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, income tax penalties and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash income taxes paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">761,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">23,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">636,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">550,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">$ 23,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ForeignWithholdingIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Withholding Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ForeignWithholdingIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (8,244)<span></span>
</td>
<td class="num">$ (130,372)<span></span>
</td>
<td class="num">$ (255,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(6,726)<span></span>
</td>
<td class="num">(9,020)<span></span>
</td>
<td class="num">(3,374)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">$ (14,970)<span></span>
</td>
<td class="num">$ (139,392)<span></span>
</td>
<td class="num">$ (259,027)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">799<span></span>
</td>
<td class="nump">3,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">799<span></span>
</td>
<td class="nump">3,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">54<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">54<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 1,171<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">$ 3,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax U.S. federal statutory rate</a></td>
<td class="num">$ (3,144)<span></span>
</td>
<td class="num">$ (29,272)<span></span>
</td>
<td class="num">$ (54,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal (national) income tax effect</a></td>
<td class="nump">836<span></span>
</td>
<td class="num">(11,367)<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(1,288)<span></span>
</td>
<td class="num">(804)<span></span>
</td>
<td class="num">(4,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount', window );">Sec. 162(m) limitation</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="nump">3,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,197<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 1,171<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">$ 3,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal (national) income tax effect</a></td>
<td class="num">(5.60%)<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent', window );">Sec. 162(m) limitation</a></td>
<td class="num">(9.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(21.40%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(5.70%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="num">(7.80%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="num">$ (319)<span></span>
</td>
<td class="num">$ (389)<span></span>
</td>
<td class="num">$ (160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="nump">2,071<span></span>
</td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">$ (77)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="num">(13.80%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="nump">$ 402<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="num">$ (3,145)<span></span>
</td>
<td class="nump">$ 37,731<span></span>
</td>
<td class="nump">$ 52,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 719<span></span>
</td>
<td class="num">$ (867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="nump">21.10%<span></span>
</td>
<td class="num">(27.10%)<span></span>
</td>
<td class="num">(20.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Limitation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Limitation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 180,809<span></span>
</td>
<td class="nump">$ 171,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">1,958<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">15,698<span></span>
</td>
<td class="nump">14,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization', window );">Research and expenditure capitalization</a></td>
<td class="nump">23,848<span></span>
</td>
<td class="nump">36,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">25,226<span></span>
</td>
<td class="nump">16,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">7,744<span></span>
</td>
<td class="nump">15,761<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">256,696<span></span>
</td>
<td class="nump">256,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(255,482)<span></span>
</td>
<td class="num">(256,270)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(1,110)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(1,110)<span></span>
</td>
<td class="num">(541)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax assets</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Research And Expenditure Capitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 42,286<span></span>
</td>
<td class="nump">$ 41,390<span></span>
</td>
<td class="nump">$ 42,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to tax positions taken during a prior year</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to tax positions taken during a prior year</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="num">(3,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to tax positions taken during the current year</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 43,382<span></span>
</td>
<td class="nump">$ 42,286<span></span>
</td>
<td class="nump">$ 41,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss Per Share - Narrative (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=arqt_PrefundedWarrantMember', window );">Prefunded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to acquire shares of common stock (in shares)</a></td>
<td class="nump">6,941,438<span></span>
</td>
<td class="nump">2,285,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">1,417,808<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=arqt_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=arqt_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Dilutive Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from the calculation of net loss per share (in shares)</a></td>
<td class="nump">12,456,103<span></span>
</td>
<td class="nump">11,414,334<span></span>
</td>
<td class="nump">10,875,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from the calculation of net loss per share (in shares)</a></td>
<td class="nump">6,436,972<span></span>
</td>
<td class="nump">5,342,909<span></span>
</td>
<td class="nump">7,919,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from the calculation of net loss per share (in shares)</a></td>
<td class="nump">6,007,515<span></span>
</td>
<td class="nump">6,055,087<span></span>
</td>
<td class="nump">2,929,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP shares subject to future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from the calculation of net loss per share (in shares)</a></td>
<td class="nump">11,616<span></span>
</td>
<td class="nump">16,338<span></span>
</td>
<td class="nump">26,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 376,072<span></span>
</td>
<td class="nump">$ 196,542<span></span>
</td>
<td class="nump">$ 59,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">36,695<span></span>
</td>
<td class="nump">19,128<span></span>
</td>
<td class="nump">4,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">77,051<span></span>
</td>
<td class="nump">76,420<span></span>
</td>
<td class="nump">110,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">274,553<span></span>
</td>
<td class="nump">229,391<span></span>
</td>
<td class="nump">185,145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">388,299<span></span>
</td>
<td class="nump">324,939<span></span>
</td>
<td class="nump">300,707<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,227)<span></span>
</td>
<td class="num">(128,397)<span></span>
</td>
<td class="num">(241,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">8,897<span></span>
</td>
<td class="nump">16,126<span></span>
</td>
<td class="nump">12,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(12,083)<span></span>
</td>
<td class="num">(27,168)<span></span>
</td>
<td class="num">(29,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="nump">3,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,141)<span></span>
</td>
<td class="num">(140,039)<span></span>
</td>
<td class="num">(262,140)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arqt_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">376,072<span></span>
</td>
<td class="nump">196,542<span></span>
</td>
<td class="nump">59,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">32,028<span></span>
</td>
<td class="nump">17,169<span></span>
</td>
<td class="nump">4,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses', window );">Research and development compensation and personnel-related expenses</a></td>
<td class="nump">39,779<span></span>
</td>
<td class="nump">39,216<span></span>
</td>
<td class="nump">44,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">274,033<span></span>
</td>
<td class="nump">228,908<span></span>
</td>
<td class="nump">184,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expenses</a></td>
<td class="nump">24,408<span></span>
</td>
<td class="nump">20,014<span></span>
</td>
<td class="nump">22,607<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">388,299<span></span>
</td>
<td class="nump">324,939<span></span>
</td>
<td class="nump">300,707<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,227)<span></span>
</td>
<td class="num">(128,397)<span></span>
</td>
<td class="num">(241,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">8,897<span></span>
</td>
<td class="nump">16,126<span></span>
</td>
<td class="nump">12,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(12,083)<span></span>
</td>
<td class="num">(27,168)<span></span>
</td>
<td class="num">(29,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="nump">3,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,141)<span></span>
</td>
<td class="num">(140,039)<span></span>
</td>
<td class="num">(262,140)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=arqt_TopicalRoflumilastProgramMember', window );">Topical roflumilast program costs | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,938<span></span>
</td>
<td class="nump">5,210<span></span>
</td>
<td class="nump">35,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=arqt_TopicalJAKInhibitorProgramMember', window );">Topical JAK inhibitor program costs | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">2,945<span></span>
</td>
<td class="nump">3,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=arqt_OtherEarlyStageProgramsMember', window );">Other early-stage programs costs | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,372<span></span>
</td>
<td class="nump">$ 11,477<span></span>
</td>
<td class="nump">$ 5,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Compensation And Personnel-Related Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arqt_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arqt_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arqt_TopicalRoflumilastProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arqt_TopicalRoflumilastProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arqt_TopicalJAKInhibitorProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arqt_TopicalJAKInhibitorProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arqt_OtherEarlyStageProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arqt_OtherEarlyStageProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>297</ContextCount>
  <ElementCount>459</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Changes in Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - License Agreements &amp; Ducentis Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/LicenseAgreementsDucentisAcquisition</Role>
      <ShortName>License Agreements &amp; Ducentis Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://arcutis.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/Revenues</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/BalanceSheetComponents</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/CommitmentsandContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/Debt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/NetLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/SegmentReporting</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/DescriptionofBusiness</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Summary of Significant Accounting Policies - Finite-Lived Intangible Assets, Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Finite-Lived Intangible Assets, Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Revenues - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails</Role>
      <ShortName>Revenues - Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Revenues - Gross Product Sales and Accounts Receivable Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails</Role>
      <ShortName>Revenues - Gross Product Sales and Accounts Receivable Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost and Fair Value of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Amortized Cost and Fair Value of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Fair Value Measurements - Change In The Fair Value Of The Embedded Derivative Instrument (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails</Role>
      <ShortName>Fair Value Measurements - Change In The Fair Value Of The Embedded Derivative Instrument (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Balance Sheet Components - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails</Role>
      <ShortName>Balance Sheet Components - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Property and Equipment, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails</Role>
      <ShortName>Property and Equipment, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - License Agreements &amp; Ducentis Acquisition - Sato License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails</Role>
      <ShortName>License Agreements &amp; Ducentis Acquisition - Sato License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - License Agreements &amp; Ducentis Acquisition - Huadong (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails</Role>
      <ShortName>License Agreements &amp; Ducentis Acquisition - Huadong (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/LicenseAgreementsDucentisAcquisition</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - License Agreements &amp; Ducentis Acquisition - AstraZeneca (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails</Role>
      <ShortName>License Agreements &amp; Ducentis Acquisition - AstraZeneca (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - License Agreements &amp; Ducentis Acquisition - Hengrui (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails</Role>
      <ShortName>License Agreements &amp; Ducentis Acquisition - Hengrui (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/LicenseAgreementsDucentisAcquisition</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - License Agreements &amp; Ducentis Acquisition - Ducentis Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails</Role>
      <ShortName>License Agreements &amp; Ducentis Acquisition - Ducentis Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Commitments and Contingencies - Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Commitments and Contingencies - Operating Lease Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/DebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Debt - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Stockholders' Equity - Schedule of Assumptions in Calculating Stock Option Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Assumptions in Calculating Stock Option Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Income Taxes - Reconciliation of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Income Taxes - Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Net Loss Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/NetLossPerShareNarrativeDetails</Role>
      <ShortName>Net Loss Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Net Loss Per Share - Dilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails</Role>
      <ShortName>Net Loss Per Share - Dilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/SegmentReportingTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="arqt-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="arqt-20251231.htm">arqt-20251231.htm</File>
    <File>arqt-20251231.xsd</File>
    <File>arqt-20251231_cal.xml</File>
    <File>arqt-20251231_def.xml</File>
    <File>arqt-20251231_lab.xml</File>
    <File>arqt-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>arqt-20251231_g1.jpg</File>
    <File>arqt-20251231_g2.jpg</File>
    <File>arqt-20251231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="970">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>101
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arqt-20251231.htm": {
   "nsprefix": "arqt",
   "nsuri": "http://arcutis.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "arqt-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "arqt-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "arqt-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arqt-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "arqt-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arqt-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 386,
   "keyCustom": 73,
   "axisStandard": 32,
   "axisCustom": 2,
   "memberStandard": 43,
   "memberCustom": 47,
   "hidden": {
    "total": 13,
    "http://fasb.org/us-gaap/2025": 6,
    "http://xbrl.sec.gov/ecd/2025": 2,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://arcutis.com/20251231": 1
   },
   "contextCount": 297,
   "entityCount": 1,
   "segmentCount": 95,
   "elementCount": 799,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 970,
    "http://xbrl.sec.gov/dei/2025": 39,
    "http://xbrl.sec.gov/ecd/2025": 21,
    "http://xbrl.sec.gov/cyd/2025": 16
   },
   "report": {
    "R1": {
     "role": "http://arcutis.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://arcutis.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://arcutis.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://arcutis.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
     "longName": "9952155 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://arcutis.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://arcutis.com/role/DescriptionofBusiness",
     "longName": "9952157 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://arcutis.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://arcutis.com/role/Revenues",
     "longName": "9952159 - Disclosure - Revenues",
     "shortName": "Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://arcutis.com/role/FairValueMeasurements",
     "longName": "9952160 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://arcutis.com/role/BalanceSheetComponents",
     "longName": "9952161 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://arcutis.com/role/PropertyandEquipmentnet",
     "longName": "9952162 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://arcutis.com/role/LicenseAgreementsDucentisAcquisition",
     "longName": "9952163 - Disclosure - License Agreements & Ducentis Acquisition",
     "shortName": "License Agreements & Ducentis Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arqt:LicenseAgreementsAndAcquisitionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arqt:LicenseAgreementsAndAcquisitionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://arcutis.com/role/CommitmentsandContingencies",
     "longName": "9952164 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://arcutis.com/role/Debt",
     "longName": "9952165 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://arcutis.com/role/StockholdersEquity",
     "longName": "9952166 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://arcutis.com/role/IncomeTaxes",
     "longName": "9952167 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://arcutis.com/role/NetLossPerShare",
     "longName": "9952168 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://arcutis.com/role/SegmentReporting",
     "longName": "9952169 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://arcutis.com/role/RevenuesTables",
     "longName": "9955513 - Disclosure - Revenues (Tables)",
     "shortName": "Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://arcutis.com/role/FairValueMeasurementsTables",
     "longName": "9955514 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://arcutis.com/role/BalanceSheetComponentsTables",
     "longName": "9955515 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://arcutis.com/role/PropertyandEquipmentnetTables",
     "longName": "9955516 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://arcutis.com/role/CommitmentsandContingenciesTables",
     "longName": "9955517 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://arcutis.com/role/DebtTables",
     "longName": "9955518 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://arcutis.com/role/StockBasedCompensationTables",
     "longName": "9955519 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://arcutis.com/role/IncomeTaxesTables",
     "longName": "9955520 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://arcutis.com/role/NetLossPerShareTables",
     "longName": "9955521 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://arcutis.com/role/SegmentReportingTables",
     "longName": "9955522 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://arcutis.com/role/DescriptionofBusinessDetails",
     "longName": "9955523 - Disclosure - Description of Business (Details)",
     "shortName": "Description of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "arqt:CashCashEquivalentsAndMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955524 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails",
     "longName": "9955525 - Disclosure - Summary of Significant Accounting Policies - Finite-Lived Intangible Assets, Future Amortization Expense (Details)",
     "shortName": "Summary of Significant Accounting Policies - Finite-Lived Intangible Assets, Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails",
     "longName": "9955526 - Disclosure - Revenues - Schedule of Disaggregation of Revenue (Details)",
     "shortName": "Revenues - Schedule of Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://arcutis.com/role/RevenuesNarrativeDetails",
     "longName": "9955527 - Disclosure - Revenues - Narrative (Details)",
     "shortName": "Revenues - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
     "longName": "9955528 - Disclosure - Revenues - Gross Product Sales and Accounts Receivable Net (Details)",
     "shortName": "Revenues - Gross Product Sales and Accounts Receivable Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails",
     "longName": "9955529 - Disclosure - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
     "longName": "9955530 - Disclosure - Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details)",
     "shortName": "Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails",
     "longName": "9955531 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost and Fair Value of Marketable Securities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Amortized Cost and Fair Value of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://arcutis.com/role/FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails",
     "longName": "9955532 - Disclosure - Fair Value Measurements - Change In The Fair Value Of The Embedded Derivative Instrument (Details)",
     "shortName": "Fair Value Measurements - Change In The Fair Value Of The Embedded Derivative Instrument (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails",
     "longName": "9955533 - Disclosure - Balance Sheet Components - Inventories (Details)",
     "shortName": "Balance Sheet Components - Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "9955534 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "arqt:PrepaidCopayAssistanceProgramAndRebates",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "arqt:PrepaidCopayAssistanceProgramAndRebates",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
     "longName": "9955535 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Components - Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "arqt:AccruedSalesDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "arqt:AccruedSalesDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails",
     "longName": "9955536 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment, net - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails",
     "longName": "9955537 - Disclosure - Property and Equipment, net - Narrative (Details)",
     "shortName": "Property and Equipment, net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails",
     "longName": "9955538 - Disclosure - License Agreements & Ducentis Acquisition - Sato License Agreement (Details)",
     "shortName": "License Agreements & Ducentis Acquisition - Sato License Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-144",
      "name": "arqt:ContractNotWithCustomerUpfrontPaymentReceivedNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails",
     "longName": "9955539 - Disclosure - License Agreements & Ducentis Acquisition - Huadong (Details)",
     "shortName": "License Agreements & Ducentis Acquisition - Huadong (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-150",
      "name": "arqt:ContractNotWithCustomerUpfrontPaymentNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
     "longName": "9955540 - Disclosure - License Agreements & Ducentis Acquisition - AstraZeneca (Details)",
     "shortName": "License Agreements & Ducentis Acquisition - AstraZeneca (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails",
     "longName": "9955541 - Disclosure - License Agreements & Ducentis Acquisition - Hengrui (Details)",
     "shortName": "License Agreements & Ducentis Acquisition - Hengrui (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails",
     "longName": "9955542 - Disclosure - License Agreements & Ducentis Acquisition - Ducentis Acquisition (Details)",
     "shortName": "License Agreements & Ducentis Acquisition - Ducentis Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-162",
      "name": "arqt:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails",
     "longName": "9955543 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-168",
      "name": "arqt:LesseeOperatingLeaseOfficeSpace",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-168",
      "name": "arqt:LesseeOperatingLeaseOfficeSpace",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails",
     "longName": "9955544 - Disclosure - Commitments and Contingencies - Operating Lease Payments (Details)",
     "shortName": "Commitments and Contingencies - Operating Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails",
     "longName": "9955545 - Disclosure - Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details)",
     "shortName": "Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseAdditionalInformationDetails",
     "longName": "9955546 - Disclosure - Commitments and Contingencies - Operating Lease Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Operating Lease Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://arcutis.com/role/DebtNarrativeDetails",
     "longName": "9955547 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails",
     "longName": "9955548 - Disclosure - Debt - Schedule of Long-Term Debt (Details)",
     "shortName": "Debt - Schedule of Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "arqt:DebtInstrumentAccruedFinalFee",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9955549 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CapitalUnitsAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CapitalUnitsAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
     "longName": "9955550 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Stockholders' Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
     "longName": "9955551 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "shortName": "Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-225",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-225",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9955552 - Disclosure - Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-230",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails",
     "longName": "9955553 - Disclosure - Stockholders' Equity - Schedule of Assumptions in Calculating Stock Option Awards (Details)",
     "shortName": "Stockholders' Equity - Schedule of Assumptions in Calculating Stock Option Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-237",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-237",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://arcutis.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955554 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arqt:ForeignWithholdingIncomeTaxes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails",
     "longName": "9955555 - Disclosure - Income Taxes - Reconciliation of Loss Before Income Taxes (Details)",
     "shortName": "Income Taxes - Reconciliation of Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails",
     "longName": "9955556 - Disclosure - Income Taxes - Income Tax Expense (Details)",
     "shortName": "Income Taxes - Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9955557 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955558 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://arcutis.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails",
     "longName": "9955559 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://arcutis.com/role/NetLossPerShareNarrativeDetails",
     "longName": "9955560 - Disclosure - Net Loss Per Share - Narrative (Details)",
     "shortName": "Net Loss Per Share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-199",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails",
     "longName": "9955561 - Disclosure - Net Loss Per Share - Dilutive Shares (Details)",
     "shortName": "Net Loss Per Share - Dilutive Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://arcutis.com/role/SegmentReportingDetails",
     "longName": "9955562 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails",
     "longName": "9955563 - Disclosure - Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-286",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arqt-20251231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "arqt_A2017EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "A2017EquityIncentivePlanMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Equity Incentive Plan",
        "label": "2017 Equity Incentive Plan [Member]",
        "documentation": "2017 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_A2020EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "A2020EquityIncentivePlanMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan",
        "label": "2020 Equity Incentive Plan [Member]",
        "documentation": "2020 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_A2022EmploymentInducementIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "A2022EmploymentInducementIncentivePlanMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Employment Inducement Incentive Plan",
        "label": "2022 Employment Inducement Incentive Plan [Member]",
        "documentation": "2022 Employment Inducement Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r930"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r1161"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1171"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net accretion on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "arqt_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and Prepaid Research and Development Expenses",
        "label": "Accrued and Prepaid Research and Development Expenses, Policy [Policy Text Block]",
        "documentation": "Accrued and Prepaid Research and Development Expenses, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "arqt_AccruedSalesDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AccruedSalesDiscounts",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued sales deductions",
        "label": "Accrued Sales Discounts",
        "documentation": "Accrued Sales Discounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r133",
      "r683"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r63",
      "r141",
      "r679",
      "r718",
      "r719",
      "r1278"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10",
      "r17",
      "r549",
      "r552",
      "r620",
      "r714",
      "r715",
      "r1094",
      "r1095",
      "r1096",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r930",
      "r1341"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1279",
      "r1344"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising costs",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r880"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r986",
      "r996",
      "r1029"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r989",
      "r999",
      "r1032"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r990",
      "r1000",
      "r1024",
      "r1033",
      "r1037",
      "r1045"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r468",
      "r477"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r161",
      "r316",
      "r323",
      "r821",
      "r830",
      "r831",
      "r833",
      "r835"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially antidilutive shares excluded from the calculation of net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails",
      "http://arcutis.com/role/NetLossPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AssetAcquisitionAnnualNetSalesOfAcquireeThreshold",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual net sales",
        "label": "Asset Acquisition, Annual Net Sales of Acquiree Threshold",
        "documentation": "Asset Acquisition, Annual Net Sales of Acquiree Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r722",
      "r1266"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred, equity interest issued and issuable",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1267",
      "r1268",
      "r1269"
     ]
    },
    "arqt_AssetAcquisitionConsiderationTransferredGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AssetAcquisitionConsiderationTransferredGross",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred",
        "label": "Asset Acquisition, Consideration Transferred, Gross",
        "documentation": "Asset Acquisition, Consideration Transferred, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration to be transferred",
        "label": "Asset Acquisition, Contingent Consideration To Be Transferred Upon The Achievement Of Regulatory Milestones",
        "documentation": "Asset Acquisition, Contingent Consideration To Be Transferred Upon The Achievement Of Regulatory Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, duration due within",
        "label": "Asset Acquisition, Contingent Payments, Duration Due Within First Enrollment",
        "documentation": "Asset Acquisition, Contingent Payments, Duration Due Within First Enrollment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r722",
      "r1266"
     ]
    },
    "arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest issued or issuable, number of shares (in shares)",
        "label": "Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Line Items]",
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r1266"
     ]
    },
    "arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future payable milestone payment",
        "label": "Asset Acquisition, Payments, Milestones, Or Royalties, Future Payable Amount",
        "documentation": "Asset Acquisition, Payments, Milestones, Or Royalties, Future Payable Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Table]",
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r1266"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r106",
      "r135",
      "r170",
      "r172",
      "r173",
      "r211",
      "r225",
      "r243",
      "r247",
      "r288",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r536",
      "r538",
      "r590",
      "r664",
      "r665",
      "r675",
      "r770",
      "r850",
      "r851",
      "r863",
      "r930",
      "r939",
      "r940",
      "r953",
      "r1214",
      "r1215",
      "r1297"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r144",
      "r170",
      "r172",
      "r173",
      "r288",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r536",
      "r538",
      "r590",
      "r930",
      "r1214",
      "r1215",
      "r1297"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r917"
     ]
    },
    "arqt_AstraZenecaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AstraZenecaMember",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AstraZeneca",
        "label": "AstraZeneca [Member]",
        "documentation": "AstraZeneca"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_AtTheMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AtTheMarketMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market",
        "label": "At-The-Market [Member]",
        "documentation": "At-The-Market"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://arcutis.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r959",
      "r982"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://arcutis.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r959",
      "r982"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://arcutis.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r959",
      "r982"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r296",
      "r674"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing in one to five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing in one to five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r669"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing within one year",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r668"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      },
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsScheduleofAmortizedCostandFairValueofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value",
        "totalLabel": "Total marketable securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r296",
      "r563",
      "r583",
      "r584",
      "r585",
      "r586",
      "r661",
      "r819",
      "r917",
      "r920",
      "r927",
      "r1175",
      "r1283",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r296"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Date [Axis]",
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Date [Domain]",
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]",
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CN",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalUnitsAuthorized",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital stock",
        "label": "Capital Units, Authorized",
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies."
       }
      }
     },
     "auth_ref": []
    },
    "arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents and debt securities, available for sale",
        "label": "Cash And Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure",
        "documentation": "Cash And Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r131",
      "r822"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets",
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Cash and cash equivalents",
        "verboseLabel": "Money market funds and cash",
        "terseLabel": "Estimated fair value",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r585",
      "r586",
      "r1281",
      "r1282"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Line Items]",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r94"
     ]
    },
    "arqt_CashAndCashEquivalentsUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CashAndCashEquivalentsUnrealizedGain",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains",
        "label": "Cash And Cash Equivalents, Unrealized Gain",
        "documentation": "Cash And Cash Equivalents, Unrealized Gain"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_CashAndCashEquivalentsUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CashAndCashEquivalentsUnrealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized losses",
        "label": "Cash And Cash Equivalents, Unrealized Loss",
        "documentation": "Cash And Cash Equivalents, Unrealized Loss"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_CashCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CashCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, restricted cash and marketable securities",
        "label": "Cash, Cash Equivalents and Marketable Securities",
        "documentation": "Cash, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r74",
      "r169"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r74"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r138",
      "r139",
      "r140",
      "r170",
      "r173",
      "r201",
      "r202",
      "r204",
      "r206",
      "r213",
      "r214",
      "r288",
      "r344",
      "r346",
      "r347",
      "r348",
      "r351",
      "r352",
      "r376",
      "r377",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r389",
      "r390",
      "r392",
      "r590",
      "r729",
      "r730",
      "r731",
      "r732",
      "r735",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r758",
      "r778",
      "r796",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r1067",
      "r1146",
      "r1148",
      "r1157"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r176",
      "r393"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to acquire shares of common stock (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ClinicalTrialAccrualCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ClinicalTrialAccrualCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trial accruals",
        "label": "Clinical Trial Accrual, Current",
        "documentation": "Clinical Trial Accrual, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_CoPromotionAgreementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CoPromotionAgreementsPolicyPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promotion Agreement",
        "label": "Co-Promotion Agreements, Policy [Policy Text Block]",
        "documentation": "Co-Promotion Agreements, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r343",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r99",
      "r676",
      "r757"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r336",
      "r337",
      "r814",
      "r1206",
      "r1211"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r944",
      "r945",
      "r947",
      "r948",
      "r949",
      "r950",
      "r1153",
      "r1154",
      "r1156",
      "r1279",
      "r1340",
      "r1344"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r758"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r54",
      "r758",
      "r776",
      "r1344",
      "r1345"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized; 123,332,672 and 117,848,033 shares issued and outstanding at December\u00a031, 2025 and 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r377",
      "r383",
      "r678",
      "r930"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r149",
      "r151",
      "r157",
      "r662",
      "r688",
      "r689"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer hardware",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r253",
      "r723",
      "r724",
      "r813",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r253",
      "r723",
      "r724",
      "r813",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r253",
      "r723",
      "r724",
      "r813",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r588"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r813",
      "r842",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r253",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r813",
      "r842",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r253",
      "r723",
      "r724",
      "r813",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r837"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation of Other Investments",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r38"
     ]
    },
    "arqt_ContractNotWithCustomerLiabilityTaxWithholdingObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ContractNotWithCustomerLiabilityTaxWithholdingObligation",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax withholding obligation",
        "label": "Contract Not With Customer, Liability, Tax Withholding Obligation",
        "documentation": "Contract Not With Customer, Liability, Tax Withholding Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ContractNotWithCustomerUpfrontPaymentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ContractNotWithCustomerUpfrontPaymentNet",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net payment received",
        "label": "Contract Not With Customer, Upfront Payment, Net",
        "documentation": "Contract Not With Customer, Upfront Payment, Net"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ContractNotWithCustomerUpfrontPaymentReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ContractNotWithCustomerUpfrontPaymentReceivedNet",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received before taxes",
        "label": "Contract Not With Customer, Upfront Payment Received, Net",
        "documentation": "Contract Not With Customer, Upfront Payment Received, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r875",
      "r877",
      "r917",
      "r931",
      "r941",
      "r1337"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r657",
      "r831",
      "r836",
      "r914",
      "r1135"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Sales",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r178",
      "r179",
      "r356",
      "r388",
      "r621",
      "r639",
      "r673",
      "r827",
      "r828",
      "r829",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1273",
      "r1274",
      "r1275",
      "r1276"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "arqt_CowenAndCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CowenAndCompanyLLCMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cowen",
        "label": "Cowen And Company LLC [Member]",
        "documentation": "Cowen And Company LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1144",
      "r1150",
      "r1263"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1144",
      "r1150"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r1144",
      "r1150"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax provision:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1144",
      "r1150",
      "r1263"
     ]
    },
    "arqt_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CustomerAMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer A",
        "label": "Customer A [Member]",
        "documentation": "Customer A"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CustomerBMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer B",
        "label": "Customer B [Member]",
        "documentation": "Customer B"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CustomerCMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer C",
        "label": "Customer C [Member]",
        "documentation": "Customer C"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r1161"
     ]
    },
    "arqt_CustomerDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CustomerDMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer D",
        "label": "Customer D [Member]",
        "documentation": "Customer D"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_CustomerEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CustomerEMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer E",
        "label": "Customer E [Member]",
        "documentation": "Customer E"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_CustomerFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "CustomerFMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer F",
        "label": "Customer F [Member]",
        "documentation": "Customer F"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r1056"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r1056"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1058"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1058"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1060"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1058"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1051"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r1052"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r1052"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r1050"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r1050"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r1050"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1053"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r1055"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r1055"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r1056"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1059"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1057"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r1054"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentAccruedFinalFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentAccruedFinalFee",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued final fee",
        "label": "Debt Instrument, Accrued Final Fee",
        "documentation": "Debt Instrument, Accrued Final Fee"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentAccruedPrepaymentPenalty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentAccruedPrepaymentPenalty",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued prepayment penalty",
        "label": "Debt Instrument, Accrued Prepayment Penalty",
        "documentation": "Debt Instrument, Accrued Prepayment Penalty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails",
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r43",
      "r44",
      "r96",
      "r98",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r928",
      "r1144",
      "r1145",
      "r1147",
      "r1152",
      "r1207",
      "r1208",
      "r1209",
      "r1293",
      "r1294",
      "r1306"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails",
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, gross",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r98",
      "r370"
     ]
    },
    "arqt_DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum net product revenue as a percentage of projected monthly net revenue",
        "label": "Debt Instrument, Covenant, Minimum Net Product Revenue As A Percentage Of Projected Net Product Revenue",
        "documentation": "Debt Instrument, Covenant, Minimum Net Product Revenue As A Percentage Of Projected Net Product Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentDefaultRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentDefaultRate",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Default rate (as a percent)",
        "label": "Debt Instrument, Default Rate",
        "documentation": "Debt Instrument, Default Rate"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentDeferredFinalFeeGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentDeferredFinalFeeGross",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred final fee",
        "label": "Debt Instrument, Deferred Final Fee, Gross",
        "documentation": "Debt Instrument, Deferred Final Fee, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentExitFeeExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentExitFeeExpirationPeriod",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exit fee expiration period (in years)",
        "label": "Debt Instrument, Exit Fee, Expiration Period",
        "documentation": "Debt Instrument, Exit Fee, Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentExitFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentExitFeePercentage",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exit fee (as a percent)",
        "label": "Debt Instrument, Exit Fee, Percentage",
        "documentation": "Debt Instrument, Exit Fee, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentExtensionFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentExtensionFeePercentage",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension fee",
        "label": "Debt Instrument, Extension Fee, Percentage",
        "documentation": "Debt Instrument, Extension Fee, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentFinalFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentFinalFeePercentage",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final fee (as a percent)",
        "label": "Debt Instrument, Final Fee, Percentage",
        "documentation": "Debt Instrument, Final Fee, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentFundingAvailabilityCovenantPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentFundingAvailabilityCovenantPeriod",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Covenant period",
        "label": "Debt Instrument, Funding Availability, Covenant, Period",
        "documentation": "Debt Instrument, Funding Availability, Covenant, Period"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentInterestRateAtPeriodEnd": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentInterestRateAtPeriodEnd",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate at end of period",
        "label": "Debt Instrument, Interest Rate At Period End",
        "documentation": "Debt Instrument, Interest Rate At Period End"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r372",
      "r602",
      "r603",
      "r928"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r354"
     ]
    },
    "arqt_DebtInstrumentInterestRateStatedPercentagePartialPrepayment": {
     "xbrltype": "pureItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentInterestRateStatedPercentagePartialPrepayment",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, stated percentage, partial prepayment",
        "label": "Debt Instrument, Interest Rate, Stated Percentage, Partial Prepayment",
        "documentation": "Debt Instrument, Interest Rate, Stated Percentage, Partial Prepayment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r547",
      "r667",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r928",
      "r1144",
      "r1145",
      "r1147",
      "r1152",
      "r1293",
      "r1294"
     ]
    },
    "arqt_DebtInstrumentMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Debt Instrument, Maximum Borrowing Capacity",
        "documentation": "Debt Instrument, Maximum Borrowing Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails",
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r928",
      "r1144",
      "r1145",
      "r1147",
      "r1152",
      "r1207",
      "r1208",
      "r1209",
      "r1293",
      "r1294",
      "r1306"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Periodic principal payment",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "arqt_DebtInstrumentPrepaymentPenalty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentPrepaymentPenalty",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, prepayment penalty",
        "label": "Debt Instrument, Prepayment Penalty",
        "documentation": "Debt Instrument, Prepayment Penalty"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentPrepaymentPremium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentPrepaymentPremium",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment premium (as a percent)",
        "label": "Debt Instrument, Prepayment Premium",
        "documentation": "Debt Instrument, Prepayment Premium"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information by period of debt redemption feature under terms of debt agreement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior to December 22, 2022",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After December 22, 2023 and prior to December 22, 2025",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After December 22, 2002 and prior to December 22, 2023",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r32",
      "r40",
      "r85",
      "r86",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r547",
      "r667",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r928",
      "r1144",
      "r1145",
      "r1147",
      "r1152",
      "r1293",
      "r1294"
     ]
    },
    "arqt_DebtInstrumentTrancheAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentTrancheAxis",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Tranche [Axis]",
        "label": "Debt Instrument, Tranche [Axis]",
        "documentation": "Debt Instrument, Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DebtInstrumentTrancheDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DebtInstrumentTrancheDomain",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Tranche [Domain]",
        "label": "Debt Instrument, Tranche [Domain]",
        "documentation": "Debt Instrument, Tranche [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r296",
      "r300",
      "r301"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1150",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1217",
      "r1292",
      "r1293",
      "r1294"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1150",
      "r1262"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r114",
      "r1144",
      "r1150"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax provision:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r97",
      "r509"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1150",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "documentation": "Deferred Tax Assets, Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, not subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "arqt_DeferredTaxAssetsResearchAndExpenditureCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DeferredTaxAssetsResearchAndExpenditureCapitalization",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and expenditure capitalization",
        "label": "Deferred Tax Assets, Research And Expenditure Capitalization",
        "documentation": "Deferred Tax Assets, Research And Expenditure Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "arqt_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use asset",
        "label": "Deferred Tax Liabilities, Right-Of-Use Asset",
        "documentation": "Deferred Tax Liabilities, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r160",
      "r830",
      "r831",
      "r833",
      "r835"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r431",
      "r462",
      "r463",
      "r466",
      "r879"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r958",
      "r959",
      "r982"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r958",
      "r959",
      "r982",
      "r1025"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails",
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "verboseLabel": "Domestic Tax Jurisdiction",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "arqt_DucentisBiotherapeuticsLTDEquityInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "DucentisBiotherapeuticsLTDEquityInterestsMember",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ducentis Biotherapeutics LTD Equity Interests",
        "label": "Ducentis Biotherapeutics LTD Equity Interests [Member]",
        "documentation": "Ducentis Biotherapeutics LTD Equity Interests"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r158",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r199",
      "r201",
      "r204",
      "r205",
      "r206",
      "r210",
      "r375",
      "r467",
      "r530",
      "r535",
      "r560",
      "r561",
      "r663",
      "r690",
      "r841"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share information:",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r158",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r201",
      "r204",
      "r205",
      "r206",
      "r210",
      "r375",
      "r467",
      "r530",
      "r535",
      "r560",
      "r561",
      "r663",
      "r690",
      "r841"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r207",
      "r208",
      "r209"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Provision for income taxes",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r882"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax U.S. federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r175",
      "r490",
      "r521",
      "r882"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r882",
      "r1144",
      "r1151",
      "r1253"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax effects",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r494",
      "r882",
      "r1144",
      "r1151",
      "r1253"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation [Line Items]",
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r882"
     ]
    },
    "arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec. 162(m) limitation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Limitation, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Limitation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec. 162(m) limitation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Limitation, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation Limitation, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r1144",
      "r1151",
      "r1253",
      "r1255"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r1144",
      "r1151",
      "r1253",
      "r1255"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r1144",
      "r1151",
      "r1253",
      "r1254"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income tax, net of federal (national) income tax effect",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r882",
      "r1144",
      "r1151",
      "r1253"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation [Table]",
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r882"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r497",
      "r1144",
      "r1151",
      "r1253"
     ]
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of the embedded derivative instrument",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability."
       }
      }
     },
     "auth_ref": [
      "r1270",
      "r1283",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of embedded derivative instrument",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period."
       }
      }
     },
     "auth_ref": [
      "r1271",
      "r1277"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1248"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition period for unrecognized compensation costs related to unvested options expected to vest (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1249"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP shares subject to future issuance",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "verboseLabel": "Stock options to purchase common stock",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r118",
      "r119",
      "r120",
      "r153",
      "r154",
      "r155",
      "r181",
      "r182",
      "r183",
      "r185",
      "r192",
      "r194",
      "r196",
      "r212",
      "r289",
      "r290",
      "r329",
      "r374",
      "r394",
      "r467",
      "r519",
      "r520",
      "r527",
      "r528",
      "r529",
      "r531",
      "r534",
      "r535",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r604",
      "r605",
      "r620",
      "r686",
      "r714",
      "r715",
      "r716",
      "r735",
      "r796"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r986",
      "r996",
      "r1029"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1026"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r575",
      "r917"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r575",
      "r917"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Assets Measured on a Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1281",
      "r1282"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r574",
      "r575",
      "r577",
      "r584",
      "r626",
      "r627",
      "r628",
      "r819",
      "r859",
      "r860",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r917",
      "r920",
      "r927"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r570",
      "r572",
      "r573",
      "r574",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r660",
      "r917",
      "r921"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r416",
      "r421",
      "r422",
      "r564",
      "r575",
      "r584",
      "r626",
      "r819",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r917",
      "r927"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r416",
      "r421",
      "r422",
      "r424",
      "r564",
      "r565",
      "r575",
      "r584",
      "r627",
      "r819",
      "r859",
      "r860",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r917",
      "r927"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r564",
      "r565",
      "r566",
      "r567",
      "r575",
      "r584",
      "r628",
      "r819",
      "r859",
      "r860",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r917",
      "r920",
      "r927"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r574",
      "r575",
      "r577",
      "r584",
      "r626",
      "r627",
      "r628",
      "r819",
      "r859",
      "r860",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r917",
      "r920",
      "r927"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (gain) from changes in fair value",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r576"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r576"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsChangeInTheFairValueOfTheEmbeddedDerivativeInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r576"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r369",
      "r391",
      "r547",
      "r558",
      "r582",
      "r589",
      "r592",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r672",
      "r687",
      "r856",
      "r917",
      "r918",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r931",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1280",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset, useful life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1202",
      "r1346"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r817",
      "r821"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r817",
      "r821"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r817",
      "r821"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r817",
      "r821"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r817",
      "r821"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r325",
      "r326",
      "r658",
      "r659",
      "r722",
      "r817",
      "r821",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r325",
      "r326",
      "r722",
      "r817",
      "r821",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total amortization",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r1201"
     ]
    },
    "arqt_FirstEquityPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "FirstEquityPublicOfferingMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Equity Public Offering",
        "label": "First Equity Public Offering [Member]",
        "documentation": "First Equity Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_FirstGrantDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "FirstGrantDateMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Date One",
        "label": "First Grant Date [Member]",
        "documentation": "First Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_FiveCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "FiveCustomersMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Five Customers",
        "label": "Five Customers [Member]",
        "documentation": "Five Customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails",
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Jurisdiction",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_ForeignTaxJurisdictionOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignTaxJurisdictionOtherMember",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Foreign Tax Jurisdiction, Other [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile, classified as other."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r1141",
      "r1258"
     ]
    },
    "arqt_ForeignWithholdingIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ForeignWithholdingIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign withholding income tax",
        "label": "Foreign Withholding Income Taxes",
        "documentation": "Foreign Withholding Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r990",
      "r1000",
      "r1033"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r990",
      "r1000",
      "r1033"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r990",
      "r1000",
      "r1033"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r990",
      "r1000",
      "r1033"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r990",
      "r1000",
      "r1033"
     ]
    },
    "arqt_FourCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "FourCustomersMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Four Customers",
        "label": "Four Customers [Member]",
        "documentation": "Four Customers"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "GB",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, net",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1194",
      "r1195"
     ]
    },
    "arqt_HengruiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "HengruiMember",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hengrui",
        "label": "Hengrui [Member]",
        "documentation": "Hengrui"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_HuadongMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "HuadongMember",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Huadong",
        "label": "Huadong [Member]",
        "documentation": "Huadong"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r959",
      "r982"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment losses",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r159",
      "r316",
      "r327"
     ]
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r155"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r174",
      "r489"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesReconciliationofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r174",
      "r489"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r332",
      "r333",
      "r541",
      "r543",
      "r544",
      "r546",
      "r569",
      "r571",
      "r576",
      "r591",
      "r592",
      "r593",
      "r711",
      "r713",
      "r781",
      "r817",
      "r819",
      "r883",
      "r884",
      "r915",
      "r916",
      "r919",
      "r927",
      "r1264",
      "r1265",
      "r1310"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r541",
      "r543",
      "r544",
      "r546",
      "r569",
      "r571",
      "r576",
      "r591",
      "r592",
      "r593",
      "r711",
      "r713",
      "r781",
      "r817",
      "r819",
      "r883",
      "r884",
      "r915",
      "r916",
      "r919",
      "r927",
      "r1264",
      "r1265",
      "r1310"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails",
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r490",
      "r491",
      "r502",
      "r515",
      "r882",
      "r1259"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails",
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r490",
      "r491",
      "r502",
      "r515",
      "r882",
      "r1259"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r1256"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r175",
      "r484",
      "r490",
      "r498",
      "r499",
      "r500",
      "r506",
      "r513",
      "r522",
      "r524",
      "r525",
      "r526",
      "r671",
      "r721",
      "r734",
      "r882"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      },
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/IncomeTaxesIncomeTaxExpenseDetails",
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails",
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r115",
      "r170",
      "r195",
      "r196",
      "r211",
      "r233",
      "r247",
      "r488",
      "r490",
      "r523",
      "r691",
      "r832",
      "r834",
      "r836",
      "r882"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r486",
      "r487",
      "r506",
      "r507",
      "r512",
      "r517",
      "r728"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r882",
      "r1253"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax effects",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r494",
      "r882",
      "r1253"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax U.S. federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r882"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r1253",
      "r1255"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r1253",
      "r1255"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r1253",
      "r1254"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income tax, net of federal (national) income tax effect",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r882",
      "r1253"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r497",
      "r1253"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash income taxes paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r168",
      "r514",
      "r515"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "documentation": "Increase (Decrease) in Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1140"
     ]
    },
    "arqt_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "label": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "documentation": "Increase (Decrease) In Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r990",
      "r1000",
      "r1024",
      "r1033",
      "r1037",
      "r1045"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1049"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1049"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1049"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r1201",
      "r1203"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r366",
      "r373",
      "r861",
      "r862",
      "r1343"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0,
       "order": 3.0
      },
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r832",
      "r836",
      "r1097"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense paid in cash",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r166",
      "r167"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r824"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails",
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Total inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r823",
      "r930"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r130",
      "r142",
      "r302",
      "r303",
      "r304",
      "r656",
      "r838"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r826"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in progress",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r825"
     ]
    },
    "arqt_KeithLeonardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "KeithLeonardMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Keith Leonard [Member]",
        "documentation": "Keith Leonard"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Supplemental Cash Flow Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "arqt_LeaseDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LeaseDescriptionAxis",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Description [Axis]",
        "label": "Lease Description [Axis]",
        "documentation": "Lease Description"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_LeaseDescriptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LeaseDescriptionDomain",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Description [Domain]",
        "label": "Lease Description [Domain]",
        "documentation": "Lease Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r618"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r619"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r619"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "arqt_LesseeOperatingLeaseAdditionalYearsOfRentPayments": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LesseeOperatingLeaseAdditionalYearsOfRentPayments",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional years of rent payments (in years)",
        "label": "Lessee, Operating Lease, Additional Years Of Rent Payments",
        "documentation": "Lessee, Operating Lease, Additional Years Of Rent Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_LesseeOperatingLeaseExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LesseeOperatingLeaseExtensionTerm",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension term of the lease (in years)",
        "label": "Lessee, Operating Lease, Extension Term",
        "documentation": "Lessee, Operating Lease, Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future lease rent payment commitments",
        "label": "Lessee, Operating Lease, Increase In Future Lease Rent Payment Commitments",
        "documentation": "Lessee, Operating Lease, Increase In Future Lease Rent Payment Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1296"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1145",
      "r1152",
      "r1306"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1145",
      "r1152",
      "r1306"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1145",
      "r1152",
      "r1306"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1145",
      "r1152",
      "r1306"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1145",
      "r1152",
      "r1306"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1145",
      "r1152",
      "r1306"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1145",
      "r1152",
      "r1306"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Amounts representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "arqt_LesseeOperatingLeaseOfficeSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LesseeOperatingLeaseOfficeSpace",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office space (in square feet)",
        "label": "Lessee, Operating Lease, Office Space",
        "documentation": "Lessee, Operating Lease, Office Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r43",
      "r44",
      "r45",
      "r47",
      "r48",
      "r49",
      "r52",
      "r170",
      "r172",
      "r173",
      "r288",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r537",
      "r538",
      "r539",
      "r590",
      "r756",
      "r844",
      "r863",
      "r953",
      "r1214",
      "r1297",
      "r1298"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r100",
      "r681",
      "r930",
      "r939",
      "r940",
      "r1144",
      "r1149",
      "r1192",
      "r1290"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r129",
      "r170",
      "r172",
      "r173",
      "r288",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r537",
      "r538",
      "r539",
      "r590",
      "r930",
      "r1214",
      "r1297",
      "r1298"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of years after first commercial sale to receive royalties",
        "label": "License Agreement, Number Of Years After First Commercial Sale To Receive Royalties",
        "documentation": "License Agreement, Number Of Years After First Commercial Sale To Receive Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_LicenseAgreementTerminationNumberOfDaysForWrittenNotice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LicenseAgreementTerminationNumberOfDaysForWrittenNotice",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of days for written notice",
        "label": "License Agreement, Termination, Number Of Days For Written Notice",
        "documentation": "License Agreement, Termination, Number Of Days For Written Notice"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_LicenseAgreementsAndAcquisitionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LicenseAgreementsAndAcquisitionsTextBlock",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreements &amp; Ducentis Acquisition",
        "label": "License Agreements And Acquisitions [Text Block]",
        "documentation": "License Agreements And Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LicenseAgreementsAndDucentisAcquisitionDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements And Ducentis Acquisition Disclosure [Abstract]",
        "documentation": "License Agreements And Ducentis Acquisition Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails",
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan agreement",
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_LoanAgreementTrancheC1ExpiringMarch312026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LoanAgreementTrancheC1ExpiringMarch312026Member",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Agreement, Tranche C-1, Expiring March 31, 2026",
        "label": "Loan Agreement, Tranche C-1, Expiring March 31, 2026 [Member]",
        "documentation": "Loan Agreement, Tranche C-1, Expiring March 31, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_LoanAgreementTrancheC2ExpiringJune302026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "LoanAgreementTrancheC2ExpiringJune302026Member",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Agreement, Tranche C-2, Expiring June 30, 2026",
        "label": "Loan Agreement, Tranche C-2, Expiring June 30, 2026 [Member]",
        "documentation": "Loan Agreement, Tranche C-2, Expiring June 30, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails",
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "totalLabel": "Total carrying value of debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r98",
      "r171",
      "r180",
      "r360",
      "r371",
      "r667",
      "r859",
      "r860",
      "r928",
      "r1308"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets",
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of long-term debt, net",
        "negatedTerseLabel": "Less current portion",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity, due 2029",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r171",
      "r180",
      "r364",
      "r667"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets",
      "http://arcutis.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, net",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://arcutis.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails",
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails",
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r30",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r865",
      "r868",
      "r933",
      "r937",
      "r1309",
      "r1311",
      "r1312",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1338",
      "r1339"
     ]
    },
    "arqt_MajorCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "MajorCustomersMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Customers",
        "label": "Major Customers [Member]",
        "documentation": "Major Customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r339",
      "r340",
      "r341",
      "r342",
      "r425",
      "r457",
      "r458",
      "r459",
      "r478",
      "r567",
      "r655",
      "r710",
      "r712",
      "r720",
      "r748",
      "r749",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r809",
      "r810",
      "r811",
      "r812",
      "r815",
      "r816",
      "r855",
      "r864",
      "r878",
      "r883",
      "r885",
      "r886",
      "r920",
      "r921",
      "r925",
      "r926",
      "r934",
      "r1216",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails",
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r339",
      "r340",
      "r341",
      "r342",
      "r425",
      "r457",
      "r458",
      "r459",
      "r478",
      "r567",
      "r655",
      "r710",
      "r712",
      "r720",
      "r748",
      "r749",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r809",
      "r810",
      "r811",
      "r812",
      "r815",
      "r816",
      "r855",
      "r864",
      "r878",
      "r883",
      "r885",
      "r886",
      "r920",
      "r921",
      "r925",
      "r934",
      "r1216",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds and cash",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1220",
      "r1221"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails",
      "http://arcutis.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r865",
      "r868",
      "r933",
      "r937",
      "r1309",
      "r1311",
      "r1312",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1338",
      "r1339"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r76",
      "r101",
      "r120",
      "r127",
      "r147",
      "r150",
      "r155",
      "r170",
      "r172",
      "r173",
      "r177",
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r203",
      "r288",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r375",
      "r378",
      "r381",
      "r385",
      "r467",
      "r530",
      "r535",
      "r561",
      "r590",
      "r685",
      "r777",
      "r794",
      "r795",
      "r832",
      "r834",
      "r836",
      "r951",
      "r1214"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r990",
      "r1000",
      "r1024",
      "r1033"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://arcutis.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r854",
      "r1166"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r832",
      "r836",
      "r845",
      "r1159",
      "r1167",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line rent expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r929"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of future minimum lease payments",
        "totalLabel": "Total operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued and other current liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails",
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, long-term",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r613"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate (as a percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r929"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r929"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://arcutis.com/role/DescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r121",
      "r122",
      "r124",
      "r725",
      "r726"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r93"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r93",
      "r148",
      "r151",
      "r192"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on marketable securities",
        "verboseLabel": "Unrealized gain (loss) on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r287"
     ]
    },
    "arqt_OtherEarlyStageProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "OtherEarlyStageProgramsMember",
     "presentation": [
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other early-stage programs costs",
        "label": "Other Early-Stage Programs [Member]",
        "documentation": "Other Early-Stage Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-cash items, net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r914"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other prepaid expenses and current assets",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1193"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r988",
      "r998",
      "r1031"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r991",
      "r1001",
      "r1034"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r991",
      "r1001",
      "r1034"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PatentsMember",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1204",
      "r1205"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r162",
      "r255"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Milestone payment for intangible asset",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r758"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r758",
      "r776",
      "r1344",
      "r1345"
     ]
    },
    "arqt_PrefundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "PrefundedWarrantMember",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prefunded Warrant",
        "label": "Prefunded Warrant [Member]",
        "documentation": "Prefunded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_PrepaidClinicalTrialTestCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "PrepaidClinicalTrialTestCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid clinical trial costs",
        "label": "Prepaid Clinical Trial Test Costs, Current",
        "documentation": "Prepaid Clinical Trial Test Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_PrepaidCopayAssistanceProgramAndRebates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "PrepaidCopayAssistanceProgramAndRebates",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid co-pay assistance program and rebates",
        "label": "Prepaid Copay Assistance Program And Rebates",
        "documentation": "Prepaid Copay Assistance Program And Rebates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "arqt_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs",
        "label": "Proceeds From Issuance Of Common Stock And Pre-Funded Warrants, Net Of Issuance Costs",
        "documentation": "Proceeds From Issuance Of Common Stock And Pre-Funded Warrants, Net Of Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of shares under ATM, net of issuance costs",
        "label": "Proceeds From Issuance of Shares Under At-the-Market Offering, Net of Issuance Costs",
        "documentation": "Proceeds From Issuance of Shares Under At-the-Market Offering, Net of Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock for ESPP",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities and sales of marketable securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r1176"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r657",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r820",
      "r831",
      "r834",
      "r836",
      "r865",
      "r866",
      "r932",
      "r934",
      "r935",
      "r938",
      "r942",
      "r1070",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1212",
      "r1213",
      "r1309",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1338",
      "r1339"
     ]
    },
    "arqt_ProductRevenuePaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ProductRevenuePaymentTerm",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment terms (in days)",
        "label": "Product Revenue, Payment Term",
        "documentation": "Product Revenue, Payment Term"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r657",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r820",
      "r831",
      "r834",
      "r836",
      "r865",
      "r866",
      "r932",
      "r934",
      "r935",
      "r938",
      "r942",
      "r1070",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1212",
      "r1213",
      "r1309",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1338",
      "r1339"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails",
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r618"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r111",
      "r112",
      "r113"
     ]
    },
    "arqt_PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, excluding leasehold improvements",
        "label": "Property, Plant and Equipment, Excluding Leasehold Improvements [Member]",
        "documentation": "Property, Plant and Equipment, Excluding Leasehold Improvements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r132",
      "r684"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails",
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets",
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment, net",
        "totalLabel": "Property, plant, and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r618",
      "r670",
      "r684",
      "r930"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r111",
      "r112",
      "r682"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails",
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r618"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails",
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r339",
      "r340",
      "r341",
      "r342",
      "r415",
      "r425",
      "r457",
      "r458",
      "r459",
      "r466",
      "r478",
      "r567",
      "r629",
      "r638",
      "r655",
      "r710",
      "r712",
      "r720",
      "r748",
      "r749",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r809",
      "r810",
      "r811",
      "r812",
      "r815",
      "r816",
      "r855",
      "r864",
      "r878",
      "r883",
      "r885",
      "r886",
      "r920",
      "r921",
      "r925",
      "r926",
      "r934",
      "r945",
      "r1210",
      "r1216",
      "r1284",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails",
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r339",
      "r340",
      "r341",
      "r342",
      "r415",
      "r425",
      "r457",
      "r458",
      "r459",
      "r466",
      "r478",
      "r567",
      "r629",
      "r638",
      "r655",
      "r710",
      "r712",
      "r720",
      "r748",
      "r749",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r809",
      "r810",
      "r811",
      "r812",
      "r815",
      "r816",
      "r855",
      "r864",
      "r878",
      "r883",
      "r885",
      "r886",
      "r920",
      "r921",
      "r925",
      "r926",
      "r934",
      "r945",
      "r1210",
      "r1216",
      "r1284",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RecordedUnconditionalPurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future purchase commitments in 2027",
        "label": "Recorded Unconditional Purchase Obligation, to be Paid, Year Two",
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future purchase commitment in 2026",
        "label": "Recorded Unconditional Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1026"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r732"
     ]
    },
    "arqt_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r178",
      "r179",
      "r356",
      "r388",
      "r621",
      "r639",
      "r673",
      "r827",
      "r828",
      "r829",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1273",
      "r1274",
      "r1275",
      "r1276"
     ]
    },
    "arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual net sales",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Annual Worldwide Net Sales Threshold",
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Annual Worldwide Net Sales Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement, cash payment",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r1252"
     ]
    },
    "arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum milestone payments for net worldwide sales",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments",
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product milestone payment for first product approval",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payment For First Product Approval",
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payment For First Product Approval"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum milestone payments for licensed products",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payments",
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales milestone payment",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Sales Milestone Payments",
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Sales Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Years from first commercial sale",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Years From First Commercial Sale",
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Years From First Commercial Sale"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development compensation and personnel-related expenses",
        "label": "Research And Development Compensation And Personnel-Related Expenses",
        "documentation": "Research And Development Compensation And Personnel-Related Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r817",
      "r832",
      "r833",
      "r850",
      "r1305"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1259"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r984",
      "r994",
      "r1027"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r985",
      "r995",
      "r1028"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r992",
      "r1002",
      "r1035"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r94",
      "r131",
      "r169",
      "r677"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1158",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs subject to future vesting",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets",
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r87",
      "r680",
      "r717",
      "r719",
      "r733",
      "r759",
      "r930"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r181",
      "r182",
      "r183",
      "r185",
      "r192",
      "r194",
      "r196",
      "r289",
      "r290",
      "r329",
      "r374",
      "r467",
      "r519",
      "r520",
      "r527",
      "r528",
      "r529",
      "r531",
      "r534",
      "r535",
      "r548",
      "r550",
      "r551",
      "r553",
      "r559",
      "r604",
      "r605",
      "r714",
      "r716",
      "r735",
      "r1344"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue, net",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r211",
      "r226",
      "r227",
      "r241",
      "r247",
      "r250",
      "r252",
      "r253",
      "r411",
      "r412",
      "r413",
      "r657"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r818"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://arcutis.com/role/Revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r413",
      "r414"
     ]
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueNotFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails",
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "label": "Revenue Not from Contract with Customer",
        "documentation": "Amount of revenue that is not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "arqt_RevenueNotFromContractWithCustomerPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "RevenueNotFromContractWithCustomerPolicyPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Revenue",
        "label": "Revenue Not From Contract With Customer, Policy [Policy Text Block]",
        "documentation": "Revenue Not From Contract With Customer, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, variable consideration amount, regulatory milestones",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount to be received upon achievement of sales milestones",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount, Sales Milestones",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount, Sales Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenues",
        "terseLabel": "Total revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r156",
      "r170",
      "r172",
      "r173",
      "r211",
      "r226",
      "r227",
      "r241",
      "r247",
      "r250",
      "r252",
      "r253",
      "r288",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r590",
      "r664",
      "r666",
      "r850",
      "r914",
      "r939",
      "r940",
      "r1214"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r929"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty expense",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "arqt_SaleOfStockAgentFeePercentageOfGrossProceeds": {
     "xbrltype": "pureItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "SaleOfStockAgentFeePercentageOfGrossProceeds",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share sales agreement, percentage of gross sales price (as a percent)",
        "label": "Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds",
        "documentation": "Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_SaleOfStockAuthorizedConsiderationOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "SaleOfStockAuthorizedConsiderationOnTransaction",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares of common stock for sales agreement",
        "label": "Sale Of Stock, Authorized Consideration On Transaction",
        "documentation": "Sale Of Stock, Authorized Consideration On Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesGrossProductSalesandAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Product Sales",
        "label": "Sales [Member]",
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r1272"
     ]
    },
    "arqt_SatoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "SatoMember",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sato",
        "label": "Sato [Member]",
        "documentation": "Sato"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r125",
      "r197",
      "r426",
      "r1068"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDilutiveSharesDetails",
      "http://arcutis.com/role/NetLossPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Shares Excluded",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalent [Table]",
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://arcutis.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r32",
      "r40",
      "r85",
      "r86",
      "r859",
      "r861",
      "r1145",
      "r1152",
      "r1293",
      "r1306"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Change in the Fair Value of Embedded Derivative Instrument",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r542",
      "r545",
      "r915"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r882",
      "r1253"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss before Income Tax, Domestic and Foreign",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1150"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r61",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Unit Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetNarrativeDetails",
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r618"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHengruiDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionHuadongDetails",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionSatoLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development, Contract to Perform for Others [Table]",
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r1252"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://arcutis.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r430",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r466"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r88"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions in Calculating Stock Option Awards",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r881"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r1202"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://arcutis.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Major Customers",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1165"
     ]
    },
    "arqt_SecondGrantDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "SecondGrantDateMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Grant Date",
        "label": "Second Grant Date [Member]",
        "documentation": "Second Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_SecondaryEquityPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "SecondaryEquityPublicOfferingMember",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secondary Equity Public Offering",
        "label": "Secondary Equity Public Offering [Member]",
        "documentation": "Secondary Equity Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails",
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r211",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r253",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r328",
      "r334",
      "r335",
      "r532",
      "r533",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r847",
      "r850",
      "r851",
      "r857",
      "r936",
      "r1309",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1338",
      "r1339"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://arcutis.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r211",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r237",
      "r239",
      "r240",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r846",
      "r848",
      "r849",
      "r850",
      "r852",
      "r853",
      "r854"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment expenses",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r239",
      "r240",
      "r247",
      "r850"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r831",
      "r832",
      "r833",
      "r836",
      "r1135"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award requisite service period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period of stock-based awards granted (in share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized for sale under the ESPP (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Base Amount Of Common Stock Shares Authorized",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Base Amount Of Common Stock Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Based number of options issuable (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Base Number Of Options Issuable",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Base Number Of Options Issuable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total grant-date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in shares available for grant, percentage of shares outstanding (as a percent)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r430",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r466"
     ]
    },
    "arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum shares to be issued",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable",
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, weighted-average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised during the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in shares)",
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant-date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value ($ in thousands)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, number of options (in shares)",
        "periodEndLabel": "Ending balance, number of options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, weighted-average exercise price (in dollars per share)",
        "periodEndLabel": "Ending balance, weighted-average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of eligible options exchanged",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Of Eligible Options Exchanged",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Of Eligible Options Exchanged"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental cost of plan modification",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First anniversary date",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r435",
      "r454",
      "r455",
      "r456",
      "r457",
      "r460",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting rights, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1222"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining contractual term, exercisable (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining Contractual Term (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total grant-date fair value of the options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": [
      "r1250"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock, as a percentage of closing trading price per share (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1250"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://arcutis.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r126",
      "r211",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r253",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r328",
      "r331",
      "r334",
      "r335",
      "r532",
      "r533",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r847",
      "r850",
      "r851",
      "r857",
      "r936",
      "r1309",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1338",
      "r1339"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r138",
      "r139",
      "r140",
      "r170",
      "r173",
      "r201",
      "r202",
      "r204",
      "r206",
      "r213",
      "r214",
      "r288",
      "r344",
      "r346",
      "r347",
      "r348",
      "r351",
      "r352",
      "r376",
      "r377",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r389",
      "r390",
      "r392",
      "r590",
      "r729",
      "r730",
      "r731",
      "r732",
      "r735",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r758",
      "r778",
      "r796",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r1067",
      "r1146",
      "r1148",
      "r1157"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
      "http://arcutis.com/role/LicenseAgreementsDucentisAcquisitionDucentisAcquisitionDetails",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r54",
      "r57",
      "r58",
      "r118",
      "r119",
      "r120",
      "r153",
      "r154",
      "r155",
      "r181",
      "r182",
      "r183",
      "r185",
      "r192",
      "r194",
      "r196",
      "r212",
      "r289",
      "r290",
      "r329",
      "r374",
      "r394",
      "r467",
      "r519",
      "r520",
      "r527",
      "r528",
      "r529",
      "r531",
      "r534",
      "r535",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r604",
      "r605",
      "r620",
      "r686",
      "r714",
      "r715",
      "r716",
      "r735",
      "r796"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r212",
      "r376",
      "r377",
      "r379",
      "r382",
      "r605",
      "r657",
      "r727",
      "r736",
      "r747",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r758",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r796",
      "r834",
      "r836",
      "r946",
      "r1342"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r125",
      "r197",
      "r426",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r212",
      "r254",
      "r376",
      "r377",
      "r379",
      "r382",
      "r605",
      "r657",
      "r727",
      "r736",
      "r747",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r758",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r796",
      "r834",
      "r836",
      "r946",
      "r1342"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r987",
      "r997",
      "r1030"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lapse of repurchasing rights related to common stock issued pursuant to early exercises",
        "label": "Stock Issued During Period, Lapse Of Repurchase Rights Pursuant To Early Stock Exercises",
        "documentation": "Stock Issued During Period, Lapse Of Repurchase Rights Pursuant To Early Stock Exercises"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to early exercises (in shares)",
        "label": "Stock Issued During Period, Lapse of Repurchase Rights Related to Common Stock Issued Pursuant to Early Exercises, Shares",
        "documentation": "Stock Issued During Period, Lapse of Repurchase Rights Related to Common Stock Issued Pursuant to Early Exercises, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued pursuant to the ESPP (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r53",
      "r54",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of shares of common stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r53",
      "r54",
      "r87",
      "r729",
      "r796",
      "r805"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon the vesting of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon the exercise of stock options (in shares)",
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r53",
      "r54",
      "r87",
      "r441"
     ]
    },
    "arqt_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued pursuant to the ESPP",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r53",
      "r54",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares of common stock, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r53",
      "r54",
      "r87",
      "r735",
      "r796",
      "r805",
      "r952"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon the exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r54",
      "r57",
      "r58",
      "r87"
     ]
    },
    "arqt_StockOptionExchangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "StockOptionExchangeMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Exchange",
        "label": "Stock Option Exchange [Member]",
        "documentation": "Stock Option Exchange"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://arcutis.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r77",
      "r760",
      "r776",
      "r797",
      "r798",
      "r930",
      "r953",
      "r1144",
      "r1148",
      "r1149",
      "r1192",
      "r1290",
      "r1344"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r622"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r622"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r622"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://arcutis.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://arcutis.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "arqt_SueJeanLinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "SueJeanLinMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sue-Jean Lin [Member]",
        "documentation": "Sue-Jean Lin"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_SueJeanLinTradingArrangementCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "SueJeanLinTradingArrangementCommonStockMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sue-Jean Lin Trading Arrangement, Common Stock [Member]",
        "documentation": "Sue-Jean Lin Trading Arrangement, Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_SueJeanLinTradingArrangementOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "SueJeanLinTradingArrangementOptionsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sue-Jean Lin Trading Arrangement, Options [Member]",
        "documentation": "Sue-Jean Lin Trading Arrangement, Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tangible asset impairment charges",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r81"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "arqt_ThirdGrantDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ThirdGrantDateMember",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Grant Date",
        "label": "Third Grant Date [Member]",
        "documentation": "Third Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_TopicalJAKInhibitorProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "TopicalJAKInhibitorProgramMember",
     "presentation": [
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Topical JAK inhibitor program costs",
        "label": "Topical JAK Inhibitor Program [Member]",
        "documentation": "Topical JAK Inhibitor Program"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_TopicalRoflumilastProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "TopicalRoflumilastProgramMember",
     "presentation": [
      "http://arcutis.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Topical roflumilast program costs",
        "label": "Topical Roflumilast Program [Member]",
        "documentation": "Topical Roflumilast Program"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Receivables, net",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1173",
      "r1174"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "arqt_TrancheATermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "TrancheATermLoanMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche A term loan",
        "label": "Tranche A Term Loan [Member]",
        "documentation": "Tranche A Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_TrancheB1TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "TrancheB1TermLoanMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B-1 term loan",
        "label": "Tranche B-1 Term Loan [Member]",
        "documentation": "Tranche B-1 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_TrancheB2TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "TrancheB2TermLoanMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B-2 term loan",
        "label": "Tranche B-2 Term Loan [Member]",
        "documentation": "Tranche B-2 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_TrancheCTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "TrancheCTermLoanMember",
     "presentation": [
      "http://arcutis.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche C term loan",
        "label": "Tranche C Term Loan [Member]",
        "documentation": "Tranche C Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r369",
      "r391",
      "r547",
      "r558",
      "r582",
      "r589",
      "r592",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r672",
      "r687",
      "r917",
      "r918",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r931",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1280",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury and agency securities",
        "verboseLabel": "U.S. Treasury and agency securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r873",
      "r875",
      "r877",
      "r917",
      "r1307"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails",
      "http://arcutis.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r503",
      "r881"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decreases related to tax positions taken during a prior year",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r881"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest and penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r881"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest expense",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r881"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to tax positions taken during the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r881"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to tax positions taken during a prior year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r881"
     ]
    },
    "arqt_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would not impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate",
        "documentation": "Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r215",
      "r218",
      "r219",
      "r220",
      "r664",
      "r666",
      "r843"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://arcutis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://arcutis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r206"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://arcutis.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r206"
     ]
    },
    "arqt_WestlakeVillageCaliforniaLeaseArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "WestlakeVillageCaliforniaLeaseArrangementMember",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Westlake Village, California Lease Arrangement",
        "label": "Westlake Village, California Lease Arrangement [Member]",
        "documentation": "Westlake Village, California Lease Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "arqt_ZORYVECream0.05Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ZORYVECream0.05Member",
     "presentation": [
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ZORYVE cream 0.05%",
        "label": "ZORYVE cream 0.05% [Member]",
        "documentation": "ZORYVE cream 0.05%"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ZORYVECream0.15Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ZORYVECream0.15Member",
     "presentation": [
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ZORYVE cream 0.15%",
        "label": "ZORYVE Cream 0.15% [Member]",
        "documentation": "ZORYVE Cream 0.15%"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ZORYVECream0.3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ZORYVECream0.3Member",
     "presentation": [
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ZORYVE cream 0.3%",
        "label": "ZORYVE Cream 0.3% [Member]",
        "documentation": "ZORYVE Cream 0.3%"
       }
      }
     },
     "auth_ref": []
    },
    "arqt_ZORYVEFoamMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcutis.com/20251231",
     "localname": "ZORYVEFoamMember",
     "presentation": [
      "http://arcutis.com/role/RevenuesScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ZORYVE foam",
        "label": "ZORYVE Foam [Member]",
        "documentation": "ZORYVE Foam"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Paragraph": "2AA",
   "Subparagraph": "(a)",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481116/815-15-25-1"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0001787306-26-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001787306-26-000018-xbrl.zip
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MJE)"D E8LG:%["U@R8N);29@S-KUW"KK-28 :.T*^&M1@DP 5M6M!!O1F$P
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M&D>9-/]+P8>Q[W!'/;'6(U]EH=-]8Y5^HXZ\M\HC-U9Y[\,(CNO%6*3BFMM
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MZK3;/VW1HQ]_#J?,__CS0+R' >3?<IRYT7#-3>:Y(_\(FW=Q 2,0./0#@T#
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M[!%+E$G5^+^%5L0]/L7=6CYMMP':+59N +)@@6S.X*CFD.M9&RR+/#3E*LD
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MUI4JS8:2)I=$"='>#F0TS-'&&P'+E,WG0?^6<852';>P%>H4&R37VK:)])(
M7!/,2EQ%'6'=J<M<F@VE2^'ZMCL%L3(3/'W&N<H[X>+6M>O(02.I8:]V6]8W
M_YDW?T_[+7_?H-NRTZFQL<9&P,:DB^C+5>.L*Z$\!TJG]V-WX$:@.)6DJEK7
M]I@[L?=VQ(4*E34A\'7:=8< \\EACTJ;5"SD4:Z:B'A=N<]<(DY0.@L$!@DU
M?[.NX\F$B3?3L*]*])H@U>D\4HFJUN]J%E*"/ >=K8_7<(PL>G;>Y[/ _SYB
M X_K6<IOO VB(A?JRG_\>2#>%Q:'K[G.+UO+"#5;R\PES]1%PWYTU-M+:NXO
MFCQ_IW:ZK7VX5A^F04C5_(X$^19N^8<[UXG&VFB4>5'B[E$[?84-PL"+H\6O
M/.5\LO\=BQ0@(]X<",Z^-]D0!CABWAV;A0B:;/,!UV\6]E5<TM*W[<:=\-#Z
MRN^LJV#"?,#ZC7#6M2_C"7EM6Q]O\ *0XQXF+._^79_QCUL+X,5[*PI**R:5
MD+OBU2[TX/BP-,DH.2O8Z/-9P'[QF#J[< W/+J[^Z%^=-#]?7/QV_O57Z_JF
M?W/ZY?3KS?5"8I794;*A]2^_7,*Z&;NAU??]&,!RQ:>!B+ X2R)U-BS7M[V8
M4M2B,;="E1IE<:P3Z'''PCJKW?8'K %HG3$9*DW?=3[HW]98E#69"I]0TWV*
M0]AF&.J?;#@$YL*:AX&X8\)I>D'P'3<4IH6[L$*-Z],6)YSY^"O,@Q\OA7N+
MP=UIQP#K,_PSHOEA49B[;/7M")_O'![NMJR^P+#(T/KD!IC?S*8</MIAPSKW
M[9:UK7YNT.@8.<G\6<.ZXPTKAB\#806Q> ?'#A3)L<+8'C^T;KA6 PX[!(D,
M8#&822"Q(;?&3 Q@L*D(;MV00 ;#/#24.B88!@[B6L+9ZN[W]4%D#B#9;J_7
ML%AHL0EZXAU:_?RC#>6>4B-V3DM&/+VWJ8!09NB=TJ&S#[:L&_CF+A!.J&$_
MX)[+;WD1 R=L5OSJSO6\XG?3 -D H)XW]S@/(W<"9U7\'D_-]>.Y[[&.)OKJ
MYM^0D)T?)_;FOKPK^Q(@^F\XR[FO/>;/+?I^FGT2P1"Z0#J8L. GD#8E8D28
M_P@;N>4S*_9M&981S1 .PQBE4HM2(T.)G)$=((-A\+7<"F ,H*&+],L=SAY
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MUF08^[8D=ZH5O10\L4 ^('QSP,D6?$,,@%&!)'^6FG\+@6 R^#LEM3*\'B@
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MA!8[E.J2$W_R(&)6."%]@PL4\%A:=T)J;Q0",=7*[:+V.BW+.I^@7J2ZPT]
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M,46G:)#)%#M7M4J3*'52&3#MEI0/';$N!51*4<2SUD=*MG+0#0)7I@<3Q!2
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M(3=R-11"1J>!)N+B:E7VT-Q<F0H?=&5EM1"X^5$L!I@-@*E#?,QNW8"*<H@
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M_3PD#L+C01YDGJD][YU?C>-F+BI0[M:>VXY0R&,3NF#TR2@<:2NLSM9;AA"
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MC9X;]A4)^M.'+D%_^IU-T-/'[00]_KHA0=\*37,4^I$R%>_,G7(I>U[%WG/
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MTKV=E_$X>KY,P9U<[9717AGME=&G3':0CVVOFO9>TBU#Q.T0;<\ N5=1Q[<
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M7[J';B)(<4\3J$\HZQ<Y^6!UH]GQMXR"BYX4<3F-#EZ\?7+(7%'DK$RJ.[%
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MR@@S'EY:7NE6+R>?7M$2Y#HP@RF=8*F>5-S[FFTF4A9286*.2A>A5?OQ=Z]
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M9V46<G@5J@9:?!1L3J2UG%'XTZF89M:J=06$]M!=&,8#EU\7YVW62 =>YJE
M#MV?NKYHFB3+2GHIR0OH[[!98#\E)7<RP*-99ZFE(YGXF7]GC \%-0-QT6]+
MLY'&. 2&?HX4F]]K=AO#2W6+9+QS20P;%>BF8_!I:= \3!& 'FZ/%27O8X7)
M8R=G##X_CEX;6*TW+0;V>KL^4Z"Z>93!_4%9'I&(8LX?V8G?;'7 FV>__7@>
MS1NR;3,'"6%0O/@VG!]4D>J>O6!O;EZH1D\8T%XO*N>!RFBBJ=8;.\?'U0/H
M"KB#+Q65[)O(":BTP')9D$W,5:9B@4<'KUX^/QPII<VO^LM<D843RTJDNKQ_
MA%/M*>J=.W,7;S!@'$_\]>5S$Q#07VDW)2/CN&,<=HZ'XX:'3'SZT0Y6YN7?
M> _M(F&=M&"O0_=VIP0BUD)1&C/';.UJB+E0LJ?Y!.]\]V/9!"YMSY&3AHA"
M29$KLX)@$$,!V%T;Y39-9]MD+2P1SQX[J -YR7&>9+K;<OLKM5#2.&@LH6A7
M?80OEEU)I#$LT1(%Y4Q3]>KY& R)?)+,339EH:_:V(E6 \@!^LB@:UL/5T7>
MF:L@-$CNN "H\,M7@NX*'[,A='Z'\O'?[?/QNY$KWN?C=S,?_U6UU!-MVL%2
MMN.I.6.(;7"?O$&(%?TZ7N?#>L0G39GT$9^T(J9AC]/@G7Y;$"5S=&0P:X-C
MO8J,QO/Z)"N5*[F,]ZC44;34 ['=NQ.U"$@P_*TTT6ICFGC1.&.L*(^?C7AI
MDGYB>OF$NSW>\@3"CMIX[+SDY.;#MR/XU7-;T(_IFS1QU8XM:EC-]#%;DS.!
M@"D@#HZO"!&>6BX4>59-8OJWVG '=]OCQIML[EO/  RJ*,$R?SUX^O;7PSL4
MO3OO+I"IO&*>@ZLIA*25FUX!-MS1D;?-2,'9>?,ECV:(;DM$2RY;9[KY<F#7
M9+D2B5%P<SR;"S'^J\)54E>WZ%^MY"-<:_G5)4/*S6][ZB>T/$T0U"9=Y-OL
MDOGWA8:!6[M4;W"9^2#B$YD@K2H9Y[.T9 82/M#"AZ%BQ#O-)G GWH9FV*1^
MP+1:Y% '7F&&2B]IY];5V(]B?:J=JDZ+I-R22_] F\.!'[!1=(+[N9?R96?6
M3M=%534NH]YN?\0%.7[R_ZVHI"G,A,MXD>08.TTPW.]%S*Q&"6?>4(0<I"5L
MK,L2OW%()5>R"C_>VCX90VJ?MZPK-)QSAD-GW*VI"P'9/NW^BR59?UE(G;"-
M!TS]"AH.=ZU7TO#76RL3E=H-4?XB:# ?UJ5XB(QY24<.J5 I-3)?,_%/_?,F
M4C(3!K0D18@HZ]\*@XS@KPM[=>513DF[[2 +95NV'4<_(ICP,89:& WB'*Y0
MWZ977BSU5AYM$H\[==1YG-J=KZ.#M\]?OCL4+I!LY<PVO:>*( I3_B1%>#-$
M"EN*),7AG4=XI(3=-$QBWT:O(?4$?'ZL=;E8:4>RI/4X//@VWC2.E@DM+.+8
M"E5*<O;&+#*%6QE?)):Q9^K5;/':VP>,US(.5A)(2=,XA=A<:(#L\9>?R)IQ
M?+-B(JYEDYM/46PMFZQ55)-8*'=F"=]!(;E&0BGK4"^ZU]+/G[\_?_?;L?R/
M/P0)J>"A",J8#$9=C$2=L5VFK1J5.L[*-XWM.84HY& K]/!%D-?]F\YN9AIP
M6_:YL/VV>9LKG'8Y'\V,&1R>5\BD7%36PM=H)Q\13-)TJD=8C,/#K4-E:->D
M?2P=10-?\ ZD$XX<!E32)KTZ3A;D_3 .CV2OH^.,]]-JBFU5L&/&S+M6>$]\
M4FYGP,V$[L,Z21^\0^?C(B&QQ':UAS14PC*/CJ8W83R8R+2T[&I6:7V[VTH[
M=5GR86.JFU+7I9R&.:&0#J0*INRE0W<D"_?4G18&3)ES5CD<ILGD].4Y?8O%
M'#P&(E@-X_>R[F"H7*?D@!]VY G^?OY&M4V9Y*&3(X05*<*)?9.0H,?[WKED
M8]]RQ6,+DF%1T[;#K)H1'C"#,6'(.R_CWR&J9/[NZ 790_)HL/I>*I+K8I-*
M82<>6L*8+_) +20%<0[SLO5/U/%N>NR0S@[3,5?.^85Q'@Q5M'MMJ%@TC");
M-&WP6^;E:YEG%D'LQL*H1N0I"SD,[A<D9>>,__)S&K?&(+LF:.H-:=*8E,*$
M_ 8K26[+7*Y,-+G1OS7UUL_IB)",E2[+;Y^CYT4E%$JP,.T)BBWZP:-T6=G'
MM1&N]I(80A][4(6 B4[(G"Y3RMGE\/S*?VL!));8?J!]G.E.L<6%3TNRXK0=
ME,\<9]*ZF-#('4 @148"$Q'MY ZO$EKF;#/$WLQ$5?%M4U;#VBN(AQ_#F5((
M2/2LF"5E*5Q%EXSP"$P'#\#C/99?'=2?7$4,Z],.L_S.XG3) MN9^)@&$/1D
ML%W 0W4S(MGJ2@S<2L #UT66J%Y Q6<)?@:>XSD( 416K=)@*AL;[YB?PE:C
M7W+KG<1GV%8<D,'BE(';P)@&;QMF;NDW'U9&UN.0NI#)T(K!.;!O4)O!][FJ
MY$*I4.-*0FJ;B ^\E:(?3-=!:,!GCXZG;(!H''1X-K&)9BI(1% ,+I00)'V]
ML\5QFSQ)IH:?;P(:8X;2>L",X?<JR:6U%W&J*R&*R(O\R NP:H",,\UK)U<P
MSEF<FA)\@$="]*:[,Z/H0Y*L_)TV\'.V*,)GQ/9D!$LK7K6=CL>]V\(H8PQ/
M\/.0"%O.S=-%FDWIS1"@?*Z?O'EZ/G+\2Z^4?@V*&S B8+YB%\8@7[F&[V*2
MT6L$V[*F8FI>S9>3/Z(SHW64__ RZ8*YD!XJ=BUMH+>GY=;$C)B5M(9M&1UG
MZ.7L<AEX"&-7L;$([-@&?)WO6QRUW^S>4QOLF$F,C+T1B5)V"%UWU31X_A&G
M"??E68NM4%'6;P0 N!O(:G./"Q(2?&8=,C2Q$VW3,AI\CTZ4;XB0GJU]-D<'
M4VD%C/BP@0+Q?1F#O$81DVD(=#7O]]P'5[GI"C><!>H3T^^Q&C^</=IC-78#
M1[#':NPD5N.+WN8VYJ]=6<OUCQZ7*4E&5"T= =D,8X*AJ7U5\5S?'E10^2%-
M6 R23"*]ODQJC3%G:D(:UZ2?#<>3\0;#J5'.+/7#4F!!"JC >PO;U,[H9$4]
MGT20VA)3D5#=M.5'P* )54_K17#U"G:3FEP@)#,3_IR5RD',;-\F36B)@;QJ
M(J\!39V09E.:XY8>)4,21E9?-81DS$8#BZ'>2$*:A4D'^E"QY+ULG*<-]+8?
MA+8FXH(+=C-,!6N\&O0&I1_NJDPNMAN)8VI^\U2ISO:I6RWJV$L>AXN@3&EF
M#QWIJ25DL.>PF\<<'IC+1L7S,E&8",/+-\U&KDLW'VZ'8D'J\3CS*DWLZ+FE
M0KYV_HXK!N$F*MTI2!*\"EMQ>;7#NQ&,/N^C2O@< FSP)#^!54,_1[,<)LF+
M5^M $/E&)C)K_78NKE)WZ,@':4CHZA>ELX!LQ%$T&-X&DX;U#E3GE2-N;I(H
M0;8O-:7=B9>HD:21!N6$7M()>+\Z*EURU%_"Z1>,X4YM^2]- _(/9ZX'8=6F
MH,BG0D+IJ#']%[GR?$.*4HRY'=M4^78P)1N^=OL@XCM82X-!]V(X/<[$C-Z'
MP';04T<Y#=@7OS#)!BO+><^1.&7?US&JT ]EC/0/99E3HG%#[&SH*03KP-/T
MSU8[*^?Y4$,*+^Q5PZTS3$*OHKL@R18RW<O;XT=?@9Q:AVP/08->K2CI9;4?
MPM#$/9=2<^]#=H? A*ZZK:->_:IYV/5*RN^ETY;ZO[U>JQE_7R,Z]5_=56EI
M;_DV:1'P G)EO*$P:26)9/%Z.6@V60=&I?;^,& L_$2A+'HOG=FT(MD17,-A
M&5L"X>&+(1($0[%+GX0_OHC33,K@7 6K!GFQJ ,6J204CFQYU9&65]GJ4IM%
M0/Y@U%DX_SRANTO5209RB5@JUBV"8*8[FR0U^^^ 8F0]V)/*A8<G1U,ZC%YI
MV8Y<]P#4VU.WI-:Y,=S2<C@;@G0P3AL;]5>?PRK8\LJ ^UA1]UTIL;K:C<@[
M:ICK_TQ9H-BT55.2!,"M,<K/UL1)4H".YYK&^2&1)A\KI,*P#$;/*6") \IA
M ZOP@=)<"N>M8L@ZM%'*J! @;\HRX:X$N NDX,;I5*'P2_2]$*Z.K<853&^+
MQSI6[.Z,Z.B+ZA*CNFAR-9/Q4!Y2&<O_"NJ'-L(06 50!6L_ZWVW./\,TKU5
MOVZ-C$J[<(6@M)[-'RPO&(AM*_//%1TABYQ,]J7 ^SJU_/04+,%LK:Z$@GAY
MCB2+)NF*1_B9=N(8X6A)$L@E8-'3=PU4Z7GUNBX #/DT+>/+$#+0\LML0L;D
MC8.L3K H/B^'H"<8XY8+X#R=B0@WW\*#O6636\E'UL\JV EWLCJBA4V&.SP7
MK$#[E@-M-/TD$OUK6:B99W!@E:ESGK!N4^X_Z3D33VQUM@<#]R#B6=SDDT6G
M+^-.B/=^ VNTA6G5TJ>C04LGFA:<9%*<#!\TK4JN6C8A((<XO8/VMI\/5-/K
M.'I^D>223NM:0::#B[PI\*PL,$R-OQ#3BI:&Y'@E:"_4U2%Y$:$])=B7DJ2N
MVJ LET8Q=D'1?197^TME-?_ ,S']:;(X$Z9ZE,^6I"-O$3SZFBFWU^4*FHY]
MA)9![R=2;\OL-EX=1T2@LWJ&69W[5 ,X2(PTH!V5B8<Q"_66^H(G)5..]QKD
MTE%PJLV%^@(IZCWU$%32J9\EE\;B.#LY&='2<-""C/E&,\X8?L!.I&P%/<^;
ML]5VS<>)K@5,K3;]._+"631))*T26O:;(:-1>6!P+TNQ3YP780'CO:\VH'M4
MB5PPJR=GS:LX2P8&.S-8!P']#AUAPZNAR76'PABBRR'+)J@$XX-2V9/2>KX<
M*C9K$#-7.C?;MM%C0XSG)C*!2)A+ .B#@4[1LS7)&'8L?2#0.=9VA-U7R'_S
MP]GW^ZSK;F0$]UG7G<RZ?O7:+6<PLGSGA.& ='=]2S,;A*B\G$Z 2M=8GBOE
MZF!H.^G6(/.YB)6WI"/_/? A*X!,^<1EU.:OGB5E_!H3X?+J2$WO:M/#D7ME
M2[6'A_MNH2&;+ L3;X6IE<%COV%,.N/;OH%Y8M-K4TO<9?-[^*8M56@JS89,
MVX&TH0B@16[FT3J)T2M9JUZ'^-:\'NVPHR_5EW->?<.V.+LT(1^B9F6\D^$M
ML-< BF/<- 5OG05!:+3TT",6L<#P,"S'5(98D59L=<,F,X_%S&>R[7D3MBC1
M#9)<?YOW<<,V^!3,-C\^:)NV0,7\^LNXBASO4V@_^8M@P8B((26Y.Z="=.CJ
M$)D<*6'P*#\D.%&#!VGCN$>1_PS[5-R(P0?ZXQA\,-EX7/O%>\)WRR]M'!(V
MW*(J_AA-("VTMMB4Q]F^:\*^)*#UONQV#TGAK?$:KT@O>S1A_A(MF06!X:H2
M!!ZZ3](KT*="%XG,K'T:/QV713PUCLL0\"44R[9NH.O,M6)5?0/S,P;:.+[7
MW=#H709OQQ,L)A[1Q2OX8&G_%.'B>76.0%Z+&D)[6I$X<"+'!0#^@D9.,'.O
M2MY+-E=&+E6^$O)3R"H_.T*E3XKZN^5?4%/\L$DBE9I^\?@^]?AW7ID"ZR1.
MH:M^W20WK3WP^66FF=JPK+@MM_.Z%58HK+1DU&][:'6^]H0V\_@"6Q$=&,8Z
M9CF>2$60*7$Y#'F&BM)U-V+WN03(G@^-;P9*98<7A:?[<1&S)#"4R6G>:(V4
MB:<X%]PSO/HKB(/ND/[Q1&BCG!ZAXH)_'/2*M#WB;><%Y$8Y"LF](/6K+M57
M >IM@BU^5R>-^.)Y=6K+D&QTO1,/?R_-+8'OD9(7,_]1#^%N.#NCC UM@:TY
MNC5WYHH<JJ[YA92IF^VP9,H6)-;:B*I5R I*0_RP34O>BBN94@!;EVYR8#UE
MWR,MBQ]9TN16";A?[VT1/R&ALD]+C=<)G8H7#R^\PN18&2@ETT+F#*IY:J."
MO9YA90_S=4O/FFX*FK(;63O!L9/;)@5R7&V=N9?]LJ6$8&_0M!?G!O'/GUZ^
ML5U6+'3C6>LUI;9:51M-QIQRUV$>&GVK*$4>V-WDBSKGUD+Z;5O*O0Q5QX]:
MDF0>7W'U!,)\$ZY@?RN\!QZ"S/S*]K],C)X3,21GC%1CGA=-/FF1\/@R2/&N
MSJ;GUUH**I^!#=_S^-I$XQJPAT_5Q6M*EK$IJ,Y"1OFR9T<@K9 ^3I>TI70B
M$^U:00<299!J/L0((6N*SW"8X5NM8R).:RJEH_V#VPFQ\EHQQ_9>^50SOI=O
MDKZ>X2(=M=N3'^B=8%IX:,Y.B5K-$HI&9&!D0:;6DG9@,FE*O32^556B(%7#
M)B*%CJ-?Q:Y-*P['KY5M_@+8$*8&$;X6^VB3V3 2QPM.^$*63P'.MTO#&[P"
M%R$)_GNR=I6M XP'(U.@R&ZX4BNO-Z[62$4N^"=P,J7?D'SK(A6"I+81:<62
MH/2Y $IA-!X!QF.DHS5ZS@O5P^)1E)T:0G<3O<<R;<YCWKG@F6T9+#:'$=,\
M>.%K4385U=GDU_,77;H!V')994ZL**E,UY#Y^V<D?WNX90>ZTX<GC[>]XOOV
M>8/M\X)3T8'%%6T:D783"ULPX(%2V@7SIJ)5'AMP9Y.92XYGM=_(FV^D0>QE
M8/T>1<^2N(Q^9EXIII5Z(U#/4@O!&4P)<0*?UN#T%+3DDU15AI^!+8B8F]>/
MW'>[\JW;F&Z_N3??7( %@&^2#7![2!N!\#3?7-8DUC)H*9#])GP.43EK*B??
M8)E!+6OJQ1 C,G99O#C^7Y_PQ'U]&GQO)%\42C4-99.A47C!J%;WS/V&?H8-
MM>&1)/T#MF$AP=F\=GL@.^[ZRF#C86R5C&,CEZ8H:V]_V!K;[\R-=R;-?R>?
M5HV2TJZZ,W$GZ47*\;U)R75<&>X?*3LXTWO<RP_W3O:XE]W 9.QQ+WO<RR?S
MQ##XC\$L',4(PC)LJ#M"R(TQ?@ZYVGA\=&ZZ("K/ZH=$2%Z%Y9J)S\)LA>E=
M+@UH1Q)!F-CR(:$MM$0)U@1R04J!.G;[@JH;84(N[1PA3\^+E=OF1R:PJJ@=
M&GL"%T4)PK/XLM*RS[FE9*-'+M)Q:NG3@P4J9K,C?AE3-X)+H3>:5&O#+2_L
M)I7)&D?J3P*9J)=@. 7PTS;T:5E*3?UZ.^E3M'&\AK4BQYF[:C%ZPTV9N4T4
M1_B5H96K6S5\[?>2](F(+='$[\UT+F1@63(7[ET+VC4'R!"H>=P8B#4Z[BD-
M];:99P/^6$'K,CK#1!!P^&J%Y0+4X55Q!H>I,U,\-KE0W  CB,+]%+#& E7&
MZ.9IBZ.U$_4ZZ&#.5**=/I#F"'IT7'(E];F+^"(5QHN5&YM=]LFB2+7<RBN:
M\I\Y(C_O$M'/D4NW^/%VNX@M[UTC.B:#V3[*+LWA;O_/YD5A4_MJP:M4-O4"
M#7^Q]AQ!3JLLB:=MFE\#T>"3?IE607N2, !LATYS/0JO-C<+N"UQ_&NFU+%[
M/Z-#^-&_XH^T5:@JN"U3V:A<WDD.22*L#TX>.'_WZ;F]Q-*D,W$EV+VEM"H!
M7#%;MZ"\+BSXQ7N$MO'P:]*9CY31^^=1>X@'X\.#TT/.GZ95NV&A9BHYBE4)
M^M%D9KEQ@>F8:S1,6/K*NFOHG6=_XCNYD$KH7NA9"-+52I@IV^'?MH GV86
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M6?$!.B/WV@G,#<PVC;^C&MR[(&DDL.E&TY*C(TK.Z9:T*3RQ,:3<-J''V*Q
M1>,@1>K\@3;?%\SAS:UYI6$]3J()'IE6_R=Q'U7Z@*D4&K=428-,?$GR)KR?
M;5T/^T2TNJEWUKE'1((!A0W3Z(^&-/X'M?CCBY>90:A9E%A@+#,$+,.'MVI:
MLM*JWJ3?Q384-@46EB+G;AR&Q\/2T_X8P/&,&,D0$>.;SBO+22^Z $2OJ2@
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MUV_>?BZ;:+*2/4G3>VS:@C%R\TU)P[.BJM[WU1L]VA1)(]DOW""GA?YO,I;
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MU<RP+XIRX/[Y)=*>L]V\^VE,KZI\W3OH6N8L<R9L0T3X*Y1MQ^9U19Q7&9$
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M]E&[)FKY4+PYZ_:+J[P!/9FPV./H@>4@MD!NR.2FO,N4>'<8@I8SWTY;K0A
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M)SZL)YL-G/#+S OUT."$]6FZ$HVPZRVW$KM>-"C$Z6\3J;Y0B0"?/1,:TX-
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MP@WN/CWLN.U#&Y%X?H-:-$D/RAYR:V"[15J+*??8!HW+ YI(Y%0#T9X^61A
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M%EZ&I*!20!IUQQ#WI#R'X21)0_NC0#S=QQ;():[Q"28I-<USLD@(L2Q<3+\
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M8N#6KD8$$;M*<.J4PF@H%S-RZ!G^^'C2:T%<"&(47O[;+B7DJEO<YYK7*XG
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M5 [!FF1P)SRFH"],FXL@F>BVG4!UQF9'UE$M]PCL,S%Z6=XDUE2<6?;E(+4
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MAB]R8YABUJA<LU=\"^^)A('JN"(:5 &/T%Y7K!'%GE)2(T6WE'GJZ$H; OF
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MQP&ZBWR)HE.J!SMGM\<Y6P<7<2L(3S1YU9M\Z4U?*I.A5];IZ?VWC*>AU4Z
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M#X0H]]7Q4/ ;,>U2U)$K5W-E5WTVG=?P\4\_X_?>EB> %:"J<C#\@<R5"4\
MSRO%YL',"I>ML1.,E']I5B)7/G6LU**^\,E'"4+-  6,$%T:EFQ'_J-6;B!'
MT\1G6\REOCB=X^I(1;)"'\ Z!.SS#RSR@=Q?O,!F)M#G%;,W5D8O21?07<.O
M]Z@E.=XZ._[I9T](G( 3A1.[GTZM-R@)<FE!&.&%F+8D />QO>5>D3=AS;$8
MU)R72#(:9S1>*%-7>#TTN%6%AE3X]7E\-]-BH5*./IPWKY87!H^,GLG88OE@
MQ43&3MU,<F'0L["DM7=6O1LWX4,M:E/?DGW&+_[GNO_UM#+S7E3H?Q)UJE],
M=XI<.';3IKI3Q44(3[USR2G3)+IJ3ETUIWXRS:E<=.J*I?CB\\^O6(K+J/-?
ML117+(4Y1/^5Y?($+/(>R>5A1#^O7!Z^\F=F)WAVE<O[B>3RHL</T'H$>?SX
M1J5?N,Z2I!FD6<'UU#/'"$WNG\OCYO;)#^4_]Q1AD7?*Q5#B*,#RZNX0FT25
M2!<KG6%:27#F$M-3AT*?,(*_IP$MQPPJ,21%/-[XP>.^J;#A#MAP$SF$.5$5
MQYESKK_UT83@"T#G*=7:20L/Q6*#<>0+.=*K47RP315C9NAA"J&5X)#$F#MC
MZ2@$-G5OG!XI[8G1*]J+A"%15-2?PL%O5N%"NP>?)[6PM!4)O-,L,;ZG"\%/
M16$')6CW%2)IS#586(:4AH5Y0<,(H.*U- RE#XT6[;9L=D] ><2H@9+ !V0A
M@BFZ"9_NZ1XG)GF*%\$6P)V92IO#N/^N7_Y.@?X]EFDF(\XH?R[2&6'('V;'
M1VPSDX%YYA<U&E:D'9(ZZ]F'&_O,G^H[X=2.LDA 15HN5#,)2>,=+\^$OHD@
M91705U3NF#L-&BYG @DS*BO,_2WC%;5Y*L?<=OT1S$RFV> ^M"82!>F:3.A)
M^6J+W*44YWN"KMC@QQU-2\:"BYK:_E;$M@IG/E#8DQ8G#TJX*/;^/U3:?#X>
MI)7E6'-F>#OV CBCY=<#,:@KP_1;V!TN3;%XD[E"NF0S$J8L*YHO;1.^_*JF
MOJG7(I.GS#?^6@WV_"CAD;NA_T#ULU<])0Y?.GHT>B^!77]/'_[6??@%)],^
M_MUO@:'>4?,X=_X,YRY]]OV6/ +1&[!*A1^M>@7C@6.=8 B8A6!=G3JI4K54
M-\[IZYQG40Z<*F^'TOC<_.PTU"PJ7&HY48>FA*?G',6*P0A$X$;RS$M>SNJ4
M\=9;?2"4'"XGZ.Y$5]KDT> E#+!M)_9#FL_:<>QEW]ZUH!NNYJQD,C+94D]7
M?_:$?+[6RAEP!I>E3CT<=YDA](G-F@WA?PJO[* -GO-.ON T8TPB'S>B7;Y+
MX1(-0YAYO5Y4+8Z1G]&JH3,O&JM8CMF-W&L,CB__B515M5!T'O\=#JE.LO_0
M;=C-]Q:I6H55,N-")&8^ )9K+90;A$S9>= (P=&D=Y-6X:0%.K<D+LJ:_#7+
MR>E-9V<A [3PFT76)_<8.B'#[N2_3^Y".<>1RR+;*;@W=:^R?3$]M2FE(I,Y
M(ETM[<2@/LKG\B(NBZ^LI=?U#L/=XYIS7 HM+7,H*>PLCLY(_'NX#TI+37N^
MZ=J;JN<GG58N"CJC]P76EMCL;8(^=V%>]UP/GK(2A9?C=E.:%81JL/'!"==+
MR/Z$10U;^W<85>EC%'?[Q3JE=4SN.E( LILMQ[7@Z4TYMEQ<K^/EQQ7\GG<*
M>TF).K"&]1>"6OQFL>_T/%/?%)>_K0?W$< 6%<*=B46EN+DEP=14T<PLR/Q@
MNUR8-EP5'-* ],#2J5;I[]:-)"#-ZEK?P&6<^I=2'P0"9=!.[^4^X@P.CL4;
M"*I3RX'=D^[:H9E(>['O!)6PT;AYV]/2ZB8;866B6V5/!X27W/&ZOJ,E9]8+
M?NP#JQW=3_L"&VZANF=&^;1Q%(B6XWE =:5P0R PHS1!*.""7M;H)$3/6T7F
M+L1JJ(<A%0!E,TF<RKDU$XQ3TC& *(;9)<Y2G?2+%"B)I J=^JZ-[!B7<9@C
M#>UD>@"/C1 ?SJI$8\4^ZFW7/**C*>$#$9I/0"&,(C;,<M*&---ALR1^^I6)
MZ\4G,'27T8,>C<V]6/-9O4CPD=XXN>3)8DQ;*RH.V76C^,R0PCG-C>'O)E_\
MX Y;?8=6'WO2W#YEEJ+CC]O#^3LE^6=[.R]$&8SM:U*T'C9]O:9PH1DJSHP<
M^-H0=_M!V@FDO]BWE^UP7G]4FG:B=DF,O\C+1]?4R9%3N5Y%79/"<LN%E#Z2
M/@I9(_G"!?87T)\Z^4&GY,':Y#.LO)PI(DM]16=\\?EOKNB,RT .7-$9[SDZ
MX^?QX,ZZ%S"H%8V:+R(QI9'E."+MU8(GYCNQG<-(/!HU8G8/$U9YZL-X9-(R
MEP%-S&LR&M..9K%Q*4:F)4#?3Q%+>FF3./HH->W =7:PV,OKK*GUZ(ZS)-$_
M ;![J'MIC8P<@H^^B72>MF]:7WA///B<]SRRVC]PSX-NDN1*:!+NN[XY4_!^
MGSSM+X5IQ)6&W";<)@DQ0U%(C#;C:JIK[;KW;$?(7'' R2DWH4ID<G_FB[3@
M*<NWO!A"=/U_J[!92^[Y)92+E;GF%B"Z@F&LM_6Z%CETZS2(9^<A] B[3O9M
MR[SQTD^*Y&D$IR Y=KRESN.YG'Q&3J^=*BC5TA>K+KM+Q,>9?GD;S"]G"Q4A
MC9!=PA0#%?/G!">B&_O<>Q>I^ P/WTO%)+0<A?K#0[D7O! */;MJ2TI%'-;2
MVR[KH3^E^WJ@3'-[%'++V3.YV'_A&)LUM]H:YU^Z7Q97D-DQZ6G422#=VQP0
M)@G3?0DYTH7OXM:8;F:#6 XF8;Y[:@4_M=^CQ#6)DEYX=$J89]5=ZVXT1M)I
MCA^M9"S;QSE<4%)[SKS=V-/8.(8.QX3Z)V(VU]']VJ?H':N^IW$GU6:,9T;9
MB'HN_6V+CE-L%$):D.&0.VI^@WR/6,<M@C9KNV)4\D:9@OTC&.?=EN-T%AU@
M*O7':SY5Q-AGS3^78?>_5@E=$.=('VTK[0?4XA'I0FF*PN%C'(*#2J2WQ$,F
M5(U8MN\I.H=(R&HX!1=%=%;%DCG#E=@B_?U9&\>=>:CXI.[=8R4(_+Y]V!2F
MG$1#FM3?DQ=6'U?;FC81=9_%5!"XI2<MAEF;"])]BF28+^&$^;BKN\:*C#E0
M3);"I..>)M1JOKW/Z4F=7[Z'R2IXD\3&O8KJC-JVDW7L82F8<'C(&8>5ZIR<
MZ:3]YXC<#OTYZ\M%59$MUSTD%U]I947<#/>2*4M;?" ::(9AU+TN(PB.??=Z
M)AO'33A3GMJD $UV0QA.$MF,F"C2#F"I5BI+NQDO$QRB[JEM)1B@]E1XRY6D
MS_952?FMW=@\7;W8A,"/5IPN6+\@V?H_T-C)=/#F:!D7D<DB^8RB-R4.:AEK
MH=;J>Y[L1R^O3F.=2RDJOKRE)CT<(Z^C%A9?*_/^)[L)AJO+>7(WPAR]#]ME
MX'9G8K2IO'4+7R9'770]UM ^*VO#+Z71J@4Z:E NXQ[[?N)AW9:$4BTW1U6;
M(B3'GK/L]\'G>T(MDS[]3VB^/5U"]= X*!FVG?NIS+I54FG6QU:N(I-K8ZLW
MC#W.B&&&8KR?6O;,^"A$P5]8O>4#%#.0"'Z@-]':5+G'G'M8/_Z88XF_5.7M
MZ<EW>T11>VJ%+4/ P>W[A!_[(/F#S?'#U7W)?.&5N+%A7_)-G?VEA"%HF&]'
MM,E2S.+/NVS]\)!LZZLS)X_P=5LNQ,2BZ'TYQV@Y))!&66QCLI:/3_IK^#T\
MT[;0H%)++PNBL9FA"Z.Z5VB4+0]R,MNQYW>ZH80YQ6XXB<<4[99-EJ:.C+,]
MWI9WE9\H9PS"G=)MF(/2"*AG'RN\,>RB%*X-51N2XO06#$<CR-,^\7&E)3/9
M0I]D5T9M+ONFJ<H>K&3Q!B+[(FN6[Q0 ZN%E"G[3:K[Y59^!W_('X6W)ONFQ
M?I\/9Z&)D!]?/1<R^TD!/4L:+!HSD9$=<JT:SW-0E5MICM:JZW3N=&H?,8N%
MGZ,TI3G3O7U(TDS)G%_0%40&Y;OQ0-Z9-+W3/=2/U)!%9$ZTH:WA7*IP=2M6
MAR&TAK9@1U4G]AQJSTJF%"QIT%3WFW%/AF53"><GR9CJXY3;SI['+(/^"4,=
M'#")SR:2#-@%0&+;%CEIAAK,A%)&G;;).,\D[D,HD (/O Y[7,^@D,O0%&Z@
M(+*=^SI+B,\Y0 73\V@^Y.DJ8L@A&L*'6IAXL'PON_:F1ZR!X4GB2J0B$V2M
MR]&YG@,\D&\$GS85C2;8=R8=<;J4=+<ENE"\6 LSZ(&(@BL5GSTO5XCFJF1>
ME8B),FH,T>/G)2M!W-50:2 [OXDNJ[^.LI>=Z3>8^*K$@AP?1E_'4P33W:S6
MW=:$U5P=89]][E8@<8912AX20<ORB,&-F@6%W*C)(/[DTUR>%B;Y!Z/TEFU@
M&D3I+&4HLGA>]95F/089&J\RI;#$$58WCC;\M.=,@WN[-L);78O^7WS^VVO1
M_S(*TM>B_[7H_Y";QC<-Q7^4O57K28;:]2I+V)BE7I?"@85VX)Q?R+MLZ6UP
M6?ZMND3Q[EW1_5131DI<QY@P=A4QSBAI#$O!6XQGJ).8?56'1/Y]>;I]\@>B
M1'U!S5#?.W=LYKO+%3%;/?OH>:J^UP*/W0Z[JI?NR+ZO[CITQQ0<Y![*>OMD
M// _Y!K'LSY^SAQ4M/SWK;0FRTB2P7&R0< >KMIY0RT:TKW-CY<Q[BG$#DO)
M/Q0I.OE._MG7,W]!8:1X0'$"4 :7AD<*R[S?7W@R>?1@=$H?S\4LM+EW(DE
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M,YTMS!"=Q%::64@ J]',<?)>WT=S/7]9Q#,2;I?PM:82C%585!K@/*KG/GR
MD3SM0DST%WB5$@YR*L2.PT0PPCK-W3;0+*YD522R'GQHS3491W1Z!^\A-?[X
M-"8._:Z AG%"8S@^X7R3_-01!PBEGF/0Z R]Q[O/)2EHTU?G".7_&HQ]3Z6=
M99JSE*/S(1)*S3M3;,S[)=\A!:.=C-NGKIJMZV"]K^PXQD(6CF1?^9+I7!9*
MB![>8*DI@<KELRTGU>PUL8?IS:6^AD(9RA0WX%@D&S#4DN%@1#QW)_[S(+@&
M.@%RSTHBMI!R3W!BE"#4)RMG<U*\PR._Z2/./O(MZ9WC^YLC8.(Q9NK[":Q
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MJ#[D#CI>9TM$:D!)50*%;K#")6/[Q)$SIHGDU>[_IKG\+LHPI-8Y)3DX,L!
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M9.,#06O6@0Z!(W9H;9X:D;"*H=Z,K[QOE!D@)[J9ZG?&A5O\,]7=FQ%)9:]
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MU-F/N^>3=T0*_2* H]/?O70\O)06X&EJ2$')7]O9-,.O=1\>\#A&K8Y@SX[
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MS"@5P[)R9QLS#>>I9 5X(10RK0S3&R#_'ZE8^HW,VP=!HAT9Z.R/K<ZW][^
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MG",R[,R",@5JZCE W7B-O07X2M10EWTV6-L^//%K2O?ODV&DLR/P;E<X+\3
MT8(PAX8W69I007*FH\?"ZNV$=8T/2SMBN182?Y;?//3,@>!UB6P#SA3')[%[
M:]Q+5S4.N"(R' .20^)(:H$92I=Y=B>*ZXRG.5%V$)=T//CYY/3@H9P66>\L
M1.^&E1,N?$4ZH[[P#2HYLMA,*J>7S34GEQ6'(>Q^\19@!EI\:O+"]2%HY>7-
M]U8J/:G,WO^M,;,9"AG8!,5K%D:CF<@L^4 &(#=+4HD<63T>V@3%3:&T<@^0
M*F .<<C'7:&?W1079UAZVE"*3QAV]%\?<<.#!9T/%A95$J FA(YO<YDQXJ?U
M][=(AT]<*6X3'(QH/5%%KIIH)!&\+&@KDBQJ4([K+"[T*_WR+@S@2C&)GN5E
MQF$6O]0[KK!;K2)WJ487& P41V >QI9-7R0YR&G&M?L]:Q%:,R AT1!UH%ZM
M+;I8G"TVY>(C<<WI\K"]V;$Q6>OCSUKD!'-R0M_J/9L#_C399*XV)<K4QQ!-
M/>99S[2U^#]F"UBJGJLNRR9.94Q+RS2J< P+UFLB#A8N&QT5&M-67"L53!2;
MYV=+2#%Q8(PN O&X$D9]T6H+QI!!(3GIS8>W_[K#K:5TL^/L4?6Z7,!)4:2;
MEVQE_+I.%?_2U_0/"QX#M7I)Q;NK_1D1WVXC,<)1R_B8)NHVLMOGU%070S$,
M,BJD/E5T<(:%]A(6SI2L4"I!AADR;FL6<80O,?(':9/T_O')DTW2>ST2LIND
M]SU/>G^9D/RUKH4+E&GE-T.V. &X(*:1IR;K@(N5EBL,<NRIX#KTPEE(B^ V
MGAO+(90%5FQ>=HW8M?#5C@/N=.K*5"VO$0;QI,3*<]% !#EBA^EF[T=AP8?<
MYT6XXM+9Y:+@Q .E,098X@:Z._9>8'%(8'3!.^P)"?V+<MO$874P)B;()GGP
M+^LMJ9=ZVH+,Z71X:4:MG?F#5Z>G#[O.HX_6FN1?!]_;C]P4LQ6;D_[XIBJW
M]&T'$HD,K=3D'0</\3D7C@S=)]=<SN]G;%:QV)8MX8+3ID,X%.L2;PT<A\#D
M=SZ$#FFYYZ&^VACE)F[_!(3Q7P?ILET!45)C@K\?5E0WB9KOU%F]3#??"W[U
M(&;3HCI;.]7X0]*$N+@_$ET(\A9E<,[#0SHA1X5M;*5;@O>AH%#>C*51G)T<
M'QZ<'"74$)Z[,MRY/T@K1/\DXA?&\#XY^O=9L;YUD6'= NNP25/+V[G7:UG5
M+S5FYQKR%D@M2AL%I1QH,NM2N*%(F9H*^^$KK9-_GKLN#6VI.@BZ$:-R9"D=
M"-H&I-Y6)P%G0__L',>@,#HJ?8XFJ'4- <@OS[C3(S:CF&@7TX&@*430U)KE
M&]=H]!_"[ST)JQ18%4!%(XSI(C:C#PB1E]5,HOO3(BM+Q2+P[TN#J$&GX)M#
M&)(ZSH;@H0@X(T@+9.\YCP*B!_?$J\NJ,-2 F61#.U;QI+%_X47S,6"^D=C6
M<S0[J%30Q@<AF!69Q[\+>N=TF@)4P=,9<%E]5' .%\Z?OJ#"?NX*Z:(>:*DT
M7SQ%06W8'YS:D^+!Y=&"6KU>#9+YJH^)H<12W@2^<&PSV27M+898=A[C<H/X
M(I%K3%*/?I\12YR=$)>XE'BTF86AI/#0=]E*@]*:6%XR^:,)R%H[(W),CETP
MB6B]KENHSRF26 ]A^R[H,'(H1BZ,I9P,M&$?4PK0SK5O*.Q.]<R0.,@(BQ+N
M2+#DX"&=DA95C-+H[*5Q?8Q'' <]0G0E64Q;!T&BK)2@HA*7834U*J1IN!YV
MK[F^"H/3K2K_ #E$2<[NF%&9$% 41(5<Z,.X?BE)J%(GZ4C:,GI8;+7%(>($
M8,[7)J!,B2<8Y2JY7!-0"X[=0:O[I G2^I::$7$&6=CZ6$O'JXXS"__J"8/$
MBNDI*W-]ER C;A3J,1Z4[-2?7WLDUGB4/&\Z07!Q0;*H9ZT3M9UY1'HQN,*V
MTLI^+VC9]H\/DT/6)%XFMP4H"L>+U-X2D==G(J*S!F:BUS2BL6[(&N=1^9N#
M.I59\=,X_T_1=+%B)90>%2O&@V1/9K0L_ALY,6&^BMO+*&$5KCSBJ?11-G.X
M'?&74V:UHDE)?MITS'"7S',NK"9-M ^;L,^=G^42P>[T^ESA0E+:>\(W)<9N
M9+'QY2%2O__>>,*F\R[AL5.=HDA1RG&CHI$@+^F:^U9^V0'.6$9&X0O'7.ER
MAYYJX12B-99XD4E&%'#8)M5,OFBOZY;=6^OZM60.G\^9_Q9G.B#)MCO3-B9&
M8P 32_=W^KCK;(ZZNLS/E?).3C^9K]$\XA5H7$8NR+!I.B,F;-"BSKBN(ZCH
M<)W'-70T&[%"V.RK3,F][<.-^MJ=MSN[@B^B')52;GD]XQ7SEZ#245H@V7D.
M5EO,%WLT!(*85]>=-ZXF/"? WRAV!K'$\2KJ>DU1V,5;%9 91H<.1PT7=R0<
M:\%[ B+!48=L$9[/2O.%X]2@(-[A#LBH/)*DO@0'-C /_!.5W66!9NMZ[BI)
MM:,[?Y(+:(_]8V,<5C*Y8^*!2IN++H2G?/$+2;5_W(DO??[9F$T)!S;7 ^EI
MQ[H5SS'L7"*;:I)L#_;^OC!.TB93X9$TF8MK69?6FH7)M+&39-474G9:[3-#
M<1QU<V1DL*5< \5U ,EC*:BCDW;!@Z\*JTV><TO#LN'M[*\\O@R_M0L%13]#
M#=YGOW][]??;VSVR^F2+ #K [=T_(*LP,[J-?FB[]-C]:'S/$V?C+@QM7%VS
M<<& OBC='\32EZ7[PRL;<VYUO_U5=YVS$=6O0:@MKOBS)8?!+?JU!U]+&AI[
M!*9,YE*-YC>^=&=WR5O1YZ.BC^$W94M%:OHR<-:RVKW$HK!%%$C8*!FU9)87
M+"PA:4-K83U\\:APP(%07I$M4Z SYV:29](]YB,,#2M(">K(NG-Y\QY!)8I%
M&V%UTM930,](HU%!H"%L9*#QAXV3<S.C8N!F/IE:*S(CD!B851_8Z8,I'R&>
M>0S23;W"CT^>;NH5UB.7OJE7V-0KW-B['UBLVNY)K,0,3"?$()<F@T5$_Y6^
MC"L?F_-MH?#UA1B64>_9][AUH_WR$+GS/U;TLSO]^XNN\C4.;NB,!L@"89.
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M+=I-8C4W(W?UH>UIX9G;*"B6LPMZBM\=^-_AA!]:YY3#IX>(K-E-??WZ$%_
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M)]?;- (4YI-)N=;39L+B.*J&LYJ:59,S0HWJ;H13'_:#H$.<^5JTIB5AK#M
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MV\!<4$QZLV!G+C!-9; U#5<YUB!'T=JV'A77#=\!&EQ+9 )$< 3JAE3FPJ8
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MQPJQM> 75ET5F9:_4B,(=?O0F,\SP5AD)#+/_A/@F8H/13><0EJ^N!I72L(
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M(+H3E35Q]10\/Q<K630OX!_U&"-L=JCA;=^+D&) #PLM+,4A\#IJRL]X=E4
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MIP3A2IW5>,:9ZT)+XG/H\P0/WAR?GB6'IZ\>4K8Z)R NPZHG![$[>W2&03.
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M[+Y"@+ZU=HOU/8MD+R0\&,)2HF,DJ'5#H(.#.]NZN@4L.@JFT:]'UN:G!R^
M&X+XGC5NULXJ<HB'R=[VEO7WB=J0#JG=7S*@G+74(Q#ZS:I%I=ILM.JM;2:P
M5YB9,#WG;  ?M!>MO7H[3('QF#<PWC8MHP=I"*&QT'9 %H]$\G"LIW$478"G
M9G@$D6N.8:,M9_;\A5^R;J&5X_<>= .%]&?F0]9Q7JS? XYHBHR3&R,N$#%
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MG WAZ&<\.)J5]53)GR+&36%!6I"$RF7KPT?N(-E+3^2@Y<6"64G+L]K!\QQ
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M#@<N93;.-#7FK?>$[1*Z03[?^H /_NK;I78/>%A/%49D1D[Q$Y!W 1=3%8U
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M^.AR>R*3H(*<C4!+\**:-WQAU*LO"%57;ZV$BL](5(HD8),DK.**"(A8,/C
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M7X- #L4=Z.D3W9Z#5/^0A4\R&(A(-O.1<#<$DN>.I2^!,7--Z/[$_^ECKZ
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MP589JGX)"\[?D.OJNW0L:GCMQM(5PQV:LB?-XC_E.SJ>I?5-Y1O+^K%]<1.
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MQT+7?6IHD].*5J F<%12"Z.1N,!-98SKW!7E W$H.)U[7P)DZ?X'?YGNU3B
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MY>71:<+5_@*74:^P@S@>=QP7L[L<%\N?2F7M5P$/^ $?Z;=TWWWZNT"]^9L
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M/<AIA_/OXIMRT%5KN [M%^>@Y3U]A7O:S<F/SQ( ZXH L JLFFVGVWI)MSM
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M=#XA!8>W'DS6]UR+VN[O2VN[/SPR1E D#/S&QO;(SN^>4P4,7)H]L'M5=3W
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MW2:;N#)C$!1>*5I79Z+.I.(A@?+X;Z=:_/<XPP([F7"IS&CEVE!GHLYDAR9
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MDSC7@EXZ\UQK/H)G!\]FH#V;+XS4H)D;T"43O!6T1<!UGWZ8FO\&N/C/KA<
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MF=R+0%H=)T5XVLSU>+;?>FC*GYRJQCA-F+3YZX@T2]='-PX/^Z!GB[TP# 4
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M%-))J.V;HAX+:$#8KUR!3-J\ AL_X0L^KW$JI]I]_NH )QG(2SQM#YA!('X
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MB7D!)PTTEB6FO-Y&CS^>-L2[M,U<%',V+0U')<96%[@+T$^.W8D!9.4I"HS
M-D,19Q=UK? +Q_J5E979<Q6S>E?)M8G^@$.L/H^=FO_,.]1%#^>ER[ 4,L&F
MV%A'$+,[]ZDA4M1(SXUF3G)M%1[S;,_(=A;YL(EQ0DB4W'BCWG:QUQ(#]-">
M2'Q%IOA".7-8FV^YC#<0BJ\>+\'%ES^("J4F5ZGN;?\G;W2'?T7"J7FX8BBQ
M/]+Z>-\IW"#1(!=-^)&7[_YP1&NP@VG7'"E/V/#*F\?:&\=)WY_3V,<$@6/W
MM!@[&,6!10Q+=OY$:,D&S%$/.#&*)&M$<F9?4ST<Z+#0&VQQ7#-Z@+"GJ\7(
M!.1-BYDEIK;AD%,OP2QPXW8PEV,?9+<$K#M,W87SOA:[K?$2?=<719>Q34N)
M^B*JIK!QYMA$0A^"S+9#X92S%JQA(O\<]F1#( $O&+XMM&CC_0@6>WV%946B
M[VEHS&?TQMU)!48NI66CX3N4@2QV!'X,)ZYF]C2,CG71)1D3 Y'3E8"\LK]>
M.(!'#IZ@-@>B<2B?1!'O=%=FT?^5:7NH9K/?F8FXC82_='IFRV@=+B?'W6JT
M72VVWX/@T%GZRSB+:Y/*+LN4.?UC*W0Q>(J[BZG2J26=_^D1#7H6\L>^G)EO
MX3<T\&9B\WXU(8.F2 ,US[?84&@I"Y[M< K51B_F0F#QY5P;_Q5ZXN&X(U_[
M0A=VWO _:C5_JIW[HK%3?.W(V$.YYV:8.5ZDI&*/E+"!KFC2SW_F1E@T5P=/
M8Z&7=7)H>7YH8V%YL1WS($^TX;7\.>^.V=SIS;$F=I)1\6R0B*>@;NRA.D#M
MCX9\\NWJ!OQ\[$+ GER/@B:QH0H$5"PZ1@C+/N.I]C\\JC2;\]8)%I\13SPD
MC6@TP#L6X0%Y3XU'>4L;5"UXUVL:X,#/^Y5LC:&4WC%!0.$K_C=8%$'F3=2;
M #$;+0J<3&2&L'R+VG/14%J3FI1/L2F$:;V R@:R#L261%?IY@]?FWB.*;P!
MV,P\,EY@!<$KMIF6<RFH^S:\RHF&(TPC?DL-'4ZUR+L3L-&S8_\Q9VG0QDY^
M"O(2W@"H#@?(@WF\N9D[Q'ZJ@BCI@!"7J _$PI5S)W4M9TWF'+BD)TWZI[G-
M!_^ZB<;FL2W0H"EXB@W8A0X!&D]Q G@;1P/M&3YC43N?Y8"!1Q#@HH59WG.C
M8L;\ZL4%ZA5Q\!/,X2#R?5]Z_DZDU" I97RY31T.V="PS;G#Z]^QYY.8:R(&
MFM#T93H)CE!\H GO*#:B7KA\[(:79/U!)J)].6@P&@*,UQQVG^1\ ]-)P2R:
M]2!.X#/O[\4-#.YH0H/+HQ"]_!0=3S[ERSX'4EU(OCD^;";[9-+GB02:?DIT
MPNL\4CXKE+SH[N#O.>PS;XHS_Y'F5M%FL=TAGXTRQ$DR08 !*?262B8LO(:R
MD9N\;=%SEYNLL CR,JV..^H@'KS=@8@.SAT+YZO-(M,CP^AH9\0VVH<<VY @
MH.,)]W]<,0T\H.1&F=PH1\: U"OR,H-LISP84.IYIQ2&O?7 :D$=#!YZJGV+
M?4+)/,M^,'98-"<C\0@^IS*@23>>B8L^H9$E?((%3_DAE2SL51"F_+Q$_G9!
M$$*))]6-NE,E@(P=KD[L7R?/M@7G<(8 Z-0&8/B+0T5Z6]YEJ[\VG:QHLO4*
M2AI8>Q'Y=&N#,?)?2MY8Q*M3$!B@#3_3!) I=BN3N@B.8I%0YT:-N0!'H7]+
M,))-Q?NA<:4X#ZXX.!#G!(IQ"K^;-$<GG$E LU,]V:"2<IRM>)?(Q7&E/%26
MMIE"9TL.LJ#4F;F^3XEB&^6[)6:'+MIMD:$;9;R9;S+?+9[IEN&1I^QYGH13
M:H[48SS9*,I#NN -68OD&O5*3HHJ;V5%\\KVM;!F/7.:3Z'TK$3N7VQP5E9B
MEI;,R5H_)>LC)F UZBH#2V5@J0RL0\_ 2ML*^&VG: ;6=TQ%8:0:Y39 ;AZP
M!<)W=A NXIP9"C;7JZ(FD=3?WZ.#Y?,\A99ITMA+-N.&Q#VIK^[X!+V"G^YO
M?WR6"K['1)@D,\LD3)V9TWBI^,!+KMM)#TJDVG*O-GU,^K:7O2>9R3,U?\HG
MAMTE<<(5OC9LD4N_BRA+:GIOUCOH!O(V1J4#F)AB<QV<_ZQK)G5BC_F_>7?U
MN(^-J^NDD,1?&'.? X0E@#/!H=/X!=[54XY=D%NF;K^PHIC?^''!R0<O3$-X
M<9*AA'?HYUB :&C!1&>7M#%P[H,8U#'B+P8X#%W/$Y, :+!DXI6VP]5"RBT*
M!V"80=[.]&2*W3JK%L/(PN,4K?+%3 I1.0+<@ ]>91D["OCXAN@:_DQ0;RS,
MS@@SI,($B_ P4R!>.),(F*$?,0PX^I2*M+ 92J>:R6;^\"\\-P-45(7C:])W
M3$3'+[,I\X3L2[I(C@+@*7:\YW]BS  E](WXWH@;IIH2ID@S)!8!\60ESFH#
M.0^]Y%"(B&<1^^"S'B@WP'5.1DB;'(W$'  YEN]91)82+$K4.R5X5+S@2\PB
ML7%.RRL9FSQ##P[?=_'(*2&3$E[B<4I>[O0+>W"+E[@SR:PHS\22P3AJV'NJ
MW8EWD+7+'9881UJ\:7%L\@(GM25* 6/A+-YS)S*>)A8C,T'YLP\C_)D5V!=2
M*Y;Y*^E&_ +@0H0(R8,/3(DR2>19(5ZP23@W!)F#SV:F%^8RQNZE>",<+0D0
M[CGA7/M4NYI[&$18F+TLGRO]/CPH/1&$),2M-B/524=,F]I!P#.9Y&),FME#
MF!L3(6(*<MA3G=J[AY,XX59!?%PNH0<)KVH8<CX\<03?USXM+LO_O&27)?BW
MJ97U.4]+.'>L.W)C6=F]K47IOK\\VZ:9D=3?/.BD?@$>0E4!(.T^/E$E!B--
M NFH_.+-C%Q_S'5 +R6'AQ!#?FZ:2W)F:.Y FECF. X GX\".?HJ*AJ0PV9C
M@ZP2X\<D,\>[D5H \.%0(3\ 28(*7/A-@&#+GX5%8B=<E(PK1@.&S(5<TM@D
MJ$R-?,4D'G_13\S!',3>&JHPN$ <EBO#TQ*\81#@U?5^TI)P<)8E5 Q*3?)X
MM@"QHQC3CE($1 J)30&\):#GXIIS5/%;]+S%!->?L+0XM&3F"L>::/EVLAR"
ME/.LS"G'"O%/@F8B/=S98\8H8PK/E0;,TRT X2G3?CKNJ[-0/$'Z&E>APP<+
M-0LE6H04Y2:GWZ,'?\ZNP%*2(P3^"6=Q(9(O<_EN>K(C?'?(?%< 8J7!+QRW
MZ">K$C.]BU4TB?GPB(@/0BOP =&LR.K]=/YP\5GKU#L[ZBQ?,*]9P)[;ZQ(-
MA?YR$:8![S_Y&<&$4/J<I-70HD$.RU=.5J$932YWA]S#(O1P,4)R:B,SY9,?
M,86#\[!\+AP+D,D7D?[NL3$JEW)*)C>-A$=$6#Q\')X?KV3B2?L\LXYS%DQ\
M7;$:6=1%F1#A8#\,EL(ALQFHE!:;Y%3!D5[*MW!&I5URZ&'2]Y(/F-B0/$*)
M+[R<*UF7!$^)E[ M>1I*T/AT]\B1E&CT$7O:&X_Q4IW2*(@O!VA=KC^Q.EA>
MAJ$?3P:DA)[X^^0AHEV,MSA1$FWB;/'Y+Y\I\ST)P-33PY%]V9O]PBOCX%D+
MCJD$-G]"2\#_G,!\'Q[@CQ$?2.!E/S_?KJR*(0DPGBR@]@)"TURPD _ES;2W
MQ5 L,< ^BQQE?:D84HE%@!-NOR_08@8EAB^1::O1&!S!9TZU6TH)B'1).RK;
M"V=A(A\5J.N/W!GY 01GX\DE\E[I UYD=['T 7EM@M#Y%G.P#3= N:D 5QO]
M/#2)C>[@^.OG(FJ"^M)<4O!@TX]QQSC/S*$-,>A6T!&'TA)TYL?/:[VR+T#K
M6Q"&19G(LI8S_+;0T)08P:3R[_:F).5H&7QFH"8$MJ[=+ Y_7'=GE6$%/IM,
M?)D#0YL#=$C6'PG:^8%=PBP>O./VP(7IF):973P;W1[-:1&%#< QA*02@VE=
M;?9L EZ-R%A\9N8$%)\1B:OD^.09(!2W=:[3II4@Z5Q=!=LYR3UZ<8V+#^X2
M:,[B57.DQ<25&/Q]N;-!Y4I0KD1#Y4JH7 F5*W'(N1+"H9'AYC!RG9<\DR(K
MOZ*[@E1WP(8619(4.-*#&;S-1#L-FCSO\W(OH::]I77-+#$GI_#R, .*K"?F
MB')P6?:TU"/5J2>B T+#$ J&&-#Y" _/3.2US*B_3[-5&S33PW)/5KR^4=;K
MV[5!IYUZ/5RR&#K9>LY:TA/U[JZGA/=&*AA<IS 34SX#4<4M?Q66,&C,B$Y&
M_4O:3*8?&E^2+O<%YW.VM2P])=0QA);VR?R,8^M=- )DETON8T6?P2P(<9F\
MY6!U>/:0>@R$SN8Q0_WLT_ SV&I (DYX-2SV!6.&\ 0P<#PVQ+7IF!/M/3%L
M[ H?HE?B'>)1H\\QE2R8>V+ _2?KL_ 88Q&P>P+/Q3"<+7J(PBU/GCD5BQ<Z
M(87L7U&YQ*P5\F!P, /LY[R)RBE%DKP7<3)Q![PT0M>!;"*M@9M;Z!#P'&[^
M<*-S-#'M:729')1+2^*LQ(NO1:;E\#QV+URRJ-I,MFV@H?,8\1;USM31)^9\
M\S(]^(O7QT(-I]H_*<!/Q<)PF#S=))X,$M@34J)Y/'W&0[NR/I%J)5+9*;&'
M2:,T'I=:"\*+49>L*,\SH(7K47@)5^;9F NBRV8WH<D^%S/6L:ID#C>\)>+(
MNH;C/M$WQZ,3LDQ*)/A3X!P>9Y&GS )(P_T@JDV.S"X<CDGI)N$A#.<\JX*L
M%DY7@*D 'T?6E(9V^C("MOU4TD/:I,>B@6',B2;#3XGD$]-/63_D!DJV )$N
MEY2O)QEZPR=X/G46R' ZQ(89RU?%%D(N(XSND]3EW8Q$QZ,P;B2.2] 6,8$X
M:("G$0[Q?L"\'AJ!8-ECK&X.\]X6427$/>I#)9!"M,3%8WA;X];LN!7WX\0N
MXAR;5V";-"X^TP"E6!RP#L"5T- 6R3N$\X0;% R+Q\[>S\58T&'R+2Y&'H08
MN6)1F&E_8OHLX3]CSI/Y)'-$7I]=X*K F46S%6(%YB1XB_DE>#<VL1L6=YCP
M9EY.1/L+(00@?\ZX%E\CND!EO\Y$$<F+9Z4[5##!,\YXPF@K<B3D4LC2>&\:
MY#9QZ0M8BM%=7[1=XKX4*=1Y:P/,H;.I<6)R\1&W3I)YEG[@DU07\B]L.9#P
MJ%#"0D0R&;PL3":-WD7[#AMH"S4*/I'1BO!,J>K5],D5=S:B5@9*N/9-ZD[O
M33;"'P>XZ'+P)SV%/,4!&1A:GM@E26I]0@^RO5 %M<<+N(%*7LQ53YD-L@4'
M'/88-#ZV##FYO.*]*%!BQ!],20D$3[3+$IF_T5HY6HOESH,)"5+)D^<>T%,\
MZRXT[P@;7UW>UD(VN.%*IPBNS">3I(3T$QHXBAR$XY.'S=NS)$16KZDX'1"%
MR!L28O]H2$'XW<E&J P5Q!B;[,$E$PA#X<#M&I:9#92=M"2NY_$PGA\I ETQ
MMSD_9GZI+C0V6%+@N6^+]:]ALT=NBF*#'%GBP)\@Q@\<1#[LM>B61VV2)"PF
MYMSA 2Q0G!;24,,T."&R7VP?I0U)5K(/I>$9LH6T@A]FDV?++'I67$CY:TDI
MV5!JH4D<%Z$RIDIK<'D:OU!8%RQF769X4V"1QV/Y@WCVPY@Z\@9^(B.0;]GC
M;3_E!L5+P'0T)U*#Y;IK%&),ZJB8'DNW<LWAQN5PP+?@4<=^7#8O(*\J==.P
M8<6XUT6HB+T'XSJ/*X*BP2ZWD]!.3DBQ*!&3>7_Q0TF=R*F(E-@PFSSZ*A7]
M^XL?A<SI,9PSQ1Z"O_V4]I/PFL%S:WS12)68=K>XNA!]<G;BL"<WX.5%HH$,
MZ:/Q2Z(U_&6QV6+B)W/TQ]SF<3?R22U501+*!&?@/O9-"!NLL(G-Q\Z,><^
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MW_EA>",7,L&CUBX^'J?0IB/W4Q";ZLMM].247]+!Q9@,&F(B>KK&!Z9^G9@
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M.JO-531F+,ZAI4 +TY9B&4N8?S!Q?>[2$D&RL8UZJASQI8NZV2!S3Y)$DCV
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M+^9FH5@V?5\GCM2-?WON9@5$Z"0 /YI(N/B\1%69I=<<\R;'K'J7,!4W^N_
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MSY<>,(;N;DCE8A -Y3]$/,&CA@)Z&Q<!V\4UZG!'X>- ]/'H\$JA1?B[!TJ
M!@=&?*(E [/"__*'PU\7'JPU_)HO)EL:[_!/?]>!$*#-3D$4OB=83*%;% @!
M;,AT, W6.MQU!%DW_L4-V1^*#?SU)"A"7"O^)AE=G#Z/<V6??.S476^]7O(P
M69@!N 854I-^K@6B%MVFRG]^ 8L,K*N-8L*FA3FM!GQK/Q(K..P)&<L&?:&O
MT22"C1"_)EFT!*<['%M5+C)],PIUMX=YRV<M$NU_"T)+;A6;%%+H'Y>_7!(?
M,*1</'PATL4\*APS9-,F<6VE<PXK)S Y&;"N@:K26\\=>!/P]ROQ/7R]FI,P
M&*1["1PM$A4D/.6KO?DGR,9'SP5",N<'?^DW_LY[L1SRQ)-N! (P#SM9#0?2
MF<"31396UC:J:R#NTM^H@GXR?@='ZO)W@LXRW\'F%7YAZ$] *9!B^.@*X=.W
M(,,PAPSW($E@Y-RS%3 I6/G?F$.6,5P[=[[Z^(<.+ &7%(X),T'MTB]O:#GW
MON3]9B[!_K<MYJ:1"EN@NH6D\M8VERK0:R;CC@UN6 I12,Y7_NN(P)?F"1&-
M\/#SZ36YN-9VIQ<?@!*0JJ/<6C[+@?:$']+5V]7CZU7J'Y1'W35=H5BM&?J%
M(# K#OT!>G034KGT>ER.Z\T6Z>_Q=2:<QL9<<I,+SHV/ D-!(+_RY]IT(A<,
MV1.@-DU0Z$O=7$EM#/8@ Z,'KBJ:42U2.L) 6LJ7QRPB:9YQXRJIHF!+H)AQ
MJR4VHG)63"X[Q+O2"#0WW!PK]5CX'#P9'EW@#@]R_3#XUB-S[N;_0I?V!@=?
M?L%3^^@?&O+F=ULHOGO[55_BG5C.7YZ"Y\ZL='=9H2F;._.)JI3QNL4E]V9&
MGO:[[<C3(RZC'7G:CCQ-[*?RR%,*,*6%G;34L%.FZ7]0W1.^1\G(E8;MTGX1
MN:(KPWPRR158F<;5AL$-$?D#W-%(.%!.BB/O&S1-\"*0?I)*_A_X:N82(^:N
M^#V9?GX<A06_WW#P6\M".P!ARK@E!%*'885TCR[5;>,K0GM=#I&K&#C@G/%O
M<"_,^>O1O+)>7\02P@F&A)7#.<_EMMA.YF&ZU78OB/D=%A%+;%0W]7QK;L-F
M"PO#0*^',=1.VD8;=^NPT3))T%%2 E8K_55YY*P'>G;##7!F4OZ)@E?X=8KO
M -\Y#'_F1V^'/H)+(1V@8(:)9JB@*3-;1,16Q]D!#%6*:1MT'BF/>H0['"T"
M$V\ \.0V';YB7*>_R#0)T4' 4,?%ETMNV$Y'_EV\UJ0'T.E_ M/LB^W\TS$W
M<&!P;\%74H_8T%^#X^U=7$^[B7.%C_BJ\84_4+'HB1WEA[7$ F?/8A8\?,;(
M/.&ND+Y>@Y31+Y;Z2S124TBLE#/%3\0TN4)2Y2MP3C:"DW0P84C(DCH\WG2,
M@%?$A_RDY S\/)7K")14^*J_%T2L?26]#VL6\7+;D?\2&R3)+_ ..6>'=Z\O
M7;N !'S+M!?XD@&$F&TP+&G#]N&& 47)Q#PG58'[#Z-A/F74"%TXF68B:(5\
M[2JS!=PW?,&Z\H2JS\+7XL7G;1:V([66KCR;]M+7;[@4'4[E"BQ9QUMO1 H>
M?K&R+?8*1TVG#]2%)8!9Q /(2-2?:]LA\IDK^I=(,B!ST >$YL3/H^Q%)+,P
M#)C.'V[BB@?C 7G7#^3RXQ J(132Q@4E ]2A,"^2HB@JP<GGYUM(K= &P*4H
M9?$>/10+7.OP I1J\:\(=LOMUR_Q)+N(@8%>^N+8*QE-#8=2"X?N= .UU;^X
MMNQD/0;7V@Y_55"/L(Z%EV-B%Z[>B!5O*+)N8XN:D\$XO^BD#$42@;ZQ5BJ&
M[&^]Q-X&C6',BAGKOWFZ88-./\VD]:VEW'A/<-)4![1-NOIONO7TGX7M*?^S
M #*LF*E(BF3DL)5+\8%WH,#!GK8QLV"_6(PTI@NW(6;005W)Y_R&22^LW FR
MX+FI&CT]2T-I;9X@DT]N3&I;+JC>[+::D=X&)WRAS, .77%<,1O^ =Q(;XFE
MOG=*:%_&9".<+(=O_A56@);[QP78(LHEIB66N![Z657^AM_\OS9>Z+_I,]WC
MN_FNFR^Z]8[^_6"#Q<!PI3>N"4^XM0S,%YCPY0<P!'2X[H$&: %]6\#%O%X#
M$[GX"]W$%\%S7W4+I%%5/CA@29JJ\E%?/=H&/N!7W7;QQ4LP0O%G?-\_3+8!
M[?DNV!A8P&"P@-$"/-$8!98K\'+E=::HU;(Y:GD/9/)%C4GHL.$K8CST-%_@
MI9C*144+"P*ARBD:2)$98$E,G$6V&>*2TV"2&Y<CY,L$H$\C03*I2H/<4];E
M("AP&29'N.Y(_FZMFT9$*^I@+EM7#IO#.[AS)Q+K<_ KXJ94EOHG%Q<G-*#3
M!6?_P-8;;G7@;1?ED2")3Z&W[?/WDUWS]^EY^_$ ;*YQD<TE U1BP $SN,-0
MSQ9VLQF')9/#T?H)<O/I6 .W?J/_)/;"$F4\V:!D" ^97R<'.3<Y7>;UN_[S
MG\&"@G1Z&AVP"[>(#+&4=WJQR8Y\.MT3GV+W9TH9?_28X9Q^TQU@5#3]X[5+
ML;H />(@HS9.JZ@HPRG[D?AA=T^4G%1LV1EF-&#LO)!IU85D]%[LNI )8OVE
MM$ 4_R+!?52$"$?M^Z&\7-=G2NYK?\4^!?'7H5K IV6XU*W.IG[4KF0EUONZ
M2[&&&7TKARS%FB""7W'$H:BTJ-01J;779>V5@L5U69/^Q?6@V\GJA=VV+DN5
M-6Q K+3$Z0*,Q93,*7@"&%7(2J!&\IX%S@(ZI_ I;O*\V-[2P)1-.+-2QF@X
M$:,\G@A-F-.A7"@E0;,(AWG0K+\)9P?8RGD5P7&@$'XC\4N9-0UJX,KF3M_[
MB5.#DBGS_ 2JB*KP/&I,!><PQV5Q2G-XO)3F1-LQI9E]OB&Q3)X*-WQ2<\6Z
MRY.16<_EUU*2[5(SI11CPMR72:GYS%!:J7ZT-U<9UVLKX]K*N+8R[M0KX[34
MRKA!<V=FWD52E]Q"YO>M:6'Y"5E1$A\@XRH.A0 K P@,,QH8=HH\31 !,\5U
M\!OGJV=5L]99=[!H,L2>_R205H!"$.[<5_,2K5$$@(Z2?=1XQN*X]WG4HWT<
M]>CB.LU+W.6H,]99^U&/\:B3>)F['O4@[Z@/)-7[J$&89#4;[7+6&0NM_:RG
MZ3'@7<]::XPG6[&(X@8A.OZ'66RFGVXAQ=^]Y2N<0F^25T813D!F),W"Q+CY
MH%R&?GZG\MR;+"(,LF7@7RZ-%\P\)IZO\L?Z^3L4[: V#7[OV-[30EEYX+VN
M,5)B4I%?U&D++>(J5,L0J7A0@W*'6'#-L,'CPVB/R&?8R. ,8ZVAG'/E-OVU
M[&K&!?'@6207BS77(D6+'CD&C%SEA2V7^+\&0YP76)O[ZH*)Z"(0E,$I!=(F
M)4XWP'\R<>]^H77H!9<SF_KVA)CB%V[^YRI9[:#ZI12&J3]9MKLQ9RIU^BU>
MERC[,PEXDZRS($B W"H+?.TG_^^O C, :V0+LK-A1J.G1#@O QUBH1.I&*DH
MC$:*:E5<:R2%'JX=2,V@IQ0&I%%/ELXGMI@L7\#W %^X"R0U4##T4HJ9ZZYM
MD;O&Y@A%X$;J;43) SX#([%9]0^BZB:^)59]_>$T!'[@!UQ-\#UR68!7;T%Y
M E,]K&$AJO)7_+8EF$Q\\O\"PQOV2E7@ K%FL'^>^L2E\;KV4]&<E,.G:ND_
M/%U"1<%]UH^R'A4)5+K1<S-B]T(%W5C&IX!Q;QP@YA-QOKSQO]LB)O_%=LB6
M<L79^E%WD;6"OU.$4/SY1K!,B@4P[2(V418ZNK1@L$ T))(Z5I6#V(&B]HL=
M9!$,_/P_=_?_^L=G4=C5[6A_DA%7M-C\6DQ\"&; -K!+$V6!$*XHX7PWV]A!
M*FQ'RN>G/+:F?#3;(>B>EO28]M)=@5P*4PHDEOYHQ+9OJ"GLG_*2_\IXVN?[
M M@!+<XT N"TGFYQQ05HH<!X\+,OF;RC"%!I-##@"IHMKKPU7)/8*T84$W[#
M3'><5[R0@3D]YD._I;'=;_JKR*_NR')YR!D'83FM%%Y$[3RWIWUOPW-8I#3<
MEN<XZ,B>&2Z<6C==3.DB KHTJ..?ISI$FP,[B*PDX@:BU>&C!<[I;069IDG<
MZ?UBXB7^*Q:@W/HOO<%W%@#^H1,8$'R(+)?('W$(2!_C0J;9TI-)F/=9 "E$
M4R,:O"MO%4IV8]\(_ FL+?(A1( @U5CDI9:/C&R;^9QAUB@,,K\]N&A1:##\
MEKMYC*2ITCK"L&!!H5)%T-&BH%;U15(U51FPGFKK+(C(5%_G)!V<-+).:8Z6
MM"WKR?-<7"L5WUN#3;L]%*OZ=H@4!9UMNJ_B-Z.''6%RJ"E6NM)_CU1CS71W
M$8!CQ:Y\T*DIU465[_U\M*>ZG9M4L9\6Q-NS:HKPY,VYR8PT%SM<+I<& 9CF
M97>4?\8^B6>4ZH^'K<R("^^&"MI3;S=L\Q2H:&"S1EPSJH 214\*UIMG(T6\
M*@X=MY76UI"'&8%_2<.-B)1,4:M[VKXCO15A^DN,"%5"*%!TC)=S8 $YWB]I
M3\2JH)1?ATN(PH5#(9"%I1Z"@Y;&23:0 LC^%?TE<BQ7?N]S. @9C@7J<00&
MHHU<#RZS C;P#@)%]4.8VD@I'RI3+#3NYN(?E(0R2SNJ&$W 5DN&&%);7R*Q
M!C/<1!B+V3R";D/W9N9X/#PK2_U @GA=7D0U2K<3L<9]+X":Y\,V.!X=/1+^
MN!3Y%VRN\>O-I)4)M)26?=FK. !%K]U$%:O[S!>75*?C+E:Y]CK]NC#P"W.L
MA0OJUYU/+<P%%BY)0TMS6C)WUAR[HFI;,;.>0&24SWXVYVZ]D10_W129;G%\
M[ I9,CO8=R*/06 IE*86Y$I01B2__FZ"FG8]_W,I/<67XF_O4 ?!6AY?_4_[
MK</AE%O*&A$U@V<19-HLT6V8GOI*9A/2<EM"&Z]QY E\US6?_')+N5)06>8S
MM5V#1K3,1VRQ1J*[RN^F1:,47M=,Z0&9%^:C2; >L2R9CW4M?9@-MNGZ=MOO
M6$5ONCB6 2YS^!=-4W&#%E".E"^3'K&<AD <DM,=/GL(=@F4A(\!^2Y-"ZA%
MU=G48;S4"0TDF?%X1W'#4.M&;QKCII](2;SI>'XH=DZ!F1=DQ,3Z-PQ10G2+
MV9Z+@-$K?F-$/PN'"#>,W,5&M'<2ZDK@ BP1]07W \O2+=W0<YJZ4GR)J -1
MC\?0&^8U?1W$91AW,4285^B2&A -[-49*!9BUIQ>CK*.1&!!2FDC+LBF?.#?
M-? 0?M-_8N"N;+AZW!WB2>26T,BNCRLPWH%,(7+R7]B!I@MUR<0![)[MI;=*
M.0(]<0#-N:YS;[(T5W-=R;W,N:_"+J;HE0FL9@2O$%^-]\I0*CE.T!C8! <7
MBSB8_J_"GB4841CQDSC)*W"B(CXMKR#AS3UA_Y:PCWS6$*M/\,,C2)G;0N*F
M%?[WV\+_MO"_+?P_]<+_W!+_@^J4@IA?(A\JVB*Y(8I74'#W1,'N*7YWV7O'
M8R@E$%"CLXEBI8,Q$-3$-986O+OLI[X\!PE5I"_9,V*'I+TC\@'Q+@$I&_\X
MAC83C\@+?7:4FY!O$+7_TPCONW2A@PONVM@-392U7ZZPBDH:"O@[>4OC-1]T
M\A*TB@B5^=<^QTBA>G <@<2;&D42.0)E" ]">R%P:%--:94?6,@Z )6+)7@4
MF77CD#L@#?B9!)/XAKGQC#5N)U/2]G?/8BGAT!BF&D$%+=D&Q2D.G2./'TM?
M+2:I[D.DB4.&;3)D.HG\'$"/A0<IE3 \0QPC,=CXMT*N5[AQ4U4";UU'5$^+
M'Y^$UY1AY^!Y)V+<?^?8D_B?'=RZ5/#)K5V[C[:[<6^MF>< \_S5L5VW/$[E
MN#NJ"-\QZC9U)^.J.^DU=2>35.S0XE\$@8F5;A#"KN$Q 2]L,4Z2B/[(*T50
M,E(?IZ%EO]A+N/+"@5'0I++-'=$G0;WU'F$MGO$J+W?P9 UNM2<K#MF2#Z+%
M+"Y<C<K<<ZAQ*@+/.U=N[O^_J_YPB)'5E+@IZ>EH!#8UD*K#$W%L+6:Z](W>
M'-U8,4_ASR_]8-JA_@57^?7[I^A,TV9LKVB$9P 1QT=XYM_?#PM,5'[S0(/H
MD<N41#"7-I?RKQS+T@=9V=BSW[&Z$C0,X1.)3ZD1T#N>)(VD(Y#4%&WAF"CX
M-\0BA,N:KF@&?R8<<ER_R[L2_/7-:03 N^S[SL5]NDGUVL]0KQ3*I&*Q$ M\
MIB7<BA7<NJ['C#L'_Q<]:0FV\2!>56:$?$B?3B^N1[VNVA^F#,CFJX_A2/[9
MI>B<+4BN\KI1 WM**'S\DX9"+U\K!G='!4.^XT2) /I\AVO'G3.\4-*(!9>4
MI%9*.+>'X%C]PIZ"ZEV1HSPTK[+[$1=D<M4<V"F9STT4#&-87AB=/)<S#^?^
M?0'P48G>B=Y[1*BO/9$RBM9<CW)I(F/P 4C3G>.CQ7SQL.'M&Z^&X(A.:60B
M"*>2X(\<D(4\.5EE40$8*]RY%<],AC, O&,LV.6[CO+ 7?0DU64BK"H29576
M$R^.,J']@848\0=0 DS\FX .=_-R(&3C7KGZ?@DDB(89W@-FT9@-W&6I?4E&
M^N3QK7WRV#_I!518]-G"IDS\0*FBHM[@XAH=2S0,BVJ*# ZA*C0H_QUO3)3Q
M)6:)CE!A:/'/"",L2-IM:. !&6CA;D?#\9["F6YY,_U9^?1PU=<&?H!EAM>9
M08,F+/N%VV+:(!K%PO[8F;FF7$1HXB-YHW)!$:.0KS7:>C:*96O->0A,+&H3
M4+:&<K8^O_/:>9,C>NLT0BJK)M"?;9&<^N3#BLL@"/LY8XRN\YW$:)++;KSM
M0W9[W,UON&)ER;Z/:<!+V(:0>?4\2E#3DS "(ZPTHQ">/\( ;*6U-/8PY99G
M5,E&NRLXOAF"/LJZ#]*I8:?B\O;;_?_25^M?/KT372=Z<!Q4TK&A"@$+>&D)
MK[)X,\R<;@[L0U%% EQVS=2D9?.=Y.P2K1Z.&)YV1@5ZDD^""5?$)"@CZ_C\
MRRL@"RJ!CG)#2=;DA4/.<6@T:K:=SMM5?-J]+!B. ,*(+)S;(R]1%*TO0M3M
M&?C\LH;E%542?X+H+@8GP=V0\<@[E/F=O+9-:Y-4&WZ=+;Z8O$W\B+Q!0-P$
MIJ$@A$'S8?0UN6?_84@L^#W',[0BC_!9BM>6\-L..YN=WXF_9N#G4$#U9(1R
MJZ#<:'BT !#=N^"Y).[=RD&LXJDV!]]#56CBT;AY>YC6&H([WSA;@",1'865
MH5-3C".ATOE4+,9^5[Y\NHFTKD>M0=_8"PQ"8>AQ' VX$RGR)E Q3+QM T0,
M 0,Q3[Q$/H.2;?C@Q"P6E;=[AC C<*P88I9N4@L:2X%7(KL5%Q0@]E A'QPY
MUC?IE&R8D$+]D<8?DJR 7/M^S S<WD^FBX,9P(#Y#@_XL+1GO_N2V>\F<//@
M=_AX!K;&&NMT'(]=7(<>3V<>>4'<I8D>57KJ7KPEY=W]HV+V53RGNS6YO@CA
MBG6Z14HF<R;O\7KMAMB1^#T2K%OB5DC^32H7<+!,=\.4!=,-X;JYRF5V!/./
M^29Y*T5F/G2C8,!@LC/FDY(H>4<3$!_6>FRH98D 9;\'-G%?'0V2*-R*B^MG
M.-F$8C)\SJ+BXFO>20^6>]9?V*,C"^BG?KN\+%+&/IRU8R[Q;NGB3U2;S0UL
M$#":]VC3M(,74;^,,[?P->3L!CT\\<1(+&G-L,Z;OS4HAZ8TM+PD_#P^'1HH
MV8( R+20])_Q!2Z&<^#QI>(;?9#9.?I)J5U3JEBR3!_QE88J22@"$I!D@KL4
M"%\:C8Z!:R1!B84NITGPYG?*!EE^V4,T_"S\-_YFWZ9X?-TI_CS.&T:11MA;
MOCSX7QZ)I%_>!\&FD))-<?7Z&C8()0$J8W%)X$I0+: 9R%02E08178*G>&7^
MO%J8!JB;]_CH 3\_H;["Q=?<QJ):GY#3QR,V,W3DT+,1&%</'Y7)H!^?H;*"
M77J.*.Q?H_]I;:+($4%P.'9 ! !!GQ!BQ_].;!]UPRUY]OZ6XS.L;%]3\X=$
M MKP+/;3Y!-CJ:[CRIY?(:H5_RR/%-CSW=@E#R!)LL8G)EDDRCKWN*B[^0^7
MXP*DL<>PHI^0M1YI410MR4=C3%L,AB52,@W%J8=- I^*3PB)-TN:;L!:R"RG
M8=]_]]4?C1EQ&,7[HH7LE!/'>2,@8<\X/H_&*_/")8Q4@BB9,M2Q$'3A,"$8
M& .%B_^DQ@H14L-O5>75XC"5>--'>!$:G/ _F$<#N<Y27P2Z6C08HWK*;%R0
M!=QFJ82P4113T]WP4)MH?ZMT.P?Y+9)M)3Y5XFMM)7Y;B=]6XI]R)3YWW-/<
M><TW2TI&,M(L9]_6^$T'PYD0H($/4\(9TWC@HLF6@ __Q1.2:&&'AHME#6/-
M,F1?"VXDA^#'YE3)YV(#,#S=]EQL$'OW7I[TAN3;OTO0J;U"Y%U][;+W\A^_
M&*:[7NJO[TV+-D9?^B4:XD#5"]8[S:,6#$;TYG\.M'*GRS7SQH'_;\@WBS]W
MX$]_2?Y^,NKT)NE_ZG9ZJ;_/>E2OUQGU"Q\%&T?R_)\+L#7$9R0)@*\9?NHO
MM $GZ^-K=*FLI_==I0>,EOE4^;'^^B=^,"F><9IR<M;#N9,B'40GQ>MF @6S
M,6HBT:,^^_W)P8;[*[&!V8R!;_]+#E&6;)Y@LSI)4BS,1!,L8H@3I&A70KA0
M&<&F%%+G"BXPLM^NTMQ=__>>MAS>*CGC#=AK)9<D&A?2*EUP0=T1^PJ/_/["
MEL_L-WC^(O!4-/^^TQ#;>)H$L>&Z?S_G@W^J=$YUZ=#DNN?T_TY#08PS-6:_
MV@Y35<);EA/$_/K^8J>)!P)3#[)JI4J+1SJ;-44(3NF6G&PE!"D[;(4@30C
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M$S=&XB+B6[$;%RXC81+S]4^%AQP+NJPIM JL&0N_P-</PM&WXJW8\4&5'T;
MP(($ 052N1:]M;1+X$_ 9QZO!) 5Z!CNT-]5WT\O8S_IQL@'W37=![AR=./.
M^H<..AL(C?OKI:X?'+-^9Y@:S///AES-1WYX-JATKHX>,,H$XG?WS!P+=;RL
MH@&=A.]3+A_NOMR_D^&$F*E"^3SK"=Z1$DC"C"D/N<O*;=!],Y+6#?R#1]$<
MRMQRK+0_/).7ZOG1P>=W,2OY59A""1/2S; A \]3";4TP'>= (BUH@&2$:':
MV;0>@PO6+Q$%B<21PY8A#_9NS:&CFB/,XP'VJ*8Q)>&06:_AQ9,#%+D;9<[
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M+-M<<,"]6[8571%NVBMW( @(WU6*C$<WT&\MY6ZVL;%!&1$.HI!7-**$<&S
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MA/3UP^7IJ>7=_FT74<U4MRF35T'2I#B%&]7>EEA'L&A9272)2XB=M;@;XQS
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M\8%MNHSNSV_LH?W'/B-R%$X1S!:[RY-?K/WT90]WYO%]X3.#\-R%UQ8#]F[
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M8 =44:UO!GA8UR(NVNE4-,Q%,@(&B .I+;>LG(N.XDPTS$4(1R\W42K7K@P
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MJ7BXNKT\SW:=XT7A[_W/_6[YN!V K?CEV;/?X#_3<#X;_1]02P,$%     @
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M)Z5),L34+"T#V^W-)"HVM[F$R5>U6][]';HS/$?OOOM_4$L#!!0    ( /.
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M-J-E DP>R4 WA.!C >T"-I>$2+5PZ[OK,,84)#%SX-!-Y],&&WL[\6B*-,F
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M%],Y[>G/TX]]HRZOXL4IJ6&\>#Q_YG _[Q,L9WOU%AD>U(&]28Z\:TR]3>[
M0^_$1#639*;82"?9KT:J )'B+A!-9VTT2A.XB^WN1G2HKKSCTV_8^5]HE]]^
MPME'_.MBOGZ_FB3CDBV>G(7:6U0VTSO.6WH]?8P!T9$CP3W<XC#$8ZI69.3:
M5<5Z1+&RF>V'8?Z_F)9OB5(XT4I829M!.-'W0CJ$Z(VF/Y*VON:2#/?A_YY0
MQQ24C(9\^PGR,5GW:3&)K355>I/D)#M4K2!*I8 VQ[M@?$7#?55F+Z!C:@HR
M+L8]4(B/R+<7]+L3&X1WF4)S\J8[5A\A1DU?)D1RM[50[G$-[3G2,552CHIQ
M#Q;C(U'N:5OC\@O@T(HQ.96NC@48+1-D9Q(4HTDCUU)3XN[6< #<,=5JCH9\
M^POT,97>XG0Y:4W7*'0F#R X,")H"$HV$+&94$)H47&?<.R'=$S7"$?#N[W$
M.%0.YT6:+O\SS4[QKYA6I\MMH]0OWURT[2K.?E@7\_2Z)\C[_>T?TFJZ.B!1
MP_3D [,Q0ZR?*>5RENTYQ]+OK<P6'<:D1>U$J$13'7VON),0C.['$ZU)'766
MD=OIN17,P2,QMEVNKO2VNFG5&+4WJM'[D;T"DYN G$N!%J-KH32#[-58.X,;
M4_J$AS?7QN,,(B>>*JR;L?5.:)C7%Z9773GKNPE\:D**YAVDG!*!WV38L0#Y
MG[4J=$5(>9]F8\8TINP(+[<>4WA'-:@_KM;3D]Z,_,RJ],6F:VM._6"ZMTCI
MR[Q8#L%K8UG #&%V^7>)RQ)?X=X59FY=O'XI;+7>> 63['Q,!0UHDV-O9$.>
MG:"8UH<2T281A>.N/7\HQH-O3-_]O%).3SHIL/YEN5BMODX7[&,%?\"V6/8Y
MO1,1G5369:B*7EMCE:8WUDF(19#V*(@B<MMT%N"CJN :E)[7;E4?7>Y\E_SW
MA-Z[67R%WLBA\1DC6&TLF"(2Y"@D4/A6T7M1&G+7>K$ 'Y4;\2TP=G^Q#\;8
MRS62%VK5FK*UJ2)!9DL^MTF-'"_I^X!8E:*O#@-W.G)7;&,Z:GE4WK$(CV\4
MY<UN]_I96BX_3^?O-C[81%EE,87<F]NJ/FHS0)+>]JP8-I]*B(&[P<E.P 8(
M%R^_^).:30J8'4C7+Q*H2/',9N2R=,Y4E82UZ8! \/+3QI0^X"?&#N'> 9L_
M\!MQ4YRI2HU>N@3"]]*^UFO3+7I $U3Q-01,W.X]:R;JF--8AJ'2L#(;,BMU
MV2.>5(4E]]$N5?;!G%4;"-D4T-%6WR_&$NU9U$Q_VJB*LA]9SSQX]X^:,'I3
MWF,]G?4#B(M.29K7"V<3QT@6'0QDB$01[^X\5I)(R%B4]P94\QXV]Y:31^SW
M2T24.6B9V)O'/7*2Z+(+?'8+A[[JHS"G\Y?SS=GH)1C7=FES"5,V*)H>AU&$
M[(8.MQ^.>DS^W*"\?%C,PR[P(P7:7W%O:D8(]MOWR\7IN_>]<J2O8'7G$OHM
MQI"3A:#)6J',R>6AW^R#%C F'W*4].6GP?%31E_0F=0T^"0:Q! T1*-#;?13
M],=5K+>EC(YD=KZX#E=WIH4$21<2GBNAF*::4MR760Y#/&9SP\(_%C.SGX!'
M8V)NA>]UA&3)3"HE16FY>BNXB^S9P(_9M#PJ57G%/E2P^D.:]6$';]XCKGL/
MU,5\.XGP2S?" ^+/G3_[P)!ROS4P18GGC_G<:TY)CBIXWT#GUN?Z6H0HJX7B
M8DO]?KBKW->M+S[_\!YJ9Y_U.GTB(N-RFF;;H1BO<87+C[V'0M*N)M*OT6QZ
M [8 .6<#V232M6B#T=P]"NY'-29SN3<?KC=(8Q4&8Z.],UQ_6RS_WCM*+@JN
MK@ S*8C6&RAG)268("U$710T%6/**AKTW/7L.\ :DZGBIPF3./AYTHOI5^^Q
M_F6QJ%> E6:;C#%"RX$(7+*"V+"G]'V)6.E_[*>1.\ :TP$W/T^8Q'%<A^2L
M;^W9A8M>,KCI[?;L=+FD'V^+6-D]E8<\=! 79N]5,_DVEY]_N4OP&8B)06&L
ME!Y*DA&,U;47ZPH*PIS/DKSIF+D[U>T Z\ 9<)O/?[;XD#[3IT[[043IO7_>
M+=/)9H!W)GM,YM?EFI)+8%N@US&$!BGU60$-F^]++V6WH[X='S@F-X>;&E>&
MM_$+@&L\X!89_7!* GC;G;*WN%IOAL6=KUM9:TJKCL!4[/<E+(2"%8H-/O4=
ML<4^B!=W/6U,3LU12,&V];P=8"^O_1Q/3C499PSH0'^8$B($U1PX'TR(+H1J
MN-OCWXYF3'[-4%1AELEQO9SK';#9?9K;'S&(![/CBKA.[*\][5SF&EU0-A?R
M;,TF G*][VB"YIU5,<B*F3L@O17,H>KF1Y+^XC,2T39%SC>LUID^J5$AE#XP
MU111>G\9!][6))-KVB+W==)[08W)>>'AR565PRL7'G_E;*4]3[WZ,B=O(IS0
MI9 ZE2AZ?X2::97D-Z506C,I>]G43@[*C1\_)H^$5]),6\I4C7C1$=J 2K,O
M1+.]YZARY %I<H.<TQ"M:_2',";Z5JS83<!W/&1,WL0 8N;:7EXO\XZ%2FN;
M5PE"M)D6BAZ")L_7T9J-$A*3XC[]OQO1F/HC#:/P&24RE)]YWK X7>A5/,?U
MUWK+FW[A *?SH.<=Z('RK94M?79+M^B>R]71R>H5A:99*S">_LC:&8B"M$L?
M2"$=^S38._ P--J_^;,W=_ FIL1>]:V@)>%[7"[[@;L"3W81-3;CX@#]].]
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MGG8M>-Y3]$P[%6U;Z'4ALFB*#X+NI98N@ZV^D7?OBW'<KLI=>$9E4_C8P"0
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M"L&HJOI BT360!>R.<8'28%9R.(^S3H<O#'9ZH').1(9LSF&NRSEYB037MO
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MO$I^\G8PQD>53[MC]-_(TX=,(/F A["1*6AI8JS=<^ ABI/=CIR,$,.JBNG
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M!%KW[%-E$=93ZK"B<"OG@BWPE/-Q@6B\'*[4 %3%3,&-0(Z?&=A>1P\57DG
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MD2Q$0V6S1,(U'_[X%=A28,=PN]ZC%8+?@*O$'MQ6)K0@59!$1I!H/#*@M/,
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MP9P\A1[/(O3X8HQ"_:\T2 $Z#C^N>5+W(<A=RSNG,*2&8+2/D8#0Z'UD%@B
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M+,BL?;-\ZG%07YG8T+0-XL<#L.^*P'9N.>_6CVT[2L(F<!(C*ZYCBBXK2N)
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M@K\W86"BKV$^PG;D")L@%P>7X/_R0?L*\+$RJ[ I,#%( XQ\#$Q\#+0V  0
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M-" LI\P8R1GFB2:3D:$0X\7DNYW3F^BEGSZD]:$]4MG!P0LJ2<LISJ *1D5
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M/*8_S=1FP7C&Y*>;OR&+7+;A8ERCMQ_7(AN8_S6^2SW-A-X&OI,I05Q"S-*
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M-A>3_'T'VQ'[.DI8.P_TF745V.$X_W'[N&_6O7NR <I>[1#,&W3%Z1*2.76
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MI$@O(8 H-0$-T11.WN_;X]RSR[UCW'//&6./>_:_C,E<S[/6FK^2E373QU'
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M6>#6E*K#>:2[!@G\E+6PCKLS&T22[O_CM5L51-;S+31\VRK0OC!O4/9Q1^6
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MD1SZ*@&M%O<[.!_5-W<"I*-Y&2ZW\X041X,J5H5/ #X'">C&Z; A'#!]5]]
MH_<@<2+?,NTYK_:29(++M;;UL*5'$=B9NEY@Y@H#Z;ADK)K$V$]$R+Y/>/K
MSW]$AJ,[N\%DS47UBCQ'R6PONAFUN[=^< 8Q6[ JMDOCG4=\D6!!3]T217%
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MIU?JXX[QP#[=KJ+R[1#OUN.PW,7%;=N>&RT-JOP.UI<N.IASJ+(,;XA0-F?
M]T\ "[,XR$!6TLIE4AI!H5MD=X7OJVM7(FY2L[G-?L9[Y3HG%XH;'K_F7/]S
MI&[R#X#RA51'K[QQNEJ/1@CLH'DHMPGH057XC8F?(X&F*0?-,I8AP3F-%SE'
MO7IT;%):X4M<7W]B*+QU.'"ZX47$"(UGMC/08&"_ 1,44'#LFA* S;2UWW1#
M$"3=PPG^&)WQ1^!F((6'W UJ@F3"[0AL.P/%Y[[ G:KZA%=D6O-NQJRUF+F[
M<R>;V3VTL(\H);TW%4+16#T)L_TG &':J>U\A$)[TNTN?$OEPG61O]@JE97Z
MO0D;%ROTC/@YF"\*ZF]D QN]_\TI]X:&"A<L<0MW!E6YN.-R,X'#Z<'[I;[(
M$(KV0DC.B(Y0;5?;"[JGU[4M6A<%<UIXT;ZT6PV/2;C?VXB^&9(7]\7.ZH9I
M&F+^#ZU\+7#>"8>H>;VM]<2DRNNUE5+SK_@])KSVH+"XF:<A=G9P%7\#O;CJ
M2/!<*<*7XSY2-U?JD**0-12/;X.:>45%F&UKKNDWDZ5<ICSY(--KX><QL\C6
M0,KS@P$T&0"A*N#H^ZU!ES9)3X-):"]/<FY:34$(ZI81XRH64<H.#J%Z+9H#
M@VR)DORN)K-L(1G=KXK+R&$42P(R'OP0,Y]T_0O\;LWW0LWZF@7C=SX+8:4:
M'S]N:Y8&I#>:I M<N?O<S!4F\UBC@ ZGM^EJ['%6\BJ@4P.[*@&+ZR[M;SUN
MC_KZ.:$"X_^A<^9R:;NQ5,0+_1E)WJ5H$RMX715MZAC:5+?'398#G74<]UQ'
M<9!RARQFUPKETIMVWCDQ*+.(6B;(YE6^OS_%_W.6P@^FW60GVIP ZF.15(6I
M"D:OV]34$X!O8,*"!JT>"UI W2,D=HC=7Y_LM R4-C*<X6QVQ$7^92NM/0JX
MR7B657H.>1^TR+5#?(4?1)?!RBVL&'$J\5M.5KZ],AX9APZV=VQ';K?K\.?)
M^T!-^'^)MK]NO,Q6J6JN#;#[!J7P/CF<'82V@O94<*M<3?YKYONU\'=*&T=2
MS\8K] 8NMM[0'5"(UF9XK\W'L+^*OX7*7#CN@R0\ <;"V2N6Z8:/6Q]9:?S&
M1\T>LK'46^P649NI<\MRZ.S]6/VE6)9:*(VUF5 PF&1'RL+KX;H:PZLHU_#.
MY,\%3Y[N+$-"O3_QIXY("^;PCZK6@X)AU 3X.*&*.(K7I.^RTQ=?#"+4XNQG
M*-)XXHH5R+3Y2[[.&%120:9,-E<=8"ZS%)>W:3S-I7/ BUA& 4/!BXO=*&$*
M\_V:[[JA&S8^$HI)]UI;6WA[AT9\CO@: A:Y,[H>A@2\Q.(9R,8NG'3(W28!
M\2\&,M;J>"FF4]7-'S8.'S2W)$9BSO4 JFN8 NJY<[(WW%_^U-B?YS7^"U[%
M)0ZL"X)FKPB1[E8A>@MGT_/6!7</W EUW06%<<MU6;F3G!;?5CCC#SR?BI5H
MC_U.5+SL_C%Q*1I12$(34TBA6&@"-^7&5XK-PZ[3>6.'OZJT-SM3(9>)YVS8
M.BXI#5Y9_^B+(2![-5=9D_I'-/R[6'1O[;C?(:L/43E+>5CA-<5>2Y)[BQTM
M:@-P<[(?;*S;T/#OIFN8*O@E,RS>INU]YNC,^?1KTTJXQ.17Y 0G:7$#[8$G
MA@U7Z5$W3>-. .J57"@BEP5@CEI)NPAS6J<O_A$=C.#"E<B'I!#K23F!6;17
M/E!M[ ,W>N1B5;KNI4V3H)PAC4U0/6J/C >N'>S^P"_VN$B18@3R<'KL?(WM
MS2C+C_,<;TW6WIY]UOT[T2EL8BG=3A;?1[,NJD3.*=P] 4Q5?]V!-@CNUN"1
MN*1==ZP@0:4OD'T5NOU'V&G<B7R1">WV"3NL?/=Z)=:=2U2:L1! YC4A&.;@
MP%R+?@LWR_PKO5NMV9^I[);Q&JE?]]!5W;@T5 :?.@$ 3:G/T-_?G@ V&>^<
M #9\"1B2#+$FT@^?M\X<=[/DS]NXM2($CE/Y>[9U:>G^?&9_"9Q+[9S!3B)]
M.LPH[*00@COQ":%H*+V3?6V5SP7(/>9=4%A;P#G0;R-J&5(OZZD<+>"FF1-K
M+O:%>0J%_XF<3Z.E!M*L-2 TD[H20U&X#1XU"&3OP8%/[Q!=I"<>Z-GNCUKU
MV ,LM+&E'.E5 ),(_M]C?]_W)YW&KP_8046;D+PDT3Z:@C-C/]*UH6WV\5R@
M;*;8Z(NK.4Z@[9CA?:O'4/P-3D/P:<04J%D^]N=K(DUL,O1;[.?^RX<X^[H
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MAC";J_#3EEYF9\ D^:0!4);N8%H%8@HDO$G(1Y6;;V5QD,) C0Z-B>O',5(
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M+'BUH!L"O6USA?O>HG&$OU(GH?J+1:*.=-!33VDF[B5N*,J(R$(BD VW_VR
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M+_7LD=DWK^UH>2L&?[S[_5HP&V+<OP0Q,TGR*PXDK<3![R"0%]-FJ4&XHC<
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MNK#]KH0+U=-X)SSTC85XPO9N#YW@<NR<*GH77FA;^[UA ?Q0/^C>&U$7(ME
MH([BR<\TP]F,B7]D ']TM>!#FC!WZ5URCY97-6L)'/8Q,#=Z\HB2S@#-21-Z
M.<W+/#P"RR!+JNC+VD);O<0&DZ7X^\0?BOK;^G>2NIU_R<Q0E7F]^1+Y0/4O
M,7=^B\,(-YE28\3*WK):&=GS*\QQ):Z1]_/D]$H!UL8:&E;%X]@-;!8%QYM
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M+#86=I'B 94VSG!8<TYM'!QQ//<RCT9%[FQFU//IG[(?.U\!DO8N2EIWC:X
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M 6[*D74C-6]@[5"=#=^WSIX+<QH.;8\.Q_A0\'.^^[$^/:RHA&>A-]]*Z<\
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MA3;)H_;((&-7@!?G2A%-,K0_F"Q/8 \NLH1H!#K??E.<!S!:2NY$(EI$+OM
MA'(@^X>;ET"T>GGMUVZFKMI^-]G2W_0R.ME$%-\8)>\H,^;[A3F./,0*EMHM
M$8'L9$:")N7$)R[O8J5PTF<KUD:-]*EG>(.NOR_2=@'SH]_,JBUD4FUNQ;;J
M3]U&IRZ#.J_CIO2+=.> )KY"K-.B28O;W#W;@K:V ^YW8RIQQY^.Y H:9]7G
MJ;X3\WY)^+^W3&[+++#UOLI>M&^4%+*L=43W"YBE/T8E\Q0^/26N-RZ,.HRC
MLF.JB1&**E:RM,9K+,]]]]0U8=OKCL4;%$ZZP?FM[MZ3+Y%\-/]AA\K_1&@U
M#A2_33@Y[@J5+M=ES]3*"U2$VHP0/-#\XW)L\@"V4!7#==R:JYEG)S)K^U.9
M:9<;D>G$N.WE6\^ @HV6G7!EZ=!H*?_5W8^_ <&LR2@SJ+>SEYLEWLGCM8=#
MG&;9C[8U5>N-X1%B<"I32(9B_5@U[XY[$0-SHQ>P3\*M1VH ,V%>YO%Z25W%
MY%DD;][+_WJ32AJ -MLB3S*7S6C>BYUWGY./V@NG^,H@1CH3OI;YFS6S$RD-
M?M\#Q>,%:YX1\02XN,63O7^;/J$^O;G^;W;O_JO"-Y@[K5G47:1BC9<Z*M2W
M:W C00F(OS5_:56NQU^TX<^=VDLGX=D0K87UX^@Z+MQ[Y)8M,OQ.:H0!=_;5
MX>/UY[K_/VNC!Q#0%G2#8#+M#A_>6\E<_5S3R&" /ZV1017LY9BS8%FYX1C2
MQH2CSK2B @^?7?4'6C&D".+U)'+PU821=KV>U2,1'@"L,:F_M[5,QD;]2.)Z
M4A1N_^F([V\BZHVJ#E4I2'@;*BZTK]SVH(B1,ZD-X%4X]='_9]K4H3I]NU%X
M+49P+Z$HX,9"85>H47C?W:#$G5A\5L_YQX22XOU17>/M9IMO[7 /U5L3M*(R
M/^INKQR1JIZ@&L475E+IV,D98-\VM"KEN;^E(9$KT0\#S_)8\)\QO=C='R\9
MKYI3O]]#PL^L[U"Z_#+!:*Z'(U:<]691VZWIUYLY- \"ON(#6&ZH@?M.>]RB
MABO(6K@-W>.4R_O]G3W]/)@H<MCT0]SD'F"AA9 OJZRJ$AF*&-921];4</>A
MBB7#FT_O&0<Q$NEP\Y ROW'2[7:?T$N6I]0CT=+-X6$43!_-4'U@GZ*ZGH0
M=34KF;2VH NC[M=68_RS&&!#U8IJCAH_*W0: D1DO)DMHCA[NM^I-CDLIH%E
M<2^;V:C''9I<6:+P%FDR[1X-K 0XO#?-?;-_!U\1L$(0^[AW@'_]B=<[*;9?
M%^H=]?.5/YIU2G#*+0;>+5< <>S\J;$.N9EVLD-')"_\N^2?>ZK]3?+'EV-E
MTBSU1RU<).I>DI@7:+Z/K!\APAKIC.&L2^U2#2=24^CMGC]^H<$Q>%-R_7'
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M" F^KN)+)8ZZ=:6WA#M@:5_>AK@>6.W(M9U0V%(!SQZ'(9IE.E-3"</Z$Z\
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M%F>,GFRYCCJ?5,CG-@]4];JJSXO+:BDLE"U,I[EVU%WEGO?:A7J(9L62A,[
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M%8;&6H7>W/:^U29!31@!4;?[O"/%_3@W:TYHA#JE(XY,QS<;2QC+6=+IV14
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MI87M_2R+9S2:(9:K#13;Y(:/ /=Y<H5TB6GX*K&;L-2[,N^-2Y 6T$H^F!@
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M5>N%5:];SQD(3^@8GX^7 WL1J&)5H*(8?H7BZZIO".5Z5A>Q#:M?SM3SG"O
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MZ&I]Z %$<I56>S)K>/HPY91>\[4RG_&+/N6P019V2XZ2,0UMA9L!1O+T7F1
MI-2#UA>J-C/%AX^$5DHF+\"]3SDX?P6*330,-"?*W*.E=KK.L)NJ&\.S4^_<
MTGEF(O>(X1T)ISK\88F/)QQ[O%9T>"1O]:+QQ,;*"S^6RZG^7"*F![]YH89@
MT7=+(C._S%D:]P1$M@SN7ML?"2Z;MVZ"9#YZ1W7HEM]TG&O$J J,IU-AH-R\
M4W_O6&%+ N[7O-KJ'<EH0)#5M#I\K*GLO_T"62U2KC14!LO^(Z:QY)SHY\7_
M)7KRQZR9/9>R,VG_ ZY*L21SY[@.A"QN8:' I=",<JV* :=U&?=$TJ]*O)D
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MH$EUN7E;J&CPYRM7#?]..0&?)96S%\C@;QDTJIZ?!RW*;B_"^0R,Y 72X5>
MFXU%S\<K59>%)8^[Q7#J@R'">=9U2LS5$_;WJX/)3#@4 L@(.^Y&]B[SC+5@
MK6:H]$C=GRP[R:!4>P=S]W%9T&2A5Y;^A)6@A)7:F+\S/5\>:U?4R9$F_I'B
MFZ@R%?L7*KISDV]M9BBO7/4+<_!GPC#,P]<K=VK2MG'?01YW_]#/K1C0NE!#
MN,4Y*CSN<_ED&J.\R;IH?Z*PLF>ZNJ1CQ+O&V".IKIHF%[1&&6XY4[//LRJD
M0OZA-^8.B]8/8VWUQ[$*Y"?V0DJ:UJD/#?N^O"I<#P()HZPP=X8O),#B/:EJ
MK;D0R8N'97E+O;Y6SI>UA>U) FH,0O,S. ;XG^"!A$XVWW_<TQP=O*Q"RY>B
M5-: '65^W1T8'F1=\F<[X?/,;,)W EZ"=]8T+$VCB!JT%R>0C<GW#:A[O=DZ
M#^=G5F%],"+UU6'&EVWC+7K8>*Z\H1*RICQ9D,HD7"=E (E96]?L[FB@K[&D
MJUJR3K**ZM.I4Y$X%=:$D7QSN;$(*R:&GHB?XF=K#:.GH##&FR>M][(;4-6,
MT:7F$_)1$;SVI92\WN,F!T14'5R$N#&W;Z7.R$H*2K5!,Z\ 5NTDNV+"?2O1
M( ()N1+0CHON3B4X4LY78?N SB:Y,O!!],<$Y@CK39F"@RVL*.!HTK'__GWK
M%3S,8X@ :HK@P83;3U#7,ENBP]/MY)C/CSZ>XI$/A(>?N"I[T!Z D"L1@O[$
MF#G0O1;RO%W*:7V=T$\[#&PSW%P%X+5F@B$[&[I5-6JYFG+RIO>XM4X@LI-#
M<K3=9:4[87#0&BBRY1[\@O"6P>XR,.A@K;(Q8;-\GCD%7>=T>Z'/^6B=+G7O
M"F"9A6J0IO03@&A8$-IXE10$UW@=.4U[N[R/?V^58]B"7L_(_#@B%7X%>,2%
M%+Y,I 5=BJ1^]I2,A,.ZJ*4(4=['2HE]&&[DAA9LBW4EJI;8WYV(XT:T^>W&
M%X%.LCM>?9R#_B9#TQ-H8B1MIY1NX$*GL<2TFXH(*2US[?$[)(>+TZ<7,G0F
M^*_;TJ ?KP"F*J*. EE14AP0WZR>=N+3DB'5+/=/,?(!2J*B@^$_BY;$8RUC
M"W[U&?RCZ@;\#*O>5/700ZY]=[S)NDQDG4Q4J2==P"P=?F;!S=H27AU$7Q+4
M:&YQ94[153+M,&"!*1M-R!S0.;!6^ZCY#NCOG79_MGHEL00,51X]Q>.DW9T,
M/$ &=M)RDO2+T 4$P*BOG\:A*0G>/#O@&;"^3F/12*\.Q?(F,!1J!I. ?_M;
MCY'@7VKINAY\[M+DVV)"118%QLNYE/6A1,\Z8X[3"60Z!M<3./6K:GGQ;/3;
M"BP*C?44)3=3OI+4N82*TEGAXL9GAN;93GA\9_7+_K.]73H$>>OVG,I(^IA0
M9\ZR2_@MP5>L"LIXB0LLQ.A=[Z)%ZVE*( *D:H%='X<O[X0,_"X9JS&)<?M;
M0YE+!'ON;]OB_EN\2P_7>_55\UMO17+O/"P0.XRY6<#BND*%&]0I6F;[I0%1
ME^0)E2T=LJ#=><DSL,6R0>!CA7WDQ2Q8HKKP*>D\^'_7MJ0M&/UPQGB<UVWH
M^[LS8(6RO83JV+H[1\>E[(.R,1D&7,3R^8$DA2H6T.4:]87F8H;:>0 VSV]L
M&II)>UA_>2XI'#^E1&^A@E193<+4%\JN0>_ '"W6\40@0?0+?/JV=? /%#/X
MV1%O>]Z_YQ2P^!AL8:6P?A(;=NZ^7'096=(K'2+QO$4HMO0&?KG3G<="'H9,
MBU+@E$G20+F;N,>,Y$YMS)P],.*G!*]8%E1]TTY\$[Z?U:><S+XPM.U54%]&
MCY1'<&+UM$F,HA\B90M!O M;N'OG[E4"/Y*QW8EEJ6Q8)*5V,EMF.C1S-%NF
MQ#1<$N=8/7\PC[IH !,K/7LR[U<C\H-\2U:JN?-R+16)BZQ<1Q^P;Z:$WRT6
M97DK*C@%H4;T7@&"VQCG%$N98HW:$XS4-606>CQ)!\9K9!L&HAZ',1[T<<8A
M_+LS'/O\6";0&NNT'N,"PZ+H?<ZNWFF%XX8%=_!0$A^O^ --;?Z6#[YMP.J9
MDU@<Q.:+U'>5(GFVM=P%1^7+4,^C8RD[VG#MC1SZ. UY\G.-K7]$94!>RZUP
MCTV]L;7)_L,9LJ;J,?5]F<&UHFL =,; ,S[S<B)C^>8FX<=F/5UWW&/R/($G
MB\\07R*Y-!\!%:GQ"5\JYLD5V-2ERA?/SQG(VS@T<M*QD\M*@LE.*L46J_\*
MN<;?BK[8NC-%QMVA)#MBW*5??TP_?U'\,OBG+J?)CTXFFNG"DVB*+IAF4VO@
MR&U'GENL&<PW5G:\,Z=RN8>+DE2.OMMK_%/_<=*@W^-AH$:3Z,L<_'6F*)JI
MTC)-Y?MZR^SH;6T\%J^^(UPLJ=-?!,(0!<(@-'4!BDW] TR-7\#EBX5ERH\G
M+#=F;[P%E,U_@]PHWS5F&G_8,'U2G6>8^S626D%U*""HMO% P6>MR78KZ;!H
M@M9 YL^4VXJJTPRM%1X*Q*\.?$I8RI6VXTM:=7DR>=)WD#X#U&MJ#W=KO66G
M6XLW6\;2Y!M7&GK((-WC.I$Z_JNQ;?5762-XI1<Z^P.^U2_I1^_:MXQ=,74:
M]I;1(4:OS"*.(% A>'0 5X;1D\X-JHI(#CJ1O@'VALDBOB5:?;:>MJE:[NLC
MCV#O<W$JV5%F.65)\!*$RHO7?RJ-X> -7+X3NM:S0DK:?;:[GE*JD'K>]V/9
MOE]^KMG2^]Z%)Q%@!$#^!0*ZC&LCA'A-]A6LQ][</A\I%+HUR9Q@H))R\Y$V
M(1=!#!PKZ@ESP/<G>V0:'H$#QXS7#G.U<-<5X*WS@ 0.?%A<)E.>_8==FT^!
M46]=S5&UDH(NPH >5^;)]J2&BM/S?E[$\:^*%'(;RE2KX)/.?'UCD'J189!
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MIY(EA7DU8*CNM<P2!/3,KPWY(TI *:0VYWN.QI1 M-"6VVOW*.H',0IT;^<
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ML/-\&7&O.]7CY6X:(B]K8.FKUKL+WT@WR!< T512YCJUV-L8YB5@8-JC&:L
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MBR/TH;K2M)8NC<<A[^DVTFC&4XE5I+MP&W^!+GW7X_G]&>:GM@);DKB-*.'
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MGW+<UPW;6X_>70:"[(^,KF\Y#/]!*2'0_.[+D[NIOWM<!C:/WZ*W>71 ^-J
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M*C]2D/RYPH]T:Q 5Y#EG)HDG*<FATX2U1Z<DH<X0Y-&^BN6&W,VIIGF&JB)
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MBAE6Y'H0QLNKQSG<"GA&X'GIH*CF%*L2G\A*+[V#,C?N:LH)*2[=9'AA)^>
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MLF*-JL!JUQ#_E:C2-4B3QF"[@7E]0^"\ZHS%'=& 9]%K&6F:W &;>I!4K%"
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MX[T$TTEFP3SW?CQ9)=G!0U)RY_=X#V 4=VK@&8KB+7:)W@$>1**,WX+:N/F
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MA),;_.Z_IR3ZN1E#GY('K1_MU!%%7TSC%V0&L)ASTCSX_&OJZBU\&(.I%\U
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M]RLMML!L3M01YMS<<O4R%]/G^1O'7Y3D.V/.5QKTI+BLROMC3]>2]W:1:9>
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MJ^!Q2V89?>$!LN6LK.=2*$W:=3])3'<"FHUF6VC?5P<ITZ_V\6*K7#I$CR.
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M9#56SMQP,JGBRQWD-M/'EGQM?G1>> FP%B*^"@&4X5@)E'Z(FR, M]L:)M;
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M'0:H)-](G'IT5>S71ML2,!32+MU=G+,VR<XU=J_8HC;H:=5[\\3M<55J;@E
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MS!TNDODU@O\XZN0/Z@=!#-:JQ7:Q-(R#4E;>YR$B(?TP>##)Q\L)1:@W^G*
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MO$ >' ZX?.I4< )F/,3C2\Z;/[G!;_2\X"^3%O]#P22="DK2T>EW<P01&>[
M73LZ;2@6[J_7X<"T]-"7W&W\&RZ^RSLQ%FW/HEXUG-V,:'QUJ_X9FM,(6"W)
M^GGR?THC-;7$YK8A$[:\'2,;)6PFYWE_T!O;8NLS[3Q<[$60(6:T4E.Q3&;
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M+[U6W?,E&9@97C)>M&VR=FJL8G;VMG19XUV((W\Z G;[5T7L"]$L)PZ*#!,
M?>K<#L,,%SBTX%-LVW;Z%5?@C8MGO/[9</QEDCJFW-<"GUM3N+CNZ_K>QGW[
MUQ<>.K]V9A-:OT'_<1ZE&7-6A_FO_M*LPP*9NG!Y)3]KA7&QXK_NAW^%M'P5
M1I@U4@:<#S;#]NL$<%,SJ.XK]-;X3A L7NORQYK8"CG9VM)/YV/5FFNE.?4;
MQ>DW1$B+Q]$G@*6W".HV2O(@F0L'2E8ZVA(^9V4<]K.#^:7&YWRC#RZWU3[0
M7MZ$5+X] :"W$36P8R8;!)E.%DE,'#V.!KJ?)5$<R1(M=8CQ2YKRTSU9XPZO
MB^NDI$+7*"H*/7XL*4?JV06T8]IB3P"Q^DN@0S:2Y@D@NAA(3 0DH;E[$$RD
M1\30=T14I\J]16*X^<_(08T11=E%NV&&[SQGKN _K@1_#;8PN34F'<A_MBQP
M7BI"[;/T0?!4NK3I>T-)^K<4&8;+C4J/HNA3/>YA>$6?4Z6K/7?QT:'LH'E7
M[/-E$'RUP0(<E>QLJ7IO9DGXX0B-;QQ4LA"B]=G(^,*$38=XW'W[[96J]B&K
MS!$*6\[/)/5&O.94B@*D9%$]'*U^=DJS\>J28\Z[U$;AZ_869W0DX%\3Q@,N
M+.FMJ(HM"-L<.)-YN,D5*H2H$T#GV@F@UG+2XN<P]M*RMV\OW\Y+'+ ]I-(=
M V>?UYA;K?%:^X(CI'P>?'2V5R*-O"E[?<$(QD2I 2($$8TK-V&UWZ?*T:!D
M80Z2!:ZYPULI91^5I''O,/9]8PFG2SC$R4+WZO5FN?.,C%'4O6/@F1. !RR%
M+)>$T8_78B1)<HEA9%N]#G-VJHJ+L^:[#IU4]9H@-4<#O E6(SC;73_PG)80
MA%*':+V4PMWIP%MEKWYC3"9C:NR;H82I_GW)+*='1D*&XKG&4"PN!@O"X2KA
M)X"Y2(<3P#83Y9'<$<KE!^++UOS0MS?^8U$RND><Q%3;[BDYF"<P69Z83.V6
M-6T5S:38SW%1M&O@:FP[K]V;-QF/ NYK,9 LB8^7A)-UEA"]@C?ZNM5:%W/G
MLF-;7)V]":;E'5Q4HR8 ">=/\%W!(D\S;-:A5YOM<?D983BJ^M=L/0Q\*E7[
MH.\N))3;$?]Q@2 ^Y27I(B4W =F(ETN">9P HF ,@2A!"**=+(B/WO(N68#<
M(5H[--;5&Z)GE7NEXNZ=%;1X$:$D<9RJ$;24Q/]Z-QY9Z]L]A:>/A3CAAPJY
MFHN^F*_HX35N65BY&HFYN @(..*%ZX>?0HW1H'D&PH-)J"!:CGBGQ=!7.$%K
MX"W,4[<HHC+HC=<)8(,M.J&. 2B6\T(@W0C/0.@@'J&QEIUM?%-DNG74V0JH
M/>P87@0IZG:0CK?X6-_HXI0W-B6]JWK ^9113\TEBN4Z#I:H87SD$MFGEF3K
ME9U+08R];+=1C?)0R;2)R+2H>Y9WM>41[0_[$5<CX>?]UWK!3<>99,4%DC=1
MQSF\?#X'V-ND6)E/?'T[C3K<_A:C='NQ)#W)H 7QO$^I[DB=Q-5 I,05W,(]
M"7O6]&U%3F8QK^3+:S["CB>?X>IL9JU"5>?*$D ^;/H+HIX"#]L>P.L-8X0[
M#V3$$)AW(T2%>^-RH,%ZN&4ZCY67,_V=/8MTNT#'TC>9VD)%A9 "6^+:D95#
M1_Z634I\%R+NXM2KJ/&*Q8M!.8]<[WE_/ZO_4K#6A:U(JO5 X'Y(+PLO&$ES
M G@X'!OV=;'Y@W!\FUKUZ\X0FX>_XK>Y7KU](/-ND%UY,L/!Z7-R3I$F>+:-
MFG1^7(N:)#>J(?S>X!?(.;GU&VE- 61_#:79G3*9LU##%J&-M=/'EN-*CC"H
M[0T,6) ]#%)DP+HUQ_$1^Y.-/-JR'NVSI.#M,D ^!H270R=Q-=V'OWI\YUDP
MD94TC<5%42TLKK2Q,GLO=EY8VVVF).P4>3S#>HI1.U$W\HIQ(H6Q^@4-V^$G
M (;NDM=7T2BLF?<G2D+YZ\CA-\M:L!URG3M!A6@)PV42(G"K.14&X\0"LY]*
M7Q^AVU$2Q_,OWW^+HC'_= ?1?I%R31.(;D,>Z4;.P6HEX_=9DH$<&H+Y$(O:
M^^.U)P!:8JX1#SN6R_8=C;+E714]EL_<64X!KPBH,Y&]0%PTL<\ 3TN2,TG1
M.D\>SG$G#TZW@ BO^=_ J$9#Q<*$ED7;PG"[7:B$7,WC%J1G(=$?#R9S.L_5
M1_DBR*S-WL[8CC)8\%5U%CFWZ2-D.$R3.@*("T'+]2*HB5U'^GT(H5-U[KP.
M<H><^E$P-%/UV D@S."W*]^R#OPB[1S7YJ(T/_^]>Q_T^X29L23?B(*%KQ'^
M'H$;MQ,_+K-D%.& %U>;-I=)0<NE"-K%]2F<Q_AF$NQJRJ*H-OPY#P^M^)J(
M0" P_H%V]&DS>HCSQ9'#H)K*)*CO.UN=H++9/J;6Q 7GSX9K+\_K9XHSE;@L
M7!=3]U]LS6]$/D6RU HG+IZ=@HIADJ@G]@0=OI578*T3=\SZS\?1?Q2YXOCH
M+-6CB[P_6^.W09ACG\5!:[P^5A+O!N(Z\!0?\^!K48O,7@.P#+I\?':IF6AX
M$$_3^A.M'ZMAN%1);;,A)(5_0E:;$LFRV[)4]K<9D-;3NRHE[NSI"O?*VNQF
M1W'^G&SH@LV)$;RJ4N4H(%E]RR'1TF;GB.X]V])UG_*L<%77(V,&TZL+:,P%
MV #KIR/X+ F&.P'T@>)5A"Z/OFVJ?M7I619D+[0?_,US^B,<97NK@)@M1A5$
M)41\2X_@18)9GB!JL%^4V[3PO8BWJ,])HE;4&:N[SFR<7\Z5]I][+N9OYQ=:
M@4"#>H%4)!_<9TA,>YO$1[SL,P/+K,^W:V7-KQ@ZJT(05(*IG'&AG ='1_R1
M$P0UR=@@Q%.;['9$DI8B'I6\;]2J8X8'Q;5<4&(P=&97])NW77AI_B+_IOD<
M@.)YG&KE+2([QA;%15[XY7 %U]<)?(ID:KF*$688 &/DB+=(\H&#MJ^)KBQ4
MZ&?5+^D5+AA2'0ID:O,)72"6+YT 8A X4U]>8DSOHN@X2:$ 'L_E)S.5=^6Z
M^/N]CRFTEH^*NR]'&]SS[Z@,(EX[<H+R$X]*VK*70$)68+62N </I,VL%U3O
M,G D!NKY40@4BU7F58I6X8;@&!;B9<FG[I.*I3*W(M31D^5?GS4$;TC9WO*E
MYQ639NZ=VVGD4752X]L&^J+.6(%!-8A$J#V +R2)).A]W)P/KN_/W_D<'LP&
M@"?'.O):AYWK2P0<WC#DXIDSY-'G._/EBQ] T%#IYVKAJ?=*?9RKB. 19EP@
MF8U.FS$[R_&92.1_'+K>9/6%,F^3G)O?LD7H(L)ARR:STTN+3U.T<FA[AL]Y
MJ'&5BAM_'^#,P21(:NO?:'\H-OK"<F(.U 6B]VBCAW<0' 3&17#5MDF@[<=>
M<3/=  KKLUU^M':9J1Z484,_4*:U<9MCD!UO]^OB9IWH,5VQ\\_CJ5C[15M8
M,-S8HR,@5'9Z;51#!R]W)\F\(</ O6$<6^'[1?[\W,;YAD3M9.;K]T56A'7L
MAK?UQ=N8\/J]J">X;R9!Z!, )?&EWM/,-\>IGW=8U6SRR"O>2-X5FKT>!3+=
M+B/XU-)0.#MQZP3 OK_G>2:EYV:QMN2(S\,(DW) >$]?+XC*&JI83XP-P42H
M=758*N/M=<L7!U=L:Q\YZCTB'G5'T=XSX%EMF3]5CFB<)*8/[JW!BS81UBF%
M9&!/+2>E\4I1ZY<4TFR6L<X^'+G\:?+R4NFG5E]V;QJY_]6FZ)/K)1L\%CR4
MY OG+">JYCHXKG2G]:;? *1P:IL#'+T%/ZIBHK2$\46]""HHPVF])$A7MY &
M7K H;B^+Z OF"+#W<<LRJ>>>Y;LHC:WCP=XU[+MUR+ TC8W!A1 >3Q:.D6B7
M2P5]+5*LR1WB"C9V\L74+T5S6'.TQ22N"T8PA;K%N_J&GO:Y)O[!I^A+7X!,
MV]^3OFC/"X#\!G.?N/S0](0MY9WVVQZ"G@0D9H.I@G.E<$7)BMEUD^?Y)8\T
M&J0$1K@%7BQ<^9S+K+E.N77)U0B2:VWOG,)1H_Z&FC+#<%MJK>^4[1CRT"BQ
M0T,^4LHCWC1X3M+T4M40W2I.<K:]7>/EU3?,[RPY3YE0P!\/QVK1$=V[1JTW
M&PA:"GB+N,<?YM;]7\KM2-NU9';X1*7\^"S&6K+BLZ@76F8(\V*A^8K#DFA@
M+JB4TJ5?M<J@F0'<@>ZG)Q7?\C2V*5./ X8"M(4?@--FMB)Y)LY_^N3_?M&Z
M/\/.IE\G],X3+CV'@-H55FSB3Y-983T<5\R1!O'&,#JUX0,$WC[ B)QMRBT;
MXT^8'O+['M/':Z?JQ^T4!6COE1HZ 3P @]@W0%6367!,N93]Z,X>',O H.[+
M-E-7B*LV%%=>='E(P9-<DNSR ")N*7QT&;*SA8:1V*:-\!')3F L2^=A?9Y/
MRLB@P/3MEX0%&@_*V3:9R#D4523-%CR?.(SARGF_Q?K1NO;(XWWKIZCG"U15
M\^]2>$5B?C[N$,IO94<C>H09H,ZXH.S$%OXRG8IU[J@#[H\%;YW4HBLHI2@[
M[E%0G=,62?QA,F.)?I^T5#G;W,'WK;SL$22F)\Q.Z/Q47:BYTN3^MP6P!EP\
M/NM[.^5;>BD4%ON@5L_@?"J'F[L47RSUB^]PP0'QS(57@%?_L_N/3'J!S%@-
MUU*/7[^X0Y1WWP^LBM[0$UXU0^4=Z(LV?5[1\%Q.&F8 \TD\KT_2*A3*D\OZ
MJ6? ^H/6\9&?X9H@4+;M\6\;*O_H18]G&N4X2>JU>#=D@5?-MX7KLJ_08ZI/
MYXB.7=<V^C>ERBMT>MI46W"HI[6:RDQ<$3<$;VC# WA%='\"(("5J!"!Y<<'
MBF*5_]%%BO^9LD(RQNT,=Y,E1_<_[%0\0!@[#@C<I(8JHW.7<S]A[5W]R9?P
M/:AXDD6^YQ6/<517\166WYEPQ$<STTJ*^]O'7OV'T_G95=3@?MZ9(CF_)Z:&
M^G#]Z+GQSF-);T:\0D]A$J[S-<BB'YPK,[F'XM]0TZR(EUE\'9CW'GFWQWE
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MSY$7)%6J>W07YC:<?!62''L_<5H_.D+1P/S*F1/ $.OS#MZ'C +1\E?O:S%
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M)OOQ5K5+-B@I*?V/4\Z [V3!32WQB;W0=WC-9\$J^<%68U=31I?.&0SL&)"
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M7\YJQFW9@<[96$."#WMWUJT6;*H_U8>8BWJ,O@"L))_1<MXU#SP!'-PB%)T
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MY%Z36WIX"'7-XE<J.5%;_5^%(FP<$6'W3:):C,(Q2.:>8I!G9>'0T.!*6R@
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M"\EG-F1&?T#;66@'[WO>@<SSL[=7OL-BQ\86+XKR.Z?<N+@'<+1,((GCRD\
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MO6$V4 V\>S<J=E%DRGTZT)K$Z9(]/7=[FA9*R)CWT?L10^I?3F;_?1M@Z03
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MA@MO.$1)=J B?+=SHB=,K"S/*73((@_..+J 7B@(65*[5*T^PTR868]HXH.
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M3Q.5)?$%&+&LKOE<-NLNOSG&3CY#E?$T'I]8VZHP >:B?A*[3+_KG6FF^Z&
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MO\&]4U,"3;NK_/$C+-D@Z&1@MD GW$S0 PTJ!_#= *!#%0N(U+@SP&7_KC/
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M^N-\P;!V@0\,:G()'"YG $*RU0(;23NBG1J=>WS5?)A(6WT&(&H4$)D@;&>
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M'2CNUHA]E4-5J'2D<(U_*S?8*9><$% ]WA-;6GYY4J;;:5QVX=KZUB&?T@M
M-_5(E&6H5-&UIU(,Y)Y@>O#C5DH88]<4_]6I9FT,))9X:5S[YDL$CM0J6+]Z
M3Z4O[.:'JQMWW:[+\3*K\#N<>#G[AYQ'DO 0TQ_3>UP>U2C4O':T>YF@OW%Q
M)U%@>G9R[0S 2Z1USJVF[/C82@&+VM2K&MLI%RNW=I.ZI]5Q5^I!*(>&Y445
MQH%Q)87I/#W*_F,@X=U\YQG@2'L;<; R.;P$Y J9/ -4RW79D"+:!Z9;N/#2
M;5)FIO% \L4KA64(F=& ;K1%E+HSIG];K_G&-T;X*3,4:W&O"K\>C#,3KR%%
MBPY1@!GZGHP)SY(WZCK2<3B> :0]N[4QP(X<:#(>>7(9!D:OQ0W'@Z;@ALOG
MFR4U5"Z&P%K:5[@(H3F=2 GM7:8+-=-"=L,X 5@KGN6A821BOFYYZHUPIP07
M['AJK>-XJU(;HZ,FL>,68_J3[(5Z@M'G6T\P'GS0=7"B395'9,A-J_7&FI7C
MHBB"U?NK5G)=RGQ-4!WU$7X_2BY&_@ 15-9\NN52>^[,6@>"3M&S"-^]V1VB
MA/L9>_!C+7S  %<18Z,?Y.RH\OE>?,W#J]TA.]Y+ !(/#,=6P7NX-<X4)VC#
MI'P91FGJ;##GTLR.UI(YK$_TKK&B:?3?  B3"L<!5I69X*KX,.SF41B8K$4
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M/IB5-_8F2_QA<F/G^WV??>:H+4B3'=[PN& B3D4A3O:C=>R;X%IE$[:NF^N
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M1D7:AJ""@K3"O=^-L.?/D_K:?/\+T ?.SWZX-/%$],S=4"2&+%\[BS22CDA
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M[(O4&&]'QS2Y0Y3:RG7C9)_/OI2-OB)E,!J\RJIT9%?](%K1?8V?$NK9GXS
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MV2MKTZA:C>>@L'$8WVD:03(7FI(793^).+%.W7_X/3,Z=FJI/FZ>8T4B^#Y
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M-GZ2O:-Y5!F^.AB^1Q#%^']JY2NC^N9E**M57=L6XM>5)N>]&=?V-N6FO:!
M@C_73LD_K4_TEOTYC =C5,X9QJ%;3U01,9F"UW,OG]<<L8M;?S6\??84FFL:
MVY+8LY?%LMF6N/5>1_$_ -V>*C3[<UK<XL8,NST%DZC\J6R\Z,/@7GI3#R%T
M[M$U%K9AWK$7<X^,-VH:6S,XGS=%F=NHY/LRWKB]57! N$K>_R?S:GFZ(CHO
M_U$OD2_YPY+NRSGEY'.Q:YH//19TUM[O!Y!5?B@;M75Q5WUDX,92=\>3)RZH
MEO^97R#KLW]^_O[NE1/AYQVY=E&QMZ[7XRCM,Z?0'3Z+72&Z]QL?LT.BMCY2
M7UM-12DM7UB&=E-+"%Q+WPZ9?D#Y9W#3 Q'>9RAKB*W("1..6UVQ$OF>^."/
M[&G*#=75 [YL_)8S56U3TD^IC&61%NU_0U:^3X<4&=G_6UAI_D<3@W 5*(LD
M^Y8\H;INT3=U4ROULI8H!:9\Y1R^9VJ0B\O9^^$(G8Y.S.!-LA"&/(%#7@FO
MM\HI3SDN_7'*+ XQRWV5C1MJ=,%T=Y I].$!>9#(GP7S2E,M?&0Q-+P_HRH<
MC6PQZ-!P]Q72O(2K-ND>*^7U.V2=>7SC6S?+_OT$G62#>!EM34[LE&AI+G7)
M?V]*<)1_M/F'N$>4<3%EXOL/$KL)RM,S_PZI8E>N)@SUT;TG2^X'/.'T!-F/
M>%.=C#G3F1RS9E^$=LJWS&<)YQ=KQI[!N;;*WF,TXNK/Y@6G9+ 3%L3B?L_&
MOOD!MP!%-C7OA<JX?TH%;I( 'KQ;']<A+E8DNH)7G-L\>G& ,VV4D^.DRY]#
M0VPM8T?B'1;>QRO1K>CGTIF_D2Z]6!!XSS]X-<B\A0?66P1J>'7PI\BR_L$R
M^.0PLUT5VUS"7Q,K&M,A$*GM$@J9WV4)?O3<03K<<9"J2MM^,&-]%=66GU4L
M_OUHB?K0EQN[C]?I:H;6A%X-XRK_I)&L$:R0L?[F6+9PW\)MEV(SA![7UKSL
MU;>NE)B;+U['*)*WT?Q0U<=2&6 J6PJ=3,M>NGJQTS)K<XBW/,VM&=KU?_Z:
M5^VOF)#^*<"_W<_'.7<(9G5,._9N1 1F.GY:LCAOLW'QFRH]MV!\9K'%]O8[
M+$.?I$2O^I7)>DCW2]?#,[<\[OJ_@R1TE>OGYA_T773_<>#PT9FK(2Z9(^D8
MM_Q5EF#*5&[[2R1(<L)8[M1BT#1BV-;7S9]C"[=?'A0H<,+5]+\@C3K>")6O
MT!U4UJF 5'04I3D'@9[2DET>/HLS%B_P'/1[LXYL\S,>C#+W(]S"'0S".CH?
M#&T&?5A/:%$:$P9I.D5L_1FRK9NG!KW6 JU88DZ9Y;;+^4@Z2_NIWNOTOD3^
MUC_2 >(DJBN?DP 4?4HQ_O-8KTSDU[Q7F3,I9+%0(7+/]^_Y@N8,[VEILQAQ
M_$G^C/_IJQA8U#5/RT4O6%H6U;9DL,>IA/+T]3%R!$B(?K(X7XC,H=>V_;AE
M^'&IK(XS/;VZ )/;),I';*@H=TYP]#/^D>?9MH.KD9M\P>GRD?HF7[L)/$35
MQF$M]J*\"DO&38-Z>]$''->WQQ/\<+DZZ#^I7^3->_301Y:3[4X5SDVMZVD(
ME^7 ,;O^B.AK%U8Q"D&/;2L](#65EK?PD470D'Z_XG!TTJJU$S(F_@H0VQ#<
M./4>H\?S.GOZPI;C7QG^?S=B1:-+&19ANTHB]1DW[??M[>SU;V3%Z%+Q30.I
MJ0H(F+5Q1;O)Q'KCT .!X:V7XG[?U7D=N?;"7YF[-)Q:GEB@BQWT%>MV;IUG
M]P1 MP+J^KU>_5,Z8?++H&[:FJJU/OC[:@!6;J+LW<+)2&+W$:OS'[1@>,\^
M"_09\H:7DP#[;I<;_@6+(S\J37FI1H,8/K^DAU3GDN=V9%64;Z2\M+CY[9.:
MS'EGO[*/)&!(ZA>QN8L8[$@QJ&'+']NZ@6;]HVXJBB%24NY$TL%4,1@J5[(>
MMP0K:\FS^KB[(U,CIF0[K*9LVCCW60-C /I]PRV,!.PYPX\]6JO\\#.HLBIR
M&"]V+O):?I+E$O^MSFD!O32I26W7W5R&)R6Y#+Q8![3B&C\O?KM/G0K/@.35
MZ#_."5\_$:E!501B*^K5E'="B/'ONI-0CU4,"J +XPD@6B2<.7!FF6=.;@9;
M'*+."6W2:>]H:FI.[LZH^/[V&'8-:=_LU:;#](:.WYE1+S9<.$R>!#SMHIO'
MV^)T\,^O3:?+2XJK6>\[\;0G+R[^<++S5DTR'[,.(D-T' >IVYZVD@#G#A_<
M0TQ.\.$HK7;]7%AA):V+SB1*C ]4K4N7_$1.A==[B%6&LTD\)ND"ZX'TFW;C
M0OQ&SS$HXI5!\]Y!K-&LRHC!NW>L2:(//NNHQ<*^G=R_T+"'6,"!,7T8^9G"
MT94(MTH;NR7..$E%M[$=V*2RSY:$"DZA,V<UK2\G@K\NK.+E&%6XO?+1&Z'L
M>^W'DB.I^P,_A-LCJ6_Y)_G3  =N"Z*X,T\A[!E>WA^E0JO7 &:UZOHF9RAN
MAM!R=Z^OD[TB4Q,G9^*-T*6-B8DZX ]>5H-'P:D(E]8X;>.H#T_9QAZE7GU-
MS9/44[E%)A3$&;&>G64(:W'(RT%DKAWU,YP]M^@N2ICZY!Z!&PD=8N#M)R0D
MEBQ5C4S;VU R7>#+G:L,[&Y-VNJJ6>DQ?[LN$DK'Z_G%;@#^.)<&C'E0]5N6
M(6H%1\-_K*Q\!*>'#W44GEEN.?@8J+I  H)#X</O8"8DH/H!"9B8F&O#>Q*U
MT=+$CK-0=/P< )V+[%2!+-.>5L)$,7/F#9-K&+?H ^[,+.X'QHEN],6NR*+7
MPQZAJA\X;+1&Z W]&V"#). <!2:%</;A$GC9\1([5J/7T&BEOU';_D9:U/G1
M+]KAF'KA85X<F?5L#FN[\@JU;I]G  >F":>!0[8MTD2[B8XNY1S!+8!5@@JV
MRAH+1UNA<L+]#+,S14-4Q?(L%R%<B>9<F\YI#*W<KYXNL-X1:",OK(M+F8*I
MC!-%?G8Q$N"^:_R7?BHWA52Y(N&T3K,FG5;];\AN7/ER8NHN&2P#SE,)NLP^
M^L?J)IUS(H&W%4L"(B5'NZ*(@EN>^(^GG-$<^>]0LXQZ'(]?/P.>VHK4_!V=
M/."GV-T5:Y'35Q7-SP&3]K5Q<K)=K3":NU^?>G' \K40'T3US7LO 0#8]-N(
MFT,-9*).P<BNB/)VLC)SQT#9[(FIN]->'(0AR0TBF]?\&J]?OFWE[&:@&(9]
M)PV3CXL_+8$[G?FV$9VL).!-U-X][,6W;$EPQR7$;SV<H]DSZ@<\"4I*5:YX
M+":M)X=2PP849<V(,4DYC48N2--M59W+00CGV.KSQ&W *K]Z? &)=O$\.#^'
MYH'IYQ+[NA@UFKS,*MM-(:LC>0&E3B6SV.%7DJ!TH=L?R;\)3B%:QX(O@4$G
M,GAR-1EH18,H)BR[L>YKYJ22X5M_SK3FB\&Z?OMN$2O[,5D&Q&$_^,\&R$P@
M'0D8KH2R$_L6^$^OW 7F\9<+H">W\#8?S B@N5=[3%"4D$W)EM\]/L/VT8XH
MM%7$3:O<A AJ2C3KTMQ05PU5[$X@)PGHODD01J'OJ3@AV$)+MDQI<GR3)*+3
M+_"M2U'-5@=>"OSL)XUVPLQIX].Q^VN/L5\K4.],S6K&OY9Y.A4YSM9^1^<%
M<_O$7[OBGO8BN7E#-(D,U\^*W=CYAIFZ@V<^ 1.T\?ZK8^B+LMTFRRQ37K0N
M3 %W45O+R[ZNHK^X;L@V+JZ)9F_,%F-[K(DS)*"!*CJ0U1 E::J-AZQ>5/@*
M8C1S;))V4JB#0RN$;NC+V/3=&&@1+["ORYX'CO>C\-%K5#M+^8']<(8&AK,9
MCFRM"S,Z&.:]LK7,GF;:TC(EWW;]LQ33XZQU"8'XE,27.MW@YU!/JP:L;OA!
MQ_/AZ&_."C56GP;;/02\-!)9R-9R>+L<>1UZ^!3&.[E@2N/E!%.L[I.&Y =1
M8P];KIL[->IY9[8U/3"[#$\Q]GUV@=)4&%F%8$#E]*Q$6+-BT@;1%#W>UZ&-
MFS^/%:/:V;U>OB(!C6LW$"#>H5^7UM<ER+4$.;:T^8-]<A9( .8!&*&,0I*E
MW9I452FTJ%&2H&O<>[GJ1[YQ$S<J2F A(@_BO]%:SZ&]BXKSG%M-BFUN<.X7
M&VP:FP72]V)S&<HE,O&1Y=!P38QW80#2D%R#&1\F_]"AT! JR>3PG/;772V:
MC]3/W"?N*_6[(49PT8Z%@DZO+M;CADH=*=9( !?!YO2C.JVC<E4<P6FU*BS[
M"D8]G=L:[&3-/"V=;%+?0"D[9-<,%G_$XQ]]CL*=DX/'= (#,\4L#?8\Q I+
MPU%OE15Q1XBO9&R=H/=F,8?4"VJ0[SF(/5R7\OTT5'R8VVH..U1YS$0&[[>'
M4HQ\I?^H%_?@'B7(BZ4FDLL]\H+F+;'GAE_.ZQU3].90MPM6!GXQ 5\\L-*7
MUS@'ACYQ3&W-*O_PT!TBW/16Q/11V&)%,Z/[* "%D8#ZO4$W!JC"PAI;%X8$
M]%03.+*7>6]9B7S%?2<8VMJ(&4D5TGTXCXCA_0!^1S'W7:1C$/<&CV3O'@N5
MP8<;-,8_P=(789V(W),43[<RWA L^_(%$@DNP=<C!@59?\U6K+HA5 9( $T^
MGJP,+ZLY!5-&O%(6)@']'(=#/PS**&GBGDWAJ(V0:QR_XSX9>([/+(D.\C%C
MX_L['J$&H[PR QA6-WJLB-R8[\M%HRSL&567K)9*;$Y&@R3;7Z2/^+[+9:@@
M")\VJDH7PGONXHR@;Q #7A1%?5A+WQ,=+%-=&^7%!)F^M0[(7 :,[;2@DRMP
M',?N V> 63F@Y.L'$0*Q=F$H0)_&FM/8[L'=]TS--U?G"O\M^^B<987"5Z*9
M4$M#&,K >X5VA,.6VZ]4,&17?,:=*(_9B&BHL+W3/-&0LS-B8.YCI=T2GM%"
ME<OA2L;A^J=W9\H\BQ#63RS'W"%TORP;-^V2KH]R'AKI:!T;?UPC6")7+CEW
M"H[O'F39.1T'E+^N1$=?_Z6S"@)L:F6NSU-4 -Y_-J(UR3&L;VT)1OF;/6\.
M2J:KU>%<$ZV<U-%%FD#BL:!PF.Y':-7MSLG#1-M"1+6B=^$[WWSO/[J_^;O5
MBW7^/T[0>BR_Y',?TQD-+W<^JG9J-7[#X.7EZR6@EQO)4M=6\P>CZ<PQ9BS&
MU' M/L+"X0U'<N[F>'_%5HWM]]9FF>NUH<W=CQT+TM,JOS>I45,-CWJ*F]^G
M*5)H'+?T\1?^Y<<]42A^R'KS4%:*X([JBGY=W)A! CXM,P3T+'.$IY1M7=JG
MK-40F>'P*.GJ[#8:Y7Y^PV@0"0K9D<[^#5,J7G2^GV<W767#KICT^KU;MM6D
MQK);^^ >_R,K*U9"6J8[G_U[8\\JXY*.#YD/P5*=E3LG%AQW'PLZ5O@?*DGJ
M(D5#&E3Z.^#T9A9;>N4U6R:7 I+V!=RSTBZY),HV!&XSM*J)X]+7X&PP$7>I
M/!_?-;?S8J='[[.?5Q05^Y@\)*9QQ=U-W"!+XGKTIN)8O#9;Z$NMW\=7XDU\
M-2[-76D@X^>LF+=E9?J0E=)MO_L5#E5.J1FIF3X7<3D^3'_4U!* _H@-$M_J
M#;X@$*SFO 1UZ_8?Q(#B&^#G.#DV6]_+0%KE)(]<GBA7H%O=>]Q2Q5+T167O
MG6<%^+Z#9WVM;0T4NA\-3."?5VT>5R6/XS.F"W7RBZ5>:[.8?GSV#_MMU@;<
M3I6V+4G+8E)7..),-*W47OI%U3P);$-6!)* 0:[[I?85#97QKKE/S%R?"BD)
M$?+#A@0\IW@>4/V_)7+_ZW;.7&Y$R6VMPU^/#R=\->TB5SHKZ $W)P6BPI2_
M]"PB,=5@E#LU63!GW'S0WP@A'_WUGH>0ZZ(TM/X^QM3FSQ$F_%V[^,K\4N*T
M3'6WD<R% WG>B@*VZ]<4,(-N-!LOW*\:\^+)R[:]FQ01VNB.E+'YW>^AD]Q!
MLM];."[BN3YCV*++\/#>&O-MO\09MY1O,=^_8:B1/HJ2<;[JS6A-7MX_.SS3
MJ $$;;JK8%.42J3[C[LE%)W*=H<:L6:5&KV=G-CSF6N&#D9=LX@C_5:JG5GM
M=Q&UG^+?8MHT)0:?K(__S>OY[T7SH.WER9M5W\34./3AUN[\5Q:ZC-2,SQR,
M.EJK(9H<ZG38SLRU#@7+)=FOE[3%0E/M$)^"&$I7@R5R/V9XI]@7:#ZMK@O^
M?+&_O0V:*K_H]QXX[[ST3T&BI[HD/J0 +[5]OVDZPT;X5TK\Y_B73QBI7?W^
MLJ0X8W1TMW9ZF:J]KJD5R@TS5+W[0^'P21P#1:+))O W+(L5CZQ89U*"[&V"
M+PQ="5)G.8M=W +'<VA5+YYPXBGN8$7[JBY X>:-+K?'IAJL_&81*$E$Z$CE
MYK+F2(J]3>*0P('\85P(5A0Y-H!6,9]055S3H,</L#<XNJ$/U"R6L?E1#X9_
M12PU!BL"H+QR-[S=7C#_@0Z1GP0@I6U)P$!9$4:C^\RU(]S(WH53045[LYDS
MT,920N,'[ZYEV!O=#;]Q)15(#O*S&Z<:6:G;&%13Q!G5AZSJ#L3>DKZPY'@.
MB1F,DE?8KQ_UO[?R+MWA*9/2,_K2*S< &SW1]_XN1^AHC/KG7X;UH*AEYFG7
M0^Z2\HJ*@PHCB=]V&?IL<E8)[.*TRH0^X+R^ +EN"32^ETLC^B#]H,)?OV;V
M8'BZO-$BMO;);0&!8$X>5D'*.-U;D"R,6[=&> Z]FU ;)B>H_08RNM2],X!;
MMZG>9\ ]-9;EO:O;E^-QJBB84:ATUVJN!@7K.[8:S&S7J[)%-L;!G*'L=O<'
MQ 4P)0R.VL#$]X%#7O8%BD.?F^_8F+NRG6NI;HW]D&Z>-0%*-;=_DGWA!;D>
MU4\Q@G3^$WS4'#A3OR;-JN$UVN50M_&V%YV4%G322%'\!I!"1?DZ.Z54D\\-
M UK]FH5YM)H=NLJK^KOF)TY$(CI)9DZ1GA8DZY>6F-7%8QH'[Y9V<V@[C2#R
MZWIP@!R/0^LDI";;W':O%SSU(*/ 5'W<%NWE8QHG,!<4I2"7V$'C<O4^B=?J
MVQXWOC:?KZN^0Z;U7"@Y3E]HG"KL++RXU;7^15T"/G\5OKFYO410(@%7<&DD
MP+H&ODG>[H#;Q/RH0.U]DT!9Q^<Y^;3.5OD41:!WY$Y\LGTS1V/0>N-LMD'W
M ;3U6*X.9M/BE8>$4*0+5^WU;LJK9]IX#3S?7?KMB?G2G3K$HL[X"/,^+X?-
MVQ-&O:I1?TBLHY,1L>_[[B@*7_."N%1[[\Q=Y-'JE'$;D*T/R+S<6LU)%7)L
M8]:%"87Z$YE6\'>[JE^-X?6)(SA^=%?-(&ZE;G=I_?>"SV__EH7W#N\?G,]*
M><\5\)ZM<>(:&T:G1IN)CE*; _ ')+[O?0LGWM_ 59Y%\XVA)*#H%_BQR?TT
MI!KSG9E#%]/[$_4G%Q^90M>GW2I<C)3VS-F=Y;[FRH6:!IF]IS\'P$(P;:C!
M-T0*XKQ&O<)K+&T?EUOP6(3K08>_;ON<VY7ZIHXFA2)%,:$8=O%-4UX/AKPJ
M@]-"=4&H)0J^XX!-,\'$1\CM,?U\"/5_U !!2R$=0D8-O!?SIE->V'E0\\S5
MX%>0\2&=(A8+"]#>'C_^*'3%RI<P7C?#,*S@BTLM=SY^XF&243,TB_X4R!G2
MXX9T;%<I&$2&-RG$?RB,N36<*U'?9[-0733.[GHC[H8FOP9TZE[;+'PUDSW5
MA&URV=H0T\TF 65L3U+$.6,^*HG.>T#*3M.) E W%/].(=(@YR+$VV+:A(^S
M<6I/??"Z=T-+W"AEPN>.AW,Q9<!+K4TM];EBI]D,]1R(C0WD8DILN<&YCH;Z
M9S?S8C5I(O+)'@, 1= Y!T=UNC-O/[3B\(*<%>V]28%I5[Y=G KMS57+TJQ;
M[;7G )44XW.90J$4J@^HAE=J18,8^L%X$:G0U9G,G;TJJ-OCJ22WWS_VQSRB
M!N>9+EJ<)L*=24!X)Q=>#%D%$&YAU9,Q:X/9U#7AO8C&<%3F9OWOA^C$9Z:W
M)<2'*J-B:)+GL%5EJBK(+/YNBXN-\<C3*R-W)M LT0$J]QH-H%<H4R\+:K)Z
MZ*N2#8MT:F%7!L<NXO>,F^KQH2?<,&VL>A?DI,3B5S>;17^YCF8QM?<D"TV@
M5=_+&V/B+\G@JPS]&C0$Z],V=;'M0/I9@;EZ1\+E0D1 YS0S79)P7W_C#> F
M=]!B"R>E0\A#,#3D[FD2"7BQQX<O'C :+L SH"K"<H34A;(8YLN]N*\N"[JH
M!CV3OL'O5_?ROJYMW"#.!N^R)M9Y%7^"&HR%R;NMZLRA7QP$,/0\-."I_7D<
MT+C/Y1V]SB"HCHX^4F;^>?"\HL!L&_'J.+#0WJUD_HG4<(4KROQ98@"G&:-N
M32Y#D@9$ \'> ^=09W/NHE9GQD?KX"/7]KA[3U,@#KDKPCL*"7K=#BTMJ;S;
M+.Z#S=_C/$R!N1EU&LSTV1OT#D&>>"^Y%<QKV7 >FN4_YO\PPT )NX8!]]XL
MCNXF,H[#Q'B[EV0<,^S8GMT>O';%>'C5ZX!U>IQJ*%L1>[%J9_C$T5E=#6N@
M6P13PD?G6?Q,4Q=(CP@!S;C07DCRC-%)NC5O*LK]FN=9#=P9'!G(>EHNC('_
M44*.:S9MK:YRVR2-*-0V43FY.V4XZ5)H7N1D'^]!Y5'RL67]O7LBV ["I9"#
MXI79,)QYX=*@IOR=SA-A?:NV7SS[X]"G,+X^$]-@(@\>A.QXDZK.A!F(14+$
MP%_\7=A!45\5W8QJ/@8';%(DG7[0< 33$+^ Z?D'LJ7BB%;"KLA:LU?-;.;9
M^O3G6=--@?//#.A9UD0!-+1W33&8R(<7Z>U?%L6>*WJ-'%FCZ88'WG.T,%[B
M4'VI-[Q1I%1! ICQH#O8RD21%!0O-VBNOH57R%_R_HS4T^<Z=#$/NXV,@YZZ
M=P-1+;Y%"&<%D(,7Y-QH9HE)4\9U;#4OF=&-N', M#BNZP4H* /\ID',K5,8
MJMMG,JF)54@L=&X\#AW]\5UP6._*<P?I(_<8NR"(!)'Z]VH.(YX"!\)8IZ L
M)6+%?_>/KBM;3:D8V+K(]R5U4^R1O7[L-20H>%/@DG4F$A2D0:=*5295BJP*
MYV/"X(K*JJU_6O!6E'=[<'.OQ2C(?'3/SO4S]=?DHSVQ(.C-RKG1.8$95)E?
M,J,TXHM=!/6O:D&NWLALPU'A!2+J'$[Z-=?GD@DP#'LH$7#FKT5W[%SZ1N#'
M/*_R="D=\VY#5VSXL\=]_K&:<(M(J)$:)"LX8CW<66:=<%75=T-QOO*GEC_Q
M]ZX/-_9_K/A0\POG!W/WYLL"3+FKB>^-.PP,ZV9?.-1VU0<??_;Z)MGPY9G>
M^J,S_U@@WE:37^PGWTU,6G_\0E.O\F"OFH,!ED<9%++W 6M2D_=$>+1N\-KX
M:1A5AHSQHO*];H^[,1A9L*4)0T@[%3(G/,,4YQ *4RG .Q@N@G?\U&),$G9%
MA79B-;_J;_!N^_V%1Q#.#KL]V<[I7XP 2_:EL7\Q$7I-X4>7I,>3=.XYO&=T
MNFLS&UI'Q->2@/6,'6FY,EX=B*]K.7K7OLD%TSXA46^X5? 7!^V/JN.AF:7P
M"56LPRG6G@0,R_W]__]2<IS-M9 $W/G5GW/4?S;E"DV0 %I%(Q+PP1<U=H(:
M(0%)D+^4'#=O33ME'F.#K["!"<FZA&M+!L3(C6B-O6AIHOZ_5QM_O@4^ *F:
MDP"8.7S?D!]3YR5]+)I]C01T7NOZ+?+OI=#_-:C_;PSJ^18_3^[$WN7Z:55!
ME 'W,!;G[VLT7=_W'FAN%JSB2;3.-):JS^3>SO2/SE3QCX[V;.6TCS1'J7_4
M&_J_V'OON"B7+&&X)8HD0:*$1@%!HB"9)DL2 0')200D)TD--%ER1@&%"T@&
M"2TYYPR2HV2ZR;$;"4UJ7IS9V;WW[NPW._?N]^Z==^:/^N,\OZ=.G:HZ=4)5
MG3H;(I[/<8'_B1++7W>)?WY$DI;EE[1D_;I'4^ZR ,?T7XU0S"_[8SA/=J/M
MU^/SZPZYNSS'Q?L74?_(1'TTOGA3/0HU*6M&Q(1Q[)<(1'CIFE8N"NA;SD8$
MB"![R7/^,_M_J1VUA7(5[]ES[*[75@L'6[W2 @^=<_S8^?M_2TA.O0?+'1B:
M=AF3'.E'*,V+P_8-)6V/B+D'JG5V.. OVAZSXEI![$$]W9%+WLS&XEO#LLNJ
MT>(/QVA/33N^R,!HE/?1E?!P=M$<255ZG?"1%-K7*_394VMH!K4";<:4O&-S
MBDMNAX&LB7ZFK##MK8^ULF3:![7'/W99<!EANUK[[6A1E,5G7?VY127Z>C[2
M:5V.UUXU9F,.-Z(@7<\?P815&4.5/8=^.290T>'B.YT2M W"EJ4<(ZA7D][V
M'F\>.X!&&G.^=!=V,R.'3("-7I>^FH[8=]^7L=G;P-[8C!Y?$D=^74ECGLV)
M_N_-3+,<*.L?8Z;Y4UV170OM:A'*=8BDT-U*Q:I3 75YF[6G5$OD':N>@>/1
M"9L)6G:\@[!CFEX[AO@]P!.-AI>]5&+25;P2MP#PYG\$S?(OHOXP1('Z?*.U
MCNN2K9RO+7['K5'3_E++74@W;@9PD\:+/K?BU_SD1FJEI6%-8JQH87\RPM6S
MI\?,F_D]EH8:\]W89/'P'U-I_(NH?Q'U=Q"U/N5+P55QKFMO?X$-*_2R?-%0
M+J*[*TL;[_1&!;=2-A=BCIZO%A31#@0I%\S@L')QPBMN*FR)V_AYG6EG]-Y5
MHI';HJ,B-S>)E=JZF5]DR^G2;U957A4\.B^^\TB.A'(#E^Q&UQ^QWW_(R?@7
M4;^9J*3617*7*P"U3;4>2,\^)\^:HK3AG2PDCC#%X)ZZNMPZY^'2=\-*S4"E
M\LKZM"T:A7MUZ?2V(UV?#TQSUS!9D)_P7_SLJ.@/=:U465N;6IW*+#+:@\YJ
M'/!",((C\1T3Z4T+LY?Q)+'%T42B2^,3JIJIG+8+5@9,:@%[W5\ \=9F.R5\
M)3LO(:*C$*G,C;)VF+(B/WO7AS(18;L"?__X&Z  W[M;96*R;^C)D6ZI<'8\
M^\-O=+!HF3L>H2^" ?3ITNS6I:YZGEGFBOQ9_&_$9*GI,\OR<W8A(3L- P8Q
M:G+R^46?68^;I/Y!P*^J=)9-#R;V#RV&^<&'&PP?*D>%&3U7G8;IYG!.57 E
MDDSBMM@CD(+1?% \@VFI_'XF!_"JZ7207RLUR_ ;=I^"">^W!5QK)?+Y68SC
M6IKDXE,]/OU?)WJ.R,P\P_LR8VQ6Z/_IP4YD;@CLFEE'6$;XWX[M[*X.S#U3
M^$[)<(SK#HBD=2UI9AS7IH1QTUH948SSG;.?,NE"4VR];G^A]4\4"U8H/LO3
M/";-KD^NI<^,C%'3??'BW/C>.?=C;<9QM>NY80L7@\9Z_;\":M^#S=_I2$X/
MK1 M!FHKT0DL/%O0+R=9(VQ) XB6W: 2ZK33PFF$1W&W)S>EYBXT!*Q=!G20
M"-Z()Z,0"U;FUVR,366JMK"*VV+M.2)/D.6V69$P7[->\0SG%9,U5Y.O/"#^
M?Q%\A<IZ@GR0!2LFW7\Z,=JO6/W2@?-C**_?-Y I85PWDVFQZRE]9DVQ0[>(
M<<A1H^C3!@^*K0M_BO&^R*J1FN->6-VM/,WBX02FL_]A'M/&1;HOKRR(#1?G
MCMIGC5VH9@\<SS\X,#A]99BC]U!RI?U^?#0NX[V0K^'RJK*FNAH=&@EW2QO,
MBL:V/JKEPL8SC^1#4!9=MVU.*#U=!QKJY$.+'G$?VGS%VPW;:"_OZJ K*]'T
M6T)(;K#G(ZO;58DADOH6DQQ*1GJT,UL498V-\Z5,=U8'J(D^+9D[!W=1D70Z
M5DO@@NQR9SZX $.1S]Q)R\!YTDHGFDRIM57)8T)8 !450"\+$QHS&>P>%J4-
MJK)^[LVT,S4XZ1LH'I]H2J/W>:IGM,2]8X$W1+:Y;,361*0[O)+<-,\R5NB.
M"IG?*,\5(-$QPWR1'5(8*_SJLXLMF@@\IE9-8G,%((&'[A,,+=OA<5"_O^WV
M>DV_ 3.2])&CRJV?2.91+,O5(6CZ5L<Z_K#HM8U ]WR#OA-*=UN<&\D>^*+P
M+RP 1P"MIKD1'8Q94Y4W^;GQ:Z[=4Z-)I7V?E"#;+H%*9NB':XL"2$RSC YR
M/M[N'&^0^:SBX*I_A,7Q[C89T\O+Z2S)_,"1-V^^=IS\25M!%RT/GN?=?9%E
MV:G+/,*XMJK<6RM8^._*K-@;&B?^NP4@>?=V$Q!)?A+-%_6T6X^BCK/.W]FT
M-N3#&^<#_^ >AC?@+EF[*8D"U/K348B2:88!* "-P*1ZT1<9CZ-:BU.@Z6#&
MHLCY;>8OC*[Q#ZMA_X;^-52217*@)<:.\ V-A" 29%X694RKT40^!B_7&>/!
MW>M3UR, VP<YY>B",V?;#_H9QKG(>/W>YF])LHPO35YJ?)Z28E,\^O?)*SAN
MDCDV>OT7?4SF9<SP3P^:1]DOK)W(-U:7UE(DQ;=M$EQ"JAEO-&/JBF.,'$7A
MML?IV=3%CA]ANYD*N4$>@@B_WI#0V(Z>>)!7()-M-24XQ:&UL""0*)W%8DDM
M1*[4AF8M1?K$UP6G#;[DZGD249D0\EQ^Q;JQL'*'VPQJD_KZG\\4(N\!.[<O
MW!^[L"JV%HFNJ$X6Z[D_VO,8R+Z&!<DV<8N,?EPOS%^I@Z9!3B84H]+51SB-
M9+Q?%9D3?-"H#*@BAI!B&U@+B^J$::AIUTY=V_>EL7^)V%H1_'G$L!;W%0!^
MMHZN$_S.;]0<S&/<7;!U!7A\J -A/;+#1$LF2AQU^B:0_2P7,G37H/JR*P3%
M>,KX_6RQ(ZD0E!O."H7=.7P\Y?*S.WH3=C]S/2Z'@M#8$K*GP%15F(DL><>%
M&:IY.=WO"D!4Z4"#:MK2%\-5)CD]D,)7OF?%I#.B21FO5!<C]5,\X$&=@KCA
M90/(E+M=8@;_V +I5EM@9"5!M%-9N&UGM(4W(T1J17H'-XTLJO^\VOX-1G9:
MPR4N4AO>W2Z!#WDX>2%5 NZ6$0>^4WU_&K<HSSV3$.L7A_7*[/4@1HGB$/FJ
M<07QKOZYZ,(%)2+["G"'R4Z_9?%V,7/MV,L4I60'X7L\%$QL>V$C.<_H;XH1
MDR/%PYRN %BK(Z[3E?<ALOD<ZGCJ7<><TDJ0P-A;2Q2TWI-,]&]))(&6OJV<
M?/-*SR[#0#>3(WEGP\R;TKX]4,_K]>K]J(-YP1G?<D)P<RG\K*_&(<"7]((9
MZ;7L%@B#8C1= ? 6Y)GT?#CUIMEDV%M>R$FR83YI(7#!I-5VEL36;'Z.L'M)
MK=B*F[$T\3FKL AJ<K]EFW:%A.9+CU9K*V,S_QV4KB,J[F.N%84(9VV@:D5P
M'VGG5T<Y$D4QA"A"@JW:8,B/ R*3MTG:#5.JV><F^-K3(S7S@984L/\.-:5L
MX.!<:GOMD=X+^COODI+M'T;0J2UY]0MQI<V?M(W)474M9(F)$/=H]JV";+)0
M,1J-HT#I<?C8<K#ZU-..J.VXZ&[W&S5"VZ>N+@L]"3777!G^/Q;RO[!Q+/+^
M^+NA;JLS9[E#T&HD3U3-JN+FL(]TB?9#V"6PPS.Q.$LY<\O*U HKI03^2LHI
M;A9+\(?3<%%7Y_#J^>\BIL ]6]=X;G;.X%LKZ'B@CIHI\K&<]XNT!/M:8[)-
M>L9F)$Z$4[:UVHS5L +A'(<"ER#!L6A9+950Z^7=N:32B=\[$&R&5A3:U6XG
MVA2.RL[VBL&ZC 3(]&/%%<VZ59!B-CC^I&.&?S"I0-XFIZ5EOJ4CD&%^B.JT
MK.&-''MA;D= .&OVWYNX[$_E<_FFEK;@EP5E*ZQJ1XS[J7#L8?IZ_?P+,>N)
M-\F3$3#V9NI-[2J13/V-+_F4 F]C#5;6(TW*;M*F\2B3#I9<M_K\MP8DJQC>
M[[*3NUZ 0O1GS*Q)G%2\K(>$4[47 P8E&FJC('G!Z"*'XDJ^",EHD+*E8C^]
M<]<CYVYA^.F1RS=6ULQPV?^Q>]Z)3&F"T4]T&1TUXX)E,%NQZ"<(H]-M<F9R
M*E,;M*HV3UX%8>0?+;WP[&R<F'SG01@)FSE6T#7Y&"PMC&LE(1/^%2&>6K1I
M! Q?-&S4/T?L/ M7,E%<(I5DV4:YY0VG;#F,_-X58I^4HZNW12D8.R-%/K<=
M9A'-3\R2"Q]'\VVM@YBSP/%#79X#:UF?F2=C1-++9DK>I#]B[Q)J6W'T&+1Y
MZDN2H/IVSS(S?$?X+_'5Q/=^?LV[].=O^5SPA*/%5+5/TS/;E^4+?Z8WLGZV
M>^5KO=J\QR?1"NP%ID^BF1IU5_G49'UOIV>DU>?Y]HA/H6NY#\A?%UHM'A!7
M7M=6N@C2A>Y!N!$/S[A[+K9\[]SJ1W('N\106VK7<37FZMF(B.WX: X$7;#S
MW>$VX'W$$.GG<5C\E#T[<-UW1AXNWTK\S:&=GK@<B0XRI7_'FCCT9,R.#UQ"
ML2"4*+9-IG-Z&_.VJ)SXQB$4ZPH0$H/N 1YR^J[F4:*T%B_(GL*X0X!4$A8Q
M$<G'20\*ER1N;9TD)B_T.TM\D^WK*.W3P+HMP+..2I!<#;K6J55#NQKGPN#T
M8Q/DZ[#E>>-V-/O4T;F:58[5#/\7KZ :KF+:(HQ BC;,BVFF$@ 3S$_L"G!L
M<UF.QH.X-XO?0;E^9@[.LKDS1!$BYE]J2@\SS#3 LE=\11;_.%YD:H3_- <I
MVDJ*NM/=_"7AW$KKS*%S-B6"G<[J4Q"IU:XZC7GC'5Z_HI&B,H)WZ:G':\U*
MEH#/GMG(F6\-HS71K =[ZYGY6/'6JYKC)&;5,WW4.DN%! $\:A)!2<1AM.O!
M$.U<5%V74C&7,XBGY]6KGA][<R'3@7I'\@K#AY<8WXH/MQ6*,BRXU)E;.!QY
M?>^=:F[!W9I"7C56WOH>,X,+*VK&;:*ROKL:U2!X=G'0GFN9#%G9J1^W9R+1
M?^(H-6/H;TMR4$@;?NAY.M81#XQ8K*+W7[X"L PB3MHY1<]]CGI%];7JM<)'
MA)8^+'U?66^(D,9Q]2W'[?+6@'/[<><@Q1(2$^!1F)IUPQ<R>5;G';<-V^_1
M9)&:MXF0N?:"!'B=DK>;'H./C8/2;UY8P*DXQIZG2([L'?%5Q/5Q#! H,TBW
MD-Z8C3R?>KM%6MTR-%O6!1>7#VKBMI*;>5Y:U3%9)&?Z2FHF5\F-O:>?]PC6
M^/BXX0KP3@O5> 5XE99W!<@NTZC*+HZA1P"CKP V^Z'HVXB3R,,4XH XE*]!
M:?5$,0=7SL0DTBY7-H'1'? IR12@@.WN'*F=?4%QF7GD0 V1G$#37$@A7-(P
M4"&Y,[Z6.9^-F.<3\RS6R"@IR@DH +MS19]*EM-DL!'[W[ZC;ST\%T-1+@';
M8XBVC23.'U1F@QU4OC16WN7*8$D :8UDA]7:]551*_0PT7?5.P2)1&>=*Z#'
M1%2[E+DEQUTD0NZR!.>.\46I:H?L?+>)G^LI&>W$$TW$TER>)NST-[B60'MA
MJC:/)\7%T"-WY5MF[4A[K)*:V)!)H27BW1E@?<7NF2,\.4':-,:H&]@K]F3:
MJ?(EZ&E*=ZL":%#3[>E-)EP1[,&"_*;,+,L^FO>J+$ZVL=*Q-S!_>EWN0_OA
MPNH*@$V*JO<MD&&< W.W>ZJ\R_X8]HW6_:D]BXL!G&/:<!Y\OZFD8#JG  [$
MN )8KJ)RH#9I!->+&@K!1;)(1C&/-XCZ;+,U<+;-S0PV<R HX(ZMN '"6.=B
MD/ISY9F\8%\KAV_=G3-@'AM*O?FIX#T]GH'.]\=[7V.V2(8?'3(EG\307.@@
MY-L?E!M3@?O;T60VPVOC-LG9%'*.'Q;+!USGJ]^LTPD2'&5/F>3-A<"&(OGW
M,5#T)UJ([K?<$->20GGRW#!S)[IZ9<::YT:Z1(Q1SHFVM "51WA <3 4EK>K
M@6B6'X?8P%0Q(")3%_?RNNSW#H$$6X+-LP+'V\%Q'?'YP>JA5+&?*'8W?-XA
MC#LD;ETHC+T>!S'#[("=(A#>% _[0WT4]'[T<TPRBZ@/..T/6]<)B#T/%F=B
M8%_3:! -:1B(XB]3/@]0;:,VA)3R$6L'$^-9"P; 4PN'VZ\Z9P,D,?DX=TW$
MH,[C34 P7 GU<<D.LS.9*>9!7+&NC*_U:.[4P8IDRZ.==B'&\;O(&#J;*T E
M42F,4Q&$N>P07$<49.'$)/ =U?V\L;9VG$2%XH62IF8H+<_,RD^\AZU0==1#
MQ QWX+5!"F)<RK=7AFWHV0IPOI$#K<O>2*?SMXT5?5WJ X(X2V#R*7%*@O&[
M?$0%E=E.Q8E&F^8F9RG=-M'F!\/K-+4;8%A04Z"7]4OTH''%@PRDLQHR*0BD
MNSR.B.F0P%F0MRFR>C2/_X&:61UA(//@!NMV#Y:9T[;1! @Y*\,TIE J>S?)
M@W994Y[IW;1V'["4.\R%.,*'%Y6!U#XW^HJ:[7#7JII)"LI<J*:GJZJ2"\:W
MFI25YXTO,3P.XKA5<(_7,WWFUM9WN&#,88R_Y[,AHG?>=I?%<*\:,U:D%4TX
M<_*75;.Z6#*QFU%,C/D9Q;9,A[6#8/;CEBDTH\\8/3FB)&IY6T&< A70K9:N
M/+5/CI[ZS/_I1IZ_NU_BZJQUHK3!PY>2]YN*H(D7OKDSEHO5$BU*^#3@78YB
M"'>)%'8#&SECE/KMSY]<  # ,;2 U9M#:%'_VKA6_[G!<R,09DRS*7ZGIC10
M_2,L'AG>08)/] A/:$.8O/'%$>'==LUXW,:R@,W=68@RGTFX(&WDX88$6ZVJ
M$I[!C[=EA!RB%LELT000-B0PD@MF\RYW)K&J(M)\KT3G;0 6W;<5,TE<"7X/
M[IUTI$3W"?T#9%X[,*(N^RXTYI#$YG.KMX,%W6?#S1.>AS2DC\A.-?!><?JI
M]J<Y:XGS/+T"D#=;&0=? 0A?Z:P/7X@4PQUN9P&6/H1%J :%-*SFM%X!TABC
MCX+.]1Y#&%"UB!BX=XU+Z5@E,4H6\M1T&M,J*<_VC;"]6Z>0'/RGZESKT=$N
MNR,QA^-DY%HQHOG8!WD2P4=M&J([<ABVS\F4S'.?([P6JV IQKH=97RN?L&#
M% P",1.N=QKC&*+2GY=5*!93&I53DL[WWL61(JVY]_5ME)^K$&:ES+D]+;IG
MD4)A\PIP\VA(]<0:&+!8'M-FZ4,/)M:+6?8-O*-CR-:&=,5&7'ZJN1.JUI&I
MRNUVN2BPLPY:YV/75ZM?E)FS2&/784JV(J4R5=]GBB37E.QE2@-@-KYI(D,U
M+TG0;VF+. 1#['Z$T@HT;^_RI6KA%[S:$G>)ZC4*R=^Q68^)+I5!GA_7()):
M"8ULXI:B6-K+P/T&8QGON^F+8,MVN[NY;&]&V.EV4FD8ATVS40/G-!"!6I1K
M@1&8I4V/VP]DE:77ZYV!"FE/Y)F>FYF7"\IZ#0[X2)9P(W#E=G<C.U>&^_"9
MB ?\/S+6"K=]CE9D^5*"XS##N*S<5,>G>"TJ1#C-OE;!5;Q]A@VH=?Q*3WU>
M[W;$8L!9[C?0= /)]GSXKP"MO-<&%8WQS:ZL0O #F-(0LUM&S0O+-3918AXJ
M_VEM-83\L3:*'WJ!@R";B6F#XBP8&J/<NFQ2:EW839TXXO6S1#^Z.<SIA@TZ
M#U H.38>B\=I:4OVR3RDQGIS$\J"TES^QA<3?@4@VP?"BA;XS^UV*](1X0W(
M&D3/09-.%>YKU4>0EMM^?D1X_4#.RP^P&M3#<TF(-(K$+G_(>VE ]%D%DB5H
MMV3%(W>L.-<MVL:89SHQRNS6<WI)T]X!G<N/S2L[5P#K]/-;&[YGDI:5)92-
M,5D-RK !XE:]9W704-=4":E1V!5 UZM@GKGBX9$[ W''I&\ ^@%* J;<,$5/
MBC0*@7VXYTQ;ME'W7C \$L#$$_4!,U@C<$O,9M4X< $+,;3KA2R'-7< 0T5>
MB+.--C##V&-P4,Y2$[&JIJ\3^VE4)6*_R7D8OD]\"0:X49UYM5P!<"YP$7WH
MX^^M:()AR$,G[[NR;V:X4LD_?'Q>^KR-_[FC;FV71T9V<(J%J2S9B_=_3Q3A
M2U1@UXQV,/?AN>AIFO"^L:W4CQ.L=QN\DL5;>;Z9T];O] <\S+&_5NTV428^
MZA+83AA2"3PH?#]?]V?A\-?= :@(RA]IU2!6Q!T"$LX!DH)S1LP2B85D;/*Z
M6A(2]VQ)_4N#GFC'U07-4$^EDX1FO<UAFUC)(J_WO)]%R=)/[N;)2;Y\QY*>
M%7E'B24,Y/RYAUDYM[T=-5K\:N6G+#GE+D=)YCS&52SLW@$ZB67EW"BGXU31
M#K1@5>ULA:(3G%#E5)[A"O"Y+DVG%UY@K+;0+%((HU!5L2?1B-_++$;U2K0<
M4ACK%F[$9%A"B<J02=%-=$^@!<^N "1\5._QS)7 2Y.O,/<5JQ[%SKDQJ]VW
M)QI>"8(:(1;#^(8H-Q*3NV(\Z- I+BFP-)"?G )#8$#1388"0,!-AMNRWKFZ
M*4OEGCY3N!H?.2<'//.@&TZ:.2)<8UI\&YGAQ\\"_MI+4E]<AVBLC.@F7'9%
MCE\K%:[ADV928+( WDV3.NE///TN^V6\Q*[$ONA3;=KT7K"B*<%(&M&+M%3<
M567]_-0S2LO?\?S7C_+(-?WNIAY.9=ZF]CN0NWO'33]I[7<59L>]\-/)(_7Z
M$5ON?<Z]/=NEM+6Y->KL2(K(*T"99WB]\O332^G?ZL\7T2EUS6B]@RG1$<&T
M]<];"*SSG_XX0K"-E770%(VZV[:'QM\L^I1X<",T#]SJ<D:?57"Q6>AZIUEZ
ME4Q-X;=&;N,0KD=5% +OS%J2?H6KU1CV9."I30'2-0+U)U0,[[9Y/[UV\UFO
MW?Q9NGXY@E#A)4&U<?3K$@VW#6:?C/_)1\[TU<=?CKJ<I\SF?G-PH%%BO!%/
M1I#&EA1TH68"VV5V)11+_<3Q/(S2AIWH4TQ?Q5JP:&@:M9IYN"S;!OR>_];-
MPWR778$IQ4I]?7;+8KLQYA^>/\N[EKR<L,G59-;,.*G?$=A^0Y?^+G+P70DX
M27W$SMRMJ8QP+5B:;/=E<> BEK_>X0"+?&G%>(G#R_( FOJ@CO+LEZ*7JAIZ
M&M4"N9K<_1GELF3:)CU_L%LG4O!KLU2B:S_$& --LJ77W-'S:KP"?]A6+O2X
M]\U,2MF[%0[5@RKI>'<326HF[1;Z6Y=YXD07;,BW1H_&FTV5C5M\Z,/!"U.=
MNWG4SV@^L,;*,SVD]?6*X9)6!3B'GT!1K!VE*$J8[\X14K7#TW:FNST&;WL*
MOT2*5L[$]OO-IJ$WO0$WY:)"65 !^:O;M:CR'Z\X7:86-]VQ28I'P161+RB3
M(:6Y068$4X)!P_XDH9&Y.TL?!?SGP@%GN.TB26]].#:,:)&Y"?3I4)VA6PN;
M(EF2)<A"Z$+4!WNY5@;_ &&<NKK3$#1>Z9*=^_+)CL.2F& 'Q8'NPF#UW;=N
M92N@YZJ@^(Z;8GC:A-&SC3:;6P"VZ"\/;/"PZ]D&I0Z^=;T0('J\^Y/F5D'!
MU\3C8HY(QBCQUZ^7 #=Z_VVKMQN,L]B1> 8JA%EEI1U^[7I,/_>VI<O-3V0=
M49)<UB &\W[<J>7@FF.(7T/RU;955\$6,_(1;@9YH8&#MTK-;L9'6 S))IH(
ML5 (M9["L\K9="M;F!]<N4&KEN'^2O63^K5_X]=<9G[2M8@CT3EO X-V7 $P
MKSV)V_;F2.RNE&5BDN*@SZWLU=_(\M\FFE<?R"F*!_H;.VY[TJ?"#._O/YTX
M/#?45FJ(;'<V]\88P-H LVZT%#[<N]FI4U$1T#9*HZ]C6E45A.4D<^NMPH@<
M1C[MM:5\0UF4\T;A'H3NVI_M2(X)\*'8$A='7 $Z]\-]'B&U ZA!BMG3X.H.
MX(Q6FET]'NVI-+-=%P\#M@Z]XQL\\KUF6HA''D3M,@CD#KMDCK":6?3G=E@>
MPM92$K3+FR.5HO\TU:R*Y?ZHEV"DJ%0AAUZ06DNC%<N=/,QB"4A@A29VP)M!
M.2M6(<JEF$N'ETO#.)YQIR(_8.S,S*:P1]+^=)25?!Z1.$OO>_YHLRIY:"<!
MD=MVMB!:3P/%WG14=> -5F2T86UGQQR_K7"_(6^)^;)[IQGYV<%/I'.^LSNP
M,C1W @TT7OA*VWWKISDK\YBO R3,8\*B>+T;[%O%+(JEPR[U8H^?E56/5<RR
MJB],#HXRAU/=E[T5&OH)6Q, ^/02 /B<//3V4)5D8=,]N20J;\O=\WH-6W])
M.YY@CA^U-?T:]N$.#3RJ/U#V!-\6TH\<<&W^-G0<7(E:-<TQWE[ G'3)/^2F
MGK&*\YBBP&#A=,B_V3*WX?^1%K/M>V":F,#8<1>*TCLK-P_8N8A37)[W@=3.
M^F9>=P-'FZ1W^/I,8WB3_66&A%D4>Y=G= B\.62&..C0.,R'KA$]7)W\_5F4
M7:73ZJF=';@GX^-3/_+!I[=Y6OG8Q5ISJX1],6VT@57$N\3+Z:%Z/A\+="'W
M$01W^C.L[T:5SUP!'*R=/\DXD=ECGI)TJ$R^Y.V.@6%N7!NJ%RP(^8[)<@<J
ML& [FMV& 3:^G6Q F0M 7?OP<K/UUNMT;I&')>Q+ZYV+=\'-^DGM:?PHI6(4
MKD9E^>.JC.,4KX'[K[5?/"1#-NU^I>(MD#HH7*?Q.#JCN:M'?P\9T8$FNHSR
MN8$J[$!3(!)#/K4Z5.X>-G*-THG/;)UI*;SB];#^S/O4WGE$HP3;XPK0 KQ[
M08K2M\H'!W9(T()P80YA1O=F!9IA#R^43.ODMCB7Z1WV=N$;^4)PEK1T)12T
MM0XWAD_7Q?>.I:=#J$N8KI$2H=:H:*$[FY2Z:2PYT^V;/4OAR[[+">)X5X 1
M>@0Q^@Z%\85UZD0E>>JA*/06N%\2N19!4;J<ZJR,)(ICYY7WS3'L=K5?523
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MQG=9V\".=&_S; Y$W^PN!&_#Z L<'J02%GGR3U3<?5'&SI+JP3&2*1?V_4[
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M[TSY0FOFV3/"%=6)KITTGD%M_YY.5]=VW[8]A SH%?"VWOR3CN"T^88>V!7
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M)M^^%R##9+7>OY;?.AM778(+=%&3?;"'I_.WXO2IZO8C7=()%W5FK"G%GYU
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M/^R"_1/.9&!."/\9Z(:T8O7?O=/U=S+JF^PGV=NL_>-9M?G_30!02P,$%
M  @ \X!97$FN_EM 50$ 9+4! !0   !A<G%T+3(P,C4Q,C,Q7V<R+FIP9^RZ
M>3Q4;]@_?JPCV]AW1B%%R):L0[(E2840TR9;MA!E&$N1/80/%94D629[66;L
MBF3+7F:A9)\AXS#;=WJ>W_)ZGN_W]=O^_7W.S/EGYC[GNJ_KOJ[W]7[?YS"G
MF7A Z(RUG37 QL8&7&5] .8<8 EPL+/__;(.3M:7BX>+BY.3BQ<"X>;AY^7G
MY^/EXQ,0%!$2$!06Y.,3DA 2%A43%Q?GATI*28A)B8B)B_V]"1L'ZQI.K@-<
M7 ?$!/@$Q/Y?'\P.0)B'795SDX/M$, NS,8AS,;L 6  P,;%]A\'\+\=;.RL
M.7)#> [P\K$&- H![&P<'.R<'']GS?HWAO4_P"G,)7)0VX);U.D:Y%"HF$Y\
M]DL>I5.UG>(71DG*NM?O)!S@E9"4DI91.:QZY*B:GOX)@Y.&1I:GK:QM;.W.
M7+SD[.)ZV<W]QDWO6SZ^?OYAX1%W(Z/NW4]\\# I^5%*:D[ND[S\@G\*BUZ5
MOBY[4_ZVXEU=?4-C4_.'CRU=W3V]??V?/@^,C7^;F)R:GIDE$!<6?_Y:^KV\
M0M[:_K-#V07W]O_ZQ09PL/WOQ__2+V&67^R<G!R<D+]^L;%'_AT@S,EU4)M;
MQ,()<BU4])!./(_8J>R7M9T'E'0OD,2OWQGEE5#6(ZB0_[KV'Y[]/W,LX?^3
M9_^'8_^G7[, /P<;:_$XA $X0(>,F6A'5'OHD>QX#WT\I7Q=, 1Z-<9_EZ9H
ME$RC-#$!S%,FD%)= C"!3PK!^QNX?=XI>\30=W4"&OIKYK"D?&KZWHKUQI@?
M8F27;/CPOG,9S^PG/(K ]@V^U-A,_X.C.<!(<2NP[=DYQGXPXW#KBOH*EB@2
MTK_ER 0X? PHQ4HMU$P(0TC>DA'M@<(Y,(&>42; (_B2"9A68S??, %B .95
M%OC@F38MEPET3*/\B,;H#_^7)HXP@4=VW;#/<)I \K\&_C7PKX%_#?QKX%\#
M_QKXU\"_!OXU\*^!?PW\:^#_YP8FK=&O'5Y]KQ*M,ZZ#<.O8]MEN0,KN5X>8
MF3&!QSWPG4[4G\/HKU'4.)US\I]5,COZSO@[N0^L#,<(TB1.--[_GCL]0X+2
MXG\Q@9IU)O"B.KQQ* K",-]&3=UE B,N+>[T[CCLXC\=3" ^]C:9C-T4W3G4
MTI+4-QGPM+"TN?DA?\Z0.M?I\SIN*7B VTZ?U!4[@9.%!VA)K,PBUN9>^>ZK
MQNM5)@:$DOEZ0S]F_K+XYM&;.+W(GAG:T%S0*KX*(SDQ 5%<E U%%2Q#E7^Z
M_B%G8+[G_4DSSZ'O$EM9O2JAX%0@]2 (.PO>HVHCM4<;WHI(29K7?WSR*G#;
MIT@EWX]GQT]^#NM.'7]$,MY,AC>K)@3..8^;:42I$X^1$I9.383;5KG<1K';
MB3GE.%(O*.*1$\O8NLCU^&"JQ?> >5&R9CP\WDPMRKLIP$NJ];JM-,?7!\\D
MTG-TC&I^_DQ4-QAM)$6NRY:K=C,!\&C6VC:Q'4:7H?:>B"PZ\3:;5ADFYCM0
M1MY])*J%V/L)V[4"8A:L[I1(F$0P 5XLP2>]S9L"6X>#-N$>/Q!K7L%YE*SZ
MCJV]:$K3CSGM5K^^L,2Q]R@?K?0;E'A0E8!XI&1K!*7\;!VF/PN*'5T,S%OH
M+ZPUB/FRY+MJKI!KY3RA95WXQG->;)NK3>NH>6BK?VXZ0WP17J>U+@?W+TD\
M$6NFH, $'MQ8EXR42':D!L]2]AR:(PM_]C_;Z9LW_<TQ>P3]G&',F'9'=: R
M2P3;V-[]?HQY2GRKJ1G49AE:P>?;\.$E9WV=U*<(-COE%OS]J6=74)WF;=[$
M3>-+H#/5**J?"$M4NGN99J7,!&8^1[T[=[,IY>7=/%NY<-67 -D<YC/J9B8R
M&82T(3A(NK2/;>@9#U*/!)6/:Y*7W%K[JD8P\)0#:C&=U?X 6$^$K/N078F;
M?<$B2'7Z,Z1QJ9<#H="J!KN $&F-21BX_?A&AFB.<UZN\96<K <=/TZ7<&,#
M6T."K])?( _>"]?I/ON1]%UXMK;_NTYU[>,C.WU1-:Z, RE$!^..6&5P@I3;
M$\G>3[1"IVOIVVEL0@M,=^J5_973#339,DJ4X,<&?@@&;,X"():@NEZXL,E%
MNS7&@,:.%HO6DII3&G/K+<@GTM?"VYT_=Y5_.3>IRLL#O_=$Y[!U[ @ZGPG@
M7\#K'5.9@!\L>5ZPF22[? *C2=I]1)BXVCY1'N5RTN6HY;LZ);E"DZ0^R/?5
M?C,L>8$(2XN5 H56O?C F BREAOU4@@3N.Z&TRC="VP-;YV!/>S :QF_9<,*
MQ,*C;(C]F6TQ!!CTBJ=#%7AH0UWCFFJS[ZC*XP$Q)1A&E_-9EL6J5Q8B&UO7
MO XE!W3B&J#KTE5@-"5VP@11M3H[4;7?E\+=]-CLH5K[S.7G7P1^Y>O8ZK O
M#)B$]2]KK5')6GT(<:1D9"6X0&C$=:U[J>\V9MFT?9,@_WQ@(WN,,*G7<6RC
M-90)'/L\K,>VW.#Z!2Z,"AH61*K27^L')Q6KC1''].2UNLM[)+W4BIC 0[GK
MPK</#>J*B(<LU@NQYP1D-M';8@^#*>N-"#[&H-G)21/9.ZN+_E,&]@$1QV[&
M*7L@CJ9<?&R!2P][=AXR\\?5F PA0I,QXJ#Q);)KZLYE/4^.LVE#+>T?5/WY
MXP .E7]J><78[10!.W1V.*L2CV1EF"DK%V5U(69:^\Q,2!UW;1M;YQK'#W[H
M5/RG7NQEDLVM3QMLQ#BS[Z\P5T 8];XO0@2CU$]:Z)L7F&*(("V?FPQZRO;4
MKF>2PGIT'K>F= OGG9_>LU=0G\7H@;@>K"!#WM]]]P%2G(5<7DV^IQ5@C6T>
M;IH<MN\6;9UK&R\W_S"<FWL+E!*@6?/"Y/[>82G:B;$:S==D^(.%),]SAAH#
MIQ.<71QJHH*DPM$VZ$^;"24--KW5')0A\ <Q0YT2,Z&_*18@0;&O "]H!"H5
MV!Z0NR;]:XLG-PH@5:;OHD=1,SA6#F"._79OW,QDB,_3U-H;/EX.7$-'J+0;
M..5]?GP\XT1<5!]T,L[4/W4;EXE0,)%F%2CO4N^\P03W\S>GNXZ\RH@<CM#F
MK#I?[AJ6^!O@S &4D:.0=3+Y1H]$915X@^)(;JHF^$E^265L@.X_[&&[.7.?
M[LQ(*07(+27.QYG-O&J#4&[1&TR$J6>_^Q>=* E^"WKTM5BC&I#JZ![%]@<<
M2=[2>]\,(*5'E>[46,?LQ_&J+\)2X20G3U4;,#>:M$MPC-/'97AICD^7T=SY
M[MV]6R7(V]AA9WBQ6[Z5;>&N!?MF'!,(YGM$0Y2" 0O0+I0(4J)]TH=ZXGF%
M?XUF0\4O^!W1N\+LK??%.S9LQ-AV,L0));7]ZT;P ,0#QX5X0CW!L^C);.A[
M:N0<?.+="2:@.YB%+AP/EEKQQZZ54"]FS;H/]TM,,:05!,D&B3L?]0+MK1DC
MU*"NC^R.N@-92>&%H<T,-X5[>([YWZ_:8'@FL'XZ5ILQ A=C*/@52VTU(-A,
M7)H5E!DC\YI!T^O''YG4U@<HXTNTL1/ALA^ W=0EAB*X= ;TQL=$]A8MYEB5
M_FZZ@_-LTRZ4LY+)#WQGJ,I1%BY.1M'$[!=4>^!\- /R5.(?1.(4XS IMHQP
M;V@WX^#$A2.LC#Y^)B<H<>#ZO/N[VKTIX]8(1=@EFBZ85HIT)TFD+,"@=GHM
MFK5!FM4*45^"SN>PJ=U7,')U1+ JKZY\W8F,[<35H^/"':&Q@_O]:7\\-+0/
M-DQ=)8N8%[P]T).@>[O7XL_G941IB]7WW7V'O(F)TLM7AMCM-$J;%OCRN!X7
M+XI8Q[QE_R&^[=K/!.8JNQ!<M !H7(,IU TL(!_VYC?1)CPR6;[*Z8U< AY\
MZISE.,XI BB6&&*80$)2U":!*'"16+XVNJ#%"9X]+AIPUR"M0N6]JFP90NUX
MHG)$T)W0W$Z &I3ZBR&/M"(M]99P^\6JDXHKN1M?K#@="*S!FPB/5'(,U#VV
M5 <N)?!PNMJ9BT4,!?5WNVN^K%PI<)KQ*XII*XATU7FFK'TH/S+XZHO</^BD
M-BWJJ=@Q5)-)00NVT]2@&R=@)FT30J'$'B&?M292:*7B=U./&=U0DCH:=\>D
MRX)C&3&[W36+S4#=@J;*'$X4:Y9I_Q5_-Y]"8K_Y_,'-O3.0"WAQ#LS*-@Y4
MA?1L\H%,@'*.=*+DA6<G_25AE7-<W]/P\H'J(*''7Y:_'3A^$_+RQY1B'%OW
M#YH._0,-)OQ-;S@]EI?\IS:AWV[BS\DJE[/ASE'7+MBQ>L2WT,E6](P!9:!D
M(3E%GPDDQYJ0VHH!\".A!_?V]QUMWQHE3@X]SNWF8\E!'LDN+B%WS(K1^8Q#
MC"\,M4EL,#0)*V-BMN]9$__:3]2O!9\?:?_T^><[%8^Z\I#W/G^^MFOSEW;8
M6=V#K".HYDR@^SA2>-+L(.HJ$^BRIS_7;T#,X&Y350M_?:E=^K*UV&?@L_%L
M02X"?9:$:3*Q)U2KN@K1G_E+//[QR#YHIITC\"MWZ#,?,;9RJQ"X D8-F@"#
MF'@L=+]!!:*N3K=O4J(^;)G0A$[L/?4(]FIU'*M&2H"99L>1RJ3DC+X2.HO7
M'N N"*Z(2?ZZC1G^I1CXE%*SYB,]J_O["$?#*TPP_14\",9+XR-GE,2'MW.X
M@QEDA2WM8UZ2I"\*X>2CG@.WKCTOE(L3?\JI?9Y'=0B-#1Y.5>!KCO'H1]5A
M,TQ,";X6.0N7QM%3YZ.CDE46'UE*F4.4Z^,WS6&WIYXAPT$Z 38SU6WDU;Z@
MGE89"+\P<6AT/:.L]>Q0Z"';WSSRW-,E)<'WL:3@!9L'9F91@L.]C ,3N2ZC
M06ZEQ\1>/Q[X\$/L[3T;:6E(+>=-(<<E29HX9 '1@Q+Y;12<I%^2*).<U*9=
M&K4AK8<5=ZA4'@T0$(NTXU4^I7ACVZG((C_P98B%*0!W]D4_,9./G4#)(3T6
MJJ'64UCO=I^N(OV=68O(ZB'BR5_V1SYWG[FX-OA!ZTJ0^(Y$8_7EJ# ;S$2C
MQR>]=9T^R,>6UH\AV98B1WTB;W2<9U,N.0.T6B$OX$A.=!NB1"4*V@F+9VB
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M?V\)E=V>";S4 .[MTD03*3T?Z6\9$C\N@^_(+%)$6#I0<3SE(/6FH%W23R?
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MD4L+?GT;Y@ U,W5O&.^XKD(V($;V2))VTS%  !,0"/_5D+\A'[3MY-%Z=WJ
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M?]4^CM9H5.=[^$.^MZKRV(6C&])VG#'JPXUST >XAL;B=H+G!2T!FGG:J=8
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M.YF;Z^J#%_F-,R5OZ_1!O]9M=9O$BO]A C2C!0HK_*]81#2/?I&E77TY!IC
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M%-GL\99=68"+D+]+L)K8W23?2=O!HS_/34I#RFZ/FG-%U1123X <K,SKSY)
MWL5@6H)%_2?] D,CJGY844S-5"Z=[7YR4<)%[X)]L<[)[V'KSGN->&C2A;];
MUK&&-&NR5D_U#:?@A[$'IE1&&N \EW^8" TKWQ/0*PNQ%)_NR?JG8%9*#3 W
M&W]*J02/!NIEVY,3.[3M9<7#4:(SW!=.*B9J<6/LZ>D1PU /5.<IK.\/U0ZC
MIL)WH*QS;?UDZ5.;#YG$,?N<@WXR!NE/3N:L$,X9*9SL4_]MCYCFH$0U-&=*
M,41_\S\ZD:AFIP2KU!6)?3TU#*LKB$<:D*88O,'DS>Y8D;'U< 1T&@SJ#*PZ
MEG3H48.+EB*':F5][H8#X,X*V 03^%P5Y<'H-T;0#V+031A9I,FHF5@4U)*4
ME7RL]/UH0]JEQN94?;['I06W(VX9WKKQ^9;R5@ 1 6H@6*OV$+L6UOAWU5:H
MC#@S%N8F--),QFAV5)65XF-%/R0]21D[SW^5(+''1O:FM#T^O>M^)JR68^0M
MMN.$N$0[3.::2C,3!PVNM =.M12G>4<;RB_F<-ZE7YZ*0W4Z,8'%'L9A)O"=
MA=[G\O/62UBI3'N,2F("K+:"W;>7!Y!^5"#*?8JXRV*O%K3;4P0'&]<FLEB+
M0L8Q<LYMPH6!NZ(=P2J!"Y\6CUP;_80>\;MN1XPJL\HQN%"5J2.E\"*3B!%E
MS=G=J_KYU#H?X6/3F[(W4905CT?-R &YAAM*<@*3F\.U?]"MOSFV RB*(*(<
M*<,:G\48\1(9T^A]D^=3EK*N\>3:M:1[@34B^K ?SD^.4-BQ=@%X],RJ:_,D
M2[97PAN\>^LA&7KJQM<MAH?%[FJ?I$E+N<XW *[_\W/(@(U4$/$_[6P ,:-6
M8N<A@PC21?@CHZQN]/14OZ21<_<LPA_E,R;A^Y6WWV2@GB6;&R7_P9+4=AQG
MT@B:621[O$VBR='2F7[?_-G;(IXM1P1"P\F5#KK9S^H-52M8N,'FQ<(-KMNU
M19L4#3)_K>9BX[<_>V7P'Q>-WJ VRYW J0D4=,<^)K@C5O9;H)Q=0.2;N2NG
M\ G2"BK>AIR)G?("P!U80W-7H.1"<,>F5-3%*_6I*[+59GX:S[])-'V\/-VM
M([KKY@$Q*X0D6-V3I(E"^XN2L[ WX)R#%4,J0_/Y4T:.SP]^]B44/K!D<$AG
MP/'Z?X*S=HQC)#N*E;YI+@J[N_LU&XC:]@!O:W6UE<D=D&HD"YDYL^N+YBA:
M(S?S>%7Z*M[:"\-[7ETO9 *8O&2"N8(S"S!_I9!U&;P[I"5[,M>S^TF%P81_
M=CC\=)(RW10E<ZSE%'B3G:]#(4%0;JQM !XNQ00&;M!8D;A^J61?<PM#>P&-
MP_K"!69I.JRE?D;C),?&BUSV @?F-\]-2L">>.Z%_K/[27OP=HYVR?[UXD+T
M*WA0,&R>IDW/B56-2G3X>"*2[&<]QI<7DR'ZW3:?\(1RU?N3V0>TX'_;[5R&
MDR[0#P<&4&#@RV"(9CXE4I4#?LQU<JN98904I\G"&--885_< =3-34! 9U:E
MG2Q8$(Q>,3CS(3JEYKJ;]0+NNH[BGP->#ZD.2/TQ,PW61*=8L&S5VMPR%J0@
MUR=/>*YT*^D2#&?#V[V<N0-9>UG=2]2:22:<>"F6_?D7Z'I61"I)S+:IMBH5
M<OOD-=#5CRQZ,<L*1!$#3WEBG-\41H10<=<)UV\9!OW=%MB*I(FH,\X.V[&2
M]J\*3A>O)*)!M:P.1VZP]/*(OL9%=T^;,VU%?3]OC-WT%NGY"8-\&"@.4/^?
MB1'U3)R9!A-(;F%\93$UB2DLR5$5G)HRXR/?*EG8A/AZJ8XIV.E5^W<)G!GZ
M>2IS9$CFL[2W2<5LM^*?ZJ(C' 04J(J@%63-4AD# OV,/*^I'^(D+$T4S;#O
M7X]A M[<"TS@#)I52@"--JJOP4?4HHD[]K>49T3P\?P93C82J'X3+UAA9"5G
M<$%9<^QM6$+'8(C%BDYR0BDLD ETC9%\Z *S4 8_JRT0*[<7;.E/S>1HK Z3
M\(2&(NWV;$(S8JZ--]!='1+7FUVPZA:W:_#=RMZUOPX]6^1XYCJ"_>];4(?!
MYQ51D:R[T<2&\4NI;<)OE[=A"I?G?1F'DNV+#47PKV@YMD)TXEE5Y>U%*)(N
M0(U&?7Z&9-'6]\K8?9$)K60F0')$Q<'XD#ZOP?HN!AOCR]2?"LRH3R2]_JW#
M3S.>KY\UI3T2HA136__KI2,0&*M>/H&>KY!&]&P3^9@W<]8M)2D' STNM$US
MYG[:Z!0K;G5B?RMO5%P5L#)+TII699Q=(!C0XP\Q@9&B=DH<W!!UO83C]RR.
M)@:G/"-K[#R+-*I)KO@L47(L5?;3]M(3V]7B=!?%CW*$?R+U][65_?0"Y5+E
MI<2]KSVV6.%!QZ.N.>Z9P697&=W'60S<:B)FSQSVE#6[\LX2P2@/RBK]I49U
MH$4=Z>&J//=0_:(?+NB.M_;AD.HZ*>)WPR,?OJK_N3=ZT]KF_$ WE^TGI3&,
M+#T3^[>( AS_RN8GC;OZ %*8RN][%\<'#]2:11$V4H3J2=]<3[@_KTZW$9HM
M^$Z]<>6:M2I?_(AUZ3->ZCQ&FEZ(^JD":V "]'O+)?MJ:M2BN).P60Z&+;PG
MBRK1J$57R6ES9!P(966M*FF0043MA[>BP\"?WF9EI(M$KN=5#J9#_<F-/*]2
MC%H;&^+-=Y5325J@RJWR0!15,(J;1\5-I>[IA>8/Y^]E6KZ]8BM&7<N&TGC.
M0U[$CB+D8E5H*A,- 0@VFLBW6'4/+_,M3\\9_^6;&G+'>1](W?QNJ[R4F4<P
M*J")61*#$TT0^'98/ZK^5BF^%2X6<&)?O^EE--$[ GHL]?5#":SV^;G:[&<1
MXKO.R*,L(%?_F+E--%C#ONR8OUL9L3#G1V@\YUEJ=]4E^(6.EAGC&]NN9ZPO
M"U9$,9*_LVFZ9&R/36-FL+!C5=-#^<$7&EQMYRVT+YFZ1I\SN('.+\[;]T0
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MP2.<EH<"U O6%Q=R+Z7>GSK*\O%&B;ZW65)8M\RD#?9TNO?IJ\A]';O)9,K
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MVG\1GI&[JY!K4C'].153 1%"+L2]5^/?A$R1Y$9+DZ-N"TEI47YVI,[3Q4Z
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MK.@!QO:[T48UQ#%%8#SFY\<GGN\#LDUT'X_*^&]?W-R:?/5IS'/)37NP@%_
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M/K!Z*F#GJV_4*C&+QSXUOMX%-A.]I&+7J";!A3,YG:! 4,><4A@\^4!G/-A
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MUEB(\SBV-:H "QE!0Q)J!> N-08=);T[53W?D].3P=%4@9NS)^,K, ":NU8
M2R9ER)9\+*!9-=!C@6.'HTM_LI!3I2A \37!#25-J(6D6[[C5J*W>U1];D6D
M6HM@:VZKM@8B#8X)M2XJ4X,] #1@EQT1'DL-529O>Q7<%A(+17_,OR0H5.H2
MGUA@] 3AM;,:(VZ7#"KGA;:GI=1R3 +CM6IBK_N?Q^0G-'A\Q*?:#3U2<;6U
M5\X*E@\XA6U"L_MEHU"8=7"*Z%P?]7[950[4%##A:D'/_,<'HZWW@'<MM-55
MZQXK9K&WIU^#, [IA29K,X#.3_>.F;V;K<Y:JYBZ>R8 I1P;^.83=$1^,RY
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MKXK!%'MDR0_:7\;WJ/GF[]>LV$WN?1M/69=__,J ?$ELN+@[H=]/UZS[E"I
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M*GIZTFY1YWP1#,_JCA7[#<$AK3:%!ONK;-5U)F\X:@>\:EOKN$E'XT&CKQX
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M[36_@;HN?XQ*1LN@[U(T%P"824M,\VW.O>W/IP,L\HSM)%:^2*3\%'NDZKO
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MEC)ZW'UN"#!. TMAG\.6(/?7!MB9IX^J&H3NCT)*:PIH)5]BGC%ZEOHOHPH
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MV>F1G2O])NN$W/;W?['Q\>(92MJ0EEH&.K=!%! &9QG7 Z!$.4\IW2>]E[!
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MS'ATDQDG-A'SUH,2JR;K0>5\/-#$</MO\GE14O+#A&=+%"8V*2EC.B^1"K=
MXW!)=BE,GPA(\8"^B9W;JTR;IS'Z\G$.8:)![9%R4J@%@4Y:,)'PJ?[-,RV=
M?7W*31,M"T\RNL;R I,OD7*'2T<)1I&!6KS1'.=96OJ(YFL @EN''.),'GR@
MDR\T?BR7SWNX121[DN,5YW -&$B$&& D&HJP?%UIV HVYO5%J[71<G4[DC&
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M8)YN4-\LHL33-5+< _1O&-+-5$#@&O#C@#UX:8A4M.U%:=K0.^Y\/1>.>^!
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M?9A4E-;%?J:EC!%,06:+!GS;;33K^/HV*ICT0RX!1:%WJNB!A= ! _K("%N
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M[&'Z?%Q&B9$#J]^6E$\]J8 R =^6CAI!5NVF.?%5+DP1!6?#(E2;IT_8Y!1
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M0)IS?N%2NMN[_.MF5+V< '1\;S9A?5?TT,\#;[G1_0-+C3^NC,OJZTC>GEV
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MX.SYDIA>U7197LOD$5=[35)RUOR;1,F_HHD45KOMU#C^' ?%N;]ID34!H&M
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MFB$5=&9:D--:)D_[E- ILS=1ZKWSO"AQ=D;\L27!1*M/5(J@X+O98T4.JHA
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M!+9J&V(T7>6=Z1.R8LJ>J*$HM%0TDRPUN+N]J,+A#&ULVT=(!*DCB*45O2Z
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M%MJ.I/MUS5*@PIW# ;!'2.'8^06^]";7Z-KFKG#L1_>\M6L 1U$+%;J_YQI
MVT)7B*TVQD:C H3-IM^:8+DF7.4SV/0^$44^![SKT&D<&!B1/5:.:DC.C(?G
MMOG58S,1T.PS,XQ/L:_762#?>%[S9(6PT]>>/J@ZYWN&O@DEW7[8&L=C(!6,
M'Q-6B2X%8^2S:5M>RYL(?4X[P_3Z9G#!OF%ZT*L77]^*T6KP9/G1)2Y4'ON
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M=8+]B:X1*ZT2N[7PP#/>#Q7(Y<!ZWJ,8*]E.)3[L=]XM*QB7=E5>O&R?Z&L
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M(-[GPYKH+8.I0"$<-48UNQ0;=^B?R:3=/*G:F+L88=4:=\= [9CN7DI*!T\
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M#I> !J*/H2Y%G3(HQ<]??%)4%O:R8]<>'ESI)>4)Z"NIFP#AAJR7TUF"8*E
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MM+^(\.U\X"D,=QW5GIF?^GUO;RKO\YIF<E*OV(-7UTK7;W9#SG\."YIY,[Q
M,8@'MELC B .#">?)?*&)NH&U^O!#C>]:1R#V AU,.A%1MZ/,WRV"\=,;67(
MSYUOW6\0&B'2;CJP9-;F7%FRD$]6ZL<@?%,E/7V[9X7H!=ADHS7)J3<R ?3.
MH-! XY9##Y0=Y:8^5HQ^,E?0)<%CN #4.(&ZZ52(QPNH0O!OV$#YNP@TA<Y]
MX(!0+T;>W]TAH<4GL QT?3]LA*]UX!NPN-J_\#2LH7?SV#5-T95^C<C("Y+>
M',DN]DM+$\XH%ZB%O7-(08C_A$F>1_>WF20[T(7NM1Q:7:JRHXA4AJ"F[![?
M^RJ]DYI[F'>O"]( U9GB2E5@R:ATP.MP,7B?0#T=1@.[H$V>I4]O#MBPQY Q
ML83;4WY]HM0TJ'',N_KQ2\_=Q)L;LA<  ?1A2&$HS 5,"KP6P=JRQK!C/S""
MB2\7ZH^S1"CWY^@R$2'VA72G93NQLF#1WWX>'\XMW++9ZG.$)M*-.23+0VMD
MR6(9+Z%U=T6$,S)HC2N=T,*[V*DM!\LF O*.>H')<T)=)8^_F4A++*Y4S)^,
M-W6VTIK>'_9XN\V/;-R^/_?$,>V7("UB"5@&&:R$1H^QFSFJ+,L&,(XV?#C:
M2U^&9="::6^R*5RE=R';!&;4CC5]O:]IWX40E]1S]JA<2._MXRU7L#3W:.U.
M(NV,/@\JD(Y8B47$Z0UW6*J ES:*'4;T[8M^QY"#+J?WYU,+;S0EG.NZPBOY
M2; 4FDX(=%7H< #-%"BX))064P:<(Z5W8A18BLT)Y,8XED>1YU&MU@I/O]IW
M.R)/YFOGJ9RK4C;)R#V7:ZMYY0[B H)4BA"PU.$,$FD.#BE$7K2@ER+*DX)+
MN%U8\+1H6A@];/%@K_S4!QX+\N-P:6!]WW$EW$(S0Y%NPY)N@J6:8&OT6?)B
MC,LC:.ESW_ BM[B \/*XZP&]_OI%EB9C=EMS6Y 3Q:U(P20^*O Q=3Y,W&2;
M4Y_B$?PPEMJH3;4-86J#JTS&SIP3<#D](Z4]*#G)^JNU'M,S77W:DY.>C\)/
M)-%W79+SLKIB)HC/AQ,\&)_9SS"D8HP<RH,6RTB'#. /CG=Q@3J79J:E'Q>
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MIL-]LRE1$:?.!(^\>;"'^# MA)+^#I,,IP7ULF3S&6=:0&?F>=9A>FF,Y?X
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M\%B4,:7@'&<P<A^R]8F+:Y9%[GIIH\+-!Y]5(FJ/,/M,T#? ;N9>S@B>9C\
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M%/.BK0J\2:LEKW78\Z ,:7,=+K?M\TA-'C;K)VSHQQ?U-#!U77F0M80M,[@
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M@.*S&'#@[8SKH):;K3Y6?O&<-/$79<8DCTZZQX.M;T[>KFMF*WQ#'2UH)'-
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MJB4_[P6%D*)(1HU!ZN=;SSY"JV6BWB<O_B$$&%V/6A7WDM[]PN."H]?_Q0?
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M&%.TCCY"&\2UK)*P=!LJ+J7>PE/$0N)35)"2@?T9W$VCZW?ZBBWF]AWR CT
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M)XG= ^5GCLFKM(@ N(OG[P0]?YUQ,';NFF)[;39D<"8;^D%[&<,X.VE9]N<
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M^_L3T\6"1<:H3C/D]IUE]PDQ>-NU#Y'O@GS@PG8]L'>YR%4?$CDX\KR N*7
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M#K/N6)]*LH?(]XS+X_8,&' ,;</VT)NZ\;;7_(>CE@:%Y5]]MPE:3L3JS7)
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MUFL.:#J7H&C@9&^01 "/N_UL%*![=[ /=50\WDXMD8ME7HGUI/+1<P!7A@6
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M+98$!_1B0RBU/F2: TJL%2,HT]J3 BM*]J)9@[\I>KU>THRO,:H=9O$H/"V
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M@U87+V4:9\-2LV_OQ.(NU"'F#KRYROK$ 5W?ZMA'*X!)L5D5B\P9\3O:3-$
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M;CD50[9T001YRAE[3)?ZE.X%BL?PY_OQFY%!.CIB]\+@VV))P+L?*J+7B^F
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M.?<'/KZ7L529"WT%R;KB]4OCE*JZ9K5+RIQ%:,NE:P\N JZ(H?RH^7]*>>D
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M)EG1,8UHU:G<*YZ4\H)/5(*B:"^O/K/OS, GOXM>_SWQR=\NYJ,*>@$H19+
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MJR5>JZFY KFB?Y4%WP%2)BV23RE@_-CLI]J*STE8W'0XQO2.Z4NAI<7=E^\
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M-@@<AU(E<+S]2%H&$SA?SJ[=054..^>NSJK=$KK?72&1_U;\"2_D2NQ+XM-
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M8=WI" U@@(Z-) )&DP3.#<.,<7"\_5@ZX&@2^O,5,B=SH]>,8BO3N9R(+V6
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M!VS&Q) _Z[9-?I!WE?D6Z$>)2C%0^54<\36"KF.@K+2GQI'*7:1V&DS0F&C
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M*DJ].#2N.?QF  F>U=<_0T(V]-7 1@=&-S*"HR NEW@O?NQK,\<?,-[>-\(
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M>E=HUCD5@=*[98*LN53#L]=\@=Y+1QGX57J/CID$P'7TI?!.VT/(KQ8M)1D
M!OL3V]7W:CX]"GJ&&M!L8-L>8%"X1*B[]D3W&FPY R7( #V@L]8$89ZJ@0DX
MEN\AX?B]H*YG:J/C+\] WT[07[/>M9EF)LP@T#2[]*JR+)XS\RE)[C.))TWV
M4O%OWZXTH>%6C,^)]Z]-J$Y]7\4YRY40EGL@6\_C\/K6!O7[[V-^K.?^[KKT
MOP0$)A6(_%%J@84A4795!Y]#SBY Q:/WBNE1X?96?4A=&L8?+'?:7^2HGHKP
M+V=H,[)P=RF$$NPDMS V^9.UIO')F5@M:7$?R7,?=@Z(YN NSL(Y?>AG.W64
M>DIZ#KX< "[Q[J(F2D5*--8&:VK3:V9H\3CETJ?AV1;0_KA)V2VCW.U+35PD
M5GPH=( ^FF-')X&VUN_-Z*+?;ZAW\=7;F\RBGNQAHS89(((L8!)PGN=Z0"9O
M"F=+B[6Z#H45B[O1!_B29GJL4Y'JLT_M8"86/ZE_CB&$&:!2+\?.D"N6$7BZ
MQ'U!J.M1R&S&I;:9^?PK/;1QKD6VYE-*P]RU90_&8@9BNY<M<TC6?O6$89BG
M:&G)%IQHI)V3V"R)'0=G_?\.I,ZU%)<L-\C$9Z25A8@T<7$V5;: F$$2Q3(5
M43BK$T/U+<*P424&"G_]%"*>%;_[+2E+#$Y&PVX AHHD_DC@>/SQRYZ(V S3
M; /?X9+)&&T.6Z5"^>H@>[)1?\_/M_:.$FM#.74I_=)#]"A'$L<, Q2IQG+"
MIEMB;(<3F69<)[VQ"+"NKM\^_II@% ,3D36S)=G-6KGNJ],0,.5%[]V/PE+6
M][;+TPF;']2EKR7Y]PKJ-J2],61:RA:77,_ZQ4V,;U==T/95D,!^G&I^*])I
M)L)J!N@W.O*DF? D7R)09J!]T,(']2,A>6#:M7"E";\OI0,O>WOGRJ"[%_%"
M%I8DUR0QC3N*D#82"HC:WHDQ5.LVDKL18MW( )WZSCZ4$TOKE>UY)VC(+G"3
M3[(__Z!+IY2VU",]%_2K4HNRH$3_$S[!=:5_IP+,?]SN8_\3X /GHA\# F8.
MR/C=LG$[A0H(Y@[9O#H+1*VH!UO::B&:-/#U$GQ.OCU5-EQEVL&=^ECM+%+R
MLOB G6!?1(?#1?-4&SGOY!5<F672K! $C0PDVIH:<0#D3_K-2GD\TI[G6BKJ
M*7A:2IAZZ7 UF,ME4G+ S/);S>&-DZ'Q4:G0I_ZLW_M7&PZA9^PN&TC<?I>X
M,*FQ)1Z>O<-:!)W-^&F'(BPFAAY9,9K!1:7W3[C2G!\G?"Y=/HUNP:T?_;UD
M8Y2>0!4$0@J<DKL*.V+;NGKHH?VQV][P'@'*E"82!YL<](;XG66 R,,,$.1R
ML"+?1Z02T$'8A&C7&K;UFG)LC7ZDPOY/.(+%CKT/CI&#2G\B_'F1AOS<OK<D
M>5+.SE$\8P6=U7'WDO*YKZF(]]T!]!K[WQU9W_M&_*=,-O>PM>K?/L&F:'"?
M+NV.Z+2WM@4%!V/N=K\M'<F.R#TWE)=[N.!'IMZ?_;OMN4O/YW+Y'O4H?D1>
M![H)F'VYHZ5Q7W0@,J]D=\$4#RK,L&5B%4U2ZI0]3M48-(J \BX/Y,# CPZ)
M.RV_VHX)Z849IC82-Z<O)!#J[)P[##/2LE^/6]V7S!QDV>VMIS:.$!!37._1
MB23?'N7]R7XSO]P<2R363DV8QL%;,I8+SSWR4&YQVK[U\^U9VX.V\D'-YHHD
M& E6B8-D15TJ0$C/P#I7@1T&2,B^.3'MZ-)ICCII!NCFMSWTK-=(?E!=1!.$
ML'G(%7^32'[U3$+4<2<07*IDBOI8=D5Z#2&-%T:'KQI!5/3YT,74FP;PH+S,
M">W=.;26P':EIX7.T;NO'+Q)MY*-\VJ?^NF/-&ZA'O_VZQIS_SF3_YL I8 A
M^LIV8KB0I@Q06#K5B9:%<\,DM$@0>\.@$*1PY2#] ,+PDZO8 %*KS$#D:>*
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M.:?8A9F_-QD5%)1ENW']^$ 3 6LNZ1B')-AA)R^^?WM9]0BGMJB;WT)*?,Y
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M^PJ5H#5"Q0!]J[YJ==_?0E33V1CDX??=4Y'#/SCFVL:YQ\Z^=YP/H,L\_IW
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MFX B#B25E)OD&((XU&)7PCEST?=8."<0]&H<M>GW$0F)16:9G2G=VG.UX$3
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M$(0A.](D^CE$F-S1_J29W='**/$*WL[0N%XS[[ZF7W#Z\DW[.[-V,ENC7[G
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M\.TH4[;"JEA-TYHGQ))X6-Y:($/JIR"T1JCAQ==,Y1^$+E<0MA-]>*Z.1?0
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M_/M-'X^]#+>7'!C7=RZRRHH:SRE.V2PYBTY<1C4=+A"(I;D>4M:W2P:"00=
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M\^0Y=8IU_:TF*A"LFS&W^]9<1S^*F'X&W O1QK7S/*G,E%#1 9IB&26S'9;
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MD>#'#U73&)8@UP=7SRI, IF9A;B\N7H/+MNV+O"J5>7^V@K<(I57Z;[A@;'
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MY$Z^ JKU#LNL>NE15/3,\#FRFIE+14D=X;@K8'E*"E?W8E\./^]EV"/"[=V
M/?;<]^;PO:MJSHI6WH7K788LPX1[-(<LPERVK0Y@%H4<LC3&8<*3).'AT,#D
MM;V^/>ZU5&:WX8EA&'B@^#TZ?_N3^=K^G]T$?><NX.8;^*?R H_.Q7?O".YS
M_G^(+WAT2N9S!X^S8'ZPU_7MH[>,U7^JJ]73NW(3=-,\W!L98N)-?4\92-)
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M2&+JL]H=04!5BK?AC=BA2C2OMT8):GA*VI.Q)>;PLNFD(*YNC@X)S'L-=%+
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MNJY[ <[E3YN?4,T^$ZZ.NN9C?-XSL]DGY.#P;7X.;-/,'A[R!D6P1K0OU'T
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MV.&]HX9XKM'WCU!Z&Z#]TR*?Q-0?>,7N _VC*#E=WQ?Y_W FQV^3]*HMP:8
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MKXCZ,(BY_ WG/,ZT,KR/#3[U=4Y+#7PT0*O>EW_8SL9*969>.X%LNK_N2V:
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M'-837JDR#W\998F<*8QA%/BIPNC!D,1!!%5CNSA)9#R#C$JAWD"&R3=R+5U
M=X2!'.AA ?B.6_!;G0IN"'OQ%E.NMZM[YQ-IYF!=HNCW!%N @_8FNZ^E)QU0
MXKT?A/T14_-.P/=M)/A+X?*/F"+7D/UC6+$^("^YY.8C;_Z\+FX>Z\+AXOZS
M^O?G').Z(U]]^$:2*("4Q1Y,,@5Y2FD$Y8P1&B>>2$E@>%JN1WGB-6=+%:P4
M6;#JZ!J?HVLJ4OM0W;UZC$_8:]+@MXZ)OZD=\TYA-2/@\UF%V9RWFPGO[O!=
MD^[<)_%FZCAR+&\X@)TW^=A"/]WA7TU/>743T/ZLQ7M1<7[Y7 /$75!:2C=6
M+4421YAQ"BE5<$U!QB#Q.(,<4R](L2"^;U1B8\?&U$%Y2Z8^'"M;\F8^QE*]
M>@YG>J69>9^.=GW#UW"T:&[[NE]L&QET?-6J[3ASYXW&:<:1:[)D8E8_-4Y1
M^TYKY&@C !3DJ\LP$30-J0^%"!E$/" R6/=\&$0^CV/!!"):>)+[ \^59JAH
M66 C*-&'_<48@0P]@)8L=K '/<;'01VH@>:'-^BQ?Q32H/][NZ5\6W)[73P^
M;:K/ZDP^[&IC8D8HB@5D<1!#A/P,9B+R8.Q%E#'$,$JIR7H]0&MB<ZE)@=!L
M&1Y2C=Y:ZTA@,W/JU_0W=!>@E?]\68WQHJDAHJ.5<8C2K,N?ALC[:YS.*Y:%
M+;A4QP75+2_K(X?=!0V.*<D"#T',4 91F 0P2S"#8<8C$GI>)CRCW?9)2A/;
M[E>^ 9]5BVA)N#E--*QL.:DA/2-V(K>9"7<D=R)/E/!V5C97M2XGZ<Q;[W).
MW(.:E[,OF%]!]T"2OW&Z?N;ERW7!ON('+<31X1&F-D5)0O\6>4#0\Y?';F0T
M,[L>3= 156LHRY]SINX<!N4WNAT^+Y[5I?# L+/=!9\7K7\%K/&T)3X78S78
M%U[=XIQ=%Y?X,=_@U3+$F%#.4^A1RN6FEJ0P386,_WB0IDGH)<@WVM2>H#/U
M*=.6*E M!F%> -H0-@3..J$EO:71@>QF%MH36U%4Q]279\0V!YT:%LH5A-0)
M*O,"0@V+>@#O=.9Q,T.MRLWRMERS)[JY*;_S\CFG_.)77BW#T$NI'Q/( RXM
M-(H]B)%0Z10LC3CCB&.MEI:G"$QLFBW)!CNMH0I^*+J:Z:8G]3)LDRZD-3-&
M"T&UC?&<-$-6*-_M6:#\U\[Z3@X[B]F=$ZJSM[//N0'/;VO\TS!@*" Q3!,L
M(**<0,QY ..8HS0-618E1NE*Q\E,O1[NXZM;5FR>T)'F<CA:<L/5T%SHT>CP
MDT AG"#RIMCMPV (9YX>8:!5UV?<BRGB49) A@A1!1X9S*B'8(B]V(L22@27
M=KF6"["!75:7YDW(=S2TO\P[]<JH!NRO=6%@?S826IA=-4%?]:/\NS2Q[=CS
M6]:^6$<-ZN A\QWE-Y6"U6PC!1&>D.M:B",$49I$$/MI+/\CF$<\1IFOM:Z]
M&G7B94PUS\FK3:Y:'GWA6&6HUS=CIOO'G1;.;QJM9#.S&$NQC':+!V*,V"+N
MQIIM7WC ?G\S>/A+"^2[;:-ESC[6N-L-PDC3N>T?6"4O;KK,1,Z:(EQ>(^%Y
M!"8<>Y#X-($)(G$64(&RE&@#XYG1GMC(.CH*Q?6QY% \%8PS\&?+AGG#11OU
M#MOEQ$HSM=ZN9;K44L-)"_K3]61<@(X=L.5G.M49 /M-IT([W#_'JC3#"+13
MQB"$H.&0\R$,VLGZ"H#0<@B+FL3[^\VGLE2IY":(OZ_>FCJ\OK\O^;UJR2A)
MK@N^?JKVBCZ&T6_/R3SL#<>):[BY'RFI68W@4:'LR@%?#S5?Y=]1$5X5^1U_
M8D0]WX?SE1<?ABLO>'5=-.9<1ZK7Q48:>)73I@=(0M,LHBB&3,CP&Y%0P$RJ
M!8:,1RR+TR!A6O@C<S(]L0/8$@//BIK:.JT;YKJ"/;F@L69!V_SDX+'FTZ)P
M;^JYU3M)>&\S9KAA<U^:QRMUU]9M579?0RV)XS*\F?3NLNYN:I;G+[2;:1*.
M5M;-17L$?/Q%FP?J(9I&"CPZQ($/D6J\ER4\A;'\*8^#!&.NE4UP;/")7?H6
M@_S" F3]PAP^WD(J,[>W$V@,?/R%/7R\A80CX>-/3YT=?/R%!7S\Q9O!QU]H
MP,?O/V,>GMUR7OY>KI\>ZUBPK*X*8ZB8@2&F3D:0E$%-&K2T%^!JO=X4:UU(
MZG,J.!^Z.9+>S!D,">XXF5931JNP;FC<V6(\#>'Z 9_.XS;GUURRRGY7QRX*
M$KNK44DB+PI\"JG"64%QS&":D 32."*9D%&<KW?+<YK$U%<^-4U0$S5 BA]0
MB<[1\EA!#0.2?1EM%NCCPIH<!H\5VO+,5WN"#8]SA\09/K4]^N:,A[-#G+\^
M@QU\TNX(J0:34]%%R7_* "-_Y@V:K:HQ^<HW-^(._[I=EW7<L9%Q WG:U(A4
MZUM<YR($@9^&&"'HBRR&B!$&"96^AP<9B[TLQ+$?FN1EC.1GEDR.M>(1T#Z3
M(&^ F7];23X-(9K&3H'>(<Z,BC5SAS5CX!5GH(6Y_DTQ][<%4$5/:Z'JX!>@
MY1'TF:Q!-;';]!-'^G)TKC*6FUF/3!RI;O\TQ-6P=HZR0PO)>9>7<T&J&I1H
M&7L,IYBFT NP]($X2V&:D1 &#$5I0$.4A48YHZ=)37X(TJ2HK78,_*>9+QO0
MDIZ;<B.[F0?JT=SFL8$?'5V'Z:/GA7/D+@8(S>H)S@N\;^0:;[A#Z;F4_\XW
ME[@L7\2ZK.$W.T3>921MFGJ<0!XE%*+4PY @AF <AXR&)"">KP6%84E_8DM_
M!5K->J#5&_P+T)HM!S ]0_K5<P<3:LW,1YP$YFFX :_8:<!Y%$/3XO%H:&)"
M()XAZF^.P*.A&AWH'9UAWN;N?E=^UL-OWFU)TACC5#HN'C(&D4]]F"+.H(\$
M]N*(I)FGE:\X"[=3GRG5%[M$\P*8#%X ]THN7\%FG]\LO,%'H.=BW\W4&IZB
M.;S6MY_5V>_TM;3]3B[SAWG]2]WB:ZG=]?6]'M&9EY\M>(]<(Y\>&D:_Y=6_
MKDHNXW'IGGFU^:9.)_,B?WAZ6*:<1BQ"(<R25 ;'F8@A]C"!U&.,IUC(3;96
M_?+<C$^] 9>4H9"D0=[2!J4DO@ /#?F9UA'3V9QX29EPCF9?77;(8Z GC0P-
MI#Q "00ZB<"W>N:_G)GY^=8:RVEXZV7'E.V_Q@ID.1G.%B-;^NX0&/WV=C.B
MF&8\P!"EF6KRAF)($B^%?A3(981[4>(;!34#M";V_@T"H3\>@=$?C<!H(;"9
M*SV-P.C/A,#HSX; Z+\7!$;?'(%Q_Y41^\JJAV.U]%.<I8(FT/<I@BC&J8RQ
M&889\5(_H7Y* KQL,N2_;W"Y,=@&]NF8?,#[U+2_Y0_\/B_JYBL$RU]0;EX>
M>5I169 E,:(II*DZLTE\!+,H\R%B,:?8IUDDPE91GPHVFYHZ6MI*^M1@QDV@
M(8/=IZW,%MM$Z<]ZQ!QOWX[)X7*?]6K\^3=$Q\0[NG,Y^J E2.S#XVK]PGF+
M)71B8[2J)TC^[48H*+[[(O\?N2^J+>)R76UZ34S#1'#L(0(%D5X.H1#!E(H$
M,AH$OL H9#$R@I9UR]^,IZO;"*C?^;1%K6?U55,+DJ9X7;3%@R-ZT+J>23W_
M\H;S8Q_$3C@UYCB[TRC0%3JO8^[FQ?2=1K4'2, 3D7'5SJONB\%9+YE@B4D0
M1DQZZ<C'<G<5^@K[1FZQ&"&4AQ%/Y4_&=?(Z)#JQZVT)]M-UQK;O.J(X/:?H
M6AUFGNY$TZY.09\U%.2@7==IB2?KU'6$Y!LWZ3JMA//]N0;>==,/X&.^>MIP
MIK9L./3]%#*DG &3@2G&<LM&,AEK81_AE*9CN@&T=":V?Y46J_*-57UY$V(M
M &LHUU'7']\_[GYE&'R=TISF%FF\/LP<P&&/@ 5HB4[7'V!/JHFZ W14WK0W
MP)ZHYSH#[#]NB0!)J=J%5G+SP/-GE<LKO_@.!#%B.,DBGT-$%"ZRGX20L(3#
MU/>XYZ=QF@5&^7E#Q":VX[L2,P[*+>%J 0JN"1^CI2L]HW6E 3/+[:B"'=D%
MP&*CZGGE!O+/^@Q)K,LNT4YE>T^!-JDAO"OPR2%2\V)1:@A] $VI\XZ=O5_B
MZN>5G/*ODGOYU^OBF5>J6^=%P:[R0GX(ZN]TDS_76X-=3L0VX4DP$?EA1J 7
M,1^B*$M@YK,$>EF4\"")TM S6M;',C3UT<L?M[>?/WWY]/7NXC/X>/W]\O/-
M]S^^??H.;J[ UYNO\/+B^W^!ZZ]___3][OKK[^#BZT=P=?WUXNNE^M?UUZN;
M;U\N[JYOOAKF^(^>)CUW-*?RS5R6X@PHUA:@90YLN:N/4K;\@1V#O<RR21++
M7*G+D9,;S<ZLCM"5\O:=I;-Q+2_C\(K?B!JZ[^N3NMR3_Z@/TQL@O^M"[CR*
M2M)1U<)A1&D0A GTL8?DKHH1%0[)K54B8LRCQ(N142L8$^)3!THU?55"V%Q$
M@;S!G)0QTF;'Q(B;*A,]:UYB3:0]PQ-DR8526\V']'9;/3:\=-B=4F\]=AS>
M@%DHP=7EF GI>>_-+)1R<*5F,\8(@*C+-DV%T(CZ"?9@BD0@@S9.(<Y\"KD7
M>F'J!6% L3% U.6\ %&7%C!*E^8 4192&>YBM@*- 8BZM >(LI!P)$#4Z:FS
M XBZM "(NGPS@*A+#8"H_6?,;%YU8[YXDE'ZNOS<7OTLJ9 6'P89Q(Q(D\\"
M!C'/,AAC&O+,SX(HTDK:.S+VU-<K#370D=-O++ZO@V&S'RF9X7&+KE!&'<9/
ML&_59'Q_K-GZC)\0HM]J_-0C;EI0W:G3E&60!#0+ PPI0R%$*,&0Q 3#"(=A
MBN62*=)1':AJ*E.;SF$OIIKLR/Y3C8(T3S/'BFUH5\82CVX^]4JBB7I/-33>
MM/74*S'/=9YZ_;"E63[C?*7&N5J7:J/\G=.GL@G0.=GL_M6=KB-!A%S7$/28
M$!#%*8+$BS'D<N6+_#B( [-31T/Z$YOR%US^BS<H.]66M*$9&RI4T\"G4Y.9
MZ2MR8$=O ;:<0;$NH>)MB@L+._%=^0E#ZO-Z$#O5'/@6RV$L\4GD]ELUA;I4
MMROE2U?RD@8DH;X'$5=7G5B$TK<P 4,?44($9X(8@>\?I3*Q![GB4@NFK9B/
MJ\/S,YJHNA],@P0F-*8P)8)"(4(O$S+,\)"_?.8E6<^FD#XU?9?14JT11/Z7
M_(XJE@^?G1DH2<]]CA;<T$F>DGB"&J!!T5P!HARE,2_LR9"8!^ F@P^/K-7[
MRC<?>9D_RZ#HF==;LBZ%ZZ5M<,=NBF_*8:J6&!]PE5=_%&M2\;*^0&Z*D%2*
M:$'E2W5H]3O."W75?UW0U1-31Y)=CLDRX4&04:X*8T0J'6/D01)1(AUCD'AA
MY >(^<NB;ENC627S-H)H&5O6&%M?'&V;4V3!;_>2@;\!]?D ^E/E?M?-*X2J
MRGL>[%?QGN9<SZ>]XWD<73JIDOUV,C405."WK5A_ZUI),B!]ZE8T4,NV 'WI
MVBI,\%J^!5 2MI";H)-2?2J=G!,4:;[)/+FN_YQ7B+<I+7V3B3I9M?HVW%CB
MAG+)'[]YE%M@=?/_664Z;[G]HV!Y5>=3<?;I%Y6/-H4W2T)X)E"<R45-[?LC
M1B%.$@89C7RBD+TRSKHU[LX 6=2&&8MUZLZF)+ZJ_K.M.ZI R1_ELS*J4CZL
M0T@QA"*U4KS>0C.='NT 3&MV%*!5RQ"H.5IL"Q]>U JPXPHT;#GKWN=$+:Z@
M3ZUXF!<5=8R:#@!31PUFGZAY43#UQZ=_/TD_O)*6VJNC1)%(?($P1)F72>^5
M>#"-I/=*DIBS* PRG!E5Q)ZA-_7-OTKP:RHDY5]Z#(RH7#VG03TWY% O9@YG
MI$JLDALU!'68NSA$;?;41 W1CV4>ZKQFYP".(J.JENS+,$YP&@H9C0>!:$P_
M\[P$1H&/LX2'?IH%)J9_DM+$1G\"VA?\4+0-C?VTMO3,W(D.S S<4GQCPSXK
MFB.3/DUG5F,^*^Z^&9]_P;(P4@BN\H[;%@J2C(+P>AT2?5T7,A!ZDH_)F*F%
M"JA[,*AC>$+D8@Y#+ *8>%D$L]"+H1\&29IE(?<#K30^)]Q,[ AJ&H:UDZ.4
MJ^<39E.9F=_8LM6U<%&.1'%V<-KTBKD.B4*&,(J_A2KCI$ZO2YWHRU6%YRA>
MYJT#=:&V@VI1)X-:8T4T)'EUBW/VE6]J;R9$$D#?]Q.81#R"A&-/[F!B'G(2
MH8@;12N').8(4-H&5!M%%CQ*NL90$/MZT7-$XZ0U\RX[GR)E5-3J8W&GD XG
M9'$'X+!/8&ZXAA,"'@%G./6DY65A7N0;_EE:/;LN-G)6E6$W?18N'E37IO^I
M[;XU]?_FN+S[<[T,:1*)&&$8A&&@@!HH))0G4)HEQY2CB'(SR$\;+B8V7_F5
M)(:7<%:ZU+Q#FUI#AE=@-3NPY@?L&&KNOQH$*ZI.-/N\+8!B"TB^'%Y9C5&+
MJQLG*Q[FO3 :HZ:#^YY1@]FVB2*;ZZ+:E'6=21UUJ1K-YG(@B7VY'9#13N1S
MZ8UBY,$LDQ$0C[#P*:8H(;Y93ZC3Q"9V.I_7Q3V4[ST )IE8@/MR71EW?!I0
ME9ZS<:4 P^L2)?N=DOUC+?OO@[);=&HZ+Y2SMDP#I&;NP71>Z,.&2QKO3-3>
MHCK3>Z/NLEM=%PU<W3]X?O]3+C,7S[S$]S(>D>%I7O';,J=\F<:91SS.(?5C
MJG!["<S",(111AB.O# 0OE'^]XR\3^QD:D9:,"JV7JUP65D#4LTYHWK.ZYW.
MDYDOU&ET4>GV46H$4CE#C4@+T D%6JE )Q:HY9JQUX7[R9BKW85#SM]7QPOW
M4V+<]&("%LQ+9C\5FWSS\@^^6OWO8OUG\9WC:EW(/:^JQ2^7?IBDJ5"-2.,D
M@RB@D0R!"8-9@C%GB 9^J 5<>I;2Q(M!0QLHXO!?BCKHR#<P$IJ'[.<5-NR]
MG:K!\'#<6@-&Q;A:TEF5Y@Z//%NAKI: _;)=O1?&H<E_XZLZ0_N@?_'2IPG)
MI 7#@" 9-28\A<1/L=P?4I:QQ,^\)++!AS])<6)#[E!U:<^EVN&VG]:9YB68
M2TT8VG)+&I8-[3[&\ 35?MJ2.@9!/TWO36#-SXI_"JC\_(MVUG];KF5 LWFY
ME1_'YJ)@*M>F;J2]P_*ZX[\V'Z0P_UIZ),;,\S.889[(E1QA2 (A8$R93X1/
M>!1R$T=@0GQBG]"Q4B>%;?FPP#$U4JB>EYA*368.H^-B 6H^7BOJ%3B@8@;4
MW#A,M+%1@B-?8D1Z5K=BHY1]#V,UQ@2E!&WP4GU\XLN,I2P):0H#Y F(A)?)
M'4<<2Y>395%&>""CAN5FO<$K/4>C2]C(R6S)ZR>EJ5>Z!JE@50/^/[;4'=8&
M]#6IYV&FT(_AD;9&!<!F#0BOK\UGRO@_(OD<2?Y]LN\GK_^(,HQ2^8^];^=&
MZC0:=1Y2\I]R_[[-P_FC*'G3_^>_UBO59ZNKB;HI=F '%V5>R5]]?%*55<VI
MR%>^N1%W^-<R3)B@248@(0A!Y(4<8L$SF(8X2"+?QY@9[6^F8G3BO="./:!J
M;U4]YL-X$)7)9BV.PM0/LA2**.-RUE(&<1PRZ$=RKQK1.(DI-\-4> _S9@7+
ML#]SOZWJ8MAW/H%Z:]1[F!2S->WF\GH!M,!U>O/6"M$O9E[(94\^R\$%^^=3
MM6D"DZ;#@.3?W5HXM88=K9V3L3GK6CNULO?7YLGIC83@.%/MO)=<>[I^NF/_
M^P9OZAN2&]$(^NG71LDM!_R<5YME3$(:BM"' J,4HD@N&"E.4BB_MH#[61AG
MJ5$)P%L),O%>P 3!8:$#VS"$VK  6V$51G>;+:M:I_2_V^[G/W:* )^*IX=Z
MU[DN#&N;WNP#U%OU_@J?E=FJ^/_2%V4/'/)&T^D:.F1N,=X&/.2-)NLD?,A;
M\6.VQ'/*EG<ENRC+3[\>\\:4/DI".JOJJ7>GON+?$@.*FMY*<E+.80_O0D0S
MSZO:M-4]?7;I(T!78FU/=TZL@7M[^6KK?"C;^9R3 \[B"\Z)T]GHV>=&I(&2
M@?R?-OV'G$C_^3NO-GP_[:?."5+,;1W*TB<!YR2I&X^IJG?YGXP*!CE#D? %
M#6-BA-D]$]\3NX.&"W?9GS-,I-ZN\AU.CYDKT\GZU$WZ;(0YDNI9"U2[1;#;
MM#K.^)QO$EQF>\[ ]?R9GO--Q=$LSQG)SU4 >26?7494(#]A'O3]T%.7*BE,
MO2R% ?9B3D024SIQ!:1B8^*5(O!";^H2R%J;FJ<&D^O(,.:W+X)4C+UE%61?
M,6]6!EDS\<[K(/N*&E\(^6HTB\9MWW@E1Z$*0NHC?^:K=9W2TG.IE^NB[E!Y
MM[[EI5B7#U?KLCXCKV[+M<)M^)*OI%M=%[QUN/+W5WE9;=I?7SP^ENMGO%HR
MG_N"1QS&?DP@0BB"1& *4Y02''DHI:E6V\EYV9X^G4Y1 P\=-UV>2]T)6RB&
MP&/[#&Y9,FC>-M_L#OO;]SMG9OZY$Z%.ZNL)T=].+T GATK$:26II[.190&Z
M2=^*L]UR2X% +='VF8OW/.D&O0#?Y>3;=1E\AQ^!65?#V>=BL%_B?-S,UXEQ
M=@V_ZO$X/W7'.?4*E$AN"0+FX01F(E7A$,H@B<,8"IX*CZK,ULRH2_40L9ER
MYA?@41%?U(Z#3Y$[7RO.E[K*B(P>L\2'2& ,24(\2,,L]/W,"P-LE!/L3''F
M><#S*DXO9'2E#K.-QV!1@6-P+!T)IZX8F!TP2T=H[8H >Q M=3VBSK8NZ.8)
MKU8O*HG[[Y4<KX7IVE;$:-X-ZHPUL?=[?>S<\E)GIX/GZC_JU(:&(?U;1"T-
MG;]5=*T<,Y/6UHOC0B%3R:TN(K4(S'8Q:2)N_Z+2Z#UKF,I2I?]_Y,V?U\4%
MK7'\5=L2GM?)"LLH1@&AJK XC2*(<((@]L,(QCQBB*51D#%NT21$A[;6]S^Z
M)TA'%Y1;PA:KNY8N]59Y9ZJQA;^LJ8+?.OI_4U@K6RWM>' *B:DML3N0S/,D
MYX;-U%;"$2!-_7=MG<6SW%VLRY?;]2JG+[NU+O&9EU#/AR'Q,XC2$,$TY +Z
MA$:1EV&?949)NJ<(3;Q5V)(UM?L3:M&U]?'"FMIW2U%NYVN:X$?[YR0EP><$
M=&;.)\C,;,+#PAZ:[9GGK<\V*.>LNI(,*O@1+)F_$?7M=/5'(<>1[D+25:F&
M!3N.7J3"BFH9\-!#+/1@&.($HB0DD*0IAIZ?,IYY+$+("'3.%6/3GYG4;#;]
M+/.6496;+'=?#W+'7&WD)-4GJI^^W]X:'P.XF1SM(X/956Y\O%!SN #7/4TW
M'"Z.)P?US[H__5*]]%3*9)-HL05_<UB [%J)[DXPW+ U]VF'4V4>.1EQ.[XM
MUEH+_O*-/ZK;\^)>97 _5<O4SSS*/ 0CS *(J"<@YIF H0CD;HE$<4"UTCC/
M$9HZ#;O!&6MI@RUQT% WQ5D[H:QA)^=2!69.RU9Z"XRU8=%&0*R=&'AFA+5A
M\0X!ULX\;W[D62?I59>K=<7OUE^*QUQAJMS5\;KF0>?I$2:VP88PJ"FK(/TN
M5\TYUN#+U]OK'MJ/IC&>4<;Y,TTW>C S1%T5@!\U(X[.,,]+:G5R.3#L;.>5
MYT7KGU)J/&T7PVPK\*_6I:J_W]4YJV+]+]+FFW_](]_\S(N;HDY(:_/4U&)>
MU2UW:) D/F217%X33&.89@&%6*0DP)SY-#6JEQC/TL3NH&%!+D)_UAP E=CQ
M(GDP"U <:%XO-)E7GV9N10L18LL+4,PL0,ORB_S-JO8?\C?JLO2[G),5W_ZZ
MKE9H,V>E5.["%'<*=12@.&!HUM#$G0+W@Q*'(X]L2?:Z\'3[XS:M]P,ON,@W
M%YLK+L?&JWIWI4ZH7G516^(@Y#Z/$&14=4S*X@3B,(DA)@$1"67$SQ*K;F8N
MN)O8RZIF@W_\Q_?_ *)A E0=%Z#4KD>=9EJT[Y?>1MF&(99FET> -Z!E$6QY
MW']GX;P-_21:=-T!S@EO;],\SJ5:3_:=<TK$NF(+2Q;P:M>DIN[:["68B"CD
M$ 5A"!'R DBR*(,\%B&G"(<(&_6X/D%G8F>YI0IV9*W:6Y]2DY[+<R"\F?.R
MD=NF4&I(*G>54$>IS%WJ-"3JD5JFP<=MV[8)7I:<2<-OZJ+JGEX7I*H3FI<1
MS@(_#87J59U!1(B *5(A/O6)"%)"46@$P3],;F+#[8BK7J\ U^3_T[1SVZ"V
M] S7G0Y,X[]6?+6!:"BW+=RD%;?4'5JRGIC.^KD-$INYHYN.X(<]W;3>LH3S
MV 'M;-W([;K*ZW)OLZ]79ZCION%7J%J[!:EC8)(/V41B5V '.B3G12HP4,(!
MS(#)N^:7'9]^<?JD@JI+2>9>;F7K393F/<?1EZ>^9NQH@HZHYC)T6MKS%QFC
M!36,= ]D=+95/"N-U3W%\1%GNZ(8%*A_.S'\H&4KINY8XE40N ?GMBX85\5J
MJH2^#2:/9QIT%Q6$)$D$$Y9@F,B_0X+D/Q$/?1J@A/),&/5N<L[BQ$;^7>53
MP1HY94S#)_<SH[?,OZV^ISE56X!7'(.698V$K%M>JOP:AVVI)E.OJSY6[AF<
MM_'59 H^Z)0U':7IO'F]);LHV&?YI:ZVS_&J]=LQAMQ+*$RX.J(C<0AQ3+TX
MEO])0Z-.[6.8F=Q#*Q>A+C.5O4H]-LYC@W_5M3(JPNBN0WXK:D;QZF^]IP"O
M97/OT$].CCO7[4+E4SGIW;S4W/6>5Y?6;^**SZEK1J=[DI5WYU[/*<W&D9X=
MTP*RJ3YNN:#_?LK;D+0HGO#J*]^H2^WJ1M2_*CF_D[-<_5ROF-R'TR2,J ^%
M%T;JJCB 64(QI%&:^;Y'?>8A;>@E8_)3)^#5]&L/6"D.#)!RS#4Y[-&FUX^9
M#VMPXGN\+$"K+55=7/.C5HV.([!E:5(=&J &3:I+._0?]SHU ^^Q5LD@"(_Y
MJ/.!Z5A+_ H4QWZ4D0U;!G#EOW"L$F/936&$5/]MO5I=K4N5]KGTLX1$(D,P
MIKXO77N8P!1Q#+TLIL0/D\"C=NU9)F5[ZAMO@]89H)-&=?\R[Z(!?BBQ0"N7
M;4^5:;\1S?OY=S?SAM?][V_2[=N>S#('KIN<3,OTV[0TF64B3C8PF8>Z>7%=
M6P!TE5<RK%%ILI\*5K?R$/)_ 4(A#&(N(XV Q)!X1$ O37V4\0S%::9;6'>*
MR,2+1U=/UM!M4L0_*:1'[<3200T-.V-7<INY3BN1C<KHSLED54)W<M#9RN?.
MB=4OG3O[[,R=3[9.1OJ5IX<&(+\#&+_CY8._C&F<,M7A-V:40(2C#&(1)3#(
M4"2HP&$0QK,T.SG+ZN07X"WNNGSWH6YSHDIZJKE:FYR?*;T=WOO0OYEK<M#
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MNJ;JLM)D4"QG92;'J<Q<8S(HZF&!R?#C=H:K:IGO>/F@G,07O&F12K_QQ^:
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ML^^GK,>QS>>_?2*KG%ZMUGBS1$E"/2_B,$.40L3\&*8Q09"+./6%_)4GM)"
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MWEN-5E,=OS;5\0OM[B\54E*#JW_UTZ)FE,Y_[EV%I%+ZT3CV#+!\!':VPXC
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M DM !N84V*[@&# H*SY?5D^KMN6,7%3-<'A9&[9OE]6ZJN=7,5I)<=>D;U7
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MV%@V>%GH$L\HP+2+(8ZVU$VOIA:1F@&D.;A"-0^>@0'H(,\ N6DE#T#!5!9
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M?A06VOU+S?P(FN",)"3D(LX%MVI+>Y+"R-N]H8DV1%%#U;Y0[S@LPSO:B[#
M6 ]03E#=WJ L3L5[QU><K()O4*!^&=_PA6[?W#=4/SDNOWZ3<MUFY/?"NYNX
M8I!D<<@*A5,S28'(7&!&TP@7,4UX')EC%M",2CNR(V_'E@E4<X%:-G8/'<Y'
M)2]!U>Y3[!\KV&[V A/XJPR3VM.GV9+HI-]G&!#['VG@W0Y%-C<+OC(&P#O9
M_'FS.&X8E+(R\=LX#/("![D(]0<\$CC7-CM6*F&)RK(TRG/K*AP X1<RXTO;
MR8Y@((<UQYCPP'1'QP3ZJ6/C9U2:_)L=$Q]]'!TP0!712,"YE1EY!!!6E.2
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M+5%TC4Q0%LTU74"*^@E8AO>2)V'!NZJ5TU!$AJ3+<-@3 @.2\2\7W"T+_P@
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M#/!O4CS-Y:UZ2RN38F7^,+GPSW1>Q]I,H]]9J.(H4'&"B\"4; F6X9R% O.
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M*%UY83@\7C;-MC]$J+9MT^*NRQ<633]R:8;^K__AQ]Z_A_X*B*]3/LE_0"O
M7W]BN;!<UR^:,1*OYTE-WUR"OIYRZ8'_V@$OB:W 1PF5Q:"$,^+8BC)X/?RR
M80-GA#N* SCWG$$0Y1?&%<R6?6$B#X1_Q7U%?E$4X8:LRP?<%5RK2V& 7%>;
MIJ1]ANO5HRC\=-@DN[F/(^91T4&2HH!"Q#P"TPQQ3PB'29(G*48H58Z_M,R<
MZT.076L@+*F+&Q;"^)+/&5_O%&R?Q+US_JWD4@T%*1K9L?YQQZ)&&*3MF9O6
M)V\]'WJZJ&=T!7:L@A&O8,^L4%0=N^" 7] QO *29?#KCS!!&B&N;SA19M&Q
M;S!A>H&VCA"=C-&U37.Y\%Y':!U$!KNB86Y&E^U0XKHK"/' -KE(FV$>\KV
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M5$0%3$/";2*/:X@8^0GQ"^63O#EJCO5#3QYP^J <& !/'0<Z6D -.H7#/IN
MZ*W^,18[VJ G;I(3- N'QI&@35C,C@<GX;%T5*@JY>2QX>P@RQTAJLIS<)RH
M_)*A(RAJ;/V,&T;']]:CL(>?7_:/]*$-5\(4DW]\8?_<EDW9LJ^L?BYS=LNX
M>TK]^SA&),@]"C-I..5<,V99[,$P\5&:D8!XD9)2=,JE8V4J28-ZH V:CCAX
MDM1E@M$+P[5N\S8W$Z;H4+[U-&CZFH(7*)EY%96QYUBT=1L_-Z3^2(Y7W7_
MCG/0LPXZWBWZH2Z1M>6B.N%Q6>_5)<Q'CJU38D9%[S]N:/E<TBU>ZQ>[/WK7
MM?Y<K\&(IE9M^V,YIQ6<#1'U=-,KZ>R7L#\KBVGI^N,!ERQ9?U:<5Z7JSS]G
M9A]]JC8/(B-8-*6XXT.\JT3]JWL_QEX4) CFGN]!% ;<U*%9 +.0A4D<A"G#
M6C6F3I-Q'<3!B4)!57:D6@%!&/S>D=;,,CP#DYI9<;GP>FM/RGVG*[?VGCXM
MEJ5-^0R117?5:4%?;XLS3YLM4]%'2!9G'45O:89%3 WA[EL<-4 ZB"5T$/Z@
M(J"EKW*2U*+?IHK0K[]0I7<L=98\WQXV#GU,,AK#G$0BZ95&,$V3!'I%G&0I
MB7P<AC::2KYQ9]Z#?I)//2\R@X?--H.]%&+%*PB[B%EK([E4!UU]^5TUC_Q!
MNN#J S+;,M)V)UMA#7_@\E4;]H7EU3.K7[AE_!D_,E6/[_3;CBU204+=T3LC
MX+RK=[ELFIM\1P\,!%<CUP],RJSE]4V+9>3WG1ER,<]O6J2Q[S?SI/[RN?ZV
M>?BX^2 L@9OB9MLV=// 5^9OF^>FY>NS?;GZLZ;-+_6FI1\WMW7]]UKS3,68
M@.-%^'>&:RA A.(G</U-G%>!<C-NULGWZKX(I#RL:L O-5=<C(K';NNRJH%X
MMP%WWW +,-^L;L:=._@^Q:5D33O1J\+B?,PKA$6F0D]G+#H+EH^?+H;32%>9
M4UU,G5T,S%CC73Z803S$^Z+H&NI\W.35([O#W[]PPU]HW4U>KDMYQ/VYVE F
MJG^59,W>?Q='WVQ\!/ZI?"S;46GXOB%U4,#0BY"(*XU@)OY*<)(3CV01(^I=
M3%QPZ%CC?N7?-O#CX*?'OX#UCK1&;(&369E6FS\$UGHJ=<<MZ-B5,:>"87#(
M\0H<\ QZIE>'EXA[OE=:Z>WN)DPC@.2M)\XLZ.3-)E O;L4EN).Q+DX(+Q<?
MXQ*W@Y@:IX1,&A\PTG[<-&TMU\3[[V7[@8D+7U%W#S^P>S_,/ ]%"<P]45^7
MQ12F88 A8TD<>X1ZN:?4(U"%F..M3M #!6/@)]P +()A!%V=*KMS8"EL6Q8A
MT-N!!&&PI[P"$@Y.? 7VY"UBH=.!P!XFAAT'+L)&L]. FK#3G05FQEBPDX":
M-(>= Q3?N2"JD,R'OI#7H2_#;0#W7E\%<?>\W5,O(KXH,QXD80917HAK$9Q#
M0@I6,!(@Y"7:H85.6'6L20?ZX$DP<)S$,=:O?$;E ^NJ$:Y_VU?L[][DSW2M
M5HUT\@)3KG9-\V-,I-Y^8"%"<?<9W Z?P6%GV%X&RZ&*3G&V&:_HAM'E@Q:=
M GXR<M$M1;-]Y>H9EVN1 _BAJD75O:\LW]:R2*W8SW[%;?^WKUR[K5G_]Y=W
MW+CG1GK=BL3"ZZII^4(J]^$AW>E3$H@S)P\FHL0T3FD*O3 K4!A$.$FT.G"[
M8-)UK.5 6";YZ"E^)W.BIO+?&FD#XW_/X@KLV(=%54,AP H,3/+?KJ4N[CN?
M=R+L?@V$$/+8HI\W(8>3J"&7&%M2]$Y87%3%NP3YM7)W2LLDPY+O*ODW=BT"
M,C]5>--?VF5I@OV,)##.$+?SPSR$HBH:C#&C:9#$>:;6S6."AF.EVA,%U[*E
M$%ASNCKI@J=A43C=N%Q8/;VVEU/&U J21OF1IP76R8J\6'##7,AC &QE0$Y*
M-)WW>/K5!;,=)WD_S'&<?E0_=N-]7<L*L1N\?N%J:E\X13$TX]S[K@]'Z[K:
ML&K;O'(&>S;48R7.RC^M/FR)KGDM-RVUY;JJ*C(:A1^<'72QZ((YL<;! [//
M&J;+L*9A['4)Q$^[EE-\XT9%$8I='<<0H2R&. P#&/,]G3M:,8X#HI4W,TW/
M\7KMJ*^ I+\ZK!+ZR;1AUQR$:JZ116#T5O.EF.BGV:A):BO?9H;:LHDW:J(?
M9> HOJ:_[W[9KIGOD<B_JNN[^G'3T@]K_*"ZZYY^V_$:%D2!H K]@U-788N4
M&ZP5HGA&_/E-]W+)]1;IO-#@=\&!I?UV6CRCW?;,D(OMM=,BC7?:F2<M]<[C
M/USSOY?M-:[KEZ(KE];<9W[&2!8%D(5\LA'%*4P)"V&.4L88C2.6!3K[K2)=
MUYXU_@YR217D8[(7MM$[@Z':ANL &=WCQ1-M]<3/'1?@6@FIRWOM3<OMJN?>
M&:IOVWMO&HK9'GPSKQL45>X+R'ZH:I;CINV/6!@WR,.<>3 L&($H#P*(\XA"
MY/F^7T0!C@LE)7&>A&-],!#3J*=\&HGII6Y'/KU5/="Q&*$_+\8E195/#[Q<
M5>5)P0[**D\_:7SH-&0@R5JEF@=.!^\N==BT[M-'7L<@#,QH'SL=(J!\Y&0L
MO.%QTYS<?>%ANV=.)X6\Y+SI<,"ESYI.BG/BG.GT<V:V[U%#ZI_9)O_VB.L_
M^JHC.,I3EN( Y@5%$/DXAL3GFUH>QAX+T]@/<JU#ICF"CA?JB6;H.P8,R[7,
M0JAF\]H$1F\17X;)Y6WBSPCJJEG\:W)OVS+^C/"SC>//O:>G!B@K[_L[ZQ<_
M('=ERS<9+V8T2Q,$:5C$$&5Y"C'+4NCG <$Q"XL"*;6$/C6X:V=6T!!Q>W[P
M$_G+$""BN.N>!&-Z\5XJHMY"U95.>6E.B3&QG_+7NA7(?]@OO).#+;+(IL08
M%M3D,S;O:3J#C?M^"8N* J9!+"I:)RG,<.;#, J1GQ9QD>J=&4W0>L/[F1G;
M3ANU2ZYE'%N\%\!@Z39FSMJU=Q.SH!FL(;+:#8P-XU@TQ_VX^:]RP__D*X8U
M[7U <1;'<0+#%&.(D!] C*(<DA!'3/R"("4_]3P)Q\OX<[6!W$/_!LJ>'F!=
M/IYN8:@C:-06[64"ZZU500N6&RBH@8&<S5I.YT2Q5K/IB,#"M9G."7A<@^GL
MDV9+[SVN-^7FH;EEM8R.UPQF/O>ZPY.0GJ+($>E23)Q$$,\)9NG+.TMFT>]O
M3MC77^'L\T;IQ+N+A$\E)N5:QO-^*1^^M3?%;PV3MPOW29!1% <!1"+C 3&4
M0A(1$6";$)^$"?\?TJ@OJ$Y9Z8.^N*Z@) JK FX;!K"@JY57JX+@]+JV#,CE
M=X(C!E:@@^>F@)R)[K;0.CQ:R<>683)-0;8 EVXFLH;D,_G(*B,MF96L(=FK
MW&2=-R]Q@&^>F#B>VCQ(4WP@]C*49WRW9:* UH?RF8DL,5(P5D O0A%,@HA
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ML281'I@#/7?V5*(%B"SIPDLX650)6H#LM?:S,:1A4A\N:]EBZJIIF*@LAT5
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MH,Z4;@Y*@,F>0@A<4"(]B:S^B*^=I S;5N/\R.HFBP94UX>TO./!,IFDUG@
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MOF)GKC< G3NMXGY+Q? ;&6-%4&4*:^G@+!P3:.@IAN=+!A.(=S'TV*MV3<3
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M)["FX-' <>FM':LH4[RL8>!+4KPP*I6Q%@Y"(-$J+Y2H/IIHV'Z]_Q O=$W
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M6]!+>QL8KC-%\'87-.".W&K4.OJKGFO#L\I*Z>I5LIT;A)ZK)4VG>ZT:VQO
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M)<G'VJ[K?HJ&U8K-@;"B^!H X[J$[-_'4_P5/S4MEB.TNM&2P9.47"H]^;4
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M\PUHJ;P>S,."RYZ75JT.[2J#RA"O1]R&U(I&(7CRXOA#?_WQPSRQG./4G\3
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MDMFG:&H,5)T0\"2\.HBC 7AMDI<6GU-(XQ_E]-V&U<H^,BB!GJ4VFH#W''V
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M%Q]GXP:MWZW&U?@Z7>(Y%(I2#IRF"@HCQ'NKB*W?&NP)@L9U'!M"7BVE-8#
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M?4DQ3_? 2O%OUOFS8IBWMEK[N4T58@9Y@5-?3,=XE,-"DLE:AK&@<R"H1A]
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M2AU/=!$L4P:HMX$2)Y+DK+([]G<=U8$GXF@ .&W0OYHMEHMWTW!5R/['?+;
MXT0Y%RV)((-T(#+38"QZRK@3"!^)CBG;=M#_D($74#RU%_[J&<"!8!C[Y!\B
M@V!L,*K,2HZF/'%4VJ%O)? [;REST8MD>"?_8:QL4=MU4GV WH2N3QCKO[H_
M)Y=7EX^4BS%'$IZ]I8$A.HN">0N&AC+!&<T]4B\HZ_8 82@*7T"-U!BHKZ?U
M$[WCW_57P][W/['B,>[^NS(\\MMJBG /!,%OHRN])S(8)BTDE8S4+B8,7-O.
M ZSJ:NZLL(YA! E68;@"T4DT=*D96E29(,'+U7+@.;OJ55&["#G)V_E]0/&@
M_.E@=300T6TSL;KGDSYX$91"'K@$$00!&X4!G:T02FC.<^V.?KOH&#>^JJ#>
M9P"SMZP;Q,OF#I ZG4*B$3ACI?EP%N")=< =C]&EF(FHG5?<34E;F-E?P\]
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M^;U%1U9Z'Y7-:LBON6S8IQ33Y:IA],<TG\SB>DRM+)GD,B<ARO*:S):K%YV
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MTUN-N^'00Z8- .(1.UH9"MH2VMN':=J=@A8Z@L\)OV/,,BT8H[GVV;0'>4V
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MHD;NN#(V FNJK $,[IRM\=M5N97ZD#^G<#6?+"=I\<I=7*3XR\_-[RTVO_A
MF,[GTB,IX1>O \V>ZCQ0X^2^)(_<8&%DM_&(ZFX W7=FH'V<3\*C09EC#ER*
M#E+V3#)N- O5KQ\?H67D-TWCXK&*@AH VDZ[>O-GFH?)(JTXN_GAC3'1!Y(K
M/;,#=1"9X%&*@-_71F$O0D>NFFYPRZRJVE;Q^]"UY@:(% PTMQ:<Y12XMT8*
M2;VVU2^[GZ%I[ J\!F'95V,-(/#NN-)K?V05X!4W.\5WTSOC2[<%1U5&WC1#
MZU+<Y124(+6'=.Y#W]C5-<V<Z74U.?9[M;M#N&^NO%[-IHL)*G0EXP^[>+L9
MB>$(N.@-"(]'@!**JNW.@X\]8]QOX;'3U./ ;W 5M02_KRBSMZFXRZ77M/N*
M/_C'?+987-]/;#.F;:F,1 G*& VQP0BY/3RK _:>6[4;\%Y:2F98Y31P--^Y
MWMIDV]?[^2?4[_Q'BF]G\[=7RZMYNKX1VS5&P=CD@?JHM.,J)EJ[N'5O(KN!
M]:7F<8;5Z>A;95_AOIN&><*_?#>][[J<_7"3BU(ZA7)9/;R^:]P[$Q%W924C
M'BM6."#>.):L(F;[>NFQW7=<1KK9R$M+-[4@^;T@=++F5O[B6DKK;I2K(&%5
MH[@E %9>+RI.(#.51'DGHK@>UH:>H*Z;8;RT+%@;RF[ (^HM@VO^SV*<E']R
M?>P^+*&XVXC5$QZ!9TZSD9:1ZB_'!F2GFZ&\U'1;*SAY"2;SR"GZP"\5')PB
M$:+13@H1DZ>U'S\-Q4LW8WFQN< 6$'+*EK+ZLGG A,[E9!;I-N^^O+?-+H)4
M)"7EO+>J^NB<BO1WLXB7FGH<#0FG; 4;UQ*M/Z=)N<%8O)NN9;#=$$4)"M93
M7=KD*9=S%%PW<U0\SD:W%Q<O->\Y-BY.-M:^>]WPYF+R=8)'Y$8FUT,*'TC"
M1 ]6J !!9J:5L]0(/FS0W87,;A;PTO*KC:G_E,^(ZTF_B^7\:O5<]L/R6YI_
M02EL1+)R'!_=()+T96PGA^B-2MD'D1)IY>#8D[=NMO32DL5-(^B4+6LU\W@6
M)WD25O]D=1M>?NHN[G[2J]EBN2T3&00X;1-P&7.@6M.0:V<)C\%7-XMZ:5GP
M9I%SRM:T^O(IX5ZSF"S3YS3_L:Z1OA_0K86 KBH81PUDZP7U.E,7FCF4GF*D
MF[V\U$3\^-@X90.Y\6#7Y=@WY^V7&6X;[Z;+^62ZF(35@_Q;F1B=+6A'&5A)
M#'!+G+1!QU2]A/D8?'4SGY>6HV\6.:U8DW]>)OX1F92+PU*GNQ;(6S>9K\1
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M;MF>KJ9S_^8NT^M9"=G//=6<:A:!)(4R4-2"DUE!>9FBC:9-%:H]SL>XX#X
M5M7JQ"KIN &<[_#J%I\^__YK6N4Z?6EGFBB!I".>1(X3C(21-Q:)R8%1%G/M
MQT)/$M1XEGMPO,R&4EX#2.P=(+^_Z0@L!9$:SR20WA,0I2.P%TE#B8UEE(2'
MV$P/MANJ1TXO-^$J'%GWIXSV9\=NWHPYN]NAPF9E),T84KC 2]4F'I@4Y:22
M-4I3A9M/,]UV>G'8^,E0&;]'F^%Z,)C^&J:V*0W+DGF5B '.,^I0608V.XM'
M.[6&&!KQ/#X]*SOI L,C(/SXQM@#;J?3ZZ"W>.Z_1C_G47!M./J[3%@06GHP
MCBAP(H:@LC<I-%.0N"=O)UJ1^))L\0"PO>@C\?[0]_/(:& N<8A!XQ;EB03G
M'0:BT@K)9';2G([?>9^W$ZU&?$E&> #87D"?R&?%LWEG?E="-A(,T3'((*9<
M"5$*7E$-)G*6J:=.174RYOB O1,M17Q)%GD8Y$Z[V?'>_KND3H=@ B0K2\AO
M%7CC(B1#(M5<)&YK#W%J*UQLKVKQ)=GB(7 []??1W86S55R]\NM?XV9R,\?^
MKJ)=#"FA5L%RW,<$[ETH0G3S>20J)&.Y=,V\J!Y&!"<:>I[,/>M@<'S146=W
M\9T':Q)1)I8W$@DC=6)0_QBSQYQX9!K#=5]]-$T#?+_XZ]OA#*?!36 O%/_E
MKGZ?%U_*7@O+BIM6RN4E,V!8%F "5^@-A9#DT9O@'HOY$SW!_U([P9!X;L41
M..#%R3\[[I)4N:B5XF $1U^/V(AJ=@ILTH%FXH@?9F#*\*R]^,OGXQIQ8UAL
MQ42'O"(LS]>>EYIBQK.<&4BB(P@;?2F,-$!(=EXR:9,XG?S1/IR_^+OL%W!*
M#X;D%VW_>T0YJBBVO'R*MO0S"-F")YY#CHEEA_NI\<TT9CMVK'[*=^<OP/8'
M0G'5>_?C/(1>_>R!C-_\6;Y- SV%[K3FD(^A]V>ZC>?001J3RR,0']"B,&3$
M0)$S"8Y;)KT.93#Y"WT._09!-_N9TN<T_S$)Z9&MX6+UD?C=A_PIA=G7Z>2_
MD:B5<:THW;QU""RY*#1(%EV9VTO1K3<9F K4X1=N<W6W= A&3OJ9]#Y8?OR9
M]%BP:,#'>S?%O2Y]1H6OSL+W&Q97[RJ#8U+;P"#FTM\M>X9RU2A<HTM'D619
MKCV1Z ER6GE./1I89L-HKET07K^.)$8Y&P($IQD(3GSI<./ ID"S%43$ZB,$
MGB1H7"!64WLW./7000. ^H0Z00*^G4WCZ_0C7<R^%YXVKMGF:6Q"M]L%E\$G
M;\O+"07&H>U)HJ+67"G+:KM!'<AJ$EQ]0/#PF7)5C30 LL_I G_T]1]IBE'?
M!3)V%B\GTTGQ3):3'VG#VV+#7"0^\$ 24$:0.4\QF%6$0/(B6255DK:ZN[@/
M@>.F!(<#WG!::@""=7R1V\(H1@S)A#HP*J&@?9DRIH4"Q153/G/JDZP,TLHL
MM/*2OA4O<4R$-& @&\Y2W,WXQOKQY$DYV(AR382"()R6Q%R&E*QG(1*93>TJ
M[&Z4C>L.C J>[4Y2]35Y8MTFSQ:+J\OUS?-D^LI=A*L+7&KZ=?5OUE?2JWOK
MQ4 7KGNO/^3EZV'":.0BUN:<;.+@HT9G([!5MQ0!'O4A6#2$^]H=JENYB#VT
MT8QF-L3@"&1N#(B$WWGC-$1KN1#"A,2J=U'[NR_EGI@=KB_E/NH?T0M9S)?G
MGPI+J]L9PRWQA&(4DY!4$5RIU\63RNFDC.+XO>OD7..GWL$K_ND6J_<6;.7"
M]*C*GATJ^1;@L@E&J=?*,5V2QAH9)V7>42(.)(DVY$"3IYU>&G4!S)BW3P<H
M:UO=/20WLL)_G4PGEU>7-_</UID8+%BD$3WD8, EW&BI$4%[SP4+G5R"9U1^
M;]&1E=Y'9;,:\AM;\>[/.X1[0X*1B/JD*!(N'2U/TCC$Z(3@,?@@.N7:GE/\
MW47'N2NIIOC>\FOA7N)> UN,4*76S  MC^2%E QLH/C%8#B;>" QU4ZT[M^I
M^@3:3_;Q% [72 -PZB^X)[K2)A:2Y88#)2*5KK1X!AN>@'FKB69.9GWTA\XG
MWJEZ+U@=HU/U/CIN .<W%Y*WMSR;_5^@6XA$!R#6X_[OC,>05 D@.AA#=$S&
MVJ$R%]O$-/[.=G"</):".$AI#:"O0N<!3T(61')0"<U>./1S#(L,B"/<L4 8
M2;5A>CC5(S\T:\(].++N6T%[GT=Q-U7O=^[H2WHFK%NF7=)S3YTFPA"0BG 0
M6:*S[I4#2H5,7%*MQ2">Q2#<-+[;5\9EK9>3=4'2BKGT4<13DOCGK&2U+B;+
MGY_<,FVN.LXS\8$Z)]"+)!D$$[P\([/ C!261F*LJQTN'H^[$VU-4-&<V@/1
M7\2\UA=*YTK+$'DPZ)42C4&:1P42CEZ#$-GF2$.0S33XVIN[$VT:<#KFU0-$
M+\V\/DT6_WX[3V42;$* +>]N.UZ2($+B8#(7(,KY;D*.P)-FFGIBI6FFZ\Z>
MO)WH<_T&3:L6@/X2AK79<)(W932H &Y">0E7SG/K @CEK HQ<G+\N8*5>#O1
MM_"G8E@] /32#.OZ+'\]^3&):1J+7,YCS%Q:I<"I@!ZR%@8\,Q2T5EG&\I;*
MGH0?>)>I3J:D_C:E(T"FP>KC]2N<+^[/M/C-S=</9 XH)G[JXPZM#>Y,:J52
MWYOU;NLG;VHBHU;&2(([)UF5M2?[_]O[MN9&;B3K]_TOV"W<@9>-4*N[O3WK
MD10MV1-^4N"JY@S%TA1)V=I?_P$4)5&\%JM0 NC/+[:[):,R\QPDD(E$ BB%
M#:BLLLQ)BRJ6VE'L$2?-9=PP]'D]B175;F*>GO/G4@@DH3. "1O8C2$# O)
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MA-5ASA&(.<7>#5-@MRE+(<ZI!\Y'M*1O;?0"R+.K,W'4@0,:TX.\@@X(J"I
M&%)A!XDXYS0Q<3HW@L[2D+X]PBT;0;<V=T;*F&>A;W_ZM&Z">(M<0*X!%E92
MK4681OL*Y*;._.==_?A?RQ&?^;'\PQLUWKZ7EPC],:M[&;  R,\OUB5&4@&%
M( >28FT"YY6M]L7SQT%^?I$W5YX<\B,-6,["$/S?ZFL'E[,?KGEOCQ>%& M^
MT# "F%*>0%I9[P9Z+F"W4'ES/<EH,PP(!;!JYX,L40D&F$,(<&L$$,HJ8"%R
M1!F'A4M=;]W]!9PL[Y9TWG#T-WAGUCRZ1M>)%J!?KE]DEH!!1<*2*>)==X&
ME9 09RS&=%_NY;@%Z)?KS$4$_6&K>UFP %_1)@?P\^HU^=5)XAP%6F"VL%+E
M)2>*IEZ-CA(PKV_YF'S*<(@50,<CS@G?U'^G^EM5))1:<U$!:B@/^FH(E! 0
M$ ZYX)Z$?Z=NF)M.^O(3@QTIUNZ ;6B\2V+Z>W5V&.3LY4Y,+/"9AY&?WD&S
M5)Y+0!T*^U]AP^X%80\44;*B%:HH&8SL*10H) OUP2S<-1D^G!+ESH?M!6W+
M5P96U&/4 (5#Q,>=)='LPOC4IX1'BEA(H%,DIY/ 6BYKUXO>XH3\/ JK:D1N
MI,;K:CH3>^%Y K!0 B%#/=>#G1H=)VHAA3U%LC@IS.6R^>5-C8TFRIO/<:QO
M!HET0%%N .:QNM@S6 W4;Z2/U(4\9U$DQX<"OURZW[RT!M]8C00-JH7X/-H3
M*FTYEN:#-AEO0A7RTD619.T(W?%<E,]<G+B[X/+M39I^W&W"[HLZ5AW.PZ_I
ML5MB<%[?QW\OP_+[T9(-;R\@K=A!"0FTKP1 8:IZ[9A@XF#MYF#2%?+R11XN
MEX%YN7YXF]K7/P*RG]34V54#G-?33:45!9IK"YAT6EA+9,4&:W+;1_!"GMPH
MTI\/2('3XOWB-'IC35,<".LDP-XSX2O/G!SLND=+&0MY[^-DV'P\L.42=Z'+
MF?WG?#J[#V!M[,$DU$"%$  H6$'"'$/!H!_#UW71"GD^I$B:]H*Q)'9N>;IX
M-1F#;&S:9 $*^R/-L1>0#=9*NTOOA.$?!2F$?CUP*N!NYO8=_#9C;MW<KYF2
M.Z!IS'<'VX7-2WSTO=+&(L65%*E;$"82O?RJBS2'U3F0+L"?MC'PD8>16C(@
MJJ"R-!H3")&0R=/""<0NL0IC8+IU*#9*B?V)T+WM\:6!-MYV<@ &)85?M&)+
MO<?H(V^)GKL\@B=!^T28?>R1I@@ZBU@LK9R*>44-J4]];2V%W'F/L4^%Z4G1
M/Q'&]SC@5%X!R:4'B$N.O,#2L=1O$"56(>]1]ZG,@Z$X<2)38O<Q*G'Q*"G$
M^UQ"!#UWVJ <[KZ4X_!3(71'1/^4!^-7KC%N\Y24A']($2:NYYQ"C8AS8BTF
M_9"3\:5X>8_&<_*Z$,A/Q%?W.R)U# (MI +6>,RUJ"IC4I^2I]<B[Y'YJ?C\
M 9EQPG-CZX$KT@[(RJK8Q4]@C923R2^']1(X[['Z*3/^>+Q/A-R'CFFI%D!(
M3H&74 2C:\M0ZJYF7>3,>_1^*E3NA6ZQ#-YFYW7-*H-B#T,3U+,T7@ 2(GDC
MK/;293ZJ+Y>NO:$\E;ZX&SD@-;$_CY0.-IZ-=CP,WZ,E;LO/#=(-MXNJ'] (
MUUIJE"(8&!8?(=). ^DP!HAK2%CP?C#Y2U%[Q$G50O[5R#\U\=G@USZNQ"F/
M@K+4*PN(@W'V" ]$!7'8K'!8F=0[T_T2%7(UNR<O=C6(3X!" :OMAC9+GSRY
MBT]2GZNF>?)U\[MJ[/160@9UK-$2% 6K*4O#5KA" !.F*AX?NK9#O=_20KPR
MGA5*P8I#A$L$48GL^ZFN[>^C\?AL8K\%]"9W,1Y[_M&MP-X(YV0(O1@/DY9I
MH#'VH#)::*+"/C;YE;ICY"OC^:"/X%\JD$HDX.MQQ[MY]3V &>3\<5L10RL?
MNWM)CX-Z2 &IG0,,<X\%0V8C\Y^>@_M%+./-H(^@84*H,C)Q<6:QH=N+%F&*
M+;)10<NP?SE7#Z,0P8S^;X'G+0\SRQD/ 1>" !+^" 0*:GJ*F)%4(\SMH4BB
M^^?+>!XH(=$^"(E"O=[+WRV3GU'MYM%-@]IGQC1S-9[>!F4JSP@$WF $2&7#
M-@-Z!:AF5C-.!(3)^X!VDC3OR?X'^\#$P!7G"G]V*HR[S"4\W5JCD-+&QB81
M#!#AXE33"D K,:UPQ=GZJPEMG=[[#^4]1?\P]];#NJ?AR%9/*\.<6%X5FNXY
MSC3<<A0?CH-(AMFB*A$SGAX@:47E*JR43)U5'D*/O$?=>9W@L*"72/R%>6^M
M]))36P&I# U[7BN!$)@'OT\4EAQ2ZX9ZR?2])'E/G3\T&#[:\ 7</&Q3G<IU
MF!$6:T"8]H @&&)ZK3C0C CM,:44ICX43E6%/-@9\$<2JR<D^0LP=VIVX6:W
MTC(7XB0-+(GZ:,. 4)4&C&/%.8,6L:%>IU^5(_,A[4?RZ5BKE^6F5@X3W\Q#
M>06IBB_\(AZF@T% HK!P4Q^";Q]"'J$&//#:(E$A?5N'._#JBT)9.Z<5;:Z:
M^L$ULZ>KL9K,8JKGW_/1P_VB\)<0ZDSPM%B'L)E@CX$D8=[($ L)PHFU>,!H
MH(V(Q1Q\]69'*^*E@2K_\K@>CZ^H^'UT]V-VZ7^9/I^JW%85-(C$YBDLIA>M
MQD#;X+:=TD)*[)7 :P>OAW,>NS]7S$%6*CX-9.G\%%JWV>L*L*+AK4#:&1<"
M$A-F!R!2.B H=, SC"CACE8F]<W#??(4<SXUE+?J#4)O7@T7)H8]Y*NM(.)"
MA>TDB.%MV%+$HH,0[@)/,6:*(\G5X-4@*_(4TFU\Z&*CK@B4M?-:YI[?)D@,
M3DSE$2-5!:RI@N]U(OA>30U@DKA@0>P1'_QXZ;U(Q>RL>F)_B%0]@#B56MQ?
M)HTS]=UD]'\+O5\RPM_K\?CK<^5 ZG+<]E\<I"*WH\(?4)2KE625"X0U8:F-
M_=XP4%X;$$_)5<6I]<F3U ,6Y:Y=OMAE]R]_F/'<CB9WSXV6IU<AA%&C2?B+
MF_K+'^I^-%G\^G<WFS>3591N!?-*&H8!%AP!XH6-K6G#GH1QA+"&#M'4 >C0
M.I5;&'P,-]?=:E%,*&"]WZ'_K:PL=C#L@*F/8;K08>EB42'G?0C3'6&6)2;T
M#E'R\K LOM3IP>O,P0?7C&I[/5/-;$@F!D?0Q/*'6.,U'\>"ZJ\!I*OP[>9J
M(4'XW:MZ.GJ]H600ES+X FX!ISR$<)9PX)%43FFM?/)^)BGDSIO-.46.#T>+
M<IWR9W>,S@I;1#P5P*M86HNQ H)4)BR53$L#0[";_ 6]%'+G31&<XE08CA;E
M)$^/\@+G\R9BO45Y:ZAV<?9;36/F>/$*O X05 *)^(:FJ5*72Z21/&\=]RG.
MBB&I4>X2<5MYHJR&%"CL*2"59T 9CP#E5BM(L5,V==S>9]\^6'WW*5+V*/!Z
M[MN_3.P@>;T+-XL7'H,=%W6<%ZJ)MR ?78_$W:$A^V;FCA(Y4>KMBVHBR5X_
M^I;;D(Q3*1& E%2!5A4'6E8"*.FY@TY039-W+MHA2U\7]9+FO/1GD]G(CL;S
M:-5K9^;-(HO]//><7?CE^OYA/EO.U76!;I0>NUNE#47*&6"@%X!P)H&48?[!
ML&]AX>^EPJDS$FDUR-QN/@7CUAU91H@+6(//QVHZO?3_B YC,KML%G4*9W^,
MXB;;.5^I"D"!@R+4&" 0E:#"7%GDN)8H]2J\4YB\M,O)D'H(N$KEW>?Z/FQ<
M;A'DU-(*@LIC#XBB\0$49$!5,4:,(Q72U4<P[UF<O-Q+!'@;&G6P?NX[?%?A
MH_.XE5EJ\G=WKUUSZQ"7IF(>>,5C(81V0!BH@&7828NQJBP\M&/;,WZ!C.B"
M79W6D 4XE9[N^>?7)YB8MI5RT@$9U 3$R&!'%N:655 @9RJHA4WL@5+)GC<-
M7]!2F84,!4R"K?[A8A[G\Z5_,\2Y&H^=_?2T_+WI\A>GMUI+:972 #%( !%4
M <$Q =1Y!2M)!$?D(U;?]B+G]<=Y>-9F01\(]&0<'RQC\_D%COB'/NT/6XV;
M.'?30OBA$SC&>1.<+0:>.@6((QAHC#C 89-92>J]TZE#OQ-)X 1F*,J0#[ML
M6P$"E0R6":L2DI03P;0+__@K@7-\ N<8Q@V<P#D&X@*6^YXZ?WK:/L BQ/25
M8T(Q :RV846R' .APJK O8!$:62E2KT5&%"=/U42Z2B6IMT9)Z-,L;/G0MV[
M940=-D9.(.Z 8SSH@X2.#\E!(+7 BAO,N$Y]^>203">]W4U'GE:D[HAD <S\
M$O:G]9-SU[/:_.OR(5ISF92!VBN"*@W,HG62M6'J0^$!1%XJY(,PR=N3[A2F
M1"YVQ7R]IWP2 #HSZ=$UND[$I>\N;+-&9N;L0IE?)O%^QO4O+TD^XG183@2H
M;(4!(1(!22T%3F ++825IJD[9.P5*&\&:U!.I0.B- ^U5,$[:YWV/!B'!>,0
MPH' P4+"4R,\X\PF+T[;(D;>^LN/\TH=C%Z$/TJ6,C,6*ZT% <)4'!"**B K
MI@ UW%FF+*Z\+RM ^7/FZ3-&(]W(4(#[[*GW<['?;5517!DJ '(^S'U&$!!,
M*0"IT%!IXA 29<V 9\%+W#@.S;FTQ.] @ (S]]?N+K;4^>X>ZB86./=(UN\:
MJF]^OI6(B5+RZ]]Z39 R3S@CK@H!,86 .![6^$J10+1*P@IB)&7JE/PN6?HZ
MOI=CJ>>!X_JQ_%*83F$:,2=C_V@:IA.S86=$3*QID6%K8S@W+K4WVRU-YGQA
M"B:LNYQ$IC\!/_+6GV#])]\FOF[N%]_23\L?)O0ZW3Z<VD<E4']PCZ8DLHYZ
M$"@;+ZMP&2]Q66"5YR'>Q=*IU"^<#.71WG;3>ZS]Z<7:SUMF3P1$,,S;"AD3
M@C;(@400 FZUTRK\$Y/4MWP[B%FJ#SR".[N/"X<!*V-H,6UB)5\=GQ>^;*Y=
M\S@R;I%8IPCQ2DH/K&"Q+E#$1^6Q!)(B1@WQUK2KY0X?6"%:^-,;R79]NY13
MMX' KA-:O@SFQ <]EAI,EPFK^+JJHV%OH$WE8T]H!Y0Q"BC&*?3<0JI:E4.V
MH\^F 'DXE ;338+T-'#NFNN;^F%DU/A[[<?S^]%836=!K[M&W2^SD3&);8PE
M .,8$CMGXL-L.NPK*ZN]=) Q?FA3U>9#V4G1%\=Z(*,60I"_G?WOM\F/D1Z%
M7WVOC$<>5A@J(+E'@, J*$.I!L:@\->:6D\.;KM;?2E/CG58BJ0Q:VZ.+-Z.
M_Z*:\=/U3-VYI2+3EX,PQ1F&F ,4+_$1"C$0''G ,(55(#_DIET;XKV?R7-*
M-! [TAFT@-1X4&'FXH;LTWPZFKCI]"5+L5A^&<5:P:H"L5%:7'X5$ 8;P"N/
M344LI<G;=^X5J)23G&%WN.FQ*8%HR_S'R^TI@J3R(@A/=#"+#L)#[ !$PJ@0
M64*_WOT\54:BA,*NA,"N4Z:SE7,O4QMYTJ4_E5I)":D$6F$&B(GW[*R+=R8@
MH=H1J=?+P'<L4#L^4$3:I0M>=6+CE>,CMKG5MW- RK2NA/7 4T*B3AP(*@0P
M(2(D4$!(2.HKRVWDREL(\^%+4VJD"F#?=_?H)G,WO968&X\0 1 R">(D 9))
M!QRRS$MD*Z]3E[J\?+L(;Y00U8VBO XF+H :\3G)2_]37=O50.*Z'MO;"I(@
M:X@"*R9C\U1E@13!A7N!C*U@" 9<Z@X\NZ7)O#\>FCZ)8"B 4"LOD'\.<V)<
M+UX[6KYT>FLT%V'OPH%3,305CH05FUI@B.-5\,U>H=3/N^P5*//:-KQ72@5&
M_DWT-DW67LZ]"M^J)Q,W_N[&L>WF4M'@E!4G AL.&+$($(IC<6LT*;&^XA1)
MP7W+K78/,?+VKAR,;!^,3P$^[MJ-PX_N?G(3UZAQ?+O>WH\FHWBN'.OP7N87
MM!XYC"L@G0GSJPJ>6]L8K4A'*L&U(##U'9MVDN7M2#FXUQL GB)(]]YLBV1M
M--:RAE-C@PA7/&P,XKTW;R50 A+ >?B!,TR8Y$OK 9%:T8R=,,W2 5( O^(6
M-&X^7YVRUZSBC$* N JS0KE8C\\5D)KKRD(C-4Y=6[4N0RL&\9-E4"^3%_#B
M\>6#BRXU6B8^4A,;D-P:QBAVF@.D=&RK;@R0IE* 5ZK"EDAO>.I%;XL8K8@C
M3I8X?0U? '>^38+K<M/9LP8+WQE?IPB1+@_;0*0KP T. 8F0%F O+:PT1\RF
MOOBW18Q6W)$GRYV^AB]@J7I18>DW+^I)_3(A;K'P!@6A0SQK=5AUH08R/F<9
MIH'BC&''W% <VB).NZQG=?)DZHM$.0]L+";$JA[/\^0E:'"44V>0 !B;H%1T
ML"HNTXQ9PCSW@B5O:+Q?HG8,.]W$>D(\BO!<R]?\EO(O7SRX199:XHB*!Z(V
M3A@(PE;0 &\-#7]"0O'41W\[1&G'I]/-M*= H  B7;C9RMY/>T8U=QI@JF,"
M0U&@98@WG5 BN&')A$I]#^2= .U(<[IY].[6SO_B\&+LJ3/_>5<__I<S]GGX
ML_AVR\WH/EY%?7U8]+W0VZZNO:/-ZJ#/C#'VC2C;OW#D';7.PO>\>!8^=?O\
ME?O%)UYIU-D<NT?LZ E6!_S[Y&$4![T):G\*/_Q7$C$W1\URAG\0BY?9VLHB
M&7WW._G<[$=M$^.U-F:6(_-N:&VW1B%8787/SIK[B?TZ5G=)D'H_8I8SZ$XX
M;;5$(2C%&7\^F=HF'4QK0V8YONWL_39M40A0_U/__B9?6@^X8^@LQYV=@-MO
MF\P OJZIHWMGO]9-/-W_58U[3[=]XV8Y0CP*NA96*6'B3<_#-MG=U*_BQDK9
MA+/OP/A9#O*.GX+MK%0LG@/!F.<T+1%ZA8#V;6)'CR,[5^/%=:\^0*T-E3<H
MVV_S^I !<D^E\?A-KI<KG;TFT;8!LR&TP^9U.P,4D.9\GO_AEP],FDXM"-^-
MG3=8;C6+]AJE +">>[.KJ;/OZC[C*T%WBTN!TT]/;[]SI9[BWRV4>=-H8J_&
M:K+2ISXMYH.(F+<+Y58RK)>J#8A, <3;W5D^+7L*[6 _*+IM&]H71(>%;&</
MX?/F^=7[Y_?)KL^^7P]"B\/?RWMYZ0/IT=KTN?=]VQ;=L!&*&J8/HEX&SE)8
MUC^,6K-+"=#],K'-^.ENY>F7^UE_W+:.FJ>"ZWC4]IFD!,B^_-&8JV:T]UF9
MECB]#96G^.EX<#:4+P&1G^+SG9_5S'U5H^97-9XG@&;+F'D*BH[':+<Y,H/U
M?F8__?U?LP65SG],[JY,/[=W8.@\93U'0=?../F;36^O9/G2+,X+!BK!V1P]
M2?G- :$3E-Y\=Z9^=,W3I=_XU@89.O&^U0=Z3-GEJ"^?Z9^<WSI@MKSB,?BL
M3M9]9LGL9..K6LO>57$-Z)VDWS9>-KSVVKUN983_KX]/!MF=M 7EKX.3OPY.
MCL+FHIY<N#H%*.]'RG?0N,_6]0'%"UI77!CR?C19V"SZUV0+S,; V9Q:UYU!
M&S/E=GEW=[.E4KVS3>^'RE8 VA6M[:;(C,^+0!,U?IJ.IFEJFW8.FJT8M.?>
M>Z=Y,J-W/?O756,NFYMI\V4Z&SW?WDE9)=_J ]DJ1;NB>HS9,B-\.9\%'Q_6
M\<E=0E>Z>]1LI:-=L3QHH'(6P(MZ]IM[7:E=JC+N-A_(5DF:8+$\:+;,"'\-
M@]83]Z)IB@/1'4-FJRCMBN)^TY2%V^>YNZF7]YN#GO$VK%ELK?LZVV.^D^VP
M.Q'";8Q8(.R_CNKQ\K'?_ZGOW7EL1=8\_:Q^'P+[O1_+=W">D@%M[%D@#8+&
M_YZK\<B/S%+Z&_7'LM=![V*)3A_,=U2?D@YM[5H6)8(;&ZO)4N!O]P_Q_<N@
M@!Z-1[.G-'NW;E_,5QN0B!3'6;:<""SE%F_/L/D*"!($867N];8(F#B.7A^V
M%8A%Y;H.VZB@4X':34-<^-W]>SYJ7OU*&J=\Q&=:@5Q4ZNMX&Y9:!73U.%0%
MT/N1DU3_[!$V0>7/E7KZ=7KEFD4#IXEQJ0M_VHS?8UX'X_2O]7D=)-N!ZQ$H
MK,[(=>US'PC]X<P\=GP_#V[BKFZ>>I>.;!\Q'TSK]JY;*I\[D3P>KXLW<HF*
M2'8/G*_Z:B\4]7%VR0S=E:L3X/0V2LZ:DL.VKO<HGK_()XATD02.];'RW84^
M$I0=1OBK5O$C5YJ_ZA/_JD\\#AO[SYMZ$8_WG1[O1\I61K5O=FQ5-C< X_&K
M6&FFQOIP^9;UK>:NV^B>&Y2[N]GBUM)D.OE5A<E[/;^_?\Y;36>3&SW^6C=G
M#V,]_JU)@=G17\NY4]N%6)W ? 7 'F4.*DZO'\WY=)8(W:V#YMS9M01QGS%R
M!S^I<>J,T3 3[9#UZW:F* 2EJZ9)#M3ZF/GF4P>L=A@D=Y;NW[.GL]\;.XTB
M)H!JVWCY.BRW<GM[3% *. -O1X[Y3KX\WAZ8MJ%Y,GN0=XI]^<.,[\(.ZOM#
M,[.;*J2>H>T^E^^2YI&8'VW!S-#_UGR9V*^QW<6E?U7BIV82!3]_;.QO33Q+
MMY.[LXG]9?(XG=D$!.C\T3*F_G'XUNF,G9DK,;SZ-EG*OR[INCYAL_%;DV(]
M[_[5,IQ&9[;T-G=FNOP:%+S[/-O*]Z!'^/$K[1/0Y/BO9=L4IJ%'9_.6XT7.
MII=^J<:E7S#X58W$[.C\T6S7/)/[D$[&SEW&_"+XL[P3N[EN/CN^KV.[T.V\
MGMCIYR;\1RKF)!(AV\72-#Q*"T1F5GU^M'9ZV5S.?C1?@H33*WLY>=7F8A;_
M_O?I=S\V4:V;V3@:*#[LD8I2*;Z?[7)K&CXEA"#WHSA.Q;JXWD>9J^-D6W3V
M'61N431WHG<I;9I:Z<W1\E5;]"N_+.W:R7E][<;.S)Q=<JCWC9/M(^8[_^^&
MUUZ[Y"XO"Z+8UUJL2^]')HS[=9)FKAT>/9\+[(9E:WOE]IG.-3\U]?SAVW0Z
M3XCHOG&S[7V[^M'#-LKM47_$WOWV5=!4*.X;-]N.LZMW/6RC['.QOHFO?*>X
MOK<^5K8N*9WGW%9;Y$?HS,SF:CQ^NE(CFPBH;4-FZX?2':\]ELE=4Q6/W(.$
MBZ@QD6O<-6:V-B<=@3M@F]S;SI>"_K/'NV2^<>>@^3J4=-UE'C!/0>@M)%OQ
M$"E!W#9VOO8B";#<8ZP27.FKJ,D=ZLZ1\S4&Z>-7#QDJ>YW/?#1[BD^;/)LR
MA#?WBR?</H]\$,8%;5.A>^2G\O4)Z0AW-U/F#AO7W,ROT\4BLGC\[4<]#E;^
M/DL521[WJ7PM1CKG[KJ8LCC\+]SLV\34]XERZ*T^D*_32#*L=YNM.(0WDLQ#
M(;WG0ZT0+RIWU,&,F9'?XGZBYLOD5QK0VWZC%=XE99^.-%YQD_QR]L,U \_O
M[=]H!75)B:LCC9=[5BL]'ZOFY]%TEO"H>_>HK> L*9UUT$"Y =ST+'TS(3N&
M;%6M4%(R:[]ILF?^7YQ_>@ /C=T*R9)262V-E7W97-O"]<5QZX"MP"LID['/
M++E;G<:5.6J4"+!MX[7"JZ3,PQZCE) K3O(\UNI K0 J*5VPS0S95[.Z=\W=
MRQBM\"@IF%]3OHQZX=YP'%OXB$J*MPNL=ZPG/RGUL!3LLYN:9K3(YR<J>#P\
M?"L02XJDVYLL^[ID1U$N-285>GS3+M4YYJ'16R%;4E#=VF"YE[7)=/)IXF?Q
M+DJR0M8=8[8J+B\IO#Y@G.Q'T6_7B-*=.6\?LQ5T)<73!XQ3:AO[;Y/I*!CS
MIE&+)PR;)A;@QO;\:Q>&>O:TW_.9) WNVZJ1H-O]QJ<V:-&Q:^S.8?ND,E^'
M^Q2?1.G?YW[K@!E;JA["XEWR<H\Q<J><7T7K?2EQ;:ALV.RU]E94"KJF>#8>
M;_$E:?JN[AZX *SVM& ]:)",F*GFW[/;Z[G[FU-QY=@4]7(1Y6Q%,/Z_"Y @
MPG !U)&CY>RR>AB4NH^%.D,Z'A3-\_K^OIY<S\(&*Q&BFR/F;+N:#M6=ELJ#
M[/.B_:=KM=]VK?NK[?Y?;?>/\X+_ZT:S'S^[>J*:K5W\=KBZ+?];SE5JMWGK
M5KH6L0QU6FD*6$S:&7^7GOG6B;_/FO&-:^ZGE_ZFL<&WILDX[1DV&TK'Q;&'
M#9,]FHU2I7BF]OU(V9J%')MGV*)^*9#<C&:]4T#OALK6]:,C*.\,D!F5[_.Q
M@Y6F,$;>MGZ8.?MUK.YZP;-KS&P=/8[#Z8!)\A\Y#X'9GF&SM? X#K;#ABG"
M 2[DBC?^U"R%$WPW7+;V'5T<X39#%.0,;YK[R2RM+UP9,EOCCNZN<-,@97G"
M1(#M'C5;SXY>?K XV%X"AN9^-%$)/>'ZB/G:='3QACOL40167_YX&#4IH5H;
M,%\3CBY(;;=&$4!]GC\+E@"BUZ'RM=3H LZZ!8J Y=J9>3.:C=ST[.[N[%&-
MQKTO<^T9-U]3C"Z [;7-:90L7=7CD0D*7#6U>2]YTI*E=Y\9H&1IMQK)2Y96
M/[7!D02U2]O'[W5@N!S>K@Z=*O8^/'HAY4U[<7M_RMC27IG]\W8Y+^K94M0T
M^?[V7RDD_=\3YSWV&]ZC+W\0_Z'5U/WW?_P_4$L#!!0    ( /. 65RL.N.]
M;1(  *A/   >    97AH:6)I=#$P-#EL871H879A:7)A=F%N;V8N:'1M[5SI
M4QLY%O^^?X4V<T&5(3;D()!)E2'.Q%,)4 9"Y=.6W"W;FG2W'$F-X_GK]QU2
M=]N&#,GLQ)#:U!2,W3J>GM[Q>T?S?.+S[,7SB9+IBW\]__?6EGAIDC)7A1>)
M5=*K5)1.%V-QF2KW06QMA5%'9CJW>CSQ8J>]\T1<&OM!7TE^[K7/U(NXSO.'
M_/GY0]KD^="D\Q?/4WTE=/KK ]W>:Z>[4NZI42H?)3M/96>OL_?X2;KW^-GN
M<+?]]#^[3Q_ 7!C/DYR?9^K7![DNMB8*"=A_NC/U!S.=^LE^I]W^Z<'".*\^
M^2V9Z7&Q3^3"TY&!PX7'B<F,W?^A3?\.\,G62.8ZF^__<JYSY<2QFHF!R67Q
M2\LIJT<\QND_%6P&^]+'62 $ELATH2)AG1VDIO=IHH?:BTY[^]&SYP]Q0CS/
MRJG^26IWEJA]M$QM9P>H?21>J:$MI9WCQ;87Z:4?_,70OKCAV3<D]HWT$RG>
M26WEE2S63T_R\P^/GAX8T;5)Z;43A]KXB;)RJN!CXNXV,P?JYQ\>[QT(^G<R
M&BDKS$CT\FEFYF0/AO-XL);H%\GVW3[.2R6M( &A8]UM8OM"YN)*@=)-,R4=
M&%UO1&**D;:Y,"7>!-X'?#DW)5Z+JJ]EIOUD\6+$!DB=^/F'O9V=]L&1R:>R
MF-.GSL'FMA#O88F9SC*A"^VUS+*YL&IJK,?U<>8[G2AQ:I73*6S0$J]T(0OX
M2A?T>&H<S#,%B<<GA1M?*?%26Y5X8^-P6%B<9K(HT'G((A7=0F9SIQU38 6<
MS7F1ROG*>8"TH1)OI4TFHN.  +1$,.T<-O?*Y@YGU%S!Q9&NH2K42'LGDM):
M6 G.-;7F"@Z1HNSBD, ,(:T2THF1R3(S<U\N(%$TIC)-X7Q;F1KY_=TG<-=D
MP76!C-O?ZNQ-UV#".Y5F?M.-#Q:8\2SR(E6)L1+E9;\$MEB<]N#%F9?6HV2<
MR0Q\S5H(?O BBJ*+U.0P90)RXXBJ2A1ICE(H_J9T+&]6*3&!$UE4UHFV?AZ^
M3$&HI'5!+!L/$I ))S9^[.RU=G=WMW=W-UMB-M$@Y!I'PW]%";[_3U@P[ ]B
M[F>FWF8&*\QK(N).&S^"HK> 2YMB"OHP1\N'SR/YKAS^ ;J)ZLU[@+Y?:36#
MXXOO1^QW[H'8@W4&#J&Y1$ND"D<CUBK]+"4R<X8D';"G'F8*904^3J5.:]%$
MZ1H9FY,S2*2;"#F3-MT&PPP2K*NS1;D#K1HKC" D1@D_H3C/4=UDXG$U$%-T
M#CA32#&&F06LFJDBE2S$P>2'X3(W)?"'2*IVT.PJ/0V;:'6ER(? 3H%DN(4I
M7H0BC8 #. -^2(P-G'B;M7\J%QU/4UVFTTPG$AF";G9B,KSJ+T,^=UII=N^!
MTAP&O_[/44J+[6L/UC>YE>*L26,!W0ED''*H15"P\E -O9VB,TOT%(4>5,NJ
M<0EN0D#TG0%2U(4K+6IP2PQ-4;*?HC E@#!5(2D H[)P0H%['&;:359Q%%@#
M@8@KS@1(94T.:ID3)?C[.U*61_= 67H?2^W7BZ=N(Y1H=YE44?M$#!=:)(_.
MF^2#,%,\G:O6(V_#!A]E'[P*RF*J76)5#$CPFT,#X_!#C$F<( [1KAA+7+_U
M0MB$7S1BIBX(>R1G#.J#7HW(N@+MB)20FR',ACAM:X0+@\?!/<3&SN.?-N-
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M2ORF<5F1^[PWY:D#7L0;Q_0Q\Y+2'#JIHL"0"M%%J"B%.+"Q,G(/KA?#"U.
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M0"$2P):/]^ ^3'A^*U@?['-5II!P=6MW5^RYKJYNI2?_**G:S#TF:7Q&%+4
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MHKV0&!^-EREC\0L=5V(4$V*(7TMD5 RZNR0< ZK@IB=RE9K8Z BWR:?]OSO
M\;KL>4T2;AXJ!V(U!VT1.;IWUE=4/,56_DZDU8[_B7SM!0YY,9#=FXDM '+W
M>]X[N>.^: ;^VIQVB 47P3AG( +5,\J'I0(42G&4GU9I\Y"KW0\8+,NDM4*L
MY/610AU +9&$3J[[+L *&C5$T_B?RM_9JA*_EA(JNW54YJ$[ -C[_[;H#\_.
M_10%%0H\"531#I3VLJ$4@$&59Q^V)Q/![RAQ^@++I4Y7&KICQ]DAS;/ 5>TD
M_/Y_!5_Q"!V->*"K%4"L2DD( U.H^&H^;QLD;5-F0 3<X\RHTL'*@ZP?)R=O
MU8ZEC]0;:U!##8$6CL< %7<N7&&JYG.9S,<J'0M*:#F_K8ZW=45](BM2-15H
MG23*\QU_A%@@[(6YO;%AW-NK4ABB;-V6I^HR @J%KL/G*2^,Z,V^'(&EBY1/
M>S)W[G.=CAY/@!1P-":J1SU0O?ATJ/+-U6O\#]U&T[_)MQK_HMG$U4O^AFO:
MM]%R6_M](VAWUS8W&\':MM\:-F@U#EI__+ =4%1G??/BL/O.$]X;\+<I>/YQ
MI[TSZU#%K-<J[EGP^(4_A7')Y:K8^)K$*R[N4RP:EP#9F1AI%(O3MV^"@^91
MJUMSMTR>7-:H?/8\=[AK&]_DCU>]_+':09^G*^J#;_.#OV[P8D?\^;<65GOB
M[9O.^R/C/M>\I%_AI T749.YNF$3QVX@6K$EW<5I-EK@/^8.,]G,/2]=NEMP
MA623 &R7QE\T"CNJ8VKL))$B9H-[09<$D'HO%W8?IU4=O\VF['[Q1WM(]TM&
M[*U;!/LN-V]2!OX52YLX?_-/MN)O;< 6[PP6RKB7L3W_*F(LUMXBG-'?O L?
M8167=GV7;[EX6'WZ"Y+[[F+F_P!02P,$%     @ \X!97#KX63E "   ?RD
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M@-GA$&6:NB'H;)*;.?=8SF0)Q+@6$7P_AX&4$I86YKG.JQWQ)C?0+A#P(E5
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M,C R-3$R,S%?9S(N:G!G4$L! A0#%     @ \X!97/=F^_(KCP$  C8" !0
M             ( !)84( &%R<70M,C R-3$R,S%?9S,N:G!G4$L! A0#%
M  @ \X!97+'+G(XF7 $ HK<- !4              ( !@A0* &%R<70M,C R
M-3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( /. 65Q.'ND!,\8  /^:"0 5
M          "  =MP"P!A<G%T+3(P,C4Q,C,Q7W!R92YX;6Q02P$"% ,4
M" #S@%E<K#KCO6T2  "H3P  '@              @ %!-PP 97AH:6)I=#$P
M-#EL871H879A:7)A=F%N;V8N:'1M4$L! A0#%     @ \X!97)#Q=D]: @
MDPH  !X              ( !ZDD, &5X:&EB:70R,3%L:7-T;V9S=6)S:61I
M87)I+FAT;5!+ 0(4 Q0    ( /. 65RC!;YJO@,  ) 2   >
M  "  8!,# !E>&AI8FET,C,Q+6%U9&ET;W)S8V]N<V5N="YH=&U02P$"% ,4
M    " #S@%E<)[RD04L(  "?*0  %P              @ %Z4 P 97AH:6)I
M=#,Q,6-E;W$T,C R-2YH=&U02P$"% ,4    " #S@%E<.OA9.4 (  !_*0
M%P              @ 'Z6 P 97AH:6)I=#,Q,F-F;W$T,C R-2YH=&U02P$"
M% ,4    " #S@%E<[!(<##T%  !/&P  &@              @ %O80P 97AH
M:6)I=#,R,6-E;V-F;W$T,C R-2YH=&U02P$"% ,4    " #S@%E<R+W&U)P9
M  "_B   '@              @ 'D9@P 97AH:6)I=#0S9&5S8W)I<'1I;VYO
?9G)E9VDN:'1M4$L%!@     0 !  4@0  +R #     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>arqt-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arqt="http://arcutis.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arqt-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2026-02-20</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arqt:KeithLeonardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arqt:KeithLeonardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arqt:SueJeanLinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arqt:SueJeanLinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arqt:SueJeanLinTradingArrangementOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arqt:SueJeanLinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arqt:SueJeanLinTradingArrangementCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:SecondaryEquityPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVEFoamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVEFoamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVEFoamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.05Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.05Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:ZORYVECream0.05Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:MajorCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:MajorCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:MajorCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:FourCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arqt:FiveCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arqt:PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arqt:PropertyPlantAndEquipmentExcludingLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:SatoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:SatoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:SatoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:SatoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HuadongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-07</startDate>
            <endDate>2022-09-07</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-07</startDate>
            <endDate>2022-09-07</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-07</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arqt:DucentisBiotherapeuticsLTDEquityInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:LeaseDescriptionAxis">arqt:WestlakeVillageCaliforniaLeaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:LeaseDescriptionAxis">arqt:WestlakeVillageCaliforniaLeaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:LeaseDescriptionAxis">arqt:WestlakeVillageCaliforniaLeaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:TrancheATermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:TrancheB1TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:TrancheB2TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:LoanAgreementTrancheC1ExpiringMarch312026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:LoanAgreementTrancheC2ExpiringJune302026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-30</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-01-01</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-09</startDate>
            <endDate>2024-08-09</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:DebtInstrumentTrancheAxis">arqt:TrancheCTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arqt:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:FirstEquityPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arqt:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arqt:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arqt:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2024-02-28</startDate>
            <endDate>2024-02-28</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-06</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2022EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2022EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2022EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-16</startDate>
            <endDate>2024-01-16</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-16</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">arqt:FirstGrantDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">arqt:SecondGrantDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">arqt:ThirdGrantDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:StockOptionExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arqt:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arqt:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalRoflumilastProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalRoflumilastProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalRoflumilastProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalJAKInhibitorProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalJAKInhibitorProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:TopicalJAKInhibitorProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:OtherEarlyStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:OtherEarlyStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arqt:OtherEarlyStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arqt:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="segment">
        <measure>arqt:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0001787306</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-36">false</dei:AmendmentFlag>
    <ecd:TrdArrDuration contextRef="c-5" id="f-71">P364D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-7" id="f-72">P360D</ecd:TrdArrDuration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-58" id="f-426">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-12" id="f-608">http://fasb.org/us-gaap/2025#OtherNonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-609">http://fasb.org/us-gaap/2025#OtherNonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-142" id="f-663">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <arqt:LesseeOperatingLeaseAdditionalYearsOfRentPayments contextRef="c-170" id="f-724">P5Y</arqt:LesseeOperatingLeaseAdditionalYearsOfRentPayments>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-10" id="f-739">http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-257"
      decimals="INF"
      id="f-950"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-39186</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">ARCUTIS BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">81-2974255</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">3027 Townsgate Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Westlake Village</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">91361</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">418-5006</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ARQT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-30" unitRef="usd">1527940146</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">124033382</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">Portions of the Registrant&#x2019;s Proxy Statement for the registrant&#x2019;s 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K to the extent stated herein. The Proxy Statement will be filed within 120 days of the registrant&#x2019;s fiscal year ended December&#160;31, 2025.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-37">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk management program is integrated into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Key elements of our cybersecurity risk management program include, but are not limited to, the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;cybersecurity awareness training of our employees, including incident response personnel, and senior management; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a third-party risk management process for key service providers based on our assessment of their criticality to our operations and respective risk profile, suppliers, and vendors;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information, as well as risks of data leakage and unauthorized access to sensitive information; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;ongoing review of the controls framework to support the security of emerging technologies, including AI and generative AI (GenAI), ensuring alignment with evolving risks and regulatory expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There can be no assurance that our and our third-party service providers&#x2019;, strategic partners&#x2019;, contractors&#x2019;, consultants&#x2019;, and collaborators&#x2019; cybersecurity risk management program and processes, including policies, controls, or procedures, will be fully implemented, complied with, or effective in protecting our systems and information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;See Part I, Item 1A. Risk Factors: &#x201c;We depend on our information technology systems, and any failure of these systems or those of our CROs or other contractors or consultants that we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations, financial condition, and prospects.&#x201d;&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-38">Our cybersecurity risk management program is integrated into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-42">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-44">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program. Our Audit Committee Chair, Sue-Jean Lin, has expertise in both cybersecurity risk management and AI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Audit Committee receives quarterly reports from our Chief Digital &amp;amp; Technology Officer and internal security staff on developments in our information technology (IT) infrastructure and cybersecurity program. This includes updates, as appropriate, on key IT initiatives, new and existing cybersecurity risks, and how management is managing those risks. In addition, the Chief Digital &amp;amp; Technology Officer updates the Audit Committee, where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant per our established severity and response framework. &lt;/span&gt;&lt;/div&gt;The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program and an annual report from management on our cybersecurity risks.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-43">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-45">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-47">The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program and an annual report from management on our cybersecurity risks.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-46">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-49">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity technology team, led by the Vice President, Core Technology &amp;amp; Security (VP CT&amp;amp;S), is responsible for managing and directing day-to-day assessment and management of material risks from cybersecurity threats, including oversight of our cybersecurity tools, controls, and strategies to protect organizational assets, networks, and data. The VP CT&amp;amp;S, who reports to our Chief Digital and Technology Officer, has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. He is an ISACA certified security manager and has over 20 years of experience in IT, with over 10 years specifically focused on cybersecurity risk management. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our VP CT&amp;amp;S takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public, or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our IT environment.&lt;/span&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-48">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity technology team, led by the Vice President, Core Technology &amp;amp; Security (VP CT&amp;amp;S), is responsible for managing and directing day-to-day assessment and management of material risks from cybersecurity threats, including oversight of our cybersecurity tools, controls, and strategies to protect organizational assets, networks, and data. The VP CT&amp;amp;S, who reports to our Chief Digital and Technology Officer, has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. He is an ISACA certified security manager and has over 20 years of experience in IT, with over 10 years specifically focused on cybersecurity risk management. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our VP CT&amp;amp;S takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public, or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our IT environment.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-50">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-51">He is an ISACA certified security manager and has over 20 years of experience in IT, with over 10 years specifically focused on cybersecurity risk management.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-52">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our VP CT&amp;amp;S takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public, or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our IT environment.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-53">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-54">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-55">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-5" id="f-56">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 18, 2025, Keith Leonard, a member of our Board of Directors, entered into a Rule 10b5-1 trading plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential exercise and sale of up to 39,272 options held by Mr. Leonard between February 17, 2026 and February 16, 2027.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-5" id="f-57">November 18, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-5" id="f-58">Keith Leonard</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-5" id="f-59">member of our Board of Directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-60">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-6" decimals="INF" id="f-61" unitRef="shares">39272</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-5" id="f-62">February 16, 2027</ecd:TrdArrExpirationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-7" id="f-63">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 13, 2025, Sue-Jean Lin, a member of our Board of Directors, entered into a Rule 10b5-1 trading plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential exercise and sale of up to 77,880 options, as well as the potential sale of up to 13,004 shares of Common Stock held by Ms. Lin between February 24, 2026 and February 19, 2027.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-7" id="f-64">December 13, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-7" id="f-65">Sue-Jean Lin</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-7" id="f-66">member of our Board of Directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-7" id="f-67">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-8" decimals="INF" id="f-68" unitRef="shares">77880</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-9" decimals="INF" id="f-69" unitRef="shares">13004</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-7" id="f-70">February 19, 2027</ecd:TrdArrExpirationDate>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-73">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-74">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-75">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-76">Los Angeles, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-10" decimals="-3" id="f-77" unitRef="usd">42907000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-11" decimals="-3" id="f-78" unitRef="usd">71335000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-10" decimals="-3" id="f-79" unitRef="usd">308000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-11" decimals="-3" id="f-80" unitRef="usd">617000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-10" decimals="-3" id="f-81" unitRef="usd">178075000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-11" decimals="-3" id="f-82" unitRef="usd">156620000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-10" decimals="-3" id="f-83" unitRef="usd">146229000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-11" decimals="-3" id="f-84" unitRef="usd">73066000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-10" decimals="-3" id="f-85" unitRef="usd">22634000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-11" decimals="-3" id="f-86" unitRef="usd">14526000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-10" decimals="-3" id="f-87" unitRef="usd">21079000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-11" decimals="-3" id="f-88" unitRef="usd">19656000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-10" decimals="-3" id="f-89" unitRef="usd">411232000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-11" decimals="-3" id="f-90" unitRef="usd">335820000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-10" decimals="-3" id="f-91" unitRef="usd">1043000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-11" decimals="-3" id="f-92" unitRef="usd">1041000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-10" decimals="-3" id="f-93" unitRef="usd">14812000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-11" decimals="-3" id="f-94" unitRef="usd">9479000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-10" decimals="-3" id="f-95" unitRef="usd">4467000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-11" decimals="-3" id="f-96" unitRef="usd">1953000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-10" decimals="-3" id="f-97" unitRef="usd">1419000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-11" decimals="-3" id="f-98" unitRef="usd">596000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-10" decimals="-3" id="f-99" unitRef="usd">432973000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-11" decimals="-3" id="f-100" unitRef="usd">348889000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-10" decimals="-3" id="f-101" unitRef="usd">12528000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-11" decimals="-3" id="f-102" unitRef="usd">14220000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-10" decimals="-3" id="f-103" unitRef="usd">1000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-11" decimals="-3" id="f-104" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-10" decimals="-3" id="f-105" unitRef="usd">116310000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-106" unitRef="usd">66793000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-10" decimals="-3" id="f-107" unitRef="usd">129838000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-108" unitRef="usd">81013000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-10" decimals="-3" id="f-109" unitRef="usd">5266000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-11" decimals="-3" id="f-110" unitRef="usd">2562000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-10" decimals="-3" id="f-111" unitRef="usd">107959000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-11" decimals="-3" id="f-112" unitRef="usd">107203000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-10" decimals="-3" id="f-113" unitRef="usd">431000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-11" decimals="-3" id="f-114" unitRef="usd">570000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-10" decimals="-3" id="f-115" unitRef="usd">243494000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-11" decimals="-3" id="f-116" unitRef="usd">191348000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-10" id="f-117" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-11" id="f-118" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-119"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-120"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-10"
      decimals="INF"
      id="f-121"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-11"
      decimals="INF"
      id="f-122"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-123"
      unitRef="shares">123332672</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-10"
      decimals="INF"
      id="f-124"
      unitRef="shares">123332672</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-11"
      decimals="INF"
      id="f-125"
      unitRef="shares">117848033</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-126"
      unitRef="shares">117848033</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-10" decimals="-3" id="f-127" unitRef="usd">12000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-11" decimals="-3" id="f-128" unitRef="usd">12000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-10" decimals="-3" id="f-129" unitRef="usd">1327595000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-11" decimals="-3" id="f-130" unitRef="usd">1279479000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-10" decimals="-3" id="f-131" unitRef="usd">-44000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-11" decimals="-3" id="f-132" unitRef="usd">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-10" decimals="-3" id="f-133" unitRef="usd">-1138084000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-11" decimals="-3" id="f-134" unitRef="usd">-1121943000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-135" unitRef="usd">189479000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-136" unitRef="usd">157541000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-10" decimals="-3" id="f-137" unitRef="usd">432973000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-11" decimals="-3" id="f-138" unitRef="usd">348889000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">372072000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-12" decimals="-3" id="f-140" unitRef="usd">166542000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-13" decimals="-3" id="f-141" unitRef="usd">29186000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">4000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-12" decimals="-3" id="f-143" unitRef="usd">30000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-13" decimals="-3" id="f-144" unitRef="usd">30420000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">376072000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-3" id="f-146" unitRef="usd">196542000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-3" id="f-147" unitRef="usd">59606000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">36695000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-12" decimals="-3" id="f-149" unitRef="usd">19128000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-13" decimals="-3" id="f-150" unitRef="usd">4987000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">77051000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-12" decimals="-3" id="f-152" unitRef="usd">76420000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-3" id="f-153" unitRef="usd">110575000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">274553000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-12" decimals="-3" id="f-155" unitRef="usd">229391000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-156" unitRef="usd">185145000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">388299000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-12" decimals="-3" id="f-158" unitRef="usd">324939000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-13" decimals="-3" id="f-159" unitRef="usd">300707000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">-12227000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-3" id="f-161" unitRef="usd">-128397000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-162" unitRef="usd">-241101000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">8897000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-12" decimals="-3" id="f-164" unitRef="usd">16126000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-13" decimals="-3" id="f-165" unitRef="usd">12517000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">12083000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-12" decimals="-3" id="f-167" unitRef="usd">27168000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-13" decimals="-3" id="f-168" unitRef="usd">29712000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">443000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-170" unitRef="usd">47000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-171" unitRef="usd">-731000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">-14970000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-12" decimals="-3" id="f-173" unitRef="usd">-139392000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-13" decimals="-3" id="f-174" unitRef="usd">-259027000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">1171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-176" unitRef="usd">647000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-177" unitRef="usd">3113000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">-16141000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-179" unitRef="usd">-140039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-180" unitRef="usd">-262140000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">-206000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-12" decimals="-3" id="f-182" unitRef="usd">219000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-13" decimals="-3" id="f-183" unitRef="usd">1186000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">169000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-185" unitRef="usd">-230000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-186" unitRef="usd">-96000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">-37000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-188" unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-189" unitRef="usd">1090000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">-16178000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="-3" id="f-191" unitRef="usd">-140050000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-192" unitRef="usd">-261050000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-193"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-194"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-195"
      unitRef="usdPerShare">-1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-196"
      unitRef="usdPerShare">-1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-197"
      unitRef="usdPerShare">-3.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-198"
      unitRef="usdPerShare">-3.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-199" unitRef="shares">127234000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-200" unitRef="shares">127234000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-201" unitRef="shares">120958000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="0" id="f-202" unitRef="shares">120958000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="0" id="f-203" unitRef="shares">69305000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="0" id="f-204" unitRef="shares">69305000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-205"
      unitRef="shares">61037000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-206" unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-207" unitRef="usd">930425000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-208" unitRef="usd">-1086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-209" unitRef="usd">-719764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-210" unitRef="usd">209581000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-19" decimals="-3" id="f-211" unitRef="usd">6546000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-20"
      decimals="INF"
      id="f-212"
      unitRef="shares">33425000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="-3" id="f-213" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-214" unitRef="usd">95762000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-19" decimals="-3" id="f-215" unitRef="usd">95765000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-13" decimals="-3" id="f-216" unitRef="usd">116000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-22"
      decimals="INF"
      id="f-217"
      unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-218" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-23" decimals="-3" id="f-219" unitRef="usd">3136000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="-3" id="f-220" unitRef="usd">3136000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-22"
      decimals="INF"
      id="f-221"
      unitRef="shares">348000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-23" decimals="-3" id="f-222" unitRef="usd">1247000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-3" id="f-223" unitRef="usd">1247000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-22"
      decimals="INF"
      id="f-224"
      unitRef="shares">440000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares
      contextRef="c-22"
      decimals="INF"
      id="f-225"
      unitRef="shares">15000</arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares>
    <arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises contextRef="c-23" decimals="-3" id="f-226" unitRef="usd">0</arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises>
    <arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises contextRef="c-13" decimals="-3" id="f-227" unitRef="usd">0</arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-22"
      decimals="INF"
      id="f-228"
      unitRef="shares">272000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-23" decimals="-3" id="f-229" unitRef="usd">1175000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-13" decimals="-3" id="f-230" unitRef="usd">1175000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-231" unitRef="usd">38813000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-232" unitRef="usd">38813000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-24" decimals="-3" id="f-233" unitRef="usd">1186000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-13" decimals="-3" id="f-234" unitRef="usd">1186000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-24" decimals="-3" id="f-235" unitRef="usd">-96000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-236" unitRef="usd">-96000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-237" unitRef="usd">-262140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-238" unitRef="usd">-262140000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-239"
      unitRef="shares">96787000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-240" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-241" unitRef="usd">1070558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-242" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-243" unitRef="usd">-981904000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-244" unitRef="usd">88667000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-31" decimals="-3" id="f-245" unitRef="usd">10820000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-32"
      decimals="INF"
      id="f-246"
      unitRef="shares">18158000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-32" decimals="-3" id="f-247" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-33" decimals="-3" id="f-248" unitRef="usd">161679000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-31" decimals="-3" id="f-249" unitRef="usd">161682000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-34"
      decimals="INF"
      id="f-250"
      unitRef="shares">649000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-35" decimals="-3" id="f-251" unitRef="usd">2807000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-12" decimals="-3" id="f-252" unitRef="usd">2807000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-34"
      decimals="INF"
      id="f-253"
      unitRef="shares">1720000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-34"
      decimals="INF"
      id="f-254"
      unitRef="shares">534000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-35" decimals="-3" id="f-255" unitRef="usd">1713000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-12" decimals="-3" id="f-256" unitRef="usd">1713000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-257" unitRef="usd">42722000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-258" unitRef="usd">42722000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-36" decimals="-3" id="f-259" unitRef="usd">219000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-12" decimals="-3" id="f-260" unitRef="usd">219000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-36" decimals="-3" id="f-261" unitRef="usd">-230000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-262" unitRef="usd">-230000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-3" id="f-263" unitRef="usd">-140039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-264" unitRef="usd">-140039000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-38"
      decimals="INF"
      id="f-265"
      unitRef="shares">117848000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-266" unitRef="usd">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-267" unitRef="usd">1279479000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-268" unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-269" unitRef="usd">-1121943000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-270" unitRef="usd">157541000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-42"
      decimals="INF"
      id="f-271"
      unitRef="shares">714000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-43" decimals="-3" id="f-272" unitRef="usd">4597000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">4597000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-42"
      decimals="INF"
      id="f-274"
      unitRef="shares">2271000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <arqt:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="c-42"
      decimals="INF"
      id="f-275"
      unitRef="shares">2285000</arqt:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-42"
      decimals="INF"
      id="f-276"
      unitRef="shares">215000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-43" decimals="-3" id="f-277" unitRef="usd">2376000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">2376000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-43" decimals="-3" id="f-279" unitRef="usd">41143000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">41143000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-44" decimals="-3" id="f-281" unitRef="usd">-206000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">-206000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-44" decimals="-3" id="f-283" unitRef="usd">169000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">169000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-45" decimals="-3" id="f-285" unitRef="usd">-16141000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">-16141000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-46"
      decimals="INF"
      id="f-287"
      unitRef="shares">123333000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-288" unitRef="usd">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-289" unitRef="usd">1327595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-290" unitRef="usd">-44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-291" unitRef="usd">-1138084000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-292" unitRef="usd">189479000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">-16141000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-294" unitRef="usd">-140039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-295" unitRef="usd">-262140000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">40364000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-3" id="f-297" unitRef="usd">41730000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-3" id="f-298" unitRef="usd">38813000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">4667000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="-3" id="f-300" unitRef="usd">1959000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-3" id="f-301" unitRef="usd">750000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">1756000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-12" decimals="-3" id="f-303" unitRef="usd">5404000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-13" decimals="-3" id="f-304" unitRef="usd">4030000</us-gaap:PaidInKindInterest>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">2094000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-12" decimals="-3" id="f-306" unitRef="usd">6901000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-13" decimals="-3" id="f-307" unitRef="usd">6989000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">-652000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-12" decimals="-3" id="f-309" unitRef="usd">-769000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-13" decimals="-3" id="f-310" unitRef="usd">-1980000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">73163000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="-3" id="f-312" unitRef="usd">47259000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-13" decimals="-3" id="f-313" unitRef="usd">17349000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">7329000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-12" decimals="-3" id="f-315" unitRef="usd">400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-13" decimals="-3" id="f-316" unitRef="usd">5620000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">2007000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-12" decimals="-3" id="f-318" unitRef="usd">948000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-13" decimals="-3" id="f-319" unitRef="usd">8621000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">-1694000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-12" decimals="-3" id="f-321" unitRef="usd">2229000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-13" decimals="-3" id="f-322" unitRef="usd">3152000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">50044000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-12" decimals="-3" id="f-324" unitRef="usd">32033000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-13" decimals="-3" id="f-325" unitRef="usd">5594000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <arqt:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">-680000</arqt:IncreaseDecreaseInOperatingLeaseLiabilities>
    <arqt:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-12" decimals="-3" id="f-327" unitRef="usd">-735000</arqt:IncreaseDecreaseInOperatingLeaseLiabilities>
    <arqt:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-13" decimals="-3" id="f-328" unitRef="usd">-657000</arqt:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">-5625000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-3" id="f-330" unitRef="usd">-112158000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-3" id="f-331" unitRef="usd">-247057000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">246986000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-12" decimals="-3" id="f-333" unitRef="usd">254820000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-13" decimals="-3" id="f-334" unitRef="usd">225840000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">227419000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-12" decimals="-3" id="f-336" unitRef="usd">288783000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-13" decimals="-3" id="f-337" unitRef="usd">406500000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">686000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-12" decimals="-3" id="f-339" unitRef="usd">143000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-3" id="f-340" unitRef="usd">428000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">10000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-12" decimals="-3" id="f-342" unitRef="usd">5000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-13" decimals="-3" id="f-343" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">-30253000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-3" id="f-345" unitRef="usd">28820000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-3" id="f-346" unitRef="usd">180232000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-12" decimals="-3" id="f-348" unitRef="usd">161682000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-13" decimals="-3" id="f-349" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-12" decimals="-3" id="f-351" unitRef="usd">100000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-13" decimals="-3" id="f-352" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">4597000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-12" decimals="-3" id="f-354" unitRef="usd">2807000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-13" decimals="-3" id="f-355" unitRef="usd">1247000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">2376000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-12" decimals="-3" id="f-357" unitRef="usd">1713000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-13" decimals="-3" id="f-358" unitRef="usd">1175000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <arqt:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">0</arqt:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <arqt:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts contextRef="c-12" decimals="-3" id="f-360" unitRef="usd">0</arqt:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <arqt:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts contextRef="c-13" decimals="-3" id="f-361" unitRef="usd">95765000</arqt:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <arqt:ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">0</arqt:ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts>
    <arqt:ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts contextRef="c-12" decimals="-3" id="f-363" unitRef="usd">0</arqt:ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts>
    <arqt:ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts contextRef="c-13" decimals="-3" id="f-364" unitRef="usd">3136000</arqt:ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">6973000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-3" id="f-366" unitRef="usd">66202000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-3" id="f-367" unitRef="usd">101323000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">168000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-12" decimals="-3" id="f-369" unitRef="usd">-235000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-13" decimals="-3" id="f-370" unitRef="usd">-50000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">-28737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-3" id="f-372" unitRef="usd">-17371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-3" id="f-373" unitRef="usd">34448000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-374" unitRef="usd">71952000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-30" decimals="-3" id="f-375" unitRef="usd">89323000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-3" id="f-376" unitRef="usd">54875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-10" decimals="-3" id="f-377" unitRef="usd">43215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-378" unitRef="usd">71952000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-30" decimals="-3" id="f-379" unitRef="usd">89323000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">2858000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-12" decimals="-3" id="f-381" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-13" decimals="-3" id="f-382" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">10327000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-12" decimals="-3" id="f-384" unitRef="usd">22209000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="-3" id="f-385" unitRef="usd">25445000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-386">Description of Business&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arcutis Biotherapeutics, Inc. (the Company) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The Company&#x2019;s strategy is to focus on validated biological targets and to use its drug development platform and deep dermatology expertise to develop differentiated products that have the potential to address the major shortcomings of existing therapies in its targeted indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received U.S. Food and Drug Administration (FDA) approval of its first product, ZORYVE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (roflumilast) cream 0.3% (ZORYVE cream 0.3%), in July 2022, for the treatment of plaque psoriasis, including intertriginous psoriasis, in individuals 12 years of age and older (subsequently approved down to 6 years old in October 2023), and began U.S. commercialization in August 2022. The Company also received Health Canada approval of ZORYVE cream 0.3% in plaque psoriasis in April 2023 and began Canadian commercialization in June 2023. The Company received FDA approval of ZORYVE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (roflumilast) topical foam 0.3% (ZORYVE foam), in December 2023, for the treatment of seborrheic dermatitis in individuals 9 years of age and older, and began U.S. commercialization in January 2024. The Company received FDA approval of ZORYVE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (roflumilast) cream 0.15% (ZORYVE cream 0.15%) and began U.S. commercialization, in July 2024, for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. The Company received Health Canada approval of ZORYVE foam for seborrheic dermatitis in October 2024, and began Canadian commercialization in December 2024. The Company received Health Canada approval for ZORYVE cream 0.15% for atopic dermatitis in March 2025, and began Canadian commercialization in April 2025. The Company also received FDA approval of ZORYVE foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and adolescents 12 years of age and older in May 2025, and began U.S. commercialization in June 2025. The Company received FDA approval of ZORYVE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (roflumilast) cream 0.05% (ZORYVE cream 0.05%) in October 2025 and began commercialization for the topical treatment of mild to moderate atopic dermatitis in children ages 2 to 5 years of age.  The Company received Health Canada approval for ZORYVE foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and adolescents 12 years of age and older in October 2025, and began Canadian commercialization in November 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has incurred significant annual losses and negative cash flows from operations since its inception and had an accumulated deficit of $1,138.1 million and $1,121.9 million as of December&#160;31, 2025 and 2024, respectively. The Company may continue to incur operating losses. The Company had cash, cash equivalents, restricted cash, and marketable securities of $221.3&#160;million and $228.6&#160;million as of December&#160;31, 2025 and 2024, respectively. The Company had $100.0&#160;million outstanding under the Loan Agreement as of December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its existing capital resources will be sufficient to meet the projected operating requirements for at least 12 months from the date of issuance of its financial statements. If the Company's available cash, cash equivalents and marketable securities and anticipated future cash flows from operations are insufficient to satisfy its liquidity requirements, the Company may need to raise additional capital to fund its operations. No assurance can be given as to whether additional financing will be available on terms acceptable to the Company or at all. If sufficient funds on acceptable terms are not available when needed, the Company may be required to curtail certain planned activities. Failure to manage discretionary spending or raise additional funds, as needed, may adversely impact the Company&#x2019;s ability to achieve its intended business objectives and have an adverse effect on its results of operations and future prospects.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-10" decimals="-5" id="f-387" unitRef="usd">-1138100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-11" decimals="-5" id="f-388" unitRef="usd">-1121900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <arqt:CashCashEquivalentsAndMarketableSecurities contextRef="c-10" decimals="-5" id="f-389" unitRef="usd">221300000</arqt:CashCashEquivalentsAndMarketableSecurities>
    <arqt:CashCashEquivalentsAndMarketableSecurities contextRef="c-11" decimals="-5" id="f-390" unitRef="usd">228600000</arqt:CashCashEquivalentsAndMarketableSecurities>
    <us-gaap:LongTermDebt contextRef="c-50" decimals="-5" id="f-391" unitRef="usd">100000000.0</us-gaap:LongTermDebt>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-392">Summary of Significant Accounting Policies&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and all intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts, which are not material, have been reclassified to conform to current year presentation in the consolidated balance sheets, consolidated statements of operations and comprehensive loss, consolidated statement of cash flows and the notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions include those related to revenue recognition, accrued and prepaid research and development expenses, and income taxes. Additionally, the Company uses available market information to assess the fair value of its marketable securities. The Company regularly evaluates its estimates using historical experience, expectations of future impacts and other assumptions that the Company believes are reasonable, and the Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. If actual results differ from those estimates, the Company includes the updates in its consolidated financial statements in the period the actual amounts become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with original maturities of greater than three months are classified as marketable securities on the balance sheet. Marketable securities consist of investment grade short to intermediate-term fixed income investments that have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the consolidated balance sheets due to their highly liquid nature and availability for use in current operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive income (loss) on the consolidated balance sheets. Realized gains and losses as well as credit losses, if any, on marketable securities are included in other income (expense), net in the statements of operations and comprehensive loss. Interest on marketable securities is included in interest income in the statements of operations and comprehensive loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. In making this judgment, the Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost, the Company's intent to sell or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, the financial condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular security. To date, no such credit losses have occurred or have been recorded. The cost of investments sold is based on the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s trade accounts receivable consists of amounts due primarily from pharmaceutical wholesalers and specialty pharmacy providers in the United States and Canada (collectively, its customers) related to sales of ZORYVE and have standard payment terms. For certain customers, the trade accounts receivable for the customer is net of distribution service fees, prompt pay discounts, and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company will reserve against trade accounts receivable for estimated credit losses that may arise and any amounts determined to be uncollectible will be written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was not material as of December&#160;31, 2025 and 2024 and the amounts of trade receivable amounts written off for the years ended December&#160;31, 2025, 2024, and 2023 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values its inventories at the lower-of-cost or net realizable value. The Company determines the cost of its inventories, which includes costs related to products held for sale in the ordinary course of business, products in process of production for such sale, and items to be currently consumed in the production of goods to be available for sale, on a first-in, first-out (FIFO) basis. Due to the nature of the Company&#x2019;s supply chain process, inventory that is owned by the Company is physically stored at third-party warehouses, logistics providers, and contract manufacturers. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. If they occur, such charges are recorded as a component of cost of sales in the consolidated statements of operations and comprehensive loss. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products that may be used in clinical development programs are excluded from inventory and their costs are charged to research and development expense in the consolidated statement of operations as incurred, as long as they do not have an alternative use. Prior to the initial dates of regulatory approval, costs related to the production of inventory were recorded as research and development expense on the Company&#x2019;s consolidated statements of operations and comprehensive loss in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid a milestone payment of $7.5&#160;million to AstraZeneca in the third quarter of 2022 related to the FDA approval and launch of ZORYVE cream 0.3%. This milestone payment was capitalized as an intangible asset and will be amortized to cost of sales over its useful life of 10 years from the date of first commercial sale, as this is the minimum amount of time that the related License Agreement will be in effect. The Company paid additional milestone payments of $5.0&#160;million related to the achievement of $100.0&#160;million worldwide net sales in October 2024 and $10.0&#160;million related to the achievement of $250.0&#160;million worldwide net sales in May 2025. These milestone payments were recorded as cumulative catch-up adjustments to the carrying value of the intangible asset. Amortization expense was $4.7&#160;million, $2.0&#160;million, and $0.8&#160;million for the years ended December&#160;31, 2025, 2024, and 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively. See Note 7. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated future amortization expense for the intangible assets subsequent to December&#160;31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its long-lived assets, including intangibles, for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results. No impairment losses were recorded for the years ended December&#160;31, 2025, 2024, and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity (VIE). If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company&#x2019;s consolidated financial statements. The Company&#x2019;s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by either the financial institutions holding its cash or by its customers owing trade receivables to the extent recorded on the consolidated&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;balance sheets. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments, in addition to those presented in Note 4, include cash equivalents, accounts receivable, accounts payable, accrued liabilities, and long-term debt. The carrying amount of cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to their short maturities. As the long-term debt is subject to variable interest rates that are based on market rates which regularly reset, the Company believes that the carrying value of the long-term debt approximates its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis on the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets which range from &lt;span style="-sec-ix-hidden:f-426"&gt;two&lt;/span&gt; to five years. Leasehold improvements are depreciated on a straight-line basis over the shorter of their estimated useful lives or lease terms. Maintenance and repairs are expensed as incurred. The Company reviews the carrying values of its property and equipment for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. There were no impairments recognized during the years ended December 31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception. Right-of-use (ROU) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The classification of the Company&#x2019;s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information available at lease commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the lease liability, includes any lease payments made prior to or on lease commencement and is adjusted for lease incentives and initial direct costs incurred, as applicable. Lease expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease agreements includes lease and non-lease components and the Company has elected to not separate such components for all classes of assets. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with terms of 12 months or less (short-term leases) for all classes of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued and Prepaid Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records prepaid expenses and accrued liabilities for estimated research and development activities conducted by third-party service providers, which include the conduct of nonclinical studies, clinical trials, and contract manufacturing activities. These costs are a significant component of the Company&#x2019;s research and development expenses. The Company records these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid costs balances in each reporting period. As actual costs become known, the Company adjusts its balances for these activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue, Net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells its product to its customers in the United States and Canada. The Company&#x2019;s customers subsequently resell the products to pharmacies, health care providers, and patients. In accordance with ASC 606, the Company recognizes net product revenue from sales when the customers obtain control of the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s products, which typically occurs upon delivery to the customer. The Company&#x2019;s payment terms are generally between 30 - 65 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales are recorded at the net sales price, or &#x201c;transaction price,&#x201d; which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution service fees, (b) government and private payer rebates, chargebacks, discounts and fees, (c) product returns and (d) costs of co-pay assistance programs for patients, as well as other sales deductions. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to trade receivables, net if payable to a customer or accrued liabilities if payable to a third-party. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company&#x2019;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is recognized as product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual results vary from the Company&#x2019;s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Service Fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: data reporting, inventory management, chargeback administration, and service level commitment. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prompt Pay Discounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company provides some of its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from its gross product revenue and accounts receivable at the time such revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company provides customers a credit for all products returned in accordance with the Company&#x2019;s returned goods policy. Once the product is returned, it is destroyed. The Company does not record a right-of-return asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the early product launch period, the Company estimated its provision for sales returns based on industry data and adjusted the transaction price for such estimates at the time of sale to the customer. As the Company continues to collect data on its actual product returns, it has and will continue to refine its estimated returns rate and adjust its accrual, which affects revenue in the period of adjustment. No such material adjustments were recorded for the year ended December 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargeback&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: A chargeback is the difference between the manufacturer's invoice price to the wholesaler and the wholesaler&#x2019;s customer's contract price. The wholesaler tracks these sales and "charges back" the manufacturer for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price for such discount at the time of sale to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accrues rebates for contractually agreed-upon discounts with private payers and mandated discounts under government programs such as the Medicaid Drug Rebate Program in the United States. The Company's estimates for expected utilization of private payer rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates are generally invoiced and paid in arrears. The accrual balance consists of invoiced amounts not yet paid as well as an estimate of the amount expected to be incurred but not yet invoiced to the Company as of the end of the reporting period. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product revenue, net in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other revenue is related to the Huadong License and Collaboration Agreement and Sato License Agreement. See Note 7. The Company evaluated the agreements with Huadong and Sato and determined that they are within the scope of ASC 606. The Company applied the five-step model as required by ASC 606 to determine revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The nonrefundable upfront payments received in connection with the transfer of the license and related know-how to Huadong in September 2023 and to Sato in March 2024 were determined to be distinct performance obligations, and therefore were recognized in Other revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company evaluated whether the development and regulatory milestones are considered probable of being reached and determined that their achievement is highly dependent on factors outside of the Company&#x2019;s control. Therefore, these payments are subject to significant revenue reversal and are therefore not included in the transaction price. At the end of each reporting period, the Company will re-evaluate the probability of achievement of each milestone and, if necessary, adjust its estimate of the overall transaction price and accordingly recognize the related revenue once the probability of significant reversal of revenue is low. Any such adjustments are recorded on a cumulative catch-up basis, and would be reported in Other revenue in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The sales milestones and royalties will be recognized in Other revenue when the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes direct and indirect costs related to the manufacturing and distribution of ZORYVE, including raw materials, third-party manufacturing costs, packaging services, freight-in, third-party royalties payable on the Company&#x2019;s net product revenue, and amortization of certain intangible assets associated with ZORYVE. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon related FDA approval dates for each product. As a result, manufacturing and other inventory costs incurred prior to FDA approval were expensed and, therefore, are not included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, license fees, stock-based compensation expense, materials, supplies, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company&#x2019;s license agreements have been considered an acquisition of a business. For asset acquisitions, contingent consideration is recognized when the contingency is resolved and the consideration is paid or becomes payable. The upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when paid or become payable, provided there is no alternative future use of the rights in other research and development projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses are expensed as incurred and consist primarily of salaries and related costs, including payroll taxes, benefits, stock-based compensation, and travel, and costs related to sales and marketing of ZORYVE. Other selling, general and administrative expenses include legal costs of pursuing patent protection of the Company's intellectual property, insurance, and professional services fees for auditing, tax, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and general legal services. Advertising costs are expensed as incurred and were $25.3&#160;million, $6.9&#160;million, $11.2&#160;million for the years ended December&#160;31, 2025, 2024, and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for such awards is the date of grant and the expense is recognized on a straight-line basis over the expected vesting period. For share-based awards that vest subject to a performance condition, the Company will recognize compensation cost for awards if and when the Company concludes that it is probable that the awards with a performance condition will be achieved on an accelerated attribution method. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not. Due to the Company&#x2019;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets for the United States have been fully offset by a valuation allowance. The Company has an immaterial deferred tax asset related to foreign jurisdictions which is not offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties incurred in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company translates the assets and liabilities of its foreign subsidiaries where the local currencies have been determined to be the functional currencies into U.S. dollars using current exchange rates. Adjustments for foreign currency translation adjustments are recognized in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. The earnings or loss of these subsidiaries are translated in U.S. dollars using average exchange rates in effect during each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Promotion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n July 2024, the Company entered into a promotion agreement with Kowa Pharmaceuticals America, Inc. (Kowa) to leverage Kowa's primary care sales force to exclusively market and promote ZORYVE to primary care practitioners and pediatricians for all FDA-approved indications until July 2029. The Company recognizes all revenue and Kowa receives a commission for the net sales attributed to Kowa. The commission is recorded in selling, general and administrative expense. For the years ended December&#160;31, 2025 and 2024, revenue from sales attributed to Kowa and related commissions paid or owed to Kowa were not material. Effective January 23, 2026, Kowa and the Company mutually agreed to terminate the promotion agreement. Following this termination, Kowa ceased all sales and promotions of ZORYVE and the Company will not be required to make any further payments to Kowa.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the applicability and impact of any recent Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB). Other than the ASUs listed below, all other ASUs were assessed and determined to be either not applicable to the Company or are expected to have minimal impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Improvements to Income Tax Disclosures, which requires qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The Company adopted the guidance for the year ended December 31, 2025 and applied any presentational changes from this new standard to all prior years to allow for comparability. See Note 11. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-393">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-394">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and all intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts, which are not material, have been reclassified to conform to current year presentation in the consolidated balance sheets, consolidated statements of operations and comprehensive loss, consolidated statement of cash flows and the notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-395">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions include those related to revenue recognition, accrued and prepaid research and development expenses, and income taxes. Additionally, the Company uses available market information to assess the fair value of its marketable securities. The Company regularly evaluates its estimates using historical experience, expectations of future impacts and other assumptions that the Company believes are reasonable, and the Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. If actual results differ from those estimates, the Company includes the updates in its consolidated financial statements in the period the actual amounts become known.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-396">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-397">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with original maturities of greater than three months are classified as marketable securities on the balance sheet. Marketable securities consist of investment grade short to intermediate-term fixed income investments that have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the consolidated balance sheets due to their highly liquid nature and availability for use in current operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of other comprehensive income (loss) on the consolidated balance sheets. Realized gains and losses as well as credit losses, if any, on marketable securities are included in other income (expense), net in the statements of operations and comprehensive loss. Interest on marketable securities is included in interest income in the statements of operations and comprehensive loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. In making this judgment, the Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost, the Company's intent to sell or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, the financial condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular security. To date, no such credit losses have occurred or have been recorded. The cost of investments sold is based on the specific-identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-10" decimals="INF" id="f-398" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-399">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s trade accounts receivable consists of amounts due primarily from pharmaceutical wholesalers and specialty pharmacy providers in the United States and Canada (collectively, its customers) related to sales of ZORYVE and have standard payment terms. For certain customers, the trade accounts receivable for the customer is net of distribution service fees, prompt pay discounts, and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company will reserve against trade accounts receivable for estimated credit losses that may arise and any amounts determined to be uncollectible will be written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was not material as of December&#160;31, 2025 and 2024 and the amounts of trade receivable amounts written off for the years ended December&#160;31, 2025, 2024, and 2023 were not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-400">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values its inventories at the lower-of-cost or net realizable value. The Company determines the cost of its inventories, which includes costs related to products held for sale in the ordinary course of business, products in process of production for such sale, and items to be currently consumed in the production of goods to be available for sale, on a first-in, first-out (FIFO) basis. Due to the nature of the Company&#x2019;s supply chain process, inventory that is owned by the Company is physically stored at third-party warehouses, logistics providers, and contract manufacturers. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. If they occur, such charges are recorded as a component of cost of sales in the consolidated statements of operations and comprehensive loss. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products that may be used in clinical development programs are excluded from inventory and their costs are charged to research and development expense in the consolidated statement of operations as incurred, as long as they do not have an alternative use. Prior to the initial dates of regulatory approval, costs related to the production of inventory were recorded as research and development expense on the Company&#x2019;s consolidated statements of operations and comprehensive loss in the period incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-401">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, net&lt;/span&gt;&lt;/div&gt;The Company paid a milestone payment of $7.5&#160;million to AstraZeneca in the third quarter of 2022 related to the FDA approval and launch of ZORYVE cream 0.3%. This milestone payment was capitalized as an intangible asset and will be amortized to cost of sales over its useful life of 10 years from the date of first commercial sale, as this is the minimum amount of time that the related License Agreement will be in effect. The Company paid additional milestone payments of $5.0&#160;million related to the achievement of $100.0&#160;million worldwide net sales in October 2024 and $10.0&#160;million related to the achievement of $250.0&#160;million worldwide net sales in May 2025. These milestone payments were recorded as cumulative catch-up adjustments to the carrying value of the intangible asset.&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its long-lived assets, including intangibles, for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results. No impairment losses were recorded for the years ended December&#160;31, 2025, 2024, and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval contextRef="c-51" decimals="-5" id="f-402" unitRef="usd">7500000</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-52" id="f-403">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments contextRef="c-53" decimals="-5" id="f-404" unitRef="usd">5000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold contextRef="c-53" decimals="-5" id="f-405" unitRef="usd">100000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments contextRef="c-54" decimals="-5" id="f-406" unitRef="usd">10000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold contextRef="c-54" decimals="-5" id="f-407" unitRef="usd">250000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-55" decimals="-5" id="f-408" unitRef="usd">4700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-56" decimals="-5" id="f-409" unitRef="usd">2000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-57" decimals="-5" id="f-410" unitRef="usd">800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-411">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated future amortization expense for the intangible assets subsequent to December&#160;31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-10" decimals="-3" id="f-412" unitRef="usd">2250000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-10" decimals="-3" id="f-413" unitRef="usd">2250000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-10" decimals="-3" id="f-414" unitRef="usd">2250000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-10" decimals="-3" id="f-415" unitRef="usd">2250000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-10" decimals="-3" id="f-416" unitRef="usd">2250000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-10" decimals="-3" id="f-417" unitRef="usd">3562000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-10" decimals="-3" id="f-418" unitRef="usd">14812000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="INF" id="f-419" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-12" decimals="INF" id="f-420" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-13" decimals="INF" id="f-421" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="c-1" id="f-422">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Other Investments&lt;/span&gt;&lt;/div&gt;The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity (VIE). If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company&#x2019;s consolidated financial statements. The Company&#x2019;s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-423">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by either the financial institutions holding its cash or by its customers owing trade receivables to the extent recorded on the consolidated&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;balance sheets. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for credit losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-424">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments, in addition to those presented in Note 4, include cash equivalents, accounts receivable, accounts payable, accrued liabilities, and long-term debt. The carrying amount of cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to their short maturities. As the long-term debt is subject to variable interest rates that are based on market rates which regularly reset, the Company believes that the carrying value of the long-term debt approximates its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis on the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-425">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets which range from &lt;span style="-sec-ix-hidden:f-426"&gt;two&lt;/span&gt; to five years. Leasehold improvements are depreciated on a straight-line basis over the shorter of their estimated useful lives or lease terms. Maintenance and repairs are expensed as incurred. The Company reviews the carrying values of its property and equipment for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-59" id="f-427">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-12" decimals="INF" id="f-428" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-13" decimals="INF" id="f-429" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-430" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-431">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception. Right-of-use (ROU) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The classification of the Company&#x2019;s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information available at lease commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the lease liability, includes any lease payments made prior to or on lease commencement and is adjusted for lease incentives and initial direct costs incurred, as applicable. Lease expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease agreements includes lease and non-lease components and the Company has elected to not separate such components for all classes of assets. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with terms of 12 months or less (short-term leases) for all classes of assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <arqt:AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock contextRef="c-1" id="f-432">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued and Prepaid Research and Development Expenses&lt;/span&gt;&lt;/div&gt;The Company records prepaid expenses and accrued liabilities for estimated research and development activities conducted by third-party service providers, which include the conduct of nonclinical studies, clinical trials, and contract manufacturing activities. These costs are a significant component of the Company&#x2019;s research and development expenses. The Company records these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid costs balances in each reporting period. As actual costs become known, the Company adjusts its balances for these activities.</arqt:AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-433">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue, Net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells its product to its customers in the United States and Canada. The Company&#x2019;s customers subsequently resell the products to pharmacies, health care providers, and patients. In accordance with ASC 606, the Company recognizes net product revenue from sales when the customers obtain control of the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s products, which typically occurs upon delivery to the customer. The Company&#x2019;s payment terms are generally between 30 - 65 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales are recorded at the net sales price, or &#x201c;transaction price,&#x201d; which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution service fees, (b) government and private payer rebates, chargebacks, discounts and fees, (c) product returns and (d) costs of co-pay assistance programs for patients, as well as other sales deductions. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to trade receivables, net if payable to a customer or accrued liabilities if payable to a third-party. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company&#x2019;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is recognized as product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual results vary from the Company&#x2019;s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Service Fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: data reporting, inventory management, chargeback administration, and service level commitment. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prompt Pay Discounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company provides some of its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from its gross product revenue and accounts receivable at the time such revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company provides customers a credit for all products returned in accordance with the Company&#x2019;s returned goods policy. Once the product is returned, it is destroyed. The Company does not record a right-of-return asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the early product launch period, the Company estimated its provision for sales returns based on industry data and adjusted the transaction price for such estimates at the time of sale to the customer. As the Company continues to collect data on its actual product returns, it has and will continue to refine its estimated returns rate and adjust its accrual, which affects revenue in the period of adjustment. No such material adjustments were recorded for the year ended December 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargeback&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: A chargeback is the difference between the manufacturer's invoice price to the wholesaler and the wholesaler&#x2019;s customer's contract price. The wholesaler tracks these sales and "charges back" the manufacturer for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price for such discount at the time of sale to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accrues rebates for contractually agreed-upon discounts with private payers and mandated discounts under government programs such as the Medicaid Drug Rebate Program in the United States. The Company's estimates for expected utilization of private payer rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates are generally invoiced and paid in arrears. The accrual balance consists of invoiced amounts not yet paid as well as an estimate of the amount expected to be incurred but not yet invoiced to the Company as of the end of the reporting period. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product revenue, net in the period of adjustment.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <arqt:ProductRevenuePaymentTerm contextRef="c-60" id="f-434">P30D</arqt:ProductRevenuePaymentTerm>
    <arqt:ProductRevenuePaymentTerm contextRef="c-61" id="f-435">P65D</arqt:ProductRevenuePaymentTerm>
    <arqt:RevenueNotFromContractWithCustomerPolicyPolicyTextBlock contextRef="c-1" id="f-436">&lt;div style="margin-top:8pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other revenue is related to the Huadong License and Collaboration Agreement and Sato License Agreement. See Note 7. The Company evaluated the agreements with Huadong and Sato and determined that they are within the scope of ASC 606. The Company applied the five-step model as required by ASC 606 to determine revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The nonrefundable upfront payments received in connection with the transfer of the license and related know-how to Huadong in September 2023 and to Sato in March 2024 were determined to be distinct performance obligations, and therefore were recognized in Other revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company evaluated whether the development and regulatory milestones are considered probable of being reached and determined that their achievement is highly dependent on factors outside of the Company&#x2019;s control. Therefore, these payments are subject to significant revenue reversal and are therefore not included in the transaction price. At the end of each reporting period, the Company will re-evaluate the probability of achievement of each milestone and, if necessary, adjust its estimate of the overall transaction price and accordingly recognize the related revenue once the probability of significant reversal of revenue is low. Any such adjustments are recorded on a cumulative catch-up basis, and would be reported in Other revenue in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The sales milestones and royalties will be recognized in Other revenue when the related sales occur.&lt;/span&gt;&lt;/div&gt;</arqt:RevenueNotFromContractWithCustomerPolicyPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-437">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes direct and indirect costs related to the manufacturing and distribution of ZORYVE, including raw materials, third-party manufacturing costs, packaging services, freight-in, third-party royalties payable on the Company&#x2019;s net product revenue, and amortization of certain intangible assets associated with ZORYVE. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon related FDA approval dates for each product. As a result, manufacturing and other inventory costs incurred prior to FDA approval were expensed and, therefore, are not included in cost of sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-438">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, license fees, stock-based compensation expense, materials, supplies, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company&#x2019;s license agreements have been considered an acquisition of a business. For asset acquisitions, contingent consideration is recognized when the contingency is resolved and the consideration is paid or becomes payable. The upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when paid or become payable, provided there is no alternative future use of the rights in other research and development projects.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-439">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses are expensed as incurred and consist primarily of salaries and related costs, including payroll taxes, benefits, stock-based compensation, and travel, and costs related to sales and marketing of ZORYVE. Other selling, general and administrative expenses include legal costs of pursuing patent protection of the Company's intellectual property, insurance, and professional services fees for auditing, tax, &lt;/span&gt;&lt;/div&gt;and general legal services.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-5" id="f-440" unitRef="usd">25300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-12" decimals="-5" id="f-441" unitRef="usd">6900000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-13" decimals="-5" id="f-442" unitRef="usd">11200000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-443">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for such awards is the date of grant and the expense is recognized on a straight-line basis over the expected vesting period. For share-based awards that vest subject to a performance condition, the Company will recognize compensation cost for awards if and when the Company concludes that it is probable that the awards with a performance condition will be achieved on an accelerated attribution method. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-444">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not. Due to the Company&#x2019;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets for the United States have been fully offset by a valuation allowance. The Company has an immaterial deferred tax asset related to foreign jurisdictions which is not offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="INF" id="f-445" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-12" decimals="INF" id="f-446" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-13" decimals="INF" id="f-447" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-448">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company translates the assets and liabilities of its foreign subsidiaries where the local currencies have been determined to be the functional currencies into U.S. dollars using current exchange rates. Adjustments for foreign currency translation adjustments are recognized in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. The earnings or loss of these subsidiaries are translated in U.S. dollars using average exchange rates in effect during each reporting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <arqt:CoPromotionAgreementsPolicyPolicyTextBlock contextRef="c-1" id="f-449">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Promotion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n July 2024, the Company entered into a promotion agreement with Kowa Pharmaceuticals America, Inc. (Kowa) to leverage Kowa's primary care sales force to exclusively market and promote ZORYVE to primary care practitioners and pediatricians for all FDA-approved indications until July 2029. The Company recognizes all revenue and Kowa receives a commission for the net sales attributed to Kowa. The commission is recorded in selling, general and administrative expense. For the years ended December&#160;31, 2025 and 2024, revenue from sales attributed to Kowa and related commissions paid or owed to Kowa were not material. Effective January 23, 2026, Kowa and the Company mutually agreed to terminate the promotion agreement. Following this termination, Kowa ceased all sales and promotions of ZORYVE and the Company will not be required to make any further payments to Kowa.&lt;/span&gt;&lt;/div&gt;</arqt:CoPromotionAgreementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the applicability and impact of any recent Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB). Other than the ASUs listed below, all other ASUs were assessed and determined to be either not applicable to the Company or are expected to have minimal impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Improvements to Income Tax Disclosures, which requires qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The Company adopted the guidance for the year ended December 31, 2025 and applied any presentational changes from this new standard to all prior years to allow for comparability. See Note 11. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-451">Revenues&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized under guidance within ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The following table presents the Company's disaggregated revenue for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ZORYVE cream 0.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ZORYVE foam&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ZORYVE cream 0.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ZORYVE cream 0.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue relates primarily to the Sato and Huadong licensing agreements. See Note 7.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue, net outside the United States represented less than 10% of the Company&#x2019;s consolidated product revenue, net for the years ended December 31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major customers are defined as customers that individually accounted for greater than 10% of the Company's revenue. The following table presents each major customer that accounted for more than 10% of its gross product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.735%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;% of gross product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer F&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross product sales from major customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;* Represents less than 10% of respective balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of December&#160;31, 2025, amounts due from four of these customers each exceeded 10% of gross trade receivables and accounted for 60% of net trade receivables on a combined basis. As of December&#160;31, 2024, amounts due from five of these customers each exceeded 10% of gross trade receivables and accounted for 69% of net trade receivables on a combined basis.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-452">The following table presents the Company's disaggregated revenue for the periods presented (in thousands):&lt;div style="margin-top:8pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ZORYVE cream 0.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ZORYVE foam&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ZORYVE cream 0.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ZORYVE cream 0.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-62" decimals="-3" id="f-453" unitRef="usd">120995000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-63" decimals="-3" id="f-454" unitRef="usd">85082000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-64" decimals="-3" id="f-455" unitRef="usd">29186000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-65" decimals="-3" id="f-456" unitRef="usd">181892000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-66" decimals="-3" id="f-457" unitRef="usd">71539000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-67" decimals="-3" id="f-458" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-68" decimals="-3" id="f-459" unitRef="usd">68274000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-69" decimals="-3" id="f-460" unitRef="usd">9921000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-70" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-71" decimals="-3" id="f-462" unitRef="usd">911000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-72" decimals="-3" id="f-463" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-73" decimals="-3" id="f-464" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-465" unitRef="usd">372072000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-12" decimals="-3" id="f-466" unitRef="usd">166542000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-13" decimals="-3" id="f-467" unitRef="usd">29186000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-1" decimals="-3" id="f-468" unitRef="usd">4000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-12" decimals="-3" id="f-469" unitRef="usd">30000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-13" decimals="-3" id="f-470" unitRef="usd">30420000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-471" unitRef="usd">376072000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-3" id="f-472" unitRef="usd">196542000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-3" id="f-473" unitRef="usd">59606000</us-gaap:Revenues>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-474">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major customers are defined as customers that individually accounted for greater than 10% of the Company's revenue. The following table presents each major customer that accounted for more than 10% of its gross product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.735%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;% of gross product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer F&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross product sales from major customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;* Represents less than 10% of respective balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-74" decimals="2" id="f-475" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-476" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-477" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-77" decimals="2" id="f-478" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-78" decimals="2" id="f-479" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-79" decimals="2" id="f-480" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-80" decimals="2" id="f-481" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-81" decimals="2" id="f-482" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-82" decimals="2" id="f-483" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-83" decimals="2" id="f-484" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-84" decimals="2" id="f-485" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-85" decimals="2" id="f-486" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-86" decimals="2" id="f-487" unitRef="number">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-87" decimals="2" id="f-488" unitRef="number">0.55</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-88" decimals="2" id="f-489" unitRef="number">0.69</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-89" decimals="2" id="f-490" unitRef="number">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-90" decimals="2" id="f-491" unitRef="number">0.69</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-492">Fair Value Measurements&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company&#x2019;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds and cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,919&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds and cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,955&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,958&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds and U.S. Treasury and agency securities are valued based on quoted market prices in active markets, with no valuation adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper, certificates of deposit and corporate debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated value of the Company&#x2019;s cash, cash equivalents and marketable securities, and the gross unrealized holding gains and losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.851%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, no significant facts or circumstances were present to indicate a deterioration in the creditworthiness of the issuers of the available-for-sale securities. The Company generally holds its marketable securities until maturity and does not intend to sell, and is not required to sell, the investments that are in an unrealized loss position before the recovery of their amortized cost basis. For all securities with a fair value less than its amortized cost basis, the Company determined the decline in fair value below amortized cost basis to be non-credit related and no allowance for losses has been recorded. As of December&#160;31, 2025, there were no individual securities that were in a significant unrealized loss position. To date, the Company has not recorded any impairment charges on available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected the practical expedient to exclude the applicable accrued interest from both the fair value and the amortized cost basis of its available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable related to available-for-sale securities is presented in prepaid expenses and other current assets, separate from marketable securities, on the consolidated balance sheet. As of December&#160;31, 2025 and 2024, accrued interest receivable was immaterial. The Company has made an accounting policy election not to recognize an allowance for credit losses for accrued interest receivables on available-for-sale securities and to write-off any uncollectible accrued interest receivable by recognizing credit loss expense. The Company has not written off any accrued interest receivables for the years ended December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the amortized cost and fair value of marketable securities by contractual maturity were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturing within one year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,708&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturing in one to five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,681&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,680&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,593&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,602&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,962&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,075&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,301&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,620&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the change in the fair value of the embedded derivative instrument for the year ended December&#160;31, 2025 and 2024 (in thousands). There was no activity for the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-608"&gt;&lt;span style="-sec-ix-hidden:f-609"&gt;Loss (gain) from changes in fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of the Company&#x2019;s embedded derivative instrument is based on significant inputs not observed in the market, and thus represents a Level 3 measurement. See Note 9 for further discussion on the embedded derivative instrument.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company&#x2019;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds and cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,919&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds and cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,955&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,958&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-91" decimals="-3" id="f-494" unitRef="usd">37541000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-92" decimals="-3" id="f-495" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-93" decimals="-3" id="f-496" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-497" unitRef="usd">37541000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-95" decimals="-3" id="f-498" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-96" decimals="-3" id="f-499" unitRef="usd">5366000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-97" decimals="-3" id="f-500" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-98" decimals="-3" id="f-501" unitRef="usd">5366000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-99" decimals="-3" id="f-502" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-100" decimals="-3" id="f-503" unitRef="usd">14789000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-101" decimals="-3" id="f-504" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-102" decimals="-3" id="f-505" unitRef="usd">14789000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-103" decimals="-3" id="f-506" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-104" decimals="-3" id="f-507" unitRef="usd">78764000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-105" decimals="-3" id="f-508" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-106" decimals="-3" id="f-509" unitRef="usd">78764000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-107" decimals="-3" id="f-510" unitRef="usd">84522000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-108" decimals="-3" id="f-511" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-109" decimals="-3" id="f-512" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-110" decimals="-3" id="f-513" unitRef="usd">84522000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-111" decimals="-3" id="f-514" unitRef="usd">122063000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-515" unitRef="usd">98919000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-113" decimals="-3" id="f-516" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-10" decimals="-3" id="f-517" unitRef="usd">220982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-114" decimals="-3" id="f-518" unitRef="usd">71335000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-115" decimals="-3" id="f-519" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-116" decimals="-3" id="f-520" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-117" decimals="-3" id="f-521" unitRef="usd">71335000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-118" decimals="-3" id="f-522" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-119" decimals="-3" id="f-523" unitRef="usd">5042000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-120" decimals="-3" id="f-524" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-121" decimals="-3" id="f-525" unitRef="usd">5042000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-122" decimals="-3" id="f-526" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-123" decimals="-3" id="f-527" unitRef="usd">83955000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-124" decimals="-3" id="f-528" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-125" decimals="-3" id="f-529" unitRef="usd">83955000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-126" decimals="-3" id="f-530" unitRef="usd">67623000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-127" decimals="-3" id="f-531" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-128" decimals="-3" id="f-532" unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure contextRef="c-129" decimals="-3" id="f-533" unitRef="usd">67623000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-130" decimals="-3" id="f-534" unitRef="usd">138958000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-131" decimals="-3" id="f-535" unitRef="usd">88997000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-132" decimals="-3" id="f-536" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-11" decimals="-3" id="f-537" unitRef="usd">227955000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-539">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated value of the Company&#x2019;s cash, cash equivalents and marketable securities, and the gross unrealized holding gains and losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.851%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the amortized cost and fair value of marketable securities by contractual maturity were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturing within one year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,708&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturing in one to five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,681&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,680&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,593&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,602&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,962&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,075&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,301&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,620&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-538">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated value of the Company&#x2019;s cash, cash equivalents and marketable securities, and the gross unrealized holding gains and losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.851%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds and cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-94" decimals="-3" id="f-540" unitRef="usd">37541000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <arqt:CashAndCashEquivalentsUnrealizedGain contextRef="c-94" decimals="-3" id="f-541" unitRef="usd">0</arqt:CashAndCashEquivalentsUnrealizedGain>
    <arqt:CashAndCashEquivalentsUnrealizedLoss contextRef="c-94" decimals="-3" id="f-542" unitRef="usd">0</arqt:CashAndCashEquivalentsUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-543" unitRef="usd">37541000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-133" decimals="-3" id="f-544" unitRef="usd">5366000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <arqt:CashAndCashEquivalentsUnrealizedGain contextRef="c-133" decimals="-3" id="f-545" unitRef="usd">0</arqt:CashAndCashEquivalentsUnrealizedGain>
    <arqt:CashAndCashEquivalentsUnrealizedLoss contextRef="c-133" decimals="-3" id="f-546" unitRef="usd">0</arqt:CashAndCashEquivalentsUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-133" decimals="-3" id="f-547" unitRef="usd">5366000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-10" decimals="-3" id="f-548" unitRef="usd">42907000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <arqt:CashAndCashEquivalentsUnrealizedGain contextRef="c-10" decimals="-3" id="f-549" unitRef="usd">0</arqt:CashAndCashEquivalentsUnrealizedGain>
    <arqt:CashAndCashEquivalentsUnrealizedLoss contextRef="c-10" decimals="-3" id="f-550" unitRef="usd">0</arqt:CashAndCashEquivalentsUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-10" decimals="-3" id="f-551" unitRef="usd">42907000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-102" decimals="-3" id="f-552" unitRef="usd">14782000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-102" decimals="-3" id="f-553" unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-102" decimals="-3" id="f-554" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-102" decimals="-3" id="f-555" unitRef="usd">14789000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-106" decimals="-3" id="f-556" unitRef="usd">78687000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-106" decimals="-3" id="f-557" unitRef="usd">81000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-106" decimals="-3" id="f-558" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-106" decimals="-3" id="f-559" unitRef="usd">78764000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-110" decimals="-3" id="f-560" unitRef="usd">84493000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-110" decimals="-3" id="f-561" unitRef="usd">45000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-110" decimals="-3" id="f-562" unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-110" decimals="-3" id="f-563" unitRef="usd">84522000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-10" decimals="-3" id="f-564" unitRef="usd">177962000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-10" decimals="-3" id="f-565" unitRef="usd">134000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-10" decimals="-3" id="f-566" unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-10" decimals="-3" id="f-567" unitRef="usd">178075000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-117" decimals="-3" id="f-568" unitRef="usd">71335000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <arqt:CashAndCashEquivalentsUnrealizedGain contextRef="c-117" decimals="-3" id="f-569" unitRef="usd">0</arqt:CashAndCashEquivalentsUnrealizedGain>
    <arqt:CashAndCashEquivalentsUnrealizedLoss contextRef="c-117" decimals="-3" id="f-570" unitRef="usd">0</arqt:CashAndCashEquivalentsUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-117" decimals="-3" id="f-571" unitRef="usd">71335000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-11" decimals="-3" id="f-572" unitRef="usd">71335000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <arqt:CashAndCashEquivalentsUnrealizedGain contextRef="c-11" decimals="-3" id="f-573" unitRef="usd">0</arqt:CashAndCashEquivalentsUnrealizedGain>
    <arqt:CashAndCashEquivalentsUnrealizedLoss contextRef="c-11" decimals="-3" id="f-574" unitRef="usd">0</arqt:CashAndCashEquivalentsUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-11" decimals="-3" id="f-575" unitRef="usd">71335000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-121" decimals="-3" id="f-576" unitRef="usd">5042000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-121" decimals="-3" id="f-577" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-121" decimals="-3" id="f-578" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-121" decimals="-3" id="f-579" unitRef="usd">5042000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-125" decimals="-3" id="f-580" unitRef="usd">83855000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-125" decimals="-3" id="f-581" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-125" decimals="-3" id="f-582" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-125" decimals="-3" id="f-583" unitRef="usd">83955000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-129" decimals="-3" id="f-584" unitRef="usd">67404000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-129" decimals="-3" id="f-585" unitRef="usd">219000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-129" decimals="-3" id="f-586" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-129" decimals="-3" id="f-587" unitRef="usd">67623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-11" decimals="-3" id="f-588" unitRef="usd">156301000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-11" decimals="-3" id="f-589" unitRef="usd">319000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-11" decimals="-3" id="f-590" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-11" decimals="-3" id="f-591" unitRef="usd">156620000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-10" decimals="-3" id="f-592" unitRef="usd">138281000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-10" decimals="-3" id="f-593" unitRef="usd">138395000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-11" decimals="-3" id="f-594" unitRef="usd">143708000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-11" decimals="-3" id="f-595" unitRef="usd">144018000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-10" decimals="-3" id="f-596" unitRef="usd">39681000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-10" decimals="-3" id="f-597" unitRef="usd">39680000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-11" decimals="-3" id="f-598" unitRef="usd">12593000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-11" decimals="-3" id="f-599" unitRef="usd">12602000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-10" decimals="-3" id="f-600" unitRef="usd">177962000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-10" decimals="-3" id="f-601" unitRef="usd">178075000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-11" decimals="-3" id="f-602" unitRef="usd">156301000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-11" decimals="-3" id="f-603" unitRef="usd">156620000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-604">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the change in the fair value of the embedded derivative instrument for the year ended December&#160;31, 2025 and 2024 (in thousands). There was no activity for the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-608"&gt;&lt;span style="-sec-ix-hidden:f-609"&gt;Loss (gain) from changes in fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-13" decimals="INF" id="f-605" unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="c-11" decimals="-3" id="f-606" unitRef="usd">570000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="c-30" decimals="-3" id="f-607" unitRef="usd">849000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-610" unitRef="usd">139000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-12" decimals="-3" id="f-611" unitRef="usd">279000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="c-10" decimals="-3" id="f-612" unitRef="usd">431000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="c-11" decimals="-3" id="f-613" unitRef="usd">570000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-614">Balance Sheet Components&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid co-pay assistance program and rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales deductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-615">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-10" decimals="-3" id="f-616" unitRef="usd">5047000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-11" decimals="-3" id="f-617" unitRef="usd">4300000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-10" decimals="-3" id="f-618" unitRef="usd">5033000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-11" decimals="-3" id="f-619" unitRef="usd">584000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-10" decimals="-3" id="f-620" unitRef="usd">12554000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-11" decimals="-3" id="f-621" unitRef="usd">9642000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-10" decimals="-3" id="f-622" unitRef="usd">22634000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-11" decimals="-3" id="f-623" unitRef="usd">14526000</us-gaap:InventoryNet>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-624">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid co-pay assistance program and rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <arqt:PrepaidCopayAssistanceProgramAndRebates contextRef="c-10" decimals="-3" id="f-625" unitRef="usd">9485000</arqt:PrepaidCopayAssistanceProgramAndRebates>
    <arqt:PrepaidCopayAssistanceProgramAndRebates contextRef="c-11" decimals="-3" id="f-626" unitRef="usd">7369000</arqt:PrepaidCopayAssistanceProgramAndRebates>
    <arqt:PrepaidClinicalTrialTestCostsCurrent contextRef="c-10" decimals="-3" id="f-627" unitRef="usd">2577000</arqt:PrepaidClinicalTrialTestCostsCurrent>
    <arqt:PrepaidClinicalTrialTestCostsCurrent contextRef="c-11" decimals="-3" id="f-628" unitRef="usd">3244000</arqt:PrepaidClinicalTrialTestCostsCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-10" decimals="-3" id="f-629" unitRef="usd">9017000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-11" decimals="-3" id="f-630" unitRef="usd">9043000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-10" decimals="-3" id="f-631" unitRef="usd">21079000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-11" decimals="-3" id="f-632" unitRef="usd">19656000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-633">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales deductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <arqt:AccruedSalesDiscounts contextRef="c-10" decimals="-3" id="f-634" unitRef="usd">78308000</arqt:AccruedSalesDiscounts>
    <arqt:AccruedSalesDiscounts contextRef="c-11" decimals="-3" id="f-635" unitRef="usd">38430000</arqt:AccruedSalesDiscounts>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-10" decimals="-3" id="f-636" unitRef="usd">20533000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-637" unitRef="usd">20747000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <arqt:ClinicalTrialAccrualCurrent contextRef="c-10" decimals="-3" id="f-638" unitRef="usd">425000</arqt:ClinicalTrialAccrualCurrent>
    <arqt:ClinicalTrialAccrualCurrent contextRef="c-11" decimals="-3" id="f-639" unitRef="usd">0</arqt:ClinicalTrialAccrualCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-10" decimals="-3" id="f-640" unitRef="usd">17044000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-641" unitRef="usd">7616000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-10" decimals="-3" id="f-642" unitRef="usd">116310000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-643" unitRef="usd">66793000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-644">Property and Equipment, net&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $0.7 million, $0.6 million, and $0.8 million for the years ended December&#160;31, 2025, 2024, and 2023 respectively. Leasehold improvements are depreciated over the term of the lease, which is the shorter of the improvements' expected useful lives and the lease term. All other fixed asset depreciation is recorded using the straight-line method over the estimated useful lives of the assets (&lt;span style="-sec-ix-hidden:f-663"&gt;two&lt;/span&gt; to five years).&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-645">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-134" decimals="-3" id="f-646" unitRef="usd">1349000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-135" decimals="-3" id="f-647" unitRef="usd">1272000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-136" decimals="-3" id="f-648" unitRef="usd">1270000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-137" decimals="-3" id="f-649" unitRef="usd">661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-138" decimals="-3" id="f-650" unitRef="usd">104000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-139" decimals="-3" id="f-651" unitRef="usd">104000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-140" decimals="-3" id="f-652" unitRef="usd">1568000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-141" decimals="-3" id="f-653" unitRef="usd">1568000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-10" decimals="-3" id="f-654" unitRef="usd">4291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-11" decimals="-3" id="f-655" unitRef="usd">3605000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-10" decimals="-3" id="f-656" unitRef="usd">3248000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-11" decimals="-3" id="f-657" unitRef="usd">2564000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-10" decimals="-3" id="f-658" unitRef="usd">1043000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-11" decimals="-3" id="f-659" unitRef="usd">1041000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-660" unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="-5" id="f-661" unitRef="usd">600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-662" unitRef="usd">800000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-143" id="f-664">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <arqt:LicenseAgreementsAndAcquisitionsTextBlock contextRef="c-1" id="f-665">License Agreements &amp;amp; Ducentis Acquisition&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sato License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 27, 2024, the Company entered into a license agreement with Sato Pharmaceutical Co., Ltd. (Sato). Pursuant to the terms of the license agreement with Sato (the Sato Agreement), the Company grants to Sato an exclusive, sublicensable (under certain circumstances) license under certain patent rights and know-how controlled by the Company for Sato to develop, conduct medical affairs activities for, manufacture, commercialize and otherwise exploit roflumilast formulations (the Sato Licensed Products) for all therapeutic uses for certain dermatological indications in humans (the Sato Field) in Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Sato Agreement sets forth each party&#x2019;s respective obligations with respect to the development, medical affairs activities, manufacture, supply and commercialization of the Sato Licensed Products. Pursuant to the terms of the Sato Agreement, Sato will, at its expense, develop, obtain regulatory approval for, commercialize and conduct medical affairs activities related to the Sato Licensed Products in the Sato Field in Japan, subject to certain of the Company&#x2019;s approval and oversight rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Sato Agreement, the Company received an upfront payment of $25.0&#160;million and will potentially receive additional payments (i) up to an aggregate amount of $10.0&#160;million upon the achievement of certain regulatory milestones and (ii) up to an aggregate amount of $30.0&#160;million upon the achievement of certain sales milestones. In addition, on a Sato Licensed Product-by-Sato Licensed Product basis, commencing from the first commercial sale of such Sato Licensed Product in Japan until the latest of (i) the expiration of the last valid claim in the intellectual property rights licensed by the Company to Sato under the Sato Agreement covering such Sato Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Sato Licensed Product in Japan, or (iii) ten years after the first commercial sale of such Sato Licensed Product in Japan, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company will receive low double-digit to mid-teen double-digit percentage royalties on Sato&#x2019;s, its affiliates&#x2019; and sublicensees&#x2019; total annual net sales of all Sato Licensed Products, subject to certain royalty reductions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The term of the Sato Agreement continues until, on a Sato Licensed Product-by-Sato Licensed Product basis, the expiration of the Royalty Term, which is the (i) the expiration of the last valid claim in the licensed technology covering such Sato Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product in Japan, or (iii) ten years after the first commercial sale of such Licensed Product in Japan. The Sato Agreement may be terminated by either party in its entirety if the other party commits a material breach, subject to a cure period, or if the other party becomes insolvent. Sato may terminate the Sato Agreement at-will in its entirety upon 90 days&#x2019; written notice. Unless unenforceable under applicable law, the Company may terminate the Sato Agreement in its entirety if Sato, its affiliate or sublicensee contests or assists a third party in contesting the scope, validity or enforceability of any patent or patent application licensed by the Company to Sato. The Company may also terminate the Sato Agreement if Sato or any director, officers, employee, agent, affiliate, sublicensee or subcontractor is charged by a governmental authority for a violation of any anti-corruption, anti-money laundering, sanctions or export or import control laws or regulations, or, subject to the terms of the Sato Agreement, if Sato, its affiliates and sublicensees do not conduct any material development or commercialization activities of a Sato Licensed Product in Japan for a certain period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no other revenue recorded pursuant to the Sato Agreement for the year ended December 31, 2025 and $25.0&#160;million recorded for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Huadong License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company entered into a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (Huadong), a wholly owned subsidiary of Huadong Medicine Co., Ltd. Pursuant to the terms of the agreement, the Company granted to Huadong an exclusive, sublicensable (under certain circumstances) license under certain patent rights and know-how controlled by the Company for Huadong to develop, conduct medical affairs activities for, manufacture, commercialize, and otherwise exploit both cream and foam topical roflumilast for all therapeutic uses for certain dermatological indications (Huadong Licensed Products) in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and Southeast Asia (Indonesia, Singapore, The Philippines, Thailand, Myanmar, Brunei, Cambodia, Laos, Malaysia, and Vietnam) (Huadong Territories).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Huadong will, at its expense, develop, obtain regulatory approval for, commercialize, and conduct medical affairs activities for the Huadong Licensed Products, subject to certain of the Company&#x2019;s approval and oversight rights. The Company will retain exclusive rights for the development, manufacture and commercialization of topical roflumilast outside the Huadong Territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the rights granted under the license agreement with Huadong (the Huadong Agreement), Huadong paid the Company a non-refundable upfront fee pursuant to the terms of the agreement, upon closing in September 2023. The Company received a net payment of $27.0&#160;million, which consisted of a $30.0&#160;million upfront payment less the applicable tax withholding obligation in China of $3.0&#160;million. In addition, the Company received a net payment of $2.7&#160;million in March 2024 related to the achievement of a development and regulatory milestone less the applicable tax withholding. The Company received a net payment of $1.8&#160;million in each of December 2024, March 2025 and November 2025, related to the achievement of development and regulatory milestones less the applicable tax withholding. The Company may also potentially receive additional payments: (i) up to an aggregate amount of $15.0&#160;million upon the achievement of certain development and regulatory milestones, (ii) up to an aggregate amount of $40.3&#160;million upon the achievement of certain sales milestones, and (iii) low double-digit to high-teen double-digit tiered percentage royalties on net sales of the Huadong Licensed Products, all of which would be subject to applicable tax withholding obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The term of the Huadong Agreement continues on a Huadong Licensed Product-by-Huadong Licensed Product and country or region-by-country or region basis, until the expiration of the Royalty Term, which is: (i) the date of expiration of the last valid patent claim related to the Huadong Licensed Products, (ii) ten years after the first commercial sale of a Huadong Licensed Product and (iii) the expiration of any regulatory exclusivity as to a Huadong Licensed Product. The Huadong Agreement may be terminated by both parties under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue and related income tax expense related to the Huadong agreement was $4.0 million and $0.4 million, respectively, for the year ended December&#160;31, 2025. Other revenue and related tax income expense related to the Huadong agreement was $5.0 million and $0.5 million, respectively, for the year ended December&#160;31, 2024. Other revenue and related income tax expense related to the Huadong agreement was $30.0 million and $3.0 million, respectively, for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the Company entered into an exclusive license agreement with AstraZeneca AB (AstraZeneca), granting the Company a worldwide exclusive license, with the right to sublicense through multiple tiers, under certain AstraZeneca-controlled patent rights, know-how and regulatory documentation, to research, develop, manufacture, commercialize and otherwise exploit products containing roflumilast in topical forms, as well as delivery systems sold with or for the administration of roflumilast (collectively, the AZ-Licensed Products), for all diagnostic, prophylactic and therapeutic uses for human dermatological indications (the Dermatology Field). Under the license agreement with AstraZeneca (the AstraZeneca Agreement), the Company has sole responsibility for development, regulatory and commercialization activities for the AZ-Licensed Products in the Dermatology Field, at its expense, and it shall use commercially reasonable efforts to develop, obtain and maintain regulatory approvals for, and commercialize the AZ-Licensed Products in the Dermatology Field in each of the United States, Italy, Spain, Germany, the United Kingdom, France, China and Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third quarter of 2022, the Company paid $7.5&#160;million to AstraZeneca as a result of the approval of ZORYVE cream 0.3%, which was recorded as an intangible asset. In October 2024, the Company paid $5.0&#160;million to AstraZeneca upon achievement of $100.0&#160;million in worldwide net sales, which was recorded as a cumulative catch-up adjustment to the carrying value of the intangible asset. In May 2025, the Company paid $10.0&#160;million to AstraZeneca upon achievement of $250.0&#160;million in worldwide net sales and was recorded as a cumulative catch-up adjustment to the carrying value of the intangible asset. The Company is amortizing the intangible asset to cost of sales over its useful life of 10 years from the date of first commercial sale as this is the minimum amount of time that the related AstraZeneca Agreement will be in effect. Amortization expense was $4.7&#160;million, $2.0&#160;million and $0.8&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the years ended December&#160;31, 2025, 2024, and 2023,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has agreed to make additional cash payments to AstraZeneca of up to an aggregate of $5.0 million upon the achievement of specified regulatory approval milestones with respect to the AZ-Licensed Products. With respect to any AZ-Licensed Products the Company commercializes under the AstraZeneca Agreement, it will pay AstraZeneca a low to high single-digit percentage royalty rate on the Company&#x2019;s, its affiliates&#x2019; and its sublicensees&#x2019; net sales of such AZ-Licensed Products, subject to specified reductions, until, as determined on an AZ-Licensed Product-by-AZ-Licensed Product and country-by-country basis, the later of the date of the expiration of the last-to-expire AstraZeneca-licensed patent right containing a valid claim in such country and ten years from the first commercial sale of such AZ-Licensed Product in such country. As a result of the commercialization of ZORYVE cream in August 2022, the Company began accruing royalties payable to AstraZeneca, which are recorded in cost of sales and accrued liabilities. Royalty expense during the years ended December&#160;31, 2025, 2024 and 2023 was $11.2 million, $5.0 million and $0.9 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hengrui Exclusive Option and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company entered into an exclusive option and license agreement, or the Hengrui License Agreement, with Jiangsu Hengrui Medicine Co., Ltd. (Hengrui), whereby Hengrui granted the Company an exclusive option to obtain certain exclusive rights to research, develop, and commercialize products containing the compound designated by Hengrui as ivarmacitinib, a Janus kinase type 1 inhibitor, in topical formulations for the treatment of skin diseases, disorders, and conditions in the United States, Japan, and the European Union (including for clarity the United Kingdom). In December 2019, the Company exercised its exclusive option under the agreement and contemporaneously amended the agreement to expand the territory to additionally include Canada. In addition, the Company has agreed to make cash payments of up to an aggregate of $20.5 million upon achievement of specified clinical development and regulatory approval milestones with respect to the licensed products and cash payments of up to an additional aggregate of $200.0 million in sales-based milestones based on certain aggregate annual net sales volumes with respect to a licensed product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to any products the Company commercializes under the Hengrui License Agreement, it will pay tiered royalties to Hengrui on net sales of each licensed product by the Company, or its affiliates, or its sublicensees, ranging from mid single-digit to sub-teen percentage rates based on tiered annual net sales bands &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subject to specified reductions. The Company is obligated to pay royalties until the later of (1)&#160;expiration of the last valid claim of the licensed patent rights covering such licensed product in such country and (2)&#160;expiration of regulatory exclusivity for the relevant licensed product in the relevant country, on a licensed product-by-licensed product and country-by-country basis. Additionally, the Company is obligated to pay Hengrui a specified percentage, ranging from the low-thirties to the sub-teens, of certain non-royalty sublicensing income it receives from sublicensees of its rights to the licensed products, such percentage decreasing as the development stage of the licensed products advance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company entered into a side letter agreement with Hengrui and one of its subsidiaries to extend certain rights and obligations under the Hengrui License Agreement to the subsidiary under specified circumstances, including a change of control of such subsidiary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no payments made or due in connection with Hengrui for the years ended December 31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the completion of a Phase 1b study in the middle of 2025, the Company elected to halt further development of ARQ-255, a topical formulation of ivarmacitinib, for the treatment of alopecia areata. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ducentis Biotherapeutics LTD Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 7, 2022, the Company entered into a Share Purchase Agreement with Ducentis Biotherapeutics LTD (Ducentis) and certain stockholders of Ducentis, pursuant to which the Company acquired all of the outstanding equity interests in Ducentis for (i) 610,258 shares of the Company's common stock, valued at approximately $12.5&#160;million and $15.9&#160;million in cash, inclusive of liabilities acquired, and (ii) contingent payments of up to an aggregate of $400&#160;million, which may become payable upon the achievement of certain development, regulatory, and commercial milestones (the Acquisition). Such contingent payments include a $10.0&#160;million payment due within one year from the first dosing of the first human subject enrolled in the first Phase 1 clinical trial of a therapeutic drug containing Ducentis' DS-234 product candidate, now ARQ-234. The Company anticipates commencing such Phase 1 study in the first quarter of 2026. In addition, if applicable, the Company will make payments amounting to a mid-single-digit percentage of any annual net sales of certain products exceeding $1.5&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for this purchase of equity interests in Ducentis as an in-process research and development (IPR&amp;amp;D) asset acquisition as it has no alternative future use, and recorded a $29.6&#160;million charge to research and development expense on the acquisition date. Any contingent payments made under the Share Purchase Agreement will be recorded when it is probable that they will occur and they can be reasonably estimated, at which point the Company will determine whether the payment should be expensed or capitalized depending on whether the IPR&amp;amp;D has achieved market acceptance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no payments made or due for the years ended December 31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Share Purchase Agreement, the Company will develop and seek FDA approval of a therapeutic product containing ARQ-234 for an atopic dermatitis indication, and if FDA approval of ARQ-234 is obtained by the Company, to commercially launch it in the United States.&lt;/span&gt;&lt;/div&gt;</arqt:LicenseAgreementsAndAcquisitionsTextBlock>
    <arqt:ContractNotWithCustomerUpfrontPaymentReceivedNet contextRef="c-144" decimals="-5" id="f-666" unitRef="usd">25000000.0</arqt:ContractNotWithCustomerUpfrontPaymentReceivedNet>
    <arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones contextRef="c-145" decimals="-5" id="f-667" unitRef="usd">10000000.0</arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones>
    <arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones contextRef="c-145" decimals="-5" id="f-668" unitRef="usd">30000000.0</arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones>
    <arqt:LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties contextRef="c-144" id="f-669">P10Y</arqt:LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties>
    <arqt:LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties contextRef="c-144" id="f-670">P10Y</arqt:LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties>
    <arqt:LicenseAgreementTerminationNumberOfDaysForWrittenNotice contextRef="c-144" id="f-671">P90D</arqt:LicenseAgreementTerminationNumberOfDaysForWrittenNotice>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-146" decimals="INF" id="f-672" unitRef="usd">0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-147" decimals="-5" id="f-673" unitRef="usd">25000000.0</us-gaap:RevenueNotFromContractWithCustomer>
    <arqt:ContractNotWithCustomerUpfrontPaymentNet contextRef="c-148" decimals="-5" id="f-674" unitRef="usd">27000000.0</arqt:ContractNotWithCustomerUpfrontPaymentNet>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-148" decimals="-5" id="f-675" unitRef="usd">30000000.0</us-gaap:RevenueNotFromContractWithCustomer>
    <arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation contextRef="c-148" decimals="-5" id="f-676" unitRef="usd">3000000.0</arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation>
    <arqt:ContractNotWithCustomerUpfrontPaymentNet contextRef="c-149" decimals="-5" id="f-677" unitRef="usd">2700000</arqt:ContractNotWithCustomerUpfrontPaymentNet>
    <arqt:ContractNotWithCustomerUpfrontPaymentNet contextRef="c-150" decimals="-5" id="f-678" unitRef="usd">1800000</arqt:ContractNotWithCustomerUpfrontPaymentNet>
    <arqt:ContractNotWithCustomerUpfrontPaymentNet contextRef="c-151" decimals="-5" id="f-679" unitRef="usd">1800000</arqt:ContractNotWithCustomerUpfrontPaymentNet>
    <arqt:ContractNotWithCustomerUpfrontPaymentNet contextRef="c-152" decimals="-5" id="f-680" unitRef="usd">1800000</arqt:ContractNotWithCustomerUpfrontPaymentNet>
    <arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones contextRef="c-153" decimals="-5" id="f-681" unitRef="usd">15000000.0</arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones>
    <arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones contextRef="c-153" decimals="-5" id="f-682" unitRef="usd">40300000</arqt:RevenueRemainingPerformanceObligationVariableConsiderationAmountSalesMilestones>
    <arqt:LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties contextRef="c-154" id="f-683">P10Y</arqt:LicenseAgreementNumberOfYearsAfterFirstCommercialSaleToReceiveRoyalties>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-155" decimals="-5" id="f-684" unitRef="usd">4000000.0</us-gaap:RevenueNotFromContractWithCustomer>
    <arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation contextRef="c-155" decimals="-5" id="f-685" unitRef="usd">400000</arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-156" decimals="-5" id="f-686" unitRef="usd">5000000.0</us-gaap:RevenueNotFromContractWithCustomer>
    <arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation contextRef="c-156" decimals="-5" id="f-687" unitRef="usd">500000</arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-157" decimals="-5" id="f-688" unitRef="usd">30000000.0</us-gaap:RevenueNotFromContractWithCustomer>
    <arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation contextRef="c-157" decimals="-5" id="f-689" unitRef="usd">3000000.0</arqt:ContractNotWithCustomerLiabilityTaxWithholdingObligation>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval contextRef="c-51" decimals="-5" id="f-690" unitRef="usd">7500000</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments contextRef="c-53" decimals="-5" id="f-691" unitRef="usd">5000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold contextRef="c-53" decimals="-5" id="f-692" unitRef="usd">100000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments contextRef="c-54" decimals="-5" id="f-693" unitRef="usd">10000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold contextRef="c-54" decimals="-5" id="f-694" unitRef="usd">250000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-158" id="f-695">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-55" decimals="-5" id="f-696" unitRef="usd">4700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-56" decimals="-5" id="f-697" unitRef="usd">2000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-57" decimals="-5" id="f-698" unitRef="usd">800000</us-gaap:AmortizationOfIntangibleAssets>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments contextRef="c-55" decimals="-5" id="f-699" unitRef="usd">5000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale contextRef="c-1" id="f-700">P10Y</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale>
    <us-gaap:RoyaltyExpense contextRef="c-55" decimals="-5" id="f-701" unitRef="usd">11200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="c-56" decimals="-5" id="f-702" unitRef="usd">5000000.0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="c-57" decimals="-5" id="f-703" unitRef="usd">900000</us-gaap:RoyaltyExpense>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments contextRef="c-159" decimals="-5" id="f-704" unitRef="usd">20500000</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments contextRef="c-159" decimals="-5" id="f-705" unitRef="usd">200000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="c-159" decimals="INF" id="f-706" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="c-160" decimals="INF" id="f-707" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="c-161" decimals="INF" id="f-708" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <arqt:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares
      contextRef="c-162"
      decimals="INF"
      id="f-709"
      unitRef="shares">610258</arqt:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable contextRef="c-163" decimals="-5" id="f-710" unitRef="usd">12500000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <arqt:AssetAcquisitionConsiderationTransferredGross contextRef="c-162" decimals="-5" id="f-711" unitRef="usd">15900000</arqt:AssetAcquisitionConsiderationTransferredGross>
    <arqt:AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount contextRef="c-164" decimals="-6" id="f-712" unitRef="usd">400000000</arqt:AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount>
    <arqt:AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones contextRef="c-162" decimals="-5" id="f-713" unitRef="usd">10000000.0</arqt:AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones>
    <arqt:AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment contextRef="c-162" id="f-714">P1Y</arqt:AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment>
    <arqt:AssetAcquisitionAnnualNetSalesOfAcquireeThreshold contextRef="c-162" decimals="-8" id="f-715" unitRef="usd">1500000000</arqt:AssetAcquisitionAnnualNetSalesOfAcquireeThreshold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-162" decimals="-5" id="f-716" unitRef="usd">29600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="c-165" decimals="INF" id="f-717" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="c-166" decimals="INF" id="f-718" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="c-167" decimals="INF" id="f-719" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-720">Commitments and Contingencies&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company's lease for its corporate headquarters (22,643 square feet of office space) commenced in February 2019 and was amended in April 2020 in order to relocate to a new expanded space. In August 2025, the Company entered into a second amendment to extend the term of the lease by five years, extending the lease expiration from August 2028 to July 2033. This second amendment had a net effect of increasing the Company's future lease payments by approximately $5.4&#160;million, primarily due to the &lt;span style="-sec-ix-hidden:f-724"&gt;five&lt;/span&gt; additional years of rent payments. In accordance with ASC 842, the Company remeasured the present value of the aggregate lease payments over the amended lease term and recorded an increase to the Company&#x2019;s operating lease liabilities and existing right-of-use lease asset of approximately $2.9&#160;million in the third quarter 2025 as a result of this remeasurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease also requires the Company to have an available letter of credit which has a related restricted cash account of  $0.3&#160;million and $0.6&#160;million as of December&#160;31, 2025 and 2024, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The minimum annual rental payments of the Company&#x2019;s operating lease liability as of December&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-739"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, long-term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs recognized was $0.8&#160;million, $0.7&#160;million, and $0.7&#160;million for the years ended December&#160;31, 2025, 2024, and 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following information represents supplemental disclosure for the consolidated statements of cash flows related to the Company&#x2019;s operating lease (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flows from operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes additional information related to the operating lease:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Manufacturing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into manufacturing supply agreements for the commercial supply of ZORYVE which include certain minimum purchase commitments. As of December 31, 2025, firm future purchase commitments that are subject to these agreements with a term of greater than one year, excluding those recognized on the consolidated balance sheets, are $1.7&#160;million in 2026 and $0.9&#160;million in 2027, respectively. These future purchase commitments do not represent all of the Company&#x2019;s anticipated purchases, but instead represents only the contractually obligated minimum purchases or firm commitments of non-cancelable minimum amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reason of their status or service as directors or officers to the fullest extent permitted by the provisions of the Company's Bylaws and the Delaware General Corporation Law. The Company currently has directors&#x2019; and officers&#x2019; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes any potential loss exposure under these indemnification agreements in excess of applicable insurance coverage is minimal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, the Company may be involved in legal proceedings, as well as demands, claims, and threatened litigation, which arise in the normal course of business or otherwise. The ultimate outcome of any litigation is uncertain, and unfavorable outcomes could have a negative impact on the Company's results of operations and financial condition. Regardless of outcome, litigation can have an adverse impact on the Company because of the defense costs, the diversion of management resources, and other factors. &lt;/span&gt;&lt;/div&gt;As of December 31, 2025 and 2024, the Company determined that no loss contingencies from legal proceedings&#x2014;including the patent infringement complaint filed against the Company by Teva Pharmaceutical Industries, Ltd.&#x2014;met the threshold of "probable" and "reasonably estimable", as defined in ASC 450.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <arqt:LesseeOperatingLeaseOfficeSpace contextRef="c-168" decimals="0" id="f-721" unitRef="sqft">22643</arqt:LesseeOperatingLeaseOfficeSpace>
    <arqt:LesseeOperatingLeaseExtensionTerm contextRef="c-169" id="f-722">P5Y</arqt:LesseeOperatingLeaseExtensionTerm>
    <arqt:LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments contextRef="c-170" decimals="-5" id="f-723" unitRef="usd">5400000</arqt:LesseeOperatingLeaseIncreaseInFutureLeaseRentPaymentCommitments>
    <arqt:IncreaseDecreaseInOperatingLeaseRightOfUseAsset contextRef="c-171" decimals="-5" id="f-725" unitRef="usd">2900000</arqt:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-171" decimals="-5" id="f-726" unitRef="usd">2900000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-172" decimals="-5" id="f-727" unitRef="usd">300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-173" decimals="-5" id="f-728" unitRef="usd">600000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-729">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The minimum annual rental payments of the Company&#x2019;s operating lease liability as of December&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-739"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, long-term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-10" decimals="-3" id="f-730" unitRef="usd">792000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-10" decimals="-3" id="f-731" unitRef="usd">545000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-10" decimals="-3" id="f-732" unitRef="usd">862000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-10" decimals="-3" id="f-733" unitRef="usd">1255000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-10" decimals="-3" id="f-734" unitRef="usd">1292000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-10" decimals="-3" id="f-735" unitRef="usd">3398000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-10" decimals="-3" id="f-736" unitRef="usd">8144000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-10" decimals="-3" id="f-737" unitRef="usd">2584000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-10" decimals="-3" id="f-738" unitRef="usd">5560000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-10" decimals="-3" id="f-740" unitRef="usd">294000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-10" decimals="-3" id="f-741" unitRef="usd">5266000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-10" decimals="-3" id="f-742" unitRef="usd">5560000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-743" unitRef="usd">800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-12" decimals="-5" id="f-744" unitRef="usd">700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-5" id="f-745" unitRef="usd">700000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-746">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following information represents supplemental disclosure for the consolidated statements of cash flows related to the Company&#x2019;s operating lease (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flows from operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes additional information related to the operating lease:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-747" unitRef="usd">1027000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-12" decimals="-3" id="f-748" unitRef="usd">994000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-13" decimals="-3" id="f-749" unitRef="usd">965000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-10" id="f-750">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-11" id="f-751">P3Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-10" decimals="3" id="f-752" unitRef="number">0.093</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-11" decimals="3" id="f-753" unitRef="number">0.070</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear contextRef="c-10" decimals="-5" id="f-754" unitRef="usd">1700000</us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear contextRef="c-10" decimals="-5" id="f-755" unitRef="usd">900000</us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear>
    <us-gaap:LongTermDebtTextBlock contextRef="c-1" id="f-756">Debt&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 22, 2021, the Company entered into a loan and security agreement (the Prior Loan Agreement) with SLR Investment Corp. (SLR) and the lenders party thereto. The Prior Loan Agreement was amended and restated on January 10, 2023 (the AR Loan Agreement) to include Arcutis Canada, Inc. as a borrower and party. On November 1, 2023, the Company entered into an amendment to the AR Loan Agreement to, among others, (i) modify the financial covenant relating to minimum net product revenue, and (ii) include an additional minimum financing covenant. On August 9, 2024, the Company entered into a second amendment to the AR Loan Agreement (the AR Loan Agreement, as amended by the first and second amendments, the Loan Agreement), which it determined to be a modification, to, among others, (i) permit, during the period commencing on October 7, 2024 and ending on December 15, 2024, an optional partial prepayment of term loans outstanding, subject to a 1.0% prepayment penalty (the 2024 Partial Prepayment), (ii) add the tranche C-1 and tranche C-2 term loans, and (iii) facilitate certain other changes, including with respect to the applicable interest rate and maturity date in the event of a 2024 Partial Prepayment. As security for the obligations under the Loan Agreement, the Company granted SLR, for the benefit of the lenders, a continuing security interest in substantially all of the Company's assets, including its intellectual property, subject to certain exceptions. The term loan facility is comprised of (i) a tranche A term loan of $75.0&#160;million, (ii) a tranche B-1 term loan of $50.0&#160;million, (iii) a tranche B-2 term loan of up to $75.0&#160;million, (iv) a tranche C-1 term loan of up to $50.0&#160;million, and (v) a tranche C-2 term loan of up to $50.0&#160;million (collectively, the Term Loans). The tranche A term loan was funded on December 22, 2021. With the approval of ZORYVE cream 0.3% on July 29, 2022, the tranche B term loans were funded on August 2, 2022. As of December&#160;31, 2025 and 2024, the aggregate principal amount outstanding under the Loan Agreement was $100.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 8, 2024, the Company made a 2024 Partial Prepayment of $100.0&#160;million, which reduced the aggregate principal amount outstanding under the Loan Agreement to $100.0&#160;million. In connection with the 2024 Partial Prepayment, the Company is obligated to pay a prepayment penalty of $1.0&#160;million by June 30, 2026 and a final fee of $6.95&#160;million, representing the final fee applicable to the amount of the 2024 Partial Prepayment, on January 1, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As a result of such 2024 Partial Prepayment, subject to the Company generating a minimum net product revenue for the trailing six (6) month period ending as of the month prior to the borrowing date equal to 80% of the Company&#x2019;s projected net product revenue as set forth in its annual plan for the respective period, the Company will be able to draw down the tranche C-1 and tranche C-2 term loans. The tranche C-1 term loan availability will expire on March 31, 2026 and the tranche C-2 term loan availability will expire on June 30, 2026. In addition, as a result of the 2024 Partial Prepayment, (i) the maturity date of the Loan Agreement is August 1, 2029, (ii) the applicable per annum interest rate is equal to 5.95% plus the greater of (a) 2.50% per annum and (b) the one-month Secured Overnight Financing Rate (SOFR), (iii) the Company is no longer subject to certain cost and purchase price restrictions regarding acquisitions, and (iv) the Company may prepay principal amounts outstanding under the Term Loans in minimum increments of $25.0&#160;million, subject to a prepayment premium of (a) 3.0% for any prepayment made prior to the first anniversary of the second amendment, (b) 2.0% for any prepayment made prior after the first anniversary of the second amendment and prior to the second anniversary of the second amendment, or (c) 1.0% &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;for any prepayment made prior after the second anniversary of the second amendment and prior to the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Principal amounts outstanding under the Term Loans will accrue interest at a floating rate equal to the applicable rate in effect from time to time, as determined by SLR on the third business day prior to the funding date of the applicable Term Loan and on the first business day of the month prior to each payment date of each Term Loan. Prior to the 2024 Partial Prepayment, the applicable rate was a per annum interest rate equal to 7.45% plus the greater of (a) 0.10% and (b) the one-month SOFR. As a result of such 2024 Partial Prepayment, the applicable interest rate will be a per annum interest rate equal to 5.95% plus the greater of (a) 2.50% and (b) the one-month SOFR. On December&#160;31, 2025, the rate was 9.79%. The benchmark SOFR is subject to change in the event of certain events with respect to the benchmark rate. Interest payments are payable monthly following the funding of any Term Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Term Loans are accelerated due to, among others, the occurrence of a bankruptcy or insolvency event, the Company is required to make mandatory prepayments of (i) all principal amounts outstanding under the Term Loans, plus accrued and unpaid interest thereon through the prepayment date, (ii) any fees applicable by reason of such prepayment, (iii) the prepayment premiums set forth in the paragraph above, plus (iv) all other obligations that are due and payable, including expenses and interest at the Default Rate (as defined below) with respect to any past due amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on the Company&#x2019;s ability to dispose of its business or property, to change its line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on its property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. The Company also agreed to a financial covenant whereby the Company must generate a minimum net product revenue equal to 75% of its projected net product revenue as set forth in the Company's annual plan for the respective period, tested on a trailing six-month basis, as of the end of each month. Each annual plan shall be approved by the Company&#x2019;s board of directors and SLR, in its capacity as collateral agent, in its reasonable discretion. Any failure by the Company to deliver such annual plan on or before December 15 of the prior year shall be an immediate event of default. The Company was in compliance with all covenants under the Loan Agreement as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Loan Agreement contains customary events of default that entitle the lenders to cause any indebtedness under the Loan Agreement to become immediately due and payable, and to exercise remedies against the Company and the collateral securing the Term Loans. Under the Loan Agreement, an event of default will occur if, among other things, the Company fails to make payments under the Loan Agreement, the Company breaches any of the covenants under the Loan Agreement, subject to specified cure periods with respect to certain breaches, the lenders determine that a material adverse change has occurred, or the Company or the Company's assets become subject to certain legal proceedings, such as bankruptcy proceedings. Upon the occurrence and for the duration of an event of default, an additional default interest rate, or the Default Rate, equal to 4.0% per annum will apply to all obligations owed under the Loan Agreement. The prepayment upon default and other potential additional interest provisions under the Loan Agreement were determined to be a compound embedded derivative instrument to be bifurcated from the loan and accounted for as a separate liability for accounting purposes under the guidance in ASC 815, Derivatives and Hedging. At the inception of the Loan Agreement, the fair value of the embedded derivative was determined to be immaterial. The embedded derivative instrument is remeasured at fair value each reporting period with any future changes in fair value reported in Other income, net in the consolidated statement of operations and comprehensive loss. The amounts recognized in Other income, net related to the change in fair value of the embedded derivative instrument during the year ended December 31, 2025 and 2024 were not material. No gain or loss was recognized during the year ended December 31, 2023. The fair value of the embedded derivative instrument as of December&#160;31, 2025 and 2024 was a liability of $0.4 million and $0.6 million, respectively, and is included in Other-long term liabilities in the accompanying consolidated balance sheets. See Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n connection with the Loan Agreement, the Company is obligated to pay (i) a final fee equal to 6.95% of the aggregate original principal amount of the Term Loans outstanding as of the date of the second amendment (x) with respect to any 2024 Partial Prepayment, upon the earliest to occur of (a) January 1, 2027, (b) the acceleration of all &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding Term Loans and (c) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, and (y) with respect to the Term Loans outstanding as of the date of the second amendment (other than the 2024 Partial Prepayment), upon the earliest to occur of (a) the maturity date, (b) the acceleration of all outstanding Term Loans and (c) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, (ii) a 2.00% fee with respect to tranche C term loans, due and payable on the earliest to occur of (a) the maturity date, (b) the acceleration of all outstanding Term Loans and (c) the prepayment, or refinancing, substitution or replacement of all outstanding Term Loans, (iii) a 2.00% extension fee with respect to tranche C term loans which remain unfunded after December 31, 2025, which shall accrue during the period commencing January 1, 2026, and ending on the earliest to occur of (a) the expiration of the tranche C term loan availability, and (b) the date on which tranche C term loan is fully drawn, and (iv) a certain amount of lenders&#x2019; expenses incurred in connection with the execution of the Loan Agreement. Additionally, in connection with the original Prior Loan Agreement, the Company previously had entered into an Exit Fee Agreement, whereby the Company agreed to pay an exit fee in the amount of 3.0% of each Term Loan funded upon (i) any change of control transaction or (ii) a revenue milestone, calculated on a trailing six-month basis. Notwithstanding the prepayment or termination of the Term Loan, the exit fee will expire 10 years from the date of the Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The debt issuance costs have been recorded as a debt discount which are being accreted to interest expense through the maturity date of the term loan. Interest expense is calculated using the effective interest method, and is inclusive of non-cash amortization of debt issuance costs. The final maturity payment of $13.9&#160;million is recognized over the life of the term loan through interest expense. At December&#160;31, 2025 and 2024, the effective interest rate was 10.92% and 11.57%, respectively. Interest expense relating to the term loan was $12.1&#160;million, $27.2&#160;million and $29.7&#160;million, respectively, for the years ended December&#160;31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes additional information related to the Company's long-term debt (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued prepayment penalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the contractual maturity of the Company's long term debt, a payment of principal and final fees of $107.0 million is due on August 1, 2029.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <arqt:DebtInstrumentPrepaymentPremium
      contextRef="c-174"
      decimals="INF"
      id="f-757"
      unitRef="number">0.010</arqt:DebtInstrumentPrepaymentPremium>
    <arqt:DebtInstrumentMaximumBorrowingCapacity contextRef="c-175" decimals="-5" id="f-758" unitRef="usd">75000000.0</arqt:DebtInstrumentMaximumBorrowingCapacity>
    <arqt:DebtInstrumentMaximumBorrowingCapacity contextRef="c-176" decimals="-5" id="f-759" unitRef="usd">50000000.0</arqt:DebtInstrumentMaximumBorrowingCapacity>
    <arqt:DebtInstrumentMaximumBorrowingCapacity contextRef="c-177" decimals="-5" id="f-760" unitRef="usd">75000000.0</arqt:DebtInstrumentMaximumBorrowingCapacity>
    <arqt:DebtInstrumentMaximumBorrowingCapacity contextRef="c-178" decimals="-5" id="f-761" unitRef="usd">50000000.0</arqt:DebtInstrumentMaximumBorrowingCapacity>
    <arqt:DebtInstrumentMaximumBorrowingCapacity contextRef="c-179" decimals="-5" id="f-762" unitRef="usd">50000000.0</arqt:DebtInstrumentMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-50" decimals="-5" id="f-763" unitRef="usd">100000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-180" decimals="-5" id="f-764" unitRef="usd">100000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-181" decimals="-5" id="f-765" unitRef="usd">100000000.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-182" decimals="-5" id="f-766" unitRef="usd">100000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <arqt:DebtInstrumentPrepaymentPenalty contextRef="c-183" decimals="-5" id="f-767" unitRef="usd">1000000.0</arqt:DebtInstrumentPrepaymentPenalty>
    <arqt:DebtInstrumentPrepaymentPenalty contextRef="c-184" decimals="-4" id="f-768" unitRef="usd">6950000</arqt:DebtInstrumentPrepaymentPenalty>
    <arqt:DebtInstrumentFundingAvailabilityCovenantPeriod contextRef="c-181" id="f-769">P6M</arqt:DebtInstrumentFundingAvailabilityCovenantPeriod>
    <arqt:DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue
      contextRef="c-182"
      decimals="INF"
      id="f-770"
      unitRef="number">0.80</arqt:DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue>
    <arqt:DebtInstrumentInterestRateStatedPercentagePartialPrepayment
      contextRef="c-182"
      decimals="INF"
      id="f-771"
      unitRef="number">0.0595</arqt:DebtInstrumentInterestRateStatedPercentagePartialPrepayment>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-181"
      decimals="INF"
      id="f-772"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-185" decimals="-5" id="f-773" unitRef="usd">25000000.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <arqt:DebtInstrumentPrepaymentPremium
      contextRef="c-186"
      decimals="INF"
      id="f-774"
      unitRef="number">0.030</arqt:DebtInstrumentPrepaymentPremium>
    <arqt:DebtInstrumentPrepaymentPremium
      contextRef="c-187"
      decimals="INF"
      id="f-775"
      unitRef="number">0.020</arqt:DebtInstrumentPrepaymentPremium>
    <arqt:DebtInstrumentPrepaymentPremium
      contextRef="c-188"
      decimals="INF"
      id="f-776"
      unitRef="number">0.010</arqt:DebtInstrumentPrepaymentPremium>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-189"
      decimals="INF"
      id="f-777"
      unitRef="number">0.0745</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-190"
      decimals="INF"
      id="f-778"
      unitRef="number">0.0010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <arqt:DebtInstrumentInterestRateStatedPercentagePartialPrepayment
      contextRef="c-182"
      decimals="INF"
      id="f-779"
      unitRef="number">0.0595</arqt:DebtInstrumentInterestRateStatedPercentagePartialPrepayment>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-181"
      decimals="INF"
      id="f-780"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <arqt:DebtInstrumentInterestRateAtPeriodEnd contextRef="c-50" decimals="4" id="f-781" unitRef="number">0.0979</arqt:DebtInstrumentInterestRateAtPeriodEnd>
    <arqt:DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue
      contextRef="c-174"
      decimals="INF"
      id="f-782"
      unitRef="number">0.75</arqt:DebtInstrumentCovenantMinimumNetProductRevenueAsAPercentageOfProjectedNetProductRevenue>
    <arqt:DebtInstrumentFundingAvailabilityCovenantPeriod contextRef="c-191" id="f-783">P6M</arqt:DebtInstrumentFundingAvailabilityCovenantPeriod>
    <arqt:DebtInstrumentDefaultRate contextRef="c-189" decimals="3" id="f-784" unitRef="number">0.040</arqt:DebtInstrumentDefaultRate>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="c-50" decimals="-5" id="f-785" unitRef="usd">400000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="c-180" decimals="-5" id="f-786" unitRef="usd">600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <arqt:DebtInstrumentFinalFeePercentage contextRef="c-189" decimals="4" id="f-787" unitRef="number">0.0695</arqt:DebtInstrumentFinalFeePercentage>
    <arqt:DebtInstrumentFinalFeePercentage contextRef="c-192" decimals="4" id="f-788" unitRef="number">0.0200</arqt:DebtInstrumentFinalFeePercentage>
    <arqt:DebtInstrumentExtensionFeePercentage contextRef="c-192" decimals="3" id="f-789" unitRef="number">0.0200</arqt:DebtInstrumentExtensionFeePercentage>
    <arqt:DebtInstrumentExitFeePercentage contextRef="c-189" decimals="3" id="f-790" unitRef="number">0.030</arqt:DebtInstrumentExitFeePercentage>
    <arqt:DebtInstrumentFundingAvailabilityCovenantPeriod contextRef="c-190" id="f-791">P6M</arqt:DebtInstrumentFundingAvailabilityCovenantPeriod>
    <arqt:DebtInstrumentExitFeeExpirationPeriod contextRef="c-190" id="f-792">P10Y</arqt:DebtInstrumentExitFeeExpirationPeriod>
    <arqt:DebtInstrumentDeferredFinalFeeGross contextRef="c-189" decimals="-5" id="f-793" unitRef="usd">13900000</arqt:DebtInstrumentDeferredFinalFeeGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-50" decimals="4" id="f-794" unitRef="number">0.1092</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-180" decimals="4" id="f-795" unitRef="number">0.1157</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt contextRef="c-193" decimals="-5" id="f-796" unitRef="usd">12100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-194" decimals="-5" id="f-797" unitRef="usd">27200000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-195" decimals="-5" id="f-798" unitRef="usd">29700000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-799">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes additional information related to the Company's long-term debt (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued prepayment penalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-10" decimals="-3" id="f-800" unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-11" decimals="-3" id="f-801" unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <arqt:DebtInstrumentAccruedFinalFee contextRef="c-10" decimals="-3" id="f-802" unitRef="usd">8824000</arqt:DebtInstrumentAccruedFinalFee>
    <arqt:DebtInstrumentAccruedFinalFee contextRef="c-11" decimals="-3" id="f-803" unitRef="usd">7324000</arqt:DebtInstrumentAccruedFinalFee>
    <arqt:DebtInstrumentAccruedPrepaymentPenalty contextRef="c-10" decimals="-3" id="f-804" unitRef="usd">1000000</arqt:DebtInstrumentAccruedPrepaymentPenalty>
    <arqt:DebtInstrumentAccruedPrepaymentPenalty contextRef="c-11" decimals="-3" id="f-805" unitRef="usd">1000000</arqt:DebtInstrumentAccruedPrepaymentPenalty>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-10" decimals="-3" id="f-806" unitRef="usd">865000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-11" decimals="-3" id="f-807" unitRef="usd">1121000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-10" decimals="-3" id="f-808" unitRef="usd">108959000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-11" decimals="-3" id="f-809" unitRef="usd">107203000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-10" decimals="-3" id="f-810" unitRef="usd">1000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-11" decimals="-3" id="f-811" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-10" decimals="-3" id="f-812" unitRef="usd">107959000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-11" decimals="-3" id="f-813" unitRef="usd">107203000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-10" decimals="-5" id="f-814" unitRef="usd">107000000.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-815">Stockholders' Equity&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's authorized capital stock consists of 310,000,000 shares, all with a par value of $0.0001 per share, of which 300,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock. There were no shares of preferred stock outstanding as of December&#160;31, 2025 and 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, the Company completed a public sale of its common stock, receiving aggregate net proceeds of $95.8&#160;million. In addition to the sale of common stock, the Company issued prefunded warrants to purchase 7,500,000 shares of the Company's common stock at $2.4999 per underlying share of common stock. The exercise price of the warrants is $0.0001 per underlying share of common stock, were fully exercisable upon issuance, and have no expiration date. In October 2025, certain prefunded warrants were exercised, resulting in the issuance of 2,285,000 shares. As of December&#160;31, 2025, prefunded warrants to purchase 5,215,000 shares of the Company's common stock remained outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2024, the Company completed a public sale of its common stock, receiving aggregate net proceeds of $161.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market (ATM) Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 6, 2021, the Company entered into a sales agreement (Sales Agreement) with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through ATM offerings for an aggregate offering price of up to $100.0&#160;million. Cowen will act as the Company's sales agent for the ATM program and is entitled to compensation for its services up to 3% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In December 2023, the Company sold 1,250,000 shares under the ATM for $2.60 per share and received $3.1&#160;million in net proceeds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2024, the Company amended and restated its Sales Agreement with Cowen to reset the ATM program and provide for the offer and sale of shares of common stock having an aggregate gross offering price of up to $100.0&#160;million. All other terms of the amended and restated Sales Agreement are substantially the same as the original Sales Agreement. The Company has not yet issued or sold any common stock under the amended and restated Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the Company&#x2019;s board of directors approved the 2020 Equity Incentive Plan (2020 Plan), which became effective January 30, 2020 in connection with the IPO. The 2020 Plan serves as the successor incentive award plan to the Company&#x2019;s 2017 Equity Incentive Plan (2017 Plan) and initially reserved 2,134,000 shares of common stock available for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit (RSU) awards, and other stock-based awards, plus 1,550,150 shares of common stock that were reserved for issuance pursuant to future awards under the 2017 Plan at the time the 2020 Plan became effective, plus shares represented by awards outstanding under the 2017 Plan that are forfeited or lapsed unexercised and which following the effective date of the 2020 Plan are not issued under the 2017 Plan. In addition, the 2020 Plan reserve will increase on January 1 of each year beginning in 2021 through 2030, by an amount equal to the lesser of (a) 4% of the shares of stock outstanding (on an as converted basis) on the day immediately prior to the date of increase and (b) such smaller number of shares of stock as determined by the Company's board of directors; provided, however, that no more than 11,000,000 shares of stock may be issued upon the exercise of incentive stock options. Accordingly, on January 1, 2026, 2025 and 2024, the 2020 Plan reserve increased by 4,933,306, 4,713,921, and 3,871,494 shares, respectively. As of December&#160;31, 2025, the Company had 4,093,603 shares available for future grant under the 2020 Plan.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Plan provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors, and consultants of the Company under terms and provisions established by the board of directors. Under the terms of the 2020 Plan, options may be granted at an exercise price not less than fair market value. The Company generally grants stock-based awards with service conditions. Options granted typically vest over a four-year period but may be granted with different vesting terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the Company&#x2019;s IPO and in connection with the effectiveness of the Company&#x2019;s 2020 Plan, the 2017 Plan terminated and no further awards will be granted under that plan. However, all outstanding awards under the 2017 Plan will continue to be governed by their existing terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2021, the Company&#x2019;s board of directors approved the 2022 Employment Inducement Incentive Plan (2022 Plan). The 2022 Plan initially reserved 1,250,000 shares of common stock available for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, RSU awards, and other stock-based awards. In November 2022, the 2022 Plan reserve was increased by 1,500,000. As of December&#160;31, 2025, the Company had 111,533 shares available for future grant under the 2022 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Stock Option Exchange Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 16, 2024, the Company commenced an offer to certain eligible employees and consultants to exchange certain outstanding eligible options to purchase shares of the Company&#x2019;s common stock for a lesser number of restricted stock unit (RSU) awards pursuant to an option exchange program (the Option Exchange). The Option Exchange expired on February 12, 2024. Pursuant to the Option Exchange, eligible option holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of 5,059,129 shares of the Company&#x2019;s common stock, representing approximately 98% of the total shares of common stock underlying the eligible options. On February 13, 2024, immediately following the expiration of the Option Exchange, the Company granted 2,129,594 shares of Replacement RSU Awards, pursuant to the terms of the Option Exchange. The Replacement RSU Awards will vest based on continued service with the Company over a period of either 1, 2 or 3 years, depending on the grant date of the exchanged options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exchange of stock options was treated as a modification for accounting purposes, which requires an incremental expense of $8.6&#160;million to be recognized for the Replacement RSU Awards over their new service periods (1 - 3 years). In addition, any unamortized expense remaining on the exchanged options as of the modification will be recognized over their original remaining service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes option activity:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value ($ in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance&#x2014;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(714,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance&#x2014;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,436,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&#x2014;December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock as of December&#160;31, 2025. The intrinsic value of options exercised for the years ended December&#160;31, 2025, 2024, and 2023 were $10.0 million, $4.2 million and $1.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total grant-date fair value of the options vested during the years ended December&#160;31, 2025, 2024, and 2023 were $8.5 million, $4.0 million and $28.0 million, respectively. The weighted-average grant-date fair value of options granted during the years ended December&#160;31, 2025, 2024, and 2023 were $9.94, $3.70 and $8.01, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Unit Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding the Company's RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance&#x2014;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,055,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,275,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(835,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested Balance&#x2014;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,007,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of an RSU equals the closing price of the Company's common stock on the grant date. The total grant-date fair value of the RSUs vested during the years ended December&#160;31, 2025, 2024, and 2023 were $18.8&#160;million, $17.4&#160;million, and $9.3&#160;million, respectively. RSUs generally vest equally over four years, except for those issued in connection with the Option Exchange, as previously described.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in the consolidated statements of operations and comprehensive loss was as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, there was $25.7 million of total unrecognized compensation cost related to unvested options that are expected to vest, which is expected to be recognized over a weighted-average period of 2.6 years. As of December&#160;31, 2025, there was $47.5 million of total unrecognized compensation cost related to RSUs that are expected to vest, which is expected to be recognized over a weighted-average period of 2.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the fair value of the stock options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value of common stock&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses its closing stock price as reported on Nasdaq on the grant date for the fair value of its stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding. The Company uses the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term as it does not have sufficient prior exercise data to calculate based on historical data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company uses its own historical stock price for expected volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock option awards granted was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 &#x2013; 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8 &#x2013; 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 &#x2013; 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.9&#160;&#x2013;&#160;79.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.1&#160;&#x2013;&#160;83.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.2%&#160;&#x2013; 78.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 &#x2013; 4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6 &#x2013; 5.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5 &#x2013; 4.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted the 2020 Employee Stock Purchase Plan, or the ESPP, which became effective on January 30, 2020 in connection with the IPO. The ESPP is designed to allow the Company&#x2019;s eligible employees to purchase shares of the Company&#x2019;s common stock, at semi-annual intervals, with their accumulated payroll deductions. Under the ESPP, participants are offered the option to purchase shares of the Company&#x2019;s common stock at a discount during a series of successive offering periods. The option purchase price will be the lower of 85% of the closing trading price per share of the Company&#x2019;s common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each offering period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP is intended to qualify under Section 423 of the U.S. Internal Revenue Service Code of 1986, as amended. The maximum number of the Company&#x2019;s common stock which will be authorized for sale under the ESPP is equal to the sum of (a) 351,000 shares of common stock and (b) an annual increase on the first day of each year beginning in 2021 and ending in 2030, equal to the lesser of (i) 1% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company&#x2019;s board of directors; provided, however, no more than 5,265,000 shares of the Company&#x2019;s common stock may be issued under the ESPP. Accordingly, on January 1, 2026, 2025 and 2024, the ESPP reserve increased by 1,216,890, 1,178,480, and 967,873 shares, respectively. As of December&#160;31, 2025, the Company had 2,806,818 shares available for future grant under the ESPP. &lt;/span&gt;&lt;/div&gt;Stock-based compensation expense related to the ESPP was $1.0 million, $0.9 million, and $0.9 million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="c-10"
      decimals="INF"
      id="f-816"
      unitRef="shares">310000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-817"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-10"
      decimals="INF"
      id="f-818"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-10"
      decimals="INF"
      id="f-819"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-820"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-821"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-196" decimals="-5" id="f-822" unitRef="usd">95800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-197"
      decimals="INF"
      id="f-823"
      unitRef="shares">7500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-197"
      decimals="INF"
      id="f-824"
      unitRef="usdPerShare">2.4999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-197"
      decimals="INF"
      id="f-825"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-198"
      decimals="INF"
      id="f-826"
      unitRef="shares">2285000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-199"
      decimals="INF"
      id="f-827"
      unitRef="shares">5215000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-200" decimals="-5" id="f-828" unitRef="usd">161700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arqt:SaleOfStockAuthorizedConsiderationOnTransaction contextRef="c-201" decimals="-5" id="f-829" unitRef="usd">100000000.0</arqt:SaleOfStockAuthorizedConsiderationOnTransaction>
    <arqt:SaleOfStockAgentFeePercentageOfGrossProceeds contextRef="c-202" decimals="2" id="f-830" unitRef="number">0.03</arqt:SaleOfStockAgentFeePercentageOfGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-203"
      decimals="INF"
      id="f-831"
      unitRef="shares">1250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-204"
      decimals="2"
      id="f-832"
      unitRef="usdPerShare">2.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-203" decimals="-5" id="f-833" unitRef="usd">3100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arqt:SaleOfStockAuthorizedConsiderationOnTransaction contextRef="c-205" decimals="-5" id="f-834" unitRef="usd">100000000.0</arqt:SaleOfStockAuthorizedConsiderationOnTransaction>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-206"
      decimals="INF"
      id="f-835"
      unitRef="shares">2134000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-207"
      decimals="INF"
      id="f-836"
      unitRef="shares">1550150</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="c-206"
      decimals="INF"
      id="f-837"
      unitRef="number">0.04</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable
      contextRef="c-206"
      decimals="INF"
      id="f-838"
      unitRef="shares">11000000</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-208"
      decimals="INF"
      id="f-839"
      unitRef="shares">4933306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-209"
      decimals="INF"
      id="f-840"
      unitRef="shares">4713921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-210"
      decimals="INF"
      id="f-841"
      unitRef="shares">3871494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-211"
      decimals="INF"
      id="f-842"
      unitRef="shares">4093603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-212" id="f-843">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-213"
      decimals="INF"
      id="f-844"
      unitRef="shares">1250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-214"
      decimals="INF"
      id="f-845"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-215"
      decimals="INF"
      id="f-846"
      unitRef="shares">111533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-216"
      decimals="INF"
      id="f-847"
      unitRef="shares">5059129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged contextRef="c-217" decimals="2" id="f-848" unitRef="number">0.98</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEligibleOptionsExchanged>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-218"
      decimals="INF"
      id="f-849"
      unitRef="shares">2129594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-219" id="f-850">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-220" id="f-851">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-221" id="f-852">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c-222" decimals="-5" id="f-853" unitRef="usd">8600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-223" id="f-854">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-224" id="f-855">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-856">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes option activity:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value ($ in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance&#x2014;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(714,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance&#x2014;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,436,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&#x2014;December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-11"
      decimals="INF"
      id="f-857"
      unitRef="shares">5342909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-858"
      unitRef="usdPerShare">6.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-12" id="f-859">P8Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-11" decimals="-3" id="f-860" unitRef="usd">43120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-861" unitRef="shares">2345398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-862"
      unitRef="usdPerShare">14.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-863" unitRef="shares">714125</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-864"
      unitRef="usdPerShare">6.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-865" unitRef="shares">534345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-866"
      unitRef="usdPerShare">9.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-867" unitRef="shares">2865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-868"
      unitRef="usdPerShare">26.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-10"
      decimals="INF"
      id="f-869"
      unitRef="shares">6436972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-10"
      decimals="2"
      id="f-870"
      unitRef="usdPerShare">9.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-871">P7Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-10" decimals="-3" id="f-872" unitRef="usd">127945000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-10"
      decimals="INF"
      id="f-873"
      unitRef="shares">2903391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-10"
      decimals="2"
      id="f-874"
      unitRef="usdPerShare">8.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-875">P6Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-10" decimals="-3" id="f-876" unitRef="usd">59750000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-877" unitRef="usd">10000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-12" decimals="-5" id="f-878" unitRef="usd">4200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-13" decimals="-5" id="f-879" unitRef="usd">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-1" decimals="-5" id="f-880" unitRef="usd">8500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-12" decimals="-5" id="f-881" unitRef="usd">4000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-13" decimals="-5" id="f-882" unitRef="usd">28000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-883"
      unitRef="usdPerShare">9.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-12"
      decimals="2"
      id="f-884"
      unitRef="usdPerShare">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-13"
      decimals="2"
      id="f-885"
      unitRef="usdPerShare">8.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-886">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding the Company's RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance&#x2014;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,055,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,275,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(835,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested Balance&#x2014;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,007,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-225"
      decimals="INF"
      id="f-887"
      unitRef="shares">6055087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-225"
      decimals="2"
      id="f-888"
      unitRef="usdPerShare">8.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-226"
      decimals="INF"
      id="f-889"
      unitRef="shares">3063418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-226"
      decimals="2"
      id="f-890"
      unitRef="usdPerShare">14.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-226"
      decimals="INF"
      id="f-891"
      unitRef="shares">2275607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c-226"
      decimals="2"
      id="f-892"
      unitRef="usdPerShare">8.24</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-226"
      decimals="INF"
      id="f-893"
      unitRef="shares">835383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-226"
      decimals="2"
      id="f-894"
      unitRef="usdPerShare">10.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-227"
      decimals="INF"
      id="f-895"
      unitRef="shares">6007515</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-227"
      decimals="2"
      id="f-896"
      unitRef="usdPerShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-226" decimals="-5" id="f-897" unitRef="usd">18800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-228" decimals="-5" id="f-898" unitRef="usd">17400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-229" decimals="-5" id="f-899" unitRef="usd">9300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-226" id="f-900">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-901">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in the consolidated statements of operations and comprehensive loss was as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-230" decimals="-3" id="f-902" unitRef="usd">12336000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-231" decimals="-3" id="f-903" unitRef="usd">13509000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-232" decimals="-3" id="f-904" unitRef="usd">15544000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-233" decimals="-3" id="f-905" unitRef="usd">28028000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-234" decimals="-3" id="f-906" unitRef="usd">28221000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-235" decimals="-3" id="f-907" unitRef="usd">23269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-908" unitRef="usd">40364000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-3" id="f-909" unitRef="usd">41730000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-910" unitRef="usd">38813000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-236" decimals="-5" id="f-911" unitRef="usd">25700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-237" id="f-912">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-227" decimals="-5" id="f-913" unitRef="usd">47500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-226" id="f-914">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-238"
      decimals="INF"
      id="f-915"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-916">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock option awards granted was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 &#x2013; 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8 &#x2013; 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 &#x2013; 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.9&#160;&#x2013;&#160;79.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.1&#160;&#x2013;&#160;83.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.2%&#160;&#x2013; 78.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 &#x2013; 4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6 &#x2013; 5.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5 &#x2013; 4.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-239" id="f-917">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-240" id="f-918">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-241" id="f-919">P1Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-242" id="f-920">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-243" id="f-921">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-244" id="f-922">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-237" decimals="3" id="f-923" unitRef="number">0.729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-237" decimals="3" id="f-924" unitRef="number">0.795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-245" decimals="3" id="f-925" unitRef="number">0.791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-245" decimals="3" id="f-926" unitRef="number">0.832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-246" decimals="3" id="f-927" unitRef="number">0.752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-246" decimals="3" id="f-928" unitRef="number">0.784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-237" decimals="3" id="f-929" unitRef="number">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-237" decimals="3" id="f-930" unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-245" decimals="3" id="f-931" unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-245" decimals="3" id="f-932" unitRef="number">0.050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-246" decimals="3" id="f-933" unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-246" decimals="3" id="f-934" unitRef="number">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-237" decimals="0" id="f-935" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-245" decimals="0" id="f-936" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-246" decimals="0" id="f-937" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-247"
      decimals="INF"
      id="f-938"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-247"
      decimals="INF"
      id="f-939"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized
      contextRef="c-248"
      decimals="INF"
      id="f-940"
      unitRef="shares">351000</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="c-249"
      decimals="INF"
      id="f-941"
      unitRef="number">0.01</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable
      contextRef="c-248"
      decimals="INF"
      id="f-942"
      unitRef="shares">5265000</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-250"
      decimals="INF"
      id="f-943"
      unitRef="shares">1216890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-251"
      decimals="INF"
      id="f-944"
      unitRef="shares">1178480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-252"
      decimals="INF"
      id="f-945"
      unitRef="shares">967873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-253"
      decimals="INF"
      id="f-946"
      unitRef="shares">2806818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-254" decimals="-3" id="f-947" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-255" decimals="-3" id="f-948" unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-256" decimals="-3" id="f-949" unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-951">Income Taxes&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded income tax expense of $1.2&#160;million during the year ended December&#160;31, 2025. Of the $1.2 million recorded, $0.4 million was related to foreign withholding taxes on the milestone payments received in connection with the Huadong Agreement and the remaining related to U.S. state income tax expense and other foreign tax expense. The Company recorded income tax expense of $0.6&#160;million during the year ended December&#160;31, 2024. Of the $0.6&#160;million recorded, $0.5&#160;million was related to foreign withholding taxes on the up-front fee in connection with the Huadong Agreement and the remaining was related to other foreign tax expense. The Company recorded income tax expense of $3.1 million during the year ended December&#160;31, 2023. Of the $3.1 million recorded, $3.0&#160;million was related to foreign withholding taxes on the up-front fee in connection with the Huadong Agreement and the remaining was related to other foreign tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of loss before income taxes for domestic and foreign locations for the years ended December&#160;31, 2025, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(259,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of provision for income taxes for the years ended December&#160;31, 2025, 2024 and 2023 is as follows (in thousands):&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current tax provision:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax provision:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax computed at federal statutory rates to the reported provision for income taxes for the years ended December&#160;31, 2025, 2024 and 2023 is as follows (in thousands)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.913%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax U.S. federal statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local income tax, net of federal income tax effect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United Kingdom&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statutory tax rate differential&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;China&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sec. 162(m) limitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) The prior years included in the effective tax rate table have been recast from the financial statements filed previously to align with the new presentation created through adherence to ASU 2023-09. Consideration has only been given to 2025 amounts in terms of the balances that are separately stated within the table.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) The states and local jurisdictions that contribute to a majority (greater than 50%) of the tax effect in this category include Texas, California and New York based on the distribution of sales and the current year state income tax obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.884%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and expenditure capitalization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly evaluates the positive and negative evidence in determining the realizability of its deferred tax assets. Based upon the weight of available evidence, which includes historical operating performance and reported cumulative net losses since inception, a valuation allowance on the majority of net deferred tax assets has been recorded as of December&#160;31, 2025 and 2024. The Company intend to maintain its substantially full valuation allowance on its deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The Company has an immaterial deferred tax asset related to a foreign jurisdiction. The valuation allowance decreased by approximately $0.8 million and increased by approximately $40.1 million during the years ended December&#160;31, 2025 and 2024, respectively, due to similar changes in the underlying deferred tax asset balances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has net operating loss (NOL) carryforwards for federal and state income tax purposes of $761.3 million and $636.1 million, respectively, as of December&#160;31, 2025. Of the federal NOLs, $3.5 million originated before the 2018 tax year and will expire beginning in 2036. Under the Tax Cuts and Jobs Act of 2017, the remaining $757.8 million of NOLs generated after December 31, 2017 will be carried forward indefinitely and will be available to offset 80% of taxable income in future years. Of the $636.1 million in state net operating loss carryforwards, $550.2 million will begin to expire in 2027 and the remaining NOLs carry forward indefinitely. In addition, the Company has foreign NOL carry forwards of $23.2&#160;million as of December&#160;31, 2025, which can be carried forward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company also had federal and California research and development tax credit carryforwards of $23.2 million and $4.6 million, respectively. The federal research and development tax credit carryforwards will begin to expire in 2037. The California research and development tax credit carryforwards are available indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Internal Revenue Code Sections 382, as amended, and 383, substantial restrictions exist on the utilization of tax attributes in the event a corporation experienced an &#x201c;ownership change.&#x201d; Generally, a Section 382 &#x201c;ownership change&#x201d; occurs if one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#x2019;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Accordingly, the Company's ability to utilize net operating loss and tax credit carryforwards may be limited as a result of such ownership changes, and such a limitation could result in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expiration of carryforwards before they are utilized. The Company has completed Section 382 studies that concluded the Company has experienced ownership changes since inception. However, this is not expected to result in the expiration of federal tax attribute carryforwards prior to utilization. Similar rules may apply under state tax laws. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted into law. The OBBBA contains numerous business tax provisions, including business extenders made permanent such as restoration of 100% bonus depreciation, IRC Section 174 expensing for US-based research, and the EBITDA-based business interest expense limitation under Section 163(j). The enacted legislation had an immaterial impact on the Company&#x2019;s effective tax rate for the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to tax positions taken during a prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decreases related to tax positions taken during a prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to tax positions taken during the current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in unrecognized tax benefits of $43.4 million at December&#160;31, 2025 was $36.2 million of tax benefits that, if recognized, would not impact the Company's income tax benefit or effective tax rate to the extent that the Company continues to maintain a full valuation allowance against its deferred tax assets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files tax returns in the United States, state jurisdictions, Canada, and the United Kingdom. The tax years for 2016 and forward are subject to examination by the U.S. tax authorities and the tax years for 2016 and forward are subject to examination by the state tax authorities. Due to net operating loss carryforwards and research and development credits in the United States and state tax jurisdictions, all years effectively remain open. The Company is subject to examination by the tax authorities in Canada and the United Kingdom for the year ended December 31, 2022 to the present period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company's policy to recognize interest and/or penalties related to uncertain tax benefits as a component of the provision for income taxes. For the years ended December&#160;31, 2025, 2024 and 2023, the Company has not recognized any interest or penalties related to income taxes. The Company has no accrued interest and penalties as of December&#160;31, 2025 and 2024 due to available tax losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of cash income taxes paid were not material for the years ended December&#160;31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-952" unitRef="usd">1200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-953" unitRef="usd">1200000</us-gaap:IncomeTaxExpenseBenefit>
    <arqt:ForeignWithholdingIncomeTaxes contextRef="c-1" decimals="-5" id="f-954" unitRef="usd">400000</arqt:ForeignWithholdingIncomeTaxes>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-955" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-956" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <arqt:ForeignWithholdingIncomeTaxes contextRef="c-12" decimals="-5" id="f-957" unitRef="usd">500000</arqt:ForeignWithholdingIncomeTaxes>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-958" unitRef="usd">3100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-959" unitRef="usd">3100000</us-gaap:IncomeTaxExpenseBenefit>
    <arqt:ForeignWithholdingIncomeTaxes contextRef="c-13" decimals="-5" id="f-960" unitRef="usd">3000000.0</arqt:ForeignWithholdingIncomeTaxes>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-961">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of loss before income taxes for domestic and foreign locations for the years ended December&#160;31, 2025, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(259,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-962" unitRef="usd">-8244000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-12" decimals="-3" id="f-963" unitRef="usd">-130372000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="-3" id="f-964" unitRef="usd">-255653000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-965" unitRef="usd">-6726000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-12" decimals="-3" id="f-966" unitRef="usd">-9020000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="-3" id="f-967" unitRef="usd">-3374000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-1" decimals="-3" id="f-968" unitRef="usd">-14970000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-12" decimals="-3" id="f-969" unitRef="usd">-139392000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-13" decimals="-3" id="f-970" unitRef="usd">-259027000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-971">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of provision for income taxes for the years ended December&#160;31, 2025, 2024 and 2023 is as follows (in thousands):&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current tax provision:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax provision:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-972" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-973" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-974" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-975" unitRef="usd">273000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-976" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-977" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-978" unitRef="usd">844000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-979" unitRef="usd">799000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-980" unitRef="usd">3113000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-981" unitRef="usd">1117000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-982" unitRef="usd">799000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-983" unitRef="usd">3113000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-984" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-985" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-986" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-987" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-988" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-989" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-990" unitRef="usd">54000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-991" unitRef="usd">-152000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-992" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-993" unitRef="usd">54000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-994" unitRef="usd">-152000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-995" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-996" unitRef="usd">1171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-997" unitRef="usd">647000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-998" unitRef="usd">3113000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-999">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax computed at federal statutory rates to the reported provision for income taxes for the years ended December&#160;31, 2025, 2024 and 2023 is as follows (in thousands)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.913%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax U.S. federal statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local income tax, net of federal income tax effect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United Kingdom&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statutory tax rate differential&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;China&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sec. 162(m) limitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) The prior years included in the effective tax rate table have been recast from the financial statements filed previously to align with the new presentation created through adherence to ASU 2023-09. Consideration has only been given to 2025 amounts in terms of the balances that are separately stated within the table.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) The states and local jurisdictions that contribute to a majority (greater than 50%) of the tax effect in this category include Texas, California and New York based on the distribution of sales and the current year state income tax obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-1000" unitRef="usd">-3144000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1001" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="-3" id="f-1002" unitRef="usd">-29272000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="3" id="f-1003" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="-3" id="f-1004" unitRef="usd">-54396000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="3" id="f-1005" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-1006" unitRef="usd">836000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1007" unitRef="number">-0.056</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="-3" id="f-1008" unitRef="usd">-11367000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="3" id="f-1009" unitRef="number">0.082</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="-3" id="f-1010" unitRef="usd">1512000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="3" id="f-1011" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-258" decimals="-3" id="f-1012" unitRef="usd">-319000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c-258"
      decimals="3"
      id="f-1013"
      unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-259" decimals="-3" id="f-1014" unitRef="usd">-389000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c-259"
      decimals="3"
      id="f-1015"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-260" decimals="-3" id="f-1016" unitRef="usd">-160000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c-260"
      decimals="3"
      id="f-1017"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-258" decimals="-3" id="f-1018" unitRef="usd">2071000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c-258"
      decimals="3"
      id="f-1019"
      unitRef="number">-0.138</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-259" decimals="-3" id="f-1020" unitRef="usd">2427000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c-259"
      decimals="3"
      id="f-1021"
      unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-260" decimals="-3" id="f-1022" unitRef="usd">999000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c-260"
      decimals="3"
      id="f-1023"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-258" decimals="-3" id="f-1024" unitRef="usd">-77000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c-258"
      decimals="3"
      id="f-1025"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-259" decimals="-3" id="f-1026" unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c-259"
      decimals="3"
      id="f-1027"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-260" decimals="-3" id="f-1028" unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c-260"
      decimals="3"
      id="f-1029"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-261" decimals="-3" id="f-1030" unitRef="usd">402000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c-261"
      decimals="3"
      id="f-1031"
      unitRef="number">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-262" decimals="-3" id="f-1032" unitRef="usd">500000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c-262"
      decimals="3"
      id="f-1033"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-263" decimals="-3" id="f-1034" unitRef="usd">3000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c-263"
      decimals="3"
      id="f-1035"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-264" decimals="-3" id="f-1036" unitRef="usd">233000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c-264"
      decimals="3"
      id="f-1037"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-265" decimals="-3" id="f-1038" unitRef="usd">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c-265"
      decimals="3"
      id="f-1039"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-266" decimals="-3" id="f-1040" unitRef="usd">-6000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c-266"
      decimals="3"
      id="f-1041"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-1" decimals="-3" id="f-1042" unitRef="usd">1288000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-1043" unitRef="number">-0.086</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-12" decimals="-3" id="f-1044" unitRef="usd">804000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-12" decimals="3" id="f-1045" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-13" decimals="-3" id="f-1046" unitRef="usd">4763000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-13" decimals="3" id="f-1047" unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-267" decimals="-3" id="f-1048" unitRef="usd">-3145000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c-267"
      decimals="3"
      id="f-1049"
      unitRef="number">0.211</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-268" decimals="-3" id="f-1050" unitRef="usd">37731000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c-268"
      decimals="3"
      id="f-1051"
      unitRef="number">-0.271</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-269" decimals="-3" id="f-1052" unitRef="usd">52716000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c-269"
      decimals="3"
      id="f-1053"
      unitRef="number">-0.202</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount contextRef="c-1" decimals="-3" id="f-1054" unitRef="usd">1426000</arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount>
    <arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent contextRef="c-1" decimals="3" id="f-1055" unitRef="number">-0.095</arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent>
    <arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount contextRef="c-12" decimals="-3" id="f-1056" unitRef="usd">633000</arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount>
    <arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent contextRef="c-12" decimals="3" id="f-1057" unitRef="number">-0.005</arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent>
    <arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount contextRef="c-13" decimals="-3" id="f-1058" unitRef="usd">3386000</arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationAmount>
    <arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent contextRef="c-13" decimals="3" id="f-1059" unitRef="number">-0.013</arqt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationLimitationPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-1060" unitRef="usd">3197000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1061" unitRef="number">-0.214</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-12" decimals="-3" id="f-1062" unitRef="usd">-185000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-12" decimals="3" id="f-1063" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-13" decimals="-3" id="f-1064" unitRef="usd">1787000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-13" decimals="3" id="f-1065" unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="-3" id="f-1066" unitRef="usd">857000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-1067" unitRef="number">-0.057</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-12" decimals="-3" id="f-1068" unitRef="usd">654000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-12" decimals="3" id="f-1069" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-13" decimals="-3" id="f-1070" unitRef="usd">-95000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-13" decimals="3" id="f-1071" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-267" decimals="-3" id="f-1072" unitRef="usd">122000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c-267"
      decimals="3"
      id="f-1073"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-268" decimals="-3" id="f-1074" unitRef="usd">719000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c-268"
      decimals="3"
      id="f-1075"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-269" decimals="-3" id="f-1076" unitRef="usd">-867000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c-269"
      decimals="3"
      id="f-1077"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1078" unitRef="usd">1171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1079" unitRef="number">-0.078</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1080" unitRef="usd">647000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-12" decimals="3" id="f-1081" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1082" unitRef="usd">3113000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-13" decimals="3" id="f-1083" unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1084">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.884%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and expenditure capitalization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-10" decimals="-3" id="f-1085" unitRef="usd">180809000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-11" decimals="-3" id="f-1086" unitRef="usd">171681000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-10" decimals="-3" id="f-1087" unitRef="usd">1958000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-11" decimals="-3" id="f-1088" unitRef="usd">1400000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-10" decimals="-3" id="f-1089" unitRef="usd">15698000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-11" decimals="-3" id="f-1090" unitRef="usd">14944000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <arqt:DeferredTaxAssetsResearchAndExpenditureCapitalization contextRef="c-10" decimals="-3" id="f-1091" unitRef="usd">23848000</arqt:DeferredTaxAssetsResearchAndExpenditureCapitalization>
    <arqt:DeferredTaxAssetsResearchAndExpenditureCapitalization contextRef="c-11" decimals="-3" id="f-1092" unitRef="usd">36255000</arqt:DeferredTaxAssetsResearchAndExpenditureCapitalization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-10" decimals="-3" id="f-1093" unitRef="usd">25226000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-11" decimals="-3" id="f-1094" unitRef="usd">16085000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <arqt:DeferredTaxAssetsLeaseLiability contextRef="c-10" decimals="-3" id="f-1095" unitRef="usd">1413000</arqt:DeferredTaxAssetsLeaseLiability>
    <arqt:DeferredTaxAssetsLeaseLiability contextRef="c-11" decimals="-3" id="f-1096" unitRef="usd">837000</arqt:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-10" decimals="-3" id="f-1097" unitRef="usd">7744000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-11" decimals="-3" id="f-1098" unitRef="usd">15761000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-10" decimals="-3" id="f-1099" unitRef="usd">256696000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-11" decimals="-3" id="f-1100" unitRef="usd">256963000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-10" decimals="-3" id="f-1101" unitRef="usd">255482000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-1102" unitRef="usd">256270000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-10" decimals="-3" id="f-1103" unitRef="usd">1214000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-11" decimals="-3" id="f-1104" unitRef="usd">693000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-10" decimals="-3" id="f-1105" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-11" decimals="-3" id="f-1106" unitRef="usd">58000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <arqt:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-10" decimals="-3" id="f-1107" unitRef="usd">1110000</arqt:DeferredTaxLiabilitiesRightOfUseAsset>
    <arqt:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-11" decimals="-3" id="f-1108" unitRef="usd">483000</arqt:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-10" decimals="-3" id="f-1109" unitRef="usd">1110000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-11" decimals="-3" id="f-1110" unitRef="usd">541000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-10" decimals="-3" id="f-1111" unitRef="usd">104000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-11" decimals="-3" id="f-1112" unitRef="usd">152000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-1113" unitRef="usd">-800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-12" decimals="-5" id="f-1114" unitRef="usd">40100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-270" decimals="-5" id="f-1115" unitRef="usd">761300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-271" decimals="-5" id="f-1116" unitRef="usd">636100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-10" decimals="-5" id="f-1117" unitRef="usd">3500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-10" decimals="-5" id="f-1118" unitRef="usd">757800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-271" decimals="-5" id="f-1119" unitRef="usd">636100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-271" decimals="-5" id="f-1120" unitRef="usd">550200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-272" decimals="-5" id="f-1121" unitRef="usd">23200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-273" decimals="-5" id="f-1122" unitRef="usd">23200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-274" decimals="-5" id="f-1123" unitRef="usd">4600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1124">&lt;div style="margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to tax positions taken during a prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decreases related to tax positions taken during a prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to tax positions taken during the current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-11" decimals="-3" id="f-1125" unitRef="usd">42286000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-30" decimals="-3" id="f-1126" unitRef="usd">41390000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-18" decimals="-3" id="f-1127" unitRef="usd">42505000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1128" unitRef="usd">403000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-12" decimals="-3" id="f-1129" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-1130" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1131" unitRef="usd">91000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-12" decimals="-3" id="f-1132" unitRef="usd">131000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-1133" unitRef="usd">3097000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1134" unitRef="usd">784000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-12" decimals="-3" id="f-1135" unitRef="usd">1027000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-1136" unitRef="usd">1982000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-10" decimals="-3" id="f-1137" unitRef="usd">43382000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-11" decimals="-3" id="f-1138" unitRef="usd">42286000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-30" decimals="-3" id="f-1139" unitRef="usd">41390000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-10" decimals="-5" id="f-1140" unitRef="usd">43400000</us-gaap:UnrecognizedTaxBenefits>
    <arqt:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate contextRef="c-10" decimals="-5" id="f-1141" unitRef="usd">36200000</arqt:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="INF" id="f-1142" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-12" decimals="INF" id="f-1143" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-13" decimals="INF" id="f-1144" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-10" decimals="INF" id="f-1145" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-11" decimals="INF" id="f-1146" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-1147" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-12" decimals="-3" id="f-1148" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-13" decimals="-3" id="f-1149" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1150">Net Loss Per Share&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average common shares outstanding. Pre-funded warrants to purchase 6,941,438, 7,500,000, and 1,417,808 shares of the Company's stock were included in the weighted-average common shares outstanding used in calculating net loss per share for the years ended December&#160;31, 2025, 2024 and 2023, respectively, as the exercise price of the pre-funded warrants is negligible and the pre-funded warrants are fully vested and exercisable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential dilutive securities, which include unvested RSUs and unvested performance-based RSUs for which established performance criteria have been achieved as of the end of the respective periods, vested and unvested options to purchase common stock and shares to be issued under the Company's employee stock purchase plan (ESPP), have been excluded from the calculation of diluted net loss per common share in each period in which the Company recorded a net loss, as the effect is antidilutive. The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,436,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,919,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs subject to future vesting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,007,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,055,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,929,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP shares subject to future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,456,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,875,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-199"
      decimals="INF"
      id="f-1151"
      unitRef="shares">6941438</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-275"
      decimals="INF"
      id="f-1152"
      unitRef="shares">7500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-276"
      decimals="INF"
      id="f-1153"
      unitRef="shares">1417808</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1154">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,436,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,919,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs subject to future vesting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,007,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,055,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,929,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP shares subject to future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,456,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,875,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-277"
      decimals="0"
      id="f-1155"
      unitRef="shares">6436972</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-278"
      decimals="0"
      id="f-1156"
      unitRef="shares">5342909</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-279"
      decimals="0"
      id="f-1157"
      unitRef="shares">7919699</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-280"
      decimals="0"
      id="f-1158"
      unitRef="shares">6007515</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-281"
      decimals="0"
      id="f-1159"
      unitRef="shares">6055087</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-282"
      decimals="0"
      id="f-1160"
      unitRef="shares">2929602</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-283"
      decimals="0"
      id="f-1161"
      unitRef="shares">11616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-284"
      decimals="0"
      id="f-1162"
      unitRef="shares">16338</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-285"
      decimals="0"
      id="f-1163"
      unitRef="shares">26368</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-1164" unitRef="shares">12456103</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-12" decimals="0" id="f-1165" unitRef="shares">11414334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-13" decimals="0" id="f-1166" unitRef="shares">10875669</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1167">Segment Reporting&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases. The Company&#x2019;s Chief Operating Decision Maker (CODM) is its Chief Executive Officer. The CODM evaluates financial information on a consolidated basis for the purposes of allocating resources and assessing performance. Substantially all of the Company's assets are located in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Topical roflumilast program costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Topical JAK inhibitor program costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other early-stage programs costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development compensation and personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment and consolidated net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(262,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Other segment expenses include professional services related to research and development, medical affairs, depreciation and amortization expenses.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1168"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1169">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Topical roflumilast program costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Topical JAK inhibitor program costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other early-stage programs costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development compensation and personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment and consolidated net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(262,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Other segment expenses include professional services related to research and development, medical affairs, depreciation and amortization expenses.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c-286" decimals="-3" id="f-1170" unitRef="usd">376072000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-287" decimals="-3" id="f-1171" unitRef="usd">196542000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-288" decimals="-3" id="f-1172" unitRef="usd">59606000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-286" decimals="-3" id="f-1173" unitRef="usd">32028000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-287" decimals="-3" id="f-1174" unitRef="usd">17169000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-288" decimals="-3" id="f-1175" unitRef="usd">4237000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-289" decimals="-3" id="f-1176" unitRef="usd">10938000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-290" decimals="-3" id="f-1177" unitRef="usd">5210000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-291" decimals="-3" id="f-1178" unitRef="usd">35607000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-292" decimals="-3" id="f-1179" unitRef="usd">741000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-293" decimals="-3" id="f-1180" unitRef="usd">2945000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-294" decimals="-3" id="f-1181" unitRef="usd">3334000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-295" decimals="-3" id="f-1182" unitRef="usd">6372000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-296" decimals="-3" id="f-1183" unitRef="usd">11477000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-297" decimals="-3" id="f-1184" unitRef="usd">5681000</us-gaap:ResearchAndDevelopmentExpense>
    <arqt:ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses contextRef="c-286" decimals="-3" id="f-1185" unitRef="usd">39779000</arqt:ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses>
    <arqt:ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses contextRef="c-287" decimals="-3" id="f-1186" unitRef="usd">39216000</arqt:ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses>
    <arqt:ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses contextRef="c-288" decimals="-3" id="f-1187" unitRef="usd">44613000</arqt:ResearchAndDevelopmentCompensationAndPersonnelRelatedExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-286" decimals="-3" id="f-1188" unitRef="usd">274033000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-287" decimals="-3" id="f-1189" unitRef="usd">228908000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-288" decimals="-3" id="f-1190" unitRef="usd">184628000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-286" decimals="-3" id="f-1191" unitRef="usd">24408000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-287" decimals="-3" id="f-1192" unitRef="usd">20014000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-288" decimals="-3" id="f-1193" unitRef="usd">22607000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:CostsAndExpenses contextRef="c-286" decimals="-3" id="f-1194" unitRef="usd">388299000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-287" decimals="-3" id="f-1195" unitRef="usd">324939000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-288" decimals="-3" id="f-1196" unitRef="usd">300707000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-286" decimals="-3" id="f-1197" unitRef="usd">-12227000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-287" decimals="-3" id="f-1198" unitRef="usd">-128397000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-288" decimals="-3" id="f-1199" unitRef="usd">-241101000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther contextRef="c-286" decimals="-3" id="f-1200" unitRef="usd">8897000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-287" decimals="-3" id="f-1201" unitRef="usd">16126000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-288" decimals="-3" id="f-1202" unitRef="usd">12517000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpenseNonoperating contextRef="c-286" decimals="-3" id="f-1203" unitRef="usd">12083000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-287" decimals="-3" id="f-1204" unitRef="usd">27168000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-288" decimals="-3" id="f-1205" unitRef="usd">29712000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-286" decimals="-3" id="f-1206" unitRef="usd">443000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-287" decimals="-3" id="f-1207" unitRef="usd">47000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-288" decimals="-3" id="f-1208" unitRef="usd">-731000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-286" decimals="-3" id="f-1209" unitRef="usd">1171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-287" decimals="-3" id="f-1210" unitRef="usd">647000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-288" decimals="-3" id="f-1211" unitRef="usd">3113000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-286" decimals="-3" id="f-1212" unitRef="usd">-16141000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-287" decimals="-3" id="f-1213" unitRef="usd">-140039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-288" decimals="-3" id="f-1214" unitRef="usd">-262140000</us-gaap:NetIncomeLoss>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
